PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Cullis, DN; Philip, B; Baleja, JD; Feig, LA				Cullis, DN; Philip, B; Baleja, JD; Feig, LA			Rab11-FIP2, an adaptor protein connecting cellular components involved in internalization and recycling of epidermal growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEINS; EH DOMAIN; COMPLEX; ENDOCYTOSIS; IDENTIFICATION; TRAFFICKING; EXOCYTOSIS; INTERACTS; EFFECTOR; EXOCYST	Rab11-FIP2 is a member of a newly identified family of Rab11-binding proteins that have been implicated in the function of recycling endosomes. Here we show that Rab11-FIP2 may also be involved with the process of receptor-mediated endocytosis. First we demonstrate that Rab11-FIP2 contains an NPF motif that allows it to bind Reps1, a member of a family of EH domain proteins involved in endocytosis. We also show that Rab11-FIP2 associates with the a-adaptin subunit of AP-2 complexes, which are known to recruit receptors into clathrin-coated vesicles. Finally, we find that overexpression of Rab11-FIP2 suppresses the internalization of epidermal growth factor receptors, but not transferrin receptors, through binding sites that promote complex formation with Rab11, Reps1, and alpha-adaptin. These findings suggest that Rab11-FIP2 may participate in the coupling of receptor-mediated endocytosis to the subsequent sorting of receptor-containing vesicles in endosomes.	Tufts Univ, Sch Med, Dept Biochem, Boston, MA 02111 USA	Tufts University	Feig, LA (corresponding author), Tufts Univ, Sch Med, Dept Biochem, 136 Harrison Ave, Boston, MA 02111 USA.				PHS HHS [NIH R01 47717] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BIELINSKI DF, 1993, BIOCHIM BIOPHYS ACTA, V1151, P246, DOI 10.1016/0005-2736(93)90109-D; Brymora A, 2001, J BIOL CHEM, V276, P29792, DOI 10.1074/jbc.C100320200; Hales CM, 2001, J BIOL CHEM, V276, P39067, DOI 10.1074/jbc.M104831200; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jullien-Flores V, 2000, J CELL SCI, V113, P2837; Kariya K, 2000, J BIOL CHEM, V275, P18399, DOI 10.1074/jbc.M000521200; Kim S, 2001, BIOCHEMISTRY-US, V40, P6776, DOI 10.1021/bi002700m; Lindsay AJ, 2002, J BIOL CHEM, V277, P12190, DOI 10.1074/jbc.M108665200; LINDSAY AJ, 2002, J BIOL CHEM; Mark BL, 1996, BIOCHEM BIOPH RES CO, V225, P40, DOI 10.1006/bbrc.1996.1128; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Moskalenko S, 2002, NAT CELL BIOL, V4, P66, DOI 10.1038/ncb728; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; NGSEE JK, 1991, J BIOL CHEM, V266, P2675; Polzin A, 2002, MOL CELL BIOL, V22, P1714, DOI 10.1128/MCB.22.6.1714-1722.2002; Prekeris R, 2001, J BIOL CHEM, V276, P38966, DOI 10.1074/jbc.M106133200; Prekeris R, 2000, MOL CELL, V6, P1437, DOI 10.1016/S1097-2765(00)00140-4; Santolini E, 1999, EXP CELL RES, V253, P186, DOI 10.1006/excr.1999.4694; Sheff D, 2002, J CELL BIOL, V156, P797, DOI 10.1083/jcb.20111048; Sugihara K, 2002, NAT CELL BIOL, V4, P73, DOI 10.1038/ncb720; TerBush DR, 1996, EMBO J, V15, P6483, DOI 10.1002/j.1460-2075.1996.tb01039.x; Wallace DM, 2002, BIOCHEM BIOPH RES CO, V292, P909, DOI 10.1006/bbrc.2002.6736; Wang XY, 2000, J BIOL CHEM, V275, P29138, DOI 10.1074/jbc.M004410200; Yamaguchi A, 1997, J BIOL CHEM, V272, P31230, DOI 10.1074/jbc.272.50.31230; Zerial M, 2001, NAT REV MOL CELL BIO, V2, P107, DOI 10.1038/35052055	26	79	86	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49158	49166		10.1074/jbc.M206316200	http://dx.doi.org/10.1074/jbc.M206316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12364336	hybrid			2022-12-25	WOS:000180028900009
J	Sun, Y; Cheng, ZJ; Ma, L; Pei, G				Sun, Y; Cheng, ZJ; Ma, L; Pei, G			beta-arrestin2 is critically involved in CXCR4-mediated chemotaxis, and this is mediated by its enhancement of p38 MAPK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; DOUBLE-STRANDED-RNA; CHEMOKINE RECEPTORS; BETA-ARRESTIN; LYMPHOCYTE CHEMOATTRACTANT; KINASE ACTIVATION; MICE LACKING; CXCR4; CELLS; SDF-1	Chemotaxis mediated by chemokine receptors such as CXCR4 plays a key role in lymphocyte homing and hematopoiesis as well as in breast cancer metastasis. We have demonstrated previously that beta-arrestin2 functions to attenuate CXCR4-mediated G protein activation and to enhance CXCR4 internalization. Here we show further that the expression of beta-arrestin2 in both HeLa and human embryonic kidney 293 cells significantly enhances the chemotactic efficacy of stromal cell-derived factor 1alpha, the specific agonist of CXCR4, whereas the suppression of beta-arrestin2 endogenous expression by antisense or RNA-mediated interference technology considerably attenuates stromal cell-derived factor 1alpha-induced cell migration. Expression of beta-arrestin2 also augmented chemokine receptor CCR5-mediated but not epidermal growth factor receptor-mediated chemotaxis, indicating the specific effect of beta-arrestin2. Further analysis reveals that expression of beta-arrestin2 strengthened CXCR4-mediated activation of both p38 MAPK and ERK, and the suppression of beta-arrestin2 expression blocked the activation of two kinases. Interestingly, inhibition of p38 MAPK activation (but not ERK activation) by its inhibitors or by expression of a dominant-negative mutant of p38 MAPK effectively blocked the chemotactic effect of beta-arrestin2. Expression of a dominant-negative mutant of ASK1 also exerted the similar blocking effect. The results of our study suggest that beta-arrestin2 can function not only as a regulator of CXCR4 signaling but also as a mediator of stromal cell-derived factor la-induced chemotaxis and that this activity probably occurs via the ASK1/p38 MAPK pathway.	Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Lab Mol Cell Biol, Shanghai 200031, Peoples R China; Fudan Univ, Med Ctr, Natl Lab Med Neurobiol, Shanghai 200031, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Fudan University	Pei, G (corresponding author), Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, Lab Mol Cell Biol, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.		Ma, Lan/B-9295-2009	Ma, Lan/0000-0001-9034-5472				Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Ayala JM, 2000, J LEUKOCYTE BIOL, V67, P869, DOI 10.1002/jlb.67.6.869; Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Chuang CF, 2000, P NATL ACAD SCI USA, V97, P4985, DOI 10.1073/pnas.060034297; de Parseval A, 2001, J VIROL, V75, P4528, DOI 10.1128/JVI.75.10.4528-4539.2001; Fong AM, 2002, P NATL ACAD SCI USA, V99, P7478, DOI 10.1073/pnas.112198299; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hoffman T L, 1998, AIDS, V12 Suppl A, pS17; Jing Q, 2000, CIRC RES, V87, P52, DOI 10.1161/01.RES.87.1.52; Jing Q, 1999, CIRC RES, V84, P831; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McGrath KE, 1999, DEV BIOL, V213, P442, DOI 10.1006/dbio.1999.9405; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Mundell SJ, 1999, BIOCHEMISTRY-US, V38, P8723, DOI 10.1021/bi990361v; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Neptune ER, 1997, P NATL ACAD SCI USA, V94, P14489, DOI 10.1073/pnas.94.26.14489; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; TASHIRO K, 1993, SCIENCE, V261, P600, DOI 10.1126/science.8342023; Tuschl T, 1999, GENE DEV, V13, P3191, DOI 10.1101/gad.13.24.3191; Wells TNC, 1996, J LEUKOCYTE BIOL, V59, P53, DOI 10.1002/jlb.59.1.53; Yu QM, 1999, ACTA BIOCH BIOPH SIN, V31, P344; Zhang LQ, 1998, J VIROL, V72, P5035, DOI 10.1128/JVI.72.6.5035-5045.1998; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	41	293	306	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49212	49219		10.1074/jbc.M207294200	http://dx.doi.org/10.1074/jbc.M207294200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12370187	hybrid			2022-12-25	WOS:000180028900015
J	Misra, P; Owuor, ED; Li, WG; Yu, ST; Qi, C; Meyer, K; Zhu, YJ; Rao, MS; Kong, ANT; Reddy, JK				Misra, P; Owuor, ED; Li, WG; Yu, ST; Qi, C; Meyer, K; Zhu, YJ; Rao, MS; Kong, ANT; Reddy, JK			Phosphorylation of transcriptional coactivator peroxisome proliferator-activated receptor (PPAR)-binding protein (PBP) - Stimulation of transcriptional regulation by mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; NUCLEAR RECEPTORS; EMBRYONIC-DEVELOPMENT; TRAP220 COMPONENT; MOLECULAR-CLONING; GENE-EXPRESSION; COMPLEX; P300; CBP; INTERACTS	Peroxisome proliferator-activated receptor (PPAR)binding protein (PBP) is an important coactivator for PPARgamma and other transcription factors. PBP is an integral component of a multiprotein thyroid hormone receptor-associated protein (TRAP)/vitamin D-3 receptor-interacting protein (DRIP)/activator-recruited cofactor (ARC) complex required for transcriptional activity. To study the regulation of PBP by cellular signaling pathways, we identified the phosphorylation sites of PBP. Using a combination of in vitro and in vivo approaches and mutagenesis of PBP phosphorylation sites, we identified six phosphorylation sites on PBP: one exclusive protein kinase A (PKA) phosphorylation site at serine 656, two protein kinase C (PKC) sites at serine 796 and serine 1345, a common PKA/PKC site at serine 756, and two extracellular signal-regulated kinase 2 sites of the mitogen-activated protein kinase (MAPK) family at threonine 1017 and threonine 1444. Binding of PBP to PPARgamma1 or retinoid-X-receptor for 9-cis-retinoic acid (RXR) is independent of their phosphorylation states, implying no changes in protein-protein interaction after modification by phosphorylation. Overexpression of RafBXB, an activated upstream kinase of the MAPK signal transduction pathway, exerts a significant additive inductive effect on PBP coactivator function. This effect is significantly diminished by overexpression of Raf-BXB301, a dominant negative mutant of RafBXB. These results identify phosphorylation as a regulatory modification event of PBP and demonstrate that PBP phosphorylation by Raf/MEK/MAPK cascade exerts a positive effect on PBP coactivator function. The functional role of PKA and PKC phosphorylation sites in PBP remains to be elucidated.	Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA; Rutgers State Univ, Dept Pharmaceut, Coll Pharm, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Dr Reddys Labs Ltd, Hyderabad 500050, Andhra Pradesh, India	Northwestern University; Feinberg School of Medicine; Rutgers State University New Brunswick; Dr. Reddy's Laboratories Ltd.	Reddy, JK (corresponding author), Northwestern Univ, Dept Pathol, Feinberg Sch Med, 303 E Chicago Ave, Chicago, IL 60611 USA.	jkreddy@northwestern.edu	Kong, Ah-Ng Tony/AAX-2828-2020		NATIONAL CANCER INSTITUTE [R01CA084472] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [K08ES000356] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023750, R37GM023750] Funding Source: NIH RePORTER; NCI NIH HHS [CA-73647, CA84472, CA-888898] Funding Source: Medline; NIEHS NIH HHS [K08 ES00356] Funding Source: Medline; NIGMS NIH HHS [GM23750] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; Crawford SE, 2002, J BIOL CHEM, V277, P3585, DOI 10.1074/jbc.M107995200; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Goodman RH, 2000, GENE DEV, V14, P1553; Gusterson R, 2002, J BIOL CHEM, V277, P2517, DOI 10.1074/jbc.M104626200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0; Ito M, 2000, MOL CELL, V5, P683, DOI 10.1016/S1097-2765(00)80247-6; Ito M, 2001, TRENDS ENDOCRIN MET, V12, P127, DOI 10.1016/S1043-2760(00)00355-6; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jung DJ, 2002, J BIOL CHEM, V277, P1229, DOI 10.1074/jbc.M110417200; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Ko L, 2002, MOL CELL BIOL, V22, P357, DOI 10.1128/MCB.22.1.357-369.2002; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Kung AL, 2000, GENE DEV, V14, P272; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; LIN J, 1998, CELL, V92, P829; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Misra P, 2002, J BIOL CHEM, V277, P20011, DOI 10.1074/jbc.M201739200; Naar AM, 1999, NATURE, V398, P828, DOI 10.1038/19789; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Oike Y, 1999, BLOOD, V93, P2771; ONATE SA, 1995, SCIENCE, V270, P1354; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; RAY LB, 1988, P NATL ACAD SCI USA, V85, P3753, DOI 10.1073/pnas.85.11.3753; Reddy JK, 1996, ANN NY ACAD SCI, V804, P176, DOI 10.1111/j.1749-6632.1996.tb18616.x; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Rowan BG, 2000, MOL CELL BIOL, V20, P8720, DOI 10.1128/MCB.20.23.8720-8730.2000; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; See RH, 2001, J BIOL CHEM, V276, P16310, DOI 10.1074/jbc.M008113200; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Surapureddi S, 2002, P NATL ACAD SCI USA, V99, P11836, DOI 10.1073/pnas.182426699; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yu R, 1999, J BIOL CHEM, V274, P27545, DOI 10.1074/jbc.274.39.27545; Yu R, 2000, J BIOL CHEM, V275, P9612, DOI 10.1074/jbc.275.13.9612; Yu R, 2000, J BIOL CHEM, V275, P39907, DOI 10.1074/jbc.M004037200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200; ZHU YJ, 1993, J BIOL CHEM, V268, P26817; Zhu YJ, 1996, GENE EXPRESSION, V6, P185; Zhu YJ, 1997, J BIOL CHEM, V272, P25500, DOI 10.1074/jbc.272.41.25500; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848; Zhu YJ, 2001, P NATL ACAD SCI USA, V98, P10380, DOI 10.1073/pnas.181347498	69	61	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48745	48754		10.1074/jbc.M208829200	http://dx.doi.org/10.1074/jbc.M208829200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356758	hybrid			2022-12-25	WOS:000179789600101
J	Pandini, V; Caprini, G; Thomsen, N; Aliverti, A; Seeber, F; Zanetti, G				Pandini, V; Caprini, G; Thomsen, N; Aliverti, A; Seeber, F; Zanetti, G			Ferredoxin-NADP(+)' reductase and ferredoxin of the protozoan parasite Toxoplasma gondii interact productively in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-TRANSFER; NADP+ REDUCTASE; APICOMPLEXAN PARASITES; PLASMODIUM-FALCIPARUM; SPINACH LEAVES; PROTEINS; PLASTIDS; APICOPLAST; ORIGIN; OXIDOREDUCTASE	Toxoplasma gondii possesses an apicoplast-localized, plant-type ferredoxin-NADP(+) reductase. We have cloned a [2Fe-2S] ferredoxin from the same parasite to investigate the interplay of the two redox proteins. A detailed characterization of the two purified recombinant proteins, particularly as to their interaction, has been performed. The two-protein complex was able to catalyze electron transfer from NADPH to cytochrome c with high catalytic efficiency. The redox potential of the flavin cofactor (FAD/FADH(-)) of the reductase was shown to be more positive than that of the NADP(+)/NADPH couple, thus favoring electron transfer from NADPH to yield reduced ferredoxin. The complex formation between the reductase and ferredoxins from various sources was studied both in vitro by several approaches (enzymatic activity, cross-linking, protein fluorescence quenching, affinity chromatography) and in vivo by the yeast two-hybrid system. Our data show that the two proteins yield an active complex with high affinity, strongly suggesting that the two proteins of T. gondii form a physiological redox couple that transfers electrons from NADPH to ferredoxin, which in turn is used by some reductive biosynthetic pathway(s) of the apicoplast. These data provide the basis for the exploration of this redox couple as a drug target in apicomplexan parasites.	Univ Milan, Dipartimento Fisiol & Biochim Gen, I-20133 Milan, Italy; Univ Marburg, FB Biol Parasitol, D-35032 Marburg, Germany	University of Milan; Philipps University Marburg	Zanetti, G (corresponding author), Univ Milan, Dipartimento Fisiol & Biochim Gen, Via Celoria 26, I-20133 Milan, Italy.		Aliverti, Alessandro/B-7875-2017	Aliverti, Alessandro/0000-0002-1226-3655; Seeber, Frank/0000-0002-2271-3699				ALIVERTI A, 1994, FEBS LETT, V343, P247, DOI 10.1016/0014-5793(94)80565-2; Aliverti A, 1999, METH MOL B, V131, P9; Aliverti A, 2001, BIOCHEMISTRY-US, V40, P14501, DOI 10.1021/bi011224c; ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; Aliverti A, 1997, BIOCHEMISTRY-US, V36, P14771, DOI 10.1021/bi971791t; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; BOWSHER CG, 1993, PLANT J, V3, P463, DOI 10.1111/j.1365-313X.1993.tb00166.x; BUJARD H, 1987, METHOD ENZYMOL, V155, P416; Corrado ME, 1996, EUR J BIOCHEM, V239, P662, DOI 10.1111/j.1432-1033.1996.0662u.x; DeRocher A, 2000, J CELL SCI, V113, P3969; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; Fashena SJ, 2000, METHOD ENZYMOL, V328, P14, DOI 10.1016/S0076-6879(00)28387-0; Fast NM, 2001, MOL BIOL EVOL, V18, P418, DOI 10.1093/oxfordjournals.molbev.a003818; Golemis EA, 2002, BIOTECHNIQUES, V32, P636, DOI 10.2144/02323dd01; He CY, 2001, J BIOL CHEM, V276, P28436, DOI 10.1074/jbc.M102000200; Jelenska J, 2001, P NATL ACAD SCI USA, V98, P2723, DOI 10.1073/pnas.051629998; Jomaa H, 1999, SCIENCE, V285, P1573, DOI 10.1126/science.285.5433.1573; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; Knaff D.B., 1996, OXYGENIC PHOTOSYNTHE, V4, P333; Kohler S, 1997, SCIENCE, V275, P1485, DOI 10.1126/science.275.5305.1485; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; Marechal E, 2001, TRENDS PLANT SCI, V6, P200, DOI 10.1016/S1360-1385(01)01921-5; MASSEY V, 1977, J BIOL CHEM, V252, P5612; McFadden GI, 1999, TRENDS MICROBIOL, V7, P328, DOI 10.1016/S0966-842X(99)01547-4; Morales R, 2000, EMBO REP, V1, P271, DOI 10.1093/embo-reports/kvd057; Neuhaus HE, 2000, ANNU REV PLANT PHYS, V51, P111, DOI 10.1146/annurev.arplant.51.1.111; Onda Y, 2000, PLANT PHYSIOL, V123, P1037, DOI 10.1104/pp.123.3.1037; PANDINI V, 2002, FLAVINS FLAVOPROTEIN, P899; Piubelli L, 1996, EUR J BIOCHEM, V236, P465, DOI 10.1111/j.1432-1033.1996.00465.x; PIUBELLI L, 1995, PROTEIN EXPRES PURIF, V6, P298, DOI 10.1006/prep.1995.1039; Roos DS, 1999, CURR OPIN MICROBIOL, V2, P426, DOI 10.1016/S1369-5274(99)80075-7; Roos DS, 2002, PHILOS T R SOC B, V357, P35, DOI 10.1098/rstb.2001.1047; Seeber F, 2002, INT J PARASITOL, V32, P1207, DOI 10.1016/S0020-7519(02)00022-X; Striepen B, 2000, J CELL BIOL, V151, P1423, DOI 10.1083/jcb.151.7.1423; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vollmer M, 2001, J BIOL CHEM, V276, P5483, DOI 10.1074/jbc.M009452200; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; Waller RF, 1998, P NATL ACAD SCI USA, V95, P12352, DOI 10.1073/pnas.95.21.12352; Wilson RJM, 2002, J MOL BIOL, V319, P257, DOI 10.1016/S0022-2836(02)00303-0; Wilson RJM, 1996, J MOL BIOL, V261, P155, DOI 10.1006/jmbi.1996.0449; WONG SY, 1993, AIDS, V7, P299, DOI 10.1097/00002030-199303000-00001; ZANETTI G, 1988, BIOCHEMISTRY-US, V27, P3753, DOI 10.1021/bi00410a035; Ziegler GA, 1999, J MOL BIOL, V289, P981, DOI 10.1006/jmbi.1999.2807; TAXOPLASMA GONDII 35	45	40	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48463	48471		10.1074/jbc.M209388200	http://dx.doi.org/10.1074/jbc.M209388200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12370173	hybrid			2022-12-25	WOS:000179789600066
J	Kobayashi, T; Tanaka, K; Inoue, K; Kakizuka, A				Kobayashi, T; Tanaka, K; Inoue, K; Kakizuka, A			Functional ATPase activity of p97/valosin-containing protein (VCP) is required for the quality control of endoplasmic reticulum in neuronally differentiated mammalian PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; VALOSIN-CONTAINING PROTEIN; MACHADO-JOSEPH DISEASE; AAA-ATPASE; ALZHEIMERS-DISEASE; RESPIRATORY-CHAIN; MEMBRANE-FUSION; DEGRADATION; ER; PATHWAY	Abnormal protein accumulation and cell death with cytoplasmic vacuoles are hallmarks of several neurodegenerative disorders. We previously identified p97/valosin-containing protein (VCP), an AAA ATPase with two conserved ATPase domains (D1 and D2), as an interacting partner of the Machado-Joseph disease (MJD) protein with expanded polyglutamines that causes Machado-Joseph disease. To reveal its pathophysiological roles in neuronal cells, we focused on its ATPase activity. We constructed and characterized PC12 cells expressing wild-type p97/VCP and p97(K524A), a D2 domain mutant. The expression level, localization, and complex formation of both proteins were indistinguishable, but the ATPase activity of p97(K524A) was much lower than that of the wild type. p97(K524A) induced cytoplasmic vacuoles that stained with an endoplasmic reticulum (ER) marker, and accumulation of polyubiquitinated proteins in the nuclear and membrane but not cytoplasmic fractions was observed, together with the elevation of ER stress markers. These results show that p97/VCP is essential for degrading membrane-associated ubiquitinated proteins and that profound deficits in its ATPase activity severely affect ER quality control, leading to abnormal ER expansion and cell death. Excessive accumulation of misfolded proteins may inactivate p97/VCP in several neurodegenerative disorders, eventually leading to the neurodegenerations.	Kyoto Univ, Grad Sch Biostudies, Kyoto 6068501, Japan; Osaka Biosci Inst, Dept 4, Suita, Osaka 5650874, Japan; Japan Sci & Technol Corp, CREST, Kawaguchi 3320012, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Kakizuka, A (corresponding author), Kyoto Univ, Grad Sch Biostudies, Kyoto 6068501, Japan.		KOBAYASHI, TAEKO/GSJ-2693-2022	KOBAYASHI, TAEKO/0000-0002-5514-0866; Tanaka-Yamamoto, Keiko/0000-0002-1246-9784				Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Dai RM, 2001, NAT CELL BIOL, V3, P740, DOI 10.1038/35087056; Dai RM, 1998, J BIOL CHEM, V273, P3562, DOI 10.1074/jbc.273.6.3562; Dalal S, 2001, CELL, V104, P5, DOI 10.1016/S0092-8674(01)00186-6; Ghoshal N, 1999, AM J PATHOL, V155, P1163, DOI 10.1016/S0002-9440(10)65219-4; Hetzer M, 2001, NAT CELL BIOL, V3, P1086, DOI 10.1038/ncb1201-1086; Higashiyama H, 2002, CELL DEATH DIFFER, V9, P264, DOI 10.1038/sj.cdd.4400955; Hirabayashi M, 2001, CELL DEATH DIFFER, V8, P977, DOI 10.1038/sj.cdd.4400907; Ikeda H, 1996, NAT GENET, V13, P196, DOI 10.1038/ng0696-196; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; Kakizuka A, 1997, CURR OPIN NEUROL, V10, P285, DOI 10.1097/00019052-199708000-00002; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; Kobayashi T, 1997, P NATL ACAD SCI USA, V94, P11857, DOI 10.1073/pnas.94.22.11857; Kobayashi T, 2001, MOL MICROBIOL, V39, P158, DOI 10.1046/j.1365-2958.2001.02229.x; Kobayashi T, 1999, EMBO J, V18, P1192, DOI 10.1093/emboj/18.5.1192; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Lam YA, 2000, P NATL ACAD SCI USA, V97, P9902, DOI 10.1073/pnas.170173897; LATTERICH M, 1995, CELL, V82, P885, DOI 10.1016/0092-8674(95)90268-6; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lord JM, 2002, CURR BIOL, V12, pR182, DOI 10.1016/S0960-9822(02)00738-8; Meyer HH, 2000, EMBO J, V19, P2181, DOI 10.1093/emboj/19.10.2181; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; RABOUILLE C, 1995, CELL, V82, P905, DOI 10.1016/0092-8674(95)90270-8; Rockel B, 2002, J MOL BIOL, V317, P673, DOI 10.1006/jmbi.2002.5448; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Skinner PJ, 2001, AM J PATHOL, V159, P905, DOI 10.1016/S0002-9440(10)61766-X; TOKUDA H, 1993, BIOCHEM BIOPH RES CO, V195, P1415, DOI 10.1006/bbrc.1993.2201; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Xiong XM, 1999, J BIOL CHEM, V274, P2616, DOI 10.1074/jbc.274.5.2616; Yasuda S, 1999, GENES CELLS, V4, P743, DOI 10.1046/j.1365-2443.1999.00294.x; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	42	126	130	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47358	47365		10.1074/jbc.M207783200	http://dx.doi.org/10.1074/jbc.M207783200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351637	hybrid			2022-12-25	WOS:000179663700068
J	Lepourcelet, M; Shivdasani, RA				Lepourcelet, M; Shivdasani, RA			Characterization of a novel mammalian groucho isoform and its role in transcriptional regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSDUCIN-LIKE-ENHANCER; AMINO-TERMINAL ENHANCER; EPITHELIAL STEM-CELL; BETA-CATENIN; COLORECTAL-CANCER; MEDIATED TRANSCRIPTION; DROSOPHILA ENHANCER; SIGNALING ACTIVITY; XENOPUS EMBRYOS; BINDING-PROTEIN	The Wnt/beta-catenin/Tcf pathway serves important functions in embryonic development and is constitutively activated in human colorectal cancer. The nuclear output of Wnt signaling is mediated by a complex between DNA-binding proteins of the TCF family and the transcriptional coactivator beta-catenin. Groucho proteins act to repress transcriptional activation by beta-cateninTcf complexes, probably by interacting directly with Tcf transcription factors. We have identified several splice forms of the mouse Groucho Grg1 gene expressed in the developing intestine. Prominent among these is a novel and abundant isoform, Grg1-S, which we characterize in this report. Grg1-S has highest homology with the TLE family of large Groucho proteins but features only the amino-terminal Q and glycine- and proline-rich domains typical of the Groucho/AES subfamily. Grg1-S is expressed in development and in several adult mouse tissues. Expression in the adult small intestine is highest at the base of the crypts of Lieberkuhn. Grg1-S acts to antagonize beta-catenin activity in Xenopus axis duplication and luciferase reporter assays in mammalian cells. Taken together, these findings suggest that Grg1-S may operate in conjunction with beta-catenin and Tcf factors to regulate vertebrate gut epithelial cell differentiation.	Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Shivdasani, RA (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, 44 Binney St, Boston, MA 02115 USA.							ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; Barker N, 1999, AM J PATHOL, V154, P29, DOI 10.1016/S0002-9440(10)65247-9; Barker N, 2000, ADV CANCER RES, V77, P1; Bauer A, 2000, EMBO J, V19, P6121, DOI 10.1093/emboj/19.22.6121; Bonifacino J. S., 1998, CURRENT PROTOCOLS CE; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Brannon M, 1999, DEVELOPMENT, V126, P3159; Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982; Chen GQ, 2000, GENE, V249, P1, DOI 10.1016/S0378-1119(00)00161-X; Chen GQ, 1998, MOL CELL BIOL, V18, P7259, DOI 10.1128/MCB.18.12.7259; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; Choudhury BK, 1997, GENE, V195, P41, DOI 10.1016/S0378-1119(97)00150-9; da Costa LT, 1999, ONCOGENE, V18, P5010, DOI 10.1038/sj.onc.1202872; DEHNI G, 1995, MECH DEVELOP, V53, P369, DOI 10.1016/0925-4773(95)00452-1; Eberhard D, 2000, EMBO J, V19, P2292, DOI 10.1093/emboj/19.10.2292; Fisher AL, 1998, GENE DEV, V12, P1931, DOI 10.1101/gad.12.13.1931; Grbavec D, 1998, EUR J BIOCHEM, V258, P339, DOI 10.1046/j.1432-1327.1998.2580339.x; Hovanes K, 2001, NAT GENET, V28, P53, DOI 10.1038/88264; Hurlstone A, 2002, EMBO J, V21, P2303, DOI 10.1093/emboj/21.10.2303; Husain J, 1996, BIOCHEM J, V317, P523, DOI 10.1042/bj3170523; Imai Y, 1998, BIOCHEM BIOPH RES CO, V252, P582, DOI 10.1006/bbrc.1998.9705; Javed A, 2000, J CELL SCI, V113, P2221; Jimenez G, 1997, GENE DEV, V11, P3072, DOI 10.1101/gad.11.22.3072; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Larabell CA, 1997, J CELL BIOL, V136, P1123, DOI 10.1083/jcb.136.5.1123; Lee YJ, 1999, J BIOL CHEM, V274, P1566, DOI 10.1074/jbc.274.3.1566; Levanon D, 1998, P NATL ACAD SCI USA, V95, P11590, DOI 10.1073/pnas.95.20.11590; MagiGalluzzi C, 1997, LAB INVEST, V76, P37; MALLO M, 1995, DEV DYNAM, V204, P338, DOI 10.1002/aja.1002040311; McLarrent FW, 2001, J BIOL CHEM, V276, P1578, DOI 10.1074/jbc.M007629200; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 2000, MECH DEVELOP, V91, P311, DOI 10.1016/S0925-4773(99)00259-2; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Nuthall HN, 2002, MOL CELL BIOL, V22, P389, DOI 10.1128/MCB.22.2.389-399.2002; PAROUSH Z, 1994, CELL, V79, P805, DOI 10.1016/0092-8674(94)90070-1; Pinto M, 1996, J BIOL CHEM, V271, P33026, DOI 10.1074/jbc.271.51.33026; Polakis P, 1999, ADV EXP MED BIOL, V470, P23; Potten CS, 1997, INT J EXP PATHOL, V78, P219, DOI 10.1046/j.1365-2613.1997.280362.x; Pukrop T, 2001, J BIOL CHEM, V276, P8968, DOI 10.1074/jbc.M007533200; Ren B, 1999, GENE DEV, V13, P125, DOI 10.1101/gad.13.1.125; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; Roose J, 1999, SCIENCE, V285, P1923, DOI 10.1126/science.285.5435.1923; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; Sakamoto I, 2000, J BIOL CHEM, V275, P32871, DOI 10.1074/jbc.M004089200; Sambrook J, 2001, MOL CLONING LAB MANU, V3; Sampson EM, 2001, EMBO J, V20, P4500, DOI 10.1093/emboj/20.16.4500; Shoichet SA, 2000, P NATL ACAD SCI USA, V97, P4076, DOI 10.1073/pnas.97.8.4076; Snider L, 2001, MOL CELL BIOL, V21, P1866, DOI 10.1128/MCB.21.5.1866-1873.2001; Sparks AB, 1998, CANCER RES, V58, P1130; Stappenbeck TS, 1998, CURR OPIN CELL BIOL, V10, P702, DOI 10.1016/S0955-0674(98)80110-5; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; SWEETSER DA, 1988, GENE DEV, V2, P1318, DOI 10.1101/gad.2.10.1318; Tago K, 2000, GENE DEV, V14, P1741; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; Waltzer L, 1998, NATURE, V395, P521, DOI 10.1038/26785; Wang JCW, 2000, J BIOL CHEM, V275, P18418, DOI 10.1074/jbc.M910211199; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Yao J, 2000, MECH DEVELOP, V93, P105, DOI 10.1016/S0925-4773(00)00278-1; Yu X, 2001, MOL CELL BIOL, V21, P4614, DOI 10.1128/MCB.21.14.4614-4625.2001; Zorn AM, 1999, MOL CELL, V4, P487, DOI 10.1016/S1097-2765(00)80200-2	67	18	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47732	47740		10.1074/jbc.M208154200	http://dx.doi.org/10.1074/jbc.M208154200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359720	hybrid			2022-12-25	WOS:000179663700116
J	Lim, JW; Kim, H; Kim, KH				Lim, JW; Kim, H; Kim, KH			Expression of Ku70 and Ku80 mediated by NF-kappa B and cyclooxygenase-2 is related to proliferation of human gastric cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GROWTH-FACTOR RECEPTOR; DNA END-BINDING; PROSTAGLANDIN E-2; CATALYTIC SUBUNIT; BCL-2 EXPRESSION; IL-8 PRODUCTION; EGF RECEPTOR; APOPTOSIS; AUTOANTIGEN	Cyclooxygenase-2 (COX-2) expression is mediated by constitutive NF-kappaB and regulates human gastric cancer cell growth and proliferation. Inactivating Ku70 or Ku80 suppresses cell growth and induces apoptosis. It has been hypothesized that Ku70 and Ku80 expression may be associated with NF-kappaB activation and COX-2 expression and is involved in cell proliferation. In this study, we found that inhibition of constitutive NF-kappaB (by transfecting a mutated IkappaBalpha gene) and of COX-2 (by treatment with indomethacin and NS-398) suppressed Ku70 and Ku80 expression in cells. Treatment with prostaglandin E-2 adenocarcinoma gastric (AGS) increased expression of these Ku proteins in cells with low constitutive NF-kappaB levels. Inhibition of the Ku DNA end-binding activity by transfection. with the C-terminal Ku80 expression gene suppressed cell proliferation. Ku70 or Ku80 overexpression by transfection with the Ku70 or Ru80 expression gene, respectively, enhanced proliferation of cells with low NF-kappaB levels. These results demonstrate that Ku70 and Ku80 expression is mediated by constitutively activated NF-kappaB and constitutively expressed COX-2 in gastric cancer cells and that the high Ku DNA end-binding activity contributes to cell proliferation. Ku70 and Ku80 expression may be related to gastric cell proliferation and carcinogenesis.	Yonsei Univ, Coll Med, Dept Pharmacol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Inst Gastroenterol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea.	kim626@yumc.yonsei.ac.kr		Kim, Hyeyoung/0000-0002-7019-917X				AARONSON SA, 1991, SCIENCE, V254, P1146, DOI 10.1126/science.1659742; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bandyopadhyay D, 1998, J BIOL CHEM, V273, P1568, DOI 10.1074/jbc.273.3.1568; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Battu S, 1998, ANTICANCER RES, V18, P2397; Battu S, 1998, ANTICANCER RES, V18, P3579; BHUYAN BK, 1986, CANCER RES, V46, P1688; BLIER PR, 1993, J BIOL CHEM, V268, P7594; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bureau F, 2002, BLOOD, V99, P3683, DOI 10.1182/blood.V99.10.3683; Cary RB, 1998, NUCLEIC ACIDS RES, V26, P974, DOI 10.1093/nar/26.4.974; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Erickson BA, 1999, J SURG RES, V81, P101, DOI 10.1006/jsre.1998.5511; Factor V, 2001, HEPATOLOGY, V34, P32, DOI 10.1053/jhep.2001.25270; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; Gao HJ, 2000, WORLD J GASTROENTERO, V6, P848, DOI 10.3748/wjg.v6.i6.848; Gao YJ, 1998, IMMUNITY, V9, P367, DOI 10.1016/S1074-7613(00)80619-6; Ghoshal K, 1998, P NATL ACAD SCI USA, V95, P10390, DOI 10.1073/pnas.95.18.10390; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Gu YS, 2000, P NATL ACAD SCI USA, V97, P2668, DOI 10.1073/pnas.97.6.2668; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; HAIMOVITZFRIEDMAN A, 1991, CANCER RES, V51, P2552; Hida T, 1998, ANTICANCER RES, V18, P775; Higashi Y, 2000, INT J CANCER, V86, P667, DOI 10.1002/(SICI)1097-0215(20000601)86:5<667::AID-IJC10>3.3.CO;2-P; Jin SF, 1997, CANCER SURV, V29, P221; Jol H, 2000, ONCOGENE, V19, P841, DOI 10.1038/sj.onc.1203392; Kim H, 2000, DIGEST DIS SCI, V45, P621, DOI 10.1023/A:1005474013988; Kim H, 1999, PHARMACOLOGY, V59, P201, DOI 10.1159/000028321; Kim SH, 2000, LEUKEMIA RES, V24, P917, DOI 10.1016/S0145-2126(00)00061-8; Kinoshita T, 1999, BBA-MOL CELL BIOL L, V1438, P120, DOI 10.1016/S1388-1981(99)00034-7; Klein A, 2000, LEUKEMIA, V14, P40, DOI 10.1038/sj.leu.2401636; KUMAR R, 1991, Current Opinion in Oncology, V3, P70, DOI 10.1097/00001622-199102000-00011; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; Li JJ, 1997, CANCER RES, V57, P3569; Lim JW, 2001, LAB INVEST, V81, P349, DOI 10.1038/labinvest.3780243; Lipart C, 2002, J VIROL METHODS, V101, P1, DOI 10.1016/S0166-0934(01)00413-X; Liu L, 1998, MOL CELL BIOL, V18, P4221, DOI 10.1128/MCB.18.7.4221; Liu XH, 1998, CANCER RES, V58, P4245; MaleckaPanas E, 1997, HEPATO-GASTROENTEROL, V44, P435; Marangoni E, 2000, NUCLEIC ACIDS RES, V28, P4778, DOI 10.1093/nar/28.23.4778; Mendelsohn J, 1997, J NATL CANCER I, V89, P341, DOI 10.1093/jnci/89.5.341; MIMORI T, 1990, P NATL ACAD SCI USA, V87, P1777, DOI 10.1073/pnas.87.5.1777; MIMORI T, 1986, J BIOL CHEM, V261, P375; Molina MA, 1999, CANCER RES, V59, P4356; Moorghen M, 1998, CELL PROLIFERAT, V31, P59, DOI 10.1046/j.1365-2184.1998.00111.x; NAKAJIMAIIJIMA S, 1985, P NATL ACAD SCI USA, V82, P6133, DOI 10.1073/pnas.82.18.6133; Narumiya S, 1999, PHYSIOL REV, V79, P1193, DOI 10.1152/physrev.1999.79.4.1193; Nussenzweig A, 1996, NATURE, V382, P551, DOI 10.1038/382551a0; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Osipovich O, 1999, BIOCHEM BIOPH RES CO, V261, P802, DOI 10.1006/bbrc.1999.1118; Ouyang H, 1997, J EXP MED, V186, P921, DOI 10.1084/jem.186.6.921; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; Pucci S, 2001, ONCOGENE, V20, P739, DOI 10.1038/sj.onc.1204148; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; Rayet B, 1999, ONCOGENE, V18, P6938, DOI 10.1038/sj.onc.1203221; Raz A, 2002, BIOCHEM PHARMACOL, V63, P343, DOI 10.1016/S0006-2952(01)00857-7; RESNICK MB, 1995, CANCER-AM CANCER SOC, V76, P187, DOI 10.1002/1097-0142(19950715)76:2<187::AID-CNCR2820760205>3.0.CO;2-C; Sadji Z, 2000, CELL SIGNAL, V12, P745, DOI 10.1016/S0898-6568(00)00126-1; Sasaki N, 2001, CLIN CANCER RES, V7, P4136; Sawaoka H, 1998, AM J PHYSIOL-GASTR L, V274, pG1061, DOI 10.1152/ajpgi.1998.274.6.G1061; SEIBERT K, 1995, AGENT ACTION SUPPL, V46, P41; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1998, CANCER RES, V58, P362; Shimada N, 1998, J GASTROEN HEPATOL, V13, P794, DOI 10.1111/j.1440-1746.1998.tb00735.x; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Sovak MA, 1999, CELL GROWTH DIFFER, V10, P537; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; Tai DI, 2000, CANCER, V89, P2274, DOI 10.1002/1097-0142(20001201)89:11<2274::AID-CNCR16>3.0.CO;2-2; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA, P121; Taylor MT, 2000, CANCER RES, V60, P6607; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; Tjandrawinata RR, 1997, BRIT J CANCER, V75, P1111, DOI 10.1038/bjc.1997.192; Tuteja R, 2000, CRIT REV BIOCHEM MOL, V35, P1, DOI 10.1080/10409230091169177; Um JH, 2001, ONCOGENE, V20, P6048, DOI 10.1038/sj.onc.1204732; Wang JS, 1998, J BIOL CHEM, V273, P842, DOI 10.1074/jbc.273.2.842; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Wu XT, 1996, MOL CELL BIOL, V16, P5186; Wulczyn FG, 1996, J MOL MED, V74, P749, DOI 10.1007/s001090050078; YANG X, 1998, AM J PHYSIOL, V275, pC1058; Zhao YL, 2000, CARCINOGENESIS, V21, P2005, DOI 10.1093/carcin/21.11.2005	87	74	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46093	46100		10.1074/jbc.M206603200	http://dx.doi.org/10.1074/jbc.M206603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324457	hybrid			2022-12-25	WOS:000179529300052
J	Fujita, H; Katoh, H; Ishikawa, Y; Mori, K; Negishi, M				Fujita, H; Katoh, H; Ishikawa, Y; Mori, K; Negishi, M			Rapostlin is a novel effector of Rnd2 GTPase inducing neurite branching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; RHO-FAMILY GTPASES; PC12 CELLS; ACTIN CYTOSKELETON; IN-VIVO; GROWTH CONE; BINDING; NEURONS; IDENTIFICATION; MICROTUBULES	Rho family GTPases are central regulators of neuronal morphology. Recently, Rnd proteins, Rnd1, Rnd2, and Rnd3/RhoE, have been identified as new members of Rho family GTPases. Of these, Rnd2 is specifically expressed in neurons in brain; however, the signaling pathways of RnA2 are not known. Here we have performed a yeast two-hybrid screen using Rnd2 as a bait and identified a novel Rnd2-effector protein, expressed predominantly in brain. We named it Rapostlin (apostle of Rnd2). Rapostlin has two functional domains, Fer-CIP4 homology (FCH) domain at the amino terminus and SH3 (Src homology 3) domain at the carboxyl terminus. In in vitro binding assays, Rapostlin specifically binds to Rnd2 among the Rho family GTPases in a GTP-dependent manner, and the Rnd2-binding domain of Rapostlin is localized between FCH and SH3 domains. Rapostlin directly binds to microtubules, and the aminoterminal region containing the FCH domain of Rapostlin is essential for this interaction. In PC 12 cells, Rapostlin induces neurite branching in response to Rnd2, and at least the amino-terminal region of Rapostlin is necessary for this activity. Therefore, Rapostlin is the first effector of RnA2, regulating neurite branch formation.	Kyoto Univ, Mol Neurobiol Lab, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Negishi, M (corresponding author), Kyoto Univ, Mol Neurobiol Lab, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan.			Katoh, Hironori/0000-0002-8191-8117				Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Aspenstrom P, 1997, CURR BIOL, V7, P479, DOI 10.1016/S0960-9822(06)00219-3; Banzai Y, 2000, J BIOL CHEM, V275, P11987, DOI 10.1074/jbc.275.16.11987; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Chan DC, 1996, EMBO J, V15, P1045, DOI 10.1002/j.1460-2075.1996.tb00442.x; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Foster R, 1996, MOL CELL BIOL, V16, P2689; Fuchs U, 2001, P NATL ACAD SCI USA, V98, P8756, DOI 10.1073/pnas.121433898; Fujita H, 2000, BIOCHEM J, V346, P617, DOI 10.1042/0264-6021:3460617; Guasch RM, 1998, MOL CELL BIOL, V18, P4761, DOI 10.1128/MCB.18.8.4761; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; Joberty G, 1999, MOL CELL BIOL, V19, P6585; Katoh H, 2000, MOL CELL BIOL, V20, P7378, DOI 10.1128/MCB.20.19.7378-7387.2000; Katoh H, 2002, MOL CELL BIOL, V22, P2952, DOI 10.1128/MCB.22.9.2952-2964.2002; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Li Z, 2000, NAT NEUROSCI, V3, P217, DOI 10.1038/72920; Linder S, 2000, J CELL SCI, V113, P4165; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; MANSER E, 1995, METHOD ENZYMOL, V256, P130; Nakayama AY, 2000, J NEUROSCI, V20, P5329, DOI 10.1523/JNEUROSCI.20-14-05329.2000; Nishi M, 1999, MOL BRAIN RES, V67, P74, DOI 10.1016/S0169-328X(99)00039-X; Nobes CD, 1998, J CELL BIOL, V141, P187, DOI 10.1083/jcb.141.1.187; Ruchhoeft ML, 1999, J NEUROSCI, V19, P8454; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Szebenyi G, 1998, J NEUROSCI, V18, P7930; Tanabe K, 2000, J NEUROSCI, V20, P4138; Tanaka H, 2002, BIOCHEM J, V365, P349, DOI 10.1042/BJ20020062; Tian L, 2000, J BIOL CHEM, V275, P7854, DOI 10.1074/jbc.275.11.7854; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200	34	68	73	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45428	45434		10.1074/jbc.M208090200	http://dx.doi.org/10.1074/jbc.M208090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244061	hybrid			2022-12-25	WOS:000179404800106
J	Lee, SF; Shah, S; Li, HQ; Yu, C; Han, WP; Yu, G				Lee, SF; Shah, S; Li, HQ; Yu, C; Han, WP; Yu, G			Mammalian APH-1 interacts with presenilin and nicastrin and is required for intramembrane proteolysis of amyloid-beta precursor protein and Notch	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SECRETASE ACTIVITY; ALZHEIMERS-DISEASE; INTRACELLULAR DOMAIN; APP; ASPARTATES; CLEAVAGE; COMPLEX; RELEASE	Presenilin and nicastrin are essential components of the gamma-secretase complex that is required for the intramembrane proteolysis of an increasing number of membrane proteins including the amyloid-beta precursor protein (APP) and Notch. By using co-immunoprecipitation and nickel affinity pull-down approaches, we now show that mammalian APH-1 (mAPH-1), a conserved multipass membrane protein, physically associates with nicastrin and the heterodimers of the presenilin aminoand carboxyl-terminal fragments in human cell lines and in rat brain. Similar to the loss of presenilin or nicastrin, the inactivation of endogenous mAPH-1 using small interfering RNAs results in the decrease of presenilin levels, accumulation of gamma-secretase substrates (APP carboxyl-terminal fragments), and reduction of gamma-secretase products (amyloid-beta peptides and the intracellular domains of APP and Notch). These data indicate that mAPH-1 is probably a functional component of the gamma-secretase complex required for the intramembrane proteolysis of APP and Notch.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yu, G (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.							Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chen FS, 2001, NAT CELL BIOL, V3, P751, DOI 10.1038/35087069; Chung HM, 2001, NAT CELL BIOL, V3, P1129, DOI 10.1038/ncb1201-1129; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kehoe P, 1999, HUM MOL GENET, V8, P237, DOI 10.1093/hmg/8.2.237; Kopan R, 2002, NEURON, V33, P321, DOI 10.1016/S0896-6273(02)00585-8; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Levitan D, 2001, DEV BIOL, V240, P654, DOI 10.1006/dbio.2001.0486; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Lopez-Schier H, 2002, DEV CELL, V2, P79, DOI 10.1016/S1534-5807(01)00109-5; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Wiltfang J, 1997, ELECTROPHORESIS, V18, P527, DOI 10.1002/elps.1150180332; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, J BIOL CHEM, V275, P27348; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; YU G, 1994, J CELL SCI, V107, P1671; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470	32	189	209	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45013	45019		10.1074/jbc.M208164200	http://dx.doi.org/10.1074/jbc.M208164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297508	hybrid			2022-12-25	WOS:000179404800055
J	Vander Heiden, MG; Choy, JS; VanderWeele, DJ; Brace, JL; Harris, MH; Bauer, DE; Prange, B; Kron, SJ; Thompson, CB; Rudin, CM				Vander Heiden, MG; Choy, JS; VanderWeele, DJ; Brace, JL; Harris, MH; Bauer, DE; Prange, B; Kron, SJ; Thompson, CB; Rudin, CM			Bcl-x(L) complements Saccharomyces cerevisiae genes that facilitate the switch from glycolytic to oxidative metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROAPOPTOTIC PROTEIN BAX; BCL-2 FAMILY-MEMBERS; REGULATES APOPTOSIS; YEAST; EXPRESSION; MITOCHONDRIA; DEATH; HETERODIMERIZATION; PROHIBITIN; CHAPERONE	All eukaryotic organisms have mechanisms to adapt to changing metabolic conditions. The mammalian cell survival gene Bcl-x(L) enables cells to adapt to changes in cellular metabolism. To identify genes whose function can be substituted by Bcl-x(L) in a unicellular eukaryote, a genetic screen was performed using the yeast Saccharomyces cerevisiae. S. cerevisiae grows by anaerobic glycolysis when glucose is available, switching to oxidative phosphorylation when carbohydrate in the media becomes limiting (diauxic shift). Given that Bcl-x(L) appears to facilitate the switch from glycolytic to oxidative metabolism in mammalian cells, a library of yeast mutants was tested for the ability to efficiently undergo diauxic shift in the presence and absence of Bcl-x(L). Several mutants were identified that have a defect in growth when switched from a fermentable to a nonfermentable carbon source that is corrected by the expression of Bcl-x(L). These genes include the mitochondrial chaperonin TCM62, as well as previously uncharacterized genes. One of these uncharacterized genes, SVF1, promotes cell survival in mammalian cells in response to multiple apoptotic stimuli. The finding that TCM62 and the analogous human prohibitin gene also inhibit mammalian cell death following growth factor withdrawal implicates mitochondrial chaperones as regulators of apoptosis. Further characterization of the genes identified in this screen may enhance our understanding of Bcl-x(L) function in mammalian cells, and of cell survival pathways in general.	Univ Chicago, Ctr Med, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Penn, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA	University of Chicago; University of Chicago; University of Pennsylvania; Pennsylvania Medicine	Rudin, CM (corresponding author), Univ Chicago, Ctr Med, Dept Med, 5841 S Maryland Ave,MC2115, Chicago, IL 60637 USA.	crudin@medicine.bsd.uchicago.edu	Rudin, Charles/R-2530-2019	Rudin, Charles/0000-0001-5204-3465; VanderWeele, David/0000-0003-4576-5034; Choy, John/0000-0001-9196-3280; Brace, Jennifer/0000-0002-7734-2450	NATIONAL CANCER INSTITUTE [K23CA081138] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281] Funding Source: NIH RePORTER; NCI NIH HHS [CA81138] Funding Source: Medline; NIGMS NIH HHS [5 T32 GM07281] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BlachlyDyson E, 1997, MOL CELL BIOL, V17, P5727, DOI 10.1128/MCB.17.10.5727; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Coates PJ, 1997, CURR BIOL, V7, P607, DOI 10.1016/S0960-9822(06)00261-2; DellOrco RT, 1996, EXP GERONTOL, V31, P245, DOI 10.1016/0531-5565(95)02009-8; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Dibrov E, 1998, J BIOL CHEM, V273, P32042, DOI 10.1074/jbc.273.48.32042; Greenhalf W, 1996, FEBS LETT, V380, P169, DOI 10.1016/0014-5793(96)00044-0; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; HANADA M, 1995, J BIOL CHEM, V270, P11962, DOI 10.1074/jbc.270.20.11962; Harris MH, 2000, MOL CELL BIOL, V20, P3590, DOI 10.1128/MCB.20.10.3590-3596.2000; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Heiden MGV, 2001, J BIOL CHEM, V276, P19414, DOI 10.1074/jbc.M101590200; Jurgensmeier JM, 1997, MOL BIOL CELL, V8, P325; Klanner C, 2000, FEBS LETT, V470, P365, DOI 10.1016/S0014-5793(00)01322-3; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madeo F, 2002, MOL CELL, V9, P911, DOI 10.1016/S1097-2765(02)00501-4; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Matsuyama S, 1998, MOL CELL, V1, P327, DOI 10.1016/S1097-2765(00)80033-7; MINN AJ, 1995, BLOOD, V86, P1903, DOI 10.1182/blood.V86.5.1903.bloodjournal8651903; Minn AJ, 1999, EMBO J, V18, P632, DOI 10.1093/emboj/18.3.632; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; RILEY J, 1990, NUCLEIC ACIDS RES, V18, P2887, DOI 10.1093/nar/18.10.2887; Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983; Schendel SL, 1998, CELL DEATH DIFFER, V5, P372, DOI 10.1038/sj.cdd.4400365; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Vander Heiden MG, 2000, P NATL ACAD SCI USA, V97, P4666, DOI 10.1073/pnas.090082297; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; Wang XD, 2001, GENE DEV, V15, P2922; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zha HB, 1996, MOL CELL BIOL, V16, P6494	36	49	50	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44870	44876		10.1074/jbc.M204888200	http://dx.doi.org/10.1074/jbc.M204888200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244097	hybrid			2022-12-25	WOS:000179404800037
J	Ko, SC; Chapple, KS; Hawcroft, G; Coletta, PL; Markham, AF; Hull, MA				Ko, SC; Chapple, KS; Hawcroft, G; Coletta, PL; Markham, AF; Hull, MA			Paracrine cyclooxygenase-2-mediated signalling by macrophages promotes tumorigenic progression of intestinal epithelial cells	ONCOGENE			English	Article						adenomatous polyps; colorectal cancer; cyclooxygenase; macrophage	FAMILIAL ADENOMATOUS POLYPOSIS; NITRIC-OXIDE SYNTHASE; CELLULAR-LOCALIZATION; INCREASED EXPRESSION; TGF-BETA; IN-VITRO; CANCER; GROWTH; RECEPTOR; INHIBITOR	In human colorectal adenomas or polyps, cyclooxygenase-2 is expressed predominantly by stromal (or interstitial) macrophages. Therefore, we tested the hypothesis that macrophage cyclooxygenase-2 has paracrine pro-tumorigenic activity using in vitro models of macrophage-epithelial cell interactions. We report that macrophages can promote tumorigenic progression of intestinal epithelial cells (evidenced by decreased cell-cell contact inhibition, increased proliferation and apoptosis, gain of anchorage-independent growth capability, decreased membranous E-cadherin expression, up-regulation of cyclooxygenase-2 expression, down-regulation of transforming growth factor-beta type 11 receptor expression and resistance to the antiproliferative activity of transforming growth factor-beta(1)) in a paracrine, cyclooxygenase-2-dependent manner. Pharmacologically relevant concentrations (1-2 muM) of a selective cyclooxygenase-2 inhibitor had no detectable, direct effect on intestinal epithelial cells but inhibited the macrophage-epithelial cell signal mediating tumorigenic progression. Cyclooxygenase-2-mediated stromal-epithelial cell signalling during the early stages of intestinal tumorigenesis provides a novel target for chemoprevention of colorectal cancer (and other gastro-intestinal epithelial malignancies, which arise on a background of chronic inflammation, such as gastric cancer) and may explain the discrepancy between the concentrations of cyclooxygenase inhibitors required to produce antineoplastic effects in vitro and in vivo.	Univ Leeds, St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England	Saint James's University Hospital; University of Leeds	Hull, MA (corresponding author), Univ Leeds, St James Univ Hosp, Mol Med Unit, Leeds LS9 7TF, W Yorkshire, England.	M.A.Hull@leeds.ac.uk	Chapple, Keith/AAL-6484-2020	Chapple, Keith/0000-0001-6523-2230				Bamba H, 1999, INT J CANCER, V83, P470, DOI 10.1002/(SICI)1097-0215(19991112)83:4<470::AID-IJC6>3.3.CO;2-6; Birchmeier C, 1996, ACTA ANAT, V156, P217; Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1; Chulada PC, 2000, CANCER RES, V60, P4705; Cordon-Cardo C, 1999, J EXP MED, V190, P1367, DOI 10.1084/jem.190.10.1367; Coussens LM, 2001, J EXP MED, V193, pF23, DOI 10.1084/jem.193.6.F23; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Farrow DC, 1998, CANCER EPIDEM BIOMAR, V7, P97; Fu SD, 1999, GASTROENTEROLOGY, V116, P1319, DOI 10.1016/S0016-5085(99)70496-8; Fujita M, 2000, J GASTROEN HEPATOL, V15, P1277, DOI 10.1046/j.1440-1746.2000.02399.x; GAGLIARDI G, 1995, VIRCHOWS ARCH, V426, P149; GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805; Giardiello FM, 2002, NEW ENGL J MED, V346, P1054, DOI 10.1056/NEJMoa012015; GOLDMAN R, 1979, J NATL CANCER I, V63, P1009; Hardwick JCH, 2001, ONCOGENE, V20, P819, DOI 10.1038/sj.onc.1204162; HAUPTMANN S, 1993, AM J PATHOL, V143, P1406; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Hull M, 2000, GASTROENTEROLOGY, V119, P600, DOI 10.1053/gast.2000.16156; Hull MA, 2000, CLIN EXP METASTAS, V18, P21, DOI 10.1023/A:1026553605636; Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Jacoby RF, 2000, CANCER RES, V60, P5040; Khan KNM, 2001, SCAND J GASTROENTERO, V36, P865, DOI 10.1080/003655201750313405; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; MANNING AM, 1991, ONCOGENE, V6, P1471; Marx J, 2001, SCIENCE, V291, P581, DOI 10.1126/science.291.5504.581; Morris CD, 2001, AM J GASTROENTEROL, V96, P990; Muller-Decker K, 1999, INT J COLORECTAL DIS, V14, P212, DOI 10.1007/s003840050213; Mutoh M, 2002, CANCER RES, V62, P28; Nau GJ, 2002, P NATL ACAD SCI USA, V99, P1503, DOI 10.1073/pnas.022649799; O'Byrne KJ, 2001, BRIT J CANCER, V85, P473, DOI 10.1054/bjoc.2001.1943; Oshima M, 2001, CANCER RES, V61, P1733; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; PARASKEVA C, 1990, ANTICANCER RES, V10, P1189; Pitot HC, 2000, ALIMENT PHARM THERAP, V14, P153, DOI 10.1046/j.1365-2036.2000.014s1153.x; QUARONI A, 1979, J CELL BIOL, V80, P248, DOI 10.1083/jcb.80.2.248; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; Rosenberger CM, 2000, J IMMUNOL, V164, P5894, DOI 10.4049/jimmunol.164.11.5894; SANO H, 1995, CANCER RES, V55, P3785; Seno H, 2002, CANCER RES, V62, P506; Sharma RA, 2001, CARCINOGENESIS, V22, P1557, DOI 10.1093/carcin/22.9.1557; Shattuck-Brandt RL, 1999, MOL CARCINOGEN, V24, P177, DOI 10.1002/(SICI)1098-2744(199903)24:3<177::AID-MC4>3.0.CO;2-6; Shattuck-Brandt RL, 2000, GASTROENTEROLOGY, V118, P337, DOI 10.1016/S0016-5085(00)70216-2; Sheehan KM, 1999, JAMA-J AM MED ASSOC, V282, P1254, DOI 10.1001/jama.282.13.1254; Sheng GG, 1997, GASTROENTEROLOGY, V113, P1883, DOI 10.1016/S0016-5085(97)70007-6; Sheng HM, 1999, ONCOGENE, V18, P855, DOI 10.1038/sj.onc.1202397; Sheng HM, 2001, J BIOL CHEM, V276, P18075, DOI 10.1074/jbc.M009689200; Sinicrope FA, 1996, CLIN CANCER RES, V2, P1999; Smith ML, 2000, EUR J CANCER, V36, P664, DOI 10.1016/S0959-8049(99)00333-0; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Soslow RA, 2000, CANCER, V89, P2637, DOI 10.1002/1097-0142(20001215)89:12<2637::AID-CNCR17>3.0.CO;2-B; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603; Sung JJY, 2000, AM J PATHOL, V157, P729, DOI 10.1016/S0002-9440(10)64586-5; Taketo MM, 1998, CLINICAL SIGNIFICANCE AND POTENTIAL OF SELECTIVE COX-2 INHIBITORS, P129; Takeuchi M, 2002, INT J COLORECTAL DIS, V17, P144, DOI 10.1007/s00384-001-0372-5; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; TSUJII M, 1995, CELL, V83, P493, DOI 10.1016/0092-8674(95)90127-2; Williams CS, 2000, CANCER RES, V60, P6045; Williams CS, 2000, J CLIN INVEST, V105, P1589, DOI 10.1172/JCI9621; WILLSON JKV, 1987, CANCER RES, V47, P2704; Wilson KT, 1998, CANCER RES, V58, P2929; Yang VW, 1998, CANCER RES, V58, P1750; Zhang T, 1997, CANCER RES, V57, P1638	64	34	37	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7175	7186		10.1038/sj.onc.1205869	http://dx.doi.org/10.1038/sj.onc.1205869			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370807				2022-12-25	WOS:000178504600005
J	Pedram, A; Razandi, M; Aitkenhead, M; Hughes, CCW; Levin, ER				Pedram, A; Razandi, M; Aitkenhead, M; Hughes, CCW; Levin, ER			Integration of the non-genomic and genomic actions of estrogen - Membrane-initiated signaling by steroid to transcription and cell biology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION; GROWTH-FACTOR; RECEPTOR REGULATION; CYCLOOXYGENASE-2; ACTIVATION; PROTEIN; PATHWAY; KINASE; ALPHA	Estrogen binds to receptors that translocate to the plasma membrane and to the nucleus. The rapid, nongenomic actions of this sex steroid are attributed to membrane action, while gene transcription occurs through nuclear receptor function. However, gene transcription can also result from estrogen signaling initiated at the membrane, but the relative importance of this mechanism is not known. In vascular endothelial cells (EC), estradiol (E-2) activates several kinase cascades, including phosphatidylinositol 3-phosphate (PI3K)/Akt, a signaling pathway that impacts EC biology. We determined here by DNA microarray that 40-min exposure to E-2 significantly increased 250 genes in EC, up-regulation that was substantially prevented by the PI3K inhibitor, LY294002. This coincided with maximum E-2-induced PI3K activity at 15-30 min. An important vascular gene strongly up-regulated by E-2 in our array produces cyclooxygenase-2 (Cox2). In cultured EC, E-2 induced both Cox-2 gene expression and new Cox-2 protein synthesis by 40 and 60 min, respectively, and rapidly stimulated the secretion of prostaglandins PGI(2) and PGE(2). The up-regulation of gene expression reflected transcriptional transactivation, shown using Cox-2 promoter/luciferase reporters in the EC. Soluble inhibitors or dominant negative constructs for PI3K and Akt prevented all these actions of E-2. Functionally, EC migration was induced by the sex steroid, and this was significantly reversed by NS-398, a Cox-2 inhibitor. Gene transcription and cell biological effects of estrogen emanate from rapid and specific signaling, integrating cell surface and nuclear actions of this steroid.	Vet Affairs Med Ctr, Div Endocrinol, Long Beach, CA 90822 USA; Univ Calif Irvine, Dept Med, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92717 USA; Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine	Levin, ER (corresponding author), UC Irvine, Long Beach Vet Adm Med Ctr, Med Serv 111I, 5901 E 7th St, Long Beach, CA 90822 USA.	ellis.levin@med.va.gov	Hughes, Christopher/F-7510-2010; Levin, Ellis/J-5402-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059890] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-59890] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akarasereenont P, 2000, INFLAMM RES, V49, P460, DOI 10.1007/s000110050617; Amano Hideki, 2002, Hum Cell, V15, P13, DOI 10.1111/j.1749-0774.2002.tb00095.x; ARONICA SM, 1994, P NATL ACAD SCI USA, V91, P8517, DOI 10.1073/pnas.91.18.8517; Chen Z, 1999, J CLIN INVEST, V103, P401, DOI 10.1172/JCI5347; Coceani F, 2001, BRIT J PHARMACOL, V132, P241, DOI 10.1038/sj.bjp.0703779; Du BH, 2000, J BIOL CHEM, V275, P39039, DOI 10.1074/jbc.M005159200; Duan RQ, 2002, BIOCHEM BIOPH RES CO, V294, P384, DOI 10.1016/S0006-291X(02)00499-0; Duan RQ, 2001, J BIOL CHEM, V276, P11590, DOI 10.1074/jbc.M005492200; Dzurba A, 1997, MOL CELL BIOCHEM, V176, P113, DOI 10.1023/A:1006835214312; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Faletti CJ, 2002, AM J PHYSIOL-CELL PH, V282, pC494, DOI 10.1152/ajpcell.00408.2001; Ferrara N, 1998, NAT MED, V4, P336, DOI 10.1038/nm0398-336; Heaney AP, 2002, J CLIN INVEST, V109, P277, DOI 10.1172/JCI200214264; Hocherl K, 2002, BRIT J PHARMACOL, V136, P1117, DOI 10.1038/sj.bjp.0704821; HYDER SM, 1995, J BIOL CHEM, V270, P8506, DOI 10.1074/jbc.270.15.8506; KANE LP, 2002, MOL CELL BIOL, V16, P5662; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Kong M, 2000, J BIOL CHEM, V275, P36035, DOI 10.1074/jbc.M005621200; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; Kumar R, 2002, NATURE, V418, P654, DOI 10.1038/nature00889; Lazennec G, 1999, MOL ENDOCRINOL, V13, P969, DOI 10.1210/me.13.6.969; Lederman RJ, 2002, LANCET, V359, P2053, DOI 10.1016/S0140-6736(02)08937-7; LeMellay V, 1997, J BIOL CHEM, V272, P11902, DOI 10.1074/jbc.272.18.11902; Levin ER, 2001, J APPL PHYSIOL, V91, P1860, DOI 10.1152/jappl.2001.91.4.1860; Li DY, 1997, AM J PHYSIOL-REG I, V273, pR1283, DOI 10.1152/ajpregu.1997.273.4.R1283; Locklin RM, 2001, J BONE MINER RES, V16, P2192, DOI 10.1359/jbmr.2001.16.12.2192; Long AD, 2001, J BIOL CHEM, V276, P19937, DOI 10.1074/jbc.M010192200; Matsumoto H, 2002, J BIOL CHEM, V277, P29260, DOI 10.1074/jbc.M203996200; Mendelsohn ME, 1999, NEW ENGL J MED, V340, P1801, DOI 10.1056/NEJM199906103402306; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Monick MM, 2002, J BIOL CHEM, V277, P32992, DOI 10.1074/jbc.M203218200; Pandey SK, 2002, ENDOCRINOLOGY, V143, P375, DOI 10.1210/en.143.2.375; PEDRAM A, 2002, J BIOL CHEM, DOI DOI 10.1074/JBC9M202391200; PIETRAS RJ, 1977, NATURE, V265, P69, DOI 10.1038/265069a0; Plant A, 2002, J CELL BIOCHEM, V84, P285, DOI 10.1002/jcb.10021; Porter W, 1997, MOL ENDOCRINOL, V11, P1569, DOI 10.1210/me.11.11.1569; Razandi M, 2000, MOL ENDOCRINOL, V14, P1434, DOI 10.1210/me.14.9.1434; Razandi M, 2000, J BIOL CHEM, V275, P38540, DOI 10.1074/jbc.M007555200; Razandi M, 1999, MOL ENDOCRINOL, V13, P307, DOI 10.1210/me.13.2.307; Ribardo DA, 2002, TOXICON, V40, P519, DOI 10.1016/S0041-0101(01)00247-1; Richards JS, 2002, MOL ENDOCRINOL, V16, P580, DOI 10.1210/me.16.3.580; Schafer U, 2000, BBA-GENE STRUCT EXPR, V1494, P269, DOI 10.1016/S0167-4781(00)00249-9; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Sherman TS, 2002, AM J RESP CELL MOL, V26, P610, DOI 10.1165/ajrcmb.26.5.4528; Sherwin BB, 1998, P SOC EXP BIOL MED, V217, P17; Simoncini T, 2000, NATURE, V407, P538, DOI 10.1038/35035131; Singer CA, 1999, J NEUROSCI, V19, P2455; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; TESARIK J, 1995, J CLIN ENDOCR METAB, V80, P1438, DOI 10.1210/jc.80.4.1438; TRUSS M, 1993, ENDOCR REV, V14, P459, DOI 10.1210/er.14.4.459; Tsai KJ, 2002, P NATL ACAD SCI USA, V99, P3990, DOI 10.1073/pnas.062405399; Tsai MS, 2002, ONCOGENE, V21, P964, DOI 10.1038/sj/onc/1205131; WATANABE Y, 1993, J BIOCHEM-TOKYO, V114, P849, DOI 10.1093/oxfordjournals.jbchem.a124267; Watters JJ, 2000, MOL ENDOCRINOL, V14, P1872, DOI 10.1210/me.14.11.1872; Watters JJ, 1997, ENDOCRINOLOGY, V138, P4030, DOI 10.1210/en.138.9.4030; Wyckoff MH, 2001, J BIOL CHEM, V276, P27071, DOI 10.1074/jbc.M100312200	57	242	249	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50768	50775		10.1074/jbc.M210106200	http://dx.doi.org/10.1074/jbc.M210106200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12372818	hybrid			2022-12-25	WOS:000180177700075
J	Brint, EK; Fitzgerald, KA; Smith, P; Coyle, AJ; Gutierrez-Ramos, JC; Fallon, PG; O'Neill, LAJ				Brint, EK; Fitzgerald, KA; Smith, P; Coyle, AJ; Gutierrez-Ramos, JC; Fallon, PG; O'Neill, LAJ			Characterization of signaling pathways activated by the interleukin 1 (IL-1) receptor homologue T1/ST2 - A Role for Jun N-terminal kinase in IL-4 induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY PROTEIN IL-1RACP; TOLL-LIKE RECEPTORS; T-CELLS; KAPPA-B; TH2 CELLS; EXPRESSION; TYPE-2; GENE; FAMILY; MEMBER	T1/ST2 is a member of the interleukin (IL)-1 receptor superfamily, possessing three immunoglobulin domains extracellularly and a Toll/IL1R (TIR) domain intracellularly. The ligand for T1/ST2 is not known. T1/ST2 is expressed on Type 2 T helper (Th2) cells, and its role appears to be in the regulation of Th2 cell function. Here, we have investigated T1/ST2 signal transduction, using either transient overexpression of T1/ST2 or a cross-linking monoclonal antibody to activate cells. We demonstrate that T1/ST2 does not activate the transcription factor NF-kappaB when overexpressed in murine thymoma EL4 cells, or in the mast cell line P815 treated with the anti-T1/ST2 antibody. However, a chimera comprising the extracellular domain of the type 1 IL-1 receptor and the intracellular domain of T1/ST2 activates NF-kappaB both by overexpression and in response to IL-1. This artificial activation requires the ILIRAcP recruited via the extracellular portion (IL1R1) of the chimera. T1/ST2 is, however, able to activate the transcription factor activator protein-1 (AP-1), increase phosphorylation of c-Jun, and activate the MAP kinases c-Jun N-terminal kinase (JNK), p42/p44 and p38. Anti-T1/ST2 also induces the selective expression of IL-4 but not IFN-gamma in naive T cells. Importantly, this effect is blocked by prior treatment with the JNK inhibitor SP600125 confirming that JNK as a key effector in TV ST2 signaling. The lack of effect on NF-kappaB when T1/ST2 is homodimerized identifies T1/ST2 as the first member of the IL-1 receptor superfamily so far studied that is apparently unable to activate NF-kappaB, consistent with evidence indicating the lack of a role for NF-kappaB in Th2 cell function.	Trinity Coll Dublin, Dept Biochem, Cytokine Res Grp, Dublin 2, Ireland; Trinity Coll Dublin, Dept Biochem, Immunomodulat Grp, Dublin 2, Ireland; Millennium Pharmaceut Inc, Dept Biol, Inflammat Div, Cambridge, MA 02139 USA	Trinity College Dublin; Trinity College Dublin; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Brint, EK (corresponding author), Trinity Coll Dublin, Dept Biochem, Cytokine Res Grp, Dublin 2, Ireland.	brinte@tcd.ie	Fallon, Padraic/Y-2711-2019; Fitzgerald, Katherine/ABE-6317-2020	Fallon, Padraic/0000-0002-8401-7293; Brint, Elizabeth/0000-0001-9214-149X; O'Neill, Luke/0000-0002-4333-2748; Fitzgerald, Kate/0000-0003-3175-609X				Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Aronica MA, 1999, J IMMUNOL, V163, P5116; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; Born TL, 2000, J BIOL CHEM, V275, P29946, DOI 10.1074/jbc.M004077200; Born TL, 1998, J BIOL CHEM, V273, P29445, DOI 10.1074/jbc.273.45.29445; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Casadio R, 2001, FEBS LETT, V499, P65, DOI 10.1016/S0014-5793(01)02515-7; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Coyle AJ, 1999, J EXP MED, V190, P895, DOI 10.1084/jem.190.7.895; Cullinan EB, 1998, J IMMUNOL, V161, P5614; Das J, 2001, NAT IMMUNOL, V2, P45, DOI 10.1038/83158; Fallon PG, 1998, EUR J IMMUNOL, V28, P1408, DOI 10.1002/(SICI)1521-4141(199804)28:04&lt;1408::AID-IMMU1408&gt;3.0.CO;2-H; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Gachter T, 1998, MOL CELL BIOL, V18, P5320; Gayle MA, 1996, J BIOL CHEM, V271, P5784, DOI 10.1074/jbc.271.10.5784; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hoshino K, 1999, J EXP MED, V190, P1541, DOI 10.1084/jem.190.10.1541; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; KUMAR S, 1995, J BIOL CHEM, V270, P27905, DOI 10.1074/jbc.270.46.27905; LAEMMLI UK, 1970, J MOL BIOL, V47, P69, DOI 10.1016/0022-2836(70)90402-X; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; Li SY, 2002, P NATL ACAD SCI USA, V99, P5567, DOI 10.1073/pnas.082100399; Lohning M, 1998, P NATL ACAD SCI USA, V95, P6930, DOI 10.1073/pnas.95.12.6930; Mansell A, 2001, J BIOL CHEM, V276, P43597, DOI 10.1074/jbc.M105202200; Meisel C, 2001, J IMMUNOL, V166, P3143, DOI 10.4049/jimmunol.166.5.3143; Mitcham JL, 1996, J BIOL CHEM, V271, P5777, DOI 10.1074/jbc.271.10.5777; Moritz DR, 1998, J IMMUNOL, V161, P4866; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; Re F, 2002, J BIOL CHEM, V277, P23427, DOI 10.1074/jbc.M202554200; Rincon M, 2001, CURR OPIN IMMUNOL, V13, P339, DOI 10.1016/S0952-7915(00)00224-7; ROSSLER U, 1995, DEV BIOL, V168, P86, DOI 10.1006/dbio.1995.1063; Senn KA, 2000, EUR J IMMUNOL, V30, P1929, DOI 10.1002/1521-4141(200007)30:7&lt;1929::AID-IMMU1929&gt;3.0.CO;2-1; SIMS JE, 1995, CYTOKINE, V7, P483, DOI 10.1006/cyto.1995.0066; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; TOMINAGA S, 1989, FEBS LETT, V258, P301, DOI 10.1016/0014-5793(89)81679-5; Townsend MJ, 2000, J EXP MED, V191, P1069, DOI 10.1084/jem.191.6.1069; Walzl G, 2001, J EXP MED, V193, P785, DOI 10.1084/jem.193.7.785; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; WERENSKIOLD AK, 1989, MOL CELL BIOL, V9, P5207, DOI 10.1128/MCB.9.11.5207; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Xu D, 1998, J EXP MED, V187, P787, DOI 10.1084/jem.187.5.787; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yamashita M, 1999, P NATL ACAD SCI USA, V96, P1024, DOI 10.1073/pnas.96.3.1024; YANAGISAWA K, 1993, FEBS LETT, V318, P83, DOI 10.1016/0014-5793(93)81333-U; Yanagisawa K, 1997, J BIOCHEM-TOKYO, V121, P95	50	72	73	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49205	49211		10.1074/jbc.M209685200	http://dx.doi.org/10.1074/jbc.M209685200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12368275	hybrid, Green Published			2022-12-25	WOS:000180028900014
J	Covian, R; Pardo, JP; Moreno-Sanchez, R				Covian, R; Pardo, JP; Moreno-Sanchez, R			Tight binding of inhibitors to bovine bc(1) complex is independent of the Rieske protein redox state - Consequences for semiquinone stabilization in the quinol oxidation site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; CYTOCHROME-C REDUCTASE; UBIQUINOL-OXIDATION; UBIHYDROQUINONE OXIDATION; ELECTRON-TRANSFER; Q(O) SITE; STIGMATELLIN; MITOCHONDRIA; MECHANISM; MOVEMENT	To determine the effect of the redox state of the Rieske protein on ligand binding to the quinol oxidation site of the bc(1) complex, we measured the binding rate constants (k(1)) for stigmatellin and myxothiazol, at different concentrations of decylbenzoquinone or decylbenzoquinol, in the bovine bc(1) complex with the Rieske protein in the oxidized or reduced state. Stigmatellin and myxothiazol bound tightly and competitively with respect to quinone or quinol, independently of the redox state of the Rieske protein. In the oxidized bc(1) complex, the k(1) values for stigmatellin (similar to2.6 x 10(6) M(-1)s(-1)) and myxothiazol (similar to8 x 10(5) M(-1)s(-1)), and the dissociation constant (K-d) for quinone, were similar between pH 6.5 and 9, indicating that ligand binding is independent of the protonation state of histidine 161 of the Rieske protein (pK(a) similar to7.6). Reduction of the Rieske protein increased the k(1) value for stigmatellin and decreased the K-d value for quinone by 50%, without modifying the k(1) for myxothiazol. These results indicate that reduction of the Rieske protein and protonation of histidine 161 do not induce a strong stabilization of ligand binding to the quinol oxidation site, as assumed in models that propose the existence of a highly stabilized semiquinone as a reaction intermediate during quinol oxidation.	Inst Nacl Cardiol, Dept Bioquim, Mexico City 14080, DF, Mexico; Univ Nacl Autonoma Mexico, Fac Med, Dept Bioquim, Mexico City 04510, DF, Mexico	National Institute of Cardiology - Mexico; Universidad Nacional Autonoma de Mexico	Covian, R (corresponding author), Inst Nacl Cardiol, Dept Bioquim, Juan Badiano 1,Secc 16, Mexico City 14080, DF, Mexico.	covianraul@correo.unam.mx	Moreno-Sanchez, Rafael/A-3158-2011	Moreno-Sanchez, Rafael/0000-0002-9587-7184				BOWYER JR, 1982, J BIOL CHEM, V257, P8321; BRANDT U, 1988, EUR J BIOCHEM, V173, P499, DOI 10.1111/j.1432-1033.1988.tb14026.x; Brandt U, 1998, BBA-BIOENERGETICS, V1365, P261, DOI 10.1016/S0005-2728(98)00078-4; BRANDT U, 1991, J BIOL CHEM, V266, P19958; BRANDT U, 1994, CRIT REV BIOCHEM MOL, V29, P165, DOI 10.3109/10409239409086800; Brandt U, 1997, BBA-BIOENERGETICS, V1321, P238, DOI 10.1016/S0005-2728(97)00060-1; Brasseur G, 1996, BBA-BIOENERGETICS, V1275, P61, DOI 10.1016/0005-2728(96)00051-5; Covian R, 2001, EUR J BIOCHEM, V268, P5783, DOI 10.1046/j.0014-2956.2001.02521.x; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15827, DOI 10.1021/bi990963e; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15807, DOI 10.1021/bi990962m; CROFTS AR, 1989, PHOTOSYNTH RES, V22, P69, DOI 10.1007/BF00114768; Crofts AR, 1999, P NATL ACAD SCI USA, V96, P10021, DOI 10.1073/pnas.96.18.10021; Crofts AR, 2000, BBA-BIOENERGETICS, V1459, P456, DOI 10.1016/S0005-2728(00)00184-5; Darrouzet E, 2000, P NATL ACAD SCI USA, V97, P4567, DOI 10.1073/pnas.97.9.4567; Darrouzet E, 2002, J BIOL CHEM, V277, P3464, DOI 10.1074/jbc.M107973200; Eyzaguirre J., 1987, CHEM MODIFICATION EN; Hong SJ, 1999, J BIOL CHEM, V274, P33931, DOI 10.1074/jbc.274.48.33931; Iwata M, 1999, J BIOENERG BIOMEMBR, V31, P169, DOI 10.1023/A:1005407410005; Junemann S, 1998, J BIOL CHEM, V273, P21603, DOI 10.1074/jbc.273.34.21603; Kim H, 1998, P NATL ACAD SCI USA, V95, P8026, DOI 10.1073/pnas.95.14.8026; LINK TA, 1994, BBA-BIOENERGETICS, V1185, P81, DOI 10.1016/0005-2728(94)90196-1; Link TA, 1997, FEBS LETT, V412, P257, DOI 10.1016/S0014-5793(97)00772-2; LJUNGDAHL PO, 1986, METHOD ENZYMOL, V126, P181; Matsuno-Yagi A, 2001, J BIOL CHEM, V276, P19006, DOI 10.1074/jbc.M101446200; MATSUURA K, 1983, J BIOL CHEM, V258, P1571; OHNISHI T, 1988, EUR J BIOCHEM, V176, P385, DOI 10.1111/j.1432-1033.1988.tb14293.x; RICH PR, 1984, BIOCHIM BIOPHYS ACTA, V768, P53, DOI 10.1016/0304-4173(84)90007-7; Snyder CH, 2000, J BIOL CHEM, V275, P13535, DOI 10.1074/jbc.275.18.13535; VONJAGOW G, 1986, METHOD ENZYMOL, V126, P253; VONJAGOW G, 1985, FEBS LETT, V185, P311, DOI 10.1016/0014-5793(85)80929-7; Zhang L, 1999, FEBS LETT, V460, P349, DOI 10.1016/S0014-5793(99)01340-X	31	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48449	48455		10.1074/jbc.M208060200	http://dx.doi.org/10.1074/jbc.M208060200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12364330	hybrid, Green Submitted			2022-12-25	WOS:000179789600064
J	Petro, JB; Gerstein, RM; Lowe, J; Carter, RS; Shinners, N; Khan, WN				Petro, JB; Gerstein, RM; Lowe, J; Carter, RS; Shinners, N; Khan, WN			Transitional type 1 and 2 B lymphocyte subsets are differentially responsive to antigen receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; X-LINKED AGAMMAGLOBULINEMIA; HEAT-STABLE ANTIGEN(HI); CELL DEVELOPMENT; NEGATIVE SELECTION; PHOSPHOLIPASE C-GAMMA-2; REPERTOIRE SELECTION; IMMATURE; ACTIVATION; MICE	Mature B-lymphocytes develop sequentially from transitional type 1 (T1) and type 2 (T2) precursors in the spleen. To elucidate the mechanisms that regulate the developmental fate of these distinct B cell subsets, we investigated their biochemical and biological responses following stimulation through the B-cell antigen receptor (BCR). As compared with the T1 subset, T2 cells are more responsive to BCR engagement, as evidenced by their robust induction of activation markers, expression of the prosurvival protein Bcl-x(L), and enhanced proliferation. BCR stimulation of T2 cells leads to the appearance of B cells with mature phenotypic characteristics, whereas T1 cells die. All of these T2 responses are dependent on the BCR signal transducer Bruton's tyrosine kinase, which is dispensable for the T1 to T2 transition. Furthermore, the serine/threonine kinases ERK, p38 MAPK, and Akt are predominantly activated in T2 compared with T1 B cells following BCR cross-linking. We conclude that T1 and T2 B cells respond differentially to BCR engagement via the induction of stage-specific signaling pathways. In turn, these signaling pathways probably govern the development and selection processes that are critical for the formation of the mature B cell compartment.	Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA; Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01655 USA	Vanderbilt University; University of Massachusetts System; University of Massachusetts Worcester	Khan, WN (corresponding author), Vanderbilt Univ, Sch Med, Dept Microbiol & Immunol, Nashville, TN 37232 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068744, T32HL069765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI050213, R01AI043534] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK032520] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL69715-01, T32 HL69765-01, 1 P01 HL68744] Funding Source: Medline; NIAID NIH HHS [R01 AI43534, R01 AI50213-01] Funding Source: Medline; NIDDK NIH HHS [5 P30 DK32520] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allman D, 2001, J IMMUNOL, V167, P6834, DOI 10.4049/jimmunol.167.12.6834; ALLMAN DM, 1992, J IMMUNOL, V149, P2533; ALLMAN DM, 1993, J IMMUNOL, V151, P4431; Aman MJ, 1998, J BIOL CHEM, V273, P33922, DOI 10.1074/jbc.273.51.33922; Anderson JS, 1996, P NATL ACAD SCI USA, V93, P10966, DOI 10.1073/pnas.93.20.10966; Batten M, 2000, J EXP MED, V192, P1453, DOI 10.1084/jem.192.10.1453; Benschop RJ, 2001, J IMMUNOL, V167, P4172, DOI 10.4049/jimmunol.167.8.4172; Brorson K, 1997, J IMMUNOL, V159, P135; Buhl AM, 2000, IMMUNOL REV, V176, P141; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; CARSETTI R, 1995, J EXP MED, V181, P2129, DOI 10.1084/jem.181.6.2129; Cherukuri A, 2001, IMMUNITY, V14, P657, DOI 10.1016/S1074-7613(01)00156-X; Chung JB, 2001, J IMMUNOL, V166, P736, DOI 10.4049/jimmunol.166.2.736; COUTINHO A, 1993, IMMUNOL TODAY, V14, P38, DOI 10.1016/0167-5699(93)90323-D; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Fleming HE, 2001, IMMUNITY, V15, P521, DOI 10.1016/S1074-7613(01)00216-3; FORSTER I, 1990, P NATL ACAD SCI USA, V87, P4781, DOI 10.1073/pnas.87.12.4781; Fruman DA, 2000, IMMUNITY, V13, P1, DOI 10.1016/S1074-7613(00)00002-9; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Glassford J, 2001, J BIOL CHEM, V276, P41040, DOI 10.1074/jbc.M105305200; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; GU H, 1991, J EXP MED, V173, P1357, DOI 10.1084/jem.173.6.1357; Hardy RR, 2001, ANNU REV IMMUNOL, V19, P595, DOI 10.1146/annurev.immunol.19.1.595; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; Khan WN, 1997, INT IMMUNOL, V9, P395, DOI 10.1093/intimm/9.3.395; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; King LB, 2000, IMMUNOL REV, V176, P86; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Kurosaki T, 2000, IMMUNITY, V12, P1, DOI 10.1016/S1074-7613(00)80153-3; Lam KP, 1997, CELL, V90, P1073, DOI 10.1016/S0092-8674(00)80373-6; Levine MH, 2000, P NATL ACAD SCI USA, V97, P2743, DOI 10.1073/pnas.050552997; Lewis CM, 2001, CURR OPIN IMMUNOL, V13, P317, DOI 10.1016/S0952-7915(00)00221-1; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Marshall AJ, 2000, IMMUNOL REV, V176, P30; Meffre E, 2000, NAT IMMUNOL, V1, P379, DOI 10.1038/80816; Melchers F, 2000, IMMUNOL REV, V175, P33, DOI 10.1111/j.1600-065X.2000.imr017510.x; Monroe JG, 2000, CURR TOP MICROBIOL, V245, P1; Monroe JG, 2000, CLIN IMMUNOL, V95, pS8, DOI 10.1006/clim.1999.4817; NORVELL A, 1995, J IMMUNOL, V154, P4404; Norvell A, 1996, J IMMUNOL, V156, P1328; Oliver AM, 1997, EUR J IMMUNOL, V27, P2366, DOI 10.1002/eji.1830270935; Petro JB, 2001, J BIOL CHEM, V276, P1715, DOI 10.1074/jbc.M009137200; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; RAWLINGS DJ, 1993, SCIENCE, V261, P358, DOI 10.1126/science.8332901; Reth M, 1997, ANNU REV IMMUNOL, V15, P453, DOI 10.1146/annurev.immunol.15.1.453; Rolink AG, 2001, CURR OPIN IMMUNOL, V13, P202, DOI 10.1016/S0952-7915(00)00205-3; Rolink AG, 1998, EUR J IMMUNOL, V28, P3738, DOI 10.1002/(SICI)1521-4141(199811)28:11<3738::AID-IMMU3738>3.0.CO;2-Q; Sakata N, 1999, EUR J IMMUNOL, V29, P2999, DOI 10.1002/(SICI)1521-4141(199909)29:09<2999::AID-IMMU2999>3.0.CO;2-L; Sandel PC, 1999, IMMUNITY, V10, P289, DOI 10.1016/S1074-7613(00)80029-1; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; Scheick WJ, 2001, RELIG LIT, V33, P1; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; SIDERAS P, 1995, ADV IMMUNOL, V59, P135, DOI 10.1016/S0065-2776(08)60631-8; Solvason N, 1998, J EXP MED, V187, P1081, DOI 10.1084/jem.187.7.1081; Su TT, 2002, J IMMUNOL, V168, P2101, DOI 10.4049/jimmunol.168.5.2101; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; THOMAS JD, 1993, SCIENCE, V261, P355, DOI 10.1126/science.8332900; VIALE AC, 1993, INT IMMUNOL, V5, P599, DOI 10.1093/intimm/5.6.599; Wang DM, 2000, IMMUNITY, V13, P25, DOI 10.1016/S1074-7613(00)00005-4; Willerford DM, 1996, CURR OPIN GENET DEV, V6, P603, DOI 10.1016/S0959-437X(96)80090-6; Wu HJ, 2001, J IMMUNOL, V167, P1263, DOI 10.4049/jimmunol.167.3.1263; Xu SL, 2000, INT IMMUNOL, V12, P397, DOI 10.1093/intimm/12.3.397	65	90	95	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48009	48019		10.1074/jbc.M200305200	http://dx.doi.org/10.1074/jbc.M200305200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356763	hybrid			2022-12-25	WOS:000179789600007
J	Bergo, MO; Gavino, BJ; Steenbergen, R; Sturbois, B; Parlow, AF; Sanan, DA; Skarnes, WC; Vance, JE; Young, SG				Bergo, MO; Gavino, BJ; Steenbergen, R; Sturbois, B; Parlow, AF; Sanan, DA; Skarnes, WC; Vance, JE; Young, SG			Defining the importance of phosphatidylserine synthase 2 in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENETIC-EVIDENCE; PHOSPHATIDYLETHANOLAMINE; CELLS; MITOCHONDRIA; CLONING; MUTANT; CDNA; OVEREXPRESSION; BIOSYNTHESIS; ETHANOLAMINE	Phosphatidylserine synthase 1 (Pss1) and phosphatidylserine synthase 2 (Pss2) produce phosphatidylserine by exchanging serine for the head groups of other phospholipids. Pss1 and Pss2 are structurally similar (similar to32% amino acid identity) but differ in their substrate specificities, with Pss1 using phosphatidylcholine for the serine exchange reaction and Pss2 using phosphatidylethanolamine. Whether Pss1 and Pss2 are both required for mammalian growth and development is not known, and no data exist on the relative contributions of the two enzymes to serine exchange activities in different tissues. To address those issues and also to define the cell type-specific expression of Pss2, we generated Pss2-deficient mice in which a beta-galactosidase marker is expressed from Pss2 regulatory sequences. Histologic studies of Pss2-deficient mice revealed very high levels of beta-galactosidase expression in Sertoli cells of the testis and high levels of expression in brown fat, neurons, and myometrium. The ability of testis extracts from Pss2-deficient mice to catalyze serine exchange was reduced by more than 95%; reductions of similar to90% were noted in the brain and liver. However, we found no perturbations in the phospholipid content of any of these tissues. As judged by Northern blots, the expression of Pss1 was not upregulated in Pss2-deficient cells and tissues. Testis weight was reduced in Pss2-deficient mice, and some of the male mice were infertile. We conclude that Pss2 is responsible for the majority of serine exchange activity in in vitro assays, but a deficiency in this enzyme does not cause perturbations in phospholipid content or severe developmental abnormalities.	Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, San Francisco, CA 94141 USA; Univ Calif San Francisco, Inst Cardiovasc Res, San Francisco, CA 94141 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94141 USA; San Francisco Gen Hosp, Med Serv, San Francisco, CA 94110 USA; Univ Alberta, Dept Med, Edmonton, AB T6G 2S2, Canada; Univ Alberta, Canadian Inst Hlth Res Grp Mol & Cell Biol Lipids, Edmonton, AB T6G 2S2, Canada; Harbor UCLA Med Ctr, Natl Hormone & Peptide Program, Torrance, CA 90509 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California San Francisco; The J David Gladstone Institutes; University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center; University of Alberta; University of Alberta; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Berkeley	Bergo, MO (corresponding author), Univ Calif San Francisco, Gladstone Inst Cardiovasc Dis, POB 419100, San Francisco, CA 94141 USA.	mbergo@gladstone.ucsf.edu		Young, Stephen/0000-0001-7270-3176	NHLBI NIH HHS [HL66590, HL66600, HL66621] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [U01HL066621, U01HL066590, U01HL066600] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Emoto K, 1999, P NATL ACAD SCI USA, V96, P12400, DOI 10.1073/pnas.96.22.12400; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; GRISWOLD MD, 1995, BIOL REPROD, V52, P211, DOI 10.1095/biolreprod52.2.211; Griswold MD, 1998, SEMIN CELL DEV BIOL, V9, P411, DOI 10.1006/scdb.1998.0203; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Kim E, 1999, J BIOL CHEM, V274, P8383, DOI 10.1074/jbc.274.13.8383; KOVACIC N, 1972, ENDOCRINOLOGY, V91, P910, DOI 10.1210/endo-91-4-910; KUGE O, 1986, J BIOL CHEM, V261, P5795; Kuge O, 1998, P NATL ACAD SCI USA, V95, P4199, DOI 10.1073/pnas.95.8.4199; Kuge O, 1999, J BIOL CHEM, V274, P23844, DOI 10.1074/jbc.274.34.23844; Kuge O, 1997, BBA-LIPID LIPID MET, V1348, P151, DOI 10.1016/S0005-2760(97)00137-9; KUGE O, 1991, J BIOL CHEM, V266, P24184; Kuge O, 1997, J BIOL CHEM, V272, P19133, DOI 10.1074/jbc.272.31.19133; Meachem SJ, 2001, EUR J ENDOCRINOL, V145, P561, DOI 10.1530/eje.0.1450561; Mitchell KJ, 2001, NAT GENET, V28, P241, DOI 10.1038/90074; Monni M, 2000, J MEMBRANE BIOL, V173, P97, DOI 10.1007/s002320001011; Saito K, 1998, J BIOL CHEM, V273, P17199, DOI 10.1074/jbc.273.27.17199; SKARNES WC, 1995, P NATL ACAD SCI USA, V92, P6592, DOI 10.1073/pnas.92.14.6592; Stone SJ, 2000, J BIOL CHEM, V275, P34534, DOI 10.1074/jbc.M002865200; Stone SJ, 1999, BIOCHEM J, V342, P57, DOI 10.1042/0264-6021:3420057; Stone SJ, 1998, J BIOL CHEM, V273, P7293, DOI 10.1074/jbc.273.13.7293; SUNDLER R, 1972, BIOCHIM BIOPHYS ACTA, V280, P559, DOI 10.1016/0005-2760(72)90136-1; SUNDLER R, 1974, FEBS LETT, V43, P303, DOI 10.1016/0014-5793(74)80667-8; Vance JE, 1996, ANTICANCER RES, V16, P1333; VANCE JE, 1991, J BIOL CHEM, V266, P89; VOELKER DR, 1986, J BIOL CHEM, V261, P1002; Voelker DR, 1996, BIOCH LIPIDS LIPOPRO, P391; ZHOU X, 1992, J LIPID RES, V33, P1233	29	67	69	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47701	47708		10.1074/jbc.M207734200	http://dx.doi.org/10.1074/jbc.M207734200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12361952	hybrid			2022-12-25	WOS:000179663700112
J	Cleverley, RM; Gierasch, LM				Cleverley, RM; Gierasch, LM			Mapping the signal sequence-binding site on SRP reveals a significant role for the NG domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE-RICH DOMAIN; RECOGNITION PARTICLE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; PROTEIN TRANSLOCATION; CONSERVED GTPASE; CROSS-LINKING; RNA; SUBUNIT; MEMBRANE	We present evidence that the signal recognition particle (SRP) recognizes signal sequences via the NG domain on the SRP54 protein subunit. Using a recently developed cross-linking method (Fancy, D. A., and Kodadek, T. (1999) Proc. Natl. Acad. Sci. U. S. A. 96, 6020-6024; Correction (1999) Proc. NatL Acad. Sci. U. S. A. 96,1317), we find that signal peptides cross-link to the Escherichia coli SRP protein Ffh (the homologue of the mammalian SRP54 subunit) via the NG domain. Within the NG domain, the cross-linking site maps to the ras-like C-terminal subdomain termed the G domain. This result stands in contrast to previous studies, which concluded based on nascent chain cross-linking that the signal sequence bound to the adjacent M domain. As independent evidence of a direct binding interaction between the NG domain and the signal sequence, we find that the NG domain of Ffh binds signal peptides as an isolated entity. Our results suggest that the NG domain forms a substantial part of the binding site for the signal sequence.	Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA; Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst	Gierasch, LM (corresponding author), Univ Massachusetts, Dept Chem, Amherst, MA 01003 USA.	gierasch@biochem.umass.edu	Gierasch, Lila M/D-1494-2009		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034962] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34962] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTHOFF S, 1994, NUCLEIC ACIDS RES, V22, P1933, DOI 10.1093/nar/22.11.1933; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; Baud C, 2002, J BIOL CHEM, V277, P13724, DOI 10.1074/jbc.M200047200; Bernstein HD, 1998, CURR BIOL, V8, pR715, DOI 10.1016/S0960-9822(98)70456-7; Cleverley RM, 2001, J BIOL CHEM, V276, P19327, DOI 10.1074/jbc.M011130200; Fancy DA, 2000, CHEM BIOL, V7, P697, DOI 10.1016/S1074-5521(00)00020-X; Fancy DA, 1999, P NATL ACAD SCI USA, V96, P6020, DOI 10.1073/pnas.96.11.6020; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Freymann DM, 1999, NAT STRUCT BIOL, V6, P793, DOI 10.1038/11572; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; HIGH S, 1991, J CELL BIOL, V113, P229, DOI 10.1083/jcb.113.2.229; JACOBSON GR, 1973, J BIOL CHEM, V248, P6583; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Lee HC, 2001, P NATL ACAD SCI USA, V98, P3471, DOI 10.1073/pnas.051484198; Lentzen G, 1996, RNA, V2, P244; Lo Conte L, 1999, J MOL BIOL, V285, P2177; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; Macao B, 1997, MOL MICROBIOL, V24, P523, DOI 10.1046/j.1365-2958.1997.3551729.x; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Montoya G, 2000, STRUCTURE, V8, P515, DOI 10.1016/S0969-2126(00)00131-3; Newitt JA, 1997, EUR J BIOCHEM, V245, P720, DOI 10.1111/j.1432-1033.1997.00720.x; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; Schmitz U, 1996, RNA, V2, P1213; Shepotinovskaya IV, 2002, BBA-PROTEIN STRUCT M, V1597, P107, DOI 10.1016/S0167-4838(02)00287-X; STANFIELD RL, 1995, CURR OPIN STRUC BIOL, V5, P103, DOI 10.1016/0959-440X(95)80015-S; Valent QA, 1997, MOL MICROBIOL, V25, P53, DOI 10.1046/j.1365-2958.1997.4431808.x; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Weber PJA, 1997, J PEPT RES, V49, P375; Zheng N, 1997, MOL CELL, V1, P79, DOI 10.1016/S1097-2765(00)80009-X; ZOPF D, 1993, J CELL BIOL, V120, P1113, DOI 10.1083/jcb.120.5.1113; ZOPF D, 1990, EMBO J, V9, P4511, DOI 10.1002/j.1460-2075.1990.tb07902.x	32	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46763	46768		10.1074/jbc.M207427200	http://dx.doi.org/10.1074/jbc.M207427200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244111	hybrid			2022-12-25	WOS:000179529300136
J	Miura, Y; Takahashi, T; Jung, SM; Moroi, M				Miura, Y; Takahashi, T; Jung, SM; Moroi, M			Analysis of the interaction of platelet collagen receptor glycoprotein VI (GPVI)with collagen - A dimeric form of GPVI, but not the monomeric form, shows affinity to fibrous collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN SUPERFAMILY; ALPHA(2)BETA(1) INTEGRIN; FC RECEPTOR; ACTIVATION; EXPRESSION; CONVULXIN; CLONING; VENOM; INVOLVEMENT; AGGREGATION	Glycoprotein VI (GPVI) is a platelet-specific glycoprotein that has been indicated to react with collagen and activate platelets. Its structure was recently identified by cDNA cloning (Clemetson, J. M., Polgar, J., Magnenat, E., Wells, T. N., and Clemetson, K. J. (1999) J. Biol. Chem. 274, 29019-29024). However, the mechanism of the interaction between collagen and GPVI has not been analyzed in detail because both collagen and GPVI are insoluble molecules. In this study, we expressed the extracellular domain of GPVI as soluble forms as follows: the monomeric form (GPVIex) and the dimeric form of GPVI fused with the human immunoglobulin Fc domain (GPVI-Fc(2)). Purified GPVIex strongly inhibited convulxin (Cvx)-induced platelet aggregation but only weakly inhibited that induced by collagen-related peptide. However, only GPVI-Fc(2), and not GPVIex, inhibited collagen-induced platelet aggregation. The dimeric form of GPVI exhibits high affinity for collagen, as concluded from measurements of GPVI bindling to immobilized collagen by both the enzyme-linked immunosorbent assay and surface plasmon resonance methods. GPVI-Fc(2) bound to the surface of immobilized collagen with a dissociation constant (K-D) of 5.76 x 10(-7) m,but the binding of GPVIex was too weak to allow estimation of this parameter. Cvx did not inhibit the binding of dimeric GPVI to collagen, indicating that the binding site of GPVI to collagen was different from that to Cvx. Taken together, our data indicate that the high affinity binding site for collagen is composed from two chains of GPVI. Furthermore, they suggest that the binding sites for Cvx are different from the collagen-binding sites and do not need to be formed by two GPVI molecules. Because dimeric GPVI is the only form that shows high affinity to fibrous collagen, our results indicate that GPVI would be present as a dimeric form on the platelet. Moreover, surface plasmon resonance indicated that there is no detectable interaction between soluble collagen and GPVI, supporting our previous observation that GPVI only reacts with fibrous collagen.	Kurume Univ, Dept Prot Biochem, Inst Life Sci, Kurume, Fukuoka 8390861, Japan; Kurume Univ, Dept Cell Biol, Inst Life Sci, Kurume, Fukuoka 8390861, Japan	Kurume University; Kurume University	Moroi, M (corresponding author), Kurume Univ, Dept Prot Chem, Inst Life Sci, 2432-3 Aikawa MAchi, Kurume, Fukuoka 8390861, Japan.		Miura, Yoshiki/U-8875-2019	Miura, Yoshiki/0000-0002-7596-0482				CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COLLER BS, 1989, BLOOD, V74, P182; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; HANDA M, 1995, THROMB HAEMOSTASIS, V73, P521; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Jung SM, 2000, J BIOL CHEM, V275, P8016, DOI 10.1074/jbc.275.11.8016; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; Jung SM, 2001, EUR J BIOCHEM, V268, P3513, DOI 10.1046/j.1432-1327.2001.02252.x; Keely PJ, 1996, J BIOL CHEM, V271, P26668, DOI 10.1074/jbc.271.43.26668; Miura Y, 2000, THROMB RES, V98, P301, DOI 10.1016/S0049-3848(00)00182-1; Moroi M, 1997, THROMB HAEMOSTASIS, V78, P439; Moroi M, 1996, BLOOD, V88, P2081, DOI 10.1182/blood.V88.6.2081.bloodjournal8862081; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; MORTON LF, 1995, BIOCHEM J, V306, P337, DOI 10.1042/bj3060337; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; RAGHAVAN M, 1995, P NATL ACAD SCI USA, V92, P11200, DOI 10.1073/pnas.92.24.11200; SUDA T, 1993, CELL, V75, P1169, DOI 10.1016/0092-8674(93)90326-L; SUGIYAMA T, 1993, INT J HEMATOL, V58, P99; SUGIYAMA T, 1987, BLOOD, V69, P1712; Watson S, 2000, PLATELETS, V11, P252; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	25	128	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46197	46204		10.1074/jbc.M204029200	http://dx.doi.org/10.1074/jbc.M204029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356768	hybrid			2022-12-25	WOS:000179529300067
J	Bowen, C; Birrer, M; Gelmann, EP				Bowen, C; Birrer, M; Gelmann, EP			Retinoblastoma protein-mediated apoptosis after gamma-irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL TYROSINE KINASE; RADIATION-INDUCED APOPTOSIS; N-TERMINAL KINASE; ETOPOSIDE-INDUCED APOPTOSIS; TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE ARREST; LARGE T-ANTIGEN; C-ABL; GENE-PRODUCT; DNA-DAMAGE	Restoration of expression of the retinoblastoma gene to DU-145 prostate-cancer cells sensitizes them to apoptosis induced by y-irradiation. In contrast, RB expression-protected cells from UV-induced cell death. RB, a caspase substrate, remained intact during apoptosis in y-irradiated DU-145 cells because serine proteases, but not caspases, were activated. In DU-145 cells, RB-mediated apoptosis involved biphasic activation of ABL kinase. ABL kinase was activated within minutes of irradiation, but in the presence of RB expression ABL kinase activation was enhanced 48 It after irradiation, coincident with the onset of cell death. Apoptosis was inhibited by RB mutants with constitutive ABL binding, but ABL overexpression overcame the effect of the RB mutant constructs. Expression of kinase-dead ABL had a dominant-negative effect on RB-mediated cell death. Activation of JUN N-terminal kinase depended on the presence of RB and occurred within 8 h of irradiation. Mutant JUN proteins that lacked the N-terminal transactivation domain and serine substrates for JUN N-terminal kinase inhibited cell death in a dominant-negative manner. Irradiation of DU-145 cells caused activation of p38 MAPK independent of the expression of RB. Inhibitors of p38 MAPK blocked apoptosis after irradiation of RB-expressing cells. The data show that after y-irradiation, intact RB mediates transcriptional activation that leads to activation of JNK and late activation of ABL kinase. In addition, p38 MAPK activation occurred independent of RB. ABL kinase, JUN N-terminal kinase, and p38 MAPK activity were all required for RB-mediated DU-145 cell death after y-irradiation.	NCI, NIH, Rockville, MD 20850 USA; Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Med, Washington, DC 20007 USA; Georgetown Univ, Vincent T Lombardi Canc Res Ctr, Dept Oncol, Washington, DC 20007 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Georgetown University; Georgetown University	Gelmann, EP (corresponding author), NCI, NIH, Ste 300,9610 Med Ctr Dr, Rockville, MD 20850 USA.				NCI NIH HHS [CA79912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079912] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMASAN A, 1995, P NATL ACAD SCI USA, V92, P5436, DOI 10.1073/pnas.92.12.5436; An B, 1998, INT J MOL MED, V1, P131; An B, 1996, CANCER RES, V56, P438; Assefa Z, 1999, J BIOL CHEM, V274, P8788, DOI 10.1074/jbc.274.13.8788; Assefa Z, 2000, J BIOL CHEM, V275, P21416, DOI 10.1074/jbc.M002634200; Barila D, 2000, EMBO J, V19, P273, DOI 10.1093/emboj/19.2.273; Baskaran R, 1997, NATURE, V387, P516, DOI 10.1038/387516a0; Berry DE, 1996, ONCOGENE, V12, P1809; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; Boutillier AL, 2000, ONCOGENE, V19, P2171, DOI 10.1038/sj.onc.1203532; Bowen C, 1998, CANCER RES, V58, P3275; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Brown PH, 1996, CELL GROWTH DIFFER, V7, P1013; BROWN PH, 1994, ONCOGENE, V9, P791; Browne SJ, 1998, CELL DEATH DIFFER, V5, P206, DOI 10.1038/sj.cdd.4400331; CARROLL A G, 1992, Journal of Urology, V147, p216A; Chen TT, 2000, MOL CELL BIOL, V20, P5571, DOI 10.1128/MCB.20.15.5571-5580.2000; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Choi KS, 1999, J BIOL CHEM, V274, P31775, DOI 10.1074/jbc.274.45.31775; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Diederich L, 1998, CELL BIOL TOXICOL, V14, P133, DOI 10.1023/A:1007434005573; Fan GS, 1996, ONCOGENE, V12, P1909; Fattman CL, 2001, ONCOGENE, V20, P2918, DOI 10.1038/sj.onc.1204414; Fattman CL, 1997, J CELL BIOCHEM, V67, P399; Gong JG, 1999, NATURE, V399, P806; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; HAUPT Y, 1995, ONCOGENE, V10, P1563; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1993, MOL CELL BIOL, V13, P3384, DOI 10.1128/MCB.13.6.3384; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HU QJ, 1990, EMBO J, V9, P1147, DOI 10.1002/j.1460-2075.1990.tb08221.x; HUANG S, 1990, EMBO J, V9, P1815, DOI 10.1002/j.1460-2075.1990.tb08306.x; Irwin M, 2000, NATURE, V407, P645, DOI 10.1038/35036614; Ishii H, 1997, AM J HEMATOL, V55, P46, DOI 10.1002/(SICI)1096-8652(199705)55:1<46::AID-AJH9>3.0.CO;2-3; Janicke RU, 1996, EMBO J, V15, P6969, DOI 10.1002/j.1460-2075.1996.tb01089.x; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; KAELIN WG, 1990, MOL CELL BIOL, V10, P3761, DOI 10.1128/MCB.10.7.3761; Kharbanda S, 1996, P NATL ACAD SCI USA, V93, P6898, DOI 10.1073/pnas.93.14.6898; KHARBANDA S, 1995, NATURE, V376, P785, DOI 10.1038/376785a0; Kharbanda S, 1995, J BIOL CHEM, V270, P30278, DOI 10.1074/jbc.270.51.30278; Knudsen ES, 1996, J BIOL CHEM, V271, P8313, DOI 10.1074/jbc.271.14.8313; Knudsen ES, 1997, MOL CELL BIOL, V17, P5771, DOI 10.1128/MCB.17.10.5771; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Lauricella M, 2001, FEBS LETT, V499, P191, DOI 10.1016/S0014-5793(01)02553-4; Lee JO, 1998, NATURE, V391, P859, DOI 10.1038/36038; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; Lundberg AS, 1998, MOL CELL BIOL, V18, P753, DOI 10.1128/MCB.18.2.753; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Martel C, 1996, CELL DEATH DIFFER, V3, P285; McConkey DJ, 1996, ONCOGENE, V13, P1693; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Moroni MC, 2001, NAT CELL BIOL, V3, P552, DOI 10.1038/35078527; Napier JR, 1999, J ENDOCRINOL, V163, P63; Nemoto S, 1998, J BIOL CHEM, V273, P16415, DOI 10.1074/jbc.273.26.16415; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Noguchi K, 2000, BIOCHEM BIOPH RES CO, V267, P221, DOI 10.1006/bbrc.1999.1952; Oh S, 2000, CANCER LETT, V148, P105, DOI 10.1016/S0304-3835(99)00319-5; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; RESNICOFF M, 1995, CANCER RES, V55, P2463; Rosini P, 2000, BIOCHEM BIOPH RES CO, V278, P753, DOI 10.1006/bbrc.2000.3871; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Shafman T, 1997, NATURE, V387, P520, DOI 10.1038/387520a0; Shangary S, 2000, J BIOL CHEM, V275, P30163, DOI 10.1074/jbc.M004302200; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shim J, 2000, J BIOL CHEM, V275, P14107, DOI 10.1074/jbc.275.19.14107; Shinohara K, 1996, BIOCHEM J, V317, P385, DOI 10.1042/bj3170385; SLACK RS, 1995, J CELL BIOL, V129, P779, DOI 10.1083/jcb.129.3.779; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Taagepera S, 1998, P NATL ACAD SCI USA, V95, P7457, DOI 10.1073/pnas.95.13.7457; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Tan XQ, 1997, J BIOL CHEM, V272, P9613; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Vigneri P, 2001, NAT MED, V7, P228, DOI 10.1038/84683; Wang JYJ, 2001, BIOCHEM SOC T, V29, P666, DOI 10.1042/0300-5127:0290666; Wang JYJ, 2001, ACTA ONCOL, V40, P689; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WELCH PJ, 1993, CELL, V75, P779, DOI 10.1016/0092-8674(93)90497-E; Whitaker LL, 1998, MOL CELL BIOL, V18, P4032, DOI 10.1128/MCB.18.7.4032; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yang GH, 2000, TOXICOL APPL PHARM, V164, P149, DOI 10.1006/taap.1999.8888; Yu JT, 2001, MOL CELL BIOL, V21, P3325, DOI 10.1128/MCB.21.10.3325-3335.2001; Yuan ZM, 1997, J BIOL CHEM, V272, P23485, DOI 10.1074/jbc.272.38.23485; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zheng L, 2001, EXP CELL RES, V264, P2, DOI 10.1006/excr.2000.5129	92	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44969	44979		10.1074/jbc.M202000200	http://dx.doi.org/10.1074/jbc.M202000200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297496	hybrid			2022-12-25	WOS:000179404800050
J	Ito, N; Yokomizo, T; Sasaki, T; Kurosu, H; Penninger, J; Kanaho, Y; Katada, T; Hanaoka, K; Shimizu, T				Ito, N; Yokomizo, T; Sasaki, T; Kurosu, H; Penninger, J; Kanaho, Y; Katada, T; Hanaoka, K; Shimizu, T			Requirement of phosphatidylinositol 3-kinase activation and calcium influx for leukotriene B-4-induced enzyme release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; FC-EPSILON-RI; MAST-CELL DEGRANULATION; GTP-BINDING PROTEIN; RBL-2H3 CELLS; B-4 RECEPTOR; NEUTROPHIL MIGRATION; SIGNAL-TRANSDUCTION; TYROSINE KINASE; CA2+ INFLUX	Leukotriene B-4 (LTB4) is a potent lipid mediator involved in host defense and inflammatory responses. It causes chemotaxis, generation of reactive oxygen species, and degranulation. However, only little is known of the molecular mechanisms by which LTB4 induces these biological activities. To analyze the intracellular signaling pathways to mediate lysosomal enzyme release through the cloned LTB4 receptor (BLT1), we transfected BLT1 to rat basophilic leukemia cells (RBL-2H3). LTB4 dose-dependently released beta-hexosaminidase, and the release was mostly inhibited when the cells were pretreated with pertussis toxin, indicating that the degranulation is mediated by G(i) proteins. LTB4 activated phosphatidylinositol 3-kinase (PI3-K) through Gi, and inhibition of PI3-K by wortmannin or LY290042 inhibited degranulation. Granulocytes from PI3-Kgamma-deficient mice showed reduced LTB4-induced degranulation, suggesting that this isozyme of PI3-K is involved in the degranulation. LTB4 also caused calcium release from intracellular stores and calcium influx from the outside milieu through Gi, but only the calcium influx is critical for the lysosomal enzyme release. Calcium influx and PI3-K activation are both downstream events of Gi, since they were inhibited by pertussis toxin. These two events are in essence independent each other, because calcium. depletion did not affect PI3-K, and inhibition of PI3-K did not attenuate calcium influx significantly. Thus, our results have clearly shown that LTB4 binds BLT1 and activates G(i)-like protein, and both PI3-Kgamma activation and a sustained calcium elevation by calcium influx are necessary for enzyme release in these cells.	Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Tokyo 1130033, Japan; Univ Tokyo, Fac Med, Dept Anesthesiol, Tokyo 1130033, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan; Japan Sci & Technol Corp, CREST, Tokyo 1130033, Japan; Japan Sci & Technol Corp, PRESTO, Tokyo 1130033, Japan; Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, Tokyo 1138613, Japan; Austrian Acad Sci, Inst Mol Biotechnol, A-1030 Vienna, Austria	University of Tokyo; University of Tokyo; University of Tokyo; Japan Science & Technology Agency (JST); Japan Science & Technology Agency (JST); Tokyo Metropolitan Institute of Medical Science; Austrian Academy of Sciences; Vienna Biocenter (VBC); Institute of Molecular Biotechnology (IMBA)	Yokomizo, T (corresponding author), Univ Tokyo, Fac Med, Dept Biochem & Mol Biol, Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.		Penninger, Josef M/I-6860-2013; Yokomizo, Takehiko/P-5673-2016	Penninger, Josef M/0000-0002-8194-3777; Yokomizo, Takehiko/0000-0002-5219-1553; Sasaki, Takehiko/0000-0003-1837-3748				Barritt GJ, 1999, BIOCHEM J, V337, P153, DOI 10.1042/0264-6021:3370153; Beaven MA, 1996, CURR OPIN IMMUNOL, V8, P766, DOI 10.1016/S0952-7915(96)80002-1; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Ching TT, 2001, J BIOL CHEM, V276, P14814, DOI 10.1074/jbc.M009851200; FERBY IM, 1994, J BIOL CHEM, V269, P30485; FORDHUTCHINSON AW, 1980, NATURE, V286, P264, DOI 10.1038/286264a0; FORDHUTCHINSON AW, 1990, CRIT REV IMMUNOL, V10, P1; Gaudreau R, 1998, BIOCHEM J, V335, P15, DOI 10.1042/bj3350015; GRIFFITHS RJ, 1995, P NATL ACAD SCI USA, V92, P517, DOI 10.1073/pnas.92.2.517; Haribabu B, 1999, J BIOL CHEM, V274, P37087, DOI 10.1074/jbc.274.52.37087; Hata D, 1998, J EXP MED, V187, P1235, DOI 10.1084/jem.187.8.1235; HIDE I, 1993, J CELL BIOL, V123, P585, DOI 10.1083/jcb.123.3.585; HIDE M, 1991, MOL PHARMACOL, V40, P473; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; Ishii I, 1997, J BIOL CHEM, V272, P7846, DOI 10.1074/jbc.272.12.7846; Iversen L, 1997, SKIN PHARMACOL, V10, P169, DOI 10.1159/000211501; KAWAKAMI Y, 1995, J IMMUNOL, V155, P3556; KELLY KL, 1992, J BIOL CHEM, V267, P3423; Kim TD, 1997, J BIOL CHEM, V272, P31225, DOI 10.1074/jbc.272.50.31225; KUCERA GL, 1990, J BIOL CHEM, V265, P5345; KUIJPERS TW, 1992, J IMMUNOL, V148, P72; Lee E, 1999, AM J RESP CRIT CARE, V160, P2079, DOI 10.1164/ajrccm.160.6.9903136; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; MURAKAMI M, 1995, J EXP MED, V182, P197, DOI 10.1084/jem.182.1.197; Noiri E, 2000, P NATL ACAD SCI USA, V97, P823, DOI 10.1073/pnas.97.2.823; Nusse O, 1998, EMBO J, V17, P1279, DOI 10.1093/emboj/17.5.1279; OKADA T, 1994, J BIOL CHEM, V269, P3563; OZAWA K, 1993, J BIOL CHEM, V268, P2280; OZAWA K, 1993, J BIOL CHEM, V268, P1749; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Penner R, 1993, Curr Opin Neurobiol, V3, P368, DOI 10.1016/0959-4388(93)90130-Q; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; SAITO H, 1987, J IMMUNOL, V138, P3927; SAMUELSSON B, 1987, SCIENCE, V237, P1171, DOI 10.1126/science.2820055; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; SEGAL DM, 1977, P NATL ACAD SCI USA, V74, P2993, DOI 10.1073/pnas.74.7.2993; SHARON P, 1984, GASTROENTEROLOGY, V86, P453; Smith AJ, 2001, J BIOL CHEM, V276, P17213, DOI 10.1074/jbc.M100417200; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; Turner CR, 1996, J CLIN INVEST, V97, P381, DOI 10.1172/JCI118426; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; YANO H, 1993, J BIOL CHEM, V268, P25846; Yokomizo T, 2000, J EXP MED, V192, P421, DOI 10.1084/jem.192.3.421; Yokomizo T, 1997, NATURE, V387, P620, DOI 10.1038/42506	47	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44898	44904		10.1074/jbc.M208051200	http://dx.doi.org/10.1074/jbc.M208051200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244116	hybrid			2022-12-25	WOS:000179404800040
J	Kikkawa, Y; Moulson, CL; Virtanen, I; Miner, JH				Kikkawa, Y; Moulson, CL; Virtanen, I; Miner, JH			Identification of the binding site for the Lutheran blood group glycoprotein on laminin alpha 5 through expression of chimeric laminin chains in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE GLYCOPROTEIN; BASEMENT-MEMBRANE; MOLECULAR-CLONING; B-CAM; ADHESION; ADULT; GENE; DOMAIN; KIDNEY; MICE	The Lutheran blood group glycoprotein (Lu), also known as basal cell adhesion molecule, is an Ig superfamily transmembrane receptor for laminin alpha5. Lu is expressed on the surface of a subset of muscle and epithelial cells in diverse tissues and is thought to be involved in both normal and disease processes, including sickle cell disease and cancer. Here we investigated the binding of Lu to laminin alpha5 in vivo and in vitro. We prepared a soluble recombinant Lu (sol-Lu) composed of the Lu extracellular domain and a His(6) tag. Sol-Lu bound specifically to laminin-10/11 (alpha5beta1/beta2gamma1) in enzyme-linked immunosorbent assays and bound to bona fide basement membranes containing laminin alpha5 in tissue sections. Sol-Lu did not bind to tissue sections of laminin alpha5 knockout embryos, despite the fact that the four other a chains were present. To identify the Lu-binding site on laminin alpha5, we prepared modified alpha5 cDNAs encoding chimeric laminins containing all or part of the laminin alpha1 G domain in place of the analogous alpha5 regions. These constructs were used to generate transgenic mice. Proteins derived from transgenes were detected in basement membranes and were assayed for their ability to bind Lu by examining the localization of endogenous Lu and the binding of sol-Lu applied to tissue sections. Our results demonstrate that the alpha5 LG3 module is essential for Lu binding to laminin a5.	Washington Univ, Sch Med, Div Renal, Dept Internal Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA; Univ Helsinki, Inst Biomed Anat Biomed Helsinki, FIN-00014 Helsinki, Finland	Washington University (WUSTL); Washington University (WUSTL); University of Helsinki	Miner, JH (corresponding author), Washington Univ, Sch Med, Div Renal, Dept Internal Med, Box 8126,660 S Euclid, St Louis, MO 63110 USA.	minerj@pcg.wustl.edu	Kikkawa, Yamato/D-1503-2010		NIDDK NIH HHS [P50 DK045181] Funding Source: Medline; NIGMS NIH HHS [R01 GM060432] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK045181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060432] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aumailley M, 1998, J ANAT, V193, P1, DOI 10.1046/j.1469-7580.1998.19310001.x; BURGESON RE, 1994, MATRIX BIOL, V14, P209, DOI 10.1016/0945-053X(94)90184-8; CAMPBELL IG, 1994, CANCER RES, V54, P5761; Champliaud MF, 2000, EXP CELL RES, V259, P326, DOI 10.1006/excr.2000.4980; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Durkin ME, 1997, FEBS LETT, V411, P296, DOI 10.1016/S0014-5793(97)00686-8; El Nemer W, 1998, J BIOL CHEM, V273, P16686; El Nemer W, 2001, J BIOL CHEM, V276, P23757, DOI 10.1074/jbc.M102978200; ELION EA, 1998, CURRENT PROTOCOLS MO, V1; ElNemer W, 1997, BLOOD, V89, P4608, DOI 10.1182/blood.V89.12.4608; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Ettner N, 1998, FEBS LETT, V430, P217, DOI 10.1016/S0014-5793(98)00601-2; GARINCHESA P, 1994, INT J ONCOL, V5, P1261; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Lee SP, 1998, BLOOD, V92, P2951, DOI 10.1182/blood.V92.8.2951.420k30_2951_2958; Libby RT, 2000, J NEUROSCI, V20, P6517, DOI 10.1523/JNEUROSCI.20-17-06517.2000; MARINKOVICH MP, 1992, J CELL BIOL, V119, P695, DOI 10.1083/jcb.119.3.695; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Miner JH, 2000, DEV BIOL, V217, P278, DOI 10.1006/dbio.1999.9546; Miner JH, 1997, J CELL BIOL, V137, P685, DOI 10.1083/jcb.137.3.685; Miner JH, 1998, J CELL BIOL, V143, P1713, DOI 10.1083/jcb.143.6.1713; Moulson CL, 2001, DEV DYNAM, V222, P101, DOI 10.1002/dvdy.1169; Muller U, 1997, CELL, V88, P603, DOI 10.1016/S0092-8674(00)81903-0; Nguyen NM, 2002, DEV BIOL, V246, P231, DOI 10.1006/dbio.2002.0658; Parsons SF, 2001, BLOOD, V97, P312, DOI 10.1182/blood.V97.1.312; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; Rahuel C, 1996, BLOOD, V88, P1865; Rahuel C, 1999, IMMUNOGENETICS, V50, P271, DOI 10.1007/s002510050602; Sasaki T, 2001, FEBS LETT, V505, P173, DOI 10.1016/S0014-5793(01)02812-5; Shimizu H, 1999, J BIOL CHEM, V274, P11995, DOI 10.1074/jbc.274.17.11995; Sorokin LM, 1997, DEV DYNAM, V210, P446, DOI 10.1002/(SICI)1097-0177(199712)210:4<446::AID-AJA8>3.0.CO;2-G; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; SUEMORI H, 1990, CELL DIFFER DEV, V29, P181, DOI 10.1016/0922-3371(90)90120-L; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Timpl R, 2000, MATRIX BIOL, V19, P309, DOI 10.1016/S0945-053X(00)00072-X; Tsubota Y, 2000, BIOCHEM BIOPH RES CO, V278, P614, DOI 10.1006/bbrc.2000.3851; UDAI M, 1998, J CLIN INVEST, V101, P2550; Virtanen I, 2000, EXP CELL RES, V257, P298, DOI 10.1006/excr.2000.4883; Zen Q, 1999, J BIOL CHEM, V274, P728, DOI 10.1074/jbc.274.2.728	44	74	74	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44864	44869		10.1074/jbc.M208731200	http://dx.doi.org/10.1074/jbc.M208731200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244066	hybrid			2022-12-25	WOS:000179404800036
J	Hamad, NM; Banik, SSR; Counter, CM				Hamad, NM; Banik, SSR; Counter, CM			Mutational analysis defines a minimum level of telomerase activity required for tumourigenic growth of human cells	ONCOGENE			English	Article						telomerase; hTERT; immortalization; transformation; tumourigenesis	HUMAN EPITHELIAL-CELLS; MALIGNANT HEMATOPOIETIC-CELLS; CATALYTIC SUBUNIT GENE; LIFE-SPAN; IMMORTAL CELLS; TUMOR-CELLS; CARCINOMA; CANCER; MAINTENANCE; PATTERNS	A hallmark of cancer cells is the ability to proliferate indefinitely. This acquisition of an immortal lifespan usually requires the activation of telomerase, the enzyme that elongates telomeres. Human telomerase is minimally composed of the reverse transcriptase subunit hTERT, and the RNA subunit hTR. While hTR is ubiquitously expressed in human cells, the hTERT subunit is generally transcriptionally repressed in most normal somatic cells, but is illegitimately activated to restore telomerase activity in cancer cells. Indeed, in the thousands of different human tumours assayed, 85% were scored positive for telomerase activity. However, the levels of telomerase activity detected in tumour samples can vary substantially and even some normal somatic cells have been found to have low levels of enzyme activity. As the functional significance of low levels of telomerase activity is unclear, we investigated whether there is a minimum level of telomerase activity required for tumourigenesis. Using mutants of hTERT that induce varying levels of telomerase activity, we show that there does indeed exist a threshold of activity required for the processes of immortalization, transformation and tumourigenesis. Thus, low levels of activity detected in certain somatic cells would not be expected to contribute to tumourigenesis, nor does the mere detection of telomerase in cancer cells necessarily signify an immortal lifespan.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Radiat Oncol, Durham, NC 27710 USA	Duke University; Duke University	Counter, CM (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.			Counter, Christopher M/0000-0003-0748-3079	NATIONAL CANCER INSTITUTE [R01CA082481, R01CA094184] Funding Source: NIH RePORTER; NCI NIH HHS [CA82481, CA94184] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Armbruster BN, 2001, MOL CELL BIOL, V21, P7775, DOI 10.1128/MCB.21.22.7775-7786.2001; BANIK SSR, 2002, IN PRESS MOL CELL BI; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; BROCCOLI D, 1995, P NATL ACAD SCI USA, V92, P9082, DOI 10.1073/pnas.92.20.9082; Buchkovich KJ, 1996, MOL BIOL CELL, V7, P1443, DOI 10.1091/mbc.7.9.1443; CIFONE MA, 1980, P NATL ACAD SCI-BIOL, V77, P1039, DOI 10.1073/pnas.77.2.1039; Counter CM, 1998, P NATL ACAD SCI USA, V95, P14723, DOI 10.1073/pnas.95.25.14723; COUNTER CM, 1995, BLOOD, V85, P2315, DOI 10.1182/blood.V85.9.2315.bloodjournal8592315; COUNTER CM, 1994, P NATL ACAD SCI USA, V91, P2900, DOI 10.1073/pnas.91.8.2900; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; Elenbaas B, 2001, GENE DEV, V15, P50, DOI 10.1101/gad.828901; Farwell DG, 2000, AM J PATHOL, V156, P1537, DOI 10.1016/S0002-9440(10)65025-0; Hahn WC, 1999, NATURE, V400, P464, DOI 10.1038/22780; Halvorsen TL, 1999, MOL CELL BIOL, V19, P1864; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Harley CB, 2002, ONCOGENE, V21, P494, DOI 10.1038/sj.onc.1205076; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Kilian A, 1997, HUM MOL GENET, V6, P2011, DOI 10.1093/hmg/6.12.2011; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kiyono T, 1998, NATURE, V396, P84, DOI 10.1038/23962; Kolquist KA, 1998, NAT GENET, V19, P182, DOI 10.1038/554; Meyerson M, 1997, CELL, V90, P785, DOI 10.1016/S0092-8674(00)80538-3; Nakamura TM, 1997, SCIENCE, V277, P955, DOI 10.1126/science.277.5328.955; Norrback KF, 1997, EUR J CANCER, V33, P774, DOI 10.1016/S0959-8049(97)00059-2; Norrback KF, 1996, BLOOD, V88, P222; Ouellette MM, 1999, BIOCHEM BIOPH RES CO, V254, P795, DOI 10.1006/bbrc.1998.0114; Rich JN, 2001, CANCER RES, V61, P3556; Sellers WR, 1998, GENE DEV, V12, P95, DOI 10.1101/gad.12.1.95; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Stewart GS, 2001, J MEMBRANE BIOL, V180, P49, DOI 10.1007/s002320010058; Vaziri H, 1998, CURR BIOL, V8, P279, DOI 10.1016/S0960-9822(98)70109-5; Yasumoto S, 1996, ONCOGENE, V13, P433; Zhu JY, 1999, P NATL ACAD SCI USA, V96, P3723, DOI 10.1073/pnas.96.7.3723	36	25	26	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7121	7125		10.1038/sj.onc.1205860	http://dx.doi.org/10.1038/sj.onc.1205860			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370834				2022-12-25	WOS:000178424900015
J	Chen, C; Bhalala, HV; Qiao, H; Dong, JT				Chen, C; Bhalala, HV; Qiao, H; Dong, JT			A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer	ONCOGENE			English	Article						chromosome 13; 13q21; KLF5; hemizygous deletion; breast cancer	COMPARATIVE GENOMIC HYBRIDIZATION; HUMAN NEOPLASMS; FACTOR FAMILY; GENE; 13Q21; PROGRESSION; DELETION	The 13q21 tumor suppressor locus, as defined by chromosomal deletion, harbors the KLF5 transcription factor which may have tumor suppressor function. To investigate whether KLF5 plays a role in breast cancer, we evaluated all genes and/or expressed sequence tags (ESTs) within a 3.3 Mb common region of deletion at 13q21. Of these, only KLF5 mRNA was expressed at high levels in non-neoplastic breast epithelial cells and in normal human mammary tissue, but at lower levels in various breast cancer cell tines. Using the real time TaqMan PCR assay, hemizygous deletion at KLF5 was detected in 13 out of 30, or 43% of breast cancer cell lines tested, and various degrees of loss of expression were detected in 21 out of 30, or 70% of these cell lines. Each of the cases with hemizygous deletion also exhibited loss of KLF5 expression, suggesting that loss of expression can result from chromosomal deletion, and that KLF5 may undergo haploinsufficiency during carcinogenesis. Only one of the 30 breast cancer cell lines tested exhibited a mutation in KLF5, and neither promoter methylation nor homozygous deletion was detected in any of the cell lines. In contrast, loss of heterozygosity (LOH) was frequently detected at KLF5. Re-expression of wild-type KLF5 in T-47D breast cancer cells significantly inhibited colony formation in these cells. Of the KLF5-transfected clones that did form colonies, none were found to express KLF5 mRNA. These findings suggest that loss of function by deletion and/or loss of expression frequently occurs at KLF5, and KLF5 suppresses tumor cell growth in breast cancer.	Univ Virginia, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Dong, JT (corresponding author), Emory Univ, Sch Med, Winship Canc Inst, 1365-B Clifton Rd,Suite B4100, Atlanta, GA 30322 USA.			Dong, Jin-Tang/0000-0003-2349-5782	NCI NIH HHS [CA87921, CA85560] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085560, R01CA087921] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Chen CS, 2001, GENE CHROMOSOME CANC, V31, P333, DOI 10.1002/gcc.1152; Conkright MD, 1999, NUCLEIC ACIDS RES, V27, P1263, DOI 10.1093/nar/27.5.1263; Dang DT, 2000, INT J BIOCHEM CELL B, V32, P1103, DOI 10.1016/S1357-2725(00)00059-5; Di Cristofano A, 1998, NAT GENET, V19, P348, DOI 10.1038/1235; Dong JT, 2000, CANCER RES, V60, P3880; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Hyytinen ER, 1999, GENE CHROMOSOME CANC, V25, P108, DOI 10.1002/(SICI)1098-2264(199906)25:2<108::AID-GCC6>3.0.CO;2-Y; Kainu T, 2000, P NATL ACAD SCI USA, V97, P9603, DOI 10.1073/pnas.97.17.9603; Knuutila S, 1999, AM J PATHOL, V155, P683, DOI 10.1016/S0002-9440(10)65166-8; Knuutila S, 1998, AM J PATHOL, V152, P1107; Narla G, 2001, SCIENCE, V294, P2563, DOI 10.1126/science.1066326; Roylance R, 1999, CANCER RES, V59, P1433; Rozenblum E, 2002, HUM GENET, V110, P111, DOI 10.1007/s00439-001-0646-6; Shi HP, 1999, NUCLEIC ACIDS RES, V27, P4807, DOI 10.1093/nar/27.24.4807; Tirkkonen M, 1997, CANCER RES, V57, P1222; Ton-That H, 1997, FEBS LETT, V419, P239, DOI 10.1016/S0014-5793(97)01465-8	18	124	135	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6567	6572		10.1038/sj.onc.1205817	http://dx.doi.org/10.1038/sj.onc.1205817			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242654				2022-12-25	WOS:000178202300002
J	Salas, A; Shimaoka, M; Chen, SQ; Carman, CV; Springer, T				Salas, A; Shimaoka, M; Chen, SQ; Carman, CV; Springer, T			Transition from rolling to firm adhesion is regulated by the conformation of the I domain of the integrin lymphocyte function-associated antigen-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSIOLOGICAL FLOW; HYDRODYNAMIC FLOW; STRUCTURAL BASIS; P-SELECTIN; BINDING; ICAM-1; LFA-1; NEUTROPHILS; MAC-1; SITE	The integrin lymphocyte function-associated antigen-1 (alpha(L)beta(2)) which is known for its ability to mediate firm adhesion and migration, can also contribute to tethering and rolling in shear How. The alpha(L) I domain can be mutationally locked with disulfide bonds into two distinct conformations, open and closed, which have high and low affinity for the ligand intercellular adhesion molecule 1 (ICAM-1), respectively. The wild type I domain exists primarily in the lower energy closed conformation. We have measured for the first time the effect of conformational change on adhesive behavior in shear flow. We show that wild type and locked open I domains, expressed in alpha(L)beta(2) heterodimers or as isolated domains on the cell surface, mediate rolling adhesion and firm adhesion, respectively. alpha(L)beta(2) is thus poised for the conversion of rolling to firm adhesion upon integrin activation in vivo. Isolated I domains are surprisingly more effective than alpha(L)beta(2) in interactions in shear flow, which may in part be a consequence of the presence Of alpha(L)beta(2) in a bent conformation. Furthermore, the force exerted on the C-terminal alpha-helix appears to stabilize the open conformation of the wild type isolated I domain and contribute to its robustness in supporting rolling. An allosteric small molecule antagonist of alpha(L)beta(2) inhibits both rolling adhesion and firm adhesion, which has important implications for its mode of action in vivo.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Springer, T (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA.		Salas, Azucena/AAN-7035-2020; Carman, Christopher/L-8108-2016; Carman, Christopher V./AAX-8995-2020	Carman, Christopher/0000-0001-7358-2548; Carman, Christopher V./0000-0001-7358-2548; Salas, Azucena/0000-0003-4572-2907	NCI NIH HHS [CA31798] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA031798, R01CA031798] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALON R, 1995, NATURE, V374, P539, DOI 10.1038/374539a0; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Cone M, 1987, FEBS LETT, V213, P316; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; de Chateau M, 2001, BIOCHEMISTRY-US, V40, P13972, DOI 10.1021/bi011582f; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DUSTIN ML, 1988, J CELL BIOL, V107, P321, DOI 10.1083/jcb.107.1.321; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Forlow SB, 2001, AM J PHYSIOL-HEART C, V280, pH634, DOI 10.1152/ajpheart.2001.280.2.H634; Forlow SB, 2000, J CLIN INVEST, V106, P1457, DOI 10.1172/JCI10555; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; Giblin PA, 2001, ANNU REP MED CHEM, V36, P181, DOI 10.1016/S0065-7743(01)36058-X; Henderson RB, 2001, J EXP MED, V194, P219, DOI 10.1084/jem.194.2.219; Huang CC, 1997, P NATL ACAD SCI USA, V94, P3162, DOI 10.1073/pnas.94.7.3162; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; Kallen J, 1999, J MOL BIOL, V292, P1, DOI 10.1006/jmbi.1999.3047; Knorr R, 1997, J EXP MED, V186, P719, DOI 10.1084/jem.186.5.719; LAWRENCE MB, 1995, EUR J IMMUNOL, V25, P1025, DOI 10.1002/eji.1830250425; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2387, DOI 10.1073/pnas.041606398; Lu CF, 1997, J IMMUNOL, V159, P268; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; MARTIN S, 1993, J VIROL, V67, P3561, DOI 10.1128/JVI.67.6.3561-3568.1993; Parkos CA, 1996, MOL MED, V2, P489, DOI 10.1007/BF03401908; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Sigal A, 2000, J IMMUNOL, V165, P442, DOI 10.4049/jimmunol.165.1.442; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; van der Merwe PA, 1999, CURR BIOL, V9, pR419; VONANDRIAN UH, 1991, P NATL ACAD SCI USA, V88, P7538, DOI 10.1073/pnas.88.17.7538; Weber C, 1997, J CLIN INVEST, V100, P2085, DOI 10.1172/JCI119742; Weitz-Schmidt G, 2001, NAT MED, V7, P687, DOI 10.1038/89058; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	38	86	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50255	50262		10.1074/jbc.M209822200	http://dx.doi.org/10.1074/jbc.M209822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12368274	hybrid			2022-12-25	WOS:000180177700008
J	Dell, EJ; Connor, J; Chen, SH; Stebbins, EG; Skiba, NP; Mochly-Rosen, D; Hamm, HE				Dell, EJ; Connor, J; Chen, SH; Stebbins, EG; Skiba, NP; Mochly-Rosen, D; Hamm, HE			The beta gamma subunit of Heterotrimeric G proteins interacts with RACK1 and two other WD repeat proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-MEDIATED ENDOCYTOSIS; PLECKSTRIN HOMOLOGY DOMAINS; GTP-BINDING PROTEIN; ACTIVATED C-KINASE; CYTOPLASMIC DYNEIN; SIGNAL-TRANSDUCTION; DEPENDENT PHOSPHORYLATION; PHOSPHODIESTERASE PDE4D5; SCAFFOLDING PROTEIN; DYNACTIN COMPLEX	A yeast two-hybrid approach was used to discern possible new effectors for the betagamma subunit of heterotrimeric G proteins. Three of the clones isolated are structurally similar to Gbeta, each exhibiting the WD40 repeat motif. Two of these proteins, the (r) under bar eceptor for (a) under bar ctivated (C) under bar (k) under bar inase 1 (RACK1) and the dynein intermediate chain, coimmunoprecipitate with Gbetagamma using an anti-Gbeta antibody. The third protein, AAH20044, has no known function; however, sequence analysis indicates that it is a WD40 repeat protein. Further investigation with RACK1 shows that it not only interacts with Gbeta(1)gamma(1) but also unexpectedly with the transducin heterotrimer Galpha(t)beta(1)gamma(1). Gat alone does not interact, but it must contribute to the interaction because the apparent EC50 value of RACK1 for Galpha(t)beta(1)y(1) is 3-fold greater than that for Gbeta(1)gamma(1) (0.1 versus 0.3 muM). RACK1 is a scaffold that interacts with several proteins, among which are activated betaIIPKC and dynamin-1 (1). betaIIPKC and dynamin-1 compete with Gbeta(1)gamma(1) and Galpha(t)beta(1)gamma(1) for interaction with RACK1. These findings have several implications: 1) that WD40 repeat proteins may interact with each other; 2) that Gbetagamma interacts differently with RACK1 than with its other known effectors; and/or 3) that the G protein-RACK1 complex may constitute a signaling scaffold important for intracellular responses.	Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60613 USA; Northwestern Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Chicago, IL 60613 USA; Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Northwestern University; Northwestern University; Stanford University; Vanderbilt University	Hamm, HE (corresponding author), Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60613 USA.		Hamm, Heidi E/G-2374-2014	Mochly-Rosen, Daria/0000-0002-6691-8733; chen, songhai/0000-0001-7316-7125	NEI NIH HHS [EY 100291] Funding Source: Medline	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ahmad FJ, 1998, J CELL BIOL, V140, P391, DOI 10.1083/jcb.140.2.391; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aragay AM, 1999, J BIOL CHEM, V274, P4807, DOI 10.1074/jbc.274.8.4807; Blackmer T, 2001, SCIENCE, V292, P293, DOI 10.1126/science.1058803; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P581; Buensuceso CS, 2001, J CELL SCI, V114, P1691; Burkhardt JK, 1997, J CELL BIOL, V139, P469, DOI 10.1083/jcb.139.2.469; Chang BY, 1998, MOL CELL BIOL, V18, P3245, DOI 10.1128/MCB.18.6.3245; Chang BY, 2001, J BIOL CHEM, V276, P20346, DOI 10.1074/jbc.M101375200; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; CORTHESYTHEULAZ I, 1992, J CELL BIOL, V118, P1333, DOI 10.1083/jcb.118.6.1333; Craft CM, 1998, BIOCHEMISTRY-US, V37, P15758, DOI 10.1021/bi980921a; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Farshori P, 1997, BIOCHEM BIOPH RES CO, V232, P810, DOI 10.1006/bbrc.1997.6379; FIELDS TA, 1995, J BIOL CHEM, V270, P23119, DOI 10.1074/jbc.270.39.23119; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Geijsen N, 1999, ONCOGENE, V18, P5126, DOI 10.1038/sj.onc.1202896; GILL SR, 1991, J CELL BIOL, V115, P1639, DOI 10.1083/jcb.115.6.1639; Gotta M, 2001, NAT CELL BIOL, V3, P297, DOI 10.1038/35060092; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Jamora C, 1997, CELL, V91, P617, DOI 10.1016/S0092-8674(00)80449-3; KARKI S, 1995, J BIOL CHEM, V270, P28806, DOI 10.1074/jbc.270.48.28806; Karki S, 1997, J BIOL CHEM, V272, P5887, DOI 10.1074/jbc.272.9.5887; Karki S, 1999, CURR OPIN CELL BIOL, V11, P45, DOI 10.1016/S0955-0674(99)80006-4; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Koehler JA, 2001, BIOCHEM BIOPH RES CO, V283, P888, DOI 10.1006/bbrc.2001.4889; Kozasa T, 1996, J BIOL CHEM, V271, P12562, DOI 10.1074/jbc.271.21.12562; Li Y, 1998, J BIOL CHEM, V273, P16265, DOI 10.1074/jbc.273.26.16265; Liliental J, 1998, J BIOL CHEM, V273, P2379, DOI 10.1074/jbc.273.4.2379; Lin HC, 1996, J BIOL CHEM, V271, P27979, DOI 10.1074/jbc.271.45.27979; Lin HC, 1998, P NATL ACAD SCI USA, V95, P5057, DOI 10.1073/pnas.95.9.5057; Liu JP, 1997, MOL CELL ENDOCRINOL, V132, P61, DOI 10.1016/S0303-7207(97)00120-2; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; MAIER O, 1995, BIOCHEM BIOPH RES CO, V208, P135, DOI 10.1006/bbrc.1995.1315; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; Mochly-Rosen D, 1998, FASEB J, V12, P35; MOCHLYROSEN D, 1995, BIOCHEM SOC T, V23, P596, DOI 10.1042/bst0230596; Mourton T, 2001, J BIOL CHEM, V276, P14896, DOI 10.1074/jbc.M010823200; Murthy KS, 2000, AM J PHYSIOL-CELL PH, V279, pC925, DOI 10.1152/ajpcell.2000.279.4.C925; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; Niclas J, 1996, J CELL BIOL, V133, P585, DOI 10.1083/jcb.133.3.585; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Rodriguez MM, 1999, BIOCHEMISTRY-US, V38, P13787, DOI 10.1021/bi991055k; RON D, 1994, J BIOL CHEM, V269, P21395; RON D, 1995, P NATL ACAD SCI USA, V92, P492, DOI 10.1073/pnas.92.2.492; RON D, 1994, P NATL ACAD SCI USA, V91, P839, DOI 10.1073/pnas.91.3.839; Schechtman D, 2001, ONCOGENE, V20, P6339, DOI 10.1038/sj.onc.1204778; Schneider T, 1997, TRENDS PHARMACOL SCI, V18, P8, DOI 10.1016/S0165-6147(96)01001-2; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Sondek J, 2001, BIOCHEM PHARMACOL, V61, P1329, DOI 10.1016/S0006-2952(01)00633-5; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Stebbins EG, 2001, J BIOL CHEM, V276, P29644, DOI 10.1074/jbc.M101044200; Steele MR, 2001, CELL SIGNAL, V13, P507, DOI 10.1016/S0898-6568(01)00167-X; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Sunahara RK, 1996, ANNU REV PHARMACOL, V36, P461, DOI 10.1146/annurev.pa.36.040196.002333; Tai AW, 1999, CELL, V97, P877, DOI 10.1016/S0092-8674(00)80800-4; Tai AW, 2001, J CELL BIOL, V153, P1499, DOI 10.1083/jcb.153.7.1499; THOMAS TC, 1993, BIOCHEMISTRY-US, V32, P8628, DOI 10.1021/bi00084a034; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Usacheva A, 2001, J BIOL CHEM, V276, P22948, DOI 10.1074/jbc.M100087200; VAUGHAN KT, 1995, J CELL BIOL, V131, P1507, DOI 10.1083/jcb.131.6.1507; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; WatermanStorer CM, 1997, P NATL ACAD SCI USA, V94, P12180, DOI 10.1073/pnas.94.22.12180; Whistler JL, 1999, J BIOL CHEM, V274, P24575, DOI 10.1074/jbc.274.35.24575; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Yarwood SJ, 1999, J BIOL CHEM, V274, P14909, DOI 10.1074/jbc.274.21.14909; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200	74	79	90	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49888	49895		10.1074/jbc.M202755200	http://dx.doi.org/10.1074/jbc.M202755200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12359736	hybrid			2022-12-25	WOS:000180028900103
J	Novotny-Diermayr, V; Zhang, T; Gu, L; Cao, XM				Novotny-Diermayr, V; Zhang, T; Gu, L; Cao, XM			Protein kinase C delta associates with the interleukin-6 receptor subunit glycoprotein (gp) 130 via Stat3 and enhances Stat3-gp130 interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; EPIDERMAL GROWTH-FACTOR; SERINE PHOSPHORYLATION; SH2 DOMAIN; TYROSINE PHOSPHORYLATION; CYTOKINE RECEPTORS; INSULIN-RECEPTOR; DOWN-REGULATION; IL-6 FAMILY; PKC-DELTA	The transcriptional regulation of Stat proteins is controlled through their C-terminal domains, which harbor both a tyrosine phosphorylation site, required for dimerization and subsequent nuclear translocation, and a serine phosphorylation site, required for maximum transcriptional activity. Previously, we reported that protein kinase CS (PKCdelta) phosphorylates and interacts with Stat3 in an interleukin (IL)-6-dependent manner. In this study, we further characterized this interaction, and investigated the potential role of such an interaction. We show here that the catalytic domain of PKCdelta interacts with the Src homology 2 domain and part of the adjacent C-terminal transactivation domain of Stat3. This interaction, which does not seem to involve a classical phosphotyrosine SH2-mediated binding, however, significantly enhances the interaction of Stat3 and the IL-6 receptor subunit glycoprotein (gp) 130, which is the initial step for Stat3 activation by IL-6. Expression of a dominant negative PKCdelta or depletion of the endogenous PKCdelta by phorbol 12-myristate 3-acetate treatment abrogates the association of Stat3 with gp130. At the same time, PKCdelta is recruited to gp130 via association with Stat3, which may facilitate its phosphorylation on the gp130 receptor. Finally, we identified Thr-890, a putative PKC phosphorylation site on gp130, to be critical for the effect of PKCdelta. Our data indicate that PKCdelta plays important regulatory roles in IL-6 signaling.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Cao, XM (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.	mcbcaoxm@imcb.nus.edu.sg						Abe K, 2001, ONCOGENE, V20, P3464, DOI 10.1038/sj.onc.1204461; Adachi M, 1996, CELL, V85, P15; AHN JC, 1993, J BIOL CHEM, V268, P7571; AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Behrmann I, 1997, J BIOL CHEM, V272, P5269, DOI 10.1074/jbc.272.8.5269; Blanchard F, 2000, J BIOL CHEM, V275, P28793, DOI 10.1074/jbc.M003986200; Braiman L, 2001, MOL ENDOCRINOL, V15, P565, DOI 10.1210/me.15.4.565; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Feinmesser RL, 1999, J BIOL CHEM, V274, P16168, DOI 10.1074/jbc.274.23.16168; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; Gibson RM, 2000, J BIOL CHEM, V275, P22574, DOI 10.1074/jbc.M907658199; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hibi M, 1996, J MOL MED-JMM, V74, P1, DOI 10.1007/BF00202068; Hirano T, 1998, Int Rev Immunol, V16, P249; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kilpatrick LE, 2000, AM J PHYSIOL-CELL PH, V279, pC2011, DOI 10.1152/ajpcell.2000.279.6.C2011; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kronfeld I, 2000, J BIOL CHEM, V275, P35491, DOI 10.1074/jbc.M005991200; Kuriyan J, 1999, NATURE, V398, P22, DOI 10.1038/17916; Li W, 1996, CURR TOP MICROBIOL, V211, P55; Li WQ, 1998, MOL CELL BIOL, V18, P5888, DOI 10.1128/MCB.18.10.5888; LI WQ, 1995, J BIOL CHEM, V270, P8311, DOI 10.1074/jbc.270.14.8311; Li WQ, 1997, J BIOL CHEM, V272, P24550, DOI 10.1074/jbc.272.39.24550; Li WQ, 1996, J BIOL CHEM, V271, P26404, DOI 10.1074/jbc.271.42.26404; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lim CP, 2001, J BIOL CHEM, V276, P21004, DOI 10.1074/jbc.M007592200; LIN CR, 1986, CELL, V44, P839, DOI 10.1016/0092-8674(86)90006-1; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Manser E, 1997, MOL CELL BIOL, V17, P1129, DOI 10.1128/MCB.17.3.1129; Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758; Park I, 1995, P NATL ACAD SCI USA, V92, P12338, DOI 10.1073/pnas.92.26.12338; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; PIETZKO D, 1993, J BIOL CHEM, V268, P4250; Ron D, 1999, FASEB J, V13, P1658, DOI 10.1096/fasebj.13.13.1658; Schmandt R, 1999, ONCOGENE, V18, P1867, DOI 10.1038/sj.onc.1202507; Schuringa JJ, 2001, J BIOL CHEM, V276, P27709, DOI 10.1074/jbc.M009821200; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; SZALLASI Z, 1994, MOL PHARMACOL, V46, P840; Uddin S, 2002, J BIOL CHEM, V277, P14408, DOI 10.1074/jbc.M109671200; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yamanaka Y, 1996, EMBO J, V15, P1557, DOI 10.1002/j.1460-2075.1996.tb00500.x; Zhang T, 2002, J BIOL CHEM, V277, P17556, DOI 10.1074/jbc.M105525200; Zhang T, 2000, MOL CELL BIOL, V20, P7132, DOI 10.1128/MCB.20.19.7132-7139.2000	56	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49134	49142		10.1074/jbc.M206727200	http://dx.doi.org/10.1074/jbc.M206727200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12361954	hybrid			2022-12-25	WOS:000180028900007
J	Paulussen, A; Raes, A; Matthijs, G; Snyders, DJ; Cohen, N; Aerssens, J				Paulussen, A; Raes, A; Matthijs, G; Snyders, DJ; Cohen, N; Aerssens, J			A novel mutation (T65P) in the PAS domain of the human potassium channel HERG results in the long QT syndrome by trafficking deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTEIN TRAFFICKING; INHERITED CARDIAC-ARRHYTHMIA; HUMAN INWARD RECTIFIER; K+-CHANNEL; GENOMIC ORGANIZATION; MISSENSE MUTATIONS; SYNDROME GENES; ACTIVATION; MUTANT; MECHANISM	The congenital long QT syndrome is a cardiac disease characterized by an increased susceptibility to ventricular arrhythmias. The clinical hallmark is a prolongation of the QT interval, which reflects a delay in repolarization caused by mutations in cardiac ion channel genes. Mutations in the HERG (human ether-a-go-go-related gene KCNH2 can cause a reduction in I-Kr, one of the currents responsible for cardiac repolarization. We describe the identification and characterization of a novel missense mutation T65P in the PAS (Per-Arnt-Sim) domain of HERG, resulting in defective trafficking of the protein to the cell membrane. Defective folding of the mutant protein could be restored by decreased cell incubation temperature and pharmacologically by cisapride and E-4031. When trafficking was restored by growing cells at 27 degreesC, the kinetics of the mutated channel resembled that of wildtype channels although the rate of activation, deactivation, and recovery from inactivation were accelerated. No positive evidence for the formation of heterotetramers was obtained by co-expression of wild-type with mutant subunits at 37 degreesC. As a consequence the clinical symptoms may be explained rather by haploinsufficiency than by dominant negative effects. This study is the first to relate a PAS domain mutation in HERG to a trafficking deficiency at body temperature, apart from effects on channel deactivation.	Johnson & Johnson Pharmaceut Res & Dev, Dept Pharmacogenom, B-2340 Beerse, Belgium; Raritan, Raritan, NJ 08869 USA; Univ Maastricht, Dept Genet & Cell Biol, Inst Cardiovasc Res, NL-6200 MD Maastricht, Netherlands; Univ Antwerp, Dept Biomed Sci, Lab Mol Biophys Physiol & Pharmacol, Antwerp, Belgium; Univ Leuven, Dept Human Genet, Louvain, Belgium	Johnson & Johnson; Janssen Pharmaceuticals; Maastricht University; University of Antwerp; KU Leuven	Paulussen, A (corresponding author), Univ Maastricht, Dept Populat Genet, POB 616 16, NL-6200 MD Maastricht, Netherlands.	paulussen.aimee@advalvas.be	Snyders, Dirk/A-2713-2013	Snyders, Dirk/0000-0001-7142-6672; Aerssens, Jeroen/0000-0002-9254-4800; Matthijs, Gert/0000-0001-6710-1912	NHLBI NIH HHS [HL59689] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059689] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Ficker E, 2002, J BIOL CHEM, V277, P4989, DOI 10.1074/jbc.M107345200; Ficker E, 2000, J MOL CELL CARDIOL, V32, P2327, DOI 10.1006/jmcc.2000.1263; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Huang FD, 2001, CIRCULATION, V104, P1071, DOI 10.1161/hc3501.093815; Jongbloed RJE, 1999, HUM MUTAT, V13, P301, DOI 10.1002/(SICI)1098-1004(1999)13:4<301::AID-HUMU7>3.3.CO;2-M; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Lees-Miller JP, 2000, CIRC RES, V86, P507, DOI 10.1161/01.RES.86.5.507; LeesMiller JP, 1997, CIRC RES, V81, P719; London B, 1997, CIRC RES, V81, P870; Nakajima T, 1999, CARDIOVASC RES, V44, P283, DOI 10.1016/S0008-6363(99)00195-9; Nakajima T, 2000, FEBS LETT, V481, P197, DOI 10.1016/S0014-5793(00)01988-8; Neyroud N, 1999, CIRC RES, V84, P290, DOI 10.1161/01.RES.84.3.290; Ottschytsch N, 2002, P NATL ACAD SCI USA, V99, P7986, DOI 10.1073/pnas.122617999; Paulussen A, 2000, Hum Mutat, V15, P483, DOI 10.1002/(SICI)1098-1004(200005)15:5<483::AID-HUMU18>3.0.CO;2-T; Pellequer JL, 1998, P NATL ACAD SCI USA, V95, P5884, DOI 10.1073/pnas.95.11.5884; Priori SG, 1999, CIRCULATION, V99, P518, DOI 10.1161/01.CIR.99.4.518; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Splawski I, 1998, GENOMICS, V51, P86, DOI 10.1006/geno.1998.5361; Tamarappoo BK, 1998, J CLIN INVEST, V101, P2257, DOI 10.1172/JCI2303; Terlau H, 1997, J PHYSIOL-LONDON, V502, P537, DOI 10.1111/j.1469-7793.1997.537bj.x; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang Q, 1996, GENOMICS, V34, P9, DOI 10.1006/geno.1996.0236; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	40	82	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48610	48616		10.1074/jbc.M206569200	http://dx.doi.org/10.1074/jbc.M206569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354768	hybrid			2022-12-25	WOS:000179789600084
J	Fisher, DI; Safrany, ST; Strike, P; McLennan, AG; Cartwright, JL				Fisher, DI; Safrany, ST; Strike, P; McLennan, AG; Cartwright, JL			Nudix hydrolases that degrade dinucleoside and diphosphoinositol polyphosphates also have 5-phosphoribosyl 1-pyrophosphate (PRPP) pyrophosphatase activity that generates the glycolytic activator ribose 1,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MUTT MOTIF; PHOSPHORIBOSYLPYROPHOSPHATE SYNTHETASE; DIADENOSINE POLYPHOSPHATES; SCHIZOSACCHAROMYCES-POMBE; SUBSTRATE SPECIFICITIES; ESCHERICHIA-COLI; GENE ENCODES; PURINE; FAMILY	A total of 17 Nudix hydrolases were tested for their ability to hydrolyze 5-phosphoribosyl 1-pyrophosphate (PRPP). All 11 enzymes that were active toward dinucleoside polyphosphates with 4 or more phosphate groups as substrates were also able to hydrolyze PRPP, whereas the 6 that could not and that have coenzyme A, NDP-sugars, or pyridine nucleotides as preferred substrates did not degrade PRPP. The products of hydrolysis were ribose 1,5-bisphosphate and P-i. Active PRPP pyrophosphatases included the diphosphoinositol polyphosphate phosphohydrolase (DIPP) subfamily of Nudix hydrolases, which also degrade the non-nucleotide diphosphoinositol polyphosphates. K-m and k(cat) values for PRPP hydrolysis for the Deinococcus radiodurans DR2356 (di)nucleoside polyphosphate hydrolase, the human diadenosine tetraphosphate hydrolase, and human DIPP-1 (diadenosine hexaphosphate and diphosphoinositol polyphosphate hydrolase) were 1 nM and 1.5 s(-1), 0.13 mM and 0.057 s(-1), and 0.38 mM and 1.0 s(-1), respectively. Active site mutants of the Caenorhabditis elegans diadenosine tetraphosphate hydrolase had no activity, confirming that the same active site is responsible for nucleotide and PRPP hydrolysis. Comparison of the specificity constants for nucleotide, diphosphoinositol polyphosphate, and PRPP hydrolysis suggests that PRPP is a significant substrate for the D. radiodurans DR2356 enzyme and for the DIPP subfamily. In the latter case, generation of the glycolytic activator ribose 1,5-bisphosphate may be a new function for these enzymes.	Univ Liverpool, Sch Biol Sci, Cell Regulat & Signalling Grp, Liverpool L69 7ZB, Merseyside, England; Univ Dundee, Sch Life Sci, Div Cell Signalling, Dundee DD1 5EH, Scotland	University of Liverpool; University of Dundee	McLennan, AG (corresponding author), Univ Liverpool, Sch Biol Sci, Cell Regulat & Signalling Grp, Life Sci Bldg, Liverpool L69 7ZB, Merseyside, England.		Safrany, Stephen/AAX-3332-2020	Safrany, Stephen/0000-0002-9592-4112				Abdelghany HM, 2001, BBA-PROTEIN STRUCT M, V1550, P27, DOI 10.1016/S0167-4838(01)00263-1; AbdelRaheim SR, 2001, ARCH BIOCHEM BIOPHYS, V388, P18, DOI 10.1006/abbi.2000.2268; Alifano P, 1996, MICROBIOL REV, V60, P44, DOI 10.1128/MMBR.60.1.44-69.1996; Ames B. N., 1966, METHOD ENZYMOL, P115, DOI DOI 10.1016/0076-6879(66)08014-5; BAGNARA AS, 1974, BIOCHIM BIOPHYS ACTA, V374, P259, DOI 10.1016/0005-2787(74)90247-0; Bailey S, 2002, STRUCTURE, V10, P589, DOI 10.1016/S0969-2126(02)00746-3; Becker MA, 2001, PROG NUCLEIC ACID RE, V69, P115, DOI 10.1016/S0079-6603(01)69046-9; BECKER MA, 1987, J BIOL CHEM, V262, P14531; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Caffrey JJ, 2000, J BIOL CHEM, V275, P12730, DOI 10.1074/jbc.275.17.12730; Caffrey JJ, 2001, GENE, V269, P53, DOI 10.1016/S0378-1119(01)00446-2; CANALES J, 1995, BBA-PROTEIN STRUCT M, V1246, P167, DOI 10.1016/0167-4838(94)00191-I; Cartwright JL, 1999, J BIOL CHEM, V274, P8604, DOI 10.1074/jbc.274.13.8604; Cartwright JL, 2002, J VIROL, V76, P1415, DOI 10.1128/JVI.76.3.1415-1421.2002; Dennis AL, 2000, J INORG BIOCHEM, V81, P73, DOI 10.1016/S0162-0134(00)00117-3; Dubois E, 2002, J BIOL CHEM, V277, P23755, DOI 10.1074/jbc.M202206200; FOX IH, 1974, CAN J BIOCHEM CELL B, V52, P1162, DOI 10.1139/o74-161; Garrison PN, 1992, AP4A OTHER DINUCLEOS, P29; Gasmi L, 1999, BIOCHEM J, V344, P331, DOI 10.1042/0264-6021:3440331; Gasmi L, 2001, BIOCHEM J, V357, P33, DOI 10.1042/0264-6021:3570033; GURANOWSKI A, 1994, BIOCHEMISTRY-US, V33, P235, DOI 10.1021/bi00167a031; Guranowski A, 2000, PHARMACOL THERAPEUT, V87, P117, DOI 10.1016/S0163-7258(00)00046-2; Hanakahi LA, 2000, CELL, V102, P721, DOI 10.1016/S0092-8674(00)00061-1; Hidaka K, 2002, J BIOL CHEM, V277, P32730, DOI 10.1074/jbc.M205476200; HISATA T, 1975, ANAL BIOCHEM, V68, P448, DOI 10.1016/0003-2697(75)90640-5; HOLMES EW, 1973, J BIOL CHEM, V248, P6035; HOVEJENSEN B, 1988, J BACTERIOL, V170, P1148, DOI 10.1128/jb.170.3.1148-1152.1988; HUTTER R, 1986, ANNU REV MICROBIOL, V40, P55, DOI 10.1146/annurev.mi.40.100186.000415; Ingram SW, 1999, BIOCHEMISTRY-US, V38, P3649, DOI 10.1021/bi982951j; INGRAM SW, IN PRESS BIOCH J; Jankowski J, 1999, ANAL BIOCHEM, V269, P72, DOI 10.1006/abio.1999.3097; Kawaguchi T, 2001, J BIOL CHEM, V276, P28554, DOI 10.1074/jbc.M101396200; Leslie NR, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-20; Lin SR, 2002, BBA-PROTEIN STRUCT M, V1594, P127, DOI 10.1016/S0167-4838(01)00296-5; MAY SR, 1976, ANAL BIOCHEM, V75, P389, DOI 10.1016/0003-2697(76)90093-2; McLennan AG, 1999, INT J MOL MED, V4, P79; MENNITI FS, 1993, J BIOL CHEM, V268, P3850; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; OGUSHI S, 1990, J BIOL CHEM, V265, P10943; PETERS GJ, 1979, INT J BIOCHEM, V10, P885, DOI 10.1016/0020-711X(79)90118-6; Petersen C, 1999, J BIOL CHEM, V274, P5348, DOI 10.1074/jbc.274.9.5348; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Safrany ST, 1999, J BIOL CHEM, V274, P21735, DOI 10.1074/jbc.274.31.21735; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Sawada M, 2000, INT J BIOCHEM CELL B, V32, P447, DOI 10.1016/S1357-2725(99)00137-5; Stuer-Lauridsen B, 1998, J BACTERIOL, V180, P457, DOI 10.1128/JB.180.3.457-463.1998; TAX WJM, 1978, COMP BIOCHEM PHYS B, V59, P219, DOI 10.1016/0305-0491(78)90250-X; TRAUT TW, 1994, MOL CELL BIOCHEM, V140, P1, DOI 10.1007/BF00928361; TREMBACZ H, 1990, BIOCHEM J, V271, P621, DOI 10.1042/bj2710621; VOLL MJ, 1967, J BIOL CHEM, V242, P1760; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; YE WL, 1995, J BIOL CHEM, V270, P1564, DOI 10.1074/jbc.270.4.1564	52	46	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47313	47317		10.1074/jbc.M209795200	http://dx.doi.org/10.1074/jbc.M209795200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370170	hybrid			2022-12-25	WOS:000179663700062
J	Jahng, AW; Strang, C; Kaiser, D; Pollard, T; Pfaffinger, P; Choe, S				Jahng, AW; Strang, C; Kaiser, D; Pollard, T; Pfaffinger, P; Choe, S			Zinc mediates assembly of the T1 domain of the voltage-gated K channel 4.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNELS; TETRAMERIZATION DOMAIN; CRYSTAL-STRUCTURE; SUBUNIT; ASSOCIATION	An intermolecular Zn2+-binding site was identified in the structure of the T1 domain of the Shaw-type potassium channels (aKv3.1). T1 is a BTB/POZ-type domain responsible for the ordered assembly of voltage-gated potassium channels and interactions with other macromolecules. In this structure, a Zn2+ ion was found to be coordinated between each of the four assembly interfaces of the T1 tetramer by three Cys and one His encoded in the sequence motif (HX5CX20CC) of the T1 domain. This sequence motif is conserved among all non-Shaker-type voltage-dependent potassium (Kv) channels, but not in Shaker-type channels. The presence of this conserved Zn2+-binding site is a primary molecular determinant that distinguishes the tetrameric assembly of non-Shaker Kv channel subunits from that of Shaker channels. We report here that tetramerization of the Shal (rKv4.2) T1 in solution requires the presence of Zn2+, and the addition/removal of Zn2+ reversibly switches the protein between a stable tetrameric or monomeric state. We further show that the conversion from tetramers to monomers is profoundly pH-dependent: as the solution pH gets lower, the dissociation rate increases significantly. The unfolding energy of the T1 tetramer as a measure of the conformational stability of the structure is also pH-dependent. Surprisingly, at a lower pH we observe a distinctly altered conformational state of the T1 tetramer trapped during the process of unfolding of the T1 tetramer in the presence of Zn2+. The conformational alteration may be responsible for increased rate of dissociation at lower pH by allowing Zn2+ to be removed more effectively by EDTA. The ability of the T1 domain to adopt stable alternative conformations may be essential to its function as a protein-protein interaction/signaling domain to modulate the ion conduction properties of intact full-length Kv channels.	Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA; Baylor Coll Med, Div Neurosci, Houston, TX 77030 USA	Salk Institute; Baylor College of Medicine	Choe, S (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, La Jolla, CA 92037 USA.	choe@salk.edu						An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Bixby KA, 1999, NAT STRUCT BIOL, V6, P38; BOLEN DW, 1988, BIOCHEMISTRY-US, V27, P8069, DOI 10.1021/bi00421a015; Choe S, 1999, TRENDS BIOCHEM SCI, V24, P345, DOI 10.1016/S0968-0004(99)01440-1; Cushman SJ, 2000, NAT STRUCT BIOL, V7, P403; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Hille B., 1992, IONIC CHANNELS EXCIT; HISI H, 2002, NAT NEUROSCI, V3, P661; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; JAN LY, 1990, TRENDS NEUROSCI, V13, P415, DOI 10.1016/0166-2236(90)90123-R; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kobertz WR, 2000, BIOCHEMISTRY-US, V39, P10347, DOI 10.1021/bi001292j; Kreusch A, 1998, NATURE, V392, P945, DOI 10.1038/31978; LEE TE, 1994, BIOPHYS J, V66, P667, DOI 10.1016/S0006-3495(94)80840-9; LI M, 1992, SCIENCE, V257, P1225, DOI 10.1126/science.1519059; Lockless SW, 1999, SCIENCE, V286, P295, DOI 10.1126/science.286.5438.295; Minor DL, 2000, CELL, V102, P657, DOI 10.1016/S0092-8674(00)00088-X; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Roosild TP, 2002, CELL, V109, P781, DOI 10.1016/S0092-8674(02)00768-7; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; SHEN NV, 1995, NEURON, V14, P625, DOI 10.1016/0896-6273(95)90319-4; Strang C, 2001, J BIOL CHEM, V276, P28493, DOI 10.1074/jbc.M010540200; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; VANDONGEN AMJ, 1990, NEURON, V5, P433, DOI 10.1016/0896-6273(90)90082-Q; Zerangue N, 2000, P NATL ACAD SCI USA, V97, P3591, DOI 10.1073/pnas.060016797; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	26	27	28	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47885	47890		10.1074/jbc.M208416200	http://dx.doi.org/10.1074/jbc.M208416200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12372826	hybrid			2022-12-25	WOS:000179663700135
J	Kim, H; Ralph, J; Lu, FC; Pilate, G; Leple, JC; Pollet, B; Lapierre, C				Kim, H; Ralph, J; Lu, FC; Pilate, G; Leple, JC; Pollet, B; Lapierre, C			Identification of the structure and origin of thioacidolysis marker compounds for cinnamyl alcohol dehydrogenase deficiency in angiosperms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSGENIC TOBACCO; DOWN-REGULATION; LIGNIN MODEL; CONIFERYL ALDEHYDE; ABNORMAL LIGNIN; SPRUCE LIGNIN; DFRC METHOD; PLANTS; BIOSYNTHESIS; LIGNIFICATION	Molecular marker compounds, derived from lignin by the thioacidolysis degradative method, for cinnamyl alcohol dehydrogenase (CAD) deficiency in angiosperms have been structurally identified as indene derivatives. They are shown to derive from hydroxycinnamyl aldehydes that have undergone 8-O-4-cross-coupling during lignification. As such, they are valuable markers for ascertaining plant responses to various levels of CAD down-regulation. Their derivation illustrates that hydroxycinnamyl aldehydes incorporate into angiosperm lignins by endwise coupling reactions in much the same way as normal monolignols do, suggesting that the hydroxycinnamyl aldehydes should be considered authentic lignin precursors.	USDA ARS, US Dairy Forage Res Ctr, Madison, WI 53706 USA; Univ Wisconsin, Dept Forestry, Madison, WI 53706 USA; INRA, Ameliorat Arbres Forestiers Stn, F-45160 Olivet, France; INRA, Inst Natl Agron Paris Grignon, Chim Biol Lab, F-78850 Grignon, France	United States Department of Agriculture (USDA); University of Wisconsin System; University of Wisconsin Madison; INRAE; AgroParisTech; INRAE	Ralph, J (corresponding author), USDA ARS, US Dairy Forage Res Ctr, 1925 Linden Dr W, Madison, WI 53706 USA.	jralph@facstaff.wisc.edu	LEPLE, Jean-Charles/H-4210-2012; Ralph, John/C-3161-2009; Lu, Fachuang/K-6487-2019; Pilate, Gilles/E-8784-2017; Lapierre, Catherine/AAD-9209-2020; Kim, Hoon/E-8245-2013; Pilate, Gilles/D-1666-2011; LEPLE, Jean-Charles/AAT-7414-2021; LEPLE, Jean charles/L-9604-2014	Ralph, John/0000-0002-6093-4521; Pilate, Gilles/0000-0003-4802-8849; Kim, Hoon/0000-0001-7425-7464; LEPLE, Jean-Charles/0000-0003-4125-0738; LEPLE, Jean charles/0000-0003-4125-0738; Lapierre, Catherine/0000-0002-6757-1524				ADLER E, 1948, ACTA CHEM SCAND, V2, P93, DOI 10.3891/acta.chem.scand.02-0093; Barcelo AR, 2001, PHYTOCHEMISTRY, V57, P1105, DOI 10.1016/S0031-9422(01)00050-4; Baucher M, 1998, CRIT REV PLANT SCI, V17, P125, DOI 10.1016/S0735-2689(98)00360-8; Baucher M, 1996, PLANT PHYSIOL, V112, P1479, DOI 10.1104/pp.112.4.1479; BECKER HD, 1980, J ORG CHEM, V45, P1596, DOI 10.1021/jo01297a010; BLAGBROUGH IS, 1982, TETRAHEDRON LETT, V23, P4843, DOI 10.1016/S0040-4039(00)85728-7; Boudet AM, 1998, TRENDS PLANT SCI, V3, P67, DOI 10.1016/S1360-1385(97)01176-X; CONNORS WJ, 1970, J ORG CHEM, V35, P1920, DOI 10.1021/jo00831a044; Dixon R, 1996, BIOTECHNOL BIOTEC EQ, V10, P45; Grima-Pettenati J, 1999, PLANT SCI, V145, P51, DOI 10.1016/S0168-9452(99)00051-5; HALPIN C, 1992, PLANT PHYSIOL, V98, P12, DOI 10.1104/pp.98.1.12; HALPIN C, 1994, PLANT J, V6, P339, DOI 10.1046/j.1365-313X.1994.06030339.x; Halpin C, 1998, PLANT J, V14, P545, DOI 10.1046/j.1365-313X.1998.00153.x; HIGUCHI T, 1994, J BIOTECHNOL, V37, P151, DOI 10.1016/0168-1656(94)90006-X; Ito T, 2002, J WOOD SCI, V48, P216, DOI 10.1007/BF00771370; Jung HG., 1990, MICROB PLANT OPPOR I, P173; Kim H, 2000, ORG LETT, V2, P2197, DOI 10.1021/ol005906o; LAPIERRE C, 1991, HOLZFORSCHUNG, V45, P61, DOI 10.1515/hfsg.1991.45.1.61; Lapierre C, 1999, PLANT PHYSIOL, V119, P153, DOI 10.1104/pp.119.1.153; Lapierre C, 2000, J AGR FOOD CHEM, V48, P2326, DOI 10.1021/jf991398p; LAPIERRE C, 1986, HOLZFORSCHUNG, V40, P113, DOI 10.1515/hfsg.1986.40.2.113; LAPIERRE C, 2001, 11 INT S WOOD PULP C, V2, P23; LAPIERRE C, 1993, FORAGE CELL WALL STR, V1, P133; Lu FC, 1997, J AGR FOOD CHEM, V45, P4655, DOI 10.1021/jf970539p; Lu FC, 1999, J AGR FOOD CHEM, V47, P1981, DOI 10.1021/jf981138s; LUNDQUIST K, 1983, ACTA CHEM SCAND B, V37, P734, DOI 10.3891/acta.chem.scand.37b-0734; NAKATSUBO F, 1975, HOLZFORSCHUNG, V29, P165, DOI 10.1515/hfsg.1975.29.5.165; PAVLIC AA, 1946, J AM CHEM SOC, V68, P1471, DOI 10.1021/ja01212a023; Pilate G, 2002, NAT BIOTECHNOL, V20, P607, DOI 10.1038/nbt0602-607; Provan GJ, 1997, J SCI FOOD AGR, V73, P133, DOI 10.1002/(SICI)1097-0010(199702)73:2&lt;133::AID-JSFA696&gt;3.0.CO;2-Q; QUIDEAU S, 1992, J AGR FOOD CHEM, V40, P1108, DOI 10.1021/jf00019a003; Ralph J, 1997, SCIENCE, V277, P235, DOI 10.1126/science.277.5323.235; Ralph J, 2001, PHYTOCHEMISTRY, V57, P993, DOI 10.1016/S0031-9422(01)00109-1; RALPH J, 1994, J CHEM SOC PERK T 1, P3485, DOI 10.1039/p19940003485; Ralph J, 1998, P NATL ACAD SCI USA, V95, P12803, DOI 10.1073/pnas.95.22.12803; RALPH J, 1983, J WOOD CHEM TECHNOL, V3, P161, DOI 10.1080/02773818308085158; Ralph J., 1999, PROGR LIGNOCELLULOSI, P55; Rolando C., 1992, METHODS LIGNIN CHEM, P334, DOI DOI 10.1007/978-3-642-74065-7_23; Sarkanen K.V., 1971, LIGNINS OCCURRENCE F; Savidge RA, 2001, PHYTOCHEMISTRY, V57, P1095, DOI 10.1016/S0031-9422(01)00142-X; Sederoff RR, 1999, CURR OPIN PLANT BIOL, V2, P145, DOI 10.1016/S1369-5266(99)80029-6; Stewart D, 1997, PLANTA, V201, P311, DOI 10.1007/s004250050072; Syrjanen K, 2000, J CHEM SOC PERK T 1, P183, DOI 10.1039/a907919j; TOLLIER MT, 1995, COLLOQ INRA, V69, P339; Tsai CJ, 1998, PLANT PHYSIOL, V117, P101, DOI 10.1104/pp.117.1.101; Vailhe MAB, 1998, J SCI FOOD AGR, V76, P505, DOI 10.1002/(SICI)1097-0010(199804)76:4&lt;505::AID-JSFA981&gt;3.0.CO;2-M; Whetten RW, 1998, ANNU REV PLANT PHYS, V49, P585, DOI 10.1146/annurev.arplant.49.1.585; Yahiaoui N, 1998, PLANTA, V204, P8, DOI 10.1007/s004250050224	48	69	71	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47412	47419		10.1074/jbc.M208860200	http://dx.doi.org/10.1074/jbc.M208860200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351655	Green Submitted, hybrid			2022-12-25	WOS:000179663700076
J	Koolpe, M; Dail, M; Pasquale, EB				Koolpe, M; Dail, M; Pasquale, EB			An ephrin mimetic peptide that selectively targets the EphA2 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; PHAGE DISPLAY LIBRARY; TUMOR VASCULATURE; CRYSTAL-STRUCTURE; LIGAND-BINDING; GROWTH-FACTOR; EXPRESSION; OVEREXPRESSION; CANCER; MOUSE	Eph receptor tyrosine kinases represent promising disease targets because they are differentially expressed in pathologic versus normal tissues. The EphA2 receptor is up-regulated in transformed cells and tumor vasculature where it likely contributes to cancer pathogenesis. To exploit EpbA2 as a therapeutic target, we used phage display to identify two related peptides that bind selectively to EphA2 with high affinity (submicromolar K-D values). The peptides target the ligand-binding domain of EphA2 and compete with ephrin ligands for binding. Remarkably, one of the peptides has ephrin-like activity in that it stimulates EphA2 tyrosine phosphorylation and signaling. Furthermore, this peptide can deliver phage particles to endothelial and tumor cells expressing EphA2. In contrast, peptides corresponding to receptor-interacting portions of ephrin ligands bind weakly and promiscuously to many Eph receptors. Bioactive ephrin mimetic peptides could be used to selectively deliver agents to Eph receptor-expressing tissues and modify Eph signaling in therapies for cancer, pathological angiogenesis, and nerve regeneration.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Pasquale, EB (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NCI NIH HHS [CA82713] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA082713] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRES AC, 1994, ONCOGENE, V9, P1461; Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, P NATL ACAD SCI USA, V99, P1527, DOI 10.1073/pnas.241655998; Carles-Kinch K, 2002, CANCER RES, V62, P2840; CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; DANIEL TO, 1996, KIDNEY INT S, V57, P73; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; Dodelet VC, 2000, ONCOGENE, V19, P5614, DOI 10.1038/sj.onc.1203856; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; DVORAK HF, 1988, AM J PATHOL, V133, P95; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; Essler M, 2002, P NATL ACAD SCI USA, V99, P2252, DOI 10.1073/pnas.251687998; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Flanagan JG, 1997, CELL, V90, P403; GANJU P, 1994, ONCOGENE, V9, P1613; Gerlag DM, 2001, ARTHRITIS RES, V3, P357, DOI 10.1186/ar327; Hess AR, 2001, CANCER RES, V61, P3250; Himanen JP, 1998, NATURE, V396, P486, DOI 10.1038/24904; Himanen JP, 2001, NATURE, V414, P933, DOI 10.1038/414933a; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Koivunen E, 1999, NAT BIOTECHNOL, V17, P768, DOI 10.1038/11703; KOIVUNEN E, 1994, J CELL BIOL, V124, P373, DOI 10.1083/jcb.124.3.373; KOIVUNEN E, 1993, J BIOL CHEM, V268, P20205; Labrador JP, 1997, EMBO J, V16, P3889, DOI 10.1093/emboj/16.13.3889; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Menzel P, 2001, DEV BIOL, V230, P74, DOI 10.1006/dbio.2000.0109; Miao H, 2001, NAT CELL BIOL, V3, P527, DOI 10.1038/35074604; Miranda JD, 1999, EXP NEUROL, V156, P218, DOI 10.1006/exnr.1998.7012; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Nemoto T, 1997, PATHOBIOLOGY, V65, P195, DOI 10.1159/000164123; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; Olson TA, 1997, INT J CANCER, V73, P865; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PASQUALINI R, 1995, J CELL BIOL, V130, P1189, DOI 10.1083/jcb.130.5.1189; Rajotte D, 1999, J BIOL CHEM, V274, P11593, DOI 10.1074/jbc.274.17.11593; Rodger J, 2001, EUR J NEUROSCI, V14, P1929, DOI 10.1046/j.0953-816x.2001.01822.x; RUIZ JC, 1994, MECH DEVELOP, V46, P87; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; WRIGHT RM, 1995, BIO-TECHNOL, V13, P165, DOI 10.1038/nbt0295-165; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YAYON A, 1993, P NATL ACAD SCI USA, V90, P10643, DOI 10.1073/pnas.90.22.10643; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2002, J CELL BIOCHEM, V85, P714, DOI 10.1002/jcb.10186; Zelinski DP, 2001, CANCER RES, V61, P2301	48	172	191	1	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46974	46979		10.1074/jbc.M208495200	http://dx.doi.org/10.1074/jbc.M208495200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351647	hybrid			2022-12-25	WOS:000179663700019
J	Montuori, N; Carriero, MV; Salzano, S; Rossi, G; Ragno, P				Montuori, N; Carriero, MV; Salzano, S; Rossi, G; Ragno, P			The cleavage of the urokinase receptor regulates its multiple functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR RECEPTOR; LIGAND-BINDING; CELL-MIGRATION; INTEGRINS; ADHESION; EXPRESSION; FORM; REQUIREMENT; CHEMOTAXIS; PLASMA	The urokinase-type plasminogen activator (uPA) is able to cleave its cell surface receptor (uPAR) anchored to the cell membrane through a glycophosphatidylinositol tail. The cleavage leads to the formation of cell surface truncated forms, devoid of the N-terminal domain 1 (D1) and unmasks or disrupts, depending on the cleavage site, a sequence in the D1-D2 linker region (residues 88-92), which in the soluble form is a potent chemoattractant for monocyte-like cells. To investigate the possible role(s) of the cleaved forms of cell surface glycophosphatidylinositol-anchored uPAR, uPAR-negative human embrional kidney 293 cells were transfected with the cDNA of intact uPAR (uPAR-293) or with cDNAs corresponding to the truncated forms of uPAR exposing (D2D3-293) or lacking (D2D3wc-293) the peptide 88-92 (P88-92). Cell adhesion assays and co-immunoprecipitation experiments indicated that the removal of D1, independently of the presence of P88-92, abolished the lateral interaction of uPAR with integrins and its capability to regulate integrin adhesive functions. The expression of intact uPAR induced also a moderate increase in 293 cell proliferation, which was accompanied by the activation of ERK. Also this effect was abolished by D1 removal, independently of the presence of P88-92. The expression of intact and truncated uPARs regulated cell directional migration toward uPA, the specific uPAR ligand, and toward fMLP, a bacterial chemotactic peptide. In fact, the uPA-dependent cell migration required the expression of intact uPAR, including D1, whereas the fMLP-dependent cell migration required the expression of a P88-92 containing uPAR and was independent of the presence of D1. Together these observations indicate that uPA-mediated uPAR cleavage and D1 removal, occurring on the cell surface of several cell types, can play a fundamental role in the regulation of multiple uPAR functions.	CNR, Ist Endocrinol & Oncol Sperimentale, I-80131 Naples, Italy; Natl Canc Inst, I-80131 Naples, Italy; Univ Naples Federico II, Dipartimento Biol & Patol Cellulare & Mol, I-80131 Naples, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto per Endocrinologia e Oncologia "Gaetano Salvatore" (IEOS-CNR); IRCCS Fondazione Pascale; University of Naples Federico II	Ragno, P (corresponding author), CNR, Ist Endocrinol & Oncol Sperimentale, Via Pansini 5, I-80131 Naples, Italy.	ragno@unina.it	Montuori, Nunzia/J-8542-2013; Carriero, Maria Vincenza/K-1240-2018	Carriero, Maria Vincenza/0000-0002-9768-2997; Montuori, Nunzia/0000-0001-8697-986X				Behrendt N, 1996, J BIOL CHEM, V271, P22885, DOI 10.1074/jbc.271.37.22885; BUSSO N, 1994, J CELL BIOL, V126, P259, DOI 10.1083/jcb.126.1.259; Carriero MV, 1999, CANCER RES, V59, P5307; DANO K, 1994, FIBRINOLYSIS, V8, P189, DOI 10.1016/0268-9499(94)90717-X; Degryse B, 2001, ONCOGENE, V20, P2032, DOI 10.1038/sj.onc.1204261; Deng G, 1996, J CELL BIOL, V134, P1563, DOI 10.1083/jcb.134.6.1563; Fazioli F, 1997, EMBO J, V16, P7279, DOI 10.1093/emboj/16.24.7279; FIBBI G, 1988, EXP CELL RES, V179, P385, DOI 10.1016/0014-4827(88)90277-7; Ghiso JAA, 1999, J CELL BIOL, V147, P89, DOI 10.1083/jcb.147.1.89; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; Holst-Hansen C, 1999, BRIT J CANCER, V81, P203, DOI 10.1038/sj.bjc.6690678; Hoyer-Hansen G, 1997, FEBS LETT, V420, P79, DOI 10.1016/S0014-5793(97)01491-9; Hoyer-Hansen G, 2001, BIOCHEM J, V358, P673, DOI 10.1042/0264-6021:3580673; HoyerHansen G, 1997, EUR J BIOCHEM, V243, P21, DOI 10.1111/j.1432-1033.1997.0021a.x; HOYERHANSEN G, 1992, J BIOL CHEM, V267, P18224; HOYERHANSEN G, 1993, BIOL VITRONECTIN THE; Irigoyen JP, 1999, CELL MOL LIFE SCI, V56, P104, DOI 10.1007/PL00000615; Koolwijk P, 2001, BLOOD, V97, P3123, DOI 10.1182/blood.V97.10.3123; Le YY, 2000, IMMUNOL REV, V177, P185, DOI 10.1034/j.1600-065X.2000.17704.x; Liang OD, 2001, J BIOL CHEM, V276, P28946, DOI 10.1074/jbc.M011437200; May AE, 1998, J EXP MED, V188, P1029, DOI 10.1084/jem.188.6.1029; MAZZIERI R, 1994, FIBRINOLYSIS, V8, P344, DOI 10.1016/0268-9499(94)90002-7; Montuori N, 1999, FEBS LETT, V460, P32, DOI 10.1016/S0014-5793(99)01314-9; Montuori N, 2000, FEBS LETT, V476, P166, DOI 10.1016/S0014-5793(00)01713-0; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Mustjoki S, 2000, CANCER RES, V60, P7126; Ossowski L, 2000, CURR OPIN CELL BIOL, V12, P613, DOI 10.1016/S0955-0674(00)00140-X; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; Ragno P, 1998, CANCER RES, V58, P1315; Resnati M, 2002, P NATL ACAD SCI USA, V99, P1359, DOI 10.1073/pnas.022652999; Resnati M, 1996, EMBO J, V15, P1572, DOI 10.1002/j.1460-2075.1996.tb00502.x; Rijneveld AW, 2002, J IMMUNOL, V168, P3507, DOI 10.4049/jimmunol.168.7.3507; RONNE E, 1995, BRIT J HAEMATOL, V89, P576, DOI 10.1111/j.1365-2141.1995.tb08366.x; Sidenius N, 2000, FEBS LETT, V470, P40, DOI 10.1016/S0014-5793(00)01282-5; Sier CFM, 1999, LAB INVEST, V79, P717; SOLBERG H, 1994, INT J CANCER, V58, P877, DOI 10.1002/ijc.2910580622; STOPPELLI MP, 2001, CELL INVASION, P128; Tarui T, 2001, J BIOL CHEM, V276, P3983, DOI 10.1074/jbc.M008220200; van der Pluijm G, 2001, AM J PATHOL, V159, P971, DOI 10.1016/S0002-9440(10)61773-7; Wahlberg K, 1998, CANCER RES, V58, P3294; WEI Y, 1994, J BIOL CHEM, V269, P32380; Wei Y, 2001, MOL BIOL CELL, V12, P2975, DOI 10.1091/mbc.12.10.2975; Wei Y, 1996, SCIENCE, V273, P1551, DOI 10.1126/science.273.5281.1551; Xue W, 1997, CANCER RES, V57, P1682; XUE W, 1994, J IMMUNOL, V152, P4630; Yebra M, 1996, J BIOL CHEM, V271, P29393, DOI 10.1074/jbc.271.46.29393; Zhou HM, 2000, EMBO J, V19, P4817, DOI 10.1093/emboj/19.17.4817	47	118	124	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46932	46939		10.1074/jbc.M207494200	http://dx.doi.org/10.1074/jbc.M207494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12297505	hybrid			2022-12-25	WOS:000179663700014
J	Novak, JP; Xu, WF; Brender, T; Yao, L; Jones, C; West, J; Brandt, C; Jelinek, L; Madden, K; McKernan, PA; Foster, DC; Jaspers, S; Chandrasekher, YA				Novak, JP; Xu, WF; Brender, T; Yao, L; Jones, C; West, J; Brandt, C; Jelinek, L; Madden, K; McKernan, PA; Foster, DC; Jaspers, S; Chandrasekher, YA			Interleukins 19, 20, and 24 signal through two distinct receptor complexes - Differences in receptor-ligand interactions mediate unique biological functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFERENTIATION-ASSOCIATED GENE; INTERFERON RECEPTOR; STAT FAMILY; MDA-7; EXPRESSION; PROTEINS; CYTOKINE; CLONING; PATHWAY; TRANSDUCTION	Cytokines that signal through Class II receptors form a distinct family that includes the interferons and interleukin 10 (IL-10). Recent identification of several IL-10 homologs has defined a cytokine subfamily that includes AK155, IL-19, IL-20, IL-22, and IL-24. Within this subfamily, IL-19, IL-20, and IL-24 exhibit substantial sharing of receptor complexes; all three are capable of signaling through IL-20RA/IL-20RB, and IL-20 and IL-24 both can also use IL-22R/IL-20RB. However, the biological effects of these three cytokines appear quite distinct: immune activity with IL-19, skin biology with IL-20, and tumor apoptosis with IL-24. To more fully elucidate their interactions with the receptor complexes, we have performed a series of in vitro assays. Reporter, proliferation, and direct STAT activation assays using cell lines expressing transfected receptors revealed differences between the receptor complexes. IL-19 and IL-24 also exhibited growth inhibition on a cell line endogenously expressing all three receptor subunits, an effect that was seen at cytokine levels two orders of magnitude above those required for STAT activation or proliferation. These results demonstrate that, although this subclass exhibits receptor complex redundancy, there are differences in ligand/receptor interactions and in signal transduction that may lead to specificity and a distinct biology for each cytokine.	Zymogenet Inc, Dept In Vitro Biol, Seattle, WA 98102 USA; Zymogenet Inc, Dept Cytokine & Receptor Biol, Seattle, WA 98102 USA; Zymogenet Inc, Dept Genet, Seattle, WA 98102 USA	Zymogenet Inc.; Zymogenet Inc.; Zymogenet Inc.	Chandrasekher, YA (corresponding author), Zymogenet Inc, Dept In Vitro Biol, 1201 Eastlake Ave E, Seattle, WA 98102 USA.							Aggarwal S, 2001, J INTERF CYTOK RES, V21, P1047, DOI 10.1089/107999001317205178; Akira S, 1999, STEM CELLS, V17, P138, DOI 10.1002/stem.170138; Blumberg H, 2001, CELL, V104, P9, DOI 10.1016/S0092-8674(01)00187-8; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Ding GJF, 1998, J BIOL CHEM, V273, P28897, DOI 10.1074/jbc.273.44.28897; Donnelly RP, 1999, J INTERF CYTOK RES, V19, P563, DOI 10.1089/107999099313695; Dumoutier L, 2001, J IMMUNOL, V167, P3545, DOI 10.4049/jimmunol.167.7.3545; Dumoutier L, 2000, P NATL ACAD SCI USA, V97, P10144, DOI 10.1073/pnas.170291697; Gallagher G, 2000, GENES IMMUN, V1, P442, DOI 10.1038/sj.gene.6363714; HAMILTON TC, 1983, CANCER RES, V43, P5379; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Ihle JN, 1998, ANN NY ACAD SCI, V865, P1, DOI 10.1111/j.1749-6632.1998.tb11157.x; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P9160, DOI 10.1073/pnas.93.17.9160; Knappe A, 2000, J VIROL, V74, P3881, DOI 10.1128/JVI.74.8.3881-3887.2000; Laskin DL, 2001, J LEUKOCYTE BIOL, V70, P163; Lebedeva IV, 2002, ONCOGENE, V21, P708, DOI 10.1038/sj.onc.1205116; MHASHILKAR M, 2000, P AM ASSOC CANC RES, V41, P752; Pataer A, 2002, CANCER RES, V62, P2239; Poulsen LK, 1998, J BIOL CHEM, V273, P6228, DOI 10.1074/jbc.273.11.6228; Saeki T, 2000, GENE THER, V7, P2051, DOI 10.1038/sj.gt.3301330; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; Semenzato G, 1996, CRIT REV CL LAB SCI, V33, P423, DOI 10.3109/10408369609084692; Soo C, 1999, J CELL BIOCHEM, V74, P1; Su ZZ, 1998, P NATL ACAD SCI USA, V95, P14400, DOI 10.1073/pnas.95.24.14400; Subramaniam PS, 1995, P NATL ACAD SCI USA, V92, P12270, DOI 10.1073/pnas.92.26.12270; Wang M, 2002, J BIOL CHEM, V277, P7341, DOI 10.1074/jbc.M106043200; Wehinger J, 1996, FEBS LETT, V394, P365, DOI 10.1016/0014-5793(96)00990-8; Wolk K, 2002, J IMMUNOL, V168, P5397, DOI 10.4049/jimmunol.168.11.5397; Xie MH, 2000, J BIOL CHEM, V275, P31335, DOI 10.1074/jbc.M005304200	31	219	296	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47517	47523		10.1074/jbc.M205114200	http://dx.doi.org/10.1074/jbc.M205114200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351624	hybrid			2022-12-25	WOS:000179663700089
J	Temiakov, D; Anikin, M; McAllister, WT				Temiakov, D; Anikin, M; McAllister, WT			Characterization of T7 RNA polymerase transcription complexes assembled on nucleic acid scaffolds	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELONGATION COMPLEXES; DNA HYBRID; KINETIC-ANALYSIS; INITIATION; PROMOTER; BACTERIOPHAGE-T7; PROCESSIVITY; MECHANISM; BINDING; BUBBLE	We have used synthetic oligomers of DNA and RNA to assemble nucleic acid scaffolds that, when mixed with T7 RNA polymerase, allow the formation of functional transcription complexes. Manipulation of the scaffold structure allows the contribution of each element in the scaffold to transcription activity to be independently determined. The minimal scaffold that allows efficient extension after challenge with 200 mM NaCl consists of an 8-nt RNA primer hybridized to a DNA template (T strand) that extends 5-10 nt downstream. Constructs in which the RNA-DNA hybrid is less than or greater than 8 bp are less salt-resistant, and the hybrid cannot be extended beyond 12-13 bp. Although the presence of a complementary nontemplate strand downstream of the primer does not affect salt resistance, the presence of DNA upstream decreases resistance. The addition of a 4-nt unpaired "tail" to the 5' end of the primer increases salt resistance, as does the presence of an impaired nontemplate strand in the region that contains the 8-bp hybrid (thereby generating an artificial transcription "bubble"). Scaffold complexes having these features remain active for over 1 week in the absence of salt and exhibit many of the properties of halted elongation complexes, including resistance to salt challenge, a similar trypsin cleavage pattern, and a similar pattern of RNA-RNA polymerase cross-linking.	SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, Brooklyn, NY 11203 USA	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center	McAllister, WT (corresponding author), SUNY Hlth Sci Ctr, Dept Microbiol & Immunol, Morse Inst Mol Genet, 450 Clarkson Ave, Brooklyn, NY 11203 USA.	pogo51@aol.com			NIGMS NIH HHS [R01 GM038147, R01 GM038147-14, GM38147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BASU S, 1986, J MOL BIOL, V190, P425, DOI 10.1016/0022-2836(86)90013-6; Brieba LG, 2001, EMBO J, V20, P6826, DOI 10.1093/emboj/20.23.6826; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Cheetham GMT, 1999, NATURE, V399, P80, DOI 10.1038/19999; DAUBE SS, 1994, BIOCHEMISTRY-US, V33, P340, DOI 10.1021/bi00167a044; DAUBE SS, 1992, SCIENCE, V258, P1320, DOI 10.1126/science.1280856; Diaz GA, 1996, BIOCHEMISTRY-US, V35, P10837, DOI 10.1021/bi960488+; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IKEDA RA, 1986, P NATL ACAD SCI USA, V83, P3614, DOI 10.1073/pnas.83.11.3614; Imburgio D, 2002, J MOL BIOL, V319, P37, DOI 10.1016/S0022-2836(02)00261-9; Jeruzalmi D, 1998, EMBO J, V17, P4101, DOI 10.1093/emboj/17.14.4101; Jia YP, 1997, BIOCHEMISTRY-US, V36, P4223, DOI 10.1021/bi9630467; Jia YP, 1996, J BIOL CHEM, V271, P30451, DOI 10.1074/jbc.271.48.30451; Jiang ML, 2001, J MOL BIOL, V310, P509, DOI 10.1006/jmbi.2001.4793; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Kireeva ML, 2000, J MOL BIOL, V299, P325, DOI 10.1006/jmbi.2000.3755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; LING ML, 1989, NUCLEIC ACIDS RES, V17, P1605, DOI 10.1093/nar/17.4.1605; Liu CH, 2002, J BIOL CHEM, V277, P2725, DOI 10.1074/jbc.M108856200; Liu CH, 2001, J MOL BIOL, V308, P465, DOI 10.1006/jmbi.2001.4601; Ma KY, 2002, J BIOL CHEM, V277, P43206, DOI 10.1074/jbc.M206658200; MARTIN CT, 1987, BIOCHEMISTRY-US, V26, P2690, DOI 10.1021/bi00384a006; MARTIN CT, 1988, BIOCHEMISTRY-US, V27, P3966, DOI 10.1021/bi00411a012; MASLAK M, 1993, BIOCHEMISTRY-US, V32, P4281, DOI 10.1021/bi00067a017; MCALLISTER WT, 1997, NUCL ACIDS MOL BIOL, V11, P15; Mentesana PE, 2000, J MOL BIOL, V302, P1049, DOI 10.1006/jmbi.2000.4114; MOOKHTIAR KA, 1991, BIOCHEMISTRY-US, V30, P6305, DOI 10.1021/bi00239a032; MULLER DK, 1988, BIOCHEMISTRY-US, V27, P5763, DOI 10.1021/bi00415a055; Place C, 1999, BIOCHEMISTRY-US, V38, P4948, DOI 10.1021/bi982689e; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)90921-R; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; SOUSA R, 1992, J MOL BIOL, V224, P319, DOI 10.1016/0022-2836(92)90997-X; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Temiakov D, 2000, PRACT APPROACH SER, P351; Temiakov D, 2000, P NATL ACAD SCI USA, V97, P14109, DOI 10.1073/pnas.250473197; TYAGARAJAN K, 1991, BIOCHEMISTRY-US, V30, P10920, DOI 10.1021/bi00109a016; Ujvari A, 1996, BIOCHEMISTRY-US, V35, P14574, DOI 10.1021/bi961165g; Ujvari A, 1997, J MOL BIOL, V273, P775, DOI 10.1006/jmbi.1997.1350; Villemain J, 1997, J MOL BIOL, V273, P958, DOI 10.1006/jmbi.1997.1358	40	38	41	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47035	47043		10.1074/jbc.M208923200	http://dx.doi.org/10.1074/jbc.M208923200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351656	hybrid			2022-12-25	WOS:000179663700028
J	Armstrong, S; Yates, SP; Merrill, AR				Armstrong, S; Yates, SP; Merrill, AR			Insight into the catalytic mechanism of Pseudomonas aeruginosa exotoxin A - Studies of toxin interaction with eukaryotic elongation factor-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION; FACTOR-II; DOMAIN-III; SACCHAROMYCES-CEREVISIAE; CONFORMATIONAL-CHANGES; ADENYLIC NUCLEOTIDES; TRYPTOPHAN RESIDUES; CRYSTAL-STRUCTURE; DIPHTHERIA-TOXIN; BINDING SITE	The molecular nature of the protein-protein interactions between the catalytic domain from Pseudomonas aeruginosa exotoxin A (PE24H) and its protein substrate, eukaryotic elongation factor-2 (eEF-2) were probed using a fluorescence resonance energy transfer method. Single cysteine mutant proteins of PE24H were prepared and site-specifically labeled with the donor fluorophore IAEDANS (5-(2-iodoacetylaminoethylamino)-1-napthalenesulfonic acid), whereas eEF-2 was labeled with the acceptor fluorophore fluorescein. The association was found to be independent of ionic strength and of the co-substrate, NAD(+) but dependent upon pH. The lack of requirement for NAD(+) to produce the toxin-eEF-2 complex demonstrates that the catalytic process is a random order mechanism, thereby disputing the current model. The previously observed pH dependence for catalytic function can be assigned to the toxin-eEF-2 binding event, as the pH dependence of binding observed in this study showed a strong correlation with enzymatic activity. The ability of the toxin to bind eEF-2 with bound GTP/GDP was assessed using nonhydrolyzable analogues. The results from the substrate binding and catalytic activity experiments indicate that PE24H is able to interact and bind with eEF-2 in all of its guanyl nucleotide-induced conformational states. Thus, the toxin ribosylates eEF-2 regardless of the nucleotide-charged state of eEF-2. These results represent the first detailed characterization of the molecular details and physiological conditions governing this protein-protein interaction.	Univ Guelph, Guelph Waterloo Ctr Grad Work Chem & Biochem, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada	University of Guelph; University of Waterloo; Guelph-Waterloo Centre for Graduate Work in Chemistry & Biochemistry	Merrill, AR (corresponding author), Univ Guelph, Guelph Waterloo Ctr Grad Work Chem & Biochem, Dept Chem & Biochem, Guelph, ON N1G 2W1, Canada.		Merrill, Rod/M-8313-2014; Armstrong, Souzan/R-9703-2019					ALLURED VS, 1986, P NATL ACAD SCI USA, V83, P1320, DOI 10.1073/pnas.83.5.1320; Althaus F R, 1987, Mol Biol Biochem Biophys, V37, P1; Armstrong S, 2001, ANAL BIOCHEM, V292, P26, DOI 10.1006/abio.2001.5052; Beattie BK, 1999, J BIOL CHEM, V274, P15646, DOI 10.1074/jbc.274.22.15646; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P9042, DOI 10.1021/bi960396k; Beattie BK, 1996, BIOCHEMISTRY-US, V35, P15134, DOI 10.1021/bi961985t; CARROLL SF, 1988, MOL MICROBIOL, V2, P293, DOI 10.1111/j.1365-2958.1988.tb00031.x; Domenighini M, 1996, MOL MICROBIOL, V21, P667, DOI 10.1046/j.1365-2958.1996.321396.x; DUMONTMISCOPEIN A, 1995, BBA-GENE STRUCT EXPR, V1263, P221, DOI 10.1016/0167-4781(95)00104-O; Elzaim HS, 1998, INFECT IMMUN, V66, P2170, DOI 10.1128/IAI.66.5.2170-2179.1998; GIOVANE A, 1987, BIOCHEM J, V244, P337, DOI 10.1042/bj2440337; Gonzalo P, 2000, BIOCHEMISTRY-US, V39, P13558, DOI 10.1021/bi000896k; HAN XY, 1995, J BIOL CHEM, V270, P679, DOI 10.1074/jbc.270.2.679; IGLEWSKI WJ, 1994, MOL CELL BIOCHEM, V138, P131, DOI 10.1007/BF00928454; KESSLER SP, 1992, J BIOL CHEM, V267, P19107; LAVERGNE JP, 1990, BIOCHIM BIOPHYS ACTA, V1048, P231, DOI 10.1016/0167-4781(90)90061-6; Li M, 1996, P NATL ACAD SCI USA, V93, P6902, DOI 10.1073/pnas.93.14.6902; LI M, 1995, P NATL ACAD SCI USA, V92, P9308, DOI 10.1073/pnas.92.20.9308; LUKAC M, 1988, BIOCHEMISTRY-US, V27, P7629, DOI 10.1021/bi00420a009; MATTHEAKIS LC, 1992, MOL CELL BIOL, V12, P4026, DOI 10.1128/MCB.12.9.4026; Mohammadi F, 2001, BIOCHEMISTRY-US, V40, P10273, DOI 10.1021/bi011035u; NILSSON L, 1985, EUR J BIOCHEM, V148, P299, DOI 10.1111/j.1432-1033.1985.tb08839.x; NILSSON L, 1988, EUR J BIOCHEM, V171, P293, DOI 10.1111/j.1432-1033.1988.tb13789.x; NYGARD O, 1990, EUR J BIOCHEM, V191, P1, DOI 10.1111/j.1432-1033.1990.tb19087.x; OPPENHEIMER NJ, 1981, J BIOL CHEM, V256, P8579; PERENTESIS JP, 1992, J BIOL CHEM, V267, P1190; Prentice GA, 1999, ANAL BIOCHEM, V272, P216, DOI 10.1006/abio.1999.4188; SANYAL G, 1993, BIOCHEMISTRY-US, V32, P3488, DOI 10.1021/bi00064a037; SONTAG B, 1993, BIOCHEMISTRY-US, V32, P1976, DOI 10.1021/bi00059a014; STEER BA, 1995, BIOCHEMISTRY-US, V34, P7225, DOI 10.1021/bi00021a038; VASIL ML, 1986, J PEDIATR-US, V108, P800, DOI 10.1016/S0022-3476(86)80748-X; Wedekind JE, 2001, J MOL BIOL, V314, P823, DOI 10.1006/jmbi.2001.5195; WU PG, 1994, ANAL BIOCHEM, V218, P1, DOI 10.1006/abio.1994.1134; Yates SP, 2001, J BIOL CHEM, V276, P35029, DOI 10.1074/jbc.M105002200	34	29	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46669	46675		10.1074/jbc.M206916200	http://dx.doi.org/10.1074/jbc.M206916200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270928	hybrid			2022-12-25	WOS:000179529300125
J	Choe, EY; Schoenberger, ES; Groopman, JE; Park, IW				Choe, EY; Schoenberger, ES; Groopman, JE; Park, IW			HIV Nef inhibits T cell migration	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 NEF; SH3 DOMAIN; ACTIVATION; PROTEIN; RECEPTOR; KINASE; CHEMOTAXIS; BINDING; DIFFERENTIATION; FACTOR-1-ALPHA	Nef is a viral regulatory protein of the human immunodeficiency virus (HIV) that has been shown to contribute to disease progression. Among its putative effects on T cell functions are the down-regulation of CD4 and major histocompatibility class I surface molecules. These effects occur in part via Nef interactions with intracellular signaling molecules. We sought to better characterize the effects of HIV Nef on T cell function by examining chemotaxis in response to stromal cell-derived factor-1alpha (SDF-1alpha) as well as CXCR4 signaling molecules. Here, we report the novel observation that HIV Nef inhibited chemotaxis in response to SDF-1alpha in both Jurkat T cells and primary peripheral CD4+ T lymphocytes. Our data indicate that HIV Nef altered critical downstream molecules in the CXCR4 pathway, including focal adhesion kinases. These findings suggest that HIV Nef may blunt the T cell response to chemokines. Because T lymphocyte migration is an integral component of host defense, HIV Nef may thereby contribute to the pathogenesis of AIDS.	Harvard Univ, Sch Med, Inst Med,Div Expt Med, Beth Israel Deaconess Med Ctr,BIDMC, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Groopman, JE (corresponding author), Harvard Univ, Sch Med, Inst Med,Div Expt Med, Beth Israel Deaconess Med Ctr,BIDMC, 4 Blackfan Circle,Rm 351, Boston, MA 02115 USA.	jgroopma@caregroup.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053745, R01HL061940] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53745, HL61940] Funding Source: Medline; NIDA NIH HHS [DA5008] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Baur AS, 1997, IMMUNITY, V6, P283, DOI 10.1016/S1074-7613(00)80331-3; BAUR AS, 1994, IMMUNITY, V1, P373, DOI 10.1016/1074-7613(94)90068-X; Brown A, 1999, J VIROL, V73, P9899, DOI 10.1128/JVI.73.12.9899-9907.1999; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Collette Y, 1996, J IMMUNOL, V156, P360; Collins KL, 1998, NATURE, V391, P397, DOI 10.1038/34929; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Cullen BR, 1999, NAT MED, V5, P985, DOI 10.1038/12417; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Denny MF, 2000, MOL CELL BIOL, V20, P1426, DOI 10.1128/MCB.20.4.1426-1435.2000; DU ZJ, 1995, CELL, V82, P665, DOI 10.1016/0092-8674(95)90038-1; Dutt P, 1998, J IMMUNOL, V161, P3652; Fackler OT, 2002, IMMUNITY, V16, P493, DOI 10.1016/S1074-7613(02)00307-2; FERNANDIS AZ, 2001, SCIENCES STKE; FOSTER R, 1998, J IMMUNOL, V160, P1522; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Graziani A, 1996, J BIOL CHEM, V271, P6590, DOI 10.1074/jbc.271.12.6590; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; Hannigan M, 2002, P NATL ACAD SCI USA, V99, P3603, DOI 10.1073/pnas.052010699; Hernandez-Lopez C, 2002, BLOOD, V99, P546, DOI 10.1182/blood.V99.2.546; Jimenez C, 2000, J CELL BIOL, V151, P249, DOI 10.1083/jcb.151.2.249; Karn T, 1998, VIROLOGY, V246, P45, DOI 10.1006/viro.1998.9157; KESTLER HW, 1991, CELL, V65, P651, DOI 10.1016/0092-8674(91)90097-I; Kiosses WB, 1999, J CELL BIOL, V147, P831, DOI 10.1083/jcb.147.4.831; LEE CH, 1995, EMBO J, V14, P5006, DOI 10.1002/j.1460-2075.1995.tb00183.x; LURIA S, 1991, P NATL ACAD SCI USA, V88, P5326, DOI 10.1073/pnas.88.12.5326; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Ottoson NC, 2001, J IMMUNOL, V167, P1857, DOI 10.4049/jimmunol.167.4.1857; Peacock JW, 1999, J IMMUNOL, V162, P215; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Renkema GH, 2000, FRONT BIOSCI-LANDMRK, V5, pD268, DOI 10.2741/Renkema; Renkema GH, 2001, J VIROL, V75, P2154, DOI 10.1128/JVI.75.5.2154-2160.2001; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; Ross TM, 1999, CURR BIOL, V9, P613, DOI 10.1016/S0960-9822(99)80283-8; Schibeci SD, 2000, AIDS, V14, P1701, DOI 10.1097/00002030-200008180-00003; Schrager JA, 2002, J BIOL CHEM, V277, P6137, DOI 10.1074/jbc.M107322200; Schrager JA, 1999, P NATL ACAD SCI USA, V96, P8167, DOI 10.1073/pnas.96.14.8167; Simmons A, 2001, IMMUNITY, V14, P763, DOI 10.1016/S1074-7613(01)00158-3; Stephens L, 2002, CURR OPIN CELL BIOL, V14, P203, DOI 10.1016/S0955-0674(02)00311-3; Swigut T, 2000, J VIROL, V74, P5691, DOI 10.1128/JVI.74.12.5691-5701.2000; Swingler S, 1999, NAT MED, V5, P997, DOI 10.1038/12433; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; Wang JK, 2000, P NATL ACAD SCI USA, V97, P394, DOI 10.1073/pnas.97.1.394; Weber KSC, 2001, MOL BIOL CELL, V12, P3074, DOI 10.1091/mbc.12.10.3074; Wolf D, 2001, NAT MED, V7, P1217, DOI 10.1038/nm1101-1217; Woo CH, 2002, J BIOL CHEM, V277, P8572, DOI 10.1074/jbc.M104766200; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	50	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46079	46084		10.1074/jbc.M204698200	http://dx.doi.org/10.1074/jbc.M204698200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12354773	hybrid			2022-12-25	WOS:000179529300050
J	Hu, JX; Reyes-Cruz, G; Chen, WZ; Jacobson, KA; Spiegel, AM				Hu, JX; Reyes-Cruz, G; Chen, WZ; Jacobson, KA; Spiegel, AM			Identification of acidic residues in the extracellular loops of the seven-transmembrane domain of the human Ca2+ receptor critical for response to Ca2+ and a positive allosteric modulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; CA2+-SENSING RECEPTOR; SIGNAL-TRANSDUCTION; ACTIVATING MUTATIONS; CHIMERIC RECEPTORS; ACID(B) RECEPTORS; TERMINAL DOMAIN; BINDING; ANTAGONIST	We investigated the role of the eight acidic residues in the extracellular loops (exo-loops) of the seven-transmembrane domain of the human Ca2+ receptor (hCaR) in receptor activation by Ca2+ and in response to a positive allosteric modulator, NPS R-568. Both in the context of the full-length receptor and of a truncated receptor lacking the extracellular domain (Rho-C-hCaR), we mutated each acidic residue to. alanine, singly and in combination, and tested the effect on expression of the receptor, on activation by Ca2+, and on NPS R-568 augmentation of sensitivity to Ca2+. Of the eight acidic residues, mutation of any of three in exo-loop 2, Asp(758), Glu(759), and Glu(767), increased the sensitivity of both the full-length hCaR and of Rho-C-hCaR to activation by Ca2+. Mutation of all five acidic residues in exo-loop 2, whether in the full-length receptor or in Rho-C-hCaR, impaired cell surface expression of the mutant receptor and thereby largely abolished response to Ca2+. Mutation of Glu(837) in exo-loop 3 to alanine did not alter Ca2+ sensitivity of the full-length receptor, but in both the latter context and in Rho-C-hCaR, alanine substitution of Glu(837) drastically reduced sensitivity to NPS R-568. Our data point to a key role of three specific acidic residues in exo-loop 2 in Wall activation and to Glu(837) at the junction between exo-loop 3 and transmembrane helix seven in response to NPS R-568. We speculate on the basis of these results that the three acidic residues we identified in exo-loop 2 help maintain an inactive conformation of the seven-transmembrane domain of the hCaR.	NIDCD, Mol Pathophysiol Sect, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Hu, JX (corresponding author), NIDCD, Mol Pathophysiol Sect, NIH, Bldg 10,Rm 8C-101,9000 Rockville Pike, Bethesda, MD 20892 USA.		Jacobson, Kenneth Alan/A-1530-2009	Jacobson, Kenneth Alan/0000-0001-8104-1493	Intramural NIH HHS [Z99 DK999999, Z01 DK031126-01] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [Z01DC000061] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Bai M, 1996, J BIOL CHEM, V271, P19537, DOI 10.1074/jbc.271.32.19537; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; BORCH RF, 1971, J AM CHEM SOC, V93, P2897, DOI 10.1021/ja00741a013; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Brown EM, 2000, CELL BIOCHEM BIOPHYS, V33, P63, DOI 10.1385/CBB:33:1:63; D'Souza-Li L, 2002, J CLIN ENDOCR METAB, V87, P1309, DOI 10.1210/jc.87.3.1309; Diaz R, 1997, AM J PHYSIOL-REG I, V273, pR1008, DOI 10.1152/ajpregu.1997.273.3.R1008; Flanagan JA, 2002, GEN COMP ENDOCR, V127, P117, DOI 10.1016/S0016-6480(02)00035-7; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Hu JX, 2002, J BONE MINER RES, V17, P1461, DOI 10.1359/jbmr.2002.17.8.1461; Knoflach F, 2001, P NATL ACAD SCI USA, V98, P13402, DOI 10.1073/pnas.231358298; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Litschig S, 1999, MOL PHARMACOL, V55, P453; Malitschek B, 1999, MOL PHARMACOL, V56, P448, DOI 10.1124/mol.56.2.448; Margeta-Mitrovic M, 2001, P NATL ACAD SCI USA, V98, P14643, DOI 10.1073/pnas.251554798; Naito T, 1998, P NATL ACAD SCI USA, V95, P5178, DOI 10.1073/pnas.95.9.5178; Nearing J, 2002, P NATL ACAD SCI USA, V99, P9231, DOI 10.1073/pnas.152294399; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; Ray K, 2002, J BIOL CHEM, V277, P18908, DOI 10.1074/jbc.M202113200; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; SAKAI K, 1993, B CHEM SOC JPN, V66, P3414, DOI 10.1246/bcsj.66.3414; Urwyler S, 2001, MOL PHARMACOL, V60, P963, DOI 10.1124/mol.60.5.963; Watanabe T, 1998, J CLIN ENDOCR METAB, V83, P2497, DOI 10.1210/jc.83.7.2497; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	31	71	76	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46622	46631		10.1074/jbc.M207100200	http://dx.doi.org/10.1074/jbc.M207100200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297503	Green Accepted, hybrid			2022-12-25	WOS:000179529300119
J	Krasnoperov, V; Lu, Y; Buryanovsky, L; Neubert, TA; Ichtchenko, K; Petrenko, AG				Krasnoperov, V; Lu, Y; Buryanovsky, L; Neubert, TA; Ichtchenko, K; Petrenko, AG			Post-translational proteolytic processing of the calciumin-dependent receptor of alpha-latrotoxin (CIRL), a natural chimera of the cell adhesion protein and the G protein-coupled recent - Role of the G protein-coupled receptor proteolysis site (GPS) motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SECRETIN FAMILY; MEMBER; 7-TRANSMEMBRANE; CLONING; CD97; SUPERFAMILY; HOMOLOGY; BINDING; DOMAIN	The calcium-independent receptor of a-latrotoxin (CIRL), a neuronal cell surface receptor implicated in the regulation of exocytosis, is a natural chimera of the cell adhesion protein and the G protein-coupled receptor (GPCR). In contrast with canonic GPCRs, CIRL consists of two heterologous non-covalently bound subunits, p120 and p85, due to endogenous proteolytic processing of the receptor precursor in the endoplasmic reticulum. Extracellularly oriented p120 contains hydrophilic cell adhesion domains, whereas p85 resembles a generic GPCR. We determined that the site of the CIRL cleavage is located within a juxtamembrane Cys- and Trp-rich domain of the N-terminal extracellular region of CIRL. Mutations in this domain make CIRL resistant to the cleavage and impair its trafficking. Therefore, we have named it GPS for G protein-coupled receptor proteolysis site. The GPS motif is found in homologous adhesion GPCRs and thus defines a novel receptor family. We postulate that the proteolytic processing and two-subunit structure is a common characteristic feature in the family of GPS-containing adhesion GPCRs.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Dept Physiol & Neurosci, New York, NY 10016 USA; NYU, Sch Med, Skirball Inst, New York, NY 10016 USA	New York University; New York University; New York University	Petrenko, AG (corresponding author), NYU, Ctr Med, Dept Pharmacol, 550 1St Ave,MSB-320A, New York, NY 10016 USA.			Petrenko, Alexander/0000-0002-6689-6546; Ichtchenko, Konstantin/0000-0002-2198-1325	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR014662] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059699] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035098] Funding Source: NIH RePORTER; NCRR NIH HHS [1 S10 RR14662-01] Funding Source: Medline; NIGMS NIH HHS [R01GM59699] Funding Source: Medline; NINDS NIH HHS [R01NS35098] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe J, 2002, J BIOL CHEM, V277, P23391, DOI 10.1074/jbc.M110877200; BAUD V, 1995, GENOMICS, V26, P334, DOI 10.1016/0888-7543(95)80218-B; Bittner MA, 1998, J NEUROSCI, V18, P2914; Coughlin SR, 2000, NATURE, V407, P258, DOI 10.1038/35025229; Gray JX, 1996, J IMMUNOL, V157, P5438; HAMANN J, 1995, J IMMUNOL, V155, P1942; Hamann J, 1996, J EXP MED, V184, P1185, DOI 10.1084/jem.184.3.1185; Hayflick JS, 2000, J RECEPT SIGNAL TR R, V20, P119, DOI 10.3109/10799890009150640; Ichtchenko K, 1999, J BIOL CHEM, V274, P5491, DOI 10.1074/jbc.274.9.5491; Krasnoperov V, 1999, J BIOL CHEM, V274, P3590, DOI 10.1074/jbc.274.6.3590; Krasnoperov VG, 1997, NEURON, V18, P925, DOI 10.1016/S0896-6273(00)80332-3; Lelianova VG, 1997, J BIOL CHEM, V272, P21504, DOI 10.1074/jbc.272.34.21504; McKnight AJ, 1996, J BIOL CHEM, V271, P486, DOI 10.1074/jbc.271.1.486; McMillan DR, 2002, J BIOL CHEM, V277, P785, DOI 10.1074/jbc.M108929200; Moy GW, 1996, J CELL BIOL, V133, P809, DOI 10.1083/jcb.133.4.809; Nechiporuk T, 2001, J BIOL CHEM, V276, P4150, DOI 10.1074/jbc.M004814200; Nishimori H, 1997, ONCOGENE, V15, P2145, DOI 10.1038/sj.onc.1201542; Osterhoff C, 1997, DNA CELL BIOL, V16, P379, DOI 10.1089/dna.1997.16.379; PETRENKO AG, 1993, J BIOL CHEM, V268, P1860; PETRENKO AG, 1990, EMBO J, V9, P2023, DOI 10.1002/j.1460-2075.1990.tb08331.x; PETRENKO AG, 1998, CELLULAR MOL MECH TO, P185; Ponting CP, 1999, CURR BIOL, V9, pR585, DOI 10.1016/S0960-9822(99)80379-0; Stacey M, 2002, J BIOL CHEM, V277, P29283, DOI 10.1074/jbc.M204306200; Stacey M, 2000, TRENDS BIOCHEM SCI, V25, P284, DOI 10.1016/S0968-0004(00)01583-8; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; Usui T, 1999, CELL, V98, P585, DOI 10.1016/S0092-8674(00)80046-X; Zhou A, 1999, J BIOL CHEM, V274, P20745, DOI 10.1074/jbc.274.30.20745	27	108	113	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46518	46526		10.1074/jbc.M206415200	http://dx.doi.org/10.1074/jbc.M206415200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270923	hybrid			2022-12-25	WOS:000179529300106
J	Leu, SJ; Lam, SCT; Lau, LF				Leu, SJ; Lam, SCT; Lau, LF			Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins alpha(v)beta(3) and alpha(6)beta(1) in human umbilical vein endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY GENE; TISSUE GROWTH-FACTOR; EXTRACELLULAR-MATRIX; BREAST-CANCER; MICE LACKING; ADHESION; ACTIVATION; EXPRESSION; PRODUCT; MIGRATION	CYR61 (CCN1) is an extracellular matrix-associated protein of the CCN family, which also includes CTGF (CCN2), NOV (CCN3), WISP-1 (CCN4), WISP-2 (CCN5), and WISP-3 (CCN6). Purified CYR61 induces neovascularization in corneal implants, and Cyr61-null mice suffer embryonic death due to vascular defects, thus establishing that CYR61 is an important regulator of angiogenesis. Aberrant expression of Cyr61 is associated with breast cancer, wound healing, and vascular diseases such as atherosclerosis and restenosis. In culture, CYR61 functions through integrin-mediated pathways to promote cell adhesion, migration, and proliferation. Here we show that CYR61 can also promote cell survival and tubule formation in human umbilical vein endothelial cells. Furthermore, we have dissected the integrin receptor requirements of CYR61 with respect to its proangiogenic activities. Thus, CYR61-induced cell adhesion and tubule formation occur through interaction with integrin alpha(6)beta(1) in early passage endothelial cells in which integrins have not been activated. By contrast, in endothelial cells in which integrins are activated by phorbol ester or vascular endothelial growth factor, CYR61-promoted cell adhesion, migration, survival, growth factor-induced mitogenesis, and endothelial tubule formation are all mediated through integrin alpha(v)beta(3). These findings indicate that CYR61 is an activation-dependent ligand of integrin alpha(v)beta(3) and an activation-independent ligand of integrin alpha(6)beta(1) and that these integrins differentially mediate the pro-angiogenic activities of CYR61. These findings help to define the mechanisms by which CYR61 acts as an angiogenic regulator, provide a molecular interpretation for the loss of vascular integrity and increased apoptosis of vascular cells in Cyr61-null mice, and underscore the importance of CYR61 in the development and homeostasis of the vascular system.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lau, LF (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, 900 S Ashland Ave, Chicago, IL 60607 USA.	lflau@uic.edu		Lau, Lester/0000-0002-4364-2914	NCI NIH HHS [CA80080, CA46565] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046565] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Babic AM, 1998, P NATL ACAD SCI USA, V95, P6355, DOI 10.1073/pnas.95.11.6355; Bader BL, 1998, CELL, V95, P507, DOI 10.1016/S0092-8674(00)81618-9; BAUER J, 1992, J CELL PHYSIOL, V153, P437, DOI 10.1002/jcp.1041530302; Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; BORNSTEIN P, 1995, J CELL BIOL, V130, P503, DOI 10.1083/jcb.130.3.503; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Byzova TV, 1998, J CELL BIOL, V143, P2081, DOI 10.1083/jcb.143.7.2081; Chen CC, 2001, J BIOL CHEM, V276, P10443, DOI 10.1074/jbc.M008087200; Chen CC, 2001, J BIOL CHEM, V276, P47329, DOI 10.1074/jbc.M107666200; Chen NY, 2000, J BIOL CHEM, V275, P24953, DOI 10.1074/jbc.M003040200; Dallabrida SM, 2000, J BIOL CHEM, V275, P32281, DOI 10.1074/jbc.M001446200; DAVIS GE, 1995, EXP CELL RES, V216, P113, DOI 10.1006/excr.1995.1015; Eliceiri BP, 2001, CURR OPIN CELL BIOL, V13, P563, DOI 10.1016/S0955-0674(00)00252-0; FASSLER R, 1995, GENE DEV, V9, P1896, DOI 10.1101/gad.9.15.1896; Folkman J, 2001, SEMIN ONCOL, V28, P536, DOI 10.1053/sonc.2001.29543; FRELINGER AL, 1991, J BIOL CHEM, V266, P17106; FRIDMAN R, 1990, P NATL ACAD SCI USA, V87, P6698, DOI 10.1073/pnas.87.17.6698; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Grzeszkiewicz TM, 2002, ENDOCRINOLOGY, V143, P1441, DOI 10.1210/en.143.4.1441; Grzeszkiewicz TM, 2001, J BIOL CHEM, V276, P21943, DOI 10.1074/jbc.M100978200; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; ISBERG RR, 1990, CELL, V60, P861, DOI 10.1016/0092-8674(90)90099-Z; Isik FF, 1998, J CELL PHYSIOL, V175, P149, DOI 10.1002/(SICI)1097-4652(199805)175:2<149::AID-JCP4>3.0.CO;2-O; Jedsadayanmata A, 1999, J BIOL CHEM, V274, P24321, DOI 10.1074/jbc.274.34.24321; Kanda S, 1999, EXP CELL RES, V248, P203, DOI 10.1006/excr.1999.4400; Kireeva ML, 1996, MOL CELL BIOL, V16, P1326; Kireeva ML, 1998, J BIOL CHEM, V273, P3090, DOI 10.1074/jbc.273.5.3090; Kireeva ML, 1997, EXP CELL RES, V233, P63, DOI 10.1006/excr.1997.3548; KLEIN S, 1993, MOL BIOL CELL, V4, P973, DOI 10.1091/mbc.4.10.973; Latinkic BV, 2001, ENDOCRINOLOGY, V142, P2549, DOI 10.1210/en.142.6.2549; Lau LF, 1999, EXP CELL RES, V248, P44, DOI 10.1006/excr.1999.4456; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; MO FE, 2002, IN PRESS MOL CELL BI; OBRIEN TP, 1990, MOL CELL BIOL, V10, P3569, DOI 10.1128/MCB.10.7.3569; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Perbal B, 2001, J CLIN PATHOL-MOL PA, V54, P57, DOI 10.1136/mp.54.2.57; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; RE F, 1994, J CELL BIOL, V127, P537, DOI 10.1083/jcb.127.2.537; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Sampath D, 2001, ENDOCRINOLOGY, V142, P2540, DOI 10.1210/en.142.6.2540; Schober JM, 2002, BLOOD, V99, P4457, DOI 10.1182/blood.V99.12.4457; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Smyth SS, 2002, J CELL BIOL, V158, P17, DOI 10.1083/jcb.200202100; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Su F, 2002, GENE DEV, V16, P46, DOI 10.1101/gad.942902; Tsai MS, 2000, CANCER RES, V60, P5603; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Xie D, 2001, J BIOL CHEM, V276, P14187, DOI 10.1074/jbc.M009755200; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; YANG GP, 1991, CELL GROWTH DIFFER, V2, P351; Yeh CH, 1999, EXP CELL RES, V251, P57, DOI 10.1006/excr.1999.4560	55	205	215	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46248	46255		10.1074/jbc.M209288200	http://dx.doi.org/10.1074/jbc.M209288200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12364323	hybrid			2022-12-25	WOS:000179529300073
J	Pahan, K; Jana, M; Liu, XJ; Taylor, BS; Wood, C; Fischer, SM				Pahan, K; Jana, M; Liu, XJ; Taylor, BS; Wood, C; Fischer, SM			Gemfibrozil, a lipid-lowering drug, inhibits the induction of nitric-oxide synthase in human astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ACTIVATED RECEPTOR-ALPHA; RAT PRIMARY ASTROCYTES; GLIAL-CELLS; TRANSCRIPTION FACTOR; CYTOKINE INDUCTION; MICROGLIAL CELLS; GENE-EXPRESSION; MESSENGER-RNA; DLD-1 CELLS	Gernfibrozil, a lipid-lowering drug, inhibited cytokine-induced production of NO and the expression of inducible nitric-oxide synthase (iNOS) in human U373MG astroglial cells and primary astrocytes. Similar to gemfibrozil, clofibrate, another fibrate drug, also inhibited the expression of iNOS. Inhibition of human iNOS promoter-driven luciferase activity by gernfibrozil in cytokine-stimulated U373MG astroglial cells suggests that this compound inhibits the transcription of iNOS. Since gemfibrozil is known to activate peroxisome proliferator-activated receptor-alpha (PPAR-alpha), we investigated the role of PPAR-alpha in gemfibrozil-mediated inhibition of iNOS. Gemfibrozil induced peroxisome proliferator-responsive element (PPRE)-dependent luciferase activity, which was inhibited by the expression of DeltahPPAR-alpha, the dominant-negative mutant of human PPAR-alpha. However, DeltahPPAR-alpha was unable to abrogate gemfibrozil-mediated inhibition of iNOS suggesting that gemfibrozil inhibits iNOS independent of PPAR-alpha. The human iNOS promoter contains consensus sequences for the binding of transcription factors, including interferon-gamma (IFN-gamma) regulatory factor-1 (IRF-1) binding to interferon-stimulated responsive element (ISRE), signal transducer and activator of transcription (STAT) binding to gamma-activation site (GAS), nuclear factor-kappaB (NF-kappaB), activator protein-1 (AP-1), and CCAAT/enhancer-binding protein beta (C/EBPbeta); therefore, we investigated the effect of gemfibrozil on the activation of these transcription factors. The combination of interleukin (IL)-1beta and IFN-gamma induced the activation of NF-kappaB, AP-1, C/EBPbeta, and GAS but not that of ISRE, suggesting that IRF-1 may not be involved in cytokine-induced expression of WOS in human astrocytes. Interestingly, gernfibrozil strongly inhibited the activation of NF-kappaB, AP-1, and C/EBPbeta but not that of GAS in cytokine-stimulated astroglial cells. These results suggest that gernfibrozil inhibits the induction of iNOS probably by inhibiting the activation of NF-kappaB, AP-1, and C/EBPbeta and that gemfibrozil, a prescribed drug for humans, may further find its therapeutic use in neuroinflammatory diseases.	Univ Nebraska, Med Ctr, Dept Oral Biol, Lincoln, NE 68583 USA; Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15261 USA; Univ Nebraska, Sch Biol Sci, Lincoln, NE 68588 USA; Univ Texas, MD Anderson Canc Inst, Smithville, TX 78957 USA	University of Nebraska System; University of Nebraska Lincoln; University of Nebraska Medical Center; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Nebraska System; University of Nebraska Lincoln; University of Texas System; UTMD Anderson Cancer Center	Pahan, K (corresponding author), Univ Nebraska, Med Ctr, Dept Oral Biol, 40th & Holdrege, Lincoln, NE 68583 USA.			Wood, Charles/0000-0002-4256-1530	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039940] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS039940, R01 NS039940-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; BLOOMFIELD RH, 2001, CIRCULATION, V103, P2828; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braun L, 1999, FEBS LETT, V458, P359, DOI 10.1016/S0014-5793(99)01184-9; Bright JJ, 1999, J IMMUNOL, V162, P6255; Coccia EM, 2000, INT IMMUNOL, V12, P977, DOI 10.1093/intimm/12.7.977; Cullingford TE, 1998, J NEUROCHEM, V70, P1366; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; deVera ME, 1996, P NATL ACAD SCI USA, V93, P1054, DOI 10.1073/pnas.93.3.1054; DRAPIER JC, 1988, J IMMUNOL, V140, P2829; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Elia G, 1996, CANCER RES, V56, P210; Feinstein DL, 1996, J BIOL CHEM, V271, P17724, DOI 10.1074/jbc.271.30.17724; FEINSTEIN DL, 1994, J NEUROCHEM, V62, P315; Fujimura M, 1997, BRAIN RES, V759, P247, DOI 10.1016/S0006-8993(97)00264-3; Gonzalez FJ, 1998, J NATL CANCER I, V90, P1702, DOI 10.1093/jnci/90.22.1702; Hsu HC, 2001, J LAB CLIN MED, V137, P414, DOI 10.1067/mlc.2001.114991; ILLINGWORTH DR, 1989, ARTERIOSCLEROSIS, V9, P1121; Jana M, 2001, J BIOL CHEM, V276, P44527, DOI 10.1074/jbc.M106771200; Kleinert H, 1998, BRIT J PHARMACOL, V125, P193, DOI 10.1038/sj.bjp.0702039; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7355, DOI 10.1073/pnas.91.15.7355; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; Kristof AS, 2001, J BIOL CHEM, V276, P8445, DOI 10.1074/jbc.M009563200; Laubach VE, 1997, BBA-GENE STRUCT EXPR, V1351, P287, DOI 10.1016/S0167-4781(96)06909-6; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; Linn SC, 1997, AM J PHYSIOL-GASTR L, V272, pG1499, DOI 10.1152/ajpgi.1997.272.6.G1499; Marks-Konczalik J, 1998, J BIOL CHEM, V273, P22201, DOI 10.1074/jbc.273.35.22201; MCCARTHY M, 1995, J NEUROVIROL, V1, P275, DOI 10.3109/13550289509114024; MERRILL JE, 1993, J IMMUNOL, V151, P2132; MITROVIC B, 1994, NEUROSCIENCE, V61, P575, DOI 10.1016/0306-4522(94)90435-9; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; Pahan K, 1997, J CLIN INVEST, V100, P2671, DOI 10.1172/JCI119812; Pahan K, 1997, J BIOL CHEM, V272, P7786, DOI 10.1074/jbc.272.12.7786; Pahan K, 2000, FEBS LETT, V472, P203, DOI 10.1016/S0014-5793(00)01465-4; Pahan K, 1998, J BIOL CHEM, V273, P12219, DOI 10.1074/jbc.273.20.12219; Pahan K, 2001, J BIOL CHEM, V276, P7899, DOI 10.1074/jbc.M008262200; Pahan K, 1999, J BIOL CHEM, V274, P7528, DOI 10.1074/jbc.274.11.7528; Pahan K, 2000, J NEUROCHEM, V74, P2288, DOI 10.1046/j.1471-4159.2000.0742288.x; RADI R, 1991, J BIOL CHEM, V266, P4244; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Roberts RA, 1998, CARCINOGENESIS, V19, P43, DOI 10.1093/carcin/19.1.43; Salzman AL, 2000, INT J MOL MED, V6, P209; Samdani AF, 1997, STROKE, V28, P1283, DOI 10.1161/01.STR.28.6.1283; Saura M, 1999, J MOL BIOL, V289, P459, DOI 10.1006/jmbi.1999.2752; Spitsin SV, 1996, MOL MED, V2, P226, DOI 10.1007/BF03401619; Taylor BS, 1998, J BIOL CHEM, V273, P15148, DOI 10.1074/jbc.273.24.15148; Taylor BS, 2000, SHOCK, V13, P413, DOI 10.1097/00024382-200006000-00001; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yeldandi AV, 2000, MUTAT RES-FUND MOL M, V448, P159, DOI 10.1016/S0027-5107(99)00234-1; Zhao ML, 1998, BRAIN RES, V813, P402, DOI 10.1016/S0006-8993(98)01023-3	53	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45984	45991		10.1074/jbc.M200250200	http://dx.doi.org/10.1074/jbc.M200250200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244038	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000179529300038
J	Sherameti, I; Sopory, SK; Trebicka, A; Pfannschmidt, T; Oelmuller, R				Sherameti, I; Sopory, SK; Trebicka, A; Pfannschmidt, T; Oelmuller, R			Photosynthetic electron transport determines nitrate reductase gene expression and activity in higher plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-REGULATED EXPRESSION; NITRITE-REDUCTASE; POSTTRANSCRIPTIONAL REGULATION; CHLOROPLAST; TRANSCRIPTION; PHYTOCHROME; LEAVES; INDUCTION; PROMOTER; AMMONIUM	The influence of photosynthetic electron flow in chloroplasts on the expression and enzyme activity of the cytosolic nitrate reductase (NR) was studied. Using light sources that predominantly excite either photosystem I (PSI) or photosystem II (PSII), we modulated photosynthetic electron transport in tobacco, Arabidopsis, and Lemna sprouts. In all instances, oxidation of components of photosynthetic electron flow by PSI light correlated with an increase in NR activity and/or transcription. This is confirmed by experiments with electron transport inhibitors 3-(3',4'-dichlorophenyl)-1,1'-dimethyl urea and 2,5-dibromo-3-methyl-6-isopropyl-p-benzoquinone. In addition, a Lemna mutant deficient in the cytochrome b(6)/f complex failed to respond to the different light sources and exhibited a constitutively high level of NR activity. These data indicate that NR is activated by the oxidized state of an electron transport component located after the plastoquinone pool. Am involvement of the cytoplasmic photoreceptor phytochrome A in this light regulation could be excluded, since an Arabidopsis phytochrome A mutant exhibited a wild-type like response. The observation that NR activity in the cytoplasm and the expression of its gene in the nucleus is controlled by signals from photosynthetic electron flow adds a new facet to the intracellular crosstalk between chloroplasts and the nucleus.	Inst Allgemeine Bot, Lehrstuhl Pflanzenphysiol, D-07743 Jena, Germany		Oelmuller, R (corresponding author), Univ Jena, Dept Plant Physiol, Inst Gen Bot, Dornburger Str 159, D-07743 Jena, Germany.	b7oera@uni-jena.de	Pfannschmidt, Thomas/AAH-5916-2021					Allen JF, 2000, PHILOS T R SOC B, V355, P1351, DOI 10.1098/rstb.2000.0697; APPENROTH KJ, 1992, PLANTA, V188, P587, DOI 10.1007/BF00197053; Appenroth KJ, 1996, BIOL PLANTARUM, V38, P95, DOI 10.1007/BF02879642; Aslam M, 1997, PHYSIOL PLANTARUM, V101, P612, DOI 10.1111/j.1399-3054.1997.tb01045.x; Bachmann M, 1996, FEBS LETT, V387, P127, DOI 10.1016/0014-5793(96)00478-4; BECKER TW, 1992, PLANTA, V188, P39, DOI 10.1007/BF00198937; BORNER T, 1986, PLANTA, V169, P202, DOI 10.1007/BF00392315; BRUCE BD, 1991, PLANT CELL, V3, P203, DOI 10.1105/tpc.3.2.203; Bueno MS, 1996, ACTA PHYSIOL PLANT, V18, P335; CABOCHE M, 1990, TRENDS GENET, V6, P187, DOI 10.1016/0168-9525(90)90175-6; Campbell WH, 1999, ANNU REV PLANT PHYS, V50, P277, DOI 10.1146/annurev.arplant.50.1.277; Campbell WH, 1996, PLANT PHYSIOL, V111, P355, DOI 10.1104/pp.111.2.355; CHENG CL, 1992, P NATL ACAD SCI USA, V89, P1861, DOI 10.1073/pnas.89.5.1861; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CRAWFORD NM, 1986, P NATL ACAD SCI USA, V83, P8073, DOI 10.1073/pnas.83.21.8073; CRAWFORD NM, 1995, PLANT CELL, V7, P859, DOI 10.1105/tpc.7.7.859; DanielVedele F, 1996, CR ACAD SCI III-VIE, V319, P961; DEANEDRUMMOND CE, 1980, PLANT CELL ENVIRON, V3, P303, DOI 10.1111/1365-3040.ep11581851; DENG MD, 1991, PLANT PHYSIOL BIOCH, V29, P239; DENG MD, 1990, PLANTA, V180, P257, DOI 10.1007/BF00194005; Douglas P, 1997, BIOCHEM J, V325, P101, DOI 10.1042/bj3250101; Douglas P, 1995, FEBS LETT, V377, P113, DOI 10.1016/0014-5793(95)01300-8; Geiger M, 1998, PLANT CELL ENVIRON, V21, P253, DOI 10.1046/j.1365-3040.1998.00277.x; GENTY B, 1989, BIOCHIM BIOPHYS ACTA, V990, P87, DOI 10.1016/S0304-4165(89)80016-9; GOWRI G, 1989, PLANT PHYSIOL, V90, P792, DOI 10.1104/pp.90.3.792; Hachtel W, 2000, PLANT SOIL, V221, P33, DOI 10.1023/A:1004739621352; HUBER JL, 1994, PLANT PHYSIOL, V106, P1667, DOI 10.1104/pp.106.4.1667; HUBER SC, 1997, PHYS PLANT, V98, P833; Hwang CF, 1997, PLANT PHYSIOL, V113, P853, DOI 10.1104/pp.113.3.853; JEFFERSON RA, 1987, EMBO J, V6, P3901; Kaiser WM, 1999, PHYSIOL PLANTARUM, V105, P385, DOI 10.1034/j.1399-3054.1999.105225.x; KAISER WM, 1991, PLANT PHYSIOL, V91, P970; KOJIMA M, 1995, PHYSIOL PLANTARUM, V93, P139, DOI 10.1034/j.1399-3054.1995.930120.x; Larios B, 2001, PLANTA, V212, P305, DOI 10.1007/s004250000395; Lejay L, 1997, PLANT PHYSIOL, V115, P623, DOI 10.1104/pp.115.2.623; LI XZ, 1993, PLANT PHYSIOL, V102, P1251, DOI 10.1104/pp.102.4.1251; Lillo C, 1998, J PHOTOCH PHOTOBIO B, V44, P205, DOI 10.1016/S1011-1344(98)00144-4; Lillo C, 1996, PLANTA, V200, P181, DOI 10.1007/BF00208307; Lillo C, 2001, BIOL RHYTHM RES, V32, P489, DOI 10.1076/brhm.32.4.489.1332; Lillo C, 2001, PLANT BIOLOGY, V3, P455, DOI 10.1055/s-2001-17732; LIN Y, 1994, PLANT PHYSIOL, V106, P477, DOI 10.1104/pp.106.2.477; LONG DM, 1992, PHYSIOL PLANTARUM, V85, P561, DOI 10.1111/j.1399-3054.1992.tb04755.x; LUBBERSTEDT T, 1994, MOL GEN GENET, V242, P602, DOI 10.1007/BF00285284; MOHR H, 1992, BOT ACTA, V105, P81, DOI 10.1111/j.1438-8677.1992.tb00270.x; MOHR H, 1984, TECHNIQUES PHOTOMORP, P12; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NUSSAUME L, 1995, PLANT CELL, V7, P611, DOI 10.1105/tpc.7.5.611; OELMULLER R, 1989, PHOTOCHEM PHOTOBIOL, V49, P229, DOI 10.1111/j.1751-1097.1989.tb04101.x; Ogawa K, 2000, J PLANT PHYSIOL, V157, P299, DOI 10.1016/S0176-1617(00)80051-6; Oswald O, 2001, P NATL ACAD SCI USA, V98, P2047, DOI 10.1073/pnas.021449998; PATTANAYAK D, 1988, J PLANT BIOCHEM BIOT, V7, P73; Pfannschmidt T, 1999, IUBMB LIFE, V48, P271, DOI 10.1080/713803507; Pfannschmidt T, 1999, NATURE, V397, P625, DOI 10.1038/17624; Pfannschmidt T, 2001, J BIOL CHEM, V276, P36125, DOI 10.1074/jbc.M105701200; PILGRIM ML, 1993, PLANT MOL BIOL, V23, P349, DOI 10.1007/BF00029010; Provan F, 1999, J PLANT PHYSIOL, V154, P605, DOI 10.1016/S0176-1617(99)80233-8; Raghuram N, 1999, BIOCHEM MOL BIOL INT, V47, P239; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; SCHUSTER C, 1989, PLANTA, V177, P74, DOI 10.1007/BF00392156; Sivasankar S, 1996, PLANT PHYSIOL BIOCH, V34, P609; Strater T, 2000, PLANT SCI, V150, P153, DOI 10.1016/S0168-9452(99)00182-X; VINCENTZ M, 1993, PLANT J, V3, P315, DOI 10.1046/j.1365-313X.1993.t01-16-00999.x; Wollman FA, 2001, EMBO J, V20, P3623, DOI 10.1093/emboj/20.14.3623; Yu XD, 1998, PLANT PHYSIOL, V116, P1091, DOI 10.1104/pp.116.3.1091	64	53	59	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46594	46600		10.1074/jbc.M202924200	http://dx.doi.org/10.1074/jbc.M202924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244040	hybrid			2022-12-25	WOS:000179529300115
J	Jonassen, T; Marbois, BN; Faull, KF; Clarke, CF; Larsen, PL				Jonassen, T; Marbois, BN; Faull, KF; Clarke, CF; Larsen, PL			Development and fertility in Caenorhabditis elegans clk-1 mutants depend upon transport of dietary coenzyme Q(8) to mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBICALLY FUNCTIONING EUKARYOTES; EMBRYONIC CELL LINEAGES; SACCHAROMYCES-CEREVISIAE; UBIQUINONE BIOSYNTHESIS; ELECTRON-TRANSPORT; LIFE-SPAN; GENE; YEAST; PROTEIN; CHAIN	The Caenorhabditis elegans clk-1 mutants lack coenzyme Q, and instead accumulate the biosynthetic intermediate demethoxy-Q(9) (DMQ(9)). clk-1 animals grow to reproductive adults, albeit slowly, if supplied with Q(8)-containing Escherichia coli. However, if Q is withdrawn from the diet, clk-1 animals either arrest development as young larvae or become sterile adults depending upon the stage at the time of the withdrawal. To understand this stage-dependent response to a Q-less diet, the quinone content was determined during development of wild-type animals. The quinone content varies in the different developmental stages in wild-type fed Q(8)-replete E. coli. The amounts peak at the second larval stage, which coincides with the stage of arrest of clk-1 larvae fed a Q-less diet from hatching. Levels of the endogenously synthesized DMQ(9) are high in the clk1(qmM30)-arrested larvae and sterile adults fed Q-less food. Comparison of quinones from animals fed a Q-replete or a Q-less diet establishes that the Q(8) present is assimilated from the E. coli. Furthermore, this E. colispecific Q(8) is present in mitochondria isolated from fertile clk-1(qm30) adults fed a Q-replete diet. These results suggest that the uptake and transport of dietary Q(8) to mitochondria prevent the arrest and sterility phenotypes of clk-1 mutants and that DMQ is not functionally equivalent to Q.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Larsen, PL (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.				NIGMS NIH HHS [GM 45952] Funding Source: Medline; PHS HHS [19777] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045952] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER S, 1974, GENETICS, V77, P71; Crane FL, 2001, J AM COLL NUTR, V20, P591, DOI 10.1080/07315724.2001.10719063; Do TQ, 2001, J BIOL CHEM, V276, P18161, DOI 10.1074/jbc.M100952200; Dutton PL, 2000, COENZYME Q OXIDATION, P65, DOI [10.1201/9781420036701.sec1b, DOI 10.1201/9781420036701.SEC1B]; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Felkai S, 1999, EMBO J, V18, P1783, DOI 10.1093/emboj/18.7.1783; Finckh B, 1995, ANAL BIOCHEM, V232, P210, DOI 10.1006/abio.1995.0009; Foll RL, 1999, COMP BIOCHEM PHYS B, V124, P269, DOI 10.1016/S0305-0491(99)00130-3; Glasgow BJ, 1998, BIOCHEMISTRY-US, V37, P2215, DOI 10.1021/bi9720888; Hihi AK, 2002, J BIOL CHEM, V277, P2202, DOI 10.1074/jbc.M109034200; Hsu AY, 1996, BIOCHEMISTRY-US, V35, P9797, DOI 10.1021/bi9602932; Jonassen T, 2001, P NATL ACAD SCI USA, V98, P421, DOI 10.1073/pnas.021337498; Jonassen T, 1998, J BIOL CHEM, V273, P3351, DOI 10.1074/jbc.273.6.3351; Jonassen T., 2000, COENZYME Q MOL MECH, P185; KAGAN VE, 1996, HDB ANTIOXIDANTS, P157; KHAN FR, 1982, EXP PARASITOL, V54, P47, DOI 10.1016/0014-4894(82)90109-6; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; Labrousse AM, 1999, MOL CELL, V4, P815, DOI 10.1016/S1097-2765(00)80391-3; Lakowski B, 1996, SCIENCE, V272, P1010, DOI 10.1126/science.272.5264.1010; Larsen PL, 2002, SCIENCE, V295, P120, DOI 10.1126/science.1064653; Lee PT, 1997, J BACTERIOL, V179, P1748, DOI 10.1128/jb.179.5.1748-1754.1997; LENAZ G, 1968, ARCH BIOCHEM BIOPHYS, V123, P539, DOI 10.1016/0003-9861(68)90175-6; Levavasseur F, 2001, J BIOL CHEM, V276, P46160, DOI 10.1074/jbc.M108980200; LIU ZC, 1991, NATURE, V350, P162, DOI 10.1038/350162a0; Lonnrot K, 1998, BIOCHEM MOL BIOL INT, V44, P727; Marbois BN, 1996, J BIOL CHEM, V271, P2995, DOI 10.1074/jbc.271.6.2995; Matthews RT, 1998, P NATL ACAD SCI USA, V95, P8892, DOI 10.1073/pnas.95.15.8892; Miyadera H, 2001, J BIOL CHEM, V276, P7713, DOI 10.1074/jbc.C000889200; NAGY M, 1992, P NATL ACAD SCI USA, V89, P8966, DOI 10.1073/pnas.89.19.8966; Nakai D, 2001, BIOCHEM BIOPH RES CO, V289, P463, DOI 10.1006/bbrc.2001.5977; Poon WW, 1999, J BIOL CHEM, V274, P21665, DOI 10.1074/jbc.274.31.21665; Proft M, 1995, EMBO J, V14, P6116, DOI 10.1002/j.1460-2075.1995.tb00302.x; Rotig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9; Santos-Ocana C, 2002, J BIOL CHEM, V277, P10973, DOI 10.1074/jbc.M112222200; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; Stenmark P, 2001, J BIOL CHEM, V276, P33297, DOI 10.1074/jbc.C100346200; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SUZUKI K, 1994, BIOSCI BIOTECH BIOCH, V58, P1814, DOI 10.1271/bbb.58.1814; Tielens AGM, 1998, BBA-BIOENERGETICS, V1365, P71, DOI 10.1016/S0005-2728(98)00045-0; Tsang WY, 2002, BIOCHEM BIOPH RES CO, V291, P8, DOI 10.1006/bbrc.2002.6394; Tsang WY, 2001, J BIOL CHEM, V276, P32240, DOI 10.1074/jbc.M103999200; Vande Weghe JG, 1999, J BIOL CHEM, V274, P13250, DOI 10.1074/jbc.274.19.13250; VanHellemond JJ, 1995, J BIOL CHEM, V270, P31065, DOI 10.1074/jbc.270.52.31065; VanHellemond JJ, 1996, MOL BIOCHEM PARASIT, V82, P217, DOI 10.1016/0166-6851(96)02738-7; WADSWORTH WG, 1989, DEV BIOL, V132, P167, DOI 10.1016/0012-1606(89)90214-5; WALLACE BJ, 1977, BIOCHIM BIOPHYS ACTA, V461, P75, DOI 10.1016/0005-2728(77)90070-6; WONG A, 1995, GENETICS, V139, P1247; Xia L, 2001, EUR J BIOCHEM, V268, P1486, DOI 10.1046/j.1432-1327.2001.02013.x; YOUNG IG, 1973, J BACTERIOL, V114, P42, DOI 10.1128/JB.114.1.42-52.1973	51	75	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45020	45027		10.1074/jbc.M204758200	http://dx.doi.org/10.1074/jbc.M204758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12324451	hybrid			2022-12-25	WOS:000179404800056
J	Kong, G; Chua, SS; Yi, YJ; Kittrell, F; Moraes, RC; Medina, D; Said, TK				Kong, G; Chua, SS; Yi, YJ; Kittrell, F; Moraes, RC; Medina, D; Said, TK			Functional analysis of cyclin D2 and p27(kip1) in cyclin D2 transgenic mouse mammary gland during development	ONCOGENE			English	Article						cyclin D2; transgenic mice; mammary gland development; cyclin D1 phosphorylation; p27(kip1)	G1 PHASE PROGRESSION; RETINOBLASTOMA PROTEIN; INCREASED EXPRESSION; BREAST CANCERS; CELL; D1; OVEREXPRESSION; ONCOGENE; GROWTH; MYC	Two mammary gland phenotypes were detected in pregnant MMTV-cyclin D2 transgenic mice; line D2-53 exhibited a lack of alveologenesis and failure to nurse, whereas line D2-58 featured a reduction in alveologenesis, but retained normal nursing behavior. In pregnant mammary glands, cyclin D2 protein levels were twofold (P<0.107) and 3.8-fold (P<0.0076) higher in line D258 and D2-53, respectively, compared to wild type. Concomitantly with the increase in cyclin D2 was a fivefold decrease in cyclin D1 hyper-phosphorylated isoform in mammary glands of pregnant cyclin D2-58 mice. Because cyclin D1 is a critical molecule in normal mammary lobuloalveolar development, these data suggest that overexpression of cyclin D2 may block mammary lobuloalveolar development through inhibition of cyclin D1 phosphorylation. During mammary gland development, p27(kip1) protein level oscillated in a similar profile in wild type and cyclin D2 transgenic mice, but was consistently higher in the cyclin D2 mice suggesting that P27(kip1) functions downstream of cyclin D2. The ratio of p27(kip1)-cdk4/p27(kip1)-cdk2 was 6.5-fold (P<0.0003) higher in cyclin D2 mammary glands compared to wild type in pregnant animals. This ratio reversed to 2.2-fold (P<0.005) higher in wild type compared to cyclin D2 mammary glands in involution suggesting that overexpression of cyclin D2 moderately induced apoptosis during pregnancy but accelerated involution. Collectively, the effects of cyclin D2 overexpression on mammary gland development during pregnancy and involution are attributed to two major factors, altered p27(kip1) protein level and inhibition of cyclin D1 phosphorylation.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Breast Ctr, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Said, TK (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.	tsaid@bcm.tmc.edu		Moraes, Ricardo/0000-0001-5455-092X	NATIONAL CANCER INSTITUTE [R01CA011944] Funding Source: NIH RePORTER; NCI NIH HHS [CA-11944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Barnes DM, 1998, BREAST CANCER RES TR, V52, P1, DOI 10.1023/A:1006103831990; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; Bouchard C, 1999, EMBO J, V18, P5321, DOI 10.1093/emboj/18.19.5321; BUCKLEY MF, 1993, ONCOGENE, V8, P2127; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; Evron E, 2001, CANCER RES, V61, P2782; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; Fantl V, 1999, DEV BIOL, V212, P1, DOI 10.1006/dbio.1999.9329; HAN EKH, 1995, ONCOGENE, V10, P953; Han EKH, 1996, CELL GROWTH DIFFER, V7, P699; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Harvey JM, 1999, J CLIN ONCOL, V17, P1474, DOI 10.1200/JCO.1999.17.5.1474; Houldsworth J, 1997, CELL GROWTH DIFFER, V8, P293; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Janz S, 1995, Curr Top Microbiol Immunol, V194, P373; JIANG W, 1993, ONCOGENE, V8, P3447; LAMMIE GA, 1991, ONCOGENE, V6, P439; LUKAS J, 1995, ONCOGENE, V10, P2125; Meyyappan M, 1998, MOL CELL BIOL, V18, P3163, DOI 10.1128/MCB.18.6.3163; MOTPOKURA T, 1991, NATURE, V350, P512; MURRAY AW, 1992, NATURE, V349, P603; NEVINS JR, 1992, SCIENCE, V258, P424; OCONNELL MJ, 1994, CURR OPIN CELL BIOL, V6, P867, DOI 10.1016/0955-0674(94)90058-2; Oyama T, 1998, CANCER RES, V58, P2876; PAGANO M, 1994, GENE DEV, V8, P1627, DOI 10.1101/gad.8.14.1627; Pajic A, 2000, INT J CANCER, V87, P787, DOI 10.1002/1097-0215(20000915)87:6<787::AID-IJC4>3.0.CO;2-6; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PESTKA S, 1987, ANNU REV BIOCHEM, V56, P727, DOI 10.1146/annurev.biochem.56.1.727; Rasmussen S. B., 2000, METHODS MAMMARY GLAN, P75; Ravanko K, 2000, CANCER RES, V60, P5244; ROSENBERG CL, 1991, ONCOGENE, V6, P449; ROSENBERG CL, 1991, P NATL ACAD SCI USA, V88, P9638, DOI 10.1073/pnas.88.21.9638; SAID TK, 1995, CARCINOGENESIS, V16, P823, DOI 10.1093/carcin/16.4.823; Said TK, 1998, MOL CARCINOGEN, V22, P128; SAID TK, 1995, CARCINOGENESIS, V16, P2507, DOI 10.1093/carcin/16.10.2507; Scovassi AI, 1997, EXP CELL RES, V237, P127, DOI 10.1006/excr.1997.3770; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; Sicinski P, 1997, J MAMMARY GLAND BIOL, V2, P335, DOI 10.1023/A:1026391128117; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; Yasogawa Y, 1998, PATHOL INT, V48, P717, DOI 10.1111/j.1440-1827.1998.tb03972.x; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500	44	19	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7214	7225		10.1038/sj.onc.1205895	http://dx.doi.org/10.1038/sj.onc.1205895			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370811				2022-12-25	WOS:000178504600009
J	Lee, KS; Hong, SH; Bae, SC				Lee, KS; Hong, SH; Bae, SC			Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein	ONCOGENE			English	Article						Runx2; junB; p38; TGF-beta 1; BMP-2; osteoblast	OSTEOBLAST DIFFERENTIATION; CLEIDOCRANIAL DYSPLASIA; GENE-EXPRESSION; MYOGENIC DIFFERENTIATION; C2C12 MYOBLASTS; DNA-BINDING; CBFA1; CELLS; OSF2/CBFA1; ACTIVATION	The Runx family of transcription factors plays pivotal roles during normal development and in neoptasias. In mammals, Runx family genes are composed of Runx1 (Pehp2alphaB/Chfa2/Aml1), Runx2 (Pebp2alphaA/Cbfa1/Aml3) and Runx3 (Pehp2alphaC/Cbfa3/Aml2). Runx1 and Runx3 are known to be involved in leukemogenesis and gastric carcinogenesis, respectively. Runx2, on the other hand, is a common target of transforming growth factor-beta1 (TGF-beta1) and bone morphogenetic protein-2 (BMP-2) and plays an essential role in osteoblast differentiation. Runx2 is induced by the receptor-activated Smad; Runx2 mediates the blockage of myogenic differentiation and induces osteoblast differentiation in C2C12 pluripotent mesenchymal precursor cells. However, Smad does not directly induce Runx2 expression; an additional step of de novo protein synthesis is required. Here we report that Smad-induced junB functions as an upstream activator of Runx2 expression. Furthermore, not only the Smad pathway but also the mitogen-activated protein kinase (MAPK) cascades are involved in the induction of Runx2 by TGF-beta1 and BMP-2. Our results demonstrate that following TGF-beta and RMP induction, both the Smad and p38 MAPK pathways converge at the Runx2 gene to control mesenchymal precursor cell differentiation.	Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea; Chungbuk Natl Univ, Inst Tumor Engn, Cheongju 361763, South Korea	Chungbuk National University; Chungbuk National University	Bae, SC (corresponding author), Chungbuk Natl Univ, Sch Med, Dept Biochem, Cheongju 361763, South Korea.	scbae@med.chungbuk.ac.kr						Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; Derynck R, 2001, NAT GENET, V29, P117, DOI 10.1038/ng1001-117; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Ducy P, 2000, DEV DYNAM, V219, P461, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1074>3.0.CO;2-C; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Gallea S, 2001, BONE, V28, P491, DOI 10.1016/S8756-3282(01)00415-X; Hanafusa H, 1999, J BIOL CHEM, V274, P27161, DOI 10.1074/jbc.274.38.27161; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Komori T, 1997, CELL, V89, P755, DOI 10.1016/S0092-8674(00)80258-5; Lee B, 1997, NAT GENET, V16, P307, DOI 10.1038/ng0797-307; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Li QL, 2002, CELL, V109, P113, DOI 10.1016/S0092-8674(02)00690-6; Lian J B, 1995, Iowa Orthop J, V15, P118; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Mundlos S, 1997, CELL, V89, P773, DOI 10.1016/S0092-8674(00)80260-3; Nishimura R, 1998, J BIOL CHEM, V273, P1872, DOI 10.1074/jbc.273.4.1872; Noguchi K, 2000, BIOCHEM BIOPH RES CO, V267, P221, DOI 10.1006/bbrc.1999.1952; North T, 1999, DEVELOPMENT, V126, P2563; Okuda T, 1996, CELL, V84, P321, DOI 10.1016/S0092-8674(00)80986-1; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; Otto F, 1997, CELL, V89, P765, DOI 10.1016/S0092-8674(00)80259-7; Reimold AM, 1996, NATURE, V379, P262, DOI 10.1038/379262a0; ROBERTS AB, 1988, RECENT PROG HORM RES, V44, P157; Sambrook J, 1988, MOL CLONING LAB MANU; Vaillant F, 1999, ONCOGENE, V18, P7124, DOI 10.1038/sj.onc.1203202; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao ZS, 1999, J CELL BIOCHEM, V74, P596, DOI 10.1002/(SICI)1097-4644(19990915)74:4<596::AID-JCB9>3.0.CO;2-F; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Yokomizo T, 2001, GENES CELLS, V6, P13, DOI 10.1046/j.1365-2443.2001.00393.x; Zhang YW, 2000, P NATL ACAD SCI USA, V97, P10549, DOI 10.1073/pnas.180309597	36	263	293	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7156	7163		10.1038/sj.onc.1205937	http://dx.doi.org/10.1038/sj.onc.1205937			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370805				2022-12-25	WOS:000178504600003
J	Rockwood, LD; Torrey, TA; Kim, JS; Coleman, AE; Kovalchuk, AL; Xiang, S; Ried, T; Morse, HC; Janz, S				Rockwood, LD; Torrey, TA; Kim, JS; Coleman, AE; Kovalchuk, AL; Xiang, S; Ried, T; Morse, HC; Janz, S			Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations	ONCOGENE			English	Article						in vivo mutant rates; MYC; mutator phenotype; B-cell neoplasia; genomic instability	DOUBLE TRANSGENIC MICE; IN-VIVO MUTATIONS; DNA; SELECTION; TARGET; MODEL	lambda-MYC-induced mouse Burkitt lymphoma (BL) harboring the shuttle vector pUR288, which includes a lacZ reporter gene to study mutagenesis, was employed to assess genomic instability associated with MYC deregulation. The frequency of lacZ mutations in lymphomas was elevated only 1.75-fold above that in normal tissue, indicating that mouse BL does not exhibit a phenotype of hypermutability. However, the nature of lacZ mutations was strikingly different in normal tissues and lymphomas. While point mutations comprised approximately 75% of the mutations found in normal tissues, apparent translocations, deletions and inversions constituted the majority of mutations (similar to65%) in lymphomas. Genomic instability in mouse BL thus seems characterized by a preponderance of illegitimate genetic rearrangements in the context of near-background mutant frequencies. SKY analyses of cell lines from primary BL tumors revealed substantial changes in chromosomal structure, confirming the lacZ studies. Bi-allelic deletions of the tumor suppressor p16(Ink4a) were detected in six out of 16 cell lines, illustrating cellular selection of advantageous mutations. Together, these approaches indicate that MYC may contribute to lymphomagenesis through the dominant mutator effect of inducing chromosomal instability. The results further suggest that a phenotype of hypermutability (elevated mutant frequency) may not always be required for oncogenesis to occur.	NCI, Genet Lab, CCR, Bethesda, MD 20892 USA; NIAID, Immunopathol Lab, Bethesda, MD 20892 USA; NCI, Genet Branch, CCR, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Janz, S (corresponding author), NCI, Genet Lab, CCR, Bldg 37,Room 2B10, Bethesda, MD 20892 USA.			Morse, Herbert/0000-0002-9331-3705; Kovalchuk, Alexander/0000-0003-2761-0442	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000858, Z01AI000858] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; BOERRIGTER METI, 1995, NATURE, V377, P657, DOI 10.1038/377657a0; Buettner VL, 1996, ONCOGENE, V13, P2407; Cole MD, 1999, ONCOGENE, V18, P2916, DOI 10.1038/sj.onc.1202748; Coleman AE, 2000, GENE CHROMOSOME CANC, V29, P70, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1009>3.0.CO;2-C; Davis CD, 1996, MUTAT RES-FUND MOL M, V356, P287, DOI 10.1016/0027-5107(96)00074-7; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Eischen CM, 2001, MOL CELL BIOL, V21, P5063, DOI 10.1128/MCB.21.15.5063-5070.2001; Felsher DW, 2000, P NATL ACAD SCI USA, V97, P10544, DOI 10.1073/pnas.190327097; GOSSEN JA, 1989, P NATL ACAD SCI USA, V86, P7971, DOI 10.1073/pnas.86.20.7971; Jakubczak JL, 1996, P NATL ACAD SCI USA, V93, P9073, DOI 10.1073/pnas.93.17.9073; KOHLER SW, 1991, ENVIRON MOL MUTAGEN, V18, P316, DOI 10.1002/em.2850180421; Kovalchuk AL, 2000, J EXP MED, V192, P1183, DOI 10.1084/jem.192.8.1183; Liyanage M, 1996, NAT GENET, V14, P312, DOI 10.1038/ng1196-312; LOEB LA, 1991, CANCER RES, V51, P3075; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; MUSHINSKI JF, 2002, IN PRESS CRIT REV ON; Roth D., 1988, GENETIC RECOMBINATIO, P621; Tomlinson I, 1999, NAT MED, V5, P11, DOI 10.1038/4687	19	23	23	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7235	7240		10.1038/sj.onc.1205697	http://dx.doi.org/10.1038/sj.onc.1205697			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370814				2022-12-25	WOS:000178504600012
J	MacFarlane, M; Harper, N; Snowden, RT; Dyer, MJS; Barnett, GA; Pringle, JH; Cohen, GM				MacFarlane, M; Harper, N; Snowden, RT; Dyer, MJS; Barnett, GA; Pringle, JH; Cohen, GM			Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia	ONCOGENE			English	Article						caspases; CD95; c-FLIP; IAPs; DISC	FLICE-INHIBITORY PROTEIN; FAS-MEDIATED APOPTOSIS; SIGNALING COMPLEX; CANCER-CELLS; CD95-MEDIATED APOPTOSIS; CASPASE-8 ACTIVATION; LEUKEMIA CELLS; DEATH DOMAIN; APO-2 LIGAND; RECEPTOR	Primary B cells from B cell chronic lymphocytic leukaemia (B-CLL) were resistant to the novel selective cytotoxic agent, TNF-related apoptosis-inducing ligand (TRAIL). Low levels of the death-inducing TRAIL receptors, TRAIL-R1 and TRAIL-R2 but not the putative 'decoy' receptors, TRAIL-R3 and TRAIL-R4, were expressed on the surface of B-CLL cells. Resistance to TRAIL was upstream of caspase-8 activation, as little or no caspase-8 was processed in TRAIL-treated B-CLL cells. Low levels of a TRAIL death-inducing signalling complex (DISC) were formed in these cells, accompanied by the recruitment of endogenous FADD, caspase-8 and c-FLIPL but not c-FLIPS. Both caspase-8 and c-FLIPL were cleaved to form two stable intermediates of similar to43 kDa, which remained associated with the DISC. Caspase-8 was not further processed to its active heterotetramer. Thus the resistance of B-CLL cells to TRAIL may be due partly to low surface expression of the death receptors resulting in low levels of DISC formation and also to the high ratio of c-FLIPL to caspase-8 within the DISC, which would prevent further activation of caspase-8. Our results highlight the possibility of sensitising B-CLL cells to TRAIL by modulation of c-FLIP levels or by upregulation of surface expression of death receptors.	Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; Univ Leicester, Dept Pathol, Leicester Royal Infirm, Leicester LE2 7LX, Leics, England; Univ Leicester, Dept Hematol, Leicester Royal Infirm, Leicester LE2 7LX, Leics, England	University of Leicester; University of Leicester; University of Leicester	Cohen, GM (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,POB 138,Lancaster Rd, Leicester LE1 9HN, Leics, England.		Cohen, Gerald M/A-1687-2008; Dyer, Martin/F-2691-2014	Dyer, Martin/0000-0002-5033-2236				Ahmad M, 2000, ONCOGENE, V19, P3363, DOI 10.1038/sj.onc.1203679; Almond JB, 2001, LEUKEMIA, V15, P1388, DOI 10.1038/sj.leu.2402201; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Bodmer JL, 2000, NAT CELL BIOL, V2, P241, DOI 10.1038/35008667; Boldin MP, 1996, CELL, V85, P803, DOI 10.1016/S0092-8674(00)81265-9; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; Fulda S, 2000, CANCER RES, V60, P3947; Griffith TS, 1998, J IMMUNOL, V161, P2833; Griffith TS, 1999, J IMMUNOL, V162, P2597; Harper N, 2001, J BIOL CHEM, V276, P34743, DOI 10.1074/jbc.M105693200; Hennino A, 2000, J IMMUNOL, V165, P3023, DOI 10.4049/jimmunol.165.6.3023; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Jo M, 2000, NAT MED, V6, P564, DOI 10.1038/75045; Keane MM, 1999, CANCER RES, V59, P734; Keogh SA, 2000, FEBS LETT, V471, P93, DOI 10.1016/S0014-5793(00)01375-2; Kim KH, 2000, CLIN CANCER RES, V6, P335; King D, 1998, LEUKEMIA, V12, P1553, DOI 10.1038/sj.leu.2401153; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; KISCHKEL FC, 1995, EMBO J, V14, P5579, DOI 10.1002/j.1460-2075.1995.tb00245.x; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lee SH, 1999, ONCOGENE, V18, P3754, DOI 10.1038/sj.onc.1202769; Leverkus M, 2000, CANCER RES, V60, P553; MacFarlane M, 2000, J CELL BIOL, V148, P1239, DOI 10.1083/jcb.148.6.1239; Marsters SA, 1996, CURR BIOL, V6, P750, DOI 10.1016/S0960-9822(09)00456-4; Mori S, 1999, J IMMUNOL, V162, P5616; Munshi A, 2001, ONCOGENE, V20, P3757, DOI 10.1038/sj.onc.1204504; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; OBRIEN KAF, 1987, TOXICOL IN VITRO, V1, P85, DOI 10.1016/0887-2333(87)90005-1; Pai SI, 1998, CANCER RES, V58, P3513; Plumas J, 1998, BLOOD, V91, P2875, DOI 10.1182/blood.V91.8.2875.2875_2875_2885; Rasper DM, 1998, CELL DEATH DIFFER, V5, P271, DOI 10.1038/sj.cdd.4400370; ROZMAN C, 1995, NEW ENGL J MED, V333, P1052, DOI 10.1056/NEJM199510193331606; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Scaffidi C, 1997, J BIOL CHEM, V272, P26953, DOI 10.1074/jbc.272.43.26953; Snell V, 1997, BRIT J HAEMATOL, V99, P618, DOI 10.1046/j.1365-2141.1997.4393250.x; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tepper CG, 1999, BLOOD, V94, P1727, DOI 10.1182/blood.V94.5.1727.417k03_1727_1737; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang DK, 1997, BRIT J HAEMATOL, V97, P409, DOI 10.1046/j.1365-2141.1997.422688.x; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Willems F, 2000, BLOOD, V95, P3478, DOI 10.1182/blood.V95.11.3478.011k10_3478_3482; Xerri L, 1998, BRIT J CANCER, V78, P225, DOI 10.1038/bjc.1998.469; Xerri L, 1997, LEUKEMIA, V11, P1868, DOI 10.1038/sj.leu.2400815; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954; Zhang J, 1996, MOL CELL BIOL, V16, P2756; Zhou T, 1999, NAT MED, V5, P42, DOI 10.1038/4723	56	166	170	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6809	6818		10.1038/sj.onc.1205853	http://dx.doi.org/10.1038/sj.onc.1205853			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360407				2022-12-25	WOS:000178315800011
J	Lee, HJ; Lee, SJ				Lee, HJ; Lee, SJ			Characterization of cytoplasmic alpha-synuclein aggregates - Fibril formation is tightly linked to the inclusion-forming process in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; PROTEIN AGGREGATION; IN-VITRO; NEURODEGENERATIVE DISEASES; ALZHEIMERS-DISEASE; BODY FORMATION; PATHOGENESIS; OLIGOMERIZATION; FIBRILLIZATION; AGGRESOMES	The alpha-synuclein fibrillation process has been associated with the pathogenesis of several neurodegenerative diseases. Here, we have characterized the cytoplasmic alpha-synuclein aggregates using a fractionation procedure with which different aggregate species can be separated. Overexpression of alpha-synuclein in cells produce two distinct types of aggregates: large juxtanuclear inclusion bodies and small punctate aggregates scattered throughout the cytoplasm. Biochemical fractionation results in an inclusion-enriched fraction and two small aggregate fractions. Electron microscopy and thioflavin S reactivity of the fractions show that the juxtanuclear inclusion bodies are filled with amyloid-like alpha-synuclein fibrils, whereas both the small aggregate fractions contain non-fibrillar spherical aggregates with distinct size distributions. These aggregates appear sequentially, with the smallest population appearing the earliest and the fibrillar inclusions the latest. Based on the structural and kinetic properties, we suggest that the small spherical aggregates are the cellular equivalents of the protofibrils. The proteins that co-exist in the Lewy bodies, such as proteasome subunit, ubiquitin, and hsp70 chaperone, are present in the fibrillar inclusions but absent in the protofibrils, suggesting that these proteins may not be directly involved in the early aggregation stage. As predicted in the aggresome model, disruption of microtubules with nocodazole reduced the number of inclusions and increased the size of the protofibrils. Despite the increased size, the protofibrils remained non-fibrillar, suggesting that the deposition of the protofibrils in the juxtanuclear region is important in fibril formation. This study provides evidence that the cellular fibrillation also involves non-fibrillar intermediate species, and the microtubule-dependent inclusion-forming process is required for the protofibril-to-fibril conversion in cells.	Parkinsons Inst, Sunnyvale, CA 94089 USA		Lee, SJ (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.			Lee, Seung-Jae/0000-0002-5155-5335				Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; Bouley DM, 2001, INFECT IMMUN, V69, P7820, DOI 10.1128/IAI.69.12.7820-7831.2001; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Gosavi N, 2002, J BIOL CHEM, V277, P48984, DOI 10.1074/jbc.M208194200; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Li J, 2001, BIOCHEMISTRY-US, V40, P11604, DOI 10.1021/bi010616g; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Poirier MA, 2002, J BIOL CHEM, V277, P41032, DOI 10.1074/jbc.M205809200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rajan RS, 2001, P NATL ACAD SCI USA, V98, P13060, DOI 10.1073/pnas.181479798; Serio TR, 2000, SCIENCE, V289, P1317, DOI 10.1126/science.289.5483.1317; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P43495, DOI 10.1074/jbc.C100551200; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509	40	140	151	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48976	48983		10.1074/jbc.M208192200	http://dx.doi.org/10.1074/jbc.M208192200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351642	hybrid			2022-12-25	WOS:000179789600130
J	Okada, T; Sonoda, E; Yamashita, YM; Koyoshi, S; Tateishi, S; Yamaizumi, M; Takata, M; Ogawa, O; Takeda, S				Okada, T; Sonoda, E; Yamashita, YM; Koyoshi, S; Tateishi, S; Yamaizumi, M; Takata, M; Ogawa, O; Takeda, S			Involvement of vertebrate Pol kappa in Rad18-independent postreplication repair of UV damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-KAPPA; ESCHERICHIA-COLI; HOMOLOGOUS RECOMBINATION; TRANSLESION SYNTHESIS; SACCHAROMYCES-CEREVISIAE; CHROMOSOMAL INTEGRITY; GENE ENCODES; RAD18 GENE; MUTAGENESIS; DINB1	DNA damage, which is left unrepaired by excision repair pathways, often blocks replication, leading to lesions such as breaks and gaps on the sister chromatids. These lesions may be processed by either homologous recombination (HR) repair or translesion DNA synthesis (TLS). Vertebrate Polkappa belongs to the DNA polymerase Y family, as do most TLS polymerases. However, the role for Polkappa in vertebrate cells is unclear because of the lack of reverse genetic studies. Here, we generated cells deficient in Polkappa (polkappa cells) from the chicken B lymphocyte line DT40. Although purified Polkappa is unable to bypass ultraviolet (UV) damage, polkappa cells exhibited increased UV sensitivity, and the phenotype was suppressed by expression of human and chicken polkappa, suggesting that Polkappa is involved in TLS of UV photoproduct. Defects in both Polkappa and Rad18, which regulates TLS in yeast, in DT40 showed an additive effect on UV sensitivity. Interestingly, the level of sister chromatid exchange, which reflects HR-mediated repair, was elevated in normally cycling polkappa cells. This implies functional redundancy between HR and Polkappa in maintaining chromosomal DNA. In conclusion, vertebrate Polkappa is involved in Rad18-independent TLS of UV damage and plays a role in maintaining genomic stability.	Kyoto Univ, Dept Radiat Genet, Sch Med, Sakyo Ku, Kyoto 6068501, Japan; Kyoto Univ, Grad Sch Med, Dept Urol, Kyoto 6068507, Japan; Kumamoto Univ, Sch Med, Inst Mol Embryol & Genet, Kumamoto 8620976, Japan; Kawasaki Med Coll, Sch Med, Dept Immunol & Mol Genet, Kurashiki, Okayama 7010192, Japan	Kyoto University; Kyoto University; Kumamoto University; Kawasaki Medical School	Takeda, S (corresponding author), Kyoto Univ, Dept Radiat Genet, Sch Med, Sakyo Ku, Yoshida Konoe Cho, Kyoto 6068501, Japan.	stakeda@rg.med.kyoto-u.ac.jp		Yamashita, Yukiko/0000-0001-5541-0216; Takeda, Shunichi/0000-0002-7924-7991; Takata, Minoru/0000-0002-4926-3675				BAILLY V, 1994, GENE DEV, V8, P811, DOI 10.1101/gad.8.7.811; Bezzubova O, 1997, CELL, V89, P185, DOI 10.1016/S0092-8674(00)80198-1; Broomfield S, 2001, MUTAT RES-DNA REPAIR, V486, P167, DOI 10.1016/S0921-8777(01)00091-X; BUERSTEDDE JM, 1991, CELL, V67, P179, DOI 10.1016/0092-8674(91)90581-I; BUERSTEDDE JM, 1990, EMBO J, V9, P921, DOI 10.1002/j.1460-2075.1990.tb08190.x; Burgers PMJ, 2001, J BIOL CHEM, V276, P43487, DOI 10.1074/jbc.R100056200; Cejka P, 2001, GENETICS, V159, P953; Chiapperino D, 2002, J BIOL CHEM, V277, P11765, DOI 10.1074/jbc.M112139200; Cleaver JE, 1999, CANCER RES, V59, P1102; Cordonnier AM, 1999, MUTAT RES-DNA REPAIR, V435, P111, DOI 10.1016/S0921-8777(99)00047-6; Evans H J, 1977, Adv Hum Genet, V8, P347; FABRE F, 1989, MOL GEN GENET, V215, P425, DOI 10.1007/BF00427039; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES, P523; Fujimori A, 2001, EMBO J, V20, P5513, DOI 10.1093/emboj/20.19.5513; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gerlach VL, 2001, J BIOL CHEM, V276, P92, DOI 10.1074/jbc.M004413200; Goodman MF, 2000, NAT REV MOL CELL BIO, V1, P101, DOI 10.1038/35040051; Hubscher U, 2000, TRENDS BIOCHEM SCI, V25, P143, DOI 10.1016/S0968-0004(99)01523-6; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Kulaeva OI, 1996, MUTAT RES-FUND MOL M, V357, P245, DOI 10.1016/0027-5107(96)00164-9; LAWRENCE C, 1994, BIOESSAYS, V16, P253, DOI 10.1002/bies.950160408; LAWRENCE CW, 1976, GENETICS, V82, P207; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Masutani C, 2000, EMBO J, V19, P3100, DOI 10.1093/emboj/19.12.3100; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; O-Wang J, 2001, CANCER RES, V61, P5366; Ogi T, 1999, GENES CELLS, V4, P607, DOI 10.1046/j.1365-2443.1999.00289.x; Ogi T, 2001, GENES CELLS, V6, P943, DOI 10.1046/j.1365-2443.2001.00478.x; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; OHMORI H, 1995, MUTAT RES LETT, V347, P1, DOI 10.1016/0165-7992(95)90024-1; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; Sonoda E, 1998, EMBO J, V17, P598, DOI 10.1093/emboj/17.2.598; Sonoda E, 1999, MOL CELL BIOL, V19, P5166; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; Suzuki N, 2002, BIOCHEMISTRY-US, V41, P6100, DOI 10.1021/bi020049c; Suzuki N, 2001, BIOCHEMISTRY-US, V40, P15176, DOI 10.1021/bi010702g; Takata M, 1998, EMBO J, V17, P5497, DOI 10.1093/emboj/17.18.5497; Tateishi S, 2000, P NATL ACAD SCI USA, V97, P7927, DOI 10.1073/pnas.97.14.7927; Tissier A, 2000, EMBO J, V19, P5259, DOI 10.1093/emboj/19.19.5259; van der Laan R, 2000, GENOMICS, V69, P86, DOI 10.1006/geno.2000.6220; Wang WS, 2000, EMBO J, V19, P3428, DOI 10.1093/emboj/19.13.3428; Wang ZG, 2001, MUTAT RES-DNA REPAIR, V486, P59, DOI 10.1016/S0921-8777(01)00089-1; Washington MT, 2002, P NATL ACAD SCI USA, V99, P1910, DOI 10.1073/pnas.032594399; Woodgate R, 2001, MUTAT RES-DNA REPAIR, V485, P83, DOI 10.1016/S0921-8777(00)00076-8; Xin H, 2000, NUCLEIC ACIDS RES, V28, P2847, DOI 10.1093/nar/28.14.2847; Yamashita YM, 2002, EMBO J, V21, P5558, DOI 10.1093/emboj/cdf534; Yuan FH, 2000, J BIOL CHEM, V275, P8233, DOI 10.1074/jbc.275.11.8233; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147	51	79	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48690	48695		10.1074/jbc.M207957200	http://dx.doi.org/10.1074/jbc.M207957200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356753	Green Submitted, hybrid			2022-12-25	WOS:000179789600094
J	Pannequin, J; Barnham, KJ; Hollande, F; Shulkes, A; Norton, RS; Baldwin, GS				Pannequin, J; Barnham, KJ; Hollande, F; Shulkes, A; Norton, RS; Baldwin, GS			Ferric ions are essential for the biological activity of the hormone glycine-extended gastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; INSULIN HEXAMER; GROWTH-FACTOR; METAL-IONS; CELL-LINE; RECEPTOR; CHOLECYSTOKININ; EXPRESSION; PROLIFERATION; PROGASTRIN	Amidated and nonamidated gastrins elicit different biological effects via distinct receptors in different tissues. Amidated gastrin 17 stimulates gastric acid secretion and the development of gastric carcinoids, whereas glycine-extended gastrin 17 stimulates proliferation of the colonic mucosa and the development of colorectal cancers. Because glycine-extended gastrin 17 binds two ferric ions with high affinity (Baldwin, G. S., Curtain, C. C., and Sawyer, W. H. (2001) Biochemistry 40, 1074110746), we have investigated the identity of the iron ligands and the role of ferric ions in biological activity. Here we report the solution structure of glycine-extended gastrin 17, determined by NMR spectroscopy. The spectral changes observed upon the addition of ferric ions revealed that Glu(7) acted as a ligand at the first ferric binding site, and that Glu(8) and Glu(9) acted as ligands at the second ferric ion binding site. Fluorescence quenching experiments confirmed that a GglyE7A mutant bound only one ferric ion. The inability of this mutant to stimulate proliferation or migration in the IMGE-5 cell line and the observation that the iron chelator desferrioxamine selectively blocked the effects of glycine-extended gastrin 17 indicated that binding of a ferric ion to Glu(7) was essential for biological activity. This is the first report of an essential role for a metal ion in the action of a hormone.	Univ Melbourne, Dept Surg, Heidelberg, Vic 3084, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Mental Hlth Res Inst, Parkville, Vic 3010, Australia; Fac Pharm Montpellier, EA MNRT 2995, Lab Signalisat Cellulaire & Tumorale, Montpellier, France; PO Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	University of Melbourne; University of Melbourne; Florey Institute of Neuroscience & Mental Health; Universite de Montpellier; Royal Melbourne Hospital; Walter & Eliza Hall Institute	Baldwin, GS (corresponding author), Univ Melbourne, Dept Surg, Austin Campus,A&RMC,Studley Rd, Heidelberg, Vic 3084, Australia.		Hollande, Frederic/E-3133-2013; Hollande, Frederic/GLS-4120-2022	Hollande, Frederic/0000-0002-7046-8392; Baldwin, Graham/0000-0002-0944-8747; pannequin, julie/0000-0002-9956-373X; Norton, Raymond/0000-0001-8893-0584				Aly A, 2001, INT J CANCER, V94, P307, DOI 10.1002/ijc.1483; BALDWIN GS, 1995, J GASTROEN HEPATOL, V10, P215, DOI 10.1111/j.1440-1746.1995.tb01083.x; Baldwin GS, 2001, BIOCHEMISTRY-US, V40, P10741, DOI 10.1021/bi010016h; Baldwin GS, 2001, J BIOL CHEM, V276, P7791, DOI 10.1074/jbc.M009985200; Barnham KJ, 1998, PROTEIN SCI, V7, P1738, DOI 10.1002/pro.5560070808; Barnham KJ, 1999, BBA-PROTEIN STRUCT M, V1435, P127, DOI 10.1016/S0167-4838(99)00214-9; De Hauwer C, 1998, J NEUROBIOL, V37, P373, DOI 10.1002/(SICI)1097-4695(19981115)37:3<373::AID-NEU3>3.0.CO;2-H; Dockray GJ, 1999, J PHYSIOL-LONDON, V518, P315, DOI 10.1111/j.1469-7793.1999.0315p.x; EMDIN SO, 1980, DIABETOLOGIA, V19, P174, DOI 10.1007/BF00275265; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Hollande F, 1997, GASTROENTEROLOGY, V113, P1576, DOI 10.1053/gast.1997.v113.pm9352860; Hollande F, 2001, AM J PHYSIOL-GASTR L, V280, pG910, DOI 10.1152/ajpgi.2001.280.5.G910; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; ITO M, 1993, J BIOL CHEM, V268, P18300; Kadima W, 1999, BIOCHEMISTRY-US, V38, P13443, DOI 10.1021/bi9903188; KAISE M, 1995, J BIOL CHEM, V270, P11155, DOI 10.1074/jbc.270.19.11155; KARLIN KD, 1993, SCIENCE, V261, P701, DOI 10.1126/science.7688141; Kermorgant S, 2001, BIOCHEM BIOPH RES CO, V285, P136, DOI 10.1006/bbrc.2001.5132; Kicic A, 2001, CANCER, V92, P3093, DOI 10.1002/1097-0142(20011215)92:12<3093::AID-CNCR10107>3.0.CO;2-B; Koh TJ, 1999, J CLIN INVEST, V103, P1119, DOI 10.1172/JCI4910; KOPIN AS, 1992, P NATL ACAD SCI USA, V89, P3605, DOI 10.1073/pnas.89.8.3605; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LONGANO SC, 1988, ARCH BIOCHEM BIOPHYS, V263, P410, DOI 10.1016/0003-9861(88)90653-4; MAMMI S, 1988, BIOCHEMISTRY-US, V27, P1374, DOI 10.1021/bi00404a043; Moore C, 1997, DNA SEQUENCE, V8, P39, DOI 10.3109/10425179709020883; Oiry C, 2000, EUR J PHARMACOL, V403, P17, DOI 10.1016/S0014-2999(00)00576-8; PALLAGHY PK, 1993, J MOL BIOL, V234, P405, DOI 10.1006/jmbi.1993.1595; PALUMBO M, 1980, FEBS LETT, V119, P158, DOI 10.1016/0014-5793(80)81020-9; PEGGION E, 1983, BIOPOLYMERS, V22, P2443, DOI 10.1002/bip.360221110; PEGGION E, 1984, BIOPOLYMERS, V23, P1225, DOI 10.1002/bip.360230707; Popescu VC, 2001, BIOCHEMISTRY-US, V40, P7984, DOI 10.1021/bi010198f; RahuelClermont S, 1997, BIOCHEMISTRY-US, V36, P5837, DOI 10.1021/bi963038q; SEVA C, 1994, SCIENCE, V265, P410, DOI 10.1126/science.8023165; SOLOFF MS, 1977, FED PROC, V36, P1861; TORDA AE, 1985, BIOCHEMISTRY-US, V24, P1720, DOI 10.1021/bi00328a023; TRACY HJ, 1964, NATURE, V204, P935, DOI 10.1038/204935a0; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691; WILLIAMS JA, 1993, PHYSIOL REV, V73, P701, DOI 10.1152/physrev.1993.73.4.701; WINZOR DJ, 1995, QUANTITATIVE CHARACT, P28; WISHART DS, 1995, J BIOMOL NMR, V6, P135, DOI 10.1007/BF00211777; Wroblewski LE, 2002, BIOCHEM J, V365, P873, DOI 10.1042/BJ20020068	42	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48602	48609		10.1074/jbc.M208440200	http://dx.doi.org/10.1074/jbc.M208440200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12270941	Green Published, hybrid			2022-12-25	WOS:000179789600083
J	Singer, AG; Ghomashchi, F; Le Calvez, C; Bollinger, J; Bezzine, S; Rouault, M; Sadilek, M; Nguyen, E; Lazdunski, M; Lambeau, G; Gelb, MH				Singer, AG; Ghomashchi, F; Le Calvez, C; Bollinger, J; Bezzine, S; Rouault, M; Sadilek, M; Nguyen, E; Lazdunski, M; Lambeau, G; Gelb, MH			Interfacial kinetic and binding properties of the complete set of human and mouse groups I, II, V, X, and XII secreted phospholipases A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; STRUCTURE-BASED DESIGN; ESCHERICHIA-COLI; VENOM PHOSPHOLIPASE-A2; RECOMBINANT EXPRESSION; COMPETITIVE INHIBITORS; MEMBRANE-BINDING; MAJOR PROTEIN; RAY STRUCTURE; CATALYSIS	Expression of the full set of human and mouse groups I, II, V, X, and XII secreted phospholipases A(2) (sPLA(2)s) in Escherichia coli and insect cells has provided pure recombinant enzymes for detailed comparative interfacial kinetic and binding studies. The set of mammalian sPLA2s display dramatically different sensitivity to dithiothreitol. The specific activity for the hydrolysis of vesicles of differing phospholipid composition by these enzymes varies by up to 4 orders of magnitude, and yet all enzymes display similar catalytic site specificity toward phospholipids with different polar head groups. Discrimination between sn-2 polyunsaturated versus saturated fatty acyl chains is <6-fold. These enzymes display apparent dissociation constants for activation by calcium in the 1-225 mu M range, depending on the phospholipid substrate. Analysis of the inhibition by a set of 12 active site-directed, competitive inhibitors reveals a large variation in the potency among the mammalian sPLA(2)s, with Me-Indoxam being the most generally potent sPLA(2) inhibitor. A dramatic correlation exists between the ability of the sPLA(2)s to hydrolyze phosphatidylcholine-rich vesicles efficiently in vitro and the ability to release arachidonic acid when added exogenously to mammalian cells; the group V and X sPLA(2)s are uniquely efficient in this regard.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; CNRS, Inst Pharmacol Mol & Cellulaire, UPR 411, F-06560 Valbonne, France	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lambeau, G (corresponding author), Univ Washington, Dept Chem & Biochem, Seattle, WA 98195 USA.	lambeau@ipme.cnrs.fr	Lambeau, Gerard/GRJ-5624-2022	Lambeau, Gerard/0000-0002-9239-518X; gelb, michael/0000-0001-7000-5219	NHLBI NIH HHS [HL36236] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANCIAN P, 1995, BIOCHEMISTRY-US, V34, P13146, DOI 10.1021/bi00040a028; [Anonymous], 1987, PHOSPHOLIPASES; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Balsinde J, 1996, J BIOL CHEM, V271, P6758, DOI 10.1074/jbc.271.12.6758; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Berg OG, 2002, INTERFACIAL ENZYME K; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; BEZZINE S, 2002, J BIOL CHEM     0919, DOI DOI 10.1074/JBC9M2203137200; Bryant MD, 1999, BIOORG MED CHEM LETT, V9, P1097, DOI 10.1016/S0960-894X(99)00147-X; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Chen YJ, 1998, BBA-LIPID LIPID MET, V1394, P57, DOI 10.1016/S0005-2760(98)00098-8; Cupillard L, 1999, J BIOL CHEM, V274, P7043, DOI 10.1074/jbc.274.11.7043; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; DEGEUS P, 1987, NUCLEIC ACIDS RES, V15, P3743, DOI 10.1093/nar/15.9.3743; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; ELSBACH P, 1990, PROG CLIN BIOL RES, V349, P1; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Fenard D, 1999, J CLIN INVEST, V104, P611, DOI 10.1172/JCI6915; Gelb M H, 2000, Tanpakushitsu Kakusan Koso, V45, P1065; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; GHOMASHCHI F, 1992, BIOCHEMISTRY-US, V31, P3814, DOI 10.1021/bi00130a012; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; Han SK, 1998, BIOCHEM J, V331, P353, DOI 10.1042/bj3310353; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1999, ARCH BIOCHEM BIOPHYS, V372, P215, DOI 10.1006/abbi.1999.1511; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Hassani O, 1999, FEBS LETT, V443, P175, DOI 10.1016/S0014-5793(98)01710-4; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; Ho IC, 2001, J BIOL CHEM, V276, P18321, DOI 10.1074/jbc.M008837200; HOLLANDER T, 1993, CARBOHYD RES, V247, P291, DOI 10.1016/0008-6215(93)84261-4; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P7330, DOI 10.1021/bi00243a038; JAIN MK, 1991, BIOCHEMISTRY-US, V30, P10256, DOI 10.1021/bi00106a025; JAIN MK, 1987, BIOCHIM BIOPHYS ACTA, V905, P1, DOI 10.1016/0005-2736(87)90002-2; JAIN MK, 1991, METHOD ENZYMOL, V197, P112; JAIN MK, 1995, PHYTOCHEMISTRY, V39, P537, DOI 10.1016/0031-9422(94)00960-2; KELLEY MJ, 1992, BIOCHIM BIOPHYS ACTA, V1118, P107, DOI 10.1016/0167-4838(92)90136-2; Kim KP, 2000, BIOCHEM J, V348, P643, DOI 10.1042/0264-6021:3480643; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; KUBELKA V, 1993, EUR J BIOCHEM, V213, P1193, DOI 10.1111/j.1432-1033.1993.tb17870.x; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; LIN HK, 1993, J AM CHEM SOC, V115, P3932, DOI 10.1021/ja00063a012; Madsen LM, 1996, INFECT IMMUN, V64, P2425, DOI 10.1128/IAI.64.7.2425-2430.1996; MaoQiang M, 1996, J INVEST DERMATOL, V106, P57, DOI 10.1111/1523-1747.ep12327246; MARSHALL LA, 1995, J PHARMACOL EXP THER, V274, P1254; Mihelich ED, 1999, BBA-MOL CELL BIOL L, V1441, P223, DOI 10.1016/S1388-1981(99)00157-2; Murakami M, 2002, J BIOL CHEM, V277, P19145, DOI 10.1074/jbc.M112385200; Murakami M, 2002, BIOCHEM BIOPH RES CO, V292, P689, DOI 10.1006/bbrc.2002.6716; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; NOEL JP, 1989, J CELL BIOCHEM, V40, P309, DOI 10.1002/jcb.240400307; Ownby CL, 1999, TOXICON, V37, P411, DOI 10.1016/S0041-0101(98)00188-3; Pan YH, 2002, J BIOL CHEM, V277, P29086, DOI 10.1074/jbc.M202531200; POTE KG, 1993, BIOCHEMISTRY-US, V32, P5017, DOI 10.1021/bi00070a007; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Schadow A, 2001, J INVEST DERMATOL, V116, P31, DOI 10.1046/j.1523-1747.2001.00179.x; SCHEVITZ RW, 1995, NAT STRUCT BIOL, V2, P458, DOI 10.1038/nsb0695-458; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snitko Y, 1999, BIOCHEMISTRY-US, V38, P7803, DOI 10.1021/bi990600e; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; VADAS P, 1993, J LIPID MEDIATOR, V8, P1; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; Verpy E, 1999, P NATL ACAD SCI USA, V96, P529, DOI 10.1073/pnas.96.2.529; VUILLARD L, 1995, ELECTROPHORESIS, V16, P295, DOI 10.1002/elps.1150160148; Wang YX, 1998, P NATL ACAD SCI USA, V95, P15345, DOI 10.1073/pnas.95.26.15345; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024	83	291	297	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48535	48549		10.1074/jbc.M205855200	http://dx.doi.org/10.1074/jbc.M205855200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359733	hybrid			2022-12-25	WOS:000179789600075
J	Pan, Y; Cohen, I; Guillerault, F; Feve, B; Girard, J; Prip-Buus, C				Pan, Y; Cohen, I; Guillerault, F; Feve, B; Girard, J; Prip-Buus, C			The extreme C terminus of rat liver carnitine palmitoyltransferase I is not involved in malonyl-CoA sensitivity but in initial protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL OUTER-MEMBRANE; INHIBITORY BINDING-SITES; FATTY-ACID OXIDATION; CATALYTIC ACTIVITY; SINGLE POLYPEPTIDE; CHIMERIC PROTEINS; HIGH-AFFINITY; CPT I; RESIDUES; EXPRESSION	We previously reported that the N-terminal domain (1-147 residues) of rat liver carnitine palmitoyltransferase I (L-CPTI) was essential for import into the outer mitochondrial membrane and for maintenance of a malonyl-CoA-sensitive conformation. Malonyl-CoA binding experiments using mitochondria of Saccharomyces cerevisiae strains expressing wild-type L-CPTI or previously constructed chimeric CPTs (Cohen, I., Kohl, C., McGarry, J.D., Girard, J., and Prip-Buus, C. (1998) J. Biol. Chem. 273, 29896-29904) indicated that the N-terminal domain was unable, independently of the C-terminal domain, to bind malonyl-CoA with a high affinity, suggesting that the modulation of malonyl-CoA sensitivity occurred through N/C intramolecular interactions. To assess the role of the C terminus in malonyl-CoA sensitivity, a series of C-terminal deletion mutants was generated. The kinetic properties of Delta772-773 and Delta767-773 deletion mutants were similar to those of L-CPTI, indicating that the last two highly conserved Lys residues in all known L-CPTI species were not functionally essential. By contrast, Delta743-773 deletion mutant was totally inactive and unfolded, as shown by its sensitivity to trypsin proteolysis. Because the C terminus of the native folded L-CPTI could be cleaved by trypsin without inducing protein unfolding, we concluded that the last 31 C-terminal residues constitute a secondary structural determinant essential for the initial protein folding of L-CPTI.	Univ Paris 05, Dept Endocrinol, INSERM, Cochin Inst,U567,CNRSUMR 8104, F-75014 Paris, France; CNRS, Enseignement Super Associec, UPR 7079, F-75006 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Prip-Buus, C (corresponding author), Univ Paris 05, Dept Endocrinol, INSERM, Cochin Inst,U567,CNRSUMR 8104, 24 Rue Faubourg St Jacques, F-75014 Paris, France.		PRIP-BUUS, Carina/P-9084-2017	Feve, Bruno/0000-0001-6577-9009; Prip-Buus, Carina/0000-0002-2153-7857				Anderson RC, 1998, CURR PHARM DESIGN, V4, P1; Battiste JL, 2002, BIOCHEMISTRY-US, V41, P2237, DOI 10.1021/bi011693e; Bergman RN, 2000, TRENDS ENDOCRIN MET, V11, P351, DOI 10.1016/S1043-2760(00)00323-4; BIRD MI, 1984, BIOCHEM J, V222, P639, DOI 10.1042/bj2220639; BROWN NF, 1994, J BIOL CHEM, V269, P26438; Cohen I, 1998, J BIOL CHEM, V273, P29896, DOI 10.1074/jbc.273.45.29896; Cohen I, 2001, J BIOL CHEM, V276, P5403, DOI 10.1074/jbc.M009555200; COOK GA, 1994, J BIOL CHEM, V269, P8803; Dai J, 2000, J BIOL CHEM, V275, P22020, DOI 10.1074/jbc.M002118200; ESSER V, 1993, J BIOL CHEM, V268, P5817; Fraser F, 1997, BIOCHEM J, V323, P711, DOI 10.1042/bj3230711; Fukao T, 2002, MOL GENET METAB, V75, P235, DOI 10.1006/mgme.2001.3288; Garcia C, 2000, BIOCHEMISTRY-US, V39, P11227, DOI 10.1021/bi0010266; HOROVITZ A, 1992, J MOL BIOL, V224, P733, DOI 10.1016/0022-2836(92)90557-Z; Jackson VN, 2000, J BIOL CHEM, V275, P38410, DOI 10.1074/jbc.M007722200; Jackson VN, 2000, J BIOL CHEM, V275, P19560, DOI 10.1074/jbc.M002177200; Jackson VN, 2001, BIOCHEMISTRY-US, V40, P14629, DOI 10.1021/bi011632g; KASHFI K, 1994, BBA-LIPID LIPID MET, V1212, P245, DOI 10.1016/0005-2760(94)90259-3; Kursula I, 2002, FEBS LETT, V518, P39, DOI 10.1016/S0014-5793(02)02639-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI JM, 1992, SCIENCE, V256, P1815, DOI 10.1126/science.1615327; LOWRY OH, 1951, J BIOL CHEM, V193, P265; McGarry JD, 2002, DIABETES, V51, P7, DOI 10.2337/diabetes.51.1.7; MCGARRY JD, 1994, J CELL BIOCHEM, V55, P29, DOI 10.1002/jcb.240550005; MCGARRY JD, 1978, J BIOL CHEM, V253, P4128; McGarry JD, 1997, EUR J BIOCHEM, V244, P1, DOI 10.1111/j.1432-1033.1997.00001.x; MILLS SE, 1983, BIOCHEM J, V214, P83, DOI 10.1042/bj2140083; Morillas M, 2002, J BIOL CHEM, V277, P11473, DOI 10.1074/jbc.M111628200; Morillas M, 2001, J BIOL CHEM, V276, P45001, DOI 10.1074/jbc.M106920200; Prentki M, 1996, DIABETES, V45, P273, DOI 10.2337/diabetes.45.3.273; Prip-Buus C, 1998, FEBS LETT, V429, P173, DOI 10.1016/S0014-5793(98)00584-5; Ruderman NB, 1999, AM J PHYSIOL-ENDOC M, V276, pE1, DOI 10.1152/ajpendo.1999.276.1.E1; Shi JY, 2000, BIOCHEMISTRY-US, V39, P712, DOI 10.1021/bi9918700; Shi JY, 1999, J BIOL CHEM, V274, P9421, DOI 10.1074/jbc.274.14.9421; Shi JY, 1998, BIOCHEMISTRY-US, V37, P11033, DOI 10.1021/bi9803426; Swanson ST, 1998, BIOCHEM J, V335, P513, DOI 10.1042/bj3350513; Unger RH, 2001, FASEB J, V15, P312, DOI 10.1096/fj.00-0590; ZAMMIT VA, 1984, BIOCHEM J, V222, P335, DOI 10.1042/bj2220335; Zammit VA, 1999, BIOCHEM J, V343, P505, DOI 10.1042/0264-6021:3430505	39	10	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47184	47189		10.1074/jbc.M208055200	http://dx.doi.org/10.1074/jbc.M208055200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351641	hybrid			2022-12-25	WOS:000179663700045
J	Planes, C; Blot-Chabaud, M; Matthay, MA; Couette, S; Uchida, T; Clerici, C				Planes, C; Blot-Chabaud, M; Matthay, MA; Couette, S; Uchida, T; Clerici, C			Hypoxia and beta(2)-agonists regulate cell surface expression of the epithelial sodium channel in native alveolar epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SUBUNITS; NA+ CHANNEL; II CELLS; LUNG; INCREASES; CLEARANCE; MEMBRANE; RATS	Alveolar hypoxia may impair sodium-dependent alveolar fluid transport and induce pulmonary edema in rat and human lung, an effect that can be prevented by the inhalation of beta(2)-agonists. To investigate the mechanism of beta(2)-agonist-mediated stimulation of sodium transport under conditions of moderate hypoxia, we examined the effect of terbutaline on epithelial sodium channel (ENaC) expression and activity in cultured rat alveolar epithelial type II cells exposed to 3% O-2 for 24 h. Hypoxia reduced transepithelial sodium current and amiloride-sensitive sodium channel activity without decreasing ENaC subunit mRNA or protein levels. The functional decrease was associated with reduced abundance of ENaC subunits (especially beta and gamma) in the apical membrane of hypoxic cells, as quantified by biotinylation. cAMP stimulation with terbutaline reversed the hypoxia-induced decrease in transepithelial sodium transport by stimulating sodium channel activity and markedly increased the abundance of beta-and gamma-ENaC in the plasma membrane of hypoxic cells. The effect of terbutaline was prevented by brefeldin X a blocker of anterograde transport. These novel results establish that hypoxia-induced inhibition of amiloride-sensitive sodium channel activity is mediated by decreased apical expression of ENaC subunits and that beta(2)-agonists reverse this effect by enhancing the insertion of ENaC subunits into the membrane of hypoxic alveolar epithelial cells.	Univ Paris 07, INSERM, U426, Dept Physiol, F-75018 Paris, France; Univ Paris 07, Fac Med Xavier Bichat, U478, F-75018 Paris, France; Univ Versailles, Dept Physiol, F-78000 Versailles, France; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; Universite Paris Saclay; University of California System; University of California San Francisco	Clerici, C (corresponding author), INSERM, U426, 16 Rue Henri Huchard,BP 416, F-75870 Paris 18, France.		Blot-Chabaud, Marcel/D-4064-2017	planes, carole/0000-0003-2286-366X	NHLBI NIH HHS [HL51854] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051854] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chen XJ, 2002, AM J PHYSIOL-LUNG C, V282, pL609, DOI 10.1152/ajplung.00356.2001; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; DUC C, 1994, J CELL BIOL, V127, P1907, DOI 10.1083/jcb.127.6.1907; GOTTARDI CJ, 1995, AM J PHYSIOL-RENAL, V268, pF285, DOI 10.1152/ajprenal.1995.268.2.F285; Guo Y, 1998, AM J PHYSIOL-LUNG C, V274, pL369, DOI 10.1152/ajplung.1998.274.3.L369; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Jain L, 2001, AM J PHYSIOL-LUNG C, V280, pL646, DOI 10.1152/ajplung.2001.280.4.L646; Jain L, 1999, AM J PHYSIOL-LUNG C, V276, pL1046, DOI 10.1152/ajplung.1999.276.6.L1046; Jiang XP, 1998, AM J PHYSIOL-CELL PH, V275, pC1610, DOI 10.1152/ajpcell.1998.275.6.C1610; Matalon S, 1999, ANNU REV PHYSIOL, V61, P627, DOI 10.1146/annurev.physiol.61.1.627; Matthay MA, 2002, PHYSIOL REV, V82, P569, DOI 10.1152/physrev.00003.2002; Planes C, 1997, AM J RESP CELL MOL, V17, P508, DOI 10.1165/ajrcmb.17.4.2680; SAKUMA T, 1994, AM J RESP CRIT CARE, V150, P305, DOI 10.1164/ajrccm.150.2.8049807; Sartori C, 2002, NEW ENGL J MED, V346, P1631, DOI 10.1056/NEJMoa013183; SENYK O, 1995, AM J PHYSIOL-CELL PH, V268, pC1148, DOI 10.1152/ajpcell.1995.268.5.C1148; Snyder PM, 2000, J CLIN INVEST, V105, P45, DOI 10.1172/JCI7869; STELZNER TJ, 1988, J CLIN INVEST, V82, P1840, DOI 10.1172/JCI113800; Vivona ML, 2001, AM J RESP CELL MOL, V25, P554, DOI 10.1165/ajrcmb.25.5.4420; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; WEST JB, 1991, J APPL PHYSIOL, V70, P1731, DOI 10.1152/jappl.1991.70.4.1731; YUE G, 1994, AM J PHYSIOL, V267, pL94, DOI 10.1152/ajplung.1994.267.1.L94	25	135	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47318	47324		10.1074/jbc.M209158200	http://dx.doi.org/10.1074/jbc.M209158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12372821	hybrid			2022-12-25	WOS:000179663700063
J	Takeda, Y; Kasamo, K				Takeda, Y; Kasamo, K			In vitro fusion of plant golgi membranes can be influenced by divalent cations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIGNA-RADIATA L; PHOSPHATIDYLSERINE-CONTAINING VESICLES; SENSITIVE ETIOLATED SEEDLINGS; LIVER ENDOPLASMIC-RETICULUM; PROTEIN-INDUCED FUSION; PLASMA-MEMBRANE; RAT-LIVER; VACUOLE FUSION; ACIDIC PH; LIPOSOMES	The fusogenic activity of plant Golgi membranes was studied in a cell-free system by assaying lipid mixing and content leakages of fluorescence probes. Golgi membranes from mung bean (Vigna radiata L.) hypocotyl cells fused to liposomes in the absence of any cytosolic proteins and nucleotides. It was demonstrated that the fusion was mediated by integral membrane protein(s), and was influenced by divalent cations (mM). Mg2+, Ca2+, and Mn2+ ions enhanced the lipid mixing by reducing repulsive forces between membranes. In the content leakage assay, Mg2+ ions also showed a stimulative effect. However, other divalent cations were inhibitory. It is suggested that the fusion system of Golgi membranes comprises at least two components: one that mediates the formation of fusion intermediates prior to pore opening, and one that mediates the subsequent processes. The latter must be sensitive to divalent cations at millimolar concentrations. The fusion of Golgi and biological membranes was induced by divalent cations. We speculated about the biological role of the fusion system studied here.	Okayama Univ, Res Inst Bioresources, Kurashiki, Okayama 7100046, Japan	Okayama University	Takeda, Y (corresponding author), RIKEN, Mol Membrane Biol Lab, 2-1 Hirosawa, Wako, Saitama 3510198, Japan.	y-takeda@postman.riken.go.jp						ALMEIDA MT, 1994, J MEMBRANE BIOL, V142, P217; Battey NH, 1999, PLANT CELL, V11, P643, DOI 10.1105/tpc.11.4.643; BRISKIN DP, 1987, METHOD ENZYMOL, V148, P542; Brugger B, 2000, EMBO J, V19, P1272, DOI 10.1093/emboj/19.6.1272; Carroll AD, 1998, PLANT CELL, V10, P1267, DOI 10.1105/tpc.10.8.1267; Chen YA, 2001, NAT REV MOL CELL BIO, V2, P98, DOI 10.1038/35052017; Colombo MI, 1997, J BIOL CHEM, V272, P7707, DOI 10.1074/jbc.272.12.7707; Corazzi L, 1998, J MEMBRANE BIOL, V165, P53, DOI 10.1007/s002329900420; DUZGUNES N, 1987, BIOCHEMISTRY-US, V26, P8435, DOI 10.1021/bi00399a061; DUZGUNES N, 1993, METHOD ENZYMOL, V220, P3, DOI 10.1016/0076-6879(93)20069-F; Eitzen G, 2001, EMBO J, V20, P5650, DOI 10.1093/emboj/20.20.5650; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; FELLE H, 1991, PLANT SIGNALLING PLA, P79; Funato K, 2001, J CELL BIOL, V155, P949, DOI 10.1083/jcb.200105033; GALLAGHER SR, 1982, PLANT PHYSIOL, V70, P1335, DOI 10.1104/pp.70.5.1335; Hatano K, 1997, PLANT CELL PHYSIOL, V38, P344, DOI 10.1093/oxfordjournals.pcp.a029172; HAUSER HO, 1971, BIOCHEM BIOPH RES CO, V45, P1049, DOI 10.1016/0006-291X(71)90443-8; Hawes C, 1996, TRENDS PLANT SCI, V1, P395, DOI 10.1016/1360-1385(96)10044-3; HERMAN EM, 1994, PLANT PHYSIOL, V106, P1313, DOI 10.1104/pp.106.4.1313; HOEKSTRA D, 1984, BIOCHEMISTRY-US, V23, P5675, DOI 10.1021/bi00319a002; Hughson FM, 1999, CURR BIOL, V9, pR49, DOI 10.1016/S0960-9822(99)80008-6; HUI SW, 1988, BIOCHIM BIOPHYS ACTA, V941, P130, DOI 10.1016/0005-2736(88)90173-3; Ikebuchi Y, 2001, TRAFFIC, V2, P654, DOI 10.1034/j.1600-0854.2001.20908.x; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; KACHAR B, 1986, BIOPHYS J, V50, P779, DOI 10.1016/S0006-3495(86)83518-4; KAGIWADA S, 1993, J BIOL CHEM, V268, P1430; KOBAYASHI T, 1988, CELL, V55, P797, DOI 10.1016/0092-8674(88)90135-3; LAU A, 1981, BIOCHIM BIOPHYS ACTA, V645, P279, DOI 10.1016/0005-2736(81)90199-1; MACDONALD RI, 1990, J BIOL CHEM, V265, P13533; MAESHIMA M, 1992, PLANT PHYSIOL, V98, P1248, DOI 10.1104/pp.98.4.1248; Maier O, 2002, CHEM PHYS LIPIDS, V116, P3, DOI 10.1016/S0009-3084(02)00017-8; Mellman I, 2000, CELL, V100, P99, DOI 10.1016/S0092-8674(00)81687-6; Monni M, 2001, EUR J BIOCHEM, V268, P2020, DOI 10.1046/j.1432-1327.2001.02079.x; Muller O, 2001, EMBO J, V20, P5657, DOI 10.1093/emboj/20.20.5657; MULLOCK BM, 1994, J CELL BIOL, V126, P1173, DOI 10.1083/jcb.126.5.1173; Nebenfuhr A, 2000, PLANT PHYSIOL, V124, P135, DOI 10.1104/pp.124.1.135; OKU N, 1982, BIOCHIM BIOPHYS ACTA, V691, P332, DOI 10.1016/0005-2736(82)90422-9; Otter-Nilsson M, 1999, EMBO J, V18, P2074, DOI 10.1093/emboj/18.8.2074; Pecheur EI, 2000, J BIOL CHEM, V275, P3936, DOI 10.1074/jbc.275.6.3936; Pecheur EI, 1999, J MEMBRANE BIOL, V167, P1, DOI 10.1007/s002329900466; Peters C, 1999, SCIENCE, V285, P1084, DOI 10.1126/science.285.5430.1084; Peters C, 2001, NATURE, V409, P581, DOI 10.1038/35054500; Peters C, 1998, NATURE, V396, P575, DOI 10.1038/25133; Pfeffer SR, 1999, NAT CELL BIOL, V1, pE17, DOI 10.1038/8967; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; Segev N, 2001, SCI STKE, V2001, pre11; Sollner TH, 2002, DEV CELL, V2, P377, DOI 10.1016/S1534-5807(02)00161-2; Sonnichsen B, 1999, PROTOPLASMA, V209, P38, DOI 10.1007/BF01415699; STEGMANN T, 1993, BIOCHEMISTRY-US, V32, P11330, DOI 10.1021/bi00093a009; SZOKA F, 1978, P NATL ACAD SCI USA, V75, P4194, DOI 10.1073/pnas.75.9.4194; Takeda Y, 2001, BBA-BIOMEMBRANES, V1513, P38, DOI 10.1016/S0005-2736(01)00342-X; Tazawa M, 2001, PLANT CELL PHYSIOL, V42, P620, DOI 10.1093/pcp/pce077; Ulrich AS, 1998, J BIOL CHEM, V273, P16748, DOI 10.1074/jbc.273.27.16748; VIDAL M, 1995, J BIOL CHEM, V270, P17823, DOI 10.1074/jbc.270.30.17823; VOGEL SS, 1992, J BIOL CHEM, V267, P25640; Wickner W, 2002, EMBO J, V21, P1241, DOI 10.1093/emboj/21.6.1241; Wickner W, 2000, ANNU REV BIOCHEM, V69, P247, DOI 10.1146/annurev.biochem.69.1.247; YAZAKI Y, 1988, PLANT CELL PHYSIOL, V29, P919; YOSHIDA S, 1986, PLANT PHYSIOL, V82, P807, DOI 10.1104/pp.82.3.807; YOSHIDA S, 1986, PLANT PHYSIOL, V80, P161, DOI 10.1104/pp.80.1.161; YOSHIDA S, 1986, PLANT PHYSIOL, V80, P152, DOI 10.1104/pp.80.1.152	61	5	6	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47756	47764		10.1074/jbc.M209199200	http://dx.doi.org/10.1074/jbc.M209199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12368278	hybrid			2022-12-25	WOS:000179663700119
J	Orcutt, SJ; Pietropaolo, C; Krishnaswamy, S				Orcutt, SJ; Pietropaolo, C; Krishnaswamy, S			Extended interactions with prothrombinase enforce affinity and specificity for its macromolecular substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-X; ACTIVE-SITE; FACTOR VA; ACTIVATION; RECOGNITION; EXPRESSION; THROMBIN; COMPLEX; ACID; CLEAVAGE	The specific action of serine proteinases on protein substrates is a hallmark of blood coagulation and numerous other physiological processes. Enzymic recognition of substrate sequences preceding the scissile bond is considered to contribute dominantly to specificity and function. We have investigated the contribution of active site docking by unique substrate residues preceding the scissile bond to the function of prothrombinase. Mutagenesis of the authentic P-1-P-3 sequence in prethrombin 2/fragment 1.2 yielded substrate variants that could be converted to thrombin by prothrombinase. Proteolytic activation was also observed with a substrate variant containing the P-1-P-3 sequence found in a coagulation zymogen not known to be activated by prothrombinase. Lower rates of activation of the variants derived from a decrease in maximum catalytic rate but not in substrate affinity. Replacement of the P, residue with Gln yielded an uncleavable derivative that retained the affinity of the wild type substrate for prothrombinase but did not engage the active site of the enzyme. Thus, active site docking of the substrate contributes to catalytic efficiency, but it is does not determine substrate affinity nor does it fully explain the specificity of prothrombinase. Therefore, extended interactions between prothrombinase and substrate regions removed from the cleavage site drive substrate affinity and enforce the substrate specificity of this enzyme complex.	Childrens Hosp Philadelphia, Joseph Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Univ Naples Federico II, Dept Biochem & Med Biotechnol, I-80131 Naples, Italy	University of Pennsylvania; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Naples Federico II	Krishnaswamy, S (corresponding author), Childrens Hosp Philadelphia, Joseph Stokes Res Inst, 302F Abramson,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	skrishna@mail.med.upenn.edu			NHLBI NIH HHS [HL-47465, HL-62523] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062523, R01HL047465] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson PJ, 2000, J BIOL CHEM, V275, P16435, DOI 10.1074/jbc.M001255200; Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; Betz A, 1998, J BIOL CHEM, V273, P10709, DOI 10.1074/jbc.273.17.10709; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BODE W, 1978, J MOL BIOL, V118, P99, DOI 10.1016/0022-2836(78)90246-2; Boskovic DS, 2000, J BIOL CHEM, V275, P38561, DOI 10.1074/jbc.M006637200; Buddai SK, 2002, J BIOL CHEM, V277, P26689, DOI 10.1074/jbc.M202507200; DEGEN SJF, 1983, BIOCHEMISTRY-US, V22, P2087, DOI 10.1021/bi00278a008; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Krem MM, 1999, J BIOL CHEM, V274, P28063, DOI 10.1074/jbc.274.40.28063; Krishnaswamy S, 1997, BIOCHEMISTRY-US, V36, P12080, DOI 10.1021/bi970979+; LOTTENBERG R, 1986, BIOCHIM BIOPHYS ACTA, V874, P326, DOI 10.1016/0167-4838(86)90032-4; LOTTENBERG R, 1983, BIOCHIM BIOPHYS ACTA, V742, P558, DOI 10.1016/0167-4838(83)90273-X; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1981, METHOD ENZYMOL, V80, P286; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MANN KG, 1990, BLOOD, V76, P1; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; PERONA JJ, 1995, PROTEIN SCI, V4, P337; RABIET MJ, 1986, J BIOL CHEM, V261, P3210; RAWLINGS ND, 1993, BIOCHEM J, V290, P205, DOI 10.1042/bj2900205; ROBERTS HR, 1998, THROMBOSIS HEMORRHAG, P773; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; Russo G, 1997, PROTEIN EXPRES PURIF, V10, P214, DOI 10.1006/prep.1997.0733; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schneider M, 2002, J BIOL CHEM, V277, P9944, DOI 10.1074/jbc.M111685200; Segel IH, 1975, ENZYME KINETICS BEHA; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; Sun WY, 2000, BLOOD, V95, P711, DOI 10.1182/blood.V95.2.711; WALKER RK, 1993, J BIOL CHEM, V268, P13920; WALKER RK, 1994, J BIOL CHEM, V269, P27441	33	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46191	46196		10.1074/jbc.M208677200	http://dx.doi.org/10.1074/jbc.M208677200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12370181	hybrid			2022-12-25	WOS:000179529300066
J	Piluso, D; Bilan, P; Capone, JP				Piluso, D; Bilan, P; Capone, JP			Host cell factor-1 interacts with and antagonizes transactivation by the cell cycle regulatory factor Miz-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS VP16-INDUCED COMPLEX; PROTEIN INTERACTION MOTIF; COACTIVATOR C1 HCF; TRANSCRIPTIONAL ACTIVATION; GENE-REGULATION; DNA-BINDING; POZ DOMAIN; VP16; ASSOCIATION; FAMILY	Human host cell factor-1 (HCF-1) is essential for cell cycle progression and is required, in conjunction with the herpes simplex virus transactivator VP16, for induction of viral immediate-early gene expression. We show here that HCF-1 directly binds to the Myc-interacting protein Miz-1, a transcription factor that induces cell cycle arrest at G(1), in part by directly stimulating expression of the cyclin-dependent kinase inhibitor p15(INK4b). A domain encompassing amino acids 750-836, contained within a subregion of HCF-1 required for cell cycle progression, was sufficient to bind Miz-1. Conversely, HCF-1 interacted with two separate regions in Miz-1: the N-terminal POZ domain and a C-terminal domain (residues 637-803) previously shown to harbor determinants for interaction with c-Myc and the coactivator p300. The latter functioned as a potent transactivation domain when tethered to DNA, indicating that HCF-1 targets a transactivation function in Miz-1. HCF-1 or a Miz-1-binding fragment of HCF-1 repressed transactivation by Gal4-Miz-1 in transfection assays. Moreover, HCF-1 repressed Miz-1-mediated transactivation of a reporter gene linked to the p15(INK4b) promoter. Protein/protein interaction studies and transient transfection assays demonstrated that HCF-1 interferes with recruitment of p300 to Miz-1, similar to what has been reported with c-Myc. Our findings identify Miz-1 as a novel HCF-1-interacting partner and illustrate cross-talk between these two proteins that may be of consequence to their respective functions in gene regulation and their opposing effects on the cell cycle.	McMaster Univ, Fac Hlth Sci, Dept Biochem, Hamilton, ON L8N 3Z5, Canada	McMaster University	Capone, JP (corresponding author), McMaster Univ, Fac Hlth Sci, Dept Biochem, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.							Ajuh PM, 2000, NUCLEIC ACIDS RES, V28, P678, DOI 10.1093/nar/28.3.678; ALBAGLI O, 1995, CELL GROWTH DIFFER, V6, P1193; Amati B, 2001, NAT CELL BIOL, V3, pE112, DOI 10.1038/35074634; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Bai C, 1997, METHOD ENZYMOL, V283, P141; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Collins T, 2001, MOL CELL BIOL, V21, P3609, DOI 10.1128/MCB.21.11.3609-3615.2001; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; ELBLE R, 1992, BIOTECHNIQUES, V13, P18; Freiman RN, 1997, GENE DEV, V11, P3122, DOI 10.1101/gad.11.23.3122; Goto H, 1997, GENE DEV, V11, P726, DOI 10.1101/gad.11.6.726; Gunther M, 2000, MOL CELL BIOCHEM, V210, P131, DOI 10.1023/A:1007177623283; Herr W, 1998, COLD SPRING HARB SYM, V63, P599, DOI 10.1101/sqb.1998.63.599; Hughes TA, 1999, J BIOL CHEM, V274, P16437, DOI 10.1074/jbc.274.23.16437; Johnson KM, 1999, J VIROL, V73, P3930, DOI 10.1128/JVI.73.5.3930-3940.1999; KRISTIE TM, 1993, J BIOL CHEM, V268, P6525; Kristie TM, 1997, J BIOL CHEM, V272, P26749, DOI 10.1074/jbc.272.42.26749; KRISTIE TM, 1995, J BIOL CHEM, V270, P4387, DOI 10.1074/jbc.270.9.4387; La Boissiere S, 1999, EMBO J, V18, P480; Lee S, 2001, J VIROL, V75, P12402, DOI 10.1128/JVI.75.24.12402-12411.2001; Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200; LIU Y, 1999, J VIROL, V74, P99; Lu R, 1997, MOL CELL BIOL, V17, P5117, DOI 10.1128/MCB.17.9.5117; Lu R, 2000, NUCLEIC ACIDS RES, V28, P2446, DOI 10.1093/nar/28.12.2446; Lu R, 1998, J VIROL, V72, P6291, DOI 10.1128/JVI.72.8.6291-6297.1998; Luciano RL, 2000, P NATL ACAD SCI USA, V97, P10757, DOI 10.1073/pnas.190062797; Mahajan SS, 2000, MOL CELL BIOL, V20, P919, DOI 10.1128/MCB.20.3.919-928.2000; Meertens LM, 1998, EMBO J, V17, P6972, DOI 10.1093/emboj/17.23.6972; Peukert K, 1997, EMBO J, V16, P5672, DOI 10.1093/emboj/16.18.5672; POPOVA B, 1995, VIROLOGY, V209, P19, DOI 10.1006/viro.1995.1227; Sakamuro D, 1999, ONCOGENE, V18, P2942, DOI 10.1038/sj.onc.1202725; Scarr RB, 2000, MOL CELL BIOL, V20, P3568, DOI 10.1128/MCB.20.10.3568-3575.2000; Schneider A, 1997, CURR TOP MICROBIOL, V224, P137; Seoane J, 2001, NAT CELL BIOL, V3, P400, DOI 10.1038/35070086; Staller P, 2001, NAT CELL BIOL, V3, P392, DOI 10.1038/35070076; Vogel JL, 2000, P NATL ACAD SCI USA, V97, P9425, DOI 10.1073/pnas.160266697; Vogel JL, 2000, EMBO J, V19, P683, DOI 10.1093/emboj/19.4.683; Wilson AC, 2000, MOL CELL BIOL, V20, P6721, DOI 10.1128/MCB.20.18.6721-6730.2000; WILSON AC, 1993, COLD SPRING HARB SYM, V58, P167, DOI 10.1101/SQB.1993.058.01.021; WILSON AC, 1995, GENE DEV, V9, P2445, DOI 10.1101/gad.9.20.2445; Wilson AC, 1997, MOL CELL BIOL, V17, P6139, DOI 10.1128/MCB.17.10.6139; WILSON AC, 1993, CELL, V74, P115, DOI 10.1016/0092-8674(93)90299-6; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Wysocka J, 2001, MOL CELL BIOL, V21, P3820, DOI 10.1128/MCB.21.11.3820-3829.2001; Zhou HJ, 2001, J BIOL CHEM, V276, P28933, DOI 10.1074/jbc.M103893200; Ziegelbauer J, 2001, MOL CELL, V8, P339, DOI 10.1016/S1097-2765(01)00313-6	46	25	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46799	46808		10.1074/jbc.M206226200	http://dx.doi.org/10.1074/jbc.M206226200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244100				2022-12-25	WOS:000179529300141
J	Tosetti, P; Turner, T; Lu, QA; Dunlap, K				Tosetti, P; Turner, T; Lu, QA; Dunlap, K			Unique isoform of G alpha-interacting protein (RGS-GAIP) selectively discriminates between two G(o)-mediated pathways that inhibit Ca2+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; SUBCELLULAR-LOCALIZATION; MEDIATED INHIBITION; DYNAMIC REGULATION; SIGNALING RGS; BETA-GAMMA; RECEPTOR; KINASE; K+	Regulators of G-protein signaling (RGS) proteins constitute a large family of GTPase-activating proteins for heterotrimeric G proteins. More than 20 RIGS genes have been identified in mammals. One of these, the Galpha-interacting protein (GAIP), preferentially interacts with members of the G(i)/G(o) subfamily of G proteins in mammalian cells, but its selectivity among members of this subfamily in vitro is limited. Here we report the cloning and functional characterization of a unique cDNA isoform of GAIP, derived from embryonic chicken dorsal root ganglion neurons. Chick GAIP is composed of 199 amino acids, organized into a conserved RGS domain (85% identical to human GAIP), and a unique, short N terminus (only 41% identical, 50% homologrous to known mammalian orthologues). Consistent with this unique primary structure, chick GAIP has physiological properties that distinguish it from mammalian GAIPs. We have explored the selectivity of chick GAIP in electro-physiologicalassays of two G(o)-mediated forms of Ca2+ channel inhibition produced by gamma-aminobutyric acid in chick dorsal root ganglion neurons, voltage-independent inhibition (mediated by G(o)alpha) and voltage-dependent inhibition (mediated by G(o)P(gamma)). Dialyzing recombinant chick GAIP in these cells selectively reduced voltage-independent inhibition without affecting voltage-dependent inhibition. Mammalian GAIP, tested under identical conditions in previous studies, demonstrated no selectivity between these two inhibitory processes; thus, our results suggest that the functional specificity of chick GAIP is likely to be determined by its unique N terminus.	Tufts Univ, Sch Med, Dept Neurosci, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA	Tufts University; Tufts Medical Center	Dunlap, K (corresponding author), Tufts Univ, Sch Med, Dept Neurosci, 136 Harrison Ave, Boston, MA 02111 USA.	kathleen.dunlap@tufts.edu		Turner, Timothy/0000-0001-9770-2647	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016483] Funding Source: NIH RePORTER; NINDS NIH HHS [NS16483] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BENVENISTE M, 1990, J PHYSIOL-LONDON, V428, P333, DOI 10.1113/jphysiol.1990.sp018215; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; BLUM S, 1990, DNA CELL BIOL, V9, P589, DOI 10.1089/dna.1990.9.589; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chen CH, 1999, J BIOL CHEM, V274, P19799, DOI 10.1074/jbc.274.28.19799; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; De Vries L, 1998, MOL BIOL CELL, V9, P1123, DOI 10.1091/mbc.9.5.1123; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; DEVRIES L, 1995, P NATL ACAD SCI USA, V92, P11916, DOI 10.1073/pnas.92.25.11916; Diverse-Pierluissi M, 2000, J BIOL CHEM, V275, P28380, DOI 10.1074/jbc.M003571200; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; DiversePierluissi M, 1996, NEURON, V16, P579, DOI 10.1016/S0896-6273(00)80077-X; DIVERSEPIERLUISSI M, 1995, NEURON, V14, P191, DOI 10.1016/0896-6273(95)90254-6; DiversePierluissi M, 1997, P NATL ACAD SCI USA, V94, P5417, DOI 10.1073/pnas.94.10.5417; Doupnik CA, 1997, P NATL ACAD SCI USA, V94, P10461, DOI 10.1073/pnas.94.19.10461; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; DUNLAP K, 1981, BRIT J PHARMACOL, V74, P579, DOI 10.1111/j.1476-5381.1981.tb10467.x; Fischer T, 2000, P NATL ACAD SCI USA, V97, P4040, DOI 10.1073/pnas.97.8.4040; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; Fujita S, 2000, J PHYSIOL-LONDON, V526, P341, DOI 10.1111/j.1469-7793.2000.00341.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Harder S, 2001, ENDOCRINOLOGY, V142, P1188, DOI 10.1210/en.142.3.1188; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; Jeong SW, 2000, J NEUROSCI, V20, P4489, DOI 10.1523/JNEUROSCI.20-12-04489.2000; Jeong SW, 2001, J PHYSIOL-LONDON, V535, P335, DOI 10.1111/j.1469-7793.2001.00335.x; Kammermeier PJ, 1999, NEURON, V22, P819, DOI 10.1016/S0896-6273(00)80740-0; Keir MJ, 1999, MOL BRAIN RES, V71, P279, DOI 10.1016/S0169-328X(99)00199-0; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Lu Q, 2001, J NEUROSCI, V21, P2949, DOI 10.1523/JNEUROSCI.21-09-02949.2001; Lu Q, 1999, J BIOL CHEM, V274, P34566, DOI 10.1074/jbc.274.49.34566; LUEBKE JI, 1994, PFLUG ARCH EUR J PHY, V428, P499, DOI 10.1007/BF00374571; Makino ER, 1999, P NATL ACAD SCI USA, V96, P1947, DOI 10.1073/pnas.96.5.1947; Melliti K, 2001, J PHYSIOL-LONDON, V532, P337, DOI 10.1111/j.1469-7793.2001.0337f.x; Melliti K, 1999, J GEN PHYSIOL, V113, P97, DOI 10.1085/jgp.113.1.97; Melliti K, 2000, J NEUROSCI, V20, P7167; Miles RR, 2000, ENDOCRINOLOGY, V141, P28, DOI 10.1210/en.141.1.28; Muller RT, 1997, MOL BIOL CELL, V8, P2039, DOI 10.1091/mbc.8.10.2039; Ogier-Denis E, 2000, J BIOL CHEM, V275, P39090, DOI 10.1074/jbc.M006198200; OgierDenis E, 1997, J BIOL CHEM, V272, P24599, DOI 10.1074/jbc.272.39.24599; Park D, 1998, J NEUROSCI, V18, P6757; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Saitoh O, 2001, J BIOL CHEM, V276, P5052, DOI 10.1074/jbc.M006917200; Saitoh O, 1997, NATURE, V390, P525, DOI 10.1038/37385; Schiff ML, 2000, NATURE, V408, P723, DOI 10.1038/35047093; Shea LD, 2000, LIFE SCI, V68, P647, DOI 10.1016/S0024-3205(00)00977-2; Srinivasa SP, 1998, P NATL ACAD SCI USA, V95, P5584, DOI 10.1073/pnas.95.10.5584; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P6477, DOI 10.1073/pnas.87.17.6477; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; TOSETTI P, 1999, SOC NEUR ABSTR, V25; TURNER TJ, 1989, ANAL BIOCHEM, V178, P8, DOI 10.1016/0003-2697(89)90347-3; Woulfe DS, 1999, J BIOL CHEM, V274, P17718, DOI 10.1074/jbc.274.25.17718; Wylie F, 1999, AM J PHYSIOL-CELL PH, V276, pC497, DOI 10.1152/ajpcell.1999.276.2.C497; Yan YB, 1997, J BIOL CHEM, V272, P11924, DOI 10.1074/jbc.272.18.11924; Zeng WZ, 1998, J BIOL CHEM, V273, P34687, DOI 10.1074/jbc.273.52.34687; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	63	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46001	46009		10.1074/jbc.M207874200	http://dx.doi.org/10.1074/jbc.M207874200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270936	hybrid			2022-12-25	WOS:000179529300040
J	Zhao, B; Bower, MJ; McDevitt, PJ; Zhao, HZ; Davis, ST; Johanson, KO; Green, SM; Concha, NO; Zhou, BBS				Zhao, B; Bower, MJ; McDevitt, PJ; Zhao, HZ; Davis, ST; Johanson, KO; Green, SM; Concha, NO; Zhou, BBS			Structural basis for Chk1 inhibition by UCN-01	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHECKPOINT KINASE CHK1; PROTEIN-KINASE; 7-HYDROXYSTAUROSPORINE UCN-01; CRYSTAL-STRUCTURE; CYTOTOXICITY	Chk1 is a serine-threonine kinase that plays an important role in the DNA damage response, including G(2)/M cell cycle control. UCN-01 (7-hydroxystaurosporine), currently in clinical trials, has recently been shown to be a potent Chk1 inhibitor that abrogates the G(2)/M checkpoint induced by DNA-damaging agents. To understand the structural basis of Chk1 inhibition by UCN-01, we determined the crystal structure of the Chk1 kinase domain in complex with UCN-01. Chk1 structures with staurosporine and its analog SB-218078 were also determined. All three compounds bind in the ATP-binding pocket of Chk1, producing only slight changes in the protein conformation. Selectivity of UCN-01 toward Chk1 over cyclin-dependent kinases can be explained by the presence of a hydroxyl group in the lactam moiety interacting with the ATP-binding pocket. Hydrophobic interactions and hydrogen-bonding interactions were observed in the structures between UCN-01 and the Chk1 kinase domain. The high structural complementarity of these interactions is consistent with the potency and selectivity of UCN-01.	GlaxoSmithKline, Dept Biol Struct, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Phys & Struct Chem, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Prot Biochem, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Gene Express Sci, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept Oncol Res, King Of Prussia, PA 19406 USA; GlaxoSmithKline, Dept High Through Put Biol, Res Triangle Pk, NC 27709 USA	GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline; GlaxoSmithKline	Zhou, BBS (corresponding author), Incyte Genom Inc, Stine Haskell Res Ctr, 1090 Elkon Rd, Newark, DE 19714 USA.	binbing_s_zhou@yahoo.com	ID, IMCACAT/D-5867-2014					BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; Bunch RT, 1996, CLIN CANCER RES, V2, P791; Busby EC, 2000, CANCER RES, V60, P2108; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; deAzevedo WF, 1996, P NATL ACAD SCI USA, V93, P2735, DOI 10.1073/pnas.93.7.2735; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Graves PR, 2000, J BIOL CHEM, V275, P5600, DOI 10.1074/jbc.275.8.5600; Gray N, 1999, CURR MED CHEM, V6, P859; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; Hu H, 1996, DRUG DISCOV TODAY, V1, P438, DOI 10.1016/S1359-6446(96)80010-9; Jackson JR, 2000, CANCER RES, V60, P566; JANIN J, 1990, J BIOL CHEM, V265, P16027; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawrie AM, 1997, NAT STRUCT BIOL, V4, P796, DOI 10.1038/nsb1097-796; Liu QH, 2000, GENE DEV, V14, P1448; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Sausville EA, 2001, J CLIN ONCOL, V19, P2319, DOI 10.1200/JCO.2001.19.8.2319; Shao RG, 1997, CANCER RES, V57, P4029; Takai H, 2000, GENE DEV, V14, P1439; Wang QZ, 1996, J NATL CANCER I, V88, P956, DOI 10.1093/jnci/88.14.956; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	26	185	196	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46609	46615		10.1074/jbc.M201233200	http://dx.doi.org/10.1074/jbc.M201233200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244092	hybrid			2022-12-25	WOS:000179529300117
J	Zhu, MH; Janssen, E; Leung, K; Zhang, WU				Zhu, MH; Janssen, E; Leung, K; Zhang, WU			Molecular cloning of a novel gene encoding a membrane-associated adaptor protein (LAX) in lymphocyte signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL RECEPTOR; ANTIGEN RECEPTOR; TYROSINE KINASE; MEDIATED ACTIVATION; LINKER PROTEINS; SLP-76; PATHWAYS; TCR; TRANSDUCTION; INTEGRATION	Membrane-associated adaptors play an important role in coupling antigen receptor engagement to downstream signaling events, such as Ras-MAPK activation, Ca2+ flux, and nuclear factor of activated T cells (NFAT) activation. Here we identified a novel membrane-associated adaptor protein, LAX. LAX is mainly expressed in B cells, T cells, and other lymphoid-specific cell types. It shares no overall sequence homology with LAT and is not localized to lipid rafts. However, like LAT, LAX has tyrosine motifs for binding Grb2, Gads, and the p85 subunit of phosphatidylinositol 3-kinase. Upon stimulation via the B or T cell receptors, LAX is rapidly phosphorylated by Src and Syk family tyrosine kinases and interacts with Grb2, Gads, and p85. Overexpression of LAX in Jurkat cells specifically inhibits T cell receptor-mediated p38 MAPK activation and NFAT/AP-1 transcriptional activation. Our data suggested that LAX functions to negatively regulate signaling in lymlphocytes.	Duke Univ, Dept Immunol, Ctr Med, Durham, NC 27710 USA	Duke University	Zhang, WU (corresponding author), Duke Univ, Dept Immunol, Ctr Med, Rm 112,Jones Bldg,Box 3010, Durham, NC 27710 USA.			Janssen, Erin/0000-0002-0687-2550	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048674] Funding Source: NIH RePORTER; NIAID NIH HHS [1R01 AI48674-01, R01 AI048674] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Boerth NJ, 2000, J EXP MED, V192, P1047, DOI 10.1084/jem.192.7.1047; Chan AC, 1996, CURR OPIN IMMUNOL, V8, P394, DOI 10.1016/S0952-7915(96)80130-0; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; Clements JL, 1999, ANNU REV IMMUNOL, V17, P89, DOI 10.1146/annurev.immunol.17.1.89; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Facchetti F, 1999, AM J PATHOL, V154, P1037, DOI 10.1016/S0002-9440(10)65356-4; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; Kelly ME, 2000, CURR OPIN IMMUNOL, V12, P267, DOI 10.1016/S0952-7915(00)00086-8; Kurosaki T, 2000, CURR OPIN IMMUNOL, V12, P276, DOI 10.1016/S0952-7915(00)00087-X; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Matsuda S, 1998, J BIOL CHEM, V273, P12378, DOI 10.1074/jbc.273.20.12378; Mulroy T, 2001, EUR J IMMUNOL, V31, P3056, DOI 10.1002/1521-4141(2001010)31:10<3056::AID-IMMU3056>3.0.CO;2-B; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rincon M, 2000, FREE RADICAL BIO MED, V28, P1328, DOI 10.1016/S0891-5849(00)00219-7; Rudd CE, 1999, CELL, V96, P5, DOI 10.1016/S0092-8674(00)80953-8; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; Tamir I, 1998, ONCOGENE, V17, P1353, DOI 10.1038/sj.onc.1202187; Wange RL, 1996, IMMUNITY, V5, P197, DOI 10.1016/S1074-7613(00)80315-5; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wong J, 2000, J BIOL CHEM, V275, P33116, DOI 10.1074/jbc.M004467200; Yablonski D, 2001, MOL CELL BIOL, V21, P4208, DOI 10.1128/MCB.21.13.4208-4218.2001; Yablonski D, 1998, SCIENCE, V281, P413, DOI 10.1126/science.281.5375.413; Yoder J, 2001, SCIENCE, V291, P1987, DOI 10.1126/science.1057176; Zhang J, 1999, J IMMUNOL, V162, P3819; Zhang WG, 2000, SEMIN IMMUNOL, V12, P35, DOI 10.1006/smim.2000.0205; Zhang WG, 1999, INT IMMUNOL, V11, P943, DOI 10.1093/intimm/11.6.943; Zhang WG, 1998, IMMUNITY, V9, P239, DOI 10.1016/S1074-7613(00)80606-8; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	33	60	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46151	46158		10.1074/jbc.M208946200	http://dx.doi.org/10.1074/jbc.M208946200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359715	hybrid			2022-12-25	WOS:000179529300060
J	Sinha, SK; Zachariah, S; Quinones, HI; Shindo, M; Chaudhary, PM				Sinha, SK; Zachariah, S; Quinones, HI; Shindo, M; Chaudhary, PM			Role of TRAF3 and -6 in the activation of the NF-kappa B and JNK pathways by X-linked ectodermal dysplasia receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; TNF RECEPTOR; MICE LACKING; ECTODYSPLASIN-A; HAIR-FOLLICLES; IKK-ALPHA; GENE; DROSOPHILA; KINASE; DEATH	X-linked ectodermal dysplasia receptor (XEDAR) is a recently isolated member of the tumor necrosis factor receptor family that has been shown to be highly expressed in ectodermal derivatives during embryonic development and binds to ectodysplasin-A2 (EDA-A2). By using a subclone of 293F cells with stable expression of XEDAR, we report that XEDAR activates the NF-kappaB and JNK pathways in an EDA-A2-dependent fashion. Treatment with EDA-A2 leads to the recruitment of TRAF3 and -6 to the aggregated XEDAR complex, suggesting a central role of these adaptors in the proximal aspect of XEDAR signaling. Whereas TRAF3 and -6, IKK1/IKKalpha, IKK2/IKKbeta, and NEMO/IKKgamma are involved in XEDAR-induced NF-kappaB activation, XEDAR-induced JNK activation seems to be mediated via a pathway dependent on TRAF3, TRAF6, and ASK1. Deletion and point mutagenesis studies delineate two distinct regions in the cytoplasmic domain of XEDAR, which are involved in binding to TRAF3 and -6, respectively, and play a major role in the activation of the NF-kappaB and JNK pathways. Taken together, our results establish a major role of TRAF3 and -6 in XEDAR signaling and in the process of ectodermal differentiation.	Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Div Hematol Oncol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chaudhary, PM (corresponding author), Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Chaudhary, Preet/E-1970-2018		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR041940] Funding Source: NIH RePORTER; NIAMS NIH HHS [P30-AR41940-09] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Baker SJ, 1996, ONCOGENE, V12, P1; Bayes M, 1998, HUM MOL GENET, V7, P1661, DOI 10.1093/hmg/7.11.1661; Belvin MP, 1996, ANNU REV CELL DEV BI, V12, P393, DOI 10.1146/annurev.cellbio.12.1.393; Bradley JR, 2001, ONCOGENE, V20, P6482, DOI 10.1038/sj.onc.1204788; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Copley RR, 1999, J MOL MED-JMM, V77, P361, DOI 10.1007/s001090050362; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Eby MT, 2000, J BIOL CHEM, V275, P15336, DOI 10.1074/jbc.275.20.15336; Gamper C, 2001, HUM IMMUNOL, V62, P1167, DOI 10.1016/S0198-8859(01)00284-1; Headon DJ, 1999, NAT GENET, V22, P370, DOI 10.1038/11943; Headon DJ, 2001, NATURE, V414, P913, DOI 10.1038/414913a; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kere J, 1996, NAT GENET, V13, P409, DOI 10.1038/ng0895-409; Knust E, 1996, CURR BIOL, V6, P379, DOI 10.1016/S0960-9822(02)00500-6; Kockel L, 1997, GENE DEV, V11, P1748, DOI 10.1101/gad.11.13.1748; Kojima T, 2000, J BIOL CHEM, V275, P20742, DOI 10.1074/jbc.M002691200; Kumar A, 2001, J BIOL CHEM, V276, P2668, DOI 10.1074/jbc.M008356200; Laurikkala J, 2002, DEVELOPMENT, V129, P2541; Lee SY, 1997, IMMUNITY, V7, P703, DOI 10.1016/S1074-7613(00)80390-8; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Monreal AW, 1999, NAT GENET, V22, P366, DOI 10.1038/11937; Munoz F, 1997, AM J HUM GENET, V61, P94; Naito A, 2002, P NATL ACAD SCI USA, V99, P8766, DOI 10.1073/pnas.132636999; PINHEIRO M, 1994, AM J MED GENET, V53, P153, DOI 10.1002/ajmg.1320530207; Qian YC, 2002, P NATL ACAD SCI USA, V99, P9386, DOI 10.1073/pnas.142294499; Schmidt-Ullrich R, 2001, DEVELOPMENT, V128, P3843; Seitz CS, 1998, P NATL ACAD SCI USA, V95, P2307, DOI 10.1073/pnas.95.5.2307; Seitz CS, 2000, J CLIN INVEST, V105, P253, DOI 10.1172/JCI7630; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Srivastava AK, 1997, P NATL ACAD SCI USA, V94, P13069, DOI 10.1073/pnas.94.24.13069; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; van Eyndhoven WG, 1999, MOL IMMUNOL, V36, P647, DOI 10.1016/S0161-5890(99)00079-6; Yan MH, 2002, CURR BIOL, V12, P409, DOI 10.1016/S0960-9822(02)00687-5; Yan MH, 2000, SCIENCE, V290, P523, DOI 10.1126/science.290.5491.523; Ye H, 1999, MOL CELL, V4, P321, DOI 10.1016/S1097-2765(00)80334-2; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	43	57	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44953	44961		10.1074/jbc.M207923200	http://dx.doi.org/10.1074/jbc.M207923200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270937	hybrid			2022-12-25	WOS:000179404800048
J	Huang, YH; Wu, JYJ; Zhang, YJ; Wu, MX				Huang, YH; Wu, JYJ; Zhang, YJ; Wu, MX			Synergistic and opposing regulation of the stress-responsive gene IEX-1 by p53, c-Myc, and multiple NF-kappa B/rel complexes	ONCOGENE			English	Article						NF-kappa B; p53; c-Myc; IEX-1 and transcription	IMMEDIATE-EARLY GENE; INDUCED CELL-DEATH; MICE LACKING; TARGET GENE; B RELA; APOPTOSIS; EXPRESSION; PROTEIN; BINDING; GROWTH	NF-kappaB/rel proteins, tumor suppressor p53, and oncogene c-Myc are critical transcription factors involved in coordinating cellular decision-making events in response to external stimuli. Consensus sequences for binding these three transcription factors are found in the promoter region of IEX-1 (Immediate Early response gene X-1) gene that can either suppress or induce apoptosis in a cell- and stimulus-dependent manner. Utilizing an electrophoretic mobility shift assay (EMSA) and a promoter/reporter assay, we show that the NF-kappaB/rel consensus sequence in the IEX-1 promoter is specifically bound and activated by multiple NF-kappaB/rel complexes in descending order p65-c-rel-->p65-50-->p50-50. Interestingly, NF-kappaB/rel-mediated activation of IEX-1 expression was synergized by p53, but strongly inhibited by c-Myc in a dose-dependent fashion. Moreover, the ability of c-Myc to inhibit IEX-1 expression requires the presence of functional p53, which may partially contribute to the varying effects of p53 on IEX-1 expression in different cells. In support of coordinated regulation of IEX-1 expression by these three transcription factors in vivo, binding of endogenous p53, c-Myc and NF-kappaB/rel proteins, including p50, p65 and c-rel, to the IEX-1 promoter was demonstrated in living cells by chromatin immunoprecipitation using specific antibodies. The study reveals a novel integrative regulation of specific gene expression by NF-kappaB/rel, p53 and c-Myc transcription factors.	Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Shionogi BioRes, Lexington, MA 02420 USA	Baylor College of Medicine; Shionogi & Company Limited	Wu, MX (corresponding author), Boston Med Ctr, Dept Mol & Cell Biol, 715 Albany St Evans 4, Boston, MA 02118 USA.				NIAID NIH HHS [AI45003] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045003] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arlt A, 2001, ONCOGENE, V20, P69, DOI 10.1038/sj.onc.1204061; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Bates S, 1999, CELL MOL LIFE SCI, V55, P28, DOI 10.1007/s000180050267; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Benoit V, 2000, ONCOGENE, V19, P4787, DOI 10.1038/sj.onc.1203831; BLACKWELL TK, 1990, SCIENCE, V250, P1149, DOI 10.1126/science.2251503; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Ceballos E, 2000, ONCOGENE, V19, P2194, DOI 10.1038/sj.onc.1203541; CHARLES CH, 1993, ONCOGENE, V8, P797; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Domachowske JB, 2000, J INFECT DIS, V181, P824, DOI 10.1086/315319; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Feldmann KA, 2001, HISTOCHEM CELL BIOL, V115, P489; GRILLI M, 1993, INT REV CYTOL, V143, P1; Grobe O, 2001, FEBS LETT, V494, P196, DOI 10.1016/S0014-5793(01)02344-4; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; HERMEKING H, 1994, SCIENCE, V265, P2091, DOI 10.1126/science.8091232; Ikeda A, 2000, BIOCHEM BIOPH RES CO, V272, P375, DOI 10.1006/bbrc.2000.2786; Im HJ, 2002, J BIOL CHEM, V277, P14612, DOI 10.1074/jbc.M109414200; Jung M, 1998, RADIAT RES, V149, P596, DOI 10.2307/3579906; Kawai H, 1999, CANCER RES, V59, P6038; Kobayashi T, 1998, BIOCHEM BIOPH RES CO, V251, P868, DOI 10.1006/bbrc.1998.9556; Kondratyev AD, 1996, CANCER RES, V56, P1498; KONTGEN F, 1995, GENE DEV, V9, P1965, DOI 10.1101/gad.9.16.1965; Kumar R, 1998, BIOCHEM BIOPH RES CO, V253, P336, DOI 10.1006/bbrc.1998.9692; LANE DP, 1993, NATURE, V362, P786, DOI 10.1038/362786a0; PARRY GCN, 1994, J BIOL CHEM, V269, P20823; Pietzsch A, 1998, BIOCHEM BIOPH RES CO, V245, P651, DOI 10.1006/bbrc.1998.8500; Prendergast GC, 1999, ONCOGENE, V18, P2967, DOI 10.1038/sj.onc.1202727; Ravi R, 1998, CANCER RES, V58, P4531; Sala A, 1996, CANCER RES, V56, P1991; Schafer H, 1998, FEBS LETT, V436, P139, DOI 10.1016/S0014-5793(98)01109-0; Schafer H, 1999, PANCREAS, V18, P378, DOI 10.1097/00006676-199905000-00008; Schafer H, 1998, ONCOGENE, V16, P2479, DOI 10.1038/sj.onc.1201788; Schilling D, 2001, ONCOGENE, V20, P7992, DOI 10.1038/sj.onc.1204965; Segev DL, 2000, J BIOL CHEM, V275, P28371, DOI 10.1074/jbc.M004554200; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Thompson EB, 1998, ANNU REV PHYSIOL, V60, P575, DOI 10.1146/annurev.physiol.60.1.575; URBAN MB, 1991, EMBO J, V10, P1817, DOI 10.1002/j.1460-2075.1991.tb07707.x; VAN AD, 1996, SCIENCE, V274, P787; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; Wadgaonkar R, 1999, J BIOL CHEM, V274, P1879, DOI 10.1074/jbc.274.4.1879; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X; Zhang Y, 2002, P NATL ACAD SCI USA, V99, P878, DOI 10.1073/pnas.022326699	50	41	46	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6819	6828		10.1038/sj.onc.1205854	http://dx.doi.org/10.1038/sj.onc.1205854			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360408				2022-12-25	WOS:000178315800012
J	Caetano, MS; Vieira-De-Abreu, A; Teixeira, LK; Werneck, MBF; Barcinski, MA; Viola, JPB				Caetano, MS; Vieira-De-Abreu, A; Teixeira, LK; Werneck, MBF; Barcinski, MA; Viola, JPB			NFATC2 transcription factor regulates cell cycle progression during lymphocyte activation: evidence of its involvement in the control of cyclin gene expression	FASEB JOURNAL			English	Article						NFAT; T cell; proliferation; apoptosis	HUMAN T-CELLS; SWISS 3T3 FIBROBLASTS; IMMUNE-RESPONSE; DEATH OCCURS; MICE LACKING; CALCINEURIN; APOPTOSIS; PHASE; IL-4; DIFFERENTIATION	Upon antigen stimulation, lymphocytes enter in cell cycle and proliferate, and most of the activated T cells die by apoptosis. Many of the proteins that regulate lymphocyte activation are under the control of transcription factors belonging to the NEAT family. As previously demonstrated, NFATC2-/- mice consistently showed a marked increase in lymphocyte proliferation. Here, we evaluate the role of NFATC2 in regulating lymphocyte proliferation and its involvement in the control of cell cycle progression during lymphocyte activation. NFATC2/- lymphocytes, including CD4(+) T cells and B cells, hyperproliferated upon stimulation when compared with NFATC2+/+ cells. Analysis of cell death demonstrated that NFATC2-/- lymphocytes displayed an increased rate of apoptosis after antigen stimulation in addition to the hyperproliferation. Cell cycle analysis after antigen stimulation showed that NFATC2-/- cultures contained more cycling cells when compared with NFATC2+/+ cultures, which is related to a shortening in time of cell division upon activation. Furthermore, hyperproliferation of NFATC2-/- lymphocytes is correlated to an overexpression of cyclins A2, B1, E, and F. Taken together, our results suggest that the NFATC2 transcription factor plays an important role in the control of cell cycle during lymphocyte activation and may act as an inhibitor of cell proliferation in normal cells.	INCA, Inst Nacl Canc, Div Expt Med, BR-20230130 Rio De Janeiro, Brazil; USP, Dept Parasitol, BR-09500900 Sao Paulo, Brazil	National Cancer Institute (Inca); Universidade de Sao Paulo	Viola, JPB (corresponding author), INCA, Inst Nacl Canc, Div Expt Med, Praca Cruz Vermelha 23-6 andar, BR-20230130 Rio De Janeiro, Brazil.	jpviola@inca.gov.br	Viola, Joao P.B./AAP-4125-2020; Werneck, Miriam B.F./H-5802-2012; Teixeira, Leonardo Karam/S-8773-2016	Viola, Joao P.B./0000-0002-0698-3146; Teixeira, Leonardo Karam/0000-0001-6117-423X; Werneck, Miriam/0000-0003-1287-8526				ANRAKU Y, 1991, BIOCHIM BIOPHYS ACTA, V1093, P169, DOI 10.1016/0167-4889(91)90119-I; Baksh S, 2000, ONCOGENE, V19, P2820, DOI 10.1038/sj.onc.1203585; Ben-Sasson SZ, 2001, J IMMUNOL, V166, P112, DOI 10.4049/jimmunol.166.1.112; Bird JJ, 1998, IMMUNITY, V9, P229, DOI 10.1016/S1074-7613(00)80605-6; Blanchard P, 2000, ELECTROCHEM COMMUN, V2, P1, DOI 10.1016/S1388-2481(99)00130-7; BOEHME SA, 1993, EUR J IMMUNOL, V23, P1552, DOI 10.1002/eji.1830230724; COHEN PL, 1991, ANNU REV IMMUNOL, V9, P243, DOI 10.1146/annurev.iy.09.040191.001331; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; Desdouets C, 1999, BIOCHEM BIOPH RES CO, V261, P118, DOI 10.1006/bbrc.1999.0575; FOTEDAR R, 1995, MOL CELL BIOL, V15, P932; Fournel S, 1996, J IMMUNOL, V157, P4309; Grogan JL, 2001, IMMUNITY, V14, P205, DOI 10.1016/S1074-7613(01)00103-0; Hodge MR, 1996, IMMUNITY, V4, P397, DOI 10.1016/S1074-7613(00)80253-8; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; Karas M, 1999, MOL BIOL CELL, V10, P4441, DOI 10.1091/mbc.10.12.4441; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; Kiani A, 1997, IMMUNITY, V7, P849, DOI 10.1016/S1074-7613(00)80403-3; Kramer A, 1998, LEUKEMIA, V12, P893, DOI 10.1038/sj.leu.2401051; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Li QS, 2000, EUR J IMMUNOL, V30, P3329, DOI 10.1002/1521-4141(200011)30:11<3329::AID-IMMU3329>3.0.CO;2-#; Lissy NA, 1998, IMMUNITY, V8, P57, DOI 10.1016/S1074-7613(00)80458-6; Liu Z, 1995, WIREL NETW, V1, P1, DOI 10.1007/BF01196254; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Ranger AM, 1998, IMMUNITY, V9, P627, DOI 10.1016/S1074-7613(00)80660-3; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rengarajan J, 2002, NAT IMMUNOL, V3, P48, DOI 10.1038/ni744; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; Roberts JM, 1999, CELL, V98, P129, DOI 10.1016/S0092-8674(00)81007-7; RUSSELL JH, 1993, P NATL ACAD SCI USA, V90, P4409, DOI 10.1073/pnas.90.10.4409; RUSSELL JH, 1993, EUR J IMMUNOL, V23, P2379, DOI 10.1002/eji.1830230951; Scuderi R, 1996, BLOOD, V87, P3360, DOI 10.1182/blood.V87.8.3360.bloodjournal8783360; TERADA N, 1991, J IMMUNOL, V147, P698; Tomono M, 1998, ARCH BIOCHEM BIOPHYS, V353, P374, DOI 10.1006/abbi.1998.0667; Tomono M, 1996, BIOCHEM J, V317, P675, DOI 10.1042/bj3170675; Trama J, 2000, J IMMUNOL, V165, P4884, DOI 10.4049/jimmunol.165.9.4884; VINDELOV LL, 1977, VIRCHOWS ARCH B, V24, P227; Viola JPB, 1998, BLOOD, V91, P2223, DOI 10.1182/blood.V91.7.2223.2223_2223_2230; Viola JPB, 1999, J CLIN IMMUNOL, V19, P98, DOI 10.1023/A:1020502516196; Xanthoudakis S, 1996, SCIENCE, V272, P892, DOI 10.1126/science.272.5263.892; Yang R, 1999, BLOOD, V93, P2067; Yoshida H, 1998, IMMUNITY, V8, P115, DOI 10.1016/S1074-7613(00)80464-1	44	71	73	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1940	+		10.1096/fj.02-0282fje	http://dx.doi.org/10.1096/fj.02-0282fje			20	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368232				2022-12-25	WOS:000179167600023
J	Planaguma, A; Titos, E; Lopez-Parra, M; Gaya, J; Pueyo, G; Arroyo, V; Claria, J				Planaguma, A; Titos, E; Lopez-Parra, M; Gaya, J; Pueyo, G; Arroyo, V; Claria, J			Aspirin (ASA) regulates 5-lipoxygenase activity and peroxisome proliferator-activated receptor alpha-mediated CINC-1 release in rat liver cells: novel actions of lipoxin A(4) (LXA(4)) and ASA-triggered 15-epi-LXA(4)	FASEB JOURNAL			English	Article						Kupffer cells; hepatocytes; nonsteroidal antiinflammatory drug; arachidonic acid metabolites	SODIUM-SALICYLATE; PPAR-ALPHA; PROTEIN; INFLAMMATION; GAMMA; CYCLOOXYGENASE; INTERLEUKIN-8; LEUKOTRIENES; EICOSANOIDS; EXPRESSION	The mechanism of action of aspirin (ASA) is related to cyclooxygenase (COX) inhibition, but additional actions cannot be excluded for their antiinflammatory properties and antithrombotic activity. In the current investigation, we examined the effects of ASA on COX and 5-lipoxygenase (5-LO) pathways and its impact on peroxisome proliferator-activated receptor alpha (PPARalpha.) and cytokine-induced neutrophil chemoattractant-1 (CINC-1) levels in rat liver cells. In Kupffer cells, the liver resident macrophages, ASA switched eicosanoid biosynthesis from prostaglandin E-2 (PGE(2)) to leukotriene B-4 (LTB4) and 15-epi-lipoxin A(4) (15-epi-LXA(4)) formation. In hepatocytes, ASA significantly inhibited PPARalpha. protein expression and CINC-1 secretion, effects that were also observed in hepatocytes exposed to the selective PPARalpha agonist Wy-14643. In contrast, treatment of hepatocytes with PGE2 in association with LTB4 had no significant effect on PPARalpha. but stimulated CINC-1 release. Interestingly, the endogenous antiinflammatory eicosanoids LXA(4) and ASA-triggered 15-epi-LXA(4), in addition to inhibiting macrophage 5-LO activity to a similar extent as PGE(2), significantly reduced PPARalpha and CINC-1 levels in hepatocytes. Taken together and because arachidonic acid-derived products, PPARalpha levels, and CINC-1 secretion are involved in the extent and duration of an inflammatory response, these findings provide additional molecular mechanisms for the pharmacological properties of ASA.	Univ Barcelona, IDIBAPS, Hosp Clin, DNA Unit, E-08036 Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Hormonal Lab, E-08036 Barcelona, Spain; Univ Barcelona, IDIBAPS, Hosp Clin, Liver Unit, E-08036 Barcelona, Spain; Quim Farmaceut Bayer SA, CC Div, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Bayer AG	Claria, J (corresponding author), Univ Barcelona, IDIBAPS, Hosp Clin, DNA Unit, Villarroel 170, E-08036 Barcelona, Spain.	jclaria@clinic.ub.es	Claria, Joan/M-7772-2019; Arroyo, Vicente/F-9189-2015; Titos, Esther/AAA-5394-2019	Arroyo, Vicente/0000-0002-2728-1848; Titos, Esther/0000-0002-2543-2243; Claria, Joan/0000-0003-4333-7749				BALCAREK JM, 1988, J BIOL CHEM, V263, P13937; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BOCHNER F, 1988, EUR J CLIN PHARMACOL, V35, P287, DOI 10.1007/BF00558267; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; BREZINSKI DA, 1992, CIRCULATION, V86, P56, DOI 10.1161/01.CIR.86.1.56; Chinetti G, 2000, INFLAMM RES, V49, P497, DOI 10.1007/s000110050622; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CLARIA J, 1995, P NATL ACAD SCI USA, V92, P9475, DOI 10.1073/pnas.92.21.9475; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; Dong ZG, 1997, J BIOL CHEM, V272, P9962; Engstrom K, 2001, PROSTAG LEUKOTR ESS, V64, P291, DOI 10.1054/plef.2001.0275; FENG L, 1993, ARCH BIOCHEM BIOPHYS, V307, P361, DOI 10.1006/abbi.1993.1601; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Grilli M, 1996, SCIENCE, V274, P1383, DOI 10.1126/science.274.5291.1383; Gronert K, 1998, J EXP MED, V187, P1285, DOI 10.1084/jem.187.8.1285; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KIM DH, 1990, BIOCHEM PHARMACOL, V40, P481, DOI 10.1016/0006-2952(90)90546-W; KOOP E, 1994, SCIENCE, V265, P956; Lee H, 2000, CIRC RES, V87, P516; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Pang LH, 1998, J IMMUNOL, V161, P2509; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; PAYAN DG, 1995, BASIC CLIN PHARM, P538; Pillinger MH, 1998, P NATL ACAD SCI USA, V95, P14540, DOI 10.1073/pnas.95.24.14540; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwenger P, 1998, MOL CELL BIOL, V18, P78, DOI 10.1128/MCB.18.1.78; SERHAN CN, 1995, BIOCHEMISTRY-US, V34, P14609, DOI 10.1021/bi00044a041; Serhan CN, 1997, PROSTAG OTH LIPID M, V53, P107, DOI 10.1016/S0090-6980(97)00001-4; SKEEL A, 1991, J EXP MED, V173, P1227, DOI 10.1084/jem.173.5.1227; THUN MJ, 1991, NEW ENGL J MED, V325, P1593, DOI 10.1056/NEJM199112053252301; Titos E, 1999, AM J PHYSIOL-CELL PH, V277, pC870, DOI 10.1152/ajpcell.1999.277.5.C870; Titos E, 2000, GASTROENTEROLOGY, V119, P794, DOI 10.1053/gast.2000.17831; VANE JR, 1971, NATURE-NEW BIOL, V231, P232, DOI 10.1038/newbio231232a0; Wang ACC, 2001, AM J RESP CELL MOL, V24, P688, DOI 10.1165/ajrcmb.24.6.4376; WATANABE K, 1989, J BIOL CHEM, V264, P19559; WATANABE K, 1991, EXP MOL PATHOL, V55, P30, DOI 10.1016/0014-4800(91)90016-Q	37	52	53	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1937	+		10.1096/fj.02-0224fje	http://dx.doi.org/10.1096/fj.02-0224fje			16	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368230				2022-12-25	WOS:000179167600026
J	Chen, XL; Varner, SE; Rao, AS; Grey, JY; Thomas, S; Cook, CK; Wasserman, MA; Medford, RM; Jaiswal, AK; Kunsch, C				Chen, XL; Varner, SE; Rao, AS; Grey, JY; Thomas, S; Cook, CK; Wasserman, MA; Medford, RM; Jaiswal, AK; Kunsch, C			Laminar flow induction of antioxidant response element-mediated genes in endothelial cells - A novel anti-inflammatory mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLUID SHEAR-STRESS; NF-KAPPA-B; ADHESION MOLECULE-1 EXPRESSION; HEME OXYGENASE-1; TRANSCRIPTION FACTOR; ATHEROSCLEROTIC LESIONS; NITRIC-OXIDE; VCAM-1 GENE; PDGF-A; C-FOS	Atherosclerotic lesions preferentially develop in areas of the vasculature exposed to nonlaminar blood flow and low fluid shear stress, whereas laminar flow and high fluid shear stress are athero-protective. We have identified a set of genes including NAD(P)H:quinone oxidoreductase-1 (NQO1), heme oxygenase-1 (HO-1), ferritin (heavy and light chains), microsomal epoxide hydrolase, glutathione S-transferase, and gamma-glutamyleysteine synthase, whose expression is induced by exposure to prolonged physiological levels of steady laminar flow (shear stress = 20 dyn/cm(2)) in endothelial cells (EC). These genes contain an antioxidant response element (ARE) or ARE-like transcriptional regulatory sequence in their promoters and generally function to protect cells against oxidant stress. We demonstrate that exposure of EC to laminar flow activates ARE-mediated transcriptional activity. Mutation of the ARE from either the NQO1 or HO-1 promoter abolished laminar flow-induced NQO1 and HO-1 transcriptional activation. Expression of antisense Nrf2 (a transcriptional factor for ARE), a dominant negative Nrf2, or the cytoplasmic inhibitor of Nrf2 (Keap1/INrf2) inhibited laminar flow-induced NQO1 promoter activation in EC. In addition, expression of NQO1 or Nrf2 inhibited tumor necrosis factor-alpha-induced activation of VCAM-1 (vascular cell adhesion molecule-1) gene expression in EC. These data define the ARE as a novel endothelial shear stress response element. Furthermore, laminar flow activation of antioxidant genes via an ARE-dependent transcriptional mechanism may represent a novel athero-protective and anti-inflammatory mechanism in the vasculature.	AtheroGenics Inc, Discovery Res, Alpharetta, GA 30004 USA; Baylor Coll Med, Dept Pharmacol, Houston, TX 77025 USA	Baylor College of Medicine	Chen, XL (corresponding author), AtheroGenics Inc, Discovery Res, Alpharetta, GA 30004 USA.	xchen@atherogenics.com						Alam J, 1999, J BIOL CHEM, V274, P26071, DOI 10.1074/jbc.274.37.26071; ASAKURA T, 1990, CIRC RES, V66, P1045, DOI 10.1161/01.RES.66.4.1045; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BALLA G, 1992, J BIOL CHEM, V267, P18148; Bao XP, 1999, ARTERIOSCL THROM VAS, V19, P996, DOI 10.1161/01.ATV.19.4.996; Chan KM, 1999, P NATL ACAD SCI USA, V96, P12731, DOI 10.1073/pnas.96.22.12731; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Chen XL, 1998, CIRC RES, V83, P952; CHEN XL, 1999, PROG INFLAM RES, P161; Chen XLL, 1997, CIRC RES, V80, P305, DOI 10.1161/01.RES.80.3.305; Chiu JJ, 1997, ARTERIOSCL THROM VAS, V17, P3570, DOI 10.1161/01.ATV.17.12.3570; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; CORNHILL JF, 1980, ATHEROSCLEROSIS, V35, P77; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; Elbirt KK, 1999, P ASSOC AM PHYSICIAN, V111, P438, DOI 10.1111/paa.1999.111.5.438; Enomoto A, 2001, TOXICOL SCI, V59, P169, DOI 10.1093/toxsci/59.1.169; Griffith OW, 1999, ADV ENZYMOL RAMB, V73, P209, DOI 10.1002/9780470123195.ch7; Hayashi S, 1999, CIRC RES, V85, P663, DOI 10.1161/01.RES.85.8.663; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; HSIEH HJ, 1991, AM J PHYSIOL, V260, pH642, DOI 10.1152/ajpheart.1991.260.2.H642; Immenschuh S, 2000, BIOCHEM PHARMACOL, V60, P1121, DOI 10.1016/S0006-2952(00)00443-3; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Ishikawa K, 2001, CIRCULATION, V104, P1831, DOI 10.1161/hc3901.095897; Ishikawa K, 2001, CIRC RES, V88, P506, DOI 10.1161/01.RES.88.5.506; Ishikawa K, 1997, J CLIN INVEST, V100, P1209, DOI 10.1172/JCI119634; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; JAISWAL AK, 1994, BIOCHEM PHARMACOL, V48, P439, DOI 10.1016/0006-2952(94)90272-0; Kataoka K, 2001, J BIOL CHEM, V276, P34074, DOI 10.1074/jbc.M105383200; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; KINSTON RE, 1995, CURRENT PRTOTOCOLS M, V1; Korenaga R, 1997, AM J PHYSIOL-CELL PH, V273, pC1506; Li N, 2000, J IMMUNOL, V165, P3393, DOI 10.4049/jimmunol.165.6.3393; LI Y, 1992, J BIOL CHEM, V267, P15097; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Minamino T, 2001, P NATL ACAD SCI USA, V98, P8798, DOI 10.1073/pnas.161272598; Mohan S, 1999, AM J PHYSIOL-CELL PH, V276, pC1100, DOI 10.1152/ajpcell.1999.276.5.C1100; MONTENEGRO MR, 1968, LAB INVEST, V18, P586; Mueller CGF, 1997, J EXP MED, V186, P655, DOI 10.1084/jem.186.5.655; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; Nagel T, 1999, ARTERIOSCL THROM VAS, V19, P1825, DOI 10.1161/01.ATV.19.8.1825; NAGEL T, 1994, J CLIN INVEST, V94, P885, DOI 10.1172/JCI117410; Nerem RM, 1998, AM J MED SCI, V316, P169, DOI 10.1097/00000441-199809000-00004; Niki E, 1997, MOL ASPECTS MED, V18, pS63; PRESTERA T, 1995, P NATL ACAD SCI USA, V92, P8965, DOI 10.1073/pnas.92.19.8965; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; RESNICK N, 1995, FASEB J, V9, P874, DOI 10.1096/fasebj.9.10.7615157; Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SHAW PM, 1991, EUR J BIOCHEM, V195, P171, DOI 10.1111/j.1432-1033.1991.tb15691.x; SHYY JYJ, 1995, P NATL ACAD SCI USA, V92, P8069, DOI 10.1073/pnas.92.17.8069; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Strange RC, 2000, TOXICOL LETT, V112, P357, DOI 10.1016/S0378-4274(99)00230-1; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Tsao PS, 1996, CIRCULATION, V94, P1682, DOI 10.1161/01.CIR.94.7.1682; Tsuji Y, 2000, MOL CELL BIOL, V20, P5818, DOI 10.1128/MCB.20.16.5818-5827.2000; Tummala PE, 2000, J MOL CELL CARDIOL, V32, P1499, DOI 10.1006/jmcc.2000.1183; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; VONSTEIN OD, 1997, NUCLEIC ACIDS RES, V25, P1469; Wasserman WW, 1997, P NATL ACAD SCI USA, V94, P5361, DOI 10.1073/pnas.94.10.5361; XIE T, 1995, J BIOL CHEM, V270, P6894, DOI 10.1074/jbc.270.12.6894	63	266	276	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					703	711		10.1074/jbc.M203161200	http://dx.doi.org/10.1074/jbc.M203161200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12370194	hybrid			2022-12-25	WOS:000180321900003
J	Hurbin, A; Dubrez, L; Coll, JL; Favrot, MC				Hurbin, A; Dubrez, L; Coll, JL; Favrot, MC			Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I RECEPTOR; EGF-RELATED PEPTIDES; EPITHELIAL-CELLS; TUMOR-CELLS; HUMAN COLON; IGF-I; INSULIN-LIKE-GROWTH-FACTOR-1 RECEPTOR; SIGNALING NETWORK; CARCINOMA CELLS; HEPARIN-BINDING	Several abnormalities in the insulin-like growth factor-1 (IGF1) and erbB receptors pathways stimulate the growth and survival of lung cancer cells, but their mechanisms of action and cooperation are poorly understood. In this report, we have identified a new mechanism of apoptosis inhibition by amphiregulin through an IGF1-dependent survival pathway in non-small cell lung cancer (NSCLC) cells: amphiregulin activates the IGF1 receptor that in turn induces the secretion of amphiregulin and IGF1. In the absence of serum, the NSCLC cell line H358 resists apoptosis and secretes factors protecting the NSCLC cell line H322 from serum deprivation apoptosis. IGF1 receptor inhibitor AG1024 as well as epidermal growth factor receptor inhibitors AG556 and ZD1839 restore apoptosis in H322 cells cultured in H358-conditioned medium. Accordingly, the anti-apoptotic activity of H358-conditioned medium is completely abolished after incubation with anti-amphiregulin neutralizing antibody and only partially with anti-IGF1 neutralizing antibody. H358-conditioned medium and amphiregulin induce IGF1 receptor phosphorylation in H322 cells, which is prevented by anti-amphiregulin neutralizing antibody but not by AG556 or ZD1839. H358 cells secrete a high level of amphiregulin that, in combination with IGF1, prevents serum deprivation apoptosis. Finally, IGF1 receptor inhibitor blocks amphiregulin and IGF1 release by H358 cells.	Inst Albert Bonniot, INSERM, EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)	Favrot, MC (corresponding author), Inst Albert Bonniot, INSERM, EMI 9924, Grp Rech Canc Poumon, F-38706 La Tronche, France.	MCFavrot@chu-grenoble.fr	Coll, Jean-Luc/G-2520-2013; Dubrez, Laurence/I-4971-2016; Laurence, Dubrez/P-9472-2019; Hurbin, Amandine/M-2693-2013	Coll, Jean-Luc/0000-0002-2453-3552; Dubrez, Laurence/0000-0002-7030-2181; Laurence, Dubrez/0000-0002-7030-2181; Hurbin, Amandine/0000-0003-0535-1945				AKAGI M, 1995, CANCER, V75, P1460, DOI 10.1002/1097-0142(19950315)75:6+<1460::AID-CNCR2820751513>3.0.CO;2-L; Alemany R, 1996, CANCER GENE THER, V3, P296; Balana ME, 2001, ONCOGENE, V20, P34, DOI 10.1038/sj.onc.1204050; Baserga R, 2000, ONCOGENE, V19, P5574, DOI 10.1038/sj.onc.1203854; Blakesley VA, 1998, J BIOL CHEM, V273, P18411, DOI 10.1074/jbc.273.29.18411; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Casamassimi A, 2000, ANN ONCOL, V11, P319, DOI 10.1023/A:1008350811639; Chakravarti A, 2002, CANCER RES, V62, P200; Chen H, 1998, CELL GROWTH DIFFER, V9, P939; Cheng HL, 2000, MOL CELL ENDOCRINOL, V170, P211, DOI 10.1016/S0303-7207(00)00324-5; COLES HSR, 1993, DEVELOPMENT, V118, P777; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAmbrosio C, 1996, CANCER RES, V56, P4013; Damstrup L, 1999, BRIT J CANCER, V80, P1012, DOI 10.1038/sj.bjc.6690456; De Luca A, 2000, ONCOGENE, V19, P5863, DOI 10.1038/sj.onc.1203979; De Luca A, 1999, INT J CANCER, V80, P589, DOI 10.1002/(SICI)1097-0215(19990209)80:4<589::AID-IJC17>3.0.CO;2-D; Dews M, 1997, RECEPT SIGNAL TRANS, V7, P231; Dubrez L, 2001, J BIOL CHEM, V276, P38980, DOI 10.1074/jbc.M102683200; Esposito DL, 1997, ENDOCRINOLOGY, V138, P2979, DOI 10.1210/en.138.7.2979; Fernandes AM, 1999, CANCER LETT, V142, P55, DOI 10.1016/S0304-3835(99)00166-4; Fontanini G, 1998, CLIN CANCER RES, V4, P241; Funatomi H, 1997, INT J CANCER, V72, P512, DOI 10.1002/(SICI)1097-0215(19970729)72:3<512::AID-IJC21>3.0.CO;2-C; Gagnon A, 2001, ENDOCRINOLOGY, V142, P205, DOI 10.1210/en.142.1.205; Grimberg A, 2000, J CELL PHYSIOL, V183, P1, DOI 10.1002/(SICI)1097-4652(200004)183:1<1::AID-JCP1>3.0.CO;2-J; Hague A, 1997, BRIT J CANCER, V75, P960, DOI 10.1038/bjc.1997.167; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Hongo A, 1996, ONCOGENE, V12, P1231; Ilio KY, 1995, J ANDROL, V16, P482; JOHNSON GR, 1992, J CELL BIOL, V118, P741, DOI 10.1083/jcb.118.3.741; Jung YK, 1996, J BIOL CHEM, V271, P5112; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Lu YH, 2001, JNCI-J NATL CANCER I, V93, P1852, DOI 10.1093/jnci/93.24.1852; Ma L, 1999, ONCOGENE, V18, P6513, DOI 10.1038/sj.onc.1203042; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; MERLO GR, 1995, J CELL BIOL, V128, P1185, DOI 10.1083/jcb.128.6.1185; MOODY TW, 1993, LIFE SCI, V52, P1161, DOI 10.1016/0024-3205(93)90098-N; MUTA K, 1993, J CELL PHYSIOL, V156, P264, DOI 10.1002/jcp.1041560207; NORMANNO N, 1995, INT J CANCER, V62, P762, DOI 10.1002/ijc.2910620619; OConnor R, 1997, MOL CELL BIOL, V17, P427, DOI 10.1128/MCB.17.1.427; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; Piepkorn M, 1998, J INVEST DERMATOL, V111, P715, DOI 10.1046/j.1523-1747.1998.00390.x; Prisco M, 1997, MOL CELL BIOL, V17, P1084, DOI 10.1128/MCB.17.3.1084; Putz T, 1999, CANCER RES, V59, P227; RAWSON CL, 1991, J CELL BIOL, V113, P671, DOI 10.1083/jcb.113.3.671; RESNICOFF M, 1995, CANCER RES, V55, P2463; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; Rozengurt Enrique, 1999, Current Opinion in Oncology, V11, P116; RUSCH V, 1995, CANCER RES, V55, P1365; Rusch V, 1997, CLIN CANCER RES, V3, P515; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; SELL C, 1995, CANCER RES, V55, P303; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Sizemore N, 1999, GASTROENTEROLOGY, V117, P567, DOI 10.1016/S0016-5085(99)70449-X; Swantek JL, 1999, ENDOCRINOLOGY, V140, P3163, DOI 10.1210/en.140.7.3163; TATEISHI M, 1990, CANCER RES, V50, P7077; VARDY DA, 1995, J CELL PHYSIOL, V163, P257, DOI 10.1002/jcp.1041630206; Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1; Werner H, 1996, ADV CANCER RES, V68, P183, DOI 10.1016/S0065-230X(08)60354-1; Wu XF, 2000, JNCI-J NATL CANCER I, V92, P737, DOI 10.1093/jnci/92.9.737; ZHU CZ, 1994, J CEREBR BLOOD F MET, V14, P237, DOI 10.1038/jcbfm.1994.30; Zushi S, 1997, INT J CANCER, V73, P917, DOI 10.1002/(SICI)1097-0215(19971210)73:6<917::AID-IJC26>3.0.CO;2-#	63	78	83	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49127	49133		10.1074/jbc.M207584200	http://dx.doi.org/10.1074/jbc.M207584200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12356750	hybrid, Green Submitted			2022-12-25	WOS:000180028900006
J	Cayabyab, FS; Tsui, FWL; Schlichter, LC				Cayabyab, FS; Tsui, FWL; Schlichter, LC			Modulation of the ERG K+ current by the tyrosine phosphatase, SHP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN INWARD RECTIFIER; STIMULATING FACTOR-I; LONG QT SYNDROME; POTASSIUM CHANNEL; MOTH-EATEN; NERVOUS-SYSTEM; SIGNAL-TRANSDUCTION; CARDIAC-ARRHYTHMIA; VOLTAGE-DEPENDENCE; XENOPUS OOCYTES	We reported previously (Cayabyab, F. S., and Schlichter, L. C. (2002) J. Biol. Chem. 277, 13673-13681) a functional interaction between the ERG-1 K+ channel and Src tyrosine kinase, which increased the current. We now show that the tyrosine phosphatase, SHP-1, which is present in microglia, is increased after brain damage, and is activated by colony-stimulating factor-1, associates with ERG-1 and regulates the current. Patch clamp recordings from the MLS-9 microglia cells were made with pipette solutions containing a recombinant SHP-1 protein: wild type (SHP-1 wild type (wt)), catalytically active (SHP-1 S6), or the substrate-trapping mutant (SHP-1 Cys --> Ser). SHP-1 wt and SHP-1 S6 proteins decreased the current, an effect that was reversed by the phosphatase inhibitor, pervanadate, whereas SHP-1 Cys --> Ser increased the current. Moreover, transient transfection with cDNA for SHP-1 wt or SHP-1 S6 decreased the ERG current without decreasing the protein level. Tyrosine phosphorylation of ERG-1 was decreased by transfection with SHP-1 wt and increased by SHP-1 Cys --> Ser. The decrease in current by active SHP-1 was partly attributed to changes in the voltage dependence of activation and steady-state conductance, whereas inactivation kinetics and voltage dependence were not affected. Our results show that ERG-1 is a SHP-1 substrate constituting the first report that an ion current is regulated by SHP-1.	Toronto Western Res Inst, Cellular & Mol Biol Div, Toronto, ON, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Schlichter, LC (corresponding author), Toronto Western Hosp, MC 9-415,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	schlicht@uhnres.utoronto.ca	Cayabyab, Francisco/HHR-8711-2022					Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; Barros F, 1998, J PHYSIOL-LONDON, V511, P333, DOI 10.1111/j.1469-7793.1998.333bh.x; Bauer CK, 1999, MOL CELL ENDOCRINOL, V148, P37, DOI 10.1016/S0303-7207(98)00241-X; Bianchi L, 1998, CANCER RES, V58, P815; Blasioli J, 1999, J BIOL CHEM, V274, P2303, DOI 10.1074/jbc.274.4.2303; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; Cayabyab FS, 2002, J BIOL CHEM, V277, P13673, DOI 10.1074/jbc.M108211200; Chen HE, 1996, MOL CELL BIOL, V16, P3685, DOI 10.1128/mcb.16.7.3685; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Dong Q, 1999, J IMMUNOL, V162, P3220; Faravelli L, 1996, J PHYSIOL-LONDON, V496, P13, DOI 10.1113/jphysiol.1996.sp021661; Fedoroff S, 1997, NEUROSCI BIOBEHAV R, V21, P187, DOI 10.1016/S0149-7634(96)00009-7; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Holmgren M, 1998, NEURON, V21, P617, DOI 10.1016/S0896-6273(00)80571-1; Horvat A, 2001, J NEUROSCI, V21, P865, DOI 10.1523/JNEUROSCI.21-03-00865.2001; Jiao HY, 1997, EXP HEMATOL, V25, P592; Johnson JP, 1999, J GEN PHYSIOL, V113, P565, DOI 10.1085/jgp.113.4.565; KIEHN J, 1995, CIRC RES, V77, P1151, DOI 10.1161/01.RES.77.6.1151; Martin A, 1999, MOL IMMUNOL, V36, P1029, DOI 10.1016/S0161-5890(99)00126-1; Martin A, 1999, J BIOL CHEM, V274, P21725, DOI 10.1074/jbc.274.31.21725; MCCORMACK K, 1991, P NATL ACAD SCI USA, V88, P2931, DOI 10.1073/pnas.88.7.2931; Mustelin T., 1998, Frontiers in Bioscience, V3, pD1060; MUTA T, 1994, NATURE, V368, P70, DOI 10.1038/368070a0; Nakajima T, 1998, CIRC RES, V83, P415, DOI 10.1161/01.RES.83.4.415; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pei DH, 1996, P NATL ACAD SCI USA, V93, P1141, DOI 10.1073/pnas.93.3.1141; Pennefather PS, 1998, J GEN PHYSIOL, V111, P795, DOI 10.1085/jgp.111.6.795; PLUTZKY J, 1992, P NATL ACAD SCI USA, V89, P1123, DOI 10.1073/pnas.89.3.1123; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; Schlichter LC, 1996, GLIA, V17, P225, DOI 10.1002/(SICI)1098-1136(199607)17:3<225::AID-GLIA5>3.0.CO;2-#; Schonherr R, 1996, J PHYSIOL-LONDON, V493, P635, DOI 10.1113/jphysiol.1996.sp021410; Shi WM, 1997, J NEUROSCI, V17, P9423; Smith GAM, 2002, J BIOL CHEM, V277, P18528, DOI 10.1074/jbc.M200592200; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Strobl JS, 1995, GEN PHARMACOL, V26, P1643, DOI 10.1016/0306-3623(95)00062-3; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; TSUI FWL, 1994, IMMUNOL REV, V138, P185, DOI 10.1111/j.1600-065X.1994.tb00852.x; Vely F, 1997, EUR J IMMUNOL, V27, P1994, DOI 10.1002/eji.1830270825; Wang JL, 1998, J GEN PHYSIOL, V112, P637, DOI 10.1085/jgp.112.5.637; Wang SM, 1997, J PHYSIOL-LONDON, V502, P45, DOI 10.1111/j.1469-7793.1997.045bl.x; Wishcamper CA, 2001, J COMP NEUROL, V441, P118; YEUNG YG, 1992, J BIOL CHEM, V267, P23447; Zhou W, 1998, J GEN PHYSIOL, V111, P781, DOI 10.1085/jgp.111.6.781; Zou AR, 1998, J PHYSIOL-LONDON, V509, P129, DOI 10.1111/j.1469-7793.1998.129bo.x	53	16	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48130	48138		10.1074/jbc.M208448200	http://dx.doi.org/10.1074/jbc.M208448200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12361947	hybrid			2022-12-25	WOS:000179789600022
J	Dell'Acqua, ML; Dodge, KL; Tavalin, SJ; Scott, JD				Dell'Acqua, ML; Dodge, KL; Tavalin, SJ; Scott, JD			Mapping the protein phosphatase-2B anchoring site on AKAP79 - Binding and inhibition of phosphatase activity are mediated by residues 315-360	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C INTERACTION; REGULATORY SUBUNIT; TARGETED INHIBITION; SIGNALING COMPLEX; ION CHANNELS; II-BETA; CALCINEURIN; RECEPTORS; EXPRESSION; NFAT	Compartmentalization of protein kinases and phosphatases with substrates is a means to increase the efficacy of signal transduction events. The A-kinase anchoring protein, AKAP79, is a multivalent anchoring protein that maintains the cAMP-dependent protein kinase, protein kinase C, and protein phosphatase-2B (PP2B/calcineurin) at the postsynaptic membrane of excitatory synapses where it is recruited into complexes with N-methyl-D-aspartic acid or alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA)-subtype glutamate receptors. We have used cellular targeting of AKAP79 truncation and deletion mutants as an assay to map the PP2B-binding site on AKAP79. We demonstrate that residues 315-360 are necessary and sufficient for AKAP79-PP2B anchoring in cells. Multiple determinants contained within this region bind directly to the A subunit of PP2B and inhibit phosphatase activity. Peptides spanning the 315-360 region of AKAP79 can antagonize PP2B anchoring in vitro and targeting in transfected cells. Electrophysiological experiments further emphasize this point by demonstrating that a peptide encompassing residues 330-357 of AKAP79 attenuates PP2B-dependent down-regulation of GluR1 receptor currents when perfused into HEK293 cells. We propose that the structural features of this AKAP79-PP2B-binding domain may share similarities with other proteins that serve to coordinate PP2B localization and activity.	Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, Portland, OR 97201 USA; Univ Colorado, Hlth Sci Ctr, Sch Med, Dept Pharmacol, Denver, CO 80262 USA	Howard Hughes Medical Institute; Oregon Health & Science University; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Scott, JD (corresponding author), Oregon Hlth Sci Univ, Vollum Inst, Howard Hughes Med Inst, L474, Portland, OR 97201 USA.			Dell'Acqua, Mark/0000-0003-3798-3461	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM048231, R01GM048231] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040701] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM48231, R01 GM048231, R37 GM048231] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen PB, 1998, J BIOL CHEM, V273, P4089, DOI 10.1074/jbc.273.7.4089; Aramburu J, 1998, MOL CELL, V1, P627, DOI 10.1016/S1097-2765(00)80063-5; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BLUMENTHAL DK, 1986, J BIOL CHEM, V261, P8140; BREGMAN DB, 1991, J BIOL CHEM, V266, P7207; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CARR DW, 1992, J BIOL CHEM, V267, P16816; CARR DW, 1991, J BIOL CHEM, V266, P14188; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; Dodge KL, 1999, ENDOCRINOLOGY, V140, P5165, DOI 10.1210/en.140.11.5165; Faux MC, 1999, BIOCHEM J, V343, P443, DOI 10.1042/0264-6021:3430443; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; Feliciello A, 2001, J MOL BIOL, V308, P99, DOI 10.1006/jmbi.2001.4585; Fink MA, 2001, CIRC RES, V88, P291, DOI 10.1161/01.RES.88.3.291; Fraser IDC, 1999, NEURON, V23, P423, DOI 10.1016/S0896-6273(00)80795-3; Hausken ZE, 1996, J BIOL CHEM, V271, P29016, DOI 10.1074/jbc.271.46.29016; HIRSCH AH, 1992, J BIOL CHEM, V267, P2131; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jordan JD, 2000, CELL, V103, P193, DOI 10.1016/S0092-8674(00)00112-4; Kameyama K, 1998, NEURON, V21, P1163, DOI 10.1016/S0896-6273(00)80633-9; Kashishian A, 1998, J BIOL CHEM, V273, P27412, DOI 10.1074/jbc.273.42.27412; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Lai MM, 2000, J BIOL CHEM, V275, P34017, DOI 10.1074/jbc.C000429200; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; Lee HK, 1998, NEURON, V21, P1151, DOI 10.1016/S0896-6273(00)80632-7; Lee HK, 2000, NATURE, V405, P955, DOI 10.1038/35016089; Lester LB, 1997, P NATL ACAD SCI USA, V94, P14942, DOI 10.1073/pnas.94.26.14942; LUO S, 1998, IMMUNITY, V8, P703; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; Park S, 2000, P NATL ACAD SCI USA, V97, P7130, DOI 10.1073/pnas.97.13.7130; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; Rothermel B, 2000, J BIOL CHEM, V275, P8719, DOI 10.1074/jbc.275.12.8719; Schillace RV, 2001, J BIOL CHEM, V276, P12128, DOI 10.1074/jbc.M010398200; Smith FD, 2002, CURR BIOL, V12, pR32, DOI 10.1016/S0960-9822(01)00646-7; Sun F, 2000, J BIOL CHEM, V275, P14360, DOI 10.1074/jbc.275.19.14360; Swope SL, 1999, ADV SEC MESS PHOSPH, V33, P49; Taigen T, 2000, P NATL ACAD SCI USA, V97, P1196, DOI 10.1073/pnas.97.3.1196; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Westphal RS, 1999, SCIENCE, V285, P93, DOI 10.1126/science.285.5424.93	45	118	122	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48796	48802		10.1074/jbc.M207833200	http://dx.doi.org/10.1074/jbc.M207833200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354762	Green Accepted, hybrid, Green Submitted			2022-12-25	WOS:000179789600107
J	Rao, MK; Wayne, CM; Wilkinson, MF				Rao, MK; Wayne, CM; Wilkinson, MF			Pem homeobox gene regulatory sequences that direct androgen-dependent developmentally regulated gene expression in different subregions of the epididymis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATED GLYCOPROTEIN-2 CLUSTERIN; MESSENGER-RIBONUCLEIC-ACID; RAT EPIDIDYMIS; EXTRAEMBRYONIC TISSUES; TRANSGENE EXPRESSION; TESTICULAR FACTORS; VENTRAL PROSTATE; PROXIMAL REGION; SEMINAL-VESICLE; SERTOLI-CELLS	The epididymis is a useful model system to understand the mechanisms that govern region-specific gene expression, as many gene products display spatially restricted expression within this organ. However, surprisingly little is known about how this regulation is achieved. Here, we report regulatory sequences from the Pent homeobox gene that drive expression in different subregions of the mouse epididymis in vivo. We found that the 0.3-kb 5'-flanking sequence (region I) from the Pent proximal promoter (Pem Pp) was sufficient to confer androgen-dependent and developmentally regulated expression in the caput region of the epididymis. Expression was restricted to the normal regions of expression of Pent in the caput (segments 2-4), but there was also aberrant expression in the corpus region. This corpus misexpression was extinguished when 0.6 kb of Pem Pp 5'-flanking sequence was included in the transgene, indicating that one or more negative regulatory elements exist between 0.6 and 0.3 kb upstream of the Pent Pp start site (region II). When heterologous sequences were introduced upstream of the Pent Pp, expression was further restricted, mainly to caput segment 3, implying that the Pent Pp has segment-specific regulatory elements. To our knowledge, the regulatory regions we have identified are the shortest so far defined that dictate regionally localized expression in the epididymis in vivo. They may be useful for identifying the factors that regulate region-specific expression in the epididymis, for expressing and conditionally knocking out genes in different subregions of the epididymis, for treating male infertility, and for generating novel methods of male contraception.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 180,1515 Holcombe Blvd, Houston, TX 77030 USA.	mwilkins@mdanderson.org			NATIONAL CANCER INSTITUTE [R01CA078023] Funding Source: NIH RePORTER; NCI NIH HHS [CA78023] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AITKEN JR, 2002, EPIDIDYMIS MOL CLIN, P435; AYERLELIEVRE C, 1988, P NATL ACAD SCI USA, V85, P2628, DOI 10.1073/pnas.85.8.2628; Barbulescu K, 2001, MOL ENDOCRINOL, V15, P1803, DOI 10.1210/me.15.10.1803; BEATO M, 1989, J STEROID BIOCHEM, V32, P737, DOI 10.1016/0022-4731(89)90521-9; BORSOOK D, 1992, MOL ENDOCRINOL, V6, P1502, DOI 10.1210/me.6.9.1502; CHAREST NJ, 1989, ENDOCRINOLOGY, V125, P942, DOI 10.1210/endo-125-2-942; Cheuk BLY, 2000, BIOL REPROD, V63, P775, DOI 10.1093/biolreprod/63.3.775; CORNWALL GA, 1995, J ANDROL, V16, P379; CORNWALL GA, 1992, MOL ENDOCRINOL, V6, P1653, DOI 10.1210/me.6.10.1653; Cyr DG, 2001, J ANDROL, V22, P124; CYR DG, 1992, ENDOCRINOLOGY, V130, P2160, DOI 10.1210/en.130.4.2160; DOUGLASS J, 1991, ANN NY ACAD SCI, V637, P384, DOI 10.1111/j.1749-6632.1991.tb27324.x; EWING LL, 1979, BIOL REPROD, V21, P765, DOI 10.1095/biolreprod21.4.765; Ezer N., 2002, EPIDIDYMIS MOL CLIN, P297, DOI [10.1007/978-1-4615-0679-9_17, DOI 10.1007/978-1-4615-0679-9_17]; GALLON C, 1989, J ANDROL, V10, P188; GARRETT JE, 1990, MOL ENDOCRINOL, V4, P108, DOI 10.1210/mend-4-1-108; GIROTTI M, 1992, BIOCHEM J, V281, P203, DOI 10.1042/bj2810203; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Han YJ, 2000, GENE, V241, P149, DOI 10.1016/S0378-1119(99)00453-9; HERMO L, 1992, ANAT RECORD, V233, P205, DOI 10.1002/ar.1092330205; HERMO L, 1994, ANAT RECORD, V240, P327, DOI 10.1002/ar.1092400306; Hermo L., 2002, EPIDIDYMIS MOL CLIN, P81, DOI [10.1007/978-1-4615-0679-9_5, DOI 10.1007/978-1-4615-0679-9_5]; HINTON BT, 1995, MICROSC RES TECHNIQ, V30, P67, DOI 10.1002/jemt.1070300106; JEANFAUCHER C, 1985, INT J ANDROL, V8, P44, DOI 10.1111/j.1365-2605.1985.tb00817.x; Jervis KM, 2001, BIOL REPROD, V65, P696, DOI 10.1095/biolreprod65.3.696; KANGASNIEMI M, 1995, ENDOCRINOLOGY, V136, P2881, DOI 10.1210/en.136.7.2881; Kuschert S, 2001, DEV BIOL, V229, P128, DOI 10.1006/dbio.2000.9971; Lahti PP, 2001, BIOL REPROD, V64, P1115, DOI 10.1095/biolreprod64.4.1115; Lan ZJ, 1998, BIOL REPROD, V58, P197, DOI 10.1095/biolreprod58.1.197; Lan ZJ, 1999, BIOL REPROD, V60, P664, DOI 10.1095/biolreprod60.3.664; Lareyre JJ, 1999, J BIOL CHEM, V274, P8282, DOI 10.1074/jbc.274.12.8282; Lareyre JJ, 1998, J REPROD FERTIL, P59; LAW GL, 1994, BIOL REPROD, V50, P669, DOI 10.1095/biolreprod50.3.669; Li YH, 1997, DEV BIOL, V188, P85, DOI 10.1006/dbio.1997.8640; LIN TP, 1994, DEV BIOL, V166, P170, DOI 10.1006/dbio.1994.1305; Lindsey JS, 1996, DEV BIOL, V179, P471, DOI 10.1006/dbio.1996.0276; Lindsey JS, 1996, BIOL REPROD, V55, P975, DOI 10.1095/biolreprod55.5.975; Maiti S, 1996, GENOMICS, V34, P304, DOI 10.1006/geno.1996.0291; Maiti S, 1996, J BIOL CHEM, V271, P17536, DOI 10.1074/jbc.271.29.17536; Maiti S, 2001, ENDOCRINOLOGY, V142, P1567, DOI 10.1210/en.142.4.1567; Pitman JL, 1998, DEV BIOL, V202, P196, DOI 10.1006/dbio.1998.8978; Rao M, 2002, EPIDIDYMIS MOL CLIN, P269, DOI 10.1007/978-1-4615-0679-9_15; RITZEN EM, 1971, ENDOCRINOLOGY, V89, P143; ROBAIRE B, 1995, BIOL REPROD, V52, P226, DOI 10.1095/biolreprod52.2.226; Rodriguez CM, 2001, REPRODUCTION, V122, P41, DOI 10.1530/reprod/122.1.41; Rodriguez CM, 2002, EPIDIDYMIS MOL CLIN, P251, DOI DOI 10.4049/JIMMUNOL.1402706; SENSIBAR JA, 1993, BIOL REPROD, V49, P233, DOI 10.1095/biolreprod49.2.233; Sutton HG, 1999, ENDOCRINOLOGY, V140, P2721, DOI 10.1210/en.140.6.2721; Sutton KA, 1998, J ANDROL, V19, P21; Sutton KA, 1997, GENOMICS, V45, P447, DOI 10.1006/geno.1997.4946; TINDALL DJ, 1975, MOL CELL ENDOCRINOL, V3, P83, DOI 10.1016/0303-7207(75)90056-8; Tramer F, 1998, BIOL REPROD, V59, P753, DOI 10.1095/biolreprod59.4.753; TULSIANI DRP, 1995, DEV BIOL, V167, P584, DOI 10.1006/dbio.1995.1050; Vernet P, 1997, MOL REPROD DEV, V47, P87, DOI 10.1002/(SICI)1098-2795(199705)47:1&lt;87::AID-MRD12&gt;3.0.CO;2-X; VIGER RS, 1992, ENDOCRINOLOGY, V131, P1534, DOI 10.1210/en.131.3.1534; WILKINSON M, 2000, ESSENTIAL MOL BIOL, P69	56	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48771	48778		10.1074/jbc.M209417200	http://dx.doi.org/10.1074/jbc.M209417200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351657	hybrid			2022-12-25	WOS:000179789600104
J	Strutz, N; Villmann, C; Breitinger, HG; Werner, M; Wenthold, RJ; Kizelsztein, P; Teichberg, VI; Hollmann, M				Strutz, N; Villmann, C; Breitinger, HG; Werner, M; Wenthold, RJ; Kizelsztein, P; Teichberg, VI; Hollmann, M			Kainate-binding proteins are rendered functional ion channels upon transplantation of two short pore-flanking domains from a kainate receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE-RECEPTOR; LIGAND-BINDING; N-GLYCOSYLATION; NERVOUS-SYSTEM; ACID RECEPTORS; SUBUNIT; EXPRESSION; IDENTIFICATION; AGONIST; GENE	Kainate-binding proteins belong to an elusive class of putative ionotropic glutamate receptors that to date have not been shown to form functional ion channels in heterologous expression systems, despite binding glutamatergic agonists with high affinity. To test the hypothesis that inefficient or interrupted signal transduction from the ligand-binding site via linker domains to the ion pore (gating) might be responsible for this apparent lack of function, we transplanted the short homologous linker sequences from the fully functional rat kainate receptor GluR6 into frog kainate-binding protein. We were able to generate chimeric receptors that are functional in the Xenopus oocyte expression system and in human embryonic kidney 293 cells. The linker domains A and B in particular appear to be crucial for gating, because a functional kainate-binding protein was observed when at least parts of both linkers were derived from GluR6. We speculate that to enable signal transduction from the ligand-binding site to the ion pore of the frog kainate-binding protein, the linker structure of the protein has to undergo an essential conformational alteration, possibly mediated by an as yet unknown subunit or modulatory protein.	Ruhr Univ Bochum, Dept Biochem Receptor Biochem 1, D-44780 Bochum, Germany; Univ Erlangen Nurnberg, Inst Biochem, D-91054 Erlangen, Germany; NIDCD, Neurochem Lab, NIH, Bethesda, MD 20892 USA; Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel	Ruhr University Bochum; University of Erlangen Nuremberg; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); Weizmann Institute of Science	Strutz, N (corresponding author), Ruhr Univ Bochum, Dept Biochem Receptor Biochem 1, D-44780 Bochum, Germany.		Breitinger, Hans-Georg/ABD-3247-2021	Breitinger, Hans-Georg/0000-0003-0111-3528; Hollmann, Michael/0000-0001-8000-7787	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000003, Z01DC000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; Brockie PJ, 2001, J NEUROSCI, V21, P1510, DOI 10.1523/JNEUROSCI.21-05-01510.2001; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; ESHHAR N, 1992, FEBS LETT, V297, P257, DOI 10.1016/0014-5793(92)80551-Q; Everts I, 1997, MOL PHARMACOL, V52, P861, DOI 10.1124/mol.52.5.861; GREGOR P, 1989, NATURE, V342, P689, DOI 10.1038/342689a0; GREGOR P, 1992, MOL BRAIN RES, V16, P179, DOI 10.1016/0169-328X(92)90223-X; HAMPSON DR, 1989, J BIOL CHEM, V264, P13329; HENLEY JM, 1994, TRENDS PHARMACOL SCI, V15, P182, DOI 10.1016/0165-6147(94)90146-5; HESS GP, 1993, BIOCHEMISTRY-US, V32, P989, DOI 10.1021/bi00055a001; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hollmann M., 1999, V141, P3; Ishimaru H, 1996, RECEPTOR CHANNEL, V4, P31; Jones KS, 2002, J NEUROSCI, V22, P2044, DOI 10.1523/JNEUROSCI.22-06-02044.2002; KIMURA N, 1993, MOL BRAIN RES, V17, P351, DOI 10.1016/0169-328X(93)90022-H; Krupp JJ, 1998, NEURON, V20, P317, DOI 10.1016/S0896-6273(00)80459-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laube B, 1997, NEURON, V18, P493, DOI 10.1016/S0896-6273(00)81249-0; Littleton JT, 2000, NEURON, V26, P35, DOI 10.1016/S0896-6273(00)81135-6; Mano I, 1996, J BIOL CHEM, V271, P15299, DOI 10.1074/jbc.271.26.15299; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Sheridan DL, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-7; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Soloviev MM, 1997, J MOL BIOL, V273, P14, DOI 10.1006/jmbi.1997.1272; Sprengel R, 2001, TRENDS PHARMACOL SCI, V22, P7, DOI 10.1016/S0165-6147(00)01588-1; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; Strutz N, 2001, J NEUROSCI, V21, P401, DOI 10.1523/JNEUROSCI.21-02-00401.2001; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Taverna F, 2000, J BIOL CHEM, V275, P8475, DOI 10.1074/jbc.275.12.8475; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UDGAONKAR JB, 1987, P NATL ACAD SCI USA, V84, P8758, DOI 10.1073/pnas.84.24.8758; Villmann C, 1997, J NEUROSCI, V17, P7634, DOI 10.1523/jneurosci.17-20-07634.1997; Villmann C, 1999, EUR J NEUROSCI, V11, P1765, DOI 10.1046/j.1460-9568.1999.00594.x; WADA K, 1989, Society for Neuroscience Abstracts, V15, P532; WADA K, 1989, NATURE, V342, P684, DOI 10.1038/342684a0; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; Wo ZG, 1996, MOL PHARMACOL, V50, P770; Zuo J, 1997, NATURE, V388, P769, DOI 10.1038/42009	40	9	9	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48035	48042		10.1074/jbc.M209647200	http://dx.doi.org/10.1074/jbc.M209647200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12370171	hybrid			2022-12-25	WOS:000179789600010
J	van Haperen, R; de Waard, M; van Deel, E; Mees, B; Kutryk, M; van Aken, T; Hamming, J; Grosveld, F; Dunker, DJ; de Crom, R				van Haperen, R; de Waard, M; van Deel, E; Mees, B; Kutryk, M; van Aken, T; Hamming, J; Grosveld, F; Dunker, DJ; de Crom, R			Reduction of blood pressure, plasma cholesterol, and atherosclerosis by elevated endothelial nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-DEFICIENT MICE; HIGH-DENSITY-LIPOPROTEIN; VASCULAR-DISEASE; KNOCKOUT MICE; SYNTHASE GENE; 2 FACES; DYSFUNCTION; ACTIVATION; CAVEOLIN; LESIONS	In the vascular system, nitric oxide is generated by endothelial NO synthase (eNOS). NO has pleiotropic effects, most of which are believed to be atheroprotective. Therefore, it has been argued that patients suffering from cardiovascular disease could benefit from an increase in eNOS activity. However, increased NO production can cause oxidative damage, cell toxicity, and apoptosis and hence could be atherogenic rather than beneficial. To study the in vivo effects of increased eNOS activity, we created transgenic mice overexpressing human eNOS. Aortic blood pressure was similar to20 min Hg lower in the transgenic mice compared with control mice because of lower systemic vascular resistance. The effects of eNOS overexpression on diet-induced atherosclerosis were studied in apolipoprotein E-deficient mice. Elevation of eNOS activity decreased blood pressure (similar to20 min Hg) and plasma levels of cholesterol (similar to17%), resulting in a reduction in atherosclerotic lesions by 40%. We conclude that an increase in eNOS activity is beneficial and provides protection against atherosclerosis.	Erasmus Univ, Erasmus Med Ctr, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Erasmus Med Ctr, Thoraxctr, Dept Expt Cardiol, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Erasmus Med Ctr, Erasmus Lab, Anim Sci Ctr, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Erasmus Med Ctr, Dept Vasc Surg, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	de Crom, R (corresponding author), Erasmus Univ, Erasmus Med Ctr, Dept Cell Biol & Genet, Dr Molewaterplein 50,POB 1738, NL-3000 DR Rotterdam, Netherlands.			Mees, Barend/0000-0001-6545-5813				Bakker CE, 2000, EXP CELL RES, V258, P162, DOI 10.1006/excr.2000.4932; Barton M, 1998, P NATL ACAD SCI USA, V95, P14367, DOI 10.1073/pnas.95.24.14367; Breslow JL, 1996, SCIENCE, V272, P685, DOI 10.1126/science.272.5262.685; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; d'Uscio LV, 2001, ARTERIOSCL THROM VAS, V21, P1017, DOI 10.1161/01.ATV.21.6.1017; Daugherty A, 2002, AM J MED SCI, V323, P3, DOI 10.1097/00000441-200201000-00002; de Crom R, 1999, BBA-MOL CELL BIOL L, V1437, P378, DOI 10.1016/S1388-1981(99)00017-7; Drummond GR, 1998, J CLIN INVEST, V102, P2033, DOI 10.1172/JCI5845; Everson WV, 2001, TRENDS CARDIOVAS MED, V11, P246, DOI 10.1016/S1050-1738(01)00119-0; Feron O, 2001, CIRCULATION, V103, P113; Feron O, 1999, J CLIN INVEST, V103, P897, DOI 10.1172/JCI4829; Forstermann U, 1998, FASEB J, V12, P773; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; GarciaCardena G, 1996, J BIOL CHEM, V271, P27237, DOI 10.1074/jbc.271.44.27237; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Govers R, 2001, AM J PHYSIOL-RENAL, V280, pF193, DOI 10.1152/ajprenal.2001.280.2.F193; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hoit BD, 2001, CIRC RES, V89, P289, DOI 10.1161/res.89.4.289; HUANG PL, 1995, NATURE, V377, P239, DOI 10.1038/377239a0; JANSSENS SP, 1992, J BIOL CHEM, V267, P14519; Kamphoven JHJ, 2001, PHYSIOL GENOMICS, V5, P171, DOI 10.1152/physiolgenomics.2001.5.4.171; Kano H, 1999, BIOCHEM BIOPH RES CO, V259, P414, DOI 10.1006/bbrc.1999.0799; Kincer JF, 2002, J BIOL CHEM, V277, P23525, DOI 10.1074/jbc.M202465200; Knowles JW, 2000, J CLIN INVEST, V105, P451, DOI 10.1172/JCI8376; Kuhlencordt PJ, 2001, CIRCULATION, V104, P448, DOI 10.1161/hc2901.091399; Laumonnier Y, 2000, J BIOL CHEM, V275, P40732, DOI 10.1074/jbc.M004696200; Lefer AM, 1997, CIRCULATION, V95, P553, DOI 10.1161/01.CIR.95.3.553; Li HG, 2000, J PATHOL, V190, P244, DOI 10.1002/(SICI)1096-9896(200002)190:3<244::AID-PATH575>3.0.CO;2-8; Libby P, 2001, AM J CARDIOL, V88, p3N; Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161/hh0801.089861; Marletta MA, 2001, TRENDS BIOCHEM SCI, V26, P519, DOI 10.1016/S0968-0004(01)01937-5; Murayama T, 1999, CIRCULATION, V99, P1740, DOI 10.1161/01.CIR.99.13.1740; NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133; Niebauer J, 1999, J AM COLL CARDIOL, V34, P1201, DOI 10.1016/S0735-1097(99)00304-6; O'Donnell VB, 2001, CIRC RES, V88, P12, DOI 10.1161/01.RES.88.1.12; Ohashi Y, 1998, J CLIN INVEST, V102, P2061, DOI 10.1172/JCI4394; Ozaki M, 2002, J CLIN INVEST, V110, P331, DOI 10.1172/JCI200215215; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; Qian HS, 1999, CIRCULATION, V99, P2979, DOI 10.1161/01.CIR.99.23.2979; Riddell DR, 1999, VITAM HORM, V57, P25; Sessa WC, 2001, TRENDS MOL MED, V7, P189, DOI 10.1016/S1471-4914(01)01985-2; Sjoland H, 2000, ARTERIOSCL THROM VAS, V20, P846, DOI 10.1161/01.ATV.20.3.846; van Haperen R, 2000, ARTERIOSCL THROM VAS, V20, P1082, DOI 10.1161/01.ATV.20.4.1082; Wever RMF, 1998, CIRCULATION, V97, P108, DOI 10.1161/01.CIR.97.1.108; Xia Y, 1998, J BIOL CHEM, V273, P25804, DOI 10.1074/jbc.273.40.25804	45	91	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48803	48807		10.1074/jbc.M209477200	http://dx.doi.org/10.1074/jbc.M209477200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12364322	hybrid, Green Published			2022-12-25	WOS:000179789600108
J	Bompard, G; Puech, C; Prebois, C; Vignon, F; Freiss, G				Bompard, G; Puech, C; Prebois, C; Vignon, F; Freiss, G			Protein-tyrosine phosphatase PTPL1/FAP-1 triggers apoptosis in human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-MEDIATED APOPTOSIS; GROWTH-FACTOR-I; RECEPTOR SUBSTRATE-1 EXPRESSION; PHOSPHATIDYLINOSITOL 3'-KINASE; SIGNALING PATHWAYS; ESTROGEN-RECEPTOR; SURVIVAL SIGNALS; INSULIN; DEATH; FAP-1	Studies in Jurkat leukemia cells have suggested that protein-tyrosine phosphatase PTPL1/FAP-1 rescues Fas-induced cell death. However, we have previously shown that this enzyme triggers 4-hydroxytamoxifen-induced growth inhibition in human breast cancer cells. The present study addresses the role of PTPL1/FAP-1 in antiestrogen-regulated apoptotic effect and insulin-like growth factor-I survival action in MCF7 cells and further identifies the impacted signaling pathway. By terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling and cytoplasmic nucleosome enzyme-linked immunosorbent assay, we demonstrated that 4-hydroxytamoxifen-induced apoptosis was totally lost in PTPL1/FAP-1 antisense transfectants in which enzyme expression was abrogated, revealing the crucial role of this phosphatase in the apoptotic process in human breast cancer cells. Time-dependent expression of PTPL1/FAP-1 in MCF7 cells completely abolished the survival action of insulin-like growth factor-1. This effect occurred through a highly significant reduction in phosphatidylinositol 3-kinase/Akt pathway activation (80% reduction in phosphatidylinositol 3-kinase activity, 55% inhibition of Akt activation) accompanied by a 65% decrease in insulin receptor substrate-1 growth factor-induced tyrosine phosphorylation. These results provide the first evidence that PTPL1/FAP-1 has a key role in the apoptotic process in human breast cancer cells independent of Fas but associated with an early inhibition of the insulin receptor substrate-1/phosphatidylinositol 3-kinase pathway. Our data therefore suggest new therapeutic routes and strengthen the importance of identifying endogenous regulators and substrates of this phosphatase in breast tumors.	INSERM, Unit 540, F-34090 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Vignon, F (corresponding author), INSERM, Unit 540, 60 Rue Navacelles, F-34090 Montpellier, France.	vignon@u540.montp.inserm.fr	Freiss, Gilles/T-2057-2019	Freiss, Gilles/0000-0002-1943-0735; Bompard, Guillaume/0000-0001-6729-4507				Ardini E, 2000, ONCOGENE, V19, P4979, DOI 10.1038/sj.onc.1203869; BANVILLE D, 1994, J BIOL CHEM, V269, P22320; BARDON S, 1987, CANCER RES, V47, P1441; BASERGA R, 1999, IGF SYSTEM, P329; Boekelheide K, 1998, TOXICOL LETT, V103, P503, DOI 10.1016/S0378-4274(98)00242-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Broome HE, 1998, CELL DEATH DIFFER, V5, P200, DOI 10.1038/sj.cdd.4400329; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Cuppen E, 1997, J BIOL CHEM, V272, P30215, DOI 10.1074/jbc.272.48.30215; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; Ellis PA, 1997, INT J CANCER, V72, P608, DOI 10.1002/(SICI)1097-0215(19970807)72:4<608::AID-IJC10>3.0.CO;2-7; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; FREISS G, 1994, MOL ENDOCRINOL, V8, P1389, DOI 10.1210/me.8.10.1389; Freiss G, 1998, MOL ENDOCRINOL, V12, P568, DOI 10.1210/me.12.4.568; FREISS G, 1993, BREAST CANCER RES TR, V27, P57, DOI 10.1007/BF00683193; Gooch JL, 1999, CANCER LETT, V144, P31, DOI 10.1016/S0304-3835(99)00208-6; Gooch JL, 1999, BREAST CANCER RES TR, V56, P1, DOI 10.1023/A:1006208721167; Guvakova MA, 1997, CANCER RES, V57, P2606; HUOVINEN R, 1993, INT J CANCER, V55, P685, DOI 10.1002/ijc.2910550429; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; Keane MM, 1996, CANCER RES, V56, P4791; Keane MM, 1996, CANCER RES, V56, P4236; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; KYPRIANOU N, 1991, CANCER RES, V51, P162; Lee AV, 1999, MOL ENDOCRINOL, V13, P787, DOI 10.1210/me.13.5.787; Li Y, 2000, INT J CANCER, V87, P473, DOI 10.1002/1097-0215(20000815)87:4<473::AID-IJC3>3.0.CO;2-1; MAEKAWA K, 1994, FEBS LETT, V337, P200, DOI 10.1016/0014-5793(94)80273-4; Migliaccio A, 1996, EMBO J, V15, P1292, DOI 10.1002/j.1460-2075.1996.tb00471.x; Molloy CA, 2000, J BIOL CHEM, V275, P12565, DOI 10.1074/jbc.275.17.12565; Mori S, 1996, CANCER RES, V56, P1874; MYERS MG, 1994, J BIOL CHEM, V269, P28783; Navarro M, 2001, ENDOCRINOLOGY, V142, P1073, DOI 10.1210/en.142.3.1073; Parrizas M, 1997, J BIOL CHEM, V272, P154; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7; PHILIPS A, 1993, J BIOL CHEM, V268, P14103; Saras J, 1997, J BIOL CHEM, V272, P20979, DOI 10.1074/jbc.272.34.20979; SARAS J, 1994, J BIOL CHEM, V269, P24082; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Thangaraju M, 1999, J BIOL CHEM, V274, P29549, DOI 10.1074/jbc.274.41.29549; Tillman DM, 1998, CELL DEATH DIFFER, V5, P450, DOI 10.1038/sj.cdd.4400369; Ungefroren H, 1998, CANCER RES, V58, P1741; VIGNON F, 1987, BIOCHEM BIOPH RES CO, V146, P1502, DOI 10.1016/0006-291X(87)90819-9; Yamada Y, 1999, CANCER LETT, V147, P215, DOI 10.1016/S0304-3835(99)00313-4; Yanagisawa J, 1997, J BIOL CHEM, V272, P8539, DOI 10.1074/jbc.272.13.8539; Zhang XH, 1997, J EXP MED, V185, P1837, DOI 10.1084/jem.185.10.1837	48	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47861	47869		10.1074/jbc.M208950200	http://dx.doi.org/10.1074/jbc.M208950200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354757	Green Published, hybrid			2022-12-25	WOS:000179663700132
J	Crane, MS; Ollosson, R; Moore, KP; Rossi, AG; Megson, IL				Crane, MS; Ollosson, R; Moore, KP; Rossi, AG; Megson, IL			Novel role for low molecular weight plasma thiols in nitric oxide-mediated control of platelet function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-NITROSO-GLUTATHIONE; RELAXING FACTOR; IN-VIVO; VASCULAR ENDOTHELIUM; AQUEOUS-SOLUTION; SERUM-ALBUMIN; HEMOGLOBIN; MECHANISM; CYSTEINE; KINETICS	Nitric oxide (NO) is a powerful antiplatelet agent, but its notoriously short biological half-life limits its potential to prevent the activation of circulating platelets. Here we used diethylamine diazeniumdiolate (DEA/NO) as an NO generator to determine whether the antiplatelet effects of NO are prolonged by the formation of a durable, plasma-borne S-nitrosothiol reservoir. Preincubation of both platelet rich plasma (PRP) and washed platelets (WP) with DEAINO (2 muM) for 1 min inhibited collagen-induced platelet aggregation by 82 +/- 5 and 91 +/- 2%, respectively. After 30 min preincubation with DEA/NO, NO was no longer detectable in either preparation, but aggregation remained markedly inhibited (72 +/- 7%) in PRP. In contrast, the inhibitory effect in MTP was almost completely lost at this time (5 +/- 3%) but was partially restored (39 +/- 10%) in WP containing human serum albumin (1%) and fully restored by co-incubation with albumin and the low molecular weight (LAW) thiols, glutathione, (5 muM), cysteinyl-glycine (10 muM), or cysteine (10 muM). This NO-mediated effect was not seen with LMW thiols in the absence of albumin and was associated with S-nitrosothiol formation. Our results demonstrate that LAW thiols play an important role in both the formation and activation of an S-nitrosoalbumin reservoir that significantly prolongs the duration of action of NO.	Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh EH8 9XD, Midlothian, Scotland; Univ Edinburgh, Ctr Inflammat Res, Edinburgh EH8 9XD, Midlothian, Scotland; UCL Royal Free & Univ Coll, Ctr Hepatol, London NW3 2PF, England	University of Edinburgh; University of Edinburgh; University of London; University College London	Megson, IL (corresponding author), Univ Edinburgh, Ctr Cardiovasc Sci, Hugh Robson Bldg, Edinburgh EH8 9XD, Midlothian, Scotland.	ian.megson@ed.ac.uk	Megson, Ian L/K-2195-2012	Megson, Ian L/0000-0001-8287-2459				Akaike T, 1997, J BIOCHEM-TOKYO, V122, P459; COCKS TM, 1985, J CELL PHYSIOL, V123, P310, DOI 10.1002/jcp.1041230304; Creager MA, 1997, HYPERTENSION, V29, P668, DOI 10.1161/01.HYP.29.2.668; Davies KM, 2001, J AM CHEM SOC, V123, P5473, DOI 10.1021/ja002899q; DEBELDER AJ, 1994, CARDIOVASC RES, V28, P691; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Espey MG, 2001, J BIOL CHEM, V276, P30085, DOI 10.1074/jbc.M101723200; FOLEY PL, 1993, ACTA NEUROCHIR, V123, P82, DOI 10.1007/BF01476290; Goldman RK, 1998, ANAL BIOCHEM, V259, P98, DOI 10.1006/abio.1998.2651; Gow AJ, 1997, J BIOL CHEM, V272, P2841, DOI 10.1074/jbc.272.5.2841; GRIFFITH TM, 1984, NATURE, V308, P645, DOI 10.1038/308645a0; HOFMANN H, 1995, BIOCHEMISTRY-US, V34, P13443, DOI 10.1021/bi00041a023; Hogg N, 1996, FEBS LETT, V382, P223, DOI 10.1016/0014-5793(96)00086-5; Inoue K, 1999, J BIOL CHEM, V274, P27069, DOI 10.1074/jbc.274.38.27069; JOCELYN PC, 1972, BIOCH SH GROUP; KHARITONOV VG, 1995, J BIOL CHEM, V270, P28158; Kugiyama K, 1998, CIRCULATION, V97, P2299, DOI 10.1161/01.CIR.97.23.2299; Lancaster JR, 1997, NITRIC OXIDE-BIOL CH, V1, P18, DOI 10.1006/niox.1996.0112; LANCASTER JR, 1994, P NATL ACAD SCI USA, V91, P8137, DOI 10.1073/pnas.91.17.8137; LEWIS RS, 1994, CHEM RES TOXICOL, V7, P568, DOI 10.1021/tx00040a013; LIJANA RC, 1979, J LAB CLIN MED, V94, P266; Liu XP, 1998, P NATL ACAD SCI USA, V95, P2175, DOI 10.1073/pnas.95.5.2175; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MANSOOR MA, 1992, ANAL BIOCHEM, V200, P218, DOI 10.1016/0003-2697(92)90456-H; Marley R, 2001, FREE RADICAL BIO MED, V31, P688, DOI 10.1016/S0891-5849(01)00627-X; Marley R, 2000, FREE RADICAL RES, V32, P1, DOI 10.1080/10715760000300011; MARTIN W, 1985, J PHARMACOL EXP THER, V232, P708; Mayer B, 1998, J BIOL CHEM, V273, P3264, DOI 10.1074/jbc.273.6.3264; McDonald L J, 1995, Adv Pharmacol, V34, P263; Morrison JA, 1999, CIRCULATION, V100, P2244, DOI 10.1161/01.CIR.100.22.2244; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; O'Donnell VB, 2000, J BIOL CHEM, V275, P38239, DOI 10.1074/jbc.M001802200; Pigazzi A, 1999, J BIOL CHEM, V274, P14368, DOI 10.1074/jbc.274.20.14368; RADOMSKI MW, 1987, LANCET, V2, P1057, DOI 10.1016/S0140-6736(87)91481-4; RADOMSKI MW, 1987, BRIT J PHARMACOL, V92, P639, DOI 10.1111/j.1476-5381.1987.tb11367.x; RADOMSKI MW, 1987, BIOCHEM BIOPH RES CO, V148, P1482, DOI 10.1016/S0006-291X(87)80299-1; Rafikova O, 2002, P NATL ACAD SCI USA, V99, P5913, DOI 10.1073/pnas.092048999; SCHARFSTEIN JS, 1994, J CLIN INVEST, V94, P1432, DOI 10.1172/JCI117480; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; SIMON DI, 1993, ARTERIOSCLER THROMB, V13, P791, DOI 10.1161/01.ATV.13.6.791; Sogo N, 2000, BIOCHEM BIOPH RES CO, V279, P412, DOI 10.1006/bbrc.2000.3976; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P7674, DOI 10.1073/pnas.89.16.7674; STAMLER JS, 1992, SCIENCE, V258, P1898, DOI 10.1126/science.1281928; STANDEFER JC, 1977, CLIN CHEM, V23, P749; Tsikas D, 1999, J CHROMATOGR B, V726, P13, DOI 10.1016/S0378-4347(99)00058-4; Tsikas D, 1999, ANAL BIOCHEM, V272, P117, DOI 10.1006/abio.1999.4177; VEDERNIKOV YP, 1992, EUR J PHARMACOL, V211, P313, DOI 10.1016/0014-2999(92)90386-I; Vita JA, 1998, J CLIN INVEST, V101, P1408, DOI 10.1172/JCI1155; WINK DA, 1994, CHEM RES TOXICOL, V7, P519, DOI 10.1021/tx00040a007	50	40	42	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46858	46863		10.1074/jbc.M208608200	http://dx.doi.org/10.1074/jbc.M208608200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12297511	hybrid			2022-12-25	WOS:000179663700005
J	Cui, J; Bian, JS; Kagan, A; McDonald, TV				Cui, J; Bian, JS; Kagan, A; McDonald, TV			CaT1 contributes to the stores-operated calcium current in Jurkat T-lymphocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CURRENT I-CRAC; EPITHELIAL CA2+ CHANNEL; MUSCARINIC RECEPTOR; SIGNAL TRANSDUCTION; GENE-EXPRESSION; ENTRY; CELLS; DEPLETION; TRP; ACTIVATION	T-lymphocyte activation requires sustained Ca2+ signaling dependent upon capacitative Ca2+ entry (CCE). The protein(s) that forms the stores-operated Ca2+ channel (SOCC) responsible for CCE has long been sought but has not been definitively identified. Members of the TRPV family (transient receptor potential superfamily-vanilloid receptor subfamily) of channel genes have been proposed to encode SOCCs responsible for CCE in non-excitable cells. Here we present evidence that a member of the TRPV group, CaT1, is involved in generating I-CRAC, the CCE current that is necessary for T-cell activation. CaT1 is expressed in Jurkat T-lymphocytes. When overexpressed in Jurkat cells, CaT1 produces a Ca2+ entry current that mimics the endogenous I-CRAC in its dependence on external Ca2+, inactivation by elevated concentration of internal Ca2+, and pharmacological block by capsaicin. Overexpressed CaT1 is partially regulated by the release of internal Ca2+ stores via thapsigargin or receptor-mediated generation of inositol 1,4,5-trisphosphate. A pore-region mutant of CaT1, TRIA-CaT1, fails to carry Ca2+ currents and associates with co-expressed wild type CaT1 to functionally suppress permeation of Ca2+ ions. Expression of the TRIA-CaT1 mutant in Jurkat cells results in suppression of the endogenous I-CRAC. Taken together these results indicate that CaT1 is the channel protein that contributes to T-lymphocyte SOCCs either alone or as a subunit in a heterogeneous channel complex.	Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine	McDonald, TV (corresponding author), Albert Einstein Coll Med, Dept Med, 1300 Morris Pk Ave, Bronx, NY 10461 USA.			Bian, Jinsong/0000-0002-7741-598X				BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Birnbaumer L, 1996, P NATL ACAD SCI USA, V93, P15195, DOI 10.1073/pnas.93.26.15195; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Choi SY, 1999, J PHARMACOL EXP THER, V291, P107; Christian EP, 1996, J MEMBRANE BIOL, V150, P63, DOI 10.1007/s002329900030; CHUNG SC, 1994, BRIT J PHARMACOL, V113, P861, DOI 10.1111/j.1476-5381.1994.tb17072.x; Clapham DE, 1996, NEURON, V16, P1069, DOI 10.1016/S0896-6273(00)80132-4; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Cui J, 2001, J BIOL CHEM, V276, P17244, DOI 10.1074/jbc.M010904200; Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9; DESAI DM, 1990, INT IMMUNOL, V2, P615, DOI 10.1093/intimm/2.7.615; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Dutta D, 2000, J BIOSCIENCE, V25, P397, DOI 10.1007/BF02703793; FASOLATO C, 1994, TRENDS PHARMACOL SCI, V15, P77, DOI 10.1016/0165-6147(94)90282-8; Fierro L, 2000, PFLUG ARCH EUR J PHY, V440, P580, DOI 10.1007/s004240050009; Fischer BS, 2001, J PHARMACOL EXP THER, V299, P238; Fomina AF, 2000, J CELL BIOL, V150, P1435, DOI 10.1083/jcb.150.6.1435; GOLDSMITH MA, 1989, J BIOL CHEM, V264, P17190; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 1999, J BIOL CHEM, V274, P8375, DOI 10.1074/jbc.274.13.8375; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Ichikawa H, 2000, NEUROSCIENCE, V101, P719, DOI 10.1016/S0306-4522(00)00427-9; Kerschbaum HH, 1999, SCIENCE, V283, P836, DOI 10.1126/science.283.5403.836; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; MCDONALD TV, 1993, J BIOL CHEM, V268, P3889; Montell C, 1997, MOL PHARMACOL, V52, P755, DOI 10.1124/mol.52.5.755; Montell C., 2001, SCI STKE; Nilius B, 2001, BRIT J PHARMACOL, V134, P453, DOI 10.1038/sj.bjp.0704272; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Peng JB, 2000, BIOCHEM BIOPH RES CO, V278, P326, DOI 10.1006/bbrc.2000.3716; Peng JB, 2001, GENOMICS, V76, P99, DOI 10.1006/geno.2001.6606; Peng JB, 1999, J BIOL CHEM, V274, P22739, DOI 10.1074/jbc.274.32.22739; PREMACK BA, 1994, J IMMUNOL, V152, P5226; Putney JW, 1999, BIOESSAYS, V21, P38; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; Schindl R, 2002, J BIOL CHEM, V277, P26950, DOI 10.1074/jbc.M203700200; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186; Vennekens R, 2000, J BIOL CHEM, V275, P3963, DOI 10.1074/jbc.275.6.3963; Voets T, 2001, J BIOL CHEM, V276, P47767, DOI 10.1074/jbc.C100607200; Wallace P, 1999, N-S ARCH PHARMACOL, V360, P368, DOI 10.1007/s002109900100; Yue LX, 2001, NATURE, V410, P705, DOI 10.1038/35070596; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	48	72	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47175	47183		10.1074/jbc.M205870200	http://dx.doi.org/10.1074/jbc.M205870200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12361955	hybrid			2022-12-25	WOS:000179663700044
J	Guida, L; Bruzzone, S; Sturla, L; Franco, L; Zocchi, E; De Flora, A				Guida, L; Bruzzone, S; Sturla, L; Franco, L; Zocchi, E; De Flora, A			Equilibrative and concentrative nucleoside transporters mediate influx of extracellular cyclic ADP-ribose into 3T3 murine fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CALCIUM; FUNCTIONAL-CHARACTERIZATION; RYANODINE RECEPTOR; MOLECULAR-BIOLOGY; ABSCISIC-ACID; CADP-RIBOSE; HUMAN CD38; CYCLASE; PROTEIN; PROLIFERATION	In mammals cyclic ADP-ribose (cADPR), a universal calcium mobilizer from intracellular stores, is generated from NAD(+) at the outer cell surface by the multifunctional ectoenzyme CD38 and by related ADP-ribosyl cyclases. Recently, influx of extracellular cADPR has been observed in 3T3 murine fibroblasts, where it elicits Ca2+-mediated enhancement of proliferation. Here we addressed the nature and the properties of cADPR influx into CD38(-) 3T3 cells, which showed pleiotropic mechanisms of both equilibrative and concentrative transport. Based on selective inhibitors or experimental conditions (e.g. abrogation of Na+-dependent active symport processes and transient transfection experiments) and on reverse transcriptase-polymerase chain reaction analysis of transcripts in 3T3 fibroblasts and comparatively in HeLa cells, we identified cADPR-transporting activities with specific nucleoside transporters (NT), both equilibrative (ENT2) and concentrative (CNT2 and a nitrobenzylthioinosine (NBMPR)-inhibitable NT). A reciprocal inhibition relationship was observed between inosine and cADPR fluxes across these NT species. Concentrative (but not equilibrative) transport of nanomolar extracellular cADPR took place in CD38(-) 3T3 cells co-cultured for 48 h in transwells on feeders of CD38-transfected, cADPR-generating 3T3 fibroblasts. These results suggest possible, hitherto unrecognized, correlations between ectocellular metabolism of nucleotides/nucleosides and cADPR-mediated regulation of intracellular calcium homeostasis.	Univ Genoa, Biochem Sect, DIMES, Dept Expt Med, I-16132 Genoa, Italy; Univ Genoa, Ctr Excellence Biomed Res, I-16132 Genoa, Italy; Ist Giannina Gaslini, I-16147 Genoa, Italy	University of Genoa; University of Genoa; University of Genoa; IRCCS Istituto Giannina Gaslini	De Flora, A (corresponding author), Univ Genoa, Biochem Sect, DIMES, Dept Expt Med, Viale Benedetto 15 1, I-16132 Genoa, Italy.	toninodf@unige.it	Bruzzone, Santina/A-4264-2015	Bruzzone, Santina/0000-0003-2034-3716				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruzzone S, 2001, J BIOL CHEM, V276, P48300, DOI 10.1074/jbc.M107308200; Bruzzone S, 2001, FASEB J, V15, P10; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; CASS CE, 1999, MEMBRANE TRANSPORTER, P313; CRAWFORD CR, 1990, J BIOL CHEM, V265, P13730; De Flora A, 2000, CHEM IMMUNOL, V75, P79; DeFlora A, 1996, BIOCHEM J, V320, P665, DOI 10.1042/bj3200665; DEFLORA A, 2002, IN PRESS CYCLIC ADP; Flanagan SA, 1997, J BIOL CHEM, V272, P18026, DOI 10.1074/jbc.272.29.18026; Franco L, 2001, J BIOL CHEM, V276, P21642, DOI 10.1074/jbc.M010536200; Franco L, 2001, AM J PHYSIOL-LUNG C, V280, pL98; Franco L, 1998, FASEB J, V12, P1507; Graeff R, 2002, BIOCHEM J, V361, P379, DOI 10.1042/bj3610379; GUAN X, 1977, J CELL BIOL, V139, P1785; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; Higashida H, 2001, PHARMACOL THERAPEUT, V90, P283, DOI 10.1016/S0163-7258(01)00142-5; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; JANAS T, 1989, AM J PHYSIOL, V257, pC601, DOI 10.1152/ajpcell.1989.257.4.C601; Kiss A, 2000, BIOCHEM J, V352, P363, DOI 10.1042/0264-6021:3520363; LEE HC, 1994, NAT STRUCT BIOL, V1, P143, DOI 10.1038/nsb0394-143; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; Lee HC, 1997, PHYSIOL REV, V77, P1133, DOI 10.1152/physrev.1997.77.4.1133; LEE HC, 1989, J BIOL CHEM, V264, P1608; Lee HC, 1997, ADV EXP MED BIOL, V419, P411; LEE HC, 1994, VITAM HORM, V48, P199, DOI 10.1016/S0083-6729(08)60499-9; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; LEE HC, 1994, NATURE, V370, P307, DOI 10.1038/370307a0; Lee HC, 1996, BIOL SIGNAL, V5, P101; Masuda W, 1997, FEBS LETT, V405, P104, DOI 10.1016/S0014-5793(97)00168-3; Mehta K, 1996, FASEB J, V10, P1408, DOI 10.1096/fasebj.10.12.8903511; Noguchi N, 1997, J BIOL CHEM, V272, P3133, DOI 10.1074/jbc.272.6.3133; Pastor-Anglada M, 2001, DRUG DEVELOP RES, V52, P431, DOI 10.1002/ddr.1144; Patel DH, 2000, GENE, V242, P51, DOI 10.1016/S0378-1119(99)00521-1; Paterson A. R. P., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P14; PLAGEMANN PGW, 1988, BIOCHIM BIOPHYS ACTA, V947, P405, DOI 10.1016/0304-4157(88)90002-0; Podesta M, 2000, FASEB J, V14, P680, DOI 10.1096/fasebj.14.5.680; Quist AP, 2000, J CELL BIOL, V148, P1063, DOI 10.1083/jcb.148.5.1063; Ritzel MWL, 2001, MOL MEMBR BIOL, V18, P65, DOI 10.1080/09687680010026313; Schaner ME, 1999, J PHARMACOL EXP THER, V289, P1487; Soler C, 1998, J BIOL CHEM, V273, P26939, DOI 10.1074/jbc.273.41.26939; Soler C, 2001, FASEB J, V15, P1979, DOI 10.1096/fj.01-0022com; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; Szkotak AJ, 2001, AM J PHYSIOL-CELL PH, V281, pC1991, DOI 10.1152/ajpcell.2001.281.6.C1991; Takasawa S, 1995, J BIOL CHEM, V270, P30257, DOI 10.1074/jbc.270.51.30257; TANAKA Y, 1995, P NATL ACAD SCI USA, V92, P3244, DOI 10.1073/pnas.92.8.3244; Tang WX, 2002, AM J PHYSIOL-HEART C, V282, pH1304, DOI 10.1152/ajpheart.00843.2001; Verderio C, 2001, J NEUROCHEM, V78, P646, DOI 10.1046/j.1471-4159.2001.00455.x; WALSETH TF, 1993, J BIOL CHEM, V268, P26686; Wang J, 1997, PHARM RES-DORDR, V14, P1524, DOI 10.1023/A:1012113931332; Ward JL, 1999, BBA-BIOMEMBRANES, V1419, P15, DOI 10.1016/S0005-2736(99)00045-0; Ward JL, 2000, J BIOL CHEM, V275, P8375, DOI 10.1074/jbc.275.12.8375; Wu Y, 1997, SCIENCE, V278, P2126, DOI 10.1126/science.278.5346.2126; Zocchi E, 1998, J BIOL CHEM, V273, P8017, DOI 10.1074/jbc.273.14.8017; Zocchi E, 2001, FASEB J, V15, P1610, DOI 10.1096/fj.00-0803fje; Zocchi E, 2001, P NATL ACAD SCI USA, V98, P14859, DOI 10.1073/pnas.261448698	60	66	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47097	47105		10.1074/jbc.M207793200	http://dx.doi.org/10.1074/jbc.M207793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12368285	hybrid			2022-12-25	WOS:000179663700035
J	Liu, T; Li, RL; Pan, T; Liu, DC; Petersen, RB; Wong, BS; Gambetti, P; Sy, MS				Liu, T; Li, RL; Pan, T; Liu, DC; Petersen, RB; Wong, BS; Gambetti, P; Sy, MS			Intercellular transfer of the cellular prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							37-KDA/67-KDA LAMININ RECEPTOR; PLASMA-MEMBRANE; KINASE-C; CULTURED-CELLS; SCRAPIE ISOFORM; IN-VIVO; SUPEROXIDE-DISMUTASE; BINDS COPPER; DOMAINS; CONVERSION	The cellular prion protein (PrPC) is a glycosylphosphatidylinositol (GPI)-anchored protein. We investigated whether PrPC can move from one cell to another cell in a cell model. Little PrPC transfer was detected when a PrPC expressing human neuroblastoma. cell line was cultured with the human erythroleukemia cells IA lacking PrPC. Efficient transfer of PrPC was detected with the presence of phorbol 12-myristate 13-acetate, an activator of protein kinase C. Maximum PrPC transfer was observed when both donor and recipient cells were activated. Furthermore, PrPC transfer required the GPI anchor and direct cell to cell contact. However, intercellular protein transfer is not limited to PrPC, another GPI-anchored protein, CD90, also transfers from the donor cells to acceptor cells after cellular activation. Therefore, this transfer process is GPI-anchor and cellular activation dependent. These findings suggest that the intercellular transfer of GPI-anchored proteins is a regulated process, and may have implications for the pathogenesis of prion disease.	Case Western Reserve Univ, Sch Med, BRB, Ctr Canc Res, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Inst Pathol, Div Neuropathol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Sy, MS (corresponding author), Case Western Reserve Univ, Sch Med, BRB, Ctr Canc Res, Rm 933,10900 Euclid Ave, Cleveland, OH 44106 USA.		Wong, Boon-Seng/G-2759-2012; Petersen, Robert/B-5075-2011	Wong, Boon-Seng/0000-0002-7118-8077; Petersen, Robert/0000-0002-3154-0072	NCI NIH HHS [P030CA43703] Funding Source: Medline; NIA NIH HHS [AG14359] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG014359] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson SM, 1996, P NATL ACAD SCI USA, V93, P5894, DOI 10.1073/pnas.93.12.5894; Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Brown DR, 1999, BIOCHEM J, V344, P1, DOI 10.1042/0264-6021:3440001; CAUGHEY B, 1988, J GEN VIROL, V69, P711, DOI 10.1099/0022-1317-69-3-711; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; Chakraborty P, 2000, J BIOCHEM-TOKYO, V127, P185, DOI 10.1093/oxfordjournals.jbchem.a022593; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DEARMOND SJ, 1995, AM J PATHOL, V146, P785; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DICKINSON AG, 1978, NATURE, V272, P54, DOI 10.1038/272054a0; EKLUND CM, 1967, J INFECT DIS, V117, P15, DOI 10.1093/infdis/117.1.15; FRASER H, 1970, NATURE, V226, P462, DOI 10.1038/226462a0; Furlong ST, 1997, J INFECT DIS, V175, P661, DOI 10.1093/infdis/175.3.661; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Gambetti P, 2001, J ALZHEIMERS DIS, V3, P87, DOI 10.3233/JAD-2001-3113; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOESSLI DC, 1983, P NATL ACAD SCI-BIOL, V80, P439, DOI 10.1073/pnas.80.2.439; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; Horiuchi M, 2001, J BIOL CHEM, V276, P15489, DOI 10.1074/jbc.M100288200; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Ilangumaran S, 1996, TRENDS CELL BIOL, V6, P163, DOI 10.1016/0962-8924(96)20012-1; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P10069, DOI 10.1073/pnas.94.19.10069; KOOYMAN DL, 1995, SCIENCE, V269, P89, DOI 10.1126/science.7541557; Kramer ML, 2001, J BIOL CHEM, V276, P16711, DOI 10.1074/jbc.M006554200; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lehmann S, 1996, J BIOL CHEM, V271, P1633, DOI 10.1074/jbc.271.3.1633; Li RL, 2000, J MOL BIOL, V301, P567, DOI 10.1006/jmbi.2000.3986; Lin T, 2001, J IMMUNOL, V166, P3733; Liu T, 2001, BRAIN RES, V896, P118, DOI 10.1016/S0006-8993(01)02050-9; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Marsh R F, 1981, Adv Exp Med Biol, V134, P359; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MEDOF ME, 1985, P NATL ACAD SCI USA, V82, P2980, DOI 10.1073/pnas.82.9.2980; Melikyan GB, 1997, J CELL BIOL, V136, P995, DOI 10.1083/jcb.136.5.995; Miller JL, 1998, J LAB CLIN MED, V131, P215, DOI 10.1016/S0022-2143(98)90092-0; Mouillet-Richard S, 2000, SCIENCE, V289, P1925, DOI 10.1126/science.289.5486.1925; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Myat MM, 1997, CURR BIOL, V7, P611, DOI 10.1016/S0960-9822(06)00262-4; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; Orito A, 2001, J NEUROSCI RES, V64, P235, DOI 10.1002/jnr.1071; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Parizek P, 2001, J BIOL CHEM, V276, P44627, DOI 10.1074/jbc.M107458200; Parolini I, 1999, J BIOL CHEM, V274, P14176, DOI 10.1074/jbc.274.20.14176; Petersen RB, 1996, J BIOL CHEM, V271, P12661, DOI 10.1074/jbc.271.21.12661; Pitto M, 1999, BIOCHEM J, V344, P177, DOI 10.1042/0264-6021:3440177; Pomorski T, 2001, SEMIN CELL DEV BIOL, V12, P139, DOI 10.1006/scdb.2000.0231; PRUSINER SB, 1989, ANNU REV MICROBIOL, V43, P345, DOI 10.1146/annurev.mi.43.100189.002021; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; ROGERS RA, 1993, J CELL SCI, V106, P485; SHYNG SL, 1993, J BIOL CHEM, V268, P15922; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; STEVENS EM, 1979, J CLIN PSYCHIAT, V40, P445; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; TAYLOR DD, 1983, BIOCHEM BIOPH RES CO, V113, P470, DOI 10.1016/0006-291X(83)91749-7; Tykocinski ML, 1996, AM J PATHOL, V148, P1; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Villalba M, 2001, J CELL BIOL, V155, P331, DOI 10.1083/jcb.200107080; VUORI K, 1993, J BIOL CHEM, V268, P21459; Wong BS, 2000, BIOCHEM BIOPH RES CO, V273, P136, DOI 10.1006/bbrc.2000.2911; Zanusso G, 1998, P NATL ACAD SCI USA, V95, P8812, DOI 10.1073/pnas.95.15.8812	68	82	84	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47671	47678		10.1074/jbc.M207458200	http://dx.doi.org/10.1074/jbc.M207458200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359724	hybrid			2022-12-25	WOS:000179663700108
J	Matias, PM; Coelho, AV; Valente, FMA; Placido, D; LeGall, J; Xavier, AV; Pereira, IAC; Carrondo, MA				Matias, PM; Coelho, AV; Valente, FMA; Placido, D; LeGall, J; Xavier, AV; Pereira, IAC; Carrondo, MA			Sulfate respiration in Desulfovibrio vulgaris Hildenborough - Structure of the 16-heme cytochrome c HmcA at 2.5-angstrom resolution and a view of its role in transmembrane electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESULFURICANS ATCC 27774; MOLECULAR-WEIGHT CYTOCHROME; 3-DIMENSIONAL STRUCTURE; REDUCING BACTERIA; C(3); REFINEMENT; HYDROGEN; ANGSTROM; OPERON; GIGAS	The crystal structure of the high molecular mass cytochrome c HmcA from Desulfovibrio vulgaris Hildenborough is described. HmcA contains the unprecedented number of sixteen hemes c attached to a single polypeptide chain, is associated with a membrane-bound redox complex, and is involved in electron transfer from the periplasmic oxidation of hydrogen to the cytoplasmic reduction of sulfate. The structure of HmcA is organized into four tetraheme cytochrome c(3)-like domains, of which the first is incomplete and contains only three hemes, and the final two show great similarity to the nine-heme cytochrome c from Desulfovibrio desulfuricans. An isoleucine residue fills the vacant coordination space above the iron atom in the five-coordinated high-spin Heme 15. The characteristics of each of the tetraheme domains of HmcA, as well as its surface charge distribution, indicate this cytochrome has several similarities with the nine-heme cytochrome c and the Type II cytochrome c(3) molecules, in agreement with their similar genetic organization and mode of reactivity and further support an analogous physiological function for the three cytochromes. Based on the present structure, the possible electron transfer sites between HmcA and its redox partners (namely Type I cytochrome c, and other proteins of the Hmc complex), as well as its physiological role, are discussed.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Univ Evora, Dept Chem, P-7001 Evora, Portugal; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Universidade Nova de Lisboa; University of Evora; University System of Georgia; University of Georgia	Carrondo, MA (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Republ,EAN,Apartado 127, P-2781901 Oeiras, Portugal.	carrondo@itqb.unl.pt	Coelho, Ana V Varela/O-3977-2014; Pereira, Inês/C-2748-2009; Coelho, Ana V/H-8885-2012; Matias, Pedro M/B-7180-2008	Coelho, Ana V Varela/0000-0002-6143-4203; Pereira, Inês/0000-0003-3283-4520; Coelho, Ana V/0000-0002-6143-4203; Matias, Pedro M/0000-0001-6170-451X; Carrondo, Maria Armenia/0000-0002-1261-1162				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BERKS BC, 1995, MOL MICROBIOL, V15, P319, DOI 10.1111/j.1365-2958.1995.tb02246.x; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BRANDIS A, 1981, J GEN MICROBIOL, V126, P249; BRENT W, 1991, J BACTERIOL, V173, P220; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHEN L, 1994, FEBS LETT, V347, P295, DOI 10.1016/0014-5793(94)00563-X; Coutinho IB, 1996, J BIOL INORG CHEM, V1, P305, DOI 10.1007/s007750050058; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; Czjzek M, 2001, ACTA CRYSTALLOGR D, V57, P670, DOI 10.1107/S0907444901003481; Dolla A, 2000, ARCH MICROBIOL, V174, P143, DOI 10.1007/s002030000183; Frazao C, 1999, J BIOL INORG CHEM, V4, P162, DOI 10.1007/s007750050299; Hamilton WA, 1998, BIODEGRADATION, V9, P201, DOI 10.1023/A:1008362304234; HIGUCHI Y, 1987, BIOCHIM BIOPHYS ACTA, V911, P341, DOI 10.1016/0167-4838(87)90075-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Keon RG, 1996, ANAEROBE, V2, P231, DOI 10.1006/anae.1996.0032; Keon RG, 1997, ARCH MICROBIOL, V167, P376, DOI 10.1007/s002030050458; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lamzin VS, 1997, METHOD ENZYMOL, V277, P269, DOI 10.1016/S0076-6879(97)77016-2; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LOUBINOUX J, 2002, FEMS MICROBIOL ECOL, V1341, P1; Louro RO, 1998, BIOCHEMISTRY-US, V37, P15808, DOI 10.1021/bi981505t; Louro RO, 2001, J BIOL CHEM, V276, P44044, DOI 10.1074/jbc.M107136200; Magro V, 1997, BBA-PROTEIN STRUCT M, V1342, P149, DOI 10.1016/S0167-4838(97)00096-4; Matias PM, 2001, J BIOL INORG CHEM, V6, P63, DOI 10.1007/s007750000167; Matias PM, 1999, J BIOL INORG CHEM, V4, P478, DOI 10.1007/s007750050334; Matias PM, 1997, J BIOL INORG CHEM, V2, P507, DOI 10.1007/s007750050162; Matias PM, 1999, STRUCTURE, V7, P119, DOI 10.1016/S0969-2126(99)80019-7; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nicholls A., 1992, GRASP GRAPHICAL REPR; Norager S, 1999, J MOL BIOL, V290, P881, DOI 10.1006/jmbi.1999.2917; ODOM JM, 1981, FEMS MICROBIOL LETT, V12, P47; OGATA M, 1993, BIOCHIMIE, V75, P977, DOI 10.1016/0300-9084(93)90148-L; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; Pereira IAC, 1998, J BIOL INORG CHEM, V3, P494, DOI 10.1007/s007750050259; Pereira IAC, 1997, J BIOL INORG CHEM, V2, P23, DOI 10.1007/s007750050102; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Pieulle L, 1996, BBA-BIOENERGETICS, V1273, P51, DOI 10.1016/0005-2728(95)00129-8; Postgate J, 1984, SULPHATE REDUCING BA, P56; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson DJ, 2000, MICROBIOL-SGM, V146, P551, DOI 10.1099/00221287-146-3-551; ROSSI M, 1993, J BACTERIOL, V175, P4699, DOI 10.1128/JB.175.15.4699-4711.1993; ROUSSEL A, 1990, 15 IUCR C BORD FRANC, P66; Saraiva LM, 1999, BIOCHEM BIOPH RES CO, V262, P629, DOI 10.1006/bbrc.1999.1238; SARAIVA LM, 2001, BIOCHIM BIOPHYS ACTA, P1; SCHOMAKER V, 1968, ACTA CRYSTALL B-STRU, VB 24, P63, DOI 10.1107/S0567740868001718; Simoes P, 1998, INORG CHIM ACTA, V273, P213, DOI 10.1016/S0020-1693(97)06018-0; Steger JL, 2002, APPL ENVIRON MICROB, V68, P1932, DOI 10.1128/AEM.68.4.1932-1937.2002; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tickle IJ, 1998, ACTA CRYSTALLOGR D, V54, P547, DOI 10.1107/S0907444997013875; TRAORE AS, 1981, J BACTERIOL, V154, P101; TSUJI K, 1980, ARCH MICROBIOL, V125, P35, DOI 10.1007/BF00403195; Umhau S, 2001, BIOCHEMISTRY-US, V40, P1308, DOI 10.1021/bi001479a; Valente FMA, 2001, CHEMBIOCHEM, V2, P895, DOI 10.1002/1439-7633(20011203)2:12<895::AID-CBIC895>3.0.CO;2-V; VERHAGEN MFJM, 1994, EUR J BIOCHEM, V225, P311, DOI 10.1111/j.1432-1033.1994.00311.x; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504	63	47	48	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47907	47916		10.1074/jbc.M207465200	http://dx.doi.org/10.1074/jbc.M207465200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356749	hybrid			2022-12-25	WOS:000179663700138
J	Sangkuhl, K; Schulz, A; Schultz, G; Schoneberg, T				Sangkuhl, K; Schulz, A; Schultz, G; Schoneberg, T			Structural requirements for mutational lutropin/choriogonadotropin receptor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE RECEPTOR; V2 VASOPRESSIN RECEPTORS; EXTRACELLULAR DOMAIN; THYROTROPIN RECEPTOR; LUTROPIN RECEPTOR; SIGNAL GENERATION; HINGE REGION; PROTEIN; RESIDUES; PORTION	Different activation mechanisms of glycoprotein hormone receptors, which are members of the G protein-coupled receptor superfamily, have been proposed. For example, the large ectodomain of glycoprotein hormone receptors may function as an inverse agonist keeping the transmembrane domain in an inactive conformation. To provide support for this hypothesis, we have generated different lutropin/choriogonadotropin receptor (LHR) constructs lacking the ectodomain. Although some ectodomain-deficient LHR constructs were targeted to the cell surface, cAMP levels remained unchanged under basal conditions and agonist application but could be increased by a mutation within the transmembrane domain 6 (D578H). Taking advantage of a constitutive activating mutation (S277N) located in the extracellular domain, we showed that the intact leucine-rich repeat-containing ectodomain is essential for constitutive activation of the LHR by mutation of the hinge region. Our findings support an activation scenario in which agonist binding or mutational alterations expose a structure within the ectodomain, which then activates the transmembrane core.	Free Univ Berlin, Klinikum Benjamin Franklin, Inst Pharmakol, D-14195 Berlin, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Schoneberg, T (corresponding author), Free Univ Berlin, Inst Pharmakol, Thielallee 69-73, D-14195 Berlin, Germany.							Abell AN, 1997, J BIOL CHEM, V272, P14586, DOI 10.1074/jbc.272.23.14586; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Biebermann H, 1998, FASEB J, V12, P1461, DOI 10.1096/fasebj.12.14.1461; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; Gruters A, 1998, J CLIN ENDOCR METAB, V83, P1431, DOI 10.1210/jc.83.5.1431; Higuchi R., 1989, PCR TECHNOLOGY, P61; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; JI I, 1991, J BIOL CHEM, V266, P13076; Krause G, 2000, MOL PHARMACOL, V57, P232; Kundu GC, 1996, J BIOL CHEM, V271, P11063, DOI 10.1074/jbc.271.19.11063; Lin ZL, 1997, PROTEIN ENG, V10, P501, DOI 10.1093/protein/10.5.501; Ling K, 1999, P NATL ACAD SCI USA, V96, P7922, DOI 10.1073/pnas.96.14.7922; Liu G, 1999, NEW ENGL J MED, V341, P1731, DOI 10.1056/NEJM199912023412304; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Schoneberg T, 2002, REV PHYSIOL BIOCH P, V144, P143; Schoneberg T, 1996, EMBO J, V15, P1283, DOI 10.1002/j.1460-2075.1996.tb00470.x; Schoneberg T, 1997, J CLIN INVEST, V100, P1547, DOI 10.1172/JCI119678; Schulz A, 2000, J BIOL CHEM, V275, P37860, DOI 10.1074/jbc.M006709200; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200; Zhang M, 2000, ENDOCRINOLOGY, V141, P3514, DOI 10.1210/en.141.9.3514; ZHANG ML, 1995, BIOCHEM BIOPH RES CO, V211, P205, DOI 10.1006/bbrc.1995.1797	26	41	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47748	47755		10.1074/jbc.M203491200	http://dx.doi.org/10.1074/jbc.M203491200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356766	hybrid			2022-12-25	WOS:000179663700118
J	Stultz, CM; Levin, AD; Edelman, ER				Stultz, CM; Levin, AD; Edelman, ER			Phosphorylation-induced conformational changes in a mitogen-activated protein kinase substrate - Implications for tyrosine hydroxylase activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL BASIS; ENERGY; DYNAMICS; SITE; IDENTIFICATION; SERINE-31; DOPAMINE; BINDING	Mitogen-activated protein (MAP) kinase-mediated phosphorylation of specific residues in tyrosine hydroxylase leads to an increase in enzyme activity. However, the mechanism whereby phosphorylation affects enzyme turnover is not well understood. We used a combination of fluorescence resonance energy transfer (FRET) measurements and molecular dynamics simulations to explore the conformational free energy landscape of a 10-residue MAP kinase substrate found near the N terminus of the enzyme. This region is believed to be part of an autoregulatory sequence that overlies the active site of the enzyme. FRET was used to measure the effect of phosphorylation on the ensemble of peptide conformations, and molecular dynamics simulations generated free energy profiles for both the unphosphorylated and phosphorylated peptides. We demonstrate how FRET transfer efficiencies can be calculated from molecular dynamics simulations. For both the unphosphorylated and phosphorylated peptides, the calculated FRET efficiencies are in excellent agreement with the experimentally determined values. Moreover, the FRET measurements and molecular simulations suggest that phosphorylation causes the peptide backbone to change direction and fold into a compact structure relative to the unphosphorylated state. These results are consistent with a model of enzyme activation where phosphorylation of the MAP kinase substrate causes the N-terminal region to adopt a compact structure away from the active site. The methods we employ provide a general framework for analyzing the accessible conformational states of peptides and small molecules. Therefore, they are expected to be applicable to a variety of different systems.	MIT, Harvard Mit Div Hlth Sci & Technol, Cambridge, MA 02139 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc Med, Boston, MA 02115 USA	Harvard University; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital	Stultz, CM (corresponding author), MIT, Harvard Mit Div Hlth Sci & Technol, Bldg 16-343,77 Massachusetts Ave, Cambridge, MA 02139 USA.	cmstultz@partners.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060407] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 60407] Funding Source: Medline; NIGMS NIH HHS [GM/HL 49039] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEECHEM JM, 1989, BIOPHYS J, V55, P1225, DOI 10.1016/S0006-3495(89)82918-2; Bevilaqua LRM, 2001, J BIOL CHEM, V276, P40411, DOI 10.1074/jbc.M105280200; Bobrovskaya L, 2001, J NEUROCHEM, V78, P490, DOI 10.1046/j.1471-4159.2001.00445.x; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1989, J MOL BIOL, V208, P159, DOI 10.1016/0022-2836(89)90093-4; BROOKS CL, 1988, PROTEINS THEORETICAL; Cohen P, 2000, TRENDS BIOCHEM SCI, V25, P596, DOI 10.1016/S0968-0004(00)01712-6; DAUBNER SC, 1992, J BIOL CHEM, V267, P12639; Feher VA, 1998, FEBS LETT, V425, P1, DOI 10.1016/S0014-5793(98)00182-3; Fitzpatrick PF, 1999, ANNU REV BIOCHEM, V68, P355, DOI 10.1146/annurev.biochem.68.1.355; Gao J, 2001, BIOPHYS J, V80, P1791, DOI 10.1016/S0006-3495(01)76149-8; Goodwill KE, 1997, NAT STRUCT BIOL, V4, P578, DOI 10.1038/nsb0797-578; Gordon GW, 1998, BIOPHYS J, V74, P2702, DOI 10.1016/S0006-3495(98)77976-7; Graves JD, 1999, PHARMACOL THERAPEUT, V82, P111, DOI 10.1016/S0163-7258(98)00056-4; HAYCOCK JW, 1990, J BIOL CHEM, V265, P11682; HAYCOCK JW, 1992, P NATL ACAD SCI USA, V89, P2365, DOI 10.1073/pnas.89.6.2365; IMPERIALI B, 1995, P NATL ACAD SCI USA, V92, P97, DOI 10.1073/pnas.92.1.97; Jiang GCT, 2000, J MOL BIOL, V302, P1005, DOI 10.1006/jmbi.2000.4097; JOHNSON LN, 1992, FASEB J, V6, P2274, DOI 10.1096/fasebj.6.6.1544539; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LEVIN AD, 2002, THESIS CAMBRIDGE MA; Lin K, 1996, SCIENCE, V273, P1539, DOI 10.1126/science.273.5281.1539; Lindgren N, 2002, EUR J NEUROSCI, V15, P769, DOI 10.1046/j.1460-9568.2002.01901.x; MacKerell AD, 2001, BIOPOLYMERS, V56, P257; McQuarrie D. A, 2000, STAT MECH; MIRANKER A, 1991, PROTEINS, V11, P29, DOI 10.1002/prot.340110104; MITCHELL JP, 1990, J BIOL CHEM, V265, P22358; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Selvin PR, 2000, NAT STRUCT BIOL, V7, P730, DOI 10.1038/78948; Stevenson LM, 2002, BIOCHEMISTRY-US, V41, P8528, DOI 10.1021/bi025812h; Stultz CM, 2002, J MOL BIOL, V319, P997, DOI 10.1016/S0022-2836(02)00421-7; SUTHERLAND C, 1993, EUR J BIOCHEM, V217, P715, DOI 10.1111/j.1432-1033.1993.tb18297.x; Tezcan FA, 2002, P NATL ACAD SCI USA, V99, P8626, DOI 10.1073/pnas.132254499; Vrana KE, 1999, NAT STRUCT BIOL, V6, P401, DOI 10.1038/8192; Wevers RA, 1999, J INHERIT METAB DIS, V22, P364, DOI 10.1023/A:1005539803576	36	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47653	47661		10.1074/jbc.M208755200	http://dx.doi.org/10.1074/jbc.M208755200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12361946	hybrid			2022-12-25	WOS:000179663700106
J	Witko-Sarsat, V; Canteloup, S; Durant, S; Desdouets, C; Chabernaud, R; Lemarchand, P; Descamps-Latscha, A				Witko-Sarsat, V; Canteloup, S; Durant, S; Desdouets, C; Chabernaud, R; Lemarchand, P; Descamps-Latscha, A			Cleavage of p21(waf1) by proteinase-3, a myeloid-specific serine protease, potentiates cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CDK-INHIBITORS; CATHEPSIN-G; EXPRESSION; P21; P21(CIP1/WAF1); AUTOANTIGEN; NEUTROPHILS; APOPTOSIS; GROWTH	In this study, we present evidence for the critical role of proteinase-3 (PR3) in the proliferation of myeloid cells via the proteolytic regulation of the cyclin-dependent kinase inhibitor p21(waf1). Expression of recombinant PR3 in rat (RBL) or human (IMCl) mast cell lines increased bromodeoxyuridine incorporation and CDK2 activity compared with RBL and HMC1 cells transfected with an enzymatically inactive PR3 mutant (PR3(S203A)) or with human neutrophil elastase. Western blot analysis of p21(waf1) showed an absence of detectable protein, despite normal levels of p21 mRNA. Ectopic overexpression of p21. restored normal levels of p21 in the RBL/PR3/p21 double transfectants and reverted the proliferative effect of PR3. Inhibition of the 26 S proteasome by lactacystin or of caspases by benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl ketone did not inhibit p21 proteolysis. p21 cleavage correlated with PR3 expression in HMC1 cells infected with recombinant adenoviral vector Ad/PR3. During in vitro studies, purified p21 was cleaved by PR3, resulting in a 10-kDa p21 fragment. Employing double immunofluorescence confocal microscopy, subcellular fractionation, and coimmunoprecipitation, we found that PR3 and p21 colocalized in the cytosol. In human neutrophils treated with tumor necrosis factor-a, which induces PR3 re-expression, we observed that p21 disappeared and was reversed by Pefabloc, a serine proteinase inhibitor. The physiopathological implications of the cleavage of p21 by PR3 have to be determined.	Hop Necker Enfants Malad, INSERM, U507, F-75015 Paris, France; Fac Med Necker Enfants Malad, INSERM, U370, F-75015 Paris, France; Fac Med, INSERM, U533, F-44000 Nantes, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	Witko-Sarsat, V (corresponding author), Hop Necker Enfants Malad, INSERM, U507, 161 Rue Sevres, F-75015 Paris, France.	witko-sarsat@necker.fr	Desdouets, Chantal/M-3430-2017; Witko-Sarsat, Veronique/L-9714-2017; lemarchand, patricia/C-3247-2011	Witko-Sarsat, Veronique/0000-0002-5296-9601; lemarchand, patricia/0000-0002-5330-2008				Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; BAGGIOLINI M, 1978, AGENTS ACTIONS, V8, P3, DOI 10.1007/BF01972395; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; Borregaard N, 1997, BLOOD, V89, P3503, DOI 10.1182/blood.V89.10.3503.3503_3503_3521; CAMPANELLI D, 1990, J EXP MED, V172, P1709, DOI 10.1084/jem.172.6.1709; Cayrol C, 1998, ONCOGENE, V17, P2437, DOI 10.1038/sj.onc.1202189; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Danel C, 1998, HUM GENE THER, V9, P1487, DOI 10.1089/hum.1998.9.10-1487; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Garwicz D, 1997, J LEUKOCYTE BIOL, V61, P113, DOI 10.1002/jlb.61.1.113; Gervais JLM, 1998, J BIOL CHEM, V273, P19207, DOI 10.1074/jbc.273.30.19207; Goldmann WH, 1999, EUR J BIOCHEM, V261, P155, DOI 10.1046/j.1432-1327.1999.00259.x; GULLBERG U, 1995, J BIOL CHEM, V270, P12912, DOI 10.1074/jbc.270.21.12912; GULLBERG U, 1994, J BIOL CHEM, V269, P25219; HARPER JW, 1993, CELL, V75, P805; HULTBERG B, 1976, BIOCHEM J, V155, P599, DOI 10.1042/bj1550599; JENNE DE, 1990, NATURE, V346, P520, DOI 10.1038/346520a0; JIANG HP, 1994, ONCOGENE, V9, P3397; Jin YH, 2000, J BIOL CHEM, V275, P30256, DOI 10.1074/jbc.M001902200; Just J, 1999, FEBS LETT, V457, P437, DOI 10.1016/S0014-5793(99)01098-4; Lutz PG, 2000, P NATL ACAD SCI USA, V97, P1601, DOI 10.1073/pnas.97.4.1601; Maki CG, 1997, MOL CELL BIOL, V17, P355, DOI 10.1128/MCB.17.1.355; McIntyre M, 1999, ONCOGENE, V18, P4577, DOI 10.1038/sj.onc.1202815; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Poon RYC, 1998, ONCOGENE, V16, P1333, DOI 10.1038/sj.onc.1201897; Rousseau D, 1999, ONCOGENE, V18, P3290, DOI 10.1038/sj.onc.1202681; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Specks U, 1996, FEBS LETT, V390, P265, DOI 10.1016/0014-5793(96)00669-2; Steinman RA, 1998, BLOOD, V91, P4531, DOI 10.1182/blood.V91.12.4531.412k10_4531_4542; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Taekema-Roelvink MEJ, 2000, J AM SOC NEPHROL, V11, P640, DOI 10.1681/ASN.V114640; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tyers M, 2000, CURR OPIN GENET DEV, V10, P54, DOI 10.1016/S0959-437X(99)00049-0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; Witko-Sarsat V, 1999, AM J RESP CELL MOL, V20, P729, DOI 10.1165/ajrcmb.20.4.3371; Witko-Sarsat V, 1999, BLOOD, V94, P2487, DOI 10.1182/blood.V94.7.2487.419k07_2487_2496; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang JJ, 1996, AM J PATHOL, V149, P1617; Yaroslavskiy B, 1999, BLOOD, V93, P2907; Zhou ZJ, 2000, J RHEUMATOL, V27, P2406	43	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47338	47347		10.1074/jbc.M202789200	http://dx.doi.org/10.1074/jbc.M202789200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354776	hybrid			2022-12-25	WOS:000179663700066
J	Chen, H; MacDonald, A; Coffino, P				Chen, H; MacDonald, A; Coffino, P			Structural elements of antizymes 1 and 2 are required for proteasomal degradation of ornithine decarboxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULOCYTE LYSATE; ANGSTROM RESOLUTION; POLYAMINES; PROTEIN; CONSERVATION; PROTEOLYSIS	The antizymes constitute a conserved gene family with at least three mammalian orthologs. As described previously, in a degradation system utilizing rabbit reticulocyte lysate, antizyme 1 (AZ1) accelerates proteasomal ornithine decarboxylase (ODC) degradation, but antizyme 2 (AZ2) does not. To examine the relationship between antizyme structure and function, we further characterized the properties of AZ1 and AZ2 and protein chimeras composed of elements of the two. AZ1 binds to ODC with about a 3-fold higher potency than AZ2, but this cannot account for their distinct degradative activities. The dissimilar degradative capacity of AZ1 and AZ2 is also observed using purified proteasomes. A series of reciprocal AZ1/ AZ2 chimeras was used to determine the sequence elements needed to direct ODC degradation. An element contained within amino acids 130-145 of AZ1 is essential for this function. Constructs in which amino acids 130-145 were exchanged between the antizymes confirmed the critical nature of this region. Within this region amino acids 131 and 145 proved responsible for the functional difference between the two forms of AZ.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Coffino, P (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.	pcoffin@itsa.ucsf.edu		Coffino, Philip/0000-0003-0344-5083	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045335] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM-45335] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; BERCOVICH Z, 1989, J BIOL CHEM, V264, P15949; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Coffino P, 2001, NAT REV MOL CELL BIO, V2, P188, DOI 10.1038/35056508; Coffino P, 2000, MOL B INT U, V12, P254; GHODA L, 1989, SCIENCE, V243, P1493, DOI 10.1126/science.2928784; ICHIBA T, 1994, BIOCHEM BIOPH RES CO, V200, P1721, DOI 10.1006/bbrc.1994.1651; Ivanov IP, 2000, P NATL ACAD SCI USA, V97, P4808, DOI 10.1073/pnas.070055897; Ivanov IP, 1998, GENOMICS, V52, P119, DOI 10.1006/geno.1998.5434; Ivanov IP, 2000, EMBO J, V19, P1907, DOI 10.1093/emboj/19.8.1907; Kern AD, 1999, STRUCTURE, V7, P567, DOI 10.1016/S0969-2126(99)80073-2; LI XQ, 1993, MOL CELL BIOL, V13, P2377, DOI 10.1128/MCB.13.4.2377; LI XQ, 1994, MOL CELL BIOL, V14, P87, DOI 10.1128/MCB.14.1.87; LI XQ, 1992, MOL CELL BIOL, V12, P3556, DOI 10.1128/MCB.12.8.3556; MAMROUDKIDRON E, 1994, EUR J BIOCHEM, V226, P547, DOI 10.1111/j.1432-1033.1994.tb20079.x; MATSUFUJI S, 1995, CELL, V80, P51, DOI 10.1016/0092-8674(95)90450-6; MURAKAMI Y, 1994, BIOCHEM J, V304, P183, DOI 10.1042/bj3040183; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; MURAKAMI Y, 1992, BIOCHEM J, V283, P661, DOI 10.1042/bj2830661; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Sambrook J., 2001, MOL CLONING LAB MANU, V3; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Zhu C, 1999, J BIOL CHEM, V274, P26425, DOI 10.1074/jbc.274.37.26425	23	32	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45957	45961		10.1074/jbc.M206799200	http://dx.doi.org/10.1074/jbc.M206799200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359729	hybrid			2022-12-25	WOS:000179529300034
J	Colombo, B; Longhi, R; Marinzi, C; Magni, F; Cattaneo, A; Yoo, SH; Curnis, F; Corti, A				Colombo, B; Longhi, R; Marinzi, C; Magni, F; Cattaneo, A; Yoo, SH; Curnis, F; Corti, A			Cleavage of chromogranin A N-terminal domain by plasmin provides a new mechanism for regulating cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONAL CHANGE; PROTEIN FAMILY; IN-VITRO; A GENE; VASOSTATINS; IDENTIFICATION; FRAGMENTS; ENDOCRINE; SECRETION; TUMORS	It has been proposed that chromogranin A (CgA), a protein secreted by many normal and neoplastic neuroendocrine cells, can play a role as a positive or a negative modulator of cell adhesion. The mechanisms that regulate these extracellular functions of CgA are unknown. We show here that plasmin can regulate the anti/pro-adhesive activity of CgA by proteolytic cleavage of the N-terminal domain. Limited proteolytic processing decreased its anti-adhesive activity and induced pro-adhesive effects in fibronectin or serum-dependent fibroblast adhesion assays. Cleavage of LyS77 -LyS78 dibasic site in CgA(1-115) was relatively rapid and associated with an increase of pro-adhesive effect. In contrast, antibodies against the region 53-90 enhanced the anti-adhesive activity of CgA and CgA(1-115). Structure-activity relationship studies showed that the conserved region 47-64 (RILSILRHQNLLKELQDL) is critical for both pro- and anti-adhesive activity. These findings suggest that CgA might work on one hand as a negative modulator of cell adhesion and on the other hand as a precursor of positive modulators, the latter requiring proteolytic processing for activation. Given the importance of plasminogen activation in tissue invasion and remodeling, the interplay between CgA and plasmin could provide a novel mechanism for regulating fibroblast adhesion and function in neuroendocrine tumors.	San Raffaele H Sci Inst, Dept Biol & Technol Res, I-20132 Milan, Italy; ICRM, CNR, I-20132 Milan, Italy; Inha Univ, Coll Med, Dept Biochem,Nam Gu, Natl Creat Res Initiat Ctr Secretory Granule Res, Inchon 402751, South Korea	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR); Inha University	Corti, A (corresponding author), San Raffaele H Sci Inst, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.		Corti, Angelo/F-7046-2012; Colombo, Barbara/AAN-5045-2020; Curnis, Flavio/AAK-3542-2020; Magni, Fulvio/A-7340-2014	Corti, Angelo/0000-0002-0893-6191; Colombo, Barbara/0000-0002-5887-5868; Curnis, Flavio/0000-0002-7231-9569; Magni, Fulvio/0000-0002-8663-0374; Subba, Rajkrishna/0000-0003-0051-0062				AARDAL S, 1993, J NEUROENDOCRINOL, V5, P405, DOI 10.1111/j.1365-2826.1993.tb00501.x; AARDAL S, 1992, REGUL PEPTIDES, V41, P9, DOI 10.1016/0167-0115(92)90509-S; BRANDT DW, 1994, P SOC EXP BIOL MED, V205, P316; Ceconi C, 2002, EUR HEART J, V23, P967, DOI 10.1053/euhj.2001.2977; Ciesielski-Treska J, 1998, J BIOL CHEM, V273, P14339, DOI 10.1074/jbc.273.23.14339; Colombo B, 2002, CANCER RES, V62, P941; CONESE M, 1995, BAILLIERE CLIN HAEM, V8, P365, DOI 10.1016/S0950-3536(05)80273-2; Corti A, 1997, EUR J BIOCHEM, V248, P692, DOI 10.1111/j.1432-1033.1997.00692.x; Corti A, 1996, EUR J BIOCHEM, V235, P275, DOI 10.1111/j.1432-1033.1996.00275.x; Corti A, 2000, ADV EXP MED BIOL, V482, P351; DEFTOS LJ, 1991, ENDOCR REV, V12, P181, DOI 10.1210/edrv-12-2-181; FERRER M, 1992, INT J PEPT PROT RES, V40, P194; Gasparri A, 1997, J BIOL CHEM, V272, P20835, DOI 10.1074/jbc.272.33.20835; Helle K. B., 2001, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V1, P119, DOI 10.2174/1568013013359087; HELLE KB, 1993, J NEUROENDOCRINOL, V5, P413, DOI 10.1111/j.1365-2826.1993.tb00502.x; Helle KB, 2000, ADV EXP MED BIOL, V482, P225; Helle KB, 2000, ADV EXP MED BIOL, V482, P3; IACANGELO A, 1988, FEBS LETT, V227, P115, DOI 10.1016/0014-5793(88)80880-9; IGUCHI H, 1992, EUR J CANCER, V28A, P1458, DOI 10.1016/0959-8049(92)90543-B; Jiang QJ, 2001, J BIOL CHEM, V276, P25022, DOI 10.1074/jbc.M101545200; KONECKI DS, 1987, J BIOL CHEM, V262, P17026; KRAMER MD, 1994, INVAS METAST, V14, P210; LANKATBUTTGEREIT B, 1988, FEBS LETT, V236, P352, DOI 10.1016/0014-5793(88)80054-1; Laslop A, 2000, ADV EXP MED BIOL, V482, P155; LIANG F, 1995, ACTA PHYSIOL SCAND, V155, P23, DOI 10.1111/j.1748-1716.1995.tb09944.x; Lugardon K, 2000, J BIOL CHEM, V275, P10745, DOI 10.1074/jbc.275.15.10745; Lugardon K, 2001, J BIOL CHEM, V276, P35875, DOI 10.1074/jbc.M104670200; MAYER M, 1990, CLIN BIOCHEM, V23, P197, DOI 10.1016/0009-9120(90)90601-P; METZBOUTIGUE MH, 1993, EUR J BIOCHEM, V217, P247, DOI 10.1111/j.1432-1033.1993.tb18240.x; Nobels FRE, 1997, J CLIN ENDOCR METAB, V82, P2622, DOI 10.1210/jc.82.8.2622; OCONNOR DT, 1984, NEW ENGL J MED, V311, P764, DOI 10.1056/NEJM198409203111204; Parmer RJ, 2000, J CLIN INVEST, V106, P907, DOI 10.1172/JCI7394; Parmer RJ, 1997, J BIOL CHEM, V272, P1976, DOI 10.1074/jbc.272.3.1976; Ratti S, 2000, J BIOL CHEM, V275, P29257, DOI 10.1074/jbc.M003796200; ROSA P, 1994, J ENDOCRINOL INVEST, V17, P207, DOI 10.1007/BF03347721; RUSSELL J, 1994, ENDOCRINOLOGY, V135, P337, DOI 10.1210/en.135.1.337; SIMON JP, 1989, BIOCHEM J, V262, P1; SOBOL RE, 1989, NEW ENGL J MED, V320, P444, DOI 10.1056/NEJM198902163200707; Soriano JV, 1999, BIOCHEM BIOPH RES CO, V259, P563, DOI 10.1006/bbrc.1999.0826; STRIDSBERG M, 1995, J ENDOCRINOL, V144, P49, DOI 10.1677/joe.0.1440049; Turquier V, 1999, ENDOCRINOLOGY, V140, P4104, DOI 10.1210/en.140.9.4104; WINKLER H, 1992, NEUROSCIENCE, V49, P497, DOI 10.1016/0306-4522(92)90222-N; WU HJ, 1991, J BIOL CHEM, V266, P13130; Wu TL, 1999, J CLIN LAB ANAL, V13, P312, DOI 10.1002/(SICI)1098-2825(1999)13:6<312::AID-JCLA11>3.0.CO;2-1; WUN TC, 1988, CRIT REV BIOTECHNOL, V8, P131, DOI 10.3109/07388558809150542; YOO SH, 1992, J BIOL CHEM, V267, P11236; YOO SH, 1993, BIOCHEMISTRY-US, V32, P8816, DOI 10.1021/bi00085a012; YOO SH, 1990, J BIOL CHEM, V265, P14414; YOO SH, 1993, FEBS LETT, V334, P373, DOI 10.1016/0014-5793(93)80715-7; YOO SH, 1991, J BIOL CHEM, V266, P7740; YOO SH, 1992, BIOCHEMISTRY-US, V31, P6134, DOI 10.1021/bi00141a025; ZIEGLER MG, 1990, KIDNEY INT, V37, P1357, DOI 10.1038/ki.1990.122	52	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45911	45919		10.1074/jbc.M202637200	http://dx.doi.org/10.1074/jbc.M202637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297497	hybrid			2022-12-25	WOS:000179529300028
J	Ge, HF; Huang, L; Pourbahrami, T; Li, C				Ge, HF; Huang, L; Pourbahrami, T; Li, C			Generation of soluble leptin receptor by ectodomain shedding of membrane-spanning receptors in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND LEPTIN; OBESE GENE; SIGNAL-TRANSDUCTION; DIABETIC MICE; DB/DB MICE; OB-R; PROTEIN; IDENTIFICATION; TISSUES; CLONING	Leptin is an adipocyte-derived hormone with potent effects on food intake and body weight. Genetically obese rodents with mutations of leptin or leptin receptor develop morbid obesity and diabetes. The receptor for leptin, OB-R, is alternatively spliced to at least five transcripts, encoding receptors designated OB-Ra, -b, -c, -d, and -e. OB-Re does not encode a transmembrane domain and is secreted. In humans, transcripts corresponding to OB-Re have not been discovered. However, soluble leptin receptor does circulate in human plasma and represents the major leptin-binding activity. In this report, we attempted to determine whether the soluble leptin receptor may also be derived from membrane-spanning receptor isoforms by ectodomain shedding. Using stable cell lines expressing both OB-Ra, the most abundant leptin receptor isoform, and OB-Rb, the signaling form of the leptin receptor, we demonstrate that soluble leptin receptor protein can indeed be generated by proteolytic cleavage of these two receptor isoforms in vitro. Experiments using adenoviruses expressing dually tagged OB-Ra or Ob-Rb also demonstrate that soluble leptin receptor may be derived from ectodomain shedding of both receptor isoforms in vivo. Because our earlier and other studies have shown that the soluble receptors modulate the levels as well as activity of leptin, our findings suggest that regulated shedding of the ectodomain of membrane-spanning leptin receptors may represent a novel mechanism of modulating leptin's biological activity.	Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Li, C (corresponding author), Univ Texas, SW Med Ctr, Touchstone Ctr Diabet Res, Dept Physiol, Dallas, TX 75390 USA.	Cai.Li@UTSouthwestern.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060137] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 60137] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baumann H, 1996, P NATL ACAD SCI USA, V93, P8374, DOI 10.1073/pnas.93.16.8374; CAMPFIELD LA, 1995, SCIENCE, V269, P546, DOI 10.1126/science.7624778; Chan JL, 2002, DIABETES, V51, P2105, DOI 10.2337/diabetes.51.7.2105; Chen GX, 1996, P NATL ACAD SCI USA, V93, P14795, DOI 10.1073/pnas.93.25.14795; Chen H, 1996, CELL, V84, P491, DOI 10.1016/S0092-8674(00)81294-5; Chua SC, 1997, GENOMICS, V45, P264, DOI 10.1006/geno.1997.4962; Cohen SL, 1996, NATURE, V382, P589, DOI 10.1038/382589a0; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; Cowley MA, 2001, NATURE, V411, P480, DOI 10.1038/35078085; Fei H, 1997, P NATL ACAD SCI USA, V94, P7001, DOI 10.1073/pnas.94.13.7001; Friedman JM, 2000, NATURE, V404, P632, DOI 10.1038/35007504; Gavrilova O, 1997, J BIOL CHEM, V272, P30546, DOI 10.1074/jbc.272.48.30546; Ghilardi N, 1996, P NATL ACAD SCI USA, V93, P6231, DOI 10.1073/pnas.93.13.6231; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HERZ J, 1993, P NATL ACAD SCI USA, V90, P2812, DOI 10.1073/pnas.90.7.2812; Huang L, 2000, Cell Res, V10, P81, DOI 10.1038/sj.cr.7290038; Huang L, 2001, J BIOL CHEM, V276, P6343, DOI 10.1074/jbc.M009795200; Kim YB, 2000, ENDOCRINOLOGY, V141, P2328, DOI 10.1210/en.141.7.2328; Lahlou N, 2002, DIABETES, V51, P1980, DOI 10.2337/diabetes.51.6.1980; Laimer M, 2002, OBES RES, V10, P597, DOI 10.1038/oby.2002.81; Lammert A, 2001, BIOCHEM BIOPH RES CO, V283, P982, DOI 10.1006/bbrc.2001.4885; Lee GH, 1996, NATURE, V379, P632, DOI 10.1038/379632a0; Lewandowski K, 1999, J CLIN ENDOCR METAB, V84, P300, DOI 10.1210/jc.84.1.300; Li C, 1998, J BIOL CHEM, V273, P10078, DOI 10.1074/jbc.273.16.10078; Li C, 1999, P NATL ACAD SCI USA, V96, P9677, DOI 10.1073/pnas.96.17.9677; Lord GM, 1998, NATURE, V394, P897, DOI 10.1038/29795; Maamra M, 2001, ENDOCRINOLOGY, V142, P4389, DOI 10.1210/en.142.10.4389; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Monteleone P, 2002, MOL PSYCHIATR, V7, P641, DOI 10.1038/sj.mp.4001043; Ogier V, 2002, INT J OBESITY, V26, P496, DOI 10.1038/sj.ijo.0801951; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Sinha MK, 1996, J CLIN INVEST, V98, P1277, DOI 10.1172/JCI118913; Tartaglia LA, 1995, CELL, V83, P1263, DOI 10.1016/0092-8674(95)90151-5; Unger RH, 1999, P NATL ACAD SCI USA, V96, P2327, DOI 10.1073/pnas.96.5.2327; van Dielen FMH, 2002, J CLIN ENDOCR METAB, V87, P1708, DOI 10.1210/jc.87.4.1708; Widjaja A, 2000, NEPHROL DIAL TRANSPL, V15, P846, DOI 10.1093/ndt/15.6.846; Wu ZD, 2002, J CLIN ENDOCR METAB, V87, P2931, DOI 10.1210/jc.87.6.2931; Yamaguchi M, 1998, BIOCHEM BIOPH RES CO, V252, P363, DOI 10.1006/bbrc.1998.9636; Zhang Y, 2000, ENDOCRINOLOGY, V141, P4342, DOI 10.1210/en.141.12.4342; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	43	138	149	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45898	45903		10.1074/jbc.M205825200	http://dx.doi.org/10.1074/jbc.M205825200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270921	hybrid			2022-12-25	WOS:000179529300026
J	Parton, RG; Molero, JC; Floetenmeyer, M; Green, KM; James, DE				Parton, RG; Molero, JC; Floetenmeyer, M; Green, KM; James, DE			Characterization of a distinct plasma membrane macrodomain in differentiated adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE CELL-LINE; 3T3-L1 ADIPOCYTES; INTERMEDIATE-FILAMENT; INSULIN; CONVERSION; PATHWAY; GLUT4; TRANSLOCATION; LOCALIZATION; FIBROBLASTS	Caveolae are small invaginations of the cell surface that are abundant in mature adipocytes. A recent study (Kanzaki, M., and Pessin, J. E. (2002) J. Biol Chem 277, 25867-25869) described novel caveolin- and actin-containing structures associated with the adipocyte cell surface that contain specific signaling proteins. We have characterized these structures, here termed "caves," using light and electron microscopy and observe that they represent surface-connected wide invaginations of the basal plasma membrane that are sometimes many micrometers in diameter. Rather than simply a caveolar domain, these structures contain all elements of the plasma membrane including clathrin-coated pits, lipid raft markers, and non-raft markers. GLUT4 is recruited to caves in response to insulin stimulation. Caves can occupy a significant proportion of the plasma membrane area and are surrounded by cortical actin. Caveolae density in caves is similar to that on the bulk plasma membrane, but because these structures protrude much deeper into the plane of focus of the light microscope molecules such as caveolin and other plasma membrane proteins appear more concentrated in caves. We conclude that the adipocyte surface membrane contains numerous wide invaginations that do not represent novel caveolar structures but rather large surface caves.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland	Parton, RG (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	R.Parton@imb.uq.edu.au	Parton, Robert G/C-5673-2009	Parton, Robert G/0000-0002-7494-5248; James, David/0000-0001-5946-5257; Floetenmeyer, Matthias/0000-0002-0133-1632				Arcangeletti C, 1997, J STRUCT BIOL, V119, P35, DOI 10.1006/jsbi.1997.3871; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; FRANKE WW, 1987, CELL, V49, P131, DOI 10.1016/0092-8674(87)90763-X; GREEN H, 1976, CELL, V7, P105, DOI 10.1016/0092-8674(76)90260-9; GREEN H, 1974, CELL, V3, P127, DOI 10.1016/0092-8674(74)90116-0; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Hill MM, 1997, ELECTROPHORESIS, V18, P2629, DOI 10.1002/elps.1150181419; Kanzaki M, 2002, J BIOL CHEM, V277, P25867, DOI 10.1074/jbc.C200292200; KURIHARCUCH W, 1977, J BIOL CHEM, V252, P2158; MACKALL JC, 1976, J BIOL CHEM, V251, P6462; NOVIKOFF AB, 1980, J CELL BIOL, V87, P180, DOI 10.1083/jcb.87.1.180; PARTON RG, 1994, J CELL BIOL, V127, P1199, DOI 10.1083/jcb.127.5.1199; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; PIPER RC, 1991, AM J PHYSIOL, V260, pC570, DOI 10.1152/ajpcell.1991.260.3.C570; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rea S, 1998, J BIOL CHEM, V273, P18784, DOI 10.1074/jbc.273.30.18784; Rea S, 1997, DIABETES, V46, P1667, DOI 10.2337/diabetes.46.11.1667; ROBINSON LJ, 1992, AM J PHYSIOL, V263, pE383, DOI 10.1152/ajpendo.1992.263.2.E383; ROBINSON LJ, 1992, J CELL BIOL, V117, P1181, DOI 10.1083/jcb.117.6.1181; RUBIN CS, 1977, J BIOL CHEM, V252, P3554; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; Saltiel AR, 2002, TRENDS CELL BIOL, V12, P65, DOI 10.1016/S0962-8924(01)02207-3; SPIEGELMAN BM, 1993, J BIOL CHEM, V268, P6823; Tellam JT, 1997, J BIOL CHEM, V272, P6179, DOI 10.1074/jbc.272.10.6179; Watson RT, 2001, J CELL BIOL, V154, P829, DOI 10.1083/jcb.200102078; WILLIAMS IH, 1977, BIOCHEM BIOPH RES CO, V77, P175, DOI 10.1016/S0006-291X(77)80180-0	27	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46769	46778		10.1074/jbc.M205683200	http://dx.doi.org/10.1074/jbc.M205683200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356772	hybrid, Green Submitted			2022-12-25	WOS:000179529300137
J	Sun, Y; Wilson, MP; Majerus, PW				Sun, Y; Wilson, MP; Majerus, PW			Inositol 1,3,4-trisphosphate 5/6-kinase associates with the COP9 signalosome by binding to CSN1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; PROTEIN-KINASE; C-JUN; COMPLEX; ARABIDOPSIS; TRANSDUCTION; PHOTOMORPHOGENESIS; DEGRADATION; LIGASE; CELLS	The COP9 signalosome (CSN) is a complex of eight proteins first identified as a repressor of plant photomorphogenesis. A protein kinase activity associated with the COP9 signalosome has been reported but not identified; we present evidence for inositol 1,3,4-trisphosphate 5/6-kinase (5/6-kinase) as a protein kinase associated with the COP9 signalosome. We have shown that 5/6-kinase exists in a complex with the eight-component COP9 signalosome both when purified from bovine brain and when transfected into HEK 293 cells. 5/6-kinase phosphorylates the same substrates as those of the COP9 signalosome, including IkappaBalpha, p53, and c-Jun but fails to phosphorylate several other substrates, including c-Jun 1-79, which are not substrates for the COP9-associated kinase. Both the COP9 signalosome-associated kinase and 5/6-kinase are inhibited by curcumin. The association of 5/6-kinase with the COP9 signalosome is through an interaction with CSN1, which immunoprecipitates with 5/6-kinase. In addition, the inositol kinase activity of 5/6-kinase is inhibited when in a complex with CSN1. We propose that 5/6-kinase is the previously described COP9 signalosome-associated kinase.	Washington Univ, Sch Med, Dept Internal Med, Div Hematol, St Louis, MO 63110 USA	Washington University (WUSTL)	Majerus, PW (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Hematol, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055672, R01HL016634] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL16634, R01-HL55672] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bech-Otschir D, 2002, J CELL SCI, V115, P467; Chamovitz DA, 2002, CURR BIOL, V12, pR232, DOI 10.1016/S0960-9822(02)00775-3; Chamovitz DA, 2001, EMBO REP, V2, P96, DOI 10.1093/embo-reports/kve028; Field J, 2000, MOL BIOCHEM PARASIT, V108, P119, DOI 10.1016/S0166-6851(00)00197-3; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; Henke W, 1999, MOL BIOL REP, V26, P29, DOI 10.1023/A:1006991419464; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Kapelari B, 2000, J MOL BIOL, V300, P1169, DOI 10.1006/jmbi.2000.3912; Kawakami T, 2001, EMBO J, V20, P4003, DOI 10.1093/emboj/20.15.4003; Lyapina S, 2001, SCIENCE, V292, P1382, DOI 10.1126/science.1059780; Naumann M, 1999, J BIOL CHEM, V274, P35297, DOI 10.1074/jbc.274.50.35297; Ohh M, 2002, EMBO REP, V3, P177, DOI 10.1093/embo-reports/kvf028; Pollmann C, 2001, CANCER RES, V61, P8416; Schwechheimer C, 2001, SCIENCE, V292, P1379, DOI 10.1126/science.1059776; Schwechheimer C, 2001, TRENDS CELL BIOL, V11, P420, DOI 10.1016/S0962-8924(01)02091-8; Seeger M, 1998, FASEB J, V12, P469, DOI 10.1096/fasebj.12.6.469; Shears SB, 2001, CELL SIGNAL, V13, P151, DOI 10.1016/S0898-6568(01)00129-2; Spain BH, 1996, MOL CELL BIOL, V16, P6698; Tomoda K, 2002, J BIOL CHEM, V277, P2302, DOI 10.1074/jbc.M104431200; Tsuge T, 2001, J MOL BIOL, V305, P1, DOI 10.1006/jmbi.2000.4288; Verbsky JW, 2002, J BIOL CHEM, V277, P31857, DOI 10.1074/jbc.M205682200; Wang XP, 2002, MOL BIOL CELL, V13, P646, DOI 10.1091/mbc.01-08-0427; WEI N, 1992, PLANT CELL, V4, P1507, DOI 10.1105/tpc.4.12.1507; Wei N, 1998, PHOTOCHEM PHOTOBIOL, V68, P237; WEI N, 1994, CELL, V78, P117, DOI 10.1016/0092-8674(94)90578-9; Wilson MP, 2001, J BIOL CHEM, V276, P40998, DOI 10.1074/jbc.M106605200; Wilson MP, 1996, J BIOL CHEM, V271, P11904, DOI 10.1074/jbc.271.20.11904; Wilson MP, 1997, BIOCHEM BIOPH RES CO, V232, P678, DOI 10.1006/bbrc.1997.6355; Yang XN, 2000, BIOCHEM J, V351, P551, DOI 10.1042/0264-6021:3510551; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X	32	80	89	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45759	45764		10.1074/jbc.M208709200	http://dx.doi.org/10.1074/jbc.M208709200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324474	hybrid			2022-12-25	WOS:000179529300007
J	van der Wel, H; Morris, HR; Panico, M; Paxton, T; Dell, A; Kaplan, L; West, CM				van der Wel, H; Morris, HR; Panico, M; Paxton, T; Dell, A; Kaplan, L; West, CM			Molecular cloning and expression of a UDP-N-acetylglucosamine (GlcNAc): hydroxyproline polypeptide GlcNAc-transferase that modifies Skp1 in the cytoplasm of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; RECOMBINANT PROTEINS; O-GLCNAC; SCF; GLYCOSYLATION; SEQUENCE; GLYCOSYLTRANSFERASES; GLYCOPROTEIN; DISCOIDEUM; PATTERNS	Skp1 is a ubiquitous eukaryotic protein found in several cytoplasmic and nuclear protein complexes, including the SCF-type E3 ubiquitin ligase. In Dictyostelium, Skp1 is hydroxylated at proline 143, which is then modified by a pentasaccharide chain. The enzyme activity that attaches the first sugar, GlcNAc, was previously shown to copurify with the GnT51 polypeptide whose gene has now been cloned using a proteomics approach based on a quadrupole/time-of-flight hybrid mass spectrometer. When expressed in Escherichia coli, recombinant GnT51 exhibits UDP-GlcNAc:hydroxyproline Skp1 GlcNAc-transferase activity. Based on amino acid sequence alignments, GnT51 defines a new family of microbial polypeptide glycosyltransferases that appear to be distantly related to the catalytic domain of mucintype LTDP-GalNAc:Ser/Thr polypeptide alpha-GalNAc-transferases expressed in the Golgi compartment of animal cells. This relationship is supported by the effects of site-directed mutagenesis of GnT51 amino acids associated with its predicted DXD-like motif, DAH. In contrast, GnT51 lacks the N-terminal signal anchor sequence present in the Golgi enzymes, consistent with the cytoplasmic localization of the Skp1 acceptor substrate and the biochemical properties of the enzyme. The first glycosylation step of Dictyostelium Skp1 is concluded to be mechanistically similar to that of animal mucin type O-linked glycosylation, except that it occurs in the cytoplasm rather than the Golgi compartment of the cell.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA; Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, London SW7 2AY, England; M SCAN Res & Training Ctr, Ascot SL5 9PZ, Berks, England	State University System of Florida; University of Florida; Imperial College London	West, CM (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.	westcm@ufl.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Busch C, 2000, CURR OPIN STRUC BIOL, V10, P528, DOI 10.1016/S0959-440X(00)00126-3; Campbell JA, 1997, BIOCHEM J, V326, P929, DOI 10.1042/bj3260929u; Chong SR, 1998, NUCLEIC ACIDS RES, V26, P5109, DOI 10.1093/nar/26.22.5109; Chong SR, 1997, GENE, V192, P271, DOI 10.1016/S0378-1119(97)00105-4; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Farras R, 2001, EMBO J, V20, P2742, DOI 10.1093/emboj/20.11.2742; Galan JM, 2001, MOL CELL BIOL, V21, P3105, DOI 10.1128/MCB.21.9.3105-3117.2001; Glockner G, 2002, NATURE, V418, P79, DOI 10.1038/nature00847; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Jung E, 1998, EUR J BIOCHEM, V253, P517, DOI 10.1046/j.1432-1327.1998.2530517.x; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; Kaplan KB, 1997, CELL, V91, P491, DOI 10.1016/S0092-8674(00)80435-3; Kreppel L, 2002, NUCLEIC ACIDS RES, V30, P84, DOI 10.1093/nar/30.1.84; Morris HR, 1996, RAPID COMMUN MASS SP, V10, P889, DOI 10.1002/(SICI)1097-0231(19960610)10:8<889::AID-RCM615>3.0.CO;2-F; Muir TW, 1998, P NATL ACAD SCI USA, V95, P6705, DOI 10.1073/pnas.95.12.6705; Nayak S, 2002, CURR BIOL, V12, P277, DOI 10.1016/S0960-9822(02)00682-6; Ohshima K, 1996, J BIOL CHEM, V271, P16784, DOI 10.1074/jbc.271.28.16784; Previato JO, 1998, J BIOL CHEM, V273, P14982, DOI 10.1074/jbc.273.24.14982; Roux Kenneth H., 1995, P53; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Seol JH, 2001, NAT CELL BIOL, V3, P384, DOI 10.1038/35070067; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; Teng-umnuay P, 1999, J BIOL CHEM, V274, P36392, DOI 10.1074/jbc.274.51.36392; van der Wel H, 2002, J BIOL CHEM, V277, P46527, DOI 10.1074/jbc.M208824200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; Vervoort EB, 2000, NUCLEIC ACIDS RES, V28, P2069, DOI 10.1093/nar/28.10.2069; Wang GF, 1999, CHIN J INORG CHEM, V15, P435; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; Yamanaka A, 2002, CURR BIOL, V12, P267, DOI 10.1016/S0960-9822(02)00657-7; Yeh KC, 2002, J BACTERIOL, V184, P525, DOI 10.1128/JB.184.2.525-530.2002; Zachara NE, 1996, EUR J BIOCHEM, V238, P511, DOI 10.1111/j.1432-1033.1996.0511z.x; Zachara NE, 2002, CHEM REV, V102, P431, DOI 10.1021/cr000406u; Zhang Z, 1998, NUCLEIC ACIDS RES, V26, P3986, DOI 10.1093/nar/26.17.3986; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	38	30	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46328	46337		10.1074/jbc.M208024200	http://dx.doi.org/10.1074/jbc.M208024200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244115	hybrid			2022-12-25	WOS:000179529300083
J	Wada, S; Niimi, M; Niimi, K; Holmes, AR; Monk, BC; Cannon, RD; Uehara, Y				Wada, S; Niimi, M; Niimi, K; Holmes, AR; Monk, BC; Cannon, RD; Uehara, Y			Candida glabrata ATP-binding cassette transporters Cdr1p and Pdh1p expressed in a Saccharomyces cerevisiae strain deficient in membrane transporters show phosphorylation-dependent pumping properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOLE ANTIFUNGAL AGENTS; HUMAN P-GLYCOPROTEIN; PROTEIN-KINASE-C; YEAST ABC PROTEINS; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; FLUCONAZOLE RESISTANCE; PLEIOTROPIC DRUG; METAL RESISTANCE; PLASMA-MEMBRANE	The expression and drug efflux activity of the ATP binding cassette transporters Cdr1p and Pdh1p are thought to have contributed to the recent increase in the number of fungal infections caused by Candida glabrata. The function of these transporters and their pumping characteristics, however, remain ill defined. We have evaluated the function of Cdr1p and Pdh1p through their heterologous hyperexpression in a Saccharomyces cerevisiae strain deleted in seven major drug efflux transporters to minimize the background drug efflux activity. Although both Cdr1p- and Pdh1p-expressing strains CDR1-AD and PDH1-AD acquired multiple resistances to structurally unrelated compounds, CDR1-AD showed, in most cases, higher levels of resistance than PDH1-AD. CDR1-AD also showed greater rhodamine 6G efflux and resistance to pump inhibitors, although plasma membrane fractions had comparable NTPase activities. These results indicate that Cdr1p makes a larger contribution than Phd1p to the reduced susceptibility of C. glabrata to xenobiotics. Both pump proteins were phosphorylated in a glucose-dependent manner. Whereas the phosphorylation of Cdr1p affected its NTPase activity, the protein kinase A-mediated phosphorylation of Pdh1p, which was necessary for drug efflux, did not. This suggests that phosphorylation of Pdh1p may be required for efficient coupling of NTPase activity with drug efflux.	Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, Tokyo 1628640, Japan; Univ Otago, Dept Oral Sci & Orthodont, Dunedin 9001, New Zealand	National Institute of Infectious Diseases (NIID); University of Otago	Niimi, M (corresponding author), Natl Inst Infect Dis, Dept Bioact Mol, Shinjuku Ku, 1-23-1 Toyamam, Tokyo 1628640, Japan.	niimi@nih.go.jp	Holmes, Ann R/G-6978-2017	Holmes, Ann R/0000-0001-9313-2114; Monk, Brian/0000-0003-2264-3480; Cannon, Richard/0000-0002-5398-2066				Albertson GD, 1996, ANTIMICROB AGENTS CH, V40, P2835, DOI 10.1128/AAC.40.12.2835; ARCECI RJ, 1992, BLOOD, V80, P1528; BALZI E, 1994, J BIOL CHEM, V269, P2206; BARNS SM, 1991, J BACTERIOL, V173, P2250, DOI 10.1128/JB.173.7.2250-2255.1991; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Borges-Walmsley MI, 2001, TRENDS MICROBIOL, V9, P71, DOI 10.1016/S0966-842X(00)01920-X; Castilla R, 1998, CELL SIGNAL, V10, P713, DOI 10.1016/S0898-6568(98)00015-1; CHAMBERS TC, 1994, BIOCHEM J, V299, P309, DOI 10.1042/bj2990309; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; Chen XJ, 2001, J BACTERIOL, V183, P3939, DOI 10.1128/JB.183.13.3939-3948.2001; Coleman DC, 1998, MED MYCOL, V36, P156; DANIEL T, 1998, METHOD ENZYMOL, V292, P130; Decottignies A, 1998, J BIOL CHEM, V273, P12612, DOI 10.1074/jbc.273.20.12612; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DECOTTIGNIES A, 1994, J BIOL CHEM, V269, P12797; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; DelSorbo G, 1997, MOL GEN GENET, V254, P417, DOI 10.1007/s004380050434; Diekema DJ, 2002, J CLIN MICROBIOL, V40, P1298, DOI 10.1128/JCM.40.4.1298-1302.2002; Egner R, 2000, MOL MICROBIOL, V35, P1255, DOI 10.1046/j.1365-2958.2000.01798.x; Egner R, 1998, MOL BIOL CELL, V9, P523, DOI 10.1091/mbc.9.2.523; Fidel PL, 1999, CLIN MICROBIOL REV, V12, P80, DOI 10.1128/CMR.12.1.80; FOXWELL BMJ, 1989, MOL PHARMACOL, V36, P543; Germann UA, 1996, J BIOL CHEM, V271, P1708, DOI 10.1074/jbc.271.3.1708; GLASS DB, 1992, BIOCHEMISTRY-US, V31, P1728, DOI 10.1021/bi00121a021; Golin J, 2000, ANTIMICROB AGENTS CH, V44, P134, DOI 10.1128/AAC.44.1.134-138.2000; HAMADA H, 1988, CANCER RES, V48, P4926; HIDAKA H, 1991, METHOD ENZYMOL, V201, P328; Higgins CF, 2001, RES MICROBIOL, V152, P205, DOI 10.1016/S0923-2508(01)01193-7; Katiyar SK, 2001, MED MYCOL, V39, P109, DOI 10.1080/mmy.39.1.109.116; Kolaczkowski M, 1996, J BIOL CHEM, V271, P31543, DOI 10.1074/jbc.271.49.31543; Kralli A, 1996, J BIOL CHEM, V271, P17152, DOI 10.1074/jbc.271.29.17152; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Litman T, 2001, CELL MOL LIFE SCI, V58, P931, DOI 10.1007/PL00000912; Lupetti A, 2002, TRENDS MOL MED, V8, P76, DOI 10.1016/S1471-4914(02)02280-3; Miyazaki H, 1998, ANTIMICROB AGENTS CH, V42, P1695, DOI 10.1128/AAC.42.7.1695; MONK BC, 1991, J BACTERIOL, V173, P6826, DOI 10.1128/jb.173.21.6826-6836.1991; NAITO M, 1992, CANCER CHEMOTH PHARM, V29, P195, DOI 10.1007/BF00686252; Nakamura K, 2001, ANTIMICROB AGENTS CH, V45, P3366, DOI 10.1128/AAC.45.12.3366-3374.2001; Nikaido H, 1998, CURR OPIN MICROBIOL, V1, P516, DOI 10.1016/S1369-5274(98)80083-0; PARDO LA, 1989, BIOCHEM SOC T, V17, P1010, DOI 10.1042/bst0171010; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PORTILLO F, 1988, EMBO J, V7, P1793, DOI 10.1002/j.1460-2075.1988.tb03010.x; Saier MH, 1998, FASEB J, V12, P265, DOI 10.1096/fasebj.12.3.265; Sanglard D, 1999, ANTIMICROB AGENTS CH, V43, P2753, DOI 10.1128/AAC.43.11.2753; SANGLARD D, 1995, ANTIMICROB AGENTS CH, V39, P2378, DOI 10.1128/AAC.39.11.2378; Sanglard D, 1997, MICROBIOL-UK, V143, P405, DOI 10.1099/00221287-143-2-405; Sanglard D, 2001, ANTIMICROB AGENTS CH, V45, P1174, DOI 10.1128/AAC.45.4.1174-1183.2001; SCHERER S, 1987, J CLIN MICROBIOL, V25, P675, DOI 10.1128/JCM.25.4.675-679.1987; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; Standards N., 1997, M27A NAT COMM CLIN L; Szabo K, 1997, J BIOL CHEM, V272, P23165, DOI 10.1074/jbc.272.37.23165; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Thevelein JM, 1999, MOL MICROBIOL, V33, P904, DOI 10.1046/j.1365-2958.1999.01538.x; Thornewell SJ, 1997, GENE, V201, P21, DOI 10.1016/S0378-1119(97)00421-6; TWENTYMAN PR, 1992, BIOCHEM PHARMACOL, V43, P109, DOI 10.1016/0006-2952(92)90668-9; Vanden Bossche H, 1998, MED MYCOL, V36, P119; WALSH DA, 1991, METHOD ENZYMOL, V201, P304; Wolfger H, 2001, RES MICROBIOL, V152, P375, DOI 10.1016/S0923-2508(01)01209-8; YUSA K, 1989, CANCER RES, V49, P5002	60	47	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46809	46821		10.1074/jbc.M207817200	http://dx.doi.org/10.1074/jbc.M207817200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244114	hybrid			2022-12-25	WOS:000179529300142
J	Zhang, L; Hosoi, M; Fukuzawa, M; Sun, H; Rawlings, RR; Weight, FF				Zhang, L; Hosoi, M; Fukuzawa, M; Sun, H; Rawlings, RR; Weight, FF			Distinct molecular basis for differential sensitivity of the serotonin type 3A receptor to ethanol in the absence and presence of agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED ION CURRENT; 5-HT3 RECEPTORS; FUNCTIONAL EXPRESSION; ALCOHOLS POTENTIATE; NEUROBLASTOMA-CELLS; SUBUNIT; RELEASE; CHANNELS; GABA(A); DOMAIN	Ethanol can potentiate serotonin type 3 (5-HT3) receptor-mediated responses in various neurons and in cells expressing 5-HT3A receptors. However, the molecular basis for alcohol modulation of 5-HT3 receptor function has not been determined. Here we report that point mutations of the arginine at amino acid 222 in the N-terminal domain of the 5-HT3A receptor can alter the EC50 value of the 5-HT concentration-response curve. Some point mutations at amino acid 222 resulted in spontaneous opening of the 5-HT3A receptor channel and an inward current activated by ethanol in the absence of agonist. Among these mutant receptors, the amplitude of the current activated by ethanol in the absence of agonist was correlated with the amplitude of the current resulting from spontaneous channel openings, suggesting that the sensitivity of the receptor to ethanol in the absence of agonist is, at least in part, dependent on the preexisting conformational equilibrium of the receptor protein. On the other hand, point mutations that conferred greater sensitivity to ethanol potentiation of agonist-activated responses were less sensitive or insensitive to ethanol in the absence of agonist. For these receptors, the magnitude of the potentiation of agonist-activated responses by ethanol was inversely correlated with the EC50 values of the 5-HT concentration-response curves, suggesting that these mutations may modulate ethanol sensitivity of the receptor by altering the EC50 value of the receptor. Thus, distinct molecular processes may determine the sensitivity of 5-HT3A receptors to ethanol in the absence and presence of agonist.	NIAAA, Mol & Cellular Neurobiol Lab, NIH, Bethesda, MD 20892 USA; NIAAA, Clin Sci Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Zhang, L (corresponding author), NIAAA, Mol & Cellular Neurobiol Lab, NIH, Pk Bldg,Rm 150, Bethesda, MD 20892 USA.	lzhang@niaaa.nih.gov		Hosoi, Masako/0000-0001-8880-5847	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000007] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aprison MH, 1996, J NEUROSCI RES, V43, P127; Belelli D, 1995, MOL PHARMACOL, V48, P1054; CAMPBELL AD, 1995, PHARMACOL BIOCHEM BE, V51, P835, DOI 10.1016/0091-3057(95)00050-7; Chang YC, 1999, BIOPHYS J, V77, P2542, DOI 10.1016/S0006-3495(99)77089-X; Chang YC, 1999, NAT NEUROSCI, V2, P219, DOI 10.1038/6313; Changeux JP, 1998, NEURON, V21, P959, DOI 10.1016/S0896-6273(00)80616-9; Coultrap SJ, 1999, J PHARMACOL EXP THER, V290, P76; Davies PA, 1999, NATURE, V397, P359, DOI 10.1038/16941; GRANT KA, 1995, DRUG ALCOHOL DEPEN, V38, P155, DOI 10.1016/0376-8716(95)01120-N; HARPAZ Y, 1994, STRUCTURE, V2, P641, DOI 10.1016/S0969-2126(00)00065-4; HIGGINS GA, 1992, NEUROSCI BIOBEHAV R, V16, P535, DOI 10.1016/S0149-7634(05)80195-2; HOPP TP, 1981, P NATL ACAD SCI-BIOL, V78, P3824, DOI 10.1073/pnas.78.6.3824; HOSOI M, 2001, SOC NEUR ABSTR, V27, P600; Johnson BA, 2000, PSYCHOPHARMACOLOGY, V149, P327, DOI 10.1007/s002130000371; Johnson BA, 2002, PSYCHOPHARMACOLOGY, V160, P408, DOI 10.1007/s00213-002-1002-9; Koyama S, 2000, J PHYSIOL-LONDON, V529, P373, DOI 10.1111/j.1469-7793.2000.00373.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lehninger A., 1993, PRINCIPLES BIOCH; LOVINGER DM, 1991, NEUROSCI LETT, V122, P57, DOI 10.1016/0304-3940(91)90192-V; LOVINGER DM, 1991, MOL PHARMACOL, V40, P263; LOVINGER DM, 1994, NEUROPHARMACOLOGY, V33, P1567, DOI 10.1016/0028-3908(94)90131-7; Lovinger DM, 2000, NEUROPHARMACOLOGY, V39, P561, DOI 10.1016/S0028-3908(99)00164-1; Lovinger DR, 1999, NEUROCHEM INT, V35, P125, DOI 10.1016/S0197-0186(99)00054-6; MACHU TK, 1994, J PHARMACOL EXP THER, V271, P898; MARICQ AV, 1991, SCIENCE, V254, P432, DOI 10.1126/science.1718042; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Morales M, 2001, J COMP NEUROL, V438, P163, DOI 10.1002/cne.1307; Nishikawa K, 2002, NEUROPHARMACOLOGY, V42, P337, DOI 10.1016/S0028-3908(01)00189-7; OrtizMiranda SI, 1997, J MEMBRANE BIOL, V158, P17, DOI 10.1007/s002329900240; SELLERS EM, 1992, TRENDS PHARMACOL SCI, V13, P69, DOI 10.1016/0165-6147(92)90026-3; Spier AD, 1999, MOL BRAIN RES, V67, P221; TECOTT LH, 1993, P NATL ACAD SCI USA, V90, P1430, DOI 10.1073/pnas.90.4.1430; Ueno S, 2000, BRIT J PHARMACOL, V131, P296, DOI 10.1038/sj.bjp.0703504; van Hooft JA, 2000, TRENDS NEUROSCI, V23, P605, DOI 10.1016/S0166-2236(00)01662-3; Ye Q, 1998, J BIOL CHEM, V273, P3314, DOI 10.1074/jbc.273.6.3314; Yu DH, 1996, MOL PHARMACOL, V50, P1010; Zeitz KP, 2002, J NEUROSCI, V22, P1010, DOI 10.1523/JNEUROSCI.22-03-01010.2002; ZHANG L, 1995, NEUROREPORT, V6, P1464, DOI 10.1097/00001756-199507100-00025; Zhang L., 2001, Alcoholism Clinical and Experimental Research, V25, p58A; Zhou Q, 1998, J PHYSIOL-LONDON, V507, P335, DOI 10.1111/j.1469-7793.1998.335bt.x; ZIMMERMAN JM, 1968, J THEOR BIOL, V21, P170, DOI 10.1016/0022-5193(68)90069-6	41	19	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46256	46264		10.1074/jbc.M207683200	http://dx.doi.org/10.1074/jbc.M207683200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12368287	hybrid			2022-12-25	WOS:000179529300074
J	Kuang, SQ; Liao, L; Zhang, H; Pereira, FA; Yuan, YH; DeMayo, FJ; Ko, L; Xu, JM				Kuang, SQ; Liao, L; Zhang, H; Pereira, FA; Yuan, YH; DeMayo, FJ; Ko, L; Xu, JM			Deletion of the cancer-amplified coactivator AIB3 results in defective placentation and embryonic lethality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-RECEPTOR COACTIVATOR-1; BINDING PROTEIN; NUCLEAR-FACTOR; BREAST-CANCER; ASC-2; CELL; GENE; TRANSACTIVATION; INDUCTION; COMPLEX	The amplified in breast cancer-3 (AIB3, ASC-2, RAP250, PRIP, TRBP, NRC, or NcoA6) gene is characterized as a cancer-amplified transcriptional coactivator for nuclear receptors, which include the peroxisome proliferator-activated receptor gamma (PPARgamma). To assess its biological function, we deleted the AIB3 gene in mice by homologous recombination. AIB3(+/-) mice are developmentally normal and fertile. AIB3(-/-) embryos exhibit growth restriction and lethality during 9.75-11.5 days postconception. The embryonic lethality is probably attributed to defects in the development of the placental vascular network and cardiac hypoplasia. These defects include the failure of labyrinthine development, the dilation of maternal blood sinuses, the massive erythrophagocytosis by trophoblasts, the alteration of trophoblast populations, and the lower proliferation of myocardium, which are similar to those encountered in mice lacking PPARgamma or the PPARgamma-binding protein (PBP, TRAP220, or DRIP205). In addition, the transcriptional activities of PPARgamma are significantly affected in mouse embryonic fibroblasts lacking AIB3. These results suggest that AIB3 is required for PPARgamma function in placental development and for normal heart development. These results also indicate that the biological function of AIB3 is not redundant with other classes of nuclear receptor coactivators such as PBP and members of the steroid receptor coactivator family.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Eli Lilly & Co, Dept Gene Regulat, Indianapolis, IN 46285 USA	Baylor College of Medicine; Eli Lilly	Xu, JM (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, 1 Baylor Plaza, Houston, TX 77030 USA.		DeMayo, Francesco/C-6255-2019	DeMayo, Francesco/0000-0002-9480-7336; Pereira, Fred/0000-0003-2100-0280				Ajiro K, 1996, J BIOL CHEM, V271, P13197, DOI 10.1074/jbc.271.22.13197; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Caira F, 2000, J BIOL CHEM, V275, P5308, DOI 10.1074/jbc.275.8.5308; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Gehin M, 2002, MOL CELL BIOL, V22, P5923, DOI 10.1128/MCB.22.16.5923-5937.2002; Guan XY, 1996, CANCER RES, V56, P3446; GUAN XY, 1994, NAT GENET, V8, P155, DOI 10.1038/ng1094-155; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hong S, 2001, BIOCHEM BIOPH RES CO, V282, P1257, DOI 10.1006/bbrc.2001.4727; Ko L, 2000, P NATL ACAD SCI USA, V97, P6212, DOI 10.1073/pnas.97.11.6212; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Krebs C, 1996, AM J OBSTET GYNECOL, V175, P1534, DOI 10.1016/S0002-9378(96)70103-5; Lee SK, 2000, MOL ENDOCRINOL, V14, P915, DOI 10.1210/me.14.6.915; Lee SK, 1999, J BIOL CHEM, V274, P34283, DOI 10.1074/jbc.274.48.34283; Mahajan MA, 2000, MOL CELL BIOL, V20, P5048, DOI 10.1128/MCB.20.14.5048-5063.2000; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Qi C, 1999, P NATL ACAD SCI USA, V96, P1585, DOI 10.1073/pnas.96.4.1585; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; VANLIJNSCHOTEN G, 1994, PLACENTA, V15, P765, DOI 10.1016/0143-4004(94)90039-6; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; XU J, 2002, REV ENDOCR METAB DIS, V3, P183; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922; Yuan YH, 2002, CIRCULATION, V105, P2653, DOI 10.1161/01.CIR.0000018947.95555.65; Zhu YJ, 2000, J BIOL CHEM, V275, P13510, DOI 10.1074/jbc.275.18.13510; Zhu YJ, 2000, J BIOL CHEM, V275, P14779, DOI 10.1074/jbc.C000121200	26	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45356	45360		10.1074/jbc.C200509200	http://dx.doi.org/10.1074/jbc.C200509200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12368298	hybrid			2022-12-25	WOS:000179404800098
J	Lemoine, FJ; Marriott, SJ				Lemoine, FJ; Marriott, SJ			Genomic instability driven by the human T-cell leukemia virus type I (HTLV-1) oncoprotein, Tax	ONCOGENE			English	Article						HTLV-1; tax gene amplification; genome stability; PALA; cell cycle	MAMMALIAN GENE AMPLIFICATION; 1ST 3 ENZYMES; WILD-TYPE P53; ASPARTATE-TRANSCARBAMYLASE; TRANSACTIVATION FUNCTION; CHROMOSOME BREAKAGE; CYCLE ARREST; DNA-DAMAGE; PROTEIN; LYMPHOCYTES	The importance of maintaining genomic stability is evidenced by the fact that transformed cells often contain a variety of chromosomal abnormalities such as euploidy, translocations, and inversions. Gene amplification is a well-characterized hallmark of genomic instability thought to result from recombination events following the formation of double-strand, chromosomal breaks. Therefore, gene amplification frequency serves as an indicator of genomic stability. The PALA assay is designed to measure directly the frequency with which a specific gene, CAD, is amplified within a cell's genome. We have used the PALA assay to analyse the effects of the human T-cell leukemia virus type I (HTLV-1) oncoprotein, Tax, on genomic amplification. We demonstrate that Tax-expressing cells are five-times more likely to undergo gene amplification than control cells. Additionally, we show that Tax alters the ability of cells to undergo the typical PALA-mediated G, phase cell cycle arrest, thereby allowing cells to replicate DNA in the absence of appropriate nucleotide pools. This effect is likely the mechanism by which Tax induces gene amplification. These data suggest that HTLV-1 Tax alters the genomic stability of cells, an effect that may play an important role in Tax-mediated, HTLV-1 associated cellular transformation.	Baylor Coll Med, Interdept Program Cell & Mol Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol Virol & Microbiol, Houston, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	Marriott, SJ (corresponding author), 1 Baylor Plaza, Houston, TX 77030 USA.				NCI NIH HHS [CA-09197, CA-77371] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077371] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akagi T, 1997, FEBS LETT, V406, P263, DOI 10.1016/S0014-5793(97)00280-9; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; BENNER SE, 1991, ANTI-CANCER DRUG, V2, P11, DOI 10.1097/00001813-199102000-00002; Cereseto A, 1996, BLOOD, V88, P1551, DOI 10.1182/blood.V88.5.1551.bloodjournal8851551; CHERNOVA OB, 1995, TRENDS BIOCHEM SCI, V20, P431, DOI 10.1016/S0968-0004(00)89094-5; COLLINS KD, 1971, J BIOL CHEM, V246, P6599; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; Gartenhaus RB, 1995, LEUKEMIA, V9, P2082; Kao SY, 2000, ONCOGENE, V19, P2240, DOI 10.1038/sj.onc.1203559; Kao SY, 1999, J VIROL, V73, P4299, DOI 10.1128/JVI.73.5.4299-4304.1999; KAO SY, 2000, RES ADV VIROL, V1, P1; KEMPE TD, 1976, CELL, V9, P541, DOI 10.1016/0092-8674(76)90036-2; KUO MT, 1994, MOL CELL BIOL, V14, P5202, DOI 10.1128/MCB.14.8.5202; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Miyake H, 1999, VIROLOGY, V253, P155, DOI 10.1006/viro.1998.9500; MONDELLO C, 1995, MUTAT RES LETT, V346, P61, DOI 10.1016/0165-7992(95)90052-7; Mulloy JC, 1998, J VIROL, V72, P8852, DOI 10.1128/JVI.72.11.8852-8860.1998; NERENBERG M, 1987, SCIENCE, V237, P1324, DOI 10.1126/science.2888190; OTTO E, 1989, J BIOL CHEM, V264, P3390; Philpott SM, 1999, J NATL CANCER I, V91, P933, DOI 10.1093/jnci/91.11.933; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 1998, J VIROL, V72, P6348, DOI 10.1128/JVI.72.8.6348-6355.1998; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P7415, DOI 10.1073/pnas.77.12.7415; Poupon MF, 1996, MOL BIOL CELL, V7, P345, DOI 10.1091/mbc.7.3.345; POZZATTI R, 1990, MOL CELL BIOL, V10, P413, DOI 10.1128/MCB.10.1.413; REID RL, 1993, ONCOGENE, V8, P3029; SMITH KA, 1995, PHILOS T ROY SOC B, V347, P49, DOI 10.1098/rstb.1995.0008; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Tlsty TD, 1997, CURR TOP MICROBIOL, V221, P37; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WETTERGREN Y, 1994, SOMAT CELL MOLEC GEN, V20, P267, DOI 10.1007/BF02254717; WINDLE B, 1991, GENE DEV, V5, P160, DOI 10.1101/gad.5.2.160; WINDLE BE, 1992, MUTAT RES, V276, P199, DOI 10.1016/0165-1110(92)90009-X; WRIGHT JA, 1990, P NATL ACAD SCI USA, V87, P1791, DOI 10.1073/pnas.87.5.1791; YAMAOKA S, 1992, ONCOGENE, V7, P433	39	30	31	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7230	7234		10.1038/sj.onc.1205898	http://dx.doi.org/10.1038/sj.onc.1205898			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370813				2022-12-25	WOS:000178504600011
J	Bachelor, MA; Silvers, AL; Bowden, GT				Bachelor, MA; Silvers, AL; Bowden, GT			The role of p38 in UVA-induced cyclooxygenase-2 expression in the human keratinocyte cell line, HaCaT	ONCOGENE			English	Article						UVA; COX-2; p38; HaCaT	MESSENGER-RNA STABILITY; COLON-CANCER CELLS; SINGLET OXYGEN; GENE-EXPRESSION; 3'-UNTRANSLATED REGION; MAP KINASE; HUMAN SKIN; POSTTRANSCRIPTIONAL CONTROL; ULTRAVIOLET-RADIATION; HEME OXYGENASE	We examined the expression of cycloxygenase-2, the rate-limiting enzyme in the production of prostaglandins, in the UVA-irradiated human keratinocyte cell line, HaCaT. UVA induced a dose-dependent increase in COX-2 at the protein level at 2 and 4 h post-irradiation and at the mRNA level at 1 and 2 h post-irradiation. Experiments using semi-quantitative RT-PCR demonstrate that UVA increased the half-life of the COX-2 message by more than fourfold in the presence of Actinomycin D (with a half life between 4 and 8 h post-irradiation), suggesting that UVA induction of COX-2 is post-transcriptionally regulated. Through the use of the specific p38 inhibitor, SB202190, increases in COX-2 message and protein levels were abrogated in UVA-irradiated cells. In UVA-irradiated cells treated with S13202190, the half-life of the COX-2 message was decreased to basal levels (between I and 2 h postirradiation), indicating that p38 was responsible for the stabilization of the message. Luciferase activity was increased in UVA-irradiated cells transfected with reporter constructs containing the 3' UTR of COX-2, a region containing AU-rich elements (AREs). These regulatory sequences of AUUUA have been proposed as one mechanism of post-transcriptional regulation. Increases observed in luciferase activity could be decreased using a p38 dominant-negative construct. We report for the first that UVA can induce COX-2 expression in the human keratinocyte cell line, HaCaT. Additionally, p38 appears to play a critical role in the UVA-induced expression of COX-2 in these keratinocytes and may serve as a potential drug target in the chemoprevention of skin cancer.	Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, Tucson, AZ 85724 USA	Arizona Center Cancer Care; University of Arizona	Bowden, GT (corresponding author), Univ Arizona, Arizona Canc Ctr, Dept Radiat Oncol, 1515 N Campbell Ave, Tucson, AZ 85724 USA.				NCI NIH HHS [CA23074, CA27502] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023074, P01CA027502] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APPLEBY SB, 1994, BIOCHEM J, V302, P723, DOI 10.1042/bj3020723; BASUMODAK S, 1993, CANCER RES, V53, P4505; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Buckman SY, 1998, CARCINOGENESIS, V19, P723, DOI 10.1093/carcin/19.5.723; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chen WX, 1999, ONCOGENE, V18, P7469, DOI 10.1038/sj.onc.1203210; Chen WX, 2001, ONCOGENE, V20, P3921, DOI 10.1038/sj.onc.1204530; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; de Gruijl FR, 2000, METHOD ENZYMOL, V319, P359; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Fischer SM, 1999, MOL CARCINOGEN, V25, P231; Fosslien E, 2000, ANN CLIN LAB SCI, V30, P3; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Gresham A, 1996, AM J PHYSIOL-CELL PH, V270, pC1037, DOI 10.1152/ajpcell.1996.270.4.C1037; GretherBeck S, 1996, P NATL ACAD SCI USA, V93, P14586, DOI 10.1073/pnas.93.25.14586; HANSON D, 1990, J INVEST DERMATOL, V95, P158, DOI 10.1111/1523-1747.ep12477928; HANSON DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P423, DOI 10.1111/j.1751-1097.1989.tb09190.x; HIAL V, 1976, EUR J PHARMACOL, V37, P367, DOI 10.1016/0014-2999(76)90044-3; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; Isoherranen K, 1999, BRIT J DERMATOL, V140, P1017; KANGROTONDO CH, 1993, AM J PHYSIOL, V264, P396; Klotz LO, 1999, EUR J BIOCHEM, V260, P917, DOI 10.1046/j.1432-1327.1999.00255.x; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; LYNCH NR, 1978, BRIT J CANCER, V38, P503, DOI 10.1038/bjc.1978.237; MATSUI MS, 1991, CANCER CELL-MON REV, V3, P8; Maziere C, 2001, BIOCHEM BIOPH RES CO, V281, P289, DOI 10.1006/bbrc.2001.4348; Nabors LB, 2001, CANCER RES, V61, P2154; Newton R, 1997, BIOCHEM BIOPH RES CO, V234, P85, DOI 10.1006/bbrc.1997.6586; Parfenova H, 1998, AM J PHYSIOL-CELL PH, V274, pC72, DOI 10.1152/ajpcell.1998.274.1.C72; PENTLAND AP, 1986, J CLIN INVEST, V77, P246, DOI 10.1172/JCI112283; Prescott SM, 2000, BBA-REV CANCER, V1470, pM69, DOI 10.1016/S0304-419X(00)00006-8; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; SCHARFFETTERKOCHANEK K, 1993, FEBS LETT, V331, P304, DOI 10.1016/0014-5793(93)80357-Z; Sheng HM, 1998, CANCER RES, V58, P362; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Silvers AL, 2002, PHOTOCHEM PHOTOBIOL, V75, P302, DOI 10.1562/0031-8655(2002)075<0302:UIIAOA>2.0.CO;2; SNYDERMAN CH, 1995, ARCH OTOLARYNGOL, V121, P1017; Soriani M, 1998, FEBS LETT, V439, P253, DOI 10.1016/S0014-5793(98)01387-8; Subbarayan V, 2001, CANCER RES, V61, P2720; Tang QB, 2001, ONCOGENE, V20, P5164, DOI 10.1038/sj.onc.1204667; Thompson EJ, 2001, NEOPLASIA, V3, P402, DOI 10.1038/sj.neo.7900182; Tsujii M, 1998, CELL, V93, P705, DOI 10.1016/S0092-8674(00)81433-6; VANDERVEEN EE, 1986, ARCH DERMATOL, V122, P407, DOI 10.1001/archderm.122.4.407; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Wlaschek M, 1997, FEBS LETT, V413, P239, DOI 10.1016/S0014-5793(97)00919-8; Zhang YG, 2002, J BIOL CHEM, V277, P3124, DOI 10.1074/jbc.M110245200; Zhang YG, 2001, J BIOL CHEM, V276, P42534, DOI 10.1074/jbc.M106044200; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200; Zhang YG, 2001, J BIOL CHEM, V276, P14572, DOI 10.1074/jbc.M004615200; Zhang YG, 2001, J BIOL CHEM, V276, P11775, DOI 10.1074/jbc.M006000200; Zhang ZH, 2000, NEOPLASIA, V2, P523, DOI 10.1038/sj.neo.7900117	54	56	58	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7092	7099		10.1038/sj.onc.1205855	http://dx.doi.org/10.1038/sj.onc.1205855			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370831				2022-12-25	WOS:000178424900012
J	Holsinger, LJ; Ward, K; Duffield, B; Zachwieja, J; Jallal, B				Holsinger, LJ; Ward, K; Duffield, B; Zachwieja, J; Jallal, B			The transmembrane receptor protein tyrosine phosphatase DEP1 interacts with p120(ctn)	ONCOGENE			English	Article						DEP1; adherens junction; p120(ctn); protein tyrosine phosphatase	CELL-CELL-ADHESION; E-CADHERIN; SIGNAL-TRANSDUCTION; BETA-CATENIN; ALPHA-CATENIN; PHOSPHORYLATION; SUBSTRATE; COMPLEX; ASSOCIATION; DIFFERENTIATION	The receptor-like protein tyrosine phosphatase DEPI, also known as CD148, is expressed predominantly in epithelial cells, in a variety of tumor cell lines, and in lymphocytes. Expression of DEP1 is enhanced at high cell density, and this observation suggests that DEP1 may function in the regulation of cell adhesion and possibly contact inhibition of cell growth. In order to investigate the function of DEPI, substrate-trapping mutants of the phosphatase were used to identify potential substrates. GST-fusion proteins containing the DEPI catalytic domain with a substrate-trapping D/A mutation were found to interact with p120(ctn), a component of adherens junctions. DEPI also interacted with other members of the catenin gene family including beta-catenin and gamma-catenin. The interaction with p120(ctn) is likely to be direct, as the interaction occurs in K562 cells lacking functional adherens junctions and E-cadherin expression. Catalytic domains of the tyrosine phosphatases PTP-PEST, CD45, and PTPbeta did not interact with proteins of the catenin family to detectable levels, suggesting that the interaction of DEN with these proteins is specific. DEN expression was concentrated at sites of cell-cell contact in A549 cells. p120(ctn) was found to colocalize with these structures. Together these data suggest an important rote for DEP-1 in the function of cell-cell contacts and adherens junctions.	SUGEN Inc, San Francisco, CA 94080 USA	Pfizer	Holsinger, LJ (corresponding author), SUGEN Inc, 230 E Grand Ave, San Francisco, CA 94080 USA.	leslie-holsinger@sugen.com						AGHIB DF, 1995, EXP CELL RES, V218, P359, DOI 10.1006/excr.1995.1167; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Anastasiadis PZ, 2000, J CELL SCI, V113, P1319; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Baker JE, 2001, MOL CELL BIOL, V21, P2393, DOI 10.1128/MCB.21.7.2393-2403.2001; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; Brady-Kalnay SM, 1998, J CELL BIOL, V141, P287, DOI 10.1083/jcb.141.1.287; BRADYKALNAY SM, 1995, J CELL BIOL, V130, P977, DOI 10.1083/jcb.130.4.977; Calautti E, 1998, J CELL BIOL, V141, P1449, DOI 10.1083/jcb.141.6.1449; DANIEL JM, 1995, MOL CELL BIOL, V15, P4819; Daniel JM, 1997, BIOESSAYS, V19, P883, DOI 10.1002/bies.950191008; de la Fuente-Garcia MA, 1998, BLOOD, V91, P2800, DOI 10.1182/blood.V91.8.2800.2800_2800_2809; Fachinger G, 1999, ONCOGENE, V18, P5948, DOI 10.1038/sj.onc.1202992; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fuchs M, 1996, J BIOL CHEM, V271, P16712, DOI 10.1074/jbc.271.28.16712; Gaya A, 1999, LEUKEMIA LYMPHOMA, V35, P237, DOI 10.3109/10428199909145726; GUMBINER BM, 1995, CURR OPIN CELL BIOL, V7, P634, DOI 10.1016/0955-0674(95)80104-9; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; Jallal B, 1997, J BIOL CHEM, V272, P12158, DOI 10.1074/jbc.272.18.12158; Keane MM, 1996, CANCER RES, V56, P4236; KINCH MS, 1995, J CELL BIOL, V130, P461, DOI 10.1083/jcb.130.2.461; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kovalenko M, 2000, J BIOL CHEM, V275, P16219, DOI 10.1074/jbc.275.21.16219; Kypta RM, 1996, J CELL BIOL, V134, P1519, DOI 10.1083/jcb.134.6.1519; Lampugnani MG, 1997, J CELL SCI, V110, P2065; LAMPUGNANI MG, 1995, J CELL BIOL, V129, P203, DOI 10.1083/jcb.129.1.203; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Osborne JM, 1998, J LEUKOCYTE BIOL, V64, P692, DOI 10.1002/jlb.64.5.692; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Ozawa M, 1998, J BIOL CHEM, V273, P6166, DOI 10.1074/jbc.273.11.6166; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; REYNOLDS AB, 1992, ONCOGENE, V7, P2439; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; Sorby M, 2001, ONCOGENE, V20, P5219, DOI 10.1038/sj.onc.1204581; STADDON JM, 1995, J CELL BIOL, V130, P369, DOI 10.1083/jcb.130.2.369; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Takahashi T, 1999, J AM SOC NEPHROL, V10, P2135; Tangye SG, 1998, J IMMUNOL, V161, P3249; Tangye SG, 1998, J IMMUNOL, V161, P3803; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zondag GCM, 2000, J BIOL CHEM, V275, P11264, DOI 10.1074/jbc.275.15.11264	49	70	80	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7067	7076		10.1038/sj.onc.1205858	http://dx.doi.org/10.1038/sj.onc.1205858			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370829				2022-12-25	WOS:000178424900010
J	Niu, G; Bowman, T; Huang, M; Shivers, S; Reintgen, D; Daud, A; Chang, A; Kraker, A; Jove, R; Yu, H				Niu, G; Bowman, T; Huang, M; Shivers, S; Reintgen, D; Daud, A; Chang, A; Kraker, A; Jove, R; Yu, H			Roles of activated Src and Stat3 signaling in melanoma tumor cell growth	ONCOGENE			English	Article						melanoma; Stat3; Src; tumor cell survival	TYROSINE KINASE INHIBITORS; BREAST-CARCINOMA CELLS; DNA-BINDING ACTIVITY; CONSTITUTIVE ACTIVATION; FACTOR RECEPTOR; SUPPRESSES GROWTH; GENE-REGULATION; IN-VIVO; C-SRC; APOPTOSIS	Activation of protein tyrosine kinases is prevalent in human cancers and previous studies have demonstrated that Stat3 signaling is a point of convergence for many of these tyrosine kinases. Moreover, a critical role for constitutive activation of Stat3 in tumor cell proliferation and survival has been established in diverse cancers. However, the oncogenic signaling pathways in melanoma cells remain to be fully defined. In this study, we demonstrate that Stat3 is constitutively activated in a majority of human melanoma cell lines and tumor specimens examined. Blocking Src tyrosine kinase activity, but not EGF receptor or JAK family kinases, leads to inhibition of Stat3 signaling in melanoma cell lines. Consistent with a role of Src in the pathogenesis of melanoma, we show that c-Src tyrosine kinase is activated in melanoma cell lines. Significantly, melanoma cells undergo apoptosis when either Src kinase activity or Stat3 signaling is inhibited. Blockade of Src or Stat3 is also accompanied by down-regulation of expression of the antiapoptotic genes, BCI-X-L and Mcl-1. These findings demonstrate that Src-activated Stat3 signaling is important for the growth and survival of melanoma tumor cells.	Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol,Mol Oncol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol,Mol Immunol Program, Tampa, FL 33612 USA; Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol,Cutaneous Oncol Program, Tampa, FL 33612 USA; Univ Michigan, Sch Med, Dept Surg, Ann Arbor, MI 48105 USA; Pfizer Global Res, Dept Canc Res, Ann Arbor, MI 48106 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; University of Michigan System; University of Michigan; Pfizer	Jove, R (corresponding author), Univ S Florida, Coll Med, H Lee Moffit Canc Ctr & Res Inst, Dept Oncol,Mol Oncol Program, Tampa, FL 33612 USA.		Shivers, Steve/E-6438-2013; Daud, Adil/T-3079-2019; Shivers, Steven/AAE-9288-2022	Shivers, Steve/0000-0001-9538-4016; Daud, Adil/0000-0002-6617-8421; YU, Hua/0000-0003-0931-1000	NCI NIH HHS [CA75243, CA82533, CA55652, CA89693] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA082533, R01CA089693, R01CA055652, R29CA075243] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Buettner R, 2002, CLIN CANCER RES, V8, P945; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Catlett-Falcone Robyn, 1999, Current Opinion in Oncology, V11, P490, DOI 10.1097/00001622-199911000-00010; Ciardiello F, 2001, CLIN CANCER RES, V7, P2958; Dorsey JF, 2000, CANCER RES, V60, P3127; Epling-Burnette PK, 2001, J CLIN INVEST, V107, P351, DOI 10.1172/JCI9940; Fry DW, 1999, PHARMACOL THERAPEUT, V82, P207, DOI 10.1016/S0163-7258(98)00050-3; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Grandis JR, 1998, J CLIN INVEST, V102, P1385, DOI 10.1172/JCI3785; Grandis JR, 2000, P NATL ACAD SCI USA, V97, P4227, DOI 10.1073/pnas.97.8.4227; HUANG M, 2002, IN PRESS ONCOGENE; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Karni R, 1999, ONCOGENE, V18, P4654, DOI 10.1038/sj.onc.1202835; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; LAUDANO AP, 1986, P NATL ACAD SCI USA, V83, P892, DOI 10.1073/pnas.83.4.892; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Moasser MM, 1999, CANCER RES, V59, P6145; Ni Z, 2000, CANCER RES, V60, P1225; Niu GL, 2002, ONCOGENE, V21, P2000, DOI 10.1038/sj.onc.1205260; Niu GL, 1999, CANCER RES, V59, P5059; Niu GL, 2001, CANCER RES, V61, P3276; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; Shen YH, 2001, P NATL ACAD SCI USA, V98, P1543, DOI 10.1073/pnas.041588198; Sinibaldi D, 2000, ONCOGENE, V19, P5419, DOI 10.1038/sj.onc.1203947; Song JI, 2000, ONCOGENE, V19, P2489, DOI 10.1038/sj.onc.1203483; Staley CA, 1997, CELL GROWTH DIFFER, V8, P269; Turkson J, 2001, J BIOL CHEM, V276, P45443, DOI 10.1074/jbc.M107527200; Turkson J, 2000, ONCOGENE, V19, P6613, DOI 10.1038/sj.onc.1204086; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Yayon A, 1997, ONCOGENE, V14, P2999, DOI 10.1038/sj.onc.1201159; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhou P, 1997, BLOOD, V89, P630, DOI 10.1182/blood.V89.2.630	41	359	381	1	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7001	7010		10.1038/sj.onc.1205859	http://dx.doi.org/10.1038/sj.onc.1205859			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370822				2022-12-25	WOS:000178424900003
J	Baldi, A; De Luca, A; Morini, M; Battista, T; Felsani, A; Baldi, F; Catricala, C; Amantea, A; Noonan, DM; Albini, A; Natali, PG; Lombardi, D; Paggi, MG				Baldi, A; De Luca, A; Morini, M; Battista, T; Felsani, A; Baldi, F; Catricala, C; Amantea, A; Noonan, DM; Albini, A; Natali, PG; Lombardi, D; Paggi, MG			The HtrA1 serine protease is down-regulated during human melanoma progression and represses growth of metastatic melanoma cells	ONCOGENE			English	Article						melanoma; tumor progression; PRSS11; HtrA1; serine protease	MALIGNANT-MELANOMA; CUTANEOUS MELANOMA; GENE-PRODUCT; EXPRESSION; MAC25; SUPPRESSOR; ASSAY	Differential gene expression of cell lines derived from a malignant melanoma or its autologous lymph node metastasis using cDNA arrays indicated down-regulation of PRSS11, a gene encoding the serine protease HtrA1, a homolog of the Escherichia coli protease HtrA, in the metastatic line. Stable PRSS11 overexpression in the metastatic cell line strongly inhibited proliferation, chemoinvasion and Nm23-H1 protein expression in vitro, as well as cell growth in vivo in nu/nu mice. A polyclonal anti-HtrA1 serum demonstrated a significantly higher expression in primary melanomas when compared to unrelated metastatic lesions in a human melanoma tissue array, and down-modulation of HtrA1 expression in autologous lymph node melanoma metastases in seven out of 11 cases examined. These results suggest that down-regulation of PRSS11 and HtrA1 expression may represent an indicator of melanoma progression.	Regina Elena Inst Canc Res, Ctr Expt Res, Dept Dev Therapeut Programs, Lab C,CRS, I-00158 Rome, Italy; Natl Inst Canc Res, Genoa, Italy; CNR, Ist Neurobiol & Med Mol, Rome, Italy; Univ Naples 2, Sect Pathol, Dept Biochem & Biophys F Cedrangolo, Naples, Italy; San Gallicano Dermatol Inst, Rome, Italy; Regina Elena Inst Canc Res, CRS, Immunol Lab, Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Genoa; IRCCS AOU San Martino IST; Consiglio Nazionale delle Ricerche (CNR); Universita della Campania Vanvitelli; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS San Gallicano Dermatological Institute (ISG); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila	Paggi, MG (corresponding author), Regina Elena Inst Canc Res, Ctr Expt Res, Dept Dev Therapeut Programs, Lab C,CRS, Via Messi Oro 156, I-00158 Rome, Italy.	paggi@ifo.it	Noonan, Douglas M/A-8620-2010; Paggi, Marco G./K-3494-2018; Felsani, Armando/D-1784-2010; Baldi, Alfonso/ABG-2397-2021; De Luca, Antonio/AAD-9562-2020	Noonan, Douglas M/0000-0001-8058-0719; Felsani, Armando/0000-0001-8851-6295; De Luca, Antonio/0000-0002-3905-6154; Albini, Adriana/0000-0002-9624-5103; Baldi, Alfonso/0000-0002-8693-3842				ALBINI A, 1987, CANCER RES, V47, P3239; BALDI A, 1995, J CELL BIOCHEM, V59, P402, DOI 10.1002/jcb.240590311; Baldi A, 2001, J CELL BIOCHEM, V83, P364, DOI 10.1002/jcb.1235; Berwick Marianne, 1997, Current Opinion in Oncology, V9, P178; Bishop JAN, 1997, CANCER METAST REV, V16, P141, DOI 10.1023/A:1005752510012; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; Burger AM, 1998, ONCOGENE, V16, P2459, DOI 10.1038/sj.onc.1201772; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893; Faccio L, 2000, J BIOL CHEM, V275, P2581, DOI 10.1074/jbc.275.4.2581; Gray CW, 2000, EUR J BIOCHEM, V267, P5699, DOI 10.1046/j.1432-1327.2000.01589.x; Guldberg P, 1997, CANCER RES, V57, P3660; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; Hu SI, 1998, J BIOL CHEM, V273, P34406, DOI 10.1074/jbc.273.51.34406; Indsto JO, 1998, CANCER GENET CYTOGEN, V100, P68, DOI 10.1016/S0165-4608(97)00016-2; Kato MV, 1996, ONCOGENE, V12, P1361; Krojer T, 2002, NATURE, V416, P455, DOI 10.1038/416455a; Leonetti C, 1999, CLIN CANCER RES, V5, P2588; Li WY, 2002, NAT STRUCT BIOL, V9, P436, DOI 10.1038/nsb795; Lombardi D, 2000, J CELL PHYSIOL, V182, P144, DOI 10.1002/(SICI)1097-4652(200002)182:2<144::AID-JCP2>3.3.CO;2-Y; Oh YM, 1996, J BIOL CHEM, V271, P30322, DOI 10.1074/jbc.271.48.30322; Pallen MJ, 1997, MOL MICROBIOL, V26, P209, DOI 10.1046/j.1365-2958.1997.5601928.x; Ponting CP, 1997, PROTEIN SCI, V6, P464; Robertson GP, 1999, CANCER RES, V59, P3596; Shridhar V, 2002, CANCER RES, V62, P262; Slominski A, 2001, ARCH PATHOL LAB MED, V125, P1295; Spiess C, 1999, CELL, V97, P339, DOI 10.1016/S0092-8674(00)80743-6; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Zumbrunn J, 1997, GENOMICS, V45, P461, DOI 10.1006/geno.1997.4953; Zumbrunn J, 1996, FEBS LETT, V398, P187, DOI 10.1016/S0014-5793(96)01229-X	30	152	167	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6684	6688		10.1038/sj.onc.1205911	http://dx.doi.org/10.1038/sj.onc.1205911			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242667				2022-12-25	WOS:000178202300015
J	Hajitou, A; Grignet-Debrus, C; Devy, L; Berndt, S; Blacher, S; Deroanne, CF; Bajou, K; Fong, T; Chiang, YW; Foidart, JM; Noel, A				Hajitou, A; Grignet-Debrus, C; Devy, L; Berndt, S; Blacher, S; Deroanne, CF; Bajou, K; Fong, T; Chiang, YW; Foidart, JM; Noel, A			The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells	FASEB JOURNAL			English	Article						angiogenesis; adenoviruses; angiostatic factors; anti-tumoral effects	IN-VIVO; ANGIOGENESIS; CANCER; INHIBITOR; GENE; ACTIVATION; GENERATION; INVASION; THERAPY; SURFACE	Endostatin and angiostatin are known as tumor-derived angiogenesis inhibitors, but their mechanisms of action are not yet completely defined. We report here that endostatin and angiostatin, delivered by adenoviral vectors, reduced in vitro the neovessel formation in the mouse aortic ring assay by 85 and 40%, respectively. We also demonstrated in vivo that both endostatin and angiostatin inhibited local invasion and tumor vascularization of transplanted murine malignant keratinocytes, and reduced by 50 and 90% the development of highly vascularized murine mammary tumors. This inhibition of tumor growth was associated with a reduction of tumor vascularization. Expression analysis of vascular endothelial growth factor (VEGF) carried out in the mouse aortic ring model revealed a 3- to 10-fold down-regulation of VEGF mRNA expression in endostatin-treated rings. A similar down-regulation of VEGF expression at both mRNA and protein levels was also observed in the two in vivo cancer models after treatment with each angiogenesis inhibitor. This suggests that endostatin and angiostatin effects may be mediated, at least in part, by their ability to down-regulate VEGF expression within the tumor. This work provides evidence that endostatin and angiostatin act on tumor cells themselves.	Univ Liege, Inst Pathol B23, Lab Tumor & Dev Biol, B-4000 Liege, Belgium; Univ Liege, Lab Connect Tissues Biol, B-4000 Liege, Belgium; Aventis, Dept Oncol, Hayward, CA 94545 USA	University of Liege; University of Liege; Sanofi-Aventis	Noel, A (corresponding author), Univ Liege, Inst Pathol B23, Lab Tumor & Dev Biol, B-4000 Liege, Belgium.	agnes.noel@ulg.ac.be		Bajou, Khalid/0000-0002-5529-9228; Noel, Agnes/0000-0002-7670-6179; Hajitou, Amin/0000-0003-1119-5686				Asahara T, 1999, CIRC RES, V85, P221, DOI 10.1161/01.RES.85.3.221; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; Blacher Silvia, 2001, Angiogenesis, V4, P133, DOI 10.1023/A:1012251229631; Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126; Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220; Chen CT, 2000, HUM GENE THER, V11, P1983, DOI 10.1089/10430340050143417; Claesson-Welsh L, 1998, P NATL ACAD SCI USA, V95, P5579, DOI 10.1073/pnas.95.10.5579; Deroanne CF, 1997, CANCER RES, V57, P5590; Devy L, 2002, FASEB J, V16, DOI 10.1096/fj.01-0552com; Dhanabal M, 1999, CANCER RES, V59, P189; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dong ZY, 1997, CELL, V88, P801, DOI 10.1016/S0092-8674(00)81926-1; Farrara N, 2000, CURR OPIN BIOTECH, V11, P617, DOI 10.1016/S0958-1669(00)00153-1; Felbor U, 2000, EMBO J, V19, P1187, DOI 10.1093/emboj/19.6.1187; Gyorffy S, 2001, AM J PATHOL, V159, P1137, DOI 10.1016/S0002-9440(10)61790-7; HAJITOU A, 1995, INT J CANCER, V63, P702, DOI 10.1002/ijc.2910630516; Hajitou A, 2001, CANCER RES, V61, P3450; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Holash J, 1999, SCIENCE, V284, P1994, DOI 10.1126/science.284.5422.1994; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Kim YM, 2000, CANCER RES, V60, P5410; Kirsch M, 1998, CANCER RES, V58, P4654; Kuo CJ, 2001, P NATL ACAD SCI USA, V98, P4605, DOI 10.1073/pnas.081615298; Liekens S, 2001, BIOCHEM PHARMACOL, V61, P253, DOI 10.1016/S0006-2952(00)00529-3; Maniotis AJ, 1999, AM J PATHOL, V155, P739, DOI 10.1016/S0002-9440(10)65173-5; Moser TL, 1999, P NATL ACAD SCI USA, V96, P2811, DOI 10.1073/pnas.96.6.2811; Munaut C, 1999, J BIOL CHEM, V274, P5588, DOI 10.1074/jbc.274.9.5588; NOEL A, 1993, BRIT J CANCER, V68, P909, DOI 10.1038/bjc.1993.453; OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Perletti G, 2000, CANCER RES, V60, P1793; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Sim BKL, 1997, CANCER RES, V57, P1329; Skobe M, 1997, NAT MED, V3, P1222, DOI 10.1038/nm1197-1222; Soff GA, 2000, CANCER METAST REV, V19, P97, DOI 10.1023/A:1026525121027; STRATFORDPERRICAUDET LD, 1990, HUM GENE THER, V1, P241, DOI 10.1089/hum.1990.1.3-241; Sun Y, 2001, IEEE J SEL TOP QUANT, V7, P1; Tarui T, 2001, J BIOL CHEM, V276, P39562, DOI 10.1074/jbc.M101815200; Wen W, 1999, CANCER RES, V59, P6052; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yokoyama Y, 2000, CANCER RES, V60, P4362	45	141	176	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1802	+		10.1096/fj.02-0109fje	http://dx.doi.org/10.1096/fj.02-0109fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354694				2022-12-25	WOS:000178441800003
J	Schwarzmann, N; Kunerth, S; Weber, K; Mayr, GW; Guse, AH				Schwarzmann, N; Kunerth, S; Weber, K; Mayr, GW; Guse, AH			Knock-down of the type 3 ryanodine receptor impairs sustained Ca2+ signaling via the T cell receptor/CD3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; RELEASE; RNA; RESISTANT; INTERFERENCE; LYMPHOCYTES; ACTIVATION; MECHANISMS	In Jurkat T cells, the type 3 ryanodine receptor (RyR) was knocked-down by stable integration of plasmid expressing type 3 ryanodine receptor antisense RNA. Stable integration of the antisense plasmid in individual clones was demonstrated by PCR of genomic DNA, expression of antisense RNA by reverse transcriptase PCR, and efficiently reduced expression of type 3 ryanodine receptor protein by Western blot. Selected clones were successfully used to analyze T cell receptor/CD3 complex-mediated Ca2+ signaling. Reduced expression of the type 3 RyR resulted in (i) significantly decreased Ca2+ signaling in the sustained phase and (ii) in permeabilized cells in a significantly impaired response toward cyclic ADP-ribose but not to D-myo-inositol 1,4,5-trisphosphate. For the first time, the role of the type 3 RyR in sustained Ca2+ signaling was directly visualized by confocal Ca2+ imaging as a significant contribution to the number and the magnitude of subcellular Ca2+ signals. These data suggest that the type 3 ryanodine receptor is essential in the sustained Ca2+ response in T cells.	Univ Hamburg, Hosp Eppendorf, Ctr Theoret Med, Inst Cellular Signal Transduct, D-20246 Hamburg, Germany	University of Hamburg	Guse, AH (corresponding author), Univ Hamburg, Hosp Eppendorf, Ctr Theoret Med, Inst Cellular Signal Transduct, Martinistr 52, D-20246 Hamburg, Germany.	guse@uke.uni-hamburg.de						Berg I, 2000, J CELL BIOL, V150, P581, DOI 10.1083/jcb.150.3.581; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; BOURGUIGNON LYW, 1995, J BIOL CHEM, V270, P17917, DOI 10.1074/jbc.270.30.17917; Coussin F, 2000, J BIOL CHEM, V275, P9596, DOI 10.1074/jbc.275.13.9596; da Silva CP, 2000, BBA-MOL CELL RES, V1498, P122, DOI 10.1016/S0167-4889(00)00089-6; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Fulceri R, 2001, BIOCHEM BIOPH RES CO, V288, P697, DOI 10.1006/bbrc.2001.5834; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; GUSE AH, 1993, BIOCHEM J, V291, P447, DOI 10.1042/bj2910447; Guse AH, 1997, J BIOL CHEM, V272, P8546, DOI 10.1074/jbc.272.13.8546; Guse AH, 2002, BIOCHEMISTRY-US, V41, P6744, DOI 10.1021/bi020171b; Guse AH, 2001, J BIOL CHEM, V276, P34722, DOI 10.1074/jbc.M100715200; Guse AH, 1999, NATURE, V398, P70, DOI 10.1038/18024; GUSE AH, 1991, J BIOL CHEM, V266, P24498; GUSE AH, 1995, J IMMUNOL, V155, P3353; Guse AH, 1996, J BIOL CHEM, V271, P23946, DOI 10.1074/jbc.271.39.23946; GUSE AH, 2002, CYCLIC ADP RIBOSE NA; Guse Andreas H., 2002, Current Molecular Medicine (Hilversum), V2, P273, DOI 10.2174/1566524024605707; HAKAMATA Y, 1994, FEBS LETT, V352, P206, DOI 10.1016/0014-5793(94)00955-4; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hohenegger M, 1999, BRIT J PHARMACOL, V128, P1235, DOI 10.1038/sj.bjp.0702935; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; Lee HC, 2001, ANNU REV PHARMACOL, V41, P317, DOI 10.1146/annurev.pharmtox.41.1.317; Mironneau J, 2001, J BIOL CHEM, V276, P11257, DOI 10.1074/jbc.M005994200; NELLEN W, 1993, TRENDS BIOCHEM SCI, V18, P419, DOI 10.1016/0968-0004(93)90137-C; Novotny J, 2001, METHOD ENZYMOL, V342, P193, DOI 10.1016/S0076-6879(01)42545-6; Ricard I, 1997, CELL SIGNAL, V9, P197, DOI 10.1016/S0898-6568(96)00141-6; Schottelndreier H, 2001, CELL SIGNAL, V13, P895, DOI 10.1016/S0898-6568(01)00225-X; Schweitzer K, 2001, ANAL BIOCHEM, V299, P218, DOI 10.1006/abio.2001.5419; Sethi JK, 1997, J BIOL CHEM, V272, P16358, DOI 10.1074/jbc.272.26.16358	34	55	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50636	50642		10.1074/jbc.M209061200	http://dx.doi.org/10.1074/jbc.M209061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12354756	hybrid			2022-12-25	WOS:000180177700059
J	Kajava, AV				Kajava, AV			What curves alpha-solenoids? Evidence for an alpha-helical toroid structure of Rpn1 and Rpn2 proteins of the 26 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; LEUCINE-RICH REPEAT; SECONDARY STRUCTURE PREDICTION; F1F0 ATP SYNTHASE; CRYSTAL-STRUCTURE; ANKYRIN REPEAT; CROSS-LINKING; SUBUNIT-C; DOMAIN; MOTIF	The alpha-helical solenoid proteins adopt a variety of elongated curved structures. They have been examined to identify the interactions that determine their curvature. A sequence pattern characteristic for strongly curved alpha-helical solenoids has been constructed and was found to match protein sequences containing the proteasome/cyclosome repeats. Based on this, a structural model of the repeat-containing domains of the Rpn1/S2 and Rpn2/S1 proteins, which represent the largest subunits of the 26 S proteasome, has been proposed. The model has a novel architecture resembling an a-helical toroid. Molecular modeling shows that these toroids have a central pore that would allow passage of an unfolded protein substrate through it. This implies that the Rpn1 and Rpn2 toroids are aligned along the common axial pores of the ATPase hexamer and form an "antechamber'' of the 26 S proteasome. The proposed quaternary structure agrees with the available experimental data. It is suggested that the function of this antechamber is assistance to the ATPases in the unfolding of protein substrates prior to proteolysis. An evolutionary link between the PC repeat-containing proteins and tetratricopeptide repeat proteins is proposed.	NIH, Ctr Mol Modeling, Ctr Informat Technol, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Center for Information Technology (CIT)	Kajava, AV (corresponding author), CNRS, Ctr Rech Biochim Macromol, UPR 1086, 1919 Route Mende, F-34293 Montpellier 5, France.		Kajava, Andrey V/E-1107-2014	Kajava, Andrey V/0000-0002-2342-6886				ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Andrade MA, 2001, J MOL BIOL, V309, P1, DOI 10.1006/jmbi.2001.4624; Batchelor AH, 1998, SCIENCE, V279, P1037, DOI 10.1126/science.279.5353.1037; Bateman A, 1998, PROTEIN SCI, V7, P1477, DOI 10.1002/pro.5560070625; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; Davy A, 2001, EMBO REP, V2, P821, DOI 10.1093/embo-reports/kve184; DAYRINGER HE, 1986, J MOL GRAPHICS, V4, P82; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Ferrell K, 2000, TRENDS BIOCHEM SCI, V25, P83, DOI 10.1016/S0968-0004(99)01529-7; Fu HY, 2001, EMBO J, V20, P7096, DOI 10.1093/emboj/20.24.7096; FUJINAGA M, 1993, J MOL BIOL, V234, P222, DOI 10.1006/jmbi.1993.1576; Gieffers C, 2001, MOL CELL, V7, P907, DOI 10.1016/S1097-2765(01)00234-9; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gorbea C, 2000, J BIOL CHEM, V275, P875, DOI 10.1074/jbc.275.2.875; Groll M, 2000, NAT STRUCT BIOL, V7, P1062, DOI 10.1038/80992; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hartmann-Petersen R, 2001, ARCH BIOCHEM BIOPHYS, V386, P89, DOI 10.1006/abbi.2000.2178; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kajava AV, 2002, PROTEIN SCI, V11, P1082, DOI 10.1110/ps.4010102; Kajava AV, 2001, MOL MICROBIOL, V42, P279, DOI 10.1046/j.1365-2958.2001.02598.x; Kajava AV, 2001, J STRUCT BIOL, V134, P132, DOI 10.1006/jsbi.2000.4328; Kobe B, 2000, TRENDS BIOCHEM SCI, V25, P509, DOI 10.1016/S0968-0004(00)01667-4; KOBE B, 1995, NATURE, V374, P183, DOI 10.1038/374183a0; KOBE B, 1994, TRENDS BIOCHEM SCI, V19, P415, DOI 10.1016/0968-0004(94)90090-6; Kobe B, 2001, CURR OPIN STRUC BIOL, V11, P725, DOI 10.1016/S0959-440X(01)00266-4; KOBE B, 1993, NATURE, V366, P751, DOI 10.1038/366751a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Larsen CN, 1997, CELL, V91, P431, DOI 10.1016/S0092-8674(00)80427-4; Laskowski R. A., 1993, J APPL CRYSTALLOGR, V26, P282; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P195, DOI 10.1016/S0968-0004(97)01058-X; McLuskey K, 2001, BIOCHEMISTRY-US, V40, P8783, DOI 10.1021/bi010309a; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Ogura T, 2001, GENES CELLS, V6, P575, DOI 10.1046/j.1365-2443.2001.00447.x; PETERS JM, 1993, J MOL BIOL, V234, P932, DOI 10.1006/jmbi.1993.1646; Peters JW, 1996, NAT STRUCT BIOL, V3, P991, DOI 10.1038/nsb1296-991; Ponting CP, 2000, J MOL BIOL, V302, P1041, DOI 10.1006/jmbi.2000.4087; RAAG R, 1988, J MOL BIOL, V200, P553, DOI 10.1016/0022-2836(88)90542-6; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; RECHSTEINER M, 1998, UBIQUITIN BIOL CELL, P147; Richmond C, 1997, J BIOL CHEM, V272, P13403, DOI 10.1074/jbc.272.20.13403; Rohrwild M, 1996, P NATL ACAD SCI USA, V93, P5808, DOI 10.1073/pnas.93.12.5808; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Sedgwick SG, 1999, TRENDS BIOCHEM SCI, V24, P311, DOI 10.1016/S0968-0004(99)01426-7; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; Steegborn C, 2001, STRUCTURE, V9, P1051, DOI 10.1016/S0969-2126(01)00665-7; ter Haar E, 1998, CELL, V95, P563, DOI 10.1016/S0092-8674(00)81623-2; THUNNISSEN AMWH, 1994, NATURE, V367, P750, DOI 10.1038/367750a0; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; Wang J, 2001, STRUCTURE, V9, P177, DOI 10.1016/S0969-2126(01)00570-6; Whitby FG, 2000, NATURE, V408, P115, DOI 10.1038/35040607; Ybe JA, 1999, NATURE, V399, P371, DOI 10.1038/20708; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zhang XD, 2000, MOL CELL, V6, P1473, DOI 10.1016/S1097-2765(00)00143-X	66	64	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49791	49798		10.1074/jbc.M204982200	http://dx.doi.org/10.1074/jbc.M204982200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12270919	hybrid			2022-12-25	WOS:000180028900092
J	Papineni, RVL; O'Connell, KMS; Zhang, HW; Dirksen, RT; Hamilton, SL				Papineni, RVL; O'Connell, KMS; Zhang, HW; Dirksen, RT; Hamilton, SL			Suramin interacts with the calmodulin binding site on the ryanodine receptor, RYR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ RELEASE CHANNEL; SKELETAL-MUSCLE; CALCIUM CHANNELS; APOCALMODULIN; INACTIVATION	Apocalmodulin and Ca2+ calmodulin bind to overlapping sites on the ryanodine receptor skeletal form, RYR1, but have opposite functional effects on channel activity. Suramin, a polysulfonated napthylurea, displaces both forms of calmodulin, leading to an inhibition of activity at low Ca2+ and an enhancement of activity at high Ca2+. Calmodulin binding motifs on RYR1 are also able to directly interact with the carboxy-terminal tail of the transverse tubule dihydropyridine receptor (DHPR) (Sencer, S., Papineni, R. V., Halling, D. B., Pate, P., Krol, J., Zhang, J. Z., and Hamilton, S. L. (2001) J. Biol. Chem. 276, 38237-38241). Suramin binds directly to a peptide that corresponds to the calmodulin binding site of RYR1 (amino acids 3609-3643) and blocks the interaction of this peptide with both calmodulin and the carboxyl-terminal tail of the DHPR alpha(1)-subunit. Suramin, added to the internal solution of voltage-clamped skeletal myotubes, produces a concentration-dependent increase in the maximal magnitude of voltage-gated Ca2+ transients without significantly altering L-channel Ca2+ channel conducting activity. Together, these results suggest that an interaction between the carboxyl-terminal tail of the DHPR alpha-subunit with the calmodulin binding region of RYR1 serves to limit sarcoplasmic reticulum Ca2+ release during excitation-contraction coupling and that suramin-induced potentiation of voltage-gated Ca2+ release involves a relief of this inhibitory interaction.	Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA; Univ Rochester, Sch Med & Dent, Dept Pharmacol & Physiol, Rochester, NY 14642 USA	Baylor College of Medicine; University of Rochester	Hamilton, SL (corresponding author), Baylor Coll Med, Dept Mol Physiol & Biophys, Houston, TX 77030 USA.			O'Connell, Kristen/0000-0002-4187-747X; Hamilton, Susan/0000-0003-0241-9369	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041802, R29AR044657, R01AR044864, R01AR044657] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR 41802, AR 44864, AR 44657] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Avila G, 2000, J GEN PHYSIOL, V115, P467, DOI 10.1085/jgp.115.4.467; Avila G, 2001, J BIOL CHEM, V276, P17732, DOI 10.1074/jbc.M009685200; BEELER GW, 1970, J PHYSIOL-LONDON, V207, P191, DOI 10.1113/jphysiol.1970.sp009056; FRANZINIARMSTRONG C, 1995, J MUSCLE RES CELL M, V16, P319, DOI 10.1007/BF00121140; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; HAWKES MJ, 1989, MEMBRANE BIOCHEM, V8, P133, DOI 10.3109/09687688909025827; Klinger M, 1999, MOL PHARMACOL, V55, P462; Klinger M, 2001, BIOCHEM J, V355, P827, DOI 10.1042/bj3550827; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Marx SO, 1998, SCIENCE, V281, P818, DOI 10.1126/science.281.5378.818; Moore CP, 1999, BIOCHEMISTRY-US, V38, P8532, DOI 10.1021/bi9907431; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Pate P, 2000, J BIOL CHEM, V275, P39786, DOI 10.1074/jbc.M007158200; Peterson BZ, 1999, NEURON, V22, P549, DOI 10.1016/S0896-6273(00)80709-6; Rodney GG, 2000, BIOCHEMISTRY-US, V39, P7807, DOI 10.1021/bi0005660; Sencer S, 2001, J BIOL CHEM, V276, P38237; Sitsapesan R, 1996, J MEMBRANE BIOL, V153, P93, DOI 10.1007/s002329900113; Slavik KJ, 1997, AM J PHYSIOL-CELL PH, V272, pC1475, DOI 10.1152/ajpcell.1997.272.5.C1475; Suko J, 2001, MOL PHARMACOL, V59, P543, DOI 10.1124/mol.59.3.543; Sun JH, 2001, P NATL ACAD SCI USA, V98, P11158, DOI 10.1073/pnas.201289098; TRIPATHY A, 1995, BIOPHYS J, V69, P106, DOI 10.1016/S0006-3495(95)79880-0; Yamaguchi N, 2001, J BIOL CHEM, V276, P22579, DOI 10.1074/jbc.M102729200; Zhang JZ, 1999, AM J PHYSIOL-CELL PH, V276, pC46; Zuhlke RD, 1999, NATURE, V399, P159, DOI 10.1038/20200	25	19	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49167	49174		10.1074/jbc.M209564200	http://dx.doi.org/10.1074/jbc.M209564200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12364321	hybrid			2022-12-25	WOS:000180028900010
J	Holmes, ML; Bartle, N; Eisbacher, M; Chong, BH				Holmes, ML; Bartle, N; Eisbacher, M; Chong, BH			Cloning and analysis of the thrombopoietin-induced megakaryocyte-specific glycoprotein VI promoter and its regulation by GATA-1, Fli-1, and Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-1; REPRESENTATIONAL DIFFERENCE ANALYSIS; COLLAGEN RECEPTOR; IIB GENE; BINDING-SITE; IX PROMOTER; EXPRESSION; PROTEIN; DIFFERENTIATION; MUTATION	The exposure of collagen fibers at sites of vascular injury results in the adherence of platelets and their subsequent activation. The platelet collagen receptor glycoprotein (GP)(1) VI plays a crucial role in platelet activation and thrombus formation and decreased levels or defective GPVI may lead to excessive bleeding. In addition, elevated levels of collagen receptors may predispose individuals to coronary heart disease or strokes. GPVI expression is restricted to platelets and their precursor cell, the megakaryocyte. In this study we investigate the regulation of GPVI expression and show that thrombopoietin induces its expression in the megakaryocytic cell line UT-7/TPO. A W-region flanking the transcription start point of the GPVI gene was cloned (-694 to +29) and we report that this putative GPVI promoter bestows megakaryocye-specific expression. Deletion analyses and site-directed mutagenesis identified Sp1(227), GATA(177), and Ets(48) sites as essential for GPVI expression. We show that transcription factors GATA-1, Fli-1, and Sp1 can bind to and activate this promoter. Finally, GPVI mRNA was detected only in megakaryocytic cell lines expressing both Fli-1 and GATA-1, and we show that overexpression of Fli-1 in a stable cell line (which expresses endogenous GATA-1 and Sp1) results in expression of the endogenous GPVI gene.	Univ New S Wales, Dept Med, St George Clin Sch, Sydney, NSW 2052, Australia; Univ New S Wales, Ctr Thrombosis & Vasc Res, St George Clin Sch, Sydney, NSW 2052, Australia	University of New South Wales Sydney; University of New South Wales Sydney	Chong, BH (corresponding author), Univ New S Wales, Dept Med, St George Clin Sch, Sydney, NSW 2052, Australia.	b.h.chong@unsw.edu.au	Chong, Beng/AAE-2617-2019; Chong, Beng/AAM-9010-2021	Holmes, Melissa/0000-0001-5894-6649				AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; Bastian LS, 1996, J BIOL CHEM, V271, P18554, DOI 10.1074/jbc.271.31.18554; Bastian LS, 1999, BLOOD, V93, P2637, DOI 10.1182/blood.V93.8.2637.408k20_2637_2644; Berlanga O, 2000, BLOOD, V96, P2740; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; CROSSLEY M, 1995, MOL CELL BIOL, V15, P2448; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Doubeikovski A, 1997, J BIOL CHEM, V272, P24300, DOI 10.1074/jbc.272.39.24300; Drachman JG, 1997, BLOOD, V89, P483, DOI 10.1182/blood.V89.2.483; Eisbacher M, 2001, CELL GROWTH DIFFER, V12, P435; Emami KH, 1998, NUCLEIC ACIDS RES, V26, P839, DOI 10.1093/nar/26.3.839; Ezumi Y, 2000, BIOCHEM BIOPH RES CO, V277, P27, DOI 10.1006/bbrc.2000.3624; Furihata K, 2002, ARCH PATHOL LAB MED, V126, P305; Gaines P, 2000, J BIOL CHEM, V275, P34114, DOI 10.1074/jbc.M006017200; Hart A, 2000, IMMUNITY, V13, P167, DOI 10.1016/S1074-7613(00)00017-0; Holmes ML, 1999, MOL CELL BIOL, V19, P4182; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Jacquelin B, 2001, J BIOL CHEM, V276, P23518, DOI 10.1074/jbc.M102019200; Jacquelin B, 2001, BLOOD, V97, P1721, DOI 10.1182/blood.V97.6.1721; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; Lagrue-Lak-Hal AH, 2001, J BIOL CHEM, V276, P15316, DOI 10.1074/jbc.M009117200; LEMARCHANDEL V, 1993, MOL CELL BIOL, V13, P668, DOI 10.1128/MCB.13.1.668; Lepage A, 1999, BLOOD, V94, P3366, DOI 10.1182/blood.V94.10.3366.422k35_3366_3380; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Ludlow LB, 1996, J BIOL CHEM, V271, P22076, DOI 10.1074/jbc.271.36.22076; Mehaffey MG, 2001, BLOOD, V98, P2681, DOI 10.1182/blood.V98.9.2681; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MOROI M, 1989, J CLIN INVEST, V84, P1440, DOI 10.1172/JCI114318; NAGATA Y, 1995, J BIOL CHEM, V270, P19673, DOI 10.1074/jbc.270.34.19673; Nichols KE, 2000, NAT GENET, V24, P266, DOI 10.1038/73480; Nieswandt B, 2001, J EXP MED, V193, P459, DOI 10.1084/jem.193.4.459; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; Prandini MH, 1996, BLOOD, V88, P2062, DOI 10.1182/blood.V88.6.2062.bloodjournal8862062; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; Shou YP, 1998, J BIOL CHEM, V273, P5716, DOI 10.1074/jbc.273.10.5716; Spyropoulos DD, 2000, MOL CELL BIOL, V20, P5643, DOI 10.1128/MCB.20.15.5643-5652.2000; Takatoku M, 1997, J BIOL CHEM, V272, P7259, DOI 10.1074/jbc.272.11.7259; Tsang AP, 1997, CELL, V90, P109, DOI 10.1016/S0092-8674(00)80318-9; WEISS MJ, 1995, EXP HEMATOL, V23, P99; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zutter MM, 1997, BLOOD, V90, P678, DOI 10.1182/blood.V90.2.678.678_678_689	44	31	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48333	48341		10.1074/jbc.M206127200	http://dx.doi.org/10.1074/jbc.M206127200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359731	hybrid			2022-12-25	WOS:000179789600049
J	Jung, JH; Yoon, T; Choi, EC; Lee, K				Jung, JH; Yoon, T; Choi, EC; Lee, K			Interaction of cofilin with triose-phosphate isomerase contributes glycolytic fuel for Na,K-ATPase via Rho-mediated signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-DEPOLYMERIZING FACTOR; LIM-KINASE; PHOSPHOINOSITIDE-BINDING; STRESS FIBERS; PHOSPHORYLATION; PROTEIN; DEPHOSPHORYLATION; ACTIVATION; PHOSPHOPROTEINS; IDENTIFICATION	We reported previously that cofilin, an actin-binding protein, interacts with Na,K-ATPase and enhances its activity (Lee, K., Jung, J., Kim, M., and Guidotti, G. (2001) Biochem. J. 353, 377-385). To understand the nature of this interaction and the role of cofilin in the regulation of Na,K-ATPase activity, we searched for cofilin-binding proteins in the rat skeletal muscle cDNA library using the yeast two-hybrid system. Several cDNA clones were isolated, some of which coded for triosephosphate isomerase, a glycolytic enzyme. The interaction of cofilin with triose-phosphate isomerase as well as Na,K-ATPase was confirmed by immunoprecipitation and confocal microscopy in HeLa cells. Cofilin was translocated to the plasma membrane along with triosephosphate isomerase by the Rho activator lysophosphatidic acid but not by the p160 Rho-associated kinase inhibitor Y-27632, suggesting that the phosphorylated form of cofilin bound to TPI interacts with Na,K-ATPase. Ouabain-sensitive Rb-86(+) uptake showed that Na,K-ATPase activity was increased by the overexpression of cofilin and lysophosphatidic acid treatment, but not by the overexpression of mutant cofilin S3A and Y-27632 treatment. Pretreatment with the glycolytic inhibitor iodoacetic acid caused a remarkable reduction of Na,K-ATPase activity, whereas pretreatment with the oxidative inhibitor carbonyl cyanide m-chlorophenylhydrazone caused no detectable changes, suggesting that the phosphorylated cofilin is involved in feeding glycolytic fuel for Na,K-ATPase activity. These findings provide a novel molecular mechanism for the regulation of Na,K-ATPase activity and for the nature of the functional coupling of cellular energy transduction.	Ewha Womans Univ, Coll Pharm, Ctr Cell Signaling Res, Seoul 120750, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea	Ewha Womans University; Ewha Womans University; Seoul National University (SNU)	Lee, K (corresponding author), Ewha Womans Univ, Coll Pharm, Ctr Cell Signaling Res, Daehyun Dong 11-1, Seoul 120750, South Korea.	klyoon@ewha.ac.kr						ABE H, 1989, J BIOCHEM-TOKYO, V106, P696, DOI 10.1093/oxfordjournals.jbchem.a122919; ABE H, 1993, EXP CELL RES, V206, P1, DOI 10.1006/excr.1993.1113; Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; BALABAN RS, 1984, BIOCHIM BIOPHYS ACTA, V804, P419, DOI 10.1016/0167-4889(84)90069-7; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; BAMBURG JR, 1987, J CELL BIOL, V105, P2817, DOI 10.1083/jcb.105.6.2817; BAORTO DM, 1992, J CELL BIOL, V117, P357, DOI 10.1083/jcb.117.2.357; CANTIELLO HF, 1995, AM J PHYSIOL-RENAL, V269, pF637, DOI 10.1152/ajprenal.1995.269.5.F637; CLARKE FM, 1975, BIOCHIM BIOPHYS ACTA, V381, P37, DOI 10.1016/0304-4165(75)90187-7; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Dizon J, 1998, AM J PHYSIOL-HEART C, V274, pH1082, DOI 10.1152/ajpheart.1998.274.4.H1082; Edwards DC, 1999, NAT CELL BIOL, V1, P253, DOI 10.1038/12963; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; HARDIN CD, 1993, AM J PHYSIOL, V265, pH1326, DOI 10.1152/ajpheart.1993.265.4.H1326; Heyworth PG, 1997, HISTOCHEM CELL BIOL, V108, P221, DOI 10.1007/s004180050162; KANAMORI T, 1995, J BIOL CHEM, V270, P8061, DOI 10.1074/jbc.270.14.8061; Kim KS, 2001, INT J SOC WELF, V10, P2, DOI 10.1111/1468-2397.00148; Kusano K, 1999, MOL CELL BIOCHEM, V190, P133, DOI 10.1023/A:1006962210692; Lee K, 2001, BIOCHEM J, V353, P377, DOI 10.1042/0264-6021:3530377; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Meberg PJ, 1998, CELL MOTIL CYTOSKEL, V39, P172, DOI 10.1002/(SICI)1097-0169(1998)39:2<172::AID-CM8>3.0.CO;2-8; MOON AL, 1993, J CELL BIOL, V120, P421, DOI 10.1083/jcb.120.2.421; Moriyama K, 2002, J CELL SCI, V115, P1591; NAGAOKA R, 1995, CELL MOTIL CYTOSKEL, V30, P1, DOI 10.1002/cm.970300102; NELSON WJ, 1989, J CELL BIOL, V108, P893, DOI 10.1083/jcb.108.3.893; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHTA Y, 1989, J BIOL CHEM, V264, P16143; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; Okamoto K, 2001, AM J PHYSIOL-ENDOC M, V281, pE479, DOI 10.1152/ajpendo.2001.281.3.E479; PAUL RJ, 1983, AM J PHYSIOL, V244, pC399, DOI 10.1152/ajpcell.1983.244.5.C399; Pfannstiel J, 2001, J BIOL CHEM, V276, P49476, DOI 10.1074/jbc.M104760200; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SAITO T, 1994, EXP CELL RES, V212, P49, DOI 10.1006/excr.1994.1117; SAMSTAG Y, 1994, P NATL ACAD SCI USA, V91, P4494, DOI 10.1073/pnas.91.10.4494; STEPHAN P, 1986, BIOCHIM BIOPHYS ACTA, V873, P127, DOI 10.1016/0167-4838(86)90198-6; Sugiyama S, 2001, MOL CELL BIOCHEM, V217, P153, DOI 10.1023/A:1007261322878; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Szaszi K, 2000, J BIOL CHEM, V275, P28599, DOI 10.1074/jbc.M001193200; TAKAI Y, 1995, TRENDS BIOCHEM SCI, V20, P227, DOI 10.1016/S0968-0004(00)89022-2; Takuma T, 1996, J BIOCHEM, V120, P35; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; WALSH JL, 1989, BIOCHIM BIOPHYS ACTA, V999, P64, DOI 10.1016/0167-4838(89)90031-9; WEISS J, 1985, J CLIN INVEST, V75, P436, DOI 10.1172/JCI111718; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; YONEZAWA N, 1991, J BIOL CHEM, V266, P17218; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443	49	43	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48931	48937		10.1074/jbc.M208806200	http://dx.doi.org/10.1074/jbc.M208806200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359716	hybrid			2022-12-25	WOS:000179789600124
J	Liu, L; Liang, XH; Uliel, S; Unger, R; Ullu, E; Michaeli, S				Liu, L; Liang, XH; Uliel, S; Unger, R; Ullu, E; Michaeli, S			RNA interference of signal peptide-binding protein SRP54 elicits deleterious effects and protein sorting defects in trypanosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION PARTICLE RECEPTOR; ENDOPLASMIC-RETICULUM MEMBRANE; DOUBLE-STRANDED-RNA; COLLOSOMA 7SL RNA; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; LEPTOMONAS-COLLOSOMA; CRYSTAL-STRUCTURE; YARROWIA-LIPOLYTICA; MOLECULAR-CLONING	Trypanosomes are protozoan parasites that have a major impact on health. This family diverged very early from the eukaryotic lineage and possesses unique RNA processing mechanisms such as trans-splicing and RNA editing. The trypanosome signal recognition particle (SRP) has a unique composition compared with all known SRP complexes, because it contains two RNA molecules, the 7SL RNA and a tRNA-like molecule. RNA interference was utilized to elucidate the essentiality of the SRP pathway and its role in protein translocation in Trypanosoma brucei. The production of double stranded RNA specific for the signal peptide-binding protein SRP54 induced the degradation of the mRNA and a loss of the SRP54 protein. SRP54 depletion elicited inhibition in growth and cytokinesis, suggesting that the SRP pathway is essential. The translocation of four signal peptide-containing proteins was examined. Surprisingly, the proteins were translocated to the endoplasmic reticulum and properly processed. However, the surface EP procyclin, the lysosomal protein p67, and the flagellar pocket protein CRAM were mislocalized and accumulated in megavesicles, most likely because of a secondary effect on protein sorting. The translocation of these proteins to the endoplasmic reticulum under SRP54 depletion suggests that an alternative pathway for protein translocation exists in trypanosomes.	Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Yale Univ, Sch Med, Dept Med & Cell Biol, New Haven, CT 06520 USA	Bar Ilan University; Yale University	Michaeli, S (corresponding author), Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel.		Michaeli, Shulamit/AAC-8255-2022	Liu, Li/0000-0002-3733-6961				AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; Al-Qahtani A, 1998, BIOCHEM J, V331, P521, DOI 10.1042/bj3310521; ALTHOFF SM, 1994, MOL CELL BIOL, V14, P7839, DOI 10.1128/MCB.14.12.7839; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Aphasizhev R, 2002, CELL, V108, P637, DOI 10.1016/S0092-8674(02)00647-5; BANGS JD, 1993, J CELL SCI, V105, P1101; Bastin P, 2000, J CELL SCI, V113, P3321; Batey RT, 2000, SCIENCE, V287, P1232, DOI 10.1126/science.287.5456.1232; BEJA O, 1993, MOL BIOCHEM PARASIT, V57, P223, DOI 10.1016/0166-6851(93)90198-7; Ben-Shlomo H, 1997, NUCLEIC ACIDS RES, V25, P4977, DOI 10.1093/nar/25.24.4977; Ben-Shlomo H, 1999, J BIOL CHEM, V274, P25642, DOI 10.1074/jbc.274.36.25642; BROWN JD, 1994, EMBO J, V13, P4390, DOI 10.1002/j.1460-2075.1994.tb06759.x; Bui N, 1999, BIOL CHEM, V380, P135, DOI 10.1515/BC.1999.021; Butikofer P, 2002, MOL BIOCHEM PARASIT, V119, P87, DOI 10.1016/S0166-6851(01)00398-X; Butikofer P, 2001, FASEB J, V15, P545, DOI 10.1096/fj.00-0415hyp; CARRUTHERS VB, 1992, P NATL ACAD SCI USA, V89, P8818, DOI 10.1073/pnas.89.18.8818; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; Estevez AM, 1999, GENE, V240, P247, DOI 10.1016/S0378-1119(99)00437-0; Estevez AM, 2001, EMBO J, V20, P3831, DOI 10.1093/emboj/20.14.3831; Field H, 1999, J CELL SCI, V112, P147; Freymann DM, 1997, NATURE, V385, P361, DOI 10.1038/385361a0; Grosshans H, 2001, J CELL BIOL, V153, P745, DOI 10.1083/jcb.153.4.745; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HE F, 1990, CURR GENET, V17, P289, DOI 10.1007/BF00314874; HE XP, 1994, J CELL SCI, V107, P903; Hegde RS, 1999, TRENDS CELL BIOL, V9, P132, DOI 10.1016/S0962-8924(99)01504-4; Herskovits AA, 2001, EMBO REP, V2, P1040, DOI 10.1093/embo-reports/kve226; Jacobson MR, 1998, P NATL ACAD SCI USA, V95, P7981, DOI 10.1073/pnas.95.14.7981; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Kelley RJ, 1999, MOL BIOCHEM PARASIT, V98, P17, DOI 10.1016/S0166-6851(98)00155-8; Lee IH, 1997, YEAST, V13, P499, DOI 10.1002/(SICI)1097-0061(199705)13:6<499::AID-YEA100>3.0.CO;2-M; LEE MGS, 1990, MOL CELL BIOL, V10, P4506, DOI 10.1128/MCB.10.9.4506; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; LUTCKE H, 1995, EUR J BIOCHEM, V228, P531, DOI 10.1111/j.1432-1033.1995.0531m.x; LUTCKE H, 1992, EMBO J, V11, P1543, DOI 10.1002/j.1460-2075.1992.tb05199.x; MICHAELI S, 1990, J BIOL CHEM, V265, P10582; MICHAELI S, 1993, EXP PARASITOL, V76, P308, DOI 10.1006/expr.1993.1037; MICHAELI S, 1992, MOL BIOCHEM PARASIT, V51, P55, DOI 10.1016/0166-6851(92)90200-4; MILLER JD, 1993, NATURE, V366, P351, DOI 10.1038/366351a0; Montoya G, 1997, NATURE, V385, P365, DOI 10.1038/385365a0; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; OGG SC, 1992, MOL BIOL CELL, V3, P895, DOI 10.1091/mbc.3.8.895; PHILLIPS GJ, 1992, NATURE, V359, P744, DOI 10.1038/359744a0; PORITZ MA, 1990, SCIENCE, V250, P1111, DOI 10.1126/science.1701272; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; Seluanov A, 1997, J BIOL CHEM, V272, P2053; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SOGIN ML, 1986, P NATL ACAD SCI USA, V83, P1383, DOI 10.1073/pnas.83.5.1383; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; WALTER P, 1981, J CELL BIOL, V91, P557, DOI 10.1083/jcb.91.2.557; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	58	29	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47348	47357		10.1074/jbc.M207736200	http://dx.doi.org/10.1074/jbc.M207736200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244113	hybrid			2022-12-25	WOS:000179663700067
J	Pu, LX; Amoscato, AA; Bier, ME; Lazo, JS				Pu, LX; Amoscato, AA; Bier, ME; Lazo, JS			Dual G(1) and G(2) phase inhibition by a novel, selective Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino)-quinoline-5,8-dione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; PROTEIN PHOSPHATASE; DEPENDENT KINASES; CDK2 ACTIVITY; ACTIVATION; PHOSPHORYLATION; TRANSITION; EXPRESSION; TARGET	The Cdc25 dual specificity phosphatases coordinate cell cycle progression, but potent and selective inhibitors have generally been unavailable. In the present study, we have examined one potential inhibitor, 7-chloro-6-(2-morpholin-4-ylethylamino)-quinoline-5,8-dione (NSC 663284), that was identified in the compound library of the National Cancer Institute. We found that NSC 663284 arrested synchronized cells at both G, and G(2)/M phase, and blocked dephosphorylation and activation of Cdk2 and Cdk1 in vivo, as predicted for a Cdc25 inhibitor. Using the natural Cdc25A substrate, Tyr(15)-phosphorylated Cdk2/cyclin A, we demonstrated that NSC 663284 blocked reactivation of Cdk2/cyclin A kinase by Cdc25A catalytic domain in vitro. In-gel trypsin digestion followed by capillary liquid chromatography-electrospray ionization mass spectrometry and tandem mass spectrometry revealed the direct binding of NSC 663284 to one of the two serine residues in the active site loop HCEFSSER of the Cdc25A catalytic domain. Cdc25 binding and inhibition could contribute to the antiproliferative activity of NSC 663284 and its ability to arrest cell cycle progression. Moreover, NSC 663284 should be a valuable reagent to probe the actions of Cdc25 phosphatases within cells and may also be useful structure for the design of more potent and selective antiproliferative agents.	Univ Pittsburgh, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15261 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University	Lazo, JS (corresponding author), Univ Pittsburgh, Dept Pharmacol, E-1340 Biomed Sci Tower, Pittsburgh, PA 15261 USA.		BIER, MARK E/F-5385-2015	BIER, MARK E/0000-0002-5220-9338; Amoscato, Andrew/0000-0002-1340-9150	NATIONAL CANCER INSTITUTE [U19CA052995, P01CA078039, U01CA052995] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52995, CA 78039] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Blomberg I, 1999, MOL CELL BIOL, V19, P6183; Booher RN, 1997, J BIOL CHEM, V272, P22300, DOI 10.1074/jbc.272.35.22300; Dixon D, 1998, EXP CELL RES, V240, P236, DOI 10.1006/excr.1998.3940; Endicott JA, 1999, CURR OPIN STRUC BIOL, V9, P738, DOI 10.1016/S0959-440X(99)00038-X; GALAKTIONOV K, 1991, CELL, V67, P1181, DOI 10.1016/0092-8674(91)90294-9; Galaktionov K, 1996, NATURE, V382, P511, DOI 10.1038/382511a0; GALAKTIONOV K, 1995, SCIENCE, V269, P1575, DOI 10.1126/science.7667636; Gasparotto D, 1997, CANCER RES, V57, P2366; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hagopian JC, 2001, J BIOL CHEM, V276, P275, DOI 10.1074/jbc.M007337200; HOFFMANN I, 1994, EMBO J, V13, P4302, DOI 10.1002/j.1460-2075.1994.tb06750.x; JINNO S, 1994, EMBO J, V13, P1549, DOI 10.1002/j.1460-2075.1994.tb06417.x; Lammer C, 1998, J CELL SCI, V111, P2445; Lazo JS, 2001, J MED CHEM, V44, P4042, DOI 10.1021/jm0102046; Nurse P, 1998, NAT MED, V4, P1103, DOI 10.1038/2594; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Tamura K, 2000, CANCER RES, V60, P1317; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Vigo E, 1999, MOL CELL BIOL, V19, P6379; WATANABE N, 1995, EMBO J, V14, P1878, DOI 10.1002/j.1460-2075.1995.tb07180.x; Wilm M, 1996, NATURE, V379, P466, DOI 10.1038/379466a0	23	76	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46877	46885		10.1074/jbc.M207902200	http://dx.doi.org/10.1074/jbc.M207902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356752	hybrid			2022-12-25	WOS:000179663700008
J	Hellman, NE; Kono, S; Mancini, GM; Hoogeboom, AJ; de Jong, GJ; Gitlin, JD				Hellman, NE; Kono, S; Mancini, GM; Hoogeboom, AJ; de Jong, GJ; Gitlin, JD			Mechanisms of copper incorporation into human ceruloplasmin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; APOCERULOPLASMIN; IDENTIFICATION; BIOSYNTHESIS; OXIDASE; CLUSTER; YEAST; GENE	Ceruloplasmin is a multicopper oxidase essential for normal iron homeostasis. To elucidate the mechanisms of copper incorporation into this protein, holocerulo-plasmin biosynthesis was examined by immunoblot analysis and Cu-64 metabolic labeling of Chinese hamster ovary cells transfected with cDNAs encoding wild-type or mutant ceruloplasmin. This analysis reveals that the incorporation of copper into newly synthesized apoceruloplasmin in vivo results in a detectable conformational change in the protein. Strikingly, despite the unique functional role of each copper site within ceruloplasmin, metabolic studies indicate that achieving this final conformation-driven state requires the occupation of all six copper-binding sites with no apparent hierarchy for copper incorporation at any given site. Consistent with these findings a missense mutation (G631R), resulting in aceruloplasminemia and predicted to alter the interactions at a single type I copper-binding site, results in the synthesis and secretion only of apoceruloplasmin. Analysis of copper incorporation into apoceruloplasmin in vitro reveals that this process is cooperative and that the failure of copper incorporation into copper-binding site mutants observed in vivo is intrinsic to the mutant proteins. These findings reveal a precise and sensitive mechanism for the formation of holoceruloplasmin under the limiting conditions of copper availability within the cell that may be generally applicable to the biosynthesis of cuproproteins within the secretory pathway.	Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, St Louis, MO 63110 USA; Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands	Washington University (WUSTL); Erasmus University Rotterdam	Gitlin, JD (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Dept Pediat, McDonnell Pediat Res Bldg,660 S Euclid Ave, St Louis, MO 63110 USA.	gitlin@kids.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061763] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 61763] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Asante-Appiah E, 1998, J BIOL CHEM, V273, P35078, DOI 10.1074/jbc.273.52.35078; Bartnikas TB, 2001, NAT STRUCT BIOL, V8, P733, DOI 10.1038/nsb0901-733; Blackburn NJ, 2000, BIOCHEMISTRY-US, V39, P2316, DOI 10.1021/bi992334a; CALABRESE L, 1989, J BIOL CHEM, V264, P6183; CARRICO RJ, 1969, J BIOL CHEM, V244, P4141; Connett JM, 1996, P NATL ACAD SCI USA, V93, P6814, DOI 10.1073/pnas.93.13.6814; Culotta V.C., 2001, METABOLIC MOL BASES, P3105; Davis-Kaplan SR, 1998, P NATL ACAD SCI USA, V95, P13641, DOI 10.1073/pnas.95.23.13641; DeFilippis V, 1996, BBA-PROTEIN STRUCT M, V1297, P119, DOI 10.1016/S0167-4838(96)00139-2; GITLIN JD, 1992, BIOCHEM J, V282, P835, DOI 10.1042/bj2820835; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; Hellman NE, 2002, ANNU REV NUTR, V22, P439, DOI 10.1146/annurev.nutr.22.012502.114457; Hellman NE, 2002, J BIOL CHEM, V277, P1375, DOI 10.1074/jbc.M109123200; HOLTZMAN NA, 1970, J BIOL CHEM, V245, P2354; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; Klomp LWJ, 1997, J BIOL CHEM, V272, P9221, DOI 10.1074/jbc.272.14.9221; Machonkin TE, 1998, BIOCHEMISTRY-US, V37, P9570, DOI 10.1021/bi980434v; Narayanan VS, 2001, J NUTR, V131, P1427, DOI 10.1093/jn/131.5.1427; Petrescu SM, 1997, J BIOL CHEM, V272, P15796, DOI 10.1074/jbc.272.25.15796; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rosenzweig AC, 2001, ACCOUNTS CHEM RES, V34, P119, DOI 10.1021/ar000012p; SATO M, 1991, J BIOL CHEM, V266, P5128; Shimizu A, 1999, BIOCHEMISTRY-US, V38, P3034, DOI 10.1021/bi9819531; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; SUGAWARA T, 1991, BIOCHEMISTRY-US, V30, P2698, DOI 10.1021/bi00224a018; TERADA K, 1995, BBA-MOL BASIS DIS, V1270, P58, DOI 10.1016/0925-4439(94)00072-X; YOSHIDA K, 1995, NAT GENET, V9, P267, DOI 10.1038/ng0395-267; Zaitseva I, 1996, J BIOL INORG CHEM, V1, P15, DOI 10.1007/s007750050018	28	123	130	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46632	46638		10.1074/jbc.M206246200	http://dx.doi.org/10.1074/jbc.M206246200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351628	hybrid			2022-12-25	WOS:000179529300120
J	Lin, PS; Dubois, MF; Dahmus, ME				Lin, PS; Dubois, MF; Dahmus, ME			TFIIF-associating carboxyl-terminal domain phosphatase dephosphorylates phosphoserines 2 and 5 of RNA polymerase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; LARGEST SUBUNIT; PHOSPHORYLATION SITES; SUBSTRATE-SPECIFICITY; ELONGATION COMPLEXES; POSSIBLE INVOLVEMENT; CAPPING ENZYME; DISTINCT ROLES; MAP KINASES; IN-VITRO	The carboxyl-terminal domain (CTD) of the largest RNA polymerase (RNAP) II subunit undergoes reversible phosphorylation throughout the transcription cycle. The unphosphorylated form of RNAP II is referred to as IIA, whereas the hyperphosphorylated form is known as IIO. Phosphorylation. occurs predominantly at serine 2 and serine 5 within the CTD heptapeptide repeat and has functional implications for RNAP II with respect to initiation, elongation, and transcription-coupled RNA processing. In an effort to determine the role of the major CTD phosphatase (FCP1) in regulating events in transcription that appear to be influenced by serine 2 and serine 5 phosphorylation, the specificity of FCP1 was examined. FCP1 is capable of dephosphorylating heterogeneous RNAP IIO populations of HeLa nuclear extracts. The extent of dephosphorylation at specific positions was assessed by immunoreactivity with monoclonal antibodies specific for phosphoserine 2 or phosphoserine 5. As an alternative method to assess FCP1 specificity, RNAP IIO isozymes were prepared in vitro by the phosphorylation of purified calf thymus RNAP IIA with specific CTD kinases and used as substrates for FCP1. FCP1 dephosphorylates serine 2 and serine 5 with comparable efficiency. Accordingly, the specificity of FCP1 is sufficiently broad to dephosphorylate RNAP IIO at any point in the transcription cycle irrespective of the site of serine phosphorylation within the consensus repeat.	Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA; Ecole Normale Super, Genet Mol Lab, F-75230 Paris 05, France	University of California System; University of California Davis; UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Dahmus, ME (corresponding author), Univ Calif Davis, Sect Mol & Cellular Biol, Davis, CA 95616 USA.				NIGMS NIH HHS [GM-33300] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033300] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARTHOLOMEW B, 1986, J BIOL CHEM, V261, P14226; BREGMAN DB, 1994, J CELL SCI, V107, P387; BREGMAN DB, 1995, J CELL BIOL, V129, P287, DOI 10.1083/jcb.129.2.287; CADENA DL, 1987, J BIOL CHEM, V262, P12468; Casse C, 1999, J BIOL CHEM, V274, P16097, DOI 10.1074/jbc.274.23.16097; CHAMBERS RS, 1995, J BIOL CHEM, V270, P14962, DOI 10.1074/jbc.270.25.14962; CHAMBERS RS, 1994, J BIOL CHEM, V269, P26243; CHESNUT JD, 1992, J BIOL CHEM, V267, P10500; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Cho H, 1999, GENE DEV, V13, P1540, DOI 10.1101/gad.13.12.1540; Dahmus ME, 1996, J BIOL CHEM, V271, P19009, DOI 10.1074/jbc.271.32.19009; Dubois MF, 1997, NUCLEIC ACIDS RES, V25, P694, DOI 10.1093/nar/25.4.694; DUBOIS MF, 1994, EMBO J, V13, P4787, DOI 10.1002/j.1460-2075.1994.tb06804.x; DUBOIS MF, 1994, J CELL PHYSIOL, V158, P417, DOI 10.1002/jcp.1041580305; GERARD M, 1991, J BIOL CHEM, V266, P20940; Hausmann S, 2002, J BIOL CHEM, V277, P21213, DOI 10.1074/jbc.M202056200; Hengartner CJ, 1998, MOL CELL, V2, P43, DOI 10.1016/S1097-2765(00)80112-4; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; KANG ME, 1993, J BIOL CHEM, V268, P25033; Kimura M, 2002, MOL CELL BIOL, V22, P1577, DOI 10.1128/MCB.22.5.1577-1588.2002; Kobor MS, 1999, MOL CELL, V4, P55, DOI 10.1016/S1097-2765(00)80187-2; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; KONTERMANN RE, 1995, BIOL CHEM H-S, V376, P473, DOI 10.1515/bchm3.1995.376.8.473; KRAMER A, 1980, MOL GEN GENET, V180, P193, DOI 10.1007/BF00267369; Lavoie SB, 1999, BIOCHEM CELL BIOL, V77, P367, DOI 10.1139/bcb-77-4-367; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; Lehman AL, 2000, J BIOL CHEM, V275, P14923, DOI 10.1074/jbc.275.20.14923; Lin PS, 2002, PROG NUCLEIC ACID RE, V72, P333, DOI 10.1016/S0079-6603(02)72074-6; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; Marshall NF, 2000, J BIOL CHEM, V275, P32430, DOI 10.1074/jbc.M005898200; Marshall NF, 1998, J BIOL CHEM, V273, P31726, DOI 10.1074/jbc.273.48.31726; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Mortillaro MJ, 1996, P NATL ACAD SCI USA, V93, P8253, DOI 10.1073/pnas.93.16.8253; Palancade B, 2001, MOL CELL BIOL, V21, P6359, DOI 10.1128/MCB.21.19.6359-6368.2001; Patturajan M, 1998, J BIOL CHEM, V273, P4689, DOI 10.1074/jbc.273.8.4689; PAYNE JM, 1993, J BIOL CHEM, V268, P80; Ramanathan Y, 2001, J BIOL CHEM, V276, P10913, DOI 10.1074/jbc.M010975200; RASMUSSEN EB, 1993, P NATL ACAD SCI USA, V90, P7923, DOI 10.1073/pnas.90.17.7923; Rodriguez CR, 2000, MOL CELL BIOL, V20, P104, DOI 10.1128/MCB.20.1.104-112.2000; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Svejstrup JQ, 1997, P NATL ACAD SCI USA, V94, P6075, DOI 10.1073/pnas.94.12.6075; THIBODEAU A, 1991, EXP CELL RES, V195, P145, DOI 10.1016/0014-4827(91)90510-2; Trigon S, 1998, J BIOL CHEM, V273, P6769, DOI 10.1074/jbc.273.12.6769; VENETIANER A, 1995, EUR J BIOCHEM, V233, P83, DOI 10.1111/j.1432-1033.1995.083_1.x; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; WARREN SL, 1992, J CELL SCI, V103, P381; WEST ML, 1995, GENETICS, V140, P1223; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Yuryev A, 1996, GENETICS, V143, P661; ZHANG J, 1991, J BIOL CHEM, V266, P2290; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000	54	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45949	45956		10.1074/jbc.M208588200	http://dx.doi.org/10.1074/jbc.M208588200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351650	hybrid			2022-12-25	WOS:000179529300033
J	Alexandrov, AI; Botchan, MR; Cozzarelli, NR				Alexandrov, AI; Botchan, MR; Cozzarelli, NR			Characterization of simian virus 40 T-antigen double hexamers bound to a replication fork - The active form of the helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; LARGE TUMOR-ANTIGEN; TERMINATION FACTOR-RHO; VIRAL ORIGIN; CRYSTAL-STRUCTURE; BINDING; PROTEIN; MECHANISM; COMPLEXES; RNA	Large T-antigen (T-ag) is a viral helicase required for the initiation and elongation of simian virus 40 DNA replication. The unwinding activity of the helicase is powered by ATP hydrolysis and is critically dependent on the oligomeric state of the protein. We confirmed that the double hexamer is the active form of the helicase on synthetic replication forks. In contrast, the single hexamer cannot unwind synthetic forks and remains bound to the DNA as ATP is hydrolyzed. This inability of the T-ag single hexamer to release the DNA fork is the likely explanation for its poor helicase activity. We characterized the interactions of T-ag single and double hexamers with synthetic forks and single-stranded (ss) DNA. We demonstrated that DNA forks promote the formation of T-ag double hexamer. The lengths of the duplex region and the 3' tail of the synthetic forks are the critical factors in assembly of the double hexamer, which is bound to a single fork. We found that the cooperativity of T-ag binding to ss oligonucleotides increased with DNA length, suggesting that multiple consecutive subunits in the hexamer engage the ssDNA.	Univ Calif Berkeley, Div Biochem & Mol Biol, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Cozzarelli, NR (corresponding author), Univ Calif Berkeley, Div Biochem & Mol Biol, Dept Mol & Cell Biol, 401 Barker Hall 3204, Berkeley, CA 94720 USA.				NCI NIH HHS [CA42414] Funding Source: Medline; NIGMS NIH HHS [GM31655] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031655] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barcena M, 1998, J MOL BIOL, V283, P809, DOI 10.1006/jmbi.1998.2128; BEAR DG, 1988, J MOL BIOL, V199, P623, DOI 10.1016/0022-2836(88)90306-3; BUJALOWSKI W, 1995, BIOCHEMISTRY-US, V34, P8513, DOI 10.1021/bi00027a001; Bullock PA, 1997, CRIT REV BIOCHEM MOL, V32, P503, DOI 10.3109/10409239709082001; COHEN GL, 1984, J VIROL, V51, P91, DOI 10.1128/JVI.51.1.91-96.1984; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DEB SP, 1987, J VIROL, V61, P3649, DOI 10.1128/JVI.61.12.3649-3654.1987; Donate LE, 2000, J MOL BIOL, V303, P383, DOI 10.1006/jmbi.2000.4132; Fouts ET, 1999, J BIOL CHEM, V274, P4447, DOI 10.1074/jbc.274.7.4447; GEISELMANN J, 1992, PROTEIN SCI, V1, P861, DOI 10.1002/pro.5560010704; HINGORANI MM, 1993, BIOCHEMISTRY-US, V32, P12478, DOI 10.1021/bi00097a028; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15345, DOI 10.1021/bi9810959; Huang SG, 1998, BIOCHEMISTRY-US, V37, P15336, DOI 10.1021/bi981094g; Jezewska MJ, 1998, J BIOL CHEM, V273, P9058, DOI 10.1074/jbc.273.15.9058; Jezewska MJ, 2000, J BIOL CHEM, V275, P27865; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Lemon KP, 2000, MOL CELL, V6, P1321, DOI 10.1016/S1097-2765(00)00130-1; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; MASTRANGELO IA, 1989, NATURE, V338, P658, DOI 10.1038/338658a0; Niedenzu T, 2001, J MOL BIOL, V306, P479, DOI 10.1006/jmbi.2000.4398; PARSONS RE, 1991, J VIROL, V65, P2798, DOI 10.1128/JVI.65.6.2798-2806.1991; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pflumm MF, 2001, DEVELOPMENT, V128, P1697; Sambrook J., 2002, MOL CLONING LAB MANU; SENGUPTA DJ, 1992, SCIENCE, V256, P1656, DOI 10.1126/science.256.5064.1656; SIMANIS V, 1985, VIROLOGY, V144, P88, DOI 10.1016/0042-6822(85)90308-3; SIMMONS DT, 1990, J VIROL, V64, P4858, DOI 10.1128/JVI.64.10.4858-4865.1990; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5; Smelkova NV, 1998, J VIROL, V72, P8676, DOI 10.1128/JVI.72.11.8676-8681.1998; Smelkova NV, 1997, J VIROL, V71, P8766, DOI 10.1128/JVI.71.11.8766-8773.1997; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; STAHL H, 1983, J VIROL, V47, P65, DOI 10.1128/JVI.47.1.65-76.1983; Stenger J E, 1992, Genet Eng (N Y), V14, P33; Valle M, 2000, MOL CELL BIOL, V20, P34, DOI 10.1128/MCB.20.1.34-41.2000; VanLoock MS, 2002, CURR BIOL, V12, P472, DOI 10.1016/S0960-9822(02)00696-6; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; VIRSHUP DM, 1992, MOL CELL BIOL, V12, P4883, DOI 10.1128/MCB.12.11.4883; Weber K, 1972, Methods Enzymol, V26, P3; Weisshart K, 1999, J VIROL, V73, P2201, DOI 10.1128/JVI.73.3.2201-2211.1999; WESSEL R, 1992, J VIROL, V66, P804, DOI 10.1128/JVI.66.2.804-815.1992; WESSEL R, 1992, VIROLOGY, V189, P293, DOI 10.1016/0042-6822(92)90705-T; Wu CX, 1998, J VIROL, V72, P10256, DOI 10.1128/JVI.72.12.10256-10259.1998; Wu CX, 2001, J VIROL, V75, P2839, DOI 10.1128/JVI.75.6.2839-2847.2001	45	28	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44886	44897		10.1074/jbc.M207022200	http://dx.doi.org/10.1074/jbc.M207022200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244108	hybrid			2022-12-25	WOS:000179404800039
J	Eroglu, B; Powers-Lee, SG				Eroglu, B; Powers-Lee, SG			Unmasking a functional allosteric domain in an allosterically nonresponsive carbamoyl-phosphate synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; COOH-TERMINAL DOMAIN; ESCHERICHIA-COLI; BINDING-SITE; REGULATORY DOMAIN; CRUCIAL RESIDUES; ACTIVATOR IMP; YEAST; ARGININE; SUBUNIT	Although carbamoyl-phosphate synthetases (CPSs) share sequence identity, multidomain structure, and reaction mechanism, they have varying physiological roles and allosteric effectors. Escherichia coli CPS (eCPS) provides CP for both arginine and pyrimidine nucleotide biosynthesis and is allosterically regulated by metabolites from both pathways, with inhibition by UMP and activation by IMP and ornithine. The arginine-specific CPS from Saccharomyces cerevisiae (sCPS), however, apparently responds to no allosteric effectors. We have designed and analyzed a chimeric CPS (chCPS, in which the C-terminal 136 residues of eCPS were replaced by the corresponding residues of sCPS) to define the structural basis for the allosteric nonresponsiveness of sCPS and thereby provide insight into the mechanism for allosteric selectivity and responsiveness in the other CPSs. Surprisingly, ornithine and UMP each had a significant effect on chCPS activity, and did so at concentrations that were similar to those effective for eCPS. We further found that sCPS bound both UMP and IMP and that chCPS bound IMP, although none of these interactions led to changes in enzymatic activity. These findings strongly suggest that the nonresponsive sCPS is not able to communicate occupancy of the allosteric site to the active site but does contain a latent allosteric interaction domain.	Northeastern Univ, Dept Biol, Boston, MA 02115 USA	Northeastern University	Powers-Lee, SG (corresponding author), Northeastern Univ, Dept Biol, Boston, MA 02115 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054423] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54423] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AITKEN DM, 1973, BIOCHIM BIOPHYS ACTA, V309, P50, DOI 10.1016/0005-2744(73)90316-1; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3157, DOI 10.1021/bi00874a012; ANDERSON PM, 1966, BIOCHEMISTRY-US, V5, P3164, DOI 10.1021/bi00874a013; ANDERSON PM, 1968, BIOCHEM BIOPH RES CO, V32, P928, DOI 10.1016/0006-291X(68)90116-2; ANDERSON PM, 1995, NITROGEN METABOLISM, P33; BOETTCHER B, 1982, J BIOL CHEM, V257, P3971; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Braxton BL, 1996, BIOCHEMISTRY-US, V35, P11918, DOI 10.1021/bi961305m; Bueso J, 1999, BIOCHEMISTRY-US, V38, P3910, DOI 10.1021/bi982871f; BUESO J, 1994, BIOCHEM BIOPH RES CO, V203, P1083, DOI 10.1006/bbrc.1994.2293; Cervera J, 1996, BIOCHEMISTRY-US, V35, P7247, DOI 10.1021/bi952549u; CZERWINSKI RM, 1995, BIOCHEMISTRY-US, V34, P13920, DOI 10.1021/bi00042a025; Delannay S, 1999, J MOL BIOL, V286, P1217, DOI 10.1006/jmbi.1999.2561; Fresquet V, 2000, J MOL BIOL, V299, P979, DOI 10.1006/jmbi.2000.3794; GLANSDORFF N, 1965, GENETICS, V51, P167; GUILLOU F, 1989, P NATL ACAD SCI USA, V86, P8304, DOI 10.1073/pnas.86.21.8304; GUTHOHRL.G, 1968, ANAL BIOCHEM, V26, P188, DOI 10.1016/0003-2697(68)90045-6; Hewagama A, 1998, BBA-PROTEIN STRUCT M, V1388, P489, DOI 10.1016/S0167-4838(98)00212-X; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; LILJELUND P, 1986, Molecular and General Genetics, V205, P74, DOI 10.1007/BF02428034; Lim AL, 1997, ARCH BIOCHEM BIOPHYS, V339, P344, DOI 10.1006/abbi.1997.9887; Lim AL, 1996, J BIOL CHEM, V271, P11400, DOI 10.1074/jbc.271.19.11400; LIU X, 1994, J BIOL CHEM, V269, P27747; LUSTY CJ, 1983, J BIOL CHEM, V258, P4466; MAREYA SM, 1994, BIOCHEMISTRY-US, V33, P2945, DOI 10.1021/bi00176a026; McCudden CR, 1996, J BIOL CHEM, V271, P18285, DOI 10.1074/jbc.271.30.18285; MEISTER A, 1978, ADV ENZYME REGUL, V16, P289; MESSENGUY F, 1983, EMBO J, V2, P1249, DOI 10.1002/j.1460-2075.1983.tb01577.x; Mora P, 1999, FEBS LETT, V446, P133, DOI 10.1016/S0014-5793(99)00197-0; NYUNOYA H, 1983, P NATL ACAD SCI-BIOL, V80, P4629, DOI 10.1073/pnas.80.15.4629; PAULUS H, 1983, CURR TOP CELL REGUL, V22, P177; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PIERARD A, 1966, SCIENCE, V154, P1572, DOI 10.1126/science.154.3756.1572; PIERARD A, 1978, J BACTERIOL, V106, P145; Pierrat OA, 2002, ARCH BIOCHEM BIOPHYS, V400, P34, DOI 10.1006/abbi.2002.2767; Pierrat OA, 2002, ARCH BIOCHEM BIOPHYS, V400, P26, DOI 10.1006/abbi.2002.2768; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; PRICE CW, 1978, J GEN MICROBIOL, V106, P145, DOI 10.1099/00221287-106-1-145; Rochera L, 2002, FEBS LETT, V514, P323, DOI 10.1016/S0014-5793(02)02392-X; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; Rose MD., 1990, METHODS YEAST GENETI; RUBINO SD, 1986, J BIOL CHEM, V261, P1320; Saeed-Kothe A, 2002, J BIOL CHEM, V277, P7231, DOI 10.1074/jbc.M110926200; Sambrook J., 1989, MOL CLONING; STEWART PM, 1980, J BIOL CHEM, V255, P5270; TATIBANA M, 1972, J BIOCHEM, V72, P549, DOI 10.1093/oxfordjournals.jbchem.a129934; Thoden JB, 1999, J BIOL CHEM, V274, P22502, DOI 10.1074/jbc.274.32.22502; Thoden JB, 1999, ACTA CRYSTALLOGR D, V55, P8, DOI 10.1107/S0907444998006234; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; Tuchman M, 1997, APPL ENVIRON MICROB, V63, P33, DOI 10.1128/AEM.63.1.33-38.1997; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; XU W, 1988, BIOCHEMISTRY-US, V27, P5507, DOI 10.1021/bi00415a018	52	3	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45466	45472		10.1074/jbc.M208185200	http://dx.doi.org/10.1074/jbc.M208185200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244118	hybrid			2022-12-25	WOS:000179404800111
J	Li, FS; Macfarlan, T; Pittman, RN; Chakravarti, D				Li, FS; Macfarlan, T; Pittman, RN; Chakravarti, D			Ataxin-3 is a histone-binding protein with two independent transcriptional corepressor activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUNTINGTONS-DISEASE; EXPANDED POLYGLUTAMINE; REPRESSES TRANSCRIPTION; MEDIATED TRANSCRIPTION; NUCLEAR MATRIX; AFFECTED BRAIN; GENE-PRODUCT; MOUSE MODEL; CELL-DEATH; INTERACTS	The mechanisms of pathology for the family of polyglutamine disease proteins are unknown; however, recently it was shown that several of these proteins inhibit transcription suggesting that transcriptional repression may be a potential mechanism for pathology. In the present study we use cell transfections, in vitro binding, co-immunoprecipitations, and reporter assays to show that the polyglutamine disease protein, ataxin-3, interacts with the major histone acetyltransferases cAMP-response-element binding protein (CREB)-binding protein, p300, and p300/CREB-binding protein-associated factor and inhibits transcription by these coactivators. Importantly, endogenous ataxin-3 is co-immunoprecipitated with each of these coactivators in non-transfected cells. The C-teriminal polyglutamine-containing domain of ataxin-3 inhibits coactivator-dependent transcription and is required for binding coactivators. The N-terminal domain of ataxin-3 inhibits histone acetylation by p300 in vitro and inhibits transcription in vivo. Histone binding and blocking access of coactivators to acetylation sites on histones appears to be the mechanism of inhibition. Together, our data provide a novel mechanism of transcriptional regulation by ataxin-3 that involves targeting histones, coactivators, and an independent mode of direct repression of transcription, and suggests that its physiological function and possibly pathological effects are linked to its interactions with these proteins.	Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania	Pittman, RN (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA.		Macfarlan, Todd/S-3750-2017	Macfarlan, Todd/0000-0003-2495-9809; Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042625] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK057079, DK57079] Funding Source: Medline; NINDS NIH HHS [NS42625] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bevivino AE, 2001, P NATL ACAD SCI USA, V98, P11955, DOI 10.1073/pnas.211305198; Boutell JM, 1999, HUM MOL GENET, V8, P1647, DOI 10.1093/hmg/8.9.1647; Chai YH, 2002, P NATL ACAD SCI USA, V99, P9310, DOI 10.1073/pnas.152101299; Chai YH, 2001, J BIOL CHEM, V276, P44889, DOI 10.1074/jbc.M106575200; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Dyer RB, 2001, NAT GENET, V29, P270, DOI 10.1038/ng745; Evert BO, 2001, J NEUROSCI, V21, P5389, DOI 10.1523/JNEUROSCI.21-15-05389.2001; Glass CK, 2000, GENE DEV, V14, P121; Goodman RH, 2000, GENE DEV, V14, P1553; Hughes RE, 2001, P NATL ACAD SCI USA, V98, P13201, DOI 10.1073/pnas.191498198; KAWAGUCHI Y, 1994, NAT GENET, V8, P221, DOI 10.1038/ng1194-221; La Spada AR, 2001, NEURON, V31, P913, DOI 10.1016/S0896-6273(01)00422-6; Lin X, 2000, NAT NEUROSCI, V3, P157, DOI 10.1038/72101; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Matilla A, 1997, NATURE, V389, P974, DOI 10.1038/40159; McCampbell A, 2000, HUM MOL GENET, V9, P2197, DOI 10.1093/hmg/9.14.2197; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Perez MK, 1999, HUM MOL GENET, V8, P2377, DOI 10.1093/hmg/8.13.2377; Perez MK, 1998, J CELL BIOL, V143, P1457, DOI 10.1083/jcb.143.6.1457; Ross CA, 1999, PHILOS T ROY SOC B, V354, P1005, DOI 10.1098/rstb.1999.0452; Ross CA, 1997, NEURON, V19, P1147, DOI 10.1016/S0896-6273(00)80405-5; Schmidt T, 1998, BRAIN PATHOL, V8, P669, DOI 10.1111/j.1750-3639.1998.tb00193.x; Seo SB, 2002, J BIOL CHEM, V277, P14005, DOI 10.1074/jbc.M112455200; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Steffan JS, 2001, NATURE, V413, P739, DOI 10.1038/35099568; Steffan JS, 2000, P NATL ACAD SCI USA, V97, P6763, DOI 10.1073/pnas.100110097; WANG SL, 1993, P NATL ACAD SCI USA, V90, P10385, DOI 10.1073/pnas.90.21.10385; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Wyttenbach A, 2001, HUM MOL GENET, V10, P1829, DOI 10.1093/hmg/10.17.1829; Zhang QH, 2000, MOL CELL BIOL, V20, P4970, DOI 10.1128/MCB.20.14.4970-4978.2000; Zhang S, 2002, CELL, V108, P45, DOI 10.1016/S0092-8674(01)00630-4; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	38	170	179	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45004	45012		10.1074/jbc.M205259200	http://dx.doi.org/10.1074/jbc.M205259200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297501	hybrid			2022-12-25	WOS:000179404800054
J	Li, Y; Inoki, K; Yeung, R; Guan, KL				Li, Y; Inoki, K; Yeung, R; Guan, KL			Regulation of TSC2 by 14-3-3 binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUBEROUS SCLEROSIS COMPLEX; CELL-GROWTH; PROLIFERATION; MUTATION; MICE; GENE	Mutation in either the TSC1 or TSC2 tumor suppressor gene is responsible for the inherited genetic disease of tuberous sclerosis complex. TSC1 and TSC2 form a physical and functional complex to regulate cell growth. Recently, it has been demonstrated that TSC1-TSC2 functions to inhibit ribosomal S6 kinase and negatively regulate cell size. TSC2 is negatively regulated by Akt phosphorylation. Here, we report that TSC2, but not TSC1, associates with 14-3-3 in vivo. Phosphorylation of Ser(1210) in TSC2 is required for its association with 14-3-3. Our data indicate that 14-3-3 association may inhibit the function of TSC2 and represents a possible mechanism of TSC2 regulation.	Univ Michigan, Dept Biol Chem, Sch Med, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Sch Med, Ann Arbor, MI 48109 USA; Univ Washington, Dept Surg, Seattle, WA 98195 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Washington; University of Washington Seattle	Guan, KL (corresponding author), Univ Michigan, Dept Biol Chem, Sch Med, 1301 E Catherine St, Ann Arbor, MI 48109 USA.		Guan, Kun-Liang/ADK-7088-2022; INOKI, KEN/A-1202-2007		NIDDK NIH HHS [R01 DK124709] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertram PG, 1998, CURR BIOL, V8, P1259, DOI 10.1016/S0960-9822(07)00535-0; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Crino PB, 1999, NEUROLOGY, V53, P1384, DOI 10.1212/WNL.53.7.1384; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Goncharova EA, 2002, J BIOL CHEM, V277, P30958, DOI 10.1074/jbc.M202678200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kobayashi T, 2001, P NATL ACAD SCI USA, V98, P8762, DOI 10.1073/pnas.151033798; Kwiatkowski DJ, 2002, HUM MOL GENET, V11, P525, DOI 10.1093/hmg/11.5.525; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mori H, 2000, FEBS LETT, V467, P61, DOI 10.1016/S0014-5793(00)01126-1; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; PORTER CJ, 2002, NAT CELL BIOL, V4, P658; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Tapon N, 2001, CELL, V105, P345, DOI 10.1016/S0092-8674(01)00332-4; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Slegtenhorst M, 1998, HUM MOL GENET, V7, P1053, DOI 10.1093/hmg/7.6.1053; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; YEUNG RS, 1994, P NATL ACAD SCI USA, V91, P11413, DOI 10.1073/pnas.91.24.11413; Young J, 1998, MOL MED TODAY, V4, P313, DOI 10.1016/S1357-4310(98)01245-3	24	91	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44593	44596		10.1074/jbc.C200510200	http://dx.doi.org/10.1074/jbc.C200510200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12364343	hybrid			2022-12-25	WOS:000179404800002
J	Obrero, M; Yu, DV; Shapiro, DJ				Obrero, M; Yu, DV; Shapiro, DJ			Estrogen receptor-dependent and estrogen receptor-independent pathways for tamoxifen and 4-hydroxytamoxifen-induced programmed cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER-CELLS; ACTIVATED PROTEIN-KINASES; CYTOCHROME-C; INDUCED APOPTOSIS; SIGNAL-TRANSDUCTION; MAP KINASES; CATHEPSIN-D; IN-VITRO; NECROSIS; P38	The therapeutic efficacy of tamoxifen (TAM) in cancer therapy is thought to arise primarily from its ability to compete with estrogens for binding to the estrogen receptor (ER). We show that TAM and its active metabolite, 4-hydroxytamoxifen (OHT), can actively induce programmed cell death through distinct ER-dependent and ER-independent pathways. The ER-independent pathway is activated by 10-20 muM TAM and OHT and by 10-20 mum 17beta-estradiol and raloxifene, and occurs in ER-negative cells. The ER dependence of a second pathway, caused by submicromolar concentrations of TAM and OHT, was demonstrated by the ability of the ER ligands 17beta-estradiol, raloxifene, and ICI 182,780 to effectively block the cell death-inducing effects of TAM and OHT. Because the p38-specific inhibitor SB203580 blocks OHT-ER-induced cell death, stress kinase pathways are likely involved. ER-independent cell death triggers classic caspase-dependent apoptosis. However, although OHT-ER triggers some hallmarks of apoptosis, including Bax translocation and cytochrome c release, the absence of poly(ADP-ribose) polymerase cleavage or DNA laddering indicates that the death pathway involved is caspase-independent. The OHT-ER-dependent cell death pathway appears to diverge from classical apoptosis at the level of caspase 9 activation. The ability to promote ER-dependent programmed cell death represents a novel activity of TAM and OHT.	Univ Illinois, Dept Biochem, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign	Shapiro, DJ (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.				NCI NIH HHS [CA90374] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA090374] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Bonetti B, 1997, ANN NEUROL, V42, P74, DOI 10.1002/ana.410420113; Chen HM, 1996, J CELL BIOCHEM, V61, P9, DOI 10.1002/(SICI)1097-4644(19960401)61:1<9::AID-JCB2>3.3.CO;2-2; Clerk A, 1998, FEBS LETT, V426, P93, DOI 10.1016/S0014-5793(98)00324-X; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dietze EC, 2001, J BIOL CHEM, V276, P5384, DOI 10.1074/jbc.M007915200; DUBIK D, 1992, ONCOGENE, V7, P1587; Eguchi Y, 1997, CANCER RES, V57, P1835; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gundimeda U, 1996, J BIOL CHEM, V271, P13504, DOI 10.1074/jbc.271.23.13504; Holler N, 2000, NAT IMMUNOL, V1, P489, DOI 10.1038/82732; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Jiang XJ, 2000, J BIOL CHEM, V275, P31199, DOI 10.1074/jbc.C000405200; Kang Y, 1996, J NATL CANCER I, V88, P279, DOI 10.1093/jnci/88.5.279; KATZENELLENBOGEN BS, 1984, CANCER RES, V44, P112; Kim JA, 1999, CANCER LETT, V147, P115, DOI 10.1016/S0304-3835(99)00284-0; Kushner PJ, 2000, J STEROID BIOCHEM, V74, P311, DOI 10.1016/S0960-0760(00)00108-4; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; Leng Y, 2000, EUR J PHARMACOL, V409, P123, DOI 10.1016/S0014-2999(00)00826-8; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Mandlekar S, 2000, CANCER RES, V60, P6601; Mandlekar S, 2000, CANCER RES, V60, P5995; Mandlekar S, 2001, APOPTOSIS, V6, P469, DOI 10.1023/A:1012437607881; Mao CJ, 2000, ENDOCRINOLOGY, V141, P2361, DOI 10.1210/en.141.7.2361; Mateo V, 1999, NAT MED, V5, P1277, DOI 10.1038/15233; Mattson MP, 2000, NAT REV MOL CELL BIO, V1, P120, DOI 10.1038/35040009; METZGER D, 1995, MOL ENDOCRINOL, V9, P579, DOI 10.1210/me.9.5.579; Nicotera P, 1999, TRENDS PHARMACOL SCI, V20, P46, DOI 10.1016/S0165-6147(99)01304-8; NICOTERA P, 1986, J BIOL CHEM, V261, P4628; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Ortiz MA, 2001, CANCER RES, V61, P8504; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Park WC, 2002, TRENDS MOL MED, V8, P82, DOI 10.1016/S1471-4914(02)02282-7; Paul C, 2002, MOL CELL BIOL, V22, P816, DOI 10.1128/MCB.22.3.816-834.2002; ROCHEFORT H, 1990, CANCER CELL-MON REV, V2, P383; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shiraishi J, 2001, AM J PHYSIOL-HEART C, V281, pH1637, DOI 10.1152/ajpheart.2001.281.4.H1637; Sohn S, 1998, NEUROSCI LETT, V240, P147, DOI 10.1016/S0304-3940(97)00936-1; SPYRATOS F, 1989, LANCET, V2, P1115; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Vercammen D, 1998, J EXP MED, V187, P1477, DOI 10.1084/jem.187.9.1477; WEBB P, 1995, MOL ENDOCRINOL, V9, P443, DOI 10.1210/me.9.4.443; Whitmarsh AJ, 1997, MOL CELL BIOL, V17, P2360, DOI 10.1128/MCB.17.5.2360; Wijayaratne AL, 1999, ENDOCRINOLOGY, V140, P5828, DOI 10.1210/en.140.12.5828; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Zhang CC, 2000, J BIOL CHEM, V275, P479, DOI 10.1074/jbc.275.1.479; Zhang CC, 1999, MOL ENDOCRINOL, V13, P632, DOI 10.1210/me.13.4.632; Zhang W, 2000, CANCER RES, V60, P5395; Zou H, 1999, J BIOL CHEM, V274, P11549, DOI 10.1074/jbc.274.17.11549	60	94	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45695	45703		10.1074/jbc.M208092200	http://dx.doi.org/10.1074/jbc.M208092200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244117	hybrid			2022-12-25	WOS:000179404800137
J	Parrot, I; Huang, PC; Khosla, C				Parrot, I; Huang, PC; Khosla, C			Circular dichroism and nuclear magnetic resonance spectroscopic analysis of immunogenic gluten peptides and their analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CELIAC-DISEASE; POLYPROLINE-II; CHEMICAL-SHIFT; ALPHA-GLIADIN; CONFORMATION; RECOGNITION; TRANSGLUTAMINASE; EPITOPE	Celiac Sprue, or gluten-sensitive enteropathy, is an inheritable human disease of the small intestine that is triggered by the dietary intake of gluten. Recently, several Pro- and Gln-rich peptide sequences (most notably PQPQLPY and analogs) have been identified from gluten with potent immunogenic activity toward CD4(+) T cells from small intestinal biopsies of Celiac Sprue patients. These peptides have three unusual properties. First, they are relatively stable toward further proteolysis by gastric, pancreatic, and intestinal enzymes. Second, they are recognized and deamidated by human tissue transglutaminase (tTGase) with high selectivity. Third, tTGase-catalyzed deamidation enhances their affinity for HLA-DQ2, the disease-specific class II major histocompatibility complex heterodimer. In an attempt to seek a mechanistic explanation for these properties, we undertook secondary structural studies on PQPQLPY and its analogs. Circular dichroism studies on a series of monomeric and dimeric analogs revealed a strong polyproline II helical propensity in a subset of them. Two-dimensional nuclear magnetic resonance spectroscopic analysis confirmed a polyproline II conformation of PQPQLPY, and was also used to elucidate the secondary structure of the most helical variant, (D-P)QPQLPY. Remarkably, a strong correlation was observed between polyproline II content of naturally occurring gluten peptides and the specificity of human tTGase toward these substrates. Analogs with up to two D-amino acid residues retained both polyproline II helical content and transglutaminase affinity. Since the Michaelis constant (K-m) is the principal determinant of tTGase specificity for naturally occurring gluten peptides and their analogs, our results suggest that the tTGase binding site may have a preference for polyproline II helical substrates. If so, these insights could be exploited for the design of selective small molecule inhibitors of this pharmacologically important enzyme.	Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; Stanford Univ, Dept Chem, Stanford, CA 94305 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Khosla, C (corresponding author), Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.	ck@chemeng.stanford.edu	parrot, isabelle/AAS-5546-2020	Khosla, Chaitan/0000-0001-6529-495X				Alfonso P, 1998, FEBS LETT, V427, P36, DOI 10.1016/S0014-5793(98)00388-3; Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; Dalcol I, 1996, J ORG CHEM, V61, P6775, DOI 10.1021/jo960987g; Dalgarno DC, 1997, BIOPOLYMERS, V43, P383; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; Fiebig KM, 1996, J PHYS CHEM-US, V100, P2661, DOI 10.1021/jp952747v; Fleckenstein B, 2002, J BIOL CHEM, V277, P34109, DOI 10.1074/jbc.M204521200; FRAZER AC, 1959, LANCET, V2, P252; GILBERT SM, 2000, BIOCHIM BIOPHYS ACTA, P135; Hausch F, 2002, AM J PHYSIOL-GASTR L, V283, pG996, DOI 10.1152/ajpgi.00136.2002; HELBECQUE N, 1982, INT J PEPT PROT RES, V19, P94; HINCK AP, 1993, BIOCHEMISTRY-US, V32, P11810, DOI 10.1021/bi00095a009; Jardetzky TS, 1996, P NATL ACAD SCI USA, V93, P734, DOI 10.1073/pnas.93.2.734; KARPLUS M, 1959, J CHEM PHYS, V30, P11, DOI 10.1063/1.1729860; Kelly MA, 2001, BIOCHEMISTRY-US, V40, P14376, DOI 10.1021/bi011043a; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; Lee KH, 2001, NAT IMMUNOL, V2, P501, DOI 10.1038/88694; Liu SP, 2002, P NATL ACAD SCI USA, V99, P2743, DOI 10.1073/pnas.042454899; MARQUSEE S, 1987, P NATL ACAD SCI USA, V84, P8898, DOI 10.1073/pnas.84.24.8898; PADI A, 1984, J MOL BIOL, V180, P741; Papadopoulos GK, 2001, J CLIN INVEST, V108, P1261; Piper JL, 2002, BIOCHEMISTRY-US, V41, P386, DOI 10.1021/bi011715x; RABANAL F, 1993, BIOPOLYMERS, V33, P1019, DOI 10.1002/bip.360330704; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RONISH EW, 1974, BIOPOLYMERS, V13, P1635, DOI 10.1002/bip.1974.360130810; Sharman GJ, 1998, J AM CHEM SOC, V120, P5291, DOI 10.1021/ja9705405; SILIGARDI G, 1995, BIOPOLYMERS, V37, P281, DOI 10.1002/bip.360370406; Sollid LM, 2000, ANNU REV IMMUNOL, V18, P53, DOI 10.1146/annurev.immunol.18.1.53; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Stapley BJ, 1999, PROTEIN SCI, V8, P587; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; TATHAM AS, 1990, BIOCHEM J, V270, P313, DOI 10.1042/bj2700313; TIFFANY ML, 1968, BIOPOLYMERS, V6, P1767, DOI 10.1002/bip.1968.360061212; Uray K, 2000, ARCH BIOCHEM BIOPHYS, V378, P25, DOI 10.1006/abbi.2000.1801; Vader LW, 2002, J EXP MED, V195, P643, DOI 10.1084/jem.20012028; Wieser H, 1996, ACTA PAEDIATR, V85, P3, DOI 10.1111/j.1651-2227.1996.tb14239.x; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Woody R. W., 1992, ADV BIOPHYS CHEM, V2, P37; Wuthrich K, 1986, NMR PROTEINS NUCL AC	42	30	42	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45572	45578		10.1074/jbc.M207606200	http://dx.doi.org/10.1074/jbc.M207606200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12324465	hybrid			2022-12-25	WOS:000179404800123
J	Liu, G; Chen, XB				Liu, G; Chen, XB			The ferredoxin reductase gene is regulated by the p53 family and sensitizes cells to oxidative stress-induced apoptosis	ONCOGENE			English	Article						FDXR; ROS; p53; p63; p73; apoptosis	COLORECTAL-CANCER CELLS; ADRENODOXIN REDUCTASE; CYCLE ARREST; TARGET GENES; DNA-DAMAGE; P21; INHIBITOR; BINDING; P73; P63	The p53 tumor suppressor protein, a transcription factor, induces cell cycle arrest and apoptosis via the upregulation of downstream target genes. Ferredoxin Reductase (protein, FR; gene, FDXR) transfers electron from NADPH to cytochrome P450 via ferredoxin in mitochondria. Here, we identified FDXR as a target gene of the p53 family, that is, p53, p63, and p73. We found that FDXR can be induced by DNA damage in cells in a p53-dependent manner and by a mutated form of p53 that is competent in inducing apoptosis. In addition, we identified a p53 response element located within the FDXR promoter that is responsive to wild-type p53, p63alpha, p63gamma, p73alpha, and p73beta. Furthermore, we showed that p53, p63alpha and p73alpha directly bind to the p53 response element in vivo and promote the accessibility of the FDXR promoter by increasing the acetylation of histones H3 and H4. To determine the role of FR in p53 tumor suppression, we generated cell lines that express FR using a tetracycline-regulated promoter. We found that overexpression of FR in lung H1299, breast MCF7, and colorectal HCT116 carcinoma cells have no effect on cell proliferation. However, we showed that FR increases the sensibility of H1299 and HCT116 cells to 5-fluorouracil-, doxorubicin- and H2O2- mediated apoptosis. Our data support a model of feed-forward loop for p53 activity, that is, various cellular stresses, including reactive oxygen species (ROS), activate p53, which induces the expression of FDXR; and the FDXR gene product, FR, in turn sensitizes cells to ROS-mediated apoptosis.	Univ Alabama Birmingham, Ctr Comprehens Canc, Dept Cell Biol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Chen, XB (corresponding author), MCLM 660, 1530 3rd Ave S, Birmingham, AL 35294 USA.	xchen@uab.edu		Liu, Gang/0000-0003-2615-131X; , Gang/0000-0002-6999-7633	NATIONAL CANCER INSTITUTE [R01CA076069, R29CA076069, R01CA081237] Funding Source: NIH RePORTER; NCI NIH HHS [CA76069, R01 CA81237] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKMAN SA, 1992, BIOCHEMISTRY-US, V31, P3500, DOI 10.1021/bi00128a026; Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen J, 1996, ONCOGENE, V13, P1395; Chen XB, 1999, MOL MED TODAY, V5, P387, DOI 10.1016/S1357-4310(99)01545-2; CHEN XB, 1995, CANCER RES, V55, P4257; Chenery HJ, 1996, APHASIOLOGY, V10, P1, DOI 10.1080/02687039608248396; Dohn M, 2001, ONCOGENE, V20, P6503, DOI 10.1038/sj.onc.1204816; Dohn M, 2001, ONCOGENE, V20, P3193, DOI 10.1038/sj.onc.1204427; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; HANUKOGLU I, 1989, EUR J BIOCHEM, V180, P479, DOI 10.1111/j.1432-1033.1989.tb14671.x; HARPER JW, 1993, CELL, V75, P805; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; Hwang PM, 2001, NAT MED, V7, P1111, DOI 10.1038/nm1001-1111; Irwin MS, 2001, CELL GROWTH DIFFER, V12, P337; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; KRAMER RE, 1982, ARCH BIOCHEM BIOPHYS, V215, P478, DOI 10.1016/0003-9861(82)90106-0; MIYASHITA T, 1995, CELL, V80, P293; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; MUNGER K, 1989, J VIROL, V63, P4417; Nakayama T, 2000, IPAP CONFERENCE SER, V1, P7, DOI 10.1109/ROMAN.2000.892461; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; WALDMAN T, 1995, CANCER RES, V55, P5187; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zhu JH, 2000, MOL CELL BIOL, V20, P5602, DOI 10.1128/MCB.20.15.5602-5618.2000; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030; Zhu JH, 2000, J BIOL CHEM, V275, P39927, DOI 10.1074/jbc.M005676200; Zhu JH, 1999, ONCOGENE, V18, P2149, DOI 10.1038/sj.onc.1202533; Zhu JH, 1998, CANCER RES, V58, P5061	41	153	156	4	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7195	7204		10.1038/sj.onc.1205862	http://dx.doi.org/10.1038/sj.onc.1205862			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370809				2022-12-25	WOS:000178504600007
J	Ehrlich, M; Jiang, GC; Fiala, E; Dome, JS; Yu, MC; Long, TI; Youn, B; Sohn, OS; Widschwendter, M; Tomlinson, GE; Chintagumpala, M; Champagne, M; Parham, D; Liang, GN; Malik, K; Laird, PW				Ehrlich, M; Jiang, GC; Fiala, E; Dome, JS; Yu, MC; Long, TI; Youn, B; Sohn, OS; Widschwendter, M; Tomlinson, GE; Chintagumpala, M; Champagne, M; Parham, D; Liang, GN; Malik, K; Laird, PW			Hypomethylation and hypermethylation of DNA in Wilms tumors	ONCOGENE			English	Article						DNA hypomethylation; DNA hypermethylation; Wilms tumors	PROMOTER METHYLATION; PERICENTROMERIC DNA; COLORECTAL TUMORS; CARCINOMA-CELLS; CPG ISLANDS; GENE; EXPRESSION; CANCERS; BREAST; 5-METHYLCYTOSINE	We quantitatively analysed hypermethylation at CpG islands in the 5' ends of 12 genes and one non-CpG island 5' region (MTHFR) in 31 Wilms tumors. We also determined their global genomic 5-methylcytosine content. Compared with various normal postnatal tissues, similar to40-90% of these pediatric kidney cancers were hypermethylated in four of the genes, MCJ, RASSF1A, TNFRSF12 and CALCA as determined by a quantitative bisulfite-based assay (MethyLight). Interestingly, the non-CpG island 5' region of MTHFR was less methylated in most tumors relative to the normal tissues. By chromatographic analysis of DNA digested to deoxynucleosides, about 60% of the Wilms tumors were found to be deficient in their overall levels of DNA methylation. We also analysed expression of the three known functional DNA methyltransferase genes. No relationship was observed between global genomic 5-methylcytosine levels and relative amounts of RNA for DNA methyltransferases DNMT1, DNMT3A, and DNMT3B. Importantly, no association was seen between CpG island hypermethylation and global DNA hypomethylation in these cancers. Therefore, the overall genomic hypomethylation frequently observed in cancers is probably not just a response or a prelude to hypermethylation elsewhere in the genome. This suggests that the DNA hypomethylation contributes independently to oncogenesis or tumor progression.	Tulane Univ, Sch Med, Tulane Canc Ctr, New Orleans, LA 70112 USA; Tulane Univ, Sch Med, Human Genet Program, New Orleans, LA 70112 USA; Amer Hlth Fdn, Dept Biochem Pharmacol, Valhalla, NY 10595 USA; St Jude Childrens Res Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Surg, Los Angeles, CA 90033 USA; Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ Texas, SW Med Ctr, Dept Pediat, Dallas, TX 75235 USA; Baylor Coll Med, Texas Childrens Canc Ctr, Houston, TX 77030 USA; Hop St Justine, Serv Hematol Oncol, Montreal, PQ H3T 1C5, Canada; Arkansas Childrens Hosp, Dept Pathol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Little Rock, AR 72205 USA; Univ Bristol, Sch Med Sci, Dept Pathol, Canc & Leukaemia Childhood Unit, Bristol BS8 1TD, Avon, England	Tulane University; Tulane University; American Health Foundation; St Jude Children's Research Hospital; University of Southern California; University of Southern California; University of Southern California; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Baylor College of Medicine; Texas Children's Cancer Center; Universite de Montreal; Arkansas Children's Hospital; University of Arkansas System; University of Arkansas Medical Sciences; University of Bristol	Ehrlich, M (corresponding author), Tulane Univ, Sch Med, Human Genet Program SL31, 1430 Tulane Ave, New Orleans, LA 70112 USA.	ehrlich@tulane.edu	Dome, Jeffrey/AAH-7825-2019; Parham, David M./AAN-1059-2020; Laird, Peter W/G-8683-2012; Tomlinson, Gail/AAR-9776-2020	Parham, David M./0000-0002-6912-9748; Laird, Peter W/0000-0001-9117-3641; Widschwendter, Martin/0000-0002-7778-8380; Liang, Gangning/0000-0001-8664-922X	NATIONAL CANCER INSTITUTE [P01CA046589, P01CA070972, R01CA075090] Funding Source: NIH RePORTER; NCI NIH HHS [P01 CA 46589, CA 75090, P01 CA 70972, CA1506, R01 CA075090] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahuja N, 1998, CANCER RES, V58, P5489; Arcellana-Panlilio MY, 2000, GENE CHROMOSOME CANC, V29, P63, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; BUSSON P, 1992, INT J CANCER, V50, P863, DOI 10.1002/ijc.2910500605; CHAPMAN V, 1984, NATURE, V307, P284, DOI 10.1038/307284a0; Cheng P, 1997, BRIT J CANCER, V75, P396, DOI 10.1038/bjc.1997.64; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 1999, CANCER RES, V59, P2302; Eads CA, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.8.e32; EHRLICH M, 1982, NUCLEIC ACIDS RES, V10, P2709, DOI 10.1093/nar/10.8.2709; Ehrlich M, 2002, ONCOGENE, V21, P5400, DOI 10.1038/sj.onc.1205651; EHRLICH M, 2002, IN PRESS CANC GENET; FEINBERG AP, 1983, NATURE, V301, P89, DOI 10.1038/301089a0; GAMASOSA MA, 1983, NUCLEIC ACIDS RES, V11, P6883, DOI 10.1093/nar/11.19.6883; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; Gaughan DJ, 2000, GENE, V257, P279, DOI 10.1016/S0378-1119(00)00392-9; Grenet J, 1998, GENOMICS, V49, P385, DOI 10.1006/geno.1998.5300; Harada K, 2002, ONCOGENE, V21, P4345, DOI 10.1038/sj.onc.1205446; Hollander M., 1973, NONPARAMETRIC STAT, P68; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Malik K, 2000, CANCER RES, V60, P2356; Mares J, 2001, CANCER LETT, V166, P165, DOI 10.1016/S0304-3835(01)00402-5; Narayan A, 1998, INT J CANCER, V77, P833, DOI 10.1002/(SICI)1097-0215(19980911)77:6<833::AID-IJC6>3.0.CO;2-V; Oswald J, 2000, CURR BIOL, V10, P475, DOI 10.1016/S0960-9822(00)00448-6; Qu GZ, 1999, CANCER GENET CYTOGEN, V109, P34, DOI 10.1016/S0165-4608(98)00143-5; Qu GZ, 1999, MUTAT RES-FUND MOL M, V423, P91, DOI 10.1016/S0027-5107(98)00229-2; RAZIN A, 1994, PROG NUCLEIC ACID RE, V48, P53, DOI 10.1016/S0079-6603(08)60853-3; RIBIERAS S, 1994, J CELL BIOCHEM, V56, P86, DOI 10.1002/jcb.240560113; Santos F, 2002, DEV BIOL, V241, P172, DOI 10.1006/dbio.2001.0501; Shridhar V, 2001, CANCER RES, V61, P4258; Strichman-Almashanu LZ, 2002, GENOME RES, V12, P543, DOI 10.1101/gr.224102; Toyota M, 2000, CANCER RES, V60, P4044; Tuckwell KD, 2000, AUSTRALAS I MIN MET, V2000, P121; Ushijima T, 1997, P NATL ACAD SCI USA, V94, P2284, DOI 10.1073/pnas.94.6.2284; Wang ECY, 2001, IMMUNOGENETICS, V53, P59, DOI 10.1007/s002510000290; Wong N, 2001, AM J PATHOL, V159, P465, DOI 10.1016/S0002-9440(10)61718-X; YOUNG R, 2001, J GERONTOL A-BIOL, V56, pR268; ZHANG XY, 1987, NUCLEIC ACIDS RES, V15, P9429, DOI 10.1093/nar/15.22.9429	39	149	165	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6694	6702		10.1038/sj.onc.1205890	http://dx.doi.org/10.1038/sj.onc.1205890			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242669				2022-12-25	WOS:000178202300017
J	Xia, SH; Hu, LP; Hu, H; Ying, WT; Xu, X; Cai, Y; Han, YL; Chen, BS; Wei, F; Qian, XH; Cai, YY; Shen, Y; Wu, M; Wang, MR				Xia, SH; Hu, LP; Hu, H; Ying, WT; Xu, X; Cai, Y; Han, YL; Chen, BS; Wei, F; Qian, XH; Cai, YY; Shen, Y; Wu, M; Wang, MR			Three isoforms of annexin I are preferentially expressed in normal esophageal epithelia but down-regulated in esophageal squamous cell carcinomas	ONCOGENE			English	Article						annexin 1; esophageal squamous cell carcinoma; down-regulated protein	LIPOCORTIN-I; PROTEIN; DIFFERENTIATION; INDUCTION; CANCER	The development and progression of human cancer are believed to be due to the alterations of multiple genes or/and their protein products. For identifying the proteins associated with esophageal cancer, we analysed the protein profiles of 24 pairs of esophageal squamous cell carcinomas/matched adjacent normal epithelia. Microdissection of routinely unstained frozen sections was performed to purify cancerous and epithelial cells. The protein expression profiles were obtained by two-dimensional electrophoresis. Selected proteins dysregulated in tumors were identified by MALDI-TOF-MS. Three isoforms of annexin I were detected in normal esophageal mucosa and down-regulated in esophageal squamous cell carcinomas. RT-PCR analysis showed annexin I mRNA levels were significantly reduced in 17 out of 24 carcinomas. Immunohistochemistry demonstrated that annexin I appeared strong positive in all normal epithelia layers except basal cells. In cancer tissues, decreased expression of annexin I was observed in 12 out of 16 well differentiated tumors, 16 out of 17 moderately differentiated tumors, and 3 out of 3 poorly differentiated tumors as compared with the corresponding normal esophageal epithelia. There was a significant correlation between annexin I expression and the status of tumor differentiation. Well differentiated tumors presented stronger immunohistochemical reaction than moderately and poorly differentiated tumors. These data suggested that there existed three different isoforms of annexin I in normal esophageal epithelia, which may be the results of post-translational modification. Down-expression of three annexin I isoforms was a frequent event in esophageal carcinogenesis.	Chinese Acad Med Sci, PUMC, Canc Inst Hosp, Natl Lab Mol Oncol, Beijing 100021, Peoples R China; Chinese Acad Med Sci, Inst Basic Med, Natl Lab Med Mol Biol, Beijing 100007, Peoples R China; Peking Union Med Coll, Beijing 100007, Peoples R China; Natl Ctr Biomed Assay, Beijing 100085, Peoples R China	Chinese Academy of Medical Sciences - Peking Union Medical College; Cancer Institute & Hospital - CAMS; Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Chinese Academy of Medical Sciences - Peking Union Medical College; Peking Union Medical College	Wang, MR (corresponding author), Chinese Acad Med Sci, PUMC, Canc Inst Hosp, Natl Lab Mol Oncol, Beijing 100021, Peoples R China.	wangmr@pubem.cicams.ac.cn	Hu, Hai/G-3864-2012					Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915; Beranova-Giorgianni S, 2000, RAPID COMMUN MASS SP, V14, P161, DOI 10.1002/(SICI)1097-0231(20000215)14:3<161::AID-RCM859>3.0.CO;2-7; Canaider S, 2000, LIFE SCI, V66, pPL265, DOI 10.1016/S0024-3205(00)00500-2; Chang MC, 2001, J FORMOS MED ASSOC, V100, P352; CROMPTON MR, 1988, CELL, V55, P1, DOI 10.1016/0092-8674(88)90002-5; de Coupade C, 2000, HEPATOLOGY, V31, P371, DOI 10.1002/hep.510310217; Emmert-Buck MR, 2000, MOL CARCINOGEN, V27, P158, DOI 10.1002/(SICI)1098-2744(200003)27:3<158::AID-MC2>3.0.CO;2-2; Koseki H, 1997, SURG TODAY, V27, P30, DOI 10.1007/BF01366936; Lam AKY, 2000, CRIT REV ONCOL HEMAT, V33, P71, DOI 10.1016/S1040-8428(99)00054-2; Ornstein DK, 2000, ELECTROPHORESIS, V21, P2235, DOI 10.1002/1522-2683(20000601)21:11<2235::AID-ELPS2235>3.3.CO;2-1; Ou K, 2001, ELECTROPHORESIS, V22, P2804, DOI 10.1002/1522-2683(200108)22:13<2804::AID-ELPS2804>3.0.CO;2-G; Paweletz CP, 2000, CANCER RES, V60, P6293; PISANI P, 1993, INT J CANCER, V55, P891, DOI 10.1002/ijc.2910550604; Rothhut B, 1997, CELL MOL LIFE SCI, V53, P522, DOI 10.1007/s000180050066; ROYCHOUDHURY S, 1988, P NATL ACAD SCI USA, V85, P2014, DOI 10.1073/pnas.85.6.2014; SCHLAEPFER DD, 1990, J CELL BIOL, V111, P229, DOI 10.1083/jcb.111.1.229; Solito E, 1998, CELL GROWTH DIFFER, V9, P327; TAIT JF, 1988, BIOCHEMISTRY-US, V27, P6268, DOI 10.1021/bi00417a011; VIOLETTE SM, 1990, J CELL PHYSIOL, V142, P70, DOI 10.1002/jcp.1041420110; VISHWANATH BS, 1992, ENDOCRINOLOGY, V130, P585, DOI 10.1210/en.130.2.585; Wu YL, 2000, BRIT J HAEMATOL, V111, P807, DOI 10.1046/j.1365-2141.2000.02397.x	21	83	90	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6641	6648		10.1038/sj.onc.1205818	http://dx.doi.org/10.1038/sj.onc.1205818			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242662				2022-12-25	WOS:000178202300010
J	Mori, H; Shimizu, Y; Ito, K				Mori, H; Shimizu, Y; Ito, K			Superactive SecY variants that fulfill the essential translocation function with a reduced cellular quantity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN-TRANSLOCATION; PREPROTEIN TRANSLOCATION; CYTOPLASMIC MEMBRANE; SYNTHETIC LETHALITY; DOMAINS; EXPORT; PRLA; INSERTION; MUTATIONS	The fifth and the sixth cytoplasmic regions (C5 and C6) of SecY are important for the SecA-driven preprotein translocation reaction. A cold-sensitive mutation, secY205 (Tyr-429 --> Asp), in C6 impairs the ATP- and precursor-dependent SecA insertion into the membrane. We now identified second site mutations that suppressed the defect. Cis-placement of these mutations proved to suppress mutations at another essential residue (Arg-357) of SecY as well. Thus, they tolerate the otherwise defective SecY alterations in the same molecule. Two alterations (Ile-195 to Ser in TM5 region and Ile-408 to Leu in TM10 region) were found to make the translocation channel more active, because it enabled cells to survive with reduced content of the SecYE complex. These mutations only very weakly suppressed a signal sequence defect of the lambda receptor protein. The mutant SecYEG translocase exhibited higher than normal activity in vitro, being accompanied by striking independence of the proton motive force as well as by stabilization of a bound and active SecA species against urea treatment. These results have been interpreted in terms of balance shifts between channel closing and channel opening alterations in the SecYEG translocase.	Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Ito, K (corresponding author), Kyoto Univ, Inst Virus Res, Sakyo Ku, Kyoto 6068507, Japan.			Mori, Hiroyuki/0000-0002-0429-1269				AKIMARU J, 1991, P NATL ACAD SCI USA, V88, P6545, DOI 10.1073/pnas.88.15.6545; AKIYAMA Y, 1987, EMBO J, V6, P3465, DOI 10.1002/j.1460-2075.1987.tb02670.x; AKIYAMA Y, 1985, EMBO J, V4, P3351, DOI 10.1002/j.1460-2075.1985.tb04088.x; BABA T, 1990, J BACTERIOL, V172, P7005, DOI 10.1128/jb.172.12.7005-7010.1990; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; Duong F, 1999, EMBO J, V18, P3263, DOI 10.1093/emboj/18.12.3263; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Eichler J, 1998, J BIOL CHEM, V273, P21675, DOI 10.1074/jbc.273.34.21675; Eichler J, 1997, P NATL ACAD SCI USA, V94, P5574, DOI 10.1073/pnas.94.11.5574; FLOWER AM, 1995, EMBO J, V14, P884, DOI 10.1002/j.1460-2075.1995.tb07070.x; KIHARA A, 1995, P NATL ACAD SCI USA, V92, P4532, DOI 10.1073/pnas.92.10.4532; LILL R, 1989, EMBO J, V8, P961, DOI 10.1002/j.1460-2075.1989.tb03458.x; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Manting EH, 2000, MOL MICROBIOL, V37, P226, DOI 10.1046/j.1365-2958.2000.01980.x; Matsumoto G, 1997, EMBO J, V16, P6384, DOI 10.1093/emboj/16.21.6384; Matsumoto G, 1998, P NATL ACAD SCI USA, V95, P13567, DOI 10.1073/pnas.95.23.13567; Matsuo E, 1998, J BIOL CHEM, V273, P18835, DOI 10.1074/jbc.273.30.18835; MAYER TH, 1996, J MOL BIOL, V285, P1789; Miller J. H., 1972, EXPT MOL GENETICS, P431; Mori H, 1998, J BIOCHEM, V124, P122, DOI 10.1093/oxfordjournals.jbchem.a022070; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; Mori H, 2001, P NATL ACAD SCI USA, V98, P5128, DOI 10.1073/pnas.081617398; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; OSBORNE RS, 1993, EMBO J, V12, P3391, DOI 10.1002/j.1460-2075.1993.tb06013.x; Price A, 1996, J BIOL CHEM, V271, P31580, DOI 10.1074/jbc.271.49.31580; RIGGS PD, 1988, GENETICS, V118, P571; SAKO T, 1988, J BACTERIOL, V170, P5389, DOI 10.1128/jb.170.11.5389-5391.1988; SCHAFER A, 1994, GENE, V145, P69, DOI 10.1016/0378-1119(94)90324-7; SCHATZ PJ, 1989, GENE DEV, V3, P1035, DOI 10.1101/gad.3.7.1035; SHIMOIKE T, 1995, J BIOL CHEM, V270, P5519, DOI 10.1074/jbc.270.10.5519; SILHAVY TJ, 1984, EXPT GENE FUSIONS, pR11; Suzuki H, 1998, MOL MICROBIOL, V29, P331, DOI 10.1046/j.1365-2958.1998.00937.x; TAURA T, 1993, J BACTERIOL, V175, P7771, DOI 10.1128/JB.175.24.7771-7775.1993; TAURA T, 1994, MOL GEN GENET, V243, P261, DOI 10.1007/BF00301061; TAURA T, 1997, BIOCHIMIE, V79, P512; Uchida K, 1995, J BIOL CHEM, V270, P30862, DOI 10.1074/jbc.270.52.30862; UEGUCHI C, 1989, MOL GEN GENET, V217, P1, DOI 10.1007/BF00330934; van der Wolk JPW, 1998, EMBO J, V17, P3631, DOI 10.1093/emboj/17.13.3631; Veenendaal AKJ, 2001, J BIOL CHEM, V276, P32559, DOI 10.1074/jbc.M103912200; Yoshihisa T, 1996, J BIOL CHEM, V271, P9429, DOI 10.1074/jbc.271.16.9429	41	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48550	48557		10.1074/jbc.M204436200	http://dx.doi.org/10.1074/jbc.M204436200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351621	hybrid			2022-12-25	WOS:000179789600076
J	Rao, MA; Cheng, H; Quayle, AN; Nishitani, H; Nelson, CC; Rennie, PS				Rao, MA; Cheng, H; Quayle, AN; Nishitani, H; Nelson, CC; Rennie, PS			RanBPM, a nuclear protein that interacts with and regulates transcriptional activity of androgen receptor and glucocorticoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTOR; HUMAN ESTROGEN-RECEPTOR; PROBASIN GENE; COACTIVATOR; SPECIFICITY; BINDING; LIGAND; TRANSACTIVATION; INDUCTION; ELEMENTS	The androgen receptor (AR) is a ligand-dependent transcription factor that has an essential role in the normal growth, development, and maintenance of the prostate gland. The AR is part of a large family of steroid receptors that also includes the glucocorticoid, progesterone, and mineralocorticoid receptors. Steroid receptor family members share significant homology at their DNA and ligand-binding domains. However, these receptors exhibit a high degree of sequence variability at their NH2-terminal domain, which suggests the possibility of receptor-specific interactions with co-regulator proteins. Transcriptional co-regulators that interact with the AR may have a role in defining AR activity and may be involved in directing AR-specific responses. Here we have identified Ran-binding protein in the microtubule-organizing center (RanBPM) to be a novel AR-interacting protein by yeast two-hybrid assay and have confirmed this interaction by glutathione S-transferase- and His-tagged pull-down assays. In addition, transient overexpression of RanBPM in prostate cancer cell lines resulted in enhanced AR activity in a ligand-dependent fashion. Glucocorticoid receptor activity was also enhanced when RanBPM was overexpressed, whereas estrogen receptor activity remained unchanged. These data demonstrate that RanBPM interacts with steroid receptors to selectively modify their activity.	Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada; Vancouver Gen Hosp, Prostate Ctr, Vancouver, BC V6H 3Z6, Canada; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Higashi Ku, Fukuoka 8128582, Japan	University of British Columbia; University of British Columbia; Kyushu University	Rennie, PS (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada.			Nishitani, Hideo/0000-0001-5907-9380				Alen P, 1999, MOL ENDOCRINOL, V13, P117, DOI 10.1210/me.13.1.117; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; Chusacultanachai S, 1999, J BIOL CHEM, V274, P23591, DOI 10.1074/jbc.274.33.23591; Dasso M, 2001, CELL, V104, P321, DOI 10.1016/S0092-8674(01)00218-5; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; FABER PW, 1989, MOL CELL ENDOCRINOL, V61, P257, DOI 10.1016/0303-7207(89)90137-8; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; GREENE GL, 1986, J STEROID BIOCHEM, V24, P1, DOI 10.1016/0022-4731(86)90024-5; Hayes SA, 2001, CANCER RES, V61, P2112; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Huang WB, 1999, J BIOL CHEM, V274, P25756, DOI 10.1074/jbc.274.36.25756; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KASPER S, 1994, J BIOL CHEM, V269, P31763; Knoke I, 1999, HUM GENET, V104, P257, DOI 10.1007/s004390050945; KUIL CW, 1995, J BIOL CHEM, V270, P27569, DOI 10.1074/jbc.270.46.27569; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; MIESFELD R, 1986, CELL, V46, P389, DOI 10.1016/0092-8674(86)90659-8; Monje P, 2002, J CELL BIOCHEM, V86, P136, DOI 10.1002/jcb.10193; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nelson CC, 1999, MOL ENDOCRINOL, V13, P2090, DOI 10.1210/me.13.12.2090; Nishitani H, 2001, GENE, V272, P25, DOI 10.1016/S0378-1119(01)00553-4; Olefsky JM, 2001, J BIOL CHEM, V276, P36863, DOI 10.1074/jbc.R100047200; ONATE SA, 1995, SCIENCE, V270, P1354; Petre CE, 2002, J BIOL CHEM, V277, P2207, DOI 10.1074/jbc.M106399200; Ponting C, 1997, TRENDS BIOCHEM SCI, V22, P193, DOI 10.1016/S0968-0004(97)01049-9; Reid KJ, 2001, J BIOL CHEM, V276, P2943, DOI 10.1074/jbc.M009170200; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Sato N, 1997, J BIOL CHEM, V272, P17485, DOI 10.1074/jbc.272.28.17485; SMITH CL, 1993, P NATL ACAD SCI USA, V90, P6120, DOI 10.1073/pnas.90.13.6120; Snoek R, 1998, PROSTATE, V36, P256; Snoek R, 1996, J STEROID BIOCHEM, V59, P243, DOI 10.1016/S0960-0760(96)00116-1; Tomic S, 2000, J MED CHEM, V43, P1780, DOI 10.1021/jm9911175; Truica CI, 2000, CANCER RES, V60, P4709; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Wang DK, 2002, J BIOL CHEM, V277, P36216, DOI 10.1074/jbc.M205111200; Weis K, 1998, TRENDS BIOCHEM SCI, V23, P185, DOI 10.1016/S0968-0004(98)01204-3; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517	40	81	87	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48020	48027		10.1074/jbc.M209741200	http://dx.doi.org/10.1074/jbc.M209741200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12361945	hybrid			2022-12-25	WOS:000179789600008
J	van Haperen, R; van Tol, A; van Gent, T; Scheek, L; Visser, P; van der Kamp, A; Grosveld, F; de Crom, R				van Haperen, R; van Tol, A; van Gent, T; Scheek, L; Visser, P; van der Kamp, A; Grosveld, F; de Crom, R			Increased risk of atherosclerosis by elevated plasma levels of phospholipid transfer protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; REVERSE CHOLESTEROL TRANSPORT; ADENOVIRUS-MEDIATED OVEREXPRESSION; LIPID TRANSFER PROTEINS; TRANSGENIC MICE; HDL METABOLISM; ESTER TRANSFER; APOA-I; ATHEROGENESIS; EXPRESSION	Plasma phospholipid transfer protein (PLTP) is thought to be involved in the remodeling of high density lipoproteins (HDL), which are atheroprotective. It is also involved in the metabolism of very low density lipoproteins (VLDL). Hence, PLTP is thought to be an important factor in lipoprotein metabolism and the development of atherosclerosis. We have overexpressed PLTP in mice heterozygous for the low density lipoprotein (LDL) receptor, a model for atherosclerosis. We show that increased PLTP activity results in a dose-dependent decrease in HDL, and a moderate stimulation of VLDL secretion (less than or equal to1.5-fold). The mice were given a high fat, high cholesterol diet, which resulted in hypercholesterolemia in all animals. HDL concentrations were dramatically reduced in PLTP-overexpressing animals when compared with LDL receptor controls, whereas VLDL + LDL cholesterol levels were identical. Susceptibility to atherosclerosis was increased in a PLTP dose-responsive manner. We conclude that PLTP increases susceptibility to atherosclerosis by lowering HDL concentrations, and therefore we suggest that an increase in PLTP is a novel, long term risk factor for atherosclerosis in humans.	Erasmus MC, Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Biochem, NL-3000 DR Rotterdam, Netherlands; Erasmus MC, Dept Vasc Surg, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	van Tol, A (corresponding author), Erasmus MC, Dept Cell Biol & Genet, Dr Molewaterplein 50,POB 1738, NL-3000 DR Rotterdam, Netherlands.	vantol@bc1.fgg.eur.nl						Albers JJ, 1996, INT J CLIN LAB RES, V26, P262, DOI 10.1007/BF02602960; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Bruce C, 1998, ANNU REV NUTR, V18, P297, DOI 10.1146/annurev.nutr.18.1.297; CAMPER SA, 1989, PROG NUCLEIC ACID RE, V36, P131; Colhoun HM, 2001, DIABETES, V50, P652, DOI 10.2337/diabetes.50.3.652; DAY JR, 1994, J BIOL CHEM, V269, P9388; Durrington PN, 2001, ARTERIOSCL THROM VAS, V21, P473, DOI 10.1161/01.ATV.21.4.473; Duverger N, 1996, SCIENCE, V273, P966, DOI 10.1126/science.273.5277.966; Ehnholm S, 1998, J LIPID RES, V39, P1248; Fielding CJ, 2001, BBA-MOL CELL BIOL L, V1533, P175, DOI 10.1016/S1388-1981(01)00162-7; Foger B, 1997, J BIOL CHEM, V272, P27393, DOI 10.1074/jbc.272.43.27393; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; Groen AK, 2001, J CLIN INVEST, V108, P843, DOI 10.1172/JCI12473; Herrera VLM, 1999, NAT MED, V5, P1383, DOI 10.1038/70956; Hoeg JM, 1996, P NATL ACAD SCI USA, V93, P11448, DOI 10.1073/pnas.93.21.11448; Hughes SD, 1997, ARTERIOSCL THROM VAS, V17, P1725, DOI 10.1161/01.ATV.17.9.1725; Huuskonen J, 2001, ATHEROSCLEROSIS, V155, P269, DOI 10.1016/S0021-9150(01)00447-6; JIANG XC, 1995, J BIOL CHEM, V270, P17133, DOI 10.1074/jbc.270.29.17133; Jiang XC, 1999, J CLIN INVEST, V103, P907, DOI 10.1172/JCI5578; Jiang XC, 2001, NAT MED, V7, P847, DOI 10.1038/89977; Jiang XC, 1996, J CLIN INVEST, V98, P2373, DOI 10.1172/JCI119050; Joyce CW, 2002, P NATL ACAD SCI USA, V99, P407, DOI 10.1073/pnas.012587699; LI H, 1993, ARTERIOSCLER THROMB, V13, P1814, DOI 10.1161/01.ATV.13.12.1814; Libby P, 2001, AM J CARDIOL, V88, p3N; Lie J, 2001, BIOCHEM J, V360, P379, DOI 10.1042/0264-6021:3600379; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; Navab M, 2001, ARTERIOSCL THROM VAS, V21, P481, DOI 10.1161/01.ATV.21.4.481; Oram JF, 2001, J LIPID RES, V42, P1173; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; Qin SC, 2000, J LIPID RES, V41, P269; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; Riemens S, 1998, ATHEROSCLEROSIS, V140, P71, DOI 10.1016/S0021-9150(98)00111-7; Shah PK, 2001, CIRCULATION, V104, P2376, DOI 10.1161/hc4401.098467; Sviridov D, 2002, ATHEROSCLEROSIS, V161, P245, DOI 10.1016/S0021-9150(01)00677-3; Sviridov D, 2002, ARTERIOSCL THROM VAS, V22, P1482, DOI 10.1161/01.ATV.0000029120.44088.FE; Tall AR, 2000, J CLIN INVEST, V106, P1205, DOI 10.1172/JCI11538; Tall AR, 2000, ARTERIOSCL THROM VAS, V20, P1185, DOI 10.1161/01.ATV.20.5.1185; Tall AR, 2001, J CLIN INVEST, V108, P1273; Van Eck M, 2002, P NATL ACAD SCI USA, V99, P6298, DOI 10.1073/pnas.092327399; van Haperen R, 2000, ARTERIOSCL THROM VAS, V20, P1082, DOI 10.1161/01.ATV.20.4.1082; van Tol A, 2002, CURR OPIN LIPIDOL, V13, P135, DOI 10.1097/00041433-200204000-00004; Voyiaziakis E, 1998, J LIPID RES, V39, P313	43	114	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48938	48943		10.1074/jbc.M209128200	http://dx.doi.org/10.1074/jbc.M209128200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12372822	hybrid, Green Published			2022-12-25	WOS:000179789600125
J	Walker, SA; Kupzig, S; Lockyer, PJ; Bilu, S; Zharhary, D; Cullen, PJ				Walker, SA; Kupzig, S; Lockyer, PJ; Bilu, S; Zharhary, D; Cullen, PJ			Analyzing the role of the putative inositol 1,3,4,5-tetrakisphosphate receptor GAP1(IP4BP) in intracellular Ca2+ homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; INS(1,3,4,5)P-4 RECEPTOR; GAP1 FAMILY; RAS; CELLS; TRISPHOSPHATE; BINDING; IDENTIFICATION; MOBILIZATION; PHOSPHATES	Inositol 1,3,4,5-tetrakisphosphate (IP4) has been linked to a potential role in the regulation of intracellular free Ca2+ concentration ([Ca2+](i)) following cellular stimulation with agonists that activate phosphoinositide-specific phospholipase C. However, despite many studies, the function of IP4 remains unclear and indeed there is still some debate over whether it has a function at all. Here we have used various molecular approaches to address whether manipulation of the potential IP4 receptor, GAP1(IP4BP), affects [Ca2+](i) following cellular stimulation. Using single cell imaging, we show that the overexpression of a constitutively active and a potential dominant negative form of GAP1(IP4BP) appear to have no effect on Ca2+ mobilization or Ca2+ entry following stimulation of HeLa cells with histamine. In addition, through the use of small interfering RNA duplexes, we have examined the effect of suppressing endogenous GAP1(IP4BP) production on [Ca2+](i). In HeLa cells in which the endogenous level of GAP1(IP4BP) has been suppressed by similar to95%, we failed to observe any effect on Ca2+ mobilization or Ca2+ entry following histamine stimulation. Thus, using various approaches to manipulate the function of endogenous GAP1(IP4BP) in intact HeLa cells, we have been unable to observe any detectable effect of GAP1(IP4BP) on [Ca2+](i).	Univ Bristol, Sch Med Sci, Dept Biochem, Integrated Signalling Labs, Bristol BS8 1TD, Avon, England; Sigma Aldrich Israel Ltd, Rehovot, Israel	University of Bristol; Merck KGaA; MilliporeSigma	Cullen, PJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem, Integrated Signalling Labs, Bristol BS8 1TD, Avon, England.	Pete.Cullen@bris.ac.uk		Walker, Simon/0000-0001-9185-4922; Cullen, Peter/0000-0002-9070-8349				Allen M, 1998, GENE, V218, P17, DOI 10.1016/S0378-1119(98)00394-1; BABA H, 1995, J NEUROSCI RES, V41, P846, DOI 10.1002/jnr.490410615; BATTY IR, 1985, BIOCHEM J, V232, P211, DOI 10.1042/bj2320211; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; Bootman MD, 1996, BIOCHEM J, V314, P347, DOI 10.1042/bj3140347; Bottomley JR, 1998, BIOCHEM BIOPH RES CO, V250, P143, DOI 10.1006/bbrc.1998.9179; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHANGYA L, 1989, FEBS LETT, V251, P43, DOI 10.1016/0014-5793(89)81425-5; Corbett KD, 2001, TRENDS BIOCHEM SCI, V26, P710, DOI 10.1016/S0968-0004(01)01974-0; Cozier GE, 2000, J BIOL CHEM, V275, P28261; CULLEN PJ, 1990, BIOCHEM J, V271, P549, DOI 10.1042/bj2710549; CULLEN PJ, 1995, BIOCHEM J, V305, P139, DOI 10.1042/bj3050139; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; Cullen PJ, 1998, BBA-MOL CELL BIOL L, V1436, P35, DOI 10.1016/S0005-2760(98)00149-0; Cullen PJ, 1997, BIOCHEM SOC T, V25, P991, DOI 10.1042/bst0250991; CULLEN PJ, 1995, FEBS LETT, V358, P240, DOI 10.1016/0014-5793(94)01435-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Harborth J, 2001, J CELL SCI, V114, P4557; Irvine R, 2001, CURR BIOL, V11, pR172, DOI 10.1016/S0960-9822(01)00086-0; IRVINE RF, 1992, FASEB J, V6, P3085, DOI 10.1096/fasebj.6.12.1325932; Irvine RF, 1999, CHEM PHYS LIPIDS, V98, P49, DOI 10.1016/S0009-3084(99)00017-1; Irvine RF, 2001, NAT REV MOL CELL BIO, V2, P327, DOI 10.1038/35073015; Li SW, 1996, GENOMICS, V35, P625, DOI 10.1006/geno.1996.0412; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; Lockyer PJ, 2001, CURR BIOL, V11, P981, DOI 10.1016/S0960-9822(01)00261-5; Loomis-Husselbee JW, 1998, BIOCHEM J, V331, P947, DOI 10.1042/bj3310947; LoomisHusselbee JW, 1996, BIOCHEM J, V314, P811, DOI 10.1042/bj3140811; LU CY, 1989, J MEMBRANE BIOL, V109, P85, DOI 10.1007/BF01870793; Lu XH, 1999, J GEN PHYSIOL, V113, P81, DOI 10.1085/jgp.113.1.81; LUCKHOFF A, 1992, NATURE, V355, P356, DOI 10.1038/355356a0; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; Minagawa T, 2001, BIOCHEM BIOPH RES CO, V288, P87, DOI 10.1006/bbrc.2001.5740; MORRIS AP, 1987, NATURE, V330, P653, DOI 10.1038/330653a0; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; SMITH PM, 1992, BIOCHEM J, V283, P27, DOI 10.1042/bj2830027; Smith PM, 2000, BIOCHEM J, V347, P77, DOI 10.1042/0264-6021:3470077; Szinyei C, 1999, J PHYSIOL-LONDON, V516, P855, DOI 10.1111/j.1469-7793.1999.0855u.x; Tsubokawa H, 1996, J PHYSIOL-LONDON, V497, P67, DOI 10.1113/jphysiol.1996.sp021750; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; Yamamoto T, 1995, J BIOL CHEM, V270, P30557, DOI 10.1074/jbc.270.51.30557	44	12	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48779	48785		10.1074/jbc.M204839200	http://dx.doi.org/10.1074/jbc.M204839200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356770	hybrid			2022-12-25	WOS:000179789600105
J	Colombo, G; Curnis, F; De Mori, GMS; Gasparri, A; Longoni, C; Sacchi, A; Longhi, R; Corti, A				Colombo, G; Curnis, F; De Mori, GMS; Gasparri, A; Longoni, C; Sacchi, A; Longhi, R; Corti, A			Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MOLECULAR-DYNAMICS; VASCULATURE; RECOGNITION; SIMULATION; DELIVERY; BINDING; MODELS; RGD	Cyclic and linear peptides containing the Asn-Gly-Arg (NGR) motif have proven useful for delivering various anti-tumor compounds and viral particles to tumor vessels. We have investigated the role of cyclic constraints on the structure and tumor-homing properties of NGR peptides using tumor necrosis factor-alpha (TNF) derivatives containing disulfide-bridged (CNGRC-TNF) and linear (GNGRG-TNF) NGR domains. Experiments carried out in animal models showed that both GNGRG and CNGRC can target TNF to tumors. However, the antitumor activity of CNGRC-TNF was > 10-fold higher than that of GNGRG-TNF. Molecular dynamic simulation of cyclic CNGRC showed the presence of a bend geometry involving residues Gly(3)-Arg(4). Molecular dynamic simulation of the same peptide without disulfide constraints showed that the most populated and thermodynamically favored configuration is characterized by the presence of a beta-turn involving residues Gly(3)-Arg(4) and hydrogen bonding interactions between the backbone atoms of Asn(2) and Cys(5). These results suggest that the NGR motif has a strong propensity to form beta-turn in linear peptides and may explain the finding that GNGRG peptide can target TNF to tumors, albeit to a lower extent than CNGRC. The disulfide bridge constraint is critical for stabilizing the bent conformation and for increasing the tumor targeting efficiency.	Ist Sci San Raffaele, Dept Biol & Technol Res, I-20132 Milan, Italy; ICRM, CNR, I-20131 Milan, Italy	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Istituto di Chimica del Riconoscimento Molecolare (ICRM-CNR)	Corti, A (corresponding author), Ist Sci San Raffaele, Dept Biol & Technol Res, Via Olgettina 58, I-20132 Milan, Italy.	corti.angelo@hsr.it	Colombo, Giorgio/A-2730-2012; Corti, Angelo/F-7046-2012; Curnis, Flavio/AAK-3542-2020; Gasparri, Anna Maria/AAN-5071-2020	Colombo, Giorgio/0000-0002-1318-668X; Corti, Angelo/0000-0002-0893-6191; Curnis, Flavio/0000-0002-7231-9569; Gasparri, Anna Maria/0000-0002-1757-8699; Subba, Rajkrishna/0000-0003-0051-0062; SACCHI, ANGELINA/0000-0002-6594-0277				Arap W, 1998, SCIENCE, V279, P377, DOI 10.1126/science.279.5349.377; Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Assa-Munt N, 2001, BIOCHEMISTRY-US, V40, P2373, DOI 10.1021/bi002101f; Bartels C, 1998, J MOL BIOL, V284, P1641, DOI 10.1006/jmbi.1998.2255; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; BERENDSEN HJC, 1987, J PHYS CHEM-US, V91, P6269, DOI 10.1021/j100308a038; BERENDSEN HJC, 1984, J CHEM PHYS, V81, P3684, DOI 10.1063/1.448118; CORTI A, 1994, J IMMUNOL METHODS, V177, P191, DOI 10.1016/0022-1759(94)90156-2; Curnis F, 2000, NAT BIOTECHNOL, V18, P1185, DOI 10.1038/81183; Curnis F, 2002, J CLIN INVEST, V110, P475, DOI 10.1172/JCI200215223; Curnis F, 2002, CANCER RES, V62, P867; Daura X, 1999, ANGEW CHEM INT EDIT, V38, P236, DOI 10.1002/(SICI)1521-3773(19990115)38:1/2<236::AID-ANIE236>3.3.CO;2-D; Ellerby HM, 1999, NAT MED, V5, P1032, DOI 10.1038/12469; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Gasparri A, 1999, CANCER RES, V59, P2917; Grifman M, 2001, MOL THER, V3, P964, DOI 10.1006/mthe.2001.0345; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIEFFER B, 1994, INT J PEPT PROT RES, V44, P70; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; Liu LQ, 2000, J VIROL, V74, P5320, DOI 10.1128/JVI.74.11.5320-5328.2000; MIYAMOTO S, 1992, J COMPUT CHEM, V13, P952, DOI 10.1002/jcc.540130805; Moro M, 1997, CANCER RES, V57, P1922; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Ruoslahti E, 1996, ANNU REV CELL DEV BI, V12, P697, DOI 10.1146/annurev.cellbio.12.1.697; van Gunsteren W, 1996, BIOMOLECULAR SIMULAT	26	159	169	1	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47891	47897		10.1074/jbc.M207500200	http://dx.doi.org/10.1074/jbc.M207500200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12372830	hybrid			2022-12-25	WOS:000179663700136
J	Lee, SJ; Gralla, JD				Lee, SJ; Gralla, JD			Promoter use by sigma(38) (rpoS) RNA polymerase - Amino acid clusters for DNA binding and isomerizatton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; GLOBAL REGULATORS; CRYSTAL-STRUCTURE; RECOGNITION; TRANSCRIPTION; REGION; SELECTIVITY; GENE; IDENTIFICATION	sigma(38) is a non-essential but highly homologous member of the sigma(70) family of transcription factors. In vitro mutagenesis and in vivo screening were used to identify 22 critical amino acids in the promoter interaction domain of Escherichia coli sigma(38). Electrophoretic mobility shift assay studies showed that residues involved in duplex DNA binding largely segregated into distinct regions that coincided with those of sigma(70). However, the majority of these amino acids were in non-conserved positions. Analysis indicates that this region of the two sigmas probably has a common overall organization but differs in how its amino acids are used to form functional open complexes. Placement of the mutations on the known sigma(70) holoenzyme structure shows two clusters; one appears to be used for duplex DNA recognition and the other for the subsequent isomerization events. Permanganate assays for DNA melting support this view.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), Univ Calif Los Angeles, Dept Chem & Biochem, POB 951569, Los Angeles, CA 90095 USA.	gralla@chem.ucla.edu			NIGMS NIH HHS [GM35754] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035754] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Azam TA, 1999, J BACTERIOL, V181, P6361, DOI 10.1128/JB.181.20.6361-6370.1999; BALKE VL, 1987, J BACTERIOL, V169, P4499, DOI 10.1128/jb.169.10.4499-4506.1987; Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Becker G, 1999, P NATL ACAD SCI USA, V96, P6439, DOI 10.1073/pnas.96.11.6439; Becker G, 2001, MOL MICROBIOL, V39, P1153, DOI 10.1046/j.1365-2958.2001.02313.x; Bouvier J, 1998, MOL MICROBIOL, V28, P971, DOI 10.1046/j.1365-2958.1998.00855.x; Colland F, 2000, EMBO J, V19, P3028, DOI 10.1093/emboj/19.12.3028; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; DEHASETH PL, 1995, MOL MICROBIOL, V16, P817, DOI 10.1111/j.1365-2958.1995.tb02309.x; DING QQ, 1995, MOL MICROBIOL, V16, P649, DOI 10.1111/j.1365-2958.1995.tb02427.x; Fenton MS, 2001, P NATL ACAD SCI USA, V98, P9020, DOI 10.1073/pnas.161085798; Fenton MS, 2000, EMBO J, V19, P1130, DOI 10.1093/emboj/19.5.1130; Gaal T, 2001, MOL MICROBIOL, V42, P939, DOI 10.1046/j.1365-2958.2001.02703.x; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Guo YL, 1997, J BACTERIOL, V179, P1239, DOI 10.1128/jb.179.4.1239-1245.1997; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; JUANG YL, 1994, J MOL BIOL, V235, P1470, DOI 10.1006/jmbi.1994.1102; Kusano S, 1996, J BIOL CHEM, V271, P1998, DOI 10.1074/jbc.271.4.1998; Kusano S, 1997, J BACTERIOL, V179, P3649, DOI 10.1128/jb.179.11.3649-3654.1997; Lee SJ, 2001, J BIOL CHEM, V276, P30064, DOI 10.1074/jbc.M102886200; LOMOVSKAYA OL, 1994, J BACTERIOL, V176, P3928, DOI 10.1128/JB.176.13.3928-3935.1994; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Ohnuma M, 2000, J BACTERIOL, V182, P4628, DOI 10.1128/JB.182.16.4628-4631.2000; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; Schellhorn HE, 1998, J BACTERIOL, V180, P6283; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; Tomsic M, 2001, J BIOL CHEM, V276, P31891, DOI 10.1074/jbc.M105027200; Vassylyev DG, 2002, NATURE, V417, P712, DOI 10.1038/nature752; WALDBURGER C, 1994, J MOL BIOL, V235, P1489, DOI 10.1006/jmbi.1994.1103; XU JM, 1995, J BACTERIOL, V177, P3166, DOI 10.1128/jb.177.11.3166-3175.1995; XU JM, 1995, J BACTERIOL, V177, P5222, DOI 10.1128/jb.177.18.5222-5231.1995	34	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47420	47427		10.1074/jbc.M208363200	http://dx.doi.org/10.1074/jbc.M208363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351645	hybrid			2022-12-25	WOS:000179663700077
J	Mohrmann, L; Kal, AJ; Verrijzer, CP				Mohrmann, L; Kal, AJ; Verrijzer, CP			Characterization of the extended Myb-like DNA-binding domain of trithorax group protein zeste	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCOMB-GROUP GENE; C-MYB; TRANSCRIPTION FACTORS; CRYSTAL-STRUCTURE; DROSOPHILA-MELANOGASTER; ULTRABITHORAX PROMOTER; TELOMERIC DNA; COMPLEX; RECOGNITION; TRANSVECTION	Zeste is a Drosophila sequence-specific DNA-binding protein that performs a variety of functions during chromatin-directed gene regulation. Its DNA-binding domain (DBD) was previously identified, but no similarities to established DNA-binding structures are known. Here we present sequence comparisons suggesting that the Zeste-DBD is a novel variant of the tri-helical Myb-DBD. Using band shift assays, we mapped the Zeste-DBD to 76 residues, corresponding to a single Myb repeat of only 50 residues. All residues involved in formation of the hydrophobic core of the Myb domain are conserved in Zeste, suggesting it forms an extended Myb domain. Mutagenesis studies determined (T/C/g)GAGTG(A/G/c) as the consensus Zeste recognition sequence. Reconstituted transcription experiments established that deviations from this optimal consensus compromise transcriptional activation by Zeste. In addition, flanking DNA is critical because Zeste-DBD binding requires a DNA sequence of minimally 16 base pairs, which is much longer than the consensus site. The DNA flanking the consensus is contacted by Zeste through sequence-independent backbone contacts. Interestingly, hydroxyl radical footprinting revealed that the Zeste-DNA backbone contacts all map to one face of the DNA. We compare the DNA-binding properties of Zeste with those of classical tri-helical DBDs harboring a helix-turn-helix motif and suggest a model for Zeste-DNA recognition.	Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Verrijzer, CP (corresponding author), Leiden Univ, Med Ctr, Ctr Biomed Genet, Dept Mol & Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.							Aasland R, 1996, TRENDS BIOCHEM SCI, V21, P87, DOI 10.1016/S0968-0004(96)30009-1; BENSON M, 1988, EMBO J, V7, P3907, DOI 10.1002/j.1460-2075.1988.tb03277.x; BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; BIGGIN MD, 1988, CELL, V53, P713, DOI 10.1016/0092-8674(88)90089-X; BIGGIN MD, 1988, CELL, V53, P699, DOI 10.1016/0092-8674(88)90088-8; Brown JL, 1998, MOL CELL, V1, P1057, DOI 10.1016/S1097-2765(00)80106-9; CHEN JD, 1993, EMBO J, V12, P2075, DOI 10.1002/j.1460-2075.1993.tb05856.x; CHEN JD, 1992, MOL CELL BIOL, V12, P598, DOI 10.1128/MCB.12.2.598; CHEN JD, 1993, EMBO J, V12, P2061, DOI 10.1002/j.1460-2075.1993.tb05855.x; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; EBNETH A, 1994, BIOCHEMISTRY-US, V33, P14586, DOI 10.1021/bi00252a026; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; GABRIELSEN OS, 1991, SCIENCE, V253, P1140, DOI 10.1126/science.1887237; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; Graf T, 1992, CURR OPIN GENET DEV, V2, P249, DOI 10.1016/S0959-437X(05)80281-3; Hanaoka S, 2001, J MOL BIOL, V312, P167, DOI 10.1006/jmbi.2001.4924; HOWE KM, 1990, EMBO J, V9, P161, DOI 10.1002/j.1460-2075.1990.tb08092.x; JUDD BH, 1995, GENETICS, V141, P245; KADONAGA JT, 1990, J BIOL CHEM, V265, P2624; Kal AJ, 2000, GENE DEV, V14, P1058; Kennison JA, 1995, ANNU REV GENET, V29, P289, DOI 10.1146/annurev.ge.29.120195.001445; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; Konig P, 1996, CELL, V85, P125, DOI 10.1016/S0092-8674(00)81088-0; Konig P, 1998, NUCLEIC ACIDS RES, V26, P1731, DOI 10.1093/nar/26.7.1731; LANEY JD, 1992, GENE DEV, V6, P1531, DOI 10.1101/gad.6.8.1531; LEWIS EB, 1954, AM NAT, V88, P225, DOI 10.1086/281833; Lyko F, 1999, BIOESSAYS, V21, P824; Mahmoudi T, 2001, ONCOGENE, V20, P3055, DOI 10.1038/sj.onc.1204330; MANSUKHANI A, 1988, MOL CELL BIOL, V8, P615, DOI 10.1128/MCB.8.2.615; Nishikawa T, 1998, STRUCT FOLD DES, V6, P1057, DOI 10.1016/S0969-2126(98)00106-3; Nishikawa T, 2001, STRUCTURE, V9, P1237, DOI 10.1016/S0969-2126(01)00688-8; Oda M, 1997, PROTEIN ENG, V10, P1407, DOI 10.1093/protein/10.12.1407; OGATA K, 1995, NAT STRUCT BIOL, V2, P309, DOI 10.1038/nsb0495-309; OGATA K, 1994, CELL, V79, P639, DOI 10.1016/0092-8674(94)90549-5; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PARO R, 1995, TRENDS GENET, V11, P295, DOI 10.1016/S0168-9525(00)89081-2; PELEGRI F, 1994, GENETICS, V136, P1341; PHILLIPS MD, 1990, GENETICS, V125, P91; Pinson B, 2001, NUCLEIC ACIDS RES, V29, P527, DOI 10.1093/nar/29.2.527; PIRROTTA V, 1988, GENE DEV, V2, P1839, DOI 10.1101/gad.2.12b.1839; Pirrotta V, 1998, CELL, V93, P333, DOI 10.1016/S0092-8674(00)81162-9; Pirrotta V, 1999, BBA-REV CANCER, V1424, pM1; RASTELLI L, 1993, EMBO J, V12, P1513, DOI 10.1002/j.1460-2075.1993.tb05795.x; Rosen C, 1998, GENETICS, V148, P1865; SAIKUMAR P, 1990, P NATL ACAD SCI USA, V87, P8452, DOI 10.1073/pnas.87.21.8452; SAKURA H, 1989, P NATL ACAD SCI USA, V86, P5758, DOI 10.1073/pnas.86.15.5758; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; SHORE D, 1994, TRENDS GENET, V10, P408, DOI 10.1016/0168-9525(94)90058-2; TANIKAWA J, 1993, P NATL ACAD SCI USA, V90, P9320, DOI 10.1073/pnas.90.20.9320; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; Wolberger C, 1996, CURR OPIN STRUC BIOL, V6, P62, DOI 10.1016/S0959-440X(96)80096-0	51	14	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47385	47392		10.1074/jbc.M202341200	http://dx.doi.org/10.1074/jbc.M202341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354778	hybrid			2022-12-25	WOS:000179663700072
J	Peek, M; Moran, P; Mendoza, N; Wickramasinghe, D; Kirchhofer, D				Peek, M; Moran, P; Mendoza, N; Wickramasinghe, D; Kirchhofer, D			Unusual proteolytic activation of pro-hepatocyte growth factor by plasma kallikrein and coagulation factor XIa	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-WEIGHT KININOGEN; KUNITZ DOMAIN INHIBITORS; SCATTER FACTOR; BLOOD-COAGULATION; FACTOR/SCATTER FACTOR; SERINE-PROTEASE; PHAGE DISPLAY; RAT PLATELETS; FACTOR VIIA; PURIFICATION	Hepatocyte growth factor (HGF), the ligand for the receptor tyrosine kinase c-Met, is composed of an alpha-chain containing four Kringle domains (K1-K4) and a serine protease domain-like beta-chain. Receptor activation by HGF is contingent upon prior proteolytic conversion of the secreted inactive single chain form (proHGF) into the biologically active two chain form by a single cleavage at the Arg(494)-Val(495) bond. By screening a panel of serine proteases we identified two new HGF activators, plasma kallikrein and coagulation factor XIa (FXIa). The concentrations of kallikrein and FXIa to cleave 50% (EC50) of I-125-labeled pro-HGF during a 4-h period were 10 and 17 nM. Unlike other known activators, both FXIa and kallikrein processed pro-HGF by cleavage at two sites. Using N-terminal sequencing they were identified as the normal cleavage site Arg(494)-Val495 and the novel site Arg(424)-His(425) located in the K4 domain of the a-chain. The identity of this unusual second cleavage site was firmly established by use of the double mutant HGF(R424A/R494E), which was completely resistant to cleavage by kallikrein and FXIa. Experiments with another mutant form, HGF(Arg(494)-->Glu), indicated that cleavage at the K4 site was independent of a prior cleavage at the primary, kinetically preferred Arg(494)-Val(495) site. The cleavage at the K4 site had no obvious consequences on HGF function, because it was fully capable of phosphorylating the c-Met receptor of A549 cells. This may be explained by the disulfide bond network in K4, which holds the cleaved a-chain together. In conclusion, the ability of plasma kallikrein and FXIa to activate pro-HGF in vitro raises the possibility that mediators of inflammation and blood coagulation may also regulate processes that involve the HGF/c-Met pathway, such as tissue repair and angiogenesis.	Genentech Inc, Dept Physiol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	Kirchhofer, D (corresponding author), Genentech Inc, Dept Physiol, 1 DNA Way, San Francisco, CA 94080 USA.							Colman RW, 1997, J CLIN INVEST, V100, P1481, DOI 10.1172/JCI119669; Colman RW, 1997, BLOOD, V90, P3819, DOI 10.1182/blood.V90.10.3819; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; Colman RW, 1999, THROMB HAEMOSTASIS, V82, P1568; Date K, 1998, ONCOGENE, V17, P3045, DOI 10.1038/sj.onc.1202231; DENNIS MS, 1995, J BIOL CHEM, V270, P25411, DOI 10.1074/jbc.270.43.25411; DENNIS MS, 1994, J BIOL CHEM, V269, P22129; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; GAILANI D, 1991, SCIENCE, V253, P909, DOI 10.1126/science.1652157; Gailani D, 1997, BLOOD COAGUL FIBRIN, V8, P134, DOI 10.1097/00001721-199703000-00008; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GRANT DS, 1993, P NATL ACAD SCI USA, V90, P1937, DOI 10.1073/pnas.90.5.1937; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; HATHAWAY WE, 1976, AM J MED, V60, P654, DOI 10.1016/0002-9343(76)90500-3; HENZEL WJ, 1987, J CHROMATOGR, V404, P41, DOI 10.1016/S0021-9673(01)86835-7; Henzel WJ, 1999, ANAL BIOCHEM, V267, P148, DOI 10.1006/abio.1998.2981; Hiscox S, 1998, BRIT J CANCER, V78, P150; HOJIMA Y, 1980, THROMB RES, V20, P149, DOI 10.1016/0049-3848(80)90381-3; Kataoka H, 2000, CANCER RES, V60, P6148; Lay AJ, 2000, NATURE, V408, P869, DOI 10.1038/35048596; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; MARS WM, 1993, AM J PATHOL, V143, P949; Matsubara Y, 1998, BIOCHEM BIOPH RES CO, V253, P477, DOI 10.1006/bbrc.1998.9808; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MICHALOPOULOS G, 1984, CANCER RES, V44, P4414; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; Miyazawa K, 1996, J BIOL CHEM, V271, P3615; MIZUNO K, 1994, BIOCHEM BIOPH RES CO, V198, P1161, DOI 10.1006/bbrc.1994.1164; Motta G, 2001, THROMB HAEMOSTASIS, V86, P840; Nagata K, 2001, BIOCHEM BIOPH RES CO, V289, P205, DOI 10.1006/bbrc.2001.5916; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NAKAMURA T, 1986, P NATL ACAD SCI USA, V83, P6489, DOI 10.1073/pnas.83.17.6489; NAKAMURA T, 1984, BIOCHEM BIOPH RES CO, V122, P1450, DOI 10.1016/0006-291X(84)91253-1; NALDINI L, 1995, J BIOL CHEM, V270, P603, DOI 10.1074/jbc.270.2.603; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Okajima A, 1997, HEPATOLOGY, V25, P97, DOI 10.1002/hep.510250118; Pediaditakis P, 2002, J BIOL CHEM, V277, P14109, DOI 10.1074/jbc.M112196200; Presta L, 2001, THROMB HAEMOSTASIS, V85, P379; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; RUSSELL WE, 1984, J CELL PHYSIOL, V119, P183, DOI 10.1002/jcp.1041190207; Schmaier AH, 1997, THROMB HAEMOSTASIS, V78, P101; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SELIGSOHN U, 1993, THROMB HAEMOSTASIS, V70, P68; SHIMOMURA T, 1995, EUR J BIOCHEM, V229, P257, DOI 10.1111/j.1432-1033.1995.0257l.x; SHIMOMURA T, 1993, J BIOL CHEM, V268, P22927; Stathakis P, 1997, J BIOL CHEM, V272, P20641, DOI 10.1074/jbc.272.33.20641; Stathakis P, 1999, J BIOL CHEM, V274, P8910, DOI 10.1074/jbc.274.13.8910; STOKER M, 1985, J CELL SCI, V77, P209; Tordai H, 1999, FEBS LETT, V461, P63, DOI 10.1016/S0014-5793(99)01416-7; Trusolino L, 1998, FASEB J, V12, P1267, DOI 10.1096/fasebj.12.13.1267; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; Ultsch M, 1998, STRUCT FOLD DES, V6, P1383, DOI 10.1016/S0969-2126(98)00138-5; van Adelsberg J, 2001, J BIOL CHEM, V276, P15099, DOI 10.1074/jbc.M006634200; van der Voort R, 2000, ADV CANCER RES, V79, P39, DOI 10.1016/S0065-230X(00)79002-6; Walsh PN, 2001, THROMB HAEMOSTASIS, V86, P75; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1991, P NATL ACAD SCI USA, V88, P7001, DOI 10.1073/pnas.88.16.7001	59	60	74	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47804	47809		10.1074/jbc.M209778200	http://dx.doi.org/10.1074/jbc.M209778200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12372819	hybrid			2022-12-25	WOS:000179663700125
J	Yang, RB; Ng, CKD; Wasserman, SM; Colman, SD; Shenoy, S; Mehraban, F; Komuves, LG; Tomlinson, JE; Topper, JN				Yang, RB; Ng, CKD; Wasserman, SM; Colman, SD; Shenoy, S; Mehraban, F; Komuves, LG; Tomlinson, JE; Topper, JN			Identification of a novel family of cell-surface proteins expressed in human vascular endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TUMOR NECROSIS FACTOR; PDGF-BETA-RECEPTOR; FACTOR-LIKE DOMAIN; IN-VIVO; GENE-EXPRESSION; HUMAN THROMBOMODULIN; PHAGE DISPLAY; TISSUE FACTOR; SHEAR-STRESS	Vascular endothelial cells (EC) play a key role in a variety of pathophysiologic processes, such as angiogenesis, inflammation, cancer metastasis, and vascular diseases. As part of a strategy to identify all genes expressed in human EC, a full-length cDNA encoding a potential secreted protein harboring 10 epidermal growth factor (EGF)-like domains and one CUB domain at the carboxyl terminus (termed, SCUBE1 for Signal peptide-CUB-EGF-like domain containing protein 1) was identified. SCUBE1 shares homology with several protein families, including members of the fibrillin and Notch families, and the anticoagulant proteins, thrombomodulin and protein C. SCUBE1 mRNA is found in several highly vascularized tissues such as liver, kidney, lung, spleen, and brain and is selectively expressed in EC by in situ hybridization. SCUBE1 is a secreted glycoprotein that can form oligomers and manifests a stable association with the cell surface. A second gene encoding a homologue (designated SCUBE2) was also identified and is expressed in EC as well as other cell types. SCUBE2 is also a cell-surface protein and can form a heteromeric complex with SCUBE1. Both SCUBE1 and SCUBE2 are rapidly down-regulated in EC after interleukin-1beta and tumor necrosis factor-a treatment in vitro and after lipopolysaccharide injection in vivo. Thus, SCUBE1 and SCUBE2 define an emerging family of human secreted proteins that are expressed in vascular endothelium and may play important roles in development, inflammation, and thrombosis.	Millennium Pharmaceut Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA; CuraGen Corp, Dept Collaborat Res, New Haven, CT 06511 USA	Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals	Topper, JN (corresponding author), Millennium Pharmaceut Inc, Dept Cardiovasc Res, San Francisco, CA 94080 USA.		Yang, Ruey-Bing/O-1494-2018	Yang, Ruey-Bing/0000-0003-3017-3714				Arap W, 2002, NAT MED, V8, P121, DOI 10.1038/nm0202-121; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Boehme MWJ, 1996, IMMUNOLOGY, V87, P134; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; Cines DB, 1998, BLOOD, V91, P3527; Clark TG, 1999, DEVELOPMENT, V126, P2631; DAVIES DR, 1995, FASEB J, V9, P50, DOI 10.1096/fasebj.9.1.7821759; DAVIS C G, 1990, New Biologist, V2, P410; DELGADILLOREYNOSO MG, 1989, J MOL EVOL, V29, P314, DOI 10.1007/BF02103619; DiChiara MR, 2000, J EXP MED, V192, P695, DOI 10.1084/jem.192.5.695; DIETZ HC, 1991, NATURE, V352, P337, DOI 10.1038/352337a0; Duke-Cohan JS, 2000, ADV EXP MED BIOL, V477, P173; Duke-Cohan JS, 1998, P NATL ACAD SCI USA, V95, P11336, DOI 10.1073/pnas.95.19.11336; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; FINELLI AL, 1994, DEVELOPMENT, V120, P861; Gilbertson DG, 2001, J BIOL CHEM, V276, P27406, DOI 10.1074/jbc.M101056200; Gleizes PE, 1997, STEM CELLS, V15, P190, DOI 10.1002/stem.150190; Grimmond S, 2000, GENOMICS, V70, P74, DOI 10.1006/geno.2000.6370; Grimmond S, 2001, MECH DEVELOP, V102, P209, DOI 10.1016/S0925-4773(00)00586-4; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; JOHNSON RC, 1993, J CELL BIOL, V121, P1423, DOI 10.1083/jcb.121.6.1423; KAPIOTIS S, 1991, BLOOD, V78, P410; Komuves LG, 2000, J INVEST DERMATOL, V115, P353, DOI 10.1046/j.1523-1747.2000.00073.x; Komuves LG, 2000, J HISTOCHEM CYTOCHEM, V48, P821, DOI 10.1177/002215540004800610; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P4855, DOI 10.1021/bi00365a020; Li SW, 1996, P NATL ACAD SCI USA, V93, P5127, DOI 10.1073/pnas.93.10.5127; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; MANTOVANI A, 1992, FASEB J, V6, P2591, DOI 10.1096/fasebj.6.8.1592209; MOORE KL, 1989, BLOOD, V73, P159; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; Munger JS, 1997, KIDNEY INT, V51, P1376, DOI 10.1038/ki.1997.188; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; Pasqualini R, 1996, NATURE, V380, P364, DOI 10.1038/380364a0; Persson E, 1998, BLOOD COAGUL FIBRIN, V9, pS79; PRIGENT S A, 1992, Progress in Growth Factor Research, V4, P1, DOI 10.1016/0955-2235(92)90002-Y; Rajotte D, 1998, J CLIN INVEST, V102, P430, DOI 10.1172/JCI3008; RAO Z, 1995, CELL, V82, P131, DOI 10.1016/0092-8674(95)90059-4; RAPAPORT SI, 1992, ARTERIOSCLER THROMB, V12, P1111, DOI 10.1161/01.ATV.12.10.1111; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Saharinen J, 1998, J BIOL CHEM, V273, P18459, DOI 10.1074/jbc.273.29.18459; Shimkets RA, 1999, NAT BIOTECHNOL, V17, P798, DOI 10.1038/11743; SMITH CW, 1993, SEMIN HEMATOL, V30, P45; Sonnhammer ELL, 1997, PROTEINS, V28, P405, DOI 10.1002/(SICI)1097-0134(199707)28:3<405::AID-PROT10>3.0.CO;2-L; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Stelnicki EJ, 1998, J INVEST DERMATOL, V110, P110, DOI 10.1046/j.1523-1747.1998.00092.x; SUN PD, 1995, ANNU REV BIOPH BIOM, V24, P269, DOI 10.1146/annurev.bb.24.060195.001413; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; THOMPSON EA, 1986, J CLIN INVEST, V78, P13, DOI 10.1172/JCI112541; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Topper JN, 1999, MOL MED TODAY, V5, P40, DOI 10.1016/S1357-4310(98)01372-0; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; YANG RB, 2002, PHYSIOLOGIST, V45, P76; YU SQ, 1994, BIOCHEMISTRY-US, V33, P823, DOI 10.1021/bi00169a025; ZUSHI M, 1991, J BIOL CHEM, V266, P19886	58	115	124	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46364	46373		10.1074/jbc.M207410200	http://dx.doi.org/10.1074/jbc.M207410200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270931	hybrid			2022-12-25	WOS:000179529300087
J	Yeh, SH; Lin, CH; Lee, CF; Gean, PW				Yeh, SH; Lin, CH; Lee, CF; Gean, PW			A requirement of nuclear factor-kappa B activation in fear-potentiated startle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; TRANSCRIPTION FACTOR; PROTEIN-SYNTHESIS; LATE-PHASE; EXPRESSION; KINASE; ALPHA; HIPPOCAMPAL; MEMORY; FAMILY	Previous studies have shown that biochemical changes that occur in the amygdala during fear conditioning in vivo are similar to those occur during long term potentiation (LTP) in vitro. Electrophoretic mobility shift assay of nuclear extracts from startle-potentiated rats showed a selective increase in the amygdala of nuclear factor-kappaB (NF-kappaB) DNA binding activity. Supershift experiments further indicated that p65 and p50 subunits but not c-Rel were involved in DNA binding. The protein levels of IkappaB-alpha were reduced by treatments that reliably induced LTP in this area of the brain. This was accompanied by a decrease of NF-kappaB in the cytoplasm concomitant with an increase in the nucleus. Quantitative analysis of IkappaB kinase activity demonstrated that fear training led to an increase in kinase activity, and this effect was inhibited by thalidomide. Paralleled behavioral tests revealed that thalidomide inhibited fear-potentiated startle. Intra-amygdala administration of kappaB decoy DNA prior to training impaired fear-potentiated startle as well as LTP induction. Similarly, NF-kappaB inhibitors blocked IkappaB-alpha degradation and startle response. These results provide the first evidence of a requirement of NF-kappaB activation in the amygdala for consolidation of fear memory.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan	National Cheng Kung University	Gean, PW (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 701, Taiwan.	powu@mail.ncku.edu.tw	Yeh, Shiu-Hwa/D-2088-2010					Albensi BC, 2000, SYNAPSE, V35, P151; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bailey DJ, 1999, BEHAV NEUROSCI, V113, P276, DOI 10.1037/0735-7044.113.2.276; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barco A, 2002, CELL, V108, P689, DOI 10.1016/S0092-8674(02)00657-8; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; CASSELLA JV, 1986, PHYSIOL BEHAV, V36, P377, DOI 10.1016/0031-9384(86)90032-6; Castagne V, 2001, NEUROSCIENCE, V108, P517, DOI 10.1016/S0306-4522(01)00430-4; CASTELLUCCI VF, 1989, J NEUROBIOL, V20, P1, DOI 10.1002/neu.480200102; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; DAVIS HP, 1984, PSYCHOL BULL, V96, P518, DOI 10.1037/0033-2909.96.3.518; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; Frey U, 1998, TRENDS NEUROSCI, V21, P181, DOI 10.1016/S0166-2236(97)01189-2; Grilli M, 1999, BIOCHEM PHARMACOL, V57, P1, DOI 10.1016/S0006-2952(98)00214-7; Hall J, 2001, EUR J NEUROSCI, V13, P1453, DOI 10.1046/j.0953-816x.2001.01531.x; HENKEL T, 1993, NATURE, V365, P182, DOI 10.1038/365182a0; Huang YY, 1998, NEURON, V21, P169, DOI 10.1016/S0896-6273(00)80524-3; Huang YY, 2000, J NEUROSCI, V20, P6317, DOI 10.1523/JNEUROSCI.20-17-06317.2000; Impey S, 1998, NAT NEUROSCI, V1, P595, DOI 10.1038/2830; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Josselyn SA, 2001, J NEUROSCI, V21, P2404, DOI 10.1523/JNEUROSCI.21-07-02404.2001; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; Lin CH, 2001, NEURON, V31, P841, DOI 10.1016/S0896-6273(01)00433-0; Lonze BE, 2002, NEURON, V35, P605, DOI 10.1016/S0896-6273(02)00828-0; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; ONeill LAJ, 1997, TRENDS NEUROSCI, V20, P252, DOI 10.1016/S0166-2236(96)01035-1; Ozes ON, 1999, NATURE, V401, P82; Paxinos G, 1986, RAT BRAIN STEREOTAXI, P27; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Pitkanen A, 1997, TRENDS NEUROSCI, V20, P517, DOI 10.1016/S0166-2236(97)01125-9; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Roshak AK, 1996, J BIOL CHEM, V271, P31496, DOI 10.1074/jbc.271.49.31496; Schafe GE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-18-j0003.2000; Schafe GE, 2000, J NEUROSCI, V20, P8177; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Stephens TD, 2000, TERATOLOGY, V61, P189, DOI 10.1002/(SICI)1096-9926(200003)61:3<189::AID-TERA6>3.0.CO;2-W; SUN SC, 1993, SCIENCE, V259, P1912, DOI 10.1126/science.8096091; ToliverKinsky T, 1997, J NEUROSCI RES, V48, P580, DOI 10.1002/(SICI)1097-4547(19970615)48:6<580::AID-JNR11>3.0.CO;2-Z; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wu M, 1996, EMBO J, V15, P4682, DOI 10.1002/j.1460-2075.1996.tb00845.x; Yu ZF, 1999, J NEUROSCI, V19, P8856, DOI 10.1523/JNEUROSCI.19-20-08856.1999	48	80	81	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46720	46729		10.1074/jbc.M206258200	http://dx.doi.org/10.1074/jbc.M206258200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351629	hybrid			2022-12-25	WOS:000179529300131
J	Rachek, LI; Grishko, VI; Musiyenko, SI; Kelley, MR; LeDoux, SP; Wilson, GL				Rachek, LI; Grishko, VI; Musiyenko, SI; Kelley, MR; LeDoux, SP; Wilson, GL			Conditional targeting of the DNA repair enzyme hOGG1 into mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; MAMMALIAN-CELLS; GENE-EXPRESSION; ALZHEIMER-DISEASE; OXIDATIVE DAMAGE; RINR-38 CELLS; GLYCOSYLASE; SITES; MICE; ENDONUCLEASE	Oxidative damage to mitochondrial DNA (mtDNA) has been suggested to be a key factor in the etiologies of many diseases and in the normal process of aging. Although the presence of a repair system to remove this damage has been demonstrated, the mechanisms involved in this repair have not been well defined. In an effort to better understand the physiological role of recombinant 8-oxoguanine DNA glycosylase/apuriniclyase (OGG1) in mtDNA repair, we constructed an expression vector containing the gene for OGG1 downstream of the mitochondrial localization sequence from manganese-superoxide dismutase. This gene construct was placed under the control of a tetracycline-regulated promoter. Transfected cells that conditionally expressed OGG1 in the absence of the tetracycline analogue doxycycline and targeted this recombinant protein to mitochondria were generated. Western blots of mitochondrial extracts from vector- and OGG1-transfected clones with and without doxycycline revealed that removal of doxycycline for 4 days caused an approximate 8-fold increase in the amount of OGG1 protein in mitochondria. Enzyme activity assays and DNA repair studies showed that the doxycycline-dependent recombinant OGG1 is functional. Functional studies revealed that cells containing recombinant OGG1 were more proficient at repairing oxidative damage in their mtDNA, and this increased repair led to increased cellular survival following oxidative stress.	Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; Indiana Univ, Sch Med, Wells Ctr Pediat Res, Dept Pediat, Indianapolis, IN 46202 USA	University of South Alabama; Indiana University System; Indiana University-Purdue University Indianapolis	Wilson, GL (corresponding author), Univ S Alabama, Coll Med, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA.			Kelley, Mark/0000-0002-6120-9532	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019602] Funding Source: NIH RePORTER; NIA NIH HHS [AG19602] Funding Source: Medline; NIEHS NIH HHS [ES05865, ES03456] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Aburatani H, 1997, CANCER RES, V57, P2151; Bandmann O, 1997, J NEUROL, V244, P262, DOI 10.1007/s004150050082; Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392; Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7; CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525; Croteau DL, 1999, MUTAT RES-DNA REPAIR, V434, P137, DOI 10.1016/S0921-8777(99)00025-7; Croteau DL, 1997, J BIOL CHEM, V272, P27338, DOI 10.1074/jbc.272.43.27338; Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526; de Souza-Pinto NC, 2001, CANCER RES, V61, P5378; Dobson AW, 2000, J BIOL CHEM, V275, P37518, DOI 10.1074/jbc.M000831200; Dobson AW, 2002, AM J PHYSIOL-LUNG C, V283, pL205, DOI 10.1152/ajplung.00443.2001; DRIGGERS WJ, 1993, J BIOL CHEM, V268, P22042; EUSTICE DC, 1991, BIOTECHNIQUES, V11, P739; FREI B, 1986, BIOCHEMISTRY-US, V25, P4438, DOI 10.1021/bi00363a040; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hazra TK, 2002, J BIOL CHEM, V277, P30417, DOI 10.1074/jbc.C200355200; Hazra TK, 2002, P NATL ACAD SCI USA, V99, P3523, DOI 10.1073/pnas.062053799; Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Nishioka K, 1999, MOL BIOL CELL, V10, P1637, DOI 10.1091/mbc.10.5.1637; Ozawa T, 1997, PHYSIOL REV, V77, P425, DOI 10.1152/physrev.1997.77.2.425; Paul R, 2001, MUTAT RES-DNA REPAIR, V486, P11, DOI 10.1016/S0921-8777(01)00069-6; PETTEPHER CC, 1991, J BIOL CHEM, V266, P3113; Pinz KG, 1998, MOL CELL BIOL, V18, P1257, DOI 10.1128/MCB.18.3.1257; RESNITZKY D, 1994, MOL CELL BIOL, V14, P1669, DOI 10.1128/MCB.14.3.1669; RoldanArjona T, 1997, P NATL ACAD SCI USA, V94, P8016, DOI 10.1073/pnas.94.15.8016; Sawyer DE, 1999, MUTAT RES-DNA REPAIR, V434, P161, DOI 10.1016/S0921-8777(99)00027-0; Schapira AHV, 1999, BBA-BIOENERGETICS, V1410, P159, DOI 10.1016/S0005-2728(98)00164-9; Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755; Stebbins MJ, 2001, P NATL ACAD SCI USA, V98, P10775, DOI 10.1073/pnas.121186498; Stierum RH, 1999, NUCLEIC ACIDS RES, V27, P3712, DOI 10.1093/nar/27.18.3712; Takao M, 1998, NUCLEIC ACIDS RES, V26, P2917, DOI 10.1093/nar/26.12.2917; Tamura T, 1996, BIOCHEM BIOPH RES CO, V222, P659, DOI 10.1006/bbrc.1996.0800; TOMKINSON AE, 1988, J BIOL CHEM, V263, P12532; Vialettes B, 1997, DIABETES METAB, V23, P52; Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WEINMANN P, 1994, PLANT J, V5, P559, DOI 10.1046/j.1365-313X.1994.5040559.x; Wooten GF, 1997, ANN NEUROL, V41, P265, DOI 10.1002/ana.410410218; Zharkov DO, 2000, J BIOL CHEM, V275, P28607, DOI 10.1074/jbc.M002441200	43	82	89	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44932	44937		10.1074/jbc.M208770200	http://dx.doi.org/10.1074/jbc.M208770200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244119	hybrid, Green Submitted			2022-12-25	WOS:000179404800045
J	Wagner, KJ; Cooper, WN; Grundy, RG; Caldwell, G; Jones, C; Wadey, RB; Morton, D; Schofield, PN; Reik, W; Latif, F; Maher, ER				Wagner, KJ; Cooper, WN; Grundy, RG; Caldwell, G; Jones, C; Wadey, RB; Morton, D; Schofield, PN; Reik, W; Latif, F; Maher, ER			Frequent RASSF1A tumour suppressor gene promoter methylation in Wilms' tumour and colorectal cancer	ONCOGENE			English	Article						methylation; RASSF1A; colorectal cancer; Wilms' tumour	DNA METHYLATION; EPIGENETIC INACTIVATION; H19 LOCUS; EXPRESSION; 3P21.3; LUNG; RAS; CARCINOMA; REGION; WT1	The 3p21.3 tumour suppressor gene (TSG) RASSF1A is inactivated predominantly by promoter methylation and rarely by somatic mutations. Recently we demonstrated that epigenetic inactivation of RASSF1A is frequent in both clear cell and papillary adult renal cell carcinomas (even though 3p21.3 allele loss is rare in papillary tumours). Wilms' tumour is the most common childhood kidney tumour, but relatively little is known about its molecular pathogenesis. Thus TSGs such as WT1, p16(CDKN2a) and p53 are inactivated in only a minority of cases. In view of the involvement of RASSF1A in adult renal cancers we investigated RASSF1A as a candidate Wilms' TSG. We detected RASSF1A hypermethylation in 21 of 39 (54%) primary Wilms' tumours. 3p21.3 allele loss was not detected in nine informative Wilms' tumours (five with RASSF1A methylation). In contrast to RASSF1A, only a minority (10.3%) of Wilms' tumours demonstrated p16 promoter methylation. As chromosome 3p allele loss is frequent in colorectal cancer, we proceeded to investigate RASSF1A promoter methylation in colorectal cancer and detected RASSF1A methylation in 80% (4/5) colorectal cancer cell lines and 45% (13/29) primary colorectal cancers. There was no correlation between RASSF1A and p16 methylation in colorectal cancer. We have demonstrated that RASSF1A inactivation is the most frequent genetic or epigenetic event yet reported in Wilms' tumourigenesis and that allelotyping studies may fail to identify regions containing important TSGs.	Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet,Dept Paediat & Child Hlth, Birmingham B15 2TT, W Midlands, England; Birmingham Childrens Hosp, Dept Paediat Oncol, Birmingham, W Midlands, England; Univ Birmingham, Dept Surg, Birmingham B15 2TT, W Midlands, England; Univ Cambridge, Dept Anat, Cambridge CB1, England; Babraham Inst, Lab Dev Genet & Imprinting, Cambridge CB2 4AT, England	University of Birmingham; University of Birmingham; University of Birmingham; University of Cambridge; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Maher, ER (corresponding author), Univ Birmingham, Sch Med, Dept Paediat & Child Hlth, Sect Med & Mol Genet,Dept Paediat & Child Hlth, Birmingham B15 2TT, W Midlands, England.		MAHER, EAMONN R/A-9507-2008; Reik, Wolf/I-6794-2012; Schofield, Paul/AAA-9414-2020	MAHER, EAMONN R/0000-0002-6226-6918; Schofield, Paul/0000-0002-5111-7263; Reik, Wolf/0000-0003-0216-9881				Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Ahuja N, 1998, CANCER RES, V58, P5489; Arcellana-Panlilio MY, 2000, GENE CHROMOSOME CANC, V29, P63, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1006>3.0.CO;2-L; Astuti D, 2001, ONCOGENE, V20, P7573, DOI 10.1038/sj.onc.1204968; BARDEESY N, 1994, NAT GENET, V7, P91, DOI 10.1038/ng0594-91; Baylin SB, 1998, ADV CANCER RES, V72, P141; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Cui HM, 1998, NAT MED, V4, P1276, DOI 10.1038/3260; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Davies R, 1999, CANCER RES, V59, p1747S; DAVIES R, 1999, CANCER RES, V59, pS1751; Hao XP, 2000, CANCER RES, V60, P18; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Issa JPJ, 1996, P NATL ACAD SCI USA, V93, P11757, DOI 10.1073/pnas.93.21.11757; Jones PA, 1999, TRENDS GENET, V15, P34, DOI 10.1016/S0168-9525(98)01636-9; Kane MF, 1997, CANCER RES, V57, P808; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lerman MI, 2000, CANCER RES, V60, P6116; LUO XN, 1995, ONCOGENE, V11, P743; Morrissey C, 2001, CANCER RES, V61, P7277; MOULTON T, 1994, NAT GENET, V7, P440, DOI 10.1038/ng0794-440; Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; Richards FM, 1996, HUM MOL GENET, V5, P639, DOI 10.1093/hmg/5.5.639; STEENMAN MJC, 1994, NAT GENET, V7, P433, DOI 10.1038/ng0794-433; Stirzaker C, 1997, CANCER RES, V57, P2229; Thiagalingam S, 1996, CANCER RES, V56, P2936; Toyota M, 2000, P NATL ACAD SCI USA, V97, P710, DOI 10.1073/pnas.97.2.710; Tycko B, 2000, J CLIN INVEST, V105, P401, DOI 10.1172/JCI9462; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; WABER PG, 1993, CANCER, V72, P3732, DOI 10.1002/1097-0142(19931215)72:12<3732::AID-CNCR2820721228>3.0.CO;2-U	35	75	83	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7277	7282		10.1038/sj.onc.1205922	http://dx.doi.org/10.1038/sj.onc.1205922			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370819				2022-12-25	WOS:000178504600017
J	Debruyne, PR; Bruyneel, EA; Karaguni, IM; Li, X; Flatau, G; Muller, O; Zimber, A; Gespach, C; Mareel, MM				Debruyne, PR; Bruyneel, EA; Karaguni, IM; Li, X; Flatau, G; Muller, O; Zimber, A; Gespach, C; Mareel, MM			Bile acids stimulate invasion and haptotaxis in human colorectal cancer cells through activation of multiple oncogenic signaling pathways	ONCOGENE			English	Article						bile acids; invasion; colorectal cancer	PROTEIN-KINASE-C; COLONIC EPITHELIAL-CELLS; DOWN-REGULATION; ADENOCARCINOMA CELLS; LITHOCHOLIC ACID; NUCLEAR RECEPTOR; CADHERIN/CATENIN COMPLEX; URSODEOXYCHOLIC ACID; CELLULAR INVASION; INDUCED APOPTOSIS	Bile acids are implicated in colorectal carcinogenesis as evidenced by epidemiological and experimental studies. We examined whether bile acids stimulate cellular invasion of human colorectal and dog kidney epithelial cells at different stages of tumor progression. Colon PC/AA/C1, PCmsrc, and HCT-8/E11 cells and kidney MDCKT23 cells were seeded on top of collagen type I gels and invasive cells were counted after 24 h incubation. Activation of the Rac1 and RhoA small GTPases was investigated by pull-down assays. Haptotaxis was analysed with modified Boyden chambers. Lithocholic acid, chenodeoxycholic acid, cholic acid and deoxycholic acid stimulated cellular invasion of SRC-and RhoA-transformed PCmsrc and MDCKT23-RhoAV14 cells, and of HCT-8/E11 cells originating from a sporadic tumor, but were ineffective in premalignant PC/AA/C1 and MDCKT23 cells. Bile acid-stimulated invasion occurred through stimulation of haptotaxis and was dependent on the RhoA/Rho-kinase pathway and signaling cascades using protein kinase C, mitogen-activated protein kinase, and cyclooxygenase-2. Accordingly, BA-induced invasion was associated with activation of the Rac1 and RhoA GTPases and expression of the farnesoid X receptor. We conclude that bile acids stimulate invasion and haptotaxis in colorectal cancer cells via several cancer invasion signaling pathways.	Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, B-9000 Ghent, Belgium; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; INSERM, U 452, UFR Med, F-06107 Nice, France; Hop St Antoine, INSERM, U482, F-75571 Paris 12, France	Ghent University; Ghent University Hospital; Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite	Mareel, MM (corresponding author), Ghent Univ Hosp, Dept Radiotherapy & Nucl Med, Expt Cancerol Lab, 1P7,Pintelaan 185, B-9000 Ghent, Belgium.	marc.mareel@rug.ac.be	Debruyne, Philip/AAU-6685-2021	Debruyne, Philip/0000-0001-5438-9697				Andre F, 1999, INT J CANCER, V83, P497, DOI 10.1002/(SICI)1097-0215(19991112)83:4<497::AID-IJC11>3.3.CO;2-4; Attoub S, 2000, FASEB J, V14, P2329, DOI 10.1096/fj.00-0162; AZNAVOORIAN S, 1990, J NATL CANCER I, V82, P1485, DOI 10.1093/jnci/82.18.1485; Batlle E, 1998, J BIOL CHEM, V273, P15091, DOI 10.1074/jbc.273.24.15091; Batta AK, 1998, CANCER RES, V58, P1684; BAYERDORFFER E, 1993, GASTROENTEROLOGY, V104, P145, DOI 10.1016/0016-5085(93)90846-5; Bracke ME, 1997, EUR J CELL BIOL, V74, P342; BRACKE ME, 1993, BRIT J CANCER, V68, P282, DOI 10.1038/bjc.1993.329; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; Dannenberg AJ, 1999, SEMIN ONCOL, V26, P499; EARNEST DL, 1994, CANCER RES, V54, P5071; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Empereur S, 1997, BRIT J CANCER, V75, P241, DOI 10.1038/bjc.1997.40; Fujita T, 1998, CANCER RES, V58, P4823; Glinghammar B, 2001, GASTROENTEROLOGY, V120, P401, DOI 10.1053/gast.2001.21188; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Halvorsen B, 2000, BIOCHEM J, V349, P189, DOI 10.1042/0264-6021:3490189; HENNIGAN RF, 1994, ONCOGENE, V9, P3591; HILL MJ, 1971, LANCET, V1, P95; Hirano F, 1996, CARCINOGENESIS, V17, P427, DOI 10.1093/carcin/17.3.427; Hofmann J, 1997, FASEB J, V11, P649, DOI 10.1096/fasebj.11.8.9240967; HUANG XP, 1992, INT J CANCER, V52, P444, DOI 10.1002/ijc.2910520319; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kamano T, 1999, DIS COLON RECTUM, V42, P668, DOI 10.1007/BF02234147; Kotelevets L, 1998, J BIOL CHEM, V273, P14138, DOI 10.1074/jbc.273.23.14138; Kozoni V, 2000, CARCINOGENESIS, V21, P999, DOI 10.1093/carcin/21.5.999; Kurtz W., 1992, Verdauungskrankheiten, V10, P153; Kurz AK, 2000, BIOCHEM J, V350, P207, DOI 10.1042/0264-6021:3500207; Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095; LATTA RK, 1993, CANCER LETT, V70, P167, DOI 10.1016/0304-3835(93)90227-Z; LEHMANN M, 1994, CANCER RES, V54, P2102; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Mareel M, 1996, J CELL BIOCHEM, V61, P524; MCMICHAEL AJ, 1985, JNCI-J NATL CANCER I, V75, P185; McMillan L, 2000, BIOCHEM BIOPH RES CO, V273, P45, DOI 10.1006/bbrc.2000.2899; Moseley R, 1999, TXB GASTROENTEROLOGY, P380; NAGENGAST FM, 1995, EUR J CANCER, V31A, P1067, DOI 10.1016/0959-8049(95)00216-6; NARISAWA T, 1974, JNCI-J NATL CANCER I, V53, P1093, DOI 10.1093/jnci/53.4.1093; Owen RW, 1997, SCAND J GASTROENTERO, V32, P76, DOI 10.1080/00365521.1997.11720725; Ozanne BW, 2000, EUR J CANCER, V36, P1640, DOI 10.1016/S0959-8049(00)00175-1; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107; Qiao D, 2001, CARCINOGENESIS, V22, P35, DOI 10.1093/carcin/22.1.35; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Rao YP, 1997, J LIPID RES, V38, P2446; REDDY BS, 1981, CANCER RES, V41, P3766; REDDY BS, 1977, CANCER RES, V37, P3228; Rodrigues S, 2001, FASEB J, V15, P1517, DOI 10.1096/fj.00-0802com; Rust C, 2000, J BIOL CHEM, V275, P20210, DOI 10.1074/jbc.M909992199; Sander EE, 1999, EUR J CANCER, V35, P1302, DOI 10.1016/S0959-8049(99)00145-8; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Sander EE, 1998, J CELL BIOL, V143, P1385, DOI 10.1083/jcb.143.5.1385; Schlottmann K, 2000, CANCER RES, V60, P4270; Shimao Y, 1999, CLIN EXP METASTAS, V17, P351; Slice LW, 2000, BIOCHEM BIOPH RES CO, V276, P406, DOI 10.1006/bbrc.2000.3487; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; SUMMERTON J, 1983, BRIT J SURG, V70, P549, DOI 10.1002/bjs.1800700914; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336; VAKAET L, 1991, INVAS METAST, V11, P249; VERMEULEN SJ, 1995, CANCER RES, V55, P4722; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLIAMS AC, 1990, CANCER RES, V50, P4724; Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398; Zhang F, 1998, J BIOL CHEM, V273, P2424, DOI 10.1074/jbc.273.4.2424; Zimber A, 2000, CANCER RES, V60, P672; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	70	69	72	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6740	6750		10.1038/sj.onc.1205729	http://dx.doi.org/10.1038/sj.onc.1205729			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360401				2022-12-25	WOS:000178315800004
J	Faehling, M; Kroll, J; Fohr, KJ; Fellbrich, G; Mayr, U; Trischler, G; Waltenberger, J				Faehling, M; Kroll, J; Fohr, KJ; Fellbrich, G; Mayr, U; Trischler, G; Waltenberger, J			Essential role of calcium in vascular endothelial growth factor A-induced signaling: mechanism of the antiangiogenic effect of carboxyamidotriazole	FASEB JOURNAL			English	Article						angiogenesis; endothelial cells; signal transduction; angiogenesis inhibitors; nitric oxide	FACTOR RECEPTOR KDR; PHASE-I TRIAL; NITRIC-OXIDE; TYROSINE PHOSPHORYLATION; TRANSDUCTION PATHWAYS; TRANSCRIPTION FACTORS; NUCLEAR FACTOR; ION CHANNELS; SOLID TUMORS; PLC-GAMMA	Vascular endothelial growth factor-A (VEGF-A) plays a major role in tumor angiogenesis and raises the concentration of intracellular free calcium ([Ca2+](i)). Carboxyamidotriazole (CAI), an inhibitor of calcium influx and of angiogenesis, is under investigation as a tumoristatic agent. We studied the effect of CAI and the role of [Ca2+](i) in VEGF-A signaling in human endothelial cells. VEGF-A induced a biphasic [Ca2+](i) signal. VEGF-A increased the level of intracellular inositol 1,4,5-trisphosphate (IP3), which suggests that VEGF-A releases Ca2+ from IP3-sensitive stores and induces store-operated calcium influx. Reduction of either extracellular or intracellular free Ca2+ inhibited VEGF-A-induced proliferation. CAI inhibited IP3 formation, both phases of the calcium signal, nitric oxide (NO) release, and proliferation induced by VEGF-A. CAI prevented neither activation of VEGF receptor-2 (VEGFR-2) (KDR/Flk-1), phospholipase C-gamma, or mitogen-activated protein kinase (MAP kinase) nor translocation of nuclear factor of activated T cells (NFAT). We conclude that calcium signaling is necessary for VEGF-A-induced proliferation. MAP kinase activation occurs independently of [Ca2+](i) but is not sufficient to induce proliferation in the absence of calcium signaling. Inhibition of the VEGF-A-induced [Ca2+](i) signal and proliferation by CAI can be explained by inhibition of IP3 formation and may contribute to the antiangiogenic action of CAI. Calcium-dependent NO formation may represent a link between calcium signaling and proliferation.	Univ Ulm, Dept Internal Med 2, D-89081 Ulm, Germany; Univ Ulm, Dept Anesthesiol, D-89081 Ulm, Germany	Ulm University; Ulm University	Waltenberger, J (corresponding author), Univ Ulm, Dept Internal Med 2, Robert Koch Str 8, D-89081 Ulm, Germany.	johannes.waltenberger@medizin.uni-ulm.de	Waltenberger, Johannes/I-1813-2013	Waltenberger, Johannes/0000-0002-2417-9880				ADAMS DJ, 1989, FASEB J, V3, P2389, DOI 10.1096/fasebj.3.12.2477294; Armesilla AL, 1999, MOL CELL BIOL, V19, P2032; Bates DO, 1997, AM J PHYSIOL-HEART C, V273, pH687, DOI 10.1152/ajpheart.1997.273.2.H687; Bauer KS, 1999, CLIN CANCER RES, V5, P2324; Bauer KS, 2000, J PHARMACOL EXP THER, V292, P31; BENZAQUEN LR, 1995, NAT MED, V1, P534, DOI 10.1038/nm0695-534; Berlin J, 1997, J CLIN ONCOL, V15, P781, DOI 10.1200/JCO.1997.15.2.781; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOESSAYS, V17, P491, DOI 10.1002/bies.950170605; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; BROCK TA, 1991, AM J PATHOL, V138, P213; CRISCUOLO GR, 1989, J NEUROSURG, V71, P884, DOI 10.3171/jns.1989.71.6.0884; Cunningham SA, 1999, AM J PHYSIOL-CELL PH, V276, pC176, DOI 10.1152/ajpcell.1999.276.1.C176; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FLEMING I, 1995, CIRC RES, V76, P522, DOI 10.1161/01.RES.76.4.522; FOHR KJ, 1993, METHOD ENZYMOL, V221, P149, DOI 10.1016/0076-6879(93)21014-Y; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Garnier-Raveaud S, 2001, GROWTH FACTORS, V19, P35, DOI 10.3109/08977190109001074; Ge SG, 2000, CLIN CANCER RES, V6, P1248; Genot E, 1996, EMBO J, V15, P3923, DOI 10.1002/j.1460-2075.1996.tb00766.x; Gerber HP, 1998, J BIOL CHEM, V273, P30336, DOI 10.1074/jbc.273.46.30336; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; GUSOVSKY F, 1993, J BIOL CHEM, V268, P7768; Hiratsuka S, 1998, P NATL ACAD SCI USA, V95, P9349, DOI 10.1073/pnas.95.16.9349; HOOD HF, 1998, AM J PHYSIOL, V274, pH1054; HUPE DJ, 1990, J CELL PHYSIOL, V144, P457, DOI 10.1002/jcp.1041440313; HUPE DJ, 1991, J BIOL CHEM, V266, P10136; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0; Kohn EC, 1996, CANCER RES, V56, P569; KOHN EC, 1992, CANCER RES, V52, P3208; Kohn EC, 2002, NEW ANGIOTHERAPY, P527; KOHN EC, 1995, P NATL ACAD SCI USA, V92, P1307, DOI 10.1073/pnas.92.5.1307; KOHN EC, 1990, J NATL CANCER I, V82, P54, DOI 10.1093/jnci/82.1.54; Kohn EC, 1997, J CLIN ONCOL, V15, P1985, DOI 10.1200/JCO.1997.15.5.1985; Kohn EC, 2001, CLIN CANCER RES, V7, P1600; Kroll J, 1997, J BIOL CHEM, V272, P32521, DOI 10.1074/jbc.272.51.32521; Kroll J, 1999, BIOCHEM BIOPH RES CO, V265, P636, DOI 10.1006/bbrc.1999.1729; Kroll J, 1998, BIOCHEM BIOPH RES CO, V252, P743, DOI 10.1006/bbrc.1998.9719; McLaughlin AP, 2001, AM J PHYSIOL-CELL PH, V281, pC1448, DOI 10.1152/ajpcell.2001.281.5.C1448; Murohara T, 1998, J CLIN INVEST, V101, P2567, DOI 10.1172/JCI1560; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; Papapetropoulos A, 1997, J CLIN INVEST, V100, P3131, DOI 10.1172/JCI119868; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Parenti A, 1998, J BIOL CHEM, V273, P4220, DOI 10.1074/jbc.273.7.4220; PUTNEY JW, 1993, CELL, V75, P199, DOI 10.1016/0092-8674(93)80061-I; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Santella L, 1998, BIOCHEM BIOPH RES CO, V244, P317, DOI 10.1006/bbrc.1998.8086; Seymour LW, 1996, LAB INVEST, V75, P427; Smits A, 1989, GROWTH FACTORS, V2, P1, DOI 10.3109/08977198909069076; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; SOLTOFF SP, 1988, ANNU REV PHYSIOL, V50, P207; Takahashi H, 1998, JPN J CANCER RES, V89, P445, DOI 10.1111/j.1349-7006.1998.tb00583.x; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; TEICHER BA, 1994, CANCER CHEMOTH PHARM, V34, P515, DOI 10.1007/BF00685664; Waltenberger J, 1997, CIRCULATION, V96, P4083; Waltenberger J, 1996, CIRCULATION, V94, P1647, DOI 10.1161/01.CIR.94.7.1647; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Ziche M, 1997, J CLIN INVEST, V99, P2625, DOI 10.1172/JCI119451	64	96	102	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1805	+		10.1096/fj.01-0938fje	http://dx.doi.org/10.1096/fj.01-0938fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354692				2022-12-25	WOS:000178441800004
J	Kataoka, K; Han, SI; Shioda, S; Hirai, M; Nishizawa, M; Handa, H				Kataoka, K; Han, SI; Shioda, S; Hirai, M; Nishizawa, M; Handa, H			MafA is a glucose-regulated and pancreatic beta-cell-specific transcriptional activator for the insulin gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; DNA-BINDING ACTIVITY; V-MAF; SYNERGISTIC ACTIVATION; NUCLEAR ONCOPROTEIN; DIABETES-MELLITUS; FACTOR NF-E2; ISLET CELLS; FACTOR NRL; II GENE	The insulin gene is specifically expressed in beta-cells of the Langerhans islets of the pancreas, and its transcription is regulated by the circulating glucose level. Previous reports have shown that an unidentified beta-cell-specific nuclear factor binds to a conserved cis-regulatory element called RIPE3b and is critical for its glucose-regulated expression. Based on the sequence similarity of the RIPE3b element and the consensus binding sequence of the Maf family of basic leucine zipper transcription factors, we here identified mammalian homologue of avian MaLA/L-Maf, an eye-specific member of the Maf family, as the RIPE3b-binding transcriptional activator. Reverse transcription-PCR analysis showed that mafA mRNA is detected only in the eyes and in pancreatic beta-cells and not in alpha-cells. MafA protein as well as its mRNA is up-regulated by glucose, consistent with the glucose-regulated binding of MafA to the RIPE3b element in beta-cell nuclear extracts. In transient luciferase assays, we also showed that expression of MafA greatly enhanced insulin promoter activity and that a dominant-negative form of MafA inhibited it. Therefore, MafA is a beta-cell-specific and glucose-regulated transcriptional activator for insulin gene expression and thus may be involved in the function and development of beta-cells as well as in the pathogenesis of diabetes.	Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, Yokohama, Kanagawa 2268503, Japan; Univ Tokyo, Grad Sch Froontier Sci, Dept Integrated Biosci, Tokyo 2778562, Japan; Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Tokyo Institute of Technology; University of Tokyo; Scripps Research Institute	Kataoka, K (corresponding author), Tokyo Inst Technol, Frontier Collaborat Res Ctr, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.							Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ANDREWS NC, 1993, P NATL ACAD SCI USA, V90, P11488, DOI 10.1073/pnas.90.24.11488; Ayer DE, 1996, MOL CELL BIOL, V16, P5772; Benkhelifa S, 1998, ONCOGENE, V17, P247, DOI 10.1038/sj.onc.1201898; Benkhelifa S, 2001, MOL CELL BIOL, V21, P4441, DOI 10.1128/MCB.21.14.4441-4452.2001; Bessant DAR, 1999, NAT GENET, V21, P355, DOI 10.1038/7678; CORDES SP, 1994, CELL, V79, P1025, DOI 10.1016/0092-8674(94)90033-7; CROWE DT, 1989, MOL CELL BIOL, V9, P1784, DOI 10.1128/MCB.9.4.1784; FUJIWARA KT, 1993, ONCOGENE, V8, P2371; GERMAN MS, 1992, GENE DEV, V6, P2165, DOI 10.1101/gad.6.11.2165; Harrington RH, 2001, J BIOL CHEM, V276, P104, DOI 10.1074/jbc.M008415200; HIRAI M, 1994, CYTOGENET CELL GENET, V66, P149, DOI 10.1159/000133687; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; IGARASHI K, 1994, NATURE, V367, P568, DOI 10.1038/367568a0; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; KARLSSON O, 1987, P NATL ACAD SCI USA, V84, P8819, DOI 10.1073/pnas.84.24.8819; KARLSSON O, 1990, NATURE, V344, P879, DOI 10.1038/344879a0; KATAOKA K, 1994, MOL CELL BIOL, V14, P700, DOI 10.1128/MCB.14.1.700; KATAOKA K, 1993, J VIROL, V67, P2133, DOI 10.1128/JVI.67.4.2133-2141.1993; KATAOKA K, 1994, MOL CELL BIOL, V14, P7581, DOI 10.1128/MCB.14.11.7581; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; Kataoka K, 2001, J BIOL CHEM, V276, P819, DOI 10.1074/jbc.M007643200; Kataoka K, 1996, ONCOGENE, V12, P53; KAWAI S, 1992, VIROLOGY, V188, P778, DOI 10.1016/0042-6822(92)90532-T; KERPPOLA TK, 1994, ONCOGENE, V9, P675; Kumar R, 1996, J BIOL CHEM, V271, P29612, DOI 10.1074/jbc.271.47.29612; KURSCHNER C, 1995, MOL CELL BIOL, V15, P246, DOI 10.1128/MCB.15.1.246; Malecki MT, 1999, NAT GENET, V23, P323, DOI 10.1038/15500; Marshak S, 1996, P NATL ACAD SCI USA, V93, P15057, DOI 10.1073/pnas.93.26.15057; Matsuoka T, 2001, J BIOL CHEM, V276, P22071, DOI 10.1074/jbc.M010321200; Mears AJ, 2001, NAT GENET, V29, P447, DOI 10.1038/ng774; Melloul D, 2002, DIABETOLOGIA, V45, P309, DOI 10.1007/s00125-001-0728-y; MIYAZAKI JI, 1990, ENDOCRINOLOGY, V127, P126, DOI 10.1210/endo-127-1-126; MONTECLARO FS, 1993, P NATL ACAD SCI USA, V90, P6726, DOI 10.1073/pnas.90.14.6726; Motohashi H, 1997, NUCLEIC ACIDS RES, V25, P2953, DOI 10.1093/nar/25.15.2953; NAYA FJ, 1995, GENE DEV, V9, P1009, DOI 10.1101/gad.9.8.1009; Naya FJ, 1997, GENE DEV, V11, P2323, DOI 10.1101/gad.11.18.2323; NISHIZAWA M, 1989, P NATL ACAD SCI USA, V86, P7711, DOI 10.1073/pnas.86.20.7711; OCHMAN H, 1988, GENETICS, V120, P621; Ogino H, 1998, SCIENCE, V280, P115, DOI 10.1126/science.280.5360.115; OHLSSON H, 1993, EMBO J, V12, P4251, DOI 10.1002/j.1460-2075.1993.tb06109.x; Ohneda K, 2000, MOL CELL BIOL, V20, P900, DOI 10.1128/MCB.20.3.900-911.2000; Ohneda K, 2000, SEMIN CELL DEV BIOL, V11, P227, DOI 10.1006/scdb.2000.0171; Olbrot M, 2002, P NATL ACAD SCI USA, V99, P6737, DOI 10.1073/pnas.102168499; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; PETERSEN HV, 1994, P NATL ACAD SCI USA, V91, P10465, DOI 10.1073/pnas.91.22.10465; Planque N, 2001, J BIOL CHEM, V276, P35751, DOI 10.1074/jbc.M104523200; Rehemtulla A, 1996, P NATL ACAD SCI USA, V93, P191, DOI 10.1073/pnas.93.1.191; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHREIBERAGUS N, 1995, CELL, V80, P777, DOI 10.1016/0092-8674(95)90356-9; SHARMA A, 1995, MOL ENDOCRINOL, V9, P1468, DOI 10.1210/me.9.11.1468; SHARMA A, 1994, MOL CELL BIOL, V14, P871, DOI 10.1128/MCB.14.2.871; SHIEH SY, 1991, J BIOL CHEM, V266, P16708; Stoffers DA, 1997, NAT GENET, V15, P106, DOI 10.1038/ng0197-106; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; SWAROOP A, 1992, P NATL ACAD SCI USA, V89, P266, DOI 10.1073/pnas.89.1.266; WHELAN J, 1989, MOL CELL BIOL, V9, P3253, DOI 10.1128/MCB.9.8.3253; Zhao L, 2000, J BIOL CHEM, V275, P10532, DOI 10.1074/jbc.275.14.10532	58	172	189	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49903	49910		10.1074/jbc.M206796200	http://dx.doi.org/10.1074/jbc.M206796200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12368292	hybrid			2022-12-25	WOS:000180028900105
J	Ozbek, S; Pertz, O; Schwager, M; Lustig, A; Holstein, T; Engel, J				Ozbek, S; Pertz, O; Schwager, M; Lustig, A; Holstein, T; Engel, J			Structure/function relationships in the minicollagen of hydra nematocysts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MINI-COLLAGENS	The minicollagens found in the inner layer of the Hydra nematocyst walls are the smallest collagens known with 12-16 Gly-X-Y repeats. Minicollagen-1, the best characterized member of this protein family so far, consists of a central collagen triple helix of 12 nm in length flanked at both ends by a polyproline stretch and a conserved cysteine-rich domain. The cysteine-rich tails are proposed to function in the assembly of soluble minicollagen trimers to high molecular structures by a switch of the disulfide linkage from intramolecular to intermolecular bonds. In this study, we investigate the trimeric nature of minicollagen-1 and its capacity to form disulfide-linked polymers in vitro. A fusion protein of minicollagen-1 with maltose-binding protein is secreted as a soluble trimer with only intrachain and no interchain disulfide bridges as confirmed by melting the collagen triple helix under reducing and non-reducing conditions. The conversion of minicollagen-1 trimers to monomers takes place between 40 and 55 degreesC with the melting point being similar to45 degreesC. Oxidative reshuffling of the minicollagen-1 trimers leads to the formation of high molecular aggregates, which upon reduction show distinct polytrimeric states. Minicollagen trimers in isolated nematocyst capsules proved to be sensitive to SDS and were engaged in polymeric structures with additional cross-links that were resistant to reducing agent.	Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Tech Univ Darmstadt, Inst Zool, D-64287 Darmstadt, Germany	University of Basel; Scripps Research Institute; Technical University of Darmstadt	Engel, J (corresponding author), Univ Basel, Biozentrum, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.		Özbek, Suat/D-3701-2014	pertz, olivier/0000-0001-8579-4919; Holstein, Thomas/0000-0003-0480-4674; Ozbek, Suat/0000-0003-2569-3942				Anderluh G, 2000, BBA-PROTEIN STRUCT M, V1476, P372, DOI 10.1016/S0167-4838(99)00237-X; BAILEY AJ, 1971, FEBS LETT, V18, P154, DOI 10.1016/0014-5793(71)80433-7; BLANQUET R, 1966, SCIENCE, V154, P152, DOI 10.1126/science.154.3745.152; Engel J, 1997, SCIENCE, V277, P1785, DOI 10.1126/science.277.5333.1785; Engel U, 2002, J CELL SCI, V115, P3923, DOI 10.1242/jcs.00084; Engel U, 2001, EMBO J, V20, P3063, DOI 10.1093/emboj/20.12.3063; HO SN, 1990, DNA PROTEIN ENG TECH, V2, P50; HOLSTEIN T, 1984, SCIENCE, V223, P830, DOI 10.1126/science.6695186; HOLSTEIN T, 1981, J ULTRA MOL STRUCT R, V75, P276, DOI 10.1016/S0022-5320(81)80085-8; HOLSTEIN TW, 1994, SCIENCE, V265, P402, DOI 10.1126/science.265.5170.402; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KURZ EM, 1991, J CELL BIOL, V115, P1159, DOI 10.1083/jcb.115.4.1159; LENHOFF HM, 1957, BIOCHIM BIOPHYS ACTA, V26, P204, DOI 10.1016/0006-3002(57)90074-4; Mazzorana M, 2001, J BIOL CHEM, V276, P27989, DOI 10.1074/jbc.M101633200; Myllyharju J, 2000, BIOCHEM SOC T, V28, P353, DOI 10.1042/bst0280353; Ozbek S, 2002, J STRUCT BIOL, V137, P11, DOI 10.1006/jsbi.2002.4436; RIGBY BJ, 1975, NATURE, V253, P277, DOI 10.1038/253277a0; SCHROEDER LA, 1981, LIMNOL OCEANOGR, V24, P1092; SKAER RJ, 1973, J CELL SCI, V13, P371; Szczepanek S, 2002, J CELL SCI, V115, P745; WAGNER DD, 1987, BLOOD, V69, P27; WEBER J, 1990, TOXICON, V28, P403, DOI 10.1016/0041-0101(90)90078-L; WEBER J, 1990, J BIOL CHEM, V265, P9664	23	32	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49200	49204		10.1074/jbc.M209401200	http://dx.doi.org/10.1074/jbc.M209401200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12368276	hybrid			2022-12-25	WOS:000180028900013
J	Paris, R; Morales, A; Coll, O; Sanchez-Reyes, A; Garcia-Ruiz, C; Fernandez-Checa, JC				Paris, R; Morales, A; Coll, O; Sanchez-Reyes, A; Garcia-Ruiz, C; Fernandez-Checa, JC			Ganglioside GD3 sensitizes human hepatoma cells to cancer therapy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MITOCHONDRIAL PERMEABILITY TRANSITION; MULTIDRUG-RESISTANCE; IONIZING-RADIATION; INDUCED APOPTOSIS; INHIBITION; CERAMIDE; EXPRESSION; ACTIVATION; CHEMORESISTANCE	Ganglioside GD3 (GD3) has emerged as a modulator of cell death pathways due to its ability to interact with mitochondria and disable survival pathways. Because NF-kappaB activation contributes to cancer therapy resistance, this study was undertaken to test whether GD3 modulates the response of human hepatoblastoma HepG2 cells to radio- and chemotherapy. NF-kappaB was activated in HepG2 cells shortly after therapeutic doses of ionizing radiation or daunorubicin treatment that translated into up-regulation of kappaB-dependent genes. These effects were accompanied by minimal killing of HepG2 cells by either ionizing radiation or daunorubicin. However, GD3 pretreatment blocked the nuclear translocation of active kappaB members, without effect on Akt phosphorylation, induced by either treatment. The suppression of kappaB-dependent gene induction by GD3 was accompanied by enhanced apoptotic cell death caused by these therapies. Furthermore, the combination of GD3 plus ionizing radiation stimulated the formation of reactive species followed by the mitochondrial release of cytochrome c and Smac/Diablo and caspase 3 activation. Pretreatment with cyclosporin A before radiotherapy protected HepG2 cells from the therapeutic combination of GD3 plus ionizing radiation. These findings underscore a key role of mitochondria in the response of tumor cells to cancer therapy and highlight the potential relevance of GD3 to overcome resistance to cancer therapy by combining its dual action as a mitochondria-interacting and NF-kappaB-inactivating agent.	Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Barcelona 08036, Spain; Hosp Clin Barcelona, Serv Radioterapia, Inst Invest Biomed Augusts Pi Suner, Barcelona 08036, Spain; CSIC, Dept Expt Pathol, Inst Invest Biomed, Barcelona 08036, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas de Barcelona (IIBB)	Fernandez-Checa, JC (corresponding author), Hosp Clin Barcelona, Liver Unit, Inst Malalties Digest, Barcelona 08036, Spain.	checa229@yahoo.com	Morales, Albert/E-2988-2013; Coll, Olga/H-6129-2015; Garcia-Ruiz, Carmen/L-8211-2014; Fernández-Checa, José Carlos/L-8342-2014	Morales, Albert/0000-0001-8702-2269; Coll, Olga/0000-0002-7946-1250; Garcia-Ruiz, Carmen/0000-0002-2652-6102; Fernández-Checa, José Carlos/0000-0003-3422-2990	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [P50AA011999] Funding Source: NIH RePORTER; NIAAA NIH HHS [P50 AA 11999] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Baldini N, 1997, NAT MED, V3, P378, DOI 10.1038/nm0497-378; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1992, GENE DEV, V6, P1899, DOI 10.1101/gad.6.10.1899; Boland MP, 1997, J BIOL CHEM, V272, P12952, DOI 10.1074/jbc.272.20.12952; BRACH MA, 1991, J CLIN INVEST, V88, P691, DOI 10.1172/JCI115354; Brenner C, 2000, SCIENCE, V289, P1150, DOI 10.1126/science.289.5482.1150; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Colell A, 2002, FEBS LETT, V526, P15, DOI 10.1016/S0014-5793(02)03106-X; Colell Anna, 2001, FASEB Journal, V15, P1068; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Cusack JC, 1999, DRUG RESIST UPDATE, V2, P271, DOI 10.1054/drup.1999.0094; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Degli Esposti M, 1998, FEBS LETT, V430, P338, DOI 10.1016/S0014-5793(98)00688-7; DeMaria R, 1997, SCIENCE, V277, P1652, DOI 10.1126/science.277.5332.1652; di Bartolomeo S, 2001, BIOCHEM BIOPH RES CO, V288, P269, DOI 10.1006/bbrc.2001.5748; FISHER DE, 1994, CELL, V78, P539, DOI 10.1016/0092-8674(94)90518-5; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 2002, J BIOL CHEM, V277, P36443, DOI 10.1074/jbc.M206021200; GarciaRuiz C, 1997, J BIOL CHEM, V272, P11369; Giammarioli AM, 2001, FEBS LETT, V506, P45, DOI 10.1016/S0014-5793(01)02776-4; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Hakomori S, 2000, GLYCOCONJUGATE J, V17, P143, DOI 10.1023/A:1026524820177; Hatano E, 2001, GASTROENTEROLOGY, V120, P1251, DOI 10.1053/gast.2001.23239; Kristal BS, 1999, J BIOL CHEM, V274, P23169, DOI 10.1074/jbc.274.33.23169; Lavie Y, 1997, J BIOL CHEM, V272, P1682, DOI 10.1074/jbc.272.3.1682; Lavie Y, 1996, J BIOL CHEM, V271, P19530, DOI 10.1074/jbc.271.32.19530; Leach JK, 2001, CANCER RES, V61, P3894; Lemasters JJ, 1999, AM J PHYSIOL-GASTR L, V276, pG1, DOI 10.1152/ajpgi.1999.276.1.G1; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; Morales A, 1998, FEBS LETT, V427, P15, DOI 10.1016/S0014-5793(98)00381-0; QuilletMary A, 1997, J BIOL CHEM, V272, P21388, DOI 10.1074/jbc.272.34.21388; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; Rippo MR, 2000, FASEB J, V14, P2047, DOI 10.1096/fj.99-1028com; Roman J, 2000, J BIOL CHEM, V275, P14684, DOI 10.1074/jbc.275.19.14684; Russo SM, 2001, INT J RADIAT ONCOL, V50, P183, DOI 10.1016/S0360-3016(01)01446-8; Scorrano L, 1999, J BIOL CHEM, V274, P22581, DOI 10.1074/jbc.274.32.22581; Shimada M, 1996, HEPATO-GASTROENTEROL, V43, P1159; SPITALNIK PF, 1989, ARCH BIOCHEM BIOPHYS, V273, P578, DOI 10.1016/0003-9861(89)90518-3; Tanaka H, 2002, MOL CELL, V9, P1017, DOI 10.1016/S1097-2765(02)00522-1; Uzzo RG, 1999, J CLIN INVEST, V104, P769, DOI 10.1172/JCI6775; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; Veldman RJ, 2002, FASEB J, V16, P1111, DOI 10.1096/fj.01-0863fje; Wang CY, 1999, MOL CELL BIOL, V19, P5923; Wang CY, 1999, NAT MED, V5, P412, DOI 10.1038/7410; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang XD, 2001, GENE DEV, V15, P2922; Watanabe R, 2002, CANCER RES, V62, P3850	52	40	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49870	49876		10.1074/jbc.M208303200	http://dx.doi.org/10.1074/jbc.M208303200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12351644	hybrid			2022-12-25	WOS:000180028900101
J	Gross, S; Blanchetot, C; Schepens, J; Albet, S; Lammers, R; den Hertog, J; Hendriks, W				Gross, S; Blanchetot, C; Schepens, J; Albet, S; Lammers, R; den Hertog, J; Hendriks, W			Multimerization of the protein-tyrosine phosphatase (PTP)-like insulin-dependent diabetes mellitus autoantigens IA-2 and IA-2 beta with receptor PTPs (RPTPs) - Inhibition of RPTP alpha enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; INTRAMOLECULAR INTERACTIONS; CAENORHABDITIS-ELEGANS; CYTOPLASMIC DOMAIN; MEMBRANE-PROTEIN; PDZ MOTIFS; TRANSMEMBRANE; DIMERIZATION; EXPRESSION; HOMOLOG	Most receptor-type protein-tyrosine phosphatases (RPTPs) contain two tandem PTP domains. For some RPTPs the enzymatically inactive membrane-distal phosphatase domains (D2) were found to bind enzymatically active membrane proximal PTP (D1) domains, and oligomerization has been proposed as a general regulatory mechanism. The RPTP-like proteins IA-2 and IA-2beta, major autoantigens in insulin-dependent diabetes mellitus, contain just a single enzymatically inactive PTP-like domain. Their physiological role is as yet enigmatic. To investigate whether the catalytically inactive cytoplasmic domains of IA-2 and IA-2beta are involved in oligomerization, we exploited interaction trap assay in yeast and glutathione S-transferase pull-down and co-immunoprecipitation strategies on lysates of transfected COS-1 cells. The results show that IA-2 and IA-2beta are capable of homo- and heterodimerization to which both the juxtamembrane region and the phosphatase-like segment can contribute. Furthermore, they can form heterodimers with some other RPTP members, most notably RPTPalpha and RPTPepsilon, and down-regulate RPTPalpha enzymatic activity. Thus, in addition to homodimerization, the enzymatic activity of receptor-type PTPs can be regulated through heterodimerization with other RPTPs, including the catalytically inactive IA-2 and IA-2beta.	Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, NL-6525 GA Nijmegen, Netherlands; Netherlands Inst Dev Biol, Hubrecht Lab, NL-3584 CT Utrecht, Netherlands; Dept Internal Med 4, D-72076 Tubingen, Germany	Radboud University Nijmegen; Royal Netherlands Academy of Arts & Sciences; Hubrecht Institute (KNAW)	Hendriks, W (corresponding author), Univ Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Cell Biol, POB 9101, NL-6500 HB Nijmegen, Netherlands.	w.hendriks@ncmls.kun.nl	Hendriks, Wiljan J.A.J./A-5214-2013; Hendriks, Wiljan/Q-4325-2019	Hendriks, Wiljan J.A.J./0000-0001-9481-8281; Hendriks, Wiljan/0000-0001-9481-8281; Blanchetot, christophe/0000-0001-9152-9978				Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Aricescu AR, 2001, BIOCHEM BIOPH RES CO, V280, P319, DOI 10.1006/bbrc.2000.4094; Berghs S, 2000, J CELL BIOL, V151, P985, DOI 10.1083/jcb.151.5.985; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; Blanchetot C, 2000, FEBS LETT, V484, P235, DOI 10.1016/S0014-5793(00)02165-7; Blanchetot C, 2000, J BIOL CHEM, V275, P12446, DOI 10.1074/jbc.275.17.12446; Blanchetot C, 2002, EMBO J, V21, P493, DOI 10.1093/emboj/21.4.493; Buist P, 1999, BIOCHEMISTRY-US, V38, P914, DOI 10.1021/bi981936b; Cai T, 2001, DIABETOLOGIA, V44, P81, DOI 10.1007/s001250051583; Chiang MK, 1996, DEVELOPMENT, V122, P2239; Cui L, 1998, J BIOL CHEM, V273, P34784, DOI 10.1074/jbc.273.52.34784; Cui L, 1996, J BIOL CHEM, V271, P24817, DOI 10.1074/jbc.271.40.24817; Cuppen E, 2000, EUR J CELL BIOL, V79, P283, DOI 10.1078/S0171-9335(04)70031-X; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; den Hertog J, 1999, MECH DEVELOP, V85, P3, DOI 10.1016/S0925-4773(99)00089-1; DESAI DM, 1993, CELL, V73, P541, DOI 10.1016/0092-8674(93)90141-C; Feiken E, 2000, J BIOL CHEM, V275, P15350, DOI 10.1074/jbc.275.20.15350; Felberg J, 1998, J BIOL CHEM, V273, P17839, DOI 10.1074/jbc.273.28.17839; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Gross S, 1999, J BIOL CHEM, V274, P26378, DOI 10.1074/jbc.274.37.26378; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hermel JM, 1999, EUR J NEUROSCI, V11, P2609, DOI 10.1046/j.1460-9568.1999.00677.x; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Jiang GQ, 2000, MOL CELL BIOL, V20, P5917, DOI 10.1128/MCB.20.16.5917-5929.2000; KARI B, 1986, J VIROL, V60, P345, DOI 10.1128/JVI.60.2.345-352.1986; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; LAN MS, 1994, DNA CELL BIOL, V13, P505, DOI 10.1089/dna.1994.13.505; Li Q, 1997, P ASSOC AM PHYSICIAN, V109, P429; Lim KL, 1998, J BIOL CHEM, V273, P28986, DOI 10.1074/jbc.273.44.28986; Lu J, 1996, P NATL ACAD SCI USA, V93, P2307, DOI 10.1073/pnas.93.6.2307; Maehama T, 1999, TRENDS CELL BIOL, V9, P125, DOI 10.1016/S0962-8924(99)01519-6; Magistrelli G, 1996, BIOCHEM BIOPH RES CO, V227, P581, DOI 10.1006/bbrc.1996.1549; MAGISTRELLI G, 1995, BIOCHEM BIOPH RES CO, V217, P154, DOI 10.1006/bbrc.1995.2758; Majeti R, 1998, SCIENCE, V279, P88, DOI 10.1126/science.279.5347.88; Majeti R, 2001, CHEM REV, V101, P2441, DOI 10.1021/cr000085m; Majeti R, 2000, CELL, V103, P1059, DOI 10.1016/S0092-8674(00)00209-9; MAURO LJ, 1994, TRENDS BIOCHEM SCI, V19, P151, DOI 10.1016/0968-0004(94)90274-7; Nam HJ, 1999, CELL, V97, P449, DOI 10.1016/S0092-8674(00)80755-2; OGATA M, 1995, J BIOL CHEM, V270, P2337, DOI 10.1074/jbc.270.25.15076; Ort T, 2001, EMBO J, V20, P4013, DOI 10.1093/emboj/20.15.4013; Ort T, 2000, EUR J CELL BIOL, V79, P621, DOI 10.1078/0171-9335-00095; OSTMAN A, 1994, P NATL ACAD SCI USA, V91, P9680, DOI 10.1073/pnas.91.21.9680; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; RABIN DU, 1994, J IMMUNOL, V152, P3183; Schaapveld R, 1997, MOL BIOL REP, V24, P247, DOI 10.1023/A:1006870016238; SCHAAPVELD RQJ, 1995, GENOMICS, V27, P124, DOI 10.1006/geno.1995.1014; Smith PD, 1996, BIOCHEM BIOPH RES CO, V229, P402, DOI 10.1006/bbrc.1996.1817; Solimena M, 1996, EMBO J, V15, P2102, DOI 10.1002/j.1460-2075.1996.tb00564.x; STREULI M, 1990, EMBO J, V9, P2399, DOI 10.1002/j.1460-2075.1990.tb07415.x; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; van den Maagdenberg AMJM, 1999, EUR J NEUROSCI, V11, P3832, DOI 10.1046/j.1460-9568.1999.00802.x; Wallace MJ, 1998, MOL CELL BIOL, V18, P2608, DOI 10.1128/MCB.18.5.2608; Wasmeier C, 1999, BIOCHEM J, V341, P563, DOI 10.1042/0264-6021:3410563; Wasmeier C, 1996, J BIOL CHEM, V271, P18161, DOI 10.1074/jbc.271.30.18161; Wishart MJ, 1998, TRENDS BIOCHEM SCI, V23, P301, DOI 10.1016/S0968-0004(98)01241-9; Zahn TR, 2001, J COMP NEUROL, V429, P127, DOI 10.1002/1096-9861(20000101)429:1&lt;127::AID-CNE10&gt;3.0.CO;2-H	56	34	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48139	48145		10.1074/jbc.M208228200	http://dx.doi.org/10.1074/jbc.M208228200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12364328	hybrid, Green Published			2022-12-25	WOS:000179789600023
J	Wu, SSH; Suen, DF; Chang, HC; Huang, AHC				Wu, SSH; Suen, DF; Chang, HC; Huang, AHC			Maize tapetum xylanase is synthesized as a precursor, processed and activated by a serine protease, and deposited on the pollen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION PATTERNS; BRASSICA-NAPUS; BARLEY-ALEURONE; ENDOXYLANASE; LAYER; COAT	Pollen coat contains ingredients that interact with the stigma surface during sexual reproduction. In maize (Zea mays L.) pollen coat, the predominant protein is a 35-kDa endoxylanase, whose mRNA is located in the tapetum. cells enclosing the maturing pollen in the anthers. This 2.0-kb mRNA was found to have an open reading frame of 1,635 nucleotides encoding a 60-kDa pre-xylanase. In developing anthers, the pre-xylanase protein appeared prior to the 35-kDa xylanase protein and enzyme activity and then peaked and declined, whereas the 35-kDa xylanase protein and activity continued to increase until anther maturation. An acid protease in the anther extract converted the inactive pre-xylanase to the active 35-kDa xylanase in vitro. The protease activity was inhibited by inhibitors of serine proteases but unaffected by inhibitors of cysteine, aspartic, or metallic proteases. Sequence analysis revealed that the 60-kDa pre-xylanase was converted to the 35-kDa xylanase with the removal of 198 and 48 residues from the N and C termini, respectively. During in vitro and in vivo conversions, no intermediates of 60-35 kDa were observed, and the 35-kDa xylanase was highly stable. The pre-xylanase was localized in the tapetum-containing anther wall, whereas the 35-kDa xylanase was found in the pollen coat. The significance of having a large non-active pre-xylanase and the mode of transfer of the xylanase to the pollen coat are discussed. A gene encoding the barley (Hordeum vulgare L.) tapetum xylanase was cloned; this gene and the gene encoding the seed aleurone-layer xylanase had strict tissue-specific expressions.	Univ Calif Riverside, Dept Bot & Plant Sci, Riverside, CA 92521 USA; Univ Calif Riverside, Ctr Plant Cell Biol, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Huang, AHC (corresponding author), Univ Calif Riverside, Dept Bot & Plant Sci, Riverside, CA 92521 USA.		Suen, Der-Fen/ACF-7547-2022					Bewley JD, 2000, BIOCH MOL BIOL PLANT, P988; Beynon R.J., 1989, PROTEOLYTIC ENZYMES; Bih FY, 1999, J BIOL CHEM, V274, P22884, DOI 10.1074/jbc.274.32.22884; Caspers MPM, 2001, PLANT J, V26, P191, DOI 10.1046/j.0960-7412.2001.01019.x; Cleemput G, 1997, PLANT PHYSIOL, V115, P619; DASHEK WV, 1977, PLANTA, V134, P251, DOI 10.1007/BF00384189; DOUGHTY J, 1993, P NATL ACAD SCI USA, V90, P467, DOI 10.1073/pnas.90.2.467; Heslop-Harrison Y, 2000, ANN BOT-LONDON, V85, P5, DOI 10.1006/anbo.1999.1063; HIRD DL, 1993, PLANT J, V4, P1023, DOI 10.1046/j.1365-313X.1993.04061023.x; HORNER HT, 1993, PROTOPLASMA, V173, P48, DOI 10.1007/BF01378861; Kachroo A, 2002, PLANT CELL, V14, pS227, DOI 10.1105/tpc.010440; Kim HU, 2002, J BIOL CHEM, V277, P22677, DOI 10.1074/jbc.M109298200; KOLTUNOW AM, 1990, PLANT CELL, V2, P1201, DOI 10.1105/tpc.2.12.1201; LOUKIDES CA, 1995, AM J BOT, V82, P1017, DOI 10.2307/2446231; MASCARENHAS JP, 1993, PLANT CELL, V5, P1303, DOI 10.1105/tpc.5.10.1303; Mayfield JA, 2001, SCIENCE, V292, P2482, DOI 10.1126/science.1060972; McCormick S, 1998, CURR OPIN PLANT BIOL, V1, P18, DOI 10.1016/S1369-5266(98)80122-2; PAUL W, 1992, PLANT MOL BIOL, V19, P611, DOI 10.1007/BF00026787; Piffanelli P, 1997, PLANT J, V11, P549, DOI 10.1046/j.1365-313X.1997.11030549.x; Ruiter RK, 1997, PLANT CELL, V9, P1621, DOI 10.1105/tpc.9.9.1621; SAINI JP, 1986, MAYDICA, V31, P227; Sambrook J., 2002, MOL CLONING LAB MANU; STAIGER D, 1994, PLANTA, V192, P221, DOI 10.1007/BF01089038; Suen DF, 1997, THEOR APPL GENET, V94, P331, DOI 10.1007/s001220050420; Ting JTL, 1998, PLANT J, V16, P541, DOI 10.1046/j.1365-313x.1998.00325.x; VERWOERD TC, 1989, NUCLEIC ACIDS RES, V17, P2362, DOI 10.1093/nar/17.6.2362; WANG SM, 1987, J BIOL CHEM, V262, P2270; Wu SSH, 1997, P NATL ACAD SCI USA, V94, P12711, DOI 10.1073/pnas.94.23.12711	30	36	40	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49055	49064		10.1074/jbc.M208804200	http://dx.doi.org/10.1074/jbc.M208804200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368281	hybrid			2022-12-25	WOS:000179789600139
J	Blystone, SD				Blystone, SD			Kinetic regulation of beta(3) integrin tyrosine phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN	Tyrosine phosphorylation of beta(3) integrins is a permissive stage in the activation of alpha(IIb)beta(3) and alpha(v)beta(3) in platelets and leukocytes, respectively. In this study we demonstrated direct phosphorylation of beta(3) integrins as a result of interaction with soluble monomeric ligand, and we characterized the differential kinetics of beta(3) phosphorylation as a consequence of alpha subunit pairing. We found that beta(3) phosphorylation is initiated by RGD peptide binding in a dose-dependent and saturable fashion with alpha(IIb)beta(3) becoming phosphorylated and dephosphorylated more rapidly than alpha(v)beta(3). Site mapping of phosphate incorporation reveals significant phosphorylation at Tyr-747 in both beta(3) integrin species with incorporation at Tyr-759 found at significant levels only in alpha(IIb)beta(3). Mutation of cytoplasmic beta(3) tyrosine residues in a transfection model prevents cell adhesion via these integrins. These data demonstrate that recognition of ligand is sufficient to induce beta(3) tyrosine phosphorylation and suggests that this event is regulated by the alpha subunit pairing of beta(3).	SUNY Upstate Med Univ, Dept Cell & Dev Biol, Syracuse, NY 13210 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	Blystone, SD (corresponding author), SUNY Upstate Med Univ, Dept Cell & Dev Biol, 750 E Adams St, Syracuse, NY 13210 USA.	blystons@mail.upstate.edu						Blystone SD, 1996, J BIOL CHEM, V271, P31458, DOI 10.1074/jbc.271.49.31458; Blystone SD, 1997, J BIOL CHEM, V272, P28757, DOI 10.1074/jbc.272.45.28757; Boettiger D, 2001, MOL BIOL CELL, V12, P1227, DOI 10.1091/mbc.12.5.1227; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Jenkins AL, 1998, J BIOL CHEM, V273, P13878, DOI 10.1074/jbc.273.22.13878; Law DA, 1999, NATURE, V401, P808, DOI 10.1038/44599; Law DA, 1996, J BIOL CHEM, V271, P10811, DOI 10.1074/jbc.271.18.10811; Liu SC, 2000, J CELL SCI, V113, P3563; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777	9	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46886	46890		10.1074/jbc.M209506200	http://dx.doi.org/10.1074/jbc.M209506200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359711	hybrid			2022-12-25	WOS:000179663700009
J	Funk, JD; Nedialkov, YA; Xu, DP; Burton, ZF				Funk, JD; Nedialkov, YA; Xu, DP; Burton, ZF			A key role for the alpha 1 helix of human RAP74 in the initiation and elongation of RNA chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-IIF; PROTEIN SECONDARY STRUCTURE; POLYMERASE-II; PREINITIATION COMPLEX; NEURAL NETWORKS; FACTOR TFIIF; SUBUNIT; RAP30; CDNA; PREDICTION	RNA polymerase II-associating protein 74 (RAP74) is the large subunit of transcription factor IIF (TFIIF), which is essential for accurate initiation and stimulates elongation by RNA polymerase II. Mutations within or adjacent to the alpha1 helix of the RAP74 subunit have been shown to decrease both initiation and elongation stimulation activities without strongly affecting the interactions of RAP74 with the RAP30 subunit or the interaction between TFIIF and RNA polymerase II. In this manuscript, mutations within the alpha1 helix are compared with mutations made throughout the neighboring conserved N-terminal domain of RAP74. Changes within the N-terminal domain include disruptions of specific contacts with the alpha1 helix, which were revealed in the recently published x-ray crystal structure (Gaiser, F., Tan, S., and Richmond, T. J. (2000) J. Mol. Biol. 302, 1119-1127). Contacts between the 134-135 loop and the alpha1 helix are shown to be largely unimportant for alpha1 helix function. Other mutations throughout the N-terminal domain are consistent with the establishment of the dimer interface with the RAP30 subunit. The RAP74-RAP30 interface is important for TFIIF function, but no particular RAP74 amino acids within this region have been identified that are required for TFIIF activities. The molecular target of the alpha1 helix remains unknown, but our studies refocus attention on this important functional motif of TFIIF.	Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University	Burton, ZF (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.							ASO T, 1992, NATURE, V355, P461, DOI 10.1038/355461a0; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; FINKELSTEIN A, 1992, NATURE, V355, P464, DOI 10.1038/355464a0; Gaiser F, 2000, J MOL BIOL, V302, P1119, DOI 10.1006/jmbi.2000.4110; GONG DW, 1993, NUCL ACIDS RES; Groft CM, 1998, P NATL ACAD SCI USA, V95, P9117, DOI 10.1073/pnas.95.16.9117; HENRY NL, 1994, GENE DEV, V8, P2868, DOI 10.1101/gad.8.23.2868; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; Kamada K, 2001, P NATL ACAD SCI USA, V98, P3115, DOI 10.1073/pnas.051631098; KEPHART DD, 1993, NUCLEIC ACIDS RES, V21, P1319, DOI 10.1093/nar/21.5.1319; Lei L, 1999, MOL CELL BIOL, V19, P8372; Lei L, 1998, MOL CELL BIOL, V18, P2130, DOI 10.1128/MCB.18.4.2130; NIU W, 1994, J MOL BIOL, V243, P595, DOI 10.1016/0022-2836(94)90034-5; PRICE DH, 1989, MOL CELL BIOL, V9, P1465, DOI 10.1128/MCB.9.4.1465; Ren DL, 1999, MOL CELL BIOL, V19, P7377; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Rost B, 1996, METHOD ENZYMOL, V266, P525; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Samkurashvili I, 1996, J BIOL CHEM, V271, P23495, DOI 10.1074/jbc.271.38.23495; SUN ZW, 1995, P NATL ACAD SCI USA, V92, P3127, DOI 10.1073/pnas.92.8.3127; TAN SY, 1994, J BIOL CHEM, V269, P25684; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; WANG BQ, 1994, PROTEIN EXPRES PURIF, V5, P476, DOI 10.1006/prep.1994.1067; WANG BQ, 1993, PROTEIN EXPRES PURIF, V4, P207, DOI 10.1006/prep.1993.1027	25	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46998	47003		10.1074/jbc.M206249200	http://dx.doi.org/10.1074/jbc.M206249200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354769	hybrid			2022-12-25	WOS:000179663700023
J	Junn, E; Lee, SS; Suhr, UT; Mouradian, MM				Junn, E; Lee, SS; Suhr, UT; Mouradian, MM			Parkin accumulation in aggresomes due to proteasome impairment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEIN LIGASE; ALPHA-SYNUCLEIN; LEWY BODIES; INCLUSION-BODIES; DROSOPHILA MODEL; BODY FORMATION; IN-VITRO; DISEASE; SYNPHILIN-1; ASSOCIATION	Parkinson's disease (PD) is characterized by loss of dopaminergic neurons in the substantia nigra and by the presence of ubiquitinated cytoplasmic inclusions known as Lewy bodies. alpha-Synuclein and Parkin are two of the proteins associated with inherited forms of PD and are found in Lewy bodies. Whereas numerous reports indicate the tendency of alpha-synuclein to aggregate both in vitro and in vivo, no information is available about similar physical properties for Parkin. Here we show that overexpression of Parkin in the presence of proteasome inhibitors leads to the formation of aggresome-like perinuclear inclusions. These eosinophilic inclusions share many characteristics with Lewy bodies, including a core and halo organization, immunoreactivity to ubiquitin, alpha-synuclein, synphilin-1, Parkin, molecular chaperones, and proteasome subunit as well as staining of some with thioflavin S. We propose that the process of Lewy body formation may be akin to that of aggresome-like structures. The tendency of wild-type Parkin to aggregate and form inclusions may have implications for the pathogenesis of sporadic PD.	NINDS, Expt Therapeut Branch, Genet Pharmacol Unit, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	Mouradian, MM (corresponding author), NINDS, Expt Therapeut Branch, Genet Pharmacol Unit, NIH, 10 Ctr Dr,MSC 1406, Bethesda, MD 20892 USA.	MouradianM@ninds.nih.gov		Mouradian, M. Maral/0000-0002-9937-412X	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002826] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARAI H, 1992, BRAIN RES, V585, P386, DOI 10.1016/0006-8993(92)91242-7; Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Baas PW, 1998, J CHEM NEUROANAT, V14, P175, DOI 10.1016/S0891-0618(98)00012-X; Choi P, 2000, NEUROREPORT, V11, P2635, DOI 10.1097/00001756-200008210-00006; Choi P, 2001, NEUROREPORT, V12, P2839, DOI 10.1097/00001756-200109170-00017; Chung KKK, 2001, NAT MED, V7, P1144, DOI 10.1038/nm1001-1144; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Dictenberg JB, 1998, J CELL BIOL, V141, P163, DOI 10.1083/jcb.141.1.163; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; ESIRI MM, 1997, GREENFIELDS NEUROPAT, V2, P153; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; GOLDMAN JE, 1983, SCIENCE, V221, P1082, DOI 10.1126/science.6308771; HARTL FU, 1995, CURR OPIN STRUC BIOL, V5, P92; Hashimoto M, 1998, BRAIN RES, V799, P301, DOI 10.1016/S0006-8993(98)00514-9; Ii K, 1997, J NEUROPATH EXP NEUR, V56, P125, DOI 10.1097/00005072-199702000-00002; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Iwatsubo T, 1996, AM J PATHOL, V148, P1517; Jenner P, 1998, ANN NEUROL, V44, pS72, DOI 10.1002/ana.410440712; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Kubo S, 2001, J NEUROCHEM, V78, P42, DOI 10.1046/j.1471-4159.2001.00364.x; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; LOWE J, 1990, J PATHOL, V161, P153, DOI 10.1002/path.1711610210; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Mayer R J, 1989, Prog Clin Biol Res, V317, P809; McNaught KSP, 2001, NEUROSCI LETT, V297, P191, DOI 10.1016/S0304-3940(00)01701-8; McNaught KSP, 2001, NAT REV NEUROSCI, V2, P589, DOI 10.1038/35086067; POLLANEN MS, 1993, J NEUROPATH EXP NEUR, V52, P183, DOI 10.1097/00005072-199305000-00001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Qiu JH, 2000, J NEUROSCI, V20, P259, DOI 10.1523/JNEUROSCI.20-01-00259.2000; Rideout HJ, 2001, J NEUROCHEM, V78, P899, DOI 10.1046/j.1471-4159.2001.00474.x; Schlossmacher MG, 2002, AM J PATHOL, V160, P1655, DOI 10.1016/S0002-9440(10)61113-3; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 2001, SCIENCE, V293, P263, DOI 10.1126/science.1060627; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Tanaka Y, 2001, HUM MOL GENET, V10, P919, DOI 10.1093/hmg/10.9.919; TROJANOWSKI JQ, 1993, BRAIN PATHOL, V3, P45, DOI 10.1111/j.1750-3639.1993.tb00725.x; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; Waelter S, 2001, MOL BIOL CELL, V12, P1393, DOI 10.1091/mbc.12.5.1393; Wakabayashi K, 2000, ANN NEUROL, V47, P521, DOI 10.1002/1531-8249(200004)47:4<521::AID-ANA18>3.3.CO;2-2; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wigley WC, 1999, J CELL BIOL, V145, P481; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	52	119	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47870	47877		10.1074/jbc.M203159200	http://dx.doi.org/10.1074/jbc.M203159200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12364339	hybrid			2022-12-25	WOS:000179663700133
J	Wang, CW; Stromhaug, PE; Shima, J; Klionsky, DJ				Wang, CW; Stromhaug, PE; Shima, J; Klionsky, DJ			The Ccz1-Mon1 protein complex is required for the late step of multiple vacuole delivery pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; TARGETING PATHWAY; SYNTAXIN HOMOLOG; AMINOPEPTIDASE-I; YEAST VACUOLE; CYTOPLASM; TRANSPORT; AUTOPHAGY; MEMBRANE; PEXOPHAGY	Mon1 and Ccz1 were identified from a gene deletion library as mutants defective in the vacuolar import of aminopeptidase I (Ape1) via the cytoplasm to vacuole targeting (Cvt) pathway. The mon1Delta and ccz1Delta strains also displayed defects in autophagy and pexophagy, degradative pathways that share protein machinery and mechanistic features with the biosynthetic Cvt pathway. Further analyses indicated that Mon1, like Ccz1, was required in nearly all membrane-trafficking pathways where the vacuole represented the terminal acceptor compartment. Accordingly, both deletion strains had kinetic defects in the biosynthetic delivery of resident vacuolar hydrolases through the CPY, ALP, and MVB pathways. Biochemical and microscopy studies suggested that Mon1 and Ccz1 functioned after transport vesicle formation but before (or at) the fusion step with the vacuole. Thus, ccz1Delta and mon1Delta are the first mutants identified in screens for the Cvt and Apg pathways that accumulate precursor Ape1 within completed cytosolic vesicles. Subcellular fractionation and co-immunoprecipitation experiments confirm that Mon1 and Ccz1 physically interact as a stable protein complex termed the Ccz1-Mon1 complex. Microscopy of Ccz1 and Mon1 tagged with a fluorescent marker indicated that the Ccz1-Mon1 complex peripherally associated with a perivacuolar compartment and may attach to the vacuole membrane in agreement with their proposed function in fusion.	Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Klionsky, DJ (corresponding author), Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA.		Klionsky, Daniel J./ABD-5189-2021	Klionsky, Daniel J./0000-0002-7828-8118; Wang, Chao-Wen/0000-0002-4073-299X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053396] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53396, R01 GM053396-13, R01 GM053396-12, R01 GM053396] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abeliovich H, 2000, J CELL BIOL, V151, P1025, DOI 10.1083/jcb.151.5.1025; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Chen LY, 2000, J CELL BIOL, V151, P731, DOI 10.1083/jcb.151.3.731; Cowles CR, 1997, EMBO J, V16, P2769, DOI 10.1093/emboj/16.10.2769; Darsow T, 1997, J CELL BIOL, V138, P517, DOI 10.1083/jcb.138.3.517; Gerhardt B, 1998, J BIOL CHEM, V273, P15818, DOI 10.1074/jbc.273.25.15818; Guan J, 2001, MOL BIOL CELL, V12, P3821, DOI 10.1091/mbc.12.12.3821; HARDING TM, 1995, J CELL BIOL, V131, P591, DOI 10.1083/jcb.131.3.591; Harding TM, 1996, J BIOL CHEM, V271, P17621, DOI 10.1074/jbc.271.30.17621; Huang WP, 2000, J BIOL CHEM, V275, P5845, DOI 10.1074/jbc.275.8.5845; Hutchins MU, 1999, J CELL SCI, V112, P4079; Kamada Y, 2000, J CELL BIOL, V150, P1507, DOI 10.1083/jcb.150.6.1507; Kim J, 2000, INT REV CYTOL, V198, P153; Kim J, 2000, ANNU REV BIOCHEM, V69, P303, DOI 10.1146/annurev.biochem.69.1.303; Kim J, 2002, J BIOL CHEM, V277, P763, DOI 10.1074/jbc.M109134200; Kim J, 2001, J CELL BIOL, V153, P381, DOI 10.1083/jcb.153.2.381; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Kirisako T, 2000, J CELL BIOL, V151, P263, DOI 10.1083/jcb.151.2.263; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; KLIONSKY DJ, 1988, MOL CELL BIOL, V8, P2105, DOI 10.1128/MCB.8.5.2105; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Klionsky DJ, 1998, J BIOL CHEM, V273, P10807, DOI 10.1074/jbc.273.18.10807; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; Klionsky DT, 1999, ANNU REV CELL DEV BI, V15, P1, DOI 10.1146/annurev.cellbio.15.1.1; Kucharczyk R, 1999, YEAST, V15, P987, DOI 10.1002/(SICI)1097-0061(199907)15:10B<987::AID-YEA403>3.0.CO;2-5; Kucharczyk R, 2000, J CELL SCI, V113, P4301; Kucharczyk R, 2001, J CELL SCI, V114, P3137; Lemmon SK, 2000, CURR OPIN CELL BIOL, V12, P457, DOI 10.1016/S0955-0674(00)00117-4; Muren E, 2001, YEAST, V18, P163, DOI 10.1002/1097-0061(20010130)18:2<163::AID-YEA659>3.0.CO;2-#; Noda T, 2000, J CELL BIOL, V148, P465, DOI 10.1083/jcb.148.3.465; PIPER RC, 1995, J CELL BIOL, V131, P603, DOI 10.1083/jcb.131.3.603; Reggiori F, 2001, EMBO J, V20, P5176, DOI 10.1093/emboj/20.18.5176; Rehling P, 1999, NAT CELL BIOL, V1, P346, DOI 10.1038/14037; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Sato TK, 2000, MOL CELL, V6, P661, DOI 10.1016/S1097-2765(00)00064-2; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; Scott SV, 2000, J BIOL CHEM, V275, P25840, DOI 10.1074/jbc.M002813200; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; Scott SV, 2001, MOL CELL, V7, P1131, DOI 10.1016/S1097-2765(01)00263-5; Seeley ES, 2002, MOL BIOL CELL, V13, P782, DOI 10.1091/mbc.01-10-0512; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; VIDA TA, 1995, J CELL BIOL, V128, P779, DOI 10.1083/jcb.128.5.779; von Mollard GF, 1999, MOL BIOL CELL, V10, P1719, DOI 10.1091/mbc.10.6.1719; Wang CW, 2001, J BIOL CHEM, V276, P30442, DOI 10.1074/jbc.M102342200; WEISMAN LS, 1988, SCIENCE, V241, P589, DOI 10.1126/science.3041591; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930	49	96	102	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47917	47927		10.1074/jbc.M208191200	http://dx.doi.org/10.1074/jbc.M208191200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12364329	Green Accepted, hybrid			2022-12-25	WOS:000179663700139
J	Wang, XQ; Sun, P; Paller, AS				Wang, XQ; Sun, P; Paller, AS			Ganglioside induces caveolin-1 redistribution and interaction with the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELANOMA B16 CELLS; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; MEDIATED MODULATION; SIGNAL-TRANSDUCTION; MEMBRANE-PROTEIN; LIPID RAFTS; BINDING; LOCALIZATION; KINASE	Although caveolin-1 is thought to facilitate the interaction of receptors and signaling components, its role in epidermal growth factor receptor (EGFR) signaling remains poorly understood. Ganglioside GM3 inhibits EGFR autophosphorylation and may thus affect the interaction of caveolin-1 and the EGFR. We report here that endogenous overexpression of GM3 leads to the clustering of GM3 on the cell membrane of the keratinocyte-derived SCC12 cell line and promotes co-immunoprecipitation of caveolin-1 and GM3 with the EGFR. Overexpression of GM3 does not affect EGFR distribution but shifts caveolin-1 to the detergent-soluble, EGFR-containing region; consistently, caveolin-1 is retained in the detergent-insoluble membrane when ganglioside is depleted. GM3 overexpression inhibits EGFR tyrosine phosphorylation and receptor dimerization and concurrently increases both the content and tyrosine phosphorylation of EGFR-associated caveolin-1, providing evidence that tyrosine phosphorylation of caveolin-1 inhibits EGFR signaling. Consistently, depletion of ganglioside both increases EGFR phosphorylation and prevents the EGF-induced tyrosine phosphorylation of caveolin-1. GM3 also induces delayed serine phosphorylation of EGFR-unassociated caveolin-1, suggesting a role for serine phosphorylation of caveolin-1 in regulating EGFR signaling. These studies suggest that GM3 modulates the caveolin-1/EGFR association and is critical for the EGF-induced tyrosine phosphorylation of caveolin-1 that is associated with its inhibition of EGFR activation.	Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Pediat, Chicago, IL 60614 USA; Northwestern Univ, Sch Med, Childrens Mem Inst Educ & Res, Dept Dermatol, Chicago, IL 60614 USA	Northwestern University; Northwestern University	Paller, AS (corresponding author), Childrens Mem Hosp, Div Dermatol, 107,2300 Childrens Plaza, Chicago, IL 60614 USA.	apaller@northwestern.edu		Paller, Amy/0000-0001-6187-6549	NIAMS NIH HHS [R01 AR44619] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR044619] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE A, 1995, J LIPID RES, V36, P611; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Badizadegan K, 2000, AM J PHYSIOL-GASTR L, V278, pG895, DOI 10.1152/ajpgi.2000.278.6.G895; BREMER EG, 1984, J BIOL CHEM, V259, P6818; BREMER EG, 1986, J BIOL CHEM, V261, P2434; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chigorno V, 2000, EUR J BIOCHEM, V267, P4187, DOI 10.1046/j.1432-1327.2000.01454.x; Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Dolo V, 2000, BBA-MOL CELL BIOL L, V1486, P265, DOI 10.1016/S1388-1981(00)00063-9; Engelman JA, 1997, J BIOL CHEM, V272, P16374, DOI 10.1074/jbc.272.26.16374; FRA AM, 1995, FEBS LETT, V375, P11, DOI 10.1016/0014-5793(95)95228-O; Galbiati F, 1998, EMBO J, V17, P6633, DOI 10.1093/emboj/17.22.6633; Gniadecki R, 2002, J INVEST DERMATOL, V118, P582, DOI 10.1046/j.1523-1747.2002.01716.x; Hakomori S, 2002, P NATL ACAD SCI USA, V99, P225, DOI 10.1073/pnas.012540899; Hayashi K, 2001, CANCER RES, V61, P2361; Iwabuchi K, 1998, J BIOL CHEM, V273, P9130, DOI 10.1074/jbc.273.15.9130; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Iwabuchi K, 2000, J BIOL CHEM, V275, P15174, DOI 10.1074/jbc.275.20.15174; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Kim YN, 2000, J BIOL CHEM, V275, P7481, DOI 10.1074/jbc.275.11.7481; KURZCHALIA TV, 1992, J CELL BIOL, V118, P1003, DOI 10.1083/jcb.118.5.1003; Lee H, 2000, MOL ENDOCRINOL, V14, P1750, DOI 10.1210/me.14.11.1750; Lee SW, 1998, ONCOGENE, V16, P1391, DOI 10.1038/sj.onc.1201661; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Mitsuda T, 2002, J BIOL CHEM, V277, P11239, DOI 10.1074/jbc.M107756200; PALLER AS, 1995, J INVEST DERMATOL, V105, P237, DOI 10.1111/1523-1747.ep12317572; PALLER AS, 1995, EXP CELL RES, V217, P118, DOI 10.1006/excr.1995.1070; PALLER AS, 1993, J INVEST DERMATOL, V100, P841, DOI 10.1111/1523-1747.ep12476755; PALLER AS, 1992, J INVEST DERMATOL, V98, P226, DOI 10.1111/1523-1747.ep12555896; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Pitto M, 2000, GLYCOCONJUGATE J, V17, P215, DOI 10.1023/A:1026593307882; Razani B, 2001, BIOCHEM SOC T, V29, P494, DOI 10.1042/BST0290494; Ringerike T, 2002, J CELL SCI, V115, P1331; Schlegel A, 2001, J BIOL CHEM, V276, P4398, DOI 10.1074/jbc.M005448200; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Sowa G, 2001, P NATL ACAD SCI USA, V98, P14072, DOI 10.1073/pnas.241409998; Sun P, 2002, J INVEST DERMATOL, V119, P107, DOI 10.1046/j.1523-1747.2002.01802.x; VANBROCKLYN J, 1993, J NEUROCHEM, V61, P371; Wada T, 1999, BIOCHEM BIOPH RES CO, V261, P21, DOI 10.1006/bbrc.1999.0973; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Wang XQ, 2001, GLYCOBIOLOGY, V11, P515, DOI 10.1093/glycob/11.7.515; Wang XQ, 2001, J BIOL CHEM, V276, P44504, DOI 10.1074/jbc.M106563200; Wang XQ, 2001, J BIOL CHEM, V276, P8436, DOI 10.1074/jbc.M006097200; Wang Y, 2002, J BIOL CHEM, V277, P26252, DOI 10.1074/jbc.M110515200; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; ZENG GC, 1995, P NATL ACAD SCI USA, V92, P8670, DOI 10.1073/pnas.92.19.8670; Zhang W, 2000, J BIOL CHEM, V275, P20717, DOI 10.1074/jbc.M909895199; ZHOU QG, 1994, J BIOL CHEM, V269, P1959	51	64	64	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47028	47034		10.1074/jbc.M208257200	http://dx.doi.org/10.1074/jbc.M208257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354760	hybrid			2022-12-25	WOS:000179663700027
J	Wu, TR; Hong, YK; Wang, XD; Ling, MY; Dragoi, AM; Chung, AS; Campbell, AG; Han, ZY; Feng, GS; Chin, YE				Wu, TR; Hong, YK; Wang, XD; Ling, MY; Dragoi, AM; Chung, AS; Campbell, AG; Han, ZY; Feng, GS; Chin, YE			SHP-2 is a dual-specificity phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues in nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED JAK/STAT PATHWAY; SH2 DOMAIN; SIGNAL-TRANSDUCTION; NEGATIVE REGULATOR; INTERFERON-ALPHA; GENE-EXPRESSION; JAK2 KINASE; PROTEIN; ACTIVATION; PHOSPHORYLATION	Signal transducer and activator of transcription (STAT) proteins are both tyrosine- and serine-phosphorylated, mediating signal transduction and gene regulation. Following gene regulation, STAT activity in the nucleus is then terminated by a nuclear protein phosphatase(s), which remains unidentified. Using novel antibody arrays to screen the Stat1-specific protein phosphatase(s), we identified a SHP-2-Stat1 interaction in the A431 cell nucleus. SHP-2 and Stat1 nuclear localization and their association in response to either epidermal growth factor or interferon-gamma (IFN-gamma) were confirmed by immunofluorescent staining and affinity precipitation assays. The SHP-2 C-terminal region containing protein-tyrosine phosphatase activity interacted with the C-terminal SH2 transcriptional activation domain of Stat1. In SHP-2-/-mouse fibroblast cells, Stat1 phosphorylation at both the tyrosine residue Tyr(701) and the serine residue Ser(727) by IFNgamma was enhanced and prolonged. Consistently, purified GST-SHP-2 dephosphorylated Stat1 at both tyrosine and serine residues when immunoprecipitated phospho-Stat1 or a peptide corresponding to the sequence surrounding Tyr(p)(701) or Ser(p)(717) of Stat1 was used as the substrate. Overexpression of SHP-2 in 293T cells inhibited IFNgamma-dependent Stat1 phosphorylation and suppressed Stat1-dependent induction of luciferase activity. Our findings demonstrate that SHP-2 is a dual-specificity protein phosphatase involved in Stat1 dephosphorylation at both tyrosine and serine residues and plays an important role in modulating STAT function in gene regulation.	Brown Univ, Sch Med, Dept Pathol & Lab Med, Providence, RI 02912 USA; Brown Univ, Sch Med, Dept Mol Microbiol & Immunol, Providence, RI 02912 USA; Burnham Inst, La Jolla, CA 92037 USA	Brown University; Brown University; Sanford Burnham Prebys Medical Discovery Institute	Chin, YE (corresponding author), Brown Univ, Sch Med, Dept Pathol & Lab Med, Providence, RI 02912 USA.		Hong, Kate/ABH-6993-2020	Hong, Kate/0000-0001-5810-8266; Campbell, Andrew G./0000-0003-4579-349X	NCI NIH HHS [R01 CA82549] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082549] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bone H, 1997, J BIOL CHEM, V272, P14470, DOI 10.1074/jbc.272.22.14470; Bromberg JF, 1998, CELL GROWTH DIFFER, V9, P505; Bromberg JF, 1996, P NATL ACAD SCI USA, V93, P7673, DOI 10.1073/pnas.93.15.7673; Chin YE, 1997, MOL CELL BIOL, V17, P5328, DOI 10.1128/MCB.17.9.5328; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; David M, 1996, J BIOL CHEM, V271, P9185, DOI 10.1074/jbc.271.16.9185; DAVID M, 1995, SCIENCE, V269, P1721, DOI 10.1126/science.7569900; DAVID M, 1995, MOL CELL BIOL, V15, P7050; David M, 1996, J BIOL CHEM, V271, P15862, DOI 10.1074/jbc.271.27.15862; Eck MJ, 1996, NATURE, V379, P277, DOI 10.1038/379277a0; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; GUAN KL, 1991, J BIOL CHEM, V266, P17992; HANNON GJ, 1994, P NATL ACAD SCI USA, V91, P1731, DOI 10.1073/pnas.91.5.1731; Haque SJ, 1998, J BIOL CHEM, V273, P33893, DOI 10.1074/jbc.273.51.33893; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Haspel RL, 1999, P NATL ACAD SCI USA, V96, P10188, DOI 10.1073/pnas.96.18.10188; HOEVE J, 2002, MOL CELL BIOL, P5662; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Jiao HY, 1996, MOL CELL BIOL, V16, P6985; Kim SO, 1998, J BIOL CHEM, V273, P2344, DOI 10.1074/jbc.273.4.2344; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; MARRERO MB, 1998, AM J PHYSIOL, V275, P1216; Moriggl R, 1996, MOL CELL BIOL, V16, P5691; Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Olayioye MA, 1999, J BIOL CHEM, V274, P17209, DOI 10.1074/jbc.274.24.17209; Ram PA, 1997, J BIOL CHEM, V272, P17694, DOI 10.1074/jbc.272.28.17694; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; Shi ZQ, 1998, J BIOL CHEM, V273, P4904, DOI 10.1074/jbc.273.9.4904; Shuai K, 1996, MOL CELL BIOL, V16, P4932; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; Su L, 1996, J BIOL CHEM, V271, P10385, DOI 10.1074/jbc.271.17.10385; Wang YJ, 2000, MOL CELL BIOL, V20, P4505, DOI 10.1128/MCB.20.13.4505-4512.2000; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yin TG, 1997, J BIOL CHEM, V272, P1032, DOI 10.1074/jbc.272.2.1032; You M, 1999, MOL CELL BIOL, V19, P2416, DOI 10.1128/mcb.19.3.2416; Yu CL, 2000, J BIOL CHEM, V275, P599, DOI 10.1074/jbc.275.1.599; ZHENG CF, 1993, J BIOL CHEM, V268, P16116; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	43	120	126	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47572	47580		10.1074/jbc.M207536200	http://dx.doi.org/10.1074/jbc.M207536200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12270932	hybrid			2022-12-25	WOS:000179663700096
J	Yik, JHN; Weigel, PH				Yik, JHN; Weigel, PH			The position of cysteine relative to the transmembrane domain is critical for palmitoylation of H1, the major subunit of the human asialoglycoprotein receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN THIOESTERASE; CYTOPLASMIC DOMAINS; FATTY ACYLATION; MICE LACKING; ENDOCYTOSIS; EXPRESSION; KINASE; CD4; RAT; IDENTIFICATION	The mammalian hepatic asialoglycoprotein receptor (ASGP-R) is an endocytic recycling receptor that mediates the internalization of desialylated glycoproteins and their delivery to lysosomes where they are degraded. The human ASGP-R is a hetero-oligomeric complex composed of two subunits designated H1 and H2. Both subunits are palmitoylated at the cytoplasmic Cys residues near their transmembrane domains (TMD). The cytoplasmic Cys(36) in H1 is located at a position that is five amino acids from the transmembrane junction. Because the sequences of subunits in all mammalian ASGP-R species are highly conserved especially at the region near the palmitoylated Cys, we sought to identify a recognition signal for the palmitoylation of H1. Various types of HI mutants were created by site-directed or deletion mutagenesis including alteration of the amino acids surrounding Cys(36), replacing portions of the TMD with that of a different protein and partial deletion of the cytoplasmic domain as well as transposing the palmitoylated Cys to positions further away from the TMD. Mutant HI cDNAs were transiently expressed in COS-7 cells, and the H1 proteins were analyzed after metabolic labeling with [H-3]palmitate. The results indicate that neither the native amino acid sequence surrounding Cys(36) nor the majority of the cytoplasmic domain sequence is critical for palmitoylation. Palmitoylation was also not dependent on the native TMD of H1. In contrast, the attachment of palmitate was abolished if the Cys residue was transposed to a position that was 30 amino acids away from the transmembrane border. We conclude that the spacing of a Cys residue relative to the TMD in the primary protein sequence of H1 is the major determinant for successful palmitoylation.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.		Yik, Jasper/C-7343-2009	Yik, Jasper/0000-0001-7532-629X	NIGMS NIH HHS [GM49696] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALVAREZ E, 1990, J BIOL CHEM, V265, P16644; ASHWELL G, 1982, ANNU REV BIOCHEM, V51, P531, DOI 10.1146/annurev.bi.51.070182.002531; BARNETTE WN, 1981, ANAL BIOCHEM, V112, P195; CADWALLADER KA, 1994, MOL CELL BIOL, V14, P4722, DOI 10.1128/MCB.14.7.4722; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CRISE B, 1992, J BIOL CHEM, V267, P13593; Duncan JA, 1998, J BIOL CHEM, V273, P15830, DOI 10.1074/jbc.273.25.15830; GEFFEN I, 1991, P NATL ACAD SCI USA, V88, P8425, DOI 10.1073/pnas.88.19.8425; GEFFEN I, 1993, J BIOL CHEM, V268, P20772; GEFFEN I, 1992, INT REV CYTOL, V137B, P181; Grosenbach DW, 1997, J BIOL CHEM, V272, P1956, DOI 10.1074/jbc.272.3.1956; Hansen SG, 1999, VIROLOGY, V254, P124, DOI 10.1006/viro.1998.9543; HAYNES PA, 1994, J BIOL CHEM, V269, P33146; ISHIBASHI S, 1994, J BIOL CHEM, V269, P27803; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2623, DOI 10.1021/bi00463a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lobo S, 2001, MOL BIOL CELL, V12, p6A; Moffett S, 1996, J BIOL CHEM, V271, P21490, DOI 10.1074/jbc.271.35.21490; Morello JP, 1996, BIOCHEM CELL BIOL, V74, P449, DOI 10.1139/o96-049; ODOWD BF, 1989, J BIOL CHEM, V264, P7564; Ponimaskin E, 1998, VIROLOGY, V249, P325, DOI 10.1006/viro.1998.9303; Resh MD, 1999, BBA-MOL CELL RES, V1451, P1, DOI 10.1016/S0167-4889(99)00075-0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schweizer A, 1996, J CELL BIOL, V132, P577, DOI 10.1083/jcb.132.4.577; SHAW AS, 1990, MOL CELL BIOL, V10, P1853, DOI 10.1128/MCB.10.5.1853; Shum L, 1996, J BIOL CHEM, V271, P28502, DOI 10.1074/jbc.271.45.28502; STOCKERT RJ, 1995, PHYSIOL REV, V75, P591, DOI 10.1152/physrev.1995.75.3.591; Ten Brinke A, 2002, BIOCHEM J, V361, P663, DOI 10.1042/0264-6021:3610663; Tozawa R, 2001, J BIOL CHEM, V276, P12624, DOI 10.1074/jbc.M011063200; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; Veit M, 1998, BBA-LIPID LIPID MET, V1394, P90, DOI 10.1016/S0005-2760(98)00097-6; VEIT M, 1989, VIROLOGY, V168, P173, DOI 10.1016/0042-6822(89)90417-0; WEDEGAERTNER PB, 1995, J BIOL CHEM, V270, P503, DOI 10.1074/jbc.270.2.503; Weigel P H, 1993, Subcell Biochem, V19, P125; WEIGEL PH, 1994, BIOESSAYS, V16, P519, DOI 10.1002/bies.950160713; WEIGEL PH, 1983, J BIOL CHEM, V258, P5089; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; Yik JHN, 2002, J BIOL CHEM, V277, P40844, DOI 10.1074/jbc.M204780200; Yik JHN, 2002, BIOCHEM BIOPH RES CO, V297, P980, DOI 10.1016/S0006-291X(02)02298-2; Yik JHN, 2002, J BIOL CHEM, V277, P23076, DOI 10.1074/jbc.M202748200; ZENG FY, 1995, J BIOL CHEM, V270, P21388, DOI 10.1074/jbc.270.36.21388; Zeng FY, 1996, J BIOL CHEM, V271, P32454, DOI 10.1074/jbc.271.50.32454	42	13	13	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47305	47312		10.1074/jbc.M208751200	http://dx.doi.org/10.1074/jbc.M208751200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370180	hybrid			2022-12-25	WOS:000179663700061
J	Im, H; Woo, MS; Hwang, KY; Yu, MH				Im, H; Woo, MS; Hwang, KY; Yu, MH			Interactions causing the kinetic trap in serpin protein folding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; CENTER LOOP INSERTION; HUMAN ALPHA(1)-ANTITRYPSIN; INFLUENZA HEMAGGLUTININ; REACTIVE CENTER; CONFORMATIONAL CHANGE; STRUCTURAL BASIS; NATIVE STRAIN; HINGE REGION; DISEASE	Conformational transition is fundamental to the mechanism of functional regulation in proteins, and serpins (serine protease inhibitors) can provide insight into this process. Serpins are metastable in their native forms, and they ordinarily undergo conformational transition to a stable state only when they form a tight complex with target proteases. The metastable native form is thus considered to be a kinetically trapped folding intermediate. We sought to understand the nature of the serpin kinetic trap as a step toward discovering how conformational transition is regulated. We found that mutations of the B/C beta-barrel of native alpha(1)-antitrypsin, a prototypical serpin, allowed conversion of the molecule into a more stable state. A 2.2 Angstrom resolution crystal structure of the stable form (PDB code, 1IZ2) showed that the reactive site loop is inserted into an A beta-sheet, as in the latent plasminogen activator inhibitor-1. Mutational analyses suggest strongly that interactions not found in the final stable form cause the kinetic trap in serpin protein folding.	Korea Inst Sci & Technol, Natl Creat Res Iniat, Prot Strain Res Ctr, Sungbuk Gu, Seoul 136791, South Korea; CrystalGenom Inc, Daeduk BioCommunity, Yuseong Gu, Taejon 305390, South Korea	Korea Institute of Science & Technology (KIST)	Yu, MH (corresponding author), Korea Inst Sci & Technol, Natl Creat Res Iniat, Prot Strain Res Ctr, Sungbuk Gu, 39-1 Hawolgok Dong, Seoul 136791, South Korea.							ABRAHAM CR, 1988, CELL, V52, P487, DOI 10.1016/0092-8674(88)90462-X; AERTGEERTS K, 1995, NAT STRUCT BIOL, V2, P891, DOI 10.1038/nsb1095-891; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; BAKER D, 1994, STRUCTURE, V2, P907, DOI 10.1016/S0969-2126(94)00091-3; Baldwin RL, 1996, FOLD DES, V1, pR1, DOI 10.1016/S1359-0278(96)00003-X; BIETH J, 1974, BIOCHEM MED METAB B, V11, P350, DOI 10.1016/0006-2944(74)90134-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; Capaldi AP, 2001, NAT STRUCT BIOL, V8, P68; Carr CM, 1997, P NATL ACAD SCI USA, V94, P14306, DOI 10.1073/pnas.94.26.14306; Carrell RW, 2001, THROMB HAEMOSTASIS, V86, P14; Dinner AR, 1998, NAT STRUCT BIOL, V5, P236, DOI 10.1038/nsb0398-236; DOBSON CM, 1994, TRENDS BIOCHEM SCI, V19, P31, DOI 10.1016/0968-0004(94)90171-6; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; HEKMAN CM, 1985, J BIOL CHEM, V260, P11581; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 1999, J BIOL CHEM, V274, P11072, DOI 10.1074/jbc.274.16.11072; Im H, 2000, PROTEIN SCI, V9, P1497, DOI 10.1110/ps.9.8.1497; KIEFHABER T, 1995, P NATL ACAD SCI USA, V92, P9029, DOI 10.1073/pnas.92.20.9029; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Kim SJ, 2001, J MOL BIOL, V306, P109, DOI 10.1006/jmbi.2000.4357; KWON KS, 1994, J BIOL CHEM, V269, P9627; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lawrence DA, 2000, J BIOL CHEM, V275, P5839, DOI 10.1074/jbc.275.8.5839; Lee C, 2001, PROTEIN SCI, V10, P1446, DOI 10.1110/ps.840101; Lee C, 2001, BIOCHEM BIOPH RES CO, V287, P636, DOI 10.1006/bbrc.2001.5638; Lee C, 2000, P NATL ACAD SCI USA, V97, P7727, DOI 10.1073/pnas.97.14.7727; Lee KN, 1998, J BIOL CHEM, V273, P2509, DOI 10.1074/jbc.273.5.2509; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; MA JY, 1994, NATURE, V372, P92, DOI 10.1038/372092a0; MAST AE, 1992, BIOCHEMISTRY-US, V31, P2720, DOI 10.1021/bi00125a012; MOTTONEN J, 1992, NATURE, V355, P270, DOI 10.1038/355270a0; OAS TG, 1988, NATURE, V336, P42, DOI 10.1038/336042a0; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ozkan SB, 2001, NAT STRUCT BIOL, V8, P765, DOI 10.1038/nsb0901-765; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; PEMBERTON PA, 1988, NATURE, V336, P257, DOI 10.1038/336257a0; Ryu SE, 1996, STRUCTURE, V4, P1181, DOI 10.1016/S0969-2126(96)00126-8; Seo EJ, 2000, J BIOL CHEM, V275, P16904, DOI 10.1074/jbc.M001006200; SOSNICK TR, 1994, NAT STRUCT BIOL, V1, P149, DOI 10.1038/nsb0394-149; Stefansson S, 1996, NATURE, V383, P441, DOI 10.1038/383441a0; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; TUCKER HM, 1995, NAT STRUCT BIOL, V2, P442, DOI 10.1038/nsb0695-442; Wang ZL, 1996, BIOCHEMISTRY-US, V35, P16443, DOI 10.1021/bi961214p; WEISSMAN JS, 1991, SCIENCE, V253, P1357; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WRIGHT HT, 1995, PROTEINS, V22, P210, DOI 10.1002/prot.340220303	53	63	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46347	46354		10.1074/jbc.M207682200	http://dx.doi.org/10.1074/jbc.M207682200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244055	hybrid			2022-12-25	WOS:000179529300085
J	Sirangelo, I; Malmo, C; Casillo, M; Mezzogiorno, A; Papa, M; Irace, G				Sirangelo, I; Malmo, C; Casillo, M; Mezzogiorno, A; Papa, M; Irace, G			Tryptophanyl substitutions in apomyoglobin determine protein aggregation and amyloid-like fibril formation at physiological pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL-CHARACTERIZATION; THERMODYNAMIC STABILITY; FAMILIAL AMYLOIDOSIS; MYOGLOBIN; INTERMEDIATE; MODEL; FIBRILLOGENESIS; CONFORMATIONS; MICROSCOPY; DISEASES	Myoglobin is an a-helical globular protein that contains two highly conserved tryptophan residues located at positions 7 and 14 in the N-terminal region of the protein. Replacement of both indole residues with phenylalanine residues, i.e. W7F/W14F, results in the expression of an unstable, not correctly folded protein that does not bind the prosthetic group. Here we report data (Congo red and thioflavine T binding assay, birefringence, and electron microscopy) showing that the double Trp/Phe replacements render apomyoglobin molecules highly susceptible to aggregation and amyloid-like fibril formation under physiological conditions in which most of the wild-type protein is in the native state. In refolding experiments, like the wild-type protein, the W7F/W14F apomyoglobin mutant formed a soluble, partially folded helical state between pH 2.0 and pH 4.0. A pH increase from 4.0 to 7.0 restored the native structure only in the case of the wild-type protein and determined aggregation of W7F/W14F. The circular dichroism spectrum recorded immediately after neutralization showed that the polypeptide consists mainly of P-structures. In conclusion, under physiological pH conditions, some mutations that affect folding may cause protein aggregation and the formation of amyloid-like fibrils.	Univ Naples 2, Dipartimento Biochim & Biofis, I-80138 Naples, Italy; Univ Naples 2, Dipartimento Med Pubbl Anat, I-80138 Naples, Italy	Universita della Campania Vanvitelli; Universita della Campania Vanvitelli	Irace, G (corresponding author), Univ Naples 2, Dipartimento Biochim & Biofis, Via L De Crecchio 7, I-80138 Naples, Italy.	gaetano.irace@unina2.it	Papa, Michele/A-7228-2017; Papa, Michele/AAB-1759-2021	Papa, Michele/0000-0003-4834-7970; Papa, Michele/0000-0002-6609-7453; Sirangelo, Ivana/0000-0002-6408-4990				Babu KR, 2000, BIOCHEMISTRY-US, V39, P14702, DOI 10.1021/bi001265t; BISMUTO E, 1992, ARCH BIOCHEM BIOPHYS, V298, P624, DOI 10.1016/0003-9861(92)90458-9; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen CD, 2001, EMBO J, V20, P6277, DOI 10.1093/emboj/20.22.6277; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Damaschun G, 2000, PROTEINS, V39, P204, DOI 10.1002/(SICI)1097-0134(20000515)39:3<204::AID-PROT20>3.0.CO;2-8; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Eliezer D, 1996, J MOL BIOL, V263, P531, DOI 10.1006/jmbi.1996.0596; EVANS SV, 1988, J BIOL CHEM, V263, P4263; Fandrich M, 2001, NATURE, V410, P165, DOI 10.1038/35065514; Gilmanshin R, 1997, PROTEIN SCI, V6, P2134; GOTO Y, 1990, J MOL BIOL, V214, P803, DOI 10.1016/0022-2836(90)90334-I; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; HUGHSON FM, 1989, BIOCHEMISTRY-US, V28, P4415, DOI 10.1021/bi00436a044; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; Inouye H, 2000, J STRUCT BIOL, V130, P123, DOI 10.1006/jsbi.2000.4258; Jamin M, 1998, J MOL BIOL, V276, P491, DOI 10.1006/jmbi.1997.1543; JENNINGS PA, 1993, SCIENCE, V262, P892, DOI 10.1126/science.8235610; Jimenez JL, 1999, EMBO J, V18, P815, DOI 10.1093/emboj/18.4.815; Kay MS, 1996, NAT STRUCT BIOL, V3, P439, DOI 10.1038/nsb0596-439; Kazmirski SL, 2002, NAT STRUCT BIOL, V9, P112, DOI 10.1038/nsb745; Kelly JW, 1996, CURR OPIN STRUC BIOL, V6, P11, DOI 10.1016/S0959-440X(96)80089-3; KLUNK WE, 1989, J HISTOCHEM CYTOCHEM, V37, P1273, DOI 10.1177/37.8.2666510; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Lansbury PT, 1999, P NATL ACAD SCI USA, V96, P3342, DOI 10.1073/pnas.96.7.3342; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lim A, 2000, J STRUCT BIOL, V130, P363, DOI 10.1006/jsbi.2000.4272; MISSMAHL HP, 1968, AMYLOIDOSIS, P22; NAIKI H, 1991, LAB INVEST, V65, P104; Pappu RV, 1998, PROTEIN SCI, V7, P480; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; SIRANGELO I, 1994, FEBS LETT, V338, P11, DOI 10.1016/0014-5793(94)80107-X; Sirangelo I, 2000, EUR J BIOCHEM, V267, P3937, DOI 10.1046/j.1432-1327.2000.01401.x; Sirangelo I, 1998, BBA-PROTEIN STRUCT M, V1385, P69, DOI 10.1016/S0167-4838(98)00038-7; SPRINGER BA, 1987, P NATL ACAD SCI USA, V84, P8961, DOI 10.1073/pnas.84.24.8961; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; TAN SY, 1994, HISTOPATHOLOGY, V25, P403, DOI 10.1111/j.1365-2559.1994.tb00001.x; TEALE FWJ, 1959, BIOCHIM BIOPHYS ACTA, V35, P543, DOI 10.1016/0006-3002(59)90407-X; TIRADORIVES J, 1993, BIOCHEMISTRY-US, V32, P4175, DOI 10.1021/bi00067a004; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; West MW, 1999, P NATL ACAD SCI USA, V96, P11211, DOI 10.1073/pnas.96.20.11211; Westermark P, 1999, AMYLOID, V6, P151, DOI 10.3109/13506129909007319; YANG JT, 1986, METHOD ENZYMOL, V130, P208	50	37	37	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45887	45891		10.1074/jbc.M207659200	http://dx.doi.org/10.1074/jbc.M207659200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244112	hybrid			2022-12-25	WOS:000179529300024
J	Cooper, CD; Lampe, PD				Cooper, CD; Lampe, PD			Casein kinase 1 regulates connexin-43 gap junction assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INTERCELLULAR COMMUNICATION; INTRACELLULAR TRAFFICKING; TYROSINE PHOSPHORYLATION; CARDIAC MYOCYTES; CELLS; INHIBITION; TURNOVER; SITES; LOCALIZATION	Phosphorylation of members of the connexin family of gap junction proteins has been correlated with gap junction assembly, but the mechanisms involved remain unclear. We have examined the role of casein kinase 1 (CKI) in connexin-43 (Cx43) gap junction assembly. Cellular co-immunoprecipitation experiments and in vitro CK1 phosphorylation reactions indicate that CK1 interacted with and phosphorylated Cx43, initially on serine(s) 325, 328, or 330. P-32(i)-Metabolically labeled cells treated with CKI-7, a specific CK1 inhibitor, showed a reduction in Cx43 phosphorylation on site(s) that can be phosphorylated by CK1 in vitro. To examine CK1 function, normal rat kidney cells were treated with CKI-7, and Cx43 content was analyzed by Triton X-100 extraction, cell-surface biotinylation, and immunofluorescence. Western blot analysis indicated a slight increase in total Cx43, whereas gap junctional (Triton-insoluble) Cx43 decreased, and non-junctional plasma membrane Cx43 increased (as detected by cell surface biotinylation). Immunofluorescence experiments in the presence of CK1 inhibitor showed increases in Cx43 plasma membrane localization but not necessarily accumulation at cell-cell interfaces. Decreased gap junctional and phosphorylated Cx43 was also detected when cells were treated with IC261, a CKI inhibitor specific for 6 or E isoforms. These data suggest CK1delta could regulate Cx43 gap junction assembly by directly phosphorylating Cx43.	Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lampe, PD (corresponding author), Univ Washington, Fred Hutchinson Canc Res Ctr, 1100 Fairview Ave N,DE-320, Seattle, WA 98109 USA.	plampe@fhcrc.org			NIGMS NIH HHS [GM55632, R01 GM055632] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055632] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beardslee MA, 1998, CIRC RES, V83, P629, DOI 10.1161/01.RES.83.6.629; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; Behrend L, 2000, EUR J CELL BIOL, V79, P240, DOI 10.1078/S0171-9335(04)70027-8; CARTER AN, 1997, CURRENT PROTOCOLS MO, V2; Chen CY, 2000, SEX TRANSM DIS, V27, P21, DOI 10.1097/00007435-200001000-00005; Cheng HL, 1999, EUR J BIOCHEM, V263, P276, DOI 10.1046/j.1432-1327.1999.00502.x; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; Cooper CD, 2000, METHODS, V20, P196, DOI 10.1006/meth.1999.0937; CROW DS, 1990, MOL CELL BIOL, V10, P1754, DOI 10.1128/MCB.10.4.1754; Decottignies A, 1999, J BIOL CHEM, V274, P37139, DOI 10.1074/jbc.274.52.37139; DESOUSA PA, 1993, DEVELOPMENT, V117, P1355; FILSON AJ, 1990, CELL GROWTH DIFFER, V1, P661; Giepmans BNG, 1998, CURR BIOL, V8, P931, DOI 10.1016/S0960-9822(07)00375-2; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GRAVES PR, 1995, J BIOL CHEM, V270, P21689, DOI 10.1074/jbc.270.37.21689; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Gross SD, 1997, J CELL SCI, V110, P3083; Jordan K, 1999, MOL BIOL CELL, V10, P2033, DOI 10.1091/mbc.10.6.2033; Kanemitsu MY, 1998, CELL GROWTH DIFFER, V9, P13; Kumar NM, 1996, CELL, V84, P381, DOI 10.1016/S0092-8674(00)81282-9; LAIRD DW, 1991, BIOCHEM J, V273, P67, DOI 10.1042/bj2730067; LAIRD DW, 1995, J CELL BIOL, V131, P1193, DOI 10.1083/jcb.131.5.1193; Lampe PD, 2000, J CELL BIOL, V149, P1503, DOI 10.1083/jcb.149.7.1503; Lampe PD, 1998, GAP JUNCTIONS, P249; Lampe PD, 1998, J CELL SCI, V111, P833; LAMPE PD, 1994, J CELL BIOL, V127, P1895, DOI 10.1083/jcb.127.6.1895; Li HY, 1996, J CELL BIOL, V134, P1019, DOI 10.1083/jcb.134.4.1019; Mashhoon N, 2000, J BIOL CHEM, V275, P20052, DOI 10.1074/jbc.M001713200; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; Murakami A, 1999, J BIOL CHEM, V274, P3804, DOI 10.1074/jbc.274.6.3804; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; MUSIL LS, 1990, J CELL BIOL, V111, P2077, DOI 10.1083/jcb.111.5.2077; MUSIL LS, 1990, J MEMBRANE BIOL, V116, P163, DOI 10.1007/BF01868674; Panek HR, 1997, EMBO J, V16, P4194, DOI 10.1093/emboj/16.14.4194; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Robinson LC, 1999, MOL BIOL CELL, V10, P1077, DOI 10.1091/mbc.10.4.1077; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Simon AM, 1998, TRENDS CELL BIOL, V8, P477, DOI 10.1016/S0962-8924(98)01372-5; SWENSON KI, 1990, CELL REGUL, V1, P989, DOI 10.1091/mbc.1.13.989; TenBroek EM, 2001, J CELL BIOL, V155, P1307, DOI 10.1083/jcb.200102017; Toyofuku T, 1998, J BIOL CHEM, V273, P12725, DOI 10.1074/jbc.273.21.12725; Walter J, 2001, J BIOL CHEM, V276, P14634, DOI 10.1074/jbc.M011116200; Warn-Cramer BJ, 1998, J BIOL CHEM, V273, P9188, DOI 10.1074/jbc.273.15.9188; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Willecke K, 2002, BIOL CHEM, V383, P725, DOI 10.1515/BC.2002.076; Yasojima K, 2000, BRAIN RES, V865, P116, DOI 10.1016/S0006-8993(00)02200-9; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	48	159	164	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44962	44968		10.1074/jbc.M209427200	http://dx.doi.org/10.1074/jbc.M209427200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270943	hybrid			2022-12-25	WOS:000179404800049
J	Li, SS; Smerdon, MJ				Li, SS; Smerdon, MJ			Nucleosome structure and repair of N-methylpurines in the GAL1-10 genes of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; CYCLOBUTANE PYRIMIDINE DIMERS; CHROMATIN STRUCTURE; REGULATORY PROTEIN; METHYLATION DAMAGE; NUCLEOTIDE LEVEL; CONTROL REGION; HUMAN-CELLS; DNA-DAMAGE; YEAST	Nucleosome structure and repair of N-methylpurines were analyzed at nucleotide resolution in the divergent GAL1-10 genes of intact yeast cells, encompassing their common upstream-activating sequence. In glucose cultures where genes are repressed, nucleosomes with fixed positions exist in regions adjacent to the upstream-activating sequence, and the variability of nucleosome positioning sharply increases with increasing distance from this sequence. Galactose induction causes nucleosome disruption throughout the region analyzed, with those nucleosomes close to the upstream-activating sequence being most striking. In glucose cultures, a strong correlation between N-methylpurine repair and nucleosome positioning was seen in nucleosomes with fixed positions, where slow and fast repair occurred in nucleosome core and linker DNA, respectively. Galactose induction enhanced N-methylpurine repair in both strands of nucleosome core DNA, being most dramatic in the clearly disrupted, fixed nucleosomes. Furthermore, N-methylpurines are repaired primarily by the Mag1-initiated base excision repair pathway, and nucleotide excision repair contributes little to repair of these lesions. Finally, N-methylpurine repair is significantly affected by nearest-neighbor nucleotides, where fast and slow repair occurred in sites between pyrimidines and purines, respectively. These results indicate that nucleosome positioning and DNA sequence significantly modulate Mag1-initiated base excision repair in intact yeast cells.	Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA	Washington State University	Smerdon, MJ (corresponding author), Washington State Univ, Sch Mol Biosci, Pullman, WA 99164 USA.		Li, Shisheng/H-9126-2012		NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004106] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES04106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bash R, 2001, PROG NUCLEIC ACID RE, V65, P197; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; DANDREA AD, 1978, P NATL ACAD SCI USA, V75, P3608, DOI 10.1073/pnas.75.8.3608; FEDOR MJ, 1989, MOL CELL BIOL, V9, P1721, DOI 10.1128/MCB.9.4.1721; FEDOR MJ, 1988, J MOL BIOL, V204, P109, DOI 10.1016/0022-2836(88)90603-1; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; Grunberger D., 1983, MOL BIOL MUTAGENS CA, P55; Hanawalt PC, 2001, MUTAT RES-DNA REPAIR, V485, P3, DOI 10.1016/S0921-8777(00)00071-9; KUO MT, 1978, NATURE, V271, P83, DOI 10.1038/271083a0; Li SS, 1996, CARCINOGENESIS, V17, P1549, DOI 10.1093/carcin/17.8.1549; Li SS, 2000, METHODS, V22, P170, DOI 10.1006/meth.2000.1058; Li SS, 1999, J BIOL CHEM, V274, P12201, DOI 10.1074/jbc.274.18.12201; LOHR D, 1987, J BIOL CHEM, V262, P15589; LOHR D, 1984, NUCLEIC ACIDS RES, V12, P8457, DOI 10.1093/nar/12.22.8457; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCGHEE JD, 1979, P NATL ACAD SCI USA, V76, P2133, DOI 10.1073/pnas.76.5.2133; Memisoglu A, 2000, J BACTERIOL, V182, P2104, DOI 10.1128/JB.182.8.2104-2112.2000; Miao F, 2000, J BIOL CHEM, V275, P28433, DOI 10.1074/jbc.M001064200; MOORE CW, 1988, CANCER RES, V48, P6837; PIEPER RO, 1998, DNA DAMAGE REPAIR, V2, P199; POSNICK LM, 1999, MUTAT RES, V257, P127; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; RYAN AJ, 1986, CARCINOGENESIS, V7, P1497, DOI 10.1093/carcin/7.9.1497; Sambrook J., 2002, MOL CLONING LAB MANU; SCICCHITANO DA, 1989, P NATL ACAD SCI USA, V86, P3050, DOI 10.1073/pnas.86.9.3050; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SIDIK K, 1990, CANCER RES, V50, P1613; SLATER ML, 1973, J BACTERIOL, V113, P263, DOI 10.1128/JB.113.1.263-270.1973; Smith SA, 2000, NUCLEIC ACIDS RES, V28, P3294, DOI 10.1093/nar/28.17.3294; SOLOMON LR, 1989, BIOCHEMISTRY-US, V28, P9932, DOI 10.1021/bi00452a009; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; THOMAS L, 1982, BIOCHEMISTRY-US, V21, P1162, DOI 10.1021/bi00535a009; vanHolde K.E, 1989, CHROMATIN, P289; WOLFFE AP, 1999, CHROMATIN STRUCTURE, P7; Xiao W, 1998, CURR GENET, V33, P92, DOI 10.1007/s002940050313; Xiao W, 2001, MUTAT RES-DNA REPAIR, V487, P137, DOI 10.1016/S0921-8777(01)00113-6; Ye N, 1998, J MOL BIOL, V284, P269, DOI 10.1006/jmbi.1998.2138; Zheng WJ, 1997, J BIOL CHEM, V272, P30350, DOI 10.1074/jbc.272.48.30350	38	37	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44651	44659		10.1074/jbc.M206623200	http://dx.doi.org/10.1074/jbc.M206623200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244104	hybrid			2022-12-25	WOS:000179404800009
J	Wang, DL; Lemon, WJ; You, M				Wang, DL; Lemon, WJ; You, M			Linkage disequilibrium mapping of novel lung tumor susceptibility quantitative trait loci in mice	ONCOGENE			English	Article						mouse; linkage disequilibrium; lung tumor; susceptibility; gene mapping	RAS PROTOONCOGENE; CANCER; ASSOCIATION; RELATIVES; RISK; POLYMORPHISMS; GENES	Linkage disequilibrium (LD) has been used to map chromosomal regions regulating quantitative traits, also called quantitative trait loci (QTLs). With the increasing number of available mouse polymorphic genetic markers, LD can be estimated for the purpose of fine-mapping a given QTL or in the identification of novel QTLs. A whole-genome LD analysis was conducted for mapping mouse lung tumor susceptibility QTLs in 25 strains of mice with known susceptibility to lung cancer using 5638 genetic markers. A total of 63 markers were found to be significantly associated with lung tumor susceptibility, many of which were novel QTLs. This study demonstrates the feasibility of using LD to map QTLs on a whole genome level. Further characterization of the newly identified lung tumor susceptibility QTLs may lead to the identification of genes whose human homologue may predispose some individuals to lung cancer.	Ohio State Univ Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, Columbus, OH 43210 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	You, M (corresponding author), Ohio State Univ Comprehens Canc, Div Human Canc Genet, Med Res Facil 514, 420 W 12th Ave, Columbus, OH 43210 USA.	you-1@medctr.osu.edu			NATIONAL CANCER INSTITUTE [P30CA016058, R01CA058554, R01CA078797] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA78797, P30CA16058, R01CA58554] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CAPORASO NE, 1992, ENVIRON HEALTH PERSP, V98, P101; CHEN B, 1994, P NATL ACAD SCI USA, V91, P1589, DOI 10.1073/pnas.91.4.1589; DEVEREUX TR, 1994, MAMM GENOME, V5, P749, DOI 10.1007/BF00292007; FESTING MFW, 1994, GENET RES, V64, P99, DOI 10.1017/S0016672300032705; GARIBOLDI M, 1993, NAT GENET, V3, P132, DOI 10.1038/ng0293-132; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; GOFFMAN TE, 1982, JAMA-J AM MED ASSOC, V247, P1020, DOI 10.1001/jama.247.7.1020; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Grupe A, 2001, SCIENCE, V292, P1915, DOI 10.1126/science.1058889; Herzog CR, 1997, J CELL BIOCHEM, P49; Herzog CR, 1997, MAMM GENOME, V8, P65, DOI 10.1007/s003359900352; Johannsson O, 1996, AM J HUM GENET, V58, P441; LI FP, 1988, CANCER RES, V48, P5358; Lin L, 1998, EXP LUNG RES, V24, P481, DOI 10.3109/01902149809087382; LYNCH HT, 1986, CANCER, V57, P1640, DOI 10.1002/1097-0142(19860415)57:8<1640::AID-CNCR2820570833>3.0.CO;2-Q; MALKINSON AM, 1989, TOXICOLOGY, V54, P241, DOI 10.1016/0300-483X(89)90062-0; Manenti G, 1999, GENOME RES, V9, P639; MANENTI G, 1995, GENOMICS, V29, P438, DOI 10.1006/geno.1995.9984; Manenti G, 1997, CARCINOGENESIS, V18, P1917, DOI 10.1093/carcin/18.10.1917; MCDUFFIE HH, 1991, J CLIN EPIDEMIOL, V44, P69, DOI 10.1016/0895-4356(91)90202-K; MINNA JD, 1993, CHEST, V103, pS449, DOI 10.1378/chest.103.4_Supplement.449S; Ott J., 1999, ANAL HUMAN GENETIC L; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; SANDERS BM, 1989, BRIT J CANCER, V60, P358, DOI 10.1038/bjc.1989.285; SELLERS TA, 1990, J NATL CANCER I, V82, P1272, DOI 10.1093/jnci/82.15.1272; SELLERS TA, 1987, AM J EPIDEMIOL, V126, P237, DOI 10.1093/aje/126.2.237; SHAW GL, 1991, J CLIN EPIDEMIOL, V44, P429, DOI 10.1016/0895-4356(91)90082-K; SHIELDS PG, 1993, LUNG CANCER, P3; STRONG LC, 1984, J NATL CANCER I, V73, P303, DOI 10.1093/jnci/73.2.303; SUGIMURA H, 1990, CANCER RES, V50, P1857; ToFigueras J, 1996, CANCER EPIDEM BIOMAR, V5, P337; TOKUHATA GEORGE K., 1963, JOUR NATL CANCER INST, V30, P289; Tripodis N, 2001, J NATL CANCER I, V93, P1484, DOI 10.1093/jnci/93.19.1484; You M, 1998, HEMATOL ONCOL CLIN N, V12, P1037, DOI 10.1016/S0889-8588(05)70040-X	34	11	12	0	1	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6858	6865		10.1038/sj.onc.1205886	http://dx.doi.org/10.1038/sj.onc.1205886			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360413				2022-12-25	WOS:000178315800017
J	Labbaye, C; Quaranta, MT; Pagliuca, A; Militi, S; Licht, JD; Testa, U; Peschle, C				Labbaye, C; Quaranta, MT; Pagliuca, A; Militi, S; Licht, JD; Testa, U; Peschle, C			PLZF induces megakaryocytic development, activates Tpo receptor expression and interacts with GATA1 protein	ONCOGENE			English	Article						megakaryopoiesis; PLZF; GATA1; Tpo receptor	ACUTE PROMYELOCYTIC LEUKEMIA; TRANSCRIPTION FACTOR GATA-1; ZINC-FINGER PROTEIN; PURIFIED HEMATOPOIETIC PROGENITORS; NORMAL ADULT HEMATOPOIESIS; PML-RAR-ALPHA; POZ-DOMAIN; HISTONE DEACETYLASE; INTERACTION MOTIF; FUSION PARTNERS	We investigated the expression of the PLZF gene in purified human hematopoietic progenitors induced to unilineage erythroid, granulocytic or megakaryocytic differentiation and maturation in serum-free culture. PLZF is expressed in quiescent progenitors: the expression level progressively rises through megakaryocytic development, whereas it gradually declines in erythroid and granulopoietic culture. To investigate the role of PLZF in megakaryopoiesis, we transduced the PLZF gene into the erythro-megakaryocytic TF1 cell line. PLZF overexpression upmodulates the megakaryocytic specific markers (CD42a, CD42b, CD61, PF4) and induces the thrombopoietin receptor (TpoR). The proximal promoter of the TpoR gene is activated in PLZF-expressing TF1 cells: in this promoter region, a PLZF DNA-binding site was identified by deletion constructs studies. Interestingly, PLZF and GATA1 proteins coimmunoprecipitate in PLZF-expressing TF1 cells: enforced expression of both PLZF and GATA1 in TF1 cells results in increased upregulation of megakaryocytic markers, as compared to exogenous PLZF or GATA1 alone, suggesting a functional role for the PLZF/GATA1 complex. Our data indicate that PLZF plays a significant stimulatory role in megakaryocytic development, seemingly mediated in part by induction of TpoR expression at transcriptional level. This stimulatory effect is potentiated by physical interaction of PLZF and GATA1, which are possibly assembled in a multiprotein transcriptional complex.	Ist Super Sanita, Dept Hematol Oncol, I-00161 Rome, Italy; Mt Sinai Sch Med, New York, NY USA; Thomas Jefferson Univ, Philadelphia, PA 19107 USA	Istituto Superiore di Sanita (ISS); Icahn School of Medicine at Mount Sinai; Jefferson University	Labbaye, C (corresponding author), Ist Super Sanita, Dept Hematol Oncol, Viale Regina Elena 299, I-00161 Rome, Italy.		Licht, Jonathan/L-4239-2019; Testa, Ugo/J-6472-2016; Quaranta, Maria Teresa/AAC-2134-2019; pagliuca, alfredo/J-3107-2012; Licht, Jonathan/AAL-9184-2020; Pagliuca, Alfredo/AAI-3689-2020; Labbaye, Catherine/J-9930-2016	Testa, Ugo/0000-0001-7900-8942; Quaranta, Maria Teresa/0000-0002-5886-507X; pagliuca, alfredo/0000-0002-8703-2077; Licht, Jonathan/0000-0002-3942-1369; Labbaye, Catherine/0000-0003-1255-4396	NATIONAL CANCER INSTITUTE [R01CA059936] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59936] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; Albagli O, 1999, ONCOGENE, V18, P5063, DOI 10.1038/sj.onc.1202892; Ball HJ, 1999, NUCLEIC ACIDS RES, V27, P4106, DOI 10.1093/nar/27.20.4106; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Barna M, 2000, NAT GENET, V25, P166, DOI 10.1038/76014; CHEN SJ, 1993, J CLIN INVEST, V91, P2260, DOI 10.1172/JCI116453; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CHEN ZX, 1991, BLOOD, V78, P1413; Condorelli GL, 1997, MOL CELL BIOL, V17, P2954, DOI 10.1128/MCB.17.5.2954; COOK M, 1995, P NATL ACAD SCI USA, V92, P2249, DOI 10.1073/pnas.92.6.2249; David G, 1998, ONCOGENE, V16, P2549, DOI 10.1038/sj.onc.1202043; Davies JM, 1999, ONCOGENE, V18, P365, DOI 10.1038/sj.onc.1202332; Deveaux S, 1996, BLOOD, V87, P4678, DOI 10.1182/blood.V87.11.4678.bloodjournal87114678; Dhordain P, 2000, ONCOGENE, V19, P6240, DOI 10.1038/sj.onc.1203976; Dong S, 1996, P NATL ACAD SCI USA, V93, P3624, DOI 10.1073/pnas.93.8.3624; GABBIANELLI M, 1990, SCIENCE, V249, P1561, DOI 10.1126/science.2218497; GODIN IE, 1993, NATURE, V364, P67, DOI 10.1038/364067a0; GREGORY RC, 1996, BLOOD, V87, P1763; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grignani F, 1998, CANCER RES, V58, P14; GUERRIERO R, 1995, BLOOD, V86, P3725, DOI 10.1182/blood.V86.10.3725.bloodjournal86103725; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hawe N, 1996, BLOOD, V88, P1151; He LZ, 1998, NAT GENET, V18, P126, DOI 10.1038/ng0298-126; Hoatlin ME, 1999, BLOOD, V94, P3737, DOI 10.1182/blood.V94.11.3737.423k39_3737_3747; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; Hung HL, 1999, MOL CELL BIOL, V19, P3496; Ivins S, 1998, BLOOD, V92, p308A; Koken MHM, 1997, P NATL ACAD SCI USA, V94, P10255, DOI 10.1073/pnas.94.19.10255; KOTANI H, 1994, HUM GENE THER, V5, P19, DOI 10.1089/hum.1994.5.1-19; Labbaye C, 1999, ONCOGENE, V18, P3529, DOI 10.1038/sj.onc.1202682; LABBAYE C, 1995, J CLIN INVEST, V95, P2346, DOI 10.1172/JCI117927; Li JY, 1997, J BIOL CHEM, V272, P22447, DOI 10.1074/jbc.272.36.22447; Long JJ, 1998, MOL CELL BIOL, V18, P1467, DOI 10.1128/MCB.18.3.1467; MAOUCHE L, 1991, BLOOD, V78, P2557; MEDVINSKY AL, 1993, NATURE, V364, P64, DOI 10.1038/364064a0; Melnick A, 1999, BLOOD, V93, P3167, DOI 10.1182/blood.V93.10.3167.410k44_3167_3215; MERIKA M, 1995, MOL CELL BIOL, V15, P2437; MIGNOTTE V, 1994, GENOMICS, V20, P5, DOI 10.1006/geno.1994.1120; ORKIN SH, 1992, BLOOD, V80, P575; PEVNY L, 1991, NATURE, V349, P257, DOI 10.1038/349257a0; RAVID K, 1991, MOL CELL BIOL, V11, P6116, DOI 10.1128/MCB.11.12.6116; REID A, 1995, BLOOD, V86, P4544, DOI 10.1182/blood.V86.12.4544.bloodjournal86124544; Shaknovich R, 1998, MOL CELL BIOL, V18, P5533, DOI 10.1128/MCB.18.9.5533; Shivdasani RA, 1997, EMBO J, V16, P3965, DOI 10.1093/emboj/16.13.3965; TABILIO A, 1984, EMBO J, V3, P453, DOI 10.1002/j.1460-2075.1984.tb01827.x; Takahashi S, 1998, BLOOD, V92, P434, DOI 10.1182/blood.V92.2.434.414k24_434_442; Testa U, 1996, BLOOD, V88, P3391, DOI 10.1182/blood.V88.9.3391.bloodjournal8893391; TSANG AH, 1997, CELL, V90, P459; VALTIERI M, 1994, CANCER RES, V54, P4398; Vignon I, 1992, P NATL ACAD SCI USA, V89, P5640; Vyas P, 1999, BLOOD, V93, P2867; Wadman IA, 1997, EMBO J, V16, P3145, DOI 10.1093/emboj/16.11.3145; Ward JO, 2001, BLOOD, V98, P3290, DOI 10.1182/blood.V98.12.3290; Wong CW, 1998, J BIOL CHEM, V273, P27695, DOI 10.1074/jbc.273.42.27695; Yamaguchi Y, 1998, BLOOD, V91, P450, DOI 10.1182/blood.V91.2.450.450_450_457; Yang E, 1996, BLOOD, V88, P386, DOI 10.1182/blood.V88.2.386.bloodjournal882386; Yeyati PL, 1999, ONCOGENE, V18, P925, DOI 10.1038/sj.onc.1202375; Zhang P, 1999, P NATL ACAD SCI USA, V96, P8705, DOI 10.1073/pnas.96.15.8705; Zhang T, 1999, P NATL ACAD SCI USA, V96, P11422, DOI 10.1073/pnas.96.20.11422; Zimmet J, 2000, EXP HEMATOL, V28, P3, DOI 10.1016/S0301-472X(99)00124-1	61	42	44	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6669	6679		10.1038/sj.onc.1205884	http://dx.doi.org/10.1038/sj.onc.1205884			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242665				2022-12-25	WOS:000178202300013
J	Schuster, R; Hildt, E; Chang, SF; Terradillos, O; Pollicino, T; Lanford, R; Gerlich, WH; Will, H; Schaefer, S				Schuster, R; Hildt, E; Chang, SF; Terradillos, O; Pollicino, T; Lanford, R; Gerlich, WH; Will, H; Schaefer, S			Conserved transactivating and pro-apoptotic functions of hepadnaviral X protein in ortho- and avihepadnaviruses	ONCOGENE			English	Article						HBx; DHBV; avihepadnavirus; HCC; apoptosis; transactivation	HEPATITIS-B VIRUS; PROGRAMMED CELL-DEATH; OPEN READING FRAME; HEPATOCELLULAR-CARCINOMA; HBX PROTEIN; TRANSGENIC MICE; GROUND-SQUIRRELS; P53-INDUCED APOPTOSIS; MEDIATED APOPTOSIS; EMBRYO FIBROBLASTS	Two established activities of the multifunctional human hepatitis B virus X-protein are its transactivating and pro-apoptotic potential. We analysed whether X-proteins from other orthohepadnaviruses and the newly discovered avihepadnaviral X-proteins have similar functions as HBx. Previously, we have shown that HBx suppresses oncogenic transformation of primary rat embryo fibroblasts (REF) by induction of apoptosis. Using this system, we found that the wildtype X-proteins of woodchuck, ground squirrel, arctic squirrel and woolly monkey hepatitis B virus exhibit similar levels of proapoptotic activity as HBx, whereas mutants with carboxyterminal deletions were severely impaired in this activity. A strong correlation between the pro-apoptotic and transactivating abilities of the mammalian X-proteins was found. The newly discovered avihepadnaviral X-like proteins showed similar and Raf-MAPK pathway-dependent transactivating abilities and induced apoptosis in the REF-assay. Our data indicate that the transactivating and pro-apoptotic activities reside in the carboxyterminal half of orthohepadnaviral X and are conserved in avihepadnaviral X-proteins.	JLU Giessen, Inst Med Virol, Giessen, Germany; Robert Koch Inst, D-1000 Berlin, Germany; Heinrich Pette Inst, Hamburg, Germany; Inst Pasteur, Paris, France; SW Fdn Biomed Res, San Antonio, TX 78284 USA	Justus Liebig University Giessen; Robert Koch Institute; Heinrich Pette Institute; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Texas Biomedical Research Institute	Schaefer, S (corresponding author), Univ Rostock, Dept Virol, Schillingallee 70, D-18055 Rostock, Germany.		Pollicino, Teresa/HDN-3708-2022; Hildt, Eberhard/A-1040-2015; Pollicino, Teresa/K-5790-2016	Pollicino, Teresa/0000-0001-6602-3035				Andrisani OM, 1999, INT J ONCOL, V15, P373; AUSUBEL FM, 1998, CURRENT PROTOCOLS MO, P974; BEASLEY RP, 1981, LANCET, V2, P1129; Becker SA, 1998, J VIROL, V72, P266, DOI 10.1128/JVI.72.1.266-272.1998; Bergametti F, 1999, ONCOGENE, V18, P2860, DOI 10.1038/sj.onc.1202643; Bouchard MJ, 2001, SCIENCE, V294, P2376, DOI 10.1126/science.294.5550.2376; BUENDIA MA, 1998, VIRAL HEPATITIS, P179; Chang SF, 2001, J VIROL, V75, P161, DOI 10.1128/JVI.75.1.161-170.2001; Chang SF, 1999, VIROLOGY, V262, P39, DOI 10.1006/viro.1999.9844; CHEN HS, 1993, J VIROL, V67, P1218, DOI 10.1128/JVI.67.3.1218-1226.1993; Chirillo P, 1997, P NATL ACAD SCI USA, V94, P8162, DOI 10.1073/pnas.94.15.8162; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; CUENDE E, 1993, EMBO J, V12, P1555, DOI 10.1002/j.1460-2075.1993.tb05799.x; DANE DS, 1970, LANCET, V1, P695; Diao JY, 2001, J BIOL CHEM, V276, P8328, DOI 10.1074/jbc.M006026200; Elmore LW, 1997, P NATL ACAD SCI USA, V94, P14707, DOI 10.1073/pnas.94.26.14707; FEITELSON MA, 1988, P NATL ACAD SCI USA, V85, P6162, DOI 10.1073/pnas.85.16.6162; Gottlob K, 1998, CANCER RES, V58, P3566; Gottlob K, 1998, J BIOL CHEM, V273, P33347, DOI 10.1074/jbc.273.50.33347; Grethe S, 2000, J VIROL, V74, P5377, DOI 10.1128/JVI.74.11.5377-5381.2000; Hu XL, 2000, P NATL ACAD SCI USA, V97, P1661, DOI 10.1073/pnas.97.4.1661; Huo TI, 2001, ONCOGENE, V20, P3620, DOI 10.1038/sj.onc.1204495; KIM CM, 1991, NATURE, V351, P317, DOI 10.1038/351317a0; Kim H, 1998, J BIOL CHEM, V273, P381, DOI 10.1074/jbc.273.1.381; Kim YC, 2001, ONCOGENE, V20, P16, DOI 10.1038/sj.onc.1203840; LAND H, 1995, METHOD ENZYMOL, V254, P37; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Lanford RE, 2000, J VIROL, V74, P2955, DOI 10.1128/JVI.74.6.2955-2959.2000; Lanford RE, 1998, P NATL ACAD SCI USA, V95, P5757, DOI 10.1073/pnas.95.10.5757; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; Lin B, 2000, INTERVIROLOGY, V43, P185, DOI 10.1159/000025037; MacDonald DM, 2000, J VIROL, V74, P4253, DOI 10.1128/JVI.74.9.4253-4257.2000; MARION PL, 1980, P NATL ACAD SCI-BIOL, V77, P2941, DOI 10.1073/pnas.77.5.2941; MARION PL, 1986, P NATL ACAD SCI USA, V83, P4543, DOI 10.1073/pnas.83.12.4543; MARION PL, 1984, P NATL ACAD SCI-BIOL, V81, P898, DOI 10.1073/pnas.81.3.898; MASON WS, 1980, J VIROL, V36, P829, DOI 10.1128/JVI.36.3.829-836.1980; Murakami S, 1999, INTERVIROLOGY, V42, P81, DOI 10.1159/000024969; Netter HJ, 1997, J GEN VIROL, V78, P1707, DOI 10.1099/0022-1317-78-7-1707; Norder H, 1996, VIROLOGY, V218, P214, DOI 10.1006/viro.1996.0181; Oguey D, 1996, HEPATOLOGY, V24, P1024, DOI 10.1002/hep.510240508; POPPER H, 1987, P NATL ACAD SCI USA, V84, P866, DOI 10.1073/pnas.84.3.866; Poussin K, 1999, INT J CANCER, V80, P497, DOI 10.1002/(SICI)1097-0215(19990209)80:4<497::AID-IJC3>3.0.CO;2-8; Pult I, 2001, VIROLOGY, V289, P114, DOI 10.1006/viro.2001.1115; RUNKEL L, 1993, VIROLOGY, V197, P529, DOI 10.1006/viro.1993.1626; Schuster R, 2000, ONCOGENE, V19, P1173, DOI 10.1038/sj.onc.1203417; SEEGER C, 1984, J VIROL, V51, P367, DOI 10.1128/JVI.51.2.367-375.1984; SEIFER M, 1991, VIRAL HEPATITIS AND LIVER DISEASE, P586; Shih WL, 2000, J BIOL CHEM, V275, P25858, DOI 10.1074/jbc.M003578200; Shintani Y, 1999, J GEN VIROL, V80, P3257, DOI 10.1099/0022-1317-80-12-3257; SHIRAKATA Y, 1989, JPN J CANCER RES, V80, P617, DOI 10.1111/j.1349-7006.1989.tb01686.x; Sirma H, 1999, ONCOGENE, V18, P4848, DOI 10.1038/sj.onc.1202867; Sitterlin D, 2000, ONCOGENE, V19, P4427, DOI 10.1038/sj.onc.1203770; Sitterlin D, 2000, ONCOGENE, V19, P4417, DOI 10.1038/sj.onc.1203771; Sitterlin D, 1997, J VIROL, V71, P6194, DOI 10.1128/JVI.71.8.6194-6199.1997; Slagle BL, 1996, MOL CARCINOGEN, V15, P261, DOI 10.1002/(SICI)1098-2744(199604)15:4<261::AID-MC3>3.0.CO;2-J; SPRENGEL R, 1988, J VIROL, V62, P3832, DOI 10.1128/JVI.62.10.3832-3839.1988; Su F, 1997, P NATL ACAD SCI USA, V94, P8744, DOI 10.1073/pnas.94.16.8744; SUMMERS J, 1978, P NATL ACAD SCI USA, V75, P4533, DOI 10.1073/pnas.75.9.4533; Takada S, 1999, ONCOGENE, V18, P6965, DOI 10.1038/sj.onc.1203188; Takahashi K, 2000, VIROLOGY, V267, P58, DOI 10.1006/viro.1999.0102; Terradillos O, 1997, ONCOGENE, V14, P395, DOI 10.1038/sj.onc.1200850; Terradillos O, 1998, ONCOGENE, V17, P2115, DOI 10.1038/sj.onc.1202432; Testut P, 1996, J VIROL, V70, P4210, DOI 10.1128/JVI.70.7.4210-4219.1996; Tu H, 2001, CANCER RES, V61, P7803; WANG XW, 1995, CANCER RES, V55, P6012; Warren KS, 1999, J VIROL, V73, P7860, DOI 10.1128/JVI.73.9.7860-7865.1999; WHITE E, 1991, J VIROL, V65, P2968, DOI 10.1128/JVI.65.6.2968-2978.1991; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; ZOULIM F, 1994, J VIROL, V68, P2026, DOI 10.1128/JVI.68.3.2026-2030.1994	69	16	19	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6606	6613		10.1038/sj.onc.1205916	http://dx.doi.org/10.1038/sj.onc.1205916			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242658				2022-12-25	WOS:000178202300006
J	Morimoto-Tomita, M; Uchimura, K; Werb, Z; Hemmerich, S; Rosen, SD				Morimoto-Tomita, M; Uchimura, K; Werb, Z; Hemmerich, S; Rosen, SD			Cloning and characterization of two extracellular heparin-degrading endosulfatases in mice and humans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATASE; FURIN; IDENTIFICATION; PROTEOGLYCANS; PRECURSOR; DATABASE; PROTEIN; XP22.3; SITES	Here we report the cloning of a full-length cDNA encoding the human ortholog (HSulf-1) of the developmentally regulated putative sulfatases QSulf-1 (Dhoot, G. K., Gustafsson, M. K., Ai, X., Sun, W., Standiford, D. M., and Emerson, C. P., Jr. (2001) Science 293, 1663-1666) and RSulfFP1 (Ohto, T., Uchida, H., Yamazaki, H., Keino-Masu, K., Matsui, A., and Masu, M. (2002) Genes Cells 7, 173-185) as well as a cDNA encoding a closely related protein, designated HSulf-2. We have also obtained cDNAs for the mouse orthologs of both Sulfs. We demonstrate that the proteins encoded by both classes of cDNAs are endoproteolytically processed in the secretory pathway and are released into conditioned medium of transfected CHO cells. We demonstrate that the mammalian Sulfs exhibit arylsulfatase activity with a pH optimum in the neutral range; moreover, they can remove sulfate from the C-6 position of glucosamine within specific subregions of intact heparin. Taken together, our results establish that the mammalian Sulfs are extracellular endosulfatases with strong potential for modulating the interactions of heparan sulfate proteoglycans in the extracellular microenvironment.	Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Thios Pharmaceut Inc, Oakland, CA 94609 USA	University of California System; University of California San Francisco	Rosen, SD (corresponding author), Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA.		Uchimura, Kenji/C-9635-2014; Uchimura, Kenji/AFV-1802-2022	Uchimura, Kenji/0000-0003-3009-248X; Uchimura, Kenji/0000-0003-3009-248X; Rosen, Steven/0000-0002-6245-701X	NCI NIH HHS [CA 72006, P01 CA072006, P01 CA072006-07] Funding Source: Medline; NIGMS NIH HHS [R37 GM023547, R37 GM023547-26, R37 GM023547-29, R37 GM 23547, R37 GM023547-27, R37 GM023547-28] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA072006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023547] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Blake JA, 2000, NUCLEIC ACIDS RES, V28, P108, DOI 10.1093/nar/28.1.108; Burset M, 2001, NUCLEIC ACIDS RES, V29, P255, DOI 10.1093/nar/29.1.255; Dhoot GK, 2001, SCIENCE, V293, P1663, DOI 10.1126/science.293.5535.1663; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; FRANCO B, 1995, CELL, V81, P15, DOI 10.1016/0092-8674(95)90367-4; Gallagher JT, 2001, J CLIN INVEST, V108, P357, DOI 10.1172/JCI13713; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Litjens T, 1997, BIOCHEM J, V327, P89, DOI 10.1042/bj3270089; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ohto T, 2002, GENES CELLS, V7, P173, DOI 10.1046/j.1356-9597.2001.00502.x; Parenti G, 1997, CURR OPIN GENET DEV, V7, P386, DOI 10.1016/S0959-437X(97)80153-0; Puca AA, 1997, GENOMICS, V42, P192, DOI 10.1006/geno.1997.4716; Reichsman F, 1996, J CELL BIOL, V135, P819, DOI 10.1083/jcb.135.3.819; ROBERTSON DA, 1992, BIOCHEM J, V288, P539, DOI 10.1042/bj2880539; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Waldow A, 1999, J BIOL CHEM, V274, P12284, DOI 10.1074/jbc.274.18.12284; Wang X, 2001, J BIOL CHEM, V276, P35953, DOI 10.1074/jbc.M103680200; WASLEY LC, 1993, J BIOL CHEM, V268, P8458; YOSHIDA K, 1989, ANAL BIOCHEM, V177, P327, DOI 10.1016/0003-2697(89)90061-4	26	326	349	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49175	49185		10.1074/jbc.M205131200	http://dx.doi.org/10.1074/jbc.M205131200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12368295	Green Accepted, hybrid			2022-12-25	WOS:000180028900011
J	Felton-Edkins, ZA; White, RJ				Felton-Edkins, ZA; White, RJ			Multiple mechanisms contribute to the activation of RNA polymerase III transcription in cells transformed by papovaviruses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING-PROTEIN; LARGE T-ANTIGEN; POLYOMAVIRUS LARGE-T; RETINOBLASTOMA PROTEIN; MIDDLE-T; SIMIAN VIRUS-40; MOUSE CELLS; RAT-CELLS; EXPRESSION; COMPLEX	RNA polymerase (pol) III transcription is abnormally active in fibroblasts transformed by polyomavirus (Py) or simian virus 40 (SV40). Several distinct mechanisms contribute to this effect. In untransformed fibroblasts, the basal pol III transcription factor (TF) IIIB is repressed through association with the retinoblastoma protein RB; this restraint is overcome by large T antigens of Py and SV40. Furthermore, cells transformed by these papovaviruses overexpress the BDP1 subunit of TFIIIB, at both the protein and mRNA levels. Despite the overexpression of BDP1, the abundance of the other TFIIIB components is unperturbed following papovavirus transformation. In contrast, mRNAs encoding all five subunits of the basal factor TFIIIC2 are found at elevated levels in fibroblasts transformed by Py or SV40. Thus, both papovaviruses stimulate pol III transcription by boosting production of selected components of the basal machinery. Py differs from SV40 in encoding a highly oncogenic middle T antigen that localizes outside the nucleus and activates several signal transduction pathways. Middle T can serve as a potent activator of a pol III reporter in transfected cells. Several distinct mechanisms therefore contribute to the high levels of pol III transcription that accompany transformation by Py and SV40.	Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Glasgow	White, RJ (corresponding author), Univ Glasgow, Inst Biomed & Life Sci, Div Biochem & Mol Biol, Davidson Bldg, Glasgow G12 8QQ, Lanark, Scotland.							Alzuherri HM, 1998, J BIOL CHEM, V273, P17166, DOI 10.1074/jbc.273.27.17166; Brown TRP, 2000, GENE EXPRESSION, V9, P15; Cairns CA, 1998, EMBO J, V17, P3112, DOI 10.1093/emboj/17.11.3112; CAREY MF, 1986, MOL CELL BIOL, V6, P3068, DOI 10.1128/MCB.6.9.3068; Chen W, 1997, J PATHOL, V183, P345, DOI 10.1002/(SICI)1096-9896(199711)183:3<345::AID-PATH930>3.0.CO;2-8; Chen W, 1997, EUR J CANCER, V33, P288, DOI 10.1016/S0959-8049(96)00453-4; Chesnokov I, 1996, MOL CELL BIOL, V16, P7084; Chu WM, 1997, J BIOL CHEM, V272, P14755, DOI 10.1074/jbc.272.23.14755; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; Damania B, 1998, MOL CELL BIOL, V18, P1331, DOI 10.1128/MCB.18.3.1331; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FREUND R, 1992, ONCOGENE, V7, P1979; GALLION HH, 1995, CANCER, V76, P1992, DOI 10.1002/1097-0142(19951115)76:10+<1992::AID-CNCR2820761315>3.0.CO;2-U; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; Gottesfeld JM, 1996, MOL CELL BIOL, V16, P1777; Hirsch HA, 2000, MOL CELL BIOL, V20, P9182, DOI 10.1128/MCB.20.24.9182-9191.2000; HOEFFLER WK, 1988, CELL, V53, P907, DOI 10.1016/S0092-8674(88)90409-6; Hsieh YJ, 1999, MOL CELL BIOL, V19, P4944; Hsieh YJ, 1999, MOL CELL BIOL, V19, P7697; ITO Y, 1979, VIROLOGY, V98, P261, DOI 10.1016/0042-6822(79)90545-2; KAPLAN D R, 1988, Biochimica et Biophysica Acta, V948, P345; KOVELMAN R, 1992, J BIOL CHEM, V267, P24446; LANE DP, 1979, NATURE, V278, P261, DOI 10.1038/278261a0; LANIA L, 1987, FEBS LETT, V219, P400, DOI 10.1016/0014-5793(87)80260-0; Larminie CGC, 1999, MOL CELL BIOL, V19, P4927; Larminie CGC, 1997, EMBO J, V16, P2061, DOI 10.1093/emboj/16.8.2061; LAROSE A, 1991, J VIROL, V65, P2308, DOI 10.1128/JVI.65.5.2308-2313.1991; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOEKEN M, 1988, CELL, V55, P1171, DOI 10.1016/0092-8674(88)90261-9; Luo Y, 1997, J CELL BIOCHEM, V64, P313, DOI 10.1002/(SICI)1097-4644(199702)64:2<313::AID-JCB13>3.0.CO;2-J; MAJELLO B, 1985, NATURE, V314, P457, DOI 10.1038/314457a0; Marti A, 1999, J GEN VIROL, V80, P2917, DOI 10.1099/0022-1317-80-11-2917; Messerschmitt AS, 1997, VIROLOGY, V227, P271, DOI 10.1006/viro.1996.8316; MORAN E, 1988, NATURE, V334, P168, DOI 10.1038/334168a0; Oliveira MLS, 1999, BRAZ J MED BIOL RES, V32, P861, DOI 10.1590/S0100-879X1999000700010; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; RIGBY PWJ, 1980, PROC R SOC SER B-BIO, V210, P437, DOI 10.1098/rspb.1980.0145; SCHAFFHAUSEN BS, 1982, MOL CELL BIOL, V2, P1187, DOI 10.1128/MCB.2.10.1187; Schramm L, 2000, GENE DEV, V14, P2650, DOI 10.1101/gad.836400; SCOTT MRD, 1983, CELL, V34, P557, DOI 10.1016/0092-8674(83)90388-4; Scott PH, 2001, J BIOL CHEM, V276, P1005, DOI 10.1074/jbc.M005417200; Shen YH, 1996, MOL CELL BIOL, V16, P4163; SINGH K, 1985, NATURE, V314, P553, DOI 10.1038/314553a0; SINN E, 1995, GENE DEV, V9, P675, DOI 10.1101/gad.9.6.675; Sutcliffe JE, 1999, MOL CELL BIOL, V19, P4255; Sutcliffe JE, 2000, MOL CELL BIOL, V20, P9192, DOI 10.1128/MCB.20.24.9192-9202.2000; Tooze J, 1980, DNA TUMOR VIRUSES; TREISMAN R, 1981, NATURE, V292, P595, DOI 10.1038/292595a0; URICH M, 1995, J BIOL CHEM, V270, P29286, DOI 10.1074/jbc.270.49.29286; VOUSDEN KH, 1995, SEMIN CANCER BIOL, V6, P109, DOI 10.1006/scbi.1995.0014; Wang HD, 1997, MOL CELL BIOL, V17, P6838, DOI 10.1128/MCB.17.12.6838; WHITE RJ, 1990, EMBO J, V9, P3713, DOI 10.1002/j.1460-2075.1990.tb07584.x; WHITE RJ, 1989, CELL, V59, P1081, DOI 10.1016/0092-8674(89)90764-2; WHITE RJ, 1995, MOL CELL BIOL, V15, P6653; White RJ, 1996, NATURE, V382, P88, DOI 10.1038/382088a0; WHITE RJ, 1995, MOL CELL BIOL, V15, P1983; WHITE RJ, 1998, RNA POLYM 3 TRANSCRI; WHITE RJ, 1992, J CELL SCI S, V16, P1; Winter AG, 2000, P NATL ACAD SCI USA, V97, P12619, DOI 10.1073/pnas.230224097; YOSHINAGA S, 1986, EMBO J, V5, P343, DOI 10.1002/j.1460-2075.1986.tb04218.x; YOSHINAGA SK, 1989, J BIOL CHEM, V264, P10726; ZHU JY, 1992, J VIROL, V66, P2780, DOI 10.1128/JVI.66.5.2780-2791.1992	64	33	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48182	48191		10.1074/jbc.M201333200	http://dx.doi.org/10.1074/jbc.M201333200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12370195	hybrid			2022-12-25	WOS:000179789600029
J	Austin, RC; Fox, JEB; Werstuck, GH; Stafford, AR; Bulman, DE; Dally, GY; Ackerley, CA; Weitz, JI; Ray, PN				Austin, RC; Fox, JEB; Werstuck, GH; Stafford, AR; Bulman, DE; Dally, GY; Ackerley, CA; Weitz, JI; Ray, PN			Identification of Dp71 isoforms in the platelet membrane cytoskeleton - Potential role in thrombin-mediated platelet adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; GLYCOPROTEIN-IV CD36; SKELETAL-MUSCLE; MONOCLONAL-ANTIBODIES; TISSUE DISTRIBUTION; NONMUSCLE TISSUES; CELL LINES; PROTEIN; GENE; BRAIN	Utrophin is a component of the platelet membrane cytoskeleton and participates in cytoskeletal reorganization (Earnest, J.P., Santos, G.F., Zuerbig, S., and Fox, J.E.B. (1995) J. Biol. Chem 270, 27259-27265). Although platelets do not contain dystrophin, the identification of smaller C-terminal isoforms of dystrophin, including Dp71, which are expressed in a wide range of nonmuscle tissues and cell lines, has not been investigated. In this report, we have identified Dp71 protein variants of 55-60 kDa (designated Dp71Delta(110)) in the membrane cytoskeleton of human platelets. Both Dp71Delta(110) and utrophin sediment from lysed platelets along with the high speed detergent-insoluble pellet, which contains components of the membrane cytoskeleton. Like the membrane cytoskeletal proteins vinculin and spectrin, Dp71Delta(110) and utrophin redistributed from the high speed detergent-insoluble pellet to the integrin-rich low speed pellet of thrombin-stimulated platelets. Immunoelectron microscopy provided further evidence that Dp71Delta(110) was localized to the submembranous cytoskeleton. In addition to Dp71Delta(110), platelets contained several components of the dystrophin-associated protein complex, including beta-dystroglycan and syntrophin. To better understand the potential function of Dp71Delta(110), collagen adhesion assays were performed on platelets isolated from wild-type or Dp71-deficient (mdx(3cv)) mice. Adhesion to collagen in response to thrombin was significantly decreased in platelets isolated from mdx(3cv) Mice, compared with wild-type platelets. Collectively, our results provide evidence that Dp71Delta(110) is a component of the platelet membrane cytoskeleton, is involved in cytoskeletal reorganization and/or signaling, and plays a role in thrombin-mediated platelet adhesion.	Henderson Res Crt, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Pathol, Hamilton, ON L8V 1C3, Canada; McMaster Univ, Dept Med, Hamilton, ON L8V 1C3, Canada; Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Dis, Cleveland, OH 44195 USA; Ottawa Hosp, Inst Res, Ottawa, ON K1H 8L6, Canada; Hosp Sick Children, Dept Genet, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Inst Res, Toronto, ON M5G 1X8, Canada	McMaster University; McMaster University; Cleveland Clinic Foundation; University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Austin, RC (corresponding author), Henderson Res Crt, 711 Concess St, Hamilton, ON L8V 1C3, Canada.		Weitz, Jeffrey/AAD-1929-2019	Weitz, Jeffrey/0000-0002-1092-7550	NHLBI NIH HHS [HL30657, HL56264] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056264, R23HL030657, R01HL030657, R37HL030657] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn AH, 1996, J BIOL CHEM, V271, P2724, DOI 10.1074/jbc.271.5.2724; AHN AH, 1993, NAT GENET, V3, P283, DOI 10.1038/ng0493-283; AUSTIN RC, 1995, HUM MOL GENET, V4, P1475; Austin RC, 2000, NEUROMUSCULAR DISORD, V10, P187, DOI 10.1016/S0960-8966(99)00105-4; BAR S, 1990, BIOCHEM J, V272, P557, DOI 10.1042/bj2720557; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; BIES RD, 1992, NUCLEIC ACIDS RES, V20, P1725, DOI 10.1093/nar/20.7.1725; Blake Derek J., 1992, Human Molecular Genetics, V1, P103, DOI 10.1093/hmg/1.2.103; Blake DJ, 2002, PHYSIOL REV, V82, P291, DOI 10.1152/physrev.00028.2001; Burton EA, 2002, CELL, V108, P5, DOI 10.1016/S0092-8674(01)00626-2; BYERS TJ, 1993, NAT GENET, V4, P77, DOI 10.1038/ng0593-77; CHELLY J, 1990, CELL, V63, P1239, DOI 10.1016/0092-8674(90)90419-F; COX GA, 1993, NAT GENET, V4, P87, DOI 10.1038/ng0593-87; COX GA, 1994, NAT GENET, V8, P333, DOI 10.1038/ng1294-333; CULLEN MJ, 1994, ACTA NEUROPATHOL, V87, P349; DANIEL JL, 1987, HEMOSTASIS THROMBOSI, P644; DICKSON G, 1988, FEBS LETT, V242, P47, DOI 10.1016/0014-5793(88)80982-7; DSOUZA VN, 1995, HUM MOL GENET, V4, P837, DOI 10.1093/hmg/4.5.837; EARNEST JP, 1995, J BIOL CHEM, V270, P27259, DOI 10.1074/jbc.270.45.27259; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1990, NATURE, V345, P315, DOI 10.1038/345315a0; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; FEENER CA, 1989, NATURE, V338, P509, DOI 10.1038/338509a0; Forst J, 1998, NEUROMUSCULAR DISORD, V8, P46, DOI 10.1016/S0960-8966(97)00145-4; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1993, THROMB HAEMOSTASIS, V70, P884; FOX JEB, 1993, J BIOL CHEM, V268, P25973; FROEHNER SC, 1987, J CELL BIOL, V104, P1633, DOI 10.1083/jcb.104.6.1633; Greenberg DS, 1996, HUM MOL GENET, V5, P1299, DOI 10.1093/hmg/5.9.1299; GREENBERG DS, 1994, NAT GENET, V8, P340, DOI 10.1038/ng1294-340; GREENBERG SM, 1988, BLOOD, V72, P1968; Howard PL, 1999, MUSCLE NERVE, V22, P16, DOI 10.1002/(SICI)1097-4598(199901)22:1<16::AID-MUS5>3.0.CO;2-R; HUGNOT JP, 1992, P NATL ACAD SCI USA, V89, P7506, DOI 10.1073/pnas.89.16.7506; JUNG D, 1993, NEUROMUSCULAR DISORD, V3, P515, DOI 10.1016/0960-8966(93)90107-U; KARPATI G, 1993, J NEUROPATH EXP NEUR, V52, P119, DOI 10.1097/00005072-199303000-00004; KRAMARCY NR, 1994, J BIOL CHEM, V269, P2870; KRAMARCY NR, 1990, FEBS LETT, V274, P171, DOI 10.1016/0014-5793(90)81356-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKONISHOK M, 1992, DEV BIOL, V152, P209, DOI 10.1016/0012-1606(92)90129-5; LEDERFEIN D, 1992, P NATL ACAD SCI USA, V89, P5346, DOI 10.1073/pnas.89.12.5346; LIDOV HGW, 1995, HUM MOL GENET, V4, P329, DOI 10.1093/hmg/4.3.329; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; LUISE M, 1993, BIOCHEM J, V293, P243, DOI 10.1042/bj2930243; MADHAVAN R, 1994, BIOCHEMISTRY-US, V33, P5797, DOI 10.1021/bi00185a018; MAN NT, 1990, FEBS LETT, V262, P237, DOI 10.1016/0014-5793(90)80199-S; MAN NT, 1991, J CELL BIOL, V115, P1695; MAN NT, 1992, FEBS LETT, V313, P19; MATSUMURA K, 1993, FEBS LETT, V326, P289, DOI 10.1016/0014-5793(93)81810-M; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Maurin N, 1998, THROMB HAEMOSTASIS, V79, P1067; MILLER F, 1992, DEV MED CHILD NEUROL, V34, P775; MILNER RE, 1993, J BIOL CHEM, V268, P21901; MORRIS GE, 1995, BIOCHEM BIOPH RES CO, V215, P361, DOI 10.1006/bbrc.1995.2474; Noordeen MHH, 1999, J PEDIATR ORTHOP B, V8, P212, DOI 10.1097/01202412-199907000-00015; PILLERS DAM, 1993, NAT GENET, V4, P82, DOI 10.1038/ng0593-82; RAPAPORT D, 1993, FEBS LETT, V328, P197, DOI 10.1016/0014-5793(93)80992-4; REECE AT, 1994, J BONE JOINT SURG S1, V76; SENTER L, 1993, BIOCHEM BIOPH RES CO, V192, P899, DOI 10.1006/bbrc.1993.1500; SUZUKI A, 1995, J CELL BIOL, V128, P373, DOI 10.1083/jcb.128.3.373; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANDON NN, 1991, BIOCHEM J, V274, P535, DOI 10.1042/bj2740535; TANDON NN, 1991, BLOOD, V78, P2809; TINSLEY JM, 1994, P NATL ACAD SCI USA, V91, P8307, DOI 10.1073/pnas.91.18.8307; ZUBRZYCKAGAARN EF, 1988, NATURE, V333, P466, DOI 10.1038/333466a0	65	23	23	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47106	47113		10.1074/jbc.M203289200	http://dx.doi.org/10.1074/jbc.M203289200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370193	hybrid			2022-12-25	WOS:000179663700036
J	Hektor, HJ; Kloosterman, H; Dijkhuizen, L				Hektor, HJ; Kloosterman, H; Dijkhuizen, L			Identification of a magnesium-dependent NAD(P)(H)-binding domain in the nicotinoprotein methanol dehydrogenase from Bacillus methanolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-FRUCTOSE OXIDOREDUCTASE; ELECTRON-MICROSCOPIC ANALYSIS; ALCOHOL-DEHYDROGENASE; ZYMOMONAS-MOBILIS; SEQUENCE-ANALYSIS; ESCHERICHIA-COLI; CLOSTRIDIUM-ACETOBUTYLICUM; MOLECULAR CHARACTERIZATION; GENE-CLUSTER; THERMOTOLERANT BACILLUS	The Bacillus methanolicus methanol dehydrogenase (MDH) is a decameric nicotinoprotein alcohol dehydrogenase (family III) with one Zn2+ ion, one or two Mg2+ ions, and a tightly bound cofactor NAD(H) per subunit. The Mg2+ ions are essential for binding of cofactor NAD(H) in MDH. A B. methanolicus activator protein strongly stimulates the relatively low coenzyme NAD(+)-dependent MDH activity, involving hydrolytic removal of the NMN(H) moiety of cofactor NAD(H) (Kloosterman, H., Vrijbloed, J. W., and Dijkhuizen, L. (2002) J. Biol. Chem. 277, 34785-34792). Members of family III of NAD(P)-dependent alcohol dehydrogenases contain three unique, conserved sequence motifs (domains A, B, and C). Domain C is thought to be involved in metal binding, whereas the functions of domains A and B are still unknown. This paper provides evidence that domain A constitutes (part of) a new magnesium-dependent NAD(P)(H)-binding domain. Site-directed mutants D100N and K103R lacked (most of the) bound cofactor NAD(H) and had lost all coenzyme NAD(+)-dependent MDH activity. Also mutants G95A and S97G were both impaired in cofactor NAD(H) binding but retained coenzyme NAD(+)-dependent MDH activity. Mutant G95A displayed a rather low MDH activity, whereas mutant S97G was insensitive to activator protein but displayed "fully activated" MDH reaction rates. The various roles of these amino acid residues in coenzyme and/or cofactor NAD(H) binding in MDH are discussed.	Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, NL-9751 NN Haren, Netherlands	University of Groningen	Dijkhuizen, L (corresponding author), Univ Groningen, Dept Microbiol, Groningen Biomol Sci & Biotechnol Inst, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Dijkhuizen, Lubbert/E-9454-2014; Dijkhuizen, Lubbert/K-3539-2019	Dijkhuizen, Lubbert/0000-0003-2312-7162				Arfman N, 1997, EUR J BIOCHEM, V244, P426, DOI 10.1111/j.1432-1033.1997.00426.x; ARFMAN N, 1991, J BIOL CHEM, V266, P3955; ARFMAN N, 1989, ARCH MICROBIOL, V152, P280, DOI 10.1007/BF00409664; Bairoch A, 1996, NUCLEIC ACIDS RES, V24, P189, DOI 10.1093/nar/24.1.189; BAIROCH A, 1992, NUCLEIC ACIDS RES, V20, P2013, DOI 10.1093/nar/20.suppl.2013; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BrõndÚn CI., 1991, INTRO PROTEIN STRUCT; BYSTRYKH LV, 1993, J BACTERIOL, V175, P1814, DOI 10.1128/JB.175.6.1814-1822.1993; CABISCOL E, 1994, J BIOL CHEM, V269, P6592; CHEN YM, 1989, J BACTERIOL, V171, P6097, DOI 10.1128/jb.171.11.6097-6105.1989; CONWAY T, 1987, J BACTERIOL, V169, P2591, DOI 10.1128/jb.169.6.2591-2597.1987; Cue D, 1997, APPL ENVIRON MICROB, V63, P1406, DOI 10.1128/AEM.63.4.1406-1420.1997; DANIEL R, 1995, J BACTERIOL, V177, P2151, DOI 10.1128/jb.177.8.2151-2156.1995; DAUBARAS DL, 1995, APPL ENVIRON MICROB, V61, P1279, DOI 10.1128/AEM.61.4.1279-1289.1995; DEHOOP M, 1991, PROTEIN ENG, V4, P821, DOI 10.1093/protein/4.7.821; DEVRIES GE, 1992, J BACTERIOL, V174, P5346, DOI 10.1128/JB.174.16.5346-5353.1992; Dixon M., 1979, ENZYMES, Vthird; FRICK DN, 1994, J BIOL CHEM, V269, P1794; GOODLOVE PE, 1989, GENE, V85, P209, DOI 10.1016/0378-1119(89)90483-6; HENSGENS CMH, 1993, J BACTERIOL, V175, P2859, DOI 10.1128/JB.175.10.2859-2863.1993; HENSGENS CMH, 1995, ARCH MICROBIOL, V164, P265, DOI 10.1007/BF02529960; JORNVALL H, 1987, EUR J BIOCHEM, V167, P195, DOI 10.1111/j.1432-1033.1987.tb13323.x; KANAGASUNDARAM V, 1992, J BACTERIOL, V174, P1439, DOI 10.1128/jb.174.5.1439-1447.1992; Kingston RL, 1996, STRUCTURE, V4, P1413, DOI 10.1016/S0969-2126(96)00149-9; Kloosterman H, 2002, J BIOL CHEM, V277, P34785, DOI 10.1074/jbc.M205617200; LAEMMLI UK, 1973, J MOL BIOL, V80, P575, DOI 10.1016/0022-2836(73)90198-8; Li DH, 1997, J BACTERIOL, V179, P4433, DOI 10.1128/jb.179.13.4433-4437.1997; MURRAY V, 1989, NUCLEIC ACIDS RES, V17, P8889, DOI 10.1093/nar/17.21.8889; NAGY I, 1995, ARCH MICROBIOL, V163, P439, DOI 10.1007/BF00272133; NAIR RV, 1994, J BACTERIOL, V176, P871, DOI 10.1128/jb.176.3.871-885.1994; PERKINS EJ, 1990, J BACTERIOL, V172, P2351, DOI 10.1128/jb.172.5.2351-2359.1990; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; Ruzheinikov SN, 2001, STRUCTURE, V9, P789, DOI 10.1016/S0969-2126(01)00645-1; Sambrook J., 2002, MOL CLONING LAB MANU; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SOFIA HJ, 1994, NUCLEIC ACIDS RES, V22, P2576, DOI 10.1093/nar/22.13.2576; Sohling B, 1996, J BACTERIOL, V178, P871; STOJILJKOVIC I, 1995, J BACTERIOL, V177, P1357, DOI 10.1128/jb.177.5.1357-1366.1995; Tamarit J, 1997, J BACTERIOL, V179, P1102, DOI 10.1128/jb.179.4.1102-1104.1997; VALENTIN HE, 1995, EUR J BIOCHEM, V227, P43, DOI 10.1111/j.1432-1033.1995.tb20358.x; VANDERMEER JR, 1991, J BACTERIOL, V173, P2425, DOI 10.1128/jb.173.8.2425-2434.1991; VONCK J, 1991, J BIOL CHEM, V266, P3949; WALTER KA, 1992, J BACTERIOL, V174, P7149, DOI 10.1128/jb.174.22.7149-7158.1992; Wiegert T, 1997, J BIOL CHEM, V272, P13126, DOI 10.1074/jbc.272.20.13126; WIERENGA RK, 1983, J MOL BIOL, V167, P725, DOI 10.1016/S0022-2836(83)80106-5; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILLIAMSON VM, 1987, MOL GEN GENET, V209, P374, DOI 10.1007/BF00329668; Wong JT, 1975, KINETICS ENZYME MECH; YANG WG, 1994, MOL BIOCHEM PARASIT, V64, P253, DOI 10.1016/0166-6851(93)00020-A; YOUNGLESON JS, 1989, GENE, V78, P355, DOI 10.1016/0378-1119(89)90238-2	51	32	39	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46966	46973		10.1074/jbc.M207547200	http://dx.doi.org/10.1074/jbc.M207547200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351635	hybrid, Green Published			2022-12-25	WOS:000179663700018
J	Xia, HH; von Zastrow, M; Malenka, RC				Xia, HH; von Zastrow, M; Malenka, RC			A novel anterograde trafficking signal present in the N-terminal extracellular domain of ionotropic glutamate receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER RETENTION SIGNAL; SUBUNIT STOICHIOMETRY; SURFACE EXPRESSION; ACETYLCHOLINE-RECEPTOR; TRANSMEMBRANE DOMAINS; TETRAMERIC STRUCTURE; AMPA RECEPTORS; NMDA; CHANNEL; MECHANISMS	Trafficking of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA) receptors to and from the postsynaptic membrane plays an important role in regulating transmission at excitatory synapses. AMPA receptor subunits contain a large extracellular N-terminal domain that is important for receptor assembly (1). To further investigate the determinants of receptor assembly and surface expression, we have epitope-tagged the N-terminal domain of the AMPA receptor subunit, GluR1, and expressed it in human embryonic kidney 293 cells and hippocampal neurons. Full-length GluR1 was readily detected on the cell surface in both cell types. However, surface expression was profoundly decreased by deletion or replacement of nine amino acids in the extreme N terminus. Immunoprecipitation experiments demonstrated that the mutant GluR1 in which this sequence was deleted still interacts with GluR2, suggesting that mutant GluR1 is capable of at least partial assembly into heteromeric structures. The mutant forms of GluR1 co-localize with an endoplasmic reticulum. marker suggesting that they are retained in this structure. These results suggest a specific function of a short sequence present in the N-terminal domain in controlling anterograde trafficking of ionotropic glutamate receptors.	Stanford Univ, Dept Psychiat & Behav Sci, Palo Alto, CA 94304 USA; Univ Calif San Francisco, Dept Psychiat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Malenka, RC (corresponding author), Stanford Univ, Dept Psychiat & Behav Sci, 1201 Welch Rd,Rm P105, Palo Alto, CA 94304 USA.							Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; Carroll RC, 1999, P NATL ACAD SCI USA, V96, P14112, DOI 10.1073/pnas.96.24.14112; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; FerrerMontiel AV, 1996, P NATL ACAD SCI USA, V93, P2741, DOI 10.1073/pnas.93.7.2741; GREEN WN, 1993, CELL, V74, P57, DOI 10.1016/0092-8674(93)90294-Z; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; Kuusinen A, 1999, J BIOL CHEM, V274, P28937, DOI 10.1074/jbc.274.41.28937; Laube B, 1998, J NEUROSCI, V18, P2954; Letts VA, 1998, NAT GENET, V19, P340, DOI 10.1038/1228; Leuschner WD, 1999, J BIOL CHEM, V274, P16907, DOI 10.1074/jbc.274.24.16907; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; Ma D, 2002, CURR OPIN NEUROBIOL, V12, P287, DOI 10.1016/S0959-4388(02)00319-7; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Madden DR, 2002, NAT REV NEUROSCI, V3, P91, DOI 10.1038/nrn725; Malinow R, 2002, ANNU REV NEUROSCI, V25, P103, DOI 10.1146/annurev.neuro.25.112701.142758; Mano I, 1998, NEUROREPORT, V9, P327, DOI 10.1097/00001756-199801260-00027; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Netzer WJ, 1998, TRENDS BIOCHEM SCI, V23, P68, DOI 10.1016/S0968-0004(97)01171-7; O'Brien RJ, 1999, NEURON, V23, P309, DOI 10.1016/S0896-6273(00)80782-5; Okabe S, 1999, J NEUROSCI, V19, P7781; Premkumar LS, 1997, J GEN PHYSIOL, V110, P485, DOI 10.1085/jgp.110.5.485; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Spiliotis ET, 2000, IMMUNITY, V13, P841, DOI 10.1016/S1074-7613(00)00081-9; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Tsui CC, 1996, J NEUROSCI, V16, P2463; Wang ZZ, 1996, J BIOL CHEM, V271, P27575, DOI 10.1074/jbc.271.44.27575; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; Xia H, 2001, NEUROPHARMACOLOGY, V41, P714, DOI 10.1016/S0028-3908(01)00103-4; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	35	27	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47765	47769		10.1074/jbc.M207122200	http://dx.doi.org/10.1074/jbc.M207122200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12368290	hybrid			2022-12-25	WOS:000179663700120
J	Lavine, N; Ethier, N; Oak, JN; Pei, L; Liu, F; Trieu, P; Rebois, RV; Bouvier, M; Hebert, TE; Van Tol, HHM				Lavine, N; Ethier, N; Oak, JN; Pei, L; Liu, F; Trieu, P; Rebois, RV; Bouvier, M; Hebert, TE; Van Tol, HHM			G protein-coupled receptors form stable complexes with inwardly rectifying potassium channels and adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; BETA(2)-ADRENERGIC RECEPTOR; SIGNALING COMPLEXES; XENOPUS OOCYTES; K+ CHANNELS; KINASE; TRAFFICKING; ACTIVATION; MEMBRANES	A large number of studies have demonstrated co-purification or co-immunoprecipitation of receptors with G proteins. We have begun to look for the presence of effector molecules in these receptor complexes. Co-expression of different channel and receptor permutations in COS-7 and HEK 293 cells in combination with co-immunoprecipitation experiments established that the dopamine D-2 and D-4, and beta(2)-adrenergic receptors (beta(2)-AR) form stable complexes with Kir3 channels. The D-4/ Kir3 and D-2 receptor/Kir3 interaction does not occur when the channel and receptor are expressed separately and mixed prior to immunoprecipitation, indicating that the interaction is not an artifact of the experimental protocol and reflects a biosynthetic event. The observed complexes are stable in that they are not disrupted by receptor activation or modulation of G protein a subunit function. However, using a peptide that binds Gbetagamma (betaARKct), we show that Gbetagamma is critical for dopamine receptor-Kir3 complex formation, but not for maintenance of the complex. We also provide evidence that Kir3 channels and another effector, adenylyl cyclase, are stably associated with the beta(2)-adrenergic receptor and can be co-immunoprecipitated by anti-receptor antibodies. Using bioluminescence resonance energy transfer, we have shown that in living cells under physiological conditions, beta(2)AR interacts directly with Kir3.1/3.4 and Kir3.1/3.2c heterotetramers as well as with adenylyl cyclase. All of these interactions are stable in the presence of receptor agonists, suggesting that these signaling complexes persist during signal transduction. In addition, we provide evidence that the receptor-effector complexes are also found in vivo. The observation that several G protein-coupled receptors form stable complexes with their effectors suggests that this arrangement might be a general feature of G protein-coupled signal transduction.	Univ Toronto, Ctr Addict & Mental Hlth, Mol Neurobiol Lab, Dept Pharmacol, Toronto, ON M5T 1R8, Canada; Univ Toronto, Inst Med Sci, Dept Psychiat, Toronto, ON M5T 1R8, Canada; Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada; NINDS, NIH, Bethesda, MD 20892 USA; Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; Universite de Montreal; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Universite de Montreal	Van Tol, HHM (corresponding author), Univ Toronto, Ctr Addict & Mental Hlth, Mol Neurobiol Lab, Dept Pharmacol, 250 Coll St, Toronto, ON M5T 1R8, Canada.	hubert.van.tol@utoronto.ca	Lavine, Natalie/AAC-9623-2021; Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100; Lavine, Natalie Elisabeth/0000-0003-4897-0092	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002784] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Barak LS, 1997, MOL PHARMACOL, V51, P177, DOI 10.1124/mol.51.2.177; BARSINAI A, 1992, EUR J BIOCHEM, V207, P703, DOI 10.1111/j.1432-1033.1992.tb17098.x; Basi NS, 1996, CELL SIGNAL, V8, P209, DOI 10.1016/0898-6568(95)02056-X; Bray D, 1998, ANNU REV BIOPH BIOM, V27, P59, DOI 10.1146/annurev.biophys.27.1.59; Chan KW, 1997, J BIOL CHEM, V272, P6548, DOI 10.1074/jbc.272.10.6548; Chidiac P, 1998, BIOCHEM PHARMACOL, V55, P549, DOI 10.1016/S0006-2952(97)00361-4; Cong M, 2001, J BIOL CHEM, V276, P15192, DOI 10.1074/jbc.M009130200; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dunigan CD, 2000, METH MOL B, V136, P329; FEINSTEIN PG, 1991, P NATL ACAD SCI USA, V88, P10173, DOI 10.1073/pnas.88.22.10173; Ganpat MM, 2000, CELL SIGNAL, V12, P113, DOI 10.1016/S0898-6568(99)00078-9; Gilchrist A, 1998, J BIOL CHEM, V273, P14912, DOI 10.1074/jbc.273.24.14912; Helms JB, 1998, J BIOL CHEM, V273, P15203, DOI 10.1074/jbc.273.24.15203; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; Husi H, 2001, J NEUROCHEM, V77, P281, DOI 10.1046/j.1471-4159.2001.t01-1-00248.x; Inanobe A, 1999, J NEUROSCI, V19, P1006; Jamora C, 1999, CELL, V98, P59, DOI 10.1016/S0092-8674(00)80606-6; Kallal L, 1998, J BIOL CHEM, V273, P322, DOI 10.1074/jbc.273.1.322; Kennedy ME, 1999, J BIOL CHEM, V274, P2571, DOI 10.1074/jbc.274.4.2571; KRAPIVINSKY G, 1995, J BIOL CHEM, V270, P28777, DOI 10.1074/jbc.270.48.28777; Lachance M, 1999, CELL SIGNAL, V11, P523, DOI 10.1016/S0898-6568(99)00024-8; LIM NF, 1995, J GEN PHYSIOL, V105, P421, DOI 10.1085/jgp.105.3.421; Ma D, 2002, NEURON, V33, P715, DOI 10.1016/S0896-6273(02)00614-1; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; NAIR LA, 1995, CIRC RES, V76, P832, DOI 10.1161/01.RES.76.5.832; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; Oldenhof J, 1998, BIOCHEMISTRY-US, V37, P15726, DOI 10.1021/bi981634+; Rebois RV, 1997, CELL SIGNAL, V9, P141, DOI 10.1016/S0898-6568(96)00133-7; REBOIS RV, 2002, IN PRESS RECEPTORS C; Rehm A, 1997, J CELL BIOL, V137, P305, DOI 10.1083/jcb.137.2.305; Robillard L, 2000, CELL SIGNAL, V12, P673, DOI 10.1016/S0898-6568(00)00118-2; Schoots O, 1999, CELL SIGNAL, V11, P871, DOI 10.1016/S0898-6568(99)00059-5; Stow JL, 1998, BBA-MOL CELL RES, V1404, P161, DOI 10.1016/S0167-4889(98)00055-X; Wellner-Kienitz MC, 2001, J BIOL CHEM, V276, P37347, DOI 10.1074/jbc.M106234200; Werner P, 1996, MOL PHARMACOL, V49, P656; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; Yamaguchi T, 2000, FEBS LETT, V470, P25, DOI 10.1016/S0014-5793(00)01284-9; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4	41	150	154	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46010	46019		10.1074/jbc.M205035200	http://dx.doi.org/10.1074/jbc.M205035200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297500	hybrid			2022-12-25	WOS:000179529300041
J	Okamoto, Y; de Avalos, SV; Hannun, YA				Okamoto, Y; de Avalos, SV; Hannun, YA			Structural requirements for selective binding of ISC1 to anionic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MONOCLONAL-ANTIBODY; PHOSPHATIDIC-ACID; MEMBRANE-BINDING; AMINO-ACIDS; L-SERINE; IDENTIFICATION; DOMAIN; MOTIF; ACTIVATION	Yeast ISC1 (Yer019w) encodes inositolphosphosphingolipid-phospholipase C and is activated by phosphatidylserine (PS) and cardiolipin (CL) (Sawai, H., Okamoto, Y., Lubert, C., Mao, C., Bielawska, A., Domae, M., and Hannun, Y. A. (2000) J. Biol. Chem. 275, 39793-39798). In this study, the structural requirements for anionic phospholipid-selective binding of ISC1 were determined using site-directed and deletion mutants. FLAG-tagged Isc1p was activated by PS, CL, and phosphatidylglycerol (PG) in a dose-dependent manner. Using lipid-protein overlay assays, Isc1p interacted specifically and directly with PS/CI/PG. Lipid-protein binding studies of a series of deletion mutants demonstrated that the second transmembrane domain (TMII) and the C terminus were required for PS binding. Moreover, the TMII and the C terminus domain were sufficient to impart PS binding to a heterologous protein, green fluorescence protein. In addition, mutations of positively charged amino acid residues at the C terminus of ISC1 reduced the activating effects of PS, suggesting involvement of these amino acids in interaction with PS/CI/PG and in the activation of the enzyme. Finally, when separate fragments containing the N terminus-TMI and TMII-C terminus were expressed heterologously, enzyme activity was reconstituted, demonstrating that the interaction of the N terminus and the C terminus is required for activity of Isc1p. These results raise the hypothesis that in the presence of PS/CL/PG, the catalytic domain in the N terminus of Isc1p is "pulled" to the membrane to interact with substrate. These studies provide unique insights into the properties of ISC1 and define a novel mechanism for activation of enzymes by lipids cofactors.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA	Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave, Charleston, SC 29425 USA.		OKAMOTO, Yasuo/J-8438-2015		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43825] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL RM, 1991, J BIOL CHEM, V266, P4661; BURKLAND AG, 2000, BIOCHIM BIOPHYS ACTA, V1483, P199; CALDERON C, 1994, J EXP MED, V180, P945, DOI 10.1084/jem.180.3.945; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; COMFURIUS P, 1994, BIOCHEMISTRY-US, V33, P10319, DOI 10.1021/bi00200a012; Dalton KA, 1998, BIOCHEM J, V329, P637; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; FOLCH J, 1957, J BIOL CHEM, V226, P497; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; IGARASHI K, 1995, J BIOL CHEM, V270, P29075, DOI 10.1074/jbc.270.49.29075; Improta-Brears T, 1999, MOL CELL BIOCHEM, V198, P171, DOI 10.1023/A:1006981411691; Johnson JE, 1997, J BIOL CHEM, V272, P30787, DOI 10.1074/jbc.272.49.30787; Jones JA, 2002, J BIOL CHEM, V277, P15530, DOI 10.1074/jbc.M111555200; Makise M, 2001, J BIOL CHEM, V276, P7450, DOI 10.1074/jbc.M009643200; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; Mao CG, 1999, BIOCHEM J, V342, P667, DOI 10.1042/0264-6021:3420667; NEWTON AC, 1994, BIOCHEMISTRY-US, V33, P6651, DOI 10.1021/bi00187a035; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; Sawai H, 2000, J BIOL CHEM, V275, P39793, DOI 10.1074/jbc.M007721200; STEKHOVEN FMAHS, 1994, BBA-BIOMEMBRANES, V1194, P155; Verdaguer N, 1999, EMBO J, V18, P6329, DOI 10.1093/emboj/18.22.6329; Watanabe Y, 1998, ARCH BIOCHEM BIOPHYS, V358, P68, DOI 10.1006/abbi.1998.0820	25	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46470	46477		10.1074/jbc.M207779200	http://dx.doi.org/10.1074/jbc.M207779200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244059	hybrid			2022-12-25	WOS:000179529300100
J	Malek, RL; Irby, RB; Guo, QBM; Lee, K; Wong, S; He, M; Tsai, J; Frank, B; Liu, ET; Quackenbush, J; Jove, R; Yeatman, TJ; Lee, NH				Malek, RL; Irby, RB; Guo, QBM; Lee, K; Wong, S; He, M; Tsai, J; Frank, B; Liu, ET; Quackenbush, J; Jove, R; Yeatman, TJ; Lee, NH			Identification of Src transformation fingerprint in human colon cancer	ONCOGENE			English	Article						Src; colon cancer; expression profiling; microarray	BETA-PROTEIN-PRECURSOR; C-SRC; GENE-EXPRESSION; V-SRC; BINDING PROTEIN; MESSENGER-RNA; SARCOMA VIRUS; ACTIVATION; OVEREXPRESSION; GROWTH	We used a classical rodent model of transformation to understand the transcriptional processes, and hence the molecular and cellular events a given cell undergoes when progressing from a normal to a transformed phenotype. Src activation is evident in 80% of human colon cancer, yet the myriad of cellular processes effected at the level of gene expression has yet to be fully documented. We identified a Src 'transformation fingerprint' within the gene expression profiles of Src-transformed rat 3Y1 fibroblasts demonstrating a progression in transformation characteristics. To evaluate the role of this gene set in human cancer development and progression, we extracted the orthologous genes present on the Affymetrix Hu95A GeneChip(TM) (12k named genes) and compared expression profiles between the Src-induced rodent cell line model of transformation and staged colon tumors where Src is known to be activated. A similar gene expression pattern between the cell line model and staged colon tumors for components of the cell cycle, cytoskeletal associated proteins, transcription factors and lysosomal proteins suggests the need for co-regulation of several cellular processes in the progression of cancer. Genes not previously implicated in tumorigenesis were detected, as well as a set of 14 novel, highly conserved genes with here-to-fore unknown function. These studies define a set of transformation associated genes whose up-regulation has implications for understanding Src mediated transformation and strengthens the role of Src in the development and progression of human colon cancer. Supportive Supplemental Data can be viewed at http:// pga.tigr.org/PGApubs.shtml.	Univ S Florida, Coll Med, Dept Surg, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Oncol, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Univ S Florida, Coll Med, Dept Biochem & Mol Biol, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA; Johns Hopkins Canc Ctr, Div Canc Biol, Baltimore, MD 21231 USA; Inst Genom Res, Dept Funct Genom, Rockville, MD 20850 USA; NCI, Div Clin Sci, Med Branch,Mol Signaling & Oncogenesis Sect, Dept Canc & Cell Biol, Bethesda, MD 20892 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; State University System of Florida; University of South Florida; Johns Hopkins University; Johns Hopkins Medicine; J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Yeatman, TJ (corresponding author), Univ S Florida, Coll Med, Dept Surg, H Lee Moffit Canc Ctr & Res Inst, Tampa, FL 33612 USA.	yeatman@moffitt.usf.edu; nhlee@tigr.org	Liu, Edison/C-4141-2008	Quackenbush, John/0000-0002-2702-5879	NATIONAL CANCER INSTITUTE [K24CA085429, R01CA077049, U01CA085052] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059781] Funding Source: NIH RePORTER; NCI NIH HHS [CA77049-02, CA85429-01, CA85052-A1] Funding Source: Medline; NHLBI NIH HHS [HL59781] Funding Source: Medline; PHS HHS [6120-119-L0-A] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akamatsu H, 1996, CANCER RES, V56, P4541; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; Ben-Dor A, 1999, J COMPUT BIOL, V6, P281, DOI 10.1089/106652799318274; BJORGE JD, 1995, J BIOL CHEM, V270, P24222, DOI 10.1074/jbc.270.41.24222; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; BYRNE JA, 1995, CANCER RES, V55, P2896; Chew CS, 2000, J CELL SCI, V113, P2035; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Freier S, 1999, GUT, V44, P704, DOI 10.1136/gut.44.5.704; Guo QM, 2000, CANCER RES, V60, P5922; IBA H, 1984, P NATL ACAD SCI-BIOL, V81, P4424, DOI 10.1073/pnas.81.14.4424; Inoue H, 1998, J VIROL, V72, P2532, DOI 10.1128/JVI.72.3.2532-2537.1998; Iravani S, 1998, LAB INVEST, V78, P365; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; JOVE R, 1989, ONCOGENE RES, V5, P49; JOVE R, 1987, ANNU REV CELL BIOL, V3, P31, DOI 10.1146/annurev.cellbio.3.1.31; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; Kraker AJ, 2000, BIOCHEM PHARMACOL, V60, P885, DOI 10.1016/S0006-2952(00)00405-6; Kumble S, 1997, GASTROENTEROLOGY, V112, P348, DOI 10.1053/gast.1997.v112.pm9024288; Lee NH, 1998, J BIOL CHEM, V273, P22317, DOI 10.1074/jbc.273.35.22317; Lee Y, 2002, GENOME RES, V12, P493, DOI 10.1101/gr.212002; LEVY JB, 1986, P NATL ACAD SCI USA, V83, P4228, DOI 10.1073/pnas.83.12.4228; Lutz MP, 1998, BIOCHEM BIOPH RES CO, V243, P503, DOI 10.1006/bbrc.1997.8043; Manenti S, 1998, CANCER RES, V58, P1429; Martin GS, 2001, NAT REV MOL CELL BIO, V2, P467, DOI 10.1038/35073094; Miller LD, 2001, MOL CELL BIOL, V21, P6626, DOI 10.1128/MCB.21.19.6626-6639.2001; MUSCHEL RJ, 1985, AM J PATHOL, V121, P1; Niinaka Y, 1998, CANCER RES, V58, P2667; Odajima J, 2000, J BIOL CHEM, V275, P24096, DOI 10.1074/jbc.M001606200; OKAMOTOINOUE M, 1990, J CELL SCI, V96, P631; PARKER RC, 1984, CELL, V37, P131, DOI 10.1016/0092-8674(84)90308-8; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; Raychaudhuri S, 2000, Pac Symp Biocomput, P455; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Sabo SL, 2001, J CELL BIOL, V153, P1403, DOI 10.1083/jcb.153.7.1403; SAITOH T, 1989, CELL, V58, P615, DOI 10.1016/0092-8674(89)90096-2; Schreiber VR, 1998, MOL MED, V4, P675, DOI 10.1007/BF03401929; SCHUBERT D, 1989, NEURON, V3, P689, DOI 10.1016/0896-6273(89)90237-7; SEFTON BM, 1980, CELL, V20, P807, DOI 10.1016/0092-8674(80)90327-X; SHALLOWAY D, 1984, P NATL ACAD SCI-BIOL, V81, P7071, DOI 10.1073/pnas.81.22.7071; SKOTZKO M, 1995, CANCER RES, V55, P5493; STUDLER JM, 1993, EUR J NEUROSCI, V5, P614, DOI 10.1111/j.1460-9568.1993.tb00527.x; TAKEKURA N, 1990, INT J CANCER, V45, P847, DOI 10.1002/ijc.2910450510; TAKEYA T, 1982, J VIROL, V44, P12, DOI 10.1128/JVI.44.1.12-18.1982; TALAMONTI MS, 1993, J CLIN INVEST, V91, P53, DOI 10.1172/JCI116200; Taylor SJ, 1996, BIOESSAYS, V18, P9, DOI 10.1002/bies.950180105; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; WICKUS G, 1975, P NATL ACAD SCI USA, V72, P746, DOI 10.1073/pnas.72.2.746; Yamashita A, 1999, ONCOGENE, V18, P4777, DOI 10.1038/sj.onc.1202852; YANO M, 1999, CANC LETT, V22, P45; Yeung KY, 2001, BIOINFORMATICS, V17, P309, DOI 10.1093/bioinformatics/17.4.309; Zuber J, 2000, NAT GENET, V24, P144, DOI 10.1038/72799	54	73	79	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7256	7265		10.1038/sj.onc.1205900	http://dx.doi.org/10.1038/sj.onc.1205900			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370817				2022-12-25	WOS:000178504600015
J	Yang, HP; Reddy, TR; Truong, KT; Suhasini, M; Wong-Staal, F				Yang, HP; Reddy, TR; Truong, KT; Suhasini, M; Wong-Staal, F			Functional interaction of Sam68 and heterogeneous nuclear ribonucleoprotein K	ONCOGENE			English	Article						Sam68; hnRNP K; RRE; CT element; protein - protein interaction	HUMAN-IMMUNODEFICIENCY-VIRUS; FAMILY TYROSINE KINASES; RNA HELICASE-A; HNRNP-K; BINDING-PROTEIN; MESSENGER-RNA; DOMAIN; SRC; IDENTIFICATION; LOCALIZATION	Sam68 is a target of the c-Src tyrosine kinase. We previously showed that overexpression of Sam68 functionally substitutes for, as well as synergies with, HIV-1 Rev in Rev-response element (RRE)-mediated gene expression and virus replication. Here we describe the identification of heterogeneous nuclear ribonucleoprotein K (hnRNP K) as a protein that specifically interacts with Sam68 in vitro and in vivo. HnRNP K did not bind to RRE-RNA directly, but formed a super complex with Sam68 and RRE in vitro. RNase treatment did not change the strength of binding of hnRNP K to Sam68. We demonstrated that hnRNP K significantly inhibited Sam68-mediated, but not Rev-mediated, RRE-dependent gene expression. We further showed that Sam68, but not a non-functional mutant Sam68p21, inhibited transcriptional activation of CT element by hnRNP K. Interestingly, the Sam68p21 with a single amino acid substitution in the nuclear localization domain exhibited less affinity for hnRNP K in vitro. We propose that the direct interaction of Sam68 and hnRNP K adversely affect the activities of both proteins in signal transduction pathways of both transcriptional and post-transcriptional events.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Wayne State Univ, Sch Med, Dept Immunol & Microbiol, Detroit, MI 48201 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; Wayne State University	Wong-Staal, F (corresponding author), Univ Calif San Diego, Dept Biol, Stein Clin Res Bldg, La Jolla, CA 92093 USA.	fwongstaal@ucsd.edu			NIAID NIH HHS [AI46240] Funding Source: Medline; NIGMS NIH HHS [GM05089] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046240] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGRAVES WS, 1990, J CELL BIOL, V111, P3155, DOI 10.1083/jcb.111.6.3155; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; Chen TP, 1999, MOL BIOL CELL, V10, P3015, DOI 10.1091/mbc.10.9.3015; Denisenko ON, 1996, J BIOL CHEM, V271, P27701, DOI 10.1074/jbc.271.44.27701; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Harfmann AM, 1999, MOL BIOL CELL, V10, P3909, DOI 10.1091/mbc.10.11.3909; Huang YQ, 1999, EMBO J, V18, P1642, DOI 10.1093/emboj/18.6.1642; Ishidate T, 1997, FEBS LETT, V409, P237, DOI 10.1016/S0014-5793(97)00455-9; JONES AR, 1995, GENE DEV, V9, P1491, DOI 10.1101/gad.9.12.1491; Lee MH, 1996, J BIOL CHEM, V271, P3420; Lin Q, 1997, J BIOL CHEM, V272, P27274, DOI 10.1074/jbc.272.43.27274; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; McBride AE, 1998, EXP CELL RES, V241, P84, DOI 10.1006/excr.1998.4047; Miau LH, 1998, J BIOL CHEM, V273, P10784, DOI 10.1074/jbc.273.17.10784; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Reddy TR, 2000, ONCOGENE, V19, P4071, DOI 10.1038/sj.onc.1203749; Reddy TR, 2000, ONCOGENE, V19, P3570, DOI 10.1038/sj.onc.1203676; Reddy TR, 2000, ONCOGENE, V19, P3110, DOI 10.1038/sj.onc.1203637; Reddy TR, 1999, NAT MED, V5, P635, DOI 10.1038/9479; REICH E, 1962, P NATL ACAD SCI USA, V48, P1238, DOI 10.1073/pnas.48.7.1238; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Resnick RJ, 1997, ONCOGENE, V15, P1247, DOI 10.1038/sj.onc.1201289; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; SIOMI H, 1994, CELL, V77, P33, DOI 10.1016/0092-8674(94)90232-1; SIOMI H, 1993, NUCLEIC ACIDS RES, V21, P1193, DOI 10.1093/nar/21.5.1193; TAYLOR SJ, 1995, J BIOL CHEM, V270, P10120, DOI 10.1074/jbc.270.17.10120; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; TOMONAGA T, 1995, J BIOL CHEM, V270, P4875, DOI 10.1074/jbc.270.9.4875; VANSEUNINGEN I, 1995, BIOCHEMISTRY-US, V34, P5644, DOI 10.1021/bi00016a040; Weighardt F, 1999, J CELL SCI, V112, P1465; Westberg C, 2000, J BIOL CHEM, V275, P21396, DOI 10.1074/jbc.M909887199; Yang JP, 1999, ONCOGENE, V18, P5177, DOI 10.1038/sj.onc.1202904; Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662	39	32	34	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7187	7194		10.1038/sj.onc.1205759	http://dx.doi.org/10.1038/sj.onc.1205759			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370808				2022-12-25	WOS:000178504600006
J	David-Pfeuty, T; Nouvian-Dooghe, Y				David-Pfeuty, T; Nouvian-Dooghe, Y			Human p14(Arf): an exquisite sensor of morphological changes and of short-lived perturbations in cell cycle and in nucleolar function	ONCOGENE			English	Article						p14(Arf); cell cycle regulation; tumor suppression; cell morphology; cyclin-dependent kinase	ARF TUMOR-SUPPRESSOR; WILD-TYPE P53; RIBOSOMAL-RNA; P53-DEPENDENT APOPTOSIS; STABILIZES P53; P19(ARF); MDM2; TRANSCRIPTION; INHIBITORS; PROTEINS	The human Ink4a/Arf tumor suppressor locus encodes two distinct products: p16(Ink4a) which prevents phosphorylation and inactivation of the retinoblastoma protein and, p14(Arf), a nucleolar protein which activates the function of the tumor suppressor p53 protein in the nucleoplasm in response to oncogenic stimulation through an as yet ill-defined mechanism. Here we show that the level of endogenous p14(Arf) and its balance between the nucleolus and the nucleoplasm in HeLa cells are exquisitely sensitive to changes in cell morphology and to short-lived perturbations in cell cycle and in nucleolar function such as those induced by the cyclin-dependent kinase inhibitor, roscovitine, and the casein kinase II and RNA synthesis inhibitor, DRB. Most remarkably, whereas p14(Arf) predominantly concentrates in the nucleolus of interphase cells and transiently disappears between metaphase and early G1 under normal growth conditions, it massively and reversibly accumulates in the nucleoplasm of postmitotic and S-phase cells upon short-term treatment with roscovitine and, at a lesser extent, DRB. In line with the fact that the nuclear level of p53 reaches a peak between mid-G1 and the G1/S border in p53-expressor cells which lack Arf expression, these results provide a clue that, in p53+/Arf+ cells, Arf proteins might serve both to speed and to amplify p53-mediated responses in conditions and cell cycle periods in which the mechanisms involved in p53 stabilization and activation are not fully operational. They further suggest that human endogenous p14(Arf) might activate p53 pathways in physiologic situations by acting inside the nucleoplasm, especially when normal cell cycle progression and nucleolar function are compromised.	Ctr Univ, CNRS, UMR 146, Inst Curie Rech, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	David-Pfeuty, T (corresponding author), Ctr Univ, CNRS, UMR 146, Inst Curie Rech, Batiment 110, F-91405 Orsay, France.	Therese.Pfeuty@curie.u-psud.fr						Agarwal ML, 1998, J BIOL CHEM, V273, P1, DOI 10.1074/jbc.273.1.1; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; Cong F, 1999, ONCOGENE, V18, P7731, DOI 10.1038/sj.onc.1203290; David-Pfeuty T, 1999, ONCOGENE, V18, P7409, DOI 10.1038/sj.onc.1203103; David-Pfeuty T, 2001, ONCOGENE, V20, P5951, DOI 10.1038/sj.onc.1204741; DavidPfeuty T, 1996, CELL GROWTH DIFFER, V7, P1211; de Stanchina E, 1998, GENE DEV, V12, P2434, DOI 10.1101/gad.12.15.2434; DeGregori J, 1997, P NATL ACAD SCI USA, V94, P7245, DOI 10.1073/pnas.94.14.7245; DellaValle V, 1997, ONCOGENE, V15, P2475, DOI 10.1038/sj.onc.1201417; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dundr M, 2000, J CELL BIOL, V150, P433, DOI 10.1083/jcb.150.3.433; Dundr M, 1998, MOL BIOL CELL, V9, P2407, DOI 10.1091/mbc.9.9.2407; DURO D, 1995, ONCOGENE, V11, P21; Eymin B, 2001, ONCOGENE, V20, P1033, DOI 10.1038/sj.onc.1204220; GAUTIER T, 1992, J CELL SCI, V102, P729; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; Goodwin EC, 2000, P NATL ACAD SCI USA, V97, P12513, DOI 10.1073/pnas.97.23.12513; GRANICK D, 1975, J CELL BIOL, V65, P418, DOI 10.1083/jcb.65.2.418; Haaf T, 1996, EXP CELL RES, V224, P163, DOI 10.1006/excr.1996.0124; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kamijo T, 1998, P NATL ACAD SCI USA, V95, P8292, DOI 10.1073/pnas.95.14.8292; Karayan L, 2001, ONCOGENE, V20, P836, DOI 10.1038/sj.onc.1204170; Khan SH, 2000, P NATL ACAD SCI USA, V97, P3266, DOI 10.1073/pnas.050560997; Khan SH, 1998, CANCER RES, V58, P396; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin AW, 2001, P NATL ACAD SCI USA, V98, P5025, DOI 10.1073/pnas.091100298; Lindstrom MS, 2000, EXP CELL RES, V256, P400, DOI 10.1006/excr.2000.4854; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Lohrum MAE, 2000, CURR BIOL, V10, P539, DOI 10.1016/S0960-9822(00)00472-3; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; MAO L, 1995, CANCER RES, V55, P2995; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nevins JR, 2001, HUM MOL GENET, V10, P699, DOI 10.1093/hmg/10.7.699; OConnor PM, 1997, CANCER SURV, V29, P151; Palmero I, 1998, NATURE, V395, P125, DOI 10.1038/25870; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; QUELLE DE, 1995, CELL, V83, P993; Radfar A, 1998, P NATL ACAD SCI USA, V95, P13194, DOI 10.1073/pnas.95.22.13194; Savino TM, 1999, J CELL SCI, V112, P1889; Savino TM, 2001, J CELL BIOL, V153, P1097, DOI 10.1083/jcb.153.5.1097; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Sherr CJ, 1998, GENE DEV, V12, P2984, DOI 10.1101/gad.12.19.2984; Sirri V, 2002, J CELL BIOL, V156, P969, DOI 10.1083/jcb.200201024; Sirri V, 2000, J CELL BIOL, V148, P259, DOI 10.1083/jcb.148.2.259; STONE S, 1995, CANCER RES, V55, P2988; Stott FJ, 1998, EMBO J, V17, P5001, DOI 10.1093/emboj/17.17.5001; TAKAHASHI K, 1994, ONCOGENE, V9, P183; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vidal A, 2000, GENE, V247, P1, DOI 10.1016/S0378-1119(00)00092-5; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; WILSON GD, 1985, CYTOMETRY, V6, P641, DOI 10.1002/cyto.990060621; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Zhang YP, 1998, CELL, V92, P725, DOI 10.1016/S0092-8674(00)81401-4; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	67	21	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6779	6790		10.1038/sj.onc.1205871	http://dx.doi.org/10.1038/sj.onc.1205871			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360404				2022-12-25	WOS:000178315800008
J	Leder, A; Lebel, M; Zhou, F; Fontaine, K; Bishop, A; Leder, P				Leder, A; Lebel, M; Zhou, F; Fontaine, K; Bishop, A; Leder, P			Genetic interaction between the unstable v-Ha-RAS transgene (Tg.AC) and the murine Werner syndrome gene: transgene instability and tumorigenesis	ONCOGENE			English	Article						transgenic mouse; v-Ha-RAS; Werner syndrome; TPA; genome instability	X-CHROMOSOME INACTIVATION; MOUSE SKIN; SYNDROME PROTEIN; DNA HELICASE; MULTISTAGE CARCINOGENESIS; REPEAT HYPOTHESIS; LINE-1 ELEMENTS; MICE; RECOMBINATION; EXONUCLEASE	Tg.AC transgenic mice provide a sensitive assay for oncogenic agents and a convenient alternative to the two-stage initiation/promoter model of skin tumorigenesis. Although extensively used, this model has remained in part an enigma since mice that carry the Tg.AC transgene (consisting of v-Ha-Ras driven by an embryonic zeta-globin promoter) would not ordinarily be expected to develop skin and other adult tumors. Cloning and characterizing the inserted transgene has provided an insight into the Tg.AC phenotype. We find that the transgene is inserted into a Line-1 element in such a way as to create extended inverted repeats consisting of both transgene and Line-1 sequences. Such structures would be expected to contribute to the instability of the Tg.AC locus and we suggest that this instability is critical to the Tg.AC phenotype. Further, we strengthen this notion by introducing an inactivating mutation in the murine Wrn gene (a gene important in maintenance of genome stability) and showing that bigenic Tg.AC/ Wrn(Deltahel/Deltahel) mice experience an eightfold increase in inactivating germline mutations at the Tg.AC locus. Similarly, Tg.AC/ Wrn(Deltahel/Deltahel) mice that retain an intact and thus active Tg.AC locus experience a sharp increase in papillomas as compared to Tg.AC/Wrn(+/+), mice. This work demonstrates a genetic interaction between the instability of the multicopy transgene and the Werner Syndrome gene. From this, we conclude that genetic instability remains a key element in this tumor promoter model.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Boston, MA 02115 USA; Univ Laval, Ctr Rech Cancerol, CHUQ, Quebec City, PQ G1R 2J6, Canada	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Laval University	Leder, P (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, 200 Longwood Ave, Boston, MA 02115 USA.			Bishop, Alexander/0000-0002-5742-4387				Akgun E, 1997, MOL CELL BIOL, V17, P5559, DOI 10.1128/MCB.17.9.5559; Bailey JA, 2000, P NATL ACAD SCI USA, V97, P6634, DOI 10.1073/pnas.97.12.6634; Battalora MS, 2001, CARCINOGENESIS, V22, P651, DOI 10.1093/carcin/22.4.651; Berenblum I, 1941, CANCER RES, V1, P807; Bestor TH, 1998, CIBA F SYMP, V214, P187; BOUTWELL RK, 1964, PROG EXP TUMOR RES, V4, P207; BRINSTER RL, 1984, CELL, V37, P367, DOI 10.1016/0092-8674(84)90367-2; Brosh RM, 2002, EXP GERONTOL, V37, P491, DOI 10.1016/S0531-5565(01)00227-3; Cannon RE, 2000, MOL CARCINOGEN, V29, P229, DOI 10.1002/1098-2744(200012)29:4<229::AID-MC1005>3.0.CO;2-9; Cannon RE, 1998, MOL CARCINOGEN, V21, P244, DOI 10.1002/(SICI)1098-2744(199804)21:4<244::AID-MC3>3.0.CO;2-K; CARDIFF RD, 1993, AM J PATHOL, V142, P1199; DIGIOVANNI J, 1993, CARCINOGENESIS, V14, P1831, DOI 10.1093/carcin/14.9.1831; DIGIOVANNI J, 1992, PHARMACOL THERAPEUT, V54, P63, DOI 10.1016/0163-7258(92)90051-Z; Dunson DB, 2000, TOXICOL SCI, V55, P293, DOI 10.1093/toxsci/55.2.293; Eastin WC, 1998, TOXICOL PATHOL, V26, P461, DOI 10.1177/019262339802600401; EPSTEIN CJ, 1966, MEDICINE, V45, P177, DOI 10.1097/00005792-196605000-00001; FANNING TG, 1987, BIOCHIM BIOPHYS ACTA, V910, P203, DOI 10.1016/0167-4781(87)90112-6; FUKUCHI K, 1990, HUM GENET, V84, P249; Gordenin DA, 1998, MUTAT RES-FUND MOL M, V400, P45, DOI 10.1016/S0027-5107(98)00047-5; Goto M, 1996, CANCER EPIDEM BIOMAR, V5, P239; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Gulezian D, 2000, TOXICOL PATHOL, V28, P482, DOI 10.1177/019262330002800320; Hansen LA, 1996, CARCINOGENESIS, V17, P1825, DOI 10.1093/carcin/17.9.1825; HANSEN LA, 1994, MOL CARCINOGEN, V9, P143, DOI 10.1002/mc.2940090306; HANSEN LA, 1994, P NATL ACAD SCI USA, V91, P7822, DOI 10.1073/pnas.91.16.7822; Honchel R, 2001, MOL CARCINOGEN, V30, P99, DOI 10.1002/1098-2744(200102)30:2<99::AID-MC1018>3.3.CO;2-Z; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Humble MC, 2000, GENOMICS, V70, P292, DOI 10.1006/geno.2000.6384; Hutchinson JN, 2000, ONCOGENE, V19, P6130, DOI 10.1038/sj.onc.1203970; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kazazian HH, 1998, NAT GENET, V19, P19, DOI 10.1038/ng0598-19; Lebel M, 2002, CARCINOGENESIS, V23, P213, DOI 10.1093/carcin/23.1.213; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; Lebel M, 2001, CELL MOL LIFE SCI, V58, P857, DOI 10.1007/s00018-001-8398-y; Leder A, 1997, BLOOD, V90, P1275, DOI 10.1182/blood.V90.3.1275.1275_1275_1282; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Lombard DB, 2000, MOL CELL BIOL, V20, P3286, DOI 10.1128/MCB.20.9.3286-3291.2000; Lyon MF, 2000, P NATL ACAD SCI USA, V97, P6248, DOI 10.1073/pnas.97.12.6248; Lyon MF, 1998, CYTOGENET CELL GENET, V80, P133, DOI 10.1159/000014969; MARASCHIO P, 1986, CLIN GENET, V30, P353; MELARAGNO MI, 1995, MECH AGEING DEV, V78, P117, DOI 10.1016/0047-6374(94)01530-Y; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; Ostertag EM, 2001, GENOME RES, V11, P2059, DOI 10.1101/gr.205701; OWENS DM, 1995, CANCER RES, V55, P3171; SCAPPATICCI S, 1982, HUM GENET, V62, P16, DOI 10.1007/BF00295599; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Shen JC, 1998, J BIOL CHEM, V273, P34139, DOI 10.1074/jbc.273.51.34139; SMIT AFA, 1995, J MOL BIOL, V246, P401, DOI 10.1006/jmbi.1994.0095; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; SPALDING JW, 1993, CARCINOGENESIS, V14, P1335, DOI 10.1093/carcin/14.7.1335; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Suzuki N, 1997, NUCLEIC ACIDS RES, V25, P2973, DOI 10.1093/nar/25.15.2973; Thompson KL, 1998, TOXICOL PATHOL, V26, P548, DOI 10.1177/019262339802600411; Thompson KL, 2001, MOL CARCINOGEN, V32, P176, DOI 10.1002/mc.10009; Waldman AS, 1999, GENETICS, V153, P1873; Yoder JA, 1997, TRENDS GENET, V13, P335, DOI 10.1016/S0168-9525(97)01181-5	56	9	9	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6657	6668		10.1038/sj.onc.1205795	http://dx.doi.org/10.1038/sj.onc.1205795			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242664				2022-12-25	WOS:000178202300012
J	Magnaghi, V; Veber, D; Morabito, A; Buccellato, FR; Melcangi, RC; Scalabrino, G				Magnaghi, V; Veber, D; Morabito, A; Buccellato, FR; Melcangi, RC; Scalabrino, G			Decreased GFAP-mRNA expression in spinal cord of cobalamin-deficient rats	FASEB JOURNAL			English	Article						CNS; hypothalamus; subacute combined degeneration; vitamin B12	FIBRILLARY ACIDIC PROTEIN; SUBACUTE COMBINED DEGENERATION; TOTALLY GASTRECTOMIZED RATS; EPIDERMAL GROWTH-FACTOR; CENTRAL-NERVOUS-SYSTEM; MYELIN BASIC-PROTEIN; GENE-EXPRESSION; GLIAL-CELLS; ORNITHINE DECARBOXYLASE; VITAMIN-B-12 COBALAMIN	We have demonstrated previously that chronic vitamin B-12 [cobalamin (Cbl)] deficiency preferentially affects glial cells in the rat central nervous system (CNS) and severely affects peripheral glial cells independently of and concomitantly with the central neuropathy. In this study, we determined the mRNA levels for myelin basic protein (MBP) and glial fibrillary acidic protein (GFAP) in different CNS areas of rats made Cbl-deficient by total gastrectomy, as well as the mRNA levels for glycoprotein P-o and peripheral myelin protein (PMP)(22) in the sciatic nerve. GFAP-mRNA levels were significantly decreased in the spinal cord (SC) and hypothalamus, but not in the cortex, hippocampus, or striatum of totally gastrectomized (TGX) rats. No differences in GFAP protein levels were found in the SC and hypothalamus of the TGX rats treated or not with Cbl. MBP-mRNA levels were significantly decreased only in the hypothalamus, and the levels of mRNA for both glial markers returned to normal with Cbl replacement therapy. The levels of mRNA for the various myelin proteins in the sciatic nerve were not modified by Cbl deficiency. These results demonstrate that: a) the neurotrophic action of Cbl in rat CNS occurs in a zonal manner; and b) Cbl deficiency does not affect myelin synthesis (with the sole exception of the hypothalamus).	Univ Milan, Inst Gen Pathol, I-20133 Milan, Italy; Univ Milan, Dept Endocrinol, I-20133 Milan, Italy; Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20133 Milan, Italy; Univ Milan, Inst Biometr & Med Stat, I-20133 Milan, Italy	University of Milan; University of Milan; University of Milan; University of Milan	Scalabrino, G (corresponding author), Univ Milan, Inst Gen Pathol, Via Mangiagalli 31, I-20133 Milan, Italy.	giuseppe.scalabrino@unimi.it	Melcangi, Roberto Cosimo/AAA-6534-2022	MELCANGI, COSIMO ROBERTO/0000-0003-0861-8967				Armitage P, 1994, STAT METHODS MED RES, P312; AVOLA R, 1988, J NEUROSCI RES, V19, P230, DOI 10.1002/jnr.490190208; Bartlett MS, 1937, PROC R SOC LON SER-A, V160, P0268, DOI 10.1098/rspa.1937.0109; Beck W S, 1991, Adv Intern Med, V36, P33; Buccellato FR, 1999, FASEB J, V13, P297, DOI 10.1096/fasebj.13.2.297; Campagnoni A, 2001, BRAIN PATHOL, V11, P74; Carenini S, 1999, GLIA, V27, P203, DOI 10.1002/(SICI)1098-1136(199909)27:3<203::AID-GLIA2>3.3.CO;2-Z; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAHL D, 1981, EUR J CELL BIOL, V24, P191; DEACON R, 1986, J NEUROL SCI, V72, P113, DOI 10.1016/0022-510X(86)90040-7; Dyer CA, 2000, J NEUROSCI RES, V60, P412, DOI 10.1002/(SICI)1097-4547(20000501)60:3<412::AID-JNR16>3.3.CO;2-5; EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X; Eng LF, 2000, NEUROCHEM RES, V25, P1439, DOI 10.1023/A:1007677003387; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; HATTEN ME, 1991, GLIA, V4, P233, DOI 10.1002/glia.440040215; LAPING NJ, 1994, BRAIN PATHOL, V1, P259; Lemke G., 1992, INTRO MOL NEUROBIOLO, P281; Liedtke W, 1996, NEURON, V17, P607, DOI 10.1016/S0896-6273(00)80194-4; MARTIN DL, 1992, GLIA, V5, P81, DOI 10.1002/glia.440050202; Martini R, 1997, GLIA, V19, P298; MCQUEEN JK, 1994, J ENDOCRINOL, V143, P411, DOI 10.1677/joe.0.1430411; Melcangi R C, 2001, Prog Brain Res, V132, P31; Melcangi RC, 1997, J NEUROENDOCRINOL, V9, P729, DOI 10.1046/j.1365-2826.1997.00621.x; Melcangi RC, 1999, J NEUROBIOL, V40, P471, DOI 10.1002/(SICI)1097-4695(19990915)40:4<471::AID-NEU5>3.0.CO;2-P; Melcangi RC, 1999, J NEUROSCI RES, V56, P349, DOI 10.1002/(SICI)1097-4547(19990515)56:4<349::AID-JNR3>3.3.CO;2-8; Melcangi RC, 1996, BRAIN RES, V711, P10, DOI 10.1016/0006-8993(95)01302-4; Morell Pierre, 1999, P69; MORRISON RS, 1985, J NEUROSCI RES, V14, P167, DOI 10.1002/jnr.490140202; Newman Sammye, 1995, P535; PANT SS, 1968, ACTA NEUROL SCAN S35, V44, P8; PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x; Powers J, 1996, MOL CHEM NEUROPATHOL, V27, P31, DOI 10.1007/BF02815031; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; SAVAGE DG, 1995, BAILLIERE CLIN HAEM, V8, P657, DOI 10.1016/S0950-3536(05)80225-2; Scalabrino G, 1999, FASEB J, V13, P2083, DOI 10.1096/fasebj.13.14.2083; SCALABRINO G, 1995, LAB INVEST, V72, P114; Scalabrino G, 2000, J NEUROPATH EXP NEUR, V59, P808, DOI 10.1093/jnen/59.9.808; SCALABRINO G, 1990, LAB INVEST, V62, P297; Shibuki K, 1996, NEURON, V16, P587, DOI 10.1016/S0896-6273(00)80078-1; Staugaitis SM, 1996, BIOESSAYS, V18, P13, DOI 10.1002/bies.950180106; TAKAHASHI Y, 1992, PROG NEUROBIOL, V38, P523, DOI 10.1016/0301-0082(92)90041-C; Tredici G, 1998, J SUBMICR CYTOL PATH, V30, P165; Tredici G, 1998, J NEUROL SCI, V156, P18, DOI 10.1016/S0022-510X(98)00005-7; Walz W, 2000, GLIA, V31, P95, DOI 10.1002/1098-1136(200008)31:2<95::AID-GLIA10>3.0.CO;2-6; Wu VW, 1998, J NEUROSCI RES, V51, P675, DOI 10.1002/(SICI)1097-4547(19980315)51:6<675::AID-JNR2>3.3.CO;2-N	45	16	16	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1820	+		10.1096/fj.02-0231fje	http://dx.doi.org/10.1096/fj.02-0231fje			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354698				2022-12-25	WOS:000178441800001
J	Joo, NS; Irokawa, T; Wu, JV; Robbins, RC; Whyte, RI; Wine, JJ				Joo, NS; Irokawa, T; Wu, JV; Robbins, RC; Whyte, RI; Wine, JJ			Absent secretion to vasoactive intestinal peptide in cystic fibrosis airway glands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; SUBMUCOSAL GLANDS; TRACHEAL GLANDS; PSEUDOMONAS-AERUGINOSA; LIQUID SECRETION; EPITHELIAL-CELLS; FLUID TRANSPORT; MUCUS SECRETION; CFTR; CHLORIDE	We are testing the hypothesis that the malfunctioning of airway gland serous cells is a component of cystic fibrosis (CF) airway disease. CF is caused by mutations that disrupt CF transmembrane conductance regulator, an anion channel essential for proper fluid secretion in some epithelia. Submucosal glands supply most of the mucus in upper airways, and gland serous cells are the primary site of CF transmembrane conductance regulator expression in airways. We have discovered a major defect in CF glands by in situ optical monitoring of secretions from single human airway glands. CF glands did not secrete to agents that elevated [cAMP](i) (0 responses/450 glands, 8 subjects), whereas glands were responsive in all donor tracheas (605/827 glands, 15 subjects) and in bronchi from subjects who were transplanted because of other lung diseases (148/166 glands, n = 10). CF glands secreted to cholinergic stimulation, and serous cells were abundant in glands from all CF subjects. The complete absence of secretion to agents that elevate [cAMP](i) suggests that altered secretion of gland mucus could contribute to CF lung disease.	Stanford Univ, Cyst Fibrosis Res Lab, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University	Wine, JJ (corresponding author), Stanford Univ, Cyst Fibrosis Res Lab, Rm 450,Bldg 420,Main Quad, Stanford, CA 94305 USA.	wine@stanford.edu			NHLBI NIH HHS [HL-60288] Funding Source: Medline; NIDDK NIH HHS [DK-51817] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051817] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ballard ST, 1999, AM J PHYSIOL-LUNG C, V277, pL694, DOI 10.1152/ajplung.1999.277.4.L694; BALTIMORE RS, 1989, AM REV RESPIR DIS, V140, P1650, DOI 10.1164/ajrccm/140.6.1650; BASBAUM CB, 1990, ANNU REV PHYSIOL, V52, P97; BECQ F, 1993, FEBS LETT, V321, P73, DOI 10.1016/0014-5793(93)80624-4; BEDROSSIAN CWM, 1976, HUM PATHOL, V7, P195, DOI 10.1016/S0046-8177(76)80023-8; CLARKE LL, 2001, PEDIAT PULMONOL, V32, P241; Cole AM, 1999, INFECT IMMUN, V67, P3267, DOI 10.1128/IAI.67.7.3267-3275.1999; Devor DC, 1999, J GEN PHYSIOL, V113, P743, DOI 10.1085/jgp.113.5.743; ENGELHARDT JF, 1992, NAT GENET, V2, P240, DOI 10.1038/ng1192-240; GASHI AA, 1986, AM J PHYSIOL, V251, pC223, DOI 10.1152/ajpcell.1986.251.2.C223; GLYNN A. A., 1960, THORAX, V15, P142, DOI 10.1136/thx.15.2.142; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; HAYS SR, 2001, PEDIAT PULMONOL, V32, P305; Huang PB, 2001, P NATL ACAD SCI USA, V98, P14120, DOI 10.1073/pnas.241318498; IMRIE JR, 1979, AM J PATHOL, V95, P697; JACQUOT J, 1993, EUR RESPIR J, V6, P169; Jayaraman S, 2001, P NATL ACAD SCI USA, V98, P8119, DOI 10.1073/pnas.131087598; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; JIANG CW, 1993, SCIENCE, V262, P424, DOI 10.1126/science.8211164; Joo NS, 2001, AM J PHYSIOL-LUNG C, V281, pL458, DOI 10.1152/ajplung.2001.281.2.L458; Joo NS, 2002, J BIOL CHEM, V277, P28167, DOI 10.1074/jbc.M202712200; Knowles MR, 2002, J CLIN INVEST, V109, P571, DOI 10.1172/JCI200215217; Kube D, 2001, AM J PHYSIOL-LUNG C, V280, pL493, DOI 10.1152/ajplung.2001.280.3.L493; Lee MC, 1998, AM J PHYSIOL-LUNG C, V274, pL450, DOI 10.1152/ajplung.1998.274.3.L450; Linden A, 1997, PEPTIDES, V18, P843, DOI 10.1016/S0196-9781(97)00017-X; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; MERTEN MD, 1993, AM J PHYSIOL, V264, pL93, DOI 10.1152/ajplung.1993.264.2.L93; MEYER KC, 1993, J LAB CLIN MED, V121, P654; MEYRICK B, 1970, J ANAT, V107, P281; MEYRICK B, 1969, THORAX, V24, P729, DOI 10.1136/thx.24.6.729; Moon S, 1997, AM J PHYSIOL-LUNG C, V273, pL1208, DOI 10.1152/ajplung.1997.273.6.L1208; OPPENHEIMER EH, 1969, J PEDIATR-US, V75, P806, DOI 10.1016/S0022-3476(69)80303-3; PEATFIELD AC, 1983, AM REV RESPIR DIS, V128, P89, DOI 10.1164/arrd.1983.128.1.89; RAMPHAL R, 1987, INFECTION, V15, P281, DOI 10.1007/BF01644139; RAMSEY B, 1992, J ALLERGY CLIN IMMUN, V90, P547, DOI 10.1016/0091-6749(92)90183-3; REID L, 1967, BIBL PAEDIATR, P195; REID LYNNE, 1960, THORAX, V15, P132, DOI 10.1136/thx.15.2.132; ROGERS DF, 1993, EXP LUNG RES, V19, P37, DOI 10.3109/01902149309071079; Said SI, 2000, REGUL PEPTIDES, V93, P21, DOI 10.1016/S0167-0115(00)00174-9; SAKAKURA Y, 1983, EUR J RESPIR DIS, V64, P348; Sharma RK, 1995, PULM PHARMACOL, V8, P91, DOI 10.1006/pulp.1995.1011; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; SHIMURA S, 1988, J APPL PHYSIOL, V65, P2537, DOI 10.1152/jappl.1988.65.6.2537; Tirouvanziam R, 2000, AM J RESP CELL MOL, V23, P121, DOI 10.1165/ajrcmb.23.2.4214; TOS M, 1966, ACTA PATHOL MIC SC, VS 68, P9; Trout L, 2001, AM J PHYSIOL-LUNG C, V281, pL639, DOI 10.1152/ajplung.2001.281.3.L639; Ulrich M, 1998, AM J RESP CELL MOL, V19, P83, DOI 10.1165/ajrcmb.19.1.3137; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WELSH MJ, 1995, SCI AM, V273, P52, DOI 10.1038/scientificamerican1295-52; Worlitzsch D, 2002, J CLIN INVEST, V109, P317, DOI 10.1172/JCI0213870; YAMAYA M, 1991, AM J PHYSIOL, V261, pL491, DOI 10.1152/ajplung.1991.261.6.L491	51	98	100	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50710	50715		10.1074/jbc.M208826200	http://dx.doi.org/10.1074/jbc.M208826200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12368280	hybrid			2022-12-25	WOS:000180177700068
J	Bruhat, A; Averous, J; Carraro, V; Zhong, C; Reimold, AM; Kilberg, MS; Fafournoux, P				Bruhat, A; Averous, J; Carraro, V; Zhong, C; Reimold, AM; Kilberg, MS; Fafournoux, P			Differences in the molecular mechanisms involved in the transcriptional activation of the CHOP and asparagine synthetase genes in response to amino acid deprivation or activation of the unfolded protein response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CCAAT/ENHANCER-BINDING PROTEIN; ENDOPLASMIC-RETICULUM; EXPRESSION; STRESS; GADD153; ELEMENTS; PROMOTER; C/EBP; IDENTIFICATION; CHOP/GADD153	A promoter element called the amino acid response element (AARE), which is essential for the induction of CHOP (a CCAAT/enhancer-binding protein-related gene) transcription by amino acid depletion, has been previously characterized. Conversely, the human asparagine synthetase (AS) promoter contains two cis-acting elements termed nutrient-sensing response elements (NSRE-1 and NSRE-2) that are required to activate the gene by either amino acid deprivation or the endoplasmic reticulum stress response. The results reported here document the comparison between CHOP and AS transcriptional control elements used by the amino acid pathway. We first establish that the AS NSRE-1 sequence shares nucleotide sequence and functional similarities with the CHOP AARE. However, we demonstrate that the CHOP AARE can function independently, whereas AS NSRE-1 is functionally weak by itself and instead requires the presence of NSRE-2. Furthermore, AS NSRE-2 can confer endoplasmic reticulum stress responsiveness to the CHOP AARE. Using activating transcription factor-2-deficient mouse embryonic fibroblasts, we also show that lack of this transcription factor does not abolish the amino acid inducibility of AS transcription, but this transcription factor is necessary to obtain the full AS response to amino acid starvation. Collectively, these results document that there are significant differences in the molecular mechanisms involved in the transcriptional activation of CHOP and AS by amino acid limitation.	INRA, Unite Nutr & Metab Prot, F-63122 St Genes Champanelle, France; Univ Florida, Coll Med, Ctr Mammalian Genet, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA; Univ Texas, SW Med Ctr, Div Rheumat Dis, Dallas, TX 75390 USA	INRAE; State University System of Florida; University of Florida; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Bruhat, A (corresponding author), INRA, Unite Nutr & Metab Prot, F-63122 St Genes Champanelle, France.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; Bruhat A, 2000, MOL CELL BIOL, V20, P7192, DOI 10.1128/MCB.20.19.7192-7204.2000; Bruhat A, 1997, J BIOL CHEM, V272, P17588, DOI 10.1074/jbc.272.28.17588; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; Fawcett TW, 1996, J BIOL CHEM, V271, P14285, DOI 10.1074/jbc.271.24.14285; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HALL C V, 1983, Journal of Molecular and Applied Genetics, V2, P101; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; HURST HC, 1987, GENE DEV, V1, P1132, DOI 10.1101/gad.1.10.1132; HUTSON RG, 1994, BIOCHEM J, V304, P745, DOI 10.1042/bj3040745; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; Jousse C, 1999, FEBS LETT, V448, P211, DOI 10.1016/S0014-5793(99)00373-7; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kawasaki H, 2000, NATURE, V405, P195, DOI 10.1038/35012097; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; Leung-Pineda V, 2002, J BIOL CHEM, V277, P16585, DOI 10.1074/jbc.M110972200; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LUETHY JD, 1992, CANCER RES, V52, P5; Maekawa T, 1999, J BIOL CHEM, V274, P17813, DOI 10.1074/jbc.274.25.17813; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Sambrook J., 2002, MOL CLONING LAB MANU; Schmitt-Ney M, 2000, J BIOL CHEM, V275, P40839, DOI 10.1074/jbc.M007440200; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Sok J, 1999, MOL CELL BIOL, V19, P495; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119; TODARO GJ, 1963, J CELL BIOL, V17, P299, DOI 10.1083/jcb.17.2.299; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	41	63	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48107	48114		10.1074/jbc.M206149200	http://dx.doi.org/10.1074/jbc.M206149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351626	hybrid, Green Published			2022-12-25	WOS:000179789600019
J	Pei, ZF; Reske, G; Huang, QH; Hammock, BD; Qi, YP; Chejanovsky, N				Pei, ZF; Reske, G; Huang, QH; Hammock, BD; Qi, YP; Chejanovsky, N			Characterization of the apoptosis suppressor protein P49 from the Spodoptera littoralis nucleopolyhedrovirus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; REACTIVE-SITE LOOP; BACULOVIRUS P35; CRYSTAL-STRUCTURE; INHIBITING GENE; CASPASES; SEQUENCE; FAMILY; PROTEASES; CLEAVAGE	Two antiapoptotic types of genes, iap and p35, were found in baculoviruses. P35 is a 35-kDa protein that can suppress apoptosis induced by virus infection or by diverse stimuli in vertebrates or invertebrates. iap homologues were identified in insects and mammals. Recently, we have identified sl-p49, a novel apoptosis suppressor gene and the first homologue of p35, in the genome of the Spodoptera littoralis nucleopolyhedrovirus. Here we show that sl-p49 encodes a 49-kDa protein, confirmed its primary structure that displays 48.8% identity to P35, and performed computer-assisted modeling of P49 based on the structure of P35. We demonstrated that P49 is able to inhibit insect and human effector caspases, which requires P49 cleavage at Asp(94). Finally we identified domains important for P49's antiapoptotic function that include a reactive site loop (RSL) protruding from a beta-barrel domain. RSL begins at an amphipathic alpha1 helix, traverses the beta-sheet central region, exposing Asp(94) at the apex, and rejoins the beta-barrel. Our model predicted seven alpha-helical motifs, three of them unique to P49. alpha-Helical motifs alpha(1), alpha2, and alpha4, were required for P49 function. The high structural homology between P49 and P35 suggests that these molecules bear a scaffold common to baculovirus "apoptotic suppressor" proteins. P49 may serve as a novel tool to analyze the contribution of different components of the caspase chain in the apoptotic response in organisms not related phylogenetically.	Agr Res Org, Inst Plant Protect, Dept Entomol, Volcani Ctr, IL-50250 Bet Dagan, Israel; Wuhan Univ, Inst Virol, Wuhan 430072, Peoples R China; Univ Calif Davis, Dept Entomol, Davis, CA 95616 USA	VOLCANI INSTITUTE OF AGRICULTURAL RESEARCH; Chinese Academy of Sciences; Wuhan Institute of Virology, CAS; Wuhan University; University of California System; University of California Davis	Chejanovsky, N (corresponding author), Agr Res Org, Inst Plant Protect, Dept Entomol, Volcani Ctr, POB 6, IL-50250 Bet Dagan, Israel.	ninar@volcani.agri.gov.il		Chejanovsky, Nor/0000-0002-6455-6521				Afonso CL, 2001, J VIROL, V75, P11157, DOI 10.1128/JVI.75.22.11157-11165.2001; Ahmad M, 1997, J BIOL CHEM, V272, P1421, DOI 10.1074/jbc.272.3.1421; Bertin J, 1996, J VIROL, V70, P6251, DOI 10.1128/JVI.70.9.6251-6259.1996; BIRNBAUM MJ, 1994, J VIROL, V68, P2521, DOI 10.1128/JVI.68.4.2521-2528.1994; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; CARTIER JL, 1994, J VIROL, V68, P7728, DOI 10.1128/JVI.68.12.7728-7737.1994; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; CHEJANOVSKY N, 1995, VIROLOGY, V209, P519, DOI 10.1006/viro.1995.1284; CLEM RJ, 1994, MOL CELL BIOL, V14, P5212, DOI 10.1128/MCB.14.8.5212; Clem RJ, 2001, CELL DEATH DIFFER, V8, P137, DOI 10.1038/sj.cdd.4400821; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Dai XJ, 1999, J GEN VIROL, V80, P1841, DOI 10.1099/0022-1317-80-7-1841; dela Cruz WP, 2001, J BIOL CHEM, V276, P32933, DOI 10.1074/jbc.M103930200; Du QS, 1999, J VIROL, V73, P1278, DOI 10.1128/JVI.73.2.1278-1285.1999; Duckett CS, 1996, EMBO J, V15, P2685, DOI 10.1002/j.1460-2075.1996.tb00629.x; Fisher AJ, 1999, EMBO J, V18, P2031, DOI 10.1093/emboj/18.8.2031; Gershburg E, 1997, J VIROL, V71, P7593, DOI 10.1128/JVI.71.10.7593-7599.1997; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HINK WF, 1970, NATURE, V226, P466, DOI 10.1038/226466b0; Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5; KAMITA SG, 1993, J VIROL, V67, P455, DOI 10.1128/JVI.67.1.455-463.1993; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; Miller LK, 1998, SEMIN VIROL, V8, P445, DOI 10.1006/smvy.1998.0149; Pang Y, 2001, VIROLOGY, V287, P391, DOI 10.1006/viro.2001.1056; Papworth C.B., 1996, STRATEGIES, V9, P3, DOI DOI 10.1080/08924562.1996.11000299; PEISCH MC, 1995, BIOTECHNOLOGY, V13, P658; Qi Y, 2001, ARCH VIROL, V146, P2149, DOI 10.1007/s007050170026; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Stennicke HR, 1999, METHODS, V17, P313, DOI 10.1006/meth.1999.0745; SUMMERS MD, 1978, TEX AGR EXP STN B, V1555; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; Zhou Q, 1998, BIOCHEMISTRY-US, V37, P10757, DOI 10.1021/bi980893w; Zoog SJ, 1999, J BIOL CHEM, V274, P25995, DOI 10.1074/jbc.274.37.25995	38	55	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48677	48684		10.1074/jbc.M208810200	http://dx.doi.org/10.1074/jbc.M208810200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12324475	hybrid			2022-12-25	WOS:000179789600092
J	Aoki, S; Li, J; Itagaki, S; Okech, BA; Egwang, TG; Matsuoka, H; Palacpac, NMQ; Mitamura, T; Horii, T				Aoki, S; Li, J; Itagaki, S; Okech, BA; Egwang, TG; Matsuoka, H; Palacpac, NMQ; Mitamura, T; Horii, T			Serine repeat antigen (SERA5) is predominantly expressed among the SERA multigene family of Plasmodium falciparum, and the acquired antibody titers correlate with serum inhibition of the parasite growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD STAGE ANTIGEN; PROTECTIVE IMMUNITY; AOTUS MONKEYS; ESCHERICHIA-COLI; TERMINAL DOMAIN; MALARIA; PROTEIN; SEQUENCE; GENES; LOCALIZATION	The Plasmodium falciparum serine repeat antigen (SERA) is one of the blood stage malaria vaccine candidates. The malaria genome project has revealed that SERA is a member of the SERA multigene family consisting of eight SERA homologues clustered on chromosome 2 and one SERA homologue on chromosome 9. Northern blotting and real time quantitative reverse transcription-PCR with five independent parasite strains, including three allelic representative forms of the SERA gene, have shown that all of the SERA homologues are transcribed most actively at trophozoite and schizont stages and that SERA5 (SERA/SERP) is transcribed predominantly among the family. Polyclonal antibodies were raised against recombinant proteins representing the N-terminal portions of four significantly transcribed SERA homologues (SERA3 to -6) in the center of the cluster on chromosome 2. Using these antibodies, indirect immunofluorescence microscopy detected the expression of SERA3 to -6, with similar localization, in all trophozoite- and schizont-infected erythrocytes. We have examined 40 sera from Ugandan adults for their antibody reactivity and found that enzyme-linked immunosorbent assay titer against SERA5 N-terminal domain, but not against other SERA proteins, is positively correlated with the inhibition of in vitro parasite growth by individual sera. Our data confirm the usefulness of the N-terminal domain of SERA5 as a promising malaria candidate vaccine.	Osaka Univ, Microbial Dis Res Inst, Dept Mol Protozool, Suita, Osaka 5650871, Japan; Med Biotech Labs, Div Med Parasitol & Trop Med, Kampala, Uganda; Jichi Med Sch, Dept Med Zool, Minami Kawachi, Tochigi 3290498, Japan	Osaka University; Jichi Medical University	Horii, T (corresponding author), Osaka Univ, Microbial Dis Res Inst, Dept Mol Protozool, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.			Horii, Toshihiro/0000-0002-3000-2045; Matsuoka, Hiroyuki/0000-0001-8839-0012; Palacpac, Nirianne Marie/0000-0003-4098-3972				Baca AM, 2000, INT J PARASITOL, V30, P113, DOI 10.1016/S0020-7519(00)00019-9; BZIK DJ, 1988, MOL BIOCHEM PARASIT, V30, P279, DOI 10.1016/0166-6851(88)90097-7; DEBRABANT A, 1992, MOL BIOCHEM PARASIT, V53, P89, DOI 10.1016/0166-6851(92)90010-H; DELPLACE P, 1985, MOL BIOCHEM PARASIT, V17, P239, DOI 10.1016/0166-6851(85)90021-0; DELPLACE P, 1987, MOL BIOCHEM PARASIT, V23, P193, DOI 10.1016/0166-6851(87)90026-0; EAKIN AE, 1989, NATURE, V342, P132, DOI 10.1038/342132b0; FOX BA, 1994, MOL BIOCHEM PARASIT, V68, P133, DOI 10.1016/0166-6851(94)00162-6; Fox BA, 1997, EXP PARASITOL, V85, P121, DOI 10.1006/expr.1996.4118; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Hanada K, 2000, BIOCHEM J, V346, P671, DOI 10.1042/0264-6021:3460671; Hanada K, 2002, J EXP MED, V195, P23, DOI 10.1084/jem.20010724; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; HIGGINS DG, 1989, NATURE, V340, P604, DOI 10.1038/340604a0; HORII T, 1988, MOL BIOCHEM PARASIT, V30, P9, DOI 10.1016/0166-6851(88)90127-2; INSELBURG J, 1983, J PARASITOL, V69, P592, DOI 10.2307/3281375; INSELBURG J, 1993, INFECT IMMUN, V61, P2048, DOI 10.1128/IAI.61.5.2048-2052.1993; INSELBURG J, 1993, INFECT IMMUN, V61, P2041, DOI 10.1128/IAI.61.5.2041-2047.1993; INSELBURG J, 1991, INFECT IMMUN, V59, P1247, DOI 10.1128/IAI.59.4.1247-1250.1991; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; KNAPP B, 1991, MOL BIOCHEM PARASIT, V44, P1, DOI 10.1016/0166-6851(91)90215-R; Kubata BK, 1998, J EXP MED, V188, P1197, DOI 10.1084/jem.188.6.1197; Li J, 2002, MOL BIOCHEM PARASIT, V120, P177, DOI 10.1016/S0166-6851(01)00452-2; LI J, 2002, PARASITOL INT, V53, P89; Liu Qing, 2000, Southeast Asian Journal of Tropical Medicine and Public Health, V31, P808; MAEDA S, 1985, NATURE, V315, P592, DOI 10.1038/315592a0; Miller SK, 2002, J BIOL CHEM, V277, P47524, DOI 10.1074/jbc.M206974200; Mitamura T, 2000, PARASITOL INT, V49, P219, DOI 10.1016/S1383-5769(00)00048-9; Morimatsu K, 1997, MOL BIOCHEM PARASIT, V86, P249, DOI 10.1016/S0166-6851(97)00038-8; MOTTRAM JC, 1989, NATURE, V342, P132, DOI 10.1038/342132c0; O'Donnell RA, 2001, J EXP MED, V193, P1403, DOI 10.1084/jem.193.12.1403; Okech BA, 2001, AM J TROP MED HYG, V65, P912, DOI 10.4269/ajtmh.2001.65.912; Pang XL, 1999, INFECT IMMUN, V67, P1821; Pang XL, 1998, VACCINE, V16, P1299, DOI 10.1016/S0264-410X(98)00057-7; Sugiyama T, 1996, VACCINE, V14, P1069, DOI 10.1016/0264-410X(95)00238-V; Suzuki H, 1997, EXP ANIM TOKYO, V46, P17, DOI 10.1538/expanim.46.17; TANABE K, 1987, J MOL BIOL, V195, P273, DOI 10.1016/0022-2836(87)90649-8; TOSTA CE, 1980, EXP PARASITOL, V50, P7, DOI 10.1016/0014-4894(80)90003-X; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; WELLEMS TE, 1990, NATURE, V345, P253, DOI 10.1038/345253a0	40	75	82	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47533	47540		10.1074/jbc.M207145200	http://dx.doi.org/10.1074/jbc.M207145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244052	hybrid			2022-12-25	WOS:000179663700091
J	Beard, WA; Shock, DD; Vande Berg, BJ; Wilson, SH				Beard, WA; Shock, DD; Vande Berg, BJ; Wilson, SH			Efficiency of correct nucleotide insertion governs DNA polymerase fidelity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS REVERSE-TRANSCRIPTASE; REPLICATION FIDELITY; ESCHERICHIA-COLI; BASE-PAIRS; BETA; IOTA; DISCRIMINATION; HYPERMUTATION; PROCESSIVITY; SPECIFICITY	DNA polymerase fidelity or specificity expresses the ability of a polymerase to select a correct nucleoside triphosphate (dNTP) from a pool of structurally similar molecules. Fidelity is quantified from the ratio of specificity constants (catalytic efficiencies) for alternate substrates (i.e. correct and incorrect dNTPs). An analysis of the efficiency of dNTP (correct and incorrect) insertion for a low fidelity mutant of DNA polymerase beta (R283A) and exonuclease-deficient DNA polymerases from five families derived from a variety of biological sources reveals that a strong correlation exists between the ability to synthesize DNA and the probability that the polymerase will make a mistake (i.e. base substitution error). Unexpectedly, this analysis indicates that the difference between low and high fidelity DNA polymerases is related to the efficiency of correct, but not incorrect, nucleotide insertion. In contrast to the loss of fidelity observed with the catalytically inefficient R283A mutant, the fidelity of another inefficient mutant of DNA polymerase beta (G274P) is not altered. Thus, although all natural low fidelity DNA polymerases are inefficient, not every inefficient DNA polymerase has low fidelity. Low fidelity polymerases appear to be an evolutionary solution to how to replicate damaged DNA or DNA repair intermediates without burdening the genome with excessive polymerase-initiated errors.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	wiIson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019	Wilson, Samuel H/0000-0002-1702-5293				Ahn J, 1997, BIOCHEMISTRY-US, V36, P1100, DOI 10.1021/bi961653o; Ahn JW, 1998, BIOCHEM J, V331, P79, DOI 10.1042/bj3310079; Beard WA, 1996, J BIOL CHEM, V271, P12141, DOI 10.1074/jbc.271.21.12141; Beard WA, 2002, J BIOL CHEM, V277, P8235, DOI 10.1074/jbc.M107286200; Bebenek A, 2001, J BIOL CHEM, V276, P10387, DOI 10.1074/jbc.M007707200; Berg BJV, 2001, J BIOL CHEM, V276, P3408, DOI 10.1074/jbc.M002884200; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; DATE T, 1991, BIOCHEMISTRY-US, V30, P5286, DOI 10.1021/bi00235a023; DONLIN MJ, 1994, BIOCHEMISTRY-US, V33, P14908, DOI 10.1021/bi00253a030; ECKERT KA, 1993, J BIOL CHEM, V268, P13462; FERSHT AR, 1982, J MOL BIOL, V156, P37, DOI 10.1016/0022-2836(82)90457-0; Friedberg EC, 2001, CELL, V107, P9, DOI 10.1016/S0092-8674(01)00509-8; Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707; GOODMAN MF, 1993, CRIT REV BIOCHEM MOL, V28, P83, DOI 10.3109/10409239309086792; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Johnson RE, 2000, NATURE, V406, P1015, DOI 10.1038/35023030; Johnson RE, 2000, P NATL ACAD SCI USA, V97, P3838, DOI 10.1073/pnas.97.8.3838; Johnson RE, 2000, J BIOL CHEM, V275, P7447, DOI 10.1074/jbc.275.11.7447; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Ohmori H, 2001, MOL CELL, V8, P7, DOI 10.1016/S1097-2765(01)00278-7; PATHAK VK, 1990, P NATL ACAD SCI USA, V87, P6019, DOI 10.1073/pnas.87.16.6019; PETRUSKA J, 1988, P NATL ACAD SCI USA, V85, P6252, DOI 10.1073/pnas.85.17.6252; POLESKY AH, 1992, J BIOL CHEM, V267, P8417; Sawaya MR, 1997, BIOCHEMISTRY-US, V36, P11205, DOI 10.1021/bi9703812; Showalter AK, 2001, J AM CHEM SOC, V123, P1776, DOI 10.1021/ja005758x; Tissier A, 2000, GENE DEV, V14, P1642; VARTANIAN JP, 1994, P NATL ACAD SCI USA, V91, P3092, DOI 10.1073/pnas.91.8.3092; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Zhang YB, 2000, NUCLEIC ACIDS RES, V28, P4147, DOI 10.1093/nar/28.21.4147; Zhang YB, 2000, MOL CELL BIOL, V20, P7099, DOI 10.1128/MCB.20.19.7099-7108.2000; ZINNEN S, 1994, J BIOL CHEM, V269, P24195	39	106	108	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47393	47398		10.1074/jbc.M210036200	http://dx.doi.org/10.1074/jbc.M210036200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370169	hybrid			2022-12-25	WOS:000179663700073
J	Hulsmeyer, M; Hillig, RC; Volz, A; Ruhl, M; Schroder, W; Saenger, W; Ziegler, A; Uchanska-Ziegler, B				Hulsmeyer, M; Hillig, RC; Volz, A; Ruhl, M; Schroder, W; Saenger, W; Ziegler, A; Uchanska-Ziegler, B			HLA-B27 subtypes differentially associated with disease exhibit subtle structural alterations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANKYLOSING-SPONDYLITIS; HLA-B-ASTERISK-2709 SUBTYPE; BINDING PEPTIDES; CUTTING EDGE; SUSCEPTIBILITY; POLYMORPHISM; PROGRAM; ANTIGEN; SPECIFICITY; COMPLEXES	The reasons for the association of the human major histocompatibility complex protein HIA-B27 with spondyloarthropathies are unknown. To uncover the underlying molecular causes, we determined the crystal structures of the disease-associated B*2705 and the nonassociated B*2709 subtypes complexed with the same nonapeptide (GRFAAALAK). Both differ in only one residue (Asp(116) and His(116), respectively) in the F-pocket that accommodates the peptide C terminus. Several different effects of the Asp(116)-->His replacement are observed. The bulkier His(116) induces a movement of peptide C-terminal pLys(9), allowing the formation of a novel salt bridge to Asp(77), whereas the salt bridge between pLys(9) and Asp(116) is converted into a hydrogen bond with His(116). His(116) but not Asp(116) adopts two alternative conformations, one of which leads to breakage of hydrogen bonds. Water molecules near residue 116 differ with regard to number, position, and contacts made. Furthermore, F-pocket atoms exhibit higher B-factors in B*2709 than in B*2705, indicating an increased flexibility of the entire region in the former subtype. These changes induce subtle peptide conformational alterations that may be responsible for the immunobiological differences between these HLA-B27 subtypes.	Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, Inst Immungenet, D-14050 Berlin, Germany	Free University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Saenger, W (corresponding author), Free Univ Berlin, Inst Kristallog, Takustr 6, D-14195 Berlin, Germany.	saenger@chemie.fu-berlin.de; barbara.uchanska-ziegler@charite.de						Allen RL, 1999, IMMUNOGENETICS, V50, P220, DOI 10.1007/s002510050596; Allen RL, 2001, J IMMUNOL, V167, P5543, DOI 10.4049/jimmunol.167.10.5543; Allen RL, 1999, J IMMUNOL, V162, P5045; Armas JB, 1999, TISSUE ANTIGENS, V53, P237, DOI 10.1034/j.1399-0039.1999.530303.x; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker BM, 2001, J EXP MED, V193, P551, DOI 10.1084/jem.193.5.551; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Boyle LH, 2001, J IMMUNOL, V167, P2619, DOI 10.4049/jimmunol.167.5.2619; BREWERTON DA, 1973, LANCET, V1, P904; Brown Matthew, 1997, Current Opinion in Rheumatology, V9, P308; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brusic V, 1998, NUCLEIC ACIDS RES, V26, P368, DOI 10.1093/nar/26.1.368; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Ciatto C, 2001, J MOL BIOL, V312, P1059, DOI 10.1006/jmbi.2001.5016; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; Dangoria NS, 2002, J BIOL CHEM, V277, P23459, DOI 10.1074/jbc.M110336200; de Castro JAL, 1998, CURR OPIN IMMUNOL, V10, P59, DOI 10.1016/S0952-7915(98)80033-2; Dedier S, 2000, J BIOL CHEM, V275, P27055; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Ferrara GB, 2001, BLOOD, V98, P3150, DOI 10.1182/blood.V98.10.3150; Fiorillo MT, 1997, EUR J IMMUNOL, V27, P368, DOI 10.1002/eji.1830270205; Fiorillo MT, 2000, J CLIN INVEST, V106, P47, DOI 10.1172/JCI9295; Fiorillo MT, 1998, EUR J IMMUNOL, V28, P2508, DOI 10.1002/(SICI)1521-4141(199808)28:08<2508::AID-IMMU2508>3.0.CO;2-1; GARBOCZI DN, 1992, P NATL ACAD SCI USA, V89, P3429, DOI 10.1073/pnas.89.8.3429; Garcia F, 1997, TISSUE ANTIGENS, V49, P580, DOI 10.1111/j.1399-0039.1997.tb02805.x; Garcia-Peydro M, 1999, J IMMUNOL, V163, P2299; GonzalezRoces S, 1997, TISSUE ANTIGENS, V49, P116, DOI 10.1111/j.1399-0039.1997.tb02724.x; Hillig RC, 2001, J MOL BIOL, V310, P1167, DOI 10.1006/jmbi.2001.4816; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Khan MA, 2000, CURR OPIN RHEUMATOL, V12, P235, DOI 10.1097/00002281-200007000-00001; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs S, 1999, PROTEIN SCI, V8, P1393, DOI 10.1110/ps.8.7.1393; Kubo H, 1998, IMMUNOGENETICS, V47, P256, DOI 10.1007/s002510050355; LATRON F, 1992, SCIENCE, V257, P964, DOI 10.1126/science.1380181; Lopez-Larrea C, 1998, MOL MED TODAY, V4, P540, DOI 10.1016/S1357-4310(98)01375-6; Luque I, 1996, EUR J IMMUNOL, V26, P1974, DOI 10.1002/eji.1830260845; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Martinez-Borra J, 2000, HUM IMMUNOL, V61, P131, DOI 10.1016/S0198-8859(99)00145-7; MCLACHLAN AD, 1982, ACTA CRYSTALLOGR A, V38, P871, DOI 10.1107/S0567739482001806; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Nasution AR, 1997, J RHEUMATOL, V24, P1111; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; Olivieri I, 2002, ARTHRITIS RHEUM-US, V46, P553, DOI 10.1002/art.10127; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Ramos M, 2002, J BIOL CHEM, V277, P28749, DOI 10.1074/jbc.M204155200; Rehm A, 2000, HUM IMMUNOL, V61, P408, DOI 10.1016/S0198-8859(99)00176-7; SCHLOSSTEIN L, 1973, NEW ENGL J MED, V288, P704, DOI 10.1056/NEJM197304052881403; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; URBAN RG, 1994, P NATL ACAD SCI USA, V91, P1534, DOI 10.1073/pnas.91.4.1534; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	57	76	82	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47844	47853		10.1074/jbc.M206392200	http://dx.doi.org/10.1074/jbc.M206392200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244049	hybrid			2022-12-25	WOS:000179663700130
J	Modur, V; Nagarajan, R; Evers, BM; Milbrandt, J				Modur, V; Nagarajan, R; Evers, BM; Milbrandt, J			FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression - Implications for PTEN mutation in prostate cancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORKHEAD TRANSCRIPTION FACTORS; CELL-SURVIVAL; PTEN/MMAC1 MUTATIONS; GERMLINE MUTATIONS; MMAC1/PTEN GENE; INACTIVATION; DEATH; SUPPRESSION; ACTIVATION; FREQUENT	Mutations in PTEN occur in 60-80% of prostate cancers and lead to a constitutive activation of the phosphatidylinositol 3-kinase pathway and a resultant loss of activity of the FOXO family of forkhead transcription factors FKHRL1 and FKHR. To provide insight into the role of PTEN mutations in prostate cancer, we used microarrays to identify genes regulated by FKHRL1 and FKHR in LAPC4 prostate carcinoma cells. These studies revealed that adenoviral overexpression of FKHRL1 and FKHR in the LAPC4 prostate cancer cell line resulted in apoptosis and induced the expression of many genes that affect cellular proliferation or survival. The expression of one of these FOXO-regulated genes, TRAIL, a pro-apoptotic member of the tumor necrosis factor family, was decreased in human metastatic prostate tumors. The altered expression of TRAIL in these tumors correlated directly with decreased PTEN expression and the resultant loss of FKHRL1 and FKHR activity. Analysis of the effects of FOXO proteins on the TRAIL promoter localized the FKHRL1 responsive element of the TRAIL promoter to nucleotides -138 to -121 and demonstrated that TRAIL is a direct target of FKHRL1. These findings suggest that the decreased activity of FKHRL1 and FKHR in prostate cancers resulting from loss of PTEN leads to a decrease in TRAIL expression that may contribute to increased survival of the tumor cells.	Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA; Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA	Washington University (WUSTL); University of Texas System; University of Texas Medical Branch Galveston	Milbrandt, J (corresponding author), Washington Univ, Sch Med, Dept Pathol & Immunol, Campus Box 8118,660 S Euclid Ave, St Louis, MO 63110 USA.			Milbrandt, Jeffrey/0000-0002-5477-7689	NATIONAL CANCER INSTITUTE [T32CA009547] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA009547-15] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cairns P, 1997, CANCER RES, V57, P4997; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Cao GW, 2001, CANCER GENE THER, V8, P497, DOI 10.1038/sj.cgt.7700333; Cheney IW, 1998, CANCER RES, V58, P2331; Dahia PLM, 1999, HUM MOL GENET, V8, P185, DOI 10.1093/hmg/8.2.185; Davies MA, 1999, CANCER RES, V59, P2551; Davies MA, 1998, CANCER RES, V58, P5285; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Di Cristofano A, 2001, NAT GENET, V27, P222, DOI 10.1038/84879; Dijkers PF, 2002, J CELL BIOL, V156, P531, DOI 10.1083/jcb.200108084; Ferris CD, 1999, NAT CELL BIOL, V1, P152, DOI 10.1038/11072; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; Guldberg P, 1997, CANCER RES, V57, P3660; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kawamura N, 1999, JPN J CANCER RES, V90, P413, DOI 10.1111/j.1349-7006.1999.tb00763.x; Kohno T, 1998, GENE CHROMOSOME CANC, V22, P152, DOI 10.1002/(SICI)1098-2264(199806)22:2<152::AID-GCC10>3.0.CO;2-S; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liaw D, 1997, NAT GENET, V16, P64, DOI 10.1038/ng0597-64; Liu WG, 1997, CANCER RES, V57, P5254; Marsh DJ, 1997, NAT GENET, V16, P333, DOI 10.1038/ng0897-333; McMenamin ME, 1999, CANCER RES, V59, P4291; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ogg S, 1998, MOL CELL, V2, P887, DOI 10.1016/S1097-2765(00)80303-2; OVERDIER DG, 1994, MOL CELL BIOL, V14, P2755, DOI 10.1128/MCB.14.4.2755; Rasheed BKA, 1997, CANCER RES, V57, P4187; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Ririe KM, 1997, ANAL BIOCHEM, V245, P154, DOI 10.1006/abio.1996.9916; SCHNEEBERGER C, 1995, PCR METH APPL, V4, P234; Sevetson BR, 2000, J BIOL CHEM, V275, P9749, DOI 10.1074/jbc.275.13.9749; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Strasser A, 2000, ANNU REV BIOCHEM, V69, P217, DOI 10.1146/annurev.biochem.69.1.217; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; Svaren J, 1998, EMBO J, V17, P6010, DOI 10.1093/emboj/17.20.6010; Tang TTL, 2002, J BIOL CHEM, V277, P14255, DOI 10.1074/jbc.M110901200; Tashiro H, 1997, CANCER RES, V57, P3935; Teng DHF, 1997, CANCER RES, V57, P5221; Wang QD, 2000, BIOCHEM BIOPH RES CO, V276, P466, DOI 10.1006/bbrc.2000.3512; Whang YE, 1998, P NATL ACAD SCI USA, V95, P5246, DOI 10.1073/pnas.95.9.5246; Wick W, 1999, ONCOGENE, V18, P3936, DOI 10.1038/sj.onc.1202774; Wittwer CT, 1997, BIOTECHNIQUES, V22, P130, DOI 10.2144/97221bi01; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054	49	309	320	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47928	47937		10.1074/jbc.M207509200	http://dx.doi.org/10.1074/jbc.M207509200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351634	hybrid			2022-12-25	WOS:000179663700140
J	Comin-Anduix, B; Boros, LG; Marin, S; Boren, J; Callol-Massot, C; Centelles, JJ; Torres, JL; Agell, N; Bassilian, S; Cascante, M				Comin-Anduix, B; Boros, LG; Marin, S; Boren, J; Callol-Massot, C; Centelles, JJ; Torres, JL; Agell, N; Bassilian, S; Cascante, M			Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly(ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL COLON CARCINOGENESIS; FATTY-ACID SYNTHESIS; ADENOCARCINOMA CELLS; GLUCOSE-6-PHOSPHATE-DEHYDROGENASE; PROTEINS; RELEASE; RIBOSE; GROWTH; CANCER; DEATH	The fermented extract of wheat germ, trade name Avemar, is a complex mixture of biologically active molecules with potent anti-metastatic activities in various human malignancies. Here we report the effect of Avemar on Jurkat leukemia cell viability, proliferation, cell cycle distribution, apoptosis, and the activity of key glycolytic/pentose cycle enzymes that control carbon flow for nucleic acid synthesis. The cytotoxic IC50 concentration of Avemar for Jurkat tumor cells is 0.2 mg/ml, and increasing doses of the crude powder inhibit Jurkat cell proliferation in a dose-dependent fashion. At concentrations higher than 0.2 mg/ml, Avemar inhibits cell growth by more than 50% (72 h of incubation), which is preceded by the appearance of a sub-G(1) peak on flow histograms at 48 h. Laser scanning cytometry of propidium iodide and annexin V-stained cells indicated that the growth-inhibiting effect of Avemar was consistent with a strong induction of apoptosis. Inhibition by benzyloxycarbonyl-Val-Ala-Asp fluoromethyl ketone of apoptosis but increased proteolysis of poly(ADP-ribose) indicate caspases mediate the cellular effects of Avemar. Activities of glucose-6-phosphate dehydrogenase and transketolase were inhibited in a dose-dependent fashion, which correlated with decreased C-13 incorporation and pentose cycle substrate flow into RNA ribose. This decrease in pentose cycle enzyme activities and carbon flow toward nucleic acid precursor synthesis provide the mechanistic understanding of the cell growth-controlling and apoptosis-inducing effects of fermented wheat germ. Avemar exhibits about a 50-fold higher IC50 (10.02 mg/ml) for peripheral blood lymphocytes to induce a biological response, which provides the broad therapeutic window for this supplemental cancer treatment modality with no toxic effects.	Univ Barcelona, Dept Biochem & Mol Biol, IDIBAPS, CeRQT PCB, E-08028 Barcelona, Spain; Univ Calif Los Angeles, Sch Med, Harbor UCLA Res & Educ Inst, Torrance, CA 90502 USA; CSIC, Dept Peptide & Prot Chem, Inst Chem & Environm Res, IIQAB, ES-08034 Barcelona, Spain; Univ Barcelona, Dept Cell Biol, IDIBAPS, Fac Med, E-08036 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Consejo Superior de Investigaciones Cientificas (CSIC); University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Cascante, M (corresponding author), Univ Barcelona, Dept Biochem & Mol Biol, IDIBAPS, CeRQT PCB, Barcelona Sci Pk,1 Marti & Franques, E-08028 Barcelona, Spain.		CASCANTE, MARTA/AFK-5991-2022; Torres, Josep Lluís/N-7256-2013; Agell, Neus/E-9640-2016; Marin, Silvia/C-5492-2017; Boren, Joan/A-8515-2012; Centelles, Josep J./K-2972-2014; CASCANTE, MARTA/AAG-4355-2022	CASCANTE, MARTA/0000-0002-2062-4633; Torres, Josep Lluís/0000-0002-5072-8265; Agell, Neus/0000-0002-1205-6074; Marin, Silvia/0000-0003-0693-2207; Centelles, Josep J./0000-0002-6289-9678; CASCANTE, MARTA/0000-0002-2062-4633	NCI NIH HHS [P01-CA42710] Funding Source: Medline; NCRR NIH HHS [M01-RR00425] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA042710] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000425] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Boren J, 2001, J BIOL CHEM, V276, P37747; Boros LG, 2002, NEW ENGL J MED, V347, P67, DOI 10.1056/NEJM200207043470116; Boros LG, 2002, DRUG DISCOV TODAY, V7, P364, DOI 10.1016/S1359-6446(02)02179-7; Boros LG, 2001, PANCREAS, V23, P141, DOI 10.1097/00006676-200108000-00004; Boros LG, 1997, CANCER RES, V57, P4242; BOYUM A, 1968, SCAND J CLIN LAB S21, V97, P51; Cascante M, 2002, NAT BIOTECHNOL, V20, P243, DOI 10.1038/nbt0302-243; Castano E, 1999, BRIT J CANCER, V81, P294, DOI 10.1038/sj.bjc.6990690; Comin-Anduix B, 2001, MOL PHARMACOL, V60, P1235; de la HABA G., 1955, JOUR BIOL CHEM, V214, P409; DEMIDOV L, 2002, 18 UICC INT CANC C O; Fajka-Boja R, 2002, INT J ONCOL, V20, P563; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; Haridas V, 2001, P NATL ACAD SCI USA, V98, P5821, DOI 10.1073/pnas.101619098; Hidvegi M, 1998, ANTICANCER RES, V18, P2353; Hidvegi M, 1999, IMMUNOPHARMACOLOGY, V41, P183, DOI 10.1016/S0162-3109(99)00002-8; Inayat-Hussain SH, 2001, TOXICOL APPL PHARM, V175, P95, DOI 10.1006/taap.2001.9221; Jakab F, 2000, HEPATO-GASTROENTEROL, V47, P393; JAKAB F, 2001, HEPATAGASTROENTER S1, V48; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee WNP, 1998, AM J PHYSIOL-ENDOC M, V274, pE843, DOI 10.1152/ajpendo.1998.274.5.E843; MOMMSEN TP, 1980, CAN J ZOOL, V58, P1785, DOI 10.1139/z80-246; Orosz F, 1999, BRIT J CANCER, V79, P1356, DOI 10.1038/sj.bjc.6690218; Patel T, 1996, FASEB J, V10, P587, DOI 10.1096/fasebj.10.5.8621058; Pique M, 2000, FEBS LETT, V480, P193, DOI 10.1016/S0014-5793(00)01922-0; Reddy BS, 2000, CANCER RES, V60, P4792; SUTTLE S, 2000, RADIAT RES, V153, P781; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Tian WN, 1999, AM J PHYSIOL-CELL PH, V276, pC1121, DOI 10.1152/ajpcell.1999.276.5.C1121; TIAN WN, 1994, J BIOL CHEM, V269, P14798; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R; Zalatnai A, 2001, CARCINOGENESIS, V22, P1649, DOI 10.1093/carcin/22.10.1649	32	79	81	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46408	46414		10.1074/jbc.M206150200	http://dx.doi.org/10.1074/jbc.M206150200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351627	Green Published, hybrid			2022-12-25	WOS:000179529300092
J	Donahue, SL; Campbell, C				Donahue, SL; Campbell, C			A DNA double strand break repair defect in Fanconi anemia fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP; CROSS-LINKS; RESTRICTION ENDONUCLEASE; CHROMOSOME STABILITY; POSITIONAL CLONING; GROUP-A; C-GENE; CELLS; BRCA1; SENSITIVITY	Fanconi anemia (FA) is a heterogeneous autosomal recessive disease characterized by congenital abnormalities, pancytopenia, and an increased incidence of cancer. Cells cultured from FA patients display elevated spontaneous chromosomal breaks and deletions and are hypersensitive to bifunctional cross-linking agents. Thus, it has been hypothesized that FA is a DNA repair disorder. We analyzed plasmid end-joining in intact diploid fibroblast cells derived from FA patients. FA fibroblasts from complementation groups A, C, D2, and G rejoined linearized plasmids with a significantly decreased efficiency compared with non-FA fibroblasts. Retrovirus-mediated expression of the respective FA cDNAs in FA cells restored their end-joining efficiency to wild type levels. Human FA fibroblasts and fibroblasts from FA rodent models were also significantly more sensitive to restriction enzyme-induced chromosomal DNA double strand breaks than were their retrovirally corrected counterparts. Taken together, these data show that FA fibroblasts have a deficiency in both extra-chromosomal and chromosomal DNA double strand break repair, a defect that could. provide an attractive explanation for some of the pathologies associated with FA.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Campbell, C (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St,S E, Minneapolis, MN 55455 USA.				NIA NIH HHS [AG16678] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG016678] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Apostolou S, 1996, NAT GENET, V14, P324, DOI 10.1038/ng1196-324; AUERBACH AD, 1991, CANCER GENET CYTOGEN, V51, P1, DOI 10.1016/0165-4608(91)90002-C; AUERBACH AD, 1993, EXP HEMATOL, V21, P731; AUERBACH AD, 1976, NATURE, V261, P494, DOI 10.1038/261494a0; BRYANT PE, 1987, INT J RADIAT BIOL, V52, P537, DOI 10.1080/09553008714552041; BRYANT PE, 1992, MUTAT RES, V268, P27, DOI 10.1016/0027-5107(92)90079-H; Busch DB, 1996, MUTAT RES-DNA REPAIR, V363, P209, DOI 10.1016/0921-8777(96)00014-6; CALDECOTT K, 1991, MUTAT RES, V255, P111, DOI 10.1016/0921-8777(91)90046-R; Carreau M, 1999, MUTAT RES-DNA REPAIR, V435, P103, DOI 10.1016/S0921-8777(99)00041-5; COSTA ND, 1993, SOMAT CELL MOLEC GEN, V19, P479, DOI 10.1007/BF01233253; DAndrea AD, 1997, BLOOD, V90, P1725, DOI 10.1182/blood.V90.5.1725; de Winter JP, 2000, NAT GENET, V24, P15, DOI 10.1038/71626; de Winter JP, 1998, NAT GENET, V20, P281, DOI 10.1038/3093; de Winter JP, 2000, AM J HUM GENET, V67, P1306, DOI 10.1016/S0002-9297(07)62959-0; de Winter JP, 2000, HUM MOL GENET, V9, P2665, DOI 10.1093/hmg/9.18.2665; Escarceller M, 1997, SOMAT CELL MOLEC GEN, V23, P401, DOI 10.1007/BF02673750; Escarceller M, 1998, J MOL BIOL, V279, P375, DOI 10.1006/jmbi.1998.1784; Garcia-Higuera I, 2001, MOL CELL, V7, P249, DOI 10.1016/S1097-2765(01)00173-3; GIACCIA AJ, 1990, MUTAT RES, V236, P67, DOI 10.1016/0921-8777(90)90034-3; GRUENERT DC, 1985, CANCER RES, V45, P5399; Harvey AN, 1997, SOMAT CELL MOLEC GEN, V23, P211, DOI 10.1007/BF02721372; Howlett NG, 2002, SCIENCE, V297, P606, DOI 10.1126/science.1073834; ISHIDA R, 1982, CANCER RES, V42, P4000; JACHYMCZYK WJ, 1981, MOL GEN GENET, V182, P196, DOI 10.1007/BF00269658; Joenje H, 2000, AM J HUM GENET, V67, P759, DOI 10.1086/303067; Joenje H, 1997, AM J HUM GENET, V61, P940, DOI 10.1086/514881; Karanjawala ZE, 2002, CURR BIOL, V12, P397, DOI 10.1016/S0960-9822(02)00684-X; KINASHI Y, 1995, RADIAT RES, V141, P153, DOI 10.2307/3579042; Kraakman-van der Zwet M, 2002, MOL CELL BIOL, V22, P669, DOI 10.1128/MCB.22.2.669-679.2002; Liu N, 1997, P NATL ACAD SCI USA, V94, P9232, DOI 10.1073/pnas.94.17.9232; Liu N, 1998, MOL CELL, V1, P783, DOI 10.1016/S1097-2765(00)80078-7; LoTenFoe JR, 1996, NAT GENET, V14, P320, DOI 10.1038/ng1196-320; Lundberg R, 2001, J BIOL CHEM, V276, P9543, DOI 10.1074/jbc.M008634200; Medhurst AL, 2001, HUM MOL GENET, V10, P423, DOI 10.1093/hmg/10.4.423; Moynahan ME, 2001, MOL CELL, V7, P263, DOI 10.1016/S1097-2765(01)00174-5; Moynahan ME, 2001, CANCER RES, V61, P4842; PAPADOPOULO D, 1990, P NATL ACAD SCI USA, V87, P8383, DOI 10.1073/pnas.87.21.8383; Patel KJ, 1998, MOL CELL, V1, P347, DOI 10.1016/S1097-2765(00)80035-0; RUNGER TM, 1993, TOXICOL LETT, V67, P309, DOI 10.1016/0378-4274(93)90064-5; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; Smith J, 1998, J MOL BIOL, V281, P815, DOI 10.1006/jmbi.1998.1971; Snouwaert JN, 1999, ONCOGENE, V18, P7900, DOI 10.1038/sj.onc.1203334; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; Taniguchi T, 2002, CELL, V109, P459, DOI 10.1016/S0092-8674(02)00747-X; Timmers C, 2001, MOL CELL, V7, P241, DOI 10.1016/S1097-2765(01)00172-1; Venkitaraman AR, 2001, J CELL SCI, V114, P3591; Whitney MA, 1996, BLOOD, V88, P49; Witt E, 2002, SCIENCE, V297, P534, DOI 10.1126/science.1074482; Xu B, 2001, MOL CELL BIOL, V21, P3445, DOI 10.1128/MCB.21.10.3445-3450.2001; Youssoufian H, 1996, J CLIN INVEST, V97, P957, DOI 10.1172/JCI118519	51	37	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46243	46247		10.1074/jbc.M207937200	http://dx.doi.org/10.1074/jbc.M207937200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12361951	hybrid			2022-12-25	WOS:000179529300072
J	Kim, JE; Jeong, HW; Nam, JO; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS				Kim, JE; Jeong, HW; Nam, JO; Lee, BH; Choi, JY; Park, RW; Park, JY; Kim, IS			Identification of motifs in the fasciclin domains of the transforming growth factor-beta-induced matrix protein beta ig-h3 that interact with the alpha v65 integrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION; IN-VITRO; GENE; ALPHA(V)BETA(3); FIBROBLASTS; BINDING; CHONDROCYTES; OSTEOPONTIN; SUPPRESSES; ACTIVATION	betaig-h3 is a TGF-beta-induced matrix protein known to mediate the adhesion of several cell types. In this study, we found that all four of the fas-1 domains in betaig-h3 mediate MRC-5 fibroblast adhesion and that this was specifically inhibited by a function-blocking monoclonal antibody specific for the alphavbeta5 integrin. Using deletion mutants of the fourth fas-1 domain revealed the MRC-5 cell adhesion motif (denoted the YH motif) is located in amino acids 548-614. Experiments with substitution mutants showed that tyrosine 571, histidine 572, and their flanking leucine and isoleucine amino acids, which are all highly conserved in many fas-1 domains, are essential for mediating MRC-5 cell adhesion. A synthetic 18-amino acid peptide encompassing these conserved amino acids could effectively block MRC-5 cell adhesion to betaig-h3. Using HEK293 cells stably trans-fected with the beta5 integrin cDNA, we confirmed that the alphavbeta5 integrin is a functional receptor for the YH motif. In conclusion, we have identified a new alphavbeta5 integrin-interacting motif that is highly conserved in the fas-1 domains of many proteins. This suggests that fas-1 domain-containing proteins may perform their biological functions by interacting with integrins.	Kyungpook Natl Univ, Sch Med, Dept Biochem,Cell & Matrix Biol Natl Res Lab, Jung Gu, Taegu 700422, South Korea; Dongguk Univ, Dept Biochem, Sch Med, Kyungju 780714, South Korea	Kyungpook National University; Dongguk University	Kim, IS (corresponding author), Kyungpook Natl Univ, Sch Med, Dept Biochem,Cell & Matrix Biol Natl Res Lab, Jung Gu, 101 Dongindong, Taegu 700422, South Korea.	iskim@knu.ac.kr	김, 인산/I-8988-2014					Bayless KJ, 2000, AM J PATHOL, V156, P1673, DOI 10.1016/S0002-9440(10)65038-9; BOSSY B, 1990, BIOCHEMISTRY-US, V29, P10191, DOI 10.1021/bi00496a006; Datta A, 2002, J BIOL CHEM, V277, P3943, DOI 10.1074/jbc.M109536200; Dieudonne SC, 2000, J CELL BIOCHEM, V76, P231, DOI 10.1002/(SICI)1097-4644(20000201)76:2<231::AID-JCB7>3.0.CO;2-X; Gimeno MJ, 2001, HISTOL HISTOPATHOL, V16, P821, DOI 10.14670/HH-16.821; Horiuchi K, 1999, J BONE MINER RES, V14, P1239, DOI 10.1359/jbmr.1999.14.7.1239; HU DD, 1995, J BIOL CHEM, V270, P26232, DOI 10.1074/jbc.270.44.26232; HU DD, 1995, J BIOL CHEM, V270, P9917, DOI 10.1074/jbc.270.17.9917; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Kawamoto T, 1998, BBA-GENE STRUCT EXPR, V1395, P288, DOI 10.1016/S0167-4781(97)00172-3; Kim IS, 1996, MOL CELL BIOL, V16, P4003; Kim JE, 2000, J CELL BIOCHEM, V77, P169, DOI 10.1002/(SICI)1097-4644(20000501)77:2<169::AID-JCB1>3.0.CO;2-L; Kim JE, 2000, J BIOL CHEM, V275, P30907, DOI 10.1074/jbc.M002752200; Kim JE, 2002, INVEST OPHTH VIS SCI, V43, P656; Kumar CC, 2001, CANCER RES, V61, P2232; LEBARON RG, 1995, J INVEST DERMATOL, V104, P844, DOI 10.1111/1523-1747.ep12607024; OBrien ER, 1996, ARTERIOSCL THROM VAS, V16, P576, DOI 10.1161/01.ATV.16.4.576; Ohno S, 1999, BBA-MOL CELL RES, V1451, P196, DOI 10.1016/S0167-4889(99)00093-2; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; Rawe IM, 1997, INVEST OPHTH VIS SCI, V38, P893; SKONIER J, 1994, DNA CELL BIOL, V13, P571, DOI 10.1089/dna.1994.13.571; SKONIER J, 1992, DNA CELL BIOL, V11, P511, DOI 10.1089/dna.1992.11.511; SMITH JW, 1990, J BIOL CHEM, V265, P11008; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X	24	161	167	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46159	46165		10.1074/jbc.M207055200	http://dx.doi.org/10.1074/jbc.M207055200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270930	hybrid			2022-12-25	WOS:000179529300061
J	Zhang, RL; Brennan, ML; Shen, ZZ; MacPherson, JC; Schmitt, D; Molenda, CE; Hazen, SL				Zhang, RL; Brennan, ML; Shen, ZZ; MacPherson, JC; Schmitt, D; Molenda, CE; Hazen, SL			Myeloperoxidase functions as a major enzymatic catalyst for initiation of lipid peroxidation at sites of inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MASS-SPECTROMETRIC QUANTIFICATION; DITYROSINE CROSS-LINKING; NITRIC-OXIDE; ARACHIDONIC-ACID; OXIDATIVE STRESS; HYDROXYEICOSATETRAENOIC ACIDS; PHOSPHOLIPID OXIDATION; NITROGEN-DIOXIDE; NITRATION	Initiation of lipid peroxidation and the formation of bioactive eicosanoids are pivotal processes in inflammation and atherosclerosis. Currently, lipoxygenases, cyclooxygenases, and cytochrome P450 monooxygenases are considered the primary enzymatic participants in these events. Myeloperoxidase (MPO), a heme protein secreted by activated leukocytes, generates reactive intermediates that promote lipid peroxidation in vitro. For example, MPO catalyzes oxidation of tyrosine and nitrite to form tyrosyl radical and nitrogen dioxide ('NO2), respectively, reactive intermediates capable of initiating oxidation of lipids in plasma. Neither the ability of MPO to initiate lipid peroxidation in vivo nor its role in generating bioactive eicosanoids during inflammation has been reported. Using a model of inflammation (peritonitis) with MPO knockout mice (MPO-/-), we examined the role for MPO in the formation of bioactive lipid oxidation products and promoting oxidant stress in vivo. Electrospray ionization tandem mass spectrometry was used to simultaneously quantify individual molecular species of hydroxy- and hydroperoxy-eicosatetraenoic acids (H(P)ETEs), F-2-isoprostanes, hydroxy- and hydroperoxy-octadecadienoic acids (H(P)ODEs), and their precursors, arachidonic acid and linoleic acid. Peritonitis-triggered formation of F-2-isoprostanes, a marker of oxidant stress in vivo, was reduced by 85% in the MPO-/- mice. Similarly, formation of all molecular species of H(P)ETEs and H(P)ODEs monitored were significantly reduced (by at least 50%) in the MPO-/- group during inflammation. Parallel analyses of peritoneal lavage proteins for protein dityrosine and nitrotyrosine, molecular markers for oxidative modification by tyrosyl radical and 'NO2, respectively, revealed marked reductions in the content of nitrotyrosine, but not dityrosine, in MPO-/- samples. Thus, MPO serves as a major enzymatic catalyst of lipid peroxidation at sites of inflammation. Moreover, MPO-dependent formation of 'NO-derived oxidants, and not tyrosyl radical, appears to serve as a preferred pathway for initiating lipid peroxidation and promoting oxidant stress in vivo.	Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University System of Ohio; Cleveland State University	Hazen, SL (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Hazen, Stanley L/ABD-5845-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062526, R01HL061878, R01HL070621] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61878, HL70621, HL62526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2000, J BIOL CHEM, V275, P37524, DOI 10.1074/jbc.275.48.37524; Abu-Soud HM, 2000, J BIOL CHEM, V275, P5425, DOI 10.1074/jbc.275.8.5425; Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P11866, DOI 10.1021/bi011206v; Abu-Soud Husam M., 2000, Nitric Oxide, V4, P179; Baldus S, 2001, J CLIN INVEST, V108, P1759; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; Bhattacharjee S, 2001, ARCH BIOCHEM BIOPHYS, V395, P69, DOI 10.1006/abbi.2001.2557; Brennan ML, 2002, J BIOL CHEM, V277, P17415, DOI 10.1074/jbc.M112400200; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Cao Y, 2000, P NATL ACAD SCI USA, V97, P11280, DOI 10.1073/pnas.200367597; Carr AC, 2001, J BIOL CHEM, V276, P1822, DOI 10.1074/jbc.M009082200; Cathcart MK, 2000, FREE RADICAL BIO MED, V28, P1726, DOI 10.1016/S0891-5849(00)00230-6; Chisolm GM, 1999, J BIOL CHEM, V274, P25959, DOI 10.1074/jbc.274.37.25959; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Dworski R, 2001, CLIN EXP ALLERGY, V31, P387, DOI 10.1046/j.1365-2222.2001.01055.x; Eiserich JP, 2002, SCIENCE, V296, P2391, DOI 10.1126/science.1106830; Exner M, 2001, FEBS LETT, V490, P28, DOI 10.1016/S0014-5793(01)02131-7; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; Gaut JP, 2002, J CLIN INVEST, V109, P1311, DOI 10.1172/JCI200215021; Goss SPA, 1999, FREE RADICAL RES, V31, P597, DOI 10.1080/10715769900301171; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; Heinecke JW, 2002, TOXICOLOGY, V177, P11, DOI 10.1016/S0300-483X(02)00192-0; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HENDERSON WR, 1983, J BIOL CHEM, V258, P3522; Hogg N, 1998, FREE RADICAL RES, V28, P593, DOI 10.3109/10715769809065815; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; KUEHL FA, 1980, SCIENCE, V210, P978, DOI 10.1126/science.6254151; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P3520, DOI 10.1074/jbc.272.6.3520; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Mallat Z, 1999, J CLIN INVEST, V103, P421, DOI 10.1172/JCI3985; Marathe GK, 2000, FREE RADICAL BIO MED, V28, P1762, DOI 10.1016/S0891-5849(00)00234-3; Mukhopadhyay CK, 1998, BIOCHEMISTRY-US, V37, P14222, DOI 10.1021/bi981137t; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; Noguchi N, 2000, J BIOCHEM-TOKYO, V127, P971, DOI 10.1093/oxfordjournals.jbchem.a022713; O'Donnell VB, 1999, CHEM RES TOXICOL, V12, P83, DOI 10.1021/tx980207u; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Podrez EA, 2002, J BIOL CHEM, V277, P38517, DOI 10.1074/jbc.M205924200; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Pratico D, 1998, P NATL ACAD SCI USA, V95, P3449, DOI 10.1073/pnas.95.7.3449; Prescott SM, 2000, ANNU REV BIOCHEM, V69, P419, DOI 10.1146/annurev.biochem.69.1.419; PRYOR WA, 1983, SCIENCE, V220, P425, DOI 10.1126/science.6301009; ROBERTS LJ, 1994, ANN NY ACAD SCI, V744, P237, DOI 10.1111/j.1749-6632.1994.tb52741.x; Roberts LJ, 2000, FREE RADICAL BIO MED, V28, P505, DOI 10.1016/S0891-5849(99)00264-6; SANTANAM N, 1995, J CLIN INVEST, V95, P2594, DOI 10.1172/JCI117961; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; Schmitt D, 1999, BIOCHEMISTRY-US, V38, P16904, DOI 10.1021/bi991623w; SEVANIAN A, 1982, J TOXICOL ENV HEALTH, V10, P743, DOI 10.1080/15287398209530292; Shigenaga MK, 1997, P NATL ACAD SCI USA, V94, P3211, DOI 10.1073/pnas.94.7.3211; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; Subbanagounder G, 2000, FREE RADICAL BIO MED, V28, P1751, DOI 10.1016/S0891-5849(00)00233-1; van Dalen CJ, 2000, J BIOL CHEM, V275, P11638, DOI 10.1074/jbc.275.16.11638; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; Wink DA, 1995, TOXICOL LETT, V82-3, P221, DOI 10.1016/0378-4274(95)03557-5; Yla-Herttuala S, 1999, ANN NY ACAD SCI, V874, P134, DOI 10.1111/j.1749-6632.1999.tb09231.x; Zhang RL, 2002, BLOOD, V99, P1802, DOI 10.1182/blood.V99.5.1802.h8001802_1802_1810	64	330	366	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46116	46122		10.1074/jbc.M209124200	http://dx.doi.org/10.1074/jbc.M209124200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359714	hybrid			2022-12-25	WOS:000179529300055
J	Kiat, LS; Hui, KM; Gopalan, G				Kiat, LS; Hui, KM; Gopalan, G			Aurora-a kinase interacting protein (AIP), a novel negative regulator of human aurora-A kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLE-DEPENDENT EXPRESSION; ANAPHASE-PROMOTING COMPLEX; POLO-LIKE KINASES; CELL-CYCLE; CHROMOSOME SEGREGATION; MICROTUBULE DYNAMICS; BREAST-CANCER; YEAST; SPINDLE; FAMILY	Aurora kinases have evolved as a new family of mitotic centrosome- and microtubule-associated kinases that regulate the structure and function of centrosomes and spindle. One of its members, Aurora-A, is a potential oncogene. Overexpression of Aurora-A is also implicated in defective centrosome duplication and segregation, leading to aneuploidy and tumorigenesis in various cancer cell types. However, the regulatory pathways for mammalian Aurora-A are not well understood. Exploiting the lethal phenotype associated with the overexpression of Aurora-A in yeast, we performed a dosage suppressor screen in yeast and report here the identification of a novel negative regulator of Aurora-A, named AIP (Aurora-A kinase Interacting Protein). AIP is a ubiquitously expressed nuclear protein that interacts specifically with human Aurora-A in vivo. Ectopic expression of AIP with Aurora-A in NIH 3T3 and COS cells results in the down-regulation of ectopically expressed Aurora-A protein levels, and this down-regulation is demonstrated to be the result of destabilization of Aurora-A through a proteasome-dependent protein degradation pathway. A noninteracting deletion mutant of AIP does not down-regulate Aurora-A protein, suggesting that the interaction is important for the protein degradation. AIP could therefore be a potential useful target gene for anti-tumor drugs.	Natl Canc Ctr, Gene Struct & Express Lab, Div Cellular & Mol Res, Singapore 169610, Singapore	National Cancer Centre Singapore (NCCS)	Gopalan, G (corresponding author), Natl Canc Ctr, Gene Struct & Express Lab, Div Cellular & Mol Res, Level 6,11 Hosp Dr, Singapore 169610, Singapore.	cmrgop@nccs.com.sg	Hui, Kam/C-6186-2011	Hui, Kam/0000-0003-1820-1399				Adams RR, 1998, GENE DEV, V12, P1483, DOI 10.1101/gad.12.10.1483; Andersen SSL, 1999, BIOESSAYS, V21, P53, DOI 10.1002/(SICI)1521-1878(199901)21:1<53::AID-BIES7>3.0.CO;2-L; Biggins S, 1999, GENE DEV, V13, P532, DOI 10.1101/gad.13.5.532; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; CENTONZE VE, 1990, J CELL SCI, V95, P405; CHAN CSM, 1993, GENETICS, V135, P677; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Courjal F, 1996, BRIT J CANCER, V74, P1984, DOI 10.1038/bjc.1996.664; Craig KL, 1999, PROG BIOPHYS MOL BIO, V72, P299, DOI 10.1016/S0079-6107(99)00010-3; De Angelis PM, 1999, BRIT J CANCER, V80, P526; Donaldson MM, 2001, J CELL SCI, V114, P2357; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farruggio DC, 1999, P NATL ACAD SCI USA, V96, P7306, DOI 10.1073/pnas.96.13.7306; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Geiser JR, 1997, MOL BIOL CELL, V8, P1035, DOI 10.1091/mbc.8.6.1035; Giet R, 1999, J CELL SCI, V112, P3591; Giet R, 1999, J BIOL CHEM, V274, P15005, DOI 10.1074/jbc.274.21.15005; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Glover DM, 1998, GENE DEV, V12, P3777, DOI 10.1101/gad.12.24.3777; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gopalan G, 1997, J CELL BIOL, V138, P643, DOI 10.1083/jcb.138.3.643; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hilioti Z, 2001, CURR BIOL, V11, P1347, DOI 10.1016/S0960-9822(01)00399-2; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Inoue T, 2001, J BIOL CHEM, V276, P45255, DOI 10.1074/jbc.M107477200; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; Kimura M, 1999, J BIOL CHEM, V274, P7334, DOI 10.1074/jbc.274.11.7334; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Mayor T, 1999, FEBS LETT, V452, P92, DOI 10.1016/S0014-5793(99)00534-7; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1996, EXP CELL RES, V229, P174, DOI 10.1006/excr.1996.0356; Nigg EA, 2001, E SCHERING RES FDN W, V34, P19; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; NIGG EA, 1995, BIOESSAYS, V17, P471, DOI 10.1002/bies.950170603; Niwa H, 1996, GENE, V169, P197, DOI 10.1016/0378-1119(95)00809-8; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sassoon I, 1999, GENE DEV, V13, P545, DOI 10.1101/gad.13.5.545; SATO T, 1994, P NATL ACAD SCI USA, V91, P9238, DOI 10.1073/pnas.91.20.9238; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Straight AF, 1997, CURR BIOL, V7, pR613, DOI 10.1016/S0960-9822(06)00315-0; TANNER MM, 1994, CANCER RES, V54, P4257; Tatsuka M, 1998, CANCER RES, V58, P4811; Terada Y, 1998, EMBO J, V17, P667, DOI 10.1093/emboj/17.3.667; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; VANDRE DD, 1989, J CELL SCI, V94, P245; VANDRE DD, 1986, EUR J CELL BIOL, V41, P72; VANDRE DD, 1984, P NATL ACAD SCI-BIOL, V81, P4439, DOI 10.1073/pnas.81.14.4439; VERDE F, 1990, NATURE, V343, P233, DOI 10.1038/343233a0; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	57	31	34	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45558	45565		10.1074/jbc.M206820200	http://dx.doi.org/10.1074/jbc.M206820200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244051	hybrid			2022-12-25	WOS:000179404800121
J	Nayak, BK; Das, GM				Nayak, BK; Das, GM			Stabilization of p53 and transactivation of its target genes in response to replication blockade	ONCOGENE			English	Article						p53; transactivation; p21; replication blockade; hydroxyurea; aphidicolin	TUMOR-SUPPRESSOR PROTEIN; CELL-CYCLE; DNA-DAMAGE; ARREST; P21; TRANSCRIPTION; COACTIVATORS; CHECKPOINT; MODULATION; APOPTOSIS	Although it is clear that p53 plays a pivotal role in G1/G2 checkpoints to conserve genomic integrity, its role in S phase checkpoint is less well understood. Recently, it has been reported that p53 is transcriptionally impaired even though it is stabilized during replication blockade. However, the mechanisms underlying this phenomenon are not known. In the present study, it has been shown that p53 accumulates and transactivates its target genes such as p21, gadd45 and bax in response to replication blockade in normal and cancer cells. Lack of transcriptional activation under similar conditions in cells lacking p53 shows that p53-target gene activation during replication blockade is indeed p53-dependent. Further, transactivation of p21 in response to replication blockade by hydroxyurea and aphidicolin is similar to that in response to ionizing radiation except that the latter is more immediate compared to the response to replication blockade. These findings suggest that impairment of transcriptionally active p53 in response to replication blockade is not a general phenomenon.	Univ Texas, Hlth Sci Ctr, Dept Surg, Mol Oncol Res Program, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Das, GM (corresponding author), Roswell Pk Canc Inst, Dept Pharmacol & Therapeut, Elm & Carlton St, Buffalo, NY 14263 USA.		Das, Gokul M/A-5772-2013	Das, Gokul M/0000-0003-2937-8093	NCI NIH HHS [R01 CA079911] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079911] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chan TA, 2000, GENE DEV, V14, P1584; Chaudhry MA, 2002, ONCOGENE, V21, P1934, DOI 10.1038/sj.onc.1205264; DAS G, 1995, NATURE, V374, P657, DOI 10.1038/374657a0; DEBBAS M, 1993, GENE DEV, V7, P546, DOI 10.1101/gad.7.4.546; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottifredi V, 2001, P NATL ACAD SCI USA, V98, P1036, DOI 10.1073/pnas.021282898; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Ji C, 1997, ONCOGENE, V15, P2749, DOI 10.1038/sj.onc.1201441; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Ryan KM, 2001, CURR OPIN CELL BIOL, V13, P332, DOI 10.1016/S0955-0674(00)00216-7; Scolnick DM, 1997, CANCER RES, V57, P3693; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Taylor WR, 1999, ONCOGENE, V18, P283, DOI 10.1038/sj.onc.1202516; TOMMASINO M, 1995, BIOESSAYS, V17, P509, DOI 10.1002/bies.950170607; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	29	34	35	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7226	7229		10.1038/sj.onc.1205889	http://dx.doi.org/10.1038/sj.onc.1205889			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370812				2022-12-25	WOS:000178504600010
J	Xie, SH; Lin, H; Sun, T; Arlinghaus, RB				Xie, SH; Lin, H; Sun, T; Arlinghaus, RB			Jak2 is involved in c-Myc induction by Bcr-Abl	ONCOGENE			English	Article						Philadelphia chromosome leukemia; Bcr-Abl oncoprotein; Jak2 tyrosine kinase; c-Myc induction	NF-KAPPA-B; CHRONIC MYELOGENOUS LEUKEMIA; TYROSINE PHOSPHORYLATION; HEMATOPOIETIC-CELLS; SIGNAL TRANSDUCER; STAT5 ACTIVATION; FACTOR-RECEPTOR; KINASE-ACTIVITY; FUSION PROTEIN; MYELOID CELLS	We have previously shown that the Jak2 tyrosine kinase is activated in Bcr-Abl positive cell lines and blood cells from CML blast crisis patients by tyrosine phosphorylation. We are searching for downstream targets of Jak2 in Bcr-Abl positive cells. It is known that c-Myc expression is required for the oncogenic effects of Bcr-Abl, and that over-expression of c-Myc complements the transformation defect of the Bcr-Abl SH2 deletion mutant. Moreover, the Bcr-Abl SH2 deletion mutant and an Abl C-terminal deletion mutant are deficient in activating c-Myc expression. Since the Jak2 binds to the C-terminal domain of Bcr-Abl and optimal Jak2 activation requires the SH2 domain, we tested whether Jak2 was involved in c-Myc protein induction by Bcr-Abl. We treated the 32Dp210 Bcr-Abl cells with the Jak2 specific tyrosine kinase inhibitor, AG490, and found that this drug, like the Abl tyrosine kinase inhibitor STI-571, inhibited c-Myc protein induction by Bcr-Abl. Treatment of 32Dp210 Bcr-Abl cells with AG490 also inhibited c-MYC RNA expression. It is also known that c-Myc protein is a labile protein that is increased in amounts in response to various growth factors by a mechanism not involving new Myc protein formation. Treatment of 32Dp210 Bcr-Abl cells with both the proteasome inhibitor MG132 and AG490 blocked the reduction of the c-Myc protein observed by AG490 alone. An adaptor protein SH2-Bbeta is involved in the enhancement of the tyrosine kinase activity of Jak2 following ligand/receptor interaction. In this regard we showed that the Jak2/Bcr-Abl complex contains SH2-Bbeta. Expression of the SH2-Bbeta R555E mutant in 32Dp210 Bcr-Abl cells reduced c-Myc expression about 40% compared to a vector control. Interestingly, we found the reduction of the c-Myc protein in several clones of dominant-negative (DN) Jak2 expressing K562 cells correlated very well with the reduction of tumor growth of these cells in nude mice as compared to vector transfected K562 cells. Both STI-571 and AG490 also induced apoptosis in 32Dp210 cells. Of interest, IL-3 containing medium reversed the STI-571 induced apoptosis of 32Dp210 cells but did not reverse the induction of apoptosis by AG490, which strongly supports the specificity of the inhibitory effects of AG490 on the Jak2 tyrosine kinase. In summary, our findings indicate that Jak2 mediates the increase in c-Myc expression that is induced by Bcr-Abl. Our results indicate that activated Jak2 not only mediates an increase of c-MYC RNA expression but also interferes with proteasome-dependent degradation of c-Myc protein.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Arlinghaus, RB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd, Houston, TX 77030 USA.				NCI NIH HHS [CA 16672, CA 49639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA049639, P30CA016672] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AFAR DEH, 1994, SCIENCE, V264, P424, DOI 10.1126/science.8153630; Besancon F, 1998, P NATL ACAD SCI USA, V95, P8081, DOI 10.1073/pnas.95.14.8081; Carlesso N, 1996, J EXP MED, V183, P811, DOI 10.1084/jem.183.3.811; Chai SK, 1997, J IMMUNOL, V159, P4720; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; CIECHANOVER A, 1991, P NATL ACAD SCI USA, V88, P139, DOI 10.1073/pnas.88.1.139; Danial NN, 1998, MOL CELL BIOL, V18, P6795, DOI 10.1128/MCB.18.11.6795; de Groot RP, 1999, BLOOD, V94, P1108, DOI 10.1182/blood.V94.3.1108.415k07_1108_1112; Deininger MWN, 2000, BLOOD, V96, P3343, DOI 10.1182/blood.V96.10.3343; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Flinn EM, 1998, MOL CELL BIOL, V18, P5961, DOI 10.1128/MCB.18.10.5961; Gesbert F, 2000, BLOOD, V96, P2269, DOI 10.1182/blood.V96.6.2269.h8002269_2269_2276; Gross-Mesilaty S, 1998, P NATL ACAD SCI USA, V95, P8058, DOI 10.1073/pnas.95.14.8058; GUO JQ, 1993, HEMATOL PATHOL, V7, P91; HANN SR, 1984, MOL CELL BIOL, V4, P2486, DOI 10.1128/MCB.4.11.2486; Horita M, 2000, J EXP MED, V191, P977, DOI 10.1084/jem.191.6.977; Ilaria RL, 1996, J BIOL CHEM, V271, P31704, DOI 10.1074/jbc.271.49.31704; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; LAROSA FA, 1994, MOL CELL BIOL, V14, P1039, DOI 10.1128/MCB.14.2.1039; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; Miyamoto N, 2001, LEUKEMIA, V15, P1758, DOI 10.1038/sj.leu.2402260; Mui ALF, 1996, EMBO J, V15, P2425, DOI 10.1002/j.1460-2075.1996.tb00600.x; Nieborowska-Skorska M, 1999, J EXP MED, V189, P1229, DOI 10.1084/jem.189.8.1229; Okuda K, 1998, BLOOD, V92, P3848, DOI 10.1182/blood.V92.10.3848.422k44_3848_3856; RAMSAY G, 1986, MOL CELL BIOL, V6, P4450, DOI 10.1128/MCB.6.12.4450; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Rui LY, 2000, MOL CELL BIOL, V20, P3168, DOI 10.1128/MCB.20.9.3168-3177.2000; Rui LY, 1999, P NATL ACAD SCI USA, V96, P7172, DOI 10.1073/pnas.96.13.7172; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Sambrook J., 1989, MOL CLONING; SAWYERS CL, 1992, CELL, V70, P901, DOI 10.1016/0092-8674(92)90241-4; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; SHUI K, 1996, ONCOGENE, V13, P247; Sillaber C, 2000, BLOOD, V95, P2118, DOI 10.1182/blood.V95.6.2118; Skorski T, 1997, EMBO J, V16, P6151, DOI 10.1093/emboj/16.20.6151; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; STEWART MJ, 1995, LEUKEMIA, V9, P1499; Takeshita T, 1997, IMMUNITY, V6, P449, DOI 10.1016/S1074-7613(00)80288-5; Watanabe S, 1996, J BIOL CHEM, V271, P12681, DOI 10.1074/jbc.271.21.12681; WilsonRawls J, 1996, CANCER RES, V56, P3426; Xie SH, 2001, ONCOGENE, V20, P6188, DOI 10.1038/sj.onc.1204834; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	44	111	118	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7137	7146		10.1038/sj.onc.1205942	http://dx.doi.org/10.1038/sj.onc.1205942			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370803				2022-12-25	WOS:000178504600001
J	Bruce, JIE; Yule, DI; Shuttleworth, TJ				Bruce, JIE; Yule, DI; Shuttleworth, TJ			Ca2+-dependent protein kinase-A modulation of the plasma membrane Ca2+-ATPase in parotid acinar cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ PUMP CONTAINS; CALCIUM-PUMP; CA-2+ PUMP; ENDOPLASMIC-RETICULUM; CYCLIC-AMP; SARCOPLASMIC-RETICULUM; PHOSPHORYLATION SITE; HUMAN ERYTHROCYTES; MOLECULAR-CLONING; C PHOSPHORYLATES	Cross-talk between cAMP and [Ca2+](i) signaling pathways represents a general feature that defines the specificity of stimulus-response coupling in a variety of cell types including parotid acinar cells. We have reported recently that cAMP potentiates Ca2+ release from intracellular stores, primarily because of a protein kinase A-mediated phosphorylation of type H inositol 1,4,5-trisphosphate receptors (Bruce, J. I. E., Shuttleworth, T. J. S., Giovannucci, D. R., and Yule, D. I. (2002) J. Biol. Chem. 277, 1340-1348). The aim of the present study was to evaluate the functional and molecular mechanism whereby cAMP regulates Ca2+ clearance pathways in parotid acinar cells. Following an agonist-induced increase in [Ca2+](i) the rate of Ca2+ clearance, after the removal of the stimulus, was potentiated substantially (similar to2-fold). by treatment with forskolin. This effect was prevented completely by inhibition of the plasma membrane Ca2+-ATPase (PMCA) with La. PMCA activity, when isolated pharmacologically, was also potentiated (similar to2-fold) by forskolin. Ca2+ uptake into the endoplasmic reticulum of streptolysin-O-permeabilized cells by sarco/endoplasmic reticulum Ca2+-ATPase was largely unaffected by treatment with dibutyryl cAMP. Finally, in situ phosphorylation assays demonstrated that PMCA was phosphorylated by treatment with forskolin but only in the presence of carbamylcholine (carbachol). This effect of forskolin was Ca2+-dependent, and protein kinase C-independent, as potentiation of PMCA activity and phosphorylation of PMCA by forskolin also occurred when [Ca2+](i) was elevated by the sarco/endoplasmic reticulum Ca2+-ATPase inhibitor cyclopiazonic acid and was attenuated by pre-incubation with the Ca2+ chelator, 1,2-bis(o-aminophenoxy) ethane-N,N,N',N'-tetraacetic acid (BAPTA). The present study demonstrates that elevated cAMP enhances the rate of Ca2+ clearance because of a complex modulation of PMCA activity that involves a Ca2+-dependent step. Tight regulation of both Ca2+ release and Ca2+ efflux may represent a general feature of the mechanism whereby cAMP improves the fidelity and specificity of Ca2+ signaling.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Bruce, JIE (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Sch Med & Dent, 601 Elmwood Ave, Rochester, NY 14642 USA.	jason_bruce@urmc.rochester.edu			NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE014756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R56DE014756, P01DE013539] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE 14756, DEO 13539] Funding Source: Medline; NIGMS NIH HHS [GM 40457] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDYSWALIGORSKA A, 1987, BIOCHIM BIOPHYS ACTA, V929, P190, DOI 10.1016/0167-4889(87)90175-3; Belan PV, 1996, J BIOL CHEM, V271, P7615, DOI 10.1074/jbc.271.13.7615; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BOBYOCK E, 1989, J DENT RES, V68, P1489, DOI 10.1177/00220345890680110401; Bootman MD, 2001, J CELL SCI, V114, P2213; Bootman MD, 2001, SEMIN CELL DEV BIOL, V12, P3, DOI 10.1006/scdb.2000.0211; Brini M, 2000, CELL MOL LIFE SCI, V57, P354, DOI 10.1007/PL00000698; Brittsan AG, 2000, J MOL CELL CARDIOL, V32, P2131, DOI 10.1006/jmcc.2000.1270; Brown BJ, 1996, BBA-BIOMEMBRANES, V1283, P10, DOI 10.1016/0005-2736(96)00108-3; Bruce JIE, 2002, J BIOL CHEM, V277, P1340, DOI 10.1074/jbc.M106609200; CARAFOLI E, 1994, J NEUROBIOL, V25, P312, DOI 10.1002/neu.480250311; Carafoli E, 2002, P NATL ACAD SCI USA, V99, P1115, DOI 10.1073/pnas.032427999; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1992, ANN NY ACAD SCI, V671, P58, DOI 10.1111/j.1749-6632.1992.tb43784.x; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; Castle AM, 2002, J CELL SCI, V115, P2963; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dean WL, 1997, J BIOL CHEM, V272, P15113, DOI 10.1074/jbc.272.24.15113; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; Enyedi A, 1997, J BIOL CHEM, V272, P27525, DOI 10.1074/jbc.272.44.27525; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FODER B, 1992, CELL CALCIUM, V13, P581, DOI 10.1016/0143-4160(92)90038-T; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; Giovannucci DR, 2000, J BIOL CHEM, V275, P33704, DOI 10.1074/jbc.M004278200; Giovannucci DR, 2002, J PHYSIOL-LONDON, V540, P469, DOI 10.1113/jphysiol.2001.013453; GREEB J, 1989, J BIOL CHEM, V264, P18569; Gromadzinska E, 2001, BBA-PROTEIN STRUCT M, V1549, P19, DOI 10.1016/S0167-4838(01)00244-8; Herscher CJ, 1997, ANN NY ACAD SCI, V834, P407, DOI 10.1111/j.1749-6632.1997.tb52284.x; Herscher CJ, 1996, BIOCHEMISTRY-US, V35, P14917, DOI 10.1021/bi961879r; HERSCHER CJ, 1994, J BIOL CHEM, V269, P10400; HOFMANN F, 1993, J BIOL CHEM, V268, P10252; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; LARSSON O, 1989, ACTA PHYSIOL SCAND, V137, P231, DOI 10.1111/j.1748-1716.1989.tb08743.x; Lee MG, 1997, J BIOL CHEM, V272, P15771, DOI 10.1074/jbc.272.25.15771; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MASON MJ, 1991, J BIOL CHEM, V266, P20856; Matsushita M, 1999, J BIOL CHEM, V274, P10086, DOI 10.1074/jbc.274.15.10086; MCKINNEY JS, 1989, AM J PHYSIOL, V257, pC651, DOI 10.1152/ajpcell.1989.257.4.C651; Monteith GR, 1998, J PHARMACOL TOXICOL, V40, P183, DOI 10.1016/S1056-8719(99)00004-0; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NEYSES L, 1985, J BIOL CHEM, V260, P283; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Penniston JT, 1998, J MEMBRANE BIOL, V165, P101, DOI 10.1007/s002329900424; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; Rizzuto R, 1999, CELL CALCIUM, V26, P193, DOI 10.1054/ceca.1999.0076; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Segawa A, 1998, CELL TISSUE RES, V291, P325, DOI 10.1007/s004410051002; Straub SV, 2002, J BIOL CHEM, V277, P31949, DOI 10.1074/jbc.M204318200; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1983, J MOL CELL CARDIOL, V15, P565, DOI 10.1016/0022-2828(83)90267-5; TAKEMURA H, 1989, BIOCHEM J, V258, P409, DOI 10.1042/bj2580409; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; TAO JG, 1992, BIOCHIM BIOPHYS ACTA, V1107, P213, DOI 10.1016/0005-2736(92)90407-D; TEPIKIN AV, 1992, J BIOL CHEM, V267, P3569; TEPIKIN AV, 1992, J BIOL CHEM, V267, P14073; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; vandePut FHMM, 1997, J BIOL CHEM, V272, P27764, DOI 10.1074/jbc.272.44.27764; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG KKW, 1991, J BIOL CHEM, V266, P9078; WANG KKW, 1991, ARCH BIOCHEM BIOPHYS, V289, P103, DOI 10.1016/0003-9861(91)90448-R; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; WRIGHT LC, 1993, ARCH BIOCHEM BIOPHYS, V306, P277, DOI 10.1006/abbi.1993.1512; Yoshimura K, 1998, BBA-MOL CELL RES, V1402, P171, DOI 10.1016/S0167-4889(98)00007-X; Zylinska L, 1998, BBA-MOL CELL RES, V1448, P99, DOI 10.1016/S0167-4889(98)00128-1	70	38	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48172	48181		10.1074/jbc.M208393200	http://dx.doi.org/10.1074/jbc.M208393200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368283	hybrid			2022-12-25	WOS:000179789600028
J	Gao, ZG; Hwang, D; Bataille, F; Lefevre, M; York, D; Quon, M; Ye, JP				Gao, ZG; Hwang, D; Bataille, F; Lefevre, M; York, D; Quon, M; Ye, JP			Serine phosphorylation of insulin receptor substrate 1 by inhibitor kappa B kinase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; TNF-ALPHA; OKADAIC ACID; PHOSPHATIDYLINOSITOL 3-KINASE; SKELETAL-MUSCLE; IKK-BETA; RESISTANCE; PATHWAY; IRS-1	Insulin resistance contributes importantly to the pathophysiology of type 2 diabetes mellitus. One mechanism mediating insulin resistance may involve the phosphorylation of serine residues in insulin receptor substrate-1 (IRS-1), leading to impairment in the ability of IRS-1 to activate downstream phosphatidylinositol 3-kinase-dependent pathways. Insulin-resistant states and serine phosphorylation of IRS-1 are associated with the activation of the inhibitor kappaB kinase (IKK) complex. However, the precise molecular mechanisms by which IKK may contribute to the development of insulin resistance are not well understood. In this study, using phosphospecific antibodies against rat IRS-1 phosphorylated at Ser(307) (equivalent to Ser(312) in human IRS-1), we observed serine phosphorylation of IRS-1 in response to TNF-alpha or calyculin A treatment that paralleled surrogate markers for IKK activation. The phosphorylation of human IRS-1 at Ser(312) in response to tumor necrosis factor-alpha was significantly reduced in cells pretreated with the IKK inhibitor 15 deoxy-prostaglandin J(2) as well as in cells derived from IKK knock-out mice. We observed interactions between endogenous IRS-1 and IKK in intact cells using a co-immunoprecipitation approach. Moreover, this interaction between IRS-1 and IKK in the basal state was reduced upon IKK activation and increased serine phosphorylation of IRS-1. Data from in vitro kinase assays using recombinant IRS-1 as a substrate were consistent with the ability of IRS-1 to function as a direct substrate for IKK with multiple serine phosphorylation sites in addition to Ser(312). Taken together, our data suggest that IRS-1 is a novel direct substrate for IKK and that phosphorylation of IRS-1 at Ser(312) (and other sites) by IKK may contribute to the insulin resistance mediated by activation of inflammatory pathways.	Louisiana State Univ, Pennington Biomed Res Ctr, Gene Regulat Lab, Baton Rouge, LA 70808 USA; NIH, Diabet Unit, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA	Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine	Ye, JP (corresponding author), Louisiana State Univ, Pennington Biomed Res Ctr, Gene Regulat Lab, 6400 Perkins Rd, Baton Rouge, LA 70808 USA.		Quon, Michael/B-1970-2008; Lefevre, Michael/B-5030-2014; Ye, Jianping/N-1998-2017	Lefevre, Michael/0000-0002-2046-3593; Ye, Jianping/0000-0003-3875-365X; QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [ZIAAT000002, Z01AT000002] Funding Source: NIH RePORTER	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine)		Aguirre V, 2002, J BIOL CHEM, V277, P1531, DOI 10.1074/jbc.M101521200; Aguirre V, 2000, J BIOL CHEM, V275, P9047, DOI 10.1074/jbc.275.12.9047; ARAKI E, 1993, DIABETES, V42, P1041, DOI 10.2337/diabetes.42.7.1041; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Boden G, 1997, DIABETES, V46, P3, DOI 10.2337/diabetes.46.1.3; Cam MC, 2000, CAN J PHYSIOL PHARM, V78, P829, DOI 10.1139/cjpp-78-10-829; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; DeFea K, 1997, J BIOL CHEM, V272, P31400, DOI 10.1074/jbc.272.50.31400; DeFea K, 1997, BIOCHEMISTRY-US, V36, P12939, DOI 10.1021/bi971157f; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; EldarFinkelman H, 1997, P NATL ACAD SCI USA, V94, P9660, DOI 10.1073/pnas.94.18.9660; Engelman JA, 2000, MOL ENDOCRINOL, V14, P1557, DOI 10.1210/me.14.10.1557; Ghanim H, 2001, J CLIN ENDOCR METAB, V86, P1306, DOI 10.1210/jc.86.3.1306; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783; Hotamisligil GS, 1999, J INTERN MED, V245, P621, DOI 10.1046/j.1365-2796.1999.00490.x; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Itani SI, 2002, DIABETES, V51, P2005, DOI 10.2337/diabetes.51.7.2005; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; JULLIEN D, 1993, J BIOL CHEM, V268, P15246; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Li JP, 1999, J BIOL CHEM, V274, P9351, DOI 10.1074/jbc.274.14.9351; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu YF, 2001, J BIOL CHEM, V276, P14459, DOI 10.1074/jbc.M007281200; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Ogihara T, 1997, J BIOL CHEM, V272, P25267, DOI 10.1074/jbc.272.40.25267; Ouchi N, 2000, CIRCULATION, V102, P1296, DOI 10.1161/01.CIR.102.11.1296; Ozes ON, 2001, P NATL ACAD SCI USA, V98, P4640, DOI 10.1073/pnas.051042298; Paz K, 1999, J BIOL CHEM, V274, P28816, DOI 10.1074/jbc.274.40.28816; Peraldi P, 1998, MOL CELL BIOCHEM, V182, P169, DOI 10.1023/A:1006865715292; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Ravichandran LV, 2001, J BIOL CHEM, V276, P3543, DOI 10.1074/jbc.M007231200; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Rui LY, 2001, J CLIN INVEST, V107, P181, DOI 10.1172/JCI10934; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Su TT, 2002, NAT IMMUNOL, V3, P780, DOI 10.1038/ni823; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Sun XJ, 1999, DIABETES, V48, P1359, DOI 10.2337/diabetes.48.7.1359; Sun ZM, 2000, NATURE, V404, P402, DOI 10.1038/35006090; TANASIJEVIC MJ, 1993, J BIOL CHEM, V268, P18157; TANTI JF, 1991, J BIOL CHEM, V266, P2099; TANTI JF, 1994, J BIOL CHEM, V269, P6051; Tojima Y, 2000, NATURE, V404, P778, DOI 10.1038/35008109; White MF, 1998, CURR TOP MICROBIOL, V228, P179; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Ye JP, 1999, MOL CELL BIOCHEM, V198, P193, DOI 10.1023/A:1006969008056; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Ye JP, 2001, J BIOL CHEM, V276, P5360, DOI 10.1074/jbc.M008814200; Young VM, 1998, METABOLISM, V47, P566, DOI 10.1016/S0026-0495(98)90241-4; Yuan MS, 2001, SCIENCE, V293, P1673, DOI 10.1126/science.1061620	62	554	582	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48115	48121		10.1074/jbc.M209459200	http://dx.doi.org/10.1074/jbc.M209459200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351658	hybrid			2022-12-25	WOS:000179789600020
J	Guigal, N; Rodriguez, M; Cooper, RN; Dromaint, S; Di Santo, JP; Mouly, V; Boutin, JA; Galizzi, JP				Guigal, N; Rodriguez, M; Cooper, RN; Dromaint, S; Di Santo, JP; Mouly, V; Boutin, JA; Galizzi, JP			Uncoupling protein-3 (UCP3) mRNA expression in reconstituted human muscle after myoblast transplantation in RAG2(-/-)/(gamma)c/C5(-) immunodeficient mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; SKELETAL-MUSCLE; GENE-EXPRESSION; THYROID-HORMONE; ADIPOSE-TISSUE; UP-REGULATION; MYOTUBES; CLONING; OBESITY; REGION	Uncoupling protein-3 (UCP3), which is expressed abundantly in skeletal muscle, is one of the carrier proteins dissipating the transmitochondrial electrochemical gradient as heat and has therefore been implicated in the regulation of energy metabolism. Myoblasts or differentiated muscle cells in vitro expressed little if any UCP3, compared with the levels detected in biopsies of skeletal muscle. In the present report, we sought to investigate UCP3 mRNA expression in human muscle generated by myoblast transplantation in the skeletal muscle of an immunodeficient mouse model. Time course experiments demonstrated that 7-8 weeks following transplantation fully differentiated human muscle fibers were formed. The presence of differentiated human muscle fibers was assessed by quantitative PCR measurement of the human a-actin mRNA together with immunohistochemical staining using specific antibodies for spectrin and the slow adult myosin heavy chain. Interestingly, we found that the expression of UCP3 mRNA was dependant on human muscle differentiation and that the UCP3 mRNA level was comparable with that found in human muscle biopsies. Moreover, the human UCP3 (hUCP3) promoter seems to be fully functional, since triiodothyronine treatment of the mice not only stimulated the mouse UCP3 (mUCP3) mRNA expression but also strongly stimulated the hUCP3 mRNA expression in human fibers formed after myoblast transplantation. To our knowledge, this is the first time that primary myoblasts could be induced to express the UCP3 gene at a level comparable of that found in human muscle fibers.	Inst Rech Servier, Div Pharmacol Mol & Cellulaire, F-78290 Croissy Sur Seine, France; Univ Paris 06, CNRS, UMR 7000, F-75634 Paris 13, France; Inst Pasteur, Unite Cytokines & Dev Lymphoide, F-75724 Paris 15, France	Servier; Institut de Recherches Internationales Servier; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Boutin, JA (corresponding author), Inst Rech Servier, Div Pharmacol Mol & Cellulaire, 125 Chemin Ronde, F-78290 Croissy Sur Seine, France.		Di Santo, James P/M-4298-2014; Boutin, Jean Albert/W-9103-2019	Di Santo, James P/0000-0002-7146-1862; Boutin, Jean Albert/0000-0003-0068-7204; Mouly, Vincent/0000-0003-3809-4033				Acin A, 1999, BIOCHEM BIOPH RES CO, V258, P278, DOI 10.1006/bbrc.1999.0530; Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Bouillaud F, 1999, INT J OBESITY, V23, pS19, DOI 10.1038/sj.ijo.0800938; Brun S, 1999, FEBS LETT, V453, P205, DOI 10.1016/S0014-5793(99)00722-X; Brun S, 1999, DIABETES, V48, P1217, DOI 10.2337/diabetes.48.6.1217; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Clapham JC, 2000, NATURE, V406, P415, DOI 10.1038/35019082; Cooper RN, 2001, HUM GENE THER, V12, P823, DOI 10.1089/104303401750148784; Decary S, 1996, HUM GENE THER, V7, P1347, DOI 10.1089/hum.1996.7.11-1347; Edom-Vovard F, 1999, J CELL SCI, V112, P191; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Harper JA, 2002, BIOCHEM J, V361, P49, DOI 10.1042/0264-6021:3610049; Hwang CS, 1999, BIOCHEM BIOPH RES CO, V258, P464, DOI 10.1006/bbrc.1999.0662; Irintchev A, 1997, J PHYSIOL-LONDON, V500, P775, DOI 10.1113/jphysiol.1997.sp022057; KAUFMAN SJ, 1988, P NATL ACAD SCI USA, V85, P9606, DOI 10.1073/pnas.85.24.9606; Khalfallah Y, 2000, DIABETES, V49, P25, DOI 10.2337/diabetes.49.1.25; Matsuda J, 1997, FEBS LETT, V418, P200, DOI 10.1016/S0014-5793(97)01381-1; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; Millet L, 1997, J CLIN INVEST, V100, P2665, DOI 10.1172/JCI119811; Nagase I, 1999, FEBS LETT, V461, P319, DOI 10.1016/S0014-5793(99)01477-5; Otabe S, 2000, DIABETOLOGIA, V43, P245, DOI 10.1007/s001250050037; Otabe S, 1999, DIABETES, V48, P206; Solanes G, 1997, J BIOL CHEM, V272, P25433, DOI 10.1074/jbc.272.41.25433; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X	28	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47407	47411		10.1074/jbc.M208048200	http://dx.doi.org/10.1074/jbc.M208048200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351640	hybrid			2022-12-25	WOS:000179663700075
J	Jarad, G; Wang, BC; Khan, S; DeVore, J; Miao, H; Wu, K; Nishimura, SL; Wible, BA; Konieczkowski, M; Sedor, JR; Schelling, JR				Jarad, G; Wang, BC; Khan, S; DeVore, J; Miao, H; Wu, K; Nishimura, SL; Wible, BA; Konieczkowski, M; Sedor, JR; Schelling, JR			Fas activation induces renal tubular epithelial cell beta(8) integrin expression and function in the absence of apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-2 MESSENGER-RNA; CONFER IMMUNE PRIVILEGE; DOWN-REGULATION; LIGAND; CD95; ALPHA-V-BETA-8; VITRONECTIN; MECHANISM; ADHESION; FIBROSIS	Cell fate following Fas (CD95) ligand or agonistic anti-Fas antibody stimulation is determined by multiple factors, including Fas expression level, microdomain localization, and modulating cytokines. Highly expressed Fas clusters and activates a canonical apoptosis signaling pathway. In less susceptible cells, Fas transduces apoptosis-independent signals, which are not well defined, but have been linked to inflammation, angiogenesis, and fibrosis. To identify apoptosis-independent Fas pathways, cultured renal tubular epithelial cells were stimulated with agonistic anti-Fas antibodies under conditions that did not cause cell death. Analysis of filter cDNA microarrays revealed beta(8) integrin subunit mRNA induction in Fas-stimulated cells. beta(8) integrin mRNA expression increased within 3-6 h of Fas ligation due to enhanced mRNA stabilization, and mRNA increases were sustained for 48-72 h. Expression of plasma membrane beta(8) integrin, as well as its heterodimer partner alpha(v), was increased by Fas activation with a similar kinetic pattern. Fas-induced alpha(v)beta(8), expression correlated with increased migration to vitronectin, the ligand for alpha(v)beta(8). Results from studies with function-blocking antibodies against other alpha(v)beta integrins or suppression of beta(8) integrin expression by RNA interference demonstrated that induced beta(8) integrin expression mediated Fas-stimulated migration. We conclude that alpha(v)beta(8) integrin induction defines an unexpected role for Fas in cell migration, rather than as a cell death receptor.	Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Educ & Res, Dept Med, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44109 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44109 USA; Univ Calif San Francisco, Sch Med, Dept Pathol, Div Pulm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Lung Biol, San Francisco, CA 94143 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Schelling, JR (corresponding author), Case Western Reserve Univ, Sch Med, Rammelkamp Ctr Educ & Res, Dept Med, MetroHlth Med Ctr Campus,2500 Metrohlth Dr,G531, Cleveland, OH 44109 USA.				NATIONAL CANCER INSTITUTE [R01CA096533] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178, R01DK038558, R21DK057933] Funding Source: NIH RePORTER; NCI NIH HHS [CA96533] Funding Source: Medline; NIDDK NIH HHS [DK38558, DK54178, DK57933] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allison J, 1997, P NATL ACAD SCI USA, V94, P3943, DOI 10.1073/pnas.94.8.3943; Aznavoorian S, 1996, J BIOL CHEM, V271, P3247, DOI 10.1074/jbc.271.6.3247; Biancone L, 1997, J EXP MED, V186, P147, DOI 10.1084/jem.186.1.147; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; Boonstra JG, 1997, J AM SOC NEPHROL, V8, P1517; Cambier S, 2000, CANCER RES, V60, P7084; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; Chen CY, 2000, GENE DEV, V14, P1236; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chervonsky AV, 1997, CELL, V89, P17, DOI 10.1016/S0092-8674(00)80178-6; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Grassme H, 2001, J BIOL CHEM, V276, P20589, DOI 10.1074/jbc.M101207200; Hohlbaum AM, 2002, CLIN IMMUNOL, V103, P1, DOI 10.1006/clim.2001.5165; Huang DCS, 1999, P NATL ACAD SCI USA, V96, P14871, DOI 10.1073/pnas.96.26.14871; Kang SM, 1997, NAT MED, V3, P738, DOI 10.1038/nm0797-738; KATAGIRI Y, 1995, J BIOL CHEM, V270, P1785, DOI 10.1074/jbc.270.4.1785; Khan S, 2001, KIDNEY INT, V60, P65, DOI 10.1046/j.1523-1755.2001.00771.x; Khan S, 1999, LAB INVEST, V79, P1089; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Milner R, 1997, DEV BIOL, V185, P215, DOI 10.1006/dbio.1997.8547; Milner R, 1999, J CELL SCI, V112, P4271; MOYLE M, 1991, J BIOL CHEM, V266, P19650; Mu DZ, 2002, J CELL BIOL, V157, P493, DOI 10.1083/jcb.200109100; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; NISHIMURA SL, 1994, J BIOL CHEM, V269, P28708; OGASAWARA J, 1995, J EXP MED, V181, P485, DOI 10.1084/jem.181.2.485; OGASAWARA J, 1993, NATURE, V364, P806, DOI 10.1038/364806a0; OrtizArduan A, 1996, AM J PHYSIOL-RENAL, V271, pF1193; Parlato S, 2000, EMBO J, V19, P5123, DOI 10.1093/emboj/19.19.5123; Peruzzi L, 1996, KIDNEY INT, V50, P1310, DOI 10.1038/ki.1996.443; PYTELA R, 1987, METHOD ENZYMOL, V144, P475; Racusen LC, 1997, J LAB CLIN MED, V129, P318, DOI 10.1016/S0022-2143(97)90180-3; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; Retta SF, 2001, MOL BIOL CELL, V12, P3126, DOI 10.1091/mbc.12.10.3126; RoyChaudhury P, 1997, KIDNEY INT, V52, P103, DOI 10.1038/ki.1997.309; Salvesen GS, 1999, P NATL ACAD SCI USA, V96, P10964, DOI 10.1073/pnas.96.20.10964; Schelling JR, 1999, KIDNEY INT, V56, P1313, DOI 10.1046/j.1523-1755.1999.00684.x; SCHELLING JR, 1994, KIDNEY INT, V46, P675, DOI 10.1038/ki.1994.320; Schelling JR, 1998, LAB INVEST, V78, P813; Schelling JR, 1996, AM J PHYSIOL-RENAL, V270, pF682, DOI 10.1152/ajprenal.1996.270.4.F682; Schneider P, 1998, J EXP MED, V187, P1205, DOI 10.1084/jem.187.8.1205; Seiffert D, 1997, HISTOL HISTOPATHOL, V12, P787; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; VENSTROM K, 1995, MOL BIOL CELL, V6, P419, DOI 10.1091/mbc.6.4.419; YAMAMOTO T, 1994, KIDNEY INT, V45, P916, DOI 10.1038/ki.1994.122; Yang JW, 2001, AM J PATHOL, V159, P1465, DOI 10.1016/S0002-9440(10)62533-3; Yang XL, 1998, MOL CELL, V1, P319, DOI 10.1016/S1097-2765(00)80032-5; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zeisberg M, 2001, AM J PATHOL, V159, P1313, DOI 10.1016/S0002-9440(10)62518-7	55	35	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47826	47833		10.1074/jbc.M204901200	http://dx.doi.org/10.1074/jbc.M204901200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324452	hybrid			2022-12-25	WOS:000179663700128
J	Jin, YJ; Blue, EK; Dixon, S; Shao, ZL; Gallagher, PJ				Jin, YJ; Blue, EK; Dixon, S; Shao, ZL; Gallagher, PJ			A death-associated protein kinase (DAPK)-interacting protein, DIP-1, is an E3 ubiquitin ligase that promotes tumor necrosis factor-induced apoptosis and regulates the cellular levels of DAPK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME PATHWAY; IDENTIFICATION; DOMAINS; DEGRADATION; SMART; RING; MEDIATORS; INHIBITOR; CASPASE-3; FAMILY	Death-associated protein kinase (DAPK) is a multidomain Ser/Thr protein kinase with an important role in apoptosis regulation. In these studies we have identified a DAPK-interacting protein called DIP-1, which is a novel multi-RING finger protein. The RING finger motifs of DIP-1 have E3 ligase activity that can auto-ubiquitinate DIP-1 in vitro. In vivo, DIP-1 is detected as a polyubiquitinated protein, suggesting that the intracellular levels of DIP-1 are regulated by the ubiquitin-proteasome system. Transient expression of DIP-1 in HeLa cells antagonizes the anti-apoptotic function of DAPK to promote a caspase-dependent apoptosis. These studies also demonstrate that DAPK is an in vitro and in vivo target for ubiquitination by DIP-1, thereby providing a mechanism by which DAPK activities can be regulated through proteasomal degradation.	Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis	Gallagher, PJ (corresponding author), Indiana Univ, Sch Med, Dept Cellular & Integrat Physiol, 635 Barnhill Dr, Indianapolis, IN 46202 USA.	pgallag@iupui.edu		Blue, Emily/0000-0001-8290-4473	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054118] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL054118, R01 HL054118-04, R01HL54118] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Borden KLB, 2000, J MOL BIOL, V295, P1103, DOI 10.1006/jmbi.1999.3429; Ciechanover A, 2002, HEPATOLOGY, V35, P3, DOI 10.1053/jhep.2002.30316; Ciechanover A, 2000, BIOESSAYS, V22, P442, DOI 10.1002/(SICI)1521-1878(200005)22:5<442::AID-BIES6>3.0.CO;2-Q; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Ciechanover A, 2000, J CELL BIOCHEM, P40; Cohen O, 2001, CELL DEATH DIFFER, V8, P6, DOI 10.1038/sj.cdd.4400794; Cohen O, 1997, EMBO J, V16, P998, DOI 10.1093/emboj/16.5.998; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; ESSER C, 1995, CYTOMETRY, V21, P382, DOI 10.1002/cyto.990210411; Freemont PS, 2000, CURR BIOL, V10, pR84, DOI 10.1016/S0960-9822(00)00287-6; Gallagher PJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1078, DOI 10.1152/ajpcell.2000.279.4.C1078; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Huang HK, 2000, J BIOL CHEM, V275, P26661; Inbal B, 2002, J CELL BIOL, V157, P455, DOI 10.1083/jcb.200109094; ISAKSSON A, 1996, BIOCHIM BIOPHYS ACTA, V1288, P21; Jesenberger V, 2002, NAT REV MOL CELL BIO, V3, P112, DOI 10.1038/nrm731; Jin YJ, 2001, J BIOL CHEM, V276, P39667, DOI 10.1074/jbc.M101886200; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kogel D, 2001, BIOESSAYS, V23, P352, DOI 10.1002/bies.1050; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Levy-Strumpf N, 1998, ONCOGENE, V17, P3331, DOI 10.1038/sj.onc.1202588; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Naujokat C, 2002, LAB INVEST, V82, P965, DOI 10.1097/01.LAB.0000022226.23741.37; Palaga T, 2002, NAT CELL BIOL, V4, pE149, DOI 10.1038/ncb0602-e149; Ponting CP, 1999, NUCLEIC ACIDS RES, V27, P229, DOI 10.1093/nar/27.1.229; Saurin AJ, 1996, TRENDS BIOCHEM SCI, V21, P208, DOI 10.1016/S0968-0004(96)80017-X; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Schwartz AL, 1999, ANNU REV MED, V50, P57; Shohat G, 2001, J BIOL CHEM, V276, P47460, DOI 10.1074/jbc.M105133200; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Wojcik C, 2002, J CELL MOL MED, V6, P25, DOI 10.1111/j.1582-4934.2002.tb00309.x; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yang YL, 2000, CELL RES, V10, P169, DOI 10.1038/sj.cr.7290046	36	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46980	46986		10.1074/jbc.M208585200	http://dx.doi.org/10.1074/jbc.M208585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351649	hybrid, Green Accepted			2022-12-25	WOS:000179663700020
J	Rakhit, R; Cunningham, P; Furtos-Matei, A; Dahan, S; Qi, XF; Crow, JP; Cashman, NR; Kondejewski, LH; Chakrabartty, A				Rakhit, R; Cunningham, P; Furtos-Matei, A; Dahan, S; Qi, XF; Crow, JP; Cashman, NR; Kondejewski, LH; Chakrabartty, A			Oxidation-induced misfolding and agagaregation of superoxide dismutase and its implications for amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTIC HYALINE INCLUSIONS; ALS-LINKED SOD1; COPPER CHAPERONE; CU,ZN-SUPEROXIDE DISMUTASE; MOTOR-NEURONS; GENE MUTATION; MUTANT; DISEASE; AGGREGATION; PROTEIN	The presence of intracellular aggregates that contain Cu/Zn superoxide dismutase (SOD1) in spinal cord motor neurons is a pathological hallmark of amyotrophic lateral sclerosis (ALS). Although SOD1 is abundant in all cells, its half-life in motor neurons far exceeds that in any other cell type. On the basis of the premise that the long half-life of the protein increases the potential for oxidative damage, we investigated the effects of oxidation on misfolding/aggregation of SOD1 and ALS-associated SOD1 mutants. Zinc-deficient wild-type SOD1 and SOD1 mutants were extremely prone to form visible aggregates upon oxidation as compared with wild-type holo-protein. Oxidation of select histidine residues that bind metals in the active site mediates SOD1 aggregation. Our results provide a plausible model to explain the accumulation of SOD1 aggregates in motor neurons affected in ALS.	Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Ontario Canc Inst, Dept Biochem, Toronto, ON M5G 2M9, Canada; Caprion Pharmaceut Inc, St Laurent, PQ H4S 2C8, Canada; Univ Alabama Birmingham, Dept Anesthesiol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Pharmacol Toxicol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Toronto, Ctr Res Neurodegenerat Dis, Toronto, ON M5S 3H2, Canada; Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M5S 3H2, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Chakrabartty, A (corresponding author), Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2M9, Canada.	chakrab@uhnres.utoronto.ca		Chakrabartty, Avi/0000-0001-7002-8381				BANCI L, 1991, EUR J BIOCHEM, V196, P123, DOI 10.1111/j.1432-1033.1991.tb15794.x; Borchelt DR, 1998, NEUROBIOL DIS, V5, P27, DOI 10.1006/nbdi.1998.0178; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BOWLING AC, 1993, J NEUROCHEM, V61, P2322, DOI 10.1111/j.1471-4159.1993.tb07478.x; Bruening W, 1999, J NEUROCHEM, V72, P693, DOI 10.1046/j.1471-4159.1999.0720693.x; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Cleveland DW, 2001, NAT REV NEUROSCI, V2, P806, DOI 10.1038/35097565; Crow JP, 1997, J NEUROCHEM, V69, P1936; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; Estevez AG, 1999, SCIENCE, V286, P2498, DOI 10.1126/science.286.5449.2498; Ferrante RJ, 1997, J NEUROCHEM, V69, P2064; Hart PJ, 1998, PROTEIN SCI, V7, P545; HUDSON AJ, 1981, BRAIN, V104, P217, DOI 10.1093/brain/104.2.217; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kato S, 1999, ACTA NEUROPATHOL, V97, P260, DOI 10.1007/s004010050983; Kato S, 1996, J NEUROPATH EXP NEUR, V55, P1089, DOI 10.1097/00005072-199655100-00009; Kato S, 2001, NEUROPATHOLOGY, V21, P67, DOI 10.1046/j.1440-1789.2001.00359.x; Kato S, 1997, AM J PATHOL, V151, P611; Khossravi M, 2000, BIOCHEMISTRY-US, V39, P5876, DOI 10.1021/bi9924720; KIRSCHNER DA, 1987, P NATL ACAD SCI USA, V84, P6953, DOI 10.1073/pnas.84.19.6953; KLAPPER I, 1986, Proteins Structure Function and Genetics, V1, P47, DOI 10.1002/prot.340010109; Klunk WE, 1999, METHOD ENZYMOL, V309, P285; Koide T, 1998, NEUROSCI LETT, V257, P29, DOI 10.1016/S0304-3940(98)00800-3; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; LI SH, 1995, BIOCHEMISTRY-US, V34, P5762, DOI 10.1021/bi00017a008; Liochev SI, 2002, J BIOL CHEM, V277, P34674, DOI 10.1074/jbc.M204726200; Liochev SI, 2002, ARCH BIOCHEM BIOPHYS, V402, P166, DOI 10.1016/S0003-9861(02)00074-7; Lyons TJ, 1996, P NATL ACAD SCI USA, V93, P12240, DOI 10.1073/pnas.93.22.12240; Okado-Matsumoto A, 2002, P NATL ACAD SCI USA, V99, P9010, DOI 10.1073/pnas.132260399; OKAMOTO K, 1991, NEUROSCI LETT, V129, P233, DOI 10.1016/0304-3940(91)90469-A; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Requena JR, 2001, P NATL ACAD SCI USA, V98, P7170, DOI 10.1073/pnas.121190898; Rice ME, 2000, TRENDS NEUROSCI, V23, P209, DOI 10.1016/S0166-2236(99)01543-X; Rodriguez JA, 2002, J BIOL CHEM, V277, P15932, DOI 10.1074/jbc.M112088200; SMITT PAES, 1993, CLIN NEUROPATHOL, V12, P88; STADTMAN ER, 1993, ANNU REV BIOCHEM, V62, P797, DOI 10.1146/annurev.bi.62.070193.004053; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; Subramaniam JR, 2002, NAT NEUROSCI, V5, P301, DOI 10.1038/nn823; WiedauPazos M, 1996, SCIENCE, V271, P515, DOI 10.1126/science.271.5248.515; Wong PC, 2000, P NATL ACAD SCI USA, V97, P2886, DOI 10.1073/pnas.040461197; Yim MB, 1996, P NATL ACAD SCI USA, V93, P5709, DOI 10.1073/pnas.93.12.5709	43	262	279	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47551	47556		10.1074/jbc.M207356200	http://dx.doi.org/10.1074/jbc.M207356200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356748	hybrid			2022-12-25	WOS:000179663700093
J	Chen, ZY; Shie, JL; Tseng, CC				Chen, ZY; Shie, JL; Tseng, CC			Gut-enriched Kruppel-like factor represses ornithine decarboxylase gene expression and functions as checkpoint regulator in colonic cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR WT1; ZINC-FINGER PROTEIN; CHROMATIN IMMUNOPRECIPITATION; TRANSCRIPTIONAL TARGET; PROMOTER ACTIVITY; CARCINOMA CELLS; C-MYC; GROWTH; INDUCTION; TRANSFORMATION	Gut-enriched Kruppel-like factor (GKLF, KLF4) is an epithelial-specific transcription factor that expresses in the gastrointestinal tract and mediates growth arrest of colonic epithelium. The molecular mechanisms governing its growth inhibitory effect have not been fully elucidated. In the present study, we showed that induction of GKLF mRNA and protein expression by interferon-gamma treatment was associated with reduction of ornithine decarboxylase (ODC) gene expression and enzyme activity in colon cancer HT-29 cells. Overexpression of GKLF in HT-29 cells significantly reduced ODC mRNA and protein levels as well as enzyme activity and resulted in growth arrest, indicating that ODC might be a downstream target of GYCLF. This conclusion was further supported by data showing that GKLF mRNA and protein concentrations were the highest at the G(1)/S boundary of the cell cycle, where ODC mRNA and protein levels were the lowest and that overexpression of GKLF resulted in cell arrested at the G, phase. Reporter gene transfection studies and electrophoretic mobility gel shift assays demonstrated that GYCLF repressed ODC promoter activity and that these effects appeared to be mediated through interaction with a GC box in the proximal portion of the promoter. Transfection studies using reporter constructs and chromatin immunoprecipitation assays also demonstrated that GKLF inhibited transactivation of the ODC gene by interfering with the binding of Sp1 to the ODC promoter. These results indicate that GKLF may function as a G(1)/S checkpoint regulator and exert its growth arrest effect through down-regulation of ODC gene expression. Furthermore, GKLF is a transcriptional repressor of the ODC gene, and these effects are mediated by interaction with the GC-rich region on the promoter.	Vet Affairs Boston Healthcare Syst, Gastroenterol Sect, Boston, MA 02118 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Tseng, CC (corresponding author), Boston Univ, Sch Med, Gastroenterol Sect, EBRC X-513,650 Albany St, Boston, MA 02118 USA.				NCI NIH HHS [CA-82593] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082593] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAMSEN MS, 1992, J BIOL CHEM, V267, P18866; ABRAHAMSEN MS, 1992, J BIOL CHEM, V10, P5525; AUVINEN M, 1992, NATURE, V360, P355, DOI 10.1038/360355a0; BELLOFERNANDEZ C, 1993, P NATL ACAD SCI USA, V90, P7804, DOI 10.1073/pnas.90.16.7804; BOWLIN TL, 1986, CELL IMMUNOL, V98, P341, DOI 10.1016/0008-8749(86)90294-7; Chen ZY, 2000, FEBS LETT, V477, P67, DOI 10.1016/S0014-5793(00)01764-6; Eberhardy SR, 2000, J BIOL CHEM, V275, P33798, DOI 10.1074/jbc.M005154200; GarrettSinha LA, 1996, J BIOL CHEM, V271, P31384, DOI 10.1074/jbc.271.49.31384; HIETALA OA, 1990, CANCER RES, V50, P2088; HOLTTA E, 1988, J BIOL CHEM, V263, P4500; JAGGI R, 1998, J STEROID BIOCHEM, V29, P457; Jenkins TD, 1998, J BIOL CHEM, V273, P10747, DOI 10.1074/jbc.273.17.10747; KOZA RA, 1992, BIOCHEM J, V281, P87, DOI 10.1042/bj2810087; KUMAR AP, 1995, J BIOL CHEM, V270, P4341, DOI 10.1074/jbc.270.39.22980; Law GL, 1998, J BIOL CHEM, V273, P19955, DOI 10.1074/jbc.273.32.19955; Li RS, 1999, EXP CELL RES, V247, P257, DOI 10.1006/excr.1998.4361; LI RS, 1994, J BIOL CHEM, V269, P7941; LUC GD, 1984, NEW ENGL J MED, V311, P80; Merchant JL, 1996, MOL CELL BIOL, V16, P6644; Moshier JA, 1996, NUCLEIC ACIDS RES, V24, P1149, DOI 10.1093/nar/24.6.1149; MOSHIER JA, 1993, CANCER RES, V53, P2618; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PARK J, 1995, MOL CELL BIOL, V15, P2374; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PENA A, 1993, J BIOL CHEM, V268, P27277; PORTER CW, 1987, CANCER, V60, P1275, DOI 10.1002/1097-0142(19870915)60:6<1275::AID-CNCR2820600619>3.0.CO;2-I; Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806; Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969; Shields JM, 1996, J BIOL CHEM, V271, P20009, DOI 10.1074/jbc.271.33.20009; TAKANO S, 1981, CANCER RES, V41, P624; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WRIGHTON C, 1993, MOL CELL BIOL, V13, P4657, DOI 10.1128/MCB.13.8.4657	32	61	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46831	46839		10.1074/jbc.M204816200	http://dx.doi.org/10.1074/jbc.M204816200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297499	hybrid			2022-12-25	WOS:000179529300144
J	Giese, KC; Vierling, E				Giese, KC; Vierling, E			Changes in oligomerization are essential for the chaperone activity of a small heat shock protein in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ALPHA-CRYSTALLIN; CYANOBACTERIUM SYNECHOCOCCUS; MOLECULAR CHAPERONE; DENATURED PROTEINS; PHOTOSYSTEM-II; THERMOTOLERANCE; EXPRESSION; STRESS; CLPB	The ability of small heat shock proteins (sHSPs) to prevent thermal aggregation of other proteins may require disassembly and reassembly of sHSP oligomers. We investigated the role of changes in sHSP oligomerization by studying a mutant with reduced oligomeric stability. In HSP16.6, the single sHSP in the cyanobacterium. Synechocystis sp. PCC 6803, the mutation L66A causes oligomer instability and reduced chaperone activity in vitro. Because thermotolerance of Synechocystis depends on HSP16.6, a phenotype that is enhanced in a DeltaClpB1 strain, the effect of mutations can also be assayed in vivo. L66A causes severe defects in thermotolerance, suggesting that oligomeric stability of sHSPs is required for cellular function. This hypothesis was supported by a selection for intragenic suppressors of L66A, which identified mutations that stabilize oligomers of both L66A and wild-type HSP16.6. Analysis of both over- and under-oligoinerizing mutants suggests that sHSPs must disassemble before they can release substrates. Furthermore, the suppressor mutations not only restore in vivo activity to L66A, they also ameliorate chaperone defects in vitro, and thus provide the first direct evidence for a chaperone function of an sHSP in cellular thermotolerance.	Univ Arizona, Dept Biochem & Mol Biophys, Tucson, AZ 85721 USA	University of Arizona	Vierling, E (corresponding author), Univ Arizona, Dept Biochem & Mol Biophys, 1007 E Lowell St, Tucson, AZ 85721 USA.	vierling@email.arizona.edu		Vierling, Elizabeth/0000-0002-0066-4881	NIGMS NIH HHS [R01 GM42762, F32 GM18966] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM018966, R01GM042762] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLOS J, 1994, PROTEIN EXPRES PURIF, V5, P133, DOI 10.1006/prep.1994.1020; de Jong WW, 1998, INT J BIOL MACROMOL, V22, P151, DOI 10.1016/S0141-8130(98)00013-0; Ehrnsperger M, 1997, EMBO J, V16, P221, DOI 10.1093/emboj/16.2.221; ELHAI J, 1988, GENE, V68, P119, DOI 10.1016/0378-1119(88)90605-1; Eriksson MJ, 1996, J BACTERIOL, V178, P4839, DOI 10.1128/jb.178.16.4839-4846.1996; Eriksson MJ, 2001, J BACTERIOL, V183, P7392, DOI 10.1128/JB.183.24.7392-7396.2001; Feil IK, 2001, J BIOL CHEM, V276, P12024, DOI 10.1074/jbc.M010856200; GHOSH S, 1988, ANAL BIOCHEM, V169, P227, DOI 10.1016/0003-2697(88)90278-3; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haslbeck M, 1999, EMBO J, V18, P6744, DOI 10.1093/emboj/18.23.6744; HORWITZ J, 1992, P NATL ACAD SCI USA, V89, P10449, DOI 10.1073/pnas.89.21.10449; Kaneko T, 1996, DNA Res, V3, P109; Kim KK, 1998, NATURE, V394, P595, DOI 10.1038/29106; Kuczynska-Wisnik D, 2002, MICROBIOL-SGM, V148, P1757, DOI 10.1099/00221287-148-6-1757; LAVOIE JN, 1993, J BIOL CHEM, V268, P3420; Lee GJ, 2000, PLANT PHYSIOL, V122, P189, DOI 10.1104/pp.122.1.189; Lee GJ, 1998, METHOD ENZYMOL, V290, P350, DOI 10.1016/S0076-6879(98)90031-3; Lee GJ, 1997, EMBO J, V16, P659, DOI 10.1093/emboj/16.3.659; Lee S, 2000, CURR MICROBIOL, V40, P283, DOI 10.1007/s002849910056; Leung DW, 1989, TECHNIQUE, V1, P11; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PARSELL DA, 1994, NATURE, V372, P475, DOI 10.1038/372475a0; PETKO L, 1986, CELL, V45, P885, DOI 10.1016/0092-8674(86)90563-5; PLESOFSKYVIG N, 1995, P NATL ACAD SCI USA, V92, P5032, DOI 10.1073/pnas.92.11.5032; RADZICKA A, 1988, BIOCHEMISTRY-US, V27, P1664, DOI 10.1021/bi00405a042; RIPPKA R, 1979, J GEN MICROBIOL, V111, P1, DOI 10.1099/00221287-111-1-1; Soto A, 1999, PLANT PHYSIOL, V120, P521, DOI 10.1104/pp.120.2.521; Thomas JG, 1998, J BACTERIOL, V180, P5165, DOI 10.1128/JB.180.19.5165-5172.1998; Torok Z, 2001, P NATL ACAD SCI USA, V98, P3098, DOI 10.1073/pnas.051619498; van Boekel MAM, 1999, BBA-PROTEIN STRUCT M, V1434, P114, DOI 10.1016/S0167-4838(99)00178-8; Van Montfort R, 2002, ADV PROTEIN CHEM, V59, P105; van Montfort RLM, 2001, NAT STRUCT BIOL, V8, P1025, DOI 10.1038/nsb722; Veinger L, 1998, J BIOL CHEM, V273, P11032, DOI 10.1074/jbc.273.18.11032; Vermaas WFJ, 1998, METHOD ENZYMOL, V297, P293; WILLIAMS JGK, 1988, METHOD ENZYMOL, V167, P766; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	38	125	126	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46310	46318		10.1074/jbc.M208926200	http://dx.doi.org/10.1074/jbc.M208926200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297515	Green Published, hybrid			2022-12-25	WOS:000179529300081
J	Hara, M; Ma, TH; Verkman, AS				Hara, M; Ma, TH; Verkman, AS			Selectively reduced glycerol in skin of aquaporin-3-deficient mice may account for impaired skin hydration, elasticity, and barrier recovery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PATHOLOGIC STRATUM-CORNEUM; UVB-INDUCED ALTERATIONS; IN-VIVO; MECHANICAL-PROPERTIES; WATER-CONTENT; BOUND-WATER; PERMEABILITY; EPIDERMIS; INVIVO; TUMORS	Deletion of the epidermal water/glycerol transporter aquaporin-3 (AQP3) in mice reduced superficial skin conductance by similar to2-fold (Ma, T., Hara, M., Sougrat, R., Verbavatz, J. M., and Verkman, A. S. (2002) J. Biol. Chem. 277, 17147-17153), suggesting defective stratum corneum. (SC) hydration. Here, we demonstrate significant impairment of skin hydration, elasticity, barrier recovery, and wound healing in AQP3 null mice in a hairless (SKH1) genetic background and investigate the cause of the functional defects by analysis of SC morphology and composition. Utilizing a novel (H2O)-H-3 distribution method, SC water content was reduced by similar to50% in AQP3 null mice. Skin elasticity measured by cutometry was significantly reduced in AQP3 null mice with similar to50% reductions in elasticity parameters Uf, Ue, and Ur. Although basal skin barrier function was not impaired, AQP3 deletion produced an similar to2-fold delay in recovery of barrier function as measured by transepidermal water loss after tape stripping. Another biosynthetic skin function, wound healing, was also similar to2-fold delayed by AQP3 deletion. By electron microscopy AQP3 deletion did not affect the structure of the unperturbed SC. The SC content of ions (Na+, K+, Ca2+, Mg2+) and small solutes (urea, lactic acid, glucose) was not affected by AQP3 deletion nor was the absolute amount or profile of lipids and free amino acids. However, AQP3 deletion produced significant reductions in glycerol content in SC and epidermis (in nmol/mug protein: 5.5 +/- 0.4 versus 2.3 +/- 0.7 in SC; 0.037 +/- 0.007 versus 0.022 +/- 0.005 in epidermis) but not in dermis or blood. These results establish hydration, mechanical, and biosynthetic defects in skin of AQP3-deficient mice. The selective reduction in epidermal and SC glycerol content in AQP3 null mice may account for these defects, providing the first functional evidence for physiologically important glycerol transport by an aquaporin.	Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Inst Cardiovasc Res, Dept Physiol, San Francisco, CA 94143 USA; Kanebo Ltd, Basic Res Lab, Odawara, Kanagawa, Japan	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Inst Cardiovasc Res, Dept Med, 1246 Hlth Sci Tower,Box 0521, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu		Ma, Tonghui/0000-0001-9338-1030	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, R01DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL60288] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK35124] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ablett S, 1996, MAGN RESON IMAGING, V14, P357, DOI 10.1016/0730-725X(95)02105-3; AGACHE PG, 1980, ARCH DERMATOL RES, V269, P221, DOI 10.1007/BF00406415; BLANK IH, 1965, J INVEST DERMATOL, V45, P249, DOI 10.1038/jid.1965.125; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Caspers PJ, 2001, J INVEST DERMATOL, V116, P434, DOI 10.1046/j.1523-1747.2001.01258.x; DENDA M, 1992, ARCH DERMATOL RES, V284, P363, DOI 10.1007/BF00372041; Dobrev H, 2000, SKIN RES TECHNOL, V6, P239, DOI 10.1034/j.1600-0846.2000.006004239.x; Elias PM, 2001, SKIN PHARMACOL APPL, V14, P28, DOI 10.1159/000056387; FRIGERI A, 1995, J CELL SCI, V108, P2993; Fujimura T, 2000, J DERMATOL SCI, V24, P105, DOI 10.1016/S0923-1811(00)00090-6; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; HARA M, 1993, ACTA DERM-VENEREOL, V73, P283; Haratake A, 1997, J INVEST DERMATOL, V108, P319, DOI 10.1111/1523-1747.ep12286474; HASHIMOTOKUMASAKA K, 1993, ACTA DERM-VENEREOL, V73, P335; Holleran WM, 1997, PHOTODERMATOL PHOTO, V13, P117, DOI 10.1111/j.1600-0781.1997.tb00214.x; HORII I, 1989, BRIT J DERMATOL, V121, P587, DOI 10.1111/j.1365-2133.1989.tb08190.x; IMOKAWA G, 1991, J INVEST DERMATOL, V96, P845, DOI 10.1111/1523-1747.ep12474562; JACOBSON TM, 1990, J INVEST DERMATOL, V95, P296, DOI 10.1111/1523-1747.ep12484970; Ma TH, 2002, J BIOL CHEM, V277, P17147, DOI 10.1074/jbc.M200925200; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Marchell NL, 1998, J INVEST DERMATOL, V110, P383, DOI 10.1046/j.1523-1747.1998.00145.x; Nishimori Y, 2001, J INVEST DERMATOL, V117, P1458; POTTS RO, 1985, ARCH DERMATOL RES, V277, P489, DOI 10.1007/BF00510068; PROKSCH E, 1993, BRIT J DERMATOL, V128, P473, DOI 10.1111/j.1365-2133.1993.tb00222.x; Sakai S, 2000, SKIN RES TECHNOL, V6, P128, DOI 10.1034/j.1600-0846.2000.006003128.x; SCHEUPLEIN RJ, 1971, PHYSIOL REV, V51, P702, DOI 10.1152/physrev.1971.51.4.702; Sougrat R, 2002, J INVEST DERMATOL, V118, P678, DOI 10.1046/j.1523-1747.2002.01710.x; TAGAMI H, 1994, ACTA DERM-VENEREOL, P29; TAGAMI H, 1985, ARCH DERMATOL, V121, P642, DOI 10.1001/archderm.121.5.642; Tagami H, 2001, J INVEST DERM SYMP P, V6, P87, DOI 10.1046/j.0022-202x.2001.00016.x; TAKEMA Y, 1994, BRIT J DERMATOL, V131, P641, DOI 10.1111/j.1365-2133.1994.tb04975.x; TAKENOUCHI M, 1986, J INVEST DERMATOL, V87, P574, DOI 10.1111/1523-1747.ep12455817; Taljebini M, 1996, SKIN PHARMACOL, V9, P111; THUNE P, 1989, ACTA DERM-VENEREOL, P133; TRIEBSKORN A, 1983, DERMATOLOGICA, V167, P64, DOI 10.1159/000249750; Tsukahara K, 2001, BRIT J DERMATOL, V144, P452, DOI 10.1046/j.1365-2133.2001.04067.x; WATANABE M, 1991, ARCH DERMATOL, V127, P1689, DOI 10.1001/archderm.127.11.1689	37	177	195	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46616	46621		10.1074/jbc.M209003200	http://dx.doi.org/10.1074/jbc.M209003200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270942	hybrid			2022-12-25	WOS:000179529300118
J	Ego, T; Ariumi, Y; Shimotohno, K				Ego, T; Ariumi, Y; Shimotohno, K			The interaction of HTLV-1 Tax with HDAC1 negatively regulates the viral gene expression	ONCOGENE			English	Article						HTLV-1; Tax; HDAC; HAT; CBP	NF-KAPPA-B; HISTONE DEACETYLASE; TRANSCRIPTIONAL ACTIVITY; DNA METHYLATION; PROTEIN; CREB; ACETYLATION; REPRESSOR; COMPLEX; FAMILY	Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are known to interact with several transcription factors and regulate their transcriptional activities. The human T-cell leukemia virus type I (HTLV1) Tax oncoprotein activates transcription from its long terminal repeat (LTR) through interaction with cellular factors such as CREB and a transcriptional coactivator CBP/p300. However, little is known about the interaction between Tax and transcriptional repressors. Here, we demonstrate the physical and functional interaction between Tax and HDAC1. We found that HDAC1 represses the trans-activation function of Tax in 293T and MT4 cells. However, this repression was restored by treatment with an HDAC inhibitor, Trichostatin A. We also observed physical interaction between Tax and HDAC1 both in vitro and in vivo. The N-terminal region of HDAC I (amino acid residues 28-97) was required for this binding. Moreover, HDAC1 inhibited the synergistic trans-activation of Tax observed on ectopic expression of CBP. However, this repression was relieved by overexpression of CBP. Thus, HDAC1 is likely to compete with CBP in binding with Tax and functions as a negative regulator for the transcriptional activation by Tax.	Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan	Kyoto University	Shimotohno, K (corresponding author), Kyoto Univ, Inst Virus Res, Dept Viral Oncol, Sakyo Ku, Kyoto 6068507, Japan.	kshimoto@virus.kyoto-u.ac.jp	Ariumi, Yasuo/F-5804-2013					Akagi T, 1997, ONCOGENE, V14, P2071, DOI 10.1038/sj.onc.1201045; Ariumi Y, 2000, ONCOGENE, V19, P1491, DOI 10.1038/sj.onc.1203450; Ariumi Y, 2001, BIOCHEM BIOPH RES CO, V287, P556, DOI 10.1006/bbrc.2001.5626; Billin AN, 2000, MOL CELL BIOL, V20, P6882, DOI 10.1128/MCB.20.18.6882-6890.2000; Brehm A, 1999, EMBO J, V18, P2449, DOI 10.1093/emboj/18.9.2449; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Colgin MA, 1998, J VIROL, V72, P9396, DOI 10.1128/JVI.72.11.9396-9399.1998; Gwack Y, 2001, J VIROL, V75, P1909, DOI 10.1128/JVI.75.4.1909-1917.2001; JEANG KT, 1990, SCIENCE, V247, P1082, DOI 10.1126/science.2309119; Juan LJ, 2000, J BIOL CHEM, V275, P20436, DOI 10.1074/jbc.M000202200; Kihara-Negishi F, 2001, ONCOGENE, V20, P6039, DOI 10.1038/sj.onc.1204756; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Krithivas A, 2000, J VIROL, V74, P9637, DOI 10.1128/JVI.74.20.9637-9645.2000; Kwok RPS, 1996, NATURE, V380, P642, DOI 10.1038/380642a0; Lemasson I, 1997, J VIROL, V71, P1975, DOI 10.1128/JVI.71.3.1975-1983.1997; Martinez-Balbas MA, 2000, EMBO J, V19, P662, DOI 10.1093/emboj/19.4.662; Marzio G, 2000, J BIOL CHEM, V275, P10887, DOI 10.1074/jbc.275.15.10887; Nicot C, 2000, ONCOGENE, V19, P2155, DOI 10.1038/sj.onc.1203536; Punga T, 2000, FEBS LETT, V476, P248, DOI 10.1016/S0014-5793(00)01739-7; Robertson KD, 2001, ONCOGENE, V20, P3139, DOI 10.1038/sj.onc.1204341; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; SAGGIORO D, 1991, VIROLOGY, V182, P68, DOI 10.1016/0042-6822(91)90649-V; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Uchiyama T, 1997, ANNU REV IMMUNOL, V15, P15, DOI 10.1146/annurev.immunol.15.1.15; Yamaoka S, 1996, EMBO J, V15, P873, DOI 10.1002/j.1460-2075.1996.tb00422.x; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	30	59	61	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 17	2002	21	47					7241	7246		10.1038/sj.onc.1205701	http://dx.doi.org/10.1038/sj.onc.1205701			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370815				2022-12-25	WOS:000178504600013
J	Liu, J; Lu, M				Liu, J; Lu, M			An alanine-zipper structure determined by long range intermolecular interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN DESIGN; ENERGY LANDSCAPE; COILED-COILS; HIV-1 GP41; PATHWAYS; RESOLUTION; STABILITY; PREDICTION; SEQUENCES; PEPTIDES	A major challenge in protein folding is to identify and quantify specific structural determinants that allow native proteins to acquire their unique folded structures. Here we report the engineering of a 52-residue protein (Ala-14) that contains exclusively alanine residues at the hydrophobic a and d positions of a natural heptad-repeat sequence. Ala-14 is unfolded under normal solution conditions yet forms a parallel three-stranded alpha-helical coiled coil in crystals. Ala-14 trimers in the solid state associate with each other through the pairing of polar side chains and formation of an extended network of water-mediated hydrogen bonds. In contrast to the classical view that local intramolecular tertiary interactions dictate the three-dimensional structure of small single-domain proteins, Ala-14 shows that long range intermolecular interactions can be essential in determining the metastable alanine-zipper structure. A similar interplay between short range local and longer range global forces may underlie the conformational properties of the growing class of natively unstructured proteins in biological processes.	Cornell Univ, Dept Biochem, Weill Med Coll, New York, NY 10021 USA	Cornell University	Lu, M (corresponding author), Cornell Univ, Dept Biochem, Weill Med Coll, 1300 York Ave, New York, NY 10021 USA.				NIAID NIH HHS [AI 42382] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI042382, R01AI042382, R56AI042382] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P26, DOI 10.1016/S0968-0004(98)01346-2; Beasley JR, 1997, J BIOL CHEM, V272, P2031, DOI 10.1074/jbc.272.4.2031; Bonneau R, 2001, ANNU REV BIOPH BIOM, V30, P173, DOI 10.1146/annurev.biophys.30.1.173; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; BRYSON JW, 1995, SCIENCE, V270, P935, DOI 10.1126/science.270.5238.935; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Dinner AR, 2000, TRENDS BIOCHEM SCI, V25, P331, DOI 10.1016/S0968-0004(00)01610-8; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Fersht AR, 2002, CELL, V108, P573, DOI 10.1016/S0092-8674(02)00620-7; GERNERT KM, 1995, PROTEIN SCI, V4, P2252, DOI 10.1002/pro.5560041102; Guerois R, 2001, CURR OPIN STRUC BIOL, V11, P101, DOI 10.1016/S0959-440X(00)00170-6; HARBURY PB, 1994, NATURE, V371, P80, DOI 10.1038/371080a0; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; Hodges R. S., 1972, COLD SPRING HARB SYM, V37, P299; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; KIM PS, 1990, ANNU REV BIOCHEM, V59, P631, DOI 10.1146/annurev.biochem.59.1.631; Liu J, 2002, J MOL BIOL, V318, P877, DOI 10.1016/S0022-2836(02)00138-9; Luo PZ, 1997, BIOCHEMISTRY-US, V36, P8413, DOI 10.1021/bi9707133; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; MUNOZ V, 1996, FOLDING DESIGN, V1, P71; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Onuchic JN, 2000, ADV PROTEIN CHEM, V53, P87; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pande VS, 1998, CURR OPIN STRUC BIOL, V8, P68, DOI 10.1016/S0959-440X(98)80012-2; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; Plaxco KW, 2000, BIOCHEMISTRY-US, V39, P11177, DOI 10.1021/bi000200n; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; Rumbley J, 2001, P NATL ACAD SCI USA, V98, P105, DOI 10.1073/pnas.98.1.105; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Shu W, 2000, J BIOL CHEM, V275, P1839, DOI 10.1074/jbc.275.3.1839; Shu W, 1999, BIOCHEMISTRY-US, V38, P5378, DOI 10.1021/bi990199w; Shu W, 2000, J MOL BIOL, V299, P1101, DOI 10.1006/jmbi.2000.3776; Ventura S, 2002, NAT STRUCT BIOL, V9, P485, DOI 10.1038/nsb799; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	46	17	20	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48708	48713		10.1074/jbc.M208773200	http://dx.doi.org/10.1074/jbc.M208773200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368282	hybrid			2022-12-25	WOS:000179789600096
J	Zhang, X; Kim, WS; Hatcher, N; Potgieter, K; Moroz, LL; Gillette, R; Sweedler, JV				Zhang, X; Kim, WS; Hatcher, N; Potgieter, K; Moroz, LL; Gillette, R; Sweedler, JV			Interfering with nitric oxide measurements - 4,5-Diaminofluorescein reacts with dehydroascorbic acid and ascorbic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPILLARY-ELECTROPHORESIS; ENDOTHELIAL-CELLS; OXIDATIVE STRESS; ANTIOXIDANTS; NO; SYNTHASE; DAF-2; INDICATOR; GLUTATHIONE	4,5-Diaminofluorescein (DAF-2) is widely used for detection and imaging of NO based on its sensitivity, non-cytotoxicity, and specificity. In the presence of oxygen, NO and NO-related reactive nitrogen species nitrosate 4,5-diaminofluorescein to yield the highly fluorescent DAF-2 triazole (DAF-2T). However, as reported here, the DAF-2 reaction to form a fluorescent product is not specific to NO because it reacts with dehydroascorbic acid (DHA) and ascorbic acid (AA) to generate new compounds that have fluorescence emission profiles similar to that of DAF-2T. When DHA is present, the formation of DAF-2T is attenuated because the DHA competes for DAF-2, whereas AA decreases the nitrosation of DAF-2 to a larger extent, possibly because of additional reducing activity that affects the amount of available N2O3 from the NO. The reaction products of DAF-2 with DHA and AA have been characterized using capillary electrophoresis with laser-induced fluorescence detection and electrospray mass spectrometry. The reactions of DAF-2 with DHA and AA are particularly significant because DHA and AA often colocalize with nitric-oxide synthase in the central nervous, cardiovascular, and immune systems, indicating the importance of understanding this chemistry.	Univ Illinois, Dept Chem, Urbana, IL 61801 USA; Univ Illinois, Beckman Inst, Urbana, IL 61801 USA; Univ Illinois, Dept Mol & Integrat Physiol, Urbana, IL 61801 USA; Univ Florida, Whitney Lab, Dept Neurosci, St Augustine, FL 32080 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; State University System of Florida; University of Florida	Sweedler, JV (corresponding author), Univ Illinois, Dept Chem, 1209 W Calif St, Urbana, IL 61801 USA.	sweedler@scs.uiuc.edu	Sweedler, Jonathan V/A-9405-2009	Sweedler, Jonathan V/0000-0003-3107-9922				Agus DB, 1997, J CLIN INVEST, V100, P2842, DOI 10.1172/JCI119832; Awad LF, 2000, CARBOHYD RES, V326, P34, DOI 10.1016/S0008-6215(00)00019-7; Beckman JS, 1996, METHODS NITRIC OXIDE, P61; Bogdan C, 2001, NAT IMMUNOL, V2, P907, DOI 10.1038/ni1001-907; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; Broillet MC, 2001, FEBS LETT, V491, P227, DOI 10.1016/S0014-5793(01)02206-2; Calabrese V, 2000, NEUROCHEM RES, V25, P1315, DOI 10.1023/A:1007604414773; Carr A, 2000, FREE RADICAL BIO MED, V28, P1806, DOI 10.1016/S0891-5849(00)00225-2; Carr A, 1999, FASEB J, V13, P1007, DOI 10.1096/fasebj.13.9.1007; Dawson VL, 1998, PROG BRAIN RES, V118, P215; Deutsch JC, 2000, J CHROMATOGR A, V881, P299, DOI 10.1016/S0021-9673(00)00166-7; Deutsch JC, 1998, ANAL BIOCHEM, V265, P238, DOI 10.1006/abio.1998.2940; EK A, 1995, BIOCHEM PHARMACOL, V50, P1339; Floyd RA, 1999, P SOC EXP BIOL MED, V222, P236, DOI 10.1046/j.1525-1373.1999.d01-140.x; Foissner I, 2000, PLANT J, V23, P817, DOI 10.1046/j.1365-313X.2000.00835.x; Fuller RR, 1998, NEURON, V20, P173, DOI 10.1016/S0896-6273(00)80446-8; Grace SC, 2000, PHILOS T R SOC B, V355, P1499, DOI 10.1098/rstb.2000.0710; GRUNEWALD RA, 1993, BRAIN RES REV, V18, P123, DOI 10.1016/0165-0173(93)90010-W; Heller R, 1999, J BIOL CHEM, V274, P8254, DOI 10.1074/jbc.274.12.8254; HRABIE JA, 1993, J ORG CHEM, V58, P1472, DOI 10.1021/jo00058a030; HUGHES DE, 1989, ANALYST, V114, P169, DOI 10.1039/an9891400169; Itoh Y, 2000, ANAL BIOCHEM, V287, P203, DOI 10.1006/abio.2000.4859; Jourd'Heuil D, 2002, FREE RADICAL BIO MED, V33, P676, DOI 10.1016/S0891-5849(02)00955-3; KIMOTO E, 1993, ANAL BIOCHEM, V214, P38, DOI 10.1006/abio.1993.1453; Knight JA, 2000, ANN CLIN LAB SCI, V30, P145; Kojima H, 1998, NEUROREPORT, V9, P3345, DOI 10.1097/00001756-199810260-00001; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Kuo RK, 2000, NATURE, V406, P633, DOI 10.1038/35020577; Leikert JF, 2001, FEBS LETT, V506, P131, DOI 10.1016/S0014-5793(01)02901-5; Lopez-Figueroa MO, 2000, BRAIN RES, V852, P239, DOI 10.1016/S0006-8993(99)02241-6; Lopez-Figueroa MO, 2001, BBA-MOL CELL RES, V1540, P253, DOI 10.1016/S0167-4889(01)00138-0; LUCK MR, 1995, BIOL REPROD, V52, P262, DOI 10.1095/biolreprod52.2.262; May James M., 1998, Frontiers in Bioscience, V3, pD1; May JM, 2000, FREE RADICAL BIO MED, V28, P1421, DOI 10.1016/S0891-5849(00)00269-0; Nagano T, 2002, CHEM REV, V102, P1235, DOI 10.1021/cr010152s; Nagano T, 1999, LUMINESCENCE, V14, P283, DOI 10.1002/(SICI)1522-7243(199911/12)14:6<283::AID-BIO572>3.0.CO;2-G; Nagata N, 1999, J BIOCHEM-TOKYO, V125, P658, DOI 10.1093/oxfordjournals.jbchem.a022333; Nakatsubo N, 1998, FEBS LETT, V427, P263, DOI 10.1016/S0014-5793(98)00440-2; PARISH HA, 1982, CARBOHYD RES, V102, P302, DOI 10.1016/S0008-6215(00)88073-8; Park YN, 1999, ANAL CHEM, V71, P4997, DOI 10.1021/ac990659r; Reutov VP, 2002, BIOCHEMISTRY-MOSCOW+, V67, P293, DOI 10.1023/A:1014832416073; Rice ME, 1998, NEUROSCIENCE, V82, P1213; Roychowdhury S, 2002, GLIA, V38, P103, DOI 10.1002/glia.10024; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Shaul PW, 2002, ANNU REV PHYSIOL, V64, P749, DOI 10.1146/annurev.physiol.64.081501.155952; Singh VK, 2000, IMMUNOL RES, V22, P1, DOI 10.1385/IR:22:1:1; SOMOGYI L, 1995, LIEBIGS ANN, P721; Suzuki N, 2002, J BIOL CHEM, V277, P47, DOI 10.1074/jbc.M108195200; Szabo C, 1996, BRAIN RES BULL, V41, P131, DOI 10.1016/S0361-9230(96)00159-1; WASHKO PW, 1993, J BIOL CHEM, V268, P15531; WINKLER BS, 1992, BIOCHIM BIOPHYS ACTA, V1117, P287, DOI 10.1016/0304-4165(92)90026-Q; Yang JH, 1997, TALANTA, V44, P855, DOI 10.1016/S0039-9140(96)02129-7; Zhang X, 2001, FRESEN J ANAL CHEM, V369, P206, DOI 10.1007/s002160000654	54	159	162	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48472	48478		10.1074/jbc.M209130200	http://dx.doi.org/10.1074/jbc.M209130200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12370177	hybrid			2022-12-25	WOS:000179789600067
J	Chang, TL; Naqvi, A; Anand, SP; Kramer, MG; Munshi, R; Khan, SA				Chang, TL; Naqvi, A; Anand, SP; Kramer, MG; Munshi, R; Khan, SA			Biochemical characterization of the Staphylococcus aureus PcrA helicase and its role in plasmid rolling circle replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; INITIATOR PROTEIN; ESCHERICHIA-COLI; BACTERIAL PLASMIDS; CRYSTAL-STRUCTURES; PT181; ORIGIN; MECHANISM; COMPLEXES; SITE	Previous genetic studies have suggested that a putative chromosome-encoded helicase, PcrA, is required for the rolling circle replication of plasmid pT181 in Staphylococcus aureus. We have overexpressed and purified the staphylococcal PcrA protein and studied its biochemical properties in vitro. Purified PcrA helicase supported the in vitro replication of plasmid pT181. It had ATPase activity that was stimulated in the presence of single-stranded DNA. Unlike many replicative helicases, PcrA was highly active as a 5' --> 3' helicase and had a weaker 3' --> 5' helicase activity. The RepC initiator protein encoded by pT181 nicks at the origin of replication and becomes covalently attached to the 5' end of the DNA. The 3' OH end at the nick then serves as a primer for displacement synthesis. PcrA helicase showed an origin-specific unwinding activity with supercoiled plasmid pT181 DNA that had been nicked at the origin by Rep,C. We also provide direct evidence for a protein-protein interaction between PcrA and RepC proteins. Our results are consistent with a model in which the PcrA helicase is targeted to the pT181 origin through a protein-protein interaction with RepC and facilitates the movement of the replisome by initiating unwinding from the RepC-generated nick.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Khan, SA (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E 1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.							Bird LE, 1998, NUCLEIC ACIDS RES, V26, P2686, DOI 10.1093/nar/26.11.2686; Bird LE, 2000, BIOCHEMISTRY-US, V39, P171, DOI 10.1021/bi9918801; Bruand C, 2000, MOL MICROBIOL, V35, P204, DOI 10.1046/j.1365-2958.2000.01700.x; Chang TL, 2000, J BIOL CHEM, V275, P13529, DOI 10.1074/jbc.275.18.13529; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; del Solar G, 1998, MICROBIOL MOL BIOL R, V62, P434, DOI 10.1128/MMBR.62.2.434-464.1998; DEMPSEY LA, 1992, P NATL ACAD SCI USA, V89, P3083, DOI 10.1073/pnas.89.7.3083; Dillingham MS, 1999, NUCLEIC ACIDS RES, V27, P3310, DOI 10.1093/nar/27.16.3310; Dillingham MS, 2001, P NATL ACAD SCI USA, V98, P8381, DOI 10.1073/pnas.131009598; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; IORDANESCU S, 1991, J MOL BIOL, V221, P1183, DOI 10.1016/0022-2836(91)90927-X; IORDANESCU S, 1993, J BACTERIOL, V175, P3916, DOI 10.1128/JB.175.12.3916-3917.1993; IORDANESCU S, 1993, MOL GEN GENET, V241, P185, DOI 10.1007/BF00280216; IORDANESCU S, 1989, J BACTERIOL, V171, P4501, DOI 10.1128/JB.171.8.4501-4503.1989; Jiang Y, 2002, MOL MICROBIOL, V44, P971, DOI 10.1046/j.1365-2958.2002.02921.x; Jin RZ, 1997, EMBO J, V16, P4456, DOI 10.1093/emboj/16.14.4456; Khan SA, 1997, MICROBIOL MOL BIOL R, V61, P442, DOI 10.1128/.61.4.442-455.1997; KOEPSEL RR, 1985, J BIOL CHEM, V260, P8571; KOEPSEL RR, 1985, P NATL ACAD SCI USA, V82, P6845, DOI 10.1073/pnas.82.20.6845; KOEPSEL RR, 1986, P NATL ACAD SCI USA, V83, P5484, DOI 10.1073/pnas.83.15.5484; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Kramer MG, 1999, MOL MICROBIOL, V33, P466, DOI 10.1046/j.1365-2958.1999.01471.x; Kramer MG, 1998, P NATL ACAD SCI USA, V95, P10505, DOI 10.1073/pnas.95.18.10505; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Mechanic LE, 1999, J BIOL CHEM, V274, P12488, DOI 10.1074/jbc.274.18.12488; NOIROT P, 1990, P NATL ACAD SCI USA, V87, P8560, DOI 10.1073/pnas.87.21.8560; Petit MA, 1998, MOL MICROBIOL, V29, P261, DOI 10.1046/j.1365-2958.1998.00927.x; Sambrook J., 2002, MOL CLONING LAB MANU; Soultanas P, 2000, CURR OPIN STRUC BIOL, V10, P124, DOI 10.1016/S0959-440X(99)00059-7; Soultanas P, 1999, NUCLEIC ACIDS RES, V27, P1421, DOI 10.1093/nar/27.6.1421; Soultanas P, 2000, EMBO J, V19, P3799, DOI 10.1093/emboj/19.14.3799; Subramanya HS, 1996, NATURE, V384, P379, DOI 10.1038/384379a0; THOMAS CD, 1995, J MOL BIOL, V254, P381, DOI 10.1006/jmbi.1995.0625; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; Zhao AC, 1997, MOL MICROBIOL, V24, P535, DOI 10.1046/j.1365-2958.1997.3641730.x	35	31	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45880	45886		10.1074/jbc.M207383200	http://dx.doi.org/10.1074/jbc.M207383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244110	hybrid			2022-12-25	WOS:000179529300023
J	D'Amico, S; Gerday, C; Feller, G				D'Amico, S; Gerday, C; Feller, G			Dual effects of an extra disulfide bond on the activity and stability of a cold-adapted alpha-amylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTEROMONAS-HALOPLANCTIS; TEMPERATURE ADAPTATION; PSYCHROPHILIC ENZYMES; ANGSTROM RESOLUTION; GLOBULAR-PROTEINS; INHIBITOR; MUTANTS; BARNASE; FLEXIBILITY; ACTIVATION	Chloride-dependent alpha-amylases constitute a well conserved family of enzymes thereby allowing investigation of the characteristics of each member to understand, for example, relevant properties required for environmental adaptation. In this context, we have constructed a double mutant (Q58C/A99C) of the cold-active and heat-labile alpha-amylase from the Antarctic bacterium Pseudoalteromonas haloplanktis, defined on the basis of its strong similarity with the mesophilic enzyme from pig pancreas. This mutant was characterized to understand the role of an extra disulfide bond specific to warm-blooded animals and located near the entrance of the catalytic cleft. We show that the catalytic parameters of the mutant are drastically modified and similar to those of the mesophilic enzyme. Calorimetric studies demonstrated that the mutant is globally stabilized (DeltaDeltaG = 1.87 kcal/mol at 20 degreesC) when compared with the wild-type enzyme, although the melting point (T-m) was not increased. Moreover, fluorescence quenching experiments indicate a more compact structure for the mutated a-amylase. However, the strain imposed on the active site architecture induces a 2-fold higher thermal inactivation rate at 45 degreesC as well as the appearance of a less stable calorimetric domain. It is concluded that stabilization by the extra disulfide bond arises from an enthalpy-entropy compensation effect favoring the enthalpic contribution.	Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium	University of Liege	Feller, G (corresponding author), Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium.	sdamico@ulg.ac.be						Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; Aghajari N, 1998, PROTEIN SCI, V7, P564, DOI 10.1002/pro.5560070304; BETZ SF, 1993, PROTEIN SCI, V2, P1551, DOI 10.1002/pro.5560021002; CLARKE J, 1995, J MOL BIOL, V253, P493, DOI 10.1006/jmbi.1995.0568; CLARKE J, 1995, J MOL BIOL, V253, P505, DOI 10.1006/jmbi.1995.0569; D'Amico S, 2000, GENE, V253, P95, DOI 10.1016/S0378-1119(00)00229-8; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; D'Amico S, 2001, J BIOL CHEM, V276, P25791, DOI 10.1074/jbc.M102741200; DOIG AJ, 1991, J MOL BIOL, V217, P389, DOI 10.1016/0022-2836(91)90551-G; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Feller G, 1996, J BIOL CHEM, V271, P23836, DOI 10.1074/jbc.271.39.23836; Feller G, 1998, APPL ENVIRON MICROB, V64, P1163; Johnson CM, 1997, J MOL BIOL, V268, P198, DOI 10.1006/jmbi.1997.0928; Kumar S, 2002, BIOCHEMISTRY-US, V41, P5359, DOI 10.1021/bi012154c; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; LARSON SB, 1994, J MOL BIOL, V235, P1560, DOI 10.1006/jmbi.1994.1107; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; Lonhienne T, 2001, BBA-PROTEIN STRUCT M, V1545, P349, DOI 10.1016/S0167-4838(00)00296-X; LOW PS, 1973, P NATL ACAD SCI USA, V70, P430, DOI 10.1073/pnas.70.2.430; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; PACE CN, 1988, J BIOL CHEM, V263, P11820; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Privalov Peter L., 1992, P83; QIAN MX, 1993, J MOL BIOL, V231, P785, DOI 10.1006/jmbi.1993.1326; QIAN MX, 1994, BIOCHEMISTRY-US, V33, P6284, DOI 10.1021/bi00186a031; SEDLAK J, 1968, ANAL BIOCHEM, V25, P192, DOI 10.1016/0003-2697(68)90092-4; VOGL T, 1995, J MOL BIOL, V254, P481, DOI 10.1006/jmbi.1995.0632; Wintrode PL, 2001, ADV PROTEIN CHEM, V55, P161, DOI 10.1016/S0065-3233(01)55004-4; Zavodszky M, 2001, PROTEIN SCI, V10, P149, DOI 10.1110/ps.26801; Zavodszky P, 1998, P NATL ACAD SCI USA, V95, P7406, DOI 10.1073/pnas.95.13.7406; Zecchinon L, 2001, EXTREMOPHILES, V5, P313, DOI 10.1007/s007920100207	31	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46110	46115		10.1074/jbc.M207253200	http://dx.doi.org/10.1074/jbc.M207253200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324460	Green Published, hybrid			2022-12-25	WOS:000179529300054
J	Moncion, A; Truong, NT; Garrone, A; Beaune, P; Barouki, R; de Waziers, I				Moncion, A; Truong, NT; Garrone, A; Beaune, P; Barouki, R; de Waziers, I			Identification of a 16-nucleotide sequence that mediates post-transcriptional regulation of rat CYP2E1 by insulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-PROTEIN INTERACTIONS; HISTONE MESSENGER-RNA; DOWN-REGULATION; GROWTH-HORMONE; GENE PROMOTER; CODING REGION; CYTOCHROME-P450; EXPRESSION; BINDING; STABILITY	Insulin directly down-regulates the gene expression of the rat CYP2E1 by altering its mRNA stability (De Waziers, I., Garlatti, M., Bouguet, J., Beaune, P. H., and Barouki, R. (1995) Mol. Pharmacol 47, 474-479). Because the regulation of CYP mRNA stability was poorly understood, the molecular mechanisms involved in this regulation in the rat hepatoma H4IIEC3 cell line were studied. By using RNase T1 protection methods, the formation of a major CYP2E1 RNA-protein complex was observed. By competition experiments, the binding site of this complex was located on a 16-nucleotide sequence in the 5'-proximal region of the CYP2E1-coding sequence. Insulin did not modify the binding pattern of proteins to this sequence. and transfections of expression vectors or antisense oligonucleotides were undertaken to demonstrate the actual functionality of the 16-mer sequence. The insertion of this sequence in a luciferase gene was sufficient to render the chimeric mRNA sensitive to insulin. Furthermore, transfection of H4IIEC3 cells with antisense oligonucleotide complementary to this sequence blocked the insulin effect on the CYP2E1 mRNA expression, i.e. its rapid degradation. All these results demonstrate that this 16-nucleotide sequence is implicated in the CYP2E1 post-transcriptional regulation by insulin.	INSERM, Fac Med, Mol Toxicol Lab, U490, F-75270 Paris 06, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	de Waziers, I (corresponding author), INSERM, Fac Med, Mol Toxicol Lab, U490, 45 Rue St Peres, F-75270 Paris 06, France.	Isabelle.Waziers@biomedicale.univ-paris5.fr	De Waziers, Isabelle/N-5453-2018	Beaune, Philippe/0000-0002-6569-9014; de Waziers, Isabelle/0000-0002-7859-3315				AGGERBECK M, 1993, BIOCHEMISTRY-US, V32, P9065, DOI 10.1021/bi00086a011; BERNSTEIN PL, 1992, GENE DEV, V6, P642, DOI 10.1101/gad.6.4.642; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Coon MJ, 1996, FASEB J, V10, P428, DOI 10.1096/fasebj.10.4.8647341; CORCOS L, 1988, FEBS LETT, V233, P37, DOI 10.1016/0014-5793(88)81351-6; DANDEKAR T, 1995, TRENDS GENET, V11, P45, DOI 10.1016/S0168-9525(00)88996-9; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; Derry JJ, 2000, MOL CELL BIOL, V20, P6114, DOI 10.1128/MCB.20.16.6114-6126.2000; DESCHATRETTE J, 1974, BIOCHIMIE, V56, P1603; DEWAZIERS I, 1992, PHARMACOGENETICS, V2, P12, DOI 10.1097/00008571-199202000-00003; DEWAZIERS I, 1995, MOL PHARMACOL, V47, P474; Dogra SC, 1998, CLIN EXP PHARMACOL P, V25, P1, DOI 10.1111/j.1440-1681.1998.tb02135.x; DONG ZG, 1988, ARCH BIOCHEM BIOPHYS, V263, P29, DOI 10.1016/0003-9861(88)90610-8; EKSTROM G, 1986, BIOCHEM J, V233, P755, DOI 10.1042/bj2330755; Geneste O, 1996, BIOCHEM J, V313, P1029, DOI 10.1042/bj3131029; GONZALEZ FJ, 1994, DRUG METAB REV, V26, P165, DOI 10.3109/03602539409029789; GUENGERICH FP, 1991, CHEM RES TOXICOL, V4, P391, DOI 10.1021/tx00022a001; Hall Robert K., 1999, Journal of Basic and Clinical Physiology and Pharmacology, V10, P119; Hannon-Fletcher MPA, 2001, FOOD CHEM TOXICOL, V39, P125, DOI 10.1016/S0278-6915(00)00119-8; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; Jammi NV, 2001, NUCLEIC ACIDS RES, V29, P3020; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOOP DR, 1986, ALCOHOL CLIN EXP RES, V10, pS44, DOI 10.1111/j.1530-0277.1986.tb05179.x; Lieber CS, 1997, PHYSIOL REV, V77, P517, DOI 10.1152/physrev.1997.77.2.517; Lucas D, 1998, FUNDAM CLIN PHARM, V12, P553, DOI 10.1111/j.1472-8206.1998.tb00985.x; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Novak RF, 2000, ARCH PHARM RES, V23, P267, DOI 10.1007/BF02975435; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Ostrowski J, 2001, P NATL ACAD SCI USA, V98, P9044, DOI 10.1073/pnas.161284098; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PAVEPREUX M, 1990, J BIOL CHEM, V265, P4444; Peng HM, 1998, MOL PHARMACOL, V54, P740; PETER R, 1990, CHEM RES TOXICOL, V3, P566, DOI 10.1021/tx00018a012; RaffalliMathieu F, 1997, EUR J BIOCHEM, V245, P17, DOI 10.1111/j.1432-1033.1997.00017.x; SHIMOJO N, 1993, BIOCHEM PHARMACOL, V46, P621, DOI 10.1016/0006-2952(93)90547-A; Sidhu JS, 2001, MOL PHARMACOL, V59, P1138, DOI 10.1124/mol.59.5.1138; SONG BJ, 1987, MOL ENDOCRINOL, V1, P542, DOI 10.1210/mend-1-8-542; Staton JM, 2000, J MOL ENDOCRINOL, V25, P17, DOI 10.1677/jme.0.0250017; Thulke-Gross M, 1998, BIOCHEM J, V331, P473, DOI 10.1042/bj3310473; THUMMEL KE, 1990, MOL PHARMACOL, V37, P119; Tilloy-Ellul A, 1999, BIOCHEM J, V339, P695, DOI 10.1042/0264-6021:3390695; Troy CM, 1996, J NEUROSCI, V16, P253; WATKINS JB, 1988, TOXICOL APPL PHARM, V93, P329, DOI 10.1016/0041-008X(88)90133-0; WELLINGTON CL, 1993, MOL CELL BIOL, V13, P5034, DOI 10.1128/MCB.13.8.5034; WILLIAMS AS, 1995, NUCLEIC ACIDS RES, V23, P654, DOI 10.1093/nar/23.4.654; Wilson GM, 1999, PROG NUCLEIC ACID RE, V62, P257; Woodcroft KJ, 2002, HEPATOLOGY, V35, P263, DOI 10.1053/jhep.2002.30691; Woodcroft KJ, 1997, CHEM-BIOL INTERACT, V107, P75, DOI 10.1016/S0009-2797(97)00075-6; Woodcroft KJ, 1999, J PHARMACOL EXP THER, V289, P1121; YAMAZOE Y, 1989, ARCH BIOCHEM BIOPHYS, V268, P567, DOI 10.1016/0003-9861(89)90324-X; YANG CS, 1990, DRUG METAB REV, V22, P147, DOI 10.3109/03602539009041082; YEN TJ, 1988, MOL CELL BIOL, V8, P1224, DOI 10.1128/MCB.8.3.1224	54	26	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45904	45910		10.1074/jbc.M207841200	http://dx.doi.org/10.1074/jbc.M207841200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270935	hybrid			2022-12-25	WOS:000179529300027
J	Smith, L; Smith, JRB				Smith, L; Smith, JRB			Lack of constitutive activity of the free kinase domain of protein kinase C zeta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PHOSPHOINOSITIDE-DEPENDENT KINASE; INDUCED APOPTOSIS; PHOSPHATIDYLINOSITOL 3,4,5-TRISPHOSPHATE; RAT ADIPOCYTES; PKC-ZETA; ACTIVATION; PHOSPHORYLATION; ISOFORMS; TRANSLOCATION	Following the induction of apoptosis in mammalian cells, protein kinase C zeta (PKC zeta) is processed between the regulatory and catalytic domains by caspases, which increases its kinase activity. The catalytic domain fragments of PKC isoforms are considered to be constitutively active, because they lack the autoinhibitory amino-terminal regulatory domain, which includes a pseudosubstrate segment that plugs the active site. Phosphorylation of the activation loop at Thr(410) is known to be sufficient to activate the kinase function of full-length PKC zeta, apparently by inducing a conformational change, which displaces the amino-terminal pseudosubstrate segment from the active site. Amino acid substitutions for Thr(410) of the catalytic domain of PKzeta (CAT zeta) essentially abolished the kinase function of ectopically expressed CAT zeta in mammalian cells. Similarly, substitution of Ala for a Phe of the docking motif for phosphoinositide-dependent kinase-1 prevented activation loop phosphorylation and abolished the kinase activity of CAT zeta. Treatment of purified CAT zeta with the catalytic subunit of protein phosphatase 1 decreased activation loop phosphorylation and kinase activity. Recombinant CAT zeta from bacteria lacked detectable kinase activity. Phosphoinositide-dependent kinase-1 phosphorylated the activation loop and activated recombinant CAT zeta from bacteria. Treatment of HeLa cells with fetal bovine serum markedly increased the phosphothreonine 410 content of CAT zeta and stimulated its kinase activity. These findings indicate that the catalytic domain of PKC zeta is intrinsically inactive and dependent on the transphosphorylation of the activation loop.	Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA; Univ Alabama, Sch Dent, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Smith, JRB (corresponding author), Univ Alabama, Sch Med, Dept Pharmacol & Toxicol, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060383] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60383] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Balendran A, 2000, J BIOL CHEM, V275, P20806, DOI 10.1074/jbc.M000421200; Bandyopadhyay G, 1999, BIOCHEM J, V337, P461, DOI 10.1042/0264-6021:3370461; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Berra E, 1997, MOL CELL BIOL, V17, P4346, DOI 10.1128/MCB.17.8.4346; Bourbon NA, 2000, J BIOL CHEM, V275, P35617, DOI 10.1074/jbc.M007346200; Carlin S, 1999, AM J PHYSIOL-LUNG C, V276, pL506, DOI 10.1152/ajplung.1999.276.3.L506; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Cenni V, 2002, BIOCHEM J, V363, P537, DOI 10.1042/0264-6021:3630537; CEPKO C, 1995, METHOD ENZYMOL, V254, P387; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Datta R, 1997, J BIOL CHEM, V272, P20317, DOI 10.1074/jbc.272.33.20317; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Endo K, 2000, J BIOL CHEM, V275, P18476, DOI 10.1074/jbc.M002266200; Fallaux FJ, 1996, HUM GENE THER, V7, P215, DOI 10.1089/hum.1996.7.2-215; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; Gao TY, 2001, J BIOL CHEM, V276, P19588, DOI 10.1074/jbc.M101357200; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; HerreraVelit P, 1997, J BIOL CHEM, V272, P16445, DOI 10.1074/jbc.272.26.16445; Hrabetova S, 2001, MOL BRAIN RES, V95, P146, DOI 10.1016/S0169-328X(01)00185-1; Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Lallena MJ, 1999, MOL CELL BIOL, V19, P2180; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee HW, 1996, J BIOL CHEM, V271, P20973, DOI 10.1074/jbc.271.35.20973; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; Murray NR, 1997, J BIOL CHEM, V272, P27521, DOI 10.1074/jbc.272.44.27521; Mutter R, 2000, BIOORGAN MED CHEM, V8, P1841, DOI 10.1016/S0968-0896(00)00150-4; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; Newton AC, 2001, CHEM REV, V101, P2353, DOI 10.1021/cr0002801; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ORR JW, 1994, J BIOL CHEM, V269, P8383; Smith L, 2000, J BIOL CHEM, V275, P40620, DOI 10.1074/jbc.M908517199; Sonnenburg ED, 2001, J BIOL CHEM, V276, P45289, DOI 10.1074/jbc.M107416200; Standaert ML, 1999, J BIOL CHEM, V274, P25308, DOI 10.1074/jbc.274.36.25308; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Stempka L, 1997, J BIOL CHEM, V272, P6805, DOI 10.1074/jbc.272.10.6805; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Toker A, 2000, MOL PHARMACOL, V57, P652, DOI 10.1124/mol.57.4.652; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200	49	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45866	45873		10.1074/jbc.M206420200	http://dx.doi.org/10.1074/jbc.M206420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244101	hybrid			2022-12-25	WOS:000179529300021
J	Sullivan, WP; Owen, BAL; Toft, DO				Sullivan, WP; Owen, BAL; Toft, DO			The influence of ATP and p23 on the conformation of hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; CO-CHAPERONE P23; PROGESTERONE-RECEPTOR; TERMINAL DOMAIN; GLUCOCORTICOID RECEPTOR; SIGNAL-TRANSDUCTION; IN-VIVO; BINDING; HEAT-SHOCK-PROTEIN-90; HYDROLYSIS	The chaperoning activity of the heat shock protein hsp90 is directed, in part, by the binding and hydrolysis of ATP and also by association with co-chaperone proteins. One co-chaperone, p23, binds to hsp90 only when hsp90 is in a conformation induced by the binding of ATP. Once formed, the p23-hsp90 complex is very stable upon the removal of ATP and dissipates at 30degrees with a half-life of about 45 min. This was shown to be due to the high stability of the ATP-induced state of hsp,90, not to the rate of p23 dissociation. Further stabilization of this ATP-induced state is achieved by including molybdate or by use of the ATP analogue ATPgammaS. This conformational state of hsp90 is correlated with the tight binding of ADP resulting from hydrolysis of bound ATP. Both p23 and molybdate enhance and stabilize the nucleotide-bound state of hsp90, and this state is maximized by the presence of both agents. These results can be explained in a model where the binding of ATP induces a conformational transition in hsp90 that traps the nucleotide and is committed to ATP hydrolysis. p23 specifically recognizes this state and may also facilitate subsequent steps in the chaperoning cycle.	Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Mayo Grad Sch, Rochester, MN 55905 USA	Mayo Clinic	Toft, DO (corresponding author), Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Mayo Grad Sch, 200 1st St SW, Rochester, MN 55905 USA.		Owen, Barbara/AAD-2322-2021		NIDDK NIH HHS [DK 46249, DK 59284] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046249, R01DK059284] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Dittmar KD, 1997, J BIOL CHEM, V272, P21213, DOI 10.1074/jbc.272.34.21213; Freeman BC, 2000, GENE DEV, V14, P422; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Freeman BC, 2001, TRENDS BIOCHEM SCI, V26, P285, DOI 10.1016/S0968-0004(01)01834-5; Garnier C, 2002, J BIOL CHEM, V277, P12208, DOI 10.1074/jbc.M111874200; Grenert JP, 1997, J BIOL CHEM, V272, P23843, DOI 10.1074/jbc.272.38.23843; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Hartson SD, 1999, BIOCHEMISTRY-US, V38, P3837, DOI 10.1021/bi983027s; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Holt SE, 1999, GENE DEV, V13, P817, DOI 10.1101/gad.13.7.817; HOUSLEY PR, 1990, BIOCHEMISTRY-US, V29, P3578, DOI 10.1021/bi00466a022; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Marcu MG, 2000, J BIOL CHEM, V275, P37181, DOI 10.1074/jbc.M003701200; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Morishima Y, 2001, BIOCHEMISTRY-US, V40, P1109, DOI 10.1021/bi002399+; Nair SC, 1996, CELL STRESS CHAPERON, V1, P237, DOI 10.1379/1466-1268(1996)001<0237:APOMCI>2.3.CO;2; NISHIGORI H, 1980, BIOCHEMISTRY-US, V19, P77, DOI 10.1021/bi00542a012; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Prapapanich V, 1998, MOL CELL BIOL, V18, P944, DOI 10.1128/MCB.18.2.944; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; Soti C, 2002, J BIOL CHEM, V277, P7066, DOI 10.1074/jbc.M105568200; Sullivan W, 1997, J BIOL CHEM, V272, P8007, DOI 10.1074/jbc.272.12.8007; Weaver AJ, 2000, J BIOL CHEM, V275, P23045, DOI 10.1074/jbc.M003410200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; Young JC, 2000, EMBO J, V19, P5930, DOI 10.1093/emboj/19.21.5930; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079	39	83	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45942	45948		10.1074/jbc.M207754200	http://dx.doi.org/10.1074/jbc.M207754200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324468	hybrid			2022-12-25	WOS:000179529300032
J	MacDonald, PE; Sewing, S; Wang, JL; Joseph, JW; Smukler, SR; Sakellaropoulos, G; Wang, J; Saleh, MC; Chan, CB; Tsushima, RG; Salapatek, AMF; Wheeler, MB				MacDonald, PE; Sewing, S; Wang, JL; Joseph, JW; Smukler, SR; Sakellaropoulos, G; Wang, J; Saleh, MC; Chan, CB; Tsushima, RG; Salapatek, AMF; Wheeler, MB			Inhibition of Kv2.1 voltage-dependent K+ channels in pancreatic beta-cells enhances glucose-dependent insulin secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRICULAR MYOCYTES; TRANSIENT OUTWARD CURRENT; B-CELLS; EXTERNAL TETRAETHYLAMMONIUM; ION CHANNELS; ISLET CELLS; TEDISAMIL; QUININE; BLOCK; DEPOLARIZATION	Voltage-dependent (Kv) outward K+ currents repolarize beta-cell action potentials during a glucose stimulus to limit Ca2+ entry and insulin secretion. Dominant-negative "knockout" of Kv2 family channels enhances glucose-stimulated insulin secretion. Here we show that a putative Kv2.1 antagonist (C-1) stimulates insulin secretion from MIN6 insulinoma cells in a glucose- and dose-dependent manner while blocking voltage-dependent outward K+ currents. C-1-blocked recombinant Kv2.1-mediated currents more specifically than currents mediated by Kv1, -3, and -4 family channels (Kv1.4, 3.1, 4.2). Additionally, C-1 had little effect on currents recorded from MIN6 cells expressing a dominant-negative Kv2.1 a-subunit. The insulinotropic effect of acute Kv2.1 inhibition resulted from enhanced membrane depolarization and augmented intracellular Ca2+ responses to glucose. Immunohistochemical staining of mouse pancreas sections showed that expression of Kv2.1 correlated highly with insulin-containing beta-cells, consistent with the ability of C-1 to block voltage-dependent outward K+ currents in isolated mouse beta-cells. Antagonism of Kv2.1 in an ex vivo perfused mouse pancreas model enhanced first- and second-phase insulin secretion, whereas glucagon secretion was unaffected. The present study demonstrates that Kv2.1 is an important component of beta-cell stimulus-secretion coupling, and a compound that enhances, but does not initiate, beta-cell electrical activity by acting on Kv2.1 would be a useful antidiabetic agent.	Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Lilly Res Labs, D-22419 Hamburg, Germany; Univ Prince Edward Isl, Atlantic Vet Coll, Charlottetown, PE C1A 4P3, Canada	University of Toronto; University of Toronto; Eli Lilly; Lilly Deutschland GmbH; University of Prince Edward Island	Wheeler, MB (corresponding author), Univ Toronto, Dept Physiol, 1 Kings Coll Circle,Rm 3352, Toronto, ON M5S 1A8, Canada.	michael.wheeler@utoronto.ca	MacDonald, Patrick/A-4154-2008; Chan, Catherine/C-1162-2011	Chan, Catherine/0000-0003-3882-0592; Wheeler, Michael B./0000-0002-7480-7267; MacDonald, Patrick/0000-0002-5439-6288				Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; ASHCROFT FM, 1989, PROG BIOPHYS MOL BIO, V54, P87, DOI 10.1016/0079-6107(89)90013-8; ATWATER I, 1979, J PHYSIOL-LONDON, V288, P561; ATWATER I, 1983, CELL CALCIUM, V4, P451, DOI 10.1016/0143-4160(83)90021-0; Berger F, 1998, N-S ARCH PHARMACOL, V357, P291, DOI 10.1007/PL00005170; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P311, DOI 10.1113/jphysiol.1990.sp018024; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; BOYD AE, 1992, J CELL BIOCHEM, V48, P234, DOI 10.1002/jcb.240480303; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; CONLEY EC, 1999, ION CHANNEL FACTSBOO, V4, P374; CONLEY EC, 1999, ION CHANNEL FACTS BO, V4, P617; DagogoJack S, 1997, ARCH INTERN MED, V157, P1802, DOI 10.1001/archinte.157.16.1802; Doggrell SA, 2001, EXPERT OPIN INV DRUG, V10, P129, DOI 10.1517/13543784.10.1.129; Dukes ID, 1996, DIABETES, V45, P845, DOI 10.2337/diabetes.45.7.845; Dunne MJ, 1999, TRENDS ENDOCRIN MET, V10, P146, DOI 10.1016/S1043-2760(98)00135-0; Eberhardson M, 1996, BBA-BIOMEMBRANES, V1283, P67, DOI 10.1016/0005-2736(96)00075-2; FATHERAZI S, 1991, J MEMBRANE BIOL, V120, P105, DOI 10.1007/BF01872393; FINDLAY I, 1985, FEBS LETT, V185, P4, DOI 10.1016/0014-5793(85)80729-8; FINDLAY I, 1985, J MEMBRANE BIOL, V83, P169, DOI 10.1007/BF01868748; Gopel S, 1999, J PHYSIOL-LONDON, V521, P717, DOI 10.1111/j.1469-7793.1999.00717.x; Gopel SO, 2000, J PHYSIOL-LONDON, V528, P497, DOI 10.1111/j.1469-7793.2000.00497.x; GRODSKY GM, 1963, AM J PHYSIOL, V205, P638, DOI 10.1152/ajplegacy.1963.205.4.638; Hayward RA, 1997, JAMA-J AM MED ASSOC, V278, P1663, DOI 10.1001/jama.278.20.1663; HENQUIN JC, 1977, BIOCHEM BIOPH RES CO, V77, P551, DOI 10.1016/S0006-291X(77)80014-4; HENQUIN JC, 1990, PFLUG ARCH EUR J PHY, V416, P568, DOI 10.1007/BF00382691; HENQUIN JC, 1979, BIOCHIM BIOPHYS ACTA, V587, P579, DOI 10.1016/0304-4165(79)90010-2; Himmel HM, 1999, AM J PHYSIOL-HEART C, V277, pH107, DOI 10.1152/ajpheart.1999.277.1.H107; HWANG PM, 1993, J NEUROSCI, V13, P1569; Kozak JA, 1998, J PHYSIOL-LONDON, V509, P355, DOI 10.1111/j.1469-7793.1998.355bn.x; LEBRUN P, 1983, FEBS LETT, V161, P41, DOI 10.1016/0014-5793(83)80726-1; Leung YM, 2002, BIOCHEM BIOPH RES CO, V292, P980, DOI 10.1006/bbrc.2002.6712; LIGHT DB, 1987, J MEMBRANE BIOL, V95, P63, DOI 10.1007/BF01869631; MacDonald PE, 2001, MOL ENDOCRINOL, V15, P1423, DOI 10.1210/me.15.8.1423; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; McLarnon JG, 1997, EUR J PHARMACOL, V339, P279, DOI 10.1016/S0014-2999(97)01394-0; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; OLEARY ME, 1994, J GEN PHYSIOL, V104, P507, DOI 10.1085/jgp.104.3.507; Pederson RA, 1998, DIABETES, V47, P1046, DOI 10.2337/diabetes.47.7.1046; Philipson LH, 1999, HORM METAB RES, V31, P455, DOI 10.1055/s-2007-978774; PHILIPSON LH, 1994, J BIOL CHEM, V269, P27787; Roe MW, 1996, J BIOL CHEM, V271, P32241, DOI 10.1074/jbc.271.50.32241; Rorsman P, 1997, DIABETOLOGIA, V40, P487, DOI 10.1007/s001250050706; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; Schon U, 1998, J MED CHEM, V41, P318, DOI 10.1021/jm970120q; Silvestre RA, 2001, AM J PHYSIOL-ENDOC M, V280, pE443, DOI 10.1152/ajpendo.2001.280.3.E443; SMITH PA, 1989, PFLUG ARCH EUR J PHY, V413, P441, DOI 10.1007/BF00584497; Su JP, 2001, PFLUG ARCH EUR J PHY, V442, P49, DOI 10.1007/s004240000508; Swartz KJ, 1997, NEURON, V18, P665, DOI 10.1016/S0896-6273(00)80306-2; Wettwer E, 1998, BRIT J PHARMACOL, V125, P659, DOI 10.1038/sj.bjp.0702110	49	143	151	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44938	44945		10.1074/jbc.M205532200	http://dx.doi.org/10.1074/jbc.M205532200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270920	hybrid			2022-12-25	WOS:000179404800046
J	Rekas, A; Alattia, JR; Nagai, T; Miyawaki, A; Ikura, M				Rekas, A; Alattia, JR; Nagai, T; Miyawaki, A; Ikura, M			Crystal structure of Venus, a yellow fluorescent protein with improved maturation and reduced environmental sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANTS; MECHANISM	Yellow emission variants of green fluorescent protein (GFP) have been found useful in a variety of applications in biological systems due to their red-shifted emission spectrum and sensitivity to environmental parameters, such as pH and ionic strength. However, slow maturation properties and new requirements for more intense fluorescence necessitated further mutagenesis studies of these proteins. Venus, a new variant with improved maturation and brightness, as well as reduced environmental dependence, was recently developed by introducing five mutations into the well characterized variant, enhanced yellow fluorescent protein (EYFP). In this paper, we present the crystal structure of Venus at 2.2 Angstrom resolution, which enabled us to correlate its novel features with these mutation points. The rearrangement of several side chains near the chromophore, initiated by the F46L mutation, was found to improve maturation at 37degreesC by removing steric and energetic constraints, which may hinder folding of the polypeptide chain, and by accelerating the oxidation of the Calpha-Cbeta bond of Tyr(66) during chromophore formation. M153T, V163A, and S175G were also found to improve the rate of maturation by creating regions of greater flexibility. F64L induced large conformational changes in the molecule, leading to the removal of halide sensitivity by preventing ion access to the binding site.	Univ Toronto, Div Mol & Struct Biol, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; JST, PRESTO, Nakagyo Ku, Kyoto 6040847, Japan; RIKEN, Brain Sci Inst, Adv Technol Dev Ctr, Lab Cell Funct & Dynam, Wako, Saitama 3510198, Japan	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; Japan Science & Technology Agency (JST); RIKEN	Ikura, M (corresponding author), Univ Toronto, Div Mol & Struct Biol, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada.	mikura@uhnres.utoronto.ca	Miyawaki, Atsushi/K-3569-2014	Miyawaki, Atsushi/0000-0002-2329-3235; Ikura, Mitsuhiko/0000-0002-9524-1303; Nagai, Takeharu/0000-0003-2650-9895				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BASTIANUTTA R, 2000, PROTEINS, V41, P429; Bevis BJ, 2002, NAT BIOTECHNOL, V20, P83, DOI 10.1038/nbt0102-83; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Elsliger MA, 1999, BIOCHEMISTRY-US, V38, P5296, DOI 10.1021/bi9902182; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; HEIM R, 1994, P NATL ACAD SCI USA, V91, P12501, DOI 10.1073/pnas.91.26.12501; HEIM R, 1995, NATURE, V373, P663, DOI 10.1038/373663b0; Jayaraman S, 2000, J BIOL CHEM, V275, P6047, DOI 10.1074/jbc.275.9.6047; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Nagai T, 2002, NAT BIOTECHNOL, V20, P87, DOI 10.1038/nbt0102-87; Ormo M, 1996, SCIENCE, V273, P1392, DOI 10.1126/science.273.5280.1392; Phillips GN, 1997, CURR OPIN STRUC BIOL, V7, P821, DOI 10.1016/S0959-440X(97)80153-4; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; Takahashi A, 2001, BIOTECHNIQUES, V30, P804, DOI 10.2144/01304rv01; Tsien R, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P97; Wachter RM, 2000, J MOL BIOL, V301, P157, DOI 10.1006/jmbi.2000.3905; Wachter RM, 1999, CURR BIOL, V9, pR628, DOI 10.1016/S0960-9822(99)80408-4; Wachter RM, 1998, STRUCTURE, V6, P1267, DOI 10.1016/S0969-2126(98)00127-0; Ward WW, 1998, GREEN FLUORESCENT PROTEIN: PROPERTIES, APPLICATIONS, AND PROTOCOLS, P45; Yang F, 1996, NAT BIOTECHNOL, V14, P1246, DOI 10.1038/nbt1096-1246; Yarbrough D, 2001, P NATL ACAD SCI USA, V98, P462, DOI 10.1073/pnas.98.2.462; Yokoe E, 1996, NAT BIOTECHNOL, V14, P1252, DOI 10.1038/nbt1096-1252	25	145	150	1	31	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50573	50578		10.1074/jbc.M209524200	http://dx.doi.org/10.1074/jbc.M209524200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12370172	hybrid			2022-12-25	WOS:000180177700051
J	Boulanger, N; Munks, RJL; Hamilton, JV; Vovelle, F; Brun, R; Lehane, MJ; Bulet, P				Boulanger, N; Munks, RJL; Hamilton, JV; Vovelle, F; Brun, R; Lehane, MJ; Bulet, P			Epithelial innate immunity - A novel antimicrobial peptide with antiparasitic activity in the blood-sucking insect Stomoxys calcitrans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEMI-DEFINED MEDIUM; ANOPHELES-GAMBIAE; TRYPANOSOMA-BRUCEI; MOSQUITO; MIDGUT; CLONING; GENE; EXPRESSION; DEFENSIN; VECTOR	The gut epithelium is an essential interface in insects that transmit parasites. We investigated the role that local innate immunity might have on vector competence, taking Stomoxys calcitrans as a model. S. calcitrans is sympatric with tsetse flies, feeds on many of the same vertebrate hosts, and is thus regularly exposed to the trypanosomes that cause African sleeping sickness and nagana. Despite this, S. calcitrans is not a cyclical vector of these trypanosomes. Trypanosomes develop exclusively in the lumen of digestive organs, and so epithelial immune mechanisms, and in particular antimicrobial peptides (AMPs), may be the prime determinants of the fate of an infection. To investigate why S. calcitrans is not a cyclical vector of trypanosomes, we have looked in its midgut for AMPs with trypanolytic activity. We have identified a new AMP of 42 amino acids, which we named stomoxyn, constitutively expressed and secreted exclusively in the anterior midgut of S. calcitrans. It displays an amphipathic helical structure and exhibits a broad activity spectrum affecting the growth of microorganisms. Interestingly, this AMP exhibits trypanolytic activity to Trypanosoma brucei rhodesiense. We argue that stomoxyn may help to explain why S. calcitrans is not a vector of trypanosomes causing African sleeping sickness and nagana.	Inst Biol Mol & Cellulaire, F-67084 Strasbourg, France; Univ Coll N Wales, Sch Biol Sci, Bangor LL57 2UW, Gwynedd, Wales; CNRS, Ctr Biophys Mol, F-45071 Orleans 2, France; Swiss Trop Inst, CH-4002 Basel, Switzerland	Bangor University; Centre National de la Recherche Scientifique (CNRS); University of Basel; Swiss Tropical & Public Health Institute	Boulanger, N (corresponding author), Inst Biol Mol & Cellulaire, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	nboulanger@aspirine.u-strasbg.fr	Boulanger, Nathalie/ABF-1353-2020; BULET, Philippe/C-8557-2014	BULET, Philippe/0000-0001-9016-265X; Gkoutos, Georgios/0000-0002-2061-091X				ABDALLY MH, 1996, STUDY MIDGUT RESERVO; Ayabe T, 2000, NAT IMMUNOL, V1, P113, DOI 10.1038/77783; BALTZ T, 1985, EMBO J, V4, P1273, DOI 10.1002/j.1460-2075.1985.tb03772.x; Bevins CL, 1999, GUT, V45, P911, DOI 10.1136/gut.45.6.911; BILLINGSLEY PF, 1996, INSECT MIDGUT STRUCT, P3; Boulanger N, 2002, INSECT BIOCHEM MOLEC, V32, P369, DOI 10.1016/S0965-1748(02)00029-2; BRUN R, 1979, ACTA TROP, V36, P289; Dimopoulos G, 2001, CURR OPIN IMMUNOL, V13, P79, DOI 10.1016/S0952-7915(00)00186-2; Dimopoulos G, 1997, P NATL ACAD SCI USA, V94, P11508, DOI 10.1073/pnas.94.21.11508; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Hamilton JV, 2002, INSECT MOL BIOL, V11, P197, DOI 10.1046/j.1365-2583.2002.00325.x; Hao ZR, 2001, P NATL ACAD SCI USA, V98, P12648, DOI 10.1073/pnas.221363798; Hetru C, 1997, Methods Mol Biol, V78, P35; Hoffmann R, 1999, BBA-GEN SUBJECTS, V1426, P459, DOI 10.1016/S0304-4165(98)00169-X; Jordao BP, 1996, INSECT BIOCHEM MOLEC, V26, P445, DOI 10.1016/0965-1748(95)00112-3; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Lehane MJ, 1997, P NATL ACAD SCI USA, V94, P11502, DOI 10.1073/pnas.94.21.11502; Lehane SM, 1998, EUR J BIOCHEM, V254, P290, DOI 10.1046/j.1432-1327.1998.2540290.x; Lowenberger CA, 1996, EXP PARASITOL, V83, P191, DOI 10.1006/expr.1996.0066; MACVICKER JAK, 1993, J EXP BIOL, V174, P167; Munks RJL, 2001, INSECT MOL BIOL, V10, P561, DOI 10.1046/j.0962-1075.2001.00296.x; NEIMARK J, 1993, PEPTIDE RES, V6, P219; O'Brochta DA, 2000, INSECT MOL BIOL, V9, P531, DOI 10.1046/j.1365-2583.2000.00217.x; Raz B, 1997, ACTA TROP, V68, P139, DOI 10.1016/S0001-706X(97)00079-X; SAMAKOVLIS C, 1991, EMBO J, V10, P163, DOI 10.1002/j.1460-2075.1991.tb07932.x; Shahabuddin M, 1998, EXP PARASITOL, V89, P103, DOI 10.1006/expr.1998.4212; Silva PI, 2000, J BIOL CHEM, V275, P33464, DOI 10.1074/jbc.M001491200; Tarver AP, 1998, INFECT IMMUN, V66, P1045, DOI 10.1128/IAI.66.3.1045-1056.1998; Tzou P, 2000, IMMUNITY, V13, P737, DOI 10.1016/S1074-7613(00)00072-8; Vizioli J, 2000, INSECT MOL BIOL, V9, P75, DOI 10.1046/j.1365-2583.2000.00164.x; Vizioli J, 2001, P NATL ACAD SCI USA, V98, P12630, DOI 10.1073/pnas.221466798; Welburn SC, 1999, PARASITOL TODAY, V15, P399, DOI 10.1016/S0169-4758(99)01512-4	32	75	84	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49921	49926		10.1074/jbc.M206296200	http://dx.doi.org/10.1074/jbc.M206296200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12372834	hybrid, Green Published			2022-12-25	WOS:000180028900107
J	Chen, W; White, MA; Cobb, MH				Chen, W; White, MA; Cobb, MH			Stimulus-specific requirements for MAP3 kinases in activating the JNK pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; SIGNAL-TRANSDUCTION PATHWAY; BINDING PROTEINS RAC1; CELL SHEET MOVEMENT; DROSOPHILA MORPHOGENESIS; TRANSCRIPTIONAL ACTIVITY; MOLECULAR-CLONING; FAMILY; CASCADE; PHOSPHORYLATES	Mitogen-activated protein kinases (MAPKs) are activated by numerous ligands typically through a protein kinase cascade minimally composed of the MAPK in series with a MAPK kinase (MAP2K) and a MAP3K. This arrangement is thought to confer specificity and appropriate kinetic properties on the activation of MAPKs in response to physiological stimuli. Surprisingly, more than a dozen MAP3Ks have been identified that activate the c-Jun N-terminal kinases (JNKs) when overexpressed, but there is no clear understanding of which kinases actually mediate JNK activation by ligands. Here, we use double-stranded RNA-mediated interference of gene expression to reveal the explicit participation of discrete MAP3Ks in controlling JNK activity by multiple stimuli. Maximal activation of JNK by lipopolysaccharide requires the AL4LP3K TAK1. On the other hand, sorbitol requires expression of four MAP3Ks to cause maximal JNK activation. Thus, we demonstrate that specific stimuli use different mechanisms to recruit distinct MAP3Ks to regulate the JNK pathway.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Neurosci & Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NCI NIH HHS [CA 71443] Funding Source: Medline; NIGMS NIH HHS [GM 53032, GM 56498] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071443] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON NG, 1991, J BIOL CHEM, V266, P10131; Blank JL, 1996, J BIOL CHEM, V271, P5361, DOI 10.1074/jbc.271.10.5361; Chen Z, 2001, J BIOL CHEM, V276, P16070, DOI 10.1074/jbc.M100681200; CHOU MM, 1995, J BIOL CHEM, V270, P7359, DOI 10.1074/jbc.270.13.7359; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Fan G, 1996, J BIOL CHEM, V271, P24788, DOI 10.1074/jbc.271.40.24788; Fanger GR, 1997, CURR OPIN GENET DEV, V7, P67, DOI 10.1016/S0959-437X(97)80111-6; Ferrell JE, 1996, TRENDS BIOCHEM SCI, V21, P460, DOI 10.1016/S0968-0004(96)20026-X; Foltz IN, 1998, J BIOL CHEM, V273, P9344, DOI 10.1074/jbc.273.15.9344; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Glise B, 1997, GENE DEV, V11, P1738, DOI 10.1101/gad.11.13.1738; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HARDEN N, 1995, DEVELOPMENT, V121, P903; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hirai S, 1997, J BIOL CHEM, V272, P15167, DOI 10.1074/jbc.272.24.15167; Holland PM, 1997, J BIOL CHEM, V272, P24994, DOI 10.1074/jbc.272.40.24994; Hou XS, 1997, GENE DEV, V11, P1728, DOI 10.1101/gad.11.13.1728; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Inoue H, 2001, EMBO J, V20, P5421, DOI 10.1093/emboj/20.19.5421; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Karandikar M, 2000, J BIOL CHEM, V275, P40120, DOI 10.1074/jbc.M005926200; KhosraviFar R, 1998, ADV CANCER RES, V72, P57; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lawler S, 1998, CURR BIOL, V8, P1387, DOI 10.1016/S0960-9822(98)00019-0; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; Mihaly J, 2001, MECH DEVELOP, V102, P67, DOI 10.1016/S0925-4773(01)00285-4; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; Noselli S, 1999, CURR OPIN GENET DEV, V9, P466, DOI 10.1016/S0959-437X(99)80071-9; Plowman GD, 1999, P NATL ACAD SCI USA, V96, P13603, DOI 10.1073/pnas.96.24.13603; Rana A, 1996, J BIOL CHEM, V271, P19025, DOI 10.1074/jbc.271.32.19025; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; Sajan MP, 2002, BIOCHEM J, V362, P665, DOI 10.1042/0264-6021:3620665; Salmeron A, 1996, EMBO J, V15, P817, DOI 10.1002/j.1460-2075.1996.tb00417.x; Sluss HK, 1996, GENE DEV, V10, P2745, DOI 10.1101/gad.10.21.2745; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Takatsu Y, 2000, MOL CELL BIOL, V20, P3015, DOI 10.1128/MCB.20.9.3015-3026.2000; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1996, EMBO J, V15, P7026, DOI 10.1002/j.1460-2075.1996.tb01094.x; Tournier C, 2001, GENE DEV, V15, P1419, DOI 10.1101/gad.888501; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VAN AL, 1997, GENE DEV, V11, P2295; Wallner EI, 2001, RENAL FAILURE, V23, P311, DOI 10.1081/JDI-100104715; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wang XHS, 1996, J BIOL CHEM, V271, P31607; Wang XHSN, 1998, BIOCHEM BIOPH RES CO, V253, P33, DOI 10.1006/bbrc.1998.9749; WORBY CA, 2001, SCI STKE, pL1; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Xu SC, 1997, J BIOL CHEM, V272, P32056, DOI 10.1074/jbc.272.51.32056; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Young PR, 1998, CYTOKINE GROWTH F R, V9, P239, DOI 10.1016/S1359-6101(98)00011-2; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	65	70	74	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49105	49110		10.1074/jbc.M204934200	http://dx.doi.org/10.1074/jbc.M204934200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12351623	hybrid			2022-12-25	WOS:000180028900003
J	Pearson, GW; Cobb, MH				Pearson, GW; Cobb, MH			Cell condition-dependent regulation of ERK5 by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; EPIDERMAL GROWTH-FACTOR; MAP KINASE; SIGNALING PATHWAY; TYROSINE KINASES; SKELETAL-MUSCLE; CYCLIC-AMP; PC12 CELLS; S6 KINASE; RECEPTOR	ERK5 activity is increased by agents known to activate receptor tyrosine kinases, G-protein coupled receptors, and stress response pathways. We now find a role for cAMP in the regulation of ERK5. ERK5 is activated by forskolin, isoproterenol, and epinephrine in NIH3T3 cells and C2C12 myoblasts. ERK1/2 are also activated by cAMP in NIH3T3 cells, but not in C2C12 myoblasts, demonstrating differential regulation of ERK5 and ERK1/2 by cAMP. We examined the effect of cell context on activation of ERK5 and discovered ERK5 activity is inhibited, rather than activated, by cAMP in confluent, serum-deprived NIH3T3 cells and C2C12 myoblasts. Our results suggest that regulation of MAP kinase pathways by cAMP is not only dictated by cell type, but also by cell context.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Cobb, MH (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Cobb, Melanie/0000-0003-0833-5473	NIDDK NIH HHS [DK34128] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034128, R01DK034128] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABELL CW, 1973, J CELL BIOL, V59, P549, DOI 10.1083/jcb.59.3.549; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Calleja V, 1997, ENDOCRINOLOGY, V138, P1111, DOI 10.1210/en.138.3.1111; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; Cavanaugh JE, 2001, J NEUROSCI, V21, P434, DOI 10.1523/JNEUROSCI.21-02-00434.2001; Chao TH, 1999, J BIOL CHEM, V274, P36035, DOI 10.1074/jbc.274.51.36035; ChoChung YS, 1995, CRIT REV ONCOL HEMAT, V21, P33, DOI 10.1016/1040-8428(94)00166-9; Ciardiello F, 1998, CLIN CANCER RES, V4, P821; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; De Potter IY, 2001, EXP CELL RES, V271, P315, DOI 10.1006/excr.2001.5390; Diaz-Meco MT, 2001, MOL CELL BIOL, V21, P1218, DOI 10.1128/MCB.21.4.1218-1227.2001; Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo-reports/kve177; Dong F, 2001, J BIOL CHEM, V276, P10811, DOI 10.1074/jbc.M008748200; English JM, 1999, J BIOL CHEM, V274, P31588, DOI 10.1074/jbc.274.44.31588; Faour WH, 2001, J BIOL CHEM, V276, P31720, DOI 10.1074/jbc.M104036200; GILMAN AG, 1995, BIOSCIENCE REP, V15, P65, DOI 10.1007/BF01200143; Hayashi M, 2001, J BIOL CHEM, V276, P8631, DOI 10.1074/jbc.C000838200; Holcik M, 2001, APOPTOSIS, V6, P253, DOI 10.1023/A:1011379307472; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kato Y, 2000, J BIOL CHEM, V275, P18534, DOI 10.1074/jbc.M001573200; Kato Y, 1998, NATURE, V395, P713, DOI 10.1038/27234; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; Li XA, 2001, J SURG RES, V100, P197, DOI 10.1006/jsre.2001.6238; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Napoli R, 1998, DIABETES, V47, P1549, DOI 10.2337/diabetes.47.10.1549; Pearson G, 2001, J BIOL CHEM, V276, P7927, DOI 10.1074/jbc.M009764200; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; PETRITSCH C, 1995, J BIOL CHEM, V270, P26619, DOI 10.1074/jbc.270.44.26619; Pomerance M, 2000, J BIOL CHEM, V275, P40539, DOI 10.1074/jbc.M002097200; Ramakrishna G, 2000, EXP LUNG RES, V26, P659, DOI 10.1080/01902140150216747; Richards JS, 2001, MOL ENDOCRINOL, V15, P209, DOI 10.1210/me.15.2.209; Sanada S, 2001, CIRCULATION, V104, P705, DOI 10.1161/hc3201.092216; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; Sun WY, 2001, J BIOL CHEM, V276, P5093, DOI 10.1074/jbc.M003719200; Tokuda H, 2001, J ENDOCRINOL, V170, P629, DOI 10.1677/joe.0.1700629; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Watson FL, 2001, NAT NEUROSCI, V4, P981, DOI 10.1038/nn720; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yan C, 1999, J BIOL CHEM, V274, P143, DOI 10.1074/jbc.274.1.143; YOUNG SW, 1994, FEBS LETT, V338, P212, DOI 10.1016/0014-5793(94)80367-6; Zhen XC, 1998, MOL PHARMACOL, V54, P453, DOI 10.1124/mol.54.3.453; Zheng M, 2000, J BIOL CHEM, V275, P40635, DOI 10.1074/jbc.M006325200	49	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48094	48098		10.1074/jbc.M208535200	http://dx.doi.org/10.1074/jbc.M208535200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12297510	hybrid			2022-12-25	WOS:000179789600017
J	Tomita, K; Weiner, AM				Tomita, K; Weiner, AM			Closely related CC- and A-adding enzymes collaborate to construct and repair the 3 '-terminal. CCA of tRNA in Synechopystis sp and Deinococcus radiodurans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA NUCLEOTIDYLTRANSFERASE; COMPLETE GENOME SEQUENCE; ESCHERICHIA-COLI; SULFOLOBUS-SHIBATAE; POLY(A) POLYMERASE; BACILLUS-SUBTILIS; AQUIFEX-AEOLICUS; AMINOACYLATION; SUPERFAMILY; ALIGNMENT	The 3'-terminal CCA sequence of tRNA is faithfully constructed and repaired by the CCA-adding enzyme (ATP(CTP):tRNA nucleotidyltransferase) using CTP and ATP as substrates but no nucleic acid template. Until recently, all CCA-adding enzymes from all three kingdoms appeared to be composed of a single kind of polypeptide with dual specificity for adding both CTP and ATP; however, we recently found that in Aquifex aeolicus, which lies near the deepest root of the eubacterial 16 S rRNA-based phylogenetic tree, CCA addition represents a collaboration between closely related CC-adding and A-adding enzymes (Tomita, K. and Weiner, A. M. (2001) Science 294,1334-1336). Here we show that in Synechocystis sp. and Deinococcus radiodurans, as in A aeolicus, CCA is added by homologous CC- and A-adding enzymes. We also find that the eubacterial CCA-, CC-, and A-adding enzymes, as well as the related eubacterial poly(A) polymerases, each fall into phylogenetically distinct groups derived from a common ancestor. Intriguingly, the Thermatoga maritima CCA-adding enzyme groups with the A-adding enzymes, suggesting that these distinct tRNA nucleotidyltransferase activities can intraconvert over evolutionary time.	Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Weiner, AM (corresponding author), Univ Washington, Sch Med, Dept Biochem, Seattle, WA 98195 USA.	amweiner@u.washington.edu	Tomita, Kozo/J-5746-2013; Tomita, Kozo/E-9390-2017	Tomita, Kozo/0000-0002-7374-3898	NIGMS NIH HHS [GM59804] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059804] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AEBI M, 1990, J BIOL CHEM, V265, P16216; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; CAZENAVE C, 1994, P NATL ACAD SCI USA, V91, P6972, DOI 10.1073/pnas.91.15.6972; Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DEUTSCHER MP, 1972, J BIOL CHEM, V247, P459; DEUTSCHER MP, 1983, TRNA NUCLEOTIDYLTR 2, P159; Feng WQ, 2002, P NATL ACAD SCI USA, V99, P5412, DOI 10.1073/pnas.082682699; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; GUERRIERTAKADA C, 1984, CELL, V38, P219, DOI 10.1016/0092-8674(84)90543-9; Gupta RS, 1997, J BACTERIOL, V179, P345, DOI 10.1128/jb.179.2.345-357.1997; Gupta RS, 1998, J MOL EVOL, V46, P716, DOI 10.1007/PL00006352; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P345, DOI 10.1016/S0968-0004(00)89071-4; KALAPOS MP, 1994, BIOCHEM BIOPH RES CO, V198, P459, DOI 10.1006/bbrc.1994.1067; Kaneko T, 1996, DNA Res, V3, P109; Kim DF, 1999, MOL CELL, V4, P859, DOI 10.1016/S1097-2765(00)80395-0; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Martin G, 1996, EMBO J, V15, P2593, DOI 10.1002/j.1460-2075.1996.tb00617.x; MASTERS M, 1990, MOL GEN GENET, V220, P341; Mohan A, 1999, RNA, V5, P245, DOI 10.1017/S1355838299981256; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; OH BK, 1994, NUCLEIC ACIDS RES, V22, P4087, DOI 10.1093/nar/22.20.4087; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Raynal LC, 1998, J BACTERIOL, V180, P6276; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Sprinzl M, 1979, Prog Nucleic Acid Res Mol Biol, V22, P1, DOI 10.1016/S0079-6603(08)60798-9; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; TAMURA K, 1994, J BIOL CHEM, V269, P22173; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomari Y, 2000, GENES CELLS, V5, P689, DOI 10.1046/j.1365-2443.2000.00360.x; Tomita K, 2001, SCIENCE, V294, P1334, DOI 10.1126/science.1063816; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571; Woese CR, 2000, P NATL ACAD SCI USA, V97, P8392, DOI 10.1073/pnas.97.15.8392; Yue DX, 1996, RNA, V2, P895; ZHU LQ, 1987, EMBO J, V6, P2473, DOI 10.1002/j.1460-2075.1987.tb02528.x	45	41	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48192	48198		10.1074/jbc.M207527200	http://dx.doi.org/10.1074/jbc.M207527200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12370185	hybrid			2022-12-25	WOS:000179789600030
J	Whitehead, SE; Jones, KW; Zhang, X; Cheng, XD; Terns, RM; Terns, MP				Whitehead, SE; Jones, KW; Zhang, X; Cheng, XD; Terns, RM; Terns, MP			Determinants of the interaction of the spinal muscular atrophy disease protein SMN with the dimethylarginine-modified box EUACA small nucleolar ribonucleoprotein GAR1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-BINDING PROTEIN; SPLICEOSOMAL-U-SNRNP; ARGININE METHYLATION; RIBOSOMAL-RNA; IN-VITRO; COILED BODIES; SUBCELLULAR-LOCALIZATION; GENE-PRODUCT; PSEUDOURIDINE SYNTHASE; H/ACA SNORNPS	Deletion or mutation of the SMN1 (survival of motor neurons) gene causes the common, fatal neuromuscular disease spinal muscular atrophy. The SMN protein is important in small nuclear ribonucleoprotein (snRNP) assembly and interacts with snRNP proteins via arginine/glycine-rich domains. Recently, SMN was also found to interact with core protein components of the two major families of small nucleolar RNPs, fibrillarin and GAR1, suggesting that SMN may also function in the assembly of small nucleolar RNPs. Here we present results that indicate that the interaction of SMN with GAR1 is mediated by the Tudor domain of SMN. Single point mutations within the Tudor domain, including a spinal muscular atrophy patient mutation, impair the interaction of SMN with GAR1. Furthermore, we find that either of the two arginine/glycine-rich domains of GAR1 can provide for interaction with SMN, but removal of both results in loss of the interaction. Finally, we have found that unlike the interaction of SMN with the Sm snRNP proteins, interaction with GAR1 and fibrillarin is not enhanced by arginine dimethylation. Our results argue against post-translational arginine dimethylation as a general requirement for SMN recognition of proteins bearing arginine/glycine-rich domains.	Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA; Univ Georgia, Dept Genet, Athens, GA 30602 USA; Emory Univ, Sch Med, Dept Biochem, Atlanta, GA 30322 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Emory University	Terns, MP (corresponding author), Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA.	mterns@bmb.uga.edu	Terns, Michael/N-6435-2016		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061355, R01GM054682] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM61355, GM54682] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bagni C, 1998, J BIOL CHEM, V273, P10868, DOI 10.1074/jbc.273.18.10868; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Bechade C, 1999, EUR J NEUROSCI, V11, P293, DOI 10.1046/j.1460-9568.1999.00428.x; Bedford MT, 2000, J BIOL CHEM, V275, P16030, DOI 10.1074/jbc.M909368199; Brahms H, 2000, J BIOL CHEM, V275, P17122, DOI 10.1074/jbc.M000300200; Brahms H, 2001, RNA, V7, P1531, DOI 10.1017/S135583820101442X; Branscombe TL, 2001, J BIOL CHEM, V276, P32971, DOI 10.1074/jbc.M105412200; Buhler D, 1999, HUM MOL GENET, V8, P2351, DOI 10.1093/hmg/8.13.2351; Carvalho T, 1999, J CELL BIOL, V147, P715, DOI 10.1083/jcb.147.4.715; Cavaille J, 2000, P NATL ACAD SCI USA, V97, P14311, DOI 10.1073/pnas.250426397; CHRISTENSEN ME, 1988, BIOCHEM BIOPH RES CO, V155, P1278, DOI 10.1016/S0006-291X(88)81279-8; de los Santos T, 2000, AM J HUM GENET, V67, P1067, DOI 10.1086/303106; Dez C, 2001, NUCLEIC ACIDS RES, V29, P598, DOI 10.1093/nar/29.3.598; Dragon F, 2000, MOL CELL BIOL, V20, P3037, DOI 10.1128/MCB.20.9.3037-3048.2000; Filipowicz W, 1999, ACTA BIOCHIM POL, V46, P377, DOI 10.18388/abp.1999_4171; Fischer U, 1997, CELL, V90, P1023, DOI 10.1016/S0092-8674(00)80368-2; Francis JW, 1998, P NATL ACAD SCI USA, V95, P6492, DOI 10.1073/pnas.95.11.6492; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Friesen MJ, 2000, J BIOL CHEM, V275, P26370, DOI 10.1074/jbc.M003299200; Friesen WJ, 2001, MOL CELL BIOL, V21, P8289, DOI 10.1128/MCB.21.24.8289-8300.2001; Friesen WJ, 2001, MOL CELL, V7, P1111, DOI 10.1016/S1097-2765(01)00244-1; Gall JG, 2000, ANNU REV CELL DEV BI, V16, P273, DOI 10.1146/annurev.cellbio.16.1.273; Ganot P, 1997, GENE DEV, V11, P941, DOI 10.1101/gad.11.7.941; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Green DM, 2002, J BIOL CHEM, V277, P7752, DOI 10.1074/jbc.M110053200; Hebert MD, 2001, GENE DEV, V15, P2720, DOI 10.1101/gad.908401; Henras A, 1998, EMBO J, V17, P7078, DOI 10.1093/emboj/17.23.7078; Henras A, 2001, NUCLEIC ACIDS RES, V29, P2733, DOI 10.1093/nar/29.13.2733; Henry MF, 1996, MOL CELL BIOL, V16, P3668; Jones KW, 2001, J BIOL CHEM, V276, P38645, DOI 10.1074/jbc.M106161200; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Le TT, 2000, NEUROGENETICS, V3, P7, DOI 10.1007/s100480000090; Lefebvre S, 1998, HUM MOL GENET, V7, P1531, DOI 10.1093/hmg/7.10.1531; LEFEBVRE S, 1995, CELL, V80, P155, DOI 10.1016/0092-8674(95)90460-3; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; Liu Q, 1997, CELL, V90, P1013, DOI 10.1016/S0092-8674(00)80367-0; Liu Q, 1996, EMBO J, V15, P3555, DOI 10.1002/j.1460-2075.1996.tb00725.x; LIU Q, 1995, MOL CELL BIOL, V15, P2800; Lorson CL, 1998, NAT GENET, V19, P63, DOI 10.1038/ng0598-63; Lukowiak AA, 2001, RNA, V7, P1833; Matera AG, 1998, AM J HUM GENET, V63, P317, DOI 10.1086/301992; McBride AE, 2001, CELL, V106, P5, DOI 10.1016/S0092-8674(01)00423-8; Meguro M, 2001, HUM MOL GENET, V10, P383, DOI 10.1093/hmg/10.4.383; Meister G, 2000, HUM MOL GENET, V9, P1977, DOI 10.1093/hmg/9.13.1977; Meister G, 2001, CURR BIOL, V11, P1990, DOI 10.1016/S0960-9822(01)00592-9; Meister G, 2001, NAT CELL BIOL, V3, P945, DOI 10.1038/ncb1101-945; Mishra RK, 1997, P NATL ACAD SCI USA, V94, P4972, DOI 10.1073/pnas.94.10.4972; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Mitchell JR, 1999, NATURE, V402, P551, DOI 10.1038/990141; Mourelatos Z, 2001, EMBO J, V20, P5443, DOI 10.1093/emboj/20.19.5443; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; Narayanan A, 1999, MOL BIOL CELL, V10, P2131, DOI 10.1091/mbc.10.7.2131; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Pagliardini S, 2000, HUM MOL GENET, V9, P47, DOI 10.1093/hmg/9.1.47; Pellizzoni L, 1999, P NATL ACAD SCI USA, V96, P11167, DOI 10.1073/pnas.96.20.11167; Pellizzoni L, 1998, CELL, V95, P615, DOI 10.1016/S0092-8674(00)81632-3; Pellizzoni L, 2001, J CELL BIOL, V152, P75, DOI 10.1083/jcb.152.1.75; Pellizzoni L, 2001, CURR BIOL, V11, P1079, DOI 10.1016/S0960-9822(01)00316-5; Pogacic V, 2000, MOL CELL BIOL, V20, P9028, DOI 10.1128/MCB.20.23.9028-9040.2000; Ponting CP, 1997, TRENDS BIOCHEM SCI, V22, P51, DOI 10.1016/S0968-0004(96)30049-2; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; Rossoll W, 2002, HUM MOL GENET, V11, P93, DOI 10.1093/hmg/11.1.93; Samarsky DA, 1998, EMBO J, V17, P3747, DOI 10.1093/emboj/17.13.3747; Selenko P, 2001, NAT STRUCT BIOL, V8, P27; Sendtner M, 2001, CURR OPIN NEUROL, V14, P629, DOI 10.1097/00019052-200110000-00012; Siebel CW, 1996, P NATL ACAD SCI USA, V93, P13641, DOI 10.1073/pnas.93.24.13641; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Snaar S, 2000, J CELL BIOL, V151, P653, DOI 10.1083/jcb.151.3.653; Tang J, 2000, J BIOL CHEM, V275, P19866, DOI 10.1074/jbc.M000023200; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; Terns MP, 2002, GENE EXPRESSION, V10, P17; Terns MP, 2001, CURR BIOL, V11, pR862, DOI 10.1016/S0960-9822(01)00517-6; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; Valentini SR, 1999, RNA, V5, P272, DOI 10.1017/S1355838299981633; Verheggen C, 2001, EMBO J, V20, P5480, DOI 10.1093/emboj/20.19.5480; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Young PJ, 2000, HUM MOL GENET, V9, P2869, DOI 10.1093/hmg/9.19.2869; Young PJ, 2001, EXP CELL RES, V265, P252, DOI 10.1006/excr.2001.5186; Young PJ, 2000, EXP CELL RES, V256, P365, DOI 10.1006/excr.2000.4858	83	44	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48087	48093		10.1074/jbc.M204551200	http://dx.doi.org/10.1074/jbc.M204551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12244096	hybrid			2022-12-25	WOS:000179789600016
J	Dorsam, RT; Kim, S; Jin, JG; Kunapuli, SP				Dorsam, RT; Kim, S; Jin, JG; Kunapuli, SP			Coordinated signaling through both G(12/13) and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBIT ADENYLYL CYCLASE; SHAPE CHANGE; G-PROTEINS; INTEGRIN ALPHA(IIB)BETA(3); ANTITHROMBOTIC DRUGS; THROMBOXANE A(2); MOLECULAR-BASIS; ADP RECEPTORS; KINASE; THROMBIN	Activation of GPIIb/IIIa is known to require agonist-induced inside-out signaling through G(q), G(i), and G(z). Although activated by several platelet agonists, including thrombin and thromboxane A(2), the contribution of the G(12/13) signaling pathway to GPIIb/IIIa activation has not been investigated. In this study, we used selective stimulation of G protein pathways to investigate the contribution of G(12/13) activation to platelet fibrinogen receptor activation. YFLLRNP is a PAR-1-specific partial agonist that, at low concentrations (60 muM), selectively activates the G(12/13) signaling cascade resulting in platelet shape change without stimulating the G(q) or G(i) signaling pathways. YFLLRNP-mediated shape change was completely inhibited by the p160(ROCK) inhibitor, Y-27632. At this low concentration, YFLLRNP-mediated G(12/13) signaling caused platelet aggregation and enhanced PAC-1 binding when combined with selective G(i) or G(z) signaling, via selective stimulation of the P2Y(12) receptor or alpha(2A)-adrenergic receptor, respectively. Similar data were obtained when using low dose U46619 (10 nM), a thromboxane A(2) mimetic, to activate G(12/13) in the presence of G(i) signaling. These results suggest that selective activation of G(12/13) causes platelet GPIIb/IIIa activation when combined with G(i) signaling. Unlike either G(12/13) or G(i) activation alone, co-activation of both G(12/13) and G(i) resulted in a small increase in intracellular calcium. Chelation of intracellular calcium with dimethyl BAPTA dramatically blocked G(12/13) and G(i)-mediated platelet aggregation. No significant effect on aggregation was seen when using selective inhibitors for p160(ROCK), PKC, or MEKK1. PI 3-kinase inhibition lead to near abolishment of platelet aggregation induced by co-stimulation of G(q) and G(i) pathways, but not by G(12/13) and G(i) pathways. These data demonstrate that co-stimulation of G(12/13) and G(i) pathways is sufficient to activate GPIIb/IIIa in human platelets in a mechanism that involves intracellular calcium, and that PI 3-kinase is an important signaling molecule downstream of G(q) but not downstream of G(12/13) pathway.	Temple Univ, Sch Med, Dept Physiol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19140 USA; Temple Univ, Sch Med, Sol Sherry Thrombosis Res Ctr, Philadelphia, PA 19140 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Kunapuli, SP (corresponding author), Temple Univ, Sch Med, Dept Physiol, Rm 224,OMS,3420 Broad St, Philadelphia, PA 19140 USA.	kunapuli@nimbus.temple.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060683, T32HL007777, P01HL064943] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64943, T32 HL07777, HL60683] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banfic H, 1998, J BIOL CHEM, V273, P13, DOI 10.1074/jbc.273.1.13; Bauer M, 1999, BLOOD, V94, P1665, DOI 10.1182/blood.V94.5.1665.417k33_1665_1672; Bauer M, 2001, THROMB HAEMOSTASIS, V85, P331, DOI 10.1055/s-0037-1615689; BRASS LF, 1988, J BIOL CHEM, V263, P5348; Brass LF, 1997, THROMB HAEMOSTASIS, V78, P581; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Coughlin SR, 1999, P NATL ACAD SCI USA, V96, P11023, DOI 10.1073/pnas.96.20.11023; Dangelmaier C, 2001, THROMB HAEMOSTASIS, V85, P341, DOI 10.1055/s-0037-1615690; Daniel JL, 1998, J BIOL CHEM, V273, P2024, DOI 10.1074/jbc.273.4.2024; Foster CJ, 2001, J CLIN INVEST, V107, P1591, DOI 10.1172/JCI12242; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hirsch E, 2001, FASEB J, V15, P2019, DOI 10.1096/fj.00-0810fje; Hollopeter G, 2001, NATURE, V409, P202, DOI 10.1038/35051599; HUNG DT, 1992, J BIOL CHEM, V267, P20831; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; Jin JG, 1998, J BIOL CHEM, V273, P2030, DOI 10.1074/jbc.273.4.2030; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; Klages B, 1999, J CELL BIOL, V144, P745, DOI 10.1083/jcb.144.4.745; KUNAPULI SP, 1994, BIOCHEM J, V298, P263, DOI 10.1042/bj2980263; LANZA F, 1988, AM J PHYSIOL, V255, pH1276, DOI 10.1152/ajpheart.1988.255.6.H1276; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; McNicol A, 1998, BIOCHEM PHARMACOL, V55, P1759, DOI 10.1016/S0006-2952(97)00632-1; MILLIGAN G, 1992, FEBS LETT, V297, P186, DOI 10.1016/0014-5793(92)80357-M; Mills DCB, 1996, THROMB HAEMOSTASIS, V76, P835; NIESWANDT B, 2002, J BIOL CHEM; Offermanns S, 2000, BIOL CHEM, V381, P389, DOI 10.1515/BC.2000.051; OFFERMANNS S, 1994, P NATL ACAD SCI USA, V91, P504, DOI 10.1073/pnas.91.2.504; Offermanns S, 1997, NATURE, V389, P183, DOI 10.1038/38284; Ohkubo S, 1996, BRIT J PHARMACOL, V117, P1095, DOI 10.1111/j.1476-5381.1996.tb16702.x; Pasquet JM, 2002, THROMB HAEMOSTASIS, V88, P115; Paul BZS, 1999, J BIOL CHEM, V274, P29108, DOI 10.1074/jbc.274.41.29108; Paul BZS, 1999, J BIOL CHEM, V274, P28293, DOI 10.1074/jbc.274.40.28293; QUINTON TM, 2002, IN PRESS BIOCH J; RASMUSSEN UB, 1993, J BIOL CHEM, V268, P14322; RAYCHOWDHURY MK, 1995, J BIOL CHEM, V270, P7011, DOI 10.1074/jbc.270.12.7011; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; Rosado JA, 2001, J BIOL CHEM, V276, P15659, DOI 10.1074/jbc.M009218200; Salomon Y, 1979, Adv Cyclic Nucleotide Res, V10, P35; Shattil SJ, 1998, BLOOD, V91, P2645, DOI 10.1182/blood.V91.8.2645.2645_2645_2657; SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMPSON AWM, 1986, FEBS LETT, V201, P301, DOI 10.1016/0014-5793(86)80628-7; STEEN VM, 1993, THROMB HAEMOSTASIS, V70, P506; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597	46	103	103	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47588	47595		10.1074/jbc.M208778200	http://dx.doi.org/10.1074/jbc.M208778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12297512	hybrid			2022-12-25	WOS:000179663700098
J	Moore, KJ; El Khoury, J; Medeiros, LA; Terada, K; Geula, C; Luster, AD; Freeman, MW				Moore, KJ; El Khoury, J; Medeiros, LA; Terada, K; Geula, C; Luster, AD; Freeman, MW			A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE SCAVENGER RECEPTORS; NITRIC-OXIDE SYNTHASE; ALZHEIMERS-DISEASE; PPAR-GAMMA; TNF-ALPHA; MICROGLIA; CD36; ATHEROSCLEROSIS; NEUROTOXICITY; PATHWAYS	beta-Amyloid accumulation is associated with pathologic changes in the brain in Alzheimer's disease and has recently been identified in plaques of another chronic inflammatory disorder, atherosclerosis. The class B scavenger receptor, CD36, mediates binding of fibrillar beta-amyloid to cells of the monocyte/macrophage lineage, including brain macrophages (microglia). In this study, we demonstrate that in microglia and other tissue macrophages, beta-amyloid initiates a CD36-dependent signaling cascade involving the Src kinase family members, Lyn and Fyn, and the mitogen-activated protein kinase, p44/42. Interruption of this signaling cascade, through targeted disruption of Src kinases downstream of CD36, inhibits macrophage inflammatory responses to beta-amyloid, including reactive oxygen and chemokine production, and results in decreased recruitment of microglia to sites of amyloid deposition in vivo. The finding that engagement of CD36 by beta-amyloid initiates a Src kinase-dependent production of inflammatory mediators in cells of the macrophage lineage reveals a novel receptor-mediated pro-inflammatory signaling pathway of potential therapeutic importance.	Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lipid Metab Unit, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med,Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA; Harvard Univ, Massachusetts Gen Hosp, Neurosurg Serv, Boston, MA 02114 USA; Beth Israel Deaconess Med Ctr, Div Aging, Boston, MA 02114 USA	Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Harvard Medical School; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Beth Israel Deaconess Medical Center	Freeman, MW (corresponding author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Lipid Metab Unit, 55 Fruit St,GRJ 1328, Boston, MA 02114 USA.		Luster, Andrew/ABE-6504-2020; Moore, Kathryn/ABE-6416-2020	Luster, Andrew/0000-0001-9679-7912; Moore, Kathryn/0000-0003-2505-2547	NHLBI NIH HHS [R01 HL45098] Funding Source: Medline; NIA NIH HHS [R01AG20255-01] Funding Source: Medline; NIDDK NIH HHS [P01 DK50305] Funding Source: Medline; NINDS NIH HHS [NS41330-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K08NS041330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG020255] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiyama H, 2000, NEUROBIOL AGING, V21, P383, DOI 10.1016/S0197-4580(00)00124-X; Combs CK, 2000, J NEUROSCI, V20, P558, DOI 10.1523/JNEUROSCI.20-02-00558.2000; Combs CK, 2001, J NEUROSCI, V21, P1179; Combs CK, 1999, J NEUROSCI, V19, P928; Coraci IS, 2002, AM J PATHOL, V160, P101, DOI 10.1016/S0002-9440(10)64354-4; De Meyer GRY, 2002, CIRC RES, V90, P1197, DOI 10.1161/01.RES.0000020017.84398.61; El Khoury J, 1998, NEUROBIOL AGING, V19, pS81, DOI 10.1016/S0197-4580(98)00036-0; ElKhoury J, 1996, NATURE, V382, P716; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Frautschy SA, 1998, AM J PATHOL, V152, P307; Geula C, 1998, NAT MED, V4, P827, DOI 10.1038/nm0798-827; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; Jimenez B, 2000, NAT MED, V6, P41, DOI 10.1038/71517; Klein AM, 1999, ANN NY ACAD SCI, V893, P314, DOI 10.1111/j.1749-6632.1999.tb07845.x; McDonald DR, 1997, J NEUROSCI, V17, P2284; McDonald DR, 1998, J NEUROSCI, V18, P4451; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; Podrez EA, 2000, J CLIN INVEST, V105, P1095, DOI 10.1172/JCI8574; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sakaguchi H, 1998, LAB INVEST, V78, P423; Smits HA, 2001, J NEUROIMMUNOL, V115, P144, DOI 10.1016/S0165-5728(01)00254-5; Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0; Tedgui A, 2002, CIRC RES, V90, P1145, DOI 10.1161/01.RES.0000023048.87638.92; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Weldon DT, 1998, J NEUROSCI, V18, P2161; WOOD JG, 1991, NEUROSCI LETT, V121, P12, DOI 10.1016/0304-3940(91)90637-9	30	280	293	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47373	47379		10.1074/jbc.M208788200	http://dx.doi.org/10.1074/jbc.M208788200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12239221	hybrid			2022-12-25	WOS:000179663700070
J	Nappi, VM; Schaefer, JA; Petti, LM				Nappi, VM; Schaefer, JA; Petti, LM			Molecular examination of the transmembrane requirements of the platelet-derived growth factor beta receptor for a productive interaction with the bovine papillomavirus E5 oncoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN READING FRAME; TRANSFORMING PROTEIN; ALPHA-HELICES; AMINO-ACIDS; CELLULAR-TRANSFORMATION; MUTATIONAL ANALYSIS; TYROSINE KINASE; C127 CELLS; DOMAIN; ACTIVATION	The small transmembrane E5 protein of bovine papillomavirus (BPV) transforms cells by forming a stable complex with and activating the platelet-derived growth factor beta receptor (PDGFbetaR). The E5/PDGFbetaR interaction is thought to involve specific physical contacts between the transmembrane domains of the two proteins. Lys(499) at the extracellular juxtamembrane position and Thr(513) within the transmembrane domain of the PDGFbetaR are required for the interaction and are predicted to contact analogously positioned residues in the E5 protein. Here, mutagenic analysis of the transmembrane region of the PDGFbetaR was performed to further characterize the nature of the E5/PDGFbetaR interaction. We show that the receptor transmembrane domain with minimal extracellular and intracellular sequence: is sufficient for the interaction. In addition, we provide evidence that the polar nature of Thr(513) as well; as its positioning along the transmembrane a-helix is Important for the interaction. We also identify the receptor transmembrane amino acids Ile(506) and Leu(520) as additional requirements for the interaction. Because Lys(499), Thr(513), Ile(506), and Leu(520) all align along the same face of the predicted PDGFbetaR transmembrane alpha-helix, our data support the model that the PDGFbetaR contacts the E5 protein via multiple amino acids along a single alpha-helical interface.	Albany Med Coll, Albany, NY 12208 USA	Albany Medical College	Petti, LM (corresponding author), Albany Med Coll, Albany, NY 12208 USA.				NATIONAL CANCER INSTITUTE [R29CA073682] Funding Source: NIH RePORTER; NCI NIH HHS [CA73682] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adduci AJ, 1999, J BIOL CHEM, V274, P10249, DOI 10.1074/jbc.274.15.10249; Bell CA, 2000, MOL BIOL CELL, V11, P3589, DOI 10.1091/mbc.11.10.3589; BERGMAN P, 1988, ONCOGENE, V2, P453; BURKHARDT A, 1987, EMBO J, V6, P2381, DOI 10.1002/j.1460-2075.1987.tb02515.x; BURKHARDT A, 1989, VIROLOGY, V170, P334, DOI 10.1016/0042-6822(89)90391-7; CLAESSONWELSH L, 1988, MOL CELL BIOL, V8, P3476, DOI 10.1128/MCB.8.8.3476; COHEN BD, 1993, MOL CELL BIOL, V13, P6462, DOI 10.1128/MCB.13.10.6462; COHEN BD, 1993, J VIROL, V67, P5303, DOI 10.1128/JVI.67.9.5303-5311.1993; Cornea RL, 2000, J BIOL CHEM, V275, P41487, DOI 10.1074/jbc.M008195200; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DRUMMONDBARBOSA D, 1995, MOL CELL BIOL, V15, P2570; DVORETZKY I, 1980, VIROLOGY, V103, P369, DOI 10.1016/0042-6822(80)90195-6; GOLDSTEIN DJ, 1990, EMBO J, V9, P137, DOI 10.1002/j.1460-2075.1990.tb08089.x; GOLDSTEIN DJ, 1992, EMBO J, V11, P4851, DOI 10.1002/j.1460-2075.1992.tb05591.x; GOLDSTEIN DJ, 1991, NATURE, V352, P347, DOI 10.1038/352347a0; GOLDSTEIN DJ, 1994, J VIROL, V68, P4432, DOI 10.1128/JVI.68.7.4432-4441.1994; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HORWITZ BH, 1988, MOL CELL BIOL, V8, P4071, DOI 10.1128/MCB.8.10.4071; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Klein O, 1998, J VIROL, V72, P8921, DOI 10.1128/JVI.72.11.8921-8932.1998; KULKE R, 1992, J VIROL, V66, P505, DOI 10.1128/JVI.66.1.505-511.1992; Lai CC, 1998, P NATL ACAD SCI USA, V95, P15241, DOI 10.1073/pnas.95.26.15241; LANCASTER WD, 1982, MICROBIOL REV, V46, P191, DOI 10.1128/MMBR.46.2.191-207.1982; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, Q REV BIOPHYS, V27, P157, DOI 10.1017/S0033583500004522; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LI SC, 1993, J BIOL CHEM, V268, P22975; Liu LP, 1998, J BIOL CHEM, V273, P23645, DOI 10.1074/jbc.273.37.23645; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; Mattoon D, 2001, ONCOGENE, V20, P3824, DOI 10.1038/sj.onc.1204523; MEYER AN, 1994, P NATL ACAD SCI USA, V91, P4634, DOI 10.1073/pnas.91.11.4634; Nappi VM, 2002, J VIROL, V76, P7976, DOI 10.1128/JVI.76.16.7976-7986.2002; NILSON LA, 1995, J VIROL, V69, P5869, DOI 10.1128/JVI.69.9.5869-5874.1995; NILSON LA, 1993, MOL CELL BIOL, V13, P4137, DOI 10.1128/MCB.13.7.4137; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; Petrache HI, 2000, J MOL BIOL, V302, P727, DOI 10.1006/jmbi.2000.4072; PETTI L, 1991, EMBO J, V10, P845, DOI 10.1002/j.1460-2075.1991.tb08017.x; PETTI L, 1994, J VIROL, V68, P3582, DOI 10.1128/JVI.68.6.3582-3592.1994; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Petti LM, 1997, J VIROL, V71, P7318, DOI 10.1128/JVI.71.10.7318-7327.1997; Petti LM, 2000, CELL GROWTH DIFFER, V11, P395; SCHILLER JT, 1986, J VIROL, V57, P1; SCHLEGEL R, 1986, SCIENCE, V233, P464, DOI 10.1126/science.3014660; SEVERINSSON L, 1989, EUR J BIOCHEM, V182, P679, DOI 10.1111/j.1432-1033.1989.tb14879.x; Sharpe S, 2000, BIOCHEMISTRY-US, V39, P6572, DOI 10.1021/bi000038o; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STAEBLER A, 1995, J VIROL, V69, P6507, DOI 10.1128/JVI.69.10.6507-6517.1995; TREUTLEIN HR, 1992, BIOCHEMISTRY-US, V31, P12726, DOI 10.1021/bi00166a003; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YARDEN Y, 1986, NATURE, V323, P226, DOI 10.1038/323226a0; Zhou FX, 2000, NAT STRUCT BIOL, V7, P154	54	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47149	47159		10.1074/jbc.M209582200	http://dx.doi.org/10.1074/jbc.M209582200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351659	hybrid			2022-12-25	WOS:000179663700041
J	Park, JH; Na, HJ; Kwon, YG; Ha, KS; Lee, SJ; Kim, CK; Lee, KS; Yoneyama, T; Hatakeyama, K; Kim, PKM; Billiar, TR; Kim, YM				Park, JH; Na, HJ; Kwon, YG; Ha, KS; Lee, SJ; Kim, CK; Lee, KS; Yoneyama, T; Hatakeyama, K; Kim, PKM; Billiar, TR; Kim, YM			Nitric oxide (NO) pretreatment increases cytokine-induced NO production in cultured rat hepatocytes by suppressing GTP cyclohydrolase I feedback inhibitory protein level and promoting inducible NO synthase dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-INDUCED APOPTOSIS; CELL-LINE; SMOOTH-MUSCLE; L-ARGININE; TETRAHYDROBIOPTERIN; EXPRESSION; BIOSYNTHESIS; ASSOCIATION; SUBUNITS; NECROSIS	Nitric oxide (NO) regulates the biological activity of many enzymes and other functional proteins as well as gene expression. In this study, we tested whether pretreatment with NO regulates NO production in response to cytokines in cultured rat hepatocytes. Hepatocytes were recovered in fresh medium for 24 h following pretreatment with the NO donor S-nitroso-N-acetyl-D,L-penicillamine (SNAP) and stimulated to express the inducible NO synthase (iNOS) with interleukin-1beta and interferon-gamma or transfected with the human iNOS gene. NO pretreatment resulted in a significant increase in NO production without changing iNOS expression for both conditions. This effect, which did not occur in macrophages and smooth muscle cells, was inhibited when NO was scavenged using red blood cells. Pretreatment with oxidized SNAP, 8-Br-cGMP, N-2(-), or NO3- did not increase the cytokine-induced NO production. SNAP pretreatment increased cytosolic iNOS activity measured only in the absence of exogenous tetrahydrobiopterin (BH4). SNAP pretreatment suppressed the level of GTP cyclohydrolase I (GTPCHI) feedback regulatory protein (GFRP) and increased GTPCHI activity without changing GTPCHI protein level. SNAP pretreatment also increased total cellular levels of biopterin and active iNOS dimer. These results suggest that SNAP pretreatment increased NO production from iNOS by elevating cellular BH4 levels and promoting iNOS subunit dimerization through the suppression of GFRP levels and subsequent activation of GTPCHI.	Kangweon Natl Univ, Dept Mol & Cellular Biochem, Sch Med, Chunchon 200701, South Korea; Kangweon Natl Univ, Vasc Syst Res Ctr, Sch Med, Chunchon 200701, South Korea; Univ Pittsburgh, Sch Med, Dept Surg, Pittsburgh, PA 15261 USA	Kangwon National University; Kangwon National University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kim, YM (corresponding author), Kangweon Natl Univ, Dept Mol & Cellular Biochem, Sch Med, Chunchon 200701, South Korea.		Ha, Kwon-Soo/AAU-4417-2020; Yoneyama, Tohru/ABG-2670-2020	Kim, Chunki/0000-0003-2410-9118; Lee, Seon-Jin/0000-0001-7214-7536; Ha, Kwon-Soo/0000-0002-4219-1787	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM044100, R01GM044100, R37GM044100] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM44100] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BILLIAR TR, 1989, J EXP MED, V169, P1467, DOI 10.1084/jem.169.4.1467; BILLIAR TR, 1992, AM J PHYSIOL, V262, pC1077, DOI 10.1152/ajpcell.1992.262.4.C1077; BURG AW, 1968, J BIOL CHEM, V243, P2349; Cavicchi M, 2000, GUT, V47, P771, DOI 10.1136/gut.47.6.771; DISILVIO M, 1993, ADV EXP MED BIOL, V338, P305; DUCH DS, 1984, LIFE SCI, V35, P1895, DOI 10.1016/0024-3205(84)90541-1; FIELD L, 1978, J CHEM SOC CHEM COMM, P249, DOI 10.1039/c39780000249; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; Geller DA, 2000, BIOCHEM BIOPH RES CO, V276, P633, DOI 10.1006/bbrc.2000.3537; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P522, DOI 10.1073/pnas.90.2.522; GELLER DA, 1995, J IMMUNOL, V155, P4890; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HARADA T, 1993, SCIENCE, V260, P1507, DOI 10.1126/science.8502995; Hausladen A, 1996, CELL, V86, P719, DOI 10.1016/S0092-8674(00)80147-6; KAUFMAN S, 1993, ANNU REV NUTR, V13, P261, DOI 10.1146/annurev.nu.13.070193.001401; KIM YM, 1993, FEBS LETT, V332, P255, DOI 10.1016/0014-5793(93)80644-A; Kim YM, 1998, J BIOL CHEM, V273, P31437, DOI 10.1074/jbc.273.47.31437; Kim YM, 1996, INFECT IMMUN, V64, P3074, DOI 10.1128/IAI.64.8.3074-3080.1996; Kim YM, 1997, J BIOL CHEM, V272, P1402, DOI 10.1074/jbc.272.2.1402; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kim YM, 1998, MOL MED, V4, P179, DOI 10.1007/BF03401915; Kim YM, 2000, J BIOL CHEM, V275, P10954, DOI 10.1074/jbc.275.15.10954; KLATT P, 1995, EMBO J, V14, P3687, DOI 10.1002/j.1460-2075.1995.tb00038.x; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; REIF DW, 1993, NEUROREPORT, V4, P566, DOI 10.1097/00001756-199305000-00026; Saavedra JE, 1997, J MED CHEM, V40, P1947, DOI 10.1021/jm9701031; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SCOTTBURDEN T, 1993, BIOCHEM BIOPH RES CO, V196, P1261, DOI 10.1006/bbrc.1993.2388; Shears LL, 1998, J AM COLL SURGEONS, V187, P295, DOI 10.1016/S1072-7515(98)00163-X; SHEFFLER LA, 1995, J IMMUNOL, V155, P886; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Taylor BS, 1997, ARCH SURG-CHICAGO, V132, P1177; TZENG E, 1995, P NATL ACAD SCI USA, V92, P11771, DOI 10.1073/pnas.92.25.11771; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842; XIE QW, 1994, J BIOL CHEM, V269, P4705; Yoneyama T, 1997, J BIOL CHEM, V272, P9690	41	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47073	47079		10.1074/jbc.M207053200	http://dx.doi.org/10.1074/jbc.M207053200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359727	hybrid			2022-12-25	WOS:000179663700032
J	Saharinen, P; Silvennoinen, O				Saharinen, P; Silvennoinen, O			The pseudokinase domain is required for suppression of basal activity of Jak2 and Jak3 tyrosine kinases and for cytokine-inducible activation of signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; INTERFERON-ALPHA/BETA RECEPTOR; MICE LACKING JAK3; JANUS KINASES; LYMPHOID DEVELOPMENT; CATALYTIC ACTIVITY; STAT PATHWAYS; SH2 DOMAIN; BINDING; PHOSPHORYLATION	Janus (Jak) tyrosine kinases contain a tyrosine kinase (JH1) domain adjacent to a catalytically inactive pseudokinase domain (JH2). The JH2 domain has been implicated in regulation of Jak activity, but its function remains poorly understood. Here, we found that the JH2 domain negatively regulates the activity of Jak2 and Jak3. Deletion of JH2 resulted in increased tyrosine phosphorylation of the Jak2- and Jak3-JH2 deletion mutants as well as of coexpressed STAT5. In cytokine receptor signaling, the deletion of the Jak2- and Jak3-JH2 domains resulted in interferon-gamma and interleukin-2-independent STAT activation, respectively. However, cytokine stimulations did not further induce the JH2 deletion mutant-mediated STAT activation. The deletion of the Jak2 JH2 domain also abolished interferon-gamma-inducible kinase activation, although it did not affect the reciprocal Jak1-Jak2 interaction in 293T cells. Chimeric constructs, where the JH2 domains were swapped between Jak2 and Jak3, retained low basal activity and cytokine inducible signaling, indicating functional conservation between the two JH2 domains. However, the basal activity of Jak2 was significantly lower than that of Jak3, suggesting differences in the regulation of Jak2 and Jak3 activity. In conclusion, we found that the JH2 domain has a conserved function in Jak2 and Jak3. The JH2 domain is required for two distinct functions in cytokine signaling: (i) inhibition of the basal activity of Jak2 and Jak3, and (ii) cytokine-inducible activation of signaling. The Jak-JH2 deletion mutants are catalytically active, activate STAT5, and interact with another Jak kinase, but the JH2 domain is required to connect these signaling events to receptor activation. Thus, we propose that the JH2 domain contributes to both the uninduced and ligand-induced Jak-receptor complex, where it acts as a cytokine-inducible switch to regulate signal transduction.	Univ Helsinki, Dept Virol, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Programme Dev & Reprod Biol, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Clin Microbiol, FIN-33101 Tampere, Finland	University of Helsinki; University of Helsinki; Tampere University; Tampere University; Tampere University Hospital	Silvennoinen, O (corresponding author), Univ Helsinki, Dept Virol, Haartman Inst, Haartmaninkatu 8,POB 63, FIN-00014 Helsinki, Finland.		Saharinen, Pipsa I/C-9601-2016	Saharinen, Pipsa I/0000-0003-2652-0584				Al-Lazikani B, 2001, P NATL ACAD SCI USA, V98, P14796, DOI 10.1073/pnas.011577898; Cacalano NA, 1999, EMBO J, V18, P1549, DOI 10.1093/emboj/18.6.1549; Candotti F, 1997, BLOOD, V90, P3996, DOI 10.1182/blood.V90.10.3996; Chen M, 2000, MOL CELL BIOL, V20, P947, DOI 10.1128/MCB.20.3.947-956.2000; Constantinescu SN, 2001, MOL CELL, V7, P377, DOI 10.1016/S1097-2765(01)00185-X; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Feng J, 1997, MOL CELL BIOL, V17, P2497, DOI 10.1128/MCB.17.5.2497; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; GOUILLEUX F, 1994, EMBO J, V13, P4361, DOI 10.1002/j.1460-2075.1994.tb06756.x; Greiser JS, 2002, J BIOL CHEM, V277, P26959, DOI 10.1074/jbc.M204113200; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Kampa D, 2000, BIOCHEM BIOPH RES CO, V278, P175, DOI 10.1006/bbrc.2000.3757; Kohlhuber F, 1997, MOL CELL BIOL, V17, P695, DOI 10.1128/MCB.17.2.695; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; Liu KD, 1997, CURR BIOL, V7, P817, DOI 10.1016/S0960-9822(06)00369-1; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; Myers MP, 2001, J BIOL CHEM, V276, P47771, DOI 10.1074/jbc.C100583200; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; NOSAKA T, 1995, SCIENCE, V270, P800, DOI 10.1126/science.270.5237.800; Oakes SA, 1996, IMMUNITY, V5, P605, DOI 10.1016/S1074-7613(00)80274-5; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PINE R, 1994, EMBO J, V13, P158, DOI 10.1002/j.1460-2075.1994.tb06245.x; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Richter MF, 1998, J BIOL CHEM, V273, P24723, DOI 10.1074/jbc.273.38.24723; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Saharinen P, 2000, MOL CELL BIOL, V20, P3387, DOI 10.1128/MCB.20.10.3387-3395.2000; Saharinen P, 1997, BLOOD, V90, P4341; Saito K, 2001, J BIOL CHEM, V276, P16201, DOI 10.1074/jbc.M100873200; Sasaki A, 1999, GENES CELLS, V4, P339, DOI 10.1046/j.1365-2443.1999.00263.x; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; SLIVA D, 1994, J BIOL CHEM, V269, P26208; THOMIS DC, 1995, SCIENCE, V270, P794, DOI 10.1126/science.270.5237.794; Ungureanu D, 2002, MOL CELL BIOL, V22, P3316, DOI 10.1128/MCB.22.10.3316-3326.2002; VELAZQUEZ L, 1995, J BIOL CHEM, V270, P3327, DOI 10.1074/jbc.270.7.3327; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Yeh TC, 2000, P NATL ACAD SCI USA, V97, P8991, DOI 10.1073/pnas.160130297; Zhou YJ, 1997, P NATL ACAD SCI USA, V94, P13850, DOI 10.1073/pnas.94.25.13850; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0	50	226	237	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47954	47963		10.1074/jbc.M205156200	http://dx.doi.org/10.1074/jbc.M205156200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351625	hybrid			2022-12-25	WOS:000179663700143
J	Tominaga, T; Meng, WX; Togashi, K; Urano, H; Tominaga, M				Tominaga, T; Meng, WX; Togashi, K; Urano, H; Tominaga, M			The Rho GTPase effector protein, mDia, inhibits the DNA binding ability of the transcription factor Pax6 and changes the pattern of neurite extension in cerebellar granule cells through its binding to Pax6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBER FORMATION; KINASE; SRC; ACTIVATION; CYTOSKELETON; RETRACTION; DOWNSTREAM; OUTGROWTH; MUTATIONS; MIGRATION	mDia, one of the target proteins of the GTPase Rho, is known to be involved in cytoskeletal reorganization and cytokinesis. Here, we report that mDia enters the nucleus and binds to the transcription factor, Pax6. In cultured non-neuronal cells, overexpression of mDia with Pax6 causes redistribution of some Pax6 molecules from the nucleus to the cytosol and decreases Pax6 transcriptional activity. Because Pax6 functions in the early central nervous system morphogenesis, we also examined the effects of mDia on endogenous Pax6 localization and neurite extension in cerebellar granule cells. Here too, Pax6 was partially mislocalized to the cytosol, and its expression level was decreased by mDia overexpression. In addition, mDia overexpression in these cells led to increased neurite branching and length. These results strongly suggest that mDia influences Pax6-induced transcriptional activity and axonal pathfinding in a way opposite from ROCK (Rho kinase) and that it may act via Pax6 to modulate early neuronal development.	Mie Univ, Sch Med, Dept Physiol, Tsu, Mie 5148507, Japan; Fdn Advancement Int Sci, Tsukuba, Ibaraki 3050062, Japan	Mie University	Tominaga, T (corresponding author), Mie Univ, Sch Med, Dept Physiol, Tsu, Mie 5148507, Japan.	ttomoko@doc.medic.mie-u.ac.jp						Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Ashery-Padan R, 2001, CURR OPIN CELL BIOL, V13, P706, DOI 10.1016/S0955-0674(00)00274-X; Bione S, 1998, AM J HUM GENET, V62, P533, DOI 10.1086/301761; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; Chan DC, 1996, J BIOL CHEM, V271, P23472, DOI 10.1074/jbc.271.38.23472; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Engelkamp D, 1999, DEVELOPMENT, V126, P3585; Heins N, 2002, NAT NEUROSCI, V5, P308, DOI 10.1038/nn828; HILL RE, 1991, NATURE, V354, P522, DOI 10.1038/354522a0; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Horwitz AR, 1999, SCIENCE, V286, P1102, DOI 10.1126/science.286.5442.1102; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; INGRAHAM CA, 1989, MOL CHEM NEUROPATHOL, V10, P1, DOI 10.1007/BF02969481; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Osumi N, 1997, DEVELOPMENT, V124, P2961; Sahai E, 2002, NAT CELL BIOL, V4, P408, DOI 10.1038/ncb796; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Singh S, 1998, J BIOL CHEM, V273, P21531, DOI 10.1074/jbc.273.34.21531; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Takahashi M, 2002, DEVELOPMENT, V129, P1327; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; WynshawBoris A, 1997, MOL MED, V3, P372, DOI 10.1007/BF03401684; Yamasaki T, 2001, DEVELOPMENT, V128, P3133	34	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47686	47691		10.1074/jbc.M207539200	http://dx.doi.org/10.1074/jbc.M207539200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324464	hybrid			2022-12-25	WOS:000179663700110
J	Navdaev, A; Clemetson, KJ				Navdaev, A; Clemetson, KJ			Glycoprotein Ib cross-linking/ligation on echicetin-coated surfaces or echicetin-IgM kappa in stirred suspension activates platelets by cytoskeleton modulated calcium release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TYPE LECTIN; PHOSPHOINOSITIDE 3-KINASE; BINDING; IX; ALPHA; RECEPTOR; IB/V/IX; IIB/IIIA; ADHESION; COLLAGEN	Cross-linking platelet GPIb with the snake C-type lectin echicetin provides a specific technique for activation via this receptor. This allows GPlb-dependent mechanisms to be studied without the necessity for shear stress-induced binding of von Willebrand factor or primary alpha(IIb)beta(3) involvement. We already showed that platelets are activated, including tyrosine phosphorylation, by echicetin-IgM(k)-induced GPIb cross-linking. We now investigate the mechanism further and demonstrate that platelets, without modulator reagents, spread directly on an echicetin-coated surface, by a GPIb-specific mechanism, causing exocytosis of a-granule markers (P-selectin) and activation of alpha(IIb)beta(3). This spreading requires actin polymerization and release of internal calcium stores but is not dependent on external calcium nor on src family tyrosine kinases. Cross-linking of GPIb complex molecules on platelets, either in suspension or via specific surface attachment, is sufficient to induce platelet activation.	Univ Bern, Theodor Kocher Inst, CH-3012 Bern, Switzerland	University of Bern	Clemetson, KJ (corresponding author), Univ Bern, Theodor Kocher Inst, Freiestr 1, CH-3012 Bern, Switzerland.	clemetson@tki.unibe.ch						CARROLL RC, 1982, BLOOD, V59, P466; CARTEAUX JP, 1993, J THORAC CARDIOV SUR, V106, P834; Christodoulides N, 2001, THROMB RES, V102, P133, DOI 10.1016/S0049-3848(01)00243-2; Dong JF, 1997, BIOCHEMISTRY-US, V36, P12421, DOI 10.1021/bi970636b; Dopheide SM, 2002, BLOOD, V99, P159, DOI 10.1182/blood.V99.1.159; Englund GD, 2001, J BIOL CHEM, V276, P16952, DOI 10.1074/jbc.M008048200; Feng SJ, 2000, BLOOD, V95, P551, DOI 10.1182/blood.V95.2.551; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Gante J, 1995, LETT PEPT SCI, V2, P135, DOI 10.1007/BF00119139; Kasirer-Friede A, 2002, J BIOL CHEM, V277, P11949, DOI 10.1074/jbc.M108727200; Kehrel B, 1998, BLOOD, V91, P491; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANKHOF H, 1995, BLOOD, V86, P1035, DOI 10.1182/blood.V86.3.1035.bloodjournal8631035; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; Mazzucato M, 2002, BLOOD, V100, P2793, DOI 10.1182/blood-2002-02-0514; Mistry N, 2000, BLOOD, V96, P3480; Munday AD, 2000, BLOOD, V96, P577; MUSZBEK L, 1989, J BIOL CHEM, V264, P9716; Navdaev A, 2001, BLOOD, V97, P2333, DOI 10.1182/blood.V97.8.2333; Nesbitt WS, 2002, J BIOL CHEM, V277, P2965, DOI 10.1074/jbc.M110070200; PENG ML, 1992, THROMB HAEMOSTASIS, V67, P702; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Williamson D, 2002, J BIOL CHEM, V277, P2151, DOI 10.1074/jbc.M109384200; Yap CL, 2002, BLOOD, V99, P151, DOI 10.1182/blood.V99.1.151	24	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45928	45934		10.1074/jbc.M206129200	http://dx.doi.org/10.1074/jbc.M206129200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324454	hybrid			2022-12-25	WOS:000179529300030
J	Zeng, HY; Zhao, DZ; Mukhopadhyay, D				Zeng, HY; Zhao, DZ; Mukhopadhyay, D			KDR stimulates endothelial cell migration through heterotrimeric G protein Gq/11-mediated activation of a small GTPase RhoA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTORS; MICROVASCULAR HYPERPERMEABILITY; VASCULAR ENDOTHELIUM; SIGNALING PATHWAYS; TYROSINE KINASE; FACTOR VEGF; PROLIFERATION; EXPRESSION; ANGIOGENESIS; ADHESION	Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) functions by activating two receptor tyrosine kinases, Flt-1 (VEGFR-1) and KDR (VEGFR-2), both of which are selectively expressed on the primary vascular endothelium. KDR is responsible for VPF/VEGF-stimulated endothelial cell (EC) proliferation and migration, whereas Flt-1 down-modulates KDR-mediated EC proliferation. Flt-1 mediates down-regulation of EC proliferation through pertussis toxin-sensitive G proteins, betagamma subunits, small GTPase CDC42, and partly by Rac-1. However, the molecular mechanism by which KDR mediates EC migration is not clear yet. Here we show for the first time that activation of RhoA and Rac1 is fully and partially required for KDR-mediated human umbilical vein endothelial cell (HUVEC) migration, respectively, and that CDC42, however, is not involved. Furthermore, overexpression of the RhoA dominant negative mutant RhoA-19N does not affect VPF/VEGF-stimulated KDR phosphorylation, intracellular Ca2+ mobilization, and mitogen-activated protein kinase phosphorylation. Utilizing the receptor chimeras (EGDR and EGLT) in which the extracellular domain of the epidermal growth factor receptor (EGFR) was fused to the transmembrane domain and the intracellular domains of KDR and Flt-1, respectively, we demonstrate that RhoA activation is mediated by EGDR, not by EGLT, and that EGDR mediates activation of Rac1, not CDC42. Furthermore, the EGDR-mediated RhoA and Rac1 activation is regulated by G proteins Gq/11, Gbetagamma, and phospholipase C independent of phosphatidylinositol 3-kinase and intracellular Ca2+ mobilization. Interestingly, the RhoA activation can be partially inhibited by overexpression of Rac1-17N, but overexpression of RhoA-19N has no effect on Rac1 activation. Finally, Gq/11 and Gbetagamma subunits are also required for VPF/VEGF-stimulated HUVEC migration. Taken together, our results indicate that KDR stimulates endothelial cell migration through a heterotrimeric G protein Gq/11 and Gbetagamma-mediated RhoA pathway.	Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Gastroenterol, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Mukhopadhyay, D (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, 330 Brookline Ave,RN270H, Boston, MA 02215 USA.	dmukhopa@caregroup.harvard.edu			NATIONAL CANCER INSTITUTE [R01CA078383, R29CA078383] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL070567] Funding Source: NIH RePORTER; NCI NIH HHS [CA78383] Funding Source: Medline; NHLBI NIH HHS [HL70567] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Allen WE, 1998, J CELL BIOL, V141, P1147, DOI 10.1083/jcb.141.5.1147; Aspenstrom P, 1999, CURR OPIN CELL BIOL, V11, P95, DOI 10.1016/S0955-0674(99)80011-8; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Barleon B, 1996, BLOOD, V87, P3336, DOI 10.1182/blood.V87.8.3336.bloodjournal8783336; Bernatchez PN, 1999, J BIOL CHEM, V274, P31047, DOI 10.1074/jbc.274.43.31047; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Dalle S, 2001, J BIOL CHEM, V276, P15688, DOI 10.1074/jbc.M010884200; Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97; DVORAK HF, 1995, AM J PATHOL, V146, P1029; English J, 1999, EXP CELL RES, V253, P255, DOI 10.1006/excr.1999.4687; Evers EE, 2000, EUR J CANCER, V36, P1269, DOI 10.1016/S0959-8049(00)00091-5; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; Imamura T, 1999, MOL CELL BIOL, V19, P6765; Keummerle JF, 2001, J BIOL CHEM, V276, P7187, DOI 10.1074/jbc.M011145200; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Liu F, 2001, AM J RESP CELL MOL, V24, P711, DOI 10.1165/ajrcmb.24.6.4323; Machesky LM, 1999, J CELL BIOL, V146, P267, DOI 10.1083/jcb.146.2.267; Mao JH, 1998, P NATL ACAD SCI USA, V95, P12973, DOI 10.1073/pnas.95.22.12973; Matozaki T, 2000, CELL SIGNAL, V12, P515, DOI 10.1016/S0898-6568(00)00102-9; Mehta D, 2001, J BIOL CHEM, V276, P22614, DOI 10.1074/jbc.M101927200; MILLAUER B, 1993, CELL, V72, P835, DOI 10.1016/0092-8674(93)90573-9; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Paik JH, 2001, J BIOL CHEM, V276, P11830, DOI 10.1074/jbc.M009422200; Petrova TV, 1999, EXP CELL RES, V253, P117, DOI 10.1006/excr.1999.4707; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Rahimi N, 2000, J BIOL CHEM, V275, P16986, DOI 10.1074/jbc.M000528200; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Rousseau S, 2000, TRENDS CARDIOVAS MED, V10, P321, DOI 10.1016/S1050-1738(01)00072-X; Sanchez-Blazquez P, 1998, J PHARMACOL EXP THER, V285, P820; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; Thodeti CK, 2002, BIOCHEM J, V365, P157, DOI 10.1042/BJ20020248; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Wu LW, 2000, J BIOL CHEM, V275, P5096, DOI 10.1074/jbc.275.7.5096; Zeng HY, 2002, J BIOL CHEM, V277, P4003, DOI 10.1074/jbc.M110842200; Zeng HY, 2001, J BIOL CHEM, V276, P26969, DOI 10.1074/jbc.M103213200; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	46	94	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46791	46798		10.1074/jbc.M206133200	http://dx.doi.org/10.1074/jbc.M206133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244099	hybrid			2022-12-25	WOS:000179529300140
J	Shaw, S; Bencherif, M; Marrero, MB				Shaw, S; Bencherif, M; Marrero, MB			Janus kinase 2, an early target of alpha 7 nicotinic acetylcholine receptor-mediated neuroprotection against A beta-(1-42) amyloid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; IN-VITRO; PHOSPHATIDYLINOSITOL 3-KINASE; ACTIVATION; SUBTYPES; AGONIST; CELLS; JAK2	The molecular mechanisms of alpha7 nicotinic acetylcholine receptor (nAChR)-mediated neuroprotection remain unclear. In this study we provide evidence that nicotine stimulation of alpha7 nAChR transduces signals to phosphatidylinositol 3-kinase and Akt via Janus kinase 2 (JAK2) in a cascade, which results in neuroprotection. Exposure to beta-amyloid results in the activation of the apoptotic enzyme caspase-3 and cleavage of the DNA-repairing enzyme poly-(ADP-ribose) polymerase. This cascade is inhibited by nicotine through JAK2 activation, and these effects are blocked by preincubation with the JAK2-specific inhibitor AG-490. We also found that pretreatment of cells with angiotensin II blocks the nicotine-induced activation of JAK2 via the AT(2) receptor and completely prevents alpha7 nAChR-mediated neuroprotective effects further suggesting a pivotal role for JAK2. These findings identify novel mechanisms of receptor interactions relevant to neuronal viability and suggest novel therapeutic strategies to optimize neuroprotection.	Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA; Med Coll Georgia, Dept Pharmacol & Toxicol, Augusta, GA 30912 USA; Targacept Inc, Winston Salem, NC 27101 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Marrero, MB (corresponding author), Med Coll Georgia, Vasc Biol Ctr, Augusta, GA 30912 USA.	mmarrero@mail.mcg.edu						BARNES NM, 1991, EUR J PHARMACOL, V200, P289, DOI 10.1016/0014-2999(91)90584-D; Bencherif M, 1996, J PHARMACOL EXP THER, V279, P1413; Court J, 2001, BIOL PSYCHIAT, V49, P175, DOI 10.1016/S0006-3223(00)01116-1; DEFIEBRE CM, 1995, MOL PHARMACOL, V47, P164; Dicou E, 2001, NEUROREPORT, V12, P3947, DOI 10.1097/00001756-200112210-00019; Digicaylioglu M, 2001, NATURE, V412, P641, DOI 10.1038/35088074; Dineley KT, 2001, J NEUROSCI, V21, P4125, DOI 10.1523/JNEUROSCI.21-12-04125.2001; DonnellyRoberts DL, 1996, BRAIN RES, V719, P36, DOI 10.1016/0006-8993(96)00063-7; Horiuchi M, 1998, ENDOCR RES, V24, P307, DOI 10.3109/07435809809032610; Horiuchi M, 1999, CIRC RES, V84, P876; Kem WR, 2000, BEHAV BRAIN RES, V113, P169, DOI 10.1016/S0166-4328(00)00211-4; Kihara T, 2001, J BIOL CHEM, V276, P13541, DOI 10.1074/jbc.M008035200; Kumano K, 2000, BIOCHEM BIOPH RES CO, V270, P209, DOI 10.1006/bbrc.2000.2403; Kunioku H, 2001, NEUROSCI LETT, V309, P13, DOI 10.1016/S0304-3940(01)02012-2; Liu QS, 2001, P NATL ACAD SCI USA, V98, P4734, DOI 10.1073/pnas.081553598; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Narain Y, 2000, J MED GENET, V37, P695, DOI 10.1136/jmg.37.9.695; Negoro S, 2000, CARDIOVASC RES, V47, P797, DOI 10.1016/S0008-6363(00)00138-3; Newhouse PA, 2001, BIOL PSYCHIAT, V49, P268, DOI 10.1016/S0006-3223(00)01069-6; Ryan RE, 2001, BRIT J PHARMACOL, V132, P1650, DOI 10.1038/sj.bjp.0703989; Sakai I, 1997, J BIOL CHEM, V272, P12350, DOI 10.1074/jbc.272.19.12350; Seo JH, 2001, BIOL PSYCHIAT, V49, P240, DOI 10.1016/S0006-3223(00)01124-0; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626	23	159	168	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44920	44924		10.1074/jbc.M204610200	http://dx.doi.org/10.1074/jbc.M204610200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244045	hybrid			2022-12-25	WOS:000179404800043
J	Wiethoff, CM; Gill, ML; Koe, GS; Koe, JG; Middaugh, CR				Wiethoff, CM; Gill, ML; Koe, GS; Koe, JG; Middaugh, CR			The structural organization of cationic lipid-DNA complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; GENE DELIVERY; LIPOSOME COMPLEXES; PLASMID DNA; PHYSICOCHEMICAL CHARACTERIZATION; CRYOELECTRON MICROSCOPY; IN-VITRO; MEMBRANE; FLUORESCENCE; RECEPTOR	The interaction of cationic liposomes with supercoiled plasmid DNA results in a major rearrangement of each component to form compact multilamellar structures comprised of alternating layers of two-dimensional arrays of DNA sandwiched between lipid bilayers. Fluorescence resonance energy transfer was used to estimate the distance of closest approach of DNA to the lipid bilayers in these complexes. The effect of several compositional variables on this distance, including the ratio of cationic lipid to DNA, and the charge density, intrinsic curvature, and fluidity of the lipid bilayer were examined. Additionally, the effect of ionic strength was studied. For complexes prepared at or above a 3:1 charge ratio (+/-), the observed distance of closest approach was found to be in agreement with the intercalation of DNA between lipid bilayers. As the charge ratio was decreased, a monotonic increase in the distance was observed with a maximum observed at 0.5:1. Correlations between differences in the proximity of DNA to the lipid bilayer and the hydrodynamic size of the complexes were also found. A model based on these observations and previous reports suggests the formation of discrete populations of complexes below a charge ratio of 0.5:1 and above 3:1. The structure of the negatively charged complexes is consistent with DNA extending from the surface of the particles, whereas those possessing excess positive charge were multilamellar aggregates with the DNA effectively condensed between lipid bilayers. Complexes between these two states consist of weighted fractions of these two species.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Valentis Inc, Burlingame, CA 94010 USA	University of Kansas	Middaugh, CR (corresponding author), Univ Kansas, Dept Pharmaceut Chem, 2095 Constant Ave, Lawrence, KS 66047 USA.	middaugh@ku.edu		Gill, Michelle/0000-0002-2861-355X				ARAKI T, 1987, HISTOCHEMISTRY, V87, P331, DOI 10.1007/BF00492587; BAIRD B, 1985, BIOCHEMISTRY-US, V24, P6252, DOI 10.1021/bi00343a032; BAIRD B, 1989, INT ARCH ALLER A IMM, V88, P23, DOI 10.1159/000234742; Bandyopadhyay S, 1999, J PHYS CHEM B, V103, P10075, DOI 10.1021/jp9927496; Battersby BJ, 1998, BBA-BIOMEMBRANES, V1372, P379, DOI 10.1016/S0005-2736(98)00062-5; Bhattacharya S, 1998, BIOCHEMISTRY-US, V37, P7764, DOI 10.1021/bi971772j; Birchall JC, 1999, INT J PHARM, V183, P195, DOI 10.1016/S0378-5173(99)00117-9; Chadwick SL, 1997, GENE THER, V4, P937, DOI 10.1038/sj.gt.3300481; Choosakoonkriang S, 2001, J BIOL CHEM, V276, P8037, DOI 10.1074/jbc.M010592200; Crook K, 1996, GENE THER, V3, P834; Crook K, 1998, GENE THER, V5, P137, DOI 10.1038/sj.gt.3300554; DEWEY TG, 1980, BIOPHYS J, V32, P1023, DOI 10.1016/S0006-3495(80)85033-8; Eastman SJ, 1997, BBA-BIOMEMBRANES, V1325, P41, DOI 10.1016/S0005-2736(96)00242-8; Even-Chen S, 2000, BBA-BIOMEMBRANES, V1509, P176, DOI 10.1016/S0005-2736(00)00292-3; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; Ferrari ME, 1998, HUM GENE THER, V9, P341, DOI 10.1089/hum.1998.9.3-341; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; Harries D, 1998, BIOPHYS J, V75, P159, DOI 10.1016/S0006-3495(98)77503-4; Hirsch-Lemer D, 1998, BBA-BIOMEMBRANES, V1370, P17, DOI 10.1016/S0005-2736(97)00239-3; Hirsch-Lerner D, 1999, BBA-BIOMEMBRANES, V1461, P47, DOI 10.1016/S0005-2736(99)00145-5; Huebner S, 1999, BIOPHYS J, V76, P3158, DOI 10.1016/S0006-3495(99)77467-9; JOHNSON ID, 1991, ANAL BIOCHEM, V198, P228, DOI 10.1016/0003-2697(91)90418-S; Kennedy MT, 2000, BIOPHYS J, V78, P1620, DOI 10.1016/S0006-3495(00)76714-2; Koltover I, 1999, BIOPHYS J, V77, P915, DOI 10.1016/S0006-3495(99)76942-0; Koltover I, 1998, SCIENCE, V281, P78, DOI 10.1126/science.281.5373.78; Lasic DD, 1997, J AM CHEM SOC, V119, P832, DOI 10.1021/ja962713g; Lobo BA, 2002, J PHARM SCI, V91, P454, DOI 10.1002/jps.10025; Lobo BA, 2001, ARCH BIOCHEM BIOPHYS, V386, P95, DOI 10.1006/abbi.2000.2196; MacDonald RC, 1999, BIOPHYS J, V77, P2612, DOI 10.1016/S0006-3495(99)77095-5; Marsh D., 1990, CRC HDB LIPID BILAYE; McLachlan G, 1996, GENE THER, V3, P1113; Monk KWC, 1997, BIOPHYS J, V73, P2534, DOI 10.1016/S0006-3495(97)78282-1; Nishikawa M, 2001, HUM GENE THER, V12, P861, DOI 10.1089/104303401750195836; OKUYAMA K, 1988, B CHEM SOC JPN, V61, P1485, DOI 10.1246/bcsj.61.1485; PODGORNIK R, 1994, BIOPHYS J, V66, P962, DOI 10.1016/S0006-3495(94)80877-X; Radler JO, 1997, SCIENCE, V275, P810, DOI 10.1126/science.275.5301.810; Schmutz M, 1999, P NATL ACAD SCI USA, V96, P12293, DOI 10.1073/pnas.96.22.12293; SHAHROKH Z, 1991, J BIOL CHEM, V266, P12082; SHAKLAI N, 1977, BIOCHEMISTRY-US, V16, P5585, DOI 10.1021/bi00644a031; Simberg D, 2001, J BIOL CHEM, V276, P47453, DOI 10.1074/jbc.M105588200; Smisterova J, 2001, J BIOL CHEM, V276, P47615, DOI 10.1074/jbc.M106199200; SOLODIN I, 1995, BIOCHEMISTRY-US, V34, P13537, DOI 10.1021/bi00041a033; Song YK, 1997, HUM GENE THER, V8, P1585, DOI 10.1089/hum.1997.8.13-1585; Tarahovsky YS, 2002, BIOPHYS J, V82, P264, DOI 10.1016/S0006-3495(02)75392-7; VALENZUELA CF, 1994, BIOPHYS J, V66, P674, DOI 10.1016/S0006-3495(94)80841-0; Waddill W, 1997, AM J ROENTGENOL, V169, P63, DOI 10.2214/ajr.169.1.9207502; Wiethoff CM, 2001, J BIOL CHEM, V276, P32806, DOI 10.1074/jbc.M007940200; WOLBER PK, 1979, BIOPHYS J, V28, P197, DOI 10.1016/S0006-3495(79)85171-1; Xu YH, 1999, BIOPHYS J, V77, P341, DOI 10.1016/S0006-3495(99)76894-3; YGUERABIDE J, 1994, BIOPHYS J, V66, P683, DOI 10.1016/S0006-3495(94)80842-2; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	52	50	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44980	44987		10.1074/jbc.M207758200	http://dx.doi.org/10.1074/jbc.M207758200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297507	hybrid			2022-12-25	WOS:000179404800051
J	Okamoto, T; Yamagishi, S; Inagaki, Y; Amano, S; Koga, K; Abe, R; Takeuchi, M; Ohno, S; Yoshimura, A; Makita, T				Okamoto, T; Yamagishi, S; Inagaki, Y; Amano, S; Koga, K; Abe, R; Takeuchi, M; Ohno, S; Yoshimura, A; Makita, T			Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin	FASEB JOURNAL			English	Article						vascular endothelial growth factor; receptor for AGE; reactive oxygen species	ENDOTHELIAL GROWTH-FACTOR; PROSTACYCLIN-PRODUCING ABILITY; ANGIOTENSIN-II; TIE2 RECEPTOR; PROTEIN; HYPOXIA; CELLS; ANGIOPOIETIN-2; PROLIFERATION; PENTOSIDINE	We previously have found that advanced glycation end products (AGE), senescent macroproteins formed at an accelerated rate in diabetes, arise in vivo not only from glucose but also from reducing sugars. Furthermore, we recently have shown that glyceraldehyde- and glycolaldehyde-derived AGE (glycer- and glycol-AGE) are mainly involved in loss of pericytes, the earliest histopathological hallmark of diabetic retinopathy. However, the effects of these AGE proteins on angiogenesis, another vascular derangement in diabetic retinopathy, remain to be elucidated. In this study, we investigated whether these AGE proteins elicit changes in cultured endothelial cells that are associated with angiogenesis. When human skin microvascular endothelial cells (EC) were cultured with glycer-AGE or glycol-AGE, growth and tube formation of EC, the key steps of angiogenesis, were significantly stimulated. The AGE-induced growth stimulation was significantly enhanced in AGE receptor (RAGE) -overexpressed EC. Furthermore, AGE increased transcriptional activity of nuclear factor-kappaB (NF-kappaB) and activator protein-1 (AP-1) and then up-regulated mRNA levels of vascular endothelial growth factor (VEGF) and angiopoietin-2 (Ang-2) in EC. Cerivastatin, a hydroxymethylglutaryl CoA reductase inhibitor; pyrrolidinedithiocarbamate; or curcumin was found to completely prevent the AGE-induced increase in NF-kappaB and AP-1 activity, VEGF mRNA up-regulation, and the resultant increase in DNA synthesis in microvascular EC. These results suggest that the AGE-RAGE interaction elicited angiogenesis through the transcriptional activation of the VEGF gene via NF-kappaB and AP-1 factors. By blocking AGE-RAGE signaling pathways, cerivastatin might be a promising remedy for treating patients with proliferative diabetic retinopathy.	Kurume Univ, Dept Med, Div Endocrinol & Metab, Sch Med, Kurume, Fukuoka 8300011, Japan; Hokkaido Univ, Sch Med, Dept Dermatol, Sapporo, Hokkaido 0608638, Japan; Hokuriku Univ, Dept Biochem, Kanazawa, Ishikawa 9201181, Japan; Hokkaido Univ, Sch Med, Dept Ophthalmol, Sapporo, Hokkaido 0608638, Japan; Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Fukuoka 8128582, Japan	Kurume University; Hokkaido University; Hokuriku University; Hokkaido University; Kyushu University	Yamagishi, S (corresponding author), Kurume Univ, Dept Med, Div Endocrinol & Metab, Sch Med, 67 Asahi Machi, Kurume, Fukuoka 8300011, Japan.	shoichi@med.kurume-u.ac.jp	Abe, Riichiro/A-5450-2012; Yoshimura, Akihiko/K-5515-2013					Bancroft CC, 2001, CLIN CANCER RES, V7, P435; Benjamin LE, 1998, DEVELOPMENT, V125, P1591; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNLEE M, 1988, NEW ENGL J MED, V318, P1315; BUCALA R, 1994, P NATL ACAD SCI USA, V91, P9441, DOI 10.1073/pnas.91.20.9441; Chua CC, 1998, BBA-MOL CELL RES, V1401, P187, DOI 10.1016/S0167-4889(97)00129-8; COGAN DG, 1961, ARCH OPHTHALMOL-CHIC, V66, P366, DOI 10.1001/archopht.1961.00960010368014; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Duyndam MCA, 2001, J BIOL CHEM, V276, P48066, DOI 10.1074/jbc.M106282200; DYER DG, 1991, J BIOL CHEM, V266, P11654; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; Ichiki T, 2001, ARTERIOSCL THROM VAS, V21, P1896, DOI 10.1161/hq1201.099430; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; KAWAHARA A, 1995, P NATL ACAD SCI USA, V92, P8724, DOI 10.1073/pnas.92.19.8724; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Lu M, 1998, J CLIN INVEST, V101, P1219, DOI 10.1172/JCI1277; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MAKITA Z, 1992, SCIENCE, V258, P651, DOI 10.1126/science.1411574; Nishikawa T, 2000, NATURE, V404, P787, DOI 10.1038/35008121; NOMURA M, 1995, J BIOL CHEM, V270, P28316; Oh H, 1999, J BIOL CHEM, V274, P15732, DOI 10.1074/jbc.274.22.15732; Saaristo A, 2000, ONCOGENE, V19, P6122, DOI 10.1038/sj.onc.1203969; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takeuchi M, 1999, MOL MED, V5, P393, DOI 10.1007/BF03402128; Takeuchi M, 2000, MOL MED, V6, P114, DOI 10.1007/BF03401779; Vincent L, 2001, FEBS LETT, V495, P159, DOI 10.1016/S0014-5793(01)02337-7; Yamagishi S, 1999, LAB INVEST, V79, P501; Yamagishi S, 1997, J BIOL CHEM, V272, P8723, DOI 10.1074/jbc.272.13.8723; Yamagishi S, 1998, DIABETOLOGIA, V41, P1435, DOI 10.1007/s001250051089; Yamagishi S, 1996, FEBS LETT, V384, P103, DOI 10.1016/0014-5793(96)00279-7; Yamagishi S, 1999, MICROVASC RES, V57, P329, DOI 10.1006/mvre.1999.2145; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V191, P840, DOI 10.1006/bbrc.1993.1293; Yamagishi S, 2002, BIOCHEM BIOPH RES CO, V290, P973, DOI 10.1006/bbrc.2001.6312; Yamagishi S, 1999, BIOCHEM BIOPH RES CO, V258, P353, DOI 10.1006/bbrc.1999.0625; YAMAGISHI S, 1993, BIOCHEM BIOPH RES CO, V190, P418, DOI 10.1006/bbrc.1993.1064; YAMAGISHI SI, 1995, BIOCHEM BIOPH RES CO, V213, P681, DOI 10.1006/bbrc.1995.2185; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; YAN SD, 1994, J BIOL CHEM, V269, P9889; Yoshida S, 1997, MOL CELL BIOL, V17, P4015, DOI 10.1128/MCB.17.7.4015; Zhang FL, 1996, ANNU REV BIOCHEM, V65, P241, DOI 10.1146/annurev.bi.65.070196.001325; ZIEGLER SF, 1993, ONCOGENE, V8, P663	44	230	245	0	11	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1928	+		10.1096/fj.02-0030fje	http://dx.doi.org/10.1096/fj.02-0030fje			18	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368225				2022-12-25	WOS:000179167600017
J	Sugawara, T; Lewen, A; Gasche, Y; Yu, FS; Chan, PH				Sugawara, T; Lewen, A; Gasche, Y; Yu, FS; Chan, PH			Overexpression of SOD1 protects vulnerable motor neurons after spinal cord injury by attenuating mitochondrial cytochrome c release	FASEB JOURNAL			English	Article						superoxide dismutase; superoxide; reactive oxygen species; caspase-9	AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; FOCAL CEREBRAL-ISCHEMIA; CASPASE-3 APOPTOTIC CASCADE; CUZN-SUPEROXIDE-DISMUTASE; NECROSIS-FACTOR-ALPHA; OXIDATIVE STRESS; GLIAL APOPTOSIS; UP-REGULATION; MOUSE MODEL	Defective Cu,Zn-superoxide dismutase (SOD1) is responsible for some types of amyotrophic lateral sclerosis, and ventral horn motor neurons (VMN) have been shown to die through a mitochondria-dependent apoptotic pathway after chronic exposure to high levels of reactive oxygen species (ROS). VMN are also selectively vulnerable to mild spinal cord injury (SCI); however, the involvement of SOD1, ROS, and apoptosis in their death has not been clarified. Mild compression SCI was induced in SOD1-overexpressing transgenic rats and wild-type littermates. Superoxide production, mitochondrial release of cytochrome c, and activation of caspase-9 were examined, and apoptotic DNA injury was also characterized. In the wild-type animals, increased superoxide production, mitochondrial release of cytochrome c, and cleaved caspase-9 were observed exclusively in VMN after SCI. Subsequently, a majority of VMN (75%) selectively underwent delayed apoptotic cell death. Transgenic animals showed less superoxide production, mitochondrial cytochrome c release, and caspase-9 activation, resulting in death of only 45% of the VMN. These results suggest that the ROS-initiated mitochondrial signaling pathway possibly plays a pivotal role in apoptotic VMN death after SCI and that increased levels of SOD1 in VMN reduce oxidative stress, thereby attenuating the activation of the pathway and delayed cell death.	Stanford Univ, Neurosurg Labs, Dept Neurosurg, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Dept Neurol & Neurol Sci, Sch Med, Stanford, CA 94305 USA; Stanford Univ, Program Neurosci, Sch Med, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Chan, PH (corresponding author), Stanford Univ, Neurosurg Labs, Dept Neurosurg, Sch Med, 1201 Welch Rd,MSLS P314, Stanford, CA 94305 USA.	phchan@leland.stanford.edu	Lewén, Anders/A-5156-2013	Lewén, Anders/0000-0003-4925-1348; Yu, Fengshan/0000-0001-8620-3084				Banik NL, 1998, ANN NY ACAD SCI, V844, P131, DOI 10.1111/j.1749-6632.1998.tb08228.x; Bindokas VP, 1996, J NEUROSCI, V16, P1324; BLIGHT AR, 1991, J NEUROL SCI, V103, P156, DOI 10.1016/0022-510X(91)90159-5; Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932; Buki A, 2000, J NEUROSCI, V20, P2825; Carriedo SG, 2000, J NEUROSCI, V20, P240, DOI 10.1523/JNEUROSCI.20-01-00240.2000; Casha S, 2001, NEUROSCIENCE, V103, P203, DOI 10.1016/S0306-4522(00)00538-8; Chan PH, 1996, ADV NEUROL, V71, P271; Chan PH, 1998, J NEUROSCI, V18, P8292, DOI 10.1523/jneurosci.18-20-08292.1998; Citron BA, 2000, EXP NEUROL, V166, P213, DOI 10.1006/exnr.2000.7523; Clark RSB, 1997, J NEUROSCI, V17, P9172; Copin JC, 2001, FASEB J, V15, P525, DOI 10.1096/fj.00-0330com; Crowe MJ, 1997, NAT MED, V3, P73, DOI 10.1038/nm0197-73; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Fujimura M, 1998, J CEREBR BLOOD F MET, V18, P1239, DOI 10.1097/00004647-199811000-00010; Fujimura M, 1999, J NEUROSCI, V19, P3414; Grossman SD, 2001, EXP NEUROL, V168, P273, DOI 10.1006/exnr.2001.7628; Guegn C, 2001, J NEUROSCI, V21, P6569, DOI 10.1523/JNEUROSCI.21-17-06569.2001; Hall Edward D., 1993, Journal of Emergency Medicine, V11, P31; Kamencic H, 2001, FASEB J, V15, P243, DOI 10.1096/fj.00-0228com; Keane RW, 2001, J NEUROPATH EXP NEUR, V60, P422, DOI 10.1093/jnen/60.5.422; Kim GW, 2000, J CEREBR BLOOD F MET, V20, P1690, DOI 10.1097/00004647-200012000-00008; KINOUCHI H, 1991, P NATL ACAD SCI USA, V88, P11158, DOI 10.1073/pnas.88.24.11158; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Launey T, 1998, BRAIN RES, V781, P148, DOI 10.1016/S0006-8993(97)01225-0; Lee YB, 2000, EXP NEUROL, V166, P190, DOI 10.1006/exnr.2000.7494; Lewen A, 2001, J CEREBR BLOOD F MET, V21, P914, DOI 10.1097/00004647-200108000-00003; Lewen A, 2001, NEUROBIOL DIS, V8, P380, DOI 10.1006/nbdi.2001.0396; Li M, 2000, NEUROSCIENCE, V99, P333, DOI 10.1016/S0306-4522(00)00173-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu DX, 1998, FREE RADICAL BIO MED, V25, P298, DOI 10.1016/S0891-5849(98)00055-0; Liu RG, 1998, ANN NEUROL, V44, P763, DOI 10.1002/ana.410440510; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Liu XZ, 1997, J NEUROSCI, V17, P5395; Murakami K, 1998, J NEUROSCI, V18, P205; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Pan WH, 1999, J NEUROSCI, V19, P3649; Piantadosi CA, 1996, STROKE, V27, P327, DOI 10.1161/01.STR.27.2.327; RINK A, 1995, AM J PATHOL, V147, P1575; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; ROSS IB, 1993, NEUROSURGERY, V33, P470; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Springer JE, 1999, NAT MED, V5, P943, DOI 10.1038/11387; Springer JE, 2000, J NEUROSCI, V20, P7246; SUGAWARA T, 2002, IN PRESS J NEUROSCI; Terro F, 1998, BRAIN RES, V809, P319, DOI 10.1016/S0006-8993(98)00883-X; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; vonEuler M, 1997, EXP NEUROL, V145, P502, DOI 10.1006/exnr.1997.6481; Yoshida H, 1998, CELL, V94, P739, DOI 10.1016/S0092-8674(00)81733-X; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	53	104	105	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1997	+		10.1096/fj.02-0251fje	http://dx.doi.org/10.1096/fj.02-0251fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368231				2022-12-25	WOS:000179167600024
J	Timms, JF; White, SL; O'Hare, MJ; Waterfield, MD				Timms, JF; White, SL; O'Hare, MJ; Waterfield, MD			Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells	ONCOGENE			English	Article						ErbB-2; cell cycle; cdk inhibitors; cdk2; luminal epithelial	PHOSPHATIDYLINOSITOL 3-KINASE; UP-REGULATION; CANCER CELLS; INDUCED APOPTOSIS; CDK INHIBITORS; MESSENGER-RNA; D1 EXPRESSION; KINASE; P27(KIP1); GROWTH	Most breast cancers arise from luminal epithelial cells and 25-30% of these tumours overexpress the ErbB-2 receptor. Herein, a non-transformed, immortalized cell system was used to investigate the effects of ErbB-2 overexpression in luminal epithelial cells. The phenotypic consequence of ErbB-2 overexpression is a shortening of the G1 phase of the cell cycle and early S phase entry, which leads to hyperproliferation. We show that this effect was mediated through the up-regulation of cdk6 and cyclins D1 and E, and enhanced degradation and relocalization of P27(Kip1). These changes were effected predominantly through enhanced MAPK signalling, resulting in cdk2 hyperactivation. PI3K signalling also participated in cell cycle progression, since PI3K and MAPK coordinately regulated changes in cyclin D1 and cdk6 expression. Cdk4 activity was not required for cell cycle progression in these cells, and was constitutively inhibited through its association with p16(INK4A). MAPK-dependent induction of p21(Cip1) was also necessary for G1 phase progression, although its degradation by the proteasome was required for S phase entry. These data provide new insights into the complex molecular mechanisms underlying mitogenic cell cycle control in luminal epithelial cells, the cell type relevant to primary breast cancer, and show how ErbB-2 overexpression subverts this normal control.	Ludwig Inst Canc Res, London W1W 7BS, England; UCL, Breast Canc Lab, Dept Surg, Royal Free & Univ Coll Med Sch, London W1W 7EJ, England	Ludwig Institute for Cancer Research; University of London; University College London	Timms, JF (corresponding author), Ludwig Inst Canc Res, 91 Riding House St, London W1W 7BS, England.	jtimms@ludwig.ucl.ac.uk	Timms, John/A-1556-2010	Timms, John/0000-0002-4507-835X				Adams J, 1999, CANCER RES, V59, P2615; Adams J, 2000, INVEST NEW DRUG, V18, P109, DOI 10.1023/A:1006321828515; Amati B, 1998, FRONT BIOSCI, V3, pd250, DOI [10.2741/a239, DOI 10.2741/A239]; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BENLEVY R, 1994, EMBO J, V13, P3302, DOI 10.1002/j.1460-2075.1994.tb06632.x; Bottazzi ME, 1999, J CELL BIOL, V146, P1255, DOI 10.1083/jcb.146.6.1255; Busse D, 2000, J BIOL CHEM, V275, P6987, DOI 10.1074/jbc.275.10.6987; Catzavelos C, 1997, NAT MED, V3, P227, DOI 10.1038/nm0297-227; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cover CM, 1998, J BIOL CHEM, V273, P3838, DOI 10.1074/jbc.273.7.3838; DAKSIS JI, 1994, ONCOGENE, V9, P3635; Daly JM, 1997, CANCER RES, V57, P3804; Daly JM, 1999, ONCOGENE, V18, P3440, DOI 10.1038/sj.onc.1202700; Dankort D, 2001, MOL CELL BIOL, V21, P1540, DOI 10.1128/MCB.21.5.1540-1551.2001; Dankort DL, 1997, MOL CELL BIOL, V17, P5410, DOI 10.1128/MCB.17.9.5410; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Fiddes RJ, 1998, ONCOGENE, V16, P2803, DOI 10.1038/sj.onc.1201815; Fredersdorf S, 1997, P NATL ACAD SCI USA, V94, P6380, DOI 10.1073/pnas.94.12.6380; Gille H, 1999, J BIOL CHEM, V274, P22033, DOI 10.1074/jbc.274.31.22033; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; Harari D, 2000, ONCOGENE, V19, P6102, DOI 10.1038/sj.onc.1203973; Harlow E., 1988, ANTIBODIES LAB MANUA; Harris RA, 1999, INT J CANCER, V80, P477, DOI 10.1002/(SICI)1097-0215(19990129)80:3<477::AID-IJC23>3.0.CO;2-W; Hermanto U, 2001, ONCOGENE, V20, P7551, DOI 10.1038/sj.onc.1204964; Hoshino R, 2001, J BIOL CHEM, V276, P2686, DOI 10.1074/jbc.M006132200; Hynes NE, 2001, J MAMMARY GLAND BIOL, V6, P141, DOI 10.1023/A:1009528918064; Ignatoski KMW, 2000, BRIT J CANCER, V82, P666, DOI 10.1054/bjoc.1999.0979; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Lane HA, 2000, MOL CELL BIOL, V20, P3210, DOI 10.1128/MCB.20.9.3210-3223.2000; Lenferink AEG, 2001, CANCER RES, V61, P6583; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mateyak MK, 1999, MOL CELL BIOL, V19, P4672; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Musgrove EA, 1996, J CELL BIOCHEM, V60, P363; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; PerezRoger I, 1997, ONCOGENE, V14, P2373, DOI 10.1038/sj.onc.1201197; Porter PL, 1997, NAT MED, V3, P222, DOI 10.1038/nm0297-222; Sartor CI, 2001, MOL CELL BIOL, V21, P4265, DOI 10.1128/MCB.21.13.4265-4275.2001; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; STAMPS AC, 1994, INT J CANCER, V57, P865, DOI 10.1002/ijc.2910570616; Stein GH, 1999, MOL CELL BIOL, V19, P2109; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tzahar E, 1996, MOL CELL BIOL, V16, P5276; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; Yang HY, 2000, J BIOL CHEM, V275, P24735, DOI 10.1074/jbc.C000147200; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu DH, 1998, MOL CELL, V2, P581, DOI 10.1016/S1097-2765(00)80157-4; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zhou BHP, 2001, NAT CELL BIOL, V3, P245, DOI 10.1038/35060032; Zhou BP, 2000, J BIOL CHEM, V275, P8027, DOI 10.1074/jbc.275.11.8027	64	51	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6573	6586		10.1038/sj.onc.1205847	http://dx.doi.org/10.1038/sj.onc.1205847			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242655				2022-12-25	WOS:000178202300003
J	Zuo, YH; Deutscher, MP				Zuo, YH; Deutscher, MP			Mechanism of action of RNase T II. A structural and functional model of the enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA POLYMERASE-III; MATURATION	A detailed structural and functional model of E. coli RNase T was generated based on sequence analysis, homology modeling, and experimental observation. In the accompanying article, three short sequence segments (nucleic acid binding sequences (NBS)) important for RNase T substrate binding were identified. In the model, these segments cluster to form a positively charged surface patch. However, this patch is on the face of the RNase T monomer opposite the DEDD catalytic center. We propose that by dimerization, the NBS patch from one subunit is brought to the vicinity of the DEDD center of the second monomer to form a fully functional RNase T active site. In support of this model, mutagenetic studies show that one NBS1 residue, Arg(13), sits at the catalytic center despite being on the opposite side of the monomer. Second, the complementarity of the RNase T subunits through the formation of homodimers was demonstrated by reconstitution of partial RNase T activity from monomers derived from two inactive mutant proteins, one defective in catalysis and one in substrate binding. These data explain why RNase T must dimerize to function. The model provides a detailed framework on which to explain the mechanism of action of RNase T.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.	mdeutsch@med.miami.edu	Zuo, Yuhong/H-7392-2012	Zuo, Yuhong/0000-0003-1810-4580	NIGMS NIH HHS [GM 16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; Breyer WA, 2000, NAT STRUCT BIOL, V7, P1125; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Derbyshire V, 1995, METHOD ENZYMOL, V262, P363; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; Jones S, 2001, NUCLEIC ACIDS RES, V29, P943, DOI 10.1093/nar/29.4.943; JOYCE CM, 1994, ANNU REV BIOCHEM, V63, P777, DOI 10.1146/annurev.bi.63.070194.004021; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; Li ZW, 1996, J BIOL CHEM, V271, P1133, DOI 10.1074/jbc.271.2.1133; Li ZW, 1996, J BIOL CHEM, V271, P1127, DOI 10.1074/jbc.271.2.1127; Li ZW, 1999, RNA, V5, P139, DOI 10.1017/S1355838299981669; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; MAKI H, 1987, P NATL ACAD SCI USA, V84, P4389, DOI 10.1073/pnas.84.13.4389; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PADMANABHA KP, 1991, J BACTERIOL, V173, P1376, DOI 10.1128/jb.173.4.1376-1381.1991; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Zuo YH, 2002, J BIOL CHEM, V277, P50155, DOI 10.1074/jbc.M207706200; Zuo YH, 2002, J BIOL CHEM, V277, P29654, DOI 10.1074/jbc.M204252200; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	26	20	20	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50160	50164		10.1074/jbc.M207707200	http://dx.doi.org/10.1074/jbc.M207707200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12364333	hybrid			2022-12-25	WOS:000180028900136
J	Fu, Q; Jilka, RL; Manolagas, SC; O'Brien, CA				Fu, Q; Jilka, RL; Manolagas, SC; O'Brien, CA			Parathyroid hormone stimulates receptor activator of NF kappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE BONE-MARROW; OSTEOCLAST DIFFERENTIATION FACTOR; RAT COLLAGENASE-3 PROMOTER; IN-VIVO; C-FOS; OSTEOBLASTIC CELLS; INTERLEUKIN-6; CREB; TRANSCRIPTION; GENE	Parathyroid hormone (PTH) stimulates osteoclast formation by binding to its receptor on stromal/osteoblastic cells and stimulating the production of receptor activator of NFkappaB ligand (RANKL) and inhibiting the expression of osteoprotegerin (OPG). However, the mechanisms through which PTH regulates these genes remain unknown. Here we report that PTH stimulated RANKL gene transcription and increased RANKL mRNA stability in murine stromal/osteoblastic cells stably expressing human PTH/PTH-related protein receptor 1. PTH also potently suppressed OPG mRNA in these cells. Cycloheximide did not block the effects of PTH on RANKL but did inhibit the suppression of OPG mRNA. Activation of protein kinase A (PKA) was necessary and sufficient for the effect of PTH on both genes. Conditional expression of a dominant-negative form of the transcription factor CREB, but not c-fos or Runx2, significantly reduced PTH stimulation of RANKL. CREB activity was also required for full stimulation of RANKL by oncostatin M or 1,25-dihydroxyvitamin D-3. Dominant-negative forms of CREB and c-fos reduced the suppression of OPG by PTH. These results demonstrate that PTH directly stimulates RANKL expression via a PKA-CREB pathway and that CREB may be a central regulator of RANKL expression. Furthermore, they suggest that PTH suppression of OPG involves CREB and c-fos.	Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	O'Brien, CA (corresponding author), Univ Arkansas Med Sci, Ctr Osteoporosis & Metab Bone Dis, Div Endocrinol & Metab, 4301 W Markham St,Mail Slot 587, Little Rock, AR 72205 USA.	obriencharlesa@uams.edu	O'Brien, Charles A./AAL-5078-2020		NIAMS NIH HHS [R01-AR45241] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045241] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Cappellen D, 2002, J BIOL CHEM, V277, P21971, DOI 10.1074/jbc.M200434200; Chan HM, 2001, J CELL SCI, V114, P2363; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Fan X, 2001, AM J PHYSIOL-ENDOC M, V280, pE103, DOI 10.1152/ajpendo.2001.280.1.E103; Fata JE, 2000, CELL, V103, P41, DOI 10.1016/S0092-8674(00)00103-3; FEYEN JHM, 1989, J BONE MINER RES, V4, P633, DOI 10.1002/jbmr.5650040422; GIRASOLE G, 1994, J CLIN INVEST, V93, P1516, DOI 10.1172/JCI117130; Grey A, 1999, ENDOCRINOLOGY, V140, P4683, DOI 10.1210/en.140.10.4683; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Halladay DL, 2002, J CELL BIOCHEM, V84, P1, DOI 10.1002/jcb.1273; HARPOLD MM, 1979, CELL, V17, P1025, DOI 10.1016/0092-8674(79)90341-6; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Issa LL, 1998, INFLAMM RES, V47, P451, DOI 10.1007/s000110050360; Jilka RL, 1998, BONE, V23, P75, DOI 10.1016/S8756-3282(98)00077-5; Kanzawa M, 2000, EUR J ENDOCRINOL, V142, P661, DOI 10.1530/eje.0.1420661; KERST JM, 1993, EXP HEMATOL, V21, P1550; Khosla S, 2001, ENDOCRINOLOGY, V142, P5050, DOI 10.1210/en.142.12.5050; Kondo H, 2002, J BONE MINER RES, V17, P1667, DOI 10.1359/jbmr.2002.17.9.1667; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; Lee SK, 1999, ENDOCRINOLOGY, V140, P3552, DOI 10.1210/en.140.8.3552; Lin SC, 1997, J CLIN INVEST, V100, P1980, DOI 10.1172/JCI119729; Liu BY, 1998, ENDOCRINOLOGY, V139, P1952, DOI 10.1210/en.139.4.1952; Liu BY, 2002, ENDOCRINOLOGY, V143, P627, DOI 10.1210/en.143.2.627; LOWIK CWGM, 1989, BIOCHEM BIOPH RES CO, V162, P1546, DOI 10.1016/0006-291X(89)90851-6; Ma YFL, 2001, ENDOCRINOLOGY, V142, P4047, DOI 10.1210/en.142.9.4047; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; O'Brien CA, 2002, BONE, V30, P453, DOI 10.1016/S8756-3282(01)00692-5; Olive M, 1997, J BIOL CHEM, V272, P18586, DOI 10.1074/jbc.272.30.18586; ONYIA JE, 1995, BONE, V17, P479, DOI 10.1016/8756-3282(95)00332-2; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; Pollock JH, 1996, J BONE MINER RES, V11, P754; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; Roodman GD, 2001, J CLIN ONCOL, V19, P3562, DOI 10.1200/JCO.2001.19.15.3562; Rudolph D, 1998, P NATL ACAD SCI USA, V95, P4481, DOI 10.1073/pnas.95.8.4481; Selvamurugan N, 1998, J BIOL CHEM, V273, P10647, DOI 10.1074/jbc.273.17.10647; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; Swarthout JT, 2002, GENE, V282, P1, DOI 10.1016/S0378-1119(01)00798-3; Takami M, 2000, ENDOCRINOLOGY, V141, P4711, DOI 10.1210/en.141.12.4711; TAMURA T, 1993, P NATL ACAD SCI USA, V90, P11924, DOI 10.1073/pnas.90.24.11924; Tyson DR, 1999, ENDOCRINOLOGY, V140, P1255, DOI 10.1210/en.140.3.1255; YAMASHITA T, 1990, J CELL PHYSIOL, V145, P587, DOI 10.1002/jcp.1041450327; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; YOSHIDA H, 1990, NATURE, V345, P442, DOI 10.1038/345442a0	54	166	179	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48868	48875		10.1074/jbc.M208494200	http://dx.doi.org/10.1074/jbc.M208494200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12364326	hybrid			2022-12-25	WOS:000179789600116
J	Chakraborty, A; Das, I; Datta, R; Sen, B; Bhattacharyya, D; Mandal, C; Datta, AK				Chakraborty, A; Das, I; Datta, R; Sen, B; Bhattacharyya, D; Mandal, C; Datta, AK			A single-domain cyclophilin from Leishmania donovani reactivates soluble aggregates of adenosine kinase by isomerase-independent chaperone function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDYL-PROLYL ISOMERASE; ACTIVITY IN-VITRO; ESCHERICHIA-COLI; BINDING-PROTEIN; HEAT-SHOCK; ENDOPLASMIC-RETICULUM; MOLECULAR CHAPERONES; CYCLOSPORINE-A; HIV-1 VIRIONS; HOMOLOG	Disaggregation and reactivation of aggregated proteins by chaperones is well established. However, little is known regarding such kind of function of single-domain small cyclophilins (CyPs). Here we demonstrate that, with increasing concentrations, fully active adenosine kinase (AdK) of Leishmania donovani tends to form soluble aggregates, resulting in inactivation. Using this inactive enzyme as the substrate, it is shown that a CyP from L. donovani (LdCyP) alone can cause complete disaggregation, leading to reactivation of the enzyme. The reactivating ability of LdCyP remains unaffected even in the presence of cyclosporin A and macromolecular crowding agents. The reactivation occurs noncatalytically and is reversible. A truncated LdCyP, devoid of 88 amino acids from the N terminus, is found to be required in near stoichiometric proportion to reactivate AdK, suggesting essentiality of the C-terminal region. Gel filtration and light-scattering experiments together with protein cross-linking studies revealed that both full-length LdCyP and the truncated form directly interact with AdK and convert oligomeric forms of the enzyme to monomeric state. Homology modeling studies suggest that the exposed hydrophobic residues of LdCyP, by interacting with solvent-accessible hydrophobic surface of AdK, pull apart its aggregated inactive oligomers to functional monomers. Clearly, the results are consistent with the interpretation that the higher efficiency of the truncated LdCyP is most likely due to increased exposure of the hydrophobic residues on its surface. These observations, besides establishing L. donovani AdK as one of the model enzymes to study aggregation-disaggregation of proteins, raise the possibility that single-domain small CyPs, under physiological conditions, may regulate the activity of aggregation-prone proteins by ensuring their disaggregation.	Indian Inst Chem Biol, Div Infect Dis, Leishmania Grp, Kolkata 700032, India; Indian Inst Chem Biol, Div Drug Design Dev & Mol Modelling, Kolkata 700032, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB); Council of Scientific & Industrial Research (CSIR) - India; CSIR - Indian Institute of Chemical Biology (IICB)	Datta, AK (corresponding author), Indian Inst Chem Biol, Div Infect Dis, Leishmania Grp, 4 Raja SC Mullick Rd, Kolkata 700032, India.	alokdatta@iicb.res.in						ARGAMAN M, 1994, MOL BIOCHEM PARASIT, V64, P95, DOI 10.1016/0166-6851(94)90138-4; Bagui TK, 1996, BIOCHEM J, V316, P439, DOI 10.1042/bj3160439; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; Bhattacharyya AM, 2001, J BIOL CHEM, V276, P28739, DOI 10.1074/jbc.M102500200; BHAUMIK D, 1989, J BIOL CHEM, V264, P4356; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; DATTA AK, 1987, J BIOL CHEM, V262, P5515; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; Duina AA, 1998, J BIOL CHEM, V273, P10819, DOI 10.1074/jbc.273.18.10819; Dutta M, 2001, J BIOL CHEM, V276, P19294, DOI 10.1074/jbc.M009379200; Ellis R. John, 1999, Current Opinion in Structural Biology, V9, P102, DOI 10.1016/S0959-440X(99)80013-X; Ellis RJ, 1997, CURR BIOL, V7, pR531, DOI 10.1016/S0960-9822(06)00273-9; Elowitz MB, 1999, J BACTERIOL, V181, P197, DOI 10.1128/JB.181.1.197-203.1999; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Fischer G, 1999, MOL CHAPERONES FOLDI, P461; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; FRESKGARD PO, 1992, SCIENCE, V258, P466, DOI 10.1126/science.1357751; Furutani M, 2000, BIOCHEMISTRY-US, V39, P453, DOI 10.1021/bi9911076; GHOSH M, 1994, BIOCHEM J, V298, P295, DOI 10.1042/bj2980295; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; HARDING SE, 1997, PROTEIN STRUCTURE PR, P219; ITSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3389; Jaenicke R, 1999, MOL CHAPERONES FOLDI, P407; Jaschke A, 1998, J MOL BIOL, V277, P763, DOI 10.1006/jmbi.1998.1644; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li J, 2001, J BIOL CHEM, V276, P34396, DOI 10.1074/jbc.M103392200; LIU J, 1992, BIOCHEMISTRY-US, V31, P3896, DOI 10.1021/bi00131a002; LODISH HF, 1991, J BIOL CHEM, V266, P14835; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Mandal C, 1996, NAT BIOTECHNOL, V14, P323, DOI 10.1038/nbt0396-323; MANDAL C, 1998, MODELYN ANALYN; Martin J, 1997, P NATL ACAD SCI USA, V94, P1107, DOI 10.1073/pnas.94.4.1107; Mathews II, 1998, BIOCHEMISTRY-US, V37, P15607, DOI 10.1021/bi9815445; McGwire BS, 2002, J BIOL CHEM, V277, P8802, DOI 10.1074/jbc.M109072200; NADEAU K, 1993, J BIOL CHEM, V268, P1479; Ow WB, 2001, PROTEIN SCI, V10, P2346, DOI 10.1110/ps.23301; Pak M, 1997, P NATL ACAD SCI USA, V94, P4901, DOI 10.1073/pnas.94.10.4901; Patzelt H, 2001, P NATL ACAD SCI USA, V98, P14244, DOI 10.1073/pnas.261432298; Pirkl F, 2001, J BIOL CHEM, V276, P37034, DOI 10.1074/jbc.M102595200; Pittz E P, 1973, Methods Enzymol, V27, P209; PRICE ER, 1991, P NATL ACAD SCI USA, V88, P1903, DOI 10.1073/pnas.88.5.1903; Ramm K, 2000, J BIOL CHEM, V275, P17106, DOI 10.1074/jbc.M910234199; Rassow J, 1997, TRENDS CELL BIOL, V7, P129, DOI 10.1016/S0962-8924(96)10056-8; RINFRET A, 1994, BIOCHEMISTRY-US, V33, P1668, DOI 10.1021/bi00173a008; Rivera VM, 2000, SCIENCE, V287, P826, DOI 10.1126/science.287.5454.826; ROTONDA J, 1993, J BIOL CHEM, V268, P7607; SCHREIBER SL, 1991, SCIENCE, V251, P283, DOI 10.1126/science.1702904; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; Schumacher MA, 2000, J MOL BIOL, V298, P875, DOI 10.1006/jmbi.2000.3753; Sinha KM, 1999, BIOCHEM J, V339, P667, DOI 10.1042/0264-6021:3390667; SKOWYRA D, 1990, CELL, V62, P939, DOI 10.1016/0092-8674(90)90268-J; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; SYKES K, 1993, P NATL ACAD SCI USA, V90, P5853, DOI 10.1073/pnas.90.12.5853; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van den Berg B, 1999, EMBO J, V18, P6927, DOI 10.1093/emboj/18.24.6927; von Ahsen O, 2000, J MOL BIOL, V297, P809, DOI 10.1006/jmbi.2000.3574; ZILBERSTEIN D, 1994, ANNU REV MICROBIOL, V48, P449, DOI 10.1146/annurev.mi.48.100194.002313; ZIMMERMAN SB, 1991, J MOL BIOL, V222, P599, DOI 10.1016/0022-2836(91)90499-V; ZIMMERMAN SB, 1993, ANNU REV BIOPH BIOM, V22, P27, DOI 10.1146/annurev.bb.22.060193.000331	67	39	39	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47451	47460		10.1074/jbc.M204827200	http://dx.doi.org/10.1074/jbc.M204827200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244046	hybrid			2022-12-25	WOS:000179663700081
J	Helfand, MS; Hujer, AM; Sonnichsen, FD; Bonomo, RA				Helfand, MS; Hujer, AM; Sonnichsen, FD; Bonomo, RA			Unexpected advanced generation cephalosporinase activity of the M69F variant of SHV beta-lactamase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZATION MASS-SPECTROMETRY; INHIBITOR-RESISTANT MUTANTS; ESCHERICHIA-COLI; CLAVULANIC ACID; INACTIVATION; TAZOBACTAM; MUTATIONS; TEM-1; ARGININE-244; MUTAGENESIS	Infections with bacteria that contain hydrolytic beta-lactamase enzymes are becoming a serious problem in the United States. Mutations at Met-69, an amino acid proximal to the active site Ser-70 in the TEM-1 and SHV-1 beta-lactamases, have emerged as a puzzling cause of bacterial resistance to inhibitors of beta-lactamases. Site-saturation mutagenesis of the 69 position in SHV beta-lactamase was performed to determine how mutations of this non-catalytic residue play a role in increasing 50% inhibitory concentrations (IC50 concentrations) for clinically important beta-lactamase enzyme inhibitors. Two distinct phenotypes are evident in the variant beta-lactamases studied: significantly increased minimum inhibitory concentrations (mug/ml) and IC50 concentrations to clavulanic acid for the Met69Ile, Leu, and Val substitutions, and unanticipated increased minimum inhibitory concentrations and hydrolytic activity toward ceftazidime, an advanced generation cephalosporin antibiotic, for the Met69Lys, Tyr- and Phe-substituted enzymes. Molecular modeling studies emphasize the conserved structure of these substitutions despite great variation in substrate specificity. This study demonstrates the key role of Met-69 in defining substrate specificity of SHV beta-lactamases and alerts us to new phenotypes that may emerge clinically.	Case Western Reserve Univ, Sch Med, Louis Stokes Cleveland Vet Affairs Med Ctr, Infect Dis Sect,Res Serv, Cleveland, OH 44106 USA; Univ Hosp Cleveland, Div Infect Dis, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; University Hospitals of Cleveland; Case Western Reserve University	Bonomo, RA (corresponding author), Case Western Reserve Univ, Sch Med, Louis Stokes Cleveland Vet Affairs Med Ctr, Infect Dis Sect,Res Serv, 10701 East Blvd, Cleveland, OH 44106 USA.		Sönnichsen, Frank D/D-8408-2011	Sönnichsen, Frank D/0000-0002-4539-3755				AMBLER RP, 1980, PHILOS T R SOC B, V289, P321, DOI 10.1098/rstb.1980.0049; Bevington P. R., 1969, DATA REDUCTION ERROR, P56; BLAZQUEZ J, 1993, ANTIMICROB AGENTS CH, V37, P2059, DOI 10.1128/AAC.37.10.2059; BONOMO RA, 1995, BBA-PROTEIN STRUCT M, V1247, P121, DOI 10.1016/0167-4838(94)00188-M; BRENNER DG, 1984, BIOCHEMISTRY-US, V23, P5833, DOI 10.1021/bi00319a024; Brown RPA, 1996, BIOCHEMISTRY-US, V35, P12421, DOI 10.1021/bi961044g; BUSH K, LAHEY CLIN RESISTANT; Chaibi EB, 1998, BBA-PROTEIN STRUCT M, V1382, P38, DOI 10.1016/S0167-4838(97)00127-1; CHARNAS RL, 1981, BIOCHEMISTRY-US, V20, P3214, DOI 10.1021/bi00514a035; DELAIRE M, 1992, J BIOL CHEM, V267, P20600; Farzaneh S, 1996, ANTIMICROB AGENTS CH, V40, P2434, DOI 10.1128/AAC.40.10.2434; FERSHT A, 1984, ENZYME STRUCTURE MEC, P274; Huang WZ, 1997, P NATL ACAD SCI USA, V94, P8801, DOI 10.1073/pnas.94.16.8801; Hujer AM, 2002, J CLIN MICROBIOL, V40, P1947, DOI 10.1128/JCM.40.6.1947-1957.2002; Hujer AM, 2001, BBA-PROTEIN STRUCT M, V1547, P37, DOI 10.1016/S0167-4838(01)00164-9; HUJER AM, 2002, IN PRESS ANTIMICROB, V46; IMTIAZ U, 1993, J AM CHEM SOC, V115, P4435, DOI 10.1021/ja00064a003; KNOX JR, 1995, ANTIMICROB AGENTS CH, V39, P2593, DOI 10.1128/AAC.39.12.2593; Kuzin AP, 1999, BIOCHEMISTRY-US, V38, P5720, DOI 10.1021/bi990136d; Kuzin AP, 2001, BIOCHEMISTRY-US, V40, P1861, DOI 10.1021/bi0022745; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Meroueh SO, 2002, J AM CHEM SOC, V124, P9422, DOI 10.1021/ja026547q; Minasov G, 2002, J AM CHEM SOC, V124, P5333, DOI 10.1021/ja0259640; Page MGF, 2000, DRUG RESIST UPDATE, V3, P109, DOI 10.1054/drup.2000.0137; Powers RA, 2001, BIOCHEMISTRY-US, V40, P9207, DOI 10.1021/bi0109358; Wang XJ, 2002, J BIOL CHEM, V277, P32149, DOI 10.1074/jbc.M204212200; Yang Y, 2000, J BIOL CHEM, V275, P26674	27	31	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47719	47723		10.1074/jbc.M207271200	http://dx.doi.org/10.1074/jbc.M207271200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354765	hybrid			2022-12-25	WOS:000179663700114
J	Skala-Rubinson, H; Vinh, J; Labas, V; Kahn, A; Tuy, FPD				Skala-Rubinson, H; Vinh, J; Labas, V; Kahn, A; Tuy, FPD			Novel target sequences for Pax-6 in the brain-specific activating regions of the rat aldolase C gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; DNA-BINDING ACTIVITY; TRANSCRIPTION FACTOR; PAIRED DOMAIN; IN-VIVO; EXPRESSION; PROTEINS; ROLES; LENS; SITE	Upstream activating sequences of the rat aldolase C gene are shown here to confer brain-specific expression in transgenic mice. In addition to binding sites described previously for the brain-expressed POU proteins Brn-1 and Brn-2 (Skala, H., Porten, A., Thomas, M., Szajnert, M. F., Okazawa, H., Kahn, A., and Phan-Dinh-Tuy, F. (1998) J. Biol. Chem. 273, 31806-31814), we have identified two novel DNA elements critical for an interaction with a brain-specific, high affinity DNA-binding protein. Characterization of this binding protein showed it to be sensitive to thiol oxidation and stable to heat at 100degreesC. This protein was purified on the basis of its thermostability and its selective adsorption to streptavidin magnetic particles via a biotinylated multimer of its target DNA binding site. Liquid chromatography coupled to tandem mass spectrometry analysis, binding competition with consensus oligonucleotides, and antibody supershift assays led to its identification as the homeodomain paired protein Pax-6. This result suggests that the brain-specific aldolase C gene could constitute a new target for the transcription factor Pax-6, which is implicated increasingly in neurogenesis.	Univ Paris 05, INSERM, Dept Genet Dev & Pathol Mol, CNRS,Inst Cochin, F-75014 Paris, France; Ecole Super Phys & Chim Ind Ville Paris, CNRS, F-75231 Paris 05, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Tuy, FPD (corresponding author), Univ Paris 05, INSERM, Dept Genet Dev & Pathol Mol, CNRS,Inst Cochin, 24 Rue Faubourg St Jacques, F-75014 Paris, France.	tuy@cochin.inserm.fr	Vinh, Joelle/K-1347-2015	Vinh, Joelle/0000-0001-7184-2668				ABATE C, 1990, SCIENCE, V249, P1157, DOI 10.1126/science.2118682; ANG SL, 1994, CELL, V78, P561, DOI 10.1016/0092-8674(94)90522-3; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; Arrigo AP, 1999, FREE RADICAL BIO MED, V27, P936, DOI 10.1016/S0891-5849(99)00175-6; Ashery-Padan R, 2001, CURR OPIN CELL BIOL, V13, P706, DOI 10.1016/S0955-0674(00)00274-X; Berg JM, 1996, SCIENCE, V271, P1081, DOI 10.1126/science.271.5252.1081; BOPP D, 1986, CELL, V47, P1033, DOI 10.1016/0092-8674(86)90818-4; CEREGHINI S, 1987, CELL, V50, P627, DOI 10.1016/0092-8674(87)90036-5; Chauhan BK, 2002, J BIOL CHEM, V277, P11539, DOI 10.1074/jbc.M110531200; Cvekl A, 1996, BIOESSAYS, V18, P621, DOI 10.1002/bies.950180805; EPSTEIN J, 1994, J BIOL CHEM, V269, P8355; GABRIELSEN OS, 1993, METHOD ENZYMOL, V218, P508; GARNER MM, 1981, NUCLEIC ACIDS RES, V9, P3047, DOI 10.1093/nar/9.13.3047; GLASER T, 1992, NAT GENET, V2, P232, DOI 10.1038/ng1192-232; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORSKI K, 1986, CELL, V47, P767, DOI 10.1016/0092-8674(86)90519-2; GRUSS P, 1992, CELL, V69, P719, DOI 10.1016/0092-8674(92)90281-G; Heins N, 2002, NAT NEUROSCI, V5, P308, DOI 10.1038/nn828; HOGAN B, 1996, MANIPULATING MOUSE E; HOGAN BLM, 1986, J EMBRYOL EXP MORPH, V97, P95; Holst BD, 1997, P NATL ACAD SCI USA, V94, P1465, DOI 10.1073/pnas.94.4.1465; Jun S, 1996, DEVELOPMENT, V122, P2639; KADONAGA JT, 1986, P NATL ACAD SCI USA, V83, P5889, DOI 10.1073/pnas.83.16.5889; KOZMIK Z, 1992, MOL CELL BIOL, V12, P2662, DOI 10.1128/MCB.12.6.2662; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Larsson LI, 1998, MECH DEVELOP, V79, P153, DOI 10.1016/S0925-4773(98)00182-8; Lengler J, 2001, BIOCHEM BIOPH RES CO, V287, P372, DOI 10.1006/bbrc.2001.5605; MAKEH I, 1994, J BIOL CHEM, V269, P4194; Maxam A M, 1980, Methods Enzymol, V65, P499; MCKNIGHT SL, 1982, SCIENCE, V217, P316, DOI 10.1126/science.6283634; Meech R, 1999, P NATL ACAD SCI USA, V96, P2420, DOI 10.1073/pnas.96.5.2420; Mikkola I, 2001, J BIOL CHEM, V276, P4109, DOI 10.1074/jbc.M008882200; O'Leary DDM, 2002, CURR OPIN NEUROBIOL, V12, P14, DOI 10.1016/S0959-4388(02)00285-4; OSSIPOW V, 1993, NUCLEIC ACIDS RES, V21, P6040, DOI 10.1093/nar/21.25.6040; PIETTE J, 1985, EMBO J, V4, P2675, DOI 10.1002/j.1460-2075.1985.tb03987.x; PLAZA S, 1993, CELL GROWTH DIFFER, V4, P1041; RAYMONDJEAN M, 1988, P NATL ACAD SCI USA, V85, P757, DOI 10.1073/pnas.85.3.757; Ritz-Laser B, 1999, J BIOL CHEM, V274, P4124, DOI 10.1074/jbc.274.7.4124; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; Sakai M, 2001, NUCLEIC ACIDS RES, V29, P1228, DOI 10.1093/nar/29.5.1228; Sander M, 1997, GENE DEV, V11, P1662, DOI 10.1101/gad.11.13.1662; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Skala H, 1998, J BIOL CHEM, V273, P31806, DOI 10.1074/jbc.273.48.31806; Stoykova A, 2000, J NEUROSCI, V20, P8042; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Tell G, 2000, NUCLEIC ACIDS RES, V28, P1099, DOI 10.1093/nar/28.5.1099; Tell G, 1998, J BIOL CHEM, V273, P25062, DOI 10.1074/jbc.273.39.25062; THOMAS M, 1993, EUR J BIOCHEM, V218, P143, DOI 10.1111/j.1432-1033.1993.tb18360.x; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; van Heyningen V, 2002, HUM MOL GENET, V11, P1161, DOI 10.1093/hmg/11.10.1161; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WILSON C, 1990, ANNU REV CELL BIOL, V6, P679, DOI 10.1146/annurev.cellbio.6.1.679; Zhou YH, 2000, GENE, V245, P319, DOI 10.1016/S0378-1119(00)00019-6	57	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47190	47196		10.1074/jbc.M209349200	http://dx.doi.org/10.1074/jbc.M209349200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370174	hybrid			2022-12-25	WOS:000179663700046
J	Andrews, AL; Holloway, JW; Puddicombe, SM; Holgate, ST; Davies, DE				Andrews, AL; Holloway, JW; Puddicombe, SM; Holgate, ST; Davies, DE			Kinetic analysis of the interleukin-13 receptor complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-13 RECEPTOR; FUNCTIONAL COMPONENT; SIGNAL-TRANSDUCTION; ALLERGIC-ASTHMA; ALPHA-2 CHAIN; B-CELLS; CLONING; BINDING; INTERNALIZATION; IDENTIFICATION	Interleukin (IL)-13 is a key cytokine associated with the asthmatic phenotype. It signals via its cognate receptor, a complex of IL-13 receptor alpha1 chain (IL-13Ralpha1) with IL-4Ralpha; however, a second protein, IL-13Ralpha2, also binds IL-13. To determine the binding contributions of the individual components of the IL-13 receptor to IL-13, we have employed surface plasmon resonance and equilibrium binding assays to investigate the ligand binding characteristics of shIL-13Ralpha1, shIL-13Ralpha2, and IL-4Ralpha. shIL-13Ralpha1 bound IL-13 with moderate affinity (K-D = 37.8 +/- 1.8 nm, n = 10), whereas no binding was observed for hIL-4Ralpha. In contrast, shIL-13Ralpha2 produced a high affinity interaction with IL-13 (K-D = 2.49 +/- 0.94 nm n = 10). IL-13Ra2 exhibited the binding characteristics of a negative regulator with a fast association rate and an exceptional slow dissociation rate. Although IL-13 interacted weakly with IL-4Ralpha on its own (K-D > 50 mum), the presence of hIL-4Ra significantly increased the affinity of shIL-13Ralpha1 for IL-13 but had no effect on the binding affinity of IL-13Ralpha2. Detailed kinetic analyses of the binding properties of the heteromeric complexes suggested a sequential mechanism for the binding of IL-13 to its signaling receptor, in which IL-13 first binds to IL-13Ralpha1 and this then recruits IL-4Ralpha to stabilize a high affinity interaction.	Univ Southampton, Southampton Gen Hosp, Sch Med, Infect Inflammat & Repair Div, Southampton SO16 6YD, Hants, England	University of Southampton	Davies, DE (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Infect Inflammat & Repair Div, 97 Tremona Rd, Southampton SO16 6YD, Hants, England.	donnad@soton.ac.uk	Davies, Donna E/H-2993-2012; Holloway, John W/B-5424-2009	Holloway, John W/0000-0001-9998-0464; Davies, Donna/0000-0002-5117-2991				Aman MJ, 1996, J BIOL CHEM, V271, P29265, DOI 10.1074/jbc.271.46.29265; BOCHNER BS, 1995, J IMMUNOL, V154, P799; Caput D, 1996, J BIOL CHEM, V271, P16921, DOI 10.1074/jbc.271.28.16921; Chomarat P, 1998, Int Rev Immunol, V17, P1, DOI 10.3109/08830189809084486; de Vries JE, 1998, J ALLERGY CLIN IMMUN, V102, P165, DOI 10.1016/S0091-6749(98)70080-6; de Vries JE, 1999, J ALLERGY CLIN IMMUN, V103, pS492, DOI 10.1016/S0091-6749(99)70166-1; DEFRANCE T, 1994, J EXP MED, V179, P135, DOI 10.1084/jem.179.1.135; Donaldson DD, 1998, J IMMUNOL, V161, P2317; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hilton DJ, 1996, P NATL ACAD SCI USA, V93, P497, DOI 10.1073/pnas.93.1.497; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; Kawakami K, 2001, BLOOD, V97, P2673, DOI 10.1182/blood.V97.9.2673; Kawakami K, 2001, J BIOL CHEM, V276, P25114, DOI 10.1074/jbc.M100936200; Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281; Miloux B, 1997, FEBS LETT, V401, P163, DOI 10.1016/S0014-5793(96)01462-7; Murata T, 1998, BLOOD, V91, P3884; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; WELHAM MJ, 1995, J BIOL CHEM, V270, P12286, DOI 10.1074/jbc.270.20.12286; Wills-Karp M, 2001, J ALLERGY CLIN IMMUN, V107, P9, DOI 10.1067/mai.2001.112265; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Zhang JG, 1997, J BIOL CHEM, V272, P9474; ZHOU M, 1993, BIOCHEMISTRY-US, V32, P8193, DOI 10.1021/bi00083a020; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3	26	69	103	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46073	46078		10.1074/jbc.M209560200	http://dx.doi.org/10.1074/jbc.M209560200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12354755	hybrid			2022-12-25	WOS:000179529300049
J	Rosen, K; Shi, W; Calabretta, B; Filmus, J				Rosen, K; Shi, W; Calabretta, B; Filmus, J			Cell detachment triggers p38 mitogen-activated protein kinase-dependent overexpression of Fas ligand - A novel mechanism of anoikis of intestinal epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BCL-X-L; MAMMARY-GLAND INVOLUTION; JUN NH2-TERMINAL KINASE; INDUCED APOPTOSIS; DOWN-REGULATION; EXTRACELLULAR-MATRIX; CD95 FAS/APO-1; IN-VITRO; KI-RAS; DEATH	Many cell types undergo apoptosis when they are detached from the extracellular matrix (ECM). This phenomenon has been termed anoikis. Most epithelial cells, which are normally attached to a type of ECM called basement membrane, are particularly sensitive to anoikis. Conversely, carcinoma cells tend to be resistant to anoikis, and this resistance plays a critical role in tumor invasion and metastasis. We reported previously that detachment-induced down-regulation of the antiapoptotic molecule Bel-X, makes a significant contribution to anoikis of intestinal epithelial cells. Here we demonstrate that exogenous Bcl-X-L, no matter how highly expressed in these cells, can significantly attenuate anoikis but cannot completely prevent it, suggesting that at least another pro-apoptotic event is activated by the loss of cell-ECM contacts. Indeed, in this study we identified a novel mechanism of anoikis in intestinal epithelial cells that involves detachment-induced overexpression of Fas ligand. We also demonstrated that this elevation in Fas ligand expression requires a detachment-induced increase of p38 mitogen-activated protein kinase activity. We conclude that the activation of at least two different pro-apoptotic events is required for anoikis of intestinal epithelial cells.	Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M4N 3M5, Canada; Jefferson Med Coll, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; Jefferson University	Filmus, J (corresponding author), Univ Toronto, Sunnybrook & Womens Coll Hlth Sci Ctr, 2075 Bayview Ave,S211, Toronto, ON M4N 3M5, Canada.			Rosen, Kirill/0000-0002-4317-9907				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Algeciras-Schimnich A, 2002, MOL CELL BIOL, V22, P207, DOI 10.1128/MCB.22.1.207-220.2002; Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Aragane Y, 1998, J CELL BIOL, V140, P171, DOI 10.1083/jcb.140.1.171; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; Cinatl J, 2000, J IMMUNOL, V165, P4405, DOI 10.4049/jimmunol.165.8.4405; COUCOUVANIS E, 1995, CELL, V83, P279, DOI 10.1016/0092-8674(95)90169-8; Dai CH, 1998, BLOOD, V91, P1235, DOI 10.1182/blood.V91.4.1235; Dermitzaki E, 2002, J BIOL CHEM, V277, P12280, DOI 10.1074/jbc.M111236200; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Frankel A, 2001, CANCER RES, V61, P4837; Frisch SM, 1997, CURR OPIN CELL BIOL, V9, P701, DOI 10.1016/S0955-0674(97)80124-X; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 1999, CURR BIOL, V9, P1047, DOI 10.1016/S0960-9822(99)80455-2; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Grossmann J, 1998, AM J PHYSIOL-GASTR L, V274, pG1117, DOI 10.1152/ajpgi.1998.274.6.G1117; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ikeda H, 1998, GUT, V42, P530, DOI 10.1136/gut.42.4.530; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Krestow JK, 1999, BIOCHEM BIOPH RES CO, V260, P48, DOI 10.1006/bbrc.1999.0863; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Li L, 2002, J BIOL CHEM, V277, P5977, DOI 10.1074/jbc.M111131200; Li SC, 2002, J BIOL CHEM, V277, P26912, DOI 10.1074/jbc.M200726200; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MEREDITH JE, 1997, TRENDS CELL BIOL, V7, P147; Micheau O, 1999, J BIOL CHEM, V274, P7987, DOI 10.1074/jbc.274.12.7987; Nagata S, 1999, NAT CELL BIOL, V1, pE143, DOI 10.1038/14094; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Rosen K, 1998, CURR BIOL, V8, P1331, DOI 10.1016/S0960-9822(07)00564-7; Rosen K, 2000, J CELL BIOL, V149, P447, DOI 10.1083/jcb.149.2.447; Rosen K, 2001, J BIOL CHEM, V276, P37273, DOI 10.1074/jbc.M106424200; Ruemmele FM, 2002, BIOCHEM BIOPH RES CO, V290, P1308, DOI 10.1006/bbrc.2002.6348; Rytomaa M, 1999, CURR BIOL, V9, P1043, DOI 10.1016/S0960-9822(99)80454-0; SCAFFIDI CSCAF, 2001, J BIOL CHEM, V274, P22532; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sevignani C, 1998, J CLIN INVEST, V101, P1572, DOI 10.1172/JCI919; SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203; Slee EA, 1999, CELL DEATH DIFFER, V6, P1067, DOI 10.1038/sj.cdd.4400601; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; STRANGE R, 1992, DEVELOPMENT, V115, P49; Strater J, 1996, GASTROENTEROLOGY, V110, P1776, DOI 10.1053/gast.1996.v110.pm8964403; SUX XM, 2002, J BIOL CHEM, V277, P11345; Tinhofer I, 1998, BLOOD, V91, P4273, DOI 10.1182/blood.V91.11.4273.411k25_4273_4281; Walczak H, 2000, EXP CELL RES, V256, P58, DOI 10.1006/excr.2000.4840; Walczak H, 2001, TRENDS BIOCHEM SCI, V26, P452, DOI 10.1016/S0968-0004(01)01895-3; Wang J, 2000, J CELL SCI, V113, P753; Wang XT, 2000, J BIOL CHEM, V275, P39435, DOI 10.1074/jbc.M004583200; Wiesen J, 2000, MOL REPROD DEV, V56, P534, DOI 10.1002/1098-2795(200008)56:4&lt;534::AID-MRD12&gt;3.0.CO;2-O; Zhang J, 2000, J EXP MED, V191, P1017, DOI 10.1084/jem.191.6.1017	63	68	70	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46123	46130		10.1074/jbc.M207883200	http://dx.doi.org/10.1074/jbc.M207883200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356751	hybrid			2022-12-25	WOS:000179529300056
J	Tojo, M; Matsuzaki, K; Minami, T; Honda, Y; Yasuda, H; Chiba, T; Saya, H; Fujii-Kuriyama, Y; Nakao, M				Tojo, M; Matsuzaki, K; Minami, T; Honda, Y; Yasuda, H; Chiba, T; Saya, H; Fujii-Kuriyama, Y; Nakao, M			The aryl hydrocarbon receptor nuclear transporter is modulated by the SUMO-1 conjugation system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-LIKE PROTEIN; HYPOXIA-INDUCIBLE FACTOR-1; COVALENT MODIFICATION; DNA-BINDING; INTRACELLULAR-LOCALIZATION; ANDROGEN RECEPTOR; MODIFIER-1 SUMO-1; DIOXIN RECEPTOR; TRANSCRIPTION; ACTIVATION	The aryl hydrocarbon receptor nuclear transporter (ARNT) is a member of the basic helix-loop-helix/PAS (Per-ARNT-Sim) family of transcription factors, which are important for cell regulation in response to environmental conditions. ARNT is an indispensable partner of the aryl hydrocarbon receptor (AHR) or hypoxia-inducible factor-1alpha. This protein is also able to form homodimers such as ARNT/ARNT. However, the molecular mechanism that regulates the transcriptional activity of ARNT remains to be elucidated. Here, we report that ARNT is modified by SUMO-1 chiefly at Lys(245) within the PAS domain of this protein, both in vivo and in vitro. Substitution of the target lysine with alanine enhanced the transcriptional potential of ARNT per se. Furthermore, green fluorescent protein-fused ARNT tended to form nuclear foci in similar to20% of the transfected cells, and the foci partly colocalized with PML nuclear bodies. PML, one of the well known substrates for sumoylation, was found to augment the transcriptional activities of ARNT. ARNT bound AHR or PML, whereas the sumoylated form of ARNT associated with AHR, but not with PML, resulting in a reduced effect of PML on transactivation by ARNT. Our data suggest that the sumoylation of ARNT modulates its transcriptional role through affecting the ability of ARNT to interact with cooperative molecules such as PML. This exemplifies a crucial role of protein sumoylation in modulating protein-protein interactions.	Kumamoto Univ, Dept Regenerat Med, Inst Mol Embryol & Genet, Kumamoto 8600811, Japan; Kumamoto Univ, Sch Med, Dept Tumor Genet & Biol, Kumamoto 8600811, Japan; Kyoto Univ, Grad Sch Med, Dept Gastroenterol & Hepatol, Sakyo Ku, Kyoto 6068507, Japan; Tokyo Univ Pharm & Life Sci, Sch Life Sci, Sakyo Ku, Hachioji, Tokyo 6068507, Japan; Tohoku Univ, Grad Sch Sci, Dept Chem, Aoba Ku, Sendai, Miyagi 9808578, Japan	Kumamoto University; Kumamoto University; Kyoto University; Tokyo University of Pharmacy & Life Sciences; Tohoku University	Nakao, M (corresponding author), Kumamoto Univ, Dept Regenerat Med, Inst Mol Embryol & Genet, 2-2-1 Honjo, Kumamoto 8600811, Japan.	mnakao@gpo.kumamoto-u.ac.jp	Saya, Hideyuki/J-4325-2013					Beischlag TV, 2002, MOL CELL BIOL, V22, P4319, DOI 10.1128/MCB.22.12.4319-4333.2002; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Chakrabarti SR, 2000, P NATL ACAD SCI USA, V97, P13281, DOI 10.1073/pnas.240315897; Chakrabarti SR, 1999, P NATL ACAD SCI USA, V96, P7467, DOI 10.1073/pnas.96.13.7467; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Duprez E, 1999, J CELL SCI, V112, P381; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Fujita N, 2000, MOL CELL BIOL, V20, P5107, DOI 10.1128/MCB.20.14.5107-5118.2000; FUKUNAGA BN, 1995, J BIOL CHEM, V270, P29270, DOI 10.1074/jbc.270.49.29270; Gonzalez FJ, 1998, DRUG METAB DISPOS, V26, P1194; Goodson ML, 2001, J BIOL CHEM, V276, P18513, DOI 10.1074/jbc.M008066200; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hahn SL, 1997, ONCOGENE, V15, P1489, DOI 10.1038/sj.onc.1201301; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; HATTA M, 2001, SCI STKE; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 2001, CELL, V107, P5, DOI 10.1016/S0092-8674(01)00519-0; Hong YL, 2001, J BIOL CHEM, V276, P40263, DOI 10.1074/jbc.M104714200; Huffman JL, 2001, J BIOL CHEM, V276, P40537, DOI 10.1074/jbc.M105675200; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; Johnson ES, 1999, J CELL BIOL, V147, P981, DOI 10.1083/jcb.147.5.981; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kamitani T, 1998, J BIOL CHEM, V273, P26675, DOI 10.1074/jbc.273.41.26675; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kazlauskas A, 2001, MOL CELL BIOL, V21, P2594, DOI 10.1128/MCB.21.7.2594-2607.2001; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Ko HSP, 1996, MOL CELL BIOL, V16, P430; Kobayashi A, 1996, J BIOL CHEM, V271, P12310, DOI 10.1074/jbc.271.21.12310; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kurtzman AL, 2001, P NATL ACAD SCI USA, V98, P5602, DOI 10.1073/pnas.101129698; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Ma Q, 2000, J BIOL CHEM, V275, P8432, DOI 10.1074/jbc.275.12.8432; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pongratz I, 1998, MOL CELL BIOL, V18, P4079, DOI 10.1128/MCB.18.7.4079; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rowlands JC, 1997, CRIT REV TOXICOL, V27, P109, DOI 10.3109/10408449709021615; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Saitoh H, 1998, CURR BIOL, V8, P121, DOI 10.1016/S0960-9822(98)70044-2; Salomon-Nguyen F, 2000, P NATL ACAD SCI USA, V97, P6757, DOI 10.1073/pnas.120162297; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Seeler JS, 2001, ONCOGENE, V20, P7243, DOI 10.1038/sj.onc.1204758; Seeler JS, 2001, MOL CELL BIOL, V21, P3314, DOI 10.1128/MCB.21.10.3314-3324.2001; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Shimizu Y, 2000, P NATL ACAD SCI USA, V97, P779, DOI 10.1073/pnas.97.2.779; Sogawa K, 1998, P NATL ACAD SCI USA, V95, P7368, DOI 10.1073/pnas.95.13.7368; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Wang F, 1999, BIOCHEMISTRY-US, V38, P11490, DOI 10.1021/bi982578f; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; Wilson VG, 2001, EXP CELL RES, V271, P57, DOI 10.1006/excr.2001.5366; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583	63	56	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46576	46585		10.1074/jbc.M205987200	http://dx.doi.org/10.1074/jbc.M205987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12354770	hybrid			2022-12-25	WOS:000179529300113
J	Xiong, YM; Haas, TA; Zhang, L				Xiong, YM; Haas, TA; Zhang, L			Identification of functional segments within the beta I-2-domain of integrin alpha(M)beta(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL INHIBITORY FACTOR; I-DOMAIN; LIGAND-BINDING; CRYSTAL-STRUCTURE; CD18 SUBUNIT; A-DOMAIN; RECOGNITION; CD11B/CD18; RECEPTOR; SITE	The alpha(M)beta(2) integrin plays an important role in leukocyte biology through its interactions with a diverse set of ligands. Efficient ligand binding requires the involvement of both the alpha(M) and beta(2) subunits. Past ligand binding studies have focused mainly on the alpha(M) subunit, with the beta(2) subunit being largely unexplored. Therefore, in this study we conducted homolog-scanning mutagenesis on the 1-domain (residues 125-385) within the beta(2) subunit. We identified four noncontiguous sequences (Arg(144)-Lys(148), Gln(199)-Ala(203), Leu(225)-Leu(230), and Gly(305)-His(309)) that are critical for fibrinogen and C3bi binding to alpha(M)beta(2). modeling revealed that these four sequences reside within a narrow region on the surface of the beta(2)I-domain, in close proximity to three potential cation-binding sites. Among these sequences, Gln(199)-Ala(203), Leu(225)-Leu(230), and Gly(305-)His(309) are important for the binding of both ligands, whereas Arg(144)-Lys(148) is more critical for fibrinogen than for C3bi binding. These sequences within the beta(2)I-domain are directly involved in ligand binding, since 1) switching these segments to their corresponding beta(1) sequences destroyed ligand binding; 2) loss of function was not due to a nonspecific gross conformational change, since the defective alpha(M)beta(2) mutants reacted well with a panel of conformation-dependent mAbs; 3) mutation of these functional sequences did not effect Ca2+ binding; and 4) synthetic peptides corresponding to sequences Gln(199)-Ala(203) and Gly(305)-His(309) blocked ligand binding to alpha(M)beta(2), and the peptides interacted directly with fibrinogen and C3bi. Given the similarity among all integrin beta subunits, our results may help us to understand the underlying mechanism of integrin-ligand interactions in general.	Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA; Cleveland Clin Fdn, Dept Mol Cardiol, Cleveland, OH 44195 USA	American Red Cross; Cleveland Clinic Foundation	Zhang, L (corresponding author), Amer Red Cross, Holland Lab, Dept Vasc Biol, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.				NHLBI NIH HHS [R01 HL61589-01, P01 HL054710, R01 HL061589] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL054710, R01HL061589] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alonso JL, 2002, CURR BIOL, V12, pR340, DOI 10.1016/S0960-9822(02)00852-7; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; BAJT ML, 1995, J BIOL CHEM, V270, P94, DOI 10.1074/jbc.270.1.94; BAJT ML, 1992, J BIOL CHEM, V267, P3789; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Forsyth CB, 1998, J IMMUNOL, V161, P6198; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; ROSS GD, 1985, J IMMUNOL, V134, P3307; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; Zhang L, 1996, J BIOL CHEM, V271, P18211, DOI 10.1074/jbc.271.30.18211	26	12	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46639	46644		10.1074/jbc.M207971200	http://dx.doi.org/10.1074/jbc.M207971200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324470	hybrid			2022-12-25	WOS:000179529300121
J	Biswas, TK; Getz, GS				Biswas, TK; Getz, GS			Import of yeast mitochondrial transcription factor (Mtf1p) via a nonconventional pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL TARGETING SIGNAL; OUTER-MEMBRANE PROTEIN; RNA-POLYMERASE; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; SPECIFICITY FACTOR; ADENYLATE KINASE; GENE-EXPRESSION; OXIDASE SUBUNIT; INNER MEMBRANE	The yeast mitochondrial (mt) transcription factor Mtf1p is imported into the mitochondria from the cytoplasm without a conventional mt-targeting presequence. To understand its import the mt translocation. of wild type and mutant Mtf1p constructs was investigated in vitro under various assay conditions. We report here that Mtf1p, unlike most mt matrix proteins hitherto studied, is translocated into the mitochondria independent of membrane potential, ATP hydrolysis, and membrane receptor. This unusual import of Mtf1p was also observed on ice (3 degreesC). Sub-mitochondrial fractionation demonstrated that Mtf1p was translocated in vitro to one or more of the same mt sites as the endogenous protein that includes the matrix. To identify the mt-targeting sequence of Mtf1p, various N-terminal, C-terminal, or internally deleted Mtf1p derivatives were generated. The full-length and C-terminal deletions but not the N-terminal truncated Mtf1p were imported into mitochondria, indicating the importance of its N-terminal sequence for mt targeting. However, the internal deletion of Mtf1p revealed that the first 150-amino acid N-terminal sequence alone was not sufficient for mt targeting of Mtf1p, suggesting that an extended rather than a short N-terminal sequence is required for import. We favor a model in which Mtf1p adopts an import-competent conformation during translation. Consistent with this model are three findings: most of the protein sequence appears to be required for optimal import, urea denaturation eliminates its import competence, and the import-competent form of the protein is more resistant to tryptic hydrolysis than is the denatured protein. This represents a novel mechanism for mitochondrial protein import.	Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Biswas, TK (corresponding author), Univ Chicago, Dept Pathol, 5841 S Maryland Ave, Chicago, IL 60637 USA.							ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626; ARAKAWA H, 1987, EMBO J, V6, P1361, DOI 10.1002/j.1460-2075.1987.tb02376.x; Artigues A, 2002, J BIOL CHEM, V277, P25047, DOI 10.1074/jbc.M203474200; ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cellbio.4.1.289; Bandlow W, 1998, BIOCHEM J, V329, P359, DOI 10.1042/bj3290359; Bauer MF, 2001, J INHERIT METAB DIS, V24, P166, DOI 10.1023/A:1010314900814; BISWAS TK, 1987, J BIOL CHEM, V262, P13690; Biswas TK, 1998, GENE, V212, P305, DOI 10.1016/S0378-1119(98)00133-4; BOHNI PC, 1983, J BIOL CHEM, V258, P4937; Brunner M., 1994, SIGNAL PEPTIDASES, P73; CHRISTIANSON T, 1983, J BIOL CHEM, V258, P4025; COSTANZO MC, 1990, ANNU REV GENET, V24, P91; CYR DM, 1991, J BIOL CHEM, V266, P21700; DAUM G, 1982, J BIOL CHEM, V257, P3028; DeLabre ML, 1999, FEBS LETT, V449, P201, DOI 10.1016/S0014-5793(99)00415-9; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Dietmeier K, 1997, NATURE, V388, P195, DOI 10.1038/40663; EILERS M, 1988, EMBO J, V7, P1139, DOI 10.1002/j.1460-2075.1988.tb02923.x; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; GRIVELL LA, 1995, CRIT REV BIOCHEM MOL, V30, P121, DOI 10.3109/10409239509085141; Hajek P, 1997, MOL CELL BIOL, V17, P7169, DOI 10.1128/MCB.17.12.7169; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; HOLLENBE.CP, 1970, BIOCHIM BIOPHYS ACTA, V209, P1, DOI 10.1016/0005-2787(70)90655-6; HURT EC, 1985, EMBO J, V4, P3509, DOI 10.1002/j.1460-2075.1985.tb04110.x; Isenman L, 1995, BBA-REV BIOMEMBRANES, V1241, P341, DOI 10.1016/0304-4157(95)00009-7; JANG SH, 1991, J BIOL CHEM, V266, P22671; Jiang N, 2001, J BIOL CHEM, V276, P29218, DOI 10.1074/jbc.M103686200; Kurz M, 1999, MOL BIOL CELL, V10, P2461, DOI 10.1091/mbc.10.7.2461; LAIN B, 1994, J BIOL CHEM, V269, P15588; LAW RHP, 1990, BIOCHIM BIOPHYS ACTA, V1027, P141, DOI 10.1016/0005-2736(90)90077-2; LEMIRE BD, 1989, J BIOL CHEM, V264, P20206; LILL R, 1992, EMBO J, V11, P449, DOI 10.1002/j.1460-2075.1992.tb05074.x; LISOWSKY T, 1988, MOL GEN GENET, V214, P218, DOI 10.1007/BF00337714; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; Matouschek A, 2000, EMBO REP, V1, P404, DOI 10.1093/embo-reports/kvd093; MILLER BR, 1991, J CELL BIOL, V112, P833, DOI 10.1083/jcb.112.5.833; Muckel E, 1996, J BIOL CHEM, V271, P23846, DOI 10.1074/jbc.271.39.23846; MURAKAMI H, 1988, J CELL BIOL, V107, P2051, DOI 10.1083/jcb.107.6.2051; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; NGUYEN M, 1993, J BIOL CHEM, V268, P25265; NYE SH, 1990, MOL CELL BIOL, V10, P5763, DOI 10.1128/MCB.10.11.5763; OSTERMANN J, 1989, NATURE, V341, P125, DOI 10.1038/341125a0; PFANNER N, 1990, ANNU REV BIOCHEM, V59, P331, DOI 10.1146/annurev.biochem.59.1.331; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1990, J BIOL CHEM, V265, P16324; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; PFANNER N, 1997, CURR BIOL, V7, P100; Poyton RO, 1996, ANNU REV BIOCHEM, V65, P563, DOI 10.1146/annurev.bi.65.070196.003023; Rodriguez-Cousino N, 1998, J BIOL CHEM, V273, P11527, DOI 10.1074/jbc.273.19.11527; ROISE D, 1988, EMBO J, V7, P649, DOI 10.1002/j.1460-2075.1988.tb02859.x; SANYAL A, 1995, J BIOL CHEM, V270, P11970, DOI 10.1074/jbc.270.20.11970; Schatz G, 1996, SCIENCE, V271, P1519, DOI 10.1126/science.271.5255.1519; SCHERRER LC, 1992, BIOCHEMISTRY-US, V31, P7325, DOI 10.1021/bi00147a017; SCHINKEL AH, 1987, J BIOL CHEM, V262, P12785; SCHRICKER R, 1992, MOL GEN GENET, V233, P363, DOI 10.1007/BF00265432; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; TICHO BS, 1988, J BIOL CHEM, V263, P10096; TZAGOLOFF A, 1986, ANNU REV BIOCHEM, V55, P249, DOI 10.1146/annurev.bi.55.070186.001341; von Heijne G, 1990, CURR OPIN CELL BIOL, V2, P604, DOI 10.1016/0955-0674(90)90100-S; VONHEIJNE G, 1986, EMBO J, V5, P1335, DOI 10.1002/j.1460-2075.1986.tb04364.x; Voos W, 1999, BBA-REV BIOMEMBRANES, V1422, P235, DOI 10.1016/S0304-4157(99)00007-6; WINKLEY CS, 1985, J BIOL CHEM, V260, P4214; ZARA V, 1992, J BIOL CHEM, V267, P12077	67	17	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45704	45714		10.1074/jbc.M202565200	http://dx.doi.org/10.1074/jbc.M202565200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270918	hybrid			2022-12-25	WOS:000179404800138
J	Zhang, M; Mileykovskaya, E; Dowhan, W				Zhang, M; Mileykovskaya, E; Dowhan, W			Gluing the respiratory chain together - Cardiolipin is required for supercomplex formation in the inner mitochondrial membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME BC(1) COMPLEX; SACCHAROMYCES-CEREVISIAE; ACRIDINE-ORANGE; YEAST; PROTEIN; SYSTEM; PHOSPHOLIPIDS; DIGESTION; SYNTHASE; VECTORS	Cytochrome bc(1) complex (complex III) and cytochrome c oxidase complex (complex IV) are multisubunit homodimers that are essential components of the mitochondrial respiratory chain. Complexes III and IV associate to form a supercomplex that can be displayed using blue native polyacrylamide gel electrophoresis. Both homodimeric complexes contain tightly associated cardiolipin (CL) required for function. We report here that in a crd1Delta strain of yeast (null in expression of CL synthase) similar to90% of complexes III and IV were observed as individual homodimers; only the supercomplex was observed with CRD1 wild type cells. Introduction of a plasmid born copy of the CRD1 gene under exogenous regulation by doxycycline made possible controlled variation in the in vivo CL levels. At an intermediate level of CL, a mixture of individual homodimers (30%) and supercomplex (70%) was observed. These results strongly indicate that CL plays a central role in higher order organization of components of the respiratory chain of mitochondria.	Univ Texas, Sch Med, Dept Biochem & Mol Biol, Houston, TX 77225 USA	University of Texas System	Dowhan, W (corresponding author), Univ Texas, Sch Med, Dept Biochem & Mol Biol, POB 20708, Houston, TX 77225 USA.	William.Dowhan@uth.tmc.edu	Zhang, Mei/G-8690-2014	Mileykovskaya, Eugenia/0000-0002-8775-4467	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056389] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM56389] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Chang SC, 1998, J BIOL CHEM, V273, P14933, DOI 10.1074/jbc.273.24.14933; Cruciat CM, 2000, J BIOL CHEM, V275, P18093, DOI 10.1074/jbc.M001901200; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; Ferguson AD, 2000, STRUCTURE, V8, P585; FINE JB, 1982, J LIPID RES, V23, P660; Fyfe PK, 2001, TRENDS BIOCHEM SCI, V26, P106, DOI 10.1016/S0968-0004(00)01746-1; Gari E, 1997, YEAST, V13, P837, DOI 10.1002/(SICI)1097-0061(199707)13:9<837::AID-YEA145>3.0.CO;2-T; Gomez B, 1999, BIOCHEMISTRY-US, V38, P9031, DOI 10.1021/bi990603r; Haiens TH, 2002, FEBS LETT, V528, P35, DOI 10.1016/S0014-5793(02)03292-1; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Jiang F, 1997, MOL MICROBIOL, V26, P481, DOI 10.1046/j.1365-2958.1997.5841950.x; Jiang F, 2000, J BIOL CHEM, V275, P22387, DOI 10.1074/jbc.M909868199; Lange C, 2001, EMBO J, V20, P6591, DOI 10.1093/emboj/20.23.6591; McAuley KE, 1999, P NATL ACAD SCI USA, V96, P14706, DOI 10.1073/pnas.96.26.14706; MIKELSAAR K, 1974, USP SOVREM BIOL, V78, P248; Mileykovskaya E, 2000, J BACTERIOL, V182, P1172, DOI 10.1128/JB.182.4.1172-1175.2000; Mileykovskaya E, 2001, FEBS LETT, V507, P187, DOI 10.1016/S0014-5793(01)02948-9; MIZUSHAMI T, 1999, ACTA CRYSTALLOGR A S, V55; Ostrander DB, 2001, J BIOL CHEM, V276, P25262, DOI 10.1074/jbc.M103689200; Schagger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777; SCHAGGER H, 2001, CRIT REV, V52, P119; Sedlak E, 1999, BIOCHEMISTRY-US, V38, P14966, DOI 10.1021/bi9914053; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SIKORSKI RS, 1989, GENETICS, V122, P19; Tuller G, 1998, FEBS LETT, V421, P15, DOI 10.1016/S0014-5793(97)01525-1	25	476	488	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43553	43556		10.1074/jbc.C200551200	http://dx.doi.org/10.1074/jbc.C200551200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12364341	hybrid			2022-12-25	WOS:000179272000003
J	Montero, M; Lobaton, CD; Moreno, A; Alvarez, J				Montero, M; Lobaton, CD; Moreno, A; Alvarez, J			A novel regulatory mechanism of the mitochondrial Ca2+ uniporter revealed by the p38 mitogen-activated protein kinase inhibitor sb202190	FASEB JOURNAL			English	Article						calcium; mitochondria; aequorin; MAP kinase	ADRENAL CHROMAFFIN CELLS; SIGNAL-TRANSDUCTION; MAP KINASE; ENDOPLASMIC-RETICULUM; CALCIUM-TRANSPORT; INTACT-CELLS; TRANSLOCATION; PERMEABILITY; MICRODOMAINS; TRANSIENTS	It is widely acknowledged that mitochondrial Ca2+ uptake modulates the cytosolic [Ca2+] ([Ca2+](c)) acting as a transient Ca2+ buffer. In addition, mitochondrial [Ca2+] ([Ca2+](M)) regulates the rate of respiration and may trigger opening of the permeability transition pore and start apoptosis. However, no mechanism for the physiological regulation of mitochondrial Ca2+ uptake has been described. We show here that SB202190, an inhibitor of p38 mitogen-activated protein (MAP) kinase, strongly stimulates ruthenium red-sensitive mitochondrial Ca2+ uptake, both in intact and in permeabilized HeLa cells. The [Ca2+](M) peak induced by agonists was increased about fourfold in the presence of the inhibitor, with a concomitant reduction in the [Ca2+](c), peak. The stimulation occurred fast and was rapidly reversible. In addition, experiments in permeabilized cells perfused with controlled [Ca2+] showed that SB202190 stimulated mitochondrial Ca2+ uptake by more than 10-fold, but only in the physiological [Ca2+](c), range (1-4 muM). Other structurally related p38 MAP kinase inhibitors (SB203580, PD169316, or SB220025) produced little or no effect. Our data suggest that in HeLa cells, a protein kinase sensitive to SB202190 tonically inhibits the mitochondrial Ca2+ uniporter. This novel regulatory mechanism may be of paramount importance to modulate mitochondrial Ca2+ uptake under different physiopathological conditions.	Univ Valladolid, Fac Med, Dept Bioquim & Biol Mol & Fisiol, IBGM, E-47005 Valladolid, Spain; CSIC, E-47005 Valladolid, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC-UVA - Instituto de Biologia y Genetica Molecular (IBGM); Universidad de Valladolid; Consejo Superior de Investigaciones Cientificas (CSIC)	Alvarez, J (corresponding author), Univ Valladolid, Fac Med, Dept Bioquim & Biol Mol & Fisiol, IBGM, Ramon & Cajal 7, E-47005 Valladolid, Spain.	jalvarez@ibgm.uva.es	Montero, Mayte/K-8212-2014; Alvarez, Javier/K-8210-2014; Lobaton, Carmen D/A-9134-2015	Montero, Mayte/0000-0001-7702-6653; Alvarez, Javier/0000-0003-0636-5521; Lobaton, Carmen D/0000-0001-9574-3082; Moreno, Alfredo/0000-0002-7444-5198				ALLEN DG, 1977, SCIENCE, V195, P996, DOI 10.1126/science.841325; Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; Behr TM, 2001, CIRCULATION, V104, P1292, DOI 10.1161/hc3601.094275; Bernardi P, 1999, PHYSIOL REV, V79, P1127, DOI 10.1152/physrev.1999.79.4.1127; Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Duchen MR, 2000, J PHYSIOL-LONDON, V529, P57, DOI 10.1111/j.1469-7793.2000.00057.x; Feranchak AP, 2001, J CLIN INVEST, V108, P1495, DOI 10.1172/JCI200112190; Ghatan S, 2000, J CELL BIOL, V150, P335, DOI 10.1083/jcb.150.2.335; Giovannucci DR, 1999, J NEUROSCI, V19, P9261; Gunter TE, 1998, BBA-BIOENERGETICS, V1366, P5, DOI 10.1016/S0005-2728(98)00117-0; Herlaar E, 1999, MOL MED TODAY, V5, P439, DOI 10.1016/S1357-4310(99)01544-0; Huang FY, 2000, INT J ENG SCI, V38, P275, DOI 10.1016/S0020-7225(99)00041-5; Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Lee SH, 2000, J NEUROSCI RES, V60, P623, DOI 10.1002/(SICI)1097-4547(20000601)60:5<623::AID-JNR7>3.0.CO;2-4; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Montero M, 1997, FASEB J, V11, P881, DOI 10.1096/fasebj.11.11.9285486; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Park YB, 1996, J PHYSIOL-LONDON, V492, P329, DOI 10.1113/jphysiol.1996.sp021312; Pausawasdi N, 2000, AM J PHYSIOL-GASTR L, V278, pG24, DOI 10.1152/ajpgi.2000.278.1.G24; Pozzan T, 2000, EUR J BIOCHEM, V267, P5269, DOI 10.1046/j.1432-1327.2000.01567.x; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Rustenbeck I, 1998, BIOCHEM PHARMACOL, V56, P977, DOI 10.1016/S0006-2952(98)00232-9; Sayed M, 2000, J BIOL CHEM, V275, P16569, DOI 10.1074/jbc.M000312200; Sugden PH, 1998, CIRC RES, V83, P345, DOI 10.1161/01.RES.83.4.345; Villalobos C, 2002, FASEB J, V16, DOI 10.1096/fj.01-0630com; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; WHITE HS, 1997, EPILEPSIES, V2, P1; Wilk-Blaszczak MA, 1998, J NEUROSCI, V18, P112	38	67	71	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1955	+		10.1096/fj.02-0553fje	http://dx.doi.org/10.1096/fj.02-0553fje			22	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368236				2022-12-25	WOS:000179167600027
J	Mikkers, H; Allen, J; Berns, A				Mikkers, H; Allen, J; Berns, A			Proviral activation of the tumor suppressor E2 alpha contributes to T cell lymphomagenesis in E mu Myc transgenic mice	ONCOGENE			English	Article						E2A; lymphoma; MuLv; c-Myc; transgene	MURINE LEUKEMIA-VIRUS; DNA-BINDING PROTEINS; ZINC-FINGER PROTEIN; LOOP-HELIX PROTEINS; C-MYC; TRANSCRIPTION FACTOR; E2A; GENE; PROGRESSION; APOPTOSIS	The basic helix-loop-helix factor E2A plays an important role in the development of B and T lymphocytes. In addition, E2a has been implicated as a gene with tumor suppressor activity, since mice deficient for E2a succumb to T cell lymphomas. We have performed retroviral tagging in EmuMyc transgenic mice to identify genes that contribute to lymphomagenesis. The EmuMyc transgenic mouse is a well-established model of a common translocation in human B cell lymphomas. Analyses of the proviral insertion sites in the MuLV-induced lymphomas revealed that a number of T cell lymphomas carried proviral insertions in the promoter region of E2a. These proviral insertions yield hybrid viral-E2a mRNAs resulting in a marked rise in E2A protein levels. The proviral insertions in E2a were predominantly of clonal origin indicating that E2a insertions are early events in these T cell lymphomas. The primary oncogenic effect of E2A is likely to be associated with enhancement of transcription of the c-Myc transgene via binding to the regulatory immunoglobulin enhancers. The results herein thus provide the first evidence that in a specific setting E2A overexpression can contribute to T-lymphomagenesis. This implies that E2a contains oncogenic features in addition to the previously described tumor suppressive properties.	Netherlands Canc Inst, Div Mol Genet, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Ctr Biomed Genet, NL-1066 CX Amsterdam, Netherlands	Netherlands Cancer Institute; Netherlands Cancer Institute	Berns, A (corresponding author), Netherlands Canc Inst, Div Mol Genet, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands.							ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; Adams JM, 1999, ONCOGENE, V18, P5268, DOI 10.1038/sj.onc.1202997; ALEXANDER WS, 1987, MOL CELL BIOL, V7, P1436, DOI 10.1128/MCB.7.4.1436; ALKEMA MJ, 1995, NATURE, V374, P724, DOI 10.1038/374724a0; Allen JD, 1997, ONCOGENE, V15, P1133, DOI 10.1038/sj.onc.1201288; Bain G, 1999, J EXP MED, V190, P1605, DOI 10.1084/jem.190.11.1605; Bain G, 1997, MOL CELL BIOL, V17, P4782, DOI 10.1128/MCB.17.8.4782; BAIN G, 1994, CELL, V79, P885, DOI 10.1016/0092-8674(94)90077-9; BAIN G, 1993, MOL CELL BIOL, V13, P3522, DOI 10.1128/MCB.13.6.3522; Barndt RJ, 2000, MOL CELL BIOL, V20, P6677, DOI 10.1128/MCB.20.18.6677-6685.2000; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BERNS A, 1994, COLD SPRING HARB SYM, V59, P435, DOI 10.1101/SQB.1994.059.01.049; DOMEN J, 1993, J EXP MED, V178, P1665, DOI 10.1084/jem.178.5.1665; Engel I, 1999, P NATL ACAD SCI USA, V96, P996, DOI 10.1073/pnas.96.3.996; Engel I, 2001, J EXP MED, V194, P733, DOI 10.1084/jem.194.6.733; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Fisher GH, 2001, GENE DEV, V15, P3249, DOI 10.1101/gad.947701; GILKS CB, 1993, MOL CELL BIOL, V13, P1759, DOI 10.1128/MCB.13.3.1759; GORER PA, 1950, BRIT J CANCER, V4, P372, DOI 10.1038/bjc.1950.36; Grimes HL, 1996, P NATL ACAD SCI USA, V93, P14569, DOI 10.1073/pnas.93.25.14569; HSU B, 1995, ONCOGENE, V11, P175; INABA T, 1992, SCIENCE, V257, P531, DOI 10.1126/science.1386162; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Jonkers J, 1996, BBA-REV CANCER, V1287, P29, DOI 10.1016/0304-419X(95)00020-G; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kee BL, 1998, J EXP MED, V188, P699, DOI 10.1084/jem.188.4.699; Kochetov AV, 1998, FEBS LETT, V440, P351, DOI 10.1016/S0014-5793(98)01482-3; Kuppers R, 2001, ONCOGENE, V20, P5580, DOI 10.1038/sj.onc.1204640; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; MIKKERS H, 2002, IN PRESS NATURE GENE; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Park ST, 1999, J EXP MED, V189, P501, DOI 10.1084/jem.189.3.501; PEVERALI FA, 1994, EMBO J, V13, P4291, DOI 10.1002/j.1460-2075.1994.tb06749.x; Rivera RR, 2000, IMMUNITY, V12, P17, DOI 10.1016/S1074-7613(00)80155-7; Sakamuro D, 1995, ONCOGENE, V11, P2411; Scheijen B, 1997, J VIROL, V71, P9, DOI 10.1128/JVI.71.1.9-16.1997; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SHEN CP, 1995, MOL CELL BIOL, V15, P4518; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; VANDERLUGT NMT, 1995, EMBO J, V14, P2536, DOI 10.1002/j.1460-2075.1995.tb07251.x; VANDERPUTTEN H, 1979, CELL, V18, P109, DOI 10.1016/0092-8674(79)90359-3; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9; VORONOVA AF, 1987, MOL CELL BIOL, V7, P4407, DOI 10.1128/MCB.7.12.4407; Yan W, 1997, MOL CELL BIOL, V17, P7317, DOI 10.1128/MCB.17.12.7317; Zhao F, 2001, MOL CELL BIOL, V21, P6346, DOI 10.1128/MCB.21.18.6346-6357.2001; ZHUANG Y, 1994, CELL, V79, P875, DOI 10.1016/0092-8674(94)90076-0; ZweidlerMcKay PA, 1996, MOL CELL BIOL, V16, P4024	51	14	14	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6559	6566		10.1038/sj.onc.1205930	http://dx.doi.org/10.1038/sj.onc.1205930			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242653				2022-12-25	WOS:000178202300001
J	Rhee, CS; Sen, M; Lu, DS; Wu, C; Leoni, L; Rubin, J; Corr, M; Carson, DA				Rhee, CS; Sen, M; Lu, DS; Wu, C; Leoni, L; Rubin, J; Corr, M; Carson, DA			Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas	ONCOGENE			English	Article						head and neck squamous cell carcinomas; frizzled; beta-catenin; apoptosis	BETA-CATENIN; EXPRESSION; PATTERN; ESTABLISHMENT; GENES; LMX1	The diverse receptor-ligand pairs of the Wnt and frizzled (Fz) families play important roles during embryonic development, and thus may be overexpressed in cancers that arise from immature cells. Hence, we investigated the expression and function of five Writ (Wnt-1, 5a, 7a, 10b, 13) and two Fz (Fz-2, 5) genes in 10 head and neck squamous carcinoma cell lines (HNSCC). In comparison to normal bronchial or oral epithelial cells, all the HNSCC had markedly increased mRNA levels of Wnt-1, 7a, 10b, and 13, as well as Fz-2. Moreover, the levels of Wnt-1, 10b, and Fz-2 proteins were also markedly increased in HNSCC, relative to normal epithelial cells. Treatment of one HNSCC cell line (SNU 1076) with anti-Wnt-1 antibodies reduced the activity of the Wnt/Fz dependent transcription factor LEF/TCF, and diminished the expression of cyclin D1 and beta-catenin proteins. Blocking Wnt-1 signaling also inhibited proliferation and induced apoptosis in these cells. These results show that HNSCC cell lines often overexpress one or more Wnt and Fz genes, and suggest that the growth and survival of a subset of HNSCC may depend on the Wnt/Fz pathway. Hence, the Writ and Fz receptors may be possible targets for immunotherapy therapy of this common cancer.	Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sam & Rose Stein Inst Res Aging, La Jolla, CA 92093 USA; NCI, Bethesda, MD 20892 USA; Seoul Natl Univ, Coll Med, Dept Otorhinolaryngol Head & Neck Surg, Seoul, South Korea	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Seoul National University (SNU)	Carson, DA (corresponding author), Univ Calif San Diego, Dept Med, 9500 Gilman Dr, La Jolla, CA 92093 USA.	dcarson@ucsd.edu	Lu, desheng/E-4822-2013; Rhee, Chae-Seo/D-5904-2012	Lu, desheng/0000-0002-3616-6657; Lu, Desheng/0000-0002-0314-5649	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023200] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; Kim SY, 1997, ACTA OTO-LARYNGOL, V117, P775, DOI 10.3109/00016489709113477; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Ku JL, 1999, LARYNGOSCOPE, V109, P976, DOI 10.1097/00005537-199906000-00025; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; Leethanakul C, 2000, ONCOGENE, V19, P3220, DOI 10.1038/sj.onc.1203703; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Ng JK, 1999, CURR TOP DEV BIOL, V41, P37; NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3; Parkin DM, 1999, CA-CANCER J CLIN, V49, P33, DOI 10.3322/canjclin.49.1.33; PARR BA, 1993, DEVELOPMENT, V119, P247; Ramsdell AF, 1998, TRENDS GENET, V14, P459, DOI 10.1016/S0168-9525(98)01599-6; RIDDLE RD, 1995, CELL, V83, P631, DOI 10.1016/0092-8674(95)90103-5; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Uren A, 2000, J BIOL CHEM, V275, P4374, DOI 10.1074/jbc.275.6.4374; VOGEL A, 1995, NATURE, V378, P716, DOI 10.1038/378716a0; Whiteside TL, 1998, CLIN CANCER RES, V4, P1135; YASUMURA S, 1993, CANCER RES, V53, P1461; Yoganathan TN, 2000, BIOCHEM PHARMACOL, V60, P1115, DOI 10.1016/S0006-2952(00)00444-5	22	166	192	0	5	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	SEP 26	2002	21	43					6598	6605		10.1038/sj.onc.1205920	http://dx.doi.org/10.1038/sj.onc.1205920			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242657				2022-12-25	WOS:000178202300005
J	Srivastava, M; Frolova, E; Rottinghaus, B; Boe, SP; Grinberg, A; Lee, E; Love, PE; Pfeifer, K				Srivastava, M; Frolova, E; Rottinghaus, B; Boe, SP; Grinberg, A; Lee, E; Love, PE; Pfeifer, K			Imprint control element-mediated secondary methylation imprints at the Igf2/H19 locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; MOUSE H19 GENE; DNA METHYLATION; MONOALLELIC EXPRESSION; H19/IGF2 LOCUS; DELETION; REGION; MECHANISMS; UPSTREAM; ALLELE	Understanding the molecular basis of monoallelic expression as observed at imprinted loci is helpful in understanding the mechanisms underlying epigenetic regulation. Genomic imprinting begins during gametogenesis with the establishment of epigenetic marks on the chromosomes such that paternal and maternal chromosomes are rendered distinct. During embryonic development, the primary imprint can lead to generation of secondary epigenetic modifications (secondary imprints) of the chromosomes. Eventually, either the primary imprints or the secondary imprints interfere with transcription, leading to parent-of-origin-dependent silencing of one of the two alleles. Here we investigated several aspects pertaining to the generation and functional necessity of secondary methylation imprints at the Igf2/H19 locus. At the H19 locus, these secondary imprints are, in fact, the signals mediating paternal chromosome-specific silencing of that gene. We first demonstrated that the H19 secondary methylation imprints are entirely stable through multiple cell divisions, even in the absence of the primary imprint. Second, we generated mouse mutations to determine which DNA sequences are important in mediating establishment and maintenance of the silent state of the paternal H19 allele. Finally, we analyzed the dependence of the methylation of Igf2DMR1 region on the primary methylation imprint about 90 kilobases away.	NICHD, Lab Mammalian Genes & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Srivastava, M (corresponding author), Natl Inst Immunol, Aruna Asaf Ali Rd, New Delhi 110067, India.	madhus@nii.res.in	Srivastava, Madhulika/M-8941-2019	Srivastava, Madhulika/0000-0002-0997-013X; Pfeifer, Karl/0000-0002-0254-682X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001804, ZIAHD001803] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001804, Z01HD001803] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BARTOLOMEI MS, 1993, GENE DEV, V7, P1663, DOI 10.1101/gad.7.9.1663; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; BRANDEIS M, 1993, EMBO J, V12, P3669, DOI 10.1002/j.1460-2075.1993.tb06041.x; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Cranston MJ, 2001, GENOMICS, V73, P98, DOI 10.1006/geno.2001.6514; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; Eden S, 2001, EMBO J, V20, P3518, DOI 10.1093/emboj/20.13.3518; FEIL R, 1994, DEVELOPMENT, V120, P2933; Feng CG, 2002, INT IMMUNOL, V14, P535, DOI 10.1093/intimm/dxf020; FERGUSONSMITH AC, 1993, NATURE, V362, P751, DOI 10.1038/362751a0; Forejt J, 1999, EXP CELL RES, V252, P416, DOI 10.1006/excr.1999.4627; Forne T, 1997, P NATL ACAD SCI USA, V94, P10243, DOI 10.1073/pnas.94.19.10243; GU H, 1993, CELL, V73, P1155, DOI 10.1016/0092-8674(93)90644-6; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; Kaffer CR, 2000, GENE DEV, V14, P1908; Kaffer CR, 2001, MOL CELL BIOL, V21, P8189, DOI 10.1128/MCB.21.23.8189-8196.2001; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; LaSalle JM, 1996, SCIENCE, V272, P725, DOI 10.1126/science.272.5262.725; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; LEIGHTON PA, 1995, GENE DEV, V9, P2079, DOI 10.1101/gad.9.17.2079; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; LOVE PE, 1994, J EXP MED, V179, P1485, DOI 10.1084/jem.179.5.1485; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Milligan L, 2000, ONCOGENE, V19, P5810, DOI 10.1038/sj.onc.1203965; OHLSSON R, 1994, DEVELOPMENT, V120, P361; Olek A, 1996, NUCLEIC ACIDS RES, V24, P5064, DOI 10.1093/nar/24.24.5064; Parish CR, 1999, IMMUNOL CELL BIOL, V77, P499, DOI 10.1046/j.1440-1711.1999.00877.x; Paulsen M, 2000, HUM MOL GENET, V9, P1829, DOI 10.1093/hmg/9.12.1829; Paulsen M, 1998, HUM MOL GENET, V7, P1149, DOI 10.1093/hmg/7.7.1149; Pfeifer K, 1996, P NATL ACAD SCI USA, V93, P13876, DOI 10.1073/pnas.93.24.13876; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Reik W, 1996, Int J Dev Biol, VSuppl 1, p53S; Ripoche MA, 1997, GENE DEV, V11, P1596, DOI 10.1101/gad.11.12.1596; Rougier N, 1998, GENE DEV, V12, P2108, DOI 10.1101/gad.12.14.2108; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; Srivastava M, 2000, GENE DEV, V14, P1186; Sun FL, 1997, NATURE, V389, P809, DOI 10.1038/39797; Szabo PE, 1995, GENE DEV, V9, P3097, DOI 10.1101/gad.9.24.3097; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Warnecke PM, 1998, GENOMICS, V51, P182, DOI 10.1006/geno.1998.5371; West AG, 2002, GENE DEV, V16, P271, DOI 10.1101/gad.954702	44	26	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 21	2003	278	8					5977	5983		10.1074/jbc.M208437200	http://dx.doi.org/10.1074/jbc.M208437200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	648BF	12270940	hybrid			2022-12-25	WOS:000181129400062
J	Liao, H; Bucala, R; Mitchell, RA				Liao, H; Bucala, R; Mitchell, RA			Adhesion-dependent signaling by macrophage migration inhibitory factor (MIF)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; INTEGRIN-MEDIATED ACTIVATION; CYCLIN D1 EXPRESSION; MODULATE AP-1 ACTIVITY; CELL-PROLIFERATION; REGULATORY ROLE; FACTOR GENE; MAP KINASE; G1 PHASE; C-SRC	Proper stimulation of cell cycle progression and DNA synthesis requires cooperating signals from integrin and growth factor receptors. We previously found that the proinflammatory peptide, macrophage migration inhibitory factor (MIF), functions as an autocrine mediator of growth factor-dependent ERK MAP kinase activation and cell cycle progression. We now report that MIF secretion is induced by cell adhesion to fibronectin in quiescent mouse fibroblasts. Adhesion-mediated release of MIF subsequently promotes integrin-dependent activation of MAP kinase, cyclin D1 expression, and DNA synthesis. Secretion of MIF requires protein kinase C activity, and recombinant MIF reconstitutes the activation of MAP kinases in the presence of protein kinase C inhibition. Finally, we show that cells deficient in MIF have significantly higher retinoblastoma tumor suppressor and lower E2F transcriptional activities. These results suggest that MIF is an important autocrine mediator of adhesion-dependent signaling events and may provide mechanistic insight into how MIF regulates proliferative and oncogenic processes.	Univ Louisville, James Graham Brown Canc Ctr, Louisville, KY 40292 USA; N Shore Long Isl Jewish Hlth Syst, Manhasset, NY 11030 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA	University of Louisville; Northwell Health; Yale University	Mitchell, RA (corresponding author), Univ Louisville, James Graham Brown Canc Ctr, 529 S Jackson St, Louisville, KY 40292 USA.				NIAMS NIH HHS [1R01-AR049610] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049610] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Albanell J, 2001, CANCER RES, V61, P6500; Arteaga CL, 2001, CURR OPIN ONCOL, V13, P491, DOI 10.1097/00001622-200111000-00012; Bacher M, 1996, P NATL ACAD SCI USA, V93, P7849, DOI 10.1073/pnas.93.15.7849; Berman A E, 2000, Membr Cell Biol, V13, P207; BERNHAGEN J, 1993, NATURE, V365, P756, DOI 10.1038/365756a0; BERNHAGEN J, 1994, BIOCHEMISTRY-US, V33, P14144, DOI 10.1021/bi00251a025; Bianchi E, 2000, NATURE, V404, P617, DOI 10.1038/35007098; Bozza M, 1999, J EXP MED, V189, P341, DOI 10.1084/jem.189.2.341; Busche S, 2001, ENDOCRINOLOGY, V142, P4623, DOI 10.1210/en.142.11.4623; Calandra T, 1998, P NATL ACAD SCI USA, V95, P11383, DOI 10.1073/pnas.95.19.11383; CHEN QM, 1994, J BIOL CHEM, V269, P26602; Chen QM, 1996, J BIOL CHEM, V271, P18122, DOI 10.1074/jbc.271.30.18122; Chesney J, 1999, MOL MED, V5, P181, DOI 10.1007/BF03402061; Claret FX, 1996, NATURE, V383, P453, DOI 10.1038/383453a0; Clark EA, 1996, J BIOL CHEM, V271, P14814, DOI 10.1074/jbc.271.25.14814; Honma N, 2000, IMMUNOLOGY, V100, P84, DOI 10.1046/j.1365-2567.2000.00011.x; Howe AK, 1998, J BIOL CHEM, V273, P27268, DOI 10.1074/jbc.273.42.27268; Howe AK, 2002, CURR OPIN GENET DEV, V12, P30, DOI 10.1016/S0959-437X(01)00260-X; Hudson JD, 1999, J EXP MED, V190, P1375, DOI 10.1084/jem.190.10.1375; Inoue H, 1996, VIROLOGY, V225, P223, DOI 10.1006/viro.1996.0591; Kleemann R, 2000, NATURE, V408, P211, DOI 10.1038/35041591; Kurzrock R, 2001, BIOMED PHARMACOTHER, V55, P543, DOI 10.1016/S0753-3322(01)00140-8; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lin TH, 1997, J BIOL CHEM, V272, P8849; Miranti CK, 1999, J BIOL CHEM, V274, P10571, DOI 10.1074/jbc.274.15.10571; Mitchell RA, 1999, J BIOL CHEM, V274, P18100, DOI 10.1074/jbc.274.25.18100; Mitchell RA, 2002, P NATL ACAD SCI USA, V99, P345, DOI 10.1073/pnas.012511599; Ogawa H, 2000, CYTOKINE, V12, P309, DOI 10.1006/cyto.1999.0562; Petrenko O, 1999, IMMUNITY, V10, P691, DOI 10.1016/S1074-7613(00)80068-0; Roovers K, 1999, MOL BIOL CELL, V10, P3197, DOI 10.1091/mbc.10.10.3197; Rossi AG, 1998, J CLIN INVEST, V101, P2869, DOI 10.1172/JCI1524; Sah JF, 2002, J BIOL CHEM, V277, P9728, DOI 10.1074/jbc.M110897200; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; Schlaepfer DD, 1997, J BIOL CHEM, V272, P13189, DOI 10.1074/jbc.272.20.13189; Schwartz MA, 1997, J CELL BIOL, V139, P575, DOI 10.1083/jcb.139.3.575; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; Sun PQ, 1998, SCIENCE, V282, P2270, DOI 10.1126/science.282.5397.2270; Wan M, 2002, EMBO REP, V3, P171, DOI 10.1093/embo-reports/kvf024; Watarai H, 2000, P NATL ACAD SCI USA, V97, P13251, DOI 10.1073/pnas.230445397; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Welsh CF, 2001, NAT CELL BIOL, V3, P950, DOI 10.1038/ncb1101-950; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	45	55	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 3	2003	278	1					76	81		10.1074/jbc.M208820200	http://dx.doi.org/10.1074/jbc.M208820200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	632ZX	12297513	hybrid			2022-12-25	WOS:000180255700010
J	Martinez, R; Gomes, FCA				Martinez, R; Gomes, FCA			Neuritogenesis induced by thyroid hormone-treated astrocytes is mediated by epidermal growth factor/mitogen-activated protein kinase-phosphatidylinositol 3-kinase pathways and involves modulation of extracellular matrix proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; REGULATES FIBRONECTIN; GENE-EXPRESSION; CROSS-TALK; BRAIN; NEURONS; LAMININ; CEREBELLUM; TRANSACTIVATION; HYPOTHYROIDISM	Thyroid hormone (T3) plays a crucial role in several steps of cerebellar ontogenesis. By using a neuron-astrocyte coculture model, we have investigated the effects of T3-treated astrocytes on cerebellar neuronal differentiation in vitro. Neurons plated onto T3-astrocytes presented a 40-60% increase on the total neurite length and an increment in the number of neurites. Treatment of astrocytes with epidermal growth factor (EGF) yielded similar results, suggesting that this growth factor might mediate T3-induced neuritogenesis. EGF and T3 treatment increased fibronectin and laminin expression by astrocytes, suggesting that astrocyte neurite permissiveness induced by these treatments is mostly due to modulation of extracellular matrix (ECM) components. Such increase in ECM protein expression as well as astrocyte permissiveness to neurite outgrowth was reversed by the specific EGF receptor tyrosine kinase inhibitor, tyrphostin. Moreover studies using selective inhibitors of several transduction-signaling cascades indicated that modulation of ECM proteins by EGF is mainly through a synergistic activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase pathways. In this work, we provide evidence of a novel role of EGF as an intermediary factor of T3 action on cerebellar ontogenesis. By modulating the content of ECM proteins, EGF increases neurite outgrowth. Our data reveal an important role of astrocytes as mediators of T3-induced cerebellar development and partially elucidate the role of EGF and mitogen-activated protein kinase/phosphatidylinositol 3-kinase pathways on this process.	Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, Ctr Ciencias Saude, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	Gomes, FCA (corresponding author), Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Dept Anat, Ctr Ciencias Saude, Bloco F,Iiha Fundao, BR-21941590 Rio De Janeiro, Brazil.	fgomes@anato.uf.rj.br	Gomes, Flavia/AAX-6354-2021; Gomes, Flavia/C-5383-2013	Gomes, Flavia/0000-0003-2966-0638				Alvarez-Dolado M, 1999, J NEUROSCI, V19, P6979, DOI 10.1523/JNEUROSCI.19-16-06979.1999; Alvarez-Dolado M, 1998, NEUROSCIENCE, V84, P309, DOI 10.1016/S0306-4522(97)00511-3; Anderson GW, 1997, MOL CELL ENDOCRINOL, V131, P79, DOI 10.1016/S0303-7207(97)00095-6; Anderson GW, 2001, FRONT NEUROENDOCRIN, V22, P1, DOI 10.1006/frne.2000.0208; BECK KD, 1993, NEUROSCIENCE, V52, P855, DOI 10.1016/0306-4522(93)90534-M; BERNAL J, 1995, EUR J ENDOCRINOL, V133, P390, DOI 10.1530/eje.0.1330390; BRADLEY DJ, 1992, J NEUROSCI, V12, P2288; Calloni GW, 2001, DEV BRAIN RES, V126, P121, DOI 10.1016/S0165-3806(00)00142-5; Carballada R, 2001, DEVELOPMENT, V128, P35; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.biochem.56.1.881; Cayrou C, 2002, ENDOCRINOLOGY, V143, P2242, DOI 10.1210/en.143.6.2242; Danielsen AJ, 2002, GROWTH FACTORS, V20, P1, DOI 10.1080/08977190290022185; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Fang XJ, 1999, ONCOGENE, V18, P6635, DOI 10.1038/sj.onc.1203076; Farwell AP, 1999, ENDOCRINOLOGY, V140, P5014, DOI 10.1210/en.140.11.5014; Farwell AP, 1999, ENDOCRINOLOGY, V140, P4221, DOI 10.1210/en.140.9.4221; FIGUEIREDO BC, 1993, MOL BRAIN RES, V17, P258, DOI 10.1016/0169-328X(93)90010-M; Forrest D, 2002, CURR OPIN NEUROBIOL, V12, P49, DOI 10.1016/S0959-4388(02)00289-1; Freire E, 2002, J CELL SCI, V115, P4867, DOI 10.1242/jcs.00173; Fricker-Gates RA, 2000, EXP NEUROL, V165, P237, DOI 10.1006/exnr.2000.7482; Garcia-Segura LM, 1999, J NEUROBIOL, V40, P574, DOI 10.1002/(SICI)1097-4695(19990915)40:4<574::AID-NEU12>3.0.CO;2-8; GARCIAABREU J, 1995, NEUROREPORT, V6, P761, DOI 10.1097/00001756-199503270-00014; Gomes F C, 2001, Prog Brain Res, V132, P41; Gomes FCA, 1999, GLIA, V26, P97; Gomes FCA, 2001, BRAZ J MED BIOL RES, V34, P611, DOI 10.1590/S0100-879X2001000500008; Gomes FCA, 1999, GLIA, V25, P247, DOI 10.1002/(SICI)1098-1136(19990201)25:3<247::AID-GLIA5>3.0.CO;2-2; Kaiura TL, 1999, J SURG RES, V84, P212, DOI 10.1006/jsre.1999.5646; Kim J, 2002, J BIOL CHEM, V277, P32116, DOI 10.1074/jbc.M204895200; Koibuchi N, 1999, ENDOCRINOLOGY, V140, P3955, DOI 10.1210/en.140.9.3955; Komuro H, 2001, J NEUROSCI, V21, P527, DOI 10.1523/JNEUROSCI.21-02-00527.2001; Kornblum HI, 1997, J COMP NEUROL, V380, P243, DOI 10.1002/(SICI)1096-9861(19970407)380:2<243::AID-CNE7>3.0.CO;2-3; Lima FRS, 1998, INT J DEV NEUROSCI, V16, P19, DOI 10.1016/S0736-5748(98)00002-1; Lima FRS, 2001, J NEUROSCI, V21, P2028, DOI 10.1523/JNEUROSCI.21-06-02028.2001; Lindholm D, 1997, PERSPECT DEV NEUROBI, V5, P83; Matsubara H, 2000, MOL CELL BIOCHEM, V212, P187, DOI 10.1023/A:1007189828584; Menet V, 2001, J NEUROSCI, V21, P6147; MIALE IL, 1961, EXP NEUROL, V4, P277, DOI 10.1016/0014-4886(61)90055-3; Moriguchi Y, 1999, CIRC RES, V84, P1073, DOI 10.1161/01.RES.84.9.1073; Morte B, 2002, P NATL ACAD SCI USA, V99, P3985, DOI 10.1073/pnas.062413299; Neveu I, 1996, J CELL BIOL, V133, P631, DOI 10.1083/jcb.133.3.631; NICHOLSO.JL, 1972, BRAIN RES, V44, P13, DOI 10.1016/0006-8993(72)90362-9; Ono Y, 2002, CANCER LETT, V175, P197, DOI 10.1016/S0304-3835(01)00682-6; Palu E, 2002, J NEUROSCI RES, V69, P243, DOI 10.1002/jnr.10292; Potter GB, 2001, J NEUROSCI, V21, P4373, DOI 10.1523/JNEUROSCI.21-12-04373.2001; Rescan C, 2001, MOL BIOL CELL, V12, P725, DOI 10.1091/mbc.12.3.725; SEROOGY KB, 1995, BRAIN RES, V670, P157, DOI 10.1016/0006-8993(94)01300-7; TRENTIN AG, 1995, NEUROREPORT, V6, P293, DOI 10.1097/00001756-199501000-00017; Trentin AG, 2001, AM J PHYSIOL-ENDOC M, V281, pE1088, DOI 10.1152/ajpendo.2001.281.5.E1088; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9; Yart A, 2002, BBA-MOL CELL BIOL L, V1582, P107, DOI 10.1016/S1388-1981(02)00144-0; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yu CF, 2002, J BIOL CHEM, V277, P19382, DOI 10.1074/jbc.M200732200	52	87	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49311	49318		10.1074/jbc.M209284200	http://dx.doi.org/10.1074/jbc.M209284200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12356760	hybrid			2022-12-25	WOS:000180028900027
J	Kim, BS; Cropp, TA; Beck, BJ; Sherman, DH; Reynolds, KA				Kim, BS; Cropp, TA; Beck, BJ; Sherman, DH; Reynolds, KA			Biochemical evidence for an editing role of thioesterase II in the biosynthesis of the polyketide pikromycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-CLUSTER; SACCHAROPOLYSPORA-ERYTHRAEA; ERYTHROMYCIN BIOSYNTHESIS; PEPTIDE SYNTHETASES; ESCHERICHIA-COLI; STREPTOMYCES; SYNTHASE; SPECIFICITY; SEQUENCE; DOMAIN	The pikromycin biosynthetic gene cluster contains the pikAV gene encoding a type II thioesterase (TEII). TEII is not responsible for polyketide termination and cyclization, and its biosynthetic role has been unclear. During polyketide biosynthesis, extender units such as methylmalonyl acyl carrier protein (ACP) may prematurely decarboxylate to generate the corresponding acyl-ACP, which cannot be used as a substrate in the condensing reaction by the corresponding ketosynthase domain, rendering the polyketide synthase module inactive. It has been proposed that TEII may serve as an "editing" enzyme and reactivate these modules by removing acyl moieties attached to ACP domains. Using a purified recombinant TEII we have tested this hypothesis by using in vitro enzyme assays and a range of acyl-ACP, malonyl-ACP, and methylmalonyl-ACP substrates derived from either PikAIII or the loading didomain of DEBS1 (6-deoxyerythronolide B synthase; AT(L)-ACP(L)). The pikromycin TEII exhibited high K-m values (> 100 muM) with all substrates and no apparent ACP specificity, catalyzing cleavage of methylmalonyl-ACP from both AT(L)-ACP(L) (k(cat)/K-m 3.3 +/- 1.1 M-1 s(-1)) and PikAIII (k(cat)/K-m 2.9 +/- 0.9 M-1 s(-1)). The TEII exhibited some acyl-group specificity, catalyzing hydrolysis of propionyl (k(cat)/K-m 15.8 +/- 1.8 M-1 s(-1)) and butyryl (k(cat)/K-m 17.5 +/- 2.1 M-1 s(-1)) derivatives of AT(L)-ACP(L) faster than acetyl (k(cat)/K-m 4.9 +/- 0.7 M-1 s(-1)), malonyl (k(cat)/K-m 3.9 +/- 0.5 M-1 s(-1)), or methylmalonyl derivatives. PikAIV containing a TEI domain catalyzed cleavage of propionyl derivative of ATL-ACPL at a dramatically lower rate than TEII. These results provide the first unequivocal in vitro evidence that TEII can hydrolyze acyl-ACP thioesters and a model for the action of TEII in which the enzyme remains primarily dissociated from the polyketide synthase, preferentially removing aberrant acyl-ACP species with long half-lives. The lack of rigorous substrate specificity for TEII may explain the surprising observation that high level expression of the protein in Streptomyces venezuelae leads to significant (>50%) titer decreases.	Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, Richmond, VA 23219 USA; Virginia Commonwealth Univ, Dept Med Chem, Richmond, VA 23219 USA; Univ Minnesota, Dept Microbiol, Minneapolis, MN 55455 USA; Univ Minnesota, Inst Biotechnol, Minneapolis, MN 55455 USA	Virginia Commonwealth University; Virginia Commonwealth University; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Reynolds, KA (corresponding author), Virginia Commonwealth Univ, Inst Struct Biol & Drug Discovery, 800 E Leigh St, Richmond, VA 23219 USA.	kareynol@hsc.vcu.edu		Reynolds, Kevin/0000-0003-0270-9809	NIGMS NIH HHS [GM48562] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AGGARWAL R, 1995, J CHEM SOC CHEM COMM, P1519, DOI 10.1039/c39950001519; August PR, 1998, CHEM BIOL, V5, P69, DOI 10.1016/S1074-5521(98)90141-7; AUSUBEL FM, 1991, CURRENT PROTOCOLS MO, V2; Bisang C, 1999, NATURE, V401, P502, DOI 10.1038/46829; Butler AR, 1999, CHEM BIOL, V6, P287, DOI 10.1016/S1074-5521(99)80074-X; Chen S, 2001, GENE, V263, P255, DOI 10.1016/S0378-1119(00)00560-6; Chen S, 2000, CHEM BIOL, V7, P907, DOI 10.1016/S1074-5521(00)00039-9; CORTES J, 1995, SCIENCE, V268, P1487, DOI 10.1126/science.7770773; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; Doi-Katayama Y, 2000, J ANTIBIOT, V53, P484, DOI 10.7164/antibiotics.53.484; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Gokhale RS, 1999, CHEM BIOL, V6, P117, DOI 10.1016/S1074-5521(99)80008-8; HAYDOCK SF, 1991, MOL GEN GENET, V230, P120, DOI 10.1007/BF00290659; Heathcole ML, 2001, CHEM BIOL, V8, P207, DOI 10.1016/S1074-5521(01)00002-3; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Jacobsen JR, 1998, BIOCHEMISTRY-US, V37, P4928, DOI 10.1021/bi9729920; KAO CM, 1995, J AM CHEM SOC, V117, P9105, DOI 10.1021/ja00140a043; KATZ L, 1993, ANNU REV MICROBIOL, V47, P875, DOI 10.1146/annurev.mi.47.100193.004303; Kim BS, 2002, BIOCHEMISTRY-US, V41, P10827, DOI 10.1021/bi0256779; Kotowska M, 2002, MICROBIOL-SGM, V148, P1777, DOI 10.1099/00221287-148-6-1777; KRESZE GB, 1977, EUR J BIOCHEM, V79, P191, DOI 10.1111/j.1432-1033.1977.tb11797.x; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; Lau J, 2000, BIOCHEMISTRY-US, V39, P10514, DOI 10.1021/bi000602v; Long PF, 2002, MOL MICROBIOL, V43, P1215, DOI 10.1046/j.1365-2958.2002.02815.x; MERSONDAVIES LA, 1994, MOL MICROBIOL, V13, P349, DOI 10.1111/j.1365-2958.1994.tb00428.x; NAGGERT J, 1991, BIOCHEM J, V273, P787, DOI 10.1042/bj2730787; Omura S, 2001, P NATL ACAD SCI USA, V98, P12215, DOI 10.1073/pnas.211433198; Pfeifer B, 2002, APPL ENVIRON MICROB, V68, P3287, DOI 10.1128/AEM.68.7.3287-3292.2002; PIEPER R, 1995, NATURE, V378, P263, DOI 10.1038/378263a0; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schneider A, 1998, ARCH MICROBIOL, V169, P404, DOI 10.1007/s002030050590; Schwarzer D, 2002, P NATL ACAD SCI USA, V99, P14083, DOI 10.1073/pnas.212382199; SCHWECKE T, 1995, P NATL ACAD SCI USA, V92, P7839, DOI 10.1073/pnas.92.17.7839; Smirnova N, 2001, J BACTERIOL, V183, P2335, DOI 10.1128/JB.183.7.2335-2342.2001; Tsai SC, 2001, P NATL ACAD SCI USA, V98, P14808, DOI 10.1073/pnas.011399198; VARA J, 1989, J BACTERIOL, V171, P5872, DOI 10.1128/jb.171.11.5872-5881.1989; WITKOWSKI A, 1994, J BIOL CHEM, V269, P379; WITKOWSKI A, 1991, J BIOL CHEM, V266, P18514; Witkowski A, 1999, BIOCHEMISTRY-US, V38, P11643, DOI 10.1021/bi990993h; WITKOWSKI A, 1992, J BIOL CHEM, V267, P18488; Xue YQ, 2000, NATURE, V403, P571, DOI 10.1038/35000624; Xue YQ, 1998, P NATL ACAD SCI USA, V95, P12111, DOI 10.1073/pnas.95.21.12111; Yoon YJ, 2002, CHEM BIOL, V9, P203, DOI 10.1016/S1074-5521(02)00095-9	44	94	101	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48028	48034		10.1074/jbc.M207770200	http://dx.doi.org/10.1074/jbc.M207770200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368286	hybrid			2022-12-25	WOS:000179789600009
J	Gioannini, TL; Zhang, DS; Teghanemt, A; Weiss, JP				Gioannini, TL; Zhang, DS; Teghanemt, A; Weiss, JP			An essential role for albumin in the interaction of endotoxin with lipopolysaccharide-binding protein and sCD14 and resultant cell activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOVINE-SERUM-ALBUMIN; TOLL-LIKE RECEPTOR-4; LIPID-A; SOLUBLE CD14; BACTERIAL LIPOPOLYSACCHARIDE; NEISSERIA-MENINGITIDIS; SIGNAL-TRANSDUCTION; EPITHELIAL-CELLS; LPS; MACROPHAGES	Experiments utilizing endotoxin aggregates, lipooligosaccharides (LOS) isolated from metabolically labeled Neisseria meningitidis serotype group B, demonstrate that albumin is an essential component of lipopolysaccharide binding protein- (LBP) and sCD14-dependent 1) disaggregation of LOS and 2) LOS activation of human umbilical vein endothelial cells (HUVEC). Aggregates of LOS (LOSagg) with an apparent M(r)greater than or equal to2x10(7) were isolated by gel sieving on Sephacryl HR S500 in buffered balanced salts solution plus albumin. Incubation of LOSagg with LBP and sCD14 promoted LOSagg disaggregation in an albumin-dependent fashion to complexes that contain LOS and sCD14, but no LBP, with an apparent M(r)similar to60,000 (LOS:sCD14) as determined by Sephacryl S200 chromatography. Isolation by gel filtration of LOSagg:protein aggregates formed by the interaction of LOSagg with either LBP or sCD14 alone revealed that the sequence of LOS-protein interactions as well as the step(s) at which albumin is necessary for the production of bioactive LOS: sCD14 were specific. Efficient generation of LOS:sCD14 required 1) interaction of LOSagg with LBP before interaction with CD14 and 2) the presence of albumin during the interaction of LBP with LOSagg. Activation of HUVEC by LOSagg, as measured by IL-8 production, required both LBP and sCD14 and was thirty times more potent in the presence of albumin. In contrast, LOS:sCD14 did not require additional LBP, sCD14, or albumin to activate HLTVEC but depended on the presence of albumin for optimal solubility/stability once formed. The albumin effect is apparently specific, because neither ovalbumin nor gelatin substituted for albumin in facilitating LBP:sCD14-dependent disaggregation of LOSagg or activation of endothelial cells. These results indicate that albumin is an essential facilitator of LBP/sCD14-induced LOS disaggregation that is required for activation of endothelial cells by LOSagg.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Inflammat Program,Div Infect Dis, Iowa City, IA 52242 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Gioannini, TL (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Internal Med, Inflammat Program,Div Infect Dis, GH34W, Iowa City, IA 52242 USA.			Weiss, Jerrold/0000-0003-1476-4485	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK005472, R01DK005472] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK05472] Funding Source: Medline; PHS HHS [P0144642] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Akashi S, 2000, J IMMUNOL, V164, P3471, DOI 10.4049/jimmunol.164.7.3471; Baker ME, 1998, FEBS LETT, V439, P9, DOI 10.1016/S0014-5793(98)01346-5; Bannerman DD, 1998, INFECT IMMUN, V66, P1400, DOI 10.1128/IAI.66.4.1400-1407.1998; BRANDTZAEG P, 1989, J INFECT DIS, V159, P195, DOI 10.1093/infdis/159.2.195; BRIGHT SW, 1990, J IMMUNOL, V145, P1; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; de Haas CJC, 2000, J IMMUNOL METHODS, V242, P79, DOI 10.1016/S0022-1759(00)00207-6; Denning GM, 1998, INFECT IMMUN, V66, P5777, DOI 10.1128/IAI.66.12.5777-5784.1998; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; GALANOS C, 1971, EUR J BIOCHEM, V19, P143, DOI 10.1111/j.1432-1033.1971.tb01298.x; GALANOS C, 1972, EUR J BIOCHEM, V31, P230, DOI 10.1111/j.1432-1033.1972.tb02524.x; GALANOS C, 1975, Z IMMUNITATSFORSCH, V149, P214; GALANOS C, 1971, EUR J BIOCHEM, V24, P116; GEGNER JA, 1995, J BIOL CHEM, V270, P5320, DOI 10.1074/jbc.270.10.5320; Giardina PC, 2001, J BIOL CHEM, V276, P5883, DOI 10.1074/jbc.M009273200; HAILMAN E, 1994, J EXP MED, V179, P269, DOI 10.1084/jem.179.1.269; Iovine N, 2002, J BIOL CHEM, V277, P7970, DOI 10.1074/jbc.M109622200; JUAN TSC, 1995, J BIOL CHEM, V270, P5219, DOI 10.1074/jbc.270.10.5219; KIRIKAE T, 1994, FEMS IMMUNOL MED MIC, V9, P237, DOI 10.1111/j.1574-695X.1994.tb00499.x; LEI M-G, 1990, International Reviews of Immunology, V6, P223, DOI 10.3109/08830189009056633; LEI MG, 1988, J IMMUNOL, V141, P996; LUDERITZ O, 1973, J INFECT DIS       S, V128, P17; MENDEL CM, 1988, J LIPID RES, V29, P1171; MILLER RD, 1977, INFECT IMMUN, V17, P303, DOI 10.1128/IAI.17.2.303-312.1977; MORRISON DC, 1987, ANNU REV MED, V38, P417, DOI 10.1146/annurev.me.38.020187.002221; MORRISON DC, 1990, J INFECT DIS, V162, P1063, DOI 10.1093/infdis/162.5.1063; OGAWA Y, 1986, J PHARMACOBIO-DYNAM, V9, P722, DOI 10.1248/bpb1978.9.722; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRINCE A, 1992, MICROB PATHOGENESIS, V13, P251, DOI 10.1016/0882-4010(92)90035-M; PUGIN J, 1993, P NATL ACAD SCI USA, V90, P2744, DOI 10.1073/pnas.90.7.2744; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Rahman MM, 1998, CARBOHYD RES, V307, P311; RIETSCHEL ET, 1973, INFECT IMMUN, V8, P173, DOI 10.1128/IAI.8.2.173-177.1973; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; SCHUMANN RR, 1990, SCIENCE, V249, P1429, DOI 10.1126/science.2402637; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SPECTOR AA, 1986, METHOD ENZYMOL, V128, P320; TAHRIJOUTI MA, 1990, MOL IMMUNOL, V27, P751, DOI 10.1016/0161-5890(90)90084-D; TAKAYAMA K, 1990, J BIOL CHEM, V265, P14023; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; TOBIAS PS, 1986, J EXP MED, V164, P777, DOI 10.1084/jem.164.3.777; TOBIAS PS, 1995, J BIOL CHEM, V270, P10482, DOI 10.1074/jbc.270.18.10482; Troelstra A, 1999, J IMMUNOL, V162, P4220; Underhill DM, 1999, NATURE, V401, P811, DOI 10.1038/44605; VIRIYAKOSOL S, 1995, J BIOL CHEM, V270, P361, DOI 10.1074/jbc.270.1.361; Viriyakosol S, 2001, J BIOL CHEM, V276, P38044; WOLLENWEBER HW, 1985, J BIOL CHEM, V260, P5068; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Wurfel M M, 1995, Prog Clin Biol Res, V392, P287; Wurfel MM, 1997, J IMMUNOL, V158, P3925; Yu B, 1997, J CLIN INVEST, V99, P315, DOI 10.1172/JCI119160; Zhao YW, 1996, BIOCHEMISTRY-US, V35, P7174, DOI 10.1021/bi952242v	55	82	85	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47818	47825		10.1074/jbc.M206404200	http://dx.doi.org/10.1074/jbc.M206404200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12372833	hybrid			2022-12-25	WOS:000179663700127
J	Imasato, A; Desbois-Mouthon, C; Han, JH; Kai, H; Cato, ACB; Akira, S; Li, JD				Imasato, A; Desbois-Mouthon, C; Han, JH; Kai, H; Cato, ACB; Akira, S; Li, JD			Inhibition of p38 MAPK by glucocorticoids via induction of MAPK phosphatase-1 enhances nontypeable Haemophilus influenzae-induced expression of toll-like receptor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; SIGNAL-TRANSDUCTION; IMMUNE FUNCTION; GENE-REGULATION; KINASE PATHWAY; ACTIVATION; TRANSCRIPTION; MECHANISMS; PROTEINS; INNATE	Despite the importance of glucocorticoids in suppressing immune and inflammatory responses, their role in enhancing host immune and defense response against invading bacteria is poorly understood. We have demonstrated recently that glucocorticoids synergistically enhance nontypeable Haemophilus influenzae (NTHi)-induced expression of Toll-like receptor 2 (TLR2), an important TLR family member that has been shown to play a critical role in host immune and defense response. However, the molecular mechanisms underlying the glucocorticoid-mediated enhancement of TLR2 induction still remain unknown. Here we show that glucocorticoids synergistically enhance NTHi-induced TLR2 expression via specific up-regulation of the MAPK phosphatase-1 (MKP-1) that, in turn, leads to dephosphorylation and inactivation of p38 MAPK, the negative regulator for TLR2 expression. Moreover, increased expression of TLR2 in epithelial cells greatly enhances the NTHi-induced expression of several key cytokines, including tumor necrosis factor-a and interleukins 1beta and 8, thereby contributing significantly to host immune and defense response. These studies may bring new insights into the novel role of glucocorticoids in orchestrating and optimizing host immune and defense responses during bacterial infections and enhance our understanding of the signaling mechanisms underlying the glucocorticoid-mediated attenuation of MAPKs.	Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90057 USA; Univ Paris 06, INSERM, U402, F-75571 Paris, France; The Scripps Res Inst, Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan; Forschungszentrum Karlsruhe, Inst Toxicol & Genet, D-76021 Karlsruhe, Germany; Osaka Univ, Microbial Dis Res Inst, Dept Host Def,Japan Sci & Technol Corp, Core Res Evolutional Sci & Technol, Suita, Osaka 5650871, Japan	House Research Institute; University of Southern California; University of Southern California; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Scripps Research Institute; Kumamoto University; Helmholtz Association; Karlsruhe Institute of Technology; Japan Science & Technology Agency (JST); Osaka University	Li, JD (corresponding author), Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.	jdli@hei.org	Han, J/G-4671-2010; Akira, Shizuo/C-3134-2009; Desbois-Mouthon, Christele/M-7076-2017; Cato, Andrew C. B./H-2071-2013	Desbois-Mouthon, Christele/0000-0002-0772-1711; Cato, Andrew C. B./0000-0001-8508-3834; Li, Jian-Dong/0000-0002-5593-050X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004562] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41637] Funding Source: Medline; NIDCD NIH HHS [DC04562] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Beltman J, 1996, J BIOL CHEM, V271, P27018, DOI 10.1074/jbc.271.43.27018; Butler CC, 2001, ARCH PEDIAT ADOL MED, V155, P641, DOI 10.1001/archpedi.155.6.641; Caelles C, 1997, GENE DEV, V11, P3351, DOI 10.1101/gad.11.24.3351; Cato ACB, 1996, BIOESSAYS, V18, P371, DOI 10.1002/bies.950180507; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; Haehnel V, 2002, J IMMUNOL, V168, P5629, DOI 10.4049/jimmunol.168.11.5629; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; HIRASAWA N, 1995, J IMMUNOL, V154, P5391; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Krutzik SR, 2001, CURR OPIN IMMUNOL, V13, P104, DOI 10.1016/S0952-7915(00)00189-8; Kusuhara M, 1998, CIRC RES, V83, P824, DOI 10.1161/01.RES.83.8.824; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; Means TK, 2000, LIFE SCI, V68, P241, DOI 10.1016/S0024-3205(00)00939-5; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Niewoehner DE, 1999, NEW ENGL J MED, V340, P1941, DOI 10.1056/NEJM199906243402502; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Quagliarello VJ, 1997, NEW ENGL J MED, V336, P708, DOI 10.1056/NEJM199703063361007; Shuto T, 2002, J BIOL CHEM, V277, P17263, DOI 10.1074/jbc.M112190200; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Swantek JL, 1997, MOL CELL BIOL, V17, P6274, DOI 10.1128/MCB.17.11.6274; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Tanaka K, 1998, J CELL PHYSIOL, V176, P235, DOI 10.1002/(SICI)1097-4652(199808)176:2<235::AID-JCP2>3.0.CO;2-P; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Wang XF, 2000, MOL CELL BIOL, V20, P4543, DOI 10.1128/MCB.20.13.4543-4552.2000; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1; Wilckens T, 1997, IMMUNOL TODAY, V18, P418, DOI 10.1016/S0167-5699(97)01111-0; WILCKENS T, 1995, TRENDS PHARMACOL SCI, V16, P193, DOI 10.1016/S0165-6147(00)89021-5	36	114	120	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47444	47450		10.1074/jbc.M208140200	http://dx.doi.org/10.1074/jbc.M208140200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356755	hybrid			2022-12-25	WOS:000179663700080
J	Latz, E; Visintin, A; Lien, E; Fitzgerald, KA; Monks, BG; Kurt-Jones, EA; Golenbock, DT; Espevik, T				Latz, E; Visintin, A; Lien, E; Fitzgerald, KA; Monks, BG; Kurt-Jones, EA; Golenbock, DT; Espevik, T			Lipopolysaccharide rapidly traffics to and from the golgi apparatus with the toll-like receptor 4-MD-2-CD14 complex in a process that is distinct from the initiation of signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL LIPOPOLYSACCHARIDE; IMMUNE-RESPONSE; INNATE IMMUNITY; CUTTING EDGE; CELL-SURFACE; LPS GENE; PROTEIN; MD-2; INTERNALIZATION; SEPSIS	Mammalian responses to LPS require the expression of Toll-like receptor 4 (TLR4), CD14, and MD-2. We expressed fluorescent TLR4 in cell lines and found that TLR4 densely localized to the surface and the Golgi. Similar distributions were observed in human monocytes. Confocal imaging revealed rapid recycling of TLR4-CD14-MD-2 complexes between the Golgi and the plasma membrane. Fluorescent LPS followed these trafficking pathways in CD14-positive cells. The TLR4-adapter protein, MyD88, translocated to the cell surface upon LPS exposure, and cross-linking of surface TLR4 with antibody induced signaling. Golgi-associated TLR4 expression was disrupted by brefeldin A, yet LPS signaling was preserved. We conclude that LPS signaling may be initiated by surface aggregation of TLR4 and is not dependent upon LPS trafficking to the Golgi.	Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway; Univ Massachusetts, Sch Med, Div Infect Dis, Worcester, MA 01605 USA	Norwegian University of Science & Technology (NTNU); University of Massachusetts System; University of Massachusetts Worcester	Espevik, T (corresponding author), Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway.		Monks, Brian/B-8362-2015; Latz, Eicke/H-3951-2014; Fitzgerald, Katherine/ABE-6317-2020	Monks, Brian/0000-0003-4008-3093; Latz, Eicke/0000-0003-1488-5666; Fitzgerald, Kate/0000-0003-3175-609X	NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM63244, GM54060] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM063244, R01GM054060] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; BONE RC, 1991, ANN INTERN MED, V115, P457, DOI 10.7326/0003-4819-115-6-457; BRUNBUISSON C, 1995, JAMA-J AM MED ASSOC, V274, P968, DOI 10.1001/jama.274.12.968; CDC, 1990, JAMA-J AM MED ASSOC, V263, P937; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Cowan DB, 2001, CIRC RES, V88, P491, DOI 10.1161/01.RES.88.5.491; Du X, 2000, EUR CYTOKINE NETW, V11, P362; Fearon DT, 1996, SCIENCE, V272, P50, DOI 10.1126/science.272.5258.50; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hornef MW, 2002, J EXP MED, V195, P559, DOI 10.1084/jem.20011788; Hoshino K, 1999, J IMMUNOL, V162, P3749; Ingalls RR, 1997, J IMMUNOL, V159, P433; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Lippincott-Schwartz J, 2001, HISTOCHEM CELL BIOL, V116, P97; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; LIPSKY NG, 1985, SCIENCE, V228, P745, DOI 10.1126/science.2581316; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Nagai Y, 2002, NAT IMMUNOL, V3, P667, DOI 10.1038/ni809; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; OBRIEN AD, 1980, J IMMUNOL, V124, P20; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Poussin C, 1998, J BIOL CHEM, V273, P20285, DOI 10.1074/jbc.273.32.20285; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.bi.59.070190.001021; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Sands KE, 1997, JAMA-J AM MED ASSOC, V278, P234, DOI 10.1001/jama.278.3.234; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Thieblemont N, 1998, IMMUNITY, V8, P771, DOI 10.1016/S1074-7613(00)80582-8; Thieblemont N, 1999, J EXP MED, V190, P523, DOI 10.1084/jem.190.4.523; Triantafilou M, 2002, J CELL SCI, V115, P2603; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Vasselon T, 1999, J EXP MED, V190, P509, DOI 10.1084/jem.190.4.509; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Visintin A, 2001, P NATL ACAD SCI USA, V98, P12156, DOI 10.1073/pnas.211445098; Ward TH, 2001, J CELL BIOL, V155, P557, DOI 10.1083/jcb.200107045; Yang H, 2000, J BIOL CHEM, V275, P20861, DOI 10.1074/jbc.M002896200	42	358	375	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47834	47843		10.1074/jbc.M207873200	http://dx.doi.org/10.1074/jbc.M207873200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324469	hybrid			2022-12-25	WOS:000179663700129
J	Rafty, LA; Schmidt, MT; Perraud, AL; Scharenberg, AM; Denu, JM				Rafty, LA; Schmidt, MT; Perraud, AL; Scharenberg, AM; Denu, JM			Analysis of O-acetyl-ADP-ribose as a target for Nudix ADP-ribose hydrolases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENCING PROTEIN SIR2; SACCHAROMYCES-CEREVISIAE; HISTONE DEACETYLASE; SIR2-LIKE PROTEINS; ESCHERICHIA-COLI; MUTT ENZYME; FAMILY; YEAST; GENE; PYROPHOSPHATASE	The Sir2 family of NAD(+)-dependent histone/protein deacetylases has been implicated in a wide range of biological activities, including gene silencing, life span extension, and chromosomal stability. Recent evidence has indicated that these proteins produce a novel metabolite O-acetyl-ADP-ribose (OAADPr) during deacetylation. Cellular studies have demonstrated that this metabolite exhibits biological effects when microinjected in living cells. However, the molecular targets of OAADPr remain to be identified. Here we have analyzed the ADP-ribose-specific Nudix family of hydrolases as potential in vivo metabolizing enzymes of OAADPr. In vitro, we found that the ADP-ribose hydrolases (yeast YSA1, mouse NudT5, and human NUDT9) cleaved OAADPr to the products AMP and acetylated ribose 5% phosphate. Steady-state kinetic analyses revealed that YSA1 and NudT5 hydrolyzed OAADPr with similar kinetic constants to those obtained with ADP-ribose as substrate. In dramatic contrast, human NUDT9 was 500-fold less efficient (k(cat)/K-m values) at hydrolyzing OAADPr compared with ADP-ribose. The inability of OAADPr to inhibit the reaction of NUDT9 with ADPribose suggests that NUDT9 binds OAADPr with low affinity, likely due to steric considerations of the additional acetylated-ribose moiety. We next explored whether Nudix hydrolytic activities against OAADPr could be observed in cell extracts from yeast and human. Using a detailed analysis of the products generated during the consumption of OAADPr in extracts, we identified two robust enzymatic activities that were not consistent with the known Nudix hydrolases. Instead, we identified cytoplasmic esterase activities that hydrolyze OAADPr to acetate and ADP-ribose, whereas a distinct activity residing in the nucleus is consistent with an OAADPr-specific acetyltransferase. These findings establish for the first time that select members of the ADP-ribose hydrolases are potential targets of OAADPr metabolism. However, the predominate endogenous activities observed from diverse cell extracts represent novel enzymes.	Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA; Univ Washington, Dept Pediat & Immunol, Seattle, WA 98195 USA; Childrens Hosp & Med Ctr, Seattle, WA 98195 USA	Oregon Health & Science University; University of Washington; University of Washington Seattle; Seattle Children's Hospital	Denu, JM (corresponding author), Oregon Hlth & Sci Univ, Dept Biochem & Mol Biol, L224,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	denuj@ohsu.edu						AbdelRaheim SR, 2002, BMC BIOCHEM, V3, DOI 10.1186/1472-2091-3-5; ABEYGUNAWARDANA C, 1995, BIOCHEMISTRY-US, V34, P14997, DOI 10.1021/bi00046a006; AMES BN, 1960, J BIOL CHEM, V235, P769; APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; DENU JM, 2003, IN PRESS TRENDS BIOC; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; Frye RA, 1999, BIOCHEM BIOPH RES CO, V260, P273, DOI 10.1006/bbrc.1999.0897; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Gasmi L, 1999, BIOCHEM J, V344, P331, DOI 10.1042/0264-6021:3440331; Gottschling DE, 2000, CURR BIOL, V10, pR708, DOI 10.1016/S0960-9822(00)00714-4; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Guarente L, 2000, GENE DEV, V14, P1021; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jackson AD, 2002, J BIOL CHEM, V277, P18535, DOI 10.1074/jbc.M200671200; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P4847, DOI 10.1093/nar/21.20.4847; Kwon HJ, 1998, P NATL ACAD SCI USA, V95, P3356, DOI 10.1073/pnas.95.7.3356; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lin J, 1996, BIOCHEMISTRY-US, V35, P6715, DOI 10.1021/bi953071x; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Lin SR, 2002, BBA-PROTEIN STRUCT M, V1594, P127, DOI 10.1016/S0167-4838(01)00296-5; McLennan AG, 1999, INT J MOL MED, V4, P79; MEJEAN V, 1994, MOL MICROBIOL, V11, P323, DOI 10.1111/j.1365-2958.1994.tb00312.x; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; O'Handley SF, 1998, J BIOL CHEM, V273, P3192, DOI 10.1074/jbc.273.6.3192; O'Handley SF, 2001, J BIOL CHEM, V276, P5421, DOI 10.1074/jbc.M004100200; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; RINE J, 1987, GENETICS, V116, P9; Safrany ST, 1998, EMBO J, V17, P6599, DOI 10.1093/emboj/17.22.6599; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Schwer B, 2002, J CELL BIOL, V158, P647, DOI 10.1083/jcb.200205057; Sheikh S, 1998, J BIOL CHEM, V273, P20924, DOI 10.1074/jbc.273.33.20924; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; TANUNTON J, 1996, SCIENCE, V272, P408; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Xu WL, 2002, J BIOL CHEM, V277, P23181, DOI 10.1074/jbc.M203325200; Yang HJ, 2000, J BIOL CHEM, V275, P8844, DOI 10.1074/jbc.275.12.8844	52	54	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47114	47122		10.1074/jbc.M208997200	http://dx.doi.org/10.1074/jbc.M208997200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370179	hybrid			2022-12-25	WOS:000179663700037
J	Tewari, R; Spaccapelo, R; Bistoni, F; Holder, AA; Crisanti, A				Tewari, R; Spaccapelo, R; Bistoni, F; Holder, AA; Crisanti, A			Function of region I and II adhesive motifs of Plasmodium falciparum circumsporozoite protein in sporozoite motility and infectivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCANS; MALARIA PARASITES; PROTECTIVE ANTIGEN; SALIVARY-GLANDS; THROMBOSPONDIN; BINDING; TRAP; INVASION; BERGHEI; HEPATOCYTES	The circumsporozoite protein of Plasmodium falciparum contains two conserved motifs (regions I and II) that have been proposed to interact with mosquito and vertebrate host molecules in the process of sporozoite invasion of salivary glands and hepatocytes, respectively. To study the function of this protein we have replaced the endogenous circumsporozoite protein gene of Plasmodium berghei with that of P. falciparum and with versions lacking either region I or region II. We show here that P. falciparum circumsporozoite protein functions in rodent parasite and that P. berghei sporozoites carrying the P. falciparum CS gene develop normally, are motile, invade mosquito salivary glands, and infect the vertebrate host. Region I-deficient sporozoites showed no impairment of motility or infectivity in either vector or vertebrate host. Disruption of region II abolished sporozoite motility and dramatically impaired their ability to invade mosquito salivary glands and infect the vertebrate host. These data shed new light on the role of the CS protein in sporozoite motility and infectivity.	Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England; Univ Perugia, Dept Expt Med, I-06100 Perugia, Italy; Natl Inst Med Res, Div Parasitol, London NW7 1AA, England	Imperial College London; University of Perugia; MRC National Institute for Medical Research	Crisanti, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, London SW7 2AZ, England.	acrs@ic.ac.uk	Holder, Anthony A/A-7554-2013; Tewari, Rita/M-5698-2014	Holder, Anthony A/0000-0002-8490-6058; Spaccapelo, Roberta/0000-0003-2100-6172; Crisanti, Andrea/0000-0002-2406-4426; Tewari, Rita/0000-0003-3943-1847	MRC [MC_U117532067] Funding Source: UKRI; Medical Research Council [MC_U117532067] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adams JC, 2000, DEV DYNAM, V218, P280; Adams JC, 2001, ANNU REV CELL DEV BI, V17, P25, DOI 10.1146/annurev.cellbio.17.1.25; AIKAWA M, 1981, J IMMUNOL, V126, P2494; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; CERAMI C, 1992, CELL, V70, P1021, DOI 10.1016/0092-8674(92)90251-7; FREVERT U, 1993, J EXP MED, V177, P1287, DOI 10.1084/jem.177.5.1287; Gantt SM, 1997, J BIOL CHEM, V272, P19205, DOI 10.1074/jbc.272.31.19205; Gobron S, 1996, J CELL SCI, V109, P1053; GOUNDIS D, 1988, NATURE, V335, P82, DOI 10.1038/335082a0; HOLDER AA, 1988, PARASITOLOGY, V97, P373, DOI 10.1017/S0031182000058790; Kuno K, 1997, GENOMICS, V46, P466, DOI 10.1006/geno.1997.5064; LAWLER J, 1986, J CELL BIOL, V103, P1635, DOI 10.1083/jcb.103.5.1635; McCutchan TF, 1996, P NATL ACAD SCI USA, V93, P11889, DOI 10.1073/pnas.93.21.11889; Menard R, 1997, NATURE, V385, P336, DOI 10.1038/385336a0; Morrissette NS, 2002, MICROBIOL MOL BIOL R, V66, P21, DOI 10.1128/MMBR.66.1.21-38.2002; Nunes A, 1999, MOL CELL BIOL, V19, P2895; Nussenzweig RS, 1997, NEW ENGL J MED, V336, P128, DOI 10.1056/NEJM199701093360210; NUSSENZWEIG V, 1989, ADV IMMUNOL, V45, P283, DOI 10.1016/S0065-2776(08)60695-1; PANCAKE SJ, 1992, J CELL BIOL, V117, P1351, DOI 10.1083/jcb.117.6.1351; Pinzon-Ortiz C, 2001, J BIOL CHEM, V276, P26784, DOI 10.1074/jbc.M104038200; Rathore D, 2002, J BIOL CHEM, V277, P7092, DOI 10.1074/jbc.M106862200; Rathore D, 2001, BIOCHEMISTRY-US, V40, P11518, DOI 10.1021/bi0105476; ROBSON KJH, 1995, EMBO J, V14, P3883, DOI 10.1002/j.1460-2075.1995.tb00060.x; ROBSON KJH, 1988, NATURE, V335, P79, DOI 10.1038/335079a0; Rostand KS, 1997, INFECT IMMUN, V65, P1; Sidjanski SP, 1997, MOL BIOCHEM PARASIT, V90, P33, DOI 10.1016/S0166-6851(97)00124-2; SINNIS P, 1994, J EXP MED, V180, P297, DOI 10.1084/jem.180.1.297; Sinnis P, 1997, TRENDS MICROBIOL, V5, P52, DOI 10.1016/S0966-842X(97)84657-4; Spaccapelo R, 1997, LANCET, V350, P335, DOI 10.1016/S0140-6736(97)24031-6; Sultan AA, 1997, CELL, V90, P511, DOI 10.1016/S0092-8674(00)80511-5; VANDERBERG JP, 1975, J PARASITOL, V61, P43, DOI 10.2307/3279102; Waters AP, 1997, METHODS, V13, P134, DOI 10.1006/meth.1997.0506; Wengelnik K, 1999, EMBO J, V18, P5195, DOI 10.1093/emboj/18.19.5195; Ying P, 1997, EXP PARASITOL, V85, P168, DOI 10.1006/expr.1996.4134; YOSHIDA N, 1981, J EXP MED, V154, P1225, DOI 10.1084/jem.154.4.1225; YOSHIDA N, 1980, SCIENCE, V207, P71, DOI 10.1126/science.6985745	36	92	95	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47613	47618		10.1074/jbc.M208453200	http://dx.doi.org/10.1074/jbc.M208453200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244064	hybrid			2022-12-25	WOS:000179663700101
J	Hormaeche, I; Alkorta, I; Moro, F; Valpuesta, JM; Goni, FM; de la Cruz, F				Hormaeche, I; Alkorta, I; Moro, F; Valpuesta, JM; Goni, FM; de la Cruz, F			Purification and properties of TrwB, a hexameric, ATP-binding integral membrane protein essential for R388 plasmid conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE P-GLYCOPROTEIN; IV SECRETION SYSTEM; NUCLEOTIDE-BINDING; ESCHERICHIA-COLI; BACTERIAL CONJUGATION; DNA TRANSFER; ADENOSINE 5'-TRIPHOSPHATE; COUPLING PROTEIN; BETA-SUBUNIT; SITE	TrwB is an integral membrane protein linking the relaxosome to the DNA transport apparatus in plasmid R388 conjugation. Native TrwB has been purified in monomeric and hexameric forms, in the presence of dodecylmaltoside from overexpressing bacterial cells. A truncated protein (TrwBDeltaN70) that lacked the transmembrane domain could be purified only in the monomeric form. Electron microscopy images revealed the hexameric structure and were in fact superimposable to the previously published atomic structure for TrwBDeltaN70. In addition, the electron micrographs showed an appendix, similar to25 Angstrom wide, corresponding to the transmembrane region of TrwB. TrwB was located in the bacterial inner membrane in agreement with its proposed coupling role. Purified TrwB hexamers and monomers bound tightly the fluorescent ATP analogue TNP-ATP. A mutant in the Walker A motif, TrwB-K136T, was equally purified and found to bind TNP-ATP with a similar affinity to that of the wild type. However, the TNP-ATP affinity of TrwBDeltaN70 was significantly reduced in comparison with the TrwB hexamers. Competition experiments in which ATP was used to displace TNP-ATP gave an estimate of ATP binding by TrwB (K-d(ATP) = 0.48 mm for hexamers). The transmembrane domain appears to be involved in TrwB protein hexamerization and also influences its nucleotide binding properties.	Univ Basque Country, Unidad Biofis, Ctr Mixto, CSIC, E-48080 Bilbao, Spain; Univ Basque Country, Euskal Herriko Unibertsitatea, Dept Bioquim, E-48080 Bilbao, Spain; Univ Autonoma Madrid, Ctr Nacl Biotecnol, CSIC, E-28049 Madrid, Spain; Univ Cantabria, Dept Biol Mol, Unidad Asociada, Ctr Invest Biol,CSIC, Santander 39011, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Universidad de Cantabria	Goni, FM (corresponding author), Univ Basque Country, Unidad Biofis, Ctr Mixto, CSIC, Apdo 644, E-48080 Bilbao, Spain.	gbpgourf@lg.ehu.es	Alkorta, Itziar/N-4374-2014; Goni, Felix M/M-5425-2015; Valpuesta, Jose M/AAA-6002-2019; Valpuesta, José M/T-1977-2017; Alkorta, Itziar/Y-6267-2019; Moro Pérez, Fernando/P-3891-2015; de la Cruz, Fernando/L-2812-2014	Alkorta, Itziar/0000-0002-1976-8904; Goni, Felix M/0000-0001-6270-9216; Valpuesta, José M/0000-0001-7468-8053; Moro Pérez, Fernando/0000-0002-3568-3388; de la Cruz, Fernando/0000-0003-4758-6857; ALCORTA CALVO, MIREN ITZIAR/0000-0001-6978-389X				Avila P, 1996, J MOL BIOL, V261, P135, DOI 10.1006/jmbi.1996.0447; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; BAUBICHONCORTAY H, 1994, J BIOL CHEM, V269, P22983; BOLLAND S, 1990, J BACTERIOL, V172, P5795, DOI 10.1128/jb.172.10.5795-5802.1990; Cabezon E, 1997, MOL GEN GENET, V254, P400, DOI 10.1007/s004380050432; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Cho YK, 2001, J BIOL CHEM, V276, P12573, DOI 10.1074/jbc.M011478200; COHEN SN, 1972, P NATL ACAD SCI USA, V69, P2110, DOI 10.1073/pnas.69.8.2110; Conseil G, 1998, P NATL ACAD SCI USA, V95, P9831, DOI 10.1073/pnas.95.17.9831; DATTA N, 1972, J GEN MICROBIOL, V72, P349, DOI 10.1099/00221287-72-2-349; DELACRUZ F, 1982, J BACTERIOL, V151, P223; DIVITA G, 1993, J BIOL CHEM, V268, P13178; DUPONT Y, 1982, BIOCHEM BIOPH RES CO, V106, P1272, DOI 10.1016/0006-291X(82)91250-5; GARBOCZI DN, 1988, J BIOL CHEM, V263, P812; Gomis-Ruth FX, 2002, J BIOL CHEM, V277, P7556, DOI 10.1074/jbc.M110462200; Gomis-Ruth FX, 2001, NATURE, V409, P637, DOI 10.1038/35054586; GRANDOSO G, 1994, EUR J BIOCHEM, V226, P403, DOI 10.1111/j.1432-1033.1994.tb20065.x; GRANT SGN, 1990, P NATL ACAD SCI USA, V87, P4645, DOI 10.1073/pnas.87.12.4645; GRUBMEYER C, 1981, J BIOL CHEM, V256, P3718; HARLOW E, 1988, ANTIBODIES LAB MANUA, P53; HIRATSUKA T, 1973, BIOCHIM BIOPHYS ACTA, V320, P635, DOI 10.1016/0304-4165(73)90143-8; LANKA E, 1995, ANNU REV BIOCHEM, V64, P141, DOI 10.1146/annurev.bi.64.070195.001041; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; LLOSA M, 1994, J MOL BIOL, V235, P448, DOI 10.1006/jmbi.1994.1005; Llosa M, 2002, MOL MICROBIOL, V45, P1, DOI 10.1046/j.1365-2958.2002.03014.x; LLOSA M, 1995, J MOL BIOL, V246, P54, DOI 10.1006/jmbi.1994.0065; LLOSA M, 1994, J BACTERIOL, V176, P3210, DOI 10.1128/jb.176.11.3210-3217.1994; Lu NT, 2000, ARCH BIOCHEM BIOPHYS, V375, P7, DOI 10.1006/abbi.1999.1656; Marabini R, 1996, J STRUCT BIOL, V116, P237, DOI 10.1006/jsbi.1996.0036; Marco S, 1996, ULTRAMICROSCOPY, V66, P5, DOI 10.1016/S0304-3991(96)00083-6; Miroux B, 1996, J MOL BIOL, V260, P289, DOI 10.1006/jmbi.1996.0399; Mitterauer T, 1999, BIOCHEM J, V342, P33, DOI 10.1042/0264-6021:3420033; Moncalian G, 1999, J BIOL CHEM, V274, P36117, DOI 10.1074/jbc.274.51.36117; Moncalian G, 1997, J MOL BIOL, V270, P188, DOI 10.1006/jmbi.1997.1082; Moncalian G, 1999, MOL MICROBIOL, V31, P1643, DOI 10.1046/j.1365-2958.1999.01288.x; Osborn M J, 1974, Methods Enzymol, V31, P642; PANICKER MM, 1992, J BIOL CHEM, V267, P12761; Pansegrau W, 1996, PROG NUCLEIC ACID RE, V54, P197, DOI 10.1016/S0079-6603(08)60364-5; SANDLER JR, 1980, GENE, V8, P279; Santini JM, 1998, J BACTERIOL, V180, P4093, DOI 10.1128/JB.180.16.4093-4101.1998; Schroder G, 2002, J BACTERIOL, V184, P2767, DOI 10.1128/JB.184.10.2767-2779.2002; STEWART GSAB, 1986, PLASMID, V15, P172, DOI 10.1016/0147-619X(86)90035-1; Stewart RC, 1998, BIOCHEMISTRY-US, V37, P12269, DOI 10.1021/bi980970n; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; THOMAS PJ, 1992, J BIOL CHEM, V267, P20331; UNSER M, 1987, ULTRAMICROSCOPY, V23, P39, DOI 10.1016/0304-3991(87)90225-7; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WATANABE T, 1982, J BIOL CHEM, V257, P1510; Zechner E. L., 2000, HORIZONTAL GENE POOL, P87	49	50	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46456	46462		10.1074/jbc.M207250200	http://dx.doi.org/10.1074/jbc.M207250200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244053	hybrid			2022-12-25	WOS:000179529300098
J	Liu, Z; Zhang, J; Li, P; Chen, SRW; Wagenknecht, T				Liu, Z; Zhang, J; Li, P; Chen, SRW; Wagenknecht, T			Three-dimensional reconstruction of the recombinant type 2 ryanodine receptor and localization of its divergent region 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-RELEASE CHANNEL; GREEN FLUORESCENT PROTEIN; POLYMORPHIC VENTRICULAR-TACHYCARDIA; MUSCLE SARCOPLASMIC-RETICULUM; SKELETAL-MUSCLE; CRYOELECTRON MICROSCOPY; 3-DIMENSIONAL RECONSTRUCTION; MOLECULAR-IDENTIFICATION; FK506-BINDING PROTEIN; ELECTRON-MICROSCOPY	Isoform 2 of the ryanodine receptor (RyR2) is the major calcium release channel in cardiac muscle. In the present study, two kinds of RyR2 cDNA were constructed, one encoding the wild type mouse RyR2 (RyR2(wt)) and the other encoding modified RyR2, into which was inserted a cDNA encoding green fluorescent protein (GFP). GFP was inserted into the divergent region 1 (DR1) of RyR2, after the Asp-4365 (RyR2(D4365-GFP)). HEK293 cells expressing both RyR2(wt) and RYR2D(4365-GFP) cDNAs showed caffeine- and ryanodine-sensitive calcium release, demonstrating that both wild type and modified RyR2s form functional calcium release channels. Cells expressing the fusion protein, RYR2(D4365-GFP), were readily identified by their fluorescence due to the presence of GFP, indicating that the inserted GFP folded properly. Both expressed RyR2s were purified from cell lysates in a single step by affinity chromatography using a GST-FKBP12.6 as the affinity ligand. Cryoelectron microscopy of purified RyR2s showed structurally intact receptors, and three-dimensional reconstructions were obtained by single particle image processing. The three-dimensional reconstruction of RyR2(wt) appeared very similar to that of the native RyR2 purified from dog heart. The location of the inserted GFP, and consequently of DR1, was mapped on the three-dimensidnal structure of RyR2 to one of the subunit's characteristic domains, domain 3, also known as the "handle" domain. This study describes the first internal fusion of a protein into a ryanodine receptor, and it demonstrates the potential of this technology for localizing functional and structural domains on the three-dimensional structure of RyR.	Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA; Univ Calgary, Dept Physiol & Biophys Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; SUNY Albany, Sch Publ Hlth, Dept Biomed Sci, Albany, NY 12201 USA	State University of New York (SUNY) System; Wadsworth Center; University of Calgary; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Liu, Z (corresponding author), Wadsworth Ctr, New York State Dept Hlth, Albany, NY 12201 USA.	liuz@wadsworth.org		Liu, Zheng/0000-0001-6952-3406	NIAMS NIH HHS [AR40615] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040615] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Ataka K, 2002, BIOPHYS J, V82, P509, DOI 10.1016/S0006-3495(02)75415-5; Balshaw DM, 2002, J MEMBRANE BIOL, V185, P1, DOI 10.1007/s00232-001-0111-4; Benacquista BL, 2000, BIOPHYS J, V78, P1349, DOI 10.1016/S0006-3495(00)76689-6; Bers DM, 2002, NATURE, V415, P198, DOI 10.1038/415198a; Bhat MB, 1997, BIOPHYS J, V73, P1329, DOI 10.1016/S0006-3495(97)78166-9; Chen SRW, 2002, BIOPHYS J, V82, P2436, DOI 10.1016/S0006-3495(02)75587-2; Chen SRW, 1998, J BIOL CHEM, V273, P14675, DOI 10.1074/jbc.273.24.14675; Chen SRW, 1997, J BIOL CHEM, V272, P24234, DOI 10.1074/jbc.272.39.24234; Doi N, 1999, FEBS LETT, V457, P1, DOI 10.1016/S0014-5793(99)00991-6; Du GG, 1998, J BIOL CHEM, V273, P33259, DOI 10.1074/jbc.273.50.33259; FABIATO A, 1985, J GEN PHYSIOL, V85, P247, DOI 10.1085/jgp.85.2.247; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Frank J., 1996, 3 DIMENSIONAL ELECT, P54; HAKAMATA Y, 1992, FEBS LETT, V312, P229, DOI 10.1016/0014-5793(92)80941-9; Hodel AE, 2002, MOL CELL, V10, P347, DOI 10.1016/S1097-2765(02)00589-0; INUI M, 1987, J BIOL CHEM, V262, P1740; Jeyakumar LH, 1998, J BIOL CHEM, V273, P16011, DOI 10.1074/jbc.273.26.16011; Kratz PA, 1999, P NATL ACAD SCI USA, V96, P1915, DOI 10.1073/pnas.96.5.1915; Laitinen PJ, 2001, CIRCULATION, V103, P485, DOI 10.1161/01.CIR.103.4.485; Li P, 2001, J GEN PHYSIOL, V118, P33, DOI 10.1085/jgp.118.1.33; Liu Z, 2001, P NATL ACAD SCI USA, V98, P6104, DOI 10.1073/pnas.111382798; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Malhotra A, 1998, J MOL BIOL, V280, P103, DOI 10.1006/jmbi.1998.1859; Manjunatha B, 1997, J GEN PHYSIOL, V110, P749, DOI 10.1085/jgp.110.6.749; Marks AR, 2001, J MOL CELL CARDIOL, V33, P615, DOI 10.1006/jmcc.2000.1343; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; MICHALAK M, 1988, BIOCHIM BIOPHYS ACTA, V939, P587, DOI 10.1016/0005-2736(88)90106-X; Moore RA, 1998, J CELL BIOL, V140, P843, DOI 10.1083/jcb.140.4.843; Murayama T, 1999, J BIOL CHEM, V274, P17297, DOI 10.1074/jbc.274.24.17297; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; NAKAI J, 1990, FEBS LETT, V271, P169, DOI 10.1016/0014-5793(90)80399-4; Niwa H, 1996, P NATL ACAD SCI USA, V93, P13617, DOI 10.1073/pnas.93.24.13617; OTSU K, 1990, J BIOL CHEM, V265, P13472; PENCZEK PA, 1994, ULTRAMICROSCOPY, V53, P251, DOI 10.1016/0304-3991(94)90038-8; PESSAH IN, 1985, BIOCHEM BIOPH RES CO, V128, P449, DOI 10.1016/0006-291X(85)91699-7; Priori SG, 2002, CIRCULATION, V106, P69, DOI 10.1161/01.CIR.0000020013.73106.D8; Priori SG, 2001, CIRCULATION, V103, P196; RADERMACHER M, 1994, J CELL BIOL, V127, P411, DOI 10.1083/jcb.127.2.411; Samso M, 2002, J BIOL CHEM, V277, P1349, DOI 10.1074/jbc.M109196200; Sharma MR, 1998, J BIOL CHEM, V273, P18429, DOI 10.1074/jbc.273.29.18429; SORRENTINO V, 1993, TRENDS PHARMACOL SCI, V14, P98, DOI 10.1016/0165-6147(93)90072-R; TAKESHIMA H, 1989, NATURE, V339, P439, DOI 10.1038/339439a0; Tiso N, 2001, HUM MOL GENET, V10, P189, DOI 10.1093/hmg/10.3.189; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Wagenknecht T, 1997, J BIOL CHEM, V272, P32463, DOI 10.1074/jbc.272.51.32463; WAGENKNECHT T, 1988, J MOL BIOL, V203, P753, DOI 10.1016/0022-2836(88)90207-0; Wagenknecht T, 1996, BIOPHYS J, V70, P1709, DOI 10.1016/S0006-3495(96)79733-3; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Williams AJ, 2001, Q REV BIOPHYS, V34, P61, DOI 10.1017/S0033583501003675; Zhao MC, 1999, J BIOL CHEM, V274, P25971, DOI 10.1074/jbc.274.37.25971; ZORZATO F, 1990, J BIOL CHEM, V265, P2244	51	54	56	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46712	46719		10.1074/jbc.M208124200	http://dx.doi.org/10.1074/jbc.M208124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324472	hybrid			2022-12-25	WOS:000179529300130
J	Lu, HG; Shah, P; Ennis, D; Shinder, G; Sap, J; Le-Tien, H; Fantus, IG				Lu, HG; Shah, P; Ennis, D; Shinder, G; Sap, J; Le-Tien, H; Fantus, IG			The differentiation of skeletal muscle cells involves a protein-tyrosine phosphatase-alpha-mediated C-Src signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; PTP-ALPHA; DOWN-REGULATION; NEURONAL DIFFERENTIATION; INSULIN-RECEPTOR; FAMILY KINASES; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; C2C12 MYOBLASTS; QUAIL MYOTUBES	Protein-tyrosine phosphatase-alpha (PTPalpha) plays an important role in various cellular signaling events, including proliferation and differentiation. In this study, we established L6 cell lines either underexpressing or overexpressing PTPalpha by stable transfection of cells with antisense PTPalpha or with full-length wild-type human or mouse or double catalytic site Cys --> Ala mutant (DM8) PTPalpha cDNA. Expression of PTPalpha in these cell lines was determined by immunoblotting and immunofluorescence. Cells harboring antisense PTPalpha exhibited a significantly reduced growth rate and thymidine incorporation when compared with the wild-type L6 cells. In contrast, cells overexpressing PTPalpha showed more rapid (2-fold) proliferation. Myoblasts with diminished PTPalpha failed to undergo fusion and did not form myotubes in reduced serum whereas overexpression of PTPalpha promoted myogenesis 2 days earlier than wild-type L6 cells. Overexpression of phosphatase-inactive mutant PTPalpha recapitulated the phenotype of the antisense cells. The different myogenic activities of these cell lines were correlated with the expression of myogenin and creatine kinase activity. Consistent with previous reports, PTPalpha positively regulated the activity of the protein-tyrosine kinase Src. Treatment of L6 cells with PP2 or SU6656, specific inhibitors of Src family kinases, and transient transfection of dominant-inhibitory Src inhibited the formation of myotubes and expression of myogenin. Moreover, enhanced expression of PTPalpha and activation of Src was detected during myogenesis. Together, these data indicate that PTPalpha is involved in the regulation of L6 myoblast growth and skeletal muscle cell differentiation via an Src-mediated signaling pathway.	Mt Sinai Hosp, Dept Med, Toronto, ON M5G 1X5, Canada; Mt Sinai Hosp, Dept Physiol, Toronto, ON M5G 1X5, Canada; Univ Toronto, Univ Hlth Network, Toronto, ON M5G 1X5, Canada; Univ Toronto, Banting & Best Diabet Ctr, Toronto, ON M5G 1X5, Canada; NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; NYU, Sch Med, Kaplan Canc Ctr, New York, NY 10016 USA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; New York University; New York University	Fantus, IG (corresponding author), Mt Sinai Hosp, Dept Med, 600 Univ Ave,Rm 780, Toronto, ON M5G 1X5, Canada.	fantus@mshri.on.ca						ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Arnott CH, 1999, J BIOL CHEM, V274, P26105, DOI 10.1074/jbc.274.37.26105; BJELFMAN C, 1990, MOL CELL BIOL, V10, P361, DOI 10.1128/MCB.10.1.361; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Buist A, 2000, J BIOL CHEM, V275, P20754, DOI 10.1074/jbc.M001626200; CASTELLANI L, 1995, J CELL BIOL, V130, P871, DOI 10.1083/jcb.130.4.871; Chun YK, 2000, BIOCHEM BIOPH RES CO, V276, P502, DOI 10.1006/bbrc.2000.3486; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Cong LN, 1999, BIOCHEM BIOPH RES CO, V255, P200, DOI 10.1006/bbrc.1999.0183; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; DAUM G, 1994, J BIOL CHEM, V269, P10524; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; DING W, 1994, BIOCHEM BIOPH RES CO, V202, P902, DOI 10.1006/bbrc.1994.2015; FAIVRESARRAILH C, 1992, J NEUROSCI, V12, P257; FALCONE G, 1991, MOL CELL BIOL, V11, P3331, DOI 10.1128/MCB.11.6.3331; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Galbiati F, 1999, J BIOL CHEM, V274, P30315, DOI 10.1074/jbc.274.42.30315; Galliano MF, 2000, J BIOL CHEM, V275, P13933, DOI 10.1074/jbc.275.18.13933; Gredinger E, 1998, J BIOL CHEM, V273, P10436, DOI 10.1074/jbc.273.17.10436; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Inoue D, 1998, J BIOL CHEM, V273, P4180, DOI 10.1074/jbc.273.7.4180; Jacob KK, 1998, J BIOL CHEM, V273, P4800, DOI 10.1074/jbc.273.8.4800; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Kaliman P, 1998, MOL ENDOCRINOL, V12, P66, DOI 10.1210/mend.12.1.0047; Kang Q, 2000, BIOCHEM J, V352, P883, DOI 10.1042/0264-6021:3520883; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Lammers R, 1998, BIOCHEM BIOPH RES CO, V242, P32, DOI 10.1006/bbrc.1997.7906; Lammers R, 1997, FEBS LETT, V404, P37, DOI 10.1016/S0014-5793(97)00080-X; Lee KH, 1997, BIOCHEM J, V324, P237, DOI 10.1042/bj3240237; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; LYNCH SA, 1986, SCIENCE, V234, P873, DOI 10.1126/science.3095923; McLean GW, 2000, J BIOL CHEM, V275, P23333, DOI 10.1074/jbc.M909322199; Mohamed AS, 1999, J BIOL CHEM, V274, P20529, DOI 10.1074/jbc.274.29.20529; MOLLER NPH, 1995, J BIOL CHEM, V270, P23126, DOI 10.1074/jbc.270.39.23126; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Neel BG, 1997, CURR OPIN CELL BIOL, V9, P193, DOI 10.1016/S0955-0674(97)80063-4; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; SAP J, 1990, P NATL ACAD SCI USA, V87, P6112, DOI 10.1073/pnas.87.16.6112; SCHMIDT JW, 1992, J CELL BIOL, V116, P1019, DOI 10.1083/jcb.116.4.1019; SCHNEIDER MD, 1988, NOL NEUROBIOL, V2, P1; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1994, J BIOL CHEM, V269, P18731; TABITI K, 1995, CANCER LETT, V93, P239, DOI 10.1016/0304-3835(95)03816-F; Tamir Y, 2000, J BIOL CHEM, V275, P34424, DOI 10.1074/jbc.M005815200; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; TSIANI E, 1995, ENDOCRINOLOGY, V136, P2505, DOI 10.1210/en.136.6.2505; vanInzen WG, 1996, DEV BRAIN RES, V91, P304, DOI 10.1016/0165-3806(95)00186-7; Walchli S, 2000, J BIOL CHEM, V275, P9792, DOI 10.1074/jbc.275.13.9792; WANG Y, 1991, EMBO J, V10, P3231, DOI 10.1002/j.1460-2075.1991.tb04886.x; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; YANG XH, 1991, CELL, V67, P661, DOI 10.1016/0092-8674(91)90062-4; YOON HY, 1994, ONCOGENE, V9, P801; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1994, J BIOL CHEM, V269, P23302; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; ZISCH AH, 1995, MOL CELL NEUROSCI, V6, P263, DOI 10.1006/mcne.1995.1021	66	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46687	46695		10.1074/jbc.M209643200	http://dx.doi.org/10.1074/jbc.M209643200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351660	hybrid			2022-12-25	WOS:000179529300127
J	Fukamachi, K; Matsuoka, Y; Ohno, H; Hamaguchi, T; Tsuda, H				Fukamachi, K; Matsuoka, Y; Ohno, H; Hamaguchi, T; Tsuda, H			Neuronal leucine-rich repeat protein-3 amplifies MAPK activation by epidermal growth factor through a carboxyl-terminal region containing endocytosis motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE NERVOUS-SYSTEM; SIGNAL-TRANSDUCTION; SORTING SIGNALS; FACTOR RECEPTOR; MOLECULAR-CLONING; CLATHRIN; INTERNALIZATION; RAS; EXPRESSION; COMPLEXES	Neuronal leucine-rich repeat protein-3 (NLRR-3) belongs to the LRR superfamily. Expression of rat NLRR-3 gene isolated from c-Ha-ras transgenic rat tumor is regulated mainly through the Ras-MAPK signaling pathway. NLRR-3 was found to enhance phosphorylation of MAPK when COS-7 cells were transfected with NLRR-3 and stimulated with a low concentration (0.01 ng/ml) of epidermal growth factor (EGF), but the amplification of MAPK phosphorylation by NLRR-3 was no longer observed when the carboxyl-terminal 30 amino acid stretch containing clathrin-mediated endocytosis motifs was deleted. A green fluorescent protein-tagged NLRR-3 localized at the plasma membrane was efficiently internalized in COS-7 cells, but internalization of a carboxyl-terminal-deleted version (NLRRDeltaC) was less efficient. The presence of clathrin-adaptor protein complexes containing NLRR-3 in brain lysate was confirmed by immunoprecipitation and glutathione S-transferase pull-down experiments, and affinity column chromatography revealed that the carboxyl-terminal region of NILRR-3 interacts with beta-adaptin. We propose that NLRR-3 potentiates Ras-MAPK signaling by facilitating internalization of EGF in clathrin-coated vesicles.	Natl Canc Ctr, Res Inst, Expt Pathol & Chemotherapy Div, Chuo Ku, Tokyo 1040045, Japan; Kanazawa Univ, Canc Res Inst, Div Mol Membrane Biol, Kanazawa, Ishikawa 9200934, Japan; RIKEN, Res Ctr Allergy & Immunol, Yokohama, Kanagawa 2300045, Japan	National Cancer Center - Japan; Kanazawa University; RIKEN	Matsuoka, Y (corresponding author), Natl Canc Ctr, Res Inst, Expt Pathol & Chemotherapy Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.		Ohno, Hiroshi/L-7899-2014	Ohno, Hiroshi/0000-0001-8776-9661				Alderton F, 2001, J BIOL CHEM, V276, P28578, DOI 10.1074/jbc.M102771200; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bormann P, 1999, MOL CELL NEUROSCI, V13, P167, DOI 10.1006/mcne.1999.0742; CHANG CP, 1993, J BIOL CHEM, V268, P19312; DIGUGLIELMO GM, 1994, EMBO J, V13, P4269, DOI 10.1002/j.1460-2075.1994.tb06747.x; Fukamachi K, 2001, BIOCHEM BIOPH RES CO, V287, P257, DOI 10.1006/bbrc.2001.5579; Haugh JM, 1999, J BIOL CHEM, V274, P34350, DOI 10.1074/jbc.274.48.34350; Haugh JM, 1998, J THEOR BIOL, V195, P187, DOI 10.1006/jtbi.1998.0791; Haugh JM, 1999, J BIOL CHEM, V274, P8958, DOI 10.1074/jbc.274.13.8958; Hayata T, 1998, GENE, V221, P159, DOI 10.1016/S0378-1119(98)00414-4; Howe CL, 2001, NEURON, V32, P801, DOI 10.1016/S0896-6273(01)00526-8; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Marshall C, 1999, CURR OPIN CELL BIOL, V11, P732, DOI 10.1016/S0955-0674(99)00044-7; Marshall CJ, 1996, NATURE, V383, P127, DOI 10.1038/383127a0; Matsuoka Y, 1998, J CELL BIOL, V142, P485, DOI 10.1083/jcb.142.2.485; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; ROTHBERG JM, 1990, GENE DEV, V4, P2169, DOI 10.1101/gad.4.12a.2169; Sato Y, 2001, J BIOL CHEM, V276, P11956, DOI 10.1074/jbc.M008551200; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Sorkina T, 1999, J CELL SCI, V112, P317; Taguchi A, 1996, MOL BRAIN RES, V35, P31, DOI 10.1016/0169-328X(95)00178-U; TAKAHASHI N, 1985, P NATL ACAD SCI USA, V82, P1906, DOI 10.1073/pnas.82.7.1906; Taniguchi H, 1996, MOL BRAIN RES, V36, P45, DOI 10.1016/0169-328X(95)00243-L; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279	31	38	42	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 15	2002	277	46					43549	43552		10.1074/jbc.C200502200	http://dx.doi.org/10.1074/jbc.C200502200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	615XE	12297494	hybrid			2022-12-25	WOS:000179272000002
J	Morelli, C; Karayianni, E; Magnanini, C; Mungall, AJ; Thorland, E; Negrini, M; Smith, DI; Barbanti-Brodano, G				Morelli, C; Karayianni, E; Magnanini, C; Mungall, AJ; Thorland, E; Negrini, M; Smith, DI; Barbanti-Brodano, G			Cloning and characterization of the common fragile site FRA6F harboring a replicative senescence gene and frequently deleted in human tumors	ONCOGENE			English	Article						FRA6F; fragile sites; chromosome 6q21; senescence; human tumors; schizophrenia	IMMORTAL HUMAN FIBROBLASTS; EPITHELIAL OVARIAN-CANCER; 2 DISTINCT REGIONS; CHROMOSOME 6Q; HOMOZYGOUS DELETIONS; MULTIPLE REGIONS; INTEGRATION SITE; HUMAN HOMOLOG; BROAD REGION; ALLELIC LOSS	The common fragile site FRA6GF, located at 6q21, is an extended region of about 1200 kb, with two hot spots of breakage each spanning about 200 kb. Transcription mapping of the FRA6F region identified 19 known genes, 10 within the FRA6F interval and nine in a proximal or distal position. The nucleotide sequence of FRA6F is rich in repetitive elements (LINE1 and LINE2, Alu, MIR, MER and endogenous retroviral sequences) as well as in matrix attachment regions (MARs), and shows several DNA segments with increased helix flexibility. We found that tight clusters of stem-loop structures were localized exclusively in the two regions with greater frequency of breakage. Chromosomal instability at FRA6F probably depends on a complex interaction of different factors, involving regions of greater DNA flexibility and MARs. We propose an additional mechanism of fragility at FRA6F, based on stem-loop structures which may cause delay or arrest in DNA replication. A senescence gene likely maps within FRA6F, as suggested by detection of deletion and translocation breakpoints involving this fragile site in immortal human-mouse cell hybrids and in SV40-immortalized human fibroblasts containing a human chromosome 6 deleted at q21. Deletion breakpoints within FRA6F are common in several types of human leukemias and solid tumors, suggesting the presence of a tumor suppressor gene in the region. Moreover, a gene associated to hereditary schizophrenia maps within FRA6F. Therefore, FRA6F may represent a landmark for the identification and cloning of genes involved in senescence, leukemia, cancer and schizophrenia.	Univ Ferrara, Microbiol Sect, Dept Exptl & Diagnost Med, I-44100 Ferrara, Italy; Univ Ferrara, Ctr Biotechnol, I-44100 Ferrara, Italy; Sanger Ctr, Hinxton CB10 1SA, Cambs, England; Mayo Clin & Mayo Fdn, Dept Lab Med & Pathol, Div Expt Med, Rochester, MN 55905 USA	University of Ferrara; University of Ferrara; Wellcome Trust Sanger Institute; Mayo Clinic	Barbanti-Brodano, G (corresponding author), Univ Ferrara, Microbiol Sect, Dept Exptl & Diagnost Med, Via Luigi Borsari 46, I-44100 Ferrara, Italy.		Negrini, Massimo/J-2377-2016; Mungall, Andrew J./U-7067-2018	Negrini, Massimo/0000-0002-0007-1920; Mungall, Andrew J./0000-0002-0905-2742				Bednarek AK, 2000, CANCER RES, V60, P2140; Bednarek AK, 2001, CANCER RES, V61, P8068; Bell DW, 1997, CANCER RES, V57, P4057; BODE J, 1992, SCIENCE, V255, P195, DOI 10.1126/science.1553545; Boldog F, 1997, HUM MOL GENET, V6, P193, DOI 10.1093/hmg/6.2.193; BRUKNER I, 1995, EMBO J, V14, P1812, DOI 10.1002/j.1460-2075.1995.tb07169.x; Cao QH, 1997, GENOMICS, V43, P1, DOI 10.1006/geno.1997.4815; Chen CH, 1998, HUM GENET, V103, P702, DOI 10.1007/s004390050894; Cooney KA, 1996, CANCER RES, V56, P4150; Coquelle A, 1997, CELL, V89, P215, DOI 10.1016/S0092-8674(00)80201-9; Egeli U, 2000, HEAD NECK-J SCI SPEC, V22, P591, DOI 10.1002/1097-0347(200009)22:6<591::AID-HED8>3.0.CO;2-C; Gabrielian A, 1996, FEBS LETT, V393, P65, DOI 10.1016/0014-5793(96)00855-1; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; GLOVER TW, 1984, HUM GENET, V67, P136, DOI 10.1007/BF00272988; GUALANDI F, 1994, GENE CHROMOSOME CANC, V10, P77, DOI 10.1002/gcc.2870100202; Hellman A, 2000, MOL CELL BIOL, V20, P4420, DOI 10.1128/MCB.20.12.4420-4427.2000; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Huang HJ, 1998, ONCOGENE, V16, P2311, DOI 10.1038/sj.onc.1200202; Huang HJ, 1999, GENE CHROMOSOME CANC, V24, P48, DOI 10.1002/(SICI)1098-2264(199901)24:1<48::AID-GCC7>3.0.CO;2-V; Huang NN, 1998, J CHIN INST ENG, V21, P159, DOI 10.1080/02533839.1998.9670381; HUBBARDSMITH K, 1992, MOL CELL BIOL, V12, P2273, DOI 10.1128/MCB.12.5.2273; Huebner K, 1998, ANNU REV GENET, V32, P7, DOI 10.1146/annurev.genet.32.1.7; HUSCHTSCHA LI, 1983, J CELL SCI, V63, P77; Inoue H, 1997, P NATL ACAD SCI USA, V94, P14584, DOI 10.1073/pnas.94.26.14584; Jackson A, 1998, GENOMICS, V50, P34, DOI 10.1006/geno.1998.5270; Karayianni E, 1999, CYTOGENET CELL GENET, V86, P263, DOI 10.1159/000015356; KOHWISHIGEMATSU T, 1990, BIOCHEMISTRY-US, V29, P9551, DOI 10.1021/bi00493a009; Krummel KA, 2000, GENOMICS, V69, P37, DOI 10.1006/geno.2000.6321; Le Beau MM, 1998, HUM MOL GENET, V7, P755, DOI 10.1093/hmg/7.4.755; LEBEAU MM, 1984, NATURE, V308, P607, DOI 10.1038/308607a0; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; Mangelsdorf M, 2000, CANCER RES, V60, P1683; MENASCE LP, 1994, GENE CHROMOSOME CANC, V10, P286, DOI 10.1002/gcc.2870100411; Miele ME, 2000, INT J CANCER, V86, P524, DOI 10.1002/(SICI)1097-0215(20000515)86:4<524::AID-IJC13>3.0.CO;2-W; Mimori K, 1999, P NATL ACAD SCI USA, V96, P7456, DOI 10.1073/pnas.96.13.7456; Mishmar D, 1999, AM J HUM GENET, V64, P908, DOI 10.1086/302299; Mishmar D, 1998, P NATL ACAD SCI USA, V95, P8141, DOI 10.1073/pnas.95.14.8141; Morelli C, 2000, GENE, V252, P217, DOI 10.1016/S0378-1119(00)00231-6; Morelli C, 1997, CANCER RES, V57, P4153; Morelli C, 1998, CYTOGENET CELL GENET, V83, P18, DOI 10.1159/000015157; Morelli C, 1997, CYTOGENET CELL GENET, V79, P97, DOI 10.1159/000134691; Paige AJW, 2000, CANCER RES, V60, P1690; PAPPAS GJ, 1995, GENOMICS, V25, P124, DOI 10.1016/0888-7543(95)80117-5; QUEIMADO L, 1995, GENE CHROMOSOME CANC, V14, P28, DOI 10.1002/gcc.2870140106; Queimado L, 1998, ONCOGENE, V16, P83, DOI 10.1038/sj.onc.1201480; Rassool FV, 1996, GENOMICS, V35, P109, DOI 10.1006/geno.1996.0329; RAY FA, 1992, CANCER GENET CYTOGEN, V59, P39, DOI 10.1016/0165-4608(92)90155-2; RAY FA, 1990, J CELL BIOCHEM, V42, P13, DOI 10.1002/jcb.240420103; Ried K, 2000, HUM MOL GENET, V9, P1651, DOI 10.1093/hmg/9.11.1651; SANDHU AK, 1994, P NATL ACAD SCI USA, V91, P5498, DOI 10.1073/pnas.91.12.5498; Sheng ZM, 1996, BRIT J CANCER, V73, P144, DOI 10.1038/bjc.1996.27; Shridhar V, 1999, ONCOGENE, V18, P3913, DOI 10.1038/sj.onc.1202756; Simonic I, 1996, HUM GENET, V97, P524; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Smith DI, 1998, INT J ONCOL, V12, P187; Starostik P, 2000, BLOOD, V95, P1180, DOI 10.1182/blood.V95.4.1180.004k14_1180_1187; Sutherland GR, 1998, TRENDS GENET, V14, P501, DOI 10.1016/S0168-9525(98)01628-X; Talwalkar VR, 1998, CANCER GENET CYTOGEN, V104, P111, DOI 10.1016/S0165-4608(97)00452-4; Tatarelli C, 2000, GENOMICS, V68, P1, DOI 10.1006/geno.2000.6272; Tunca B, 2000, CANCER GENET CYTOGEN, V119, P139, DOI 10.1016/S0165-4608(99)00228-9; Tunca B, 2000, CANCER LETT, V152, P201, DOI 10.1016/S0304-3835(00)00334-7; Utada Y, 2000, JPN J CANCER RES, V91, P293, DOI 10.1111/j.1349-7006.2000.tb00944.x; Wang L, 1997, GENOMICS, V41, P485, DOI 10.1006/geno.1997.4690; Wang L, 1999, HUM MOL GENET, V8, P431, DOI 10.1093/hmg/8.3.431; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; YUNIS JJ, 1984, SCIENCE, V226, P1199, DOI 10.1126/science.6239375	66	65	65	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7266	7276		10.1038/sj.onc.1205573	http://dx.doi.org/10.1038/sj.onc.1205573			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370818				2022-12-25	WOS:000178504600016
J	Jabbur, JR; Tabor, AD; Cheng, XD; Wang, H; Uesugi, M; Lozano, G; Zhang, W				Jabbur, JR; Tabor, AD; Cheng, XD; Wang, H; Uesugi, M; Lozano, G; Zhang, W			Mdm-2 binding and TAF(II)31 recruitment is regulated by hydrogen bond disruption between the p53 residues Thr18 and Asp21	ONCOGENE			English	Article						phosphorylation; radiation; p53; p21; Mdm-2; TAF(II)31; hydrogen bond	DAMAGE-INDUCED PHOSPHORYLATION; ACTIVATION DOMAIN; TRANSCRIPTIONAL ACTIVATION; IONIZING-RADIATION; ONCOPROTEIN MDM2; DNA-BINDING; IN-VITRO; PROTEIN; KINASE; DEGRADATION	Analyses of five wild-type p53 containing cell lines revealed lineage specific differences in phosphorylation of Thr18 after treatment with ionizing (IR) or ultraviolet (UV) radiation. Importantly, Thr18 phosphorylation correlated with induction of the p53 downstream targets p21(Waf1/Cip1) (p21) and Mdm-2, suggesting a transactivation enhancing role. Thr18 phosphorylation has been shown to abolish side-chain hydrogen bonding between Thr18 and Asp21, an interaction necessary for stabilizing alpha-helical conformation within the transactivation domain. Mutagenesis-derived hydrogen bond disruption attenuated the interaction of p53 with the transactivation repressor Mdm-2 but had no direct effect on the interaction of p53 with the basal transcription factor TAF(II)31. However, prior incubation of p53 mutants with Mdm-2 modulated TAF(II)31 interaction with p53, suggesting Mdm-2 blocks the accessibility of p53 to TAF(II)31. Consistently, p53-null cells transfected with hydrogen bond disrupting p53 mutants demonstrated enhanced endogenous p21 expression, whereas p53/Mdm-2-double null cells exhibited no discernible differences in p21 expression. We conclude disruption of intramolecular hydrogen bonding between Thr18 and Asp21 enhances p53 transactivation by modulating Mdm-2 binding, facilitating TAF(II)31 recruitment.	Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Canc Genom Lab, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Grad Program Canc Biol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Grad Program Genes & Dev, Houston, TX 77030 USA; Univ Texas, Med Branch, Sealy Ctr Struct Biol, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Pharmacol & Toxicol, Galveston, TX 77555 USA; Baylor Coll Med, Dept Biochem & Mol Biol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Baylor College of Medicine	Zhang, W (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Pathol, Canc Genom Lab, Box 85,1515 Holcombe Blvd, Houston, TX 77030 USA.	wzhang@mdanderson.org	Uesugi, Motonari/AAM-9777-2020		NATIONAL CANCER INSTITUTE [R29CA067987] Funding Source: NIH RePORTER; NCI NIH HHS [CA67987] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; CHEN XB, 1993, GENE DEV, V7, P1837, DOI 10.1101/gad.7.10.1837; Choi Y, 2000, J BIOL CHEM, V275, P15912, DOI 10.1074/jbc.275.21.15912; COLLINS A, 1987, INT J RADIAT BIOL, V51, P971, DOI 10.1080/09553008714551271; Craig AL, 1999, BIOCHEM J, V342, P133, DOI 10.1042/0264-6021:3420133; Drouin R, 1997, PHOTOCHEM PHOTOBIOL, V66, P719, DOI 10.1111/j.1751-1097.1997.tb03213.x; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 1999, FEBS LETT, V463, P312, DOI 10.1016/S0014-5793(99)01647-6; El-Deiry WS, 1998, SEMIN CANCER BIOL, V8, P345, DOI 10.1006/scbi.1998.0097; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Farmer G, 1996, MOL CELL BIOL, V16, P4295; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Gu JJ, 2000, MOL CELL BIOL, V20, P1243, DOI 10.1128/MCB.20.4.1243-1253.2000; Gu W, 1997, NATURE, V387, P819, DOI 10.1038/42972; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Hsieh JK, 1999, MOL CELL, V3, P181, DOI 10.1016/S1097-2765(00)80309-3; Jabbur JR, 2000, ONCOGENE, V19, P6203, DOI 10.1038/sj.onc.1204017; Jabbur JR, 2002, CANCER BIOL THER, V1, P277, DOI 10.4161/cbt.81; Jabbur JR, 2001, INT J MOL MED, V7, P163; Jimenez GS, 2000, NAT GENET, V26, P37, DOI 10.1038/79152; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Ko LJ, 1997, MOL CELL BIOL, V17, P7220, DOI 10.1128/MCB.17.12.7220; Kobayashi T, 1998, CELL DEATH DIFFER, V5, P584, DOI 10.1038/sj.cdd.4400382; Kubbutat MHG, 1998, MOL CELL BIOL, V18, P5690, DOI 10.1128/MCB.18.10.5690; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Kwek SSS, 2001, ONCOGENE, V20, P2587, DOI 10.1038/sj.onc.1204362; Lai ZH, 2000, ARCH BIOCHEM BIOPHYS, V381, P278, DOI 10.1006/abbi.2000.1998; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lill NL, 1997, NATURE, V387, P823, DOI 10.1038/42981; LIN JY, 1994, GENE DEV, V8, P1235, DOI 10.1101/gad.8.10.1235; Liu L, 1999, MOL CELL BIOL, V19, P1202; LIU X, 1993, MOL CELL BIOL, V13, P3291, DOI 10.1128/MCB.13.6.3291; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; LUNA RMD, 1995, NATURE, V378, P203; MACK DH, 1993, NATURE, V363, P281, DOI 10.1038/363281a0; MARTIN DW, 1993, J BIOL CHEM, V268, P13062; Mayo LD, 1997, CANCER RES, V57, P5013; MILNE DM, 1995, J BIOL CHEM, V270, P5511, DOI 10.1074/jbc.270.10.5511; MIYASHITA T, 1995, CELL, V80, P293; OLINER JD, 1993, NATURE, V362, P857, DOI 10.1038/362857a0; OWENSCHAUB LB, 1995, MOL CELL BIOL, V15, P3032; Prives C, 1998, CELL, V95, P5, DOI 10.1016/S0092-8674(00)81774-2; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Scolnick DM, 1997, CANCER RES, V57, P3693; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Shieh SY, 2000, GENE DEV, V14, P289; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sionov RV, 1999, J BIOL CHEM, V274, P8371, DOI 10.1074/jbc.274.13.8371; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Tao WK, 1999, P NATL ACAD SCI USA, V96, P3077, DOI 10.1073/pnas.96.6.3077; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Uesugi M, 1999, P NATL ACAD SCI USA, V96, P14801, DOI 10.1073/pnas.96.26.14801; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Unger T, 1999, EMBO J, V18, P1805, DOI 10.1093/emboj/18.7.1805; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wadgaonkar R, 1999, J BIOL CHEM, V274, P13760, DOI 10.1074/jbc.274.20.13760; Wang XW, 1999, P NATL ACAD SCI USA, V96, P3706, DOI 10.1073/pnas.96.7.3706; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; Zhan QM, 1999, ONCOGENE, V18, P2892, DOI 10.1038/sj.onc.1202667; Zhang YP, 1999, MOL CELL, V3, P579, DOI 10.1016/S1097-2765(00)80351-2	85	37	37	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7100	7113		10.1038/sj.onc.1205856	http://dx.doi.org/10.1038/sj.onc.1205856			14	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370832				2022-12-25	WOS:000178424900013
J	el-Ghissassi, F; Valsesia-Wittmann, S; Falette, N; Duriez, C; Walden, PD; Puisieux, A				el-Ghissassi, F; Valsesia-Wittmann, S; Falette, N; Duriez, C; Walden, PD; Puisieux, A			BTG2(TIS21/PC3) induces neuronal differentiation and prevents apoptosis of terminally differentiated PC12 cells	ONCOGENE			English	Article						BTG2(TIS21/PC3); PC12 cells; cell differentiation; apoptosis	NERVE GROWTH-FACTOR; PHEOCHROMOCYTOMA CELLS; PC3/BTG/TOB FAMILY; CELLULAR-RESPONSE; TOB/BTG1 FAMILY; MESSENGER-RNA; GENE; PC3; EXPRESSION; MEMBER	The p53-transcriptional target, BTG2(TIS21/PC3), was previously identified as an antiproliferative gene. However, the precise biological functions of the protein product remain to be elucidated. BTG(2TIS21/PC3) expression is induced in vivo during neurogenesis, and the gene is transiently expressed in vitro in rat pheochromocytoma PC12 cells after induction of neuronal differentiation by addition of nerve growth factor (NGF). These observations suggest that BTG2(TIS21/PC3) is functionally significant during the neuronal differentiation process. To test this hypothesis, a vector that expressed BTG2(TIS21/PC3) under the control of an inducible promoter was introduced into PC12 cells. Growth arrest and differentiation in response to NGF were greatly enhanced by BTG2(TIS21/PC3) overexpression. Furthermore, an antisense oligonucleotide complementary to BTG2(TIS21/PC3) mRNA, which was able to inhibit endogenous BTG2(TIS21/PC3) expression, triggered programmed cell death in differentiated PC12 cells. These observations confirm that BTG2(TIS21/PC3) expression promotes neuronal differentiation and that it is required for survival of terminally differentiated cells.	INSERM, Ctr Leon Berard, Unite 453, Dept Oncol Fondamentale & Appl, F-69008 Lyon, France; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NYU, Sch Med, Dept Urol, New York, NY 10016 USA; Fac Pharm Lyon, Dept Genet Mol & Biochim Clin, F-69008 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Leon Berard; New York University; New York University; UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Puisieux, A (corresponding author), INSERM, Ctr Leon Berard, Unite 453, Dept Oncol Fondamentale & Appl, 28 Rue Laennec, F-69008 Lyon, France.	puisieux@lyon.fnclcc.fr		PUISIEUX, Alain/0000-0002-9938-3798				ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; Buanne P, 2000, GENOMICS, V68, P253, DOI 10.1006/geno.2000.6288; Cimato TR, 1997, J CELL BIOL, V138, P1089, DOI 10.1083/jcb.138.5.1089; Corrente G, 2002, NEUROREPORT, V13, P417, DOI 10.1097/00001756-200203250-00011; Cortes U, 2000, MOL CARCINOGEN, V27, P57, DOI 10.1002/(SICI)1098-2744(200002)27:2<57::AID-MC1>3.3.CO;2-9; De Laurenzi V, 2000, J BIOL CHEM, V275, P15226, DOI 10.1074/jbc.275.20.15226; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Erhardt JA, 1998, J BIOL CHEM, V273, P23517, DOI 10.1074/jbc.273.36.23517; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GREENE LA, 1978, J CELL BIOL, V78, P747, DOI 10.1083/jcb.78.3.747; Guardavaccaro D, 2000, MOL CELL BIOL, V20, P1797, DOI 10.1128/MCB.20.5.1797-1815.2000; Guehenneux F, 1997, LEUKEMIA, V11, P370, DOI 10.1038/sj.leu.2400599; GUPTA M, 1987, BRAIN RES BULL, V18, P555, DOI 10.1016/0361-9230(87)90119-5; Iacopetti P, 1999, P NATL ACAD SCI USA, V96, P4639, DOI 10.1073/pnas.96.8.4639; IACOPETTI P, 1994, MECH DEVELOP, V47, P127, DOI 10.1016/0925-4773(94)90085-X; Ikematsu N, 1999, ONCOGENE, V18, P7432, DOI 10.1038/sj.onc.1203193; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; Malatesta P, 2000, MECH DEVELOP, V90, P17, DOI 10.1016/S0925-4773(99)00224-5; Marz P, 1997, EUR J NEUROSCI, V9, P2765, DOI 10.1111/j.1460-9568.1997.tb01705.x; Matsuda S, 1996, ONCOGENE, V12, P705; Montagnoli A, 1996, CELL GROWTH DIFFER, V7, P1327; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; Rouault JP, 1996, NAT GENET, V14, P482, DOI 10.1038/ng1296-482; RUDKIN BB, 1989, EMBO J, V8, P3319, DOI 10.1002/j.1460-2075.1989.tb08493.x; Tirone F, 2001, J CELL PHYSIOL, V187, P155, DOI 10.1002/jcp.1062; vanGrunsven LA, 1996, ONCOGENE, V12, P855; VINORES SA, 1981, J NEUROCHEM, V37, P597; Walden PD, 1998, EXP CELL RES, V245, P19, DOI 10.1006/excr.1998.4237; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yoshida Y, 1998, ONCOGENE, V16, P2687, DOI 10.1038/sj.onc.1201805; Zhu JH, 1998, CANCER RES, V58, P5061	32	63	65	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6772	6778		10.1038/sj.onc.1205888	http://dx.doi.org/10.1038/sj.onc.1205888			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360398				2022-12-25	WOS:000178315800007
J	Kopantzev, Y; Heller, M; Swaminathan, N; Rudikoff, S				Kopantzev, Y; Heller, M; Swaminathan, N; Rudikoff, S			IL-6 mediated activation of STAT3 bypasses Janus kinases in terminally differentiated B lineage cells	ONCOGENE			English	Article						IL-6; STAT3; MEK kinase; phosphorylation	SIGNAL TRANSDUCER GP130; JAK-TYK KINASES; TYROSINE KINASE; SERINE PHOSPHORYLATION; CYTOKINE RECEPTORS; INTERLEUKIN-6 FAMILY; PROTEIN-KINASES; IN-VIVO; INHIBITOR; ASSOCIATION	Cytokine signaling generally occurs through receptors lacking tyrosine kinase activity. Aggregation of receptors leads to activation of receptor associated Janus kinases (Jaks) which in turn phosphorylate members of a family of transcription factors (STATs) that translocate to the nucleus and regulate gene expression. In the case of Interleukin-6 (IL-6), the consensus for signaling in B lineage cells has been that Jak1, Jak2 and Tyk2 are all phosphorylated upon ligand binding and participate in activation of downstream elements, in particular STAT3. In other cell types, Jak1 has been demonstrated to be absolutely required for IL-6 mediated activation of STAT3. In the present studies, we have identified a series of end stage B cell (plasma cell) lines that fail to express Jak1, but phosphorylate STAT3 in response to IL-6. No evidence was found for a requirement of other Jak family members in the activation of STAT3. STAT3 tyrosine phosphorylation was inhibited in a dose dependent manner by the MEK inhibitor U0126, but not by inhibitors of PI-3K or Src kinases. Moreover, STAT3 phosphorylation was similarly inhibited in lines expressing Jak1 wherein Jak1 was phosphorylated upon IL-6 stimulation and Jakl phosphorylation was not inhibited by U0126. These results indicate that the MAPK pathway plays a critical role in IL-6 mediated tyrosine phosphorylation of STAT3 and suggests that Jak kinases may not be required in this cascade. Thus, it may be important to re-evaluate the role of Jak kinases in other cytokine signaling pathways as well.	NCI, Cellular & Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Rudikoff, S (corresponding author), NCI, Cellular & Mol Biol Lab, NIH, Bldg 37,Room 1D-18, Bethesda, MD 20892 USA.	rudikoff@helix.nih.gov						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BERGER LC, 1994, BIOCHEM BIOPH RES CO, V202, P596, DOI 10.1006/bbrc.1994.1970; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; EILERS A, 1995, MOL CELL BIOL, V15, P3579; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gadina M, 2001, CURR OPIN IMMUNOL, V13, P363, DOI 10.1016/S0952-7915(00)00228-4; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Hallek M, 1997, EXP HEMATOL, V25, P1367; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Hirano T, 1998, Int Rev Immunol, V16, P249; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Karaghiosoff M, 2000, IMMUNITY, V13, P549, DOI 10.1016/S1074-7613(00)00054-6; KOPF M, 1994, NATURE, V368, P339, DOI 10.1038/368339a0; Krishnan K, 1997, EUR J BIOCHEM, V247, P298, DOI 10.1111/j.1432-1033.1997.00298.x; KUMAR G, 1994, J IMMUNOL, V153, P4436; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MATSUDA T, 1995, J BIOL CHEM, V270, P11037, DOI 10.1074/jbc.270.19.11037; MATSUDA T, 1995, BLOOD, V85, P627, DOI 10.1182/blood.V85.3.627.bloodjournal853627; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; NARAZAKI M, 1994, P NATL ACAD SCI USA, V91, P2285, DOI 10.1073/pnas.91.6.2285; Nosaka T, 2000, INT J HEMATOL, V71, P309; Ogata A, 1997, J IMMUNOL, V159, P2212; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Sengupta TK, 1998, P NATL ACAD SCI USA, V95, P11107, DOI 10.1073/pnas.95.19.11107; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; Treon S P, 1998, Curr Opin Hematol, V5, P42; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; YANG YP, 1995, HUM GENE THER, V6, P1203, DOI 10.1089/hum.1995.6.9-1203; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	38	21	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6791	6800		10.1038/sj.onc.1205815	http://dx.doi.org/10.1038/sj.onc.1205815			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360405				2022-12-25	WOS:000178315800009
J	Magnard, C; Bachelier, R; Vincent, A; Jaquinod, M; Kieffer, S; Lenoir, GM; Venezia, ND				Magnard, C; Bachelier, R; Vincent, A; Jaquinod, M; Kieffer, S; Lenoir, GM; Venezia, ND			BRCA1 interacts with acetyl-CoA carboxylase through its tandem of BRCT domains	ONCOGENE			English	Article						BRCA; acetyl-CoA carboxylase; BRCT; GST pull-down	COENZYME-A CARBOXYLASE; BREAST-CANCER CELLS; NUCLEAR-LOCALIZATION SIGNAL; POLYMERASE-II HOLOENZYME; DNA-DAMAGE RESPONSE; FATTY-ACID SYNTHASE; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; OVARIAN-CANCER; MURINE BRCA1	Germ-line alterations in BRCA1 are associated with an increased susceptibility to breast and ovarian cancer. BRCA1 is a 220-kDa protein that contains a tandem of two BRCA1 C-Terminal (BRCT) domains. Among missense and nonsense BRCA1 mutations responsible for family breast cancer, some are located into the BRCT tandem of BRCA1 coding sequence. In an attempt to understand how BRCT is critical for BRCA1 function, we search for partners of this BRCT tandem of BRCA1. Using a glutathione-S-transferase (GST) pull-down assay with murine cells, we isolated only one major BRCA1-interacting protein, further identified as Acetyl Coenzyme A (CoA) Carboxylase a (ACCA). We showed that this interaction is conserved through murine and human species. We also delineated the minimum interacting region as being the whole tandem of BRCT domains. We demonstrated that BRCA1 interacts in vitro and in vivo with ACCA. This interaction is completely abolished by five distinct germline BRCA1 deleterious mutations affecting the BRCT tandem of BRCA1. Interestingly, ACCA originally known as a rate-limiting enzyme for fatty acids biosynthesis, has been recently shown to be over-expressed in breast cancers and considered as a potential target for anti-neoplastic therapy. Furthermore, our observation is making a bridge between the genetic factors involved in susceptibility to breast and ovarian cancers, and environmental factors such as nutrition considered as key elements in the etiology of those cancers.	Univ Lyon 1, CNRS, Genet Lab, Fac Med Rockefeller,UMR 5641, F-69373 Lyon 08, France; CEN Grenoble, DBMS, Lab Chim Prot, F-38054 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; CEA	Venezia, ND (corresponding author), Univ Lyon 1, CNRS, Genet Lab, Fac Med Rockefeller,UMR 5641, 8 Ave Rockefeller, F-69373 Lyon 08, France.	dalla@rockefeller.univ-lyon1.fr	VENEZIA, Nicole DALLA/C-6542-2017	VENEZIA, Nicole DALLA/0000-0002-4553-3535				Abbott DW, 1999, J BIOL CHEM, V274, P18808, DOI 10.1074/jbc.274.26.18808; Abu-Elheiga L, 2000, P NATL ACAD SCI USA, V97, P1444, DOI 10.1073/pnas.97.4.1444; ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; Anderson SE, 1998, NAT GENET, V19, P254, DOI 10.1038/930; Aprelikova ON, 1999, P NATL ACAD SCI USA, V96, P11866, DOI 10.1073/pnas.96.21.11866; Bachelier R, 2000, INT J CANCER, V88, P519, DOI 10.1002/1097-0215(20001115)88:4<519::AID-IJC2>3.0.CO;2-R; BACHELIER R, 2001, VIRCHOWS ARCH, V40, P261; BIANCHI A, 1990, J BIOL CHEM, V265, P1502; Bochar DA, 2000, CELL, V102, P257, DOI 10.1016/S0092-8674(00)00030-1; Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Brownsey RW, 1997, BIOCHEM SOC T, V25, P1232, DOI 10.1042/bst0251232; Callebaut I, 1997, FEBS LETT, V400, P25, DOI 10.1016/S0014-5793(96)01312-9; Cantor SB, 2001, CELL, V105, P149, DOI 10.1016/S0092-8674(01)00304-X; Carroll KK, 1998, LIPIDS, V33, P1055, DOI 10.1007/s11745-998-0305-8; Chai YL, 1999, ONCOGENE, V18, P263, DOI 10.1038/sj.onc.1202323; Chapman MS, 1996, NATURE, V382, P678, DOI 10.1038/382678a0; Chen CF, 1996, J BIOL CHEM, V271, P32863, DOI 10.1074/jbc.271.51.32863; CHEN YM, 1995, SCIENCE, V270, P789, DOI 10.1126/science.270.5237.789; Critchlow SE, 1997, CURR BIOL, V7, P588, DOI 10.1016/S0960-9822(06)00258-2; Deng CX, 2000, BIOESSAYS, V22, P728; Fan SJ, 2001, ONCOGENE, V20, P4827, DOI 10.1038/sj.onc.1204666; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; Gowen LC, 1998, SCIENCE, V281, P1009, DOI 10.1126/science.281.5379.1009; Hakem R, 1996, CELL, V85, P1009, DOI 10.1016/S0092-8674(00)81302-1; Hohenstein P, 2001, ONCOGENE, V20, P2544, DOI 10.1038/sj.onc.1204363; Houvras Y, 2000, J BIOL CHEM, V275, P36230, DOI 10.1074/jbc.M002539200; Hu YF, 1999, GENE DEV, V13, P637, DOI 10.1101/gad.13.6.637; Huber LJ, 2001, MOL CELL BIOL, V21, P4005, DOI 10.1128/MCB.21.12.4005-4015.2001; Jensen DE, 1998, ONCOGENE, V16, P1097, DOI 10.1038/sj.onc.1201861; Kim KH, 1997, ANNU REV NUTR, V17, P77, DOI 10.1146/annurev.nutr.17.1.77; Koonin EV, 1996, NAT GENET, V13, P266, DOI 10.1038/ng0796-266; Kuhajda FP, 2000, NUTRITION, V16, P202, DOI 10.1016/S0899-9007(99)00266-X; Li S, 1998, J BIOL CHEM, V273, P6183, DOI 10.1074/jbc.273.11.6183; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; Magdinier F, 1999, ONCOGENE, V18, P4039, DOI 10.1038/sj.onc.1202780; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; Masson M, 1998, MOL CELL BIOL, V18, P3563, DOI 10.1128/MCB.18.6.3563; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Milgraum LZ, 1997, CLIN CANCER RES, V3, P2115; Moncur JT, 1998, P NATL ACAD SCI USA, V95, P6989, DOI 10.1073/pnas.95.12.6989; Monteiro ANA, 1996, P NATL ACAD SCI USA, V93, P13595, DOI 10.1073/pnas.93.24.13595; MONTESANO R, 1997, IN VIVO CELL DEV BIO, V34, P468; Nash RA, 1997, BIOCHEMISTRY-US, V36, P5207, DOI 10.1021/bi962281m; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Pao GM, 2000, P NATL ACAD SCI USA, V97, P1020, DOI 10.1073/pnas.97.3.1020; Patterson RE, 1999, J AM DIET ASSOC, V99, P1412, DOI 10.1016/S0002-8223(99)00341-7; Paull TT, 2001, P NATL ACAD SCI USA, V98, P6086, DOI 10.1073/pnas.111125998; Pizer ES, 1996, CANCER RES, V56, P1189; Pizer ES, 1996, CANCER RES, V56, P2745; Riboli E, 2001, J NUTR, V131, p170S, DOI 10.1093/jn/131.1.170S; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Ruderman N, 2001, SCIENCE, V291, P2558, DOI 10.1126/science.1060277; Ruffner H, 1997, P NATL ACAD SCI USA, V94, P7138, DOI 10.1073/pnas.94.14.7138; Saitoh S, 1996, J CELL BIOL, V134, P949, DOI 10.1083/jcb.134.4.949; Scully R, 1997, CELL, V88, P265, DOI 10.1016/S0092-8674(00)81847-4; Scully R, 1997, CELL, V90, P425, DOI 10.1016/S0092-8674(00)80503-6; Scully R, 1996, SCIENCE, V272, P123, DOI 10.1126/science.272.5258.123; Scully R, 1997, P NATL ACAD SCI USA, V94, P5605, DOI 10.1073/pnas.94.11.5605; STOLL BA, 1995, ANN ONCOL, V6, P245, DOI 10.1093/oxfordjournals.annonc.a059153; Thakur S, 1997, MOL CELL BIOL, V17, P444, DOI 10.1128/MCB.17.1.444; THAMPY KG, 1989, J BIOL CHEM, V264, P17631; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Thupari JN, 2001, BIOCHEM BIOPH RES CO, V285, P217, DOI 10.1006/bbrc.2001.5146; Tomlinson GE, 1998, CANCER RES, V58, P3237; Venkitaraman AR, 2002, CELL, V108, P171, DOI 10.1016/S0092-8674(02)00615-3; Wang Y, 2000, GENE DEV, V14, P927; Williams RS, 2001, NAT STRUCT BIOL, V8, P838, DOI 10.1038/nsb1001-838; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; WITTERS LA, 1994, INT J BIOCHEM, V26, P589, DOI 10.1016/0020-711X(94)90018-3; Wong AKC, 1998, ONCOGENE, V17, P2279, DOI 10.1038/sj.onc.1202150; Wu LJC, 1996, NAT GENET, V14, P430, DOI 10.1038/ng1296-430; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yu X, 1998, J BIOL CHEM, V273, P25388, DOI 10.1074/jbc.273.39.25388; Zhang HT, 2000, DNA CELL BIOL, V19, P253, DOI 10.1089/10445490050021168; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	80	75	86	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6729	6739		10.1038/sj.onc.1205915	http://dx.doi.org/10.1038/sj.onc.1205915			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360400				2022-12-25	WOS:000178315800003
J	Stratton, R; Rajkumar, V; Ponticos, M; Nichols, B; Xu, SW; Black, CM; Abraham, DJ; Leask, A				Stratton, R; Rajkumar, V; Ponticos, M; Nichols, B; Xu, SW; Black, CM; Abraham, DJ; Leask, A			Prostacyclin derivatives prevent the fibrotic response to TGF beta 2 by inhibiting the Ras/MEK/ERK pathway	FASEB JOURNAL			English	Article						MAP kinase; SMAD; CTGF; iloprost	GROWTH-FACTOR-BETA; GENE-EXPRESSION; SCLERODERMA FIBROBLASTS; SYSTEMIC-SCLEROSIS; EPITHELIAL-CELLS; PROTEIN-KINASES; RAF-1 KINASE; ACTIVATION; SMAD; CAMP	The SMAD-mediated induction of connective tissue growth factor (CTGF), a fibroproliferative cytokine, by transforming growth factor (TGF)beta is required for the development of sustained fibrosis in humans. Here, we show that in fibroblasts, activation of the Ras/MEK/ERK pathway is required for the SMAD-mediated induction of CTGF by TGFbeta2. We then show that activation of protein kinase A (PKA) in fibroblasts is able to block Ras/MEK/ERK signaling and abolish the fibrotic response. Previously, we found that prostacyclin agonists were able to prevent the induction of CTGF in fibroblasts, and in patients with the fibrotic disease scleroderma. Here, we confirm the in vitro and in vivo antifibrotic effects of prostacyclin derivatives and show that these effects are due to PKA-dependent inhibition of the Ras/MEK/ERK pathway. Ras/MEK/ERK does not directly affect SMAD signaling. The coordinate and varied biological responses to TGFbeta are in part due to the interactions of signaling pathways within target cells. Specific inhibition of fibroblast Ras/MEK/ERK signaling might prevent fibrosis while leaving other physiological effects of TGFbeta unaltered.	FibroGen Inc, San Francisco, CA 94080 USA; Univ Coll, Sch Med, London NW3 2PF, England; Royal Free Hosp, Ctr Rheumatol, London NW3 2PF, England	FibroGen; University of London; University College London; UCL Medical School; University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Leask, A (corresponding author), FibroGen Inc, 225 Gateway Blvd, San Francisco, CA 94080 USA.	aleask@fibrogen.com	Leask, Andy/ABH-9433-2020; Leask, Andrew/G-5217-2015	Ponticos, Markella/0000-0001-5957-5851				Abraham DJ, 2000, J BIOL CHEM, V275, P15220, DOI 10.1074/jbc.275.20.15220; Bettoni L, 2002, CLIN RHEUMATOL, V21, P244, DOI 10.1007/PL00011223; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; BOSSEMEYER D, 1995, FEBS LETT, V369, P57, DOI 10.1016/0014-5793(95)00580-3; Brigstock DR, 1999, ENDOCR REV, V20, P189, DOI 10.1210/er.20.2.189; CHEN Y, 2002, IN PRESS KIDNEY INT; Chen YJ, 2001, EXP CELL RES, V271, P109, DOI 10.1006/excr.2001.5364; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; Daniel PB, 1998, ANNU REV NUTR, V18, P353, DOI 10.1146/annurev.nutr.18.1.353; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Duncan MR, 1999, FASEB J, V13, P1774, DOI 10.1096/fasebj.13.13.1774; Engel ME, 1999, J BIOL CHEM, V274, P37413, DOI 10.1074/jbc.274.52.37413; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Flanders KC, 2002, AM J PATHOL, V160, P1057, DOI 10.1016/S0002-9440(10)64926-7; Frey RS, 1997, CANCER LETT, V117, P41, DOI 10.1016/S0304-3835(97)00211-5; GARVEY W, 1984, STAIN TECHNOL, V59, P213, DOI 10.3109/10520298409113858; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; HARTSOUGH MT, 1995, J BIOL CHEM, V270, P7117, DOI 10.1074/jbc.270.13.7117; Heldin CH, 1997, NATURE, V390, P465, DOI 10.1038/37284; Holmes A, 2001, J BIOL CHEM, V276, P10594, DOI 10.1074/jbc.M010149200; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Kutz SM, 2001, J CELL SCI, V114, P3905; Leask A, 2001, J CLIN PATHOL-MOL PA, V54, P180, DOI 10.1136/mp.54.3.180; Leask Andrew, 2002, Curr Rheumatol Rep, V4, P136, DOI 10.1007/s11926-002-0009-x; Liu XD, 2001, CYTOKINE GROWTH F R, V12, P1, DOI 10.1016/S1359-6101(00)00031-9; MAQUART FX, 1993, J CLIN INVEST, V92, P2368, DOI 10.1172/JCI116842; McCartney-Francis N L, 1998, Int Rev Immunol, V16, P553, DOI 10.3109/08830189809043009; Mori T, 1999, J CELL PHYSIOL, V181, P153, DOI 10.1002/(SICI)1097-4652(199910)181:1<153::AID-JCP16>3.0.CO;2-K; MULDER KM, 1992, J BIOL CHEM, V267, P5029; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Shi-Wen X, 2000, EXP CELL RES, V259, P213, DOI 10.1006/excr.2000.4972; SPRUGEL KH, 1987, AM J PATHOL, V129, P601; Stratton R, 2001, J CLIN INVEST, V108, P241, DOI 10.1172/JCI12020; TAYLOR SS, 1988, COLD SPRING HARB SYM, V53, P121, DOI 10.1101/SQB.1988.053.01.018; VANRENTERGHEM B, 1994, J BIOL CHEM, V269, P24666; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Weissinger EM, 1997, MOL CELL BIOL, V17, P3229, DOI 10.1128/MCB.17.6.3229; Wotton D, 2001, CELL GROWTH DIFFER, V12, P457; Wotton D, 2001, CURR TOP MICROBIOL, V254, P145; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; WRANA JL, 2000, SCI STKE, V23, pRE1; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019	46	131	141	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1949	+		10.1096/fj.02-0204fje	http://dx.doi.org/10.1096/fj.02-0204fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368229				2022-12-25	WOS:000179167600021
J	Dawson, JF; Sablin, EP; Spudich, JA; Fletterick, RJ				Dawson, JF; Sablin, EP; Spudich, JA; Fletterick, RJ			Structure of an F-actin trimer disrupted by gelsolin and implications for the mechanism of severing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-BINDING PROTEIN; CRYSTAL-STRUCTURE; FILAMENT DYNAMICS; PLASMA GELSOLIN; RATE CONSTANTS; COMPLEX; POLYMERIZATION; IDENTIFICATION; PROFILIN; DOMAIN	Stable oligomers of filamentous actin were obtained by cross-linking F-actin with 1,4-N,N'-phenylenedimaleimide and depolymerization with excess segment-1 of gelsolin. Segment-l-bound and cross-linked actin oligomers containing either two or three actin subunits were purified and shown to nucleate actin assembly. Kinetic assembly data from mixtures of monomeric actin and the actin oligomers fit a nucleation model where cross-linked actin dimer or trimer reacts with an actin monomer to produce a competent nucleus for filament assembly. We report the three-dimensional structure of the segment-l-actin hexamer containing three actin subunits, each with a tightly bound ATP. Comparative analysis of this structure with twelve other actin structures provides an atomic level explanation for the preferential binding of ATP by the segment-l-complexed actin. Although the structure of segment-l-bound actin trimer is topologically similar to the helical model of F-actin (1), it has a distorted symmetry compared with that of the helical model. This distortion results from intercalation of segment-1 between actin protomers that increase the rise per subunit and rotate each of the actin subunits relative to their positions in F-actin. We also show that segment-1 of gelsolin is able to sever actin filaments, although the severing activity of segment-1 is significantly lower than full-length gelsolin.	Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA; Stanford Univ, Sch Med, Dept Biochem, Stanford, CA 94305 USA	University of California System; University of California San Francisco; Stanford University	Fletterick, RJ (corresponding author), Univ Calif San Francisco, Dept Biochem Biophys, San Francisco, CA 94143 USA.	flett@msg.ucsf.edu			NIGMS NIH HHS [R01 GM033289] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033289] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bubb MR, 2002, J BIOL CHEM, V277, P20999, DOI 10.1074/jbc.M201371200; Burtnick L D, 2001, Results Probl Cell Differ, V32, P201; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; Chik JK, 1996, J MOL BIOL, V263, P607, DOI 10.1006/jmbi.1996.0602; COUE M, 1986, J BIOL CHEM, V261, P1588; De La Cruz EM, 2001, SCIENCE, V293, P616, DOI 10.1126/science.1063558; EGELMAN EH, 1983, J MOL BIOL, V166, P605, DOI 10.1016/S0022-2836(83)80286-1; EGELMAN EH, 1982, NATURE, V298, P131, DOI 10.1038/298131a0; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; FRENCH BA, 1990, GENE, V88, P173, DOI 10.1016/0378-1119(90)90029-Q; Galkin VE, 2002, CURR BIOL, V12, P570, DOI 10.1016/S0960-9822(02)00742-X; Galkin VE, 2001, J CELL BIOL, V153, P75, DOI 10.1083/jcb.153.1.75; GILBERT HR, 1983, BIOCHEM BIOPH RES CO, V111, P404, DOI 10.1016/0006-291X(83)90320-0; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Head JF, 2002, BIOCHEMISTRY-US, V41, P9015, DOI 10.1021/bi026054y; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; Kinosian HJ, 1996, BIOCHEMISTRY-US, V35, P16550, DOI 10.1021/bi961891j; KNIGHT P, 1975, BIOCHEM J, V175, P1023; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1985, J BIOL CHEM, V260, P5232; LAL AA, 1984, J BIOL CHEM, V259, P8794; McGough A, 1998, BIOPHYS J, V74, P764, DOI 10.1016/S0006-3495(98)74001-9; McGough A, 1997, J CELL BIOL, V138, P771, DOI 10.1083/jcb.138.4.771; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MILLONIG R, 1988, J CELL BIOL, V106, P785, DOI 10.1083/jcb.106.3.785; MOCKRIN SC, 1981, J BIOL CHEM, V256, P8228; OOSAWA F, 1975, THERMODYNAMICS POLYM, P47; Otterbein LR, 2001, SCIENCE, V293, P708, DOI 10.1126/science.1059700; Otterbein LR, 2002, P NATL ACAD SCI USA, V99, P8003, DOI 10.1073/pnas.122126299; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page R, 1998, J MOL BIOL, V280, P463, DOI 10.1006/jmbi.1998.1879; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; Robinson RC, 1999, SCIENCE, V286, P1939, DOI 10.1126/science.286.5446.1939; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Sablin EP, 2002, P NATL ACAD SCI USA, V99, P10945, DOI 10.1073/pnas.152329899; SCHUTT CE, 1993, NATURE, V365, P810, DOI 10.1038/365810a0; SCHUTT CE, 1992, P NATL ACAD SCI USA, V89, P319, DOI 10.1073/pnas.89.1.319; SCHUTT CE, 1995, BIOPHYS J, V68, pS12; SCHUTT CE, 1989, J MOL BIOL, V209, P735, DOI 10.1016/0022-2836(89)90603-7; SCHUTT CE, 1993, FEBS LETT, V325, P59, DOI 10.1016/0014-5793(93)81413-T; Selden LA, 1998, BIOPHYS J, V75, P3092, DOI 10.1016/S0006-3495(98)77750-1; Sept D, 2001, BIOPHYS J, V81, P667, DOI 10.1016/S0006-3495(01)75731-1; SHETERLINE P, 1998, PROTEIN PROFILE ACTI, P13; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1989, J CELL BIOL, V109, P593, DOI 10.1083/jcb.109.2.593; WAY M, 1990, EMBO J, V9, P4103, DOI 10.1002/j.1460-2075.1990.tb07632.x; YIN HL, 1988, J CELL BIOL, V106, P805, DOI 10.1083/jcb.106.3.805; Zigmond SH, 2000, METHOD ENZYMOL, V325, P237	53	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1229	1238		10.1074/jbc.M209160200	http://dx.doi.org/10.1074/jbc.M209160200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12356759	hybrid			2022-12-25	WOS:000180321900070
J	Bayliss, R; Littlewood, T; Strawn, LA; Wente, SR; Stewart, M				Bayliss, R; Littlewood, T; Strawn, LA; Wente, SR; Stewart, M			GLFG and FxFG nucleoporins bind to overlapping sites on importin-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; TRANSPORT FACTOR-2 NTF2; STRUCTURAL BASIS; NUCLEOCYTOPLASMIC TRANSPORT; MOLECULAR-MECHANISM; REPEAT REGIONS; PROTEIN IMPORT; RNA EXPORT; DOMAIN; RAN	The interaction between nuclear pore proteins (nucleoporins) and transport factors is crucial for the translocation of macromolecules through nuclear pores. Many nucleoporins contain FG sequence repeats, and previous studies have demonstrated interactions between repeats containing FxFG or GLFG cores and transport factors. The crystal structure of residues 1-442 of importin-beta bound to a GLFG peptide indicates that this repeat core binds to the same primary site as FxFG cores. Importin-beta-I178D shows reduced binding to both FxFG and GLFG repeats, consistent with both binding to an overlapping site in the hydrophobic groove between the A-helices of HEAT repeats 5 and 6. Moreover, FxFG repeats can displace importin-beta or its S. cerevisiae homologue, Kap95, bound to GLFG repeats. Addition of soluble GLFG repeats decreases the rate of nuclear protein import in digitonin-permeabilized HeLa cells, indicating that this interaction has a role in the translocation of carrier-cargo complexes through nuclear pores. The binding of GLFG and FxFG repeats to overlapping sites on importin-beta indicates that functional differences between different repeats probably arise from differences in their spatial organization.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Vanderbilt Univ, Med Ctr, Dept Cell & Dev Biol, Nashville, TN 37232 USA	MRC Laboratory Molecular Biology; Vanderbilt University	Stewart, M (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.	ms@mrc-lmb.cam.ac.uk		Bayliss, Richard/0000-0003-0604-2773	NIGMS NIH HHS [GM51219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051219, R37GM051219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; Bayliss R, 2000, TRAFFIC, V1, P448, DOI 10.1034/j.1600-0854.2000.010602.x; Bayliss R, 2000, J STRUCT BIOL, V131, P240, DOI 10.1006/jsbi.2000.4297; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 1999, J MOL BIOL, V293, P579, DOI 10.1006/jmbi.1999.3166; Bayliss R, 2002, EMBO J, V21, P2843, DOI 10.1093/emboj/cdf305; Ben-Efraim I, 2001, J CELL BIOL, V152, P411, DOI 10.1083/jcb.152.2.411; Bonifaci N, 1997, P NATL ACAD SCI USA, V94, P5055, DOI 10.1073/pnas.94.10.5055; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chaillan-Huntington C, 2000, J BIOL CHEM, V275, P5874, DOI 10.1074/jbc.275.8.5874; Chi NC, 1997, MOL BIOL CELL, V8, P945, DOI 10.1091/mbc.8.6.945; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Clarkson WD, 1997, J MOL BIOL, V272, P716, DOI 10.1006/jmbi.1997.1255; Clarkson WD, 1996, J MOL BIOL, V263, P517, DOI 10.1006/jmbi.1996.0594; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Damelin M, 2000, MOL CELL, V5, P133, DOI 10.1016/S1097-2765(00)80409-8; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fribourg S, 2001, MOL CELL, V8, P645, DOI 10.1016/S1097-2765(01)00348-3; Gilchrist D, 2002, J BIOL CHEM, V277, P18161, DOI 10.1074/jbc.M112306200; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Grant RP, 2002, NAT STRUCT BIOL, V9, P247, DOI 10.1038/nsb773; Iovine MK, 1995, J CELL BIOL, V131, P1699, DOI 10.1083/jcb.131.6.1699; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuersten S, 2001, TRENDS CELL BIOL, V11, P497, DOI 10.1016/S0962-8924(01)02144-4; Kutay U, 1997, EMBO J, V16, P1153, DOI 10.1093/emboj/16.6.1153; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lei EP, 2002, DEV CELL, V2, P261, DOI 10.1016/S1534-5807(02)00134-X; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; RADU A, 1995, CELL, V81, P215, DOI 10.1016/0092-8674(95)90331-3; Reed R, 2002, CELL, V108, P523, DOI 10.1016/S0092-8674(02)00627-X; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 1998, EMBO J, V17, P6587, DOI 10.1093/emboj/17.22.6587; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Shah S, 1998, J CELL BIOL, V141, P31, DOI 10.1083/jcb.141.1.31; Shah S, 1998, CURR BIOL, V8, P1376, DOI 10.1016/S0960-9822(98)00018-9; Smith A, 1998, CURR BIOL, V8, P1403, DOI 10.1016/S0960-9822(98)00023-2; Stewart M, 1998, J MOL BIOL, V277, P635, DOI 10.1006/jmbi.1997.1602; Stewart M, 2001, FEBS LETT, V498, P145, DOI 10.1016/S0014-5793(01)02489-9; Stoffler D, 1999, CURR OPIN CELL BIOL, V11, P391, DOI 10.1016/S0955-0674(99)80055-6; Strawn LA, 2001, J BIOL CHEM, V276, P6445, DOI 10.1074/jbc.M008311200; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Wente SR, 2000, SCIENCE, V288, P1374, DOI 10.1126/science.288.5470.1374; Zhang CM, 2002, CURR BIOL, V12, P498, DOI 10.1016/S0960-9822(02)00714-5	56	179	184	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50597	50606		10.1074/jbc.M209037200	http://dx.doi.org/10.1074/jbc.M209037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12372823	hybrid			2022-12-25	WOS:000180177700054
J	Le Du, MH; Millan, JL				Le Du, MH; Millan, JL			Structural evidence of functional divergence in human alkaline phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCELLULAR CARCINOMA; UNCOMPETITIVE INHIBITION; MONOCLONAL-ANTIBODIES; PROTEIN INTERFACES; TESTICULAR-TUMORS; HOT-SPOTS; EXPRESSION; BINDING; TISSUE; CANCER	The evolution of the alkaline phosphatase (AP) gene family has lead to the existence in humans of one tissue-nonspecific (TNAP) and three tissue-specific isozymes, i.e. intestinal (UP), germ cell (GCAP), and placental AP (PLAP). To define the structural differences between these isozymes, we have built models of the TNAP, UP, and GCAP molecules based on the 1.8-Angstrom structure of PLAP (1) and have performed a comparative structural analysis. We have examined the monomer-monomer interface as this area is crucial for protein stability and enzymatic activity. We found that the interface a lows the formation of heterodimers among UP, GCAP, and PLAP but not between TNAP with any of the three tissue-specific isozymes. Secondly, the active site cleft was mapped into three regions, i.e. the active site itself, the roof of the cleft, and the floor of the cleft. This analysis led to a structural fingerprint of the active site of each AP isozyme that suggests a diversification in substrate specificity for this isozyme family.	Ctr Etud Saclay, Dept Ingn & Etud Prot, F-91191 Gif Sur Yvette, France; Burnham Inst, La Jolla, CA 92037 USA	CEA; UDICE-French Research Universities; Universite Paris Saclay; Sanford Burnham Prebys Medical Discovery Institute	Le Du, MH (corresponding author), Ctr Etud Saclay, Dept Ingn & Etud Prot, Bat 152, F-91191 Gif Sur Yvette, France.	mhledu@cea.fr	Millan, Jose Luis/B-6580-2008		NATIONAL CANCER INSTITUTE [R01CA042595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE012889] Funding Source: NIH RePORTER; NCI NIH HHS [CA 42595] Funding Source: Medline; NIAMS NIH HHS [AR 47908] Funding Source: Medline; NIDCR NIH HHS [DE 12889] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BEHRENS CM, 1983, BIOCHEM J, V211, P553, DOI 10.1042/bj2110553; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; BOSSI M, 1993, J BIOL CHEM, V268, P25409; Dabare AANPM, 1999, UROL INT, V63, P168, DOI 10.1159/000030441; DEFTOS LJ, 1991, HORM METAB RES, V23, P559, DOI 10.1055/s-2007-1003752; DEMERS LM, 1995, CLIN CHEM, V41, P1489; FARLEY JR, 1991, METABOLISM, V40, P664, DOI 10.1016/0026-0495(91)90081-7; HARRIS H, 1990, CLIN CHIM ACTA, V186, P133, DOI 10.1016/0009-8981(90)90031-M; HENDRIX PG, 1990, CLIN CHEM, V36, P1793; HENTHORN PS, 1992, CLIN CHEM, V38, P2501; Hessle L, 2002, P NATL ACAD SCI USA, V99, P9445, DOI 10.1073/pnas.142063399; HIGASHINO K, 1972, CLIN CHIM ACTA, V40, P67, DOI 10.1016/0009-8981(72)90252-5; HIGASHINO K, 1977, CLIN CHEM, V23, P1615; HIGASHINO K, 1975, ANN INTERN MED, V83, P74, DOI 10.7326/0003-4819-83-1-74; HOYLAERTS MF, 1992, BIOCHEM J, V286, P23, DOI 10.1042/bj2860023; HOYLAERTS MF, 1992, CLIN CHEM, V38, P2493; Hoylaerts MF, 1997, J BIOL CHEM, V272, P22781, DOI 10.1074/jbc.272.36.22781; HOYLAERTS MF, 1991, EUR J BIOCHEM, V202, P605, DOI 10.1111/j.1432-1033.1991.tb16414.x; Hu ZJ, 2000, PROTEINS, V39, P331, DOI 10.1002/(SICI)1097-0134(20000601)39:4<331::AID-PROT60>3.0.CO;2-A; HUMMER C, 1991, BIOCHEM J, V274, P91, DOI 10.1042/bj2740091; IMANISHI H, 1990, CANCER RES, V50, P3408; JACOBY B, 1971, CLIN CHIM ACTA, V35, P473, DOI 10.1016/0009-8981(71)90223-3; JEPPSSON A, 1984, INT J CANCER, V34, P757, DOI 10.1002/ijc.2910340604; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KIM EE, 1991, J MOL BIOL, V218, P449, DOI 10.1016/0022-2836(91)90724-K; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kozlenkov A, 2002, J BIOL CHEM, V277, P22992, DOI 10.1074/jbc.M202298200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Le Du MH, 2001, J BIOL CHEM, V276, P9158, DOI 10.1074/jbc.M009250200; LOOSE JH, 1984, AM J CLIN PATHOL, V82, P173, DOI 10.1093/ajcp/82.2.173; MAKIYA R, 1992, BIOCHEM BIOPH RES CO, V182, P624, DOI 10.1016/0006-291X(92)91778-O; MAKIYA R, 1992, EUR J BIOCHEM, V205, P341, DOI 10.1111/j.1432-1033.1992.tb16785.x; Manes T, 1998, J BIOL CHEM, V273, P23353, DOI 10.1074/jbc.273.36.23353; McComb R.B., 1979, ALKALINE PHOSPHATASE, P986; MILLAN JL, 1995, CRIT REV CL LAB SCI, V32, P1, DOI 10.3109/10408369509084680; Mornet E, 2001, J BIOL CHEM, V276, P31171, DOI 10.1074/jbc.M102788200; NATHANSO.L, 1971, CANCER, V27, P1388, DOI 10.1002/1097-0142(197106)27:6<1388::AID-CNCR2820270619>3.0.CO;2-0; Roelofs H, 1999, J PATHOL, V189, P236; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Sanchez R, 2000, METH MOL B, V143, P97; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHWARTZ JH, 1961, P NATL ACAD SCI USA, V47, P1996, DOI 10.1073/pnas.47.12.1996; She QB, 2000, FEBS LETT, V469, P163, DOI 10.1016/S0014-5793(00)01273-4; Smans KA, 1999, INT J CANCER, V83, P270, DOI 10.1002/(SICI)1097-0215(19991008)83:2<270::AID-IJC20>3.3.CO;2-9; Stefaner I, 1997, BIOCHEM J, V327, P585, DOI 10.1042/bj3270585; STINSON RA, 1987, ADV PROTEIN PHOSPHAT, V4, P127; TELFER JF, 1993, FEBS LETT, V329, P238, DOI 10.1016/0014-5793(93)80229-N; TSONIS PA, 1988, BIOCHEM J, V254, P623, DOI 10.1042/bj2540623; WAHREN B, 1979, INT J CANCER, V24, P749, DOI 10.1002/ijc.2910240608; WATANABE S, 1989, J BIOL CHEM, V264, P12611; WATANABE T, 1991, J BIOL CHEM, V266, P21174; WU LNY, 1991, J BIOL CHEM, V266, P1195; Zurutuza L, 1999, HUM MOL GENET, V8, P1039, DOI 10.1093/hmg/8.6.1039	55	97	107	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49808	49814		10.1074/jbc.M207394200	http://dx.doi.org/10.1074/jbc.M207394200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12372831	hybrid			2022-12-25	WOS:000180028900094
J	Chintala, SK; Zhang, X; Austin, JS; Fini, ME				Chintala, SK; Zhang, X; Austin, JS; Fini, ME			Deficiency in matrix metalloproteinase gelatinase B (MMP-9) protects against retinal ganglion cell death after optic nerve ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRESSURE-INDUCED ISCHEMIA; EXCITATORY AMINO-ACIDS; NEURONAL DEGENERATION; GENE KNOCKOUT; BRAIN; EXPRESSION; ADULT; LAMININ; MATRIX-METALLOPROTEINASE-9; APOPTOSIS	Loss of retinal ganglion cells is the final end point in blinding diseases of the optic nerve such as glaucoma. To enable the use of mouse genetics to investigate mechanisms underlying ganglion cell loss, we adapted an experimental model of optic nerve ligation to the mouse and further characterized post-surgical outcome. We made the novel finding that apoptosis of retinal ganglion cells correlates with specific degradation of laminin from the underlying inner limiting membrane and an increase in gelatinolytic metalloproteinase activity. These changes co-localize with a specific increase in levels of the matrix metalloproteinase, gelatinase B (GelB; MMP-9). Using a transgenic mouse line harboring a reporter gene driven by the GelB promoter, we further show that increased GelB is controlled by activation of the GelB promoter. These findings led us to hypothesize that GelB activity plays a role in ganglion cell death and degradation of laminin. Applying the genetic approach, we demonstrate that GelB-deficient mice are protected against these pathological changes. This is the first report demonstrating a causal connection between GelB activity and pathological changes to the inner retina after optic nerve ligation.	Oakland Univ, Eye Res Inst, Rochester, MI 48309 USA; Univ Miami, Sch Med, Bascom Palmer Eye Inst, Miami, FL 33101 USA; Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA; Tufts Ctr Vis Res, Boston, MA 02111 USA	Oakland University; Bascom Palmer Eye Institute; University of Miami; Tufts University	Chintala, SK (corresponding author), Oakland Univ, Eye Res Inst, 409 Dodge Hall, Rochester, MI 48309 USA.	Chintala@oakland.edu			NEI NIH HHS [EY13643, EY13078, R01 EY013643, R01 EY013643-02, EY12651] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013643, R01EY012651, P30EY013078] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Asahi M, 2000, J CEREBR BLOOD F MET, V20, P1681, DOI 10.1097/00004647-200012000-00007; Asahi M, 2001, NEUROREPORT, V12, P3003, DOI 10.1097/00001756-200109170-00050; BARNETT NL, 1995, BRAIN RES, V677, P337, DOI 10.1016/0006-8993(95)00193-T; BERKELAAR M, 1994, J NEUROSCI, V14, P4368, DOI 10.1523/jneurosci.14-07-04368.1994; BIRKEDALHANSEN H, 1982, BIOCHEM BIOPH RES CO, V107, P1173, DOI 10.1016/S0006-291X(82)80120-4; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BLOCK F, 1992, NEUROSCI LETT, V144, P124, DOI 10.1016/0304-3940(92)90731-L; BUCHI ER, 1992, JPN J OPHTHALMOL, V36, P62; CANETESOLER R, 1995, DEV BRAIN RES, V88, P37; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Clark AW, 1997, NEUROSCI LETT, V238, P53, DOI 10.1016/S0304-3940(97)00859-8; COHEN J, 1987, DEV BIOL, V122, P407, DOI 10.1016/0012-1606(87)90305-8; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; COYLE JT, 1978, J COMP NEUROL, V180, P301, DOI 10.1002/cne.901800208; DONG LJ, 1991, DIFFERENTIATION, V48, P157, DOI 10.1111/j.1432-0436.1991.tb00254.x; EPSTEIN DL, 1987, ARCH OPHTHALMOL-CHIC, V105, P1187, DOI 10.1001/archopht.1987.01060090045023; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; GARCIAVALENZUELA E, 1995, EXP EYE RES, V61, P33, DOI 10.1016/S0014-4835(95)80056-5; Giannelli G, 1997, SCIENCE, V277, P225, DOI 10.1126/science.277.5323.225; Grant G A, 1992, Matrix Suppl, V1, P217; Grossmann J, 2002, APOPTOSIS, V7, P247, DOI 10.1023/A:1015312119693; Halfter W, 2000, DEV BIOL, V220, P111, DOI 10.1006/dbio.2000.9649; HAYREH SS, 1980, BRIT J OPHTHALMOL, V64, P896, DOI 10.1136/bjo.64.12.896; Heo JH, 1999, J CEREBR BLOOD F MET, V19, P624, DOI 10.1097/00004647-199906000-00005; HUGHES WF, 1991, EXP EYE RES, V53, P573, DOI 10.1016/0014-4835(91)90215-Z; Johnson EC, 2000, INVEST OPHTH VIS SCI, V41, P431; Lafuente MP, 2001, INVEST OPHTH VIS SCI, V42, P2074; Li Y, 1999, INVEST OPHTH VIS SCI, V40, P1004; Libby RT, 1997, J COMP NEUROL, V389, P655, DOI 10.1002/(SICI)1096-9861(19971229)389:4<655::AID-CNE8>3.0.CO;2-#; LIESI P, 1989, EXP NEUROL, V105, P86, DOI 10.1016/0014-4886(89)90175-1; Lijnen HR, 1998, ARTERIOSCL THROM VAS, V18, P1035, DOI 10.1161/01.ATV.18.7.1035; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lochter A, 1997, J CELL BIOL, V139, P1861, DOI 10.1083/jcb.139.7.1861; MATSUBARA M, 1991, DEV BIOL, V147, P425, DOI 10.1016/0012-1606(91)90300-R; MEREDITH JE, 1993, MOL BIOL CELL, V4, P953, DOI 10.1091/mbc.4.9.953; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Mohan R, 1998, J BIOL CHEM, V273, P25903, DOI 10.1074/jbc.273.40.25903; Mohan R, 2002, J BIOL CHEM, V277, P2065, DOI 10.1074/jbc.M107611200; MOSINGER JL, 1989, EXP NEUROL, V105, P110, DOI 10.1016/0014-4886(89)90178-7; Murphy G, 1992, Matrix Suppl, V1, P224; NAGASE H, 1994, J BIOL CHEM, V269, P20952; Nickells RW, 1996, OPHTHALMIC GENET, V17, P145, DOI 10.3109/13816819609057889; Nickells RW, 1999, SURV OPHTHALMOL, V43, pS151, DOI 10.1016/S0039-6257(99)00029-6; Oh LYS, 1999, J NEUROSCI, V19, P8464; OSBORNE NN, 1994, NEUROSCIENCE, V59, P1071, DOI 10.1016/0306-4522(94)90306-9; OSBORNE NN, 1995, INVEST OPHTH VIS SCI, V36, P1692; Osborne NN, 1999, SURV OPHTHALMOL, V43, pS102, DOI 10.1016/S0039-6257(99)00044-2; Otori Y, 1997, SURV OPHTHALMOL, V42, pS96, DOI 10.1016/S0039-6257(97)80032-X; Planas AM, 2001, NEUROBIOL DIS, V8, P834, DOI 10.1006/nbdi.2001.0435; QUIGLEY HA, 1995, AUST NZ J OPHTHALMOL, V23, P85, DOI 10.1111/j.1442-9071.1995.tb00135.x; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; Romanic AM, 1998, STROKE, V29, P1020, DOI 10.1161/01.STR.29.5.1020; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Rosenberg GA, 1996, NEUROLOGY, V46, P1626, DOI 10.1212/WNL.46.6.1626; Rosenberg GA, 1998, STROKE, V29, P2189, DOI 10.1161/01.STR.29.10.2189; SARTHY PV, 1990, J CELL BIOL, V110, P2099, DOI 10.1083/jcb.110.6.2099; Sawada A, 1999, EXP EYE RES, V69, P525, DOI 10.1006/exer.1999.0732; SellesNavarro I, 1996, INVEST OPHTH VIS SCI, V37, P2002; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666; Sivak JM, 2000, DEV BIOL, V222, P41, DOI 10.1006/dbio.2000.9694; STEFANSSON E, 1988, INVEST OPHTH VIS SCI, V29, P1050; Strickland S, 1996, COLD SPRING HARB SYM, V61, P739; TSIRKA SE, 1995, NATURE, V377, P340, DOI 10.1038/377340a0; Tsirka SE, 1996, NATURE, V384, P123, DOI 10.1038/384123b0; Tsirka SE, 1997, J NEUROSCI, V17, P543; Vu TH, 2000, GENE DEV, V14, P2123, DOI 10.1101/gad.815400; Vu TH, 1998, CELL, V93, P411, DOI 10.1016/S0092-8674(00)81169-1; Wang XY, 2000, J NEUROSCI, V20, P7037, DOI 10.1523/JNEUROSCI.20-18-07037.2000; Woessner JF, 1998, BIOL EXTRAC, P1; YAMAMOTO T, 1988, J NEUROL SCI, V84, P1, DOI 10.1016/0022-510X(88)90169-4; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yong VW, 1998, TRENDS NEUROSCI, V21, P75; YOUNG RW, 1984, J COMP NEUROL, V229, P362, DOI 10.1002/cne.902290307; Yu Q, 2000, GENE DEV, V14, P163	74	117	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47461	47468		10.1074/jbc.M204824200	http://dx.doi.org/10.1074/jbc.M204824200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354772	hybrid			2022-12-25	WOS:000179663700082
J	Fan, B; Rosen, BP				Fan, B; Rosen, BP			Biochemical characterization of CopA, the Escherichia coli Cu(I)-translocating P-type ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COPPER-TRANSPORTING ATPASE; N-TERMINAL DOMAIN; WILSON-DISEASE; HELICOBACTER-PYLORI; ENTEROCOCCUS-HIRAE; MEMBRANE TOPOLOGY; BINDING DOMAIN; MENKES DISEASE; PURIFICATION; GENE	Escherichia coli CopA is a copper ion-translocating P-type ATPase that confers copper resistance. CopA formed a phosphorylated intermediate with [gamma(-32)P]ATP. Phosphorylation was inhibited by vanadate and sensitive to KOH and hydroxylamine, consistent with acylphosphate formation on conserved Asp-523. Phosphorylation required a monovalent cation, either Cu(I) or Ag(I). Divalent cations Cu(II), Zn(II), or Co(II) could not substitute, signifying that the substrate of this copper-translocating P-type ATPase is Cu(I) and not Cu(II). CopA purified from dodecylmaltoside-solubilized membranes similarly exhibited Cu(I)/Ag(I)-stimulated ATPase activity, with a K-m for ATP of 0.5 mM. CopA has two N-terminal Cys(X)(2)Cys sequences, Gly-Leu-Ser-Cys(14)-Gly-His-Cys(17), and Gly-Met-Ser-Cys(110)-Ala-Ser-Cys(113), and a Cys(479)-Pro-Cys(481) motif in membrane-spanning segment six. The requirement of these cysteine residues was investigated by the effect of mutations and deletions. Mutants with substitutions of the N-terminal cysteines or deletion of the first Cys-(X)(2)-Cys motif formed acylphosphate intermediates. From the copper dependence of phosphoenzyme formation, the mutants appear to have 2-3 fold higher affinity for Cu(I) than wild type CopA. In contrast, substitutions in Cys(479) or Cys(481) resulted in loss of copper resistance, transport and phosphoenzyme formation. These results imply that the cysteine residues of the Cys-Pro-Cys motif (but not the N-terminal cysteine residues) are required for CopA function.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Rosen, BP (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	brosen@med.wayne.edu	Johnson, Michael D. L./B-4352-2012	Rosen, Barry P./0000-0002-5230-4271	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052216] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52216] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; BULL PC, 1993, NAT GENET, V5, P327, DOI 10.1038/ng1293-327; Camakaris J, 1999, BIOCHEM BIOPH RES CO, V261, P225, DOI 10.1006/bbrc.1999.1073; DEY S, 1994, ARCH BIOCHEM BIOPHYS, V311, P418, DOI 10.1006/abbi.1994.1256; DiDonato M, 1997, J BIOL CHEM, V272, P33279, DOI 10.1074/jbc.272.52.33279; DiDonato M, 2000, BIOCHEMISTRY-US, V39, P1890, DOI 10.1021/bi992222j; FAIRBANKS G, 1972, Journal of Supramolecular Structure, V1, P66, DOI 10.1002/jss.400010110; Fan B, 2001, BIOCHEM BIOPH RES CO, V286, P414, DOI 10.1006/bbrc.2001.5367; Forbes JR, 1999, J BIOL CHEM, V274, P12408, DOI 10.1074/jbc.274.18.12408; Gatti D, 2000, J BIOL CHEM, V275, P34009, DOI 10.1074/jbc.R000012200; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Gupta A, 1999, NAT MED, V5, P183, DOI 10.1038/5545; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; Lutsenko S, 1997, J BIOL CHEM, V272, P18939, DOI 10.1074/jbc.272.30.18939; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Melchers K, 1999, RES MICROBIOL, V150, P507, DOI 10.1016/S0923-2508(99)00106-0; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Petris MJ, 1996, EMBO J, V15, P6084, DOI 10.1002/j.1460-2075.1996.tb00997.x; Rensing C, 1997, P NATL ACAD SCI USA, V94, P14326, DOI 10.1073/pnas.94.26.14326; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; Strausak D, 1999, J BIOL CHEM, V274, P11170, DOI 10.1074/jbc.274.16.11170; Tsai KJ, 2002, J BIOENERG BIOMEMBR, V34, P147, DOI 10.1023/A:1016085301323; Tsivkovskii R, 2002, J BIOL CHEM, V277, P976, DOI 10.1074/jbc.M109368200; VOGEL G, 1976, BIOCHEMISTRY-US, V15, P208, DOI 10.1021/bi00646a032; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE C, 1993, NAT GENET, V3, P7, DOI 10.1038/ng0193-7; Wunderli-Ye H, 2001, BIOCHEM BIOPH RES CO, V280, P713, DOI 10.1006/bbrc.2000.4176	33	103	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46987	46992		10.1074/jbc.M208490200	http://dx.doi.org/10.1074/jbc.M208490200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351646	hybrid			2022-12-25	WOS:000179663700021
J	Hamelers, IHL; van Schaik, RFMA; Sipkema, J; Sussenbach, JS; Steenbergh, PH				Hamelers, IHL; van Schaik, RFMA; Sipkema, J; Sussenbach, JS; Steenbergh, PH			Insulin-like growth factor I triggers nuclear accumulation of cyclin D1 in MCF-7S breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C SUBSTRATE; PROTEIN-KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; IGF SYSTEM; PHOSPHORYLATION; ESTROGEN; TRANSFORMATION; EXPRESSION; PROGRESSION; INHIBITION	Stimulation of the breast cancer-derived MCF-7S cell line with insulin-like growth factor I (IGF-I; 20 ng/ml) leads to enhanced expression of cyclin D1, hyperphosphorylation of pRb, DNA synthesis, and cell division. 17beta-Estradiol (E-2; 10(-9) M) is not able to stimulate proliferation of MCF-7S cells, although addition of E-2 to Serum-starved cells does result in induction of cyclin D1. However, in combination with submitogenic amounts of IGF-I (2 ng/ml), E-2 induces cell proliferation. We have previously shown that the synergistic action of E-2 and IGF-I emanates from the ability of both hormones to induce cyclin D1 expression and that IGF-I action is required to induce activity of the cyclin D1-CDK4 complex, which triggers cell cycle progression. Here, we show that IGF-I (but not E-2) is able to induce nuclear accumulation of cyclin D1 by a phosphatidylinositol 3-kinase-dependent mechanism. Nuclear accumulation of cyclin D1 and cell cycle progression were also observed when LiCl, a known inhibitor of GSK3beta, was added to E-2-stimulated cells. Thus, inhibition of GSK3beta activity appears to trigger nuclear accumulation of cyclin D1 and cell cycle progression. This notion was confirmed by overexpression of constitutively active GSK3beta, which blocks IGF-I-induced nuclear accumulation of cyclin D1 as well as S phase transition.	Univ Utrecht, Med Ctr, Utrecht Grad Sch Dev Biol, Dept Physiol Chem, NL-3508 TA Utrecht, Netherlands	Utrecht University	Steenbergh, PH (corresponding author), Univ Utrecht, Med Ctr, Utrecht Grad Sch Dev Biol, Dept Physiol Chem, POB 85060, NL-3508 TA Utrecht, Netherlands.		van Schaik, Ron H.N./G-6816-2013					Alt JR, 2002, J BIOL CHEM, V277, P8517, DOI 10.1074/jbc.M108867200; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; ARTEAGA CL, 1992, BREAST CANCER RES TR, V22, P101, DOI 10.1007/BF01833338; BASERGA R, 1994, CELL PROLIFERAT, V27, P63, DOI 10.1111/j.1365-2184.1994.tb01406.x; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; ConnellCrowley L, 1997, MOL BIOL CELL, V8, P287, DOI 10.1091/mbc.8.2.287; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dufourny B, 2000, J ENDOCRINOL, V166, P329, DOI 10.1677/joe.0.1660329; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Hamelers IHL, 2002, EXP CELL RES, V273, P107, DOI 10.1006/excr.2001.5430; Katzenellenbogen BS, 1996, BIOL REPROD, V54, P287, DOI 10.1095/biolreprod54.2.287; Kitagawa M, 1996, EMBO J, V15, P7060, DOI 10.1002/j.1460-2075.1996.tb01097.x; Lamphere L, 1997, ONCOGENE, V14, P1999, DOI 10.1038/sj.onc.1201036; Lee AV, 1998, BREAST CANCER RES TR, V47, P295, DOI 10.1023/A:1005915420341; Lee AV, 1995, BIOMED PHARMACOTHER, V49, P415, DOI 10.1016/0753-3322(96)82678-3; Lin XY, 2000, MOL CELL BIOL, V20, P7259, DOI 10.1128/MCB.20.19.7259-7272.2000; Lin XY, 2002, BIOCHEM BIOPH RES CO, V290, P1368, DOI 10.1006/bbrc.2002.6357; Nelson PJ, 1997, MOL CELL BIOCHEM, V175, P233, DOI 10.1023/A:1006836003758; Nicholson RI, 1996, ANN NY ACAD SCI, V784, P325, DOI 10.1111/j.1749-6632.1996.tb16247.x; Prall OWJ, 1998, J STEROID BIOCHEM, V65, P169, DOI 10.1016/S0960-0760(98)00021-1; Reshetnikova G, 2000, EXP CELL RES, V259, P35, DOI 10.1006/excr.2000.4966; Ryves WJ, 2002, BIOCHEM BIOPH RES CO, V290, P967, DOI 10.1006/bbrc.2001.6305; Stepanova L, 2000, MOL CELL BIOL, V20, P4462, DOI 10.1128/MCB.20.12.4462-4473.2000; Taules M, 1998, J BIOL CHEM, V273, P33279, DOI 10.1074/jbc.273.50.33279; Thomas RC, 1996, EXP CELL RES, V223, P227, DOI 10.1006/excr.1996.0076; VANDERBURG B, 1988, J CELL PHYSIOL, V134, P101, DOI 10.1002/jcp.1041340112; Vyas DR, 2002, AM J PHYSIOL-CELL PH, V283, pC545, DOI 10.1152/ajpcell.00049.2002	28	42	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47645	47652		10.1074/jbc.M208727200	http://dx.doi.org/10.1074/jbc.M208727200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12364325	hybrid			2022-12-25	WOS:000179663700105
J	Koprivnjak, T; Peschel, A; Gelb, MH; Liang, NS; Weiss, JP				Koprivnjak, T; Peschel, A; Gelb, MH; Liang, NS; Weiss, JP			Role of charge properties of bacterial envelope in bactericidal action of human group IIA phospholipase A(2) against Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANYL-LIPOTEICHOIC ACID; MAJOR PHYSIOLOGICAL-ROLE; WALL TEICHOIC-ACID; D-ALANINE; ESCHERICHIA-COLI; ANTIBACTERIAL PROPERTIES; INTERFACIAL ENZYMOLOGY; INFLAMMATORY FLUID; BACILLUS-SUBTILIS; HUMAN DEFENSINS	Mammalian Group IIA phospholipases A(2) (PLA(2)) potently kill Staphylococcus aureus. Highly cationic properties of these PLA(2) are important for Ca2+-independent binding and cell wall penetration, prerequisites for Ca2+- dependent degradation of membrane phospholipids and bacterial killing. To further delineate charge properties of the bacterial envelope important in Group IIA PLA(2) action against S. aureus, we examined the effects of mutations that prevent specific modifications of cell wall (dltA) and cell membrane (mprF) polyanions. In comparison to the parent strain, isogenic dltA(-) bacteria are similar to30-100x more sensitive to PLA(2), whereas mprF(-) bacteria are <3-fold more sensitive. Differences in PLA(2) sensitivity of intact bacteria reflect differences in cell wall, not cell membrane, properties since protoplasts from all three strains are equally sensitive to PLA(2). A diminished positive charge in PLA(2) reduces PLA(2) binding and antibacterial activity. In contrast, diminished cell wall negative charge by substitution of (lipo)teichoic acids with D-alanine reduces antibacterial activity of bound PLA(2), but not initial PLA(2) binding. Therefore, the potent antistaphylococcal activity of Group IIA PLA(2) depends on cationic properties of the enzyme that promote binding to the cell wall, and polyanionic properties of cell wall (lipo)teichoic acids that promote attack of membrane phospholipids by bound PLA(2).	Univ Iowa, Iowa City Vet Affairs Med Ctr, Dept Internal Med, Iowa City, IA 52246 USA; Univ Iowa, Iowa City Vet Affairs Med Ctr, Dept Microbiol, Iowa City, IA 52246 USA; Univ Iowa, Iowa City Vet Affairs Med Ctr, Inflammat Program, Iowa City, IA 52246 USA; Univ Tubingen, D-72076 Tubingen, Germany; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Guangxi Canc Hosp Inst, Dept Pharm, Nanning, Guangxi, Peoples R China	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System; Eberhard Karls University of Tubingen; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Weiss, JP (corresponding author), Univ Iowa, Iowa City Vet Affairs Med Ctr, Dept Internal Med, 200 Hawkins Dr, Iowa City, IA 52246 USA.	jerrold-weiss@uiowa.edu	Koprivnjak, Tomaz/A-9663-2009	gelb, michael/0000-0001-7000-5219; Weiss, Jerrold/0000-0003-1476-4485	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R23HL036235, R37HL036235, R01HL036235] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI018571] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL36235] Funding Source: Medline; NIAID NIH HHS [AI-18571] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abachin E, 2002, MOL MICROBIOL, V43, P1, DOI 10.1046/j.1365-2958.2002.02723.x; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boyd DA, 2000, J BACTERIOL, V182, P6055, DOI 10.1128/JB.182.21.6055-6065.2000; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1488, P71, DOI 10.1016/S1388-1981(00)00111-6; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1484, P195, DOI 10.1016/S1388-1981(00)00018-4; Clemans DL, 1999, INFECT IMMUN, V67, P2464, DOI 10.1128/IAI.67.5.2464-2474.1999; Dunman PM, 2001, J BACTERIOL, V183, P7341, DOI 10.1128/JB.183.24.7341-7353.2001; FISCHER W, 1994, MED MICROBIOL IMMUN, V183, P61, DOI 10.1007/BF00277157; Foreman-Wykert AK, 1999, J CLIN INVEST, V103, P715, DOI 10.1172/JCI5468; Foreman-Wykert AK, 2000, INFECT IMMUN, V68, P1259, DOI 10.1128/IAI.68.3.1259-1264.2000; FORST S, 1987, BIOCHIM BIOPHYS ACTA, V920, P221, DOI 10.1016/0005-2760(87)90098-1; Ganz T, 2001, J EXP MED, V193, pF31, DOI 10.1084/jem.193.9.F31; Gelb MH, 2000, BBA-MOL CELL BIOL L, V1488, P20, DOI 10.1016/S1388-1981(00)00106-2; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; Gross M, 2001, INFECT IMMUN, V69, P3423, DOI 10.1128/IAI.69.5.3423-3426.2001; HEPTINSTALL S, 1970, NATURE, V225, P519, DOI 10.1038/225519a0; Hyyrylainen HL, 2000, J BIOL CHEM, V275, P26696; INADA M, 1991, EUR J BIOCHEM, V197, P323, DOI 10.1111/j.1432-1033.1991.tb15914.x; IORDANESCU S, 1976, J GEN MICROBIOL, V96, P277, DOI 10.1099/00221287-96-2-277; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Laine VJO, 1999, J IMMUNOL, V162, P7402; Laine VJO, 2000, INFECT IMMUN, V68, P87, DOI 10.1128/IAI.68.1.87-92.2000; Matsuzaki K, 1999, BBA-BIOMEMBRANES, V1462, P1, DOI 10.1016/S0005-2736(99)00197-2; NEVALAINEN TJ, 1994, INVEST OPHTH VIS SCI, V35, P417; PEREGO M, 1995, J BIOL CHEM, V270, P15598, DOI 10.1074/jbc.270.26.15598; Peschel A, 2000, ANTIMICROB AGENTS CH, V44, P2845, DOI 10.1128/AAC.44.10.2845-2847.2000; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; Peschel A, 1999, J BIOL CHEM, V274, P8405, DOI 10.1074/jbc.274.13.8405; Peschel A, 2001, J EXP MED, V193, P1067, DOI 10.1084/jem.193.9.1067; Poyart C, 2001, J BACTERIOL, V183, P6324, DOI 10.1128/JB.183.21.6324-6334.2001; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; ROSE RK, 1995, BBA-GEN SUBJECTS, V1245, P94; SELSTED ME, 1985, INFECT IMMUN, V49, P202, DOI 10.1128/IAI.49.1.202-206.1985; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; TAKAYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P1505, DOI 10.1016/0006-291X(91)91064-J; Wecke J, 1997, MICROBIOL-UK, V143, P2953, DOI 10.1099/00221287-143-9-2953; Wecke J, 1996, MICROB DRUG RESIST, V2, P123, DOI 10.1089/mdr.1996.2.123; Weinrauch Y, 1996, J CLIN INVEST, V97, P250, DOI 10.1172/JCI118399; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; Weiss J, 2000, GRAM-POSITIVE PATHOGENS, P431; WEISS J, 1994, J BIOL CHEM, V269, P26331; WIMLEY WC, 1994, PROTEIN SCI, V3, P1362, DOI 10.1002/pro.5560030902; Yang L, 2000, BIOPHYS J, V79, P2002, DOI 10.1016/S0006-3495(00)76448-4; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a	50	106	113	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47636	47644		10.1074/jbc.M205104200	http://dx.doi.org/10.1074/jbc.M205104200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359734	Green Submitted, hybrid			2022-12-25	WOS:000179663700104
J	Tuckey, RC; Headlam, MJ; Bose, HS; Miller, WL				Tuckey, RC; Headlam, MJ; Bose, HS; Miller, WL			Transfer of cholesterol between phospholipid vesicles mediated by the steroidogenic acute regulatory protein (StAR)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPOID ADRENAL-HYPERPLASIA; CHAIN CLEAVAGE ENZYME; BOVINE CORPUS-LUTEUM; MOLTEN-GLOBULE; UNILAMELLAR VESICLES; CYTOCHROME P-450SCC; MECHANISM; BINDING; EXCHANGE; CELLS	The steroidogenic acute regulatory protein (StAR) mediates the acute stimulation of steroid synthesis by tropic hormones in steroidogenic cells. StAR interacts with the outer mitochondrial membrane and facilitates the rate-limiting transfer of cholesterol to the inner mitochondrial membrane where cytochrome P-450scc converts this cholesterol into pregnenolone. We tested the ability of N-62 StAR to transfer cholesterol from donor vesicles containing cholesterol but no cytochrome P-450scc to acceptor vesicles containing P-450scc but no cholesterol, using P-450scc activity as a reporter of the cholesterol content of synthetic phospholipid vesicles. N-62 StAR stimulated P-450scc activity in acceptor vesicles 5-10-fold following the addition of donor vesicles. Transfer of cholesterol to acceptor vesicles was rapid and sufficient to maintain a linear rate of pregnenolone synthesis for 10 min. The effect of N-62 StAR in stimulating P-450scc activity was specific for cholesterol transfer and was not due to vesicle fusion or P-450scc exchange between vesicles. Maximum stimulation of P-450scc activity in acceptor vesicles required preincubation of N-62 StAR with phospholipid vesicles prior to adding donor vesicles. The amount of N-62 StAR causing half-maximum stimulation of P-450scc activity in acceptor vesicles was 1.9 muM. Half-maximum stimulation required more than a 10-fold higher concentration of R182L N-62 StAR, a mutant associated with congenital lipoid adrenal hyperplasia. N-62 StAR-mediated transfer of cholesterol between vesicles showed low dependence on the cholesterol concentration in the donor vesicles. Thus StAR can transfer cholesterol between synthetic membranes without other protein components found in mitochondria.	Univ Western Australia, Dept Biochem, Crawley, WA 6009, Australia; Univ Calif San Francisco, Metab Res Unit, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA	University of Western Australia; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Tuckey, RC (corresponding author), Univ Western Australia, Dept Biochem, 35 Stirling Highway, Crawley, WA 6009, Australia.		Tuckey, Robert/H-5983-2014; Miller, Walter L/J-3696-2012; Headlam, Madeleine/H-7199-2016	Headlam, Madeleine/0000-0001-6812-2459; Tuckey, Robert/0000-0002-5022-4729	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002762, R01DK037922] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK02762, DK37922] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arakane F, 1997, J BIOL CHEM, V272, P32656, DOI 10.1074/jbc.272.51.32656; Arakane F, 1996, P NATL ACAD SCI USA, V93, P13731, DOI 10.1073/pnas.93.24.13731; Arakane F, 1998, J BIOL CHEM, V273, P16339, DOI 10.1074/jbc.273.26.16339; Artemenko IP, 2001, J BIOL CHEM, V276, P46583, DOI 10.1074/jbc.M107815200; BAR LK, 1987, BIOCHEMISTRY-US, V26, P5460, DOI 10.1021/bi00391a037; Bose HS, 2000, BIOCHEMISTRY-US, V39, P11722, DOI 10.1021/bi000911l; Bose HS, 1998, BIOCHEMISTRY-US, V37, P9768, DOI 10.1021/bi980588a; Bose HS, 1999, P NATL ACAD SCI USA, V96, P7250, DOI 10.1073/pnas.96.13.7250; Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a; Bose HS, 1996, NEW ENGL J MED, V335, P1870, DOI 10.1056/NEJM199612193352503; Caron KM, 1997, P NATL ACAD SCI USA, V94, P11540, DOI 10.1073/pnas.94.21.11540; Christensen K, 2001, J BIOL CHEM, V276, P17044, DOI 10.1074/jbc.M100903200; DHARIWAL MS, 1991, BIOCHEMISTRY-US, V30, P4940, DOI 10.1021/bi00234a015; EPSTEIN LF, 1991, J BIOL CHEM, V266, P19739; Hasegawa T, 2000, MOL ENDOCRINOL, V14, P1462, DOI 10.1210/me.14.9.1462; Huang MC, 2001, ENDOCRINOLOGY, V142, P2569, DOI 10.1210/en.142.6.2569; Kallen CB, 1998, J BIOL CHEM, V273, P26285, DOI 10.1074/jbc.273.41.26285; Kisselev P, 1998, J BIOL CHEM, V273, P1380, DOI 10.1074/jbc.273.3.1380; LAMBETH JD, 1982, J BIOL CHEM, V257, P1876; LIN D, 1995, SCIENCE, V267, P1828, DOI 10.1126/science.7892608; MCLEAN LR, 1981, BIOCHEMISTRY-US, V20, P2893, DOI 10.1021/bi00513a028; Miller WL, 1999, J STEROID BIOCHEM, V69, P131, DOI 10.1016/S0960-0760(98)00153-8; OMURA T, 1964, J BIOL CHEM, V239, P2370; Petrescu AD, 2001, J BIOL CHEM, V276, P36970, DOI 10.1074/jbc.M101939200; Roderick SL, 2002, NAT STRUCT BIOL, V9, P507, DOI 10.1038/nsb812; Romanowski MJ, 2002, P NATL ACAD SCI USA, V99, P6949, DOI 10.1073/pnas.052140699; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Song MS, 2001, BIOCHEM J, V356, P151, DOI 10.1042/0264-6021:3560151; Stocco DM, 1996, ENDOCR REV, V17, P221, DOI 10.1210/er.17.3.221; STOCCO DM, 1991, J BIOL CHEM, V266, P19731; Tsujishita Y, 2000, NAT STRUCT BIOL, V7, P408; TUCKEY RC, 1993, EUR J BIOCHEM, V217, P209, DOI 10.1111/j.1432-1033.1993.tb18235.x; TUCKEY RC, 1985, EUR J BIOCHEM, V148, P379, DOI 10.1111/j.1432-1033.1985.tb08849.x; TUCKEY RC, 1982, J BIOL CHEM, V257, P2887; TUCKEY RC, 1984, INT J BIOCHEM, V16, P489, DOI 10.1016/0020-711X(84)90165-4; TUCKEY RC, 1984, INT J BIOCHEM, V16, P497, DOI 10.1016/0020-711X(84)90166-6; Wang XJ, 1998, ENDOCRINOLOGY, V139, P3903, DOI 10.1210/en.139.9.3903; Watari H, 1997, P NATL ACAD SCI USA, V94, P8462, DOI 10.1073/pnas.94.16.8462; Woods ST, 1998, ARCH BIOCHEM BIOPHYS, V353, P109, DOI 10.1006/abbi.1998.0621	39	47	51	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47123	47128		10.1074/jbc.M206965200	http://dx.doi.org/10.1074/jbc.M206965200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12372832	hybrid			2022-12-25	WOS:000179663700038
J	Whittaker, J; Sorensen, H; Gadsboll, VL; Hinrichsen, J				Whittaker, J; Sorensen, H; Gadsboll, VL; Hinrichsen, J			Comparison of the functional insulin binding epitopes of the A and B isoforms of the insulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; GROWTH-FACTOR RECEPTOR; LIGAND-BINDING; ALPHA-SUBUNIT; STRUCTURAL BASIS; TYROSINE KINASE; CELLS; DOMAIN; SITE; IDENTIFICATION	The human insulin receptor is expressed as two isoforms that are generated by alternate splicing of its mRNA, the B isoform has 12 additional amino acids (718-729) encoded by exon 11 of the gene. The isoforms have been reported to have different ligand binding properties. To further characterize their insulin binding properties, we have performed structure-directed alanine-scanning mutagenesis of a major insulin binding site of the receptor, formed from the receptor L1 domain (amino acids 1-470) and amino acids 705-715 at the C terminus of the a subunit. Alanine mutants of each isoform were transiently expressed as recombinant secreted extracellular domain in 293 cells, and their insulin binding properties were evaluated by competitive binding assays. Mutation of Arg(86) and Phe(96) of each isoform resulted in receptors that were not secreted. The Kds of unmutated receptors were almost identical for both isoforms. Several new mutations compromising insulin binding were identified. In L1, mutation of Leu(37) decreased affinity 20- to 40-fold and mutations of Val(94), Glu(97), Glu(120), and Lys(121) 3 to 10-fold for each isoform. A number of mutations produced differential effects on the two isoforms. Mutation of Asn(15) in the L1 domain and Phe(714) at the C terminus of the a subunit inactivated the A isoform but only reduced the affinity of the B isoform 40- to 60-fold. At the C terminus of the a subunit, mutations of Asp(707), Val(713), and Val(715) produced 7- to 16-fold reductions in affinity of the A isoform but were without effect on the B isoform. In contrast, alanine mutations of Tyr(708) and Asn(711) inactivated the B isoform but only reduced the affinities of the A isoform 11- and 6-fold, respectively. In conclusion, alanine-scanning mutagenesis of the insulin receptor A and B isoforms has identified several new side chains contributing to insulin binding and indicates that the energetic contributions of certain side chains differ in each isoform, suggesting that different molecular mechanisms are used to obtain the same affinity.	Hagedorn Res Inst, Receptor Biol Lab, DK-2820 Gentofte, Denmark	Novo Nordisk; Hagedorn Research Institute	Whittaker, J (corresponding author), Case Western Reserve Univ, Dept Nutr, Dent Bldg,2123 Abington Rd,Rm 201, Cleveland, OH 44106 USA.							BRISSENDEN JE, 1984, NATURE, V310, P781, DOI 10.1038/310781a0; DELSAL G, 1989, BIOTECHNIQUES, V7, P514; DEMEYTS P, 1994, DIABETOLOGIA, V37, pS135, DOI 10.1007/BF00400837; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GRONSKOV K, 1993, BIOCHEM BIOPH RES CO, V192, P905, DOI 10.1006/bbrc.1993.1501; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Harlow E., 1988, ANTIBODIES LAB MANUA; KELLERER M, 1992, BIOCHEMISTRY-US, V31, P4588, DOI 10.1021/bi00134a008; KOSAKI A, 1995, J BIOL CHEM, V270, P20816, DOI 10.1074/jbc.270.35.20816; Kristensen C, 1997, J BIOL CHEM, V272, P12978, DOI 10.1074/jbc.272.20.12978; Kristensen C, 2002, J BIOL CHEM, V277, P18340, DOI 10.1074/jbc.M112249200; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; Kristensen C, 1999, J BIOL CHEM, V274, P37351, DOI 10.1074/jbc.274.52.37351; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; KUROSE T, 1994, J BIOL CHEM, V269, P29190; Leibiger B, 2001, MOL CELL, V7, P559, DOI 10.1016/S1097-2765(01)00203-9; LONGO N, 1993, P NATL ACAD SCI USA, V90, P60, DOI 10.1073/pnas.90.1.60; Molina L, 2000, FEBS LETT, V467, P226, DOI 10.1016/S0014-5793(00)01161-3; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; Ottensmeyer FP, 2000, BIOCHEMISTRY-US, V39, P12103, DOI 10.1021/bi0015921; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; Sambrook J, 2001, MOL CLONING LAB MANU; Savkur RS, 2001, NAT GENET, V29, P40, DOI 10.1038/ng704; SCHAEFER EM, 1990, J BIOL CHEM, V265, P13248; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SEINO S, 1989, BIOCHEM BIOPH RES CO, V159, P312, DOI 10.1016/0006-291X(89)92439-X; SEINO S, 1989, P NATL ACAD SCI USA, V86, P114, DOI 10.1073/pnas.86.1.114; Sidhu SS, 2000, METHOD ENZYMOL, V328, P333, DOI 10.1016/S0076-6879(00)28406-1; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; Sundberg EJ, 2000, STRUCTURE, V8, pR137, DOI 10.1016/S0969-2126(00)00167-2; WARD CW, 1995, PROTEINS, V22, P141, DOI 10.1002/prot.340220207; WELLS JA, 1991, METHOD ENZYMOL, V202, P390; Whittaker J, 2001, J BIOL CHEM, V276, P43980, DOI 10.1074/jbc.M102863200; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YAMAGUCHI Y, 1991, ENDOCRINOLOGY, V129, P2058, DOI 10.1210/endo-129-4-2058; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132	40	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47380	47384		10.1074/jbc.M208371200	http://dx.doi.org/10.1074/jbc.M208371200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12270939	hybrid			2022-12-25	WOS:000179663700071
J	Al Mamun, AM; Marians, KJ; Humayun, MZ				Al Mamun, AM; Marians, KJ; Humayun, MZ			DNA polymerase III from Escherichia coli cells expressing mutA mistranslator tRNA is error-prone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA GENE; MISMATCH REPAIR; BETA-SUBUNIT; DINB GENE; POL-IV; TRANSLESION REPLICATION; RECOMBINATION FUNCTIONS; MUTATIONAL SPECIFICITY; UNTARGETED MUTAGENESIS; BASE SUBSTITUTION	Translational stress-induced mutagenesis (TSM) refers to the elevated mutagenesis observed in Escherichia coli cells in which mistranslation has been increased as a result of mutations in tRNA genes (such as mutA) or by exposure to streptomycin. TSM does not require lexA-regulated SOS functions but is suppressed in cells defective for homologous recombination genes. Crude cell-free extracts from TSM-induced E. coli strains express an error-prone DNA polymerase. To determine whether DNA polymerase III is involved in the TSM phenotype, we first asked if the phenotype is expressed in cells defective for all four of the non-replicative DNA polymerases, namely polymerase I, II, IV, and V. By using a colony papillation assay based on the reversion of a lacZ mutant, we show that the TSM phenotype is expressed in such cells. Second, we asked if pol III from TSM-induced cells is error-prone. By purifying DNA polymerase III* from TSM-induced and control cells, and by testing its fidelity on templates bearing 3N(4)-ethenocytosine (a mutagenic DNA lesion), as well as on undamaged DNA templates, we show here that polymerase III* purified from mutA cells is error-prone as compared with that from control cells. These findings suggest that DNA polymerase III is modified in TSM-induced cells.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, Newark, NJ 07101 USA; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Memorial Sloan Kettering Cancer Center	Humayun, MZ (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Microbiol & Mol Genet, Int Ctr Publ Hlth, 225 Warren St, Newark, NJ 07101 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557, R01GM058253] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557, R37 GM034557, GM58253] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Al Mamun AAM, 2000, MOL MICROBIOL, V38, P368, DOI 10.1046/j.1365-2958.2000.02136.x; Al Mamun AAM, 1999, MOL MICROBIOL, V33, P732, DOI 10.1046/j.1365-2958.1999.01520.x; AlMamun AM, 1996, J BACTERIOL, V178, P3722, DOI 10.1128/jb.178.13.3722-3726.1996; Balashov S, 2002, J MOL BIOL, V315, P513, DOI 10.1006/jmbi.2001.5273; Becherel OJ, 2001, P NATL ACAD SCI USA, V98, P8566, DOI 10.1073/pnas.141113398; BONNER CA, 1990, P NATL ACAD SCI USA, V87, P7663, DOI 10.1073/pnas.87.19.7663; BROSIUS J, 1989, DNA-J MOLEC CELL BIO, V8, P759, DOI 10.1089/dna.1989.8.759; BROTCORNELANNOYE A, 1986, P NATL ACAD SCI USA, V83, P3904, DOI 10.1073/pnas.83.11.3904; CAMPBELL JL, 1974, J BACTERIOL, V119, P494, DOI 10.1128/JB.119.2.494-499.1974; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; CHEN H, 1990, DNA CELL BIOL, V9, P631, DOI 10.1089/dna.1990.9.631; COOPER DL, 1993, J BIOL CHEM, V268, P11823; Cull MG, 1995, METHOD ENZYMOL, V262, P22; CUPPLES CG, 1990, GENETICS, V125, P275; DELUCIA P, 1969, NATURE, V224, P1164, DOI 10.1038/2241164a0; Drake JW, 1998, GENETICS, V148, P1667; FAY PJ, 1982, J BIOL CHEM, V257, P5692; Fijalkowska IJ, 1997, J BACTERIOL, V179, P7435, DOI 10.1128/jb.179.23.7435-7445.1997; Friedberg E.C., 1995, DNA REPAIR MUTAGENES, P407; GEIDER K, 1974, J BIOL CHEM, V249, P3999; HILL CW, 1975, CELL, V6, P419, DOI 10.1016/0092-8674(75)90031-8; Humayun MZ, 1998, MOL MICROBIOL, V30, P905, DOI 10.1046/j.1365-2958.1998.01120.x; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim SR, 1997, P NATL ACAD SCI USA, V94, P13792, DOI 10.1073/pnas.94.25.13792; Kim SR, 2001, MOL GENET GENOMICS, V266, P207; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KORNBERG A, 1991, DNA REPLICATION, P165; KUNKEL TA, 1985, J BIOL CHEM, V260, P5787; LADUCA RJ, 1986, J BIOL CHEM, V261, P7550; LIVNEH Z, 1986, P NATL ACAD SCI USA, V83, P4599, DOI 10.1073/pnas.83.13.4599; MAKI H, 1988, J BIOL CHEM, V263, P6570; Maor-Shoshani A, 2000, P NATL ACAD SCI USA, V97, P565, DOI 10.1073/pnas.97.2.565; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MCHENRY C, 1977, J BIOL CHEM, V252, P6478; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; MICHAELS ML, 1990, P NATL ACAD SCI USA, V87, P9211, DOI 10.1073/pnas.87.23.9211; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; Mo JY, 1996, J BIOL CHEM, V271, P18947, DOI 10.1074/jbc.271.31.18947; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Murphy HS, 1997, J BACTERIOL, V179, P7507, DOI 10.1128/jb.179.23.7507-7514.1997; Napolitano R, 2000, EMBO J, V19, P6259, DOI 10.1093/emboj/19.22.6259; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; PALEJWALA VA, 1995, J BACTERIOL, V177, P6041, DOI 10.1128/jb.177.21.6041-6048.1995; PALEJWALA VA, 1994, J BIOL CHEM, V269, P27433; PALEJWALA VA, 1991, BIOCHEMISTRY-US, V30, P8736, DOI 10.1021/bi00100a004; Pham P, 2001, NATURE, V409, P366, DOI 10.1038/35053116; Pham P, 2001, P NATL ACAD SCI USA, V98, P8350, DOI 10.1073/pnas.111007198; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; Rahman MS, 1999, J BACTERIOL, V181, P1515, DOI 10.1128/JB.181.5.1515-1523.1999; Rahman MS, 1996, MOL MICROBIOL, V22, P747; Rangarajan S, 1999, P NATL ACAD SCI USA, V96, P9224, DOI 10.1073/pnas.96.16.9224; Ren L, 1999, MOL MICROBIOL, V32, P607, DOI 10.1046/j.1365-2958.1999.01378.x; Ren L, 2000, J BACTERIOL, V182, P1427, DOI 10.1128/JB.182.5.1427-1431.2000; Reuven NB, 1999, J BIOL CHEM, V274, P31763, DOI 10.1074/jbc.274.45.31763; SCHAAPER RM, 1985, GENE, V39, P181, DOI 10.1016/0378-1119(85)90312-9; SCHAAPER RM, 1986, J MOL BIOL, V189, P273, DOI 10.1016/0022-2836(86)90509-7; SCHAAPER RM, 1989, EMBO J, V8, P3511, DOI 10.1002/j.1460-2075.1989.tb08516.x; SCHEUERMANN R, 1983, P NATL ACAD SCI-BIOL, V80, P7085, DOI 10.1073/pnas.80.23.7085; SIMHA D, 1991, BIOCHEMISTRY-US, V30, P8727, DOI 10.1021/bi00100a003; SINGER M, 1989, MICROBIOL REV, V53, P1; Slupska MM, 1996, P NATL ACAD SCI USA, V93, P4380, DOI 10.1073/pnas.93.9.4380; Strauss BS, 2000, J BACTERIOL, V182, P6742, DOI 10.1128/JB.182.23.6742-6750.2000; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tomer G, 1999, BIOCHEMISTRY-US, V38, P5948, DOI 10.1021/bi982599+; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; WICKNER W, 1973, P NATL ACAD SCI USA, V70, P1764, DOI 10.1073/pnas.70.6.1764; WICKNER W, 1974, J BIOL CHEM, V249, P6244; WOODGATE R, 1992, MUTAT RES, V281, P221, DOI 10.1016/0165-7992(92)90012-7; Zhao JY, 2001, J BACTERIOL, V183, P1796, DOI 10.1128/JB.183.5.1796-1800.2001	73	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46319	46327		10.1074/jbc.M206856200	http://dx.doi.org/10.1074/jbc.M206856200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324458	hybrid			2022-12-25	WOS:000179529300082
J	Banerjee, A				Banerjee, A			Coordination of posttranslational modifications of bovine brain alpha-tubulin - Polyglycylation of Delta 2 tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-TUBULIN; MONOCLONAL-ANTIBODY; RAT-BRAIN; COLCHICINE BINDING; SINGLE-UNIT; C-TERMINUS; IN-VITRO; ISOTYPES; TYROSINE; EXPRESSION	Microtubules participate in a large number of intracellular events including cell division, intracellular transport and secretion, axonal transport, and maintenance of cell morphology. They are composed of tubulin, a heterodimeric protein, consisting of two similar polypeptides alpha and beta. In mammalian cells, both alpha- and beta-tubutin occur as seven to eight different genetic variants, which also undergo numerous posttranslational modifications that include tyrosination-detyrosination and deglutamylation, phosphorylation, acetylation, polyglutamylation, and polyglycylation. Tyrosination-detyrosination is one of the major posttranslational modifications in which the C-terminal tyrosine residue in a-tubulin is added or removed reversibly. Although this modification does not alter the assembly activity of tubulin in vitro, these two forms of tubulin have been found to be distributed differently in vivo and are also correlated with microtubule stability (Gunderson, G. G., Kalnoski, M. H., and Bulinski, J. C. (1984) Cell 38, 779789). Thus, the question arises as to whether these two forms of tubulin differ in any other modifications. In an effort to answer this question, the tyrosinated and the nontyrosinated forms of the alpha1/2 isoform have been purified from brain tubulin by immunoaffinity chromatography. matrix-assisted laser desorption/ionization-time of flight mass spectrometric analysis of the C-terminal peptide revealed that the tyrosinated form is polyglutamylated with one to four Glu residues, while the Delta2 tubulin is polyglycylated with one to three Gly residues. These results indicate that posttranslational modifications of tubulin are correlated with each other and that polyglutamylation and polyglycylation of tubulin may have important roles in regulating microtubule assembly, stability, and function in vivo.	Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Banerjee, A (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	asokb@worldnet.att.net			NCI NIH HHS [R29 CA 59711] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA059711] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDER JE, 1991, P NATL ACAD SCI USA, V88, P4685, DOI 10.1073/pnas.88.11.4685; ARGARANA CE, 1978, MOL CELL BIOCHEM, V19, P17; Avila J, 1990, MICROTUBULE PROTEINS, V1st; BANERJEE A, 1992, J BIOL CHEM, V267, P5625; Banerjee A, 1998, BIOCHEM BIOPH RES CO, V245, P349, DOI 10.1006/bbrc.1998.8426; BANERJEE A, 1988, J BIOL CHEM, V263, P3029; BANERJEE A, 1992, J BIOL CHEM, V267, P13335; BANERJEE A, 1994, J BIOL CHEM, V269, P10324; Banerjee A, 1999, BIOCHEMISTRY-US, V38, P5438, DOI 10.1021/bi981572n; Banerjee A, 1997, EUR J BIOCHEM, V246, P420, DOI 10.1111/j.1432-1033.1997.00420.x; Banerjee A, 1997, BIOCHEM BIOPH RES CO, V231, P698, DOI 10.1006/bbrc.1997.6170; BANERJEE A, 1991, J BIOL CHEM, V266, P1689; BARRA HS, 1973, J NEUROCHEM, V21, P1241, DOI 10.1111/j.1471-4159.1973.tb07578.x; BARRA HS, 1974, BIOCHEM BIOPH RES CO, V60, P1384, DOI 10.1016/0006-291X(74)90351-9; BARRA HS, 1973, J NEUROCHEM, V20, P97, DOI 10.1111/j.1471-4159.1973.tb12108.x; Bonnet C, 2001, J BIOL CHEM, V276, P12839, DOI 10.1074/jbc.M011380200; BOUCHER D, 1994, BIOCHEMISTRY-US, V33, P12471, DOI 10.1021/bi00207a014; Derry WB, 1997, BIOCHEMISTRY-US, V36, P3554, DOI 10.1021/bi962724m; Dustin P., 1978, MICROTUBULES; EDDE B, 1990, SCIENCE, V247, P83, DOI 10.1126/science.1967194; ERSFELD K, 1993, J CELL BIOL, V120, P725, DOI 10.1083/jcb.120.3.725; Geyp M, 1996, CANCER GENET CYTOGEN, V87, P117, DOI 10.1016/0165-4608(95)00235-9; GUNDERSEN GG, 1984, CELL, V38, P779, DOI 10.1016/0092-8674(84)90273-3; Hyams J.S., 1979, MICROTUBULES; JOYCE CM, 1992, J MOL BIOL, V227, P97, DOI 10.1016/0022-2836(92)90684-C; Khan IA, 1996, BIOCHEMISTRY-US, V35, P3704, DOI 10.1021/bi951247p; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; Larcher JC, 1996, J BIOL CHEM, V271, P22117, DOI 10.1074/jbc.271.36.22117; LEWIS SA, 1987, CELL, V49, P539, DOI 10.1016/0092-8674(87)90456-9; LEWIS SA, 1988, J CELL BIOL, V106, P2023, DOI 10.1083/jcb.106.6.2023; LHERNAULT SW, 1983, J CELL BIOL, V97, P258, DOI 10.1083/jcb.97.1.258; LHERNAULT SW, 1985, BIOCHEMISTRY-US, V24, P473, DOI 10.1021/bi00323a034; LOPATA MA, 1987, J CELL BIOL, V105, P1707, DOI 10.1083/jcb.105.4.1707; LUDUENA R F, 1992, Current Opinion in Cell Biology, V4, P53, DOI 10.1016/0955-0674(92)90058-K; Luduena RF, 1998, INT REV CYTOL, V178, P207; LUDUENA RF, 1993, MOL BIOL CELL, V4, P445, DOI 10.1091/mbc.4.5.445; MARY J, 1994, FEBS LETT, V353, P89, DOI 10.1016/0014-5793(94)01018-8; MONTEIRO MJ, 1988, J MOL BIOL, V199, P439, DOI 10.1016/0022-2836(88)90616-X; Nogales E, 1998, NATURE, V391, P199, DOI 10.1038/34465; OLMSTED JB, 1973, ANNU REV BIOCHEM, V42, P507, DOI 10.1146/annurev.bi.42.070173.002451; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PATURLELAFANECHERE L, 1991, BIOCHEMISTRY-US, V30, P10523, DOI 10.1021/bi00107a022; PRATT LF, 1988, EMBO J, V7, P931, DOI 10.1002/j.1460-2075.1988.tb02898.x; Raff EC, 1997, SCIENCE, V275, P70, DOI 10.1126/science.275.5296.70; RAYBIN D, 1977, J CELL BIOL, V73, P492, DOI 10.1083/jcb.73.2.492; RAYBIN D, 1977, BIOCHEMISTRY-US, V16, P2189, DOI 10.1021/bi00629a023; RAYBIN D, 1975, BIOCHEM BIOPH RES CO, V65, P1088, DOI 10.1016/S0006-291X(75)80497-9; Redeker V, 1998, BIOCHEMISTRY-US, V37, P14838, DOI 10.1021/bi981335k; REDEKER V, 1994, SCIENCE, V266, P1688, DOI 10.1126/science.7992051; RODRIGUEZ JA, 1978, BIOCHEM BIOPH RES CO, V83, P579, DOI 10.1016/0006-291X(78)91029-X; RUDIGER M, 1995, FEBS LETT, V364, P147, DOI 10.1016/0014-5793(95)00373-H; RUDIGER M, 1994, EUR J BIOCHEM, V220, P309, DOI 10.1111/j.1432-1033.1994.tb18627.x; Schwarz PM, 1998, BIOCHEMISTRY-US, V37, P4687, DOI 10.1021/bi972763d; SHARMA J, 1994, J PROTEIN CHEM, V13, P165, DOI 10.1007/BF01891975; Stanchi F, 2000, BIOCHEM BIOPH RES CO, V270, P1111, DOI 10.1006/bbrc.2000.2571; SULLIVAN KF, 1986, MOL CELL BIOL, V6, P4409, DOI 10.1128/MCB.6.12.4409; SULLIVAN KF, 1986, J BIOL CHEM, V261, P3317; SULLIVAN KF, 1986, P NATL ACAD SCI USA, V83, P4327, DOI 10.1073/pnas.83.12.4327; SULLIVAN KF, 1988, ANNU REV CELL BIOL, V4, P687, DOI 10.1146/annurev.cb.04.110188.003351; Thazhath R, 2002, NAT CELL BIOL, V4, P256, DOI 10.1038/ncb764; VILLASANTE A, 1986, MOL CELL BIOL, V6, P2409, DOI 10.1128/MCB.6.7.2409; Vinh J, 1999, BIOCHEMISTRY-US, V38, P3133, DOI 10.1021/bi982304s; WANG D, 1986, J CELL BIOL, V103, P1903, DOI 10.1083/jcb.103.5.1903	63	22	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46140	46144		10.1074/jbc.M208065200	http://dx.doi.org/10.1074/jbc.M208065200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356754	hybrid			2022-12-25	WOS:000179529300058
J	Krug, AW; Schuster, C; Gassner, B; Freudinger, R; Mildenberger, S; Troppmair, J; Gekle, M				Krug, AW; Schuster, C; Gassner, B; Freudinger, R; Mildenberger, S; Troppmair, J; Gekle, M			Human epidermal growth factor receptor-1 expression renders chinese hamster ovary cells sensitive to alternative aldosterone signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; ACTIVATED PROTEIN-KINASE; NA+/H+-EXCHANGE; RAPID ACTIVATION; EGF-RECEPTOR; STEROID-HORMONES; ANGIOTENSIN-II; MDCK CELLS; STIMULATION; REQUIRES	The epidermal growth factor (EGF) regulates cell proliferation, differentiation, and ion transport using ERK1/2 as a downstream effector. Furthermore, the EGF receptor (EGFR) is involved in signaling by G-protein-coupled receptors, growth hormone, and cytokines via transactivation. It has been suggested that steroids interact with peptide hormones. Previously, we have shown that aldosterone modulates EGF responses in Madin-Darby canine kidney cells (Gekle, M., Freudinger, R., Mildenberger, S., and Silbernagl, S. (2002) Am. J. Physiol. 282, F669-F679). Here, we tested the hypothesis that human EGFR-1 can confer alternative aldosterone responsiveness with respect to ERK1/2 phosphorylation to Chinese hamster ovary cells, which do not express EGFR. Wild-type Chinese hamster ovary cells did not respond to EGF or aldosterone. After transfection of human EGFR-1, the cells responded to EGF, but not to aldosterone. However, when submaximal concentrations of EGF were used, nanomolar concentrations of aldosterone potentiated the action of EGF within minutes, resulting in a leftward shift of the EGF dose-response curve. This was not the case in mocktransfected cells. The EGFR kinase inhibitor tyrphostin AG1478 or the MEK1/2 inhibitor U0126 completely prevented the effect. Furthermore, aldosterone enhanced Tyr phosphorylation of c-Src and EGFR, and an inhibitor of cytosolic tyrosine kinases (4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyriociaine) prevented the action of aldosterone. Our data show that aldosterone uses the EGF-EGFR-MEK1/2-ERR1/2 signaling cascade to elicit its alternative effects. In the presence of EGF, aldosterone leads to EGFR transactivation via cytosolic tyrosine kinases of the Src family.	Univ Wurzburg, Inst Physiol, D-97070 Wurzburg, Germany; Univ Wurzburg, Inst Med Strahlenkunde & Zellforsch, D-97070 Wurzburg, Germany	University of Wurzburg; University of Wurzburg	Gekle, M (corresponding author), Univ Wurzburg, Inst Physiol, Rontgenring 9, D-97070 Wurzburg, Germany.			Troppmair, Jakob/0000-0002-0611-3837				Alzamora R, 2000, HYPERTENSION, V35, P1099, DOI 10.1161/01.HYP.35.5.1099; Bokemeyer D, 2000, KIDNEY INT, V58, P549, DOI 10.1046/j.1523-1755.2000.t01-1-00201.x; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; CHRIST M, 1993, J CLIN ENDOCR METAB, V77, P1452, DOI 10.1210/jc.77.6.1452; COOPER GJ, 1994, J PHYSIOL-LONDON, V479, P423, DOI 10.1113/jphysiol.1994.sp020306; Croxtall JD, 2000, BRIT J PHARMACOL, V130, P289, DOI 10.1038/sj.bjp.0703272; Danto SI, 1998, AM J PHYSIOL-CELL PH, V275, pC82, DOI 10.1152/ajpcell.1998.275.1.C82; Doolan CM, 1996, J BIOL CHEM, V271, P8763, DOI 10.1074/jbc.271.15.8763; ELNAHAS AM, 1992, KIDNEY INT, V41, pS15; Gekle M, 2002, AM J PHYSIOL-RENAL, V282, pF669, DOI 10.1152/ajprenal.00159.2001; Gekle M, 2001, PFLUG ARCH EUR J PHY, V441, P781, DOI 10.1007/s004240000507; Gekle M, 2002, STEROIDS, V67, P499, DOI 10.1016/S0039-128X(01)00183-0; Gekle M, 1996, P NATL ACAD SCI USA, V93, P10500, DOI 10.1073/pnas.93.19.10500; Grazzini E, 1998, NATURE, V392, P509, DOI 10.1038/33176; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Ishida M, 1998, CIRC RES, V82, P7; Keely SJ, 1998, J BIOL CHEM, V273, P27111, DOI 10.1074/jbc.273.42.27111; Kelly MJ, 2001, TRENDS ENDOCRIN MET, V12, P152, DOI 10.1016/S1043-2760(01)00377-0; Khurana S, 1996, J BIOL CHEM, V271, P9919, DOI 10.1074/jbc.271.17.9919; Manegold JC, 1999, CELL MOL BIOL, V45, P805; Moghal N, 1999, CURR OPIN CELL BIOL, V11, P190, DOI 10.1016/S0955-0674(99)80025-8; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Neugarten J, 1999, AM J PHYSIOL-RENAL, V277, pF875, DOI 10.1152/ajprenal.1999.277.6.F875; OBERLEITHNER H, 1989, J MEMBRANE BIOL, V111, P49, DOI 10.1007/BF01869208; OBERLEITHNER H, 1987, P NATL ACAD SCI USA, V84, P1464, DOI 10.1073/pnas.84.5.1464; Ookawara S, 1999, MINER ELECTROL METAB, V25, P191, DOI 10.1159/000057444; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; REDEMANN N, 1992, MOL CELL BIOL, V12, P491, DOI 10.1128/MCB.12.2.491; Schramek H, 1997, J PHARMACOL EXP THER, V283, P1460; SCHWAB A, 1995, GENOMIC NONGENOMIC E, P51; Shi W, 2000, J CELL BIOL, V148, P591, DOI 10.1083/jcb.148.3.591; Stockand JD, 1999, J BIOL CHEM, V274, P35449, DOI 10.1074/jbc.274.50.35449; Urbach V, 1996, J PHYSIOL-LONDON, V491, P111, DOI 10.1113/jphysiol.1996.sp021200; Versteeg HH, 2000, BIOCHEM J, V350, P717, DOI 10.1042/0264-6021:3500717; VILELLA S, 1992, PFLUG ARCH EUR J PHY, V422, P9, DOI 10.1007/BF00381507; WARDEN DH, 1993, AM J PHYSIOL, V264, P670; WEHLING M, 1995, CIRC RES, V76, P973, DOI 10.1161/01.RES.76.6.973; Wehling M, 1997, ANNU REV PHYSIOL, V59, P365, DOI 10.1146/annurev.physiol.59.1.365; WEHLING M, 1992, AM J PHYSIOL, V263, P974; Winter DC, 1999, J MEMBRANE BIOL, V170, P17	40	79	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45892	45897		10.1074/jbc.M208851200	http://dx.doi.org/10.1074/jbc.M208851200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244120	hybrid			2022-12-25	WOS:000179529300025
J	Prusty, D; Park, BH; Davis, KE; Farmer, SR				Prusty, D; Park, BH; Davis, KE; Farmer, SR			Activation of MEK/ERK signaling promotes adipogenesis by enhancing peroxisome proliferator-activated receptor gamma (PPAR gamma) and C/EBP alpha gene expression during the differentiation of 3T3-L1 preadipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-MEDIATED PHOSPHORYLATION; MITOTIC CLONAL EXPANSION; GROWTH FACTOR-I; PROTEIN-KINASE; ADIPOCYTE DIFFERENTIATION; DNA-BINDING; CELL-CYCLE; INSULIN; CASCADE; INHIBITION	We demonstrate that exposure of post-confluent 3T3-L1 preadipocytes to insulin, isobutylmethylxanthine (MIX), dexamethasone (DEX), and fetal bovine serum induces a rapid but transient activation of MEK1 as indicated by extensive phosphorylation of ERK1 and ERK2 during the initial 2 h of adipogenesis. Inhibition of this activity by treating the cells with a MEK1-specific inhibitor (U0126 or PD98059) prior to the induction of differentiation significantly attenuated the expression of peroxisome proliferator-activated receptor (PPAR) gamma, CCAAT/enhancer-binding protein (C/EBP) alpha, perilipin, and adipocyte-specific fatty acid-binding protein (aP2). Treating the preadipocytes with troglitazone, a potent PPAR-gamma ligand, could circumvent the inhibition of adipogenic gene expression by U0126. Fibroblast growth factor-2 (FGF-2), in the presence of dexamethasone, isobutylmethylxanthine, and insulin, induces a prolonged activation of the MEK/ERK signaling pathway, which lasts for at least 12 h post-induction, and this activity is less sensitive to the MEK inhibitors. Consequently, preadipocytes treated with U0126 in the presence of fibroblast growth factor-2 (FGF-2) express normal post-induction levels of MEK activity, and, in so doing, are capable of undergoing adipogenesis. We further show that activation of MEK1 significantly enhances the transactivation of the C/EBPalpha minimal promoter during the early phase of the differentiation process. Our results suggest that activation of the MEK/ERK signaling pathway during the initial 12 h of adipogenesis enhances the activity of factors that regulate both C/EBPalpha and PPARgamma expression.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University	Farmer, SR (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	farmer@biochem.bumc.bu.edu		Farmer, Stephen/0000-0003-2483-2795	NIDDK NIH HHS [DK58825, DK51586] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK051586, R01DK051586, R01DK058825, R56DK058825] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams M, 1997, J BIOL CHEM, V272, P5128, DOI 10.1074/jbc.272.8.5128; Aubert J, 1999, J BIOL CHEM, V274, P24965, DOI 10.1074/jbc.274.35.24965; Bennett CN, 2002, J BIOL CHEM, V277, P30998, DOI 10.1074/jbc.M204527200; Boney CM, 2000, MOL ENDOCRINOL, V14, P805, DOI 10.1210/me.14.6.805; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; Brondello JM, 1997, J BIOL CHEM, V272, P1368, DOI 10.1074/jbc.272.2.1368; Camp HS, 1997, J BIOL CHEM, V272, P10811; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Chan GK, 2001, ENDOCRINOLOGY, V142, P4900, DOI 10.1210/en.142.11.4900; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; GULLER S, 1988, ENDOCRINOLOGY, V122, P2084, DOI 10.1210/endo-122-5-2084; Hansen JB, 2002, J BIOL CHEM, V277, P26335, DOI 10.1074/jbc.M203870200; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Jiang MS, 1998, P NATL ACAD SCI USA, V95, P3467, DOI 10.1073/pnas.95.7.3467; Kim SW, 2001, J BIOL CHEM, V276, P10199, DOI 10.1074/jbc.M010640200; Klemm DJ, 2001, J BIOL CHEM, V276, P28430, DOI 10.1074/jbc.M103382200; KOWENZLEUTZ E, 1994, GENE DEV, V8, P2781, DOI 10.1101/gad.8.22.2781; Machinal-Quelin F, 2002, AM J PHYSIOL-CELL PH, V282, pC853, DOI 10.1152/ajpcell.00331.2001; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; Milasincic DJ, 1996, MOL CELL BIOL, V16, P5964; Morrison RF, 1999, J CELL BIOCHEM, P59; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; MOUSTAID N, 1990, J CELL BIOCHEM, V42, P243, DOI 10.1002/jcb.240420407; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Patel YM, 2000, J BIOL CHEM, V275, P17653, DOI 10.1074/jbc.M910445199; Qiu ZL, 2001, J BIOL CHEM, V276, P11988, DOI 10.1074/jbc.M011729200; RANA B, 1995, J BIOL CHEM, V270, P18123, DOI 10.1074/jbc.270.30.18123; Reginato MJ, 1998, J BIOL CHEM, V273, P1855, DOI 10.1074/jbc.273.4.1855; Rosen ED, 2000, GENE DEV, V14, P1293; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; SCOTT RE, 1982, P NATL ACAD SCI-BIOL, V79, P845, DOI 10.1073/pnas.79.3.845; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shimba S, 2001, J CELL SCI, V114, P2809; SMITH PJ, 1988, J BIOL CHEM, V263, P9402; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; Tang QQ, 1999, MOL CELL BIOL, V19, P4855; Wu ZD, 1998, J CLIN INVEST, V101, P22, DOI 10.1172/JCI1244; WU ZD, 1995, GENE DEV, V9, P2350, DOI 10.1101/gad.9.19.2350; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zhang B, 1996, J BIOL CHEM, V271, P31771, DOI 10.1074/jbc.271.50.31771	43	404	426	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46226	46232		10.1074/jbc.M207776200	http://dx.doi.org/10.1074/jbc.M207776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270934	hybrid			2022-12-25	WOS:000179529300070
J	Aoki, M; Sobek, V; Maslyar, DJ; Hecht, A; Vogt, PK				Aoki, M; Sobek, V; Maslyar, DJ; Hecht, A; Vogt, PK			Oncogenic transformation by beta-catenin: deletion analysis and characterization of selected target genes	ONCOGENE			English	Article						beta-catenin; LEF/TCF; target genes; oncogenic transformation	ANCHORAGE-INDEPENDENT GROWTH; NEOPLASTIC TRANSFORMATION; COLORECTAL-CANCER; C-MYC; WNT; IP6; TRANSCRIPTION; ACTIVATION; EXPRESSION; CELLS	Genetic analysis of beta-catenin-induced oncogenic transformation in chicken embryo fibroblasts (CEF) revealed the following prerequisites for oncogenicity: (1) removal of the N terminal phosphorylation sites targeted by glycogen synthase kinase 3beta (GSK3beta), (2) retention of the N terminal transactivation domain, and (3) retention of the armadillo repeats. The C terminal transactivation domain played an ancillary role in the transformation of CEF. There was a rough correlation between the transforming activity of various beta-catenin constructs and their transactivation of the TOPFLASH reporter. Expression levels of the candidate target genes of beta-catenin-LEF, cyclin D1 and myc were not correlated with each other or with the transforming activity of beta-catenin constructs. A new target gene, coding for inositol hexakisphosphate kinase 2 (IP6K2) was identified. Its expression showed concordance with the transforming activity of beta-catenin constructs.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Univ Freiburg, Inst Mol Med & Zellforsch, Freiburg, Germany	Scripps Research Institute; University of Freiburg	Aoki, M (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA.	maoki@scripps.edu	Vogt, Peter K./R-7547-2019; Aoki, Masahiro/A-5149-2016	Vogt, Peter K./0000-0002-4519-7500; Aoki, Masahiro/0000-0003-4316-9490; Hecht, Andreas/0000-0003-2262-2575	NCI NIH HHS [CA 78230, CA79616] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA078230, R01CA079616] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Aoki M, 1999, P NATL ACAD SCI USA, V96, P139, DOI 10.1073/pnas.96.1.139; Barth AIM, 1999, P NATL ACAD SCI USA, V96, P4947, DOI 10.1073/pnas.96.9.4947; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Dahmen RP, 2001, CANCER RES, V61, P7039; Eastman Q, 1999, CURR OPIN CELL BIOL, V11, P233, DOI 10.1016/S0955-0674(99)80031-3; Fu SL, 1999, P NATL ACAD SCI USA, V96, P5716, DOI 10.1073/pnas.96.10.5716; Guger KA, 2000, DEV BIOL, V223, P441, DOI 10.1006/dbio.2000.9770; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; KAWAI S, 1984, MOL CELL BIOL, V4, P1172, DOI 10.1128/MCB.4.6.1172; Kolligs FT, 1999, MOL CELL BIOL, V19, P5696; Kruse U, 1997, P NATL ACAD SCI USA, V94, P12396, DOI 10.1073/pnas.94.23.12396; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Morrison BH, 2001, J BIOL CHEM, V276, P24965, DOI 10.1074/jbc.M101161200; Nagasawa Y, 1999, CANCER RES, V59, P3539; Norbis F, 1997, J MEMBRANE BIOL, V156, P19, DOI 10.1007/s002329900183; NUSSE R, 1992, CELL, V69, P1073, DOI 10.1016/0092-8674(92)90630-U; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; Safrany ST, 1999, BIOL CHEM, V380, P945, DOI 10.1515/BC.1999.117; Saiardi A, 1999, CURR BIOL, V9, P1323, DOI 10.1016/S0960-9822(00)80055-X; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Schell MJ, 1999, FEBS LETT, V461, P169, DOI 10.1016/S0014-5793(99)01462-3; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3733; Shamsuddin AM, 1999, ANTICANCER RES, V19, P3671; Staal FJT, 2002, EMBO REP, V3, P63, DOI 10.1093/embo-reports/kvf002; Sun YN, 2000, P NATL ACAD SCI USA, V97, P12613, DOI 10.1073/pnas.220158597; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Vleminckx K, 1999, MECH DEVELOP, V81, P65, DOI 10.1016/S0925-4773(98)00225-1; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Vucenik I, 1998, ANTICANCER RES, V18, P4091; Vucenik I, 1998, ANTICANCER RES, V18, P4083; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Willert K, 1998, CURR OPIN GENET DEV, V8, P95, DOI 10.1016/S0959-437X(98)80068-3; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	43	27	30	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					6983	6991		10.1038/sj.onc.1205796	http://dx.doi.org/10.1038/sj.onc.1205796			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370820				2022-12-25	WOS:000178424900001
J	Miyaki, M; Iijima, T; Yasuno, M; Kita, Y; Hishima, T; Kuroki, T; Mori, T				Miyaki, M; Iijima, T; Yasuno, M; Kita, Y; Hishima, T; Kuroki, T; Mori, T			High incidence of protein-truncating mutations of the p53 gene in liver metastases of colorectal carcinomas	ONCOGENE			English	Article						p53 mutation; protein-truncating mutation; liver metastasis; colorectal carcinoma	PROGNOSTIC-SIGNIFICANCE; ADENOMATOUS POLYPOSIS; TERM SURVIVAL; KI-RAS; CANCER; OVEREXPRESSION; ACCUMULATION; EXPRESSION; DOMAIN; BREAST	To clarify the significance of p53 mutations in liver metastasis of colorectal carcinogenesis, the characteristics of p53 mutations from 51 liver metastases and 76 primary invasive carcinomas without liver metastasis (Dukes' A, B and C) were compared. The frequency of tumors with p53 mutations was 61% (31 out of 51) in the liver metastases, and 51% (39 out of 76) in the primary carcinomas without liver metastasis. Approximately 90% of the informative cases having p53 mutation showed 17pLOH. Mutations detected within exons 4-10 of the p53 gene included missense, nonsense, frameshift, inframe deletion, and inframe insertion mutations. Out of the tumors with p53 mutations, we found that the percentage of tumors with protein-truncating mutations (nonsense and frameshift mutations) was extremely higher in liver metastases (16 out of 31, 52%) than in primary carcinomas without liver metastasis (5 out of 39, 13%) (P=0.0005). The present results suggest that protein-truncating mutations of the p53 gene are more relevant than missense mutations as one of the prognostic factors in liver metastasis of colorectal carcinomas.	Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Bunkyo Ku, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Surg, Tokyo 1138677, Japan; Tokyo Metropolitan Komagome Hosp, Dept Pathol, Tokyo 1138677, Japan; Showa Univ, Inst Mol Oncol, Tokyo 1428666, Japan	Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Tokyo Metropolitan Cancer & Infectious Diseases Center Komagome Hospital; Showa University	Miyaki, M (corresponding author), Tokyo Metropolitan Komagome Hosp, Hereditary Tumor Res Project, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138677, Japan.		Kuroki, Toshio/A-9500-2011	Kuroki, Toshio/0000-0001-6369-4351				AUVINEN A, 1994, BRIT J CANCER, V70, P293, DOI 10.1038/bjc.1994.295; BELL SM, 1993, GASTROENTEROLOGY, V104, P57, DOI 10.1016/0016-5085(93)90835-Z; CLORE GM, 1994, SCIENCE, V265, P386, DOI 10.1126/science.8023159; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; GOH HS, 1995, CANCER RES, V55, P5217; HAMELIN R, 1994, GASTROENTEROLOGY, V106, P42, DOI 10.1016/S0016-5085(94)94217-X; HARRIS CC, 1993, NEW ENGL J MED, V329, P1318, DOI 10.1056/NEJM199310283291807; HARTMANN A, 1995, ONCOGENE, V10, P681; KEMP CJ, 1993, CELL, V74, P813, DOI 10.1016/0092-8674(93)90461-X; KIKUCHIYANOSHITA R, 1992, CANCER RES, V52, P3965; Lanza G, 1996, AM J CLIN PATHOL, V105, P604; Lim BHG, 1996, INT J CANCER, V69, P200, DOI 10.1002/(SICI)1097-0215(19960621)69:3<200::AID-IJC9>3.0.CO;2-3; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; MIYAKI M, 1994, CANCER RES, V54, P3011; MORRIN M, 1994, GUT, V35, P1627, DOI 10.1136/gut.35.11.1627; MULDER JWR, 1995, BRIT J CANCER, V71, P1257, DOI 10.1038/bjc.1995.243; NIGRO JM, 1989, NATURE, V342, P705, DOI 10.1038/342705a0; PAVLETICH NP, 1993, GENE DEV, V7, P2556, DOI 10.1101/gad.7.12b.2556; SAITOH S, 1994, ONCOGENE, V9, P2869; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; Smith DR, 1996, BRIT J CANCER, V74, P216, DOI 10.1038/bjc.1996.340; Wang XW, 1996, GENE DEV, V10, P1219, DOI 10.1101/gad.10.10.1219	22	15	15	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6689	6693		10.1038/sj.onc.1205887	http://dx.doi.org/10.1038/sj.onc.1205887			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242668				2022-12-25	WOS:000178202300016
J	Shreeram, S; Sparks, A; Lane, DP; Blow, JJ				Shreeram, S; Sparks, A; Lane, DP; Blow, JJ			Cell type-specific responses of human cells to inhibition of replication licensing	ONCOGENE			English	Article						replication licensing; geminin; Cdt1	S-PHASE PROGRESSION; DNA-REPLICATION; MCM PROTEINS; IN-VIVO; CHECKPOINT; CYCLE; CHROMATIN; ORIGINS; COMPLEXES; DAMAGE	Replication origins are 'licensed' for a single initiation event by loading Mcm2-7 complexes during late mitosis and G1. Licensing is blocked at other cell cycle stages by the activity of cyclin-dependent kinases and a small protein called geminin. Here, we describe the effects of over-expressing a non-degradable form of geminin in various cell lines. Geminin expression reduced the quantity of Mcm2 bound to chromatin and blocked cell proliferation. U2OS (p53+/Rb+) cells showed an early S phase arrest with high cyclin E and undetectable cyclin A levels, consistent with the activation of an intra-S checkpoint. Saos2 (p53-/Rb-) cells showed an accumulation of cells in late S and G2/M with approximately normal levels of cyclin A, consistent with loss of this intra-S phase checkpoint. Geminin also induced apoptosis in both these cell lines. In contrast, IMR90 primary fibroblasts over-expressing geminin arrested in G1 with reduced cyclin E levels and no detectable apoptosis. A 'licensing checkpoint' may therefore act in primary cells to prevent passage into S phase in the absence of sufficient origin licensing. These results suggest that inhibition of the licensing system may cause cancer-specific cell killing and therefore represent a novel anticancer target.	Univ Dundee, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Surg & Mol Oncol, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Blow, JJ (corresponding author), Univ Dundee, Wellcome Trust Bioctr, Dow St, Dundee DD1 5EH, Scotland.		Lane, David P/C-4920-2008; Blow, J. Julian/B-3977-2009	Blow, J. Julian/0000-0002-9524-5849; Sathyavageeswaran, Shreeram/0000-0002-6111-1818; Lane, David/0000-0003-0551-3545	Cancer Research UK [A2335] Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Arentson E, 2002, ONCOGENE, V21, P1150, DOI 10.1038/sj.onc.1205175; Blow JJ, 2002, TRENDS CELL BIOL, V12, P72, DOI 10.1016/S0962-8924(01)02203-6; BLOW JJ, 1988, NATURE, V332, P546, DOI 10.1038/332546a0; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; Chew YP, 1998, ONCOGENE, V17, P2177, DOI 10.1038/sj.onc.1202443; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; Diffley JFX, 2001, CURR BIOL, V11, pR367, DOI 10.1016/S0960-9822(01)00196-8; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Donovan S, 1997, P NATL ACAD SCI USA, V94, P5611, DOI 10.1073/pnas.94.11.5611; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Gillespie PJ, 2001, BMC BIOCHEM, V2, DOI 10.1186/1472-2091-2-15; Guo N, 2000, J BIOL CHEM, V275, P1715, DOI 10.1074/jbc.275.3.1715; Harrington EA, 1998, P NATL ACAD SCI USA, V95, P11945, DOI 10.1073/pnas.95.20.11945; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hodgson B, 2002, CURR BIOL, V12, P678, DOI 10.1016/S0960-9822(02)00778-9; Hua XQH, 1998, J CELL BIOL, V140, P271, DOI 10.1083/jcb.140.2.271; Knudsen ES, 1998, GENE DEV, V12, P2278, DOI 10.1101/gad.12.15.2278; Knudsen KE, 2000, MOL CELL BIOL, V20, P7751, DOI 10.1128/MCB.20.20.7751-7763.2000; Labib K, 2001, MOL BIOL CELL, V12, P3658, DOI 10.1091/mbc.12.11.3658; Labib K, 2001, CURR OPIN GENET DEV, V11, P64, DOI 10.1016/S0959-437X(00)00158-1; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Mahbubani HM, 1997, J CELL BIOL, V136, P125, DOI 10.1083/jcb.136.1.125; MAINE GT, 1984, GENETICS, V106, P365; Maiorano D, 2000, NATURE, V404, P622, DOI 10.1038/35007104; McGarry TJ, 1998, CELL, V93, P1043, DOI 10.1016/S0092-8674(00)81209-X; Midgley CA, 2000, ONCOGENE, V19, P2312, DOI 10.1038/sj.onc.1203593; Miura M, 1999, METH MOL B, V113, P577; Musahl C, 1998, EXP CELL RES, V241, P260, DOI 10.1006/excr.1998.4041; Nishitani H, 2001, J BIOL CHEM, V276, P44905, DOI 10.1074/jbc.M105406200; Quinn LM, 2001, GENE DEV, V15, P2741, DOI 10.1101/gad.916201; Rowles A, 1999, J CELL SCI, V112, P2011; Santocanale C, 1998, NATURE, V395, P615, DOI 10.1038/27001; Saudan P, 2000, EMBO J, V19, P4351, DOI 10.1093/emboj/19.16.4351; Sever-Chroneos Z, 2001, MOL CELL BIOL, V21, P4032, DOI 10.1128/MCB.21.12.4032-4045.2001; Shirahige K, 1998, NATURE, V395, P618, DOI 10.1038/27007; Stoeber K, 1998, EMBO J, V17, P7219, DOI 10.1093/emboj/17.24.7219; Stoeber K, 2001, J CELL SCI, V114, P2027; Sun W, 2000, J CELL SCI, V113, P683; Tada S, 2001, NAT CELL BIOL, V3, P107, DOI 10.1038/35055000; Tan DF, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-6; TODOROV IT, 1995, J CELL BIOL, V129, P1433, DOI 10.1083/jcb.129.6.1433; Tsuruga H, 1997, BIOCHEM BIOPH RES CO, V236, P118, DOI 10.1006/bbrc.1997.6865; Wohlschlegel JA, 2002, AM J PATHOL, V161, P267, DOI 10.1016/S0002-9440(10)64178-8; Wohlschlegel JA, 2000, SCIENCE, V290, P2309, DOI 10.1126/science.290.5500.2309; WOODWARD A, 2002, IN PRESS CHEMTRACTS	47	153	161	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6624	6632		10.1038/sj.onc.1205910	http://dx.doi.org/10.1038/sj.onc.1205910			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242660	Green Accepted			2022-12-25	WOS:000178202300008
J	Borgius, LJ; Steffensen, KR; Gustafsson, JA; Treuter, E				Borgius, LJ; Steffensen, KR; Gustafsson, JA; Treuter, E			Glucocorticoid signaling is perturbed by the atypical orphan receptor and corepressor SHP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; DNA-BINDING DOMAIN; NUCLEAR RECEPTORS; COACTIVATOR PGC-1; TRANSCRIPTIONAL COACTIVATOR; HEPATIC GLUCONEOGENESIS; ESTROGEN-RECEPTORS; STEROID-RECEPTORS; HORMONE-RECEPTOR; LIVING CELLS	SHP (NROB2) is an atypical orphan nuclear receptor that lacks a DNA-binding domain but contains a putative ligand-binding domain. Previous studies have revealed that SHP interacts with a variety of nuclear receptors and inhibits their transcriptional activity, thereby acting as a corepressor. In this report we identify the glucocorticoid receptor (GR) as a novel downstream target receptor for SHP inhibition. SHP potently inhibits dexamethasone-induced transcriptional GR activity in mammalian cells, and the inhibition involves a functional second NR-box within SHP. Interestingly, this motif shows a high homology with the N-R-box in the glucocorticoid and cAMP-inducible GR coactivator PGC-1, indicating similar binding specificity and shared target receptors. We show that SHP antagonizes PGG-1 coactivation and, in addition, we identify the PGC-1-regulated phospho(enol)pyruvate carboxykinase (PEPCK) promoter as a novel target promoter for SHP inhibition. This implies a physiologically relevant role for SHP in modulating hepatic glucocorticoid action. Furthermore, when coexpressing green fluorescent protein-tagged GR together with SHP, an intranuclear redistribution of GR was observed. As inhibition-deficient SHP mutants were unable to induce this redistribution, intranuclear tethering of target receptors may represent yet another, previously uncovered, aspect of SHP inhibition.	Karolinska Inst, Novum, Dept Biosci, S-14157 Huddinge, Sweden	Karolinska Institutet	Borgius, LJ (corresponding author), Karolinska Inst, Ludwig Inst Canc Res, Box 240, S-17177 Stockholm, Sweden.	lotta.borgius@licr.ki.se		Treuter, Eckardt/0000-0002-4147-8989; Steffensen, Knut/0000-0001-6093-2801				Almlof T, 1997, MOL CELL BIOL, V17, P934, DOI 10.1128/MCB.17.2.934; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; Bavner A, 2002, EMBO REP, V3, P478, DOI 10.1093/embo-reports/kvf087; Chang CY, 1999, MOL CELL BIOL, V19, P8226; Delaunay F, 1997, J CLIN INVEST, V100, P2094, DOI 10.1172/JCI119743; Denson LA, 2001, GASTROENTEROLOGY, V121, P140, DOI 10.1053/gast.2001.25503; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Glass CK, 2000, GENE DEV, V14, P121; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Hu X, 2001, MOL CELL BIOL, V21, P1747, DOI 10.1128/MCB.21.5.1747-1758.2001; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Lalli E, 2000, MOL CELL BIOL, V20, P4910, DOI 10.1128/MCB.20.13.4910-4921.2000; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Ling ZC, 1998, DIABETOLOGIA, V41, P634, DOI 10.1007/s001250050961; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Maglich JM, 2001, GENOME BIOL, V2; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; MCMAHON M, 1988, DIABETES METAB REV, V4, P17, DOI 10.1002/dmr.5610040105; Nishigori H, 2001, P NATL ACAD SCI USA, V98, P575, DOI 10.1073/pnas.98.2.575; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; Sugiyama T, 2000, J BIOL CHEM, V275, P3446, DOI 10.1074/jbc.275.5.3446; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Wu XY, 2001, J BIOL CHEM, V276, P24177, DOI 10.1074/jbc.M100412200; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang M, 2001, J BIOL CHEM, V276, P41690, DOI 10.1074/jbc.M105117200; Zilliacus J, 2001, MOL ENDOCRINOL, V15, P501, DOI 10.1210/me.15.4.501	43	106	109	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49761	49766		10.1074/jbc.M205641200	http://dx.doi.org/10.1074/jbc.M205641200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12324453	hybrid			2022-12-25	WOS:000180028900088
J	Maga, G; Villani, G; Ramadan, K; Shevelev, I; Le Gac, NT; Blanco, L; Blanca, G; Spadari, S; Hubscher, U				Maga, G; Villani, G; Ramadan, K; Shevelev, I; Le Gac, NT; Blanco, L; Blanca, G; Spadari, S; Hubscher, U			Human DNA polymerase lambda functionally and physically interacts with proliferating cell nuclear antigen in normal and translesion DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; DELTA; REPLICATION; EPSILON; PCNA; BINDING; ROLES; GENE; ETA	Proliferating cell nuclear antigen (PCNA) has been shown to interact with a variety of DNA polymerases (pol) such as pol delta, pol epsilon, pol iota, pol kappa, pol eta, and pol beta. Here we show that PCNA directly interacts with the newly discovered pol lambda cloned from human cells. This interaction stabilizes the binding of pol lambda to the primer template, thus increasing its affinity for the hydroxyl primer and its processivity in DNA synthesis. However, no effect of PCNA was detected on the rate of nucleotide incorporation or discrimination efficiency by pol lambda. PCNA was found to stimulate efficient synthesis by pol lambda across an abasic (AP) site. When compared with pol delta, human pol lambda showed the ability to incorporate a nucleotide in front of the lesion. Addition of PCNA led to efficient elongation past the AP site by pol lambda but not by pol delta. However, when tested on a template containing a bulky DNA lesion, such as the major cisplatin Pt-d(GpG) adduct, PCNA could not allow translesion synthesis by pol lambda. Our results suggest that the complex between PCNA and pol lambda may play an important role in the bypass of abasic sites in human cells.	CNR, IGM, I-27100 Pavia, Italy; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; Petersburg Nucl Phys Inst, Dept Mol & Radiat Biophys, Gatchina 188300, Russia; Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, Madrid 29089, Spain	Consiglio Nazionale delle Ricerche (CNR); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); University of Zurich; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Maga, G (corresponding author), CNR, IGM, Via Abbiategrasso 207, I-27100 Pavia, Italy.		Blanco, Luis/I-1848-2015; Maga, Giovanni/C-5409-2009	Maga, Giovanni/0000-0001-8092-1552				Aoufouchi S, 2000, NUCLEIC ACIDS RES, V28, P3684, DOI 10.1093/nar/28.18.3684; Bertocci B, 2002, J IMMUNOL, V168, P3702, DOI 10.4049/jimmunol.168.8.3702; Einolf HJ, 2000, J BIOL CHEM, V275, P16316, DOI 10.1074/jbc.M001291200; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Haracska L, 2002, MOL CELL BIOL, V22, P784, DOI 10.1128/MCB.22.3.784-791.2002; Haracska L, 2001, P NATL ACAD SCI USA, V98, P14256, DOI 10.1073/pnas.261560798; Haracska L, 2001, MOL CELL BIOL, V21, P7199, DOI 10.1128/MCB.21.21.7199-7206.2001; Haracska L, 2001, MOL CELL, V8, P407, DOI 10.1016/S1097-2765(01)00319-7; Haracska L, 2001, GENE DEV, V15, P945, DOI 10.1101/gad.882301; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; HUBSCHER U, 1979, P NATL ACAD SCI USA, V76, P6284, DOI 10.1073/pnas.76.12.6284; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Kobayashi Y, 2002, MOL CELL BIOL, V22, P2769, DOI 10.1128/MCB.22.8.2769-2776.2002; LOEB LA, 1982, ANNU REV BIOCHEM, V51, P429, DOI 10.1146/annurev.bi.51.070182.002241; Maga G, 1999, J MOL BIOL, V285, P259, DOI 10.1006/jmbi.1998.2314; MAGA G, 1995, BIOCHEMISTRY-US, V34, P891, DOI 10.1021/bi00003a023; Maga G, 2001, P NATL ACAD SCI USA, V98, P14298, DOI 10.1073/pnas.251193198; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; Prosperi E, 1997, Prog Cell Cycle Res, V3, P193; Ramadan K, 2002, J BIOL CHEM, V277, P18454, DOI 10.1074/jbc.M200421200; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; Tsurimoto T., 1999, FRONT BIOSCI, V4, P849; Villani G, 2002, NUCLEIC ACIDS RES, V30, P3323, DOI 10.1093/nar/gkf463; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; WEISER T, 1991, J BIOL CHEM, V266, P10420	30	94	98	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48434	48440		10.1074/jbc.M206889200	http://dx.doi.org/10.1074/jbc.M206889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368291	hybrid, Green Accepted			2022-12-25	WOS:000179789600062
J	Nillni, EA; Xie, WH; Mulcahy, L; Sanchez, VC; Wetsel, WC				Nillni, EA; Xie, WH; Mulcahy, L; Sanchez, VC; Wetsel, WC			Deficiencies in pro-thyrotropin-releasing hormone processing and abnormalities in thermoregulation in Cpe(fat/fat) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYPEPTIDASE-E MUTATION; CENTRAL-NERVOUS-SYSTEM; OBESE FAT/FAT MICE; METALLOCARBOXYPEPTIDASE-D; PROHORMONE CONVERTASES; CPE(FAT)/CPE(FAT) MICE; FAT MUTATION; PARAVENTRICULAR NUCLEUS; TISSUE DISTRIBUTION; RAT HYPOTHALAMUS	Cpe(fat/fat) mice are obese, diabetic, and infertile. They have a mutation in carboxypeptidase E (CPE), an enzyme that converts prohormone intermediates to bioactive peptides. The Cpe(fat) mutation leads to rapid degradation of the enzyme. To test whether pro-thyrotropin-releasing hormone (TRH) conversion to TRH involves CPE, processing was examined in the Cpe(fat/fat) mouse. Hypothalamic TRH is depressed by at least 75% compared with wild-type controls. Concentrations of pro-TRH forms are increased in homozygotes. TRH-[Gly(4)-Lys(5)-Arg(6)] and TRH-[Gly(4)-Lys(5)] represent approximately 45% of the total TRH-like immunoreactivity in Cpe(fat/fat) mice; they constitute similar to1% in controls. Levels of TRH-[Gly(4)] were depressed in homozygotes. Because the hypothalamus contains some TRH, another carboxypeptidase must be responsible for processing. Immunocytochemical studies indicate that TRH neurons contain CPE- and carboxypeptidase D-like immunoreactivity. Recombinant CPE or carboxypeptidase D can convert synthetic TRH-[Gly(4)-Lys(5)] and TRH-[Gly(4) -Lys(5)-Arg(6)] to TRH-[Gly(4)]. When Cpe(fat/fat) mice are exposed to cold, they cannot maintain their body temperatures, and this loss is associated with hypothalamic TRH depletion and reduction in thyroid hormone. These findings demonstrate that the Cpe(fat) mutation can affect not only carboxypeptidase activity but also endoproteolysis. Because Cpe(fat/fat) mice cannot sustain a cold challenge, and because alterations in the hypothalamic-pituitary-thyroid axis can affect metabolism, deficits in pro-TRH processing may contribute to the obese and diabetic phenotype in these mice.	Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Mouse Blvd & Neuroendocrine Anal Core Facil, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med Endocrinol, Mouse Blvd & Neuroendocrine Anal Core Facil, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Cell Biol, Mouse Blvd & Neuroendocrine Anal Core Facil, Durham, NC 27710 USA; Brown Univ, Rhode Isl Hosp, Dept Med, Div Endocrinol, Providence, RI 02903 USA	Duke University; Duke University; Duke University; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital	Wetsel, WC (corresponding author), Duke Univ, Med Ctr, Dept Psychiat & Behav Sci, Mouse Blvd & Neuroendocrine Anal Core Facil, Durham, NC 27710 USA.	wetse001@mc.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK058148, R01DK058148] Funding Source: NIH RePORTER; NICHD NIH HHS [HD3615] Funding Source: Medline; NIDDK NIH HHS [DK58148] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 1996, NATURE, V382, P250, DOI 10.1038/382250a0; Arancibia S, 1996, NEUROENDOCRINOLOGY, V64, P257, DOI 10.1159/000127126; ARANCIBIA S, 1983, NEUROENDOCRINOLOGY, V37, P225, DOI 10.1159/000123547; Berman Y, 2001, J BIOL CHEM, V276, P1466, DOI 10.1074/jbc.M008499200; Cain BM, 1997, ENDOCRINOLOGY, V138, P4034, DOI 10.1210/en.138.9.4034; COLEMAN DL, 1990, J HERED, V81, P424, DOI 10.1093/oxfordjournals.jhered.a111019; delaCruz IP, 1996, J BIOL CHEM, V271, P22736, DOI 10.1074/jbc.271.37.22736; DONDERS SHJ, 1985, J CLIN ENDOCR METAB, V61, P56, DOI 10.1210/jcem-61-1-56; Dong W, 1999, NEUROSCIENCE, V89, P1301, DOI 10.1016/S0306-4522(98)00381-9; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Fricker LD, 1996, J BIOL CHEM, V271, P30619, DOI 10.1074/jbc.271.48.30619; Fricker LD, 2000, J NEUROSCI, V20, P639, DOI 10.1523/JNEUROSCI.20-02-00639.2000; Fricker LD, 1999, TRENDS BIOCHEM SCI, V24, P390, DOI 10.1016/S0968-0004(99)01448-6; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1982, P NATL ACAD SCI-BIOL, V79, P3886, DOI 10.1073/pnas.79.12.3886; FRICKER LD, 1994, NEUROPROTOCOLS, V5, P151; FRIEDMAN TC, 1995, ENDOCRINOLOGY, V136, P4462, DOI 10.1210/en.136.10.4462; HANSEN LF, 2000, BIOCHEM BIOPH RES CO, V267, P638; JACKSON IMD, 1974, ENDOCRINOLOGY, V95, P854, DOI 10.1210/endo-95-3-854; Jutras I, 1997, J BIOL CHEM, V272, P15184, DOI 10.1074/jbc.272.24.15184; Lacourse KA, 1998, FEBS LETT, V436, P61, DOI 10.1016/S0014-5793(98)01099-0; LECHAN RM, 1982, ENDOCRINOLOGY, V111, P55, DOI 10.1210/endo-111-1-55; Leiter EH, 1999, ENDOCRINE, V10, P57, DOI 10.1385/ENDO:10:1:57; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maddatu T, 1997, MAMM GENOME, V8, P857, DOI 10.1007/s003359900594; MANDEL G, 1987, TRENDS NEUROSCI, V10, P101, DOI 10.1016/0166-2236(87)90050-6; McGivern RF, 1997, J NEUROSCI, V17, P4886; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; NILLNI EA, 1993, ENDOCRINOLOGY, V132, P1271, DOI 10.1210/en.132.3.1271; Nillni EA, 2000, J BIOL CHEM, V275, P36124, DOI 10.1074/jbc.M003549200; Nillni EA, 1999, ENDOCR REV, V20, P599, DOI 10.1210/er.20.5.599; Nillni EA, 2001, ENDOCRINOLOGY, V142, P896, DOI 10.1210/en.142.2.896; Novikova EG, 1999, J BIOL CHEM, V274, P28887, DOI 10.1074/jbc.274.41.28887; Perloff MD, 1998, PEPTIDES, V19, P1115, DOI 10.1016/S0196-9781(98)00010-2; REDEI E, 1995, ENDOCRINOLOGY, V136, P3557, DOI 10.1210/en.136.8.3557; Reichlin S., 1998, WILLIAMS TXB ENDOCRI, P165; RONDEEL JMM, 1991, NEUROENDOCRINOLOGY, V54, P477, DOI 10.1159/000125940; ROUSSEL JP, 1991, NEUROENDOCRINOLOGY, V54, P559, DOI 10.1159/000125960; Rovere C, 1996, ENDOCRINOLOGY, V137, P2954, DOI 10.1210/en.137.7.2954; SATOH T, 1992, MOL BRAIN RES, V14, P131, DOI 10.1016/0169-328X(92)90020-C; Schaner P, 1997, J BIOL CHEM, V272, P19958, DOI 10.1074/jbc.272.32.19958; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Shen FS, 1997, P NATL ACAD SCI USA, V94, P5314, DOI 10.1073/pnas.94.10.5314; Song LX, 1996, J BIOL CHEM, V271, P28884, DOI 10.1074/jbc.271.46.28884; Steiner DF, 1998, CURR OPIN CHEM BIOL, V2, P31, DOI 10.1016/S1367-5931(98)80033-1; TACHE Y, 1989, ANN NY ACAD SCI, V553, P269; Udupi V, 1997, ENDOCRINOLOGY, V138, P1959, DOI 10.1210/en.138.5.1959; Varlamov O, 1999, J BIOL CHEM, V274, P14759, DOI 10.1074/jbc.274.21.14759; Varlamov O, 1996, J BIOL CHEM, V271, P13981, DOI 10.1074/jbc.271.24.13981; WETSEL WC, 1988, MOL ENDOCRINOL, V2, P22, DOI 10.1210/mend-2-1-22; Yamada M, 1997, P NATL ACAD SCI USA, V94, P10862, DOI 10.1073/pnas.94.20.10862; Zhu X, 1996, P NATL ACAD SCI USA, V93, P4919, DOI 10.1073/pnas.93.10.4919; ZOELLER RT, 1990, ENDOCRINOLOGY, V127, P2955, DOI 10.1210/endo-127-6-2955	53	46	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48587	48595		10.1074/jbc.M206702200	http://dx.doi.org/10.1074/jbc.M206702200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12270926	hybrid			2022-12-25	WOS:000179789600081
J	Schauer, S; Chaturvedi, S; Randau, L; Moser, J; Kitabatake, M; Lorenz, S; Verkamp, E; Schubert, WD; Nakayashiki, T; Murai, M; Wall, K; Thomann, HU; Heinz, DW; Inokuchi, H; Soll, D; Jahn, D				Schauer, S; Chaturvedi, S; Randau, L; Moser, J; Kitabatake, M; Lorenz, S; Verkamp, E; Schubert, WD; Nakayashiki, T; Murai, M; Wall, K; Thomann, HU; Heinz, DW; Inokuchi, H; Soll, D; Jahn, D			Escherichia coli glutamyl-tRNA reductase - Trapping the thioester intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA-AMINOLEVULINIC-ACID; 1-SEMIALDEHYDE AMINOTRANSFERASE; TRNA(GLU) REDUCTASE; PURIFICATION; HEME; GENE; BIOSYNTHESIS; SYNTHETASE; CHLAMYDOMONAS; EXPRESSION	In the first step of tetrapyrrole biosynthesis in Escherichia coli, glutamyl-tRNA reductase (GluTR, encoded by hemA) catalyzes the NADPH-dependent reduction of glutamyl-tRNA to glutamate-l-semialdehyde. Soluble homodimeric E. coli GluTR was made by co-expressing the hemA gene and the chaperone genes dnaJK and grpE. During Mg2+-stimulated catalysis, the reactive sulfhydryl group of Cys-50 in the E. coli enzyme attacks the a-carbonyl group of the tRNA-bound glutamate. The resulting thioester intermediate was trapped and detected by autoradiography. In the presence of NADPH, the end product, glutamate-l-semialdehyde, is formed. In the absence of NADPH, E. coli GluTR exhibited substrate esterase activity. The in vitro synthesized unmodified glutamyl-tRNA was an acceptable substrate for E. coli GluTR. Eight 5-aminolevulinic acid auxotrophic E. coli hemA mutants were genetically selected, and the corresponding mutations were determined. Most of the recombinant purified mutant GluTR enzymes lacked detectable activity. Based on the Methanopyrus kandleri GluTR structure, the positions of the amino acid exchanges are close to the catalytic domain (G7D, E114K, R314C, S22L/S164F, G44C/S105N/A326T, G106N, S145F). Only GluTR G191D (affected in NADPH binding) revealed esterase but no reductase activity.	Tech Univ Braunschweig, Inst Microbiol, D-38106 Braunschweig, Germany; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Kyoto Univ, Dept Biophys, Sakyo Ku, Kyoto 606, Japan; Genome Therapeut Corp, Waltham, MA 02154 USA; German Res Ctr Biotechnol, Dept Biol Struct, D-38124 Braunschweig, Germany	Braunschweig University of Technology; Yale University; Kyoto University; Helmholtz Association; Helmholtz-Center for Infection Research	Jahn, D (corresponding author), Tech Univ Braunschweig, Inst Microbiol, Spielmannstr 7, D-38106 Braunschweig, Germany.	d.jahn@tu-bs.de	Schubert, Wolf-Dieter/A-5617-2009	Schubert, Wolf-Dieter/0000-0003-4998-519X; Jahn, Dieter/0000-0002-4064-9205; Randau, Lennart/0000-0002-2780-2076				BEALE SI, 1973, BIOCHEM BIOPH RES CO, V52, P143, DOI 10.1016/0006-291X(73)90966-2; Carugo O, 1997, PROTEINS, V28, P29, DOI 10.1002/(SICI)1097-0134(199705)28:1<29::AID-PROT3>3.3.CO;2-C; CHEN MW, 1990, J BIOL CHEM, V265, P4058; Chen W, 1996, BBA-GENE STRUCT EXPR, V1309, P109, DOI 10.1016/S0167-4781(96)00117-0; de Marco A, 2000, PROTEIN EXPRES PURIF, V20, P81, DOI 10.1006/prep.2000.1274; Frankenberg N, 1999, BIOCHEMISTRY-US, V38, P13968, DOI 10.1021/bi9906468; HOBEN P, 1985, METHOD ENZYMOL, V113, P55; Ibba M, 2000, ANNU REV BIOCHEM, V69, P617, DOI 10.1146/annurev.biochem.69.1.617; ILAG LL, 1992, BIOCHEMISTRY-US, V31, P7143, DOI 10.1021/bi00146a016; ILAG LL, 1991, J BACTERIOL, V173, P3408, DOI 10.1128/jb.173.11.3408-3413.1991; JAHN D, 1992, TRENDS BIOCHEM SCI, V17, P215, DOI 10.1016/0968-0004(92)90380-R; JAHN D, 1991, J BIOL CHEM, V266, P2542; JAHN MJ, 1991, NUCLEIC ACIDS RES, V19, P2786, DOI 10.1093/nar/19.10.2786; LIN SX, 1992, PROTEIN EXPRES PURIF, V3, P71, DOI 10.1016/1046-5928(92)90058-5; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MAU YH, 1987, ARCH BIOCHEM BIOPHYS, V255, P75, DOI 10.1016/0003-9861(87)90295-5; MIYAMOTO K, 1991, J MOL BIOL, V219, P393, DOI 10.1016/0022-2836(91)90180-E; Moser J, 2002, BIOCHEM SOC T, V30, P579, DOI 10.1042/bst0300579; Moser J, 2001, EMBO J, V20, P6583, DOI 10.1093/emboj/20.23.6583; Moser J, 1999, J BIOL CHEM, V274, P30679, DOI 10.1074/jbc.274.43.30679; NAKAYASHIKI T, 1995, GENE, V153, P67, DOI 10.1016/0378-1119(94)00805-3; PONTOPPIDAN B, 1994, EUR J BIOCHEM, V225, P529, DOI 10.1111/j.1432-1033.1994.00529.x; RIEBLE S, 1991, J BIOL CHEM, V266, P9740; ROGERS KC, 1993, BIOCHEMISTRY-US, V32, P14210, DOI 10.1021/bi00214a021; SCHON A, 1986, NATURE, V322, P281, DOI 10.1038/322281a0; SCHRODER I, 1992, BIOCHEM J, V281, P843, DOI 10.1042/bj2810843; SCHUBERT WD, 2002, IN PRESS PHOTOSYNTH; SMITH MA, 1992, BIOCHEMISTRY-US, V31, P11249, DOI 10.1021/bi00160a041; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; VERKAMP E, 1992, J BIOL CHEM, V267, P8275; Vothknecht UC, 1996, P NATL ACAD SCI USA, V93, P9287, DOI 10.1073/pnas.93.17.9287; Vothknecht UC, 1998, PHYTOCHEMISTRY, V47, P513, DOI 10.1016/S0031-9422(97)00538-4; WALDSCHMIDT R, 1988, J BIOL CHEM, V263, P13350; Wang LY, 1999, J BACTERIOL, V181, P6033, DOI 10.1128/JB.181.19.6033-6041.1999; WILLOWS RD, 1995, BBA-GENE STRUCT EXPR, V1263, P228, DOI 10.1016/0167-4781(95)00105-P	35	48	55	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48657	48663		10.1074/jbc.M206924200	http://dx.doi.org/10.1074/jbc.M206924200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12370189	hybrid			2022-12-25	WOS:000179789600090
J	Glodowski, DR; Petersen, JM; Dahlberg, JE				Glodowski, DR; Petersen, JM; Dahlberg, JE			Complex nuclear localization signals in the matrix protein of vesicular stomatitis virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOCYTOPLASMIC TRANSPORT; UBIQUITIN LIGASE; GENE-EXPRESSION; PORE COMPLEX; EXPORT; IMPORT; INHIBITION; INTERACTS; SEQUENCE; DOMAIN	The matrix (M) protein of vesicular stomatitis virus (VSV) functions from within the nucleus to inhibit bidirectional nucleocytoplasmic transport. Here, we show that M protein can be imported into the nucleus by an active transport mechanism, even though it is small enough (similar to27 kDa) to diffuse through nuclear pore complexes. We map two distinct nuclear localization signal (NLS)-containing regions of M protein, each of which is capable of directing the nuclear localization of a heterologous protein. One of these regions, comprising amino acids 47-229, is also sufficient to inhibit nucleocytoplasmic transport. Two amino acids that are conserved among the matrix proteins of vesiculoviruses are important for nuclear localization, but are not essential for the inhibitory activity of M protein. Thus, different regions of M protein function for nuclear localization and for inhibitory activity.	Univ Wisconsin, Dept Biomol Chem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Dahlberg, JE (corresponding author), Univ Wisconsin, Dept Biomol Chem, 1300 Univ Ave, Madison, WI 53706 USA.	dahlberg@facstaff.wisc.edu			NIGMS NIH HHS [GM-30220] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030220, R01GM030220] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baake M, 2001, J CELL BIOCHEM, V81, P333, DOI 10.1002/1097-4644(20010501)81:2<333::AID-JCB1048>3.3.CO;2-4; BLACK BL, 1992, J VIROL, V66, P4058, DOI 10.1128/JVI.66.7.4058-4064.1992; CLINTON GM, 1981, VIROLOGY, V108, P510, DOI 10.1016/0042-6822(81)90459-1; Dahlberg JE, 1998, CURR OPIN CELL BIOL, V10, P400, DOI 10.1016/S0955-0674(98)80017-3; Desforges M, 2001, VIRUS RES, V76, P87, DOI 10.1016/S0168-1702(01)00251-9; Enninga J, 2002, SCIENCE, V295, P1523, DOI 10.1126/science.1067861; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Gaudier M, 2002, EMBO J, V21, P2886, DOI 10.1093/emboj/cdf284; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Grimm C, 1997, EMBO J, V16, P793, DOI 10.1093/emboj/16.4.793; Hamilton MH, 2001, J BIOL CHEM, V276, P26324, DOI 10.1074/jbc.M101205200; Harty RN, 2000, P NATL ACAD SCI USA, V97, P13871, DOI 10.1073/pnas.250277297; Harty RN, 1999, J VIROL, V73, P2921, DOI 10.1128/JVI.73.4.2921-2929.1999; Her LS, 1997, SCIENCE, V276, P1845, DOI 10.1126/science.276.5320.1845; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; KAPTUR PE, 1992, J VIROL, V66, P5384, DOI 10.1128/JVI.66.9.5384-5392.1992; LYLES DS, 1988, J VIROL, V62, P4387, DOI 10.1128/JVI.62.11.4387-4392.1988; Macara IG, 2001, MICROBIOL MOL BIOL R, V65, P570, DOI 10.1128/MMBR.65.4.570-594.2001; Makkerh JPS, 1996, CURR BIOL, V6, P1025, DOI 10.1016/S0960-9822(02)00648-6; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Michael WM, 1997, EMBO J, V16, P3587, DOI 10.1093/emboj/16.12.3587; MORRISON TG, 1978, J VIROL, V26, P115, DOI 10.1128/JVI.26.1.115-125.1978; PAIK SY, 1995, J VIROL, V69, P3529, DOI 10.1128/JVI.69.6.3529-3537.1995; PAL R, 1985, J VIROL, V55, P298, DOI 10.1128/JVI.55.2.298-306.1985; Pasquinelli AE, 1995, RNA, V1, P957; Petersen JM, 2000, MOL CELL BIOL, V20, P8590, DOI 10.1128/MCB.20.22.8590-8601.2000; Petersen JM, 2001, P NATL ACAD SCI USA, V98, P8590, DOI 10.1073/pnas.151240998; Rout MP, 2001, J BIOL CHEM, V276, P16593, DOI 10.1074/jbc.R100015200; Ryan KJ, 2000, CURR OPIN CELL BIOL, V12, P361, DOI 10.1016/S0955-0674(00)00101-0; Schwamborn K, 1998, EXP CELL RES, V244, P206, DOI 10.1006/excr.1998.4177; Segref A, 2001, RNA, V7, P351, DOI 10.1017/S1355838201002278; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Strack B, 2000, P NATL ACAD SCI USA, V97, P13063, DOI 10.1073/pnas.97.24.13063; TERNS MP, 1994, SCIENCE, V264, P959, DOI 10.1126/science.8178154; Turpin P, 1999, J BIOL CHEM, V274, P6804, DOI 10.1074/jbc.274.10.6804; von Kobbe C, 2000, MOL CELL, V6, P1243, DOI 10.1016/S1097-2765(00)00120-9; Wagner R.R., 1987, RHABDOVIRUSES, P9, DOI DOI 10.1007/978-1-4684-7032-1_2	37	32	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46864	46870		10.1074/jbc.M208576200	http://dx.doi.org/10.1074/jbc.M208576200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351648	hybrid			2022-12-25	WOS:000179663700006
J	Han, SY; Kim, SH; Heasley, LE				Han, SY; Kim, SH; Heasley, LE			Differential gene kegulation by specific gain-of-function JNK1 proteins expressed in swiss 3T3 fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; SIGNAL-TRANSDUCTION; KINASE PATHWAY; JUN; BETA; STRESS; PHOSPHORYLATION; INFLAMMATION; ENHANCEOSOME; REQUIREMENT	The c-Jun N-terminal kinases (JNKs) are encoded by three genes that yield 10 isoforms through alternative mRNA splicing. The roles of each JNK isoform in the many putative biological responses where the JNK pathway is activated are still unclear. To examine the cellular responses mediated by different JNK isoforms, gain-of-function JNK1 polypeptides were generated by fusing the upstream mitogen-activated protein kinase kinase, MKK7, with p46JN-K1alpha or p46JNK1beta. The MKK7-JNK fusion proteins, which exhibited constitutive activity in 293T cells, were stably expressed in Swiss 3T3 fibroblasts using retrovirus-mediated gene transfer. Swiss 3T3 cells expressing either of the MKK7-JNK polypeptides were equally sensitized to induction of cell death following serum withdrawal. To search for other cellular responses that may be selectively regulated by the JNK1 isoforms, the gene expression profiles of Swiss 3T3 cells expressing MKK7-JNK1alpha or MKK7-JNK1beta were compared with empty vector-transfected control cells. Affymetrix Genechips identified 46 genes for which expression was increased in MKK7-JNK-expressing cells relative to vector control cells. Twenty genes including those for c-Jun, MKP-7, interluekin-1 receptor family member ST2L/ST2, and c-Jun-binding protein were induced similarly by MKK7-JNK1alpha and MKK7-JNK1beta proteins, whereas 13 genes were selectively increased by MKK7-JNK1alpha and 13 genes were selectively increased by MKK7/JNK1beta. The set of genes selectively induced by MKK7-JNK1beta included a number of known interferon-stimulated genes (ISG12, ISG15, IGTP, and GTPI). Consistent with these gene expression changes, Swiss 3T3 cells expressing MKK7-JNK1beta exhibited increased resistance to vesicular stomatitis virus-induced cell death. These findings reveal evidence for JNK isoform-selective gene regulation and support a role for distinct JNK isoforms in specific cellular responses.	Univ Colorado, Hlth Sci Ctr, Div Renal Med, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Heasley, LE (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Med, Dept Med, C-281,4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK019928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061718] Funding Source: NIH RePORTER; NCI NIH HHS [CA58157] Funding Source: Medline; NIDDK NIH HHS [DK19928] Funding Source: Medline; NIGMS NIH HHS [GM61718] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barr RK, 2001, INT J BIOCHEM CELL B, V33, P1047, DOI 10.1016/S1357-2725(01)00093-0; Beekman A, 1998, CANCER RES, V58, P910; Brownlees J, 2000, J CELL SCI, V113, P401; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; de los Pinos E, 2001, BIOCHEM J, V353, P267, DOI 10.1042/0264-6021:3530267; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Halonen SK, 2001, INFECT IMMUN, V69, P5573, DOI 10.1128/IAI.69.9.5573-5576.2001; He T, 2002, J BIOL CHEM, V277, P10767, DOI 10.1074/jbc.M111436200; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kim T, 2000, J BIOL CHEM, V275, P16910, DOI 10.1074/jbc.M000524200; Kim TK, 2000, CANCER RES, V60, P1153; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; Sato M, 2001, CYTOKINE GROWTH F R, V12, P133, DOI 10.1016/S1359-6101(00)00032-0; Sen GC, 2001, ANNU REV MICROBIOL, V55, P255, DOI 10.1146/annurev.micro.55.1.255; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Taniguchi T, 2002, CURR OPIN IMMUNOL, V14, P111, DOI 10.1016/S0952-7915(01)00305-3; Thanos D, 1995, CELL, V83, P1091, DOI 10.1016/0092-8674(95)90136-1; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Turkson J, 1999, MOL CELL BIOL, V19, P7519; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Wolter S, 2002, J BIOL CHEM, V277, P3576, DOI 10.1074/jbc.M105800200; Zheng CJ, 1999, J BIOL CHEM, V274, P28966, DOI 10.1074/jbc.274.41.28966	30	46	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47167	47174		10.1074/jbc.M204270200	http://dx.doi.org/10.1074/jbc.M204270200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354774	hybrid			2022-12-25	WOS:000179663700043
J	Kudo, T; Iwai, T; Kubota, T; Iwasaki, H; Takayma, Y; Hiruma, T; Inaba, N; Zhang, Y; Gotoh, M; Togayachi, A; Narimatsu, H				Kudo, T; Iwai, T; Kubota, T; Iwasaki, H; Takayma, Y; Hiruma, T; Inaba, N; Zhang, Y; Gotoh, M; Togayachi, A; Narimatsu, H			Molecular cloning and characterization of a novel UDP-Gal : GaINAc alpha peptide beta 1,3-galactosyltransferase (ClGal-T2), an enzyme synthesizing a core 1 structure of O-glycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THOMSEN-FRIEDENREICH ANTIGEN; IGA NEPHROPATHY; CANCER-CELLS; R BETA-3-GALACTOSYLTRANSFERASE; N-ACETYLGALACTOSAMINE; HINGE REGION; HUMAN BREAST; TN-SYNDROME; EXPRESSION; SEQUENCE	Recently, a UDP-Gal:GalNAcalpha peptide beta1,3-galactosyltransferase (core 1 synthase 1; C1Gal-T1) has been purified from rat liver and its complementary DNA cloned from several species. We isolated a second candidate for core 1 synthase from a Colo205 cDNA library and named it C1Gal-T2. The deduced amino acid sequence of C1Gal-T2, having 26% homology to C1Gal-T1, showed a topology typical of a type II membrane protein. Real time PCR analysis revealed that the expression of C1Gal-T2 transcripts was widespread in many tissues and of relatively high level in salivary gland, stomach, small intestine, kidney, testis, thymus, and spleen. LSC cells, having no core 1 synthase activity, were transfected stably with the C1Gal-T2 gene. Their microsome fraction showed beta1,3-galactosyltransferase activity toward GalNAc-alpha-para-nitrophenyl and GalNAcalpha1 peptides resulting in the synthesis of the core 1 structure. The core 1 synthesizing activity of C1Gal-T2 was also determined by flow cytometry and lectin blotting using the LSC cells stably expressing C1Gal-T2. Finally, LSC cells, and Jurkat cells that also lack the core 1 synthase activity, were found to have null alleles of C1Gal-T2. These results indicated that C1Gal-T2 is the second candidate for core 1 synthase that plays an important role in synthesizing O-glycans in digestive organs.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glyco Funct Team, Open Space Lab, Tsukuba, Ibaraki 3058568, Japan; New Energy & Ind Technol Dev Org, Toshima Ku, Tokyo 1706028, Japan; Amersham Biosci KK, Shinjuku Ku, Tokyo 1690073, Japan; Fujirebio Inc, Fundamental Res Dept, Frontier Res Div, Tokyo 1920031, Japan; JGS Japan Genome Solut Inc, Tokyo 1920031, Japan	National Institute of Advanced Industrial Science & Technology (AIST); H.U. Group Holdings Inc	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glyco Funct Team, Open Space Lab, Cent 2,1-1-1 Umezono, Tsukuba, Ibaraki 3058568, Japan.		Yang, Fang/AAF-3024-2019; Togayachi, Akira/M-4144-2018; Kubota, Tomomi/J-1492-2018; Narimatsu, Hisashi/M-4757-2018	Togayachi, Akira/0000-0003-3600-9149; Kubota, Tomomi/0000-0002-0723-135X; Narimatsu, Hisashi/0000-0002-8402-133X				Allen AC, 1997, NEPHROL DIAL TRANSPL, V12, P701, DOI 10.1093/ndt/12.4.701; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Bai XM, 2001, J BIOL CHEM, V276, P48189, DOI 10.1074/jbc.M107339200; Berger EG, 1999, BBA-MOL BASIS DIS, V1455, P255, DOI 10.1016/S0925-4439(99)00069-1; Brockhausen I, 1999, BBA-GEN SUBJECTS, V1473, P67, DOI 10.1016/S0304-4165(99)00170-1; Brockhausen I, 1998, GLYCOCONJUGATE J, V15, P595, DOI 10.1023/A:1006967910803; BROCKHAUSEN I, 1992, BIOCHEM CELL BIOL, V70, P99, DOI 10.1139/o92-015; BROCKHAUSEN I, 1990, BIOCHEMISTRY-US, V29, P10206, DOI 10.1021/bi00496a008; CONLEY ME, 1980, J CLIN INVEST, V66, P1432, DOI 10.1172/JCI109998; Felner KM, 1998, BBA-MOL BASIS DIS, V1406, P115; Fujimoto H, 1998, GLYCOCONJUGATE J, V15, P155, DOI 10.1023/A:1006916222187; Glinsky VV, 2001, CANCER RES, V61, P4851; Glinsky VV, 2000, CANCER RES, V60, P2584; GRANOVSKY M, 1994, EUR J BIOCHEM, V221, P1039, DOI 10.1111/j.1432-1033.1994.tb18822.x; Greer MR, 1998, NEPHROL DIAL TRANSPL, V13, P1980, DOI 10.1093/ndt/13.8.1980; Hiki Y, 1998, J AM SOC NEPHROL, V9, P577; Hiki Y, 1999, J AM SOC NEPHROL, V10, P760; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Iwai T, 2002, J BIOL CHEM, V277, P12802, DOI 10.1074/jbc.M112457200; Iwase H, 1996, J BIOCHEM-TOKYO, V120, P92; Ju TZ, 2002, J BIOL CHEM, V277, P169, DOI 10.1074/jbc.M109056200; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; Kutyavin IV, 2000, NUCLEIC ACIDS RES, V28, P655, DOI 10.1093/nar/28.2.655; Okajima T, 2000, J BIOL CHEM, V275, P40498, DOI 10.1074/jbc.M006902200; PILLER V, 1990, J BIOL CHEM, V265, P9264; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; SPRINGER GF, 1995, CANCER DETECT PREV, V19, P173; SPRINGER GF, 1984, SCIENCE, V224, P1198, DOI 10.1126/science.6729450; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200	30	56	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47724	47731		10.1074/jbc.M205839200	http://dx.doi.org/10.1074/jbc.M205839200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12361956	hybrid			2022-12-25	WOS:000179663700115
J	Vallejo, AN; Bryl, E; Klarskov, K; Naylor, S; Weyand, CM; Goronzy, JJ				Vallejo, AN; Bryl, E; Klarskov, K; Naylor, S; Weyand, CM; Goronzy, JJ			Molecular basis for the loss of CD28 expression in senescent T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN; DNA-BINDING PROTEIN; TRANSCRIPTION FACTOR; RHEUMATOID-ARTHRITIS; REPLICATIVE SENESCENCE; CD28-DEFICIENT MICE; INITIATOR ELEMENTS; GENE; REPERTOIRE; PROMOTERS	CD28(null) T cells are the most consistent biological indicator of the aging immune system in humans and are predictors of immunoincompetence in the elderly. The loss of CD28 is the result of an inoperative transcriptional initiator (INR), which consists of two nonoverlapping alpha and beta motifs that have distinct protein binding profiles but function as a unit. In CD28(null) T cells, there is a coordinate loss of alpha-/beta-bound complexes, hence the alphabeta-INR is inactive. In the present work therefore, studies were conducted to identify the components of such complexes that may account for the trans-activation of the alphabeta-INR. By affinity chromatography and tandem mass spectrometry, two proteins, namely, nucleolin and the A isoform of heterogeneous nuclear ribonucleoprotein-D0 (hnRNP-D0A), were identified to be among the key components of the site a complex. In DNA binding assays, specific antibodies indicated their antigenic presence in alpha-bound complexes. Transcription assays showed that they are both required in the trans-activation of alphabeta-INR-driven DNA templates. Because CD28 is T cell-restricted, and nucleolin and hnRN-P-D0A are ubiquitous proteins, these results support the notion that cell-specific functions can be regulated by commonly expressed proteins. The present data also provide evidence for INR-regulated transcription that is independent of the known components of the basal transcription complex.	Mayo Clin & Mayo Fdn, Dept Med, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Immunol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Biomed Mass Spect & Funct Proteon Facil, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic	Vallejo, AN (corresponding author), Mayo Clin & Mayo Fdn, Dept Med, Guggenheim 401,200 1st St SW, Rochester, MN 55905 USA.		Weyand, Cornelia/AAH-3343-2021	Bryl, Ewa/0000-0002-1410-4287; Goronzy, Jorg/0000-0001-7670-1856	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041974, R03AR045830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015043] Funding Source: NIH RePORTER; NIAMS NIH HHS [R03 AR045830-03, R03-AR45830, R01-AR41974] Funding Source: Medline; NIA NIH HHS [R01-AG15043] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Bryl E, 2001, J IMMUNOL, V167, P3231, DOI 10.4049/jimmunol.167.6.3231; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Dempsey LA, 1998, GENOMICS, V49, P378, DOI 10.1006/geno.1998.5237; Dempsey LA, 1998, J BIOL CHEM, V273, P29224, DOI 10.1074/jbc.273.44.29224; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; EFFROS RB, 1994, EXP GERONTOL, V29, P601, DOI 10.1016/0531-5565(94)90073-6; Effros RB, 1997, IMMUNOL TODAY, V18, P450, DOI 10.1016/S0167-5699(97)01079-7; Ferguson SE, 1996, J IMMUNOL, V156, P4576; Garraway IP, 1996, P NATL ACAD SCI USA, V93, P4336, DOI 10.1073/pnas.93.9.4336; Ginisty H, 1999, J CELL SCI, V112, P761; Goronzy JJ, 2001, J VIROL, V75, P12182, DOI 10.1128/JVI.75.24.12182-12187.2001; Hanakahi LA, 1997, P NATL ACAD SCI USA, V94, P3605, DOI 10.1073/pnas.94.8.3605; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Kaufmann J, 1998, MOL CELL BIOL, V18, P233, DOI 10.1128/MCB.18.1.233; Kraus RJ, 1996, NUCLEIC ACIDS RES, V24, P1531, DOI 10.1093/nar/24.8.1531; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; LEE KP, 1990, J IMMUNOL, V145, P344; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; Lin CJ, 2001, J IMMUNOL, V166, P6134, DOI 10.4049/jimmunol.166.10.6134; Liuzzo G, 1999, CIRCULATION, V100, P2135, DOI 10.1161/01.CIR.100.21.2135; Maizels N, 1999, AM J HUM GENET, V64, P1270, DOI 10.1086/302393; Martens PB, 1997, ARTHRITIS RHEUM, V40, P1106, DOI 10.1002/art.1780400615; Michelotti EF, 1996, MOL CELL BIOL, V16, P2350, DOI 10.1128/mcb.16.5.2350; Mittrucker HW, 1996, J EXP MED, V183, P2481, DOI 10.1084/jem.183.6.2481; Monteiro J, 1996, J IMMUNOL, V156, P3587; Moosig F, 1998, CLIN EXP IMMUNOL, V114, P113; Namekawa T, 1998, ARTHRITIS RHEUM, V41, P2108; Novina CD, 1996, TRENDS GENET, V12, P351, DOI 10.1016/0168-9525(96)10034-2; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; Poland GA, 2001, VACCINE, V19, P2692, DOI 10.1016/S0264-410X(00)00505-3; POSNETT DN, 1994, J EXP MED, V179, P609, DOI 10.1084/jem.179.2.609; Powell JD, 1998, IMMUNOL REV, V165, P287, DOI 10.1111/j.1600-065X.1998.tb01246.x; Schmidt D, 1996, MOL MED, V2, P608, DOI 10.1007/BF03401644; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Srivastava M, 1999, FASEB J, V13, P1911, DOI 10.1096/fasebj.13.14.1911; Tolnay M, 1997, J IMMUNOL, V159, P5492; Tolnay M, 2000, BIOCHEM J, V348, P151, DOI 10.1042/0264-6021:3480151; Tolnay M, 1999, BIOCHEM J, V338, P417, DOI 10.1042/0264-6021:3380417; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; Usheva A, 1996, P NATL ACAD SCI USA, V93, P13571, DOI 10.1073/pnas.93.24.13571; Valdez BC, 1995, MOL IMMUNOL, V32, P1207, DOI 10.1016/0161-5890(95)00093-3; Vallejo AN, 1998, J BIOL CHEM, V273, P8119, DOI 10.1074/jbc.273.14.8119; Vallejo AN, 1999, J IMMUNOL, V162, P6572; Vallejo AN, 2001, J BIOL CHEM, V276, P2565, DOI 10.1074/jbc.M005503200; VALLEJO AN, 1994, PCR METH APPL, V4, P123; Wagner UG, 1998, P NATL ACAD SCI USA, V95, P14447, DOI 10.1073/pnas.95.24.14447; Weyand CM, 1998, MECH AGEING DEV, V102, P131, DOI 10.1016/S0047-6374(97)00161-9	51	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46940	46949		10.1074/jbc.M207352200	http://dx.doi.org/10.1074/jbc.M207352200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324461	hybrid			2022-12-25	WOS:000179663700015
J	Springs, SL; Diavolitsis, VM; Goodhouse, J; McLendon, GL				Springs, SL; Diavolitsis, VM; Goodhouse, J; McLendon, GL			The kinetics of translocation of Smac/DIABLO from the mitochondria to the cytosol in HeLa cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C; CASPASE ACTIVATION; APOPTOSIS; RELEASE; PROTEIN	Smac (second mitochondrial activator of caspases) is released from the mitochondria during apoptosis to relieve inhibition of caspases by the inhibitor of apoptosis proteins (LAPs). The release of Smac antagonizes several IAPs and assists the initiator caspase-9 and effector caspases (caspase-3, caspase-6, and caspase-7) in becoming active, ultimately leading to death of the cell. Translocation of Smac along with cytochrome c and other mitochondrial pro-apoptotic proteins represent important regulatory checkpoints for mitochondria-mediated apoptosis. Whether Smac and cytochrome c translocate by the same mechanism is not known. Here, we show that the time required for Smac efflux from the mitochondria of cells subjected to staurosporine-induced apoptosis is approximately four times longer than the time required for cytochrome c efflux. These results suggest that Smac and cytochrome c may exit the mitochondria by different pathways.	Princeton Univ, Dept Chem, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University; Princeton University	Springs, SL (corresponding author), Princeton Univ, Dept Chem, Princeton, NJ 08544 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059348] Funding Source: NIH RePORTER; NIGMS NIH HHS [5R01 GM59348-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Amsden B, 1998, MACROMOLECULES, V31, P8382, DOI 10.1021/ma980765f; Bossy-Wetzel E, 1998, EMBO J, V17, P37, DOI 10.1093/emboj/17.1.37; Chai JJ, 2000, NATURE, V406, P855, DOI 10.1038/35022514; Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Goldstein JC, 2000, ANN NY ACAD SCI, V926, P132; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Guo Y, 2002, J BIOL CHEM, V277, P13430, DOI 10.1074/jbc.M108029200; Jessel R, 2002, J CELL MOL MED, V6, P82, DOI 10.1111/j.1582-4934.2002.tb00313.x; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Madesh M, 2002, J BIOL CHEM, V277, P5651, DOI 10.1074/jbc.M108171200; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Paroni G, 2002, J BIOL CHEM, V277, P15147, DOI 10.1074/jbc.M112338200; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Von Ahsen O, 2000, CELL DEATH DIFFER, V7, P1192, DOI 10.1038/sj.cdd.4400782; Vucic D, 2002, J BIOL CHEM, V277, P12275, DOI 10.1074/jbc.M112045200; Waterhouse NJ, 2002, BIOCHIMIE, V84, P113, DOI 10.1016/S0300-9084(02)01379-2; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319	23	29	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45715	45718		10.1074/jbc.C200524200	http://dx.doi.org/10.1074/jbc.C200524200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12364342	hybrid			2022-12-25	WOS:000179529300001
J	Wei, YJ; Sun, HQ; Yamamoto, M; Wlodarski, P; Kunii, K; Martinez, M; Barylko, B; Albanesi, JP; Yin, HL				Wei, YJ; Sun, HQ; Yamamoto, M; Wlodarski, P; Kunii, K; Martinez, M; Barylko, B; Albanesi, JP; Yin, HL			Type II phosphatidylinositol 4-kinase beta is a cytosolic and peripheral membrane protein that is recruited to the plasma membrane and activated by Rac-GTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							4-PHOSPHATE 5-KINASE; 4,5-BISPHOSPHATE; CELLS; FAMILY; YEAST; CYTOSKELETON; KINASES; RHO	Phosphoinositides have a pivotal role as precursors to important second messengers and as bona fide signaling and scaffold targeting molecules. Phosphatidylinositol 4-kinases (PtdIns 4-kinases or PI4Ks) are at the apex of the phosphoinsitide cascade. Sequence analysis revealed that mammalian cells contain two type 11 PtdIns 4-kinase isoforms, now termed PI4KIIalpha and PI4KIIbeta. PI4KIIalpha was cloned first. It is tightly membrane-associated and behaves as an integral membrane protein. In this study, we cloned PI4KIIbeta and compared the two isoforms by monitoring the distribution of endogenous and overexpressed proteins, their modes of association with membranes, their response to growth factor stimulation or Rac-GTP activation, and their kinetic properties. We find that the two kinases have different properties. PI4KIIbeta is primarily cytosolic, and it associates peripherally with plasma membranes, endoplasmic reticulum., and the Golgi. In contrast, PI4KIIalpha is primarily Golgi-associated. Platelet-derived growth factor promotes PI4KIIbeta recruitment to membrane ruffles. This effect is potentially mediated through Rac; overexpression of the constitutively active RacV12 induces membrane ruffling, increases PI4KIIbeta translocation to the plasma membrane, and stimulates its activity. The dominant-negative RacN17 blocks plasma membrane association and inhibits activity. RacV12 does not boost the catalytic activity of PI4KIIalpha further, probably because it is constitutively membrane-bound and already activated. Membrane recruitment is an important mechanism for PI4KIIbeta activation, because microsome-bound PI4KIIbeta is 16 times more active than cytosolic PI4KIIbeta. Membrane-associated PI4KIIbeta is as active as membrane-associated PI4KIIalpha and has essentially identical kinetic properties. We conclude that PI4KIIalpha and PI4KIIbeta may have partially overlapping, but not identical, functions. PI4KIIbeta is activated strongly by membrane association to stimulate phosphatidylinositol 4,5-bisphosphate synthesis at the plasma membrane. These findings provide new insight into how phosphoinositide cascades are propagated in cells.	Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Yin, HL (corresponding author), Univ Texas, SW Med Ctr, Dept Physiol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.			Wlodarski, Pawel/0000-0002-0683-1791	NIGMS NIH HHS [GM55562, GM5112] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; BALCH WE, 1984, CELL, V39, P405, DOI 10.1016/0092-8674(84)90019-9; Balla A, 2002, J BIOL CHEM, V277, P20041, DOI 10.1074/jbc.M111807200; Balla T, 2001, CURR PHARM DESIGN, V7, P475, DOI 10.2174/1381612013397906; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; Brown FD, 2001, J CELL BIOL, V154, P1007, DOI 10.1083/jcb.200103107; Chatah NEH, 2001, J BIOL CHEM, V276, P34059, DOI 10.1074/jbc.M104917200; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; Foti M, 2001, MOL BIOL CELL, V12, P2396, DOI 10.1091/mbc.12.8.2396; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; Holz RW, 2000, J BIOL CHEM, V275, P17878, DOI 10.1074/jbc.M000925200; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Levine TP, 2002, CURR BIOL, V12, P695, DOI 10.1016/S0960-9822(02)00779-0; Micheva KD, 2001, J CELL BIOL, V154, P355, DOI 10.1083/jcb.200102098; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Thorner Jeremy W., 2001, Nature Cell Biology, V3, pE196, DOI 10.1038/35087142; Watson RT, 2000, J BIOL CHEM, V275, P1261, DOI 10.1074/jbc.275.2.1261; Wong K, 1997, J BIOL CHEM, V272, P13236, DOI 10.1074/jbc.272.20.13236; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; YIN HL, 2003, IN PRESS ANN REV PHY; YU FX, 1994, CELL MOTIL CYTOSKEL, V27, P13, DOI 10.1002/cm.970270103; Zhao XH, 2001, J BIOL CHEM, V276, P40183, DOI 10.1074/jbc.M104048200	31	96	99	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46586	46593		10.1074/jbc.M206860200	http://dx.doi.org/10.1074/jbc.M206860200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324459	hybrid			2022-12-25	WOS:000179529300114
J	Zaganas, I; Spanaki, C; Karpusas, M; Plaitakis, A				Zaganas, I; Spanaki, C; Karpusas, M; Plaitakis, A			Substitution of Ser for Arg-443 in the regulatory domain of human housekeeping (GLUB1) glutamate dehydrogenase virtually abolishes basal activity and markedly alters the activation of the enzyme by ADP and L-leucine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLUM; METABOLISM; MECHANISMS; BRAIN; GENE	Human glutamate dehydrogenase (GDH) exists in GLUD1 (housekeeping) and in GLUD2-specified (brain-specific) isoforms, which differ markedly in their basal activity and allosteric regulation. To determine the structural basis of these functional differences, we mutagenized the GLUD1 GDH at four residues that differ from those of the GLUD2 isoenzyme. Functional analyses revealed that substitution of Ser for Arg-443 (but not substitution of Thr for Ser-331, Leu for Met-370, or Leu for Met-415) virtually abolished basal activity and totally abrogated the activation of the enzyme by L-leucine (1-10 mm) in the absence of other effectors. However, when ADP (0.025-0.1 mm) was present in the reaction mixture, L-leucine (0.3-6.0 mm) activated the mutant enzyme up to >2,000%. The R443S mutant was much less sensitive to ADP (SC50 = 383.9 +/- 14.6 mum) than the GLUD1 GDH (SC50 = 31.7 +/- 4.2 mum; p < 0.001); however, at 1 mm ADP the V-max for the mutant (136.67 mumol min(-1) mg(-1)) was comparable with that of the GLUD1 GDH (152.95 mumol min(-1) mg(-1)). Varying the composition and the pH of the reaction buffer differentially affected the mutant and the wild-type GDH. Arg-443 lies in the "antenna" structure, in a helix that undergoes major conformational changes during catalysis and is involved in intersubunit communication. Its replacement by Ser is sufficient to impair both the catalytic and the allosteric function of human GDH..	Univ Crete, Sch Hlth Sci, Med Sect, Dept Neurol, Iraklion 71500, Crete, Greece; Univ Crete, Sch Hlth Sci, Med Sect, Dept Basic Sci, Iraklion 71500, Crete, Greece	University of Crete; University of Crete	Plaitakis, A (corresponding author), Univ Crete, Sch Hlth Sci, Med Sect, Dept Neurol, Iraklion 71500, Crete, Greece.		Karpusas, Michael/AAP-5547-2021; Zaganas, Ioannis/AAE-5441-2020	Zaganas, Ioannis/0000-0002-0774-5772				AOKI C, 1987, J NEUROSCI RES, V18, P305, DOI 10.1002/jnr.490180207; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BRYLA J, 1994, METABOLISM, V43, P1187, DOI 10.1016/0026-0495(94)90064-7; CARLSON M, 1977, METHOD ENZYMOL, V277, P493; COLON AD, 1986, J NEUROCHEM, V46, P1811; Cornish-Bowden A, 2012, FUNDAMENTALS ENZYME, V3rd, DOI [10.1016/B978-0-408-10617-7.50013-4/, DOI 10.1016/B978-0-408-10617-7.50013-4]; CORNISHBOWDEN A, 1995, ANAL ENZYME KINETIC, P133; DIETER H, 1981, EUR J BIOCHEM, V115, P217; Fang J, 2002, BIOCHEM J, V363, P81, DOI 10.1042/0264-6021:3630081; FRIEDEN C, 1963, J BIOL CHEM, V238, P146; FRIEDEN C, 1959, J BIOL CHEM, V234, P815; GYLFE E, 1976, ACTA DIABETOL LAT, V13, P20, DOI 10.1007/BF02591577; HUDSON RC, 1993, COMP BIOCHEM PHYS B, V106, P767, DOI 10.1016/0305-0491(93)90031-Y; HUSSAIN MM, 1989, J BIOL CHEM, V264, P20730; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAVROTHALASSITIS G, 1988, P NATL ACAD SCI USA, V85, P3494, DOI 10.1073/pnas.85.10.3494; Nissim I, 1999, AM J PHYSIOL-RENAL, V277, pF493, DOI 10.1152/ajprenal.1999.277.4.F493; Peterson PE, 1999, STRUCTURE, V7, P769, DOI 10.1016/S0969-2126(99)80101-4; Plaitakis A, 2000, J NEUROCHEM, V75, P1862, DOI 10.1046/j.1471-4159.2000.0751862.x; Plaitakis A, 2001, J NEUROSCI RES, V66, P899, DOI 10.1002/jnr.10054; Poitry S, 2000, J NEUROSCI, V20, P1809; ROTHE F, 1994, NEUROSCIENCE, V62, P1134; SENER A, 1980, NATURE, V288, P187, DOI 10.1038/288187a0; Shashidharan P, 1997, J NEUROCHEM, V68, P1804; SHASHIDHARAN P, 1994, J BIOL CHEM, V269, P16971; Smith E.L., 1975, ENZYMES, P293, DOI DOI 10.1016/S1874-6047(08)60213-9; SMITH EL, 1979, P AM PHILOS SOC, V123, P73; Smith TJ, 2002, J MOL BIOL, V318, P765, DOI 10.1016/S0022-2836(02)00161-4; Stanley CA, 1998, NEW ENGL J MED, V338, P1352, DOI 10.1056/NEJM199805073381904; STILLMAN TJ, 1993, J MOL BIOL, V234, P1134; WRZESZCZYNSKI KO, 1994, BIOCHEMISTRY-US, V33, P11544, DOI 10.1021/bi00204a017; Zaganas I, 2002, J BIOL CHEM, V277, P26422, DOI 10.1074/jbc.M200022200; Zaganas I, 2001, J NEUROSCI RES, V66, P909, DOI 10.1002/jnr.10058	34	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46552	46558		10.1074/jbc.M208596200	http://dx.doi.org/10.1074/jbc.M208596200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324473	hybrid			2022-12-25	WOS:000179529300110
J	Park, B; Nguyen, NT; Dutt, P; Merdek, KD; Bashar, M; Sterpetti, P; Tosolini, A; Testa, JR; Toksoz, D				Park, B; Nguyen, NT; Dutt, P; Merdek, KD; Bashar, M; Sterpetti, P; Tosolini, A; Testa, JR; Toksoz, D			Association of Lbc Rho guanine nucleotide exchange factor with alpha-catenin-related protein, alpha-catulin/CTNNAL1, supports serum response factor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CADHERIN-ASSOCIATED PROTEIN; CELL-CELL ADHESION; DBL FAMILY; CHROMOSOMAL LOCALIZATION; JUNCTIONAL COMPLEX; GENE CTNNA1; KINASE-A; BINDING; IDENTIFICATION; VINCULIN	The Rho GTPase signaling pathway is required for actin cytoskeletal organization and serum response factor-dependent gene transcription. Lbc is a Rho-specific guanine nucleotide exchange factor that contains a modulatory C-terminal region. To elucidate Lbc regulatory mechanism(s), a yeast two-hybrid screen for proteins that interact with the Lbc C-terminal region was carried out, resulting in multiple isolation of cDNAs encoding the same 734-amino acid Lbc interacting protein. The Lbc interacting protein has homology with the alpha-catenin cell adhesion component and is identical to the alpha-catenin-like alpha-catulin protein of unknown function. The human alpha-catulin gene (CTNNAL1) maps to 9q31-32. Here we identify the predicted endogenous alpha-catulin product, document alpha-catulin and Lbc co-expression in multiple human cell lines, and show alpha-catulin and Lbc subcellular co-fractionation and intracellular localization. The required regions for Lbc and alpha-catulin interaction were mapped, and complex formation between Lbc and alpha-catulin in mammalian cells was detected. Functionally, alpha-catulin co-expression leads to increased Lbc-induced serum response factor activation in vivo as measured by a transcriptional reporter assay. Furthermore, alpha-catulin co-expression enhances Lbc-induced GTP-Rho formation in vivo. These results support the concept that the recently identified alpha-catulin protein may modulate Rho pathway signaling in vivo by providing a scaffold for the Lbc Rho guanine nucleotide exchange factor.	Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA; Fox Chase Canc Ctr, Human Genet Program, Philadelphia, PA 19111 USA	Tufts University; Fox Chase Cancer Center	Toksoz, D (corresponding author), Tufts Univ, Sch Med, Dept Physiol, Boston, MA 02111 USA.	dtokso01@granite.tufts.edu			NCI NIH HHS [CA62029, CA06927] Funding Source: Medline; NIDDK NIH HHS [1 P30 DK39428] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA062029, P30CA006927] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1996, J CELL BIOCHEM, V61, P514, DOI 10.1002/(SICI)1097-4644(19960616)61:4<514::AID-JCB4>3.0.CO;2-R; ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; AUSUBEL FM, 1988, CURRENT PROTOCOLS MO, P1631; BAIROCH A, 1991, NUCLEIC ACIDS RES, V19, P2241, DOI 10.1093/nar/19.suppl.2241; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BELL DW, 1995, CYTOGENET CELL GENET, V70, P263, DOI 10.1159/000134048; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Buchsbaum RJ, 2002, MOL CELL BIOL, V22, P4073, DOI 10.1128/MCB.22.12.4073-4085.2002; Bullions LC, 1997, MOL CELL BIOL, V17, P4501, DOI 10.1128/MCB.17.8.4501; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CLAVERIE JM, 1993, GENOMICS, V15, P13, DOI 10.1006/geno.1993.1004; Diviani D, 2001, J BIOL CHEM, V276, P44247, DOI 10.1074/jbc.M106629200; Fukuhara S, 1999, J BIOL CHEM, V274, P5868, DOI 10.1074/jbc.274.9.5868; Gebbink MFBG, 1997, J CELL BIOL, V137, P1603, DOI 10.1083/jcb.137.7.1603; GEIGER B, 1980, P NATL ACAD SCI-BIOL, V77, P4127, DOI 10.1073/pnas.77.7.4127; Giannini AL, 2000, EXP CELL RES, V255, P207, DOI 10.1006/excr.1999.4785; Glaven JA, 1996, J BIOL CHEM, V271, P27374, DOI 10.1074/jbc.271.44.27374; Gumbiner BM, 2000, J CELL BIOL, V148, P399, DOI 10.1083/jcb.148.3.399; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hart MJ, 1996, J BIOL CHEM, V271, P25452, DOI 10.1074/jbc.271.41.25452; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Janssens B, 1999, BBA-GENE STRUCT EXPR, V1447, P341, DOI 10.1016/S0167-4781(99)00170-0; Johns DG, 2000, J BIOMED SCI, V7, P431, DOI 10.1007/BF02253359; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Klussmann E, 2001, FEBS LETT, V507, P264, DOI 10.1016/S0014-5793(01)02995-7; KNUDSEN KA, 1995, J CELL BIOL, V130, P67, DOI 10.1083/jcb.130.1.67; Kourlas PJ, 2000, P NATL ACAD SCI USA, V97, P2145, DOI 10.1073/pnas.040569197; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Kuroda S, 1998, SCIENCE, V281, P832, DOI 10.1126/science.281.5378.832; Majumdar M, 1999, J BIOL CHEM, V274, P26815, DOI 10.1074/jbc.274.38.26815; MCPHERSON JD, 1994, GENOMICS, V19, P188, DOI 10.1006/geno.1994.1042; Meyer D, 1999, J BIOL CHEM, V274, P35113, DOI 10.1074/jbc.274.49.35113; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; PIERCEALL WE, 1995, ONCOGENE, V11, P1319; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reuther GW, 2001, J BIOL CHEM, V276, P27145, DOI 10.1074/jbc.M103565200; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; Rubino D, 1998, ONCOGENE, V16, P2513, DOI 10.1038/sj.onc.1201783; Sagi SA, 2001, J BIOL CHEM, V276, P15445, DOI 10.1074/jbc.M008961200; Sehgal RNM, 1997, J CELL BIOL, V139, P1033, DOI 10.1083/jcb.139.4.1033; Sterpetti P, 1999, MOL CELL BIOL, V19, P1334; Takahashi K, 1998, ONCOGENE, V16, P3279, DOI 10.1038/sj.onc.1201874; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TOKSOZ D, 1994, ONCOGENE, V9, P621; Toksoz D, 2002, HISTOL HISTOPATHOL, V17, P915, DOI 10.14670/HH-17.915; VAN AL, 1997, GENE DEV, V11, P2295; van Horck FPG, 2001, J BIOL CHEM, V276, P4948, DOI 10.1074/jbc.M003839200; Vasioukhin V, 2001, CELL, V104, P605, DOI 10.1016/S0092-8674(01)00246-X; Vermeulen SJ, 1999, ONCOGENE, V18, P905, DOI 10.1038/sj.onc.1202348; Watabe-Uchida M, 1998, J CELL BIOL, V142, P847, DOI 10.1083/jcb.142.3.847; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; WHITEHEAD I, 1995, J BIOL CHEM, V270, P18388, DOI 10.1074/jbc.270.31.18388; Whitehead IP, 1997, BIOCHIM BIOPHYS ACTA, V1332, P1; Zhai JB, 2001, J BIOL CHEM, V276, P41318, DOI 10.1074/jbc.M107709200; Zhang JS, 1998, GENOMICS, V54, P149, DOI 10.1006/geno.1998.5458; ZHENG Y, 1995, J BIOL CHEM, V270, P9031, DOI 10.1074/jbc.270.16.9031	64	50	52	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45361	45370		10.1074/jbc.M202447200	http://dx.doi.org/10.1074/jbc.M202447200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270917	hybrid			2022-12-25	WOS:000179404800099
J	Inaoka, T; Takahashi, K; Ohnishi-Kameyama, M; Yoshida, M; Ochi, K				Inaoka, T; Takahashi, K; Ohnishi-Kameyama, M; Yoshida, M; Ochi, K			Guanine nucleotides guanosine 5 '-diphosphate 3 '-diphosphate and GTP co-operatively regulate the production of an antibiotic bacilysin in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STREPTOMYCES-COELICOLOR A3(2); STRINGENT RESPONSE; RNA-POLYMERASE; MORPHOLOGICAL-DIFFERENTIATION; NUTRITIONAL REPRESSION; FUNCTIONAL-ANALYSIS; STATIONARY-PHASE; RIBOSOMAL L11; BETA-SUBUNIT; GENE	We found that a polycistronic operon (ywfBCDEFG) and a monocistronic gene (ywfH) are required for the biosynthesis of bacilysin in Bacillus subtilis. The disruption of these genes by plasmid integration caused loss of the ability to produce bacilysin, accompanied by a lack of bacilysin synthetase activity in the crude extract. We investigated the regulatory mechanism for bacilysin biosynthesis using the transcriptional lacZ fusion system. The transcription of these genes was found to be induced at the transition from exponential to stationary phase. Induction of transcription was accelerated by depleting a required amino acid, which was done by transferring the wild-type (rel(+)) cells to an amino acid-limited medium. In contrast, no enhancement of the gene expression was detected in relA mutant cells. In wild-type (rel(+)) cells, a forced reduction of intracellular GTP, brought about by addition of decoyinine, which is a GMP synthetase inhibitor, enhanced the expression of both the ywfBCDEFG operon and the ywfH gene, resulting in a 2.5-fold increase in bacilysin production. Disruption of the codY gene, which regulates stationary phase genes by detecting the level of GTP, also induced transcription of these genes. In contrast, the expression of ywfBCDEFG in relA cells was not activated either by decoyinine addition or codY disruption, although the expression of ywfH was induced. Moreover, the codY disruption resulted in an increase of bacilysin production only in rel(+) cells. These results indicate that guanosine 5'-diphosphate 3'-diphosphate (ppGpp) plays a crucial role in transcription of the ywfBCDEFG operon and that the transcription of these genes are dependent upon the level of intracellular GTP which is transmitted as a signal via the CodY-mediated repression system. We propose that, unlike antibiotic production in Streptomyces spp., bacilysin production in B. subtilis is controlled by a dual regulation system composed of the guanine nucleotides ppGpp and GTP.	Natl Food Res Inst, Microbial Funct Lab, Tsukuba, Ibaraki 3058642, Japan; Natl Food Res Inst, Mol Elucidat Lab, Tsukuba, Ibaraki 3058642, Japan	National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan; National Agriculture & Food Research Organization - Japan; National Food Research Institute - Japan	Ochi, K (corresponding author), Natl Food Res Inst, Microbial Funct Lab, 2-1-2 Kannondai, Tsukuba, Ibaraki 3058642, Japan.		Takahashi, Kosaku/B-7760-2012; Inaoka, Takashi/L-3649-2019					BABASAKI K, 1985, J BIOCHEM, V98, P585, DOI 10.1093/oxfordjournals.jbchem.a135315; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; Chakraburtty R, 1997, J BACTERIOL, V179, P5854, DOI 10.1128/jb.179.18.5854-5861.1997; Chatterji D, 1998, GENES CELLS, V3, P279, DOI 10.1046/j.1365-2443.1998.00190.x; Dworkin J, 2001, GENE DEV, V15, P1051, DOI 10.1101/gad.892801; FREESE EB, 1979, MOL GEN GENET, V170, P67, DOI 10.1007/BF00268581; GLASER P, 1993, MOL MICROBIOL, V10, P371, DOI 10.1111/j.1365-2958.1993.tb01963.x; GLASS RE, 1986, MOL GEN GENET, V203, P265, DOI 10.1007/BF00333964; Hesketh A, 2001, MOL MICROBIOL, V39, P136, DOI 10.1046/j.1365-2958.2001.02221.x; HILTON MD, 1988, J BACTERIOL, V170, P482, DOI 10.1128/jb.170.1.482-484.1988; HILTON MD, 1988, J BACTERIOL, V170, P1018, DOI 10.1128/jb.170.2.1018-1020.1988; Hu HF, 2002, J BACTERIOL, V184, P3984, DOI 10.1128/JB.184.14.3984-3991.2002; Inaoka T, 2002, J BACTERIOL, V184, P3923, DOI 10.1128/JB.184.14.3923-3930.2002; ISHIHAMA A, 1990, STRUCTURE FUNCTION N, P153; ITAYA M, 1989, NUCLEIC ACIDS RES, V17, P4410, DOI 10.1093/nar/17.11.4410; Kawamoto S, 1997, MOL GEN GENET, V255, P549, DOI 10.1007/s004380050528; KENIG M, 1976, J GEN MICROBIOL, V94, P37, DOI 10.1099/00221287-94-1-37; Lazazzera BA, 2000, CURR OPIN MICROBIOL, V3, P177, DOI 10.1016/S1369-5274(00)00072-2; LOPEZ JM, 1981, J BACTERIOL, V146, P605, DOI 10.1128/JB.146.2.605-613.1981; MartinezCosta OH, 1996, J BIOL CHEM, V271, P10627, DOI 10.1074/jbc.271.18.10627; Miller J.H., 1972, EXPT MOL GENETICS; Moriya S, 1998, MOL MICROBIOL, V29, P179, DOI 10.1046/j.1365-2958.1998.00919.x; OCHI K, 1984, J GEN MICROBIOL, V130, P2473; OCHI K, 1986, J GEN MICROBIOL, V132, P299; OCHI K, 1986, J GEN MICROBIOL, V132, P2621, DOI 10.1099/00221287-132-9-2621; OCHI K, 1987, J BACTERIOL, V169, P3608, DOI 10.1128/jb.169.8.3608-3616.1987; OCHI K, 1981, J BIOL CHEM, V256, P6866; OCHI K, 1990, J GEN MICROBIOL, V136, P2405, DOI 10.1099/00221287-136-12-2405; OCHI K, 1990, J BACTERIOL, V172, P4008, DOI 10.1128/jb.172.7.4008-4016.1990; Ochi K, 1997, MOL GEN GENET, V256, P488; OCHI K, 1982, J BACTERIOL, V151, P1062, DOI 10.1128/JB.151.2.1062-1065.1982; Okamoto S, 1997, J BACTERIOL, V179, P170, DOI 10.1128/jb.179.1.170-179.1997; Okamoto S, 1998, MOL MICROBIOL, V30, P107, DOI 10.1046/j.1365-2958.1998.01042.x; OZCENGIZ G, 1990, J IND MICROBIOL, V6, P91, DOI 10.1007/BF01576428; Paik SH, 1998, J BIOL CHEM, V273, P23134, DOI 10.1074/jbc.273.36.23134; Ratnayake-Lecamwasam M, 2001, GENE DEV, V15, P1093, DOI 10.1101/gad.874201; REDDY PS, 1995, MOL MICROBIOL, V15, P255, DOI 10.1111/j.1365-2958.1995.tb02240.x; SAKAJOH M, 1987, J IND MICROBIOL, V2, P201, DOI 10.1007/BF01569541; Serror P, 1996, J BACTERIOL, V178, P5910, DOI 10.1128/jb.178.20.5910-5915.1996; Shah R., 1970, J ANTIBIOT, V23, P613; Shima J, 1996, J BACTERIOL, V178, P7276, DOI 10.1128/jb.178.24.7276-7284.1996; SLACK FJ, 1995, MOL MICROBIOL, V15, P689, DOI 10.1111/j.1365-2958.1995.tb02378.x; SMITH I, 1978, P NATL ACAD SCI USA, V75, P5993, DOI 10.1073/pnas.75.12.5993; Stover AG, 1999, J BACTERIOL, V181, P1664; Sun JH, 2001, J BACTERIOL, V183, P3488, DOI 10.1128/JB.183.11.3488-3498.2001; SWANTON M, 1972, BIOCHEM BIOPH RES CO, V46, P583, DOI 10.1016/S0006-291X(72)80179-7; Tamehiro N, 2002, ANTIMICROB AGENTS CH, V46, P315, DOI 10.1128/AAC.46.2.315-320.2002; Toulokhonov II, 2001, J BIOL CHEM, V276, P1220, DOI 10.1074/jbc.M007184200; Tsuge K, 1999, ANTIMICROB AGENTS CH, V43, P2183, DOI 10.1128/AAC.43.9.2183; TSUNO T, 1986, J ANTIBIOT, V39, P1001, DOI 10.7164/antibiotics.39.1001; WALKER JE, 1970, BIOCHEM J, V118, P563, DOI 10.1042/bj1180563; Wendrich TM, 2000, FEMS MICROBIOL LETT, V190, P195, DOI 10.1016/S0378-1097(00)00335-9; Xu J, 2002, MOL GENET GENOMICS, V268, P179, DOI 10.1007/s00438-002-0730-1; Yazgan A, 2001, BBA-GENE STRUCT EXPR, V1518, P87, DOI 10.1016/S0167-4781(01)00182-8	54	108	122	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2169	2176		10.1074/jbc.M208722200	http://dx.doi.org/10.1074/jbc.M208722200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12372825	hybrid			2022-12-25	WOS:000180562000014
J	Schoorlemmer, J; Goldfarb, M				Schoorlemmer, J; Goldfarb, M			Fibroblast growth factor homologous factors and the islet brain-2 scaffold protein regulate activation of a stress-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-SECRETING CELLS; SIGNAL-TRANSDUCTION; ACTIN REORGANIZATION; INDUCED APOPTOSIS; NERVOUS-SYSTEM; JNK ACTIVATION; MAP KINASES; FACTOR FGF; FAMILY; P38-DELTA	Fibroblast growth factor homologous factors (FHFs) form native intracellular complexes with the mitogen-activated protein kinase (MAPK) scaffold protein islet-brain 2 (IB2) in adult brain. FHF binding to IB2 facilitates recruitment of the MAPK p38delta (SAPK4), while failing to stimulate binding of JNK, the preferred kinase of the related scaffold IB1 (JIP-1). We now report further biochemical evidence supporting FHFs as regulators of IB2 scaffold activity. Mixed lineage kinase 3 (MLK3) and IB2 synergistically activate p38delta but not the MAPKs JNK-1 and p38alpha. Binding of p38delta to IB2 is mediated by the carboxyl-terminal half of the scaffold (IB2(Delta1-436)). FHF2 also binds weakly to IB2(Delta1-436) and can thereby increase p388 interaction with IB2(Delta1-436). FHF-induced recruitment of p388 to IB2 is accompanied by increased levels of activated p385, and synergistic activation of p38delta by MLK3 and IB2 is further enhanced by FHF2. Consistent with a role for FHFs as signaling molecules, FHF2 isolated from rat brain is serine/threonine-phosphorylated, and FHF can serve as a substrate for p38delta in vitro. These results support the existence of a signaling module in which IB2 scaffolds a MLK3/MKK/p38delta kinase cascade. FHFs aid in recruitment of p38 to IB2 and may serve as kinase substrates.	Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Goldfarb, M (corresponding author), Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, Box 1020,1 Gustave Levy Pl, New York, NY 10029 USA.		Schoorlemmer, Jon/R-6814-2019	Schoorlemmer, Jon/0000-0001-6933-0567	NINDS NIH HHS [R01 NS039906-01, R01 NS039906] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039906] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bonny C, 2000, J BIOL CHEM, V275, P16466, DOI 10.1074/jbc.M908297199; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Coulier F, 1997, J MOL EVOL, V44, P43, DOI 10.1007/PL00006120; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DICKENS M, 1997, SCIENCE, V277, P696; Dong C, 1998, SCIENCE, V282, P2092, DOI 10.1126/science.282.5396.2092; Elion EA, 1998, SCIENCE, V281, P1625, DOI 10.1126/science.281.5383.1625; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Goedert M, 1997, EMBO J, V16, P3563, DOI 10.1093/emboj/16.12.3563; Goldstein LSB, 2001, SCIENCE, V291, P2102, DOI 10.1126/science.1059766; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; Hartung H, 1997, MECH DEVELOP, V64, P31, DOI 10.1016/S0925-4773(97)00042-7; Hollenbeck PJ, 2001, J CELL BIOL, V152, pF25, DOI 10.1083/jcb.152.5.F25; Hu MCT, 1999, J BIOL CHEM, V274, P7095, DOI 10.1074/jbc.274.11.7095; Huot J, 1998, J CELL BIOL, V143, P1361, DOI 10.1083/jcb.143.5.1361; Jiang Y, 1997, J BIOL CHEM, V272, P30122, DOI 10.1074/jbc.272.48.30122; Knebel A, 2001, EMBO J, V20, P4360, DOI 10.1093/emboj/20.16.4360; LECHLEIDER RJ, 1993, J BIOL CHEM, V268, P13434; Matsuda S, 2001, J NEUROSCI, V21, P6597; Munoz-Sanjuan I, 2000, J BIOL CHEM, V275, P2589, DOI 10.1074/jbc.275.4.2589; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Negri S, 2000, GENOMICS, V64, P324, DOI 10.1006/geno.2000.6129; Nihalani D, 2001, EMBO J, V20, P3447, DOI 10.1093/emboj/20.13.3447; Ornitz DM, 1996, J BIOL CHEM, V271, P15292, DOI 10.1074/jbc.271.25.15292; Parker CG, 1998, BIOCHEM BIOPH RES CO, V249, P791, DOI 10.1006/bbrc.1998.9250; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; SANCHEZ MP, 1994, P NATL ACAD SCI USA, V91, P1819, DOI 10.1073/pnas.91.5.1819; Schoorlemmer J, 2001, CURR BIOL, V11, P793, DOI 10.1016/S0960-9822(01)00232-9; Smallwood PM, 1996, P NATL ACAD SCI USA, V93, P9850, DOI 10.1073/pnas.93.18.9850; Taru H, 2002, J BIOL CHEM, V277, P20070, DOI 10.1074/jbc.M108372200; Tawadros T, 2002, J CELL SCI, V115, P385; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; Verdier AS, 1997, GENOMICS, V40, P151, DOI 10.1006/geno.1996.4492; Verhey KJ, 2001, J CELL BIOL, V152, P959, DOI 10.1083/jcb.152.5.959; Wang Q, 2000, MECH DEVELOP, V90, P283, DOI 10.1016/S0925-4773(99)00241-5; Wang XS, 1997, J BIOL CHEM, V272, P23668, DOI 10.1074/jbc.272.38.23668; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Whitmarsh AJ, 2001, GENE DEV, V15, P2421, DOI 10.1101/gad.922801; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Xu ZH, 2001, MOL CELL BIOL, V21, P4713, DOI 10.1128/MCB.21.14.4713-4724.2001; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103	47	74	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49111	49119		10.1074/jbc.M205520200	http://dx.doi.org/10.1074/jbc.M205520200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12244047	Green Accepted, hybrid			2022-12-25	WOS:000180028900004
J	Crowley, PB; Diaz-Quintana, A; Molina-Heredia, FP; Nieto, P; Sutter, M; Haehnel, W; De la Rosa, MA; Ubbink, M				Crowley, PB; Diaz-Quintana, A; Molina-Heredia, FP; Nieto, P; Sutter, M; Haehnel, W; De la Rosa, MA; Ubbink, M			The interactions of cyanobacterial cytochrome c(6) and cytochrome f, characterized by NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAST-ELECTRON TRANSFER; PHOTOSYSTEM-I; ESCHERICHIA-COLI; PCC 7119; PLASTOCYANIN; RESIDUES; IDENTIFICATION; PROTEINS; COMPLEX; SITE	During oxygenic photosynthesis, cytochrome c(6) shuttles electrons between the membrane-bound complexes cytochrome bf and photosystem I. Complex formation between Phormidium laminosum cytochrome f and cytochrome c(6) from both Anabaena sp. PCC 7119 and Synechococcus elongatus has been investigated by nuclear magnetic resonance spectroscopy. Chemical-shift perturbation analysis reveals a binding site on Anabaena cytochrome c(6), which consists of a predominantly hydrophobic patch surrounding the heme substituent, methyl 5. This region of the protein was implicated previously in the formation of the reactive complex with photosytem I. In contrast to the results obtained for Anabaena cytochrome c(6), there is no evidence for specific complex formation with the acidic cytochrome c(6) from Synechococcus. This remarkable variability between analogous cytochromes c(6) supports the idea that different organisms utilize distinct mechanisms of photosynthetic intermolecular electron transfer.	Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands; Univ Seville, Ctr Invest Cient Isla Cartuja, Seville 41092, Spain; CSIC, Seville 41092, Spain; Univ Freiburg, Inst Biol 2, D-79104 Freiburg, Germany	Leiden University; Leiden University - Excl LUMC; University of Sevilla; Consejo Superior de Investigaciones Cientificas (CSIC); University of Freiburg	Ubbink, M (corresponding author), Leiden Univ, Gorlaeus Labs, Leiden Inst Chem, POB 9502, NL-2300 RA Leiden, Netherlands.	m.ubbink@chem.leidenuniv.nl	De la Rosa, Miguel/B-2545-2014; Nieto, Pedro M/B-7869-2008; Ubbink, Marcellus/E-2158-2011; Molina-Heredia, Fernando P./F-7877-2015; Crowley, Peter B./A-7822-2013; Díaz-Quintana, Antonio/A-1946-2011	De la Rosa, Miguel/0000-0003-1187-5737; Nieto, Pedro M/0000-0002-4074-9011; Ubbink, Marcellus/0000-0002-2615-6914; Molina-Heredia, Fernando P./0000-0002-3637-0519; Díaz-Quintana, Antonio/0000-0001-8973-8009; Crowley, Peter/0000-0002-5365-0096				Andersson P, 1998, J BIOMOL NMR, V11, P279, DOI 10.1023/A:1008227631084; Arslan E, 1998, BIOCHEM BIOPH RES CO, V251, P744, DOI 10.1006/bbrc.1998.9549; Banci L, 1998, BIOCHEMISTRY-US, V37, P4831, DOI 10.1021/bi972765y; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Beissinger M, 1998, EMBO J, V17, P27, DOI 10.1093/emboj/17.1.27; Bergkvist A, 2001, PROTEIN SCI, V10, P2623, DOI 10.1110/ps.ps.27101; Crowley PB, 2002, CHEMBIOCHEM, V3, P526, DOI 10.1002/1439-7633(20020603)3:6<526::AID-CBIC526>3.0.CO;2-N; Crowley PB, 2001, J AM CHEM SOC, V123, P10444, DOI 10.1021/ja0112700; Fragata M, 2002, BIOPHYS J, V82, p333A; FRAZAO C, 1995, STRUCTURE, V3, P1159, DOI 10.1016/S0969-2126(01)00252-0; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gupta R, 2002, NATURE, V417, P567, DOI 10.1038/417567a; Hervas M, 1996, BIOCHEMISTRY-US, V35, P2693, DOI 10.1021/bi951876z; HERVAS M, 1995, BIOCHEMISTRY-US, V34, P11321, DOI 10.1021/bi00036a004; Hippler M, 1998, P NATL ACAD SCI USA, V95, P7339, DOI 10.1073/pnas.95.13.7339; Illerhaus J, 2000, J BIOL CHEM, V275, P17590, DOI 10.1074/jbc.275.23.17590; Kannt A, 1996, BBA-BIOENERGETICS, V1277, P115, DOI 10.1016/S0005-2728(96)00090-4; Kerfeld CA, 1998, ANNU REV PLANT PHYS, V49, P397, DOI 10.1146/annurev.arplant.49.1.397; KERFELD CA, 1995, J MOL BIOL, V250, P627, DOI 10.1006/jmbi.1995.0404; Levine RL, 1996, P NATL ACAD SCI USA, V93, P15036, DOI 10.1073/pnas.93.26.15036; MARINUS MG, 1973, J BACTERIOL, V114, P1143, DOI 10.1128/JB.114.3.1143-1150.1973; Medina M, 1997, J BIOL INORG CHEM, V2, P225, DOI 10.1007/s007750050128; Molina-Heredia FP, 1998, BIOCHEM BIOPH RES CO, V243, P302, DOI 10.1006/bbrc.1997.7953; Molina-Heredia FP, 1999, J BIOL CHEM, V274, P33565, DOI 10.1074/jbc.274.47.33565; Molina-Heredia FP, 2001, J BIOL CHEM, V276, P601, DOI 10.1074/jbc.M007081200; Navarro JA, 1997, J BIOL INORG CHEM, V2, P11, DOI 10.1007/s007750050101; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Palma PN, 2000, PROTEINS, V39, P372, DOI 10.1002/(SICI)1097-0134(20000601)39:4<372::AID-PROT100>3.0.CO;2-Q; PARK KS, 1988, ARCH BIOCHEM BIOPHYS, V267, P195, DOI 10.1016/0003-9861(88)90023-9; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sawaya MR, 2001, BIOCHEMISTRY-US, V40, P9215, DOI 10.1021/bi002679p; Schlarb BG, 1999, GENE, V234, P275, DOI 10.1016/S0378-1119(99)00198-5; Schnackenberg J, 1999, J MOL BIOL, V290, P1019, DOI 10.1006/jmbi.1999.2944; Soriano GM, 1996, BIOCHEMISTRY-US, V35, P14590, DOI 10.1021/bi9616211; Soriano GM, 1998, BIOCHEMISTRY-US, V37, P15120, DOI 10.1021/bi9807714; Sutter M, 1995, PHOTOSYNTHESIS: FROM LIGHT TO BIOSPHERE, VOL II, P563; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; Ullmann GM, 1997, BIOCHEMISTRY-US, V36, P16187, DOI 10.1021/bi971241v; Wastl J, 2002, TRENDS PLANT SCI, V7, P244, DOI 10.1016/S1360-1385(02)02280-X; WOOD PM, 1978, EUR J BIOCHEM, V87, P9, DOI 10.1111/j.1432-1033.1978.tb12346.x; Worrall JAR, 2002, BIOCHEMISTRY-US, V41, P11721, DOI 10.1021/bi026296y; Yamada S, 2000, ACTA CRYSTALLOGR D, V56, P1577, DOI 10.1107/S090744490001461X; Zuiderweg ERP, 2002, BIOCHEMISTRY-US, V41, P1, DOI 10.1021/bi011870b	43	30	31	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48685	48689		10.1074/jbc.M203983200	http://dx.doi.org/10.1074/jbc.M203983200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356767	Green Published, hybrid			2022-12-25	WOS:000179789600093
J	Gosavi, N; Lee, HJ; Lee, JS; Patel, S; Lee, SJ				Gosavi, N; Lee, HJ; Lee, JS; Patel, S; Lee, SJ			Golgi fragmentation occurs in the cells with prefibrillar alpha-synuclein aggregates and precedes the formation of fibrillar inclusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; AMYOTROPHIC-LATERAL-SCLEROSIS; PARKINSONS-DISEASE; PROTEIN AGGREGATION; TRANSGENIC MICE; IN-VITRO; DEATH; MUTANT; PATHOGENESIS; APPARATUS	Amyloid-like fibrillar aggregates of intracellular proteins are common pathological features of human neurodegenerative diseases. However, the nature of pathogenic aggregates and the biological consequences of their formation remain elusive. Here, we describe (i) a model cellular system in which prefibrillar alpha-synuclein aggregates and fibrillar inclusions are naturally formed in the cytoplasm with distinctive kinetics and (ii) a tight correlation between the presence of prefibrillar aggregates and the Golgi fragmentation. Consistent with the structural abnormality of Golgi apparatus, trafficking and maturation of dopamine transporter through the biosynthetic pathway were impaired in the presence of alpha-synuclein aggregates. Reduction in cell viability was also observed in the prefibrillar aggregate-forming condition and before the inclusion formation. The fibrillar inclusions, on the other hand, showed no correlation with Golgi fragmentation and were preceded by these events. Furthermore, at the early stage of inclusion formation, active lysosomes and mitochondria were enriched in the juxtanuclear area and co-aggregate into a compact inclusion body, suggesting that the fibrillar inclusions might be the consequence of an attempt of the cell to remove abnormal protein aggregates and damaged organelles. These results support the hypothesis that prefibrillar a-synuclein aggregates are the pathogenic species and suggest that Golgi fragmentation and subsequent trafficking impairment are the specific consequence of alpha-synuclein aggregation.	Parkinsons Inst, Sunnyvale, CA 94089 USA		Lee, SJ (corresponding author), Parkinsons Inst, 1170 Morse Ave, Sunnyvale, CA 94089 USA.			Lee, Seung-Jae/0000-0002-5155-5335				Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bouley DM, 2001, INFECT IMMUN, V69, P7820, DOI 10.1128/IAI.69.12.7820-7831.2001; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Faber PW, 1999, P NATL ACAD SCI USA, V96, P179, DOI 10.1073/pnas.96.1.179; Garcia-Mata R, 1999, J CELL BIOL, V146, P1239, DOI 10.1083/jcb.146.6.1239; Garcia-Mata R, 2002, TRAFFIC, V3, P388, DOI 10.1034/j.1600-0854.2002.30602.x; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Gonatas NK, 1998, HISTOCHEM CELL BIOL, V109, P591, DOI 10.1007/s004180050257; Hardy J, 1998, SCIENCE, V282, P1075, DOI 10.1126/science.282.5391.1075; Iwata A, 2001, J BIOL CHEM, V276, P45320, DOI 10.1074/jbc.M103736200; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; Klement IA, 1998, CELL, V95, P41, DOI 10.1016/S0092-8674(00)81781-X; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lee HJ, 2002, J BIOL CHEM, V277, P5411, DOI 10.1074/jbc.M105326200; Lee HJ, 2002, J BIOL CHEM, V277, P48976, DOI 10.1074/jbc.M208192200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Masliah E, 2000, SCIENCE, V287, P1265, DOI 10.1126/science.287.5456.1265; Melikian HE, 1999, J NEUROSCI, V19, P7699; Mourelatos Z, 1996, P NATL ACAD SCI USA, V93, P5472, DOI 10.1073/pnas.93.11.5472; Ostrerova N, 1999, J NEUROSCI, V19, P5782, DOI 10.1523/JNEUROSCI.19-14-05782.1999; Saha AR, 2000, EUR J NEUROSCI, V12, P3073, DOI 10.1046/j.1460-9568.2000.00210.x; Sakurai A, 2000, ACTA NEUROPATHOL, V100, P270, DOI 10.1007/s004010000182; Sakurai A, 2002, ACTA NEUROPATHOL, V103, P550, DOI 10.1007/s00401-001-0500-x; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Thyberg J, 1999, EXP CELL RES, V246, P263, DOI 10.1006/excr.1998.4326; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Wakabayashi K, 1998, ACTA NEUROPATHOL, V96, P445, DOI 10.1007/s004010050918; Wigley WC, 1999, J CELL BIOL, V145, P481; Yang W, 1998, MOL BIOL CELL, V9, P191, DOI 10.1091/mbc.9.1.191; Zhou WB, 2002, BRAIN RES, V926, P42, DOI 10.1016/S0006-8993(01)03292-9	43	229	237	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48984	48992		10.1074/jbc.M208194200	http://dx.doi.org/10.1074/jbc.M208194200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351643	hybrid			2022-12-25	WOS:000179789600131
J	Keeton, AB; Amsler, MO; Venable, DY; Messina, JL				Keeton, AB; Amsler, MO; Venable, DY; Messina, JL			Insulin signal transduction pathways and insulin-induced gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE; CULTURED HEPATOMA-CELLS; IMMEDIATE-EARLY GENE; C-FOS TRANSCRIPTION; MAP-KINASE; MESSENGER-RNA; PHOSPHATIDYLINOSITOL 3-KINASE; ELECTROPHORETIC TRANSFER; ORNITHINE DECARBOXYLASE	Insulin regulates metabolic activity, gene transcription, and cell growth by modulating the activity of several intracellular signaling pathways. Insulin activation of one mitogen-activated protein kinase cascade, the MEK/ERK kinase cascade, is well described. However, the effect of insulin on the parallel p38 pathway is less well understood. The present work examines the effect of inhibiting the p38 signaling pathway by use of specific inhibitors, either alone or in combination with insulin, on the activation of ERK1/2 and on the regulation of gene transcription in rat hepatoma cells. Activation of ERK1/2 was induced by insulin and was dependent on the activation of MEK1, the kinase upstream of ERK in this pathway. Treatment of cells with p38 inhibitors also induced ERK1/2 activation/phosphorylation. The addition of p38 inhibitors followed by insulin addition resulted in a greater than additive activation of ERK1/2. The two genes studied, c-Fos and Pip,92, are immediate-early genes that are dependent on the ERK1/2 pathway for insulin-regulated induction because the insulin effect was inhibited by pretreatment with a MEK1 inhibitor. The addition of p38 inhibitors induced transcription of both genes in a dose-dependent manner, and insulin stimulation of both genes was enhanced by prior treatment with p38 inhibitors. The ability of the p38 inhibitors to induce ERK1/2 and gene transcription, both alone and in combination with insulin, was abolished by prior inhibition of MEK1. These data suggest possible cross-talk between the p38 and ERK1/2 signaling pathways and a potential role of p38 in insulin signaling.	Univ Alabama, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Messina, JL (corresponding author), Univ Alabama, Dept Pathol, Div Mol & Cellular Pathol, Volker Hall,G019,1670 Univ Blvd, Birmingham, AL 35294 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040456] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40456] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANDREONE TL, 1982, J BIOL CHEM, V257, P35; BEALE EG, 1986, DIABETES, V35, P546, DOI 10.2337/diabetes.35.5.546; Bortoff KD, 1997, ENDOCRINE, V7, P199, DOI 10.1007/BF02778142; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; BUTLER PC, 1990, DIABETES, V39, P217, DOI 10.2337/diabetes.39.2.217; CHARLES CH, 1990, MOL CELL BIOL, V10, P6769, DOI 10.1128/MCB.10.12.6769; Chung KC, 1998, MOL CELL BIOL, V18, P2272, DOI 10.1128/MCB.18.4.2272; COLECLOUGH C, 1990, P NATL ACAD SCI USA, V87, P1753, DOI 10.1073/pnas.87.5.1753; Conejo R, 2001, J CELL PHYSIOL, V186, P82, DOI 10.1002/1097-4652(200101)186:1<82::AID-JCP1001>3.0.CO;2-R; Conejo R, 2001, J CELL PHYSIOL, V187, P96, DOI 10.1002/1097-4652(2001)9999:9999<::AID-JCP1058>3.0.CO;2-V; Ding XZ, 2001, BIOCHEM BIOPH RES CO, V282, P447, DOI 10.1006/bbrc.2001.4595; Flamigni F, 2001, BIOCHEM PHARMACOL, V62, P319, DOI 10.1016/S0006-2952(01)00646-3; Flamigni F, 2001, BIOCHEM PHARMACOL, V61, P25, DOI 10.1016/S0006-2952(00)00515-3; GRANNER D, 1983, NATURE, V305, P549, DOI 10.1038/305549a0; Hall-Jackson CA, 1999, ONCOGENE, V18, P2047, DOI 10.1038/sj.onc.1202603; Heidenreich KA, 1996, J BIOL CHEM, V271, P9891, DOI 10.1074/jbc.271.17.9891; HOFMANN C, 1980, DIABETES, V29, P865, DOI 10.2337/diabetes.29.11.865; Ishii Y, 2001, LEUKEMIA RES, V25, P813, DOI 10.1016/S0145-2126(01)00026-1; Ji SN, 1999, J BIOL CHEM, V274, P13434, DOI 10.1074/jbc.274.19.13434; Kalmes A, 1999, FEBS LETT, V444, P71, DOI 10.1016/S0014-5793(99)00034-4; KENDRICK NC, 1994, ANAL BIOCHEM, V219, P297, DOI 10.1006/abio.1994.1269; Kim SJ, 1997, BIOCHEM J, V323, P621, DOI 10.1042/bj3230621; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Malek AM, 1997, BIOTECHNIQUES, V22, P1150; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MESSINA JL, 1990, J BIOL CHEM, V265, P11700; MESSINA JL, 1989, ENDOCRINOLOGY, V124, P754, DOI 10.1210/endo-124-2-754; MESSINA JL, 1992, J BIOL CHEM, V267, P9223; MESSINA JL, 1990, HDB EXPT PHARM INSUL, P399; MESSINA JL, 1999, HORMONAL CONTROL GRO, V5, P783; Michael MD, 2000, MOL CELL, V6, P87, DOI 10.1016/S1097-2765(00)00010-1; MOTULSKY H, 1998, INSTAT GUIDE CHOOSIN; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NELSON JW, 2002, 9 ALPH INN CORP; NELSON JW, 2002, 26 ALPH INN CORP; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; OBRIEN RM, 1990, DIABETES CARE, V13, P327, DOI 10.2337/diacare.13.3.327; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POTTER VR, 1984, IN VITRO CELL DEV B, V20, P723; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; ROSELLA G, 1993, MOL ENDOCRINOL, V7, P1456, DOI 10.1210/me.7.11.1456; Rosner B., 2010, FUNDAMENTALS BIOSTAT; SHIMIZU N, 1991, J BIOL CHEM, V266, P12157; Singh RP, 1999, J BIOL CHEM, V274, P19593, DOI 10.1074/jbc.274.28.19593; Somwar R, 2001, BIOCHEM J, V359, P639, DOI 10.1042/0264-6021:3590639; Somwar R, 2001, J BIOL CHEM, V276, P46079, DOI 10.1074/jbc.M109093200; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; Sweeney G, 1999, J BIOL CHEM, V274, P10071, DOI 10.1074/jbc.274.15.10071; Sweeney G, 2001, ENDOCRINOLOGY, V142, P4806, DOI 10.1210/en.142.11.4806; Tarlton JF, 1996, ANAL BIOCHEM, V237, P123, DOI 10.1006/abio.1996.0209; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Westermarck J, 2001, MOL CELL BIOL, V21, P2373, DOI 10.1128/MCB.21.7.2373-2383.2001; WHITEHEAD TP, 1979, CLIN CHEM, V25, P1531; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yang XY, 1999, AM J PHYSIOL-RENAL, V277, pF176, DOI 10.1152/ajprenal.1999.277.2.F176	63	42	43	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48565	48573		10.1074/jbc.M207837200	http://dx.doi.org/10.1074/jbc.M207837200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12364332	hybrid			2022-12-25	WOS:000179789600078
J	D'Addario, M; Arora, PD; Ellen, RP; McCulloch, CAG				D'Addario, M; Arora, PD; Ellen, RP; McCulloch, CAG			Interaction of p38 and Sp1 in a mechanical force-induced, beta(1), integrin-mediated transcriptional circuit that regulates the actin-binding protein filamin-A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; SIGNAL-TRANSDUCTION; MAP KINASE; P21(WAF1/CIP1) GENE; CHAIN GENE; C-JUN; PHOSPHORYLATION; ACTIVATION; EXPRESSION; DNA	Connective tissue cells in mechanically active environments survive applied physical forces by modifying actin cytoskeletal structures that stabilize cell membranes. In fibroblasts, tensile forces induce the expression of filamin-A, a mechanoprotective actin-binding protein, but the mechanisms and protein interactions by which force activates filamin-A transcription are not defined. We found that in fibroblasts, application of tensile forces through collagen-coated magnetite beads to cell surface beta(1) integrins induced filamin-A expression. This induction required actin filaments and selective activation of the p38 mitogen-activated protein kinase. Force promoted the redistribution of p38 to the integrin/bead locus and the nucleus as well as enhanced binding of the transcription factor Sp1 to proximal, regulatory domains of the filamin-A promoter. Force application increased association of Sp1 with p38 and phosphorylation of Sp1. Transcriptional activation of filamin-A in force-treated fibroblasts was subsequently mediated by Sp1-binding sites on the filamin-A promoter. These results provide evidence for a mechanically coupled transcriptional circuit that originates at the magnetite bead/integrin locus, activates p38, tethers p38 to actin filaments, promotes binding of p38 to Sp1 in the nucleus, and induces filamin-A expression.	Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Toronto, ON M5S 3E2, Canada; Univ Toronto, Fac Dent, Inst Dent Res, Toronto, ON M5S 3E2, Canada	University of Toronto; University of Toronto	McCulloch, CAG (corresponding author), Univ Toronto, Canadian Inst Hlth Res Grp Matrix Dynam, Rm 244,Fitzgerald Bldg,150 Coll St, Toronto, ON M5S 3E2, Canada.	christopher.mcculloch@utoronto.ca						Aplin AE, 2001, J CELL BIOL, V153, P273, DOI 10.1083/jcb.153.2.273; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Arora PD, 1996, J BIOL CHEM, V271, P20516, DOI 10.1074/jbc.271.34.20516; BRENTCARTER A, 1999, J BIOL CHEM, V274, P30858; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Craig R, 2000, J BIOL CHEM, V275, P23814, DOI 10.1074/jbc.M909695199; Critchley DR, 2000, CURR OPIN CELL BIOL, V12, P133, DOI 10.1016/S0955-0674(99)00067-8; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; D'Addario M, 1999, FASEB J, V13, P2203, DOI 10.1096/fasebj.13.15.2203; D'Addario M, 2001, J BIOL CHEM, V276, P31969, DOI 10.1074/jbc.M102715200; Daniel S, 1996, J BIOL CHEM, V271, P14692, DOI 10.1074/jbc.271.25.14692; de Borja PF, 2001, EMBO J, V20, P5737; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fincham VJ, 2000, EMBO J, V19, P2911, DOI 10.1093/emboj/19.12.2911; Glogauer M, 1997, J CELL SCI, V110, P11; Glogauer M, 1998, J BIOL CHEM, V273, P1689, DOI 10.1074/jbc.273.3.1689; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Hui MZ, 1997, J CELL PHYSIOL, V172, P323, DOI 10.1002/(SICI)1097-4652(199709)172:3<323::AID-JCP6>3.0.CO;2-Q; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kainulainen T, 2002, J BIOL CHEM, V277, P21998, DOI 10.1074/jbc.M200715200; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kaytor EN, 2001, J BIOL CHEM, V276, P36896, DOI 10.1074/jbc.M104035200; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; Koutsodontis G, 2001, J BIOL CHEM, V276, P29116, DOI 10.1074/jbc.M104130200; Laniel MA, 2001, J BIOL CHEM, V276, P20766, DOI 10.1074/jbc.M010360200; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Liang FQ, 1999, J CLIN INVEST, V104, P1603, DOI 10.1172/JCI7362; McDonough PM, 1997, J BIOL CHEM, V272, P24046, DOI 10.1074/jbc.272.38.24046; McLaughlin MM, 1996, J BIOL CHEM, V271, P8488, DOI 10.1074/jbc.271.14.8488; Melnikova IN, 2001, J BIOL CHEM, V276, P19040, DOI 10.1074/jbc.M010735200; Milanini-Mongiat J, 2002, J BIOL CHEM, V277, P20631, DOI 10.1074/jbc.M201753200; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; PENDER N, 1991, J CELL SCI, V100, P187; PLOPPER G, 1993, BIOCHEM BIOPH RES CO, V193, P571, DOI 10.1006/bbrc.1993.1662; PRESTRIDGE DS, 1995, J MOL BIOL, V249, P923, DOI 10.1006/jmbi.1995.0349; Rafty LA, 2001, NUCLEIC ACIDS RES, V29, P1027, DOI 10.1093/nar/29.5.1027; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Saito T, 2001, J BIOL CHEM, V276, P38010; Shyy JYJ, 1997, CURR OPIN CELL BIOL, V9, P707, DOI 10.1016/S0955-0674(97)80125-1; Stossel TP, 2001, NAT REV MOL CELL BIO, V2, P138, DOI 10.1038/35052082; Takahashi M, 1996, J CLIN INVEST, V98, P2623, DOI 10.1172/JCI119083; Tan Y, 1996, EMBO J, V15, P4629, DOI 10.1002/j.1460-2075.1996.tb00840.x; Wang J, 2000, AM J PHYSIOL-HEART C, V279, pH2776, DOI 10.1152/ajpheart.2000.279.6.H2776; Waskiewicz AJ, 1997, EMBO J, V16, P1909, DOI 10.1093/emboj/16.8.1909; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitehurst AW, 2002, P NATL ACAD SCI USA, V99, P7496, DOI 10.1073/pnas.112495999; WILSON E, 1995, J CLIN INVEST, V96, P2364, DOI 10.1172/JCI118293; Yang TTC, 2002, MOL CELL BIOL, V22, P3892, DOI 10.1128/MCB.22.11.3892-3904.2002; Zanke BW, 1996, J BIOL CHEM, V271, P29876, DOI 10.1074/jbc.271.47.29876	56	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47541	47550		10.1074/jbc.M207681200	http://dx.doi.org/10.1074/jbc.M207681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324467	hybrid			2022-12-25	WOS:000179663700092
J	Da Poian, AT; Johnson, JE; Silva, JL				Da Poian, AT; Johnson, JE; Silva, JL			Protein-RNA interactions and virus stability as probed by the dynamics of tryptophan side chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COWPEA MOSAIC-VIRUS; VARIABLE-FREQUENCY PHASE; PRESSURE STABILITY; HYDROSTATIC-PRESSURE; ICOSAHEDRAL VIRUSES; COLD DENATURATION; DNA RECOGNITION; MODULATION DATA; ARC REPRESSOR; RESOLUTION	The correlation between dynamics and stability of icosahedral viruses was studied by steady-state and time-resolved fluorescence approaches. We compared the environment and dynamics of tryptophan side chains of empty capsids and ribonucleoprotein particles of two icosahedral viruses from the comovirus group: cowpea mosaic virus (CPMV) and bean pod mottle virus (BPMV). We found a great difference between tryptophan fluorescence emission spectra of the ribonucleoprotein particles and the empty capsids of BPMV. For CPMV, time-resolved fluorescence revealed differences in the tryptophan environments of the capsid protein. The excited-state lifetimes of tryptophan residues were significantly modified by the presence of RNA in the capsid. More than half of the emission of the tryptophans in the ribonucleoprotein particles of CPMV originates from a single exponential decay that can be explained by a similar, nonpolar environment in the local structure of most of the tryptophans, even though they are physically located in different regions of the x-ray structure. CPMV particles without RNA lost this discrete component of emission. Anisotropy decay measurements demonstrated that tryptophans rotate faster in empty particles when compared with the ribonucleoprotein particles. The increased structural breathing facilitates the denaturation of the empty particles. Our studies bring new insights into the intricate interactions between protein and RNA where part of the missing structural information on the nucleic acid molecule is compensated for by the dynamics.	Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil; Univ Fed Rio de Janeiro, Inst Ciencias Biomed, Ctr Nacl Ressonancia Magnet Nucl Macromol, BR-21941590 Rio De Janeiro, Brazil; The Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA	Universidade Federal do Rio de Janeiro; Universidade Federal do Rio de Janeiro; Scripps Research Institute	Silva, JL (corresponding author), Univ Fed Rio de Janeiro, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil.	jerson@bioqmed.ufrj.br	SILVA, JERSON Lima/GRF-1442-2022; Da Poian, Andrea T./V-1699-2019; Silva, Jerson/J-8984-2014	SILVA, JERSON Lima/0000-0001-9523-9441; Silva, Jerson/0000-0001-9523-9441; Da Poian, Andrea/0000-0002-3969-704X				ALCALA JR, 1985, ANAL INSTRUM, V14, P225; Antson AA, 2000, CURR OPIN STRUC BIOL, V10, P87, DOI 10.1016/S0959-440X(99)00054-8; Balny C, 2002, BBA-PROTEIN STRUCT M, V1595, P3, DOI 10.1016/S0167-4838(01)00331-4; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Beechem JM., 2002, TOPICS FLUORESCENCE, P241, DOI DOI 10.1007/0-306-47058-6_5; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURLEY SK, 1986, J AM CHEM SOC, V108, P7995, DOI 10.1021/ja00285a019; CHEN ZG, 1989, SCIENCE, V245, P154, DOI 10.1126/science.2749253; CHEN ZG, 1990, NEW ASPECTS OF POSITIVE-STRAND RNA VIRUSES, P218; COOPER A, 1976, P NATL ACAD SCI USA, V73, P2740, DOI 10.1073/pnas.73.8.2740; DAPOIAN AT, 1994, BIOCHEMISTRY-US, V33, P8339, DOI 10.1021/bi00193a022; DAPOIAN AT, 1995, BIOCHEMISTRY-US, V34, P2672, DOI 10.1021/bi00008a034; DAPOIAN AT, 1993, J MOL BIOL, V231, P999, DOI 10.1006/jmbi.1993.1347; De Guzman RN, 1998, BIOPOLYMERS, V48, P181, DOI 10.1002/(SICI)1097-0282(1998)48:2<181::AID-BIP7>3.0.CO;2-L; EFTINK MR, 1994, BIOPHYS J, V66, P482, DOI 10.1016/S0006-3495(94)80799-4; EGGEN R, 1988, RNA GENETICS, P49; Ervin J, 2002, BIOPHYS J, V83, P473, DOI 10.1016/S0006-3495(02)75183-7; FOGUEL D, 1994, P NATL ACAD SCI USA, V91, P8244, DOI 10.1073/pnas.91.17.8244; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P1120, DOI 10.1021/bi00004a003; Gaspar LP, 1997, J MOL BIOL, V273, P456, DOI 10.1006/jmbi.1997.1299; GRATTON E, 1984, BIOPHYS J, V46, P479, DOI 10.1016/S0006-3495(84)84044-8; GRATTON E, 1986, BIOCHEM SOC T, V14, P835, DOI 10.1042/bst0140835; Hummer G, 1998, P NATL ACAD SCI USA, V95, P1552, DOI 10.1073/pnas.95.4.1552; Johnson JE, 1997, J MOL BIOL, V269, P665, DOI 10.1006/jmbi.1997.1068; Johnson JE, 1996, P NATL ACAD SCI USA, V93, P27, DOI 10.1073/pnas.93.1.27; LAKOWICZ JR, 1984, BIOPHYS J, V46, P463, DOI 10.1016/S0006-3495(84)84043-6; Lee AL, 2001, NATURE, V411, P501, DOI 10.1038/35078119; LI TS, 1990, BIOCHEMISTRY-US, V29, P5018, DOI 10.1021/bi00473a004; LOMONOSSOFF GP, 1983, EMBO J, V2, P2253, DOI 10.1002/j.1460-2075.1983.tb01731.x; LOMONOSSOFF GP, 1991, PROG BIOPHYS MOL BIO, V55, P107, DOI 10.1016/0079-6107(91)90003-B; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Mohana-Borges R, 2000, J BIOL CHEM, V275, P4708, DOI 10.1074/jbc.275.7.4708; Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920; OLIVEIRA AC, 1994, J MOL BIOL, V240, P184, DOI 10.1006/jmbi.1994.1433; Oliveira AC, 1999, BIOPHYS J, V76, P1270, DOI 10.1016/S0006-3495(99)77290-5; Oliveira AC, 2000, J BIOL CHEM, V275, P16037, DOI 10.1074/jbc.M910145199; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Panda M, 2001, J BIOL CHEM, V276, P6253, DOI 10.1074/jbc.M009530200; Reddy VS, 1998, BIOPHYS J, V74, P546, DOI 10.1016/S0006-3495(98)77813-0; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; Royer C A, 1995, Methods Mol Biol, V40, P65; SCHMIDT T, 1983, VIROLOGY, V127, P65, DOI 10.1016/0042-6822(83)90371-9; SEHNKE PC, 1988, J CRYST GROWTH, V90, P222, DOI 10.1016/0022-0248(88)90319-3; SEMANCIK JS, 1965, VIROLOGY, V27, P476, DOI 10.1016/0042-6822(65)90172-8; SILER DJ, 1976, VIROLOGY, V71, P560, DOI 10.1016/0042-6822(76)90381-0; Silva JL, 1996, CURR OPIN STRUC BIOL, V6, P166, DOI 10.1016/S0959-440X(96)80071-6; SILVA JL, 1993, ANNU REV PHYS CHEM, V44, P89, DOI 10.1146/annurev.pc.44.100193.000513; Silva JL, 2001, TRENDS BIOCHEM SCI, V26, P612, DOI 10.1016/S0968-0004(01)01949-1; SILVA JL, 1992, J MOL BIOL, V223, P545, DOI 10.1016/0022-2836(92)90669-B; STAUFFACHER CV, 1987, NATO ASI SER, P293; Tsang SK, 2000, J MOL BIOL, V296, P335, DOI 10.1006/jmbi.1999.3483; Tuma R, 1999, BIOCHEMISTRY-US, V38, P15025, DOI 10.1021/bi991473p; VANKAMMEN A, 1970, VIROLOGY, V34, P312; VANWEZENBEEK P, 1983, EMBO J, V2, P941, DOI 10.1002/j.1460-2075.1983.tb01525.x; WEBER G, 1993, J PHYS CHEM-US, V97, P7108, DOI 10.1021/j100129a031; WHITE JM, 1980, VIROLOGY, V101, P319, DOI 10.1016/0042-6822(80)90513-9	57	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47596	47602		10.1074/jbc.M209174200	http://dx.doi.org/10.1074/jbc.M209174200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359712	hybrid			2022-12-25	WOS:000179663700099
J	Hingorani, MM; Coman, MM				Hingorani, MM; Coman, MM			On the specificity of interaction between the Saccharomyces cerevisiae clamp loader replication factor C and primed DNA templates during DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; POLYMERASE-III HOLOENZYME; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; LARGE SUBUNIT; ATP UTILIZATION; ACCESSORY PROTEINS; PYROCOCCUS-FURIOSUS; CRYSTAL-STRUCTURE; BINDING PROTEIN	Replication factor C (RFC) catalyzes assembly of circular proliferating cell nuclear antigen clamps around primed DNA, enabling processive synthesis by DNA polymerase during DNA replication and repair. In order to perform this function efficiently, RFC must rapidly recognize primed DNA as the substrate for clamp assembly, particularly during lagging strand synthesis. Earlier reports as well as quantitative DNA binding experiments from this study indicate, however, that RFC interacts with primer-template as well as single- and double-stranded DNA (ssDNA and dsDNA, respectively) with similar high affinity (apparent K(d)approximate to10 nM). How then can RFC distinguish primed DNA sites from excess ssDNA and dsDNA at the replication fork? Further analysis reveals that despite its high affinity for various DNA structures, RFC selects primer-template DNA even in the presence of a 50-fold excess of ssDNA and dsDNA. The interaction between ssDNA or dsDNA and RFC is far less stable than between primed DNA and RFC (k(off)>0.2 s(-1) versus 0.025 s(-1), respectively). We propose that the ability to rapidly bind and release single- and double-stranded DNA coupled with selective, stable binding to primer-template DNA allows RFC to scan DNA efficiently for primed sites where it can pause to initiate clamp assembly.	Wesleyan Univ, Dept Biochem & Mol Biol, Middletown, CT 06459 USA	Wesleyan University	Hingorani, MM (corresponding author), Wesleyan Univ, Dept Biochem & Mol Biol, 205 Hall Atwater Labs, Middletown, CT 06459 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064514] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064514, GM64514-01, R01 GM064514-05] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen BL, 1998, NUCLEIC ACIDS RES, V26, P3877, DOI 10.1093/nar/26.17.3877; Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BUNZ F, 1993, P NATL ACAD SCI USA, V90, P11014, DOI 10.1073/pnas.90.23.11014; BURBELO PD, 1993, P NATL ACAD SCI USA, V90, P11543, DOI 10.1073/pnas.90.24.11543; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Burgers PMJ, 1999, METHODS, V18, P349, DOI 10.1006/meth.1999.0796; Cai JS, 1996, P NATL ACAD SCI USA, V93, P12896, DOI 10.1073/pnas.93.23.12896; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Eissenberg JC, 1997, MOL CELL BIOL, V17, P6367, DOI 10.1128/MCB.17.11.6367; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; Gary SL, 1995, NUCLEIC ACIDS RES, V23, P4986, DOI 10.1093/nar/23.24.4986; Gomes XV, 2001, J BIOL CHEM, V276, P34776, DOI 10.1074/jbc.M011743200; Gomes XV, 2001, J BIOL CHEM, V276, P34768, DOI 10.1074/jbc.M011631200; Gomes XV, 2000, J BIOL CHEM, V275, P14541, DOI 10.1074/jbc.275.19.14541; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; HOWELL EA, 1994, MOL CELL BIOL, V14, P255, DOI 10.1128/MCB.14.1.255; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Keller RC, 1999, NUCLEIC ACIDS RES, V27, P3433, DOI 10.1093/nar/27.17.3433; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kolpashchikov DM, 2001, J MOL RECOGNIT, V14, P239, DOI 10.1002/jmr.538; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; LI XY, 1994, P NATL ACAD SCI USA, V91, P868, DOI 10.1073/pnas.91.3.868; LI XY, 1994, J BIOL CHEM, V269, P21880; LU Y, 1993, BIOCHEM BIOPH RES CO, V193, P779, DOI 10.1006/bbrc.1993.1693; Maga G, 2000, J MOL BIOL, V295, P791, DOI 10.1006/jmbi.1999.3394; Mayanagi K, 2001, J STRUCT BIOL, V134, P35, DOI 10.1006/jsbi.2001.4357; Mossi R, 1997, J BIOL CHEM, V272, P1769, DOI 10.1074/jbc.272.3.1769; Mossi R, 1998, EUR J BIOCHEM, V254, P209, DOI 10.1046/j.1432-1327.1998.254209.x; Neuwald AF, 1999, GENOME RES, V9, P27; NOSKOV V, 1994, NUCLEIC ACIDS RES, V22, P1527, DOI 10.1093/nar/22.9.1527; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ODONNELL ME, 1987, J BIOL CHEM, V262, P16558; Oyama T, 2001, MOL CELL, V8, P455, DOI 10.1016/S1097-2765(01)00328-8; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; Pietroni P, 2001, J MOL BIOL, V309, P869, DOI 10.1006/jmbi.2001.4687; PODUST LM, 1995, MOL CELL BIOL, V15, P3072; Podust VN, 1998, J BIOL CHEM, V273, P31992, DOI 10.1074/jbc.273.48.31992; Schmidt SLG, 2001, J BIOL CHEM, V276, P34792, DOI 10.1074/jbc.M011671200; Schmidt SLG, 2001, J BIOL CHEM, V276, P34784, DOI 10.1074/jbc.M011633200; Sexton DJ, 1998, BIOCHEMISTRY-US, V37, P7749, DOI 10.1021/bi980088h; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Uhlmann F, 1997, J BIOL CHEM, V272, P10058; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Warbrick E, 2000, BIOESSAYS, V22, P997, DOI 10.1002/1521-1878(200011)22:11<997::AID-BIES6>3.3.CO;2-R; Yuzhakov A, 1999, EMBO J, V18, P6189, DOI 10.1093/emboj/18.21.6189	55	27	27	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47213	47224		10.1074/jbc.M206764200	http://dx.doi.org/10.1074/jbc.M206764200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370190	hybrid, Green Accepted			2022-12-25	WOS:000179663700049
J	Huang, MC; Laskowska, A; Vestweber, D; Wild, MK				Huang, MC; Laskowska, A; Vestweber, D; Wild, MK			The alpha(1,3)-fucosyltransferase Fuc-TIV, but not Fuc-TVII, generates sialyl Lewis X-like epitopes preferentially on glycolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIN GLYCOPROTEIN LIGAND-1; ELAM-1-DEPENDENT CELL-ADHESION; NORMAL HUMAN-LEUKOCYTES; LEUKEMIA HL-60 CELLS; P-SELECTIN; FUCOSYL-TRANSFERASE; MYELOID CELLS; MONOCLONAL-ANTIBODY; MOLECULAR-CLONING; IN-VIVO	Fuc-TIV and Fuc-TVII are the two alpha(1, 3)-fucosyltransferases in myeloid cells responsible for the biosynthesis of sialyl Lewis X (sLe(x)), the minimal ligand structure for the selectins. We have compared the ability of Fuc-TIV and Fuc-TVII to generate sLe(x)-like epitopes in transfected Chinese hamster ovary (CHO)-Pro(-)5 cells expressing the P-selectin glycoprotein ligand-1 and the core-2 branching enzyme C2GnT. We found that mouse Fuc-TIV and Fuc-TVII can generate similar levels of cell surface sLe(x). Surprisingly however, Fuc-TIV-generated sLe(x) was resistant to proteinase K and trypsin treatment and could be removed from cells by delipidation with chloroform/methanol, whereas 80-90% of Fuc-TVII-generated sLe(x) was protease-sensitive, and most of it resistant to delipidation. Despite similar levels of sLe(x) on the cell surface, Fuc-TVII transfectants adhered to immobilized E-selectin-IgG under static and flow conditions better than Fuc-TIV transfectants. Binding was mainly protease sensitive, indicating that glycoproteins were more efficient ligands than glycolipids. In summary, we conclude that the two fucosyltransferases differ in their in vivo specificity for acceptor substrates with Fuc-TVII generating sLe(x) preferentially on glycoproteins, whereas most of the Fuc-TIV-generated sLe(x) is found on glycolipids. Interestingly, the non-catalytic portion of Fuc-TIV in a Fuc-TIV/VII chimeric enzyme mediated the specificity for glycolipid substrates.	Univ Munster, Ctr Mol Biol Inflammat, Inst Cell Biol, D-48149 Munster, Germany	University of Munster	Wild, MK (corresponding author), Univ Munster, Ctr Mol Biol Inflammat, Inst Cell Biol, Von Esmarch Str 56, D-48149 Munster, Germany.			Vestweber, Dietmar/0000-0002-3517-732X; HUANG, MIN-CHUAN/0000-0002-0704-3447				ALON R, 1995, J IMMUNOL, V154, P5356; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Borges E, 1997, J EXP MED, V185, P573, DOI 10.1084/jem.185.3.573; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; Borges E, 1997, J BIOL CHEM, V272, P28786, DOI 10.1074/jbc.272.45.28786; BOSSE R, 1994, EUR J IMMUNOL, V24, P3019, DOI 10.1002/eji.1830241215; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; FUKUSHIMA K, 1984, CANCER RES, V44, P5279; GERSTEN KM, 1995, J BIOL CHEM, V270, P25047, DOI 10.1074/jbc.270.42.25047; GOELZ S, 1994, J BIOL CHEM, V269, P1033; GOELZ SE, 1990, CELL, V63, P1349, DOI 10.1016/0092-8674(90)90430-M; Gotsch U, 1997, J CELL SCI, V110, P583; Grabenhorst E, 1998, J BIOL CHEM, V273, P30985, DOI 10.1074/jbc.273.47.30985; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; HAHNE M, 1993, J CELL BIOL, V121, P655, DOI 10.1083/jcb.121.3.655; Handa K, 1997, BIOCHEMISTRY-US, V36, P12412, DOI 10.1021/bi971181t; HANISCH FG, 1988, CARBOHYD RES, V178, P23, DOI 10.1016/0008-6215(88)80099-5; Hirata T, 2000, J EXP MED, V192, P1669, DOI 10.1084/jem.192.11.1669; HOLMES EH, 1986, J BIOL CHEM, V261, P3737; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; Huang MC, 2000, J BIOL CHEM, V275, P31353, DOI 10.1074/jbc.M005449200; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Knibbs RN, 1996, J CELL BIOL, V133, P911, DOI 10.1083/jcb.133.4.911; KUMAR R, 1991, J BIOL CHEM, V266, P21777; LENTER M, 1994, J CELL BIOL, V125, P471, DOI 10.1083/jcb.125.2.471; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; LEVINOVITZ A, 1993, J CELL BIOL, V121, P449, DOI 10.1083/jcb.121.2.449; LOWE JB, 1991, J BIOL CHEM, V266, P17467; Lowe JB, 1997, KIDNEY INT, V51, P1418, DOI 10.1038/ki.1997.194; LOWE JB, 1990, CELL, V63, P475, DOI 10.1016/0092-8674(90)90444-J; MACHER BA, 1988, J BIOL CHEM, V263, P10186; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; Mitsuoka C, 1997, BIOCHEM BIOPH RES CO, V230, P546, DOI 10.1006/bbrc.1996.6012; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; Niemela R, 1998, J BIOL CHEM, V273, P4021, DOI 10.1074/jbc.273.7.4021; OHMORI K, 1993, BLOOD, V82, P2797; Osanai T, 1996, BIOCHEM BIOPH RES CO, V218, P610, DOI 10.1006/bbrc.1996.0108; Pendl GG, 2002, BLOOD, V99, P946, DOI 10.1182/blood.V99.3.946; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; STEEGMAIER M, 1995, NATURE, V373, P615, DOI 10.1038/373615a0; STROUD MR, 1995, BIOCHEM BIOPH RES CO, V209, P777, DOI 10.1006/bbrc.1995.1568; Stroud MR, 1996, BIOCHEMISTRY-US, V35, P758, DOI 10.1021/bi951600r; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Wagers AJ, 1997, J IMMUNOL, V159, P1917; Wagers AJ, 1998, J EXP MED, V188, P2225, DOI 10.1084/jem.188.12.2225; Weninger W, 2000, IMMUNITY, V12, P665, DOI 10.1016/S1074-7613(00)80217-4; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; Yang J, 1999, J EXP MED, V190, P1769, DOI 10.1084/jem.190.12.1769; Zollner O, 1996, J BIOL CHEM, V271, P33002, DOI 10.1074/jbc.271.51.33002	56	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47786	47795		10.1074/jbc.M208283200	http://dx.doi.org/10.1074/jbc.M208283200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359718	hybrid			2022-12-25	WOS:000179663700123
J	Adachi, R; Takeuchi, K; Suzuki, K				Adachi, R; Takeuchi, K; Suzuki, K			Antisense oligonucleotide to cofilin enhances respiratory burst and phagocytosis in opsonized zymosan-stimulated mouse macrophage J774.1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-KINASE 1; ACTIN-BINDING; NADPH OXIDASE; HL-60 CELLS; RAPID DEPHOSPHORYLATION; TRIGGERED ACTIVATION; POSSIBLE INVOLVEMENT; ADF/COFILIN FAMILY; PHOSPHORYLATION; PROTEIN	Phagocytes play a central role in the host defense system, and the relationship between the mechanism of their activation and cytoskeletal reorganization has been studied. We have previously reported a possible involvement of cofilin, an actin-binding protein, in phagocyte functions through its phosphorylation/dephosphorylation. and translocation to the plasma membrane regions. In this work, we have obtained a new line of evidence showing an important role of cofilin in phagocyte functions using the mouse macrophage cell line J774.1 and an antisense oligonucleotide to cofilin. Upon stimulation with opsonized zymosan (OZ), cofilin was phosphorylated, and it accumulated around phagocytic vesicles. As the antisense oligonucleotide to cofilin, a 20-mer S-oligo corresponding to the sequence including the AUG translational initiation site was found to be effective. In the cells treated with the antisense oligonucleotide, the amount of cofilin was less than 30% of that in the control cells, and the level of F-actin was two or three times higher than that in the control cells before and throughout the cell activation. In the antisense oligonucleotide-treated cells, OZ-triggered superoxide production was three times faster than that in the control cells. Furthermore, phagocytosis of OZ was enhanced by the antisense. These results show that cofilin plays an essential role in the control of phagocyte function through regulation of actin filament dynamics.	Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan; Nagoya Univ, Div Biol Sci, Grad Sch Sci, Chigusa Ku, Nagoya, Aichi 4648602, Japan	National Institute of Health Sciences - Japan; Nagoya University	Suzuki, K (corresponding author), Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan.	ksuzuki@nihs.go.jp	Takeuchi, Kosei/AAV-3577-2021	Takeuchi, Kosei/0000-0001-6397-2243				Abe H, 1996, J CELL BIOL, V132, P871, DOI 10.1083/jcb.132.5.871; Adachi R, 2000, INT J IMMUNOPHARMACO, V22, P855, DOI 10.1016/S0192-0561(00)00045-X; Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Aizawa H, 1996, J CELL BIOL, V132, P335, DOI 10.1083/jcb.132.3.335; AIZAWA H, 1995, J BIOL CHEM, V270, P10923, DOI 10.1074/jbc.270.18.10923; Aizawa H, 2001, GENES CELLS, V6, P913, DOI 10.1046/j.1365-2443.2001.00470.x; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bamburg JR, 1999, ANNU REV CELL DEV BI, V15, P185, DOI 10.1146/annurev.cellbio.15.1.185; Bierne H, 2001, J CELL BIOL, V155, P101, DOI 10.1083/jcb.200104037; Djafarzadeh S, 1997, EXP CELL RES, V236, P427, DOI 10.1006/excr.1997.3731; DOWNEY GP, 1992, J CELL BIOL, V116, P695, DOI 10.1083/jcb.116.3.695; ELBENNA J, 1994, J BIOL CHEM, V269, P6729; Granfeldt D, 2001, INFLAMMATION, V25, P165, DOI 10.1023/A:1011084330283; GREENBERG S, 1991, J CELL BIOL, V113, P757, DOI 10.1083/jcb.113.4.757; Grogan A, 1997, J CELL SCI, V110, P3071; Heyworth PG, 1997, HISTOCHEM CELL BIOL, V108, P221, DOI 10.1007/s004180050162; Ichetovkin I, 2000, CELL MOTIL CYTOSKEL, V45, P293, DOI 10.1002/(SICI)1097-0169(200004)45:4<293::AID-CM5>3.0.CO;2-1; IIDA K, 1993, GENE, V124, P115; Iida K, 1999, GENES CELLS, V4, P21, DOI 10.1046/j.1365-2443.1999.00235.x; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; Lee KH, 2000, EUR J IMMUNOL, V30, P892, DOI 10.1002/1521-4141(200003)30:3<892::AID-IMMU892>3.0.CO;2-U; Maciver SK, 2002, GENOME BIOL, V3; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui S, 2002, J BIOL CHEM, V277, P544, DOI 10.1074/jbc.M110153200; Matsusaki H, 2000, BIOMACROMOLECULES, V1, P17, DOI 10.1021/bm9900040; May RC, 2001, J CELL SCI, V114, P1061; McGough Amy, 2001, Results and Problems in Cell Differentiation, V32, P135; Minamide LS, 2000, NAT CELL BIOL, V2, P628, DOI 10.1038/35023579; MORIYAMA K, 1990, NUCLEIC ACIDS RES, V18, P3053, DOI 10.1093/nar/18.10.3053; Nagaishi K, 1999, J BIOCHEM-TOKYO, V125, P891, DOI 10.1093/oxfordjournals.jbchem.a022365; Nagaishi K, 1999, J CELL PHYSIOL, V180, P345, DOI 10.1002/(SICI)1097-4652(199909)180:3<345::AID-JCP5>3.0.CO;2-J; NAUSEEF WM, 1991, J BIOL CHEM, V266, P5911; Nishita M, 2002, MOL CELL BIOL, V22, P774, DOI 10.1128/MCB.22.3.774-783.2002; Niwa R, 2002, CELL, V108, P233, DOI 10.1016/S0092-8674(01)00638-9; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Ojala PJ, 2001, BIOCHEMISTRY-US, V40, P15562, DOI 10.1021/bi0117697; Okada K, 1999, J CELL SCI, V112, P1553; Okada K, 1996, EXP CELL RES, V227, P116, DOI 10.1006/excr.1996.0256; OKADA K, 2002, J BIOL CHEM, V277; Samstag Y, 1996, J IMMUNOL, V156, P4167; Sumi T, 1999, J CELL BIOL, V147, P1519, DOI 10.1083/jcb.147.7.1519; Sun HQ, 1999, J BIOL CHEM, V274, P33179, DOI 10.1074/jbc.274.47.33179; SUZUKI K, 1995, BBA-MOL CELL RES, V1266, P261, DOI 10.1016/0167-4889(95)00029-R; SUZUKI K, 1995, J BIOL CHEM, V270, P19551, DOI 10.1074/jbc.270.33.19551; Tamura M, 2000, BIOCHEM J, V349, P369, DOI 10.1042/0264-6021:3490369; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735; YONEZAWA N, 1987, CELL STRUCT FUNCT, V12, P443, DOI 10.1247/csf.12.443	49	31	32	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45566	45571		10.1074/jbc.M207419200	http://dx.doi.org/10.1074/jbc.M207419200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297504	hybrid			2022-12-25	WOS:000179404800122
J	Sparla, F; Pupillo, P; Trost, P				Sparla, F; Pupillo, P; Trost, P			The C-terminal extension of glyceraldehyde-3-phosphate dehydrogenase subunit B acts as an autoinhibitory domain regulated by thioredoxins and nicotinamide adenine dinucleotide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATION-REDUCTION PROPERTIES; CHLOROPLAST ENZYMES; 3-PHOSPHATE DEHYDROGENASE; MULTIENZYME COMPLEXES; SPINACH-CHLOROPLASTS; REDOX REGULATION; ACTIVATION; NADP; LIGHT; PEA	The regulatory isoform. of glyceraidehyde-3-phosphate dehydrogenase (GAPDH) is a light-activated enzyme constituted by subunits GapA and GapB. The NADPH-dependent activity of regulatory GAPDH from spinach chloroplasts was affected by the redox potential (E-m,E-7.9, -353 +/- 11 mV) through the action of thioredoxin f The redox dependence of recombinant GapB (E-m,E-7.9, -347 +/- 9 mV) was similar to native GAPDH, whereas GapA was essentially redox-insensitive. GapB mutants having one or two C-terminal cysteines mutated into serines (C358S, C349S, C349S/C358S) were less redoxsensitive than GapB. Different mutants with other cysteines substituted by serines (C18S, C274S, C285S) still showed strong redox regulation. Fully active GapB was a tetramer of B-subunits, and, when incubated with NAD, it associated to a high molecular weight oligomer showing low NADPH-dependent activity. The C-terminal GapB mutants (C358S, C349S, C349S/C358S) were active tetramers unable to aggregate to higher oligomers in the presence of NAD, whereas other mutants (C18S, C274S, C285S) again behaved like GapB. We conclude that a regulatory disulfide, between Cys349 and Cys-358 of the C-terminal extension of GapB, does form in the presence of oxidized thioredoxin. This covalent modification is required for the NAD-dependent association into higher oligomers and inhibition of the NADPH-activity. By leading to GAPDH autoinhibition, thioredoxin and NAD may thus concur to the dark inactivation of the enzyme in vivo.	Univ Bologna, Dept Biol, Lab Plant Physiol, I-40126 Bologna, Italy	University of Bologna	Trost, P (corresponding author), Univ Bologna, Dept Biol, Lab Plant Physiol, Via Irnerio 42, I-40126 Bologna, Italy.		Trost, Paolo/F-2425-2011	Trost, Paolo/0000-0002-6347-8701; Sparla, Francesca/0000-0002-2103-4870				Baalmann E, 1996, PLANT MOL BIOL, V32, P505, DOI 10.1007/BF00019102; BAALMANN E, 1994, BOT ACTA, V107, P313, DOI 10.1111/j.1438-8677.1994.tb00801.x; Baalmann E, 1995, ARCH BIOCHEM BIOPHYS, V324, P201, DOI 10.1006/abbi.1995.0031; BIESECKER G, 1977, NATURE, V266, P328, DOI 10.1038/266328a0; BRINKMANN H, 1989, PLANT MOL BIOL, V13, P81, DOI 10.1007/BF00027337; BUCHANAN BB, 1980, ANNU REV PLANT PHYS, V31, P341, DOI 10.1146/annurev.pp.31.060180.002013; CERFF R, 1979, EUR J BIOCHEM, V94, P243, DOI 10.1111/j.1432-1033.1979.tb12891.x; Chiadmi M, 1999, EMBO J, V18, P6809, DOI 10.1093/emboj/18.23.6809; Fermani S, 2001, J MOL BIOL, V314, P527, DOI 10.1006/jmbi.2001.5172; FERRI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P36, DOI 10.1016/0167-4838(90)90119-Z; GERHARDT R, 1987, PLANT PHYSIOL, V83, P399, DOI 10.1104/pp.83.2.399; HARRIS JI, 1976, ENZYMES, V13, P1; HEINEKE D, 1991, PLANT PHYSIOL, V95, P1131, DOI 10.1104/pp.95.4.1131; Hirasawa M, 2000, BIOCHEMISTRY-US, V39, P3344, DOI 10.1021/bi9916731; HUTCHISON RS, 1995, METHOD ENZYMOL, V252, P220; Hutchison RS, 2000, BIOCHEMISTRY-US, V39, P6679, DOI 10.1021/bi0001978; Jacquot JP, 1997, FEBS LETT, V401, P143, DOI 10.1016/S0014-5793(96)01459-7; Knaff DB, 2000, PHYSIOL PLANTARUM, V110, P309, DOI 10.1034/j.1399-3054.2000.1100304.x; Lebreton S, 1999, J BIOL CHEM, V274, P20879, DOI 10.1074/jbc.274.30.20879; LEES WJ, 1993, J ORG CHEM, V58, P642, DOI 10.1021/jo00055a016; Li AD, 1997, PLANT PHYSIOL, V115, P1201, DOI 10.1104/pp.115.3.1201; MULLER B, 1969, EUR J BIOCHEM, V9, P101, DOI 10.1111/j.1432-1033.1969.tb00581.x; PUPILLO P, 1979, ARCH BIOCHEM BIOPHYS, V194, P581, DOI 10.1016/0003-9861(79)90653-2; PUPILLO P, 1975, EUR J BIOCHEM, V51, P475, DOI 10.1111/j.1432-1033.1975.tb03947.x; Qi JF, 2001, J BIOL CHEM, V276, P35247, DOI 10.1074/jbc.M103855200; Reichert A, 2000, PHYSIOL PLANTARUM, V110, P330, DOI 10.1034/j.1399-3054.2000.1100307.x; RodriguezSuarez RJ, 1997, BIOCHEM BIOPH RES CO, V232, P388, DOI 10.1006/bbrc.1997.6242; Ruelland E, 1999, TRENDS PLANT SCI, V4, P136, DOI 10.1016/S1360-1385(99)01391-6; SCAGLIARINI S, 1993, PLANTA, V190, P313, DOI 10.1007/BF00196959; Scagliarini S, 1998, J EXP BOT, V49, P1307, DOI 10.1093/jexbot/49.325.1307; Schurmann P, 2000, ANNU REV PLANT PHYS, V51, P371, DOI 10.1146/annurev.arplant.51.1.371; SEGEL IH, 1975, ENZYME KINETICS, P607; SUSS KH, 1993, P NATL ACAD SCI USA, V90, P5514, DOI 10.1073/pnas.90.12.5514; TROST P, 1993, PLANTA, V190, P320, DOI 10.1007/BF00196960; WARAASWAPATI O, 1980, PLANT PHYSIOL, V66, P34, DOI 10.1104/pp.66.1.34; Wedel N, 1998, P NATL ACAD SCI USA, V95, P9699, DOI 10.1073/pnas.95.16.9699; WERDAN K, 1975, BIOCHIM BIOPHYS ACTA, V396, P276, DOI 10.1016/0005-2728(75)90041-9; WOLOSIUK R, 1990, ARCH BIOCHEM BIOPHYS, V246, P1; WOLOSIUK RA, 1976, J BIOL CHEM, V251, P6456; WOLOSIUK RA, 1978, PLANT PHYSIOL, V61, P669, DOI 10.1104/pp.61.4.669; WOLOSIUK RA, 1977, NATURE, V266, P565, DOI 10.1038/266565a0; ZAPPONI MC, 1993, BIOL CHEM H-S, V374, P395, DOI 10.1515/bchm3.1993.374.1-6.395; ZIEGLER H, 1965, PLANTA, V65, P369, DOI 10.1007/BF00385415	43	85	88	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44946	44952		10.1074/jbc.M206873200	http://dx.doi.org/10.1074/jbc.M206873200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270927	hybrid			2022-12-25	WOS:000179404800047
J	Archey, WB; McEachern, KA; Robson, M; Offit, K; Vaziri, SAJ; Casey, G; Borg, A; Arrick, BA				Archey, WB; McEachern, KA; Robson, M; Offit, K; Vaziri, SAJ; Casey, G; Borg, A; Arrick, BA			Increased CpG methylation of the estrogen receptor gene in BRCA1-linked estrogen receptor-negative breast cancers	ONCOGENE			English	Article						BRCA1; estrogen receptor; methylation; breast cancer	SPORADIC BREAST; OVARIAN-CANCER; TRANSCRIPTIONAL ACTIVATION; DNA METHYLATION; BRCA1; CARCINOMAS; EXPRESSION; TUMORS; PROMOTER; MUTATIONS	A distinctive feature of BRCA1-linked breast cancers is that they typically do not express estrogen receptor-alpha (ERalpha). Previous investigation suggests that methylation of CpGs within the ERa promoter mediates repression of gene expression in some ERalpha-negative breast cancers. To determine if methylation of CpGs within the ERalpha promoter is associated with BRCA1-linked breast cancers, we evaluated methylation in exon 1 of the ERalpha gene in 40 ERalpha-negative breast cancers, 20 of which were non BRCA1-linked and 20 BRCA1-linked. CpG methylation was evaluated by either methylation-sensitive restriction digest (HpaII), methylation-sensitive PCR (MSP), or direct sequencing of bisulfite-treated genomic DNA. Results from HpaII digests and MSP documented a high degree of methylation, the MSP data showing slightly higher methylation in the BRCA1-linked group. CpGs analysed by direct sequencing showed an overall average methylation of 25% among non BRCA1-linked cancers and 40% among BRCA1-linked cancers (P=0.0031). The most notable difference was found at five particular CpGs, each of which exhibited a greater than twofold increase in methylation in the BRCA1-linked group compared to the non BRCA1-linked group (P < 0.03 for each CpG). Methylation of certain critical CpGs may represent an important factor in transcriptional repression of the ERa gene in BRCA1-linked breast cancers.	Dartmouth Coll Sch Med, Dept Med, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Physiol, Hanover, NH 03755 USA; Dartmouth Coll Sch Med, Dept Biochem, Hanover, NH 03755 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Univ Lund Hosp, Dept Oncol, S-22185 Lund, Sweden	Dartmouth College; Dartmouth College; Dartmouth College; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cleveland Clinic Foundation; Lund University; Skane University Hospital	Arrick, BA (corresponding author), Dartmouth Coll Sch Med, Dept Med, Kellogg Box 0128, Hanover, NH 03755 USA.			Robson, Mark/0000-0002-3109-1692	NCI NIH HHS [CA77772] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077772] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Archey WB, 1999, CANCER RES, V59, P2292; BARRETTLEE PJ, 1987, CANCER RES, V47, P6653; Berns EMJJ, 2001, BRIT J CANCER, V85, P538, DOI 10.1054/bjoc.2001.1937; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; Cervoni N, 2001, J BIOL CHEM, V276, P40778, DOI 10.1074/jbc.M103921200; CORNELIS RS, 1995, GENE CHROMOSOME CANC, V13, P203, DOI 10.1002/gcc.2870130310; DECONINCK EC, 1995, MOL CELL BIOL, V15, P2191; Dobosy JR, 2001, CELL MOL LIFE SCI, V58, P721, DOI 10.1007/PL00000895; FERGUSON AT, 1995, CANCER RES, V55, P2279; Hedenfalk I, 2001, NEW ENGL J MED, V344, P539, DOI 10.1056/NEJM200102223440801; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Iwase H, 1999, BRIT J CANCER, V80, P1982, DOI 10.1038/sj.bjc.6690631; Johannsson OT, 1997, EUR J CANCER, V33, P362, DOI 10.1016/S0959-8049(96)00469-8; Karp SE, 1997, CANCER-AM CANCER SOC, V80, P435, DOI 10.1002/(SICI)1097-0142(19970801)80:3<435::AID-CNCR11>3.0.CO;2-Y; Lapidus RG, 1998, CANCER RES, V58, P2515; Lapidus RG, 1996, CLIN CANCER RES, V2, P805; Loman N, 1998, CANCER, V83, P310, DOI 10.1002/(SICI)1097-0142(19980715)83:2<310::AID-CNCR15>3.0.CO;2-W; McPherson LA, 1997, P NATL ACAD SCI USA, V94, P4342, DOI 10.1073/pnas.94.9.4342; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; NEUHAUSEN SL, 1994, CANCER RES, V54, P6069; Penolazzi L, 2000, BBA-GENE STRUCT EXPR, V1492, P560, DOI 10.1016/S0167-4781(00)00145-7; PIVA R, 1990, BRIT J CANCER, V61, P270, DOI 10.1038/bjc.1990.50; Tang ZQ, 1997, MOL CELL BIOL, V17, P1274, DOI 10.1128/MCB.17.3.1274; Tomlinson GE, 1998, CANCER RES, V58, P3237; van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a; Vaziri SAJ, 2001, CLIN CANCER RES, V7, P1937; Wang Q, 2000, ONCOGENE, V19, P6152, DOI 10.1038/sj.onc.1203974; Welcsh PL, 2000, TRENDS GENET, V16, P69, DOI 10.1016/S0168-9525(99)01930-7; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; YAICH L, 1992, CANCER RES, V52, P77; Yang XW, 2000, CANCER RES, V60, P6890; Yarden RI, 1999, P NATL ACAD SCI USA, V96, P4983, DOI 10.1073/pnas.96.9.4983; Yoshikawa K, 1999, CLIN CANCER RES, V5, P1249; Zheng L, 2000, ONCOGENE, V19, P6159, DOI 10.1038/sj.onc.1203968	34	29	32	2	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7034	7041		10.1038/sj.onc.1205844	http://dx.doi.org/10.1038/sj.onc.1205844			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370825				2022-12-25	WOS:000178424900006
J	Leu, TH; Maa, MC				Leu, TH; Maa, MC			Tyr-863 phosphorylation enhances focal adhesion kinase autophosphorylation at Tyr-397	ONCOGENE			English	Article						Src; FAK; tyrosine kinase; tyrosol phosphorylation	PROTEIN-TYROSINE KINASE; ACTIVATION LOOP PHOSPHORYLATION; MAP KINASE; IN-VIVO; BINDING; SITE; SRC; REQUIREMENT; ASSOCIATION; FIBRONECTIN	Tyr-397 phosphorylation is important for focal adhesion kinase (FAK)-mediated signalling. In vitro FAK immunocomplex kinase experiments demonstrated that both FAK Tyr-576/577 and Tyr-863 phosphorylation regulated FAK Tyr-397 phosphorylation. While the former increased the intermolecular transphosphorylation activity of FAK, the latter was crucial for its cis-phosphorylation. This observation was further supported by the reduced complex formation between Src and 3F-FAK (576F/577F/863F-FAK) as compared to that between Src and 576F/577F-FAK or Src and 863F-FAK. Regulation of cis- and transphosphorylation activities of FAK by such a differential tyrosyl phosphorylation mechanism is unprecedented. Furthermore, in fibronectin-stimulated cells, both Tyr-576/577 and Tyr-863 phosphorylation could enhance FAK Tyr-397 phosphorylation. This observation implies that integrin-mediated FAK Tyr-397 phosphorylation was also regulated through both FAK cis- and transphosphorylation mechanisms.	Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; Chung Shan Med Univ, Inst Biochem, Taichung, Taiwan	National Cheng Kung University; Chung Shan Medical University	Leu, TH (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan.							ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; CALALB MB, 1995, MOL CELL BIOL, V15, P954; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; EIDE BL, 1995, MOL CELL BIOL, V15, P2819; Giancotti FG, 1997, CURR OPIN CELL BIOL, V9, P691, DOI 10.1016/S0955-0674(97)80123-8; GUAN JL, 1991, CELL REGUL, V2, P951, DOI 10.1091/mbc.2.11.951; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUGHES SH, 1987, J VIROL, V61, P3004, DOI 10.1128/JVI.61.10.3004-3012.1987; KANNER SB, 1990, P NATL ACAD SCI USA, V87, P3328, DOI 10.1073/pnas.87.9.3328; Keranen LM, 1995, CURR BIOL, V5, P1394, DOI 10.1016/S0960-9822(95)00277-6; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Kumar CC, 1998, ONCOGENE, V17, P1365, DOI 10.1038/sj.onc.1202172; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Maa MC, 1998, BIOCHEM BIOPH RES CO, V251, P344, DOI 10.1006/bbrc.1998.9464; Maa MC, 1999, BBA-MOL CELL RES, V1450, P341, DOI 10.1016/S0167-4889(99)00069-5; Owen JD, 1999, MOL CELL BIOL, V19, P4806; Ruest PJ, 2000, CELL GROWTH DIFFER, V11, P41; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; Schlaepfer DD, 1996, MOL CELL BIOL, V16, P5623; SCHLAEPFER DD, 1994, NATURE, V372, P786	25	33	34	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					6992	7000		10.1038/sj.onc.1205904	http://dx.doi.org/10.1038/sj.onc.1205904			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370821				2022-12-25	WOS:000178424900002
J	Viniegra, JG; Losa, JH; Sanchez-Arevalo, VJ; Cobo, CP; Soria, VMF; Cajal, SRY; Sanchez-Prieto, R				Viniegra, JG; Losa, JH; Sanchez-Arevalo, VJ; Cobo, CP; Soria, VMF; Cajal, SRY; Sanchez-Prieto, R			Modulation of PI3K/Akt pathway by E1a mediates sensitivity to cisplatin	ONCOGENE			English	Article						E1a; PI3k; Akt; downregulation; insulin; cisplatin	PROTEIN-KINASE-B; ADENOVIRUS E1A; OVARIAN-CANCER; CELL-GROWTH; INSULIN; ACTIVATION; EXPRESSION; GENE; PHOSPHORYLATION; SUPPRESSION	In order to investigate the molecular mechanisms implicated in the induction of chemo sensitivity by adenovirus E1a gene expression, we decided to investigate which signal transduction pathways could be affected by the E1a gene in Human Normal Fibroblast (IMR90). No effect was observed in SAPK pathways (p38MAPK and JNK), but E1a was able to affect the Akt activation mediated by insulin. This result was confirmed by transient transfection experiments performed in Cos-7 cells and also observed in other transformed cell lines such as A431. Furthermore, E1a expression induces a decrease in the basal status of Akt activity. Finally we demonstrated that E1a is able to block the Akt activation mediated by cisplatin and correlates with a sensitive phenotype. In summary, our data demonstrate that specific inhibition of the PI3K/Akt pathway mediates some of the biological properties of E1a such as induction of chemosensitivity.	Clin Puerta Hierro, Unidad Patol Mol, Madrid 28035, Spain	Clinica Veterinaria Puerta de Hierro; Hospital Puerta de Hierro-Majadahonda	Sanchez-Prieto, R (corresponding author), Clin Puerta Hierro, Unidad Patol Mol, C San Martin de Porres 4, Madrid 28035, Spain.		Prieto, Ricardo/AAZ-7221-2021; Sanchez-Prieto, Ricardo/AAY-4271-2021; Lobo, Victor Javier vjsal Sanchez-Arevalo/H-1069-2011; Ramon y Cajal, Santiago/H-4955-2016; Javier, Hernandez Losa/C-1173-2008; Sanchez-Prieto, Ricardo/B-6877-2008; Lobo, Victor Javier Sanchez-Arevalo/N-8641-2019	Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier vjsal Sanchez-Arevalo/0000-0002-4561-1505; Ramon y Cajal, Santiago/0000-0002-3867-1390; Javier, Hernandez Losa/0000-0003-1526-3201; Sanchez-Prieto, Ricardo/0000-0003-0882-9780; Lobo, Victor Javier Sanchez-Arevalo/0000-0002-4561-1505; Fernandez-Soria, Victor Manuel/0000-0002-4225-8697				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Brognard J, 2001, CANCER RES, V61, P3986; FRANZA BR, 1986, CELL, V44, P409, DOI 10.1016/0092-8674(86)90462-9; Frisch SM, 2001, ADV CANCER RES, V80, P39, DOI 10.1016/S0065-230X(01)80011-7; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hayakawa J, 2000, CANCER RES, V60, P5988; KIM HS, 1995, MOL ENDOCRINOL, V9, P178, DOI 10.1210/me.9.2.178; Lee WP, 1999, MOL CELL BIOL, V19, P8075; Maira SM, 2001, SCIENCE, V294, P374, DOI 10.1126/science.1062030; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; Ng SSW, 2001, CLIN CANCER RES, V7, P3269; Razzini G, 2000, FASEB J, V14, P1179, DOI 10.1096/fasebj.14.9.1179; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SanchezPrieto R, 1996, ONCOGENE, V13, P1083; See RH, 1998, MOL CELL BIOL, V18, P4012, DOI 10.1128/MCB.18.7.4012; Shao RP, 1997, J BIOL CHEM, V272, P32739, DOI 10.1074/jbc.272.52.32739; Shao RP, 2001, CANCER RES, V61, P7413; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; STEIN RW, 1989, MOL CELL BIOL, V9, P4531, DOI 10.1128/MCB.9.10.4531; TEODORO JG, 1995, ONCOGENE, V11, P467; Whalen SG, 1997, J VIROL, V71, P3545, DOI 10.1128/JVI.71.5.3545-3553.1997; YU DH, 1990, P NATL ACAD SCI USA, V87, P4499, DOI 10.1073/pnas.87.12.4499	26	35	35	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7131	7136		10.1038/sj.onc.1205934	http://dx.doi.org/10.1038/sj.onc.1205934			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370836				2022-12-25	WOS:000178424900017
J	Fanning, AS; Ma, TY; Anderson, JM				Fanning, AS; Ma, TY; Anderson, JM			Isolation and functional characterization of the actin-binding region in the tight junction protein ZO-1	FASEB JOURNAL			English	Article						MAGUK; cytoskeleton; assembly	CELL-CELL ADHESION; EPITHELIAL-CELLS; ALPHA-CATENIN; CDNA CLONING; MAGUK FAMILY; MDCK CELLS; OCCLUDIN; RHO; EXPRESSION; STRANDS	Zonula occludens (ZO)-1 is a member of the MAGUK (membrane-associated guanylate kinase homologs) family of membrane-associated signaling molecules that binds directly to both cytosolic and transmembrane components of the tight junction and is believed to organize these proteins within the apical junctional complex. It also binds directly to F-actin, although the functional relevance of this interaction is unknown. To address this issue, we have used VSVG-tagged transgenes to dissect ZO-1 and have identified a 220 amino acid region of ZO-1 that is necessary for its association with F-actin in MDCK cell pull-down assays. A GST fusion expressing this region can bind directly to F-actin in vitro, whereas a GFP fusion expressing this domain decorates actin stress fibers when expressed in MDCK cells. These results indicate that this actin-binding region (ABR) is both necessary and sufficient for binding to F-actin in vitro and in vivo. VSVG-tagged transgenes that lack the ABR still accumulate at both early and late cell-cell contacts in MDCK cells, suggesting that the ABR is not required for tight junction localization. However, accumulation of constructs lacking the ABR is markedly reduced at tight junctions in confluent cells, suggesting that the ABR does play an important role in the localization of ZO-1 at junctions. Furthermore, the ABR is required for localization to a novel actin-rich pool of ZO-1 that accumulates in puncta at the free edge of cells before initiation of cell-cell contact. We conclude that direct interactions between ZO-1 and F-actin play a role in several different steps of junction assembly.	Univ N Carolina, Dept Cell & Mol Physiol, Chapel Hill, NC 27599 USA; Univ New Mexico, Sch Med, Dept Med, Albuquerque, NM 87131 USA	University of North Carolina; University of North Carolina Chapel Hill; University of New Mexico	Fanning, AS (corresponding author), Univ N Carolina, Dept Cell & Mol Physiol, CB 7545,Med Sci Res Bldg, Chapel Hill, NC 27599 USA.	alan_fanning@med.unc.edu		Anderson, James/0000-0003-2765-7996	NIDDK NIH HHS [R01 DK061397] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061397] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; ANDERSON JM, 1989, J CELL BIOL, V109, P1047, DOI 10.1083/jcb.109.3.1047; AndoAkatsuka Y, 1996, J CELL BIOL, V133, P43, DOI 10.1083/jcb.133.1.43; BACALLAO R, 1994, J CELL SCI, V107, P3301; Blum MS, 1997, AM J PHYSIOL-HEART C, V273, pH286, DOI 10.1152/ajpheart.1997.273.1.H286; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; CITI S, 2001, TIGHT JUNCTIONS, P231; Dimitratos SD, 1999, BIOESSAYS, V21, P912, DOI 10.1002/(SICI)1521-1878(199911)21:11<912::AID-BIES3>3.0.CO;2-Z; Ebnet K, 2001, EMBO J, V20, P3738, DOI 10.1093/emboj/20.14.3738; Fanning AS, 1998, J BIOL CHEM, V273, P29745, DOI 10.1074/jbc.273.45.29745; FANNING AS, 2001, TIGHT JUNCTIONS, P265; FLEMING TP, 1989, J CELL BIOL, V108, P1407, DOI 10.1083/jcb.108.4.1407; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; Furuse M, 1999, J CELL BIOL, V147, P891, DOI 10.1083/jcb.147.4.891; Gonzalez-Mariscal L, 2000, SEMIN CELL DEV BIOL, V11, P315, DOI 10.1006/scdb.2000.0178; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HECHT G, 1992, GASTROENTEROLOGY, V102, P416, DOI 10.1016/0016-5085(92)90085-D; HIROKAWA N, 1982, J CELL BIOL, V95, P249, DOI 10.1083/jcb.95.1.249; Imamura Y, 1999, J CELL BIOL, V144, P1311, DOI 10.1083/jcb.144.6.1311; Itoh M, 1997, J CELL BIOL, V138, P181, DOI 10.1083/jcb.138.1.181; Itoh M, 1999, J BIOL CHEM, V274, P5981, DOI 10.1074/jbc.274.9.5981; ITOH M, 1993, J CELL BIOL, V121, P491, DOI 10.1083/jcb.121.3.491; Katsube T, 1998, J BIOL CHEM, V273, P29672, DOI 10.1074/jbc.273.45.29672; MADARA JL, 1987, AM J PHYSIOL, V253, P171; Martin-Padura I, 1998, J CELL BIOL, V142, P117, DOI 10.1083/jcb.142.1.117; Mattagajasingh SN, 2000, J BIOL CHEM, V275, P30573, DOI 10.1074/jbc.M004578200; McCarthy KM, 2000, J CELL SCI, V113, P3387; MEZA I, 1980, J CELL BIOL, V87, P746, DOI 10.1083/jcb.87.3.746; Mitic LL, 1998, ANNU REV PHYSIOL, V60, P121, DOI 10.1146/annurev.physiol.60.1.121; Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511; MULLIN JM, 1986, AM J PHYSIOL, V251, pC597, DOI 10.1152/ajpcell.1986.251.4.C597; NUSRAT A, 1995, P NATL ACAD SCI USA, V92, P10629, DOI 10.1073/pnas.92.23.10629; Saitou M, 2000, MOL BIOL CELL, V11, P4131, DOI 10.1091/mbc.11.12.4131; Sears CL, 2000, AM J PHYSIOL-GASTR L, V279, pG1129, DOI 10.1152/ajpgi.2000.279.6.G1129; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tsukita S, 2001, NAT REV MOL CELL BIO, V2, P285, DOI 10.1038/35067088; Turner JR, 1997, AM J PHYSIOL-CELL PH, V273, pC1378, DOI 10.1152/ajpcell.1997.273.4.C1378; Turner JR, 2000, SEMIN CELL DEV BIOL, V11, P301, DOI 10.1006/scdb.2000.0180; Van Itallie C, 2001, J CLIN INVEST, V107, P1319, DOI 10.1172/JCI12464; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; Walsh SV, 2001, GASTROENTEROLOGY, V121, P566, DOI 10.1053/gast.2001.27060; Wittchen ES, 2000, J CELL BIOL, V151, P825, DOI 10.1083/jcb.151.4.825; Wittchen ES, 1999, J BIOL CHEM, V274, P35179, DOI 10.1074/jbc.274.49.35179; Wojciak-Stothard B, 2001, J CELL SCI, V114, P1343; Yamamoto T, 1997, J CELL BIOL, V139, P785, DOI 10.1083/jcb.139.3.785; YONEMURA S, 1995, J CELL SCI, V108, P127	47	216	229	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1835	+		10.1096/fj.02-0121fje	http://dx.doi.org/10.1096/fj.02-0121fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354695				2022-12-25	WOS:000178441800006
J	de Jong, AS; Wessels, E; Dijkman, HBPM; Galama, JMD; Melchers, WJG; Willems, PHGM; van Kuppeveld, FJM				de Jong, AS; Wessels, E; Dijkman, HBPM; Galama, JMD; Melchers, WJG; Willems, PHGM; van Kuppeveld, FJM			Determinants for membrane association and permeabilization of the coxsackievirus 2B protein and the identification of the Golgi complex as the target organelle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; VIRUS PROTEIN; POLIOVIRUS INFECTION; REPLICATION COMPLEX; AMPHIPATHIC HELIX; KIN RECOGNITION; RNA-SYNTHESIS; PLUS-STRAND; RETENTION; APPARATUS	The 2B protein of enterovirus is responsible for the alterations in the permeability of secretory membranes and the plasma membrane in infected cells. The structural requirements for the membrane association and the subcellular localization of this essential virus protein, however, have not been defined. Here, we provide evidence that the 2B protein is an integral membrane protein in vivo that is predominantly localized at the Golgi complex upon individual expression. Addition of organelle-specific targeting signals to the 213 protein revealed that the Golgi localization is an absolute prerequisite for the ability of the protein to modify plasma membrane permeability. Expression of deletion mutants and heterologous proteins containing specific domains of the 2B protein demonstrated that each of the two hydrophobic regions could mediate membrane binding individually. However, the presence of both hydrophobic regions was required for the correct membrane association, efficient Golgi targeting, and the membrane-permeabilizing activity of the 2B protein, suggesting that the two hydrophobic regions are cooperatively involved in the formation of a membrane-integral complex. The formation of membrane-integral pores by the 213 protein in the Golgi complex and the possible mechanism by which a Golgi-localized virus protein modifies plasma membrane permeability are discussed.	Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Univ Med Ctr Nijmegen, Dept Pathol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	van Kuppeveld, FJM (corresponding author), Univ Med Ctr Nijmegen, Nijmegen Ctr Mol Life Sci, Dept Med Microbiol, POB 9100, NL-6500 HB Nijmegen, Netherlands.	f.vankuppeveld@ncmls.kun.nl	Dijkman, Henry/L-4274-2015; Melchers, Willem/C-8819-2015; Willems, P.H.G.M./L-4759-2015; Jong, A.S./L-4416-2015	Melchers, Willem/0000-0002-5446-2230; Willems, P.H.G.M./0000-0002-0915-1599; van Kuppeveld, Frank/0000-0001-5800-749X				Aldabe R, 1997, J VIROL, V71, P6214, DOI 10.1128/JVI.71.8.6214-6217.1997; ALDABE R, 1995, BIOCHEM BIOPH RES CO, V206, P64, DOI 10.1006/bbrc.1995.1010; Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; BIENZ K, 1987, VIROLOGY, V160, P220, DOI 10.1016/0042-6822(87)90063-8; BIENZ K, 1994, ARCH VIROL, P147; Bolten R, 1998, J VIROL, V72, P8578, DOI 10.1128/JVI.72.11.8578-8585.1998; Breton C, 2001, BIOCHIMIE, V83, P713, DOI 10.1016/S0300-9084(01)01298-6; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; CHO MW, 1994, VIROLOGY, V202, P129, DOI 10.1006/viro.1994.1329; Cuconati A, 1998, J VIROL, V72, P1297, DOI 10.1128/JVI.72.2.1297-1307.1998; de Jong AS, 2002, J GEN VIROL, V83, P783, DOI 10.1099/0022-1317-83-4-783; Deitz SB, 2000, P NATL ACAD SCI USA, V97, P13790, DOI 10.1073/pnas.250483097; Dinter A, 1998, HISTOCHEM CELL BIOL, V109, P571, DOI 10.1007/s004180050256; Dodd DA, 2001, J VIROL, V75, P8158, DOI 10.1128/JVI.75.17.8158-8165.2001; Doedens JR, 1997, J VIROL, V71, P9054, DOI 10.1128/JVI.71.12.9054-9064.1997; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Hauri HP, 2000, J CELL SCI, V113, P587; KLUMP WM, 1990, J VIROL, V64, P1573, DOI 10.1128/JVI.64.4.1573-1583.1990; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LYTTON J, 1991, J BIOL CHEM, V266, P17067; MASIBAY AS, 1993, J BIOL CHEM, V268, P9908; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; MUNRO S, 1995, EMBO J, V14, P4695, DOI 10.1002/j.1460-2075.1995.tb00151.x; Nilsson T, 1996, J CELL SCI, V109, P1975; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rust RC, 2001, J VIROL, V75, P9808, DOI 10.1128/JVI.75.20.9808-9818.2001; Sandoval IV, 1997, J VIROL, V71, P4679, DOI 10.1128/JVI.71.6.4679-4693.1997; Schlegel A, 1996, J VIROL, V70, P6576, DOI 10.1128/JVI.70.10.6576-6588.1996; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; Shai Y, 1999, BBA-BIOMEMBRANES, V1462, P55, DOI 10.1016/S0005-2736(99)00200-X; SHAI Y, 1995, TRENDS BIOCHEM SCI, V20, P460, DOI 10.1016/S0968-0004(00)89101-X; Shima DT, 1997, J CELL BIOL, V137, P1211, DOI 10.1083/jcb.137.6.1211; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; van Kuppeveld FJM, 2002, J VIROL, V76, P9446, DOI 10.1128/JVI.76.18.9446-9456.2002; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; vanKuppeveld FJM, 1997, EMBO J, V16, P3519, DOI 10.1093/emboj/16.12.3519; VANKUPPEVELD FJM, 1995, J VIROL, V69, P7782, DOI 10.1128/JVI.69.12.7782-7790.1995; vanKuppeveld FJM, 1996, J VIROL, V70, P3876, DOI 10.1128/JVI.70.6.3876-3886.1996; Watson RT, 2001, AM J PHYSIOL-CELL PH, V281, pC215, DOI 10.1152/ajpcell.2001.281.1.C215	45	79	82	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1012	1021		10.1074/jbc.M207745200	http://dx.doi.org/10.1074/jbc.M207745200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12244057	Green Published, hybrid			2022-12-25	WOS:000180321900043
J	Christiaens, V; Bevan, CL; Callewaert, L; Haelens, A; Verrijdt, G; Rombauts, W; Claessens, F				Christiaens, V; Bevan, CL; Callewaert, L; Haelens, A; Verrijdt, G; Rombauts, W; Claessens, F			Characterization of the two coactivator-interacting surfaces of the androgen receptor and their relative role in transcriptional control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL DOMAIN; LIGAND-BINDING DOMAIN; DNA-BINDING; THYROID-HORMONE; AF2 DOMAINS; ACTIVATION; PROTEIN; TRANSACTIVATION; SRC-1; IDENTIFICATION	The androgen receptor interacts with the p160 coactivators via two surfaces, one in the ligand binding domain and one in the amino-terminal domain. The ligand binding domain interacts with the nuclear receptor signature motifs, whereas the amino-terminal domain has a high affinity for a specific glutamine-rich region in the p160s. We here describe the implication of two conserved motifs in the latter interaction. The amino-terminal domain of the androgen receptor is a very strong activation domain constituent of Tau5, which is mainly active in the absence of the ligand binding domain, and Tau1, which is only active in the presence of the ligand binding domain. Both domains are, however, implicated in the recruitment of the p160s. Mutation analysis of the p160s has shown that the relative contribution of the two recruitment mechanisms via the signature motifs or via the glutamine-rich region depend on the nature of the enhancers tested. We propose, therefore, that the androgen receptor-coactivator complex has several alternative conformations, depending partially on the context of the enhancer.	Katholieke Univ Leuven, Fac Med, Div Biochem, B-3000 Louvain, Belgium; Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Prostate Canc Res Grp, London W12 0NN, England	KU Leuven; Imperial College London	Claessens, F (corresponding author), Katholieke Univ Leuven, Fac Med, Div Biochem, Campus Gasthuisberg,Herestr 49, B-3000 Louvain, Belgium.	frank.claessens@med.kuleuven.ac.be	Bevan, Charlotte/T-7769-2019; Claessens, Frank/M-8565-2016; Bevan, Charlotte L/K-2276-2012	Claessens, Frank/0000-0002-8676-7709; Bevan, Charlotte L/0000-0002-7533-0552				Alen P, 1999, MOL CELL BIOL, V19, P6085; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; Benecke A, 2000, EMBO REP, V1, P151, DOI 10.1093/embo-reports/kvd028; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan C, 1999, EXP CELL RES, V253, P349, DOI 10.1006/excr.1999.4719; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; Buchert M, 1997, BIOTECHNIQUES, V23, P396, DOI 10.2144/97233bm10; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Claessens F, 2001, J STEROID BIOCHEM, V76, P23, DOI 10.1016/S0960-0760(00)00154-0; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Dodou E, 1997, MOL CELL BIOL, V17, P1848, DOI 10.1128/MCB.17.4.1848; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HAN MA, 1999, MOL CELL BIOL, V19, P6164; He B, 2002, J BIOL CHEM, V277, P25631, DOI 10.1074/jbc.M202809200; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Imhof A, 1998, CURR BIOL, V8, pR422, DOI 10.1016/S0960-9822(98)70268-4; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Jenster G, 1998, MOL CELL ENDOCRINOL, V143, P1, DOI 10.1016/S0303-7207(98)00145-2; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; LEES JA, 1989, NUCLEIC ACIDS RES, V17, P5477, DOI 10.1093/nar/17.14.5477; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; MacLean HE, 1997, J STEROID BIOCHEM, V62, P233, DOI 10.1016/S0960-0760(97)00049-6; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Parker MG, 1996, NAT STRUCT BIOL, V3, P113, DOI 10.1038/nsb0296-113; Schoenmakers E, 2000, J BIOL CHEM, V275, P12290, DOI 10.1074/jbc.275.16.12290; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Sheppard HM, 2001, MOL CELL BIOL, V21, P39, DOI 10.1128/MCB.21.1.39-50.2001; Slagsvold T, 2000, MOL ENDOCRINOL, V14, P1603, DOI 10.1210/me.14.10.1603; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Torchia J, 1998, CURR OPIN CELL BIOL, V10, P373, DOI 10.1016/S0955-0674(98)80014-8; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Verrijdt G, 2000, J BIOL CHEM, V275, P12298, DOI 10.1074/jbc.275.16.12298; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	53	62	63	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49230	49237		10.1074/jbc.M209322200	http://dx.doi.org/10.1074/jbc.M209322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12370175	hybrid			2022-12-25	WOS:000180028900017
J	Aoki, J; Taira, A; Takanezawa, Y; Kishi, Y; Hama, K; Kishimoto, T; Mizuno, K; Saku, K; Taguchi, R; Arai, H				Aoki, J; Taira, A; Takanezawa, Y; Kishi, Y; Hama, K; Kishimoto, T; Mizuno, K; Saku, K; Taguchi, R; Arai, H			Serum lysophosphatidic acid is produced through diverse phospholipase pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATING-FACTOR-ACETYLHYDROLASE; SMOOTH-MUSCLE CELLS; SECRETORY PHOSPHOLIPASE; LYSOPHOSPHOLIPASE-D; RAT PLATELETS; RECEPTOR; FAMILY; PLASMA; IDENTIFICATION; PROLIFERATION	Lysophosphatidic acid (LPA) is a lipid mediator with multiple biological activities that accounts for many biological properties of serum. LPA is thought to be produced during serum formation based on the fact that the LPA level is much higher in serum than in plasma. In this study, to better understand the pathways of LPA synthesis in serum, we evaluated the roles of platelets, plasma, and phospholipases by measuring LPA using a novel enzyme-linked fluorometric assay. First, examination of platelet-depleted rats showed that half of the LPA in serum is produced via a platelet-dependent pathway. However, the amount of LPA released from isolated platelets after they are activated by thrombin or calcium ionophore accounted for only a small part of serum LPA. Most of the platelet-derived LPA was produced in a two-step process: lysophospholipids such as lysophosphatidylcholine (LPC), lysophosphatidylethanolamine, and lysophosphatidylserine, were released from activated rat platelets by the actions of two phospholipase, group HA secretory phospholipase A, (sPLA(2)-IIA) and phosphatidylserine-specific phospholipase A(1) (PS-PLA(1)), which were abundantly expressed in the cells. Then these lysophospholipids were converted to LPA by the action of plasma lysophospholipase D (lysoPLD). Second, accumulation of LPA in incubated plasma was strongly accelerated by the addition of recombinant lysoPLD with a concomitant decrease in LPC accumulation, indicating that the enzyme produces LPA by hydrolyzing LPC produced during the incubation. In addition, incubation of plasma isolated from human subjects who were deficient in lecithin-cholesterol acyltransferase (LCAT) did not result in increases of either LPC or LPA. The present study demonstrates multiple pathways for LPA production in serum and the involvement of several phospholipases, including PS-PIA, sPLA(2)-IIA LCAT, and lysoPLD.	Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan; Nesco Co, Azwell Inc, R&D Div, Diagnost Res & Dev Dept, Osaka 5670806, Japan; Fukuoka Univ, Dept Cardiol, Jonan Ku, Fukuoka 81480, Japan; Nagoya City Univ, Fac Pharmaceut Sci, Mizuho Ku, Nagoya, Aichi 4670027, Japan	University of Tokyo; Fukuoka University; Nagoya City University	Aoki, J (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1130033, Japan.		Saku, Keijiro/HGB-6168-2022	Aoki, Junken/0000-0001-9435-1896; Takanezawa, Yasukazu/0000-0002-9220-5825				An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Aoki J, 2002, BBA-MOL CELL BIOL L, V1582, P26, DOI 10.1016/S1388-1981(02)00134-8; Baker DL, 2000, ANN NY ACAD SCI, V905, P267; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; Bandoh K, 2000, FEBS LETT, V478, P159, DOI 10.1016/S0014-5793(00)01827-5; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Chun Jerold, 1999, Cell Biochemistry and Biophysics, V30, P213, DOI 10.1007/BF02738068; Contos JJA, 2000, MOL PHARMACOL, V58, P1188, DOI 10.1124/mol.58.6.1188; Croset M, 2000, BIOCHEM J, V345, P61, DOI 10.1042/0264-6021:3450061; DOBIASOVA M, 1986, PHYSIOL BOHEMOSLOV, V35, P464; Eder AM, 2000, CLIN CANCER RES, V6, P2482; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; GERRARD JM, 1989, BIOCHIM BIOPHYS ACTA, V1001, P282, DOI 10.1016/0005-2760(89)90112-4; Glomset J.A., 1995, METABOLIC MOL BASES, Vseventh, P1933; Hayashi K, 2001, CIRC RES, V89, P251, DOI 10.1161/hh1501.094265; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Hooks SB, 2001, J BIOL CHEM, V276, P4611, DOI 10.1074/jbc.M007782200; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P625, DOI 10.1093/jb/101.3.625; HORIGOME K, 1987, J BIOCHEM-TOKYO, V101, P53, DOI 10.1093/oxfordjournals.jbchem.a121907; Hosono H, 2001, J BIOL CHEM, V276, P29664, DOI 10.1074/jbc.M104597200; IMAMURA F, 1993, BIOCHEM BIOPH RES CO, V193, P497, DOI 10.1006/bbrc.1993.1651; JALINK K, 1995, BIOCHEM J, V307, P609, DOI 10.1042/bj3070609; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; KOMADA M, 1989, J BIOCHEM-TOKYO, V106, P545, DOI 10.1093/oxfordjournals.jbchem.a122890; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Le Balle F, 1999, ADV ENZYME REGUL, V39, P275, DOI 10.1016/S0065-2571(98)00024-7; Manning TJ, 2000, CELL MOTIL CYTOSKEL, V45, P185, DOI 10.1002/(SICI)1097-0169(200003)45:3<185::AID-CM2>3.0.CO;2-G; MAUCO G, 1978, BIOCHIMIE, V60, P653, DOI 10.1016/S0300-9084(78)80784-6; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Pilquil C, 2001, PROSTAG OTH LIPID M, V64, P83, DOI 10.1016/S0090-6980(01)00101-0; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Santamarina-Fojo S, 2001, METABOLIC MOL BASES, P2817; Sato T, 1997, J BIOL CHEM, V272, P2192; SATOH K, 1991, J CLIN INVEST, V87, P476, DOI 10.1172/JCI115020; SEKAS G, 1985, J LAB CLIN MED, V105, P190; Shen ZZ, 1998, GYNECOL ONCOL, V71, P364, DOI 10.1006/gyno.1998.5193; Sonoda H, 2002, J BIOL CHEM, V277, P34254, DOI 10.1074/jbc.M201659200; Stam JC, 1998, EMBO J, V17, P4066, DOI 10.1093/emboj/17.14.4066; Stracke ML, 1997, ADV ENZYME REGUL, V37, P135, DOI 10.1016/S0065-2571(96)00017-9; Sturm A, 1999, GASTROENTEROLOGY, V117, P368, DOI 10.1053/gast.1999.0029900368; TAMAOKU K, 1982, CHEM PHARM BULL, V30, P2492; TIGYI G, 1992, J BIOL CHEM, V267, P21360; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; Tokumura A, 1998, LIPIDS, V33, P1009, DOI 10.1007/s11745-998-0299-2; TOKUMURA A, 1994, AM J PHYSIOL, V267, pC204, DOI 10.1152/ajpcell.1994.267.1.C204; TOKUMURA A, 1995, PROG LIPID RES, V34, P151, DOI 10.1016/0163-7827(95)00001-G; TOKUMURA A, 1986, BIOCHIM BIOPHYS ACTA, V875, P31; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; Xiao YJ, 2000, ANN NY ACAD SCI, V905, P242; YOKOYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1280, DOI 10.1093/oxfordjournals.jbchem.a124856	55	333	340	1	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48737	48744		10.1074/jbc.M206812200	http://dx.doi.org/10.1074/jbc.M206812200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354767	hybrid			2022-12-25	WOS:000179789600100
J	Han, GS; Audhya, A; Markley, DJ; Emr, SD; Carman, GM				Han, GS; Audhya, A; Markley, DJ; Emr, SD; Carman, GM			The Saccharomyces cerevisiae LSB6 gene encodes phosphatidylinositol 4-kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; ESCHERICHIA-COLI; KINETIC-ANALYSIS; YEAST PROTEIN; KINASE; PURIFICATION; TRANSFORMATION; SECRETION; TRANSPORT; VACUOLE	The LSB6 gene product was identified from the Saccharomyces Genome Data Base (locus YJL100W) as a putative member of a novel type II phosphatidylinositol (PI) 4-kinase family. Cell extracts lacking the LSB6 gene had a reduced level of PI 4-kinase activity. In addition, multicopy plasmids containing the LSB6 gene directed the overexpression of PI 4-kinase activity in cell extracts of wild-type cells, in an lsb6Delta mutant, in a pik1(ts) stt4(ts) double mutant, and in an pik1(ts) stt4(ts) lsb6Delta triple mutant. The heterologous expression of the S. cerevisiae LSB6 gene in Escherichia coli resulted in the expression of a protein that possessed PI 4-kinase activity. Although the lsb6Delta mutant did not exhibit a growth phenotype and failed to exhibit a defect in phosphoinositide synthesis in vivo, the overexpression of the LSB6 gene could partially suppress the lethal phenotype of an stt4Delta mutant defective in the type III STT4-encoded PI 4-kinase indicating that Lsb6p functions as a PI 4-kinase in vivo. Lsb6p was localized to the membrane fraction of the cell, and when overexpressed, GFP-tagged Lsb6p was observed on both the plasma membrane and the vacuole membrane. The enzymological properties (pH optimum, dependence on magnesium or manganese as a cofactor, the dependence of activity on Triton X-100, the dependence on the PI surface concentration, and temperature sensitivity) of the LSB6-encoded enzyme were very similar to the membrane-associated 55-kDa PI 4-kinase previously purified from S. cerevisiae.	Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, New Brunswick, NJ 08901 USA; Univ Calif San Diego, Sch Med, Howard Hughes Med Inst, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	Rutgers State University New Brunswick; Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego	Carman, GM (corresponding author), Rutgers State Univ, Cook Coll, New Jersey Agr Expt Stn, Dept Food Sci, 65 Dudley Rd, New Brunswick, NJ 08901 USA.	carman@aesop.rutgers.edu			NCI NIH HHS [CA-58689] Funding Source: Medline; NIGMS NIH HHS [GM-28140] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028140, R37GM028140] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; Audhya A, 2000, MOL BIOL CELL, V11, P2673, DOI 10.1091/mbc.11.8.2673; Audhya A, 2002, DEV CELL, V2, P593, DOI 10.1016/S1534-5807(02)00168-5; Balla T, 1998, BBA-MOL CELL BIOL L, V1436, P69, DOI 10.1016/S0005-2760(98)00134-9; Barylko B, 2001, J BIOL CHEM, V276, P7705, DOI 10.1074/jbc.C000861200; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruns JR, 2002, J BIOL CHEM, V277, P2012, DOI 10.1074/jbc.M108571200; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1992, METHOD ENZYMOL, V209, P183; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARMAN GM, 1996, ADV LIPOBIOLOGY, P367; Carpenter CL, 1998, NAT STRUCT BIOL, V5, P843, DOI 10.1038/2283; COLODZIN M, 1965, J BIOL CHEM, V270, P3771; Cutler NS, 1997, J BIOL CHEM, V272, P27671, DOI 10.1074/jbc.272.44.27671; DeCamilli P, 1996, SCIENCE, V271, P1533, DOI 10.1126/science.271.5255.1533; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gehrmann T, 1998, EUR J BIOCHEM, V253, P357, DOI 10.1046/j.1432-1327.1998.2530357.x; HAID A, 1983, METHOD ENZYMOL, V96, P192; Hama H, 1999, J BIOL CHEM, V274, P34294, DOI 10.1074/jbc.274.48.34294; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; Innis MA, 1990, PCR PROTOCOLS GUIDE, P3; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lechler T, 1997, J CELL BIOL, V138, P95, DOI 10.1083/jcb.138.1.95; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; LIN YP, 1989, J BIOL CHEM, V264, P8641; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madania A, 1999, MOL BIOL CELL, V10, P3521, DOI 10.1091/mbc.10.10.3521; MCKENZIE MA, 1983, J BACTERIOL, V156, P421, DOI 10.1128/JB.156.1.421-423.1983; Minogue S, 2001, J BIOL CHEM, V276, P16635, DOI 10.1074/jbc.M100982200; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; PERRELLA FW, 1988, ANAL BIOCHEM, V174, P437, DOI 10.1016/0003-2697(88)90042-5; RAETZ CRH, 1978, MICROBIOL REV, V42, P614, DOI 10.1128/MMBR.42.3.614-659.1978; ROBINSON JS, 1988, MOL CELL BIOL, V8, P4936, DOI 10.1128/MCB.8.11.4936; Rose MD., 1990, METHODS YEAST GENETI; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; SINGER SJ, 1972, SCIENCE, V175, P720, DOI 10.1126/science.175.4023.720; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1995, J CELL BIOL, V129, P321, DOI 10.1083/jcb.129.2.321; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; STEINER S, 1972, J BACTERIOL, V109, P81, DOI 10.1128/JB.109.1.81-88.1972; STORER AC, 1976, BIOCHEM J, V159, P1; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Trotter PJ, 1998, J BIOL CHEM, V273, P13189, DOI 10.1074/jbc.273.21.13189; TZAGOLOFF A, 1995, EUR J BIOCHEM, V230, P582; Walch-Solimena C, 1999, NAT CELL BIOL, V1, P523, DOI 10.1038/70319; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; Wurmser AE, 1998, EMBO J, V17, P4930, DOI 10.1093/emboj/17.17.4930; YOSHIDA S, 1994, J BIOL CHEM, V269, P1166	62	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47709	47718		10.1074/jbc.M207996200	http://dx.doi.org/10.1074/jbc.M207996200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12361950	hybrid			2022-12-25	WOS:000179663700113
J	Hirzmann, J; Hintz, M; Kasper, M; Shresta, TR; Taubert, A; Conraths, FJ; Geyer, R; Stirm, S; Zahner, H; Hobom, G				Hirzmann, J; Hintz, M; Kasper, M; Shresta, TR; Taubert, A; Conraths, FJ; Geyer, R; Stirm, S; Zahner, H; Hobom, G			Cloning and expression analysis of two mucin-like genes encoding microfilarial sheath surface proteins of the parasitic nematodes Brugia and Litomosoides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARINII-MICROFILARIAE; PAHANGI MICROFILARIAE; HUMAN FILARIASIS; MESSENGER-RNA; CELLS; COMPONENTS; MALAYI; DIMETHYLAMINOETHANOL; UNRESPONSIVENESS; IDENTIFICATION	In several filarial genera the first stage larvae (microfilariae) are enclosed by an eggshell-derived sheath that provides a major interface between the parasite and the host immune system. Analysis of the polypeptide constituents of the microfilarial sheath from the cotton rat filaria Litomosoides sigmodontis identified two abundant surface glycoproteins: Shp3a and Shp3. The corresponding genes and the orthologues of the human parasite Brugia malayi and the rodent filaria Brugia pahangi were cloned and sequenced. They encode secreted, mucin-like proteins with N-terminal Ser/Thr-rich repeats and a C-terminal anchor domain rich in aromatic amino acids. About 75% of the protein molecular masses result from post-translational modifications. The Ser/Thr-rich motifs are supposed to serve as targets for dimethylaminoethanol-phosphate substitutions. These modifications were detected only on the sheaths of the late developmental stage of stretched microfilariae, corresponding with the expression of the proteins in the epithelium of the distal part of the uterus and the specific transcription of shp3 and shp3a in the anterior female worm segment. Genomic analysis of all three species demonstrated a conserved linkage of the two genes. Their transcripts undergo cis- and trans-splicing. The transcription start sites of the primary transcripts were determined for the L. sigmodontis genes. The core promoter regions are remarkably conserved between the paralogue genes Ls-shp3a and Ls-shp3 and their orthologues in Brugia, implicating conserved regulatory elements.	Inst Parasitol, D-35392 Giessen, Germany; Inst Biochem, D-35392 Giessen, Germany; Inst Microbiol & Mol Biol, D-35392 Giessen, Germany		Hirzmann, J (corresponding author), Inst Parasitol, Rudolf Buchheim Str 2, D-35392 Giessen, Germany.			Conraths, Franz/0000-0002-7400-9409				BARDEHLE G, 1992, PARASITOL RES, V78, P501, DOI 10.1007/BF00931571; BARDEHLE G, 1992, ACTA TROP, V50, P237, DOI 10.1016/0001-706X(92)90080-H; CHANDRASHEKAR R, 1984, J HELMINTHOL, V58, P69, DOI 10.1017/S0022149X00028078; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRIST H, 1992, GENE, V121, P219, DOI 10.1016/0378-1119(92)90125-9; CONRATHS FJ, 1993, MOL BIOCHEM PARASIT, V60, P111, DOI 10.1016/0166-6851(93)90034-U; DEVANEY E, 1985, TROPENMED PARASITOL, V36, P25; DINOIA JM, 1995, J BIOL CHEM, V270, P24146, DOI 10.1074/jbc.270.41.24146; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FUHRMAN A, 1983, ACTA TROP, V40, P5; Gems D, 1996, P NATL ACAD SCI USA, V93, P1665, DOI 10.1073/pnas.93.4.1665; HILKENS J, 1992, TRENDS BIOCHEM SCI, V17, P359, DOI 10.1016/0968-0004(92)90315-Z; Hintz M, 1996, MOL BIOCHEM PARASIT, V76, P325, DOI 10.1016/0166-6851(95)02541-3; Hintz M, 1998, PARASITOLOGY, V117, P265, DOI 10.1017/S0031182098002996; HINTZ M, 1994, MOL BIOCHEM PARASIT, V67, P69, DOI 10.1016/0166-6851(94)90097-3; HIRZMANN J, 1995, MOL BIOCHEM PARASIT, V70, P95, DOI 10.1016/0166-6851(95)00011-O; HIRZMANN J, 1993, NUCLEIC ACIDS RES, V21, P3597, DOI 10.1093/nar/21.15.3597; HORSTMANN RD, 1992, INFECT IMMUN, V60, P721, DOI 10.1128/IAI.60.3.721-727.1992; Ilg T, 1996, J BIOL CHEM, V271, P21583, DOI 10.1074/jbc.271.35.21583; KLONISCH T, 1991, PARASITOL RES, V77, P448, DOI 10.1007/BF00931643; LAMMLER G, 1968, Zeitschrift fuer Parasitenkunde, V30, P281; LARSEN NI, 1995, NUCLEIC ACIDS RES, V23, P1223, DOI 10.1093/nar/23.7.1223; MAIZELS RM, 1991, PARASITOL TODAY, V7, P271, DOI 10.1016/0169-4758(91)90093-4; MALETTE B, 1995, MOL REPROD DEV, V41, P384, DOI 10.1002/mrd.1080410315; MENRATH M, 1995, PARASITOLOGY, V111, P477, DOI 10.1017/S0031182000065987; Michael E, 1997, PARASITOL TODAY, V13, P472, DOI 10.1016/S0169-4758(97)01151-4; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSEN TW, 1995, MOL BIOCHEM PARASIT, V73, P1, DOI 10.1016/0166-6851(94)00107-X; OTTESEN EA, 1977, IMMUNOLOGY, V33, P413; PIESSENS WF, 1980, J CLIN INVEST, V65, P172, DOI 10.1172/JCI109648; SANGER I, 1981, ACTA TROP, V38, P277; SAYERS G, 1984, PARASITOLOGY, V89, P425, DOI 10.1017/S0031182000056675; SCHARES G, 1994, PARASITOLOGY, V109, P73, DOI 10.1017/S0031182000077787; SCHRAERMEYER U, 1987, Z PARASITENKD, V73, P550; SCHRAERMEYER U, 1987, Z PARASITENKD, V73, P557; SELKIRK ME, 1991, J BIOL CHEM, V266, P11002; SIMPSON MG, 1972, PARASITOLOGY, V64, P61, DOI 10.1017/S0031182000044656; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; ZAHNER H, 1995, PARASITOL TODAY, V11, P116, DOI 10.1016/0169-4758(95)80173-1	39	7	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47603	47612		10.1074/jbc.M205770200	http://dx.doi.org/10.1074/jbc.M205770200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356773	hybrid			2022-12-25	WOS:000179663700100
J	Li, K; Zhao, SQ; Karur, V; Wojchowski, DM				Li, K; Zhao, SQ; Karur, V; Wojchowski, DM			DYRK3 activation, engagement of protein kinase A/cAMP response element-binding protein, and modulation of progenitor cell survival	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; SACCHAROMYCES-CEREVISIAE; MAP KINASE; PHOSPHORYLATION; FAMILY; GENE; EXPRESSION; MINIBRAIN; SPECIFICITY; INHIBITION	DYRKs are a new family of (d) under bar ual-specificity (t) under bar yrosine-(r) under bar egulated (k) under bar inases with emerging roles in cell growth and development. Recently, we discovered that DYRK3 is expressed primarily in erythroid progenitor cells and modulates late erythropoiesis. We now describe 1) roles for the DYRK3 YTY signature motif in kinase activation, 2) the coupling of DYRK3 to cAMP response element (CRE)-binding protein (CREB), and 3) effects of DYRK3 on hematopoietic progenitor cell survival. Regarding the DYRK3 kinase domain, intactness of Tyr(333) (but not Tyr(331)) within subdomain loop VII-VIII was critical for activation. Tyr(331) plus Tyr(333) acidification (Tyr mutated to Glu) was constitutively activating, but kinase activity was not affected substantially by unique N- or C-terminal domains. In transfected 293 and HeLa cells, DYRK3 was discovered to efficiently stimulate CRE-luciferase expression, to activate a CREB-Ga14 fusion protein, and to promote CREB phosphorylation at Ser(133). Interestingly, this CREB/CRE response was also supported (50% of wild-type activity) by a kinase-inactive DYRK3 mutant as well as a DYRK3 C-terminal region and was blocked by protein kinase A inhibitors, suggesting functional interactions between protein kinase A and DYRK3. Finally, DYRK3 expression in cytokine-dependent hematopoietic FDCW2 cells was observed to inhibit programmed cell death. Thus, primary new insight into DYRK3 kinase signaling routes, subdomain activities, and possible biofunctions is provided.	Penn State Univ, Dept Vet Sci, University Pk, PA 16802 USA; Penn State Univ, Immunobiol Program, University Pk, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Wojchowski, DM (corresponding author), Penn State Univ, Dept Vet Sci, 115 Henning Bldg, University Pk, PA 16802 USA.	dmw@psu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040242] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK40242] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; Campbell LE, 2002, FEBS LETT, V510, P31, DOI 10.1016/S0014-5793(01)03221-5; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Casteel D, 1998, BLOOD, V91, P3193, DOI 10.1182/blood.V91.9.3193.3193_3193_3201; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Edwards AS, 2000, CURR OPIN CELL BIOL, V12, P217, DOI 10.1016/S0955-0674(99)00085-X; ES SV, 2001, J BIOL CHEM, V276, P30761; Feliciello A, 1997, CURR BIOL, V7, P1011, DOI 10.1016/S0960-9822(06)00424-6; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; GARRETT S, 1991, MOL CELL BIOL, V11, P4045, DOI 10.1128/MCB.11.8.4045; Geiger JN, 2001, BLOOD, V97, P901, DOI 10.1182/blood.V97.4.901; Griffioen G, 2001, MOL CELL BIOL, V21, P511, DOI 10.1128/MCB.21.2.511-523.2001; Guimera J, 1999, GENOMICS, V57, P407, DOI 10.1006/geno.1999.5775; Henriksson M, 2001, APOPTOSIS, V6, P133, DOI 10.1023/A:1009644716727; Himpel S, 2001, BIOCHEM J, V359, P497, DOI 10.1042/0264-6021:3590497; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Krug U, 2002, ONCOGENE, V21, P3475, DOI 10.1038/sj.onc.1205322; Lord KA, 2000, BLOOD, V95, P2838, DOI 10.1182/blood.V95.9.2838.009k29_2838_2846; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Matsuo R, 2001, J IMMUNOL METHODS, V247, P141, DOI 10.1016/S0022-1759(00)00313-6; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; Miyata Y, 1999, BIOCHEM BIOPH RES CO, V266, P291, DOI 10.1006/bbrc.1999.1705; Pircher TJ, 2001, J BIOL CHEM, V276, P8995, DOI 10.1074/jbc.M007473200; SCHAAP P, 1993, J BIOL CHEM, V268, P6323; Seshasayee D, 1998, MOL CELL BIOL, V18, P3278, DOI 10.1128/MCB.18.6.3278; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; Souza GM, 1998, DEVELOPMENT, V125, P2291; Souza GM, 1999, DEVELOPMENT, V126, P3263; Tasken K, 1997, ADV SEC MESS PHOSPH, V31, P191; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; Varone CL, 1999, ARCH BIOCHEM BIOPHYS, V372, P261, DOI 10.1006/abbi.1999.1470; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200	44	29	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47052	47060		10.1074/jbc.M205374200	http://dx.doi.org/10.1074/jbc.M205374200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356771	hybrid			2022-12-25	WOS:000179663700030
J	Tsujii-Hayashi, Y; Kitahara, M; Yamagaki, T; Kojima-Aikawa, K; Matsumoto, I				Tsujii-Hayashi, Y; Kitahara, M; Yamagaki, T; Kojima-Aikawa, K; Matsumoto, I			A potential endogenous ligand of annexin IV in the exocrine pancreas - Carbohydrate structure of GP-2, a glycosylphosphatidylinositol-anchored glycoprotein of zymogen granule membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TAMM-HORSFALL GLYCOPROTEIN; BINDING PROTEIN P33/41; LINKED OLIGOSACCHARIDES; MAJOR GLYCOPROTEIN; SECRETORY GRANULES; MAACKIA-AMURENSIS; CELLS; KIDNEY; UROMODULIN; EXPRESSION	We demonstrated previously that annexins IV, V, and VI, proteins of the calcium/phospholipid-binding annexin family, have glycosaminoglycan binding properties (Ishitsuka, R., Kojima, K., Utsumi, H., Ogawa, H., and Matsumoto, I. (1998) J. Biol. Chem. 273, 9935-9941). In this study, we investigated the endogenous ligands of annexin IV in the exocrine pancreas. Immunohistochemical study of bovine pancreas showed that annexin IV localized in the apical cytoplasmic region of pancreatic acinar cells where zymogen granules are concentrated. Because it is the major component of the zymogen granule membrane, the glycosylphosphatidylinositol-anchored glycoprotein GP-2 was suggested to play a role in apical sorting and secretion of zymogens. We isolated GP-2 from porcine pancreas extract and determined the structure of its N-linked oligosaccharides by two-dimensional mapping. The major carbohydrate structures of porcine GP-2 were trisialo-triantermary and tetrasialo-tetra-antennary complex-type oligosaccharides. Dot-blot assay showed that annexin IV interacts with GP-2 in the presence of calcium and that it recognizes the terminal sialic acid residues linked through alpha2-3 linkages to the carbohydrate of GP-2. Lectin blot assay showed that Maackia amurensis mitogen, a plant lectin specific for the trisaccharide sequence Siaalpha2-3Galbeta1-4GlcNAc of N-linked oligosaccharides, has strong affinity for GP-2. Thus, M. amurensis mitogen was used as a specific probe for GP-2 in the histochemical staining of the bovine pancreas. GP-2 was found to localize exclusively in the same apical cytoplasmic region of pancreatic acinar cells as annexin IV does. These results suggest that GP-2 is an endogenous ligand of annexin IV in the exocrine pancreas.	Ochanomizu Univ, Fac Sci, Dept Chem, Bunkyo Ku, Tokyo 1128610, Japan; Univ Tokyo, Sch Sci, Dept Chem, Bunkyo Ku, Tokyo 1130033, Japan	Ochanomizu University; University of Tokyo	Kojima-Aikawa, K (corresponding author), Ochanomizu Univ, Fac Sci, Dept Chem, Bunkyo Ku, 2-1-1 Otsuka, Tokyo 1128610, Japan.							ADAIR WL, 1974, J BIOL CHEM, V249, P4696; BACHMANN S, 1985, HISTOCHEMISTRY, V83, P531, DOI 10.1007/BF00492456; BEANZIGER JU, 1979, J BIOL CHEM, V254, P2400; BERMAN E, 1981, J BIOL CHEM, V256, P3853; BERMAN E, 1986, FEBS LETT, V204, P257, DOI 10.1016/0014-5793(86)80823-7; CODDEVILLE B, 1992, CARBOHYD RES, V236, P145, DOI 10.1016/0008-6215(92)85013-P; DULAWA J, 1988, EUR J CLIN INVEST, V18, P87, DOI 10.1111/j.1365-2362.1988.tb01171.x; EDWARDS HC, 1995, MOL CELL BIOCHEM, V149, P293, DOI 10.1007/BF01076591; FREEDMAN SD, 1993, J CLIN INVEST, V92, P83, DOI 10.1172/JCI116602; Fritz B.A., 1996, AM J PHYSIOL, V270, P176; FUKUOKA SI, 1992, P NATL ACAD SCI USA, V89, P1189, DOI 10.1073/pnas.89.4.1189; FUKUOKA SI, 1991, P NATL ACAD SCI USA, V88, P2898, DOI 10.1073/pnas.88.7.2898; HAAS M, 1989, ANNU REV PHYSIOL, V51, P443, DOI 10.1146/annurev.physiol.51.1.443; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HAVINGA JR, 1985, EUR J CELL BIOL, V39, P70; HAVINGA JR, 1983, EUR J BIOCHEM, V133, P449, DOI 10.1111/j.1432-1033.1983.tb07484.x; HOOPS TC, 1991, J BIOL CHEM, V266, P4257; Ishitsuka R, 1998, J BIOL CHEM, V273, P9935, DOI 10.1074/jbc.273.16.9935; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; Kojima K, 1996, J BIOL CHEM, V271, P7679, DOI 10.1074/jbc.271.13.7679; KOJIMA K, 1992, J BIOL CHEM, V267, P20536; KOJIMA K, 1994, FEBS LETT, V342, P313, DOI 10.1016/0014-5793(94)80523-7; KONDO A, 1990, AGR BIOL CHEM TOKYO, V54, P2169, DOI 10.1080/00021369.1990.10870232; KOPELMAN H, 1988, GASTROENTEROLOGY, V95, P349, DOI 10.1016/0016-5085(88)90490-8; KORNFELD K, 1981, J BIOL CHEM, V256, P6633; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBEL D, 1988, BIOCHEM BIOPH RES CO, V154, P818, DOI 10.1016/0006-291X(88)90213-6; LEWIS DS, 1977, FEBS LETT, V76, P115, DOI 10.1016/0014-5793(77)80133-6; LYNN KL, 1982, CLIN SCI, V62, P21, DOI 10.1042/cs0620021; MACDONAL.RJ, 1972, BIOCHEM BIOPH RES CO, V49, P377, DOI 10.1016/0006-291X(72)90421-4; Mohiti J, 1997, EXP CELL RES, V234, P98, DOI 10.1006/excr.1997.3584; OGAWA H, 1990, ANAL BIOCHEM, V190, P165, DOI 10.1016/0003-2697(90)90175-9; PEPINKY RB, 1996, NATURE, V321, P81; RADKE K, 1980, CELL, V21, P821, DOI 10.1016/0092-8674(80)90445-6; Raynal P, 1996, FEBS LETT, V392, P263, DOI 10.1016/0014-5793(96)00827-7; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; RINDLER MJ, 1990, J BIOL CHEM, V265, P20784; RINDLER MJ, 1990, EUR J CELL BIOL, V53, P154; SANDERS PW, 1990, J CLIN INVEST, V85, P570, DOI 10.1172/JCI114474; Satoh A, 1996, J BIOCHEM-TOKYO, V119, P346; SAWYER ST, 1985, J BIOL CHEM, V260, P8233; Scheele GA, 1996, PANCREAS, V12, P1, DOI 10.1097/00006676-199601000-00001; SCHEELE GA, 1994, PANCREAS, V9, P139, DOI 10.1097/00006676-199403000-00001; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; SHIBUYA N, 1989, J BIOCHEM-TOKYO, V106, P1098, DOI 10.1093/oxfordjournals.jbchem.a122972; SIKRI KL, 1979, BIOCHEM J, V181, P525, DOI 10.1042/bj1810525; SLOMIANY A, 1981, BIOCHEM BIOPH RES CO, V100, P778, DOI 10.1016/S0006-291X(81)80242-2; SWAIRJO MA, 1994, ANNU REV BIOPH BIOM, V23, P193, DOI 10.1146/annurev.bb.23.060194.001205; TAMM I, 1950, P SOC EXP BIOL MED, V74, P108, DOI 10.3181/00379727-74-17825; TOMIYA N, 1988, ANAL BIOCHEM, V171, P73, DOI 10.1016/0003-2697(88)90126-1; TRESSLER RJ, 1994, EXP CELL RES, V215, P395, DOI 10.1006/excr.1994.1358; WANG WC, 1988, J BIOL CHEM, V263, P4576; WEN Y, 1999, BIOCHEM BIOPH RES CO, V187, P1579; WIGGINS RC, 1987, CLIN CHIM ACTA, V162, P329, DOI 10.1016/0009-8981(87)90052-0; Wong SME, 1996, GENE, V171, P311, DOI 10.1016/0378-1119(96)00065-0; YEATMAN TJ, 1993, CLIN EXP METASTAS, V11, P37, DOI 10.1007/BF00880064	56	11	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47493	47499		10.1074/jbc.M206572200	http://dx.doi.org/10.1074/jbc.M206572200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324456	hybrid			2022-12-25	WOS:000179663700086
J	Nangle, LA; Lagardt, VD; Dodring, V; Schimmel, P				Nangle, LA; Lagardt, VD; Dodring, V; Schimmel, P			Genetic code ambiguity - Cell viability related to severity of editing defects in mutant tRNA synthetases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA SYNTHETASE; RIBONUCLEIC-ACID SYNTHETASE; PROTEIN-SYNTHESIS; ESCHERICHIA-COLI; AMINO-ACIDS; CLONING VECTORS; VALINE; SIEVE; ISOLEUCINE; DOMAIN	The rules of the genetic code are established in reactions that aminoacylate tRNAs with specific amino acids. Ambiguity in the code is prevented by editing activities whereby incorrect aminoacylations are cleared by specialized hydrolytic reactions of aminoacyl tRNA synthetases. Whereas editing reactions have long been known, their significance for cell viability is still poorly understood. Here we investigated in vitro and in vivo four different mutations in the center for editing that diminish the proofreading activity of valyl-tRNA synthetase (ValRS). The four mutant enzymes were shown to differ quantitatively in the severity of the defect in their ability to clear mischarged tRNA in vitro. Strikingly, in the presence of excess concentrations of a-aminobutyrate, one of the amino acids that is misactivated by ValRS, growth of bacterial strains bearing these mutant alleles is arrested. The concentration of misactivated amino acid required for growth arrest correlates in. versely in a rank order with the degree of the editing defect seen in vitro. Thus, cell viability depends directly on the suppression of genetic code ambiguity by these specific editing reactions and is finely tuned to any perturbation of these reactions.	Scripps Res Inst, Dept Mol Biol & Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Evol SA, F-91000 Evry, France	Scripps Research Institute; Scripps Research Institute	Schimmel, P (corresponding author), Scripps Res Inst, Dept Mol Biol & Chem, La Jolla, CA 92037 USA.				NIGMS NIH HHS [GM23562] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023562] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN AN, 1966, J BIOL CHEM, V241, P839; BARTOLOME B, 1991, GENE, V102, P75, DOI 10.1016/0378-1119(91)90541-I; Bishop AC, 2002, P NATL ACAD SCI USA, V99, P585, DOI 10.1073/pnas.012611299; BOCK A, 1991, MOL MICROBIOL, V5, P515, DOI 10.1111/j.1365-2958.1991.tb00722.x; CHAMBERS SP, 1988, GENE, V68, P139, DOI 10.1016/0378-1119(88)90606-3; de Pouplana LR, 2001, TRENDS BIOCHEM SCI, V26, P591, DOI 10.1016/S0968-0004(01)01932-6; Dong JS, 2000, MOL CELL, V6, P269, DOI 10.1016/S1097-2765(00)00028-9; Doring V, 2001, SCIENCE, V292, P501, DOI 10.1126/science.1057718; ELDRED EW, 1972, J BIOL CHEM, V247, P2961; Felden B, 1998, BIOCHEM BIOPH RES CO, V243, P426, DOI 10.1006/bbrc.1997.7753; FERSHT AR, 1977, BIOCHEMISTRY-US, V16, P1025, DOI 10.1021/bi00624a034; FERSHT AR, 1979, BIOCHEMISTRY-US, V18, P2627, DOI 10.1021/bi00579a030; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P354; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; Fukai S, 2000, CELL, V103, P793, DOI 10.1016/S0092-8674(00)00182-3; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hale SP, 1997, TETRAHEDRON, V53, P11985, DOI 10.1016/S0040-4020(97)00711-4; Hendrickson TL, 2002, MOL CELL, V9, P353, DOI 10.1016/S1097-2765(02)00449-5; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; JAKUBOWSKI H, 1981, NUCLEIC ACIDS RES, V9, P3105, DOI 10.1093/nar/9.13.3105; Lin L, 1996, NATURE, V384, P33, DOI 10.1038/384033b0; LOFTFIELD RB, 1972, BIOCHEM J, V128, P1353, DOI 10.1042/bj1281353; Miller JH, 1972, EXPT MOL GENETICS, P201; Mursinna RS, 2001, BIOCHEMISTRY-US, V40, P5376, DOI 10.1021/bi002915w; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; Nureki O, 1998, SCIENCE, V280, P578, DOI 10.1126/science.280.5363.578; Qiu H, 2001, EMBO J, V20, P1425, DOI 10.1093/emboj/20.6.1425; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; SCHIMMEL P, 1989, BIOCHEMISTRY-US, V28, P2747, DOI 10.1021/bi00433a001; Schimmel P, 2001, COLD SPRING HARB SYM, V66, P161, DOI 10.1101/sqb.2001.66.161; SCHMIDT E, 1995, BIOCHEMISTRY-US, V34, P11204, DOI 10.1021/bi00035a028; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; SCHREIER AA, 1972, BIOCHEMISTRY-US, V11, P1582, DOI 10.1021/bi00759a006; Sissler M, 1999, P NATL ACAD SCI USA, V96, P8985, DOI 10.1073/pnas.96.16.8985; Sissler M, 1998, RNA, V4, P647, DOI 10.1017/S1355838298980037; YARUS M, 1972, P NATL ACAD SCI USA, V69, P1915, DOI 10.1073/pnas.69.7.1915; Zhang YM, 1998, NAT GENET, V20, P123, DOI 10.1038/2417	38	63	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45729	45733		10.1074/jbc.M208093200	http://dx.doi.org/10.1074/jbc.M208093200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244062	hybrid			2022-12-25	WOS:000179529300003
J	Brantley, DM; Cheng, N; Thompson, EJ; Lin, Q; Brekken, RA; Thorpe, PE; Muraoka, RS; Cerretti, DP; Pozzi, A; Jackson, D; Lin, C; Chen, J				Brantley, DM; Cheng, N; Thompson, EJ; Lin, Q; Brekken, RA; Thorpe, PE; Muraoka, RS; Cerretti, DP; Pozzi, A; Jackson, D; Lin, C; Chen, J			Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo	ONCOGENE			English	Article						tumor angiogenesis; Eph receptor tyrosine kinase; ephrin; soluble Eph receptor; vascular window model	ENDOTHELIAL GROWTH-FACTOR; SKIN WINDOW CHAMBERS; TYROSINE KINASE; CELL-ADHESION; MOUSE; EXPRESSION; EPHRINS; GENE; MORPHOGENESIS; LIGAND	The Eph family of receptor tyrosine kinases and their ligands, known as ephrins, play a crucial role in vascular development during embryogenesis. The function of these molecules in adult angiogenesis has not been well characterized. Here, we report that blocking Eph A class receptor activation inhibits angiogenesis in two independent tumor types, the RIP-Tag transgenic model of angiogenesis-dependent pancreatic islet cell carcinoma and the 4T1 model of metastatic mammary adenocarcinoma. Ephrin-A1 ligand was expressed in both tumor and endothelial cells, and EphA2 receptor was localized primarily in tumor-associated vascular endothelial cells. Soluble EphA2-Fc or EphA3-Fc receptors inhibited tumor angiogenesis in cutaneous window assays, and tumor growth in vivo. EphA2-Fc or EphA3-Fc treatment resulted in decreased tumor vascular density, tumor volume, and cell proliferation, but increased cell apoptosis. However, EphA2-Fc had no direct effect on tumor cell growth or apoptosis in culture, yet inhibited migration of endothelial cells in response to tumor cells, suggesting that the soluble receptor inhibited blood vessel recruitment by the tumor. These data provide the first functional evidence for Eph A class receptor regulation of pathogenic angiogenesis induced by tumors and support the function of A class Eph receptors in tumor progression.	Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA; Hope Heart Inst, Dept Vasc Biol, Seattle, WA 98122 USA; Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX USA; Immunex Res & Dev Corp, Seattle, WA 98101 USA; Amersham Pharmacia Corp, St Louis, MO 63198 USA	Vanderbilt University; Vanderbilt University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Chen, J (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@mcmail.vanderbilt.edu		Chen, Jin/0000-0002-5557-2079	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD036400] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009592] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047078] Funding Source: NIH RePORTER; NCI NIH HHS [T-32 CA09592, 2P30CA68485] Funding Source: Medline; NHLBI NIH HHS [T32-HL-07751-06] Funding Source: Medline; NICHD NIH HHS [HD36400] Funding Source: Medline; NIDDK NIH HHS [DK47078] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTOMAA S, 1993, J CANCER RES CLIN, V119, P288, DOI 10.1007/BF01212727; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Arbiser JL, 1997, P NATL ACAD SCI USA, V94, P861, DOI 10.1073/pnas.94.3.861; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Brantley DM, 2000, MECH DEVELOP, V97, P149, DOI 10.1016/S0925-4773(00)00405-6; Brantley DM, 2001, MOL BIOL CELL, V12, P1445, DOI 10.1091/mbc.12.5.1445; Brekken RA, 1998, CANCER RES, V58, P1952; Chen J, 1998, J BIOL CHEM, V273, P24670, DOI 10.1074/jbc.273.38.24670; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Daniel TO, 1996, KIDNEY INT, V50, pS73; DANKORT DL, 1996, TRANSGENIC MODELS BR; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Davy A, 2000, EMBO J, V19, P5396, DOI 10.1093/emboj/19.20.5396; Davy A, 1999, GENE DEV, V13, P3125, DOI 10.1101/gad.13.23.3125; EASTY DJ, 1995, INT J CANCER, V60, P129, DOI 10.1002/ijc.2910600119; Easty DJ, 1999, INT J CANCER, V84, P494, DOI 10.1002/(SICI)1097-0215(19991022)84:5<494::AID-IJC8>3.3.CO;2-F; FOLKMAN J, 1989, NATURE, V339, P58, DOI 10.1038/339058a0; FOLKMAN J, 1994, J CLIN ONCOL, V12, P441, DOI 10.1200/JCO.1994.12.3.441; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; Gale NW, 1997, CELL TISSUE RES, V290, P227, DOI 10.1007/s004410050927; Gale NW, 1999, GENE DEV, V13, P1055, DOI 10.1101/gad.13.9.1055; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Goede V, 1998, ANTICANCER RES, V18, P2199; HANAHAN D, 1985, NATURE, V315, P115, DOI 10.1038/315115a0; Hattori M, 2000, SCIENCE, V289, P1360, DOI 10.1126/science.289.5483.1360; Holder N, 1999, DEVELOPMENT, V126, P2033; HOLZMAN LB, 1990, MOL CELL BIOL, V10, P5830, DOI 10.1128/MCB.10.11.5830; Huai JS, 2001, J BIOL CHEM, V276, P6689, DOI 10.1074/jbc.M008127200; Huang Q, 1999, NAT BIOTECHNOL, V17, P1033, DOI 10.1038/13736; Kuehn R, 1999, PANCREAS, V18, P96, DOI 10.1097/00006676-199901000-00012; Laferriere J, 2001, J BIOL CHEM, V276, P33762, DOI 10.1074/jbc.M008564200; Li CY, 2000, JNCI-J NATL CANCER I, V92, P143, DOI 10.1093/jnci/92.2.143; Lin PN, 1998, P NATL ACAD SCI USA, V95, P8829, DOI 10.1073/pnas.95.15.8829; McBride JL, 1998, MECH DEVELOP, V77, P201, DOI 10.1016/S0925-4773(98)00142-7; Muraoka RS, 2001, J CELL BIOL, V153, P917, DOI 10.1083/jcb.153.5.917; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; OWENS RB, 1974, J NATL CANCER I, V53, P261, DOI 10.1093/jnci/53.1.261; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; PAPENFUSS HD, 1979, MICROVASC RES, V18, P311, DOI 10.1016/0026-2862(79)90039-6; PASSANITI A, 1992, LAB INVEST, V67, P519; Prewett M, 1999, CANCER RES, V59, P5209; PREZIOSI R, 1995, J COMP PATHOL, V113, P301, DOI 10.1016/S0021-9975(05)80117-3; RADVANYI F, 1993, MOL CELL BIOL, V13, P4223, DOI 10.1128/MCB.13.7.4223; ROCKWELL S, 1977, INT J RADIAT BIOL, V31, P153, DOI 10.1080/09553007714550171; ROCKWELL S, 1978, BRIT J CANCER, V37, P212; ROCKWELL S, 1981, CANCER RES, V41, P527; VandenBroecke C, 1996, CLIN EXP METASTAS, V14, P282, DOI 10.1007/BF00053902; Walker-Daniels J, 1999, PROSTATE, V41, P275, DOI 10.1002/(SICI)1097-0045(19991201)41:4<275::AID-PROS8>3.0.CO;2-T; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; WEIDNER N, 1992, JNCI-J NATL CANCER I, V84, P1875, DOI 10.1093/jnci/84.24.1875; WEIDNER N, 1991, NEW ENGL J MED, V324, P1, DOI 10.1056/NEJM199101033240101; WEIDNER N, 1996, ANGIOGENESIS BREAST; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Zantek ND, 1999, CELL GROWTH DIFFER, V10, P629; Zelinski DP, 2001, CANCER RES, V61, P2301	58	272	302	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7011	7026		10.1038/sj.onc.1205679	http://dx.doi.org/10.1038/sj.onc.1205679			16	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370823				2022-12-25	WOS:000178424900004
J	Ohno, H; Hirabayashi, S; Iizuka, T; Ohnishi, H; Fujita, T; Hata, Y				Ohno, H; Hirabayashi, S; Iizuka, T; Ohnishi, H; Fujita, T; Hata, Y			Localization of p0071-interacting proteins, plakophilin-related armadillo-repeat protein-interacting protein (PAPIN) and ERBIN, in epithelial cells	ONCOGENE			English	Article						p0071; catenin; ERBIN; ErbB2; PAPIN; PDZ	DOMAIN-CONTAINING PROTEIN; BASOLATERAL PDZ PROTEIN; GUANYLATE KINASE; SCAFFOLDING MOLECULE; BETA-CATENIN; JUNCTIONS; MAGI-1; MEMBER; DENSIN-180; CLONING	PAPIN has six PDZ domains and interacts with p0071, a catenin-related protein. Recent studies have revealed that catenins determine the subcellular localization of some PDZ proteins. We have examined whether the localization of PAPIN is determined by p0071 in epithelial cells. PAPIN was localized not only on the lateral membrane but also on the apical membrane, where p0071 was absent. The targeting to both membranes was mediated by the middle region of PAPIN and did not require the p0071-interacting PDZ domain. In cells that came into contact, PAPIN was diffusely distributed on the plasma membrane, while p0071 was concentrated at immature cell-cell contacts. When epithelial cells were exposed to the low concentration of calcium, p0071 was internalized, whereas PAPIN remained on the plasma membrane. We also confirmed that the interaction with p0071 was not essential for the membrane targeting of ERBIN, a recently identified p0071- and ErbB2-binding protein. PAPIN, p0071, and ERBIN formed a complex in 293T cells. Furthermore, ERBIN and ErbB2 were colocalized with PAPIN on the lateral membrane. These findings suggest that PAPIN, p0071, and ERBIN come to the cell-cell contacts independently and interact with each other on the lateral membrane.	Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Gastroenterol, Tokyo 1138519, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Nephrol & Endocrinol, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	yuhammch@med.tmd.ac.jp						Apperson ML, 1996, J NEUROSCI, V16, P6839; Bilder D, 2000, NATURE, V403, P676, DOI 10.1038/35001108; Borg JP, 2000, NAT CELL BIOL, V2, P407, DOI 10.1038/35017038; Bryant PJ, 2000, NAT CELL BIOL, V2, pE141, DOI 10.1038/35019616; Chaib H, 2001, CANCER RES, V61, P2390; Deguchi M, 2000, J BIOL CHEM, V275, P29875, DOI 10.1074/jbc.M005384200; Dobrosotskaya I, 1997, J BIOL CHEM, V272, P31589, DOI 10.1074/jbc.272.50.31589; Dobrosotskaya IY, 2001, BIOCHEM BIOPH RES CO, V283, P969, DOI 10.1006/bbrc.2001.4880; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Hatzfeld M, 1996, J CELL SCI, V109, P2767; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Ide N, 1999, ONCOGENE, V18, P7810, DOI 10.1038/sj.onc.1203153; Izawa I, 2002, J BIOL CHEM, V277, P5345, DOI 10.1074/jbc.M110052200; Izawa I, 2002, GENES CELLS, V7, P475, DOI 10.1046/j.1365-2443.2002.00533.x; Jaulin-Bastard F, 2002, J BIOL CHEM, V277, P2869, DOI 10.1074/jbc.M109652200; Kim HG, 1999, HISTOL HISTOPATHOL, V14, P1175, DOI 10.14670/HH-14.1175; Mino A, 2000, GENES CELLS, V5, P1009, DOI 10.1046/j.1365-2443.2000.00385.x; Nagafuchi A, 2001, CURR OPIN CELL BIOL, V13, P600, DOI 10.1016/S0955-0674(00)00257-X; Nishimura W, 2002, J NEUROSCI, V22, P757, DOI 10.1523/JNEUROSCI.22-03-00757.2002; Nishimura W, 2000, J CELL PHYSIOL, V185, P358, DOI 10.1002/1097-4652(200012)185:3<358::AID-JCP6>3.3.CO;2-R; Paffenholz R, 1997, DIFFERENTIATION, V61, P293, DOI 10.1046/j.1432-0436.1997.6150293.x; Patrie KM, 2001, J AM SOC NEPHROL, V12, P667, DOI 10.1681/ASN.V124667; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Shiratsuchi T, 1998, BIOCHEM BIOPH RES CO, V247, P597, DOI 10.1006/bbrc.1998.8603; Stevenson BR, 1998, ANNU REV CELL DEV BI, V14, P89, DOI 10.1146/annurev.cellbio.14.1.89; Tsukita S, 1996, CELL STRUCT FUNCT, V21, P381, DOI 10.1247/csf.21.381; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Zhou JH, 1997, NEUROREPORT, V8, P1489, DOI 10.1097/00001756-199704140-00033	29	35	37	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7042	7049		10.1038/sj.onc.1205852	http://dx.doi.org/10.1038/sj.onc.1205852			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370826				2022-12-25	WOS:000178424900007
J	Erez, N; Milyavsky, M; Goldfinger, N; Peles, E; Gudkov, AV; Rotter, V				Erez, N; Milyavsky, M; Goldfinger, N; Peles, E; Gudkov, AV; Rotter, V			Falkor, a novel cell growth regulator isolated by a functional genetic screen	ONCOGENE			English	Article						Falkor; GSE; MEF; cisplatin	SMOOTH-MUSCLE; DNA-DAMAGE; EXPRESSION; PROTEIN; SM-20; P53; IDENTIFICATION; APOPTOSIS; FAMILY; PROLIFERATION	A novel cell growth regulator, named Falkor, was identified using a functional approach to mammalian gene cloning, the Genetic Supressor Elements (GSE) method. In this screen, expression of the C-terminal domain of Falkor conferred cells with resistance to cisplatin-induced growth arrest. Expression of the C-terminus of Falkor, but not of the full-length protein, enhanced cell growth both following genotoxic stress and under normal conditions suggesting a general role for this protein in cell growth control. This effect of the C-terminus fragment was abrogated by over-expression of the full-length Falkor, suggesting that the fragment counteracts the function of the full-length protein. Falkor is encoded by a 2-kb mRNA which is present at different levels in various tissues, and is localized in the nucleus of cells. The C-terminal domain of Falkor, isolated from the GSE library, has significant homology to a known human and rat cell growth regulator, SM-20, and to the C. elegans protein EGL-9, recently shown to modify the Hypoxia Inducible Factor-la. The homology suggests that these proteins share a functional domain that is conserved among a family of growth regulation proteins.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol, Cleveland, OH 44195 USA	Weizmann Institute of Science; Cleveland Clinic Foundation	Rotter, V (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.		Milyavsky, Michael/E-8306-2011	Peles, Elior/0000-0002-3325-0597; Gudkov, Andrei/0000-0003-2548-0154; Erez, Neta/0000-0001-6506-9074				Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ARAVIND L, 2001, GENOME BIOL, V2; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Dupuy D, 2000, GENOMICS, V69, P348, DOI 10.1006/geno.2000.6343; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Foca C, 2000, MOL HUM REPROD, V6, P712, DOI 10.1093/molehr/6.8.712; GUDKOV AV, 1994, P NATL ACAD SCI USA, V91, P3744, DOI 10.1073/pnas.91.9.3744; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; Jamerson MH, 2000, ONCOGENE, V19, P1065, DOI 10.1038/sj.onc.1203268; KASTAN MB, 1991, CANCER RES, V51, P6304; Lipscomb EA, 2001, J BIOL CHEM, V276, P5085, DOI 10.1074/jbc.M008407200; Lipscomb EA, 1999, J NEUROCHEM, V73, P429, DOI 10.1046/j.1471-4159.1999.0730429.x; Madden SL, 1996, CANCER RES, V56, P5384; PATANJALI SR, 1991, P NATL ACAD SCI USA, V88, P1943, DOI 10.1073/pnas.88.5.1943; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Seth P, 2002, ONCOGENE, V21, P836, DOI 10.1038/sj.onc.1205113; Stanelle J, 2002, NUCLEIC ACIDS RES, V30, P1859, DOI 10.1093/nar/30.8.1859; Taylor MS, 2001, GENE, V275, P125, DOI 10.1016/S0378-1119(01)00633-3; Wax SD, 1996, LAB INVEST, V74, P797; WAX SD, 1994, J BIOL CHEM, V269, P13041; Wei YF, 1996, NUCLEIC ACIDS RES, V24, P931, DOI 10.1093/nar/24.5.931	23	19	20	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6713	6721		10.1038/sj.onc.1205867	http://dx.doi.org/10.1038/sj.onc.1205867			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360397				2022-12-25	WOS:000178315800001
J	Santos, J; Montagutelli, X; Acevedo, A; Lopez, P; Vaquero, C; Fernandez, M; Arnau, MR; Szatanik, M; Salido, E; Guenet, JL; Fernandez-Piqueras, J				Santos, J; Montagutelli, X; Acevedo, A; Lopez, P; Vaquero, C; Fernandez, M; Arnau, MR; Szatanik, M; Salido, E; Guenet, JL; Fernandez-Piqueras, J			A new locus for resistance to gamma-radiation-induced thymic lymphoma identified using inter-specific consomic and inter-specific recombinant congenic strains of mice	ONCOGENE			English	Article						mouse thymic lymphomas; tumor resistance genes; inter-specific consomic (ICS); recombinant congenic (IRCS) strains	SUSCEPTIBILITY; TUMORS; MOUSE; GENE; IRRADIATION; SUPPRESSOR; MUTATION; MODELS	Mice of the C57BL/6J inbred strain develop thymic lymphomas at very high frequency after acute gamma-irradiation, while mice of several inbred strains derived from the wild progenitor of the Mus spretus species and their F1 hybrids with C57BL/6J appear extremely resistant. Analysis of the genetic determinism of the gamma-radiation-induced thymic lymphoma (RITL) resistance with the help of inter-specific consomic strains (ICS), which carry a single introgressed Mus spretus chromosome on a C57BL/6J genetic background, provide significant evidence for the existence of a thymic lymphoma resistance (Tlyr1) locus on chromosome 19. The subsequent analysis of the backcross progeny resulting from a cross between consomic mice heterozygous for the Mus spretus chromosome 19 and C57BL/6J mice, together with the study of inter-specific recombinant congenic strains (IRCS), suggest that this Tlyr1 locus maps within the D19Mit60-D19Mit40 chromosome interval. In addition to the discovery of a new locus controlling RITL development, our study emphasizes the value of ICS and IRCS for the genetic analysis of cancer predisposition.	Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain; Inst Pasteur, Unite Genet Mammiferes, F-75724 Paris, France; Univ La Laguna, Fac Med, Dept Anat Patol, Tenerife 38071, Spain	Autonomous University of Madrid; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidad de la Laguna	Santos, J (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Dept Biol, Lab Genet Mol Humana, E-28049 Madrid, Spain.		Salido, Eduardo C/I-2232-2015; Arozena, Abraham Acevedo/L-6584-2018; Santos, Javier/ABF-5755-2021; Arnau Diaz-Llanos, Maria Rosa/L-8442-2018	Salido, Eduardo C/0000-0001-9599-9854; Arozena, Abraham Acevedo/0000-0001-6127-7116; Santos, Javier/0000-0002-4168-6251; Arnau Diaz-Llanos, Maria Rosa/0000-0002-2941-1626				Angel JM, 2002, MOL CARCINOGEN, V33, P105, DOI 10.1002/mc.10026; ANGEL JM, 1993, MOL CARCINOGEN, V7, P151, DOI 10.1002/mc.2940070305; Balmain A, 1998, TRENDS GENET, V14, P139, DOI 10.1016/S0168-9525(98)01422-X; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; Manenti G, 1996, NAT GENET, V12, P455, DOI 10.1038/ng0496-455; Matin A, 1999, NAT GENET, V23, P237, DOI 10.1038/13874; Mori N, 2000, J RADIAT RES, V41, P367, DOI 10.1269/jrr.41.367; NAGASE H, 1995, NAT GENET, V10, P424, DOI 10.1038/ng0895-424; Nagase H, 1999, P NATL ACAD SCI USA, V96, P15032, DOI 10.1073/pnas.96.26.15032; NEWCOMB EW, 1988, CANCER RES, V48, P5514; OKUMOTO M, 1989, J RADIAT RES, V30, P135, DOI 10.1269/jrr.30.135; OKUMOTO M, 1990, CANCER RES, V50, P3848; Podsypanina K, 1999, P NATL ACAD SCI USA, V96, P1563, DOI 10.1073/pnas.96.4.1563; RICHIE ER, 1985, CANCER RES, V45, P2802; Saito Y, 2001, ONCOGENE, V20, P5243, DOI 10.1038/sj.onc.1204675; Santos J, 2001, ONCOGENE, V20, P2186, DOI 10.1038/sj.onc.1204297; Shibahara K, 1995, GENE, V166, P297, DOI 10.1016/0378-1119(95)00607-9; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Szymanska H, 1999, INT J CANCER, V83, P674, DOI 10.1002/(SICI)1097-0215(19991126)83:5<674::AID-IJC18>3.0.CO;2-M; WATANABEFUKUNAG.R, 1992, NATURE, V356, P317; Wielowieyski A, 1999, MAMM GENOME, V10, P623, DOI 10.1007/s003359901057; YAMADA Y, 1994, J EXP MED, V180, P2155, DOI 10.1084/jem.180.6.2155; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Zhang SL, 2001, MOL CELL BIOL, V21, P310, DOI 10.1128/MCB.21.1.310-318.2001	24	31	33	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6680	6683		10.1038/sj.onc.1205846	http://dx.doi.org/10.1038/sj.onc.1205846			4	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242666	Bronze			2022-12-25	WOS:000178202300014
J	Guo, ML; Harvey, I; Yang, WP; Coghill, L; Campopiano, DJ; Parkinson, JA; MacGillivray, RTA; Harris, WR; Sadler, PJ				Guo, ML; Harvey, I; Yang, WP; Coghill, L; Campopiano, DJ; Parkinson, JA; MacGillivray, RTA; Harris, WR; Sadler, PJ			Synergistic anion and metal binding to the ferric ion-binding protein from Neisseria gonorrhoeae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABSORPTION FINE-STRUCTURE; INDUCED CONFORMATIONAL CHANGE; DRUG TITANOCENE DICHLORIDE; HUMAN SERUM TRANSFERRIN; EXAFS DATA-ANALYSIS; TI-IV UPTAKE; NITRILOTRIS(METHYLENEPHOSPHONIC ACID); PATHOGENIC NEISSERIA; REDOX PROPERTIES; IRON REMOVAL	The 34-kDa periplasmic iron-transport protein (FBP) from Neisseria gonorrhoeae (nFBP) contains Fe(III) and (hydrogen)phosphate (synergistic anion). It has a characteristic ligand-to-metal charge-transfer absorption band at 481 nm. Phosphate can be displaced by (bi)carbonate to give Fe.CO3.nFBP (lambda(max) 459 nm). The local structures of native Fe-PO4-nFBP and Fe.CO3.nFBP were determined by EXAFS at the FeK edge using full multiple scattering analysis. The EXAFS analysis reveals that both phosphate and carbonate ligands bind to FBP in monodentate mode in contrast to transferrins, which bind carbonate in bidentate mode. The EXAFS analysis also suggests an alternative to the crystallographically determined position of the Glu ligand, and this in turn suggests that an H-bonding network may help to stabilize monodentate binding of the synergistic anion. The anions oxalate, pyrophosphate, and nitrilo-triacetate also appear to serve as synergistic anions but not sulfate or perchlorate. The oxidation of Fe(II) in the presence of nFBP led to a weak Fe(III).nFBP complex (lambda(max) 471 nm). Iron and phosphate can be removed from FBP at low pH (pH 4.5) in the presence of a large excess of citrate. Apo-FBP is less soluble and less stable than Fe.nFBP and binds relatively weakly to Ga(III) and Bi(III) but not to Co(III) ions, all of which bind strongly to apo-human serum transferrin.	Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland; CLRC, Daresbury Lab, Synchrotron Radiat Dept, Warrington WA4 4AD, Cheshire, England; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ Missouri, Dept Chem, St Louis, MO 63121 USA	University of Edinburgh; STFC Daresbury Laboratory; University of British Columbia; University of Missouri System; University of Missouri Saint Louis; Washington University (WUSTL)	Sadler, PJ (corresponding author), Univ Edinburgh, Sch Chem, Edinburgh EH9 3JJ, Midlothian, Scotland.			Parkinson, John Andrew/0000-0003-4270-6135; Campopiano, Dominic/0000-0001-8573-6735				Aisen P, 1999, CURR OPIN CHEM BIOL, V3, P200, DOI 10.1016/S1367-5931(99)80033-7; BAILEY NA, 1981, INORG CHIM A-ARTICLE, V50, P111, DOI 10.1016/S0020-1693(00)83729-9; Baker E., 1994, ADV INORG CHEM, P389, DOI [10.1016/S0898-8838(08)60176-2, DOI 10.1016/S0898-8838(08)60176-2]; BALI PK, 1991, INORG CHEM, V30, P502, DOI 10.1021/ic00003a030; BALI PK, 1990, ARCH BIOCHEM BIOPHYS, V281, P251, DOI 10.1016/0003-9861(90)90440-A; BATES GW, 1975, J BIOL CHEM, V250, P2177; BAUER HF, 1960, J AM CHEM SOC, V82, P5031, DOI 10.1021/ja01504a004; BAUER HF, 1966, INORGANIC SYNTHESES, V8, P202; BAX A, 1983, J MAGN RESON, V55, P301, DOI 10.1016/0022-2364(83)90241-X; BERISH SA, 1990, J EXP MED, V171, P1535, DOI 10.1084/jem.171.5.1535; BERISH SA, 1992, MOL MICROBIOL, V6, P2607, DOI 10.1111/j.1365-2958.1992.tb01438.x; BINSTED N, 1992, BIOCHEMISTRY-US, V31, P12117, DOI 10.1021/bi00163a021; Binsted N, 1996, J SYNCHROTRON RADIAT, V3, P185, DOI 10.1107/S0909049596005651; BINSTED N, 1998, EXCURV98 CCLR DARESB; BLACKBURN NJ, 1991, J BIOL CHEM, V266, P23120; Braun V, 1999, TRENDS BIOCHEM SCI, V24, P104, DOI 10.1016/S0968-0004(99)01359-6; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; Bruns CM, 2001, BIOCHEMISTRY-US, V40, P15631, DOI 10.1021/bi0156759; Bullen J J, 1978, Curr Top Microbiol Immunol, V80, P1; CHASTEEN ND, 1977, BIOCHEMISTRY-US, V16, P363, DOI 10.1021/bi00622a004; Cheng MC, 1999, INORG CHEM, V38, P5703, DOI 10.1021/ic990395r; Cheung KC, 2000, ACTA CRYSTALLOGR D, V56, P697, DOI 10.1107/S0907444900003310; CRUIKSHANK DWJ, 1996, CCP4 P DLCONF960001, P11; Descola P., 1996, COORDIN CHEM REV, P1; ELLIS P, 1995, THESIS U SYDNEY SYDN; ELLIS PJ, 1995, J SYNCHROTRON RADIAT, V2, P190, DOI 10.1107/S0909049595006789; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Ferreiros C, 1999, COMP BIOCHEM PHYS B, V123, P1, DOI 10.1016/S0305-0491(99)00044-9; Fonda E, 2001, EUR J INORG CHEM, P1269; GABER BP, 1974, J AM CHEM SOC, V96, P6868, DOI 10.1021/ja00829a010; Grossmann JG, 1998, J MOL BIOL, V279, P461, DOI 10.1006/jmbi.1998.1787; GUO M, 2000, THESIS U EDINBURGH E; Guo ML, 2000, J CHEM SOC DALTON, P7, DOI 10.1039/a908759a; Guo ML, 2000, BIOCHEMISTRY-US, V39, P10023, DOI 10.1021/bi000798z; Hanson BL, 2002, J SYNCHROTRON RADIAT, V9, P375, DOI 10.1107/S0909049502014577; Harris D., 1989, IRON CARRIERS IRON P, P239; HARRIS WR, 1983, BIOCHEMISTRY-US, V22, P292, DOI 10.1021/bi00271a010; HARRIS WR, 1986, BIOCHEMISTRY-US, V25, P803, DOI 10.1021/bi00352a011; HASNAIN SS, 1990, BIOPHYSICS SYNCHROTR, P104; He QY, 1996, BIOCHEM J, V318, P145, DOI 10.1042/bj3180145; Hedin L., 1969, SOLID STATE PHYS, V23, P1, DOI [10.1016/S0081-1947(08)60615-3, DOI 10.1016/S0081-1947(08)60615-3]; Jeffrey PD, 1998, BIOCHEMISTRY-US, V37, P13978, DOI 10.1021/bi9812064; KOENIG DF, 1965, ACTA CRYSTALLOGR, V18, P663, DOI 10.1107/S0365110X65001536; KOJIMA N, 1981, J BIOL CHEM, V256, P2034; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; Meitzner TA, 1998, CURR TOP MICROBIOL I, V225, P113; MIETZNER TA, 1987, J EXP MED, V165, P1041, DOI 10.1084/jem.165.4.1041; Mizutani K, 1999, J BIOL CHEM, V274, P10190, DOI 10.1074/jbc.274.15.10190; MORSE SA, 1988, REV INFECT DIS, V10, pS306; Nakajima H, 2001, J BIOL CHEM, V276, P7055, DOI 10.1074/jbc.M003972200; NOWALK AJ, 1994, BIOCHEMISTRY-US, V33, P12769, DOI 10.1021/bi00209a007; Parkhill J, 2000, NATURE, V404, P502, DOI 10.1038/35006655; PATCH MG, 1983, INORG CHEM, V22, P2630, DOI 10.1021/ic00160a033; PATCH MG, 1981, INORG CHIM A-BIOINOR, V56, pL71, DOI 10.1016/S0020-1693(00)88536-9; PECORARO VL, 1981, BIOCHEMISTRY-US, V20, P7033, DOI 10.1021/bi00527a040; Posey JE, 2000, SCIENCE, V288, P1651, DOI 10.1126/science.288.5471.1651; REHR JJ, 1991, J AM CHEM SOC, V113, P5135, DOI 10.1021/ja00014a001; REHR JJ, 1990, PHYS REV B, V41, P8139, DOI 10.1103/PhysRevB.41.8139; REHR JJ, 1993, JPN J APPL PHYS, P32; Sayers D. E., 2000, REPORT INT XAFS SOC; SCHLABACH MR, 1975, J BIOL CHEM, V250, P2182; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STRANGE RW, 1995, BIOCHEMISTRY-US, V34, P220, DOI 10.1021/bi00001a026; Sun HZ, 1999, CHEM REV, V99, P2817, DOI 10.1021/cr980430w; Taboy CH, 2001, J BIOL CHEM, V276, P2719, DOI 10.1074/jbc.M004763200; Tettelin H, 2000, SCIENCE, V287, P1809, DOI 10.1126/science.287.5459.1809; Weinberg ED, 1997, PERSPECT BIOL MED, V40, P578; ZWEIER JL, 1981, BIOCHEMISTRY-US, V20, P3505, DOI 10.1021/bi00515a031	71	58	61	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JAN 24	2003	278	4					2490	2502		10.1074/jbc.M208776200	http://dx.doi.org/10.1074/jbc.M208776200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	638FY	12372824	hybrid, Green Published			2022-12-25	WOS:000180562000058
J	Zhu, M; Souillac, PO; Ionescu-Zanetti, C; Carter, SA; Fink, AL				Zhu, M; Souillac, PO; Ionescu-Zanetti, C; Carter, SA; Fink, AL			Surface-catalyzed amyloid fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATOMIC-FORCE MICROSCOPY; IMMUNOGLOBULIN LIGHT-CHAINS; ALPHA-SYNUCLEIN; DEPOSITION DISEASE; PARKINSONS-DISEASE; HEAVY-CHAIN; PEPTIDE; AGGREGATION; MECHANISM; FIBRILLIZATION	Light chain (or AL) amyloidosis is characterized by the pathological deposition of insoluble fibrils of immunoglobulin light chain fragments in various tissues, walls of blood vessels, and basement membranes. In the present investigation, the in vitro assembly of a recombinant amyloidogenic light chain variable domain, SMA, on various surfaces was monitored using atomic force microscopy. SAU formed fibrils on native mica at pH 5.0, conditions under which predominantly amorphous aggregates form in solution. Fibril formation was accelerated significantly on surfaces compared with solution; for example, fibrils grew on surfaces at significantly faster rates and at much lower concentrations than in solution. No fibrils were observed on hydrophobic or positively charged surfaces or at pH >7.0. Two novel types. of fibril growth were observed on the surface: bidirectional linear assembly of oligomeric units, and linear growth from preformed amorphous cores. In addition to catalyzing the rate of fibrillation, the mechanism of fibril formation on the surfaces was significantly different from in solution, but it may be more physiologically relevant because in vivo the deposits are associated with surfaces.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA; Univ Calif Santa Cruz, Dept Phys, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz; University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, 1156 High St, Santa Cruz, CA 95064 USA.				NIDDK NIH HHS [DK55675] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055675] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Blackley HKL, 2000, J MOL BIOL, V298, P833, DOI 10.1006/jmbi.2000.3711; Buxbaum J, 1999, HEMATOL ONCOL CLIN N, V13, P1235, DOI 10.1016/S0889-8588(05)70123-4; BUXBAUM J, 1992, HEMATOL ONCOL CLIN N, V6, P323, DOI 10.1016/S0889-8588(18)30347-2; Ding TT, 1999, METHOD ENZYMOL, V309, P510; Gallo G, 1996, AM J PATHOL, V148, P1397; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Goldsbury C, 1999, J MOL BIOL, V285, P33, DOI 10.1006/jmbi.1998.2299; Huang THJ, 2000, J MOL BIOL, V297, P73, DOI 10.1006/jmbi.2000.3559; Ionescu-Zanetti C, 1999, P NATL ACAD SCI USA, V96, P13175, DOI 10.1073/pnas.96.23.13175; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Kim YS, 2001, J BIOL CHEM, V276, P1626, DOI 10.1074/jbc.M007766200; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Koutsos V, 1998, MACROMOLECULES, V31, P116, DOI 10.1021/ma9706182; Koutsos V, 1997, MACROMOLECULES, V30, P4719, DOI 10.1021/ma961625d; Kowalewski T, 1999, P NATL ACAD SCI USA, V96, P3688, DOI 10.1073/pnas.96.7.3688; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; LEVINE H, 1993, PROTEIN SCI, V2, P404, DOI 10.1002/pro.5560020312; Lundberg KM, 1997, CHEM BIOL, V4, P345, DOI 10.1016/S1074-5521(97)90125-3; Mueller Daniel J., 1997, Journal of Structural Biology, V119, P172; MYATT EA, 1994, P NATL ACAD SCI USA, V91, P3034, DOI 10.1073/pnas.91.8.3034; Naiki H, 1999, METHOD ENZYMOL, V309, P305; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Raffen R, 1999, PROTEIN SCI, V8, P509; Sasaki A, 1997, BRAIN RES, V755, P193, DOI 10.1016/S0006-8993(97)00097-8; Solomon A, 1998, P NATL ACAD SCI USA, V95, P9547, DOI 10.1073/pnas.95.16.9547; SOLOMON A, 1991, NEW ENGL J MED, V324, P1845, DOI 10.1056/NEJM199106273242603; Stevens FJ, 1999, IMMUNOL TODAY, V20, P451, DOI 10.1016/S0167-5699(99)01502-9; Stokes MB, 1997, MODERN PATHOL, V10, P1059; Stolz M, 2000, J STRUCT BIOL, V131, P171, DOI 10.1006/jsbi.2000.4301; Tang ZY, 2000, LANGMUIR, V16, P1696, DOI 10.1021/la981491s; van Oss CJ, 2001, COLLOID SURFACE B, V22, P285, DOI 10.1016/S0927-7765(01)00151-5; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Wall J, 1999, BIOCHEMISTRY-US, V38, P14101, DOI 10.1021/bi991131j; Wallace RW, 1996, DRUG DISCOV TODAY, V1, P46, DOI 10.1016/1359-6446(96)89080-5; WILKINSSTEVENS P, 1995, PROTEIN SCI, V4, P421; Yang ZH, 1999, LANGMUIR, V15, P1731, DOI 10.1021/la980839g; Yip CM, 2001, BIOPHYS J, V80, P1359, DOI 10.1016/S0006-3495(01)76109-7	38	223	228	1	50	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50914	50922		10.1074/jbc.M207225200	http://dx.doi.org/10.1074/jbc.M207225200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12356747	hybrid			2022-12-25	WOS:000180177700094
J	Langley, B; Thomas, M; Bishop, A; Sharma, M; Gilmour, S; Kambadur, R				Langley, B; Thomas, M; Bishop, A; Sharma, M; Gilmour, S; Kambadur, R			Myostatin inhibits myoblast differentiation by down-regulating MyoD expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; CELL-CYCLE WITHDRAWAL; MYOGENIC DIFFERENTIATION; MUSCLE DIFFERENTIATION; FACTOR-BETA; TERMINAL DIFFERENTIATION; SKELETAL-MUSCLE; TRANSCRIPTION FACTORS; GENE-EXPRESSION; KINASE-ACTIVITY	Myostatin, a negative regulator of myogenesis, is shown to function by controlling the proliferation of myoblasts. In this study we show that myostatin is an inhibitor of myoblast differentiation and that this inhibition is mediated through Smad 3. In vitro, increasing concentrations of recombinant mature myostatin reversibly blocked the myogenic differentiation of myoblasts, cultured in low serum media. Western and Northern blot analysis indicated that addition of myostatin to the low serum culture media repressed the levels of MyoD, Myf5, myogenin, and p21 leading to the inhibition of myogenic differentiation. The transient transfection of C2C12 myoblasts with MyoD expressing constructs did not rescue myostatin-inhibited myogenic differentiation. Myostatin signaling specifically induced Smad 3 phosphorylation and increased Smad 3-MyoD association, suggesting that Smad 3 may mediate the myostatin signal by interfering with MyoD activity and expression. Consistent with this, the expression of dominant-negative Smad3 rescued the activity of a MyoD promoter-reporter in C2C12 myoblasts treated with myostatin. Taken together, these results suggest that myostatin inhibits MyoD activity and expression via Smad 3 resulting in the failure of the myoblasts to differentiate into myotubes. Thus we propose that myostatin plays a critical role in myogenic differentiation and that the muscular hyperplasia and hypertrophy seen in animals that lack functional myostatin is because of deregulated proliferation and differentiation of myoblasts.	AgRes, Anim Genom, Hamilton, New Zealand; Univ Auckland, Fac Med & Hlth Sci, Auckland 1, New Zealand	AgResearch - New Zealand; University of Auckland	Kambadur, R (corresponding author), AgRes, Anim Genom, Private Bag 3123,East St, Hamilton, New Zealand.		Langley, Brett C/P-7207-2017	Langley, Brett C/0000-0003-4009-2109; Marshall, Amy/0000-0001-5803-3815				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; ARNOLD H, 2001, LIFE XY, V1, P1014; Beranger F, 2000, J BIOL CHEM, V275, P16103, DOI 10.1074/jbc.275.21.16103; Berry FB, 2001, J BIOL CHEM, V276, P25057, DOI 10.1074/jbc.M010378200; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; Carnac G, 2000, CURR BIOL, V10, P543, DOI 10.1016/S0960-9822(00)00471-1; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; CLEGG CH, 1987, J CELL BIOL, V105, P949, DOI 10.1083/jcb.105.2.949; CRESCENZI M, 1990, P NATL ACAD SCI USA, V87, P8442, DOI 10.1073/pnas.87.21.8442; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORINI JR, 1991, ANNU REV PHYSIOL, V53, P201, DOI 10.1146/annurev.ph.53.030191.001221; Grobet L, 1998, MAMM GENOME, V9, P210, DOI 10.1007/s003359900727; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; Heller H, 2001, J BIOL CHEM, V276, P37307, DOI 10.1074/jbc.M103195200; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; Hunter JG, 2001, J BIOL CHEM, V276, P38297; Kambadur R, 1997, GENOME RES, V7, P910, DOI 10.1101/gr.7.9.910; Katagiri T, 1997, EXP CELL RES, V230, P342, DOI 10.1006/excr.1996.3432; Kirk S, 2000, J CELL PHYSIOL, V184, P356, DOI 10.1002/1097-4652(200009)184:3<356::AID-JCP10>3.0.CO;2-R; Kitzmann M, 2001, CELL MOL LIFE SCI, V58, P571, DOI 10.1007/PL00000882; Kitzmann M, 1998, J CELL BIOL, V142, P1447, DOI 10.1083/jcb.142.6.1447; Kuroda K, 1999, J BIOL CHEM, V274, P7238, DOI 10.1074/jbc.274.11.7238; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Ludolph DC, 1995, FASEB J, V9, P1595, DOI 10.1096/fasebj.9.15.8529839; MARTELLI F, 1994, ONCOGENE, V9, P3579; Massague J, 2000, GENE DEV, V14, P627; McPherron AC, 1997, NATURE, V387, P83, DOI 10.1038/387083a0; McPherron AC, 1997, P NATL ACAD SCI USA, V94, P12457, DOI 10.1073/pnas.94.23.12457; Megeney LA, 1995, BIOCHEM CELL BIOL, V73, P723, DOI 10.1139/o95-080; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; Nofziger D, 1999, DEVELOPMENT, V126, P1689; Oldham JM, 2001, AM J PHYSIOL-REG I, V280, pR1488, DOI 10.1152/ajpregu.2001.280.5.R1488; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; Perry RLS, 2000, FRONT BIOSCI, V5, pD750, DOI 10.2741/Perry; Reynaud EG, 2000, J BIOL CHEM, V275, P18767, DOI 10.1074/jbc.M907412199; Rios R, 2001, BIOCHEM BIOPH RES CO, V280, P561, DOI 10.1006/bbrc.2000.4159; Sambrook J., 2002, MOL CLONING LAB MANU; SCHNEIDER MD, 1988, MOL NEUROBIOL, V2, P1, DOI 10.1007/BF02935631; Sharma M, 2001, Exerc Sport Sci Rev, V29, P155, DOI 10.1097/00003677-200110000-00004; SORRENTINO V, 1990, NATURE, V345, P813, DOI 10.1038/345813a0; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; SPIZZ G, 1986, J BIOL CHEM, V261, P9483; TAPSCOTT SJ, 1991, J CLIN INVEST, V87, P1133, DOI 10.1172/JCI115109; Thomas M, 2000, J BIOL CHEM, V275, P40235, DOI 10.1074/jbc.M004356200; VAIDYA TB, 1989, MOL CELL BIOL, V9, P3576, DOI 10.1128/MCB.9.8.3576; Walsh K, 1997, CURR OPIN GENET DEV, V7, P597, DOI 10.1016/S0959-437X(97)80005-6; WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434; Yoshida N, 1998, J CELL SCI, V111, P769; Zhang JM, 1999, EMBO J, V18, P6983, DOI 10.1093/emboj/18.24.6983; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	58	629	701	3	74	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49831	49840		10.1074/jbc.M204291200	http://dx.doi.org/10.1074/jbc.M204291200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12244043	hybrid			2022-12-25	WOS:000180028900097
J	Guo, YS; Cheng, JZ; Jin, GF; Gutkind, JS; Hellmich, MR; Townsend, CM				Guo, YS; Cheng, JZ; Jin, GF; Gutkind, JS; Hellmich, MR; Townsend, CM			Gastrin stimulates cyclooxygenase-2 expression in intestinal epithelial cells through multiple signaling pathways - Evidence for involvement of Erk5 kinase and transactivation of the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; JUN NH2-TERMINAL KINASE; COLON-CANCER-CELLS; TRANSCRIPTION FACTOR; EGF RECEPTOR; CCKB/GASTRIN RECEPTOR; INDEPENDENT PATHWAY; GENE-EXPRESSION; FACTOR-ALPHA; FACTOR-I	Gastrin is a hormone produced by G-cells in the normal gastric antrum. However, colorectal carcinoma cells may aberrantly produce gastrin and exhibit increased expression of cholecystokinin B (CCK-B)/gastrin receptors. Gastrin is trophic for the normal gastric oxyntic mucosa and exerts a growth-promoting action on gastrointestinal malignancy. Thus, gastrin may act as an autocrine/paracrine or endocrine factor in the initiation and progression of colorectal carcinoma. The molecular mechanisms involved have not been elucidated. Hypergastrinemia induced by Helicobacter pylori infection is associated with increased cyclooxygenase-2 (COX-2) expression in gastric and colorectal tissues, suggesting the possibility that gastrin up-regulates COX-2 expression in these tissues; this has not been confirmed. We report here that gastrin significantly increases the expression of COX-2 mRNA and protein, the activity of the COX-2 promoter, and the release of prostaglandin E-2 from a rat intestinal epithelial cell line transfected with the CCK-B receptor. These actions were dependent upon the activation of multiple MAPK signal pathways, including ERK5 kinase; transactivation of the epidermal growth factor receptor; and the increased expression and activities of transcription factors ELK-1, activating transcription factor-2, c-Fos, c-Jun, activator protein-1, and myocyte enhancer factor-2. Thus, our findings identify the signaling pathways coupling the CCK-B receptor with up-regulation of COX-2 expression. This effect may contribute to this hormone-dependent gastrointestinal carcinogenesis, especially in the colon.	Univ Texas, Med Branch, Dept Surg, Galveston, TX 77555 USA; Univ Texas, Med Branch, Dept Ophthalmol, Galveston, TX 77555 USA; NIDCR, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Guo, YS (corresponding author), Univ Texas, Med Branch, Dept Surg, 301 Univ Blvd, Galveston, TX 77555 USA.		Gutkind, J. Silvio/A-1053-2009; Gutkind, J. Silvio/J-1201-2016	Gutkind, J. Silvio/0000-0002-5150-4482	NIDDK NIH HHS [R01 DK48345, P01 DK35608] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551, ZIADE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551, Z01DE000558] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK035608, R01DK048345] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akagi K, 1999, BBA-MOL CELL RES, V1452, P243, DOI 10.1016/S0167-4889(99)00137-8; CICCOTOSTO GD, 1995, GASTROENTEROLOGY, V109, P1142, DOI 10.1016/0016-5085(95)90572-3; Coso OA, 1997, J BIOL CHEM, V272, P20691, DOI 10.1074/jbc.272.33.20691; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Daulhac L, 1999, J BIOL CHEM, V274, P20657, DOI 10.1074/jbc.274.29.20657; Fukuhara S, 2000, J BIOL CHEM, V275, P21730, DOI 10.1074/jbc.M002410200; Guan ZH, 1998, J BIOL CHEM, V273, P28670, DOI 10.1074/jbc.273.44.28670; Guo Y S, 2000, J Hepatobiliary Pancreat Surg, V7, P276, DOI 10.1007/s005340070049; Guo YS, 2001, J BIOL CHEM, V276, P22941, DOI 10.1074/jbc.M101801200; GUO YS, 1990, IN VITRO CELL DEV B, V26, P871; GUO YS, 1993, GASTROENTEROLOGY, V104, P1595, DOI 10.1016/0016-5085(93)90634-O; Guo YS, 1998, J CELL PHYSIOL, V175, P141, DOI 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O; GUO YS, 1999, GASTROINTESTINAL END; Hartwich J, 2001, Med Sci Monit, V7, P1171; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; Hocker M, 1997, AM J PHYSIOL-GASTR L, V272, pG822, DOI 10.1152/ajpgi.1997.272.4.G822; Hocker M, 1997, J BIOL CHEM, V272, P27015, DOI 10.1074/jbc.272.43.27015; JANKNECHT R, 1995, CARCINOGENESIS, V16, P443, DOI 10.1093/carcin/16.3.443; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; Konturek SJ, 2000, REGUL PEPTIDES, V93, P13, DOI 10.1016/S0167-0115(00)00173-7; Konturek SJ, 2001, PROSTAG OTH LIPID M, V66, P39, DOI 10.1016/S0090-6980(01)00142-3; Luttrell LM, 1997, J BIOL CHEM, V272, P4637, DOI 10.1074/jbc.272.7.4637; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; Marinissen MJ, 1999, MOL CELL BIOL, V19, P4289; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Matsuura H, 1999, J BIOL CHEM, V274, P29138, DOI 10.1074/jbc.274.41.29138; McKinsey TA, 2002, TRENDS BIOCHEM SCI, V27, P40, DOI 10.1016/S0968-0004(01)02031-X; Miyazaki Y, 1999, GASTROENTEROLOGY, V116, P78, DOI 10.1016/S0016-5085(99)70231-3; Mohan R, 2000, J BIOL CHEM, V275, P10405, DOI 10.1074/jbc.275.14.10405; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; PENNYPACKER KR, 1994, FASEB J, V8, P475, DOI 10.1096/fasebj.8.8.8181665; PODOLSKY DK, 1993, AM J PHYSIOL, V264, P179; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rozengurt E, 2001, ANNU REV PHYSIOL, V63, P49, DOI 10.1146/annurev.physiol.63.1.49; Schmitz F, 2001, EUR J CLIN INVEST, V31, P812, DOI 10.1046/j.1365-2362.2001.00870.x; SEUFFERLEIN T, 1995, CELL GROWTH DIFFER, V6, P383; Sheng HM, 2000, J BIOL CHEM, V275, P6628, DOI 10.1074/jbc.275.9.6628; Stepan VM, 1999, AM J PHYSIOL-GASTR L, V276, pG415, DOI 10.1152/ajpgi.1999.276.2.G415; Strakova Z, 1998, AM J PHYSIOL-ENDOC M, V274, pE634, DOI 10.1152/ajpendo.1998.274.4.E634; TODISCO A, 1995, J BIOL CHEM, V270, P28337; Tsai W, 1997, EMBO J, V16, P4597, DOI 10.1093/emboj/16.15.4597; UPP JR, 1989, CANCER RES, V49, P488; Varro A, 2002, GUT, V50, P827, DOI 10.1136/gut.50.6.827; Watson SA, 2000, CANCER RES, V60, P5902; Watson SA, 1999, EUR J CANCER, V35, P1286, DOI 10.1016/S0959-8049(99)00115-X; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Xie WL, 1996, J BIOL CHEM, V271, P31742, DOI 10.1074/jbc.271.49.31742; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang TX, 2000, J BIOL CHEM, V275, P23281, DOI 10.1074/jbc.M910237199	50	76	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48755	48763		10.1074/jbc.M209016200	http://dx.doi.org/10.1074/jbc.M209016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12239223	hybrid			2022-12-25	WOS:000179789600102
J	Worthington, MT; Pelo, JW; Sachedina, MA; Applegate, JL; Arseneau, KO; Pizarro, TT				Worthington, MT; Pelo, JW; Sachedina, MA; Applegate, JL; Arseneau, KO; Pizarro, TT			RNA binding properties of the AU-rich element-binding recombinant Nup475/TIS11/tristetraprolin protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MESSENGER-RNA; 3'-UNTRANSLATED REGION; POLY(A) TAIL; INTACT-CELLS; IN-VITRO; C-MYC; SEQUENCE; TRISTETRAPROLIN; EXPRESSION	Regulation of messenger RNA stability by AU-rich elements is an important means of regulating genes induced by growth factors and cytokines. Nup475 (also known as tristetraprolin, or TIS11) is the prototype for a family of zinc-binding Cys(3)His motif proteins required for proper regulation of tumor necrosis factor mRNA stability in macrophages. We developed an Escherichia coli expression system to produce soluble Nup475 protein in quantity to study its RNA binding properties. Nup475 protein bound a tumor necrosis factor AU-rich element over a broad range of pH and salt concentrations by RNA gel shift. This binding was inhibited by excess zinc metal, providing a potential mechanism for previous reports of zinc stabilization of AU-rich element (ARE) containing messenger RNAs. Immobilized Nup475 protein was used to select its optimal binding site by RNA SELEX and revealed a strong preference for the extended sequence UUAUUUALTU, rather than a simple AUUUA motif. These findings were confirmed by site-directed mutagenesis of the tumor necrosis factor ARE and RNA gel shifts on c-fos, interferon-gamma, and interferon-beta ARE fragments. A weaker binding activity toward adenine-rich sites, such as a poly(A) tail RNA fragment, can partially disrupt the Nup475-tumor necrosis factor AU-rich element complex.	Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, Charlottesville, VA 22908 USA	University of Virginia	Worthington, MT (corresponding author), Univ Virginia, Hlth Sci Ctr, Digest Hlth Ctr Excellence, MR-4 Bldg,Rm 1036,Lane Rd, Charlottesville, VA 22908 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060720, K08DK002501] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60720, DK02501] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe R, 1996, NUCLEIC ACIDS RES, V24, P4895, DOI 10.1093/nar/24.24.4895; AMREIN KE, 1995, P NATL ACAD SCI USA, V92, P1048, DOI 10.1073/pnas.92.4.1048; Anant S, 2000, MOL CELL BIOL, V20, P1982, DOI 10.1128/MCB.20.6.1982-1992.2000; Andrews LG, 1999, METH MOL B, V118, P233; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; DALE GE, 1994, PROTEIN ENG, V7, P925, DOI 10.1093/protein/7.7.925; Dember LM, 1996, J BIOL CHEM, V271, P2783, DOI 10.1074/jbc.271.5.2783; DRIESSEN C, 1995, IMMUNOLOGY, V84, P272; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; GRAFI G, 1993, MOL CELL BIOL, V13, P3487, DOI 10.1128/MCB.13.6.3487; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; Johnson BA, 2002, J BIOL CHEM, V277, P18029, DOI 10.1074/jbc.M110465200; Katahira M, 2001, J MOL BIOL, V311, P973, DOI 10.1006/jmbi.2001.4862; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; LAU LF, 1987, P NATL ACAD SCI USA, V84, P1182, DOI 10.1073/pnas.84.5.1182; Lippard S. J., 1994, PRINCIPLES BIOINORGA; MA QF, 1991, ONCOGENE, V6, P1277; Ma WJ, 1997, NUCLEIC ACIDS RES, V25, P3564, DOI 10.1093/nar/25.18.3564; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Meerarani P, 2000, AM J CLIN NUTR, V71, P81; MEIJLINK F, 1985, P NATL ACAD SCI USA, V82, P4987, DOI 10.1073/pnas.82.15.4987; Meisenholder GW, 1996, J BIOL CHEM, V271, P16260, DOI 10.1074/jbc.271.27.16260; MESNER PW, 1995, J NEUROSCI, V15, P7357; MONIA BP, 1989, J BIOL CHEM, V264, P4093; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; Raghavan A, 2001, J BIOL CHEM, V276, P47958, DOI 10.1074/jbc.M109511200; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; SAKASHITA E, 1994, NUCLEIC ACIDS RES, V22, P4082, DOI 10.1093/nar/22.20.4082; SEIDMAN CG, 1997, CURRENT PROTOCOLS MO, V1; Setzer DA, 1999, METH MOL B, V118, P115; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; TAYLOR GA, 1995, J CELL PHYSIOL, V162, P378, DOI 10.1002/jcp.1041620310; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; ZUBIAGA AM, 1995, MOL CELL BIOL, V15, P2219	40	105	110	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48558	48564		10.1074/jbc.M206505200	http://dx.doi.org/10.1074/jbc.M206505200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12324455	hybrid			2022-12-25	WOS:000179789600077
J	Baumann, SW; Baur, R; Sigel, E				Baumann, SW; Baur, R; Sigel, E			Forced subunit assembly in alpha(1)beta(2)gamma(2) GABA(A) receptors - Insight into the absolute arrangement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BENZODIAZEPINE BINDING-SITE; AMINOBUTYRIC ACID(A) RECEPTORS; A RECEPTORS; RAT-BRAIN; AGONIST BINDING; GAMMA(2) SUBUNIT; ALPHA-SUBUNIT; BETA-SUBUNIT; STOICHIOMETRY; SUBTYPES	The major isoform of the gamma-aminobutyric acid type A (GABA(A)) receptor is thought to be composed of 2alpha(1), 2beta(2), and 1gamma(2) subunit(s), which surround the ion pore. Definite evidence for the subunit arrangement is lacking. We show here that GABA(A) receptor subunits can be concatenated to a trimer that can be functionally expressed upon combination with a dimer. Many combinations did not result in the functional expression. In contrast, four different combinations of triple subunits with dual subunit constructs, all resulting in the identical pentameric receptor gamma(2)beta(2)alpha(1)beta(2)alpha(1), could be successfully expressed in Xenopus oocytes. We characterized the functional properties of these receptors in respect to agonist, competitive antagonist, and diazepam sensitivity. All properties were similar to those of wild type alpha(1)beta(2)gamma(2) GABA(A) receptors. Thus, together with information on the crystal structure of the homologous acetylcholine-binding protein (Brejc, K., van Dijk, W. J., Klaassen, R. V., Schuurmans, M., van Der Oost, J., Smit, A. B., and Sixma, T. K., (2001) Nature 411, 269-276, we provide evidence for an arrangement gamma(2)beta(2)alpha(1)beta(2)alpha(1), counterclockwise when viewed from the synaptic cleft. Forced subunit assembly will also allow receptors containing different subunit isoforms or mutant subunits to be expressed, each in a desired position. The methods established here should be applicable to the entire ion channel family comprising nicotinic acetylcholine, glycine, and 5HT(3) receptors.	Univ Bern, Dept Pharmacol, CH-3010 Bern, Switzerland	University of Bern	Sigel, E (corresponding author), Univ Bern, Dept Pharmacol, Friedbuehlstr 49, CH-3010 Bern, Switzerland.		Sigel, Erwin/F-7736-2015					AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Amin J, 1997, MOL PHARMACOL, V51, P833, DOI 10.1124/mol.51.5.833; BACKUS KH, 1993, NEUROREPORT, V5, P285, DOI 10.1097/00001756-199312000-00026; Barnard EA, 1998, PHARMACOL REV, V50, P291; Baumann SW, 2001, J BIOL CHEM, V276, P36275, DOI 10.1074/jbc.M105240200; BENKE D, 1994, J BIOL CHEM, V269, P27100; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 2002, NEUROPHARMACOLOGY, V43, P695, DOI 10.1016/S0028-3908(02)00036-9; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Buhr A, 1997, MOL PHARMACOL, V52, P676, DOI 10.1124/mol.52.4.676; Buhr A, 1997, P NATL ACAD SCI USA, V94, P8824, DOI 10.1073/pnas.94.16.8824; Buhr A, 1997, J BIOL CHEM, V272, P11799, DOI 10.1074/jbc.272.18.11799; CARUNCHO HJ, 1994, RECEPTOR CHANNEL, V2, P143; Chang YC, 1996, J NEUROSCI, V16, P5415; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; EWERT M, 1990, J CELL BIOL, V110, P2043, DOI 10.1083/jcb.110.6.2043; Farrar SJ, 1999, J BIOL CHEM, V274, P10100, DOI 10.1074/jbc.274.15.10100; FRITSCHY JM, 1995, J COMP NEUROL, V359, P154, DOI 10.1002/cne.903590111; FRITSCHY JM, 1992, P NATL ACAD SCI USA, V89, P6726, DOI 10.1073/pnas.89.15.6726; HARING P, 1985, P NATL ACAD SCI USA, V82, P4837, DOI 10.1073/pnas.82.14.4837; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Horenstein J, 2001, NAT NEUROSCI, V4, P477, DOI 10.1038/87425; Khan ZU, 1996, J NEUROCHEM, V66, P685; Klausberger T, 2001, J BIOL CHEM, V276, P16024, DOI 10.1074/jbc.M009508200; Kuhn FJP, 1999, J GEN PHYSIOL, V114, P167, DOI 10.1085/jgp.114.2.167; LAURIE DJ, 1992, J NEUROSCI, V12, P1063; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; Newell JG, 2002, J BIOL CHEM, V277, P21423, DOI 10.1074/jbc.M110312200; Newell JG, 2000, J BIOL CHEM, V275, P14198, DOI 10.1074/jbc.275.19.14198; PRITCHETT DB, 1989, NATURE, V338, P582, DOI 10.1038/338582a0; QUIRK K, 1994, MOL PHARMACOL, V45, P1061; RABOW LE, 1995, SYNAPSE, V21, P189, DOI 10.1002/syn.890210302; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1987, J PHYSIOL-LONDON, V386, P73, DOI 10.1113/jphysiol.1987.sp016523; Sigel E, 2000, J NEUROCHEM, V74, P2590, DOI 10.1046/j.1471-4159.2000.0742590.x; Sigel E, 1997, TRENDS PHARMACOL SCI, V18, P425, DOI 10.1016/S0165-6147(97)90675-1; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; Somogyi P, 1996, NEUROPHARMACOLOGY, V35, P1425, DOI 10.1016/S0028-3908(96)00086-X; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; Tretter V, 1997, J NEUROSCI, V17, P2728; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; Whiting PJ, 1997, J NEUROSCI, V17, P5027; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; WIELAND HA, 1992, J BIOL CHEM, V267, P1426; Wisden W, 1992, Curr Opin Neurobiol, V2, P263, DOI 10.1016/0959-4388(92)90113-Y	47	214	218	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46020	46025		10.1074/jbc.M207663200	http://dx.doi.org/10.1074/jbc.M207663200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324466	hybrid			2022-12-25	WOS:000179529300042
J	Goda, M; Hashimoto, Y; Takase, M; Herai, S; Iwahara, Y; Higashibata, H; Kobayashi, M				Goda, M; Hashimoto, Y; Takase, M; Herai, S; Iwahara, Y; Higashibata, H; Kobayashi, M			Isonitrile hydratase from Pseudomonas putida N19-2 - Cloning, sequencing, gene expression, and identification of its active amino acid residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHODOCOCCUS-RHODOCHROUS J1; MASS NITRILE HYDRATASE; SITE-DIRECTED MUTAGENESIS; ESCHERICHIA-COLI; INTRACELLULAR PROTEASE; ANTIMALARIAL ACTIVITY; NATURAL-PRODUCTS; MARINE SPONGES; ISOCYANIDES; PROTEINS	Isonitrile hydratase is a novel enzyme in Pseudomonas putida N19-2 that catalyzes the conversion of isonitriles to N-substituted formamides. Based on N-terminal and internal amino acid sequences, a 535-bp DNA fragment corresponding to a portion of the isonitrile hydratase gene was amplified, which was used as a probe to clone a 6.4-kb DNA fragment containing the whole gene. Sequence analysis of the 6.4-kb fragment revealed that the isonitrile hydratase gene (inhA) was 684 nucleotides long and encoded a protein with a molecular mass of 24,211 Da. Overexpression of inhA in Escherichia coli gave a large amount of soluble isonitrile hydratase exhibiting the same molecular and catalytic properties as the native enzyme from the Pseudomonas strain. The predicted amino acid sequence of inhA showed low similarity to that of an intracellular protease in Pyrococcus horikoshii (PH1704), and an active cysteine residue in the protease was conserved in the isonitrile hydratase at the corresponding position (Cys-101). A mutant enzyme containing Ala instead of Cys-101 did not exhibit isonitrile hydratase activity at all, demonstrating the essential role of this residue in the catalytic function.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan; Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Sakyo Ku, Kyoto 6068502, Japan	University of Tsukuba; Kyoto University	Kobayashi, M (corresponding author), Univ Tsukuba, Inst Appl Biochem, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.			HIGASHIBATA, Hiroki/0000-0001-7416-5316				Abeles RH, 1992, BIOCHEMISTRY-US, P193; ACHENBAC.H, 1972, CHEM BER-RECL, V105, P784, DOI 10.1002/cber.19721050307; ACHENBACH H, 1965, Z NATURFORSCH PT B, VB 20, P137, DOI 10.1515/znb-1965-0209; ANGERHOFER CK, 1992, J NAT PROD, V55, P1787, DOI 10.1021/np50090a014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURRESON BJ, 1975, J AM CHEM SOC, V97, P4763, DOI 10.1021/ja00849a053; CAFIERI F, 1973, TETRAHEDRON, V29, P4259, DOI 10.1016/0040-4020(73)80267-4; CUNNINGHAM ID, 1991, J CHEM SOC PERK T 2, P589, DOI 10.1039/p29910000589; CUNNINGHAM ID, 1988, J CHEM SOC PERK T 2, P1485, DOI 10.1039/p29880001485; Domling A, 2000, CURR OPIN CHEM BIOL, V4, P318, DOI 10.1016/S1367-5931(00)00095-8; Domling A, 2002, CURR OPIN CHEM BIOL, V6, P306, DOI 10.1016/S1367-5931(02)00328-9; Domling A, 2000, ANGEW CHEM INT EDIT, V39, P3168, DOI 10.1002/1521-3773(20000915)39:18<3168::AID-ANIE3168>3.0.CO;2-U; DRENTH W, 1962, RECL TRAV CHIM PAY B, V81, P319; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; EDENBOROUGH MS, 1988, NAT PROD REP, V5, P229, DOI 10.1039/np9880500229; EVANS JR, 1976, J ANTIBIOT, V29, P850, DOI 10.7164/antibiotics.29.850; Fusetani N, 1997, CURR ORG CHEM, V1, P127; Goda M, 2001, J BIOL CHEM, V276, P23480, DOI 10.1074/jbc.M007856200; HAGADONE MR, 1984, J AM CHEM SOC, V106, P2447, DOI 10.1021/ja00320a044; HAGEDORN J, 1957, PHARMAZIE, V12, P567; Halio SB, 1996, J BACTERIOL, V178, P2605, DOI 10.1128/jb.178.9.2605-2612.1996; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Kawarabayasi Y, 1998, DNA Res, V5, P55, DOI 10.1093/dnares/5.2.55; KELLY M, 1967, BIOCHEM J, V102, pC1, DOI 10.1042/bj1020001C; Kobayashi M, 1998, FEBS LETT, V439, P325, DOI 10.1016/S0014-5793(98)01406-9; KOBAYASHI M, 1995, P NATL ACAD SCI USA, V92, P714, DOI 10.1073/pnas.92.3.714; Kobayashi M, 1997, P NATL ACAD SCI USA, V94, P11986, DOI 10.1073/pnas.94.22.11986; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; Kobayashi M, 1999, EUR J BIOCHEM, V261, P1, DOI 10.1046/j.1432-1327.1999.00186.x; KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247; KOBAYASHI M, 1992, J BIOL CHEM, V267, P20746; Kobayashi M, 1998, NAT BIOTECHNOL, V16, P733, DOI 10.1038/nbt0898-733; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; KOBAYASHI M, 1994, FEMS MICROBIOL LETT, V120, P217, DOI 10.1016/0378-1097(94)90474-X; Komeda H, 1996, P NATL ACAD SCI USA, V93, P4267, DOI 10.1073/pnas.93.9.4267; Komeda H, 1996, J BIOL CHEM, V271, P15796, DOI 10.1074/jbc.271.26.15796; Komeda H, 1996, P NATL ACAD SCI USA, V93, P10572, DOI 10.1073/pnas.93.20.10572; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mizote T, 1996, MICROBIOL-UK, V142, P2969, DOI 10.1099/13500872-142-10-2969; Mizote T, 1999, MICROBIOL-UK, V145, P495, DOI 10.1099/13500872-145-2-495; NELSON CA, 1971, J BIOL CHEM, V246, P3895; PFEIFER S, 1972, PHARMAZIE, V27, P536; Pogulis R J, 1996, Methods Mol Biol, V57, P167; RUBINSON JF, 1983, BIOCHEMISTRY-US, V22, P6260, DOI 10.1021/bi00295a034; Sambrook J., 1989, MOL CLONING LAB MANU, V2; SCHEUER PJ, 1992, ACCOUNTS CHEM RES, V25, P433, DOI 10.1021/ar00022a001; Wright AD, 2001, J MED CHEM, V44, P873, DOI 10.1021/jm0010724; Yamada H, 1996, BIOSCI BIOTECH BIOCH, V60, P1391, DOI 10.1271/bbb.60.1391	48	31	33	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45860	45865		10.1074/jbc.M208571200	http://dx.doi.org/10.1074/jbc.M208571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244065	Green Submitted, hybrid			2022-12-25	WOS:000179529300020
J	Ray, BK; Murphy, R; Ray, P; Ray, A				Ray, BK; Murphy, R; Ray, P; Ray, A			SAF-2, a splice variant of SAF-1, acts as a negative regulator of transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM-AMYLOID-A; ZINC-FINGER PROTEIN; PRE-MESSENGER-RNA; SEQUENCE-BINDING-FACTOR; GENE-EXPRESSION; MONOCYTE/MACROPHAGE CELLS; ACTIVATING FACTOR; PROMOTER; MAZ; MYC	Serum amyloid A-activating factor-1 (SAF-1), a Cys(2)His(2)-type zinc finger transcription factor, regulates inflammation-induced expression of serum amyloid A protein that is linked to the pathogenesis of reactive amyloidosis, rheumatoid arthritis, and atherosclerosis. Here we report the identification of a novel splice variant, SAF-2, of the SAF family bearing strong sequence similarity to SAF-1. The N-terminal 426 amino acids of both SAF-1 and SAF-2 are identical containing two polyalanine tracts, one proline-rich domain, and six zinc fingers. However, the C terminus of SAF-2 containing two additional zinc fingers is different from SAF-1, which indicates the capability of different biochemical function. We show that SAF-2 interacts more avidly with the SAF-binding element, but its transactivation potential is much lower than SAF-1. Furthermore, co-expression of SAF-2 markedly suppresses SAF-1-regulated promoter function. Finally, we show that the level of SAF-2 protein is reduced during many inflammatory conditions, whereas the SAF-1 protein level remains unchanged. Together, these data suggest that the relative abundance of SAF-2 plays a critical role in the fine tuned regulation of inflammation-responsive genes that are controlled by SAF-1.	Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA	University of Missouri System; University of Missouri Columbia	Ray, BK (corresponding author), Univ Missouri, Dept Vet Pathobiol, Columbia, MO 65211 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049205] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK49205] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BOSSONE SA, 1992, P NATL ACAD SCI USA, V89, P7452, DOI 10.1073/pnas.89.16.7452; Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; Coulter LR, 1997, MOL CELL BIOL, V17, P2143, DOI 10.1128/MCB.17.4.2143; DUNCAN DD, 1995, MOL CELL BIOL, V15, P3179; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Hanke J, 1999, TRENDS GENET, V15, P389, DOI 10.1016/S0168-9525(99)01830-2; Her S, 1999, J BIOL CHEM, V274, P8698, DOI 10.1074/jbc.274.13.8698; Hewitt SM, 1996, J BIOL CHEM, V271, P8588, DOI 10.1074/jbc.271.15.8588; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jiang ZH, 1998, P NATL ACAD SCI USA, V95, P9155, DOI 10.1073/pnas.95.16.9155; KENNEDY GC, 1992, P NATL ACAD SCI USA, V89, P11498, DOI 10.1073/pnas.89.23.11498; Kosaki A, 1998, J BIOL CHEM, V273, P10331, DOI 10.1074/jbc.273.17.10331; Ladd AN, 2001, MOL CELL BIOL, V21, P1285, DOI 10.1128/MCB.21.4.1285-1296.2001; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Lou H, 1999, MOL CELL BIOL, V19, P78; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; Manley JL, 1996, GENE DEV, V10, P1569, DOI 10.1101/gad.10.13.1569; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Parks CL, 1996, J BIOL CHEM, V271, P4417; Ray A, 1999, J BIOL CHEM, V274, P4300, DOI 10.1074/jbc.274.7.4300; Ray A, 1998, MOL CELL BIOL, V18, P7327, DOI 10.1128/MCB.18.12.7327; Ray A, 2002, MOL CELL BIOL, V22, P1027, DOI 10.1128/MCB.22.4.1027-1035.2002; Ray A, 2000, J IMMUNOL, V165, P3411, DOI 10.4049/jimmunol.165.6.3411; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Ray A, 1996, MOL CELL BIOL, V16, P1584; Ray A, 2000, J BIOL CHEM, V275, P39727, DOI 10.1074/jbc.M007907200; Ray BK, 1997, J BIOL CHEM, V272, P28948, DOI 10.1074/jbc.272.46.28948; Ray BK, 2001, J IMMUNOL, V167, P2343, DOI 10.4049/jimmunol.167.4.2343; Ray BK, 1997, BIOCHEMISTRY-US, V36, P4662, DOI 10.1021/bi9624595; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; Shepard J, 2002, MOL CELL BIOL, V22, P221, DOI 10.1128/MCB.22.1.221-230.2002; SIPE JD, 1994, CRIT REV CL LAB SCI, V31, P325, DOI 10.3109/10408369409084679; Song J, 1998, J BIOL CHEM, V273, P20603, DOI 10.1074/jbc.273.32.20603; Uchida S, 2000, MOL CELL BIOL, V20, P7319, DOI 10.1128/MCB.20.19.7319-7331.2000; Uhlar CM, 1999, EUR J BIOCHEM, V265, P501, DOI 10.1046/j.1432-1327.1999.00657.x; Wang J, 1997, CURR OPIN GENET DEV, V7, P205, DOI 10.1016/S0959-437X(97)80130-X; WANG Z, 1995, RNA, V1, P21	43	12	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46822	46830		10.1074/jbc.M206299200	http://dx.doi.org/10.1074/jbc.M206299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270922	hybrid			2022-12-25	WOS:000179529300143
J	van der Wel, H; Fisher, SZ; West, CM				van der Wel, H; Fisher, SZ; West, CM			A bifunctional diglycosyltransferase forms the Fuc alpha 1,2Gal,beta 1,3-disaccharide on Skp1 in the cytoplasm of Dictyostelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE COAT; GLYCOSYLTRANSFERASES; GLYCOSYLATION; SYNTHASE; IDENTIFICATION; BIOSYNTHESIS; DISCOIDEUM; RESIDUES; FP21	Skp1 is a subunit of the Skp1 cullin-1 F-box protein (SCF) family of E3 ubiquitin ligases and of other regulatory complexes in the cytoplasm and nucleus. In Dictyostelium, Skp1 is modified by a pentasaccharide with the type I blood group H antigen (Fucalpha1,2Galbeta1,3GlcNAc-) at its core. Addition of the Fuc is catalyzed by FT85, a 768-amino acid protein whose fucosyltransferase activity maps to the C-terminal half of the protein. A strain whose FT85 gene is interrupted by a genetic insertion produces a truncated, GlcNAc-terminated glycan on Skp1, suggesting that FT85 may also have beta-galactosyltransferase activity. In support of this model, highly purified native and recombinant FT85 are each able to galactosylate Skp1 from FT85 mutant cells. Site-directed mutagenesis of predicted key amino acids in the N-terminal region of FT85 abolishes Skp1 beta-galactosyltransferase activity with minimal effects on the fucosyltransferase. In addition, a recombinant form of the N-terminal region exhibits beta-galactosyltransferase but not fucosyltransferase activity. Kinetic analysis of FT85 suggests that its two glycosyltransferase activities normally modify Skp1 processively but can have partial function individually. In conclusion, FT85 is a bifunctional diglycosyltransferase that appears to be designed to efficiently extend the Skp1 glycan in vivo.	Univ Florida, Coll Med, Dept Anat & Cell Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	West, CM (corresponding author), Univ Florida, Coll Med, Dept Anat & Cell Biol, 1600 SW Archer Rd, Gainesville, FL 32610 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037539] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01-GM37539] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARONDES SH, 1987, METHOD CELL BIOL, V28, P387; DeAngelis PL, 2002, GLYCOBIOLOGY, V12, p9R, DOI 10.1093/glycob/12.1.9R; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Garinot-Schneider C, 2000, J BIOL CHEM, V275, P31407, DOI 10.1074/jbc.M004524200; Gentzsch M, 1995, FEBS LETT, V377, P128, DOI 10.1016/0014-5793(95)01324-5; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; Guan S, 2001, J BACTERIOL, V183, P3318, DOI 10.1128/JB.183.11.3318-3327.2001; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Heldermon C, 2001, J BIOL CHEM, V276, P2037, DOI 10.1074/jbc.M002276200; Jorasch P, 2000, EUR J BIOCHEM, V267, P3770, DOI 10.1046/j.1432-1327.2000.01414.x; Kapitonov D, 1999, GLYCOBIOLOGY, V9, P961, DOI 10.1093/glycob/9.10.961; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Marks DL, 2001, J BIOL CHEM, V276, P26492, DOI 10.1074/jbc.M102612200; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Reiber DC, 1998, ANAL CHEM, V70, P1214, DOI 10.1021/ac971158d; Sassi S, 2001, GLYCOBIOLOGY, V11, P283, DOI 10.1093/glycob/11.4.283; Saxena IM, 2001, PHYTOCHEMISTRY, V57, P1135, DOI 10.1016/S0031-9422(01)00048-6; Schachter H, 1992, GLYCOCONJUGATES COMP, P263; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; Tarbouriech N, 2001, J MOL BIOL, V314, P655, DOI 10.1006/jmbi.2001.5159; Teng-umnuay P, 1998, J BIOL CHEM, V273, P18242, DOI 10.1074/jbc.273.29.18242; van der Wel H, 2002, J BIOL CHEM, V277, P46328, DOI 10.1074/jbc.M208024200; van der Wel H, 2001, J BIOL CHEM, V276, P33952, DOI 10.1074/jbc.M102555200; West CM, 2002, GLYCOBIOLOGY, V12, p17R, DOI 10.1093/glycob/12.2.17R; West CM, 1996, J BIOL CHEM, V271, P12024, DOI 10.1074/jbc.271.20.12024; West CM, 1997, GENE, V200, P1, DOI 10.1016/S0378-1119(97)00194-7; WEST CM, 2002, IN PRESS CELL MOL LI; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	28	37	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46527	46534		10.1074/jbc.M208824200	http://dx.doi.org/10.1074/jbc.M208824200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244067	hybrid			2022-12-25	WOS:000179529300107
J	Feuillet, V; Semichon, M; Restouin, A; Harriague, J; Janzen, J; Magee, A; Collette, Y; Bismuth, G				Feuillet, V; Semichon, M; Restouin, A; Harriague, J; Janzen, J; Magee, A; Collette, Y; Bismuth, G			The distinct capacity of Fyn and Lck to phosphorylate Sam68 in T cells is essentially governed by SH3/SH2-catalytic domain linker interactions	ONCOGENE			English	Article						Fyn; Lck; substrate specificity; T cells; Sam68	PROTEIN-TYROSINE KINASE; SH3 DOMAIN; MICE LACKING; LIPID RAFTS; C-SRC; CRYSTAL-STRUCTURE; BINDING-PROTEIN; KH-DOMAIN; ACTIVATION; FAMILY	Sam68 phosphorylation correlates with Fyn but not Lck expression in T cells. This substrate has been used here to explore the possible basis of the specificity of Fyn versus Lck. We show that this specificity is not based on a spatial segregation of the two kinases, since a chimeric Lck molecule containing the membrane anchoring domain of Fyn does not phosphorylate Sam68. Moreover, a Sam68 molecule targeted to the plasma membrane by the farnesylation signal of c-Ha-Ras remains poorly phosphorylated by Lck. In T cells, Fyn appears to be the active Src kinase in rafts, but Sam68 is not expressed in rafts, and its distinct phosphorylation by Fyn and Lck is not affected by raft dispersion. The Fyn/Lck specificity does not reflect a higher kinase activity of Fyn in general, as both Fyn and Lck are similarly recognized by an anti-active Src antibody. Both also strongly phosphorylate another Src substrate in vivo. Mainly, Lck phosphorylates Sam68 when the interaction between the SH3 domain and the SH2-catalytic domain linker is altered in heterologous Src molecules or after mutating key residues in the linker that increase the accessibility of the SH3 domain. Thus, the distinct potential of Fyn and Lck to phosphorylate Sam68 is likely controlled by the interaction of the kinase SH3 domain with the linker and Sam68, possibly on a competitive binding basis.	Univ Paris 05, Dept Biol Cellulaire, INSERM U567, CNRS UMR 8104,Inst Cochin, F-75014 Paris, France; Inst J Paoli I Calmettes, Lab Labellise Ligue Natl Contre Canc, F-13009 Marseille, France; Inst J Paoli I Calmettes, INSERM U119, F-13009 Marseille, France; Univ London Imperial Coll Sci Technol & Med, Sect Cell & Mol Biol, Div Biomed Sci, Fac Med, London SW7 2AZ, England	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; UNICANCER; Institut Paoli-Calmette (IPC); Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Paoli-Calmette (IPC); Imperial College London	Bismuth, G (corresponding author), Univ Paris 05, Dept Biol Cellulaire, INSERM U567, CNRS UMR 8104,Inst Cochin, F-75014 Paris, France.		Feuillet, Vincent/P-4988-2017; COLLETTE, Yves/F-2270-2013	Feuillet, Vincent/0000-0003-1898-2527; COLLETTE, Yves/0000-0001-5359-7099; Harriague, Julie/0000-0001-6824-9169				ABRAMS CS, 1995, J BIOL CHEM, V270, P333, DOI 10.1074/jbc.270.1.333; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Barlat I, 1997, J BIOL CHEM, V272, P3129, DOI 10.1074/jbc.272.6.3129; CARTWRIGHT CA, 1987, CELL, V49, P83, DOI 10.1016/0092-8674(87)90758-6; Chen TP, 1997, MOL CELL BIOL, V17, P5707, DOI 10.1128/MCB.17.10.5707; COOPER JA, 1986, SCIENCE, V231, P1431, DOI 10.1126/science.2420005; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Davidson D, 1997, J BIOL CHEM, V272, P1355, DOI 10.1074/jbc.272.2.1355; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Fusaki N, 1997, J BIOL CHEM, V272, P6214, DOI 10.1074/jbc.272.10.6214; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; Gonfloni S, 1999, NAT STRUCT BIOL, V6, P760; Groves T, 1996, IMMUNITY, V5, P417, DOI 10.1016/S1074-7613(00)80498-7; Hartley DK, 1999, J BIOL CHEM, V274, P20056, DOI 10.1074/jbc.274.29.20056; Hiroaki H, 1996, J BIOMOL NMR, V8, P105; Itoh K, 2002, J IMMUNOL, V168, P541, DOI 10.4049/jimmunol.168.2.541; Jabado N, 1998, J IMMUNOL, V161, P2798; Kabouridis PS, 2000, EUR J IMMUNOL, V30, P954, DOI 10.1002/1521-4141(200003)30:3<954::AID-IMMU954>3.3.CO;2-P; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; KLAGES S, 1994, P NATL ACAD SCI USA, V91, P2597, DOI 10.1073/pnas.91.7.2597; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; Lang V, 1997, EUR J IMMUNOL, V27, P3360, DOI 10.1002/eji.1830271235; Lang V, 1999, J IMMUNOL, V162, P7224; LEY SC, 1994, J CELL BIOL, V125, P639, DOI 10.1083/jcb.125.3.639; Marie-Cardine A, 1999, EUR J IMMUNOL, V29, P1175, DOI 10.1002/(SICI)1521-4141(199904)29:04<1175::AID-IMMU1175>3.0.CO;2-Z; Marie-Cardine A, 1998, FEBS LETT, V435, P55, DOI 10.1016/S0014-5793(98)01040-0; MarieCardine A, 1997, J BIOL CHEM, V272, P16077, DOI 10.1074/jbc.272.26.16077; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1989, P NATL ACAD SCI USA, V86, P6302, DOI 10.1073/pnas.86.16.6302; MUSTELIN T, 1990, ONCOGENE, V5, P809; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nemorin JG, 2000, J BIOL CHEM, V275, P14590, DOI 10.1074/jbc.275.19.14590; OKADA M, 1991, J BIOL CHEM, V266, P24249; Ostermeyer AG, 1999, J BIOL CHEM, V274, P34459, DOI 10.1074/jbc.274.48.34459; PIWNICAWORMS H, 1987, CELL, V49, P75, DOI 10.1016/0092-8674(87)90757-4; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Qian DP, 1997, J EXP MED, V185, P1253, DOI 10.1084/jem.185.7.1253; RICHARD S, 1995, MOL CELL BIOL, V15, P186, DOI 10.1128/MCB.15.1.186; Shen ZW, 1999, ONCOGENE, V18, P4647, DOI 10.1038/sj.onc.1203079; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; TAKEMOTO Y, 1995, EMBO J, V14, P3403, DOI 10.1002/j.1460-2075.1995.tb07346.x; Takemoto Y, 1996, INT IMMUNOL, V8, P1699, DOI 10.1093/intimm/8.11.1699; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Torgersen KM, 2001, J BIOL CHEM, V276, P29313, DOI 10.1074/jbc.C100014200; Tsygankov AY, 1996, J BIOL CHEM, V271, P27130, DOI 10.1074/jbc.271.43.27130; vanOers NSC, 1996, IMMUNITY, V5, P429, DOI 10.1016/S1074-7613(00)80499-9; Vernet C, 1997, TRENDS GENET, V13, P479, DOI 10.1016/S0168-9525(97)01269-9; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Yang WC, 1999, J BIOL CHEM, V274, P607, DOI 10.1074/jbc.274.2.607	58	6	6	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7205	7213		10.1038/sj.onc.1205929	http://dx.doi.org/10.1038/sj.onc.1205929			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370810				2022-12-25	WOS:000178504600008
J	Mark, SC; Sandercock, LE; Luchman, HA; Baross, A; Edelmann, W; Jirik, FR				Mark, SC; Sandercock, LE; Luchman, HA; Baross, A; Edelmann, W; Jirik, FR			Elevated mutant frequencies and predominance of G : C to A : T transition mutations in Msh6(-/-) small intestinal epithelium	ONCOGENE			English	Article						DNA mismatch repair; Msh6; lacI; transgenic shuttle-phage; small intestinal epithelium; Big Blue (TM)	DNA MISMATCH REPAIR; MSH2 DEFICIENT MICE; TRANSGENIC MICE; IN-VIVO; HUMAN-CELLS; GENE PMS2; CANCER; RODENTS; MOUSE; BETA	The DNA mismatch repair (MMR) system is primarily responsible for purging newly synthesized DNA of errors incurred during semi-conservative replication. Lesion recognition is initially carried out by one of two heterodimeric protein complexes, MutSalpha, or MutSbeta. While the former, comprised of MSH2 and MSH6, recognizes mispairs as well as short (1-2 nucleotide) insertions/deletions (IDLs), the latter, made up of MSH2 and MSH3, is primarily responsible for recognizing 2-6 nucleotide IDLs. As most of the functional information on these heterodimers is derived from in vitro studies, it was of interest to study the in vivo consequences of a lack of MutSalpha To this end, Big Blue(TM) mice, that carry a lacI(+) transgenic lambda shuttle-phage mutational reporter, were crossed with Msh6(-/-)mice to evaluate the specific contribution of MutSalpha to genome integrity. Consistent with the importance of MutSalpha in lesion surveillance, small intestine epithelial cell DNA derived from lacI(+) Msh6(-/-) mice exhibited striking increases (average of 41-fold) in spontaneous mutant frequencies. Furthermore, the lacI gene mutation spectrum was dominated by G:C to A:T transitions, highlighting the critical importance of the MutSalpha complex in suppressing this frequently observed type of spontaneous mutation.	Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Cell Biol, Bronx, NY 10461 USA	University of Calgary; Yeshiva University; Albert Einstein College of Medicine	Jirik, FR (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 4N1, Canada.				NATIONAL CANCER INSTITUTE [R01CA076329] Funding Source: NIH RePORTER; NCI NIH HHS [CA 76329] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Acharya S, 1996, P NATL ACAD SCI USA, V93, P13629, DOI 10.1073/pnas.93.24.13629; Andrew SE, 1996, MUTAT RES-FUND MOL M, V357, P57, DOI 10.1016/0027-5107(96)00080-2; Andrew SE, 2000, CARCINOGENESIS, V21, P1291, DOI 10.1093/carcin/21.7.1291; Andrew SE, 1997, ONCOGENE, V15, P123, DOI 10.1038/sj.onc.1201180; Andrew SE, 1998, P NATL ACAD SCI USA, V95, P1126, DOI 10.1073/pnas.95.3.1126; Aquilina G, 2001, J CELL PHYSIOL, V187, P145, DOI 10.1002/jcp.1067; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Baross-Francis A, 1998, P NATL ACAD SCI USA, V95, P8739, DOI 10.1073/pnas.95.15.8739; Baross-Francis A, 2001, ONCOGENE, V20, P619, DOI 10.1038/sj.onc.1204138; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Cariello NF, 1996, ENVIRON MOL MUTAGEN, V28, P397, DOI 10.1002/(SICI)1098-2280(1996)28:4<397::AID-EM14>3.0.CO;2-A; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Cosentino L, 2000, MUTAT RES-FUND MOL M, V454, P1, DOI 10.1016/S0027-5107(00)00125-1; de Wind N, 1999, NAT GENET, V23, P359, DOI 10.1038/15544; DEWIND N, 1995, CELL, V82, P321, DOI 10.1016/0092-8674(95)90319-4; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; DYCAICO MJ, 1994, MUTAT RES, V307, P461, DOI 10.1016/0027-5107(94)90257-7; Edelmann W, 1996, CELL, V85, P1125, DOI 10.1016/S0092-8674(00)81312-4; Edelmann W, 2000, CANCER RES, V60, P803; Edelmann W, 1997, CELL, V91, P467, DOI 10.1016/S0092-8674(00)80433-X; Genschel J, 1998, J BIOL CHEM, V273, P19895, DOI 10.1074/jbc.273.31.19895; Jiricny J, 2000, CURR OPIN GENET DEV, V10, P157, DOI 10.1016/S0959-437X(00)00066-6; Kolodner R, 1996, GENE DEV, V10, P1433, DOI 10.1101/gad.10.12.1433; Kolodner RD, 1999, CANCER RES, V59, P5068; Kuraguchi M, 2001, CANCER RES, V61, P7934; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marra G, 1999, BIOCHEM J, V338, P1, DOI 10.1042/0264-6021:3380001; MIRSALIS JC, 1993, MUTAGENESIS, V8, P265, DOI 10.1093/mutage/8.3.265; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Monroe JJ, 2001, MUTAT RES-FUND MOL M, V476, P1, DOI 10.1016/S0027-5107(01)00081-1; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; PALOMBO F, 1995, SCIENCE, V268, P1912, DOI 10.1126/science.7604265; Palombo F, 1996, CURR BIOL, V6, P1181, DOI 10.1016/S0960-9822(02)70685-4; Peltomaki P, 2001, HUM MOL GENET, V10, P735, DOI 10.1093/hmg/10.7.735; PROVOST GS, 1993, MUTAT RES, V288, P133; REITMAIR AH, 1995, NAT GENET, V11, P64, DOI 10.1038/ng0995-64; Skopek T, 1998, MUTAT RES-FUND MOL M, V400, P77, DOI 10.1016/S0027-5107(98)00040-2; Umar A, 1998, GENETICS, V148, P1637; Wang TF, 1999, P NATL ACAD SCI USA, V96, P13914, DOI 10.1073/pnas.96.24.13914; Zhang SL, 2001, ENVIRON MOL MUTAGEN, V37, P141, DOI 10.1002/em.1021	43	18	18	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7126	7130		10.1038/sj.onc.1205861	http://dx.doi.org/10.1038/sj.onc.1205861			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370835				2022-12-25	WOS:000178424900016
J	Mochizuki, Y; Tsuda, S; Kanetake, H; Kanda, S				Mochizuki, Y; Tsuda, S; Kanetake, H; Kanda, S			Negative regulation of urokinase-type plasminogen activator production through FGF-2-mediated activation of phosphoinositide 3-kinase	ONCOGENE			English	Article						FGF-2; uPA; endothelial cells; L6 myoblasts; PI3-kinase; Ras	FIBROBLAST-GROWTH-FACTOR; PROTEIN-KINASE-B; FACTOR-BETA-RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIAL-CELLS; HIGH-AFFINITY; EXPRESSION; DIFFERENTIATION; ANGIOGENESIS; INHIBITION	Activation of phosphoinositide 3-kinase (PI3-kinase) is involved in many cellular responses. FGF-2 is one of the potent inducers of urokinase-type plasminogen activator (uPA) production in endothelial cells. However, little is known about the molecular mechanisms underlying FGF-2-mediated uPA production. Here we examined the signal transduction pathways involved in the regulation of uPA production by FGF-2-treatment. FGF-2 potently upregulated uPA production in murine brain capillary endothelial cells (IBE cells), as well as porcine aortic endothelial (PAE) cells and L6 myoblasts ectopically expressing FGFR1. PI3-kinase inhibitors, wortmannin and LY294002, both enhanced FGF-2-dependent uPA production by these cells. Stable expression of activated mutant p110alpha catalytic subunit of PI3-kinase into IBE cells decreased FGF-2-mediated uPA production, suggesting that PI3-kinase exhibited the negative regulatory effect on uPA production. No increase in FGF-2-induced PI3-kinase activity was observed in proteins immunoprecipitated by anti-phosphotyrosine antibody. Although stable expression of deleted mutant p85alpha regulatory subunit, which lacks association with p110 catalytic subunit, in IBE cells showed no dominant negative effect, transient expression of dominant negative Ras inhibited FGF-2-mediated PI3-kinase activation. These results suggest that only activated Ras contributed the FGF-2-mediated PI3-kinase activation. In cells stably expressing mutant p85a subunit, FGF-2 efficiently induced uPA production. Taken together, activation of PI3-kinase by FGF-2 is Ras-dependent and results in down-regulation of uPA production.	Nagasaki Univ, Dept Urol, Nagasaki 8528051, Japan; Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, Div Endothelial Cell Biol, Nagasaki 8528051, Japan	Nagasaki University; Nagasaki University	Kanda, S (corresponding author), Nagasaki Univ, Dept Urol, 1-7-1 Sakamoto, Nagasaki 8528051, Japan.	shigeruk@net.nagasaki-u.ac.jp						Aguirre-Ghiso JA, 1999, ONCOGENE, V18, P4718, DOI 10.1038/sj.onc.1202850; Bajou K, 2001, J CELL BIOL, V152, P777, DOI 10.1083/jcb.152.4.777; Bajou K, 1998, NAT MED, V4, P923, DOI 10.1038/nm0898-923; BLASI F, 1993, BIOESSAYS, V15, P105, DOI 10.1002/bies.950150206; Boilly B, 2000, CYTOKINE GROWTH F R, V11, P295, DOI 10.1016/S1359-6101(00)00014-9; Chan TO, 1999, ANNU REV BIOCHEM, V68, P965, DOI 10.1146/annurev.biochem.68.1.965; Duronio V, 1998, CELL SIGNAL, V10, P233, DOI 10.1016/S0898-6568(97)00129-0; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Ghiso JAA, 1999, EUR J BIOCHEM, V263, P295, DOI 10.1046/j.1432-1327.1999.00507.x; Giuliani R, 1999, J CELL SCI, V112, P2597; Gum R, 1998, ONCOGENE, V17, P213, DOI 10.1038/sj.onc.1201917; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Kanda S, 1996, CELL GROWTH DIFFER, V7, P383; Kanda S, 1997, J BIOL CHEM, V272, P23347, DOI 10.1074/jbc.272.37.23347; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; Klint Peter, 1999, Frontiers in Bioscience, V4, pD165, DOI 10.2741/Klint; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; Mohammadi M, 1996, MOL CELL BIOL, V16, P977; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Ong SH, 2001, P NATL ACAD SCI USA, V98, P6074, DOI 10.1073/pnas.111114298; Pepper MS, 1996, ENZYME PROTEIN, V49, P138, DOI 10.1159/000468622; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Roghani M, 1996, J BIOL CHEM, V271, P31154, DOI 10.1074/jbc.271.49.31154; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Roymans D, 2001, EUR J BIOCHEM, V268, P487, DOI 10.1046/j.1432-1327.2001.01936.x; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Sutor SL, 1999, J BIOL CHEM, V274, P7002, DOI 10.1074/jbc.274.11.7002; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; van Weering DHJ, 1998, MOL CELL BIOL, V18, P1802, DOI 10.1128/MCB.18.4.1802; VASSALLI JD, 1987, FEBS LETT, V214, P187, DOI 10.1016/0014-5793(87)80039-X; Wang WX, 1999, ONCOGENE, V18, P4554, DOI 10.1038/sj.onc.1202833; WENNSTROM S, 1992, J BIOL CHEM, V267, P13749; Wennstrom S, 1999, MOL CELL BIOL, V19, P4279; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	43	15	15	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7027	7033		10.1038/sj.onc.1205736	http://dx.doi.org/10.1038/sj.onc.1205736			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370824				2022-12-25	WOS:000178424900005
J	Sekhar, KR; Yan, XX; Freeman, ML				Sekhar, KR; Yan, XX; Freeman, ML			Nrf2 degradation by the ubiquitin proteasome pathway is inhibited by KIAA0132, the human homolog to INrf2	ONCOGENE			English	Article						Nrf2; INrf2; ubiquitin; proteasome	GAMMA-GLUTAMYLCYSTEINE SYNTHETASE; NAPHTHOFLAVONE-INDUCED EXPRESSION; ANTIOXIDANT RESPONSE ELEMENT; TRANSCRIPTION FACTOR NRF2; SUBUNIT GENE; INDUCIBLE EXPRESSION; CATALYTIC SUBUNIT; GLUTATHIONE; PROTEIN; DOMAIN	INrf2 tethering of the transcription factor Nrf2 in the cytosol prevents Nrf2 activation of antioxidant response element (ARE) mediated gene expression. This investigation was undertaken to determine if tethering affected Nrf2 degradation. Data is presented showing that Nrf2 is degraded by the ubiquitin-proteasome pathway. Nrf2 co-immunoprecipitated with a HA tagged ubiquitin polymer and accumulated in cells expressing inactive ubiquitin activating enzyme El. Inhibition of proteasome activity resulted in accumulation of Nrf2. The rate of Nrf2 degradation, measured under conditions where the majority of Nrf2 was not tethered, exhibited a T-1/2 of approximately 3 h. Over-expression of human INrf2, KIAA0132, blocked Nrf2 conjugation to the ubiquitin polymer and blocked Nrf2 degradation. These results suggest that association of Nrf2 with INrf2 inhibits ubiquitin-proteasome degradation of Nrf2. Maintaining the majority of Nrf2 in a tethered form, resistant to ubiquitin-proteasome dependent degradation, allows a pool of Nrf2 to be available for rapid Nrf2/ARE-dependent gene transcription following stress mediated release from INrf2. Further, the observation that free Nrf2 is degraded by the ubiquitin proteasome pathway provides a potential mechanism by which ARE-dependent gene transcription is attenuated after induction.	Vanderbilt Univ, Sch Med, Dept Radiat Oncol, Nashville, TN 37232 USA	Vanderbilt University	Freeman, ML (corresponding author), Vanderbilt Univ, Sch Med, Dept Radiat Oncol, 221 Kirkland Hall, Nashville, TN 37232 USA.			Konjeti, Sekhar/0000-0003-2930-0739; Freeman, Michael/0000-0003-1881-366X	NATIONAL CANCER INSTITUTE [R55CA038079, R01CA038079] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA038079, CA-38079] Funding Source: Medline; NIEHS NIH HHS [P30ES00267] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Chan JY, 2000, BBA-GENE STRUCT EXPR, V1517, P19, DOI 10.1016/S0167-4781(00)00238-4; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; CHOWDARY DR, 1994, MOL CELL BIOL, V14, P1997, DOI 10.1128/MCB.14.3.1997; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Dhakshinamoorthy S, 2001, ONCOGENE, V20, P3906, DOI 10.1038/sj.onc.1204506; FAVREAU LV, 1991, J BIOL CHEM, V266, P4556; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Kwak MK, 2002, MOL CELL BIOL, V22, P2883, DOI 10.1128/MCB.22.9.2883-2892.2002; McMahon M, 2001, CANCER RES, V61, P3299; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; Mulcahy RT, 1997, J BIOL CHEM, V272, P7445, DOI 10.1074/jbc.272.11.7445; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Sekhar KR, 2000, BIOCHEM BIOPH RES CO, V270, P311, DOI 10.1006/bbrc.2000.2419; Sekhar KR, 2002, FREE RADICAL BIO MED, V32, P650, DOI 10.1016/S0891-5849(02)00755-4; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Wild AC, 1999, J BIOL CHEM, V274, P33627, DOI 10.1074/jbc.274.47.33627; Wild AC, 1998, BIOCHEM J, V332, P373, DOI 10.1042/bj3320373; Wolf CR, 2001, P NATL ACAD SCI USA, V98, P2941, DOI 10.1073/pnas.071042698; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497	26	111	113	13	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6829	6834		10.1038/sj.onc.1205905	http://dx.doi.org/10.1038/sj.onc.1205905			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360409				2022-12-25	WOS:000178315800013
J	Dittmar, T; Husemann, A; Schewe, Y; Nofer, JR; Niggemann, B; Zanker, KS; Brandt, BH				Dittmar, T; Husemann, A; Schewe, Y; Nofer, JR; Niggemann, B; Zanker, KS; Brandt, BH			Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via epidermal growth factor receptor	FASEB JOURNAL			English	Article						PLC-gamma 1; phosphoinositide kinetics; migration	NEU DIFFERENTIATION FACTOR; ERBB SIGNALING NETWORK; BREAST-CANCER; ACTIVATION; HETERODIMERIZATION; LOCOMOTION; CHANNELS; DOMAINS; KINASES	Induction of tumor cell migration is a key step in invasion and metastasis. Here we report that the epidermal growth factor (EGF)-induced cell migration of breast cancer cells is attributed to a transient, rather than a sustained, activation of phospholipase C (PLC)-gamma1 due to c-erbB-2 signaling. EGF stimulation of EGF receptor (EGFR) overexpressing cells resulted in long-term PLC-gamma1 tyrosine phosphorylation and sustained levels of inositol-1,4,5-triphosphate (IP3) and diacylglycerol (DAG) producing sinusoidal calcium oscillations. In contrast, c-erbB-2/EGFR expressing cells displayed baseline transient calcium oscillations after EGF treatment due to short-term PLC-gamma1 tyrosine phosphorylation and short-term IP3 and DAG turnover. A third cell line expressing a point-mutated c-erbB-2 receptor that lacks the autophosphorylation Y1248 was generated to investigate whether the different PLC-gamma1 activation was attributed to this structure. Neither PLC-gamma1 tyrosine phosphorylation nor IP3 and DAG turnover and calcium oscillations were observed in this cell line, indicating the modulation of the PLC-gamma1 activation time course by c-erbB-2 signaling. Induction of cell migration was solely observable in the c-erbB-2-positive cell line as proved by the mode of actin reorganization and a cell migration assay, using a 3D-collagen lattice. In summary, c-erbB-2 up-regulation switches on the cell migration program by modulating the time course of PLC-gamma1 activation.	Univ Witten Herdecke, Inst Immunol, D-58448 Witten, Germany; Univ Munster, Inst Clin Chem & Lab Med, D-48129 Munster, Germany	Witten Herdecke University; University of Munster	Dittmar, T (corresponding author), Univ Witten Herdecke, Inst Immunol, Stockumer Str 10, D-58448 Witten, Germany.	thomasd@uni-wh.de	Dittmar, Thomas/X-3691-2019; Dittmar, Thomas/T-6679-2019	Brandt, Burkhard/0000-0003-3681-3049				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Brandt BH, 1999, FASEB J, V13, P1939, DOI 10.1096/fasebj.13.14.1939; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; DIGIOVANNA MP, 1995, CANCER RES, V55, P1946; Entschladen F, 2000, J CANCER RES CLIN, V126, P671, DOI 10.1007/s004320000143; Feldner JC, 2002, EXP CELL RES, V272, P93, DOI 10.1006/excr.2001.5385; FRIEDL P, 1993, J IMMUNOL METHODS, V165, P157, DOI 10.1016/0022-1759(93)90341-4; GrausPorta D, 1997, EMBO J, V16, P1647, DOI 10.1093/emboj/16.7.1647; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GRUCHALLA RS, 1990, J IMMUNOL, V144, P2334; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kassis J, 1999, CLIN CANCER RES, V5, P2251; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; MARKS PW, 1990, J CELL BIOL, V110, P43, DOI 10.1083/jcb.110.1.43; Murali R, 1996, P NATL ACAD SCI USA, V93, P6252, DOI 10.1073/pnas.93.13.6252; Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159; PEPPELENBOSCH MP, 1992, CELL, V69, P295, DOI 10.1016/0092-8674(92)90410-E; QIAN XL, 1994, P NATL ACAD SCI USA, V91, P1500, DOI 10.1073/pnas.91.4.1500; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; SUTHERLAND CA, 1982, J BIOL CHEM, V257, P4006; Tang CK, 1998, HORMONES SIGNALING, P113; Tanner B, 1996, GYNECOL ONCOL, V62, P268, DOI 10.1006/gyno.1996.0226; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296	30	104	110	0	0	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	SEP	2002	16	11					1823	+		10.1096/fj.02-0096fje	http://dx.doi.org/10.1096/fj.02-0096fje			21	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354693				2022-12-25	WOS:000178441800002
J	Jover, R; Bort, R; Gomez-Lechon, MJ; Castell, JV				Jover, R; Bort, R; Gomez-Lechon, MJ; Castell, JV			Down-regulation of human CYP3A4 by the inflammatory signal interleukin 6: molecular mechanism and transcription factors involved	FASEB JOURNAL			English	Article						cytochrome P-450; gp130 receptor; JAK/STAT pathway; MAPK; C/EBP transcription factors	ACUTE-PHASE RESPONSE; CCAAT/ENHANCER-BINDING-PROTEIN; ADULT HUMAN HEPATOCYTES; GENE-TRANSCRIPTION; C/EBP ISOFORMS; MESSENGER-RNA; CYTOCHROME-P450 ENZYMES; TRANSDUCTION PATHWAY; ACTIVATED RECEPTOR; INHIBITORY PROTEIN	The hepatic drug-metabolizing cytochrome P-450 (CYP) enzymes are down-regulated during inflammation. In vitro studies with hepatocytes have shown that the cytokines released during inflammatory responses are largely responsible for this CYP repression. However, the signaling pathways and the cytokine-activated factors involved remain to be properly identified. Our research has focused on the negative regulation of CYP3A4 (the major drug-metabolizing human CYP) by interleukin 6 (IL-6) (the principal regulator of the hepatic acute-phase response). CYP3A4 down-regulation by IL-6 requires activation of the glycoprotein receptor gp130; however, it does not proceed through the JAK/STAT pathway, as demonstrated by the overexpression of a dominant-negative STAT3 factor by means of an adenoviral vector. The involvement of IL-6-activated kinases such as extracellular signal-regulated kinase ERK1/2 or p38 is also unlikely, as evidenced by the use of specific chemical inhibitors. It is noteworthy that IL-6 caused a moderated induction in the mRNA of the transcription factor C/EBPbeta (CCAAT-enhancer binding protein beta) and a marked increase in the translation of C/EBPbeta-LIP, a 20-kDa C/EBPbeta isoform lacking a transactivation domain. Adenovirus-mediated expression of C/EBPbeta-LIP caused a dose-dependent repression of CYP3A4 mRNA, whereas overexpression C/EBPalpha and C/EBPbeta-LAP (35 kDa) caused a significant induction. Our results support the idea that IL-6 down-regulates CYP3A4 through translational induction of C/EBPbeta-LIP, which competes with and antagonizes constitutive C/EBP transactivators. From a clinical point of view, these findings could be relevant in the development of therapeutic cytokines with a less repressive effect on hepatic drug-metabolizing enzymes.	Hosp Univ La Fe, Ctr Invest, Unidad Hepatol Expt, E-46009 Valencia, Spain; Univ Valencia, Fac Med, Dept Bioquim, E-46010 Valencia, Spain	Hospital Universitari i Politecnic La Fe; University of Valencia	Castell, JV (corresponding author), Hosp Univ La Fe, Ctr Invest, Unidad Hepatol Expt, Avda Campanar 21, E-46009 Valencia, Spain.	Jose.Castell@uv.es	Bort, Roque/Y-5466-2019; Castell, Jose V/I-9529-2016; Jover, Ramiro/O-9796-2017	Bort, Roque/0000-0002-7285-0536; Castell, Jose V/0000-0003-1179-6430; Jover, Ramiro/0000-0002-4914-5804				ABDELRAZZAK Z, 1993, MOL PHARMACOL, V44, P707; AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; ALAM T, 1992, J BIOL CHEM, V267, P5021; Alonzi T, 2001, MOL CELL BIOL, V21, P1621, DOI 10.1128/MCB.21.5.1621-1632.2001; An MR, 1996, MOL CELL BIOL, V16, P2295; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; ARCONE R, 1991, EUR J BIOCHEM, V198, P541, DOI 10.1111/j.1432-1033.1991.tb16048.x; Barclay TB, 1999, J PHARMACOL EXP THER, V290, P1250; BAUMANN H, 1994, IMMUNOL TODAY, V15, P74, DOI 10.1016/0167-5699(94)90137-6; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; Cantwell CA, 1998, MOL CELL BIOL, V18, P2108, DOI 10.1128/MCB.18.4.2108; Castell JV, 1997, GENE THER, V4, P455, DOI 10.1038/sj.gt.3300416; CASTELL JV, 1990, HEPATOLOGY, V12, P1179, DOI 10.1002/hep.1840120517; CASTELL JV, 1989, FEBS LETT, V242, P237, DOI 10.1016/0014-5793(89)80476-4; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Gomez-Lechon MJ, 2001, EUR J BIOCHEM, V268, P1448, DOI 10.1046/j.1432-1327.2001.02011.x; GOMEZFOIX AM, 1992, J BIOL CHEM, V267, P25129; GOMEZLECHON MJ, 1990, IN VITRO CELL DEV B, V26, P67; Greenwel P, 2000, MOL CELL BIOL, V20, P912, DOI 10.1128/MCB.20.3.912-918.2000; GUENGERICH FP, 1993, AM SCI, V81, P440; Guengrich FP, 1999, ANNU REV PHARMACOL, V39, P1, DOI 10.1146/annurev.pharmtox.39.1.1; Guillen MI, 1998, J PHARMACOL EXP THER, V285, P127; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; HEINRICH PC, 1990, BIOCHEM J, V265, P621, DOI 10.1042/bj2650621; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; Hirano Toshio, 1997, Cytokine and Growth Factor Reviews, V8, P241, DOI 10.1016/S1359-6101(98)80005-1; Iber H, 2000, ARCH BIOCHEM BIOPHYS, V377, P187, DOI 10.1006/abbi.2000.1772; Iraburu MJ, 2000, HEPATOLOGY, V31, P1086, DOI 10.1053/he.2000.5981; Jover R, 1998, FEBS LETT, V431, P227, DOI 10.1016/S0014-5793(98)00746-7; Jover R, 2001, HEPATOLOGY, V33, P668, DOI 10.1053/jhep.2001.22176; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; Kaptein A, 1996, J BIOL CHEM, V271, P5961, DOI 10.1074/jbc.271.11.5961; Kim H, 1999, MOL CELL BIOL, V19, P5326; Koj A, 1996, BBA-MOL BASIS DIS, V1317, P84, DOI 10.1016/S0925-4439(96)00048-8; Kyriakis JM, 1996, J BIOL CHEM, V271, P24313, DOI 10.1074/jbc.271.40.24313; Lin JH, 2001, ANNU REV PHARMACOL, V41, P535, DOI 10.1146/annurev.pharmtox.41.1.535; Mazuski JE, 1997, J SURG RES, V68, P161, DOI 10.1006/jsre.1997.4999; Meyer UA, 1997, ANNU REV PHARMACOL, V37, P269, DOI 10.1146/annurev.pharmtox.37.1.269; Morel Y, 1998, J BIOL CHEM, V273, P26969, DOI 10.1074/jbc.273.41.26969; Morgan ET, 1997, DRUG METAB REV, V29, P1129, DOI 10.3109/03602539709002246; Morgan ET, 2001, DRUG METAB DISPOS, V29, P207; MUNTANERELAT J, 1995, HEPATOLOGY, V22, P1143; Nakajima K, 1996, EMBO J, V15, P3651, DOI 10.1002/j.1460-2075.1996.tb00734.x; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NATSUKA S, 1991, FEBS LETT, V291, P58, DOI 10.1016/0014-5793(91)81103-F; OSSIPOW V, 1993, P NATL ACAD SCI USA, V90, P8219, DOI 10.1073/pnas.90.17.8219; Ourlin JC, 1997, J HEPATOL, V26, P54, DOI 10.1016/S0168-8278(97)80497-7; Pascussi JM, 2000, BIOCHEM BIOPH RES CO, V274, P707, DOI 10.1006/bbrc.2000.3219; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; RAMJI DP, 1993, NUCLEIC ACIDS RES, V21, P289, DOI 10.1093/nar/21.2.289; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; Rodriguez-Antona C, 2000, ARCH BIOCHEM BIOPHYS, V376, P109, DOI 10.1006/abbi.2000.1697; Runge D, 2000, BIOCHEM BIOPH RES CO, V269, P46, DOI 10.1006/bbrc.2000.2215; Siewert E, 2000, HEPATOLOGY, V32, P49, DOI 10.1053/jhep.2000.8532; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Tinel M, 1999, J PHARMACOL EXP THER, V289, P649; Trautwein C, 1996, J BIOL CHEM, V271, P22262, DOI 10.1074/jbc.271.36.22262; Watkins PJ, 1996, CANCER RES, V56, P1063; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; Welm AL, 2000, J BIOL CHEM, V275, P27406; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; Wilkinson GR, 1997, ADV DRUG DELIVER REV, V27, P129, DOI 10.1016/S0169-409X(97)00040-9; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738	72	162	171	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1799	+		10.1096/fj.02-0195fje	http://dx.doi.org/10.1096/fj.02-0195fje			29	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354697				2022-12-25	WOS:000178441800007
J	Enyeart, JJ; Xu, L; Danthi, S; Enyeart, JA				Enyeart, JJ; Xu, L; Danthi, S; Enyeart, JA			An ACTH- and ATP-regulated background K+ channel in adrenocortical cells is TREK-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL-CORTICAL CELLS; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; FASCICULATA CELLS; CLONING; LOCALIZATION; NUCLEOTIDES; STIMULATION; ANESTHETICS; MODULATION	Bovine adrenal zona fasciculata (AZF) cells express a background K+ channel (IAC) that sets the resting potential and acts pivotally in ACTH-stimulated cortisol secretion. We have cloned a bTREK-1 (KCNK2) tandempore K+ channel cDNA from AZF cells with properties that identify it as the native I-AC. The bTREK-1 cDNA is expressed robustly in AZF cells and includes transcripts of 4.9, 3.6, and 2.8 kb. In patch clamp recordings made from transiently transfected cells, bTREK-1 displayed distinctive properties of I-AC in AZF cells. Specifically, bTREK-1 currents were outwardly rectifying with a large instantaneous and smaller time-dependent component. Similar to IAC, bTREK-1 increased spontaneously in amplitude over many minutes of whole cell recording and was blocked potently by Ca2+ antagonists including penfluridol and mibefradil and by 8-(4-chlorophenyl-thio)-cAMP. Unitary TREK-1 and i(AC) currents were nearly identical in amplitude. The native I-AC current, in turn, displayed properties that together are specific to TREK-1 K+ channels. These include activation by intracellular acidification, enhancement by the neuroprotective agent riluzole, and outward rectification. bTREK-1 current differed from native K+ current only in its lack of ATP dependence. In contrast to I-AC, the current density of bTREK-1 in human embryonic kidney-293 cells was not increased by raising pipette ATP from 0.1 to 5 mm. Further, the enhancement of I-AC current in AZF cells by low pH and riluzole was facilitated by, and dependent on, ATP at millimolar concentrations in the pipette solution. Overall, these results establish the identity of IAC K+ channels, demonstrate the expression of bTREK-1 in a specific endocrine cell, identify potent new TREK-1 antagonists, and assign a pivotal role for these tandem-pore channels in the physiology of cortisol secretion. The activation of I-AC by ATP indicates that native bTREK-1 channels may function as sensors that couple the metabolic state of the cell to membrane potential, perhaps through an associated ATP-binding protein.	Ohio State Univ, Coll Med, Dept Neurosci, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Enyeart, JJ (corresponding author), Ohio State Univ, Coll Med, Dept Neurosci, 5190 Graves Hall,333 W 10th Ave, Columbus, OH 43210 USA.				NIDDK NIH HHS [R01 DK 47875] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047875] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; Bang H, 2000, J BIOL CHEM, V275, P17412, DOI 10.1074/jbc.M000445200; Bockenhauer D, 2001, NAT NEUROSCI, V4, P486, DOI 10.1038/87434; Coetzee WA, 1999, ANN NY ACAD SCI, V868, P233, DOI 10.1111/j.1749-6632.1999.tb11293.x; Duprat F, 2000, MOL PHARMACOL, V57, P906; Enyeart JA, 2000, J BIOL CHEM, V275, P34640, DOI 10.1074/jbc.M004214200; Enyeart JJ, 1997, J GEN PHYSIOL, V110, P679, DOI 10.1085/jgp.110.6.679; Enyeart JJ, 2001, MOL PHARMACOL, V60, P114, DOI 10.1124/mol.60.1.114; ENYEART JJ, 1993, MOL ENDOCRINOL, V7, P1031, DOI 10.1210/me.7.8.1031; Enyeart JJ, 1996, J GEN PHYSIOL, V108, P251, DOI 10.1085/jgp.108.4.251; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Gomora JC, 1999, MOL PHARMACOL, V56, P1192, DOI 10.1124/mol.56.6.1192; Gomora JC, 1999, J PHARMACOL EXP THER, V290, P266; Gomora JC, 1998, AM J PHYSIOL-CELL PH, V275, pC1526, DOI 10.1152/ajpcell.1998.275.6.C1526; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Maingret F, 2000, EMBO J, V19, P2483, DOI 10.1093/emboj/19.11.2483; Maingret F, 2002, BIOCHEM BIOPH RES CO, V292, P339, DOI 10.1006/bbrc.2002.6674; Maingret F, 2000, J BIOL CHEM, V275, P10128, DOI 10.1074/jbc.275.14.10128; Maingret F, 1999, J BIOL CHEM, V274, P26691, DOI 10.1074/jbc.274.38.26691; Meadows HJ, 2000, PFLUG ARCH EUR J PHY, V439, P714, DOI 10.1007/s004240050997; MLINAR B, 1993, J BIOL CHEM, V268, P8640; MLINAR B, 1993, J GEN PHYSIOL, V102, P239, DOI 10.1085/jgp.102.2.239; MLINAR B, 1995, J BIOL CHEM, V270, P20942, DOI 10.1074/jbc.270.36.20942; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; TAKANO M, 1993, PROG NEUROBIOL, V41, P21, DOI 10.1016/0301-0082(93)90039-U; Terrenoire C, 2001, CIRC RES, V89, P336, DOI 10.1161/hh1601.094979; TERZIC A, 1994, CARDIOVASC RES, V28, P746, DOI 10.1093/cvr/28.6.746; Xu L, 1999, J PHYSIOL-LONDON, V521, P81, DOI 10.1111/j.1469-7793.1999.00081.x; Xu L, 2001, AM J PHYSIOL-CELL PH, V280, pC199, DOI 10.1152/ajpcell.2001.280.1.C199; Xu L, 1999, MOL PHARMACOL, V55, P364, DOI 10.1124/mol.55.2.364	37	66	68	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49186	49199		10.1074/jbc.M207233200	http://dx.doi.org/10.1074/jbc.M207233200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12368289	hybrid			2022-12-25	WOS:000180028900012
J	Cheng, JJ; Chao, YJ; Wang, DL				Cheng, JJ; Chao, YJ; Wang, DL			Cyclic strain activates redox-sensitive proline-rich tyrosine kinase 2 (PYK2) in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EARLY GROWTH RESPONSE-1; NADPH-OXIDASE ACTIVITY; FOCAL ADHESION KINASE; SMOOTH-MUSCLE-CELLS; TYROSINE PHOSPHORYLATION; GENE-EXPRESSION; ANGIOTENSIN-II; SEQUENTIAL ACTIVATION; DEPENDENT ACTIVATION	Proline-rich tyrosine kinase 2 (PYK2), structurally related to focal adhesion kinase, has been shown to play a role in signaling cascades. Endothelial cells (ECs) under hemodynamic forces increase reactive oxygen species (ROS) that modulate signaling pathways and gene expression. In the present study, we found that bovine ECs subjected to cyclic strain rapidly induced phosphorylation of PYK2 and Src kinase. This strain-induced PYK2 and Src phosphorylation was inhibited by pretreating ECs with an antioxidant N-acetylcysteine. Similarly, ECs exposed to H2O2 increased both PYK2 and Src phosphorylation. An increased association of Src to PYK2 was observed in ECs after cyclic strain or H2O2 exposure. ECs treated with an inhibitor to Src (PPI) greatly reduced Src and PYK2 phosphorylation, indicating that Src mediated PYK2 activation. Whereas the protein kinase C (PKC) inhibitor (calphostin C) pretreatment was shown to inhibit strain-induced NADPH oxidase activity, ECs treated with either calphostin C or the inhibitor to NADPH oxidase (DPI) reduced strain-induced ROS levels and then greatly inhibited the Src and PYK2 activation. In contrast to the activation of PYK2 and Src with calcium ionophore (ionomycin), ECs treated with a Ca2+ chelator inhibited both phosphorylation, indicating that PYK2 and Src activation requires Ca2+. ECs transfected with antisense to PKCalpha, but not antisense to PKCepsilon reduced cyclic strain-induced PYK2 activation. These data suggest that cyclic strain-induced PYK2 activity is mediated via Ca2+-dependent PKCalpha that increases NADPH oxidase activity to produce ROS crucial for Src and PYK2 activation. ECs under cyclic strain thus activate redox-sensitive PYK2 via Src and PKC, and this PYK2 activation may play a key role in the signaling responses in ECs under hemodynamic influence.	Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Wang, DL (corresponding author), Acad Sinica, Inst Biomed Sci, Div Cardiovasc, Taipei 11529, Taiwan.	lingwang@ibms.sinica.edu.tw						Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Andreev J, 2001, J BIOL CHEM, V276, P20130, DOI 10.1074/jbc.M102307200; Anfosso F, 2001, J BIOL CHEM, V276, P1564, DOI 10.1074/jbc.M007065200; Azuma N, 2000, J VASC SURG, V32, P789, DOI 10.1067/mva.2000.107989; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Bayraktutan U, 2000, ARTERIOSCL THROM VAS, V20, P1903, DOI 10.1161/01.ATV.20.8.1903; Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893; Bruce-Staskal PJ, 2001, EXP CELL RES, V264, P296, DOI 10.1006/excr.2000.5137; Cheng JJ, 1998, HYPERTENSION, V31, P125, DOI 10.1161/01.HYP.31.1.125; Cheng JJ, 2001, J BIOL CHEM, V276, P31368, DOI 10.1074/jbc.M011317200; Chiu JJ, 1999, CIRC RES, V85, P238, DOI 10.1161/01.RES.85.3.238; Dang PMC, 2001, J IMMUNOL, V166, P1206, DOI 10.4049/jimmunol.166.2.1206; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Deshpande SS, 2000, FASEB J, V14, P1705, DOI 10.1096/fj.99-0910com; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Duong LT, 1998, J CLIN INVEST, V102, P881, DOI 10.1172/JCI3212; Fontayne A, 2002, BIOCHEMISTRY-US, V41, P7743, DOI 10.1021/bi011953s; Forman HJ, 2002, MOL CELL BIOCHEM, V234, P49, DOI 10.1023/A:1015913229650; Frank GD, 2000, BIOCHEM BIOPH RES CO, V270, P761, DOI 10.1006/bbrc.2000.2505; Goldschmidt ME, 2001, CIRC RES, V88, P674, DOI 10.1161/hh0701.089749; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; GYLLENHAMMAR H, 1987, J IMMUNOL METHODS, V97, P209, DOI 10.1016/0022-1759(87)90461-3; Hsieh HJ, 1998, J CELL PHYSIOL, V175, P156, DOI 10.1002/(SICI)1097-4652(199805)175:2<156::AID-JCP5>3.0.CO;2-N; Iwasaki H, 2000, AM J PHYSIOL-HEART C, V278, pH521, DOI 10.1152/ajpheart.2000.278.2.H521; Jalali S, 1998, ARTERIOSCL THROM VAS, V18, P227, DOI 10.1161/01.ATV.18.2.227; Karlsson A, 2000, J LEUKOCYTE BIOL, V67, P396, DOI 10.1002/jlb.67.3.396; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Li S, 1997, J BIOL CHEM, V272, P30455, DOI 10.1074/jbc.272.48.30455; Litvak V, 2000, J BIOL CHEM, V275, P32736, DOI 10.1074/jbc.M004200200; Matsushita H, 2001, J CELL BIOCHEM, P99; Nakamura I, 2001, J CELL BIOL, V152, P361, DOI 10.1083/jcb.152.2.361; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Ohmori T, 2000, BIOCHEM J, V347, P561, DOI 10.1042/0264-6021:3470561; Pandey P, 1999, J BIOL CHEM, V274, P10140, DOI 10.1074/jbc.274.15.10140; Rahman A, 2001, MOL CELL BIOL, V21, P5554, DOI 10.1128/MCB.21.16.5554-5565.2001; Regier DS, 1999, J BIOL CHEM, V274, P36601, DOI 10.1074/jbc.274.51.36601; Rhee S.G., 2000, SCI STKE; Rikitake Y, 2001, AM J PHYSIOL-HEART C, V281, pH266, DOI 10.1152/ajpheart.2001.281.1.H266; Robin P, 2002, AM J PHYSIOL-CELL PH, V283, pC251, DOI 10.1152/ajpcell.00601.2001; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Sandoval R, 2001, AM J PHYSIOL-LUNG C, V280, pL239, DOI 10.1152/ajplung.2001.280.2.L239; Schieffer B, 2000, CIRC RES, V87, P1195, DOI 10.1161/01.RES.87.12.1195; Shanmugam M, 1998, ONCOGENE, V16, P1649, DOI 10.1038/sj.onc.1201684; Shi CS, 2000, J BIOL CHEM, V275, P24470, DOI 10.1074/jbc.M908449199; Shi CS, 2001, J BIOL CHEM, V276, P31845, DOI 10.1074/jbc.M101043200; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Song JS, 1998, ONCOGENE, V16, P3357, DOI 10.1038/sj.onc.1201886; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Ushio-Fukai M, 2001, ARTERIOSCL THROM VAS, V21, P489, DOI 10.1161/01.ATV.21.4.489; WANG DL, 1995, J CELL PHYSIOL, V163, P400, DOI 10.1002/jcp.1041630220; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430; Wung BS, 2001, ARTERIOSCL THROM VAS, V21, P1941, DOI 10.1161/hq1201.099428; Wung BS, 1997, CIRC RES, V81, P1, DOI 10.1161/01.RES.81.1.1; Wung BS, 1999, CIRC RES, V84, P804; Yano Y, 1996, AM J PHYSIOL-CELL PH, V271, pC635, DOI 10.1152/ajpcell.1996.271.2.C635	60	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48152	48157		10.1074/jbc.M110937200	http://dx.doi.org/10.1074/jbc.M110937200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368297	hybrid			2022-12-25	WOS:000179789600025
J	Fujino, H; Srinivasan, D; Regan, JW				Fujino, H; Srinivasan, D; Regan, JW			Cellular conditioning and activation of beta-catenin signaling by the FPB prostanoid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E-CADHERIN; ISOFORMS; RAC1	FP prostanoid receptors have been identified as two isoforms named FPA and FPB. We have shown that the FPB isoform, but not the FPA, activates beta-catenin-mediated transcription. We now report that the mechanism of this FPB-specific activation of beta-catenin signaling occurs in two steps. The first is a conditioning step that involves an agonist-independent association of the FPB receptor with phosphatidylinositol 3-kinase followed by constitutive internalization of a receptor complex containing E-cadherin and beta-catenin. This constitutive internalization conditions the cell for subsequent beta-catenin signaling by increasing the cellular content of cytosolic beta-catenin. The second step involves agonist-dependent activation of Rho followed by cell rounding. Because of the conditioning step, this agonist-dependent step results in a stabilization of beta-catenin and activation of transcription. Although stimulation of the FPA isoform. activates Rho and induces cellular shape change, it does not activate beta-catenin signaling, because the FPA does not undergo constitutive internalization and does not condition the cell for beta-catenin signaling. The cellular conditioning described here for the FPB illustrates the potential of the receptor to alter the signaling environment of a cell even in the absence of agonist and has general significance for understanding G-protein-coupled receptor signaling.	Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, Tucson, AZ 85721 USA	University of Arizona	Regan, JW (corresponding author), Univ Arizona, Coll Pharm, Dept Pharmacol & Toxicol, 1703 E Mabel St,Box 210207, Tucson, AZ 85721 USA.				NATIONAL EYE INSTITUTE [R01EY011291] Funding Source: NIH RePORTER; NEI NIH HHS [EY11291] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Akhtar N, 2001, MOL BIOL CELL, V12, P847, DOI 10.1091/mbc.12.4.847; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Daniels DL, 2001, TRENDS BIOCHEM SCI, V26, P672, DOI 10.1016/S0968-0004(01)01952-1; Fujino H, 2000, J BIOL CHEM, V275, P29907, DOI 10.1074/jbc.M003467200; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Fujino H, 2000, MOL PHARMACOL, V57, P353; Fujino H, 2001, J BIOL CHEM, V276, P12489, DOI 10.1074/jbc.C100039200; Kovacs EM, 2002, J BIOL CHEM, V277, P6708, DOI 10.1074/jbc.M109640200; Nakagawa M, 2001, J CELL SCI, V114, P1829; Pierce KL, 1999, J BIOL CHEM, V274, P35944, DOI 10.1074/jbc.274.50.35944; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Srinivasan D, 2002, J PHARMACOL EXP THER, V302, P219, DOI 10.1124/jpet.302.1.219	12	29	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48786	48795		10.1074/jbc.M209393200	http://dx.doi.org/10.1074/jbc.M209393200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368277	hybrid			2022-12-25	WOS:000179789600106
J	Kitazono, AA; Kron, SJ				Kitazono, AA; Kron, SJ			An essential function of yeast cyclin-dependent kinase Cdc28 maintains chromosome stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPINDLE ASSEMBLY CHECKPOINT; CDK-ACTIVATING KINASE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; PROTEIN-KINASE; BUDDING YEAST; MUTATIONAL ANALYSIS; CRYSTAL-STRUCTURE; GENE CDC28; COMPLEX	Multiple surveillance pathways maintain genomic integrity in yeast during mitosis. Although the cyclin-dependent kinase Cdc28 is a well established regulator of mitotic progression, evidence for a direct role in mitotic surveillance has been lacking. We have now implicated a conserved sequence in the Cdc28 carboxyl terminus in maintaining chromosome stability through mitosis. Six temperature-sensitive mutants were isolated via random mutagenesis of 13 carboxyl-terminal residues. These mutants identify a Cdc28 domain necessary for proper mitotic arrest in the face of kinetochore defects or microtubule inhibitors. These chromosome stability-defective cdc28(CST) mutants inappropriately continue mitosis when the mitotic spindle is disrupted at 23 degreesC, display high rates of spontaneous chromosome loss at 30 degreesC, and suffer catastrophic aneuploidy at 35 degreesC. A dosage suppression screen identified Cak1, a kinase known to phosphorylate and activate Cdc28, as a specific high copy suppressor of cdc28(CST) temperature sensitivity and chromosome instability. Suppression is independent of the kinase activity of Cak1, suggesting that Cak1 may bind to the carboxyl terminus to serve a non-catalytic role in assembly and/or stabilization of active Cdc28 complexes. Significantly, these studies implicate Cdc28 and Cak1 in an essential surveillance function required to maintain genetic stability through mitosis.	Univ Chicago, Ctr Mol Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Kron, SJ (corresponding author), Univ Chicago, Ctr Mol Oncol, 924 E 57th St,Rm R322, Chicago, IL 60637 USA.			Kron, Stephen/0000-0003-1518-2436; Kitazono, Ana/0000-0002-6924-1799	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060443] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM60443] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Bourne Y, 1996, CELL, V84, P863, DOI 10.1016/S0092-8674(00)81065-X; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; Chun KT, 1997, MOL GEN GENET, V256, P365, DOI 10.1007/s004380050580; DEVIN AB, 1990, YEAST, V6, P231, DOI 10.1002/yea.320060308; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; Gorbsky GJ, 2001, CURR BIOL, V11, pR1001, DOI 10.1016/S0960-9822(01)00609-1; GUTHRIE C, 1991, GUIDE YEAST MOL GENE, V194; HARTWELL LH, 1985, GENETICS, V110, P381; Hoyt MA, 2001, J CELL BIOL, V154, P909, DOI 10.1083/jcb.200108010; Kaldis P, 1999, CELL MOL LIFE SCI, V55, P284, DOI 10.1007/s000180050290; Kitazono AA, 2002, YEAST, V19, P141, DOI 10.1002/yea.806; KOSHLAND D, 1987, METHOD ENZYMOL, V155, P351; KOUPRINA N, 1993, YEAST, V9, P11, DOI 10.1002/yea.320090103; Li XR, 1997, MOL CELL BIOL, V17, P2723, DOI 10.1128/MCB.17.5.2723; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; LORINCZ AT, 1986, MOL CELL BIOL, V6, P4099; MACNEILL SA, 1991, MOL GEN GENET, V229, P109, DOI 10.1007/BF00264219; Mendenhall MD, 1998, MICROBIOL MOL BIOL R, V62, P1191, DOI 10.1128/MMBR.62.4.1191-1243.1998; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Navas TA, 1996, GENE DEV, V10, P2632, DOI 10.1101/gad.10.20.2632; Ouspenski II, 1999, NUCLEIC ACIDS RES, V27, P3001, DOI 10.1093/nar/27.15.3001; Pangilinan F, 1996, MOL BIOL CELL, V7, P1195, DOI 10.1091/mbc.7.8.1195; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Russell ID, 1999, J CELL BIOL, V145, P933, DOI 10.1083/jcb.145.5.933; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Skibbens RV, 1998, ANNU REV GENET, V32, P307, DOI 10.1146/annurev.genet.32.1.307; Song HW, 2001, MOL CELL, V7, P615, DOI 10.1016/S1097-2765(01)00208-8; SPENCER F, 1990, GENETICS, V124, P237; STOLER S, 1995, GENE DEV, V9, P573, DOI 10.1101/gad.9.5.573; Straight AF, 1997, METHOD ENZYMOL, V283, P425; SURANA U, 1991, CELL, V65, P145, DOI 10.1016/0092-8674(91)90416-V; TENNISON CMV, 1998, TECHNICAL TIPS LINE; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Thuret JY, 1996, CELL, V86, P565, DOI 10.1016/S0092-8674(00)80130-0; Wagner M, 1997, EMBO J, V16, P1305, DOI 10.1093/emboj/16.6.1305; Xu BE, 2001, J BIOL CHEM, V276, P26509, DOI 10.1074/jbc.M102769200; Yu YX, 1996, MOL CELL BIOL, V16, P5254	40	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48627	48634		10.1074/jbc.M207247200	http://dx.doi.org/10.1074/jbc.M207247200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359726	hybrid			2022-12-25	WOS:000179789600086
J	Zhang, BX; Ma, XY; Yeh, CK; Lifschitz, MD; Zhu, MX; Katz, MS				Zhang, BX; Ma, XY; Yeh, CK; Lifschitz, MD; Zhu, MX; Katz, MS			Epidermal growth factor-induced depletion of the intracellular Ca2+ store fails to activate capacitative Ca2+ ntry in a human salivary cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASOPHILIC LEUKEMIA-CELLS; MEDIATED CALCIUM-ENTRY; CURRENT I-CRAC; PHOSPHOLIPASE-C; INOSITOL TRISPHOSPHATE; HUMAN-PLATELETS; PROTEIN-KINASE; RECEPTOR; INFLUX; CHANNELS	Epidermal growth factor (EGF) is a multifunctional factor known to influence proliferation and function of a variety of cells. The actions of EGF are mediated by EGF receptor tyrosine kinase pathways, including stimulation of phospholipase Cgamma and mobilization of intracellular Ca2+ ([Ca2+](i)). Generally, agonist-mediated Ca2+ mobilization involves both Ca2+ release from internal stores and Ca2+ influx activated by store depletion (i.e. capacitative or store-operated Ca2+ influx). However, the role of capacitative Ca2+ entry in EGF-mediated Ca2+ mobilization is still largely unknown. In this study, we compared [Ca2+], signals elicited by EGF with those induced by agents (the muscarinic receptor agonist carbachol and thapsigargin (Tg)) known to activate capacitative Ca2+ entry. Unlike carbachol and Tg, EGF (5 nM) elicited a transient [Ca2+](i) signal without a plateau phase in the presence of extracellular Ca2+ and also failed to accelerate Mn2+ entry. Repletion of extracellular Ca2+ to cells stimulated with EGF in the absence of Ca2+ elicited an increase in [Ca2+](i), indicating that EGF indeed stimulates Ca2+ influx. However, the influx was activated at lower EGF concentrations than those required to stimulate Ca2+ release. Interestingly, the phospholipase C inhibitor U73122 completely inhibited Ca2+ release induced by both EGF and carbachol and also reduced Ca2+ influx responsive to carbachol but had no effect on Ca2+ influx induced by EGF. EGF-induced Ca2+ influx was potentiated by low concentrations (<5 ng/ml) of oligomycm, a mitochondrial inhibitor that blocks capacitative Ca2+ influx in other systems. Transient expression of the hTRPC3 protein enhanced Ca2+ influx responsive to carbachol but did not increase EGF-activated Ca2+ influx. Both EGF and carbachol depleted internal Ca2+ stores. Our results demonstrate that EGF-induced Ca2+ release from internal stores does not activate capacitative Ca2+ influx. Rather, EGF stimulates Ca2+ influx via a mechanism distinct from capacitative Ca2+ influx induced by carbachol and Tg.	Audie L Murphy Mem Vet Adm Med Ctr, Ctr Geriatr Res Educ & Clin, Audie L Murphy Div, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; Audie L Murphy Mem Vet Adm Med Ctr, Med Res Serv, Audie L Murphy Div, S Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Med, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Dent Diagnost Sci, San Antonio, TX 78229 USA; Ohio State Univ, Dept Neurosci, Columbus, OH 43210 USA; Ohio State Univ, Neurobiotechnol Ctr, Columbus, OH 43210 USA	Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University	Katz, MS (corresponding author), 7400 Merton Minter Blvd, San Antonio, TX 78229 USA.		Lifschitz, Meyer/AAJ-5578-2020	Yeh, Chih-Ko/0000-0001-6611-9942	NIDCR NIH HHS [DE10756] Funding Source: Medline; NINDS NIH HHS [NS42183] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE010756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042183] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; BLEASDALE JE, 1990, J PHARMACOL EXP THER, V255, P756; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; CARPENTER G, 1990, HDB EXPT PHARM, V95, P69; Cho JH, 1997, BIOCHEM J, V324, P971, DOI 10.1042/bj3240971; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; DIDSBURY J, 1989, J BIOL CHEM, V264, P16378; Elliott AC, 2001, CELL CALCIUM, V30, P73, DOI 10.1054/ceca.2001.0215; Fierro L, 2000, J PHYSIOL-LONDON, V522, P247, DOI 10.1111/j.1469-7793.2000.t01-1-00247.x; GAMBERUCCI A, 1994, J BIOL CHEM, V269, P23597; Glitsch MD, 2000, J PHYSIOL-LONDON, V523, P283, DOI 10.1111/j.1469-7793.2000.t01-2-00283.x; Hartmann J, 1998, J PHYSIOL-LONDON, V513, P411, DOI 10.1111/j.1469-7793.1998.411bb.x; HE XJ, 1988, BIOCHEM BIOPH RES CO, V152, P1062; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; IRVINE RF, 1990, FEBS LETT, V263, P5, DOI 10.1016/0014-5793(90)80692-C; JAYARAMAN T, 1995, P NATL ACAD SCI USA, V92, P6007, DOI 10.1073/pnas.92.13.6007; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Luo DL, 2001, J BIOL CHEM, V276, P20186, DOI 10.1074/jbc.M100327200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; MEISENHELDER J, 1989, CELL, V57, P1109, DOI 10.1016/0092-8674(89)90048-2; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; PAREKH AB, 1995, P NATL ACAD SCI USA, V92, P7907, DOI 10.1073/pnas.92.17.7907; Parekh AB, 1997, CELL, V89, P973, DOI 10.1016/S0092-8674(00)80282-2; PAREKH AB, 1993, NATURE, V364, P814, DOI 10.1038/364814a0; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; PETERSEN CCH, 1994, J BIOL CHEM, V269, P32246; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; SAGE SO, 1989, BIOCHEM J, V258, P923, DOI 10.1042/bj2580923; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Sugawara H, 1997, EMBO J, V16, P3078, DOI 10.1093/emboj/16.11.3078; VACA L, 1994, AM J PHYSIOL-CELL PH, V267, pC1501, DOI 10.1152/ajpcell.1994.267.5.C1501; Wu XY, 2000, AM J PHYSIOL-CELL PH, V278, pC526, DOI 10.1152/ajpcell.2000.278.3.C526; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; YANAGAWA T, 1986, VIRCHOWS ARCH B, V51, P187, DOI 10.1007/BF02899028; Zhang BX, 2000, AM J PHYSIOL-CELL PH, V279, pC1024, DOI 10.1152/ajpcell.2000.279.4.C1024; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	42	14	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48165	48171		10.1074/jbc.M208077200	http://dx.doi.org/10.1074/jbc.M208077200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368284	hybrid			2022-12-25	WOS:000179789600027
J	Choi, HK; Park, NY; Kim, DI; Chung, HJ; Ryu, S; Choi, SH				Choi, HK; Park, NY; Kim, DI; Chung, HJ; Ryu, S; Choi, SH			Promoter analysis and regulatory characteristics of vvhBA encoding cytolytic hemolysin of Vibrio vulnificus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMP RECEPTOR PROTEIN; CYCLIC-AMP; CHOLERA-TOXIN; EXTRACELLULAR CYTOLYSIN; PHENOTYPIC EVALUATION; ELASTOLYTIC PROTEASE; ESCHERICHIA-COLI; ACTIVATOR TOXR; GENE; EXPRESSION	Cytolytic hemolysin, a gene product of vvhA, is a putative virulence factor of the pathogenic bacterium Vibrio vulnificus. We have previously shown that hemolysin production is repressed by adding glucose to culture media and that production can be restored by adding cAMP. In this study, hemolysin activity and the level of vvh transcript were determined to reach a maximum in late exponential phase and were repressed when cells entered stationary phase. Northern blot and primer extension analyses revealed that vvhA is cotranscribed with a second gene, vvhB, located upstream of vvhA. Transcription of the vvhBA operon begins at a single site and is under the direction of a single promoter, P-vvh. A crp null mutation decreased hemolysin production and the level of vvhBA transcript by reducing the activity of P-vvh, indicating that the P-vvh activity is under the positive control of cAMP receptor protein (CRP). A direct interaction between CRP and the regulatory region of the vvhBA operon was demonstrated by gel-mobility shift assays. The CRP binding site, centered at 59.5 bp upstream of the transcription start site, was mapped by deletion analysis of the vvhBA promoter region and confirmed by DNase I protection assays. These results demonstrate that the vvhBA expression is activated by CRP in a growth-dependent manner and that CRP exerts its effects by directly binding to DNA upstream of P-vvh.	Chonnam Natl Univ, Dept Food Sci & Technol, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Mol Biotechnol, Kwangju 500757, South Korea; Chonnam Natl Univ, Inst Biotechnol, Kwangju 500757, South Korea; Seoul Natl Univ, Sch Agr Biotechnol, Dept Food Sci & Technol, Suwon 441744, South Korea	Chonnam National University; Chonnam National University; Chonnam National University; Seoul National University (SNU)	Choi, SH (corresponding author), Chonnam Natl Univ, Dept Food Sci & Technol, Kwangju 500757, South Korea.			Choi, Sang Ho/0000-0003-3865-1039				Bang YB, 1999, J BACTERIOL, V181, P7639, DOI 10.1128/JB.181.24.7639-7642.1999; BLAKE PA, 1980, ANNU REV MICROBIOL, V34, P341, DOI 10.1146/annurev.mi.34.100180.002013; BOTSFORD JL, 1992, MICROBIOL REV, V56, P100, DOI 10.1128/MMBR.56.1.100-122.1992; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CURTISS R, 1987, INFECT IMMUN, V55, P386; EBRIGHT RH, 1993, MOL MICROBIOL, V8, P797, DOI 10.1111/j.1365-2958.1993.tb01626.x; Gonzalez-Gil G, 1998, EMBO J, V17, P2877, DOI 10.1093/emboj/17.10.2877; GRAY LD, 1985, INFECT IMMUN, V48, P62, DOI 10.1128/IAI.48.1.62-72.1985; HIGGINS DE, 1994, MOL MICROBIOL, V14, P17, DOI 10.1111/j.1365-2958.1994.tb01263.x; Higgins DE, 1996, J BACTERIOL, V178, P1080, DOI 10.1128/jb.178.4.1080-1087.1996; Jeong HS, 2001, J BIOL CHEM, V276, P13875, DOI 10.1074/jbc.M010567200; Jeong KC, 2000, INFECT IMMUN, V68, P5096, DOI 10.1128/IAI.68.9.5096-5106.2000; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; Kim SY, 1999, J BIOL CHEM, V274, P25398, DOI 10.1074/jbc.274.36.25398; KLONTZ KC, 1988, ANN INTERN MED, V109, P318, DOI 10.7326/0003-4819-109-4-318; KOTHARY MH, 1987, J GEN MICROBIOL, V133, P1783; KREGER A, 1981, INFECT IMMUN, V33, P583, DOI 10.1128/IAI.33.2.583-590.1981; Lee SE, 2000, J BACTERIOL, V182, P3405, DOI 10.1128/JB.182.12.3405-3415.2000; Linkous DA, 1999, FEMS MICROBIOL LETT, V174, P207, DOI 10.1111/j.1574-6968.1999.tb13570.x; MILLER VL, 1987, CELL, V48, P271, DOI 10.1016/0092-8674(87)90430-2; MILLER VL, 1988, J BACTERIOL, V170, P2575, DOI 10.1128/JB.170.6.2575-2583.1988; Nagai S, 1998, VET MICROBIOL, V60, P227, DOI 10.1016/S0378-1135(98)00144-8; OBYRNE CP, 1994, J BACTERIOL, V176, P905, DOI 10.1128/jb.176.3.905-912.1994; Pfau JD, 1996, MOL MICROBIOL, V20, P213, DOI 10.1111/j.1365-2958.1996.tb02502.x; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SHINODA S, 1985, MICROBIOL IMMUNOL, V29, P583, DOI 10.1111/j.1348-0421.1985.tb00862.x; Skorupski K, 1997, P NATL ACAD SCI USA, V94, P265, DOI 10.1073/pnas.94.1.265; TACKET CO, 1984, J INFECT DIS, V149, P558, DOI 10.1093/infdis/149.4.558; TESTA J, 1984, INFECT IMMUN, V45, P458, DOI 10.1128/IAI.45.2.458-463.1984; WRIGHT AC, 1991, INFECT IMMUN, V59, P192, DOI 10.1128/IAI.59.1.192-197.1991; WRIGHT AC, 1990, INFECT IMMUN, V58, P1769, DOI 10.1128/IAI.58.6.1769-1773.1990; WRIGHT AC, 1985, INFECT IMMUN, V50, P922, DOI 10.1128/IAI.50.3.922-924.1985; YAMAMOTO K, 1990, INFECT IMMUN, V58, P2706, DOI 10.1128/IAI.58.8.2706-2709.1990; YAMANAKA H, 1987, FEMS MICROBIOL LETT, V44, P253	34	57	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47292	47299		10.1074/jbc.M206893200	http://dx.doi.org/10.1074/jbc.M206893200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356775	hybrid			2022-12-25	WOS:000179663700059
J	Hickabottom, M; Parker, GA; Freemont, P; Crook, T; Allday, MJ				Hickabottom, M; Parker, GA; Freemont, P; Crook, T; Allday, MJ			Two nonconsensus sites in the Epstein-Barr virus oncoprotein EBNA3A cooperate to bind the co-repressor carboxyl-terminalbinding protein (CtBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR ANTIGEN 3C; TRANSCRIPTIONAL REPRESSION; HISTONE DEACETYLASE; DROSOPHILA EMBRYO; COREPRESSOR CTBP; B-LYMPHOCYTES; DNA-DAMAGE; IMMORTALIZATION; TRANSFORMATION; EXPRESSION	CtBP (carboxyl-terminal binding protein) has been shown to be a highly conserved co-repressor of transcription that is important in development, cell cycle regulation, and transformation. Viral proteins E1A and EBNA3C and all the various Drosophila and vertebrate transcription factors to which CtBP has been reported to bind contain a conserved "PXDLS" CtBP-interaction domain. Here we show that EBNA3A binds CtBP both in vitro and in vivo but that this interaction does not require a near consensus (PLDLR102)-P-98 motif in the NH2 terminus of EBNA3A. However, further deletion and Mutation analysis revealed that CtBP interacts with this viral protein through a cryptic, bipartite motif located in the COOH terminus of EBNA3A. The two components of this binding domain are similar to the canonical PXDLS motif but do not include the highly conserved, and normally critical, first proline residue. These nonconsensus sites, (857)ALDLS(861) and (VLDLS890,)-V-886 synergize to produce very efficient binding to CtBP. Interaction with CtBP was shown to be important in the repression of transcription by EBNA3A and in the ability of EBNA3A to cooperate with activated Ras to immortalize and transform primary rat embryo fibroblasts. Similar bipartite sequences can be found in other viral and cellular proteins that can interact with CtBP, including the retinoblastoma-interacting protein-methyltransferase RIZ, the oncoprotein EVI1, and Marek's disease virus transforming protein Meq.	Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, Ludwig Inst Canc Res,Wright Fleming Inst, London W2 1PG, England; Univ London Imperial Coll Sci Technol & Med, Dept Sci Biol, Ctr Struct Biol, London SW7 2AZ, England	Imperial College London; Ludwig Institute for Cancer Research; Imperial College London; University of London; Institute of Cancer Research - UK	Allday, MJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Fac Med, Dept Virol, Ludwig Inst Canc Res,Wright Fleming Inst, Norfolk Pl, London W2 1PG, England.	m.allday@ic.ac.uk		Freemont, Paul/0000-0002-5658-8486				Bain M, 1996, J VIROL, V70, P2481, DOI 10.1128/JVI.70.4.2481-2489.1996; Barolo S, 2002, GENE DEV, V16, P1964, DOI 10.1101/gad.987402; BOYD JM, 1993, EMBO J, V12, P469, DOI 10.1002/j.1460-2075.1993.tb05679.x; Chinnadurai G, 2002, MOL CELL, V9, P213, DOI 10.1016/S1097-2765(02)00443-4; Cludts I, 1998, J VIROL, V72, P1862, DOI 10.1128/JVI.72.3.1862-1869.1998; Criqui-Filipe P, 1999, EMBO J, V18, P3392, DOI 10.1093/emboj/18.12.3392; CROOK T, 1991, J VIROL, V65, P505, DOI 10.1128/JVI.65.1.505-510.1991; Dahiya A, 2001, MOL CELL, V8, P557, DOI 10.1016/S1097-2765(01)00346-X; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Folkers U, 2002, EMBO J, V21, P1280, DOI 10.1093/emboj/21.6.1280; Furusawa T, 1999, MOL CELL BIOL, V19, P8581; Fusco C, 1998, GENOMICS, V51, P351, DOI 10.1006/geno.1998.5368; Jiang H, 2000, J VIROL, V74, P5921, DOI 10.1128/JVI.74.13.5921-5932.2000; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kilbey A, 1998, ONCOGENE, V16, P2287, DOI 10.1038/sj.onc.1201732; Kim GT, 2002, EMBO J, V21, P1267, DOI 10.1093/emboj/21.6.1267; Koipally J, 2000, J BIOL CHEM, V275, P19594, DOI 10.1074/jbc.M000254200; Kung HJ, 2001, CURR TOP MICROBIOL, V255, P245; LEROUX A, 1994, VIROLOGY, V205, P596, DOI 10.1006/viro.1994.1687; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Li S, 1999, J BIOL CHEM, V274, P11334, DOI 10.1074/jbc.274.16.11334; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Molloy DP, 1998, J BIOL CHEM, V273, P20867, DOI 10.1074/jbc.273.33.20867; Morel V, 2001, CURR BIOL, V11, P789, DOI 10.1016/S0960-9822(01)00224-X; Nibu Y, 1998, SCIENCE, V280, P101, DOI 10.1126/science.280.5360.101; Nibu Y, 1998, EMBO J, V17, P7009, DOI 10.1093/emboj/17.23.7009; Nibu Y, 2001, P NATL ACAD SCI USA, V98, P6204, DOI 10.1073/pnas.111158298; Palmer S, 2001, J BIOL CHEM, V276, P25834, DOI 10.1074/jbc.M102343200; Palmero I, 2001, METHOD ENZYMOL, V333, P247; Parker GA, 1996, ONCOGENE, V13, P2541; Poortinga G, 1998, EMBO J, V17, P2067, DOI 10.1093/emboj/17.7.2067; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; QUINLAN MP, 1992, J VIROL, V66, P2020, DOI 10.1128/JVI.66.4.2020-2030.1992; Radkov SA, 1999, J VIROL, V73, P5688, DOI 10.1128/JVI.73.7.5688-5697.1999; Radkov SA, 1997, J VIROL, V71, P8552, DOI 10.1128/JVI.71.11.8552-8562.1997; Senyuk V, 2002, ONCOGENE, V21, P3232, DOI 10.1038/sj.onc.1205436; Sewalt RGAB, 1999, MOL CELL BIOL, V19, P777; Steele-Perkins G, 2001, GENE DEV, V15, P2250, DOI 10.1101/gad.870101; Strunk B, 2001, DEV BIOL, V239, P229, DOI 10.1006/dbio.2001.0454; TOMKINSON B, 1993, J VIROL, V67, P2014, DOI 10.1128/JVI.67.4.2014-2025.1993; Touitou R, 2001, J VIROL, V75, P7749, DOI 10.1128/JVI.75.16.7749-7755.2001; Turner J, 2001, BIOESSAYS, V23, P683, DOI 10.1002/bies.1097; Waltzer L, 1996, J VIROL, V70, P5909, DOI 10.1128/JVI.70.9.5909-5915.1996; Wu-Baer F, 2001, Nature, V414, P36, DOI 10.1038/35102118; Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199; Zhang QH, 2002, SCIENCE, V295, P1895; Zimber-Strobl U, 2001, SEMIN CANCER BIOL, V11, P423, DOI 10.1006/scbi.2001.0409	48	70	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47197	47204		10.1074/jbc.M208116200	http://dx.doi.org/10.1074/jbc.M208116200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12372828	hybrid			2022-12-25	WOS:000179663700047
J	Laursen, LS; Overgaard, MT; Weyer, K; Boldt, HB; Ebbesen, P; Christiansen, M; Sottrup-Jensen, L; Giudice, LC; Oxvig, C				Laursen, LS; Overgaard, MT; Weyer, K; Boldt, HB; Ebbesen, P; Christiansen, M; Sottrup-Jensen, L; Giudice, LC; Oxvig, C			Cell surface targeting of pregnancy-associated plasma protein A proteolytic activity - Reversible adhesion is mediated by two neighboring short consensus repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR BASIC-PROTEIN; HEPARAN-SULFATE PROTEOGLYCANS; MESSENGER-RIBONUCLEIC-ACID; A PAPP-A; COMPLEMENT CONTROL PROTEIN; BINDING PROTEIN-5; EXPRESSION; IGF; PROFORM; ACTIVATION	The activities of insulin-like growth factor (IGF)-I and -II are regulated by IGF-binding proteins (IGFBPs). Cleavage of IGFBP-4 by the metalloproteinase pregnancy-associated plasma protein-A (PAPP-A) causes release of bound IGF and has been established in several biological systems including the human reproductive system. Using flow cytometry, we first demonstrate that PAPP-A reversibly binds to the cell surface of several cell types analyzed. Heparin and heparan sulfate, but not dermatan or chondroitin sulfate, effectively compete for PAPP-A surface binding, and because incubation of cells with heparinase abrogated PAPP-A adhesion, binding is probably mediated by a cell surface heparan sulfate proteoglycan. Furthermore, the proteolytic activity of PAPP-A is preserved while bound to cells, suggesting that adhesion functions to target its activity to the vicinity of the IGF receptor, decreasing the probability that released IGF is captured by another IGFBP molecule before receptor binding. This mechanism potentially functions in both autocrine and paracrine regulation, as PAPP-A need not be synthesized in a cell to which it adheres. A truncated PAPP-A variant without the five short consensus repeats in the C-terminal third of the 1547-residue PAPP-A subunit, lacked surface binding. We also show that PAPP-A2, a recently discovered IGFBP-5 proteinase with homology to PAPP-A, does not bind cells. This finding allowed further mapping of the PAPP-A adhesion site to short consensus repeat modules 3 and 4 by the expression and analysis of nine PAPP-A/PAPP-A2 chimeras. Interestingly, the proteolytically inactive, disulfide-bound complex of PAPP-A and the proform of eosinophil major basic protein (proMBP), PAPP-A-proMBP, shows only weak surface binding, probably because the adhesion site of PAPP-A is occupied by heparan sulfate, known to be covalently bound to proMBP. This hypothesis was further substantiated by demonstrating that heparinase treatment of PAPP-A-proMBP restores surface binding. We finally propose a model in which IGF bioactivity is regulated by reversible cell surface binding of PAPP-A, which in turn is regulated by proMBP.	Aarhus Univ, Dept Biol Mol, DK-8000 Aarhus C, Denmark; Danish Canc Soc, Dept Virus & Canc, DK-8000 Aarhus C, Denmark; Statens Serum Inst, Dept Clin Biochem, DK-2300 Copenhagen S, Denmark; Stanford Univ, Dept Gynecol & Obstet, Stanford, CA 94305 USA	Aarhus University; Danish Cancer Society; Statens Serum Institut; Stanford University	Oxvig, C (corresponding author), Aarhus Univ, Dept Biol Mol, Sci Pk,Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	co@mb.au.dk	Overgaard, Michael Toft/E-1354-2011; Christiansen, Michael/B-4588-2009	Overgaard, Michael Toft/0000-0002-1423-2481; Christiansen, Michael/0000-0003-4713-755X; Laursen, Lisbeth Schmidt/0000-0002-8676-5869; Weyer, Kathrin/0000-0002-8473-7987; Oxvig, Claus/0000-0002-4715-9719	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD031579] Funding Source: NIH RePORTER; NICHD NIH HHS [HD31579-07] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRESS DL, 1995, J BIOL CHEM, V270, P28289; Bayes-Genis A, 2001, NEW ENGL J MED, V345, P1022, DOI 10.1056/NEJMoa003147; Bayes-Genis A, 2001, ARTERIOSCL THROM VAS, V21, P335, DOI 10.1161/01.ATV.21.3.335; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; BODE W, 1993, FEBS LETT, V331, P134, DOI 10.1016/0014-5793(93)80312-I; Boldt HB, 2001, BIOCHEM J, V358, P359, DOI 10.1042/0264-6021:3580359; BONNO M, 1994, LAB INVEST, V71, P560; Brooks PC, 1996, CELL, V85, P683, DOI 10.1016/S0092-8674(00)81235-0; CAMPBELL PG, 1992, ENDOCRINOLOGY, V130, P1401, DOI 10.1210/en.130.3.1401; Conover CA, 1999, J CLIN ENDOCR METAB, V84, P4742, DOI 10.1210/jc.84.12.4742; Conover CA, 2001, ENDOCRINOLOGY, V142, P2155, DOI 10.1210/en.142.5.2155; DAUGHADAY WH, 1989, ENDOCR REV, V10, P68, DOI 10.1210/edrv-10-1-68; Farr M, 2000, BBA-GENE STRUCT EXPR, V1493, P356, DOI 10.1016/S0167-4781(00)00195-0; Fowlkes JL, 1997, TRENDS ENDOCRIN MET, V8, P299, DOI 10.1016/S1043-2760(97)00112-4; GIUDICE LC, 1921, J CLIN ENDOCR METAB, V87, P2359; Haaning J, 1996, EUR J BIOCHEM, V237, P159, DOI 10.1111/j.1432-1033.1996.0159n.x; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hourvitz A, 2002, ENDOCRINOLOGY, V143, P1833, DOI 10.1210/en.143.5.1833; ISAKA K, 1986, ARCH GYNECOL OBSTET, V237, P117, DOI 10.1007/BF02133855; JONES JI, 1995, ENDOCR REV, V16, P3, DOI 10.1210/er.16.1.3; Kiessling LL, 1998, CHEM BIOL, V5, pR49, DOI 10.1016/S1074-5521(98)90056-4; Kirkitadze MD, 2001, IMMUNOL REV, V180, P146, DOI 10.1034/j.1600-065X.2001.1800113.x; KRISTENSEN T, 1994, BIOCHEMISTRY-US, V33, P1592, DOI 10.1021/bi00172a040; KUHAJDA FP, 1989, P NATL ACAD SCI USA, V86, P1188, DOI 10.1073/pnas.86.4.1188; Laursen LS, 2001, FEBS LETT, V504, P36, DOI 10.1016/S0014-5793(01)02760-0; Lawrence JB, 1999, P NATL ACAD SCI USA, V96, P3149, DOI 10.1073/pnas.96.6.3149; Mauch S, 2002, J IMMUNOL, V168, P1244, DOI 10.4049/jimmunol.168.3.1244; Mazerbourg S, 2001, ENDOCRINOLOGY, V142, P5243, DOI 10.1210/en.142.12.5243; Mulloy B, 2001, CURR OPIN STRUC BIOL, V11, P623, DOI 10.1016/S0959-440X(00)00257-8; Murthy KHM, 2001, CELL, V104, P301, DOI 10.1016/S0092-8674(01)00214-8; NORMAN DG, 1991, J MOL BIOL, V219, P717, DOI 10.1016/0022-2836(91)90666-T; Overgaard MT, 2000, J BIOL CHEM, V275, P31128, DOI 10.1074/jbc.M001384200; Overgaard MT, 1999, BIOL REPROD, V61, P1083, DOI 10.1095/biolreprod61.4.1083; Overgaard MT, 2001, J BIOL CHEM, V276, P21849, DOI 10.1074/jbc.M102191200; OXVIG C, 1994, BIOCHEM MOL BIOL INT, V33, P329; OXVIG C, 1993, J BIOL CHEM, V268, P12243; OXVIG C, 1994, BBA-GEN SUBJECTS, V1201, P415, DOI 10.1016/0304-4165(94)90071-X; Oxvig C, 1998, P NATL ACAD SCI USA, V95, P4870, DOI 10.1073/pnas.95.9.4870; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Qin QP, 1997, CLIN CHEM, V43, P2323; RemacleBonnet MM, 1997, INT J CANCER, V72, P835, DOI 10.1002/(SICI)1097-0215(19970904)72:5<835::AID-IJC21>3.0.CO;2-6; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; Sharma AK, 1996, P NATL ACAD SCI USA, V93, P10996, DOI 10.1073/pnas.93.20.10996; Smith GCS, 2002, NATURE, V417, P916, DOI 10.1038/417916a; STOCKER W, 1995, PROTEIN SCI, V4, P823; Sun IYC, 2002, J CLIN ENDOCR METAB, V87, P5235, DOI 10.1210/jc.2002-020561; Verbeke P, 2001, FREE RADICAL BIO MED, V31, P1593, DOI 10.1016/S0891-5849(01)00752-3; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200; Yu Q, 2000, GENE DEV, V14, P163; Yu WH, 2000, J BIOL CHEM, V275, P4183, DOI 10.1074/jbc.275.6.4183; Yu WH, 2002, GENE DEV, V16, P307, DOI 10.1101/gad.925702	51	90	92	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47225	47234		10.1074/jbc.M209155200	http://dx.doi.org/10.1074/jbc.M209155200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370176	hybrid			2022-12-25	WOS:000179663700050
J	Lee, SG; Pancholi, V; Fischetti, VA				Lee, SG; Pancholi, V; Fischetti, VA			Characterization of a unique glycosylated anchor endopeptidase that cleaves the LPXTG sequence motif of cell surface proteins of gram-positive bacteria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRONECTIN-BINDING PROTEIN; STAPHYLOCOCCUS-AUREUS SORTASE; COMPLETE NUCLEOTIDE-SEQUENCE; STREPTOCOCCUS-PNEUMONIAE; MOLECULAR CHARACTERIZATION; PANTETHEINE-PROTEIN; GENE; PURIFICATION; EXPRESSION; ADHESIN	The precursors of most surface proteins on Gram-positive bacteria have a C-terminal hydrophobic domain and charged tail, preceded by a conserved LPXTG motif that signals the anchoring process. This motif is the substrate for an enzyme, termed sortase, which has transpeptidation activity resulting in the cleavage of the LPXTG sequence and ultimate attachment of the protein to the peptidoglycan. While screening a group A streptococcal membrane extract for cleavage activity of the LPX-TG motif, we identified an enzyme (which we term "LPXTGase") that differs significantly from sortase but also cleaves this motif. The enzyme is heavily glycosylated, which is required for its activity. Amino acid composition and sequence analysis revealed that LPXT-Gase differs from other enzymes, in that the molecule, which is about 14 kDa in size, has no aromatic amino acids, is rich in alanine, and is 30% composed of uncommon amino acids, suggesting a nonribosomal construction. A similar enzyme found in the membrane extract of Staphylococcus aureus, indicates that this unusual molecule may be common among Gram-positive bacteria. Whereas peptide antibiotics have been reported from bacillus species that also contain unusual amino acids and are synthesized non-ribosomally on amino acid-activating polyenzyme templates, this would be the first reported enzyme that may be similarly synthesized.	Rockefeller Univ, Lab Bacterial Pathogenesis, New York, NY 10021 USA	Rockefeller University	Fischetti, VA (corresponding author), Rockefeller Univ, Lab Bacterial Pathogenesis, 1230 York Ave, New York, NY 10021 USA.	vaf@rockefeller.edu	Chen, Tianren/AAS-6018-2021; Pancholi, Vijay/E-3810-2011		NIAID NIH HHS [AI11822] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI011822, R01AI011822] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANGEL CS, 1994, J INFECT DIS, V170, P600, DOI 10.1093/infdis/170.3.600; Berkower C, 1999, MOL MICROBIOL, V31, P1463, DOI 10.1046/j.1365-2958.1999.01289.x; BERRY AM, 1994, INFECT IMMUN, V62, P1101, DOI 10.1128/IAI.62.3.1101-1108.1994; Berry AM, 1996, J BACTERIOL, V178, P4854, DOI 10.1128/jb.178.16.4854-4860.1996; Biswas B, 2002, INFECT IMMUN, V70, P204, DOI 10.1128/IAI.70.1.204-210.2002; Bongaerts RJM, 2000, INFECT IMMUN, V68, P7141, DOI 10.1128/IAI.68.12.7141-7143.2000; CHEN CC, 1990, J BIOL CHEM, V265, P3161; CLARKE VA, 1995, J BIOL CHEM, V270, P8805, DOI 10.1074/jbc.270.15.8805; COURTNEY HS, 1994, INFECT IMMUN, V62, P4868, DOI 10.1128/IAI.62.11.4868-4873.1994; Cue D, 1998, INFECT IMMUN, V66, P4593, DOI 10.1128/IAI.66.10.4593-4601.1998; Cue D, 2000, P NATL ACAD SCI USA, V97, P2858, DOI 10.1073/pnas.050587897; Dave S, 2001, INFECT IMMUN, V69, P3435, DOI 10.1128/IAI.69.5.3435-3437.2001; Dramsi S, 1998, INFECT IMMUN, V66, P4461; Drapeau G R, 1976, Methods Enzymol, V45, P469; Fernandez-Espla MD, 2000, APPL ENVIRON MICROB, V66, P4772, DOI 10.1128/AEM.66.11.4772-4778.2000; FISCHETTI VA, 1995, INFECT IMMUN, V63, P149, DOI 10.1128/IAI.63.1.149-153.1995; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; FISCHETTI VA, 1971, J EXP MED, V133, P1105, DOI 10.1084/jem.133.5.1105; Fowler T, 2000, EUR J CELL BIOL, V79, P672, DOI 10.1078/0171-9335-00104; FUJITA T, 1978, J EXP MED, V148, P1044, DOI 10.1084/jem.148.4.1044; GIGLI I, 1979, P NATL ACAD SCI USA, V76, P6596, DOI 10.1073/pnas.76.12.6596; HANSKI E, 1992, P NATL ACAD SCI USA, V89, P6172, DOI 10.1073/pnas.89.13.6172; HEIMARK RL, 1981, METHOD ENZYMOL, V80, P157; IGARASHI T, 1995, MICROBIOL IMMUNOL, V39, P853, DOI 10.1111/j.1348-0421.1995.tb03282.x; Jenkinson HF, 1997, MOL MICROBIOL, V23, P183, DOI 10.1046/j.1365-2958.1997.2021577.x; Johnsson E, 1996, J IMMUNOL, V157, P3021; Kanzaki Hiroko, 1992, Journal of Dermatological Science, V4, P87, DOI 10.1016/0923-1811(92)90064-I; KETT K, 1986, J IMMUNOL, V136, P3631; Kunji ERS, 1996, ANTON LEEUW INT J G, V70, P187, DOI 10.1007/BF00395933; Lecuit M, 1997, INFECT IMMUN, V65, P5309, DOI 10.1128/IAI.65.12.5309-5319.1997; Lee S G, 1975, Methods Enzymol, V43, P585; LEE SG, 1977, P NATL ACAD SCI USA, V74, P2343, DOI 10.1073/pnas.74.6.2343; LEE SG, 1973, BIOCHEMISTRY-US, V12, P398, DOI 10.1021/bi00727a006; LEE SG, 1974, P NATL ACAD SCI USA, V71, P607, DOI 10.1073/pnas.71.3.607; Loeffler JM, 2001, SCIENCE, V294, P2170, DOI 10.1126/science.1066869; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Molinari G, 1997, INFECT IMMUN, V65, P1357, DOI 10.1128/IAI.65.4.1357-1363.1997; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Murakami Y, 1997, INFECT IMMUN, V65, P1531, DOI 10.1128/IAI.65.4.1531-1535.1997; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; Nelson D, 2001, P NATL ACAD SCI USA, V98, P4107, DOI 10.1073/pnas.061038398; OKADA N, 1995, P NATL ACAD SCI USA, V92, P2489, DOI 10.1073/pnas.92.7.2489; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; Pallen MJ, 2001, TRENDS MICROBIOL, V9, P97, DOI 10.1016/S0966-842X(01)01956-4; PANCHOLI V, 1988, J BACTERIOL, V170, P2618, DOI 10.1128/jb.170.6.2618-2624.1988; PANGBURN MK, 1977, J EXP MED, V146, P257, DOI 10.1084/jem.146.1.257; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1992, J BIOL CHEM, V267, P4766; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; RANKIN S, 1992, INFECT IMMUN, V60, P3909, DOI 10.1128/IAI.60.9.3909-3912.1992; Rice K, 2001, INFECT IMMUN, V69, P3791, DOI 10.1128/IAI.69.6.3791-3799.2001; ROBBINS KC, 1981, METHOD ENZYMOL, V80, P379; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Siezen RJ, 1999, ANTON LEEUW INT J G, V76, P139, DOI 10.1023/A:1002036906922; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SIM RB, 1981, METHOD ENZYMOL, V80, P26; Sinha B, 1999, CELL MICROBIOL, V1, P101, DOI 10.1046/j.1462-5822.1999.00011.x; Sinha B, 2000, INFECT IMMUN, V68, P6871, DOI 10.1128/IAI.68.12.6871-6878.2000; SNYDERMAN R, 1971, J EXP MED, V134, P1131, DOI 10.1084/jem.134.5.1131; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; Tung HS, 2000, BIOCHEM J, V345, P611, DOI 10.1042/0264-6021:3450611; WANG JR, 1994, INFECT IMMUN, V62, P442, DOI 10.1128/IAI.62.2.442-448.1994; Wani JH, 1996, INFECT IMMUN, V64, P3967, DOI 10.1128/IAI.64.10.3967-3974.1996; WEXLER DE, 1985, INFECT IMMUN, V50, P757, DOI 10.1128/IAI.50.3.757-764.1985; Yeung MK, 1998, INFECT IMMUN, V66, P1482, DOI 10.1128/IAI.66.4.1482-1491.1998; Zahner D, 2000, J BACTERIOL, V182, P5919, DOI 10.1128/JB.182.20.5919-5921.2000	71	31	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46912	46922		10.1074/jbc.M208660200	http://dx.doi.org/10.1074/jbc.M208660200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370182	hybrid			2022-12-25	WOS:000179663700012
J	Skov, LK; Mirza, O; Sprogoe, D; Dar, I; Remaud-Simeon, M; Albenne, C; Monsan, P; Gajhede, M				Skov, LK; Mirza, O; Sprogoe, D; Dar, I; Remaud-Simeon, M; Albenne, C; Monsan, P; Gajhede, M			Oligosaccharide and sucrose complexes of amylosucrase - Structural implications for the polymerase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1.7 ANGSTROM RESOLUTION; ALPHA-AMYLASE FAMILY; NEISSERIA-POLYSACCHAREA; CRYSTAL-STRUCTURE; X-RAY; CYCLODEXTRIN GLYCOSYLTRANSFERASE; ENZYME; MALTOPENTAOSE; GLUCOAMYLASE; INTERMEDIATE	The glucosyltransferase amylosucrase is structurally quite similar to the hydrolase a-amylase. How this switch in functionality is achieved is an important and fundamental question. The inactive E328Q amylosucrase variant has been co-crystallized with maltoheptaose, and the structure was determined by x-ray crystallography to 2.2 Angstrom resolution, revealing a maltoheptaose binding site in the B'-domain somewhat distant from the active site. Additional soaking of these crystals with maltolieptaose resulted in replacement of Tris in the active site with maltoheptaose, allowing the mapping of the -1 to +5 binding subsites. Crystals of amylosucrase were soaked with sucrose at different concentrations. The structures at similar to2.1 Angstrom resolution revealed three new binding sites of different affinity. The highest affinity binding site is close to the active site but is not in the previously identified substrate access channel. Allosteric regulation seems necessary to facilitate access from this binding site. The structures show the pivotal role of the B'-domain in the transferase reaction. Based on these observations, an extension of the hydrolase reaction mechanism valid for this enzyme can be proposed. In this mechanism, the glycogen-like polymer is bound in the widest access channel to the active site. The polymer binding introduces structural changes that allow sucrose to migrate from its binding site into the active site and displace the polymer.	Univ Copenhagen, Dept Chem, Prot Struct Grp, DK-2100 Copenhagen, Denmark; CNRS, Unite Mixte Rech 5504, INRA,Unite Mixte Rech 792, Inst Natl Sci Appl,Dept Genie Biochim & Alimentai, F-31077 Toulouse, France	University of Copenhagen; INRAE; Universite de Toulouse; Universite Federale Toulouse Midi-Pyrenees (ComUE); Institut National des Sciences Appliquees de Toulouse; Centre National de la Recherche Scientifique (CNRS)	Skov, LK (corresponding author), Univ Copenhagen, Dept Chem, Prot Struct Grp, Univ Pk 5, DK-2100 Copenhagen, Denmark.			Gajhede, Michael/0000-0001-9864-2287; ALBENNE, Cecile/0000-0001-9856-9745; Mirza, Osman Asghar/0000-0001-9435-0690				Aghajari N, 1998, STRUCTURE, V6, P1503, DOI 10.1016/S0969-2126(98)00149-X; ALESHIN A, 1992, J BIOL CHEM, V267, P19291; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, BIOCHEMISTRY-US, V36, P10837, DOI 10.1021/bi970539i; Dauter Z, 1999, BIOCHEMISTRY-US, V38, P8385, DOI 10.1021/bi990256l; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; de Montalk GP, 2000, FEMS MICROBIOL LETT, V186, P103; de Montalk GP, 2000, FEBS LETT, V471, P219, DOI 10.1016/S0014-5793(00)01406-X; De Montalk GP, 1999, J BACTERIOL, V181, P375; Fujimoto Z, 1998, J MOL BIOL, V277, P393, DOI 10.1006/jmbi.1997.1599; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mirza O, 2001, BIOCHEMISTRY-US, V40, P9032, DOI 10.1021/bi010706l; Mosi R, 1997, BIOCHEMISTRY-US, V36, P9927, DOI 10.1021/bi970618u; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Oyama T, 1999, J BIOCHEM-TOKYO, V125, P1120, DOI 10.1093/oxfordjournals.jbchem.a022394; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Sabini E, 2000, ACTA CRYSTALLOGR D, V56, P3, DOI 10.1107/S0907444999013943; Sarcabal P, 2000, FEBS LETT, V474, P33, DOI 10.1016/S0014-5793(00)01567-2; Sevcik J, 1998, ACTA CRYSTALLOGR D, V54, P854, DOI 10.1107/S0907444998002005; Skov LK, 2001, J BIOL CHEM, V276, P25273, DOI 10.1074/jbc.M010998200; Skov LK, 2000, ACTA CRYSTALLOGR D, V56, P203, DOI 10.1107/S0907444999015887; Uitdehaag JCM, 1999, NAT STRUCT BIOL, V6, P432, DOI 10.1038/8235; Uitdehaag JCM, 2000, BIOCHEMISTRY-US, V39, P7772, DOI 10.1021/bi000340x; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Watanabe K, 1997, J MOL BIOL, V269, P142, DOI 10.1006/jmbi.1997.1018; Yoshioka Y, 1997, J MOL BIOL, V271, P619, DOI 10.1006/jmbi.1997.1222	29	78	83	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47741	47747		10.1074/jbc.M207860200	http://dx.doi.org/10.1074/jbc.M207860200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12364331	hybrid			2022-12-25	WOS:000179663700117
J	Tenno, M; Saeki, A; Kezdy, FJ; Elhammer, AP; Kurosaka, A				Tenno, M; Saeki, A; Kezdy, FJ; Elhammer, AP; Kurosaka, A			The lectin domain of UDP-GalNAc : polypeptide N-acetylgalactosaminyltransferase 1 is involved in O-glycosylation of a polypeptide with multiple acceptor sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GALACTOSAMINE; ALPHA-D-GALACTOSAMINE; STREPTOMYCES-OLIVACEOVIRIDIS E-86; BOVINE SUBMAXILLARY MUCIN; RICIN B-CHAIN; CDNA CLONING; LINKED GLYCOSYLATION; CRYSTAL-STRUCTURE; BINDING DOMAIN; TANDEM REPEAT	Mucin type O-glycosylation begins with the transfer of GalNAc to serine and threonine residues on proteins by a family of UDP-GaINAc:polypeptide N-acetylgalactosaminlytransferases. These enzymes all contain a lectin-like (QXW)(3) repeat sequence at the C terminus that consists of three tandem repeats (alpha, beta, and gamma). The putative lectin domain of one of the most ubiquitous isozymes, GalNAc-T1, is reportedly not functional. In this report, we have reevaluated the role of the GalNAc-T1 lectin domain. Deletion of the lectin domain resulted in a complete loss of enzymatic activity. We also found that GalNAc-T1 has two activities distinguished by their sensitivities to inhibition with free GalNAc; one activity is sensitive, and the other is resistant. In our experiments, the former activity is represented by the O-glycosylation of apomucin, an acceptor that contains multiple glycosylation sites, and the latter is represented by synthetic peptides that contain a single glycosylation site. Site-directed mutagenesis of the lectin domain selectively reduced the former activity and identified Asp(444) in the a repeat as the most important site for GalNAc recognition. A further reduction of the GalNAc-inhibitable activity was observed when both Asp(444) and the corresponding aspartate residues in the beta and the gamma repeats were mutated. This suggests a cooperative involvement of each repeat unit in the glycosylation of polypeptides with multiple acceptor sites.	Kyoto Sangyo Univ, Dept Biotechnol, Fac Engn, Kita Ku, Kyoto 6038555, Japan; Kyoto Sangyo Univ, Inst Comprehens Res, Kita Ku, Kyoto 6038555, Japan; Pharmacia Corp, Kalamazoo, MI 49007 USA	Kyoto Sangyo University; Kyoto Sangyo University; Pfizer	Kurosaka, A (corresponding author), Kyoto Sangyo Univ, Dept Biotechnol, Fac Engn, Kita Ku, Kyoto 6038555, Japan.	kurosaka@cc.kyoto-su.ac.jp						Bennett EP, 1996, J BIOL CHEM, V271, P17006, DOI 10.1074/jbc.271.29.17006; Bennett EP, 1998, J BIOL CHEM, V273, P30472, DOI 10.1074/jbc.273.46.30472; Bennett EP, 1999, J BIOL CHEM, V274, P25362, DOI 10.1074/jbc.274.36.25362; Bennett EP, 1999, FEBS LETT, V460, P226, DOI 10.1016/S0014-5793(99)01268-5; BHARGAVA AK, 1990, P NATL ACAD SCI USA, V87, P6798, DOI 10.1073/pnas.87.17.6798; BHAVANANDAN VP, 1987, J BIOL CHEM, V262, P5913; BLACK GW, 1995, BIOCHEM J, V307, P191, DOI 10.1042/bj3070191; Breton C, 1999, CURR OPIN STRUC BIOL, V9, P563, DOI 10.1016/S0959-440X(99)00006-8; Clausen H, 1996, GLYCOBIOLOGY, V6, P635, DOI 10.1093/glycob/6.6.635; ELHAMMER A, 1986, J BIOL CHEM, V261, P5249; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; Elhammer AP, 1999, GLYCOCONJUGATE J, V16, P171, DOI 10.1023/A:1026465232149; Fujimoto Z, 2000, J MOL BIOL, V300, P575, DOI 10.1006/jmbi.2000.3877; Fujimoto Z, 2002, J MOL BIOL, V316, P65, DOI 10.1006/jmbi.2001.5338; Hagen FK, 1999, J BIOL CHEM, V274, P6797, DOI 10.1074/jbc.274.10.6797; Hagen FK, 1997, J BIOL CHEM, V272, P13843, DOI 10.1074/jbc.272.21.13843; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; Hanisch FG, 1999, J BIOL CHEM, V274, P9946, DOI 10.1074/jbc.274.15.9946; Hanisch FG, 2000, GLYCOBIOLOGY, V10, P439, DOI 10.1093/glycob/10.5.439; Hanisch FG, 2001, GLYCOBIOLOGY, V11, P731, DOI 10.1093/glycob/11.9.731; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; Hassan H, 2000, J BIOL CHEM, V275, P38197, DOI 10.1074/jbc.M005783200; Hazes B, 1996, PROTEIN SCI, V5, P1490, DOI 10.1002/pro.5560050805; Hirabayashi J, 1998, J BIOL CHEM, V273, P14450, DOI 10.1074/jbc.273.23.14450; HOMA FL, 1993, J BIOL CHEM, V268, P12609; Imberty A, 1997, PROTEIN ENG, V10, P1353, DOI 10.1093/protein/10.12.1353; Jiang WP, 1998, BIOCHEM BIOPH RES CO, V251, P550, DOI 10.1006/bbrc.1998.9515; Jiang WP, 2000, EUR J BIOCHEM, V267, P2208, DOI 10.1046/j.1432-1327.2000.01225.x; Kato K, 2001, GLYCOBIOLOGY, V11, P821, DOI 10.1093/glycob/11.10.821; Kato K, 2001, BIOCHEM BIOPH RES CO, V287, P110, DOI 10.1006/bbrc.2001.5562; Kirnarsky L, 1998, BIOCHEMISTRY-US, V37, P12811, DOI 10.1021/bi981034a; Kuno A, 1998, J FERMENT BIOENG, V86, P434, DOI 10.1016/S0922-338X(98)80147-5; Marth JD, 1996, GLYCOBIOLOGY, V6, P701, DOI 10.1093/glycob/6.7.701; OCONNELL BC, 1993, ANAL BIOCHEM, V210, P423, DOI 10.1006/abio.1993.1219; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; RUTENBER E, 1987, NATURE, V326, P624, DOI 10.1038/326624a0; RUTENBER E, 1991, PROTEINS, V10, P260, DOI 10.1002/prot.340100310; TAHIROV TH, 1995, J MOL BIOL, V250, P354, DOI 10.1006/jmbi.1995.0382; Ten Hagen BG, 1998, J BIOL CHEM, V273, P27749; Ten Hagen KG, 1999, J BIOL CHEM, V274, P27867; Ten Hagen KG, 2001, J BIOL CHEM, V276, P17395, DOI 10.1074/jbc.M009638200; Tenno M, 2002, EUR J BIOCHEM, V269, P4308, DOI 10.1046/j.1432-1033.2002.03123.x; Toba S, 2000, BBA-GENE STRUCT EXPR, V1493, P264, DOI 10.1016/S0167-4781(00)00180-9; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; WANG YC, 1992, J BIOL CHEM, V267, P2728; White KE, 2000, GENE, V246, P347, DOI 10.1016/S0378-1119(00)00050-0; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156	48	40	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47088	47096		10.1074/jbc.M207369200	http://dx.doi.org/10.1074/jbc.M207369200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12364335	hybrid			2022-12-25	WOS:000179663700034
J	Ko, BCB; Lam, AKM; Kapus, A; Fan, LZ; Chung, SK; Chung, SSM				Ko, BCB; Lam, AKM; Kapus, A; Fan, LZ; Chung, SK; Chung, SSM			Fyn and p38 signaling are both required for maximal hypertonic activation of the osmotic response element-binding protein/tonicity-responsive enhancer-binding protein (OREBP/TonEBP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDOSE REDUCTASE GENE; TYROSINE PHOSPHORYLATION; STIMULATES TRANSCRIPTION; INOSITOL COTRANSPORTER; KIDNEY-CELLS; 3T3 CELLS; KINASE; STRESS; SRC; YEAST	When cells are challenged by hyperosmotic stress, one of the crucial adaptive responses is the expression of osmoprotective genes that are responsible for raising the intracellular level of compatible osmolytes such as sorbitol, betaine, and myo-inositol. This is achieved by the activation of the transcription factor called OREBP (also known as TonEBP or NFAT5) that specifically binds to the osmotic response element (ORE) or tonicity-responsive enhancer that enhances the transcription of these genes. Here we show that p38, a subgroup of the mitogen-activated kinases activated by hypertonic stress, and Fyn, a shrinkage-activated tyrosine kinase, are both involved in the hypertonic activation of OREBP/TonEBP. Inhibition of p38 by SB203580 or by the dominant negative p38 mutant partially blocked the hypertonic induction of ORE reporter (reporter gene regulated by ORE). Similarly, hypertonic activation of ORE reporter was partially blocked by pharmacological inhibition of Fyn or by a dominant negative Fyn and was attenuated in Fyn-deficient cells. Importantly, inhibiting p38 in Fyn-deficient cells almost completely abolished the hypertonic induction of ORE reporter activity, indicating that p38 and Fyn are the major signaling pathways for the hypertonic activation of OREBP/TonEBP. Further we show that the transactivation domain of OREBP/TonEBP is the target of p38- and Fyn-mediated hypertonic activation. These results indicate a dual control in regulating the expression of the osmoprotective genes in mammalian cells.	Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Technol Drug Discovery & Synth, Open Lab Chem Biol, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China; Toronto Gen Hosp, Dept Surg, Toronto, ON M5G 1L7, Canada; Univ Toronto, Toronto, ON M5G 1L7, Canada	University of Hong Kong; University of Hong Kong; University of Hong Kong; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto	Ko, BCB (corresponding author), Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China.		Ko, Chi-bun/ACH-7514-2022	Ko, Ben Chi Bun/0000-0003-2027-5899				Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abe JI, 2000, J BIOL CHEM, V275, P1739, DOI 10.1074/jbc.275.3.1739; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Dahl SC, 2001, AM J PHYSIOL-CELL PH, V280, pC248, DOI 10.1152/ajpcell.2001.280.2.C248; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; Ge BX, 2002, SCIENCE, V295, P1291, DOI 10.1126/science.1067289; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Haussinger D, 1999, BIOCHEM BIOPH RES CO, V255, P551, DOI 10.1006/bbrc.1998.9946; Ishino M, 2000, FEBS LETT, V474, P179, DOI 10.1016/S0014-5793(00)01597-0; Kapus A, 1999, J BIOL CHEM, V274, P8093, DOI 10.1074/jbc.274.12.8093; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Kultz D, 1997, J BIOL CHEM, V272, P13165, DOI 10.1074/jbc.272.20.13165; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Ohmiya R, 1995, MOL MICROBIOL, V18, P963, DOI 10.1111/j.1365-2958.1995.18050963.x; Pahlman AK, 2001, J BIOL CHEM, V276, P3555, DOI 10.1074/jbc.M007164200; Posas F, 2000, J BIOL CHEM, V275, P17249, DOI 10.1074/jbc.M910016199; Rep M, 2000, J BIOL CHEM, V275, P8290, DOI 10.1074/jbc.275.12.8290; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Sheikh-Hamad D, 1998, J BIOL CHEM, V273, P1832, DOI 10.1074/jbc.273.3.1832; SMARDO FL, 1992, AM J PHYSIOL, V262, pC776, DOI 10.1152/ajpcell.1992.262.3.C776; Szaszi K, 1997, J BIOL CHEM, V272, P16670, DOI 10.1074/jbc.272.26.16670; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMAS SM, 1995, NATURE, V376, P267, DOI 10.1038/376267a0; TWAMLEYSTEIN GM, 1993, P NATL ACAD SCI USA, V90, P7696, DOI 10.1073/pnas.90.16.7696; UCHIDA S, 1993, J CLIN INVEST, V91, P1604, DOI 10.1172/JCI116367; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; YAMAUCHI A, 1993, AM J PHYSIOL, V264, pF20, DOI 10.1152/ajprenal.1993.264.1.F20; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124	37	117	121	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46085	46092		10.1074/jbc.M208138200	http://dx.doi.org/10.1074/jbc.M208138200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359721	hybrid			2022-12-25	WOS:000179529300051
J	Roudier, N; Ripoche, P; Gane, P; Le Pennec, PY; Daniels, G; Cartron, JP; Bailly, P				Roudier, N; Ripoche, P; Gane, P; Le Pennec, PY; Daniels, G; Cartron, JP; Bailly, P			AQP3 deficiency in humans and the molecular basis of a novel blood group system, GIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AQUAPORIN WATER CHANNELS; KIDNEY COLLECTING DUCT; ATOMIC-STRUCTURE; GLYCEROL; EXPRESSION; PERMEABILITY; MEMBRANE; CLONING; CHIP; PROTEIN	AQP3 is a water and glycerol channel present on human erythrocytes and in various tissues. By protein and molecular biology analysis, two unrelated probands who developed alloantibodies to the high frequency antigen GIL were found to be AQP3-deficient. The defect is caused by homozygous mutation affecting the 5' donor splice site of intron 5 of the AQP3 gene. This mutation causes the skipping of exon 5 and generates a frameshift and premature stop codon. Functional studies by 90degrees light scattering using a stopped-flow spectrometer revealed the absence of facilitated glycerol transport across red cell membranes from the probands, but the water and urea transports were normal. Expression studies into COS-7 cells followed by flow cytometry analysis showed that only cells transfected with AQP3 cDNA strongly reacted with anti-GIL antibodies. These findings represent the first reported cases of AQP3 deficiency in humans and provide the molecular basis of a new blood group system, GIL, encoded by the AQP3 protein.	Inst Natl Transfus Sanguine, INSERM, U76, F-75015 Paris, France; Bristol Inst Transfus Sci, Bristol BS10 5ND, Avon, England	Institut National de la Sante et de la Recherche Medicale (Inserm)	Cartron, JP (corresponding author), Inst Natl Transfus Sanguine, INSERM, U76, 6 Rue Alexandre Cabanel, F-75015 Paris, France.	cartron@idf.inserm.fr						Agre P, 2002, J PHYSIOL-LONDON, V542, P3, DOI 10.1113/jphysiol.2002.020818; AGRE P, 1995, TRANSFUS CLIN BIOL, V2, P303, DOI 10.1016/S1246-7820(05)80096-5; CARLSEN A, 1976, ACTA PHYSIOL SCAND, V97, P501, DOI 10.1111/j.1748-1716.1976.tb10290.x; Daniels G L, 1998, Immunohematology, V14, P49; de Baey A, 2000, J EXP MED, V191, P743, DOI 10.1084/jem.191.4.743; DENKER BM, 1988, J BIOL CHEM, V263, P15634; ECHEVARRIA M, 1994, P NATL ACAD SCI USA, V91, P10997, DOI 10.1073/pnas.91.23.10997; FRIGERI A, 1995, P NATL ACAD SCI USA, V92, P4328, DOI 10.1073/pnas.92.10.4328; Hermand P, 2000, J BIOL CHEM, V275, P26002, DOI 10.1074/jbc.M002823200; Heymann JB, 1999, NEWS PHYSIOL SCI, V14, P187; INASE N, 1995, J BIOL CHEM, V270, P17913, DOI 10.1074/jbc.270.30.17913; ISHIBASHI K, 1995, GENOMICS, V27, P352, DOI 10.1006/geno.1995.1055; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; King LS, 2001, NEW ENGL J MED, V345, P175, DOI 10.1056/NEJM200107193450304; King LS, 2002, P NATL ACAD SCI USA, V99, P1059, DOI 10.1073/pnas.022626499; Kozono D, 2002, J CLIN INVEST, V109, P1395, DOI 10.1172/JCI200215851; LAIZE V, 1995, FEBS LETT, V373, P269, DOI 10.1016/0014-5793(95)01060-R; LIN ECC, 1977, ANNU REV BIOCHEM, V46, P765, DOI 10.1146/annurev.bi.46.070177.004001; LOZANO ME, 1993, TRENDS GENET, V9, P296, DOI 10.1016/0168-9525(93)90237-C; Ma TH, 2002, J BIOL CHEM, V277, P17147, DOI 10.1074/jbc.M200925200; MA TH, 1994, J BIOL CHEM, V269, P21845; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Mathai JC, 1996, J BIOL CHEM, V271, P1309, DOI 10.1074/jbc.271.3.1309; Nielsen S, 1997, AM J PHYSIOL-CELL PH, V273, pC1549, DOI 10.1152/ajpcell.1997.273.5.C1549; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; PRESTON GM, 1994, SCIENCE, V265, P1585, DOI 10.1126/science.7521540; Roudier N, 2002, J BIOL CHEM, V277, P7664, DOI 10.1074/jbc.M105411200; Roudier N, 1998, J BIOL CHEM, V273, P8407, DOI 10.1074/jbc.273.14.8407; SMITH BL, 1994, J CLIN INVEST, V94, P1043, DOI 10.1172/JCI117418; Steck T L, 1974, Methods Enzymol, V31, P172; Verkman AS, 2000, AM J PHYSIOL-RENAL, V278, pF13, DOI 10.1152/ajprenal.2000.278.1.F13; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200	33	67	72	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45854	45859		10.1074/jbc.M208999200	http://dx.doi.org/10.1074/jbc.M208999200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12239222	hybrid			2022-12-25	WOS:000179529300019
J	Song, JJ; Rhee, JG; Suntharalingam, M; Walsh, SA; Spitz, DR; Lee, YJ				Song, JJ; Rhee, JG; Suntharalingam, M; Walsh, SA; Spitz, DR; Lee, YJ			Role of glutaredoxin in metabolic oxidative stress - Glutaredoxin as a sensor of oxidative stress mediated by H2O2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN THIOLTRANSFERASE GLUTAREDOXIN; CEREBELLAR GRANULE NEURONS; DOPAMINE-INDUCED APOPTOSIS; KINASE 1 ASK1; NF-KAPPA-B; GLUCOSE DEPRIVATION; INTERACTING PROTEIN; SIGNAL-TRANSDUCTION; CELL-GROWTH; ACTIVATION	Epitope-tagged glutaredoxin (GRX) was utilized to determine the role of GRX in oxidative stress-induced signaling and cytotoxicity in glucose-deprived human cancer cells (MCF-7/ADR and DU-145). GRX-overexpressing cells demonstrated resistance to glucose deprivation-induced cytotoxicity and decreased activation of c-Jun N-terminal kinase (JNK1). Deletion mutants showed the C-terminal portion of apoptosis signal-regulating kinase 1 (ASK1) bound GRX, and glucose deprivation disrupted binding. Treatment with L-buthionine-(S,R)-sulfoximine reduced glutathione content by 99% and prevented glucose deprivation-induced dissociation of GRX from ASK1. A thiol antioxidant, N-acetyl-L-cysteine, or overexpression of an H2O2 scavenger, catalase, inhibited glucose deprivation-induced dissociation of GPX from ASK1. GRX active site cysteine residues (Cys(22) and Cys(25)) were required for dissociation of GPX from ASK1 during glucose deprivation. Kinase assays revealed that SEK1 and JNK1 were regulated in an ASK1-dependent fashion during glucose deprivation. Overexpression of GRX or catalase inhibited activation of ASK1-SEK1-JNK1 signaling during glucose deprivation. These results demonstrate that GRX is a negative regulator of ASK1 and dissociation of GRX from ASK1 activates ASK1-SEK1-JNK1 signaling leading to cytotoxicity during glucose deprivation. These results support the hypothesis that the GRX-ASK1 interaction is redox sensitive and regulated in a glutathione-dependent fashion by H2O2.	Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, Pittsburgh, PA 15232 USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15232 USA; Univ Maryland, Sch Med, Dept Radiat Oncol, Baltimore, MD 21201 USA; Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA 52242 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University System of Maryland; University of Maryland Baltimore; University of Iowa	Lee, YJ (corresponding author), Univ Pittsburgh, Hillman Canc Ctr, Dept Surg, Rm G-5A,5117 Centre Ave, Pittsburgh, PA 15232 USA.	leeyj@msx.upme.edu		Spitz, Douglas/0000-0002-1254-8765; Song, Jae/0000-0001-8183-9550	NATIONAL CANCER INSTITUTE [P01CA066081] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051469] Funding Source: NIH RePORTER; NCI NIH HHS [CA48000, CA66081] Funding Source: Medline; NHLBI NIH HHS [HL51469] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson ME, 1985, HDB METHODS OXYGEN R, P317; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Barrett WC, 1999, BIOCHEMISTRY-US, V38, P6699, DOI 10.1021/bi990240v; Blackburn RV, 1999, FREE RADICAL BIO MED, V26, P419, DOI 10.1016/S0891-5849(98)00217-2; Boveris A., 1982, SUPEROXIDE DISMUTASE, VII, P15, DOI DOI 10.1007/978-1-4615-9035-4_5; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CHAI YC, 1994, ARCH BIOCHEM BIOPHYS, V310, P273, DOI 10.1006/abbi.1994.1167; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Ciriolo MR, 1997, J BIOL CHEM, V272, P2700, DOI 10.1074/jbc.272.5.2700; Cohen G, 1997, P NATL ACAD SCI USA, V94, P4890, DOI 10.1073/pnas.94.10.4890; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Hoeflich KP, 1999, ONCOGENE, V18, P5814, DOI 10.1038/sj.onc.1202975; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Jacobson MD, 1996, TRENDS BIOCHEM SCI, V21, P83, DOI 10.1016/0968-0004(96)20008-8; LAVELLE F, 1973, BIOCHEM BIOPH RES CO, V55, P350, DOI 10.1016/0006-291X(73)91094-2; Lee YJ, 1998, J BIOL CHEM, V273, P5294, DOI 10.1074/jbc.273.9.5294; Lee YJ, 2001, J CELL SCI, V114, P677; Lee YJ, 2000, FREE RADICAL BIO MED, V28, P575, DOI 10.1016/S0891-5849(99)00267-1; LEHNINGER AL, 1976, BIOCHEMISTRY-US, P456; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Liu H, 2000, MOL CELL BIOL, V20, P2198, DOI 10.1128/MCB.20.6.2198-2208.2000; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; Maundrell K, 1997, J BIOL CHEM, V272, P25238, DOI 10.1074/jbc.272.40.25238; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; NATH KA, 1995, AM J PHYSIOL-CELL PH, V268, pC227, DOI 10.1152/ajpcell.1995.268.1.C227; Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X; PADILLA CA, 1995, EUR J BIOCHEM, V227, P27, DOI 10.1111/j.1432-1033.1995.tb20356.x; Powis G, 2000, FREE RADICAL BIO MED, V29, P312, DOI 10.1016/S0891-5849(00)00313-0; POWIS G, 1995, PHARMACOL THERAPEUT, V68, P149, DOI 10.1016/0163-7258(95)02004-7; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Schendel SL, 1999, J BIOL CHEM, V274, P21932, DOI 10.1074/jbc.274.31.21932; Song SH, 2000, FREE RADICAL BIO MED, V29, P61, DOI 10.1016/S0891-5849(00)00326-9; Spitz DR, 2000, ANN NY ACAD SCI, V899, P349, DOI 10.1111/j.1749-6632.2000.tb06199.x; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; TUTTLE SW, 1992, INT J RADIAT ONCOL, V22, P671, DOI 10.1016/0360-3016(92)90500-H; Wells W W, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P149; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yang YW, 1998, BIOCHEMISTRY-US, V37, P17145, DOI 10.1021/bi9806504; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	52	214	226	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46566	46575		10.1074/jbc.M206826200	http://dx.doi.org/10.1074/jbc.M206826200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244106	hybrid			2022-12-25	WOS:000179529300112
J	Gilot, D; Loyer, P; Corlu, A; Glaise, D; Lagadic-Gossmann, D; Atfi, A; Morel, F; Ichijo, H; Guguen-Guillouzo, C				Gilot, D; Loyer, P; Corlu, A; Glaise, D; Lagadic-Gossmann, D; Atfi, A; Morel, F; Ichijo, H; Guguen-Guillouzo, C			Liver protection from apoptosis requires both blockage of initiator caspase activities and inhibition of ASK1/JNK pathway via glutathione S-transferase regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED RAT HEPATOCYTES; CELL-DEATH; DIMETHYL-SULFOXIDE; DRUG-RESISTANCE; BCL-XL; NECROSIS; KINASE-1; INDUCTION; CANCER; PROTEINS	Hepatoprotection mediated by free radical scavenging molecules such as dimethyl sulfoxide (Me2SO) arose the question as to whether this effect involved one or several anti-apoptotic signals. Here, using primary cultures of rat hepatocytes and in vivo thioacetamide-induced liver failure, we showed that Me2SO failed to prevent any cleavage of initiator caspase-8 and -9 but constantly inhibited procaspase-3 maturation and apoptosis execution, pointing to an efficient inhibition of cleaved initiator caspase activities. Evidence was recently provided that apoptosis might require both caspase and ASK1/JNK-p38 activities. We demonstrated that this kinase pathway was strongly inhibited in the presence of Me2SO whereas overexpression of ASK1 was able to restore caspase-3 activity and apoptosis. Interestingly, we also found that GST M1/2 and GST A1/2 dropped under apoptotic conditions; furthermore transfection of GST M1, A1, or P1 to cells overexpressing ASK1, abolished caspase-3 activity and restored viability. This role of GSTs was further assessed by showing that their high expression level was tightly associated with inhibition of ASK1 activity in Me2SO-protected hepatocytes. Together, these results demonstrate that Me2SO-mediated hepatoprotection involves a dual inhibition of cleaved initiator caspase and ASK1/JNK-p38 activities. Furthermore, in highlighting the control of apoptosis by GSTs, these data provide new insights for analyzing the complex mechanisms of hepatoprotection.	Hop Pontchaillou, INSERM, U522, F-35033 Rennes, France; Fac Pharm, INSERM, U456, F-35049 Rennes, France; Hop St Antoine, INSERM, U482, F-75571 Paris, France; Tokyo Med & Dent Univ, Grad Sch, Lab Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan	CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Tokyo Medical & Dental University (TMDU)	Gilot, D (corresponding author), Hop Pontchaillou, INSERM, U522, Ave Bataille Flandre Dunkerque, F-35033 Rennes, France.		LOYER, Pascal/K-1838-2019; Corlu, Anne/U-8030-2018; LAGADIC-GOSSMANN, Dominique/I-5079-2015	Corlu, Anne/0000-0002-7370-0564; LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; Ichijo, Hidenori/0000-0002-5005-6438; LOYER, PASCAL/0000-0002-5656-2673				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Bailly-Maitre B, 2001, CELL DEATH DIFFER, V8, P279, DOI 10.1038/sj.cdd.4400815; Bour ES, 1996, AM J PATHOL, V148, P485; Bruck R, 1999, J HEPATOL, V31, P27, DOI 10.1016/S0168-8278(99)80160-3; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chen J, 2001, P NATL ACAD SCI USA, V98, P7783, DOI 10.1073/pnas.141224398; Cho SG, 2001, J BIOL CHEM, V276, P12749, DOI 10.1074/jbc.M005561200; CZAJA MJ, 1995, GASTROENTEROLOGY, V108, P1849, DOI 10.1016/0016-5085(95)90149-3; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Desmots F, 2002, J BIOL CHEM, V277, P17892, DOI 10.1074/jbc.M112351200; Deveraux QL, 1999, EMBO J, V18, P5242, DOI 10.1093/emboj/18.19.5242; DORION S, 2002, J BIOL CHEM, V19, P19; Feldmann G, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80491-6; Garrido C, 2001, BIOCHEM BIOPH RES CO, V286, P433, DOI 10.1006/bbrc.2001.5427; Gilot D, 2002, J GENE MED, V4, P415, DOI 10.1002/jgm.279; Gotoh Y, 1998, J BIOL CHEM, V273, P17477, DOI 10.1074/jbc.273.28.17477; Guguen-Guillouzo C., 2002, CULTURE EPITHELIAL C, V2nd ed., P337; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES PC, 1991, GUT, V32, P1546, DOI 10.1136/gut.32.12.1546; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; ISOM HC, 1985, P NATL ACAD SCI USA, V82, P3252, DOI 10.1073/pnas.82.10.3252; Kaplowitz N, 2002, SEMIN LIVER DIS, V22, P137, DOI 10.1055/s-2002-30100; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; Kim YM, 1997, J BIOL CHEM, V272, P31138, DOI 10.1074/jbc.272.49.31138; Kovalovich K, 2001, J BIOL CHEM, V276, P26605, DOI 10.1074/jbc.M100740200; Kroemer G, 1998, ANNU REV PHYSIOL, V60, P619, DOI 10.1146/annurev.physiol.60.1.619; Lacronique V, 1996, NAT MED, V2, P80, DOI 10.1038/nm0196-80; LEDDACOLUMBANO GM, 1991, AM J PATHOL, V139, P1099; Li JR, 1997, BIOCHEM BIOPH RES CO, V240, P419, DOI 10.1006/bbrc.1997.7672; Li JR, 1999, AM J PHYSIOL-GASTR L, V276, pG1069, DOI 10.1152/ajpgi.1999.276.5.G1069; Lind RC, 1999, TOXICOL PATHOL, V27, P342, DOI 10.1177/019262339902700310; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; Liu HL, 2002, HEPATOLOGY, V35, P772, DOI 10.1053/jhep.2002.32534; Mannick JB, 1999, SCIENCE, V284, P651, DOI 10.1126/science.284.5414.651; Matsuzawa A, 2001, J BIOCHEM-TOKYO, V130, P1; MOREL F, 1989, FEBS LETT, V258, P99, DOI 10.1016/0014-5793(89)81624-2; Morita K, 2001, EMBO J, V20, P6028, DOI 10.1093/emboj/20.21.6028; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nishitoh H, 2002, GENE DEV, V16, P1345, DOI 10.1101/gad.992302; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; PARK YJ, 1988, TOXICOLOGY, V52, P165, DOI 10.1016/0300-483X(88)90202-8; Poupon R, 2000, J HEPATOL, V32, P129, DOI 10.1016/S0168-8278(00)80421-3; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Stennicke HR, 1997, J BIOL CHEM, V272, P25719, DOI 10.1074/jbc.272.41.25719; TEW KD, 1994, CANCER RES, V54, P4313; Tobiume K, 2002, J CELL PHYSIOL, V191, P95, DOI 10.1002/jcp.10080; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; TSUCHIDA S, 1989, CANCER RES, V49, P5225; VANDENBERGHE Y, 1990, MOL PHARMACOL, V37, P372; Wang TH, 1999, J BIOL CHEM, V274, P8208, DOI 10.1074/jbc.274.12.8208; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zou XH, 2001, MOL CELL BIOL, V21, P4818, DOI 10.1128/MCB.21.14.4818-4828.2001	53	93	102	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49220	49229		10.1074/jbc.M207325200	http://dx.doi.org/10.1074/jbc.M207325200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12370186	hybrid			2022-12-25	WOS:000180028900016
J	Wiberg, C; Heinegard, D; Wenglen, C; Timpl, R; Morgelin, M				Wiberg, C; Heinegard, D; Wenglen, C; Timpl, R; Morgelin, M			Biglycan organizes collagen VI into hexagonal-like networks resembling tissue structures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL PROTEOGLYCAN; BETHLEM MYOPATHY; ARTICULAR-CARTILAGE; COLLOIDAL GOLD; MESSENGER-RNA; CORE PROTEINS; DECORIN; BINDING; EXPRESSION; CHONDROADHERIN	The ability of the leucine-rich repeat (LRR) proteins biglycan, decorin, and chondroadherin to interact with collagen VI and influence its assembly to supramolecular structures was studied by electron microscopy and surface plasmon resonance measurements in the BIA-core 2000 system. Biglyean showed a unique ability to organize collagen VI into extensive hexagonal-like networks over a time period of only a few minutes. Only the intact molecule, substituted with two dermatan sulfate chains, had this capacity. Intact decorin, with one dermatan sulfate chain only, was considerably less efficient, and aggregates of organized collagen VI were found only after several hours. Chondroadherin without glycosaminoglycan substitutions did not induce any ordered collagen VI organization. However, all three related LRR proteins were shown to interact with collagen VI using electron microscopy and surface plasmon resonance. Biglycan and decorin were exclusively found close to the N-terminal parts of the collagen VI tetramers, whereas chondroadherin was shown to bind close to both the N- and C-terminal parts of collagen VI. In the formed hexagonal networks, biglycan was localized to the intra-network junctions of the collagen VI filaments. This was demonstrated by electron microscopy after negative staining of gold-labeled biglyean in aggregation experiments with collagen VI.	Lund Univ, BMC, Dept Cell & Mol Biol, S-22184 Lund, Sweden; Max Planck Inst Biochem, D-82152 Martinsried, Germany	Lund University; Max Planck Society	Morgelin, M (corresponding author), Lund Univ, BMC, Dept Cell & Mol Biol, S-22184 Lund, Sweden.	matthias.morgelin@medkem.lu.se						Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; BASCHONG W, 1990, J ELECTRON MICR TECH, V14, P313, DOI 10.1002/jemt.1060140405; BASCHONG W, 1985, HISTOCHEMISTRY, V83, P409, DOI 10.1007/BF00509201; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BIDANSET DJ, 1992, J BIOL CHEM, V267, P5250; Blaschke UK, 1996, J BIOL CHEM, V271, P30347, DOI 10.1074/jbc.271.48.30347; Bonaldo P, 1998, HUM MOL GENET, V7, P2135, DOI 10.1093/hmg/7.13.2135; BONALDO P, 1990, BIOCHEMISTRY-US, V29, P1245, DOI 10.1021/bi00457a021; BRUNS RR, 1986, J CELL BIOL, V103, P393, DOI 10.1083/jcb.103.2.393; Burg MA, 1996, J BIOL CHEM, V271, P26110, DOI 10.1074/jbc.271.42.26110; Chakravarti S, 1998, J CELL BIOL, V141, P1277, DOI 10.1083/jcb.141.5.1277; CHOI HU, 1989, J BIOL CHEM, V264, P2876; CHU ML, 1987, EUR J BIOCHEM, V168, P309, DOI 10.1111/j.1432-1033.1987.tb13422.x; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; DAY AA, 1987, BIOCHEM J, V248, P801, DOI 10.1042/bj2480801; ENGEL J, 1985, ANN NY ACAD SCI, V460, P25, DOI 10.1111/j.1749-6632.1985.tb51154.x; ENGVALL E, 1986, J CELL BIOL, V102, P703, DOI 10.1083/jcb.102.3.703; FISHER LW, 1989, J BIOL CHEM, V264, P4571; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HEDBOM E, 1993, J BIOL CHEM, V268, P27307; HEINEGARD D, 1985, BIOCHEM J, V230, P181, DOI 10.1042/bj2300181; Hocking AM, 1998, MATRIX BIOL, V17, P1; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; Kielty Cay M., 1993, P103; Krishnan P, 1999, J BIOL CHEM, V274, P10945, DOI 10.1074/jbc.274.16.10945; Kuo HJ, 1997, J BIOL CHEM, V272, P26522, DOI 10.1074/jbc.272.42.26522; Lamande SR, 1999, J BIOL CHEM, V274, P21817, DOI 10.1074/jbc.274.31.21817; Lamande SR, 1998, HUM MOL GENET, V7, P981, DOI 10.1093/hmg/7.6.981; Landgren C, 1998, GENOMICS, V47, P84, DOI 10.1006/geno.1997.5085; LARSSON T, 1991, J BIOL CHEM, V266, P20428; Mansson B, 2001, J BIOL CHEM, V276, P32883, DOI 10.1074/jbc.M101680200; MIOSGE N, 1994, HISTOCHEM J, V26, P939; NEAME PJ, 1994, J BIOL CHEM, V269, P21547; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; OONO T, 1993, J INVEST DERMATOL, V100, P329, DOI 10.1111/1523-1747.ep12470022; PFAFF M, 1993, EXP CELL RES, V206, P167, DOI 10.1006/excr.1993.1134; POOLE CA, 1988, J CELL SCI, V90, P635; Pullig O, 1999, OSTEOARTHR CARTILAGE, V7, P191, DOI 10.1053/joca.1998.0208; RADA JA, 1993, EXP EYE RES, V56, P635, DOI 10.1006/exer.1993.1081; Sasaki T, 2000, FASEB J, V14, P761, DOI 10.1096/fasebj.14.5.761; SPISSINGER T, 1995, MATRIX BIOL, V14, P499, DOI 10.1016/0945-053X(95)90007-1; Svensson L, 1999, J BIOL CHEM, V274, P9636, DOI 10.1074/jbc.274.14.9636; SVENSSON L, 1995, J BIOL CHEM, V270, P20712, DOI 10.1074/jbc.270.35.20712; TILLET E, 1994, EUR J BIOCHEM, V221, P177, DOI 10.1111/j.1432-1033.1994.tb18727.x; TIMPL R, 1994, EXTRACELLULAR MATRIX, P208; Timpl R., 1987, STRUCTURE FUNCTION C, P105, DOI [10.1016/B978--0--12--481280-2.50008---8, DOI 10.1016/B978--0--12--481280-2.50008---8]; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; VONDERMARK H, 1984, EUR J BIOCHEM, V142, P493; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200	51	134	136	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49120	49126		10.1074/jbc.M206891200	http://dx.doi.org/10.1074/jbc.M206891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12354766	hybrid			2022-12-25	WOS:000180028900005
J	Hou, ST; Xie, XQ; Baggley, A; Park, DS; Chen, G; Walker, T				Hou, ST; Xie, XQ; Baggley, A; Park, DS; Chen, G; Walker, T			Activation of the Rb/E2F1 pathway by the nonproliferative p38 MAPK during fAs (APO1/CD95)-mediated neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR E2F1; CYCLIN-DEPENDENT KINASES; SIGNAL-TRANSDUCTION-CASCADES; TRANSIENT FOREBRAIN ISCHEMIA; JUN NH2-TERMINAL KINASE; N-TERMINAL KINASE; PROTEIN-KINASE; CELL-DEATH; CORTICAL-NEURONS; RAT-BRAIN	Aberrant activation of the Rb/E2F1 pathway in cycling cells, in response to mitogenic or nonmitogenic stress signals, leads to apoptosis through hyperphosphorylation of Rb. To test whether in postmitotic neurons the Rb/E2F1 pathway can be activated by the nonmitogenic stress signaling, we examined the role of the p38 stress-activated protein kinase (SAPK) in regulating Rb phosphorylation in response to Fas (CD95/APO1)-mediated apoptosis of cultured cerebellar granule neurons (CGNs). Anti-Fas antibody induced a dramatic and early activation of p38. Activated p38 was correlated with the induction of hyperphosphorylation of both endogenous and exogenous Rb. The p38-selective inhibitor, SB203580, attenuated such an increase in pRb phosphorylation and significantly protected CGNs from Fas-induced apoptosis. The cyclin-dependent kinase-mediated Rb phosphorylation played a lesser role in this neuronal death paradigm, since cyclin-dependent kinase inhibitors, such as olomoucine, roscovitine, and flavopiridol, did not significantly prevent anti-Fas antibody-evoked neuronal apoptosis. Hyperphosphorylation of Rb by p38 SAPK resulted in the release of Rb-bound E2F1. Increased E2F1 modulated neuronal apoptosis, since E2Fl-/- CGNs were significantly less susceptible to Fas-mediated apoptosis in comparison with the wildtype CGNs. Taken together, these studies demonstrate that neuronal Rb/E2F1 is modulated by the nonproliferative p38 SAPK in Fas-mediated neuronal apoptosis.	Natl Res Council Canada, Inst Biol Sci, Expt Stroke Grp, Ottawa, ON K1A 0R6, Canada; Univ Ottawa, Neurosci Res Inst, Ottawa, ON K1H 8M5, Canada	National Research Council Canada; University of Ottawa	Hou, ST (corresponding author), Natl Res Council Canada, Inst Biol Sci, Expt Stroke Grp, 1500 Montreal Rd, Ottawa, ON K1A 0R6, Canada.		Hou, Sheng Tao/AAM-7756-2020; Hou, Sheng Tao/O-3202-2018	Hou, Sheng Tao/0000-0001-9736-342X; Park, David/0000-0002-4490-3784				Adamchak DJ, 2001, SOC SCI J, V38, P1, DOI 10.1016/S0362-3319(00)00107-5; Azuma-Hara N, 1999, EXP CELL RES, V251, P442, DOI 10.1006/excr.1999.4593; Barone FC, 2001, MED RES REV, V21, P129, DOI 10.1002/1098-1128(200103)21:2<129::AID-MED1003>3.0.CO;2-H; Blattner C, 1999, MOL CELL BIOL, V19, P3704; Chang HY, 1998, SCIENCE, V281, P1860, DOI 10.1126/science.281.5384.1860; Cheema ZF, 1999, J NEUROSCI, V19, P1754; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dougherty CJ, 2002, BIOCHEM J, V362, P561, DOI 10.1042/0264-6021:3620561; English JM, 2002, TRENDS PHARMACOL SCI, V23, P40, DOI 10.1016/S0165-6147(00)01865-4; Felderhoff-Mueser U, 2000, BRAIN PATHOL, V10, P17; Ferguson KL, 2000, J BIOL CHEM, V275, P33593, DOI 10.1074/jbc.M004879200; Gendron TF, 2001, J NEUROCHEM, V78, P316, DOI 10.1046/j.1471-4159.2001.00423.x; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Giovanni A, 1999, J BIOL CHEM, V274, P19011, DOI 10.1074/jbc.274.27.19011; Goillot E, 1997, P NATL ACAD SCI USA, V94, P3302, DOI 10.1073/pnas.94.7.3302; Harper SJ, 2001, CELL SIGNAL, V13, P299, DOI 10.1016/S0898-6568(01)00148-6; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; Hou ST, 2001, NEUROSCI LETT, V306, P153, DOI 10.1016/S0304-3940(01)01909-7; Hou ST, 2001, J NEUROCHEM, V78, P287, DOI 10.1046/j.1471-4159.2001.00402.x; Hou ST, 2000, J NEUROCHEM, V75, P91, DOI 10.1046/j.1471-4159.2000.0750091.x; Hsieh JK, 1997, GENE DEV, V11, P1840, DOI 10.1101/gad.11.14.1840; Jin KL, 2002, J NEUROCHEM, V80, P119, DOI 10.1046/j.0022-3042.2001.00678.x; Juo P, 1997, MOL CELL BIOL, V17, P24, DOI 10.1128/MCB.17.1.24; Kawasaki H, 1997, J BIOL CHEM, V272, P18518, DOI 10.1074/jbc.272.30.18518; Kumar S, 1997, BIOCHEM BIOPH RES CO, V235, P533, DOI 10.1006/bbrc.1997.6849; Kummer JL, 1997, J BIOL CHEM, V272, P20490, DOI 10.1074/jbc.272.33.20490; Lamboley C, 2002, J HEPATOL, V36, P385, DOI 10.1016/S0168-8278(01)00284-7; Lauricella M, 2001, FEBS LETT, V499, P191, DOI 10.1016/S0014-5793(01)02553-4; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lee JC, 2000, IMMUNOPHARMACOLOGY, V47, P185, DOI 10.1016/S0162-3109(00)00206-X; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Liu ZG, 1996, NATURE, V384, P273, DOI 10.1038/384273a0; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MacManus JP, 1999, NEUROREPORT, V10, P2711, DOI 10.1097/00001756-199909090-00004; Martin-Villalba A, 2001, CELL DEATH DIFFER, V8, P679, DOI 10.1038/sj.cdd.4400882; Martin-Villalba A, 1999, J NEUROSCI, V19, P3809; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; Mehmet H, 2001, CELL DEATH DIFFER, V8, P659, DOI 10.1038/sj.cdd.4400899; Mielke K, 2000, PROG NEUROBIOL, V61, P45, DOI 10.1016/S0301-0082(99)00042-8; Nagata S, 1998, INTERNAL MED, V37, P179, DOI 10.2169/internalmedicine.37.179; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nozaki K, 2001, MOL NEUROBIOL, V23, P1, DOI 10.1385/MN:23:1:01; O'Hare MJ, 2000, J BIOL CHEM, V275, P25358, DOI 10.1074/jbc.M001725200; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; Rosenbaum DM, 2000, J NEUROSCI RES, V61, P686, DOI 10.1002/1097-4547(20000915)61:6<686::AID-JNR12>3.0.CO;2-7; Roulston A, 1998, J BIOL CHEM, V273, P10232, DOI 10.1074/jbc.273.17.10232; Schulze-Osthoff K, 1998, EUR J BIOCHEM, V254, P439, DOI 10.1046/j.1432-1327.1998.2540439.x; Shklyaev SS, 2001, THYROID, V11, P629, DOI 10.1089/105072501750362691; Sugino T, 2000, J NEUROSCI, V20, P4506, DOI 10.1523/JNEUROSCI.20-12-04506.2000; Takagi Y, 2000, NEUROSCI LETT, V294, P117, DOI 10.1016/S0304-3940(00)01552-4; Tan ZQ, 2001, NEUROREPORT, V12, P1979, DOI 10.1097/00001756-200107030-00040; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Tu YH, 1998, J CEREBR BLOOD F MET, V18, P658, DOI 10.1097/00004647-199806000-00008; Verdaguer E, 2002, NEUROREPORT, V13, P413, DOI 10.1097/00001756-200203250-00010; Wang FH, 2002, J CEREBR BLOOD F MET, V22, P171, DOI 10.1097/00004647-200202000-00005; Wang S, 1999, EMBO J, V18, P1559, DOI 10.1093/emboj/18.6.1559; Waring P, 2001, IMMUNOL CELL BIOL, V79, P264, DOI 10.1046/j.1440-1711.2001.01008.x; Willaime S, 2001, EUR J NEUROSCI, V13, P2037, DOI 10.1046/j.0953-816x.2001.01581.x; Yang XL, 1997, CELL, V89, P1067, DOI 10.1016/S0092-8674(00)80294-9; Yi FH, 2000, J NEUROIMMUNOL, V109, P211, DOI 10.1016/S0165-5728(00)00288-5; Young PR, 1997, J BIOL CHEM, V272, P12116, DOI 10.1074/jbc.272.18.12116	65	60	62	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48764	48770		10.1074/jbc.M206336200	http://dx.doi.org/10.1074/jbc.M206336200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351630	hybrid			2022-12-25	WOS:000179789600103
J	Pandak, WM; Ren, SL; Marques, D; Hall, E; Redford, K; Mallonee, D; Bohdan, P; Heuman, D; Gil, G; Hylemon, P				Pandak, WM; Ren, SL; Marques, D; Hall, E; Redford, K; Mallonee, D; Bohdan, P; Heuman, D; Gil, G; Hylemon, P			Transport of cholesterol into mitochondria is rate-limiting for bile acid synthesis via the alternative pathway in primary rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE REGULATORY PROTEIN; STEROL 27-HYDROXYLASE; MESSENGER-RNA; TRANSCRIPTIONAL ACTIVITY; EXPRESSION; CELLS; GENE; BIOSYNTHESIS; ELIMINATION; 7-ALPHA-HYDROXYLASE	Bile acid synthesis occurs mainly via two pathways: the "classic" pathway, initiated by microsomal choles. terol 7alpha-hydroxylase (CYP7A1), and an "alternative" (acidic) pathway, initiated by sterol 27-hydroxylase (CYP27). CYP27 is located in the inner mitochondrial membrane, where cholesterol content is very low. We hypothesized that cholesterol transport into mitochondria may be rate-limiting for bile acid synthesis via the "alternative" pathway. Overexpression of the gene encoding steroidogenic acute regulatory (StAR) protein, a known mitochondrial cholesterol transport protein, led to a 5-fold increase in bile acid synthesis. An increase in StAR protein coincided with an increase in bile acid synthesis. CYP27 overexpression increased bile acid synthesis by <2-fold. The rates of bile acid synthesis following a combination of StAR plus CYP27 overexpression were similar to those obtained with StAR alone. TLC analysis of C-14-labeled bile acids synthesized in cells overexpressing StAR showed a 5-fold increase in muricholic acid; in chloroform-extractable products, a dramatic increase was seen in bile acid biosynthesis intermediates (27- and 7,27-hydroxycholesterol). High-performance liquid chromatography analysis showed that 27-hydroxycholesterol accumulated in the mitochondria of StAR-overexpressing cells only. These findings suggest that cholesterol delivery to the inner mitochondrial membrane is the predominant rate-determining step for bile acid synthesis via the alternative pathway.	Virginia Commonwealth Univ, Med Coll Virginia, Richmond, VA 23298 USA; Vet Affairs Med Ctr, Dept Med, Richmond, VA 23298 USA; Vet Affairs Med Ctr, Dept Microbiol & Immunol, Richmond, VA 23298 USA; Vet Affairs Med Ctr, Dept Biochem, Richmond, VA 23298 USA	Virginia Commonwealth University; Hunter Holmes McGuire Veterinary Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Hunter Holmes McGuire Veterinary Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Hunter Holmes McGuire Veterinary Affairs Medical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Pandak, WM (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Campus,POB 980711, Richmond, VA 23298 USA.		Eckhardt, Erik/G-1567-2010		NIDDK NIH HHS [P01 DK38030] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038030] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AXELSON M, 1989, J LIPID RES, V30, P1877; Babiker A, 1997, J BIOL CHEM, V272, P26253, DOI 10.1074/jbc.272.42.26253; Bissell D M, 1980, Ann N Y Acad Sci, V349, P85, DOI 10.1111/j.1749-6632.1980.tb29518.x; BJORKHEM I, 1994, P NATL ACAD SCI USA, V91, P8592, DOI 10.1073/pnas.91.18.8592; CHIANG JYL, 1998, FRONT BIOSCI, V3, P176; Christenson LK, 1998, J BIOL CHEM, V273, P30729, DOI 10.1074/jbc.273.46.30729; Christenson LK, 2000, BBA-MOL CELL BIOL L, V1529, P175, DOI 10.1016/S1388-1981(00)00147-5; Duane WC, 1999, J LIPID RES, V40, P1194; FOLCH J, 1957, J BIOL CHEM, V226, P497; Hall E, 2001, AM J PHYSIOL-GASTR L, V281, pG293, DOI 10.1152/ajpgi.2001.281.1.G293; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; HYLEMON PB, 2001, LIVER BIOL PATHOBIOL, P231; Liu J, 1996, J ENDOCRINOL, V150, P43, DOI 10.1677/joe.0.1500043; Lund E, 1996, ARTERIOSCL THROM VAS, V16, P208, DOI 10.1161/01.ATV.16.2.208; PANDAK WM, 1991, J BIOL CHEM, V266, P3416; Pandak WM, 2001, GASTROENTEROLOGY, V120, P1801, DOI 10.1053/gast.2001.24833; PANDAK WM, 1990, J LIPID RES, V31, P79; Ponting CP, 1999, TRENDS BIOCHEM SCI, V24, P130, DOI 10.1016/S0968-0004(99)01362-6; PRINCEN HMG, 1991, BIOCHEM J, V275, P501, DOI 10.1042/bj2750501; Schwarz M, 1996, J BIOL CHEM, V271, P18024, DOI 10.1074/jbc.271.30.18017; Soccio RE, 2002, P NATL ACAD SCI USA, V99, P6943, DOI 10.1073/pnas.052143799; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; Stravitz RT, 1996, J STEROID BIOCHEM, V57, P337, DOI 10.1016/0960-0760(95)00282-0; SUGAWARA T, 1995, BIOCHEMISTRY-US, V34, P12506, DOI 10.1021/bi00039a004; SUGAWARA T, 1995, P NATL ACAD SCI USA, V92, P4778, DOI 10.1073/pnas.92.11.4778; TURLEY SD, 1988, LIVER BIOL PATHOBIOL, P617; Vlahcevic ZR, 1999, GASTROENTEROL CLIN N, V28, P1, DOI 10.1016/S0889-8553(05)70041-8; Vlahcevic ZR, 1996, AM J PHYSIOL-GASTR L, V270, pG646, DOI 10.1152/ajpgi.1996.270.4.G646	28	90	98	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48158	48164		10.1074/jbc.M205244200	http://dx.doi.org/10.1074/jbc.M205244200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368294	hybrid			2022-12-25	WOS:000179789600026
J	Sakai, H; Urano, T; Ookata, K; Kim, MH; Hirai, Y; Saito, M; Nojima, Y; Ishikawa, F				Sakai, H; Urano, T; Ookata, K; Kim, MH; Hirai, Y; Saito, M; Nojima, Y; Ishikawa, F			MBD3 and HDAC1, two components of the NuRD complex, are localized at aurora-A-positive centrosomes in M phase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; HISTONE DEACETYLASE; PROTEIN-KINASE; CHROMOSOME SEGREGATION; DNA METHYLATION; P53; BINDING; ACETYLTRANSFERASES; PHOSPHORYLATION; ACETYLATION	MBD3, a component of the histone deacetylase NuRD complex, contains the methyl-CpG-binding domain (MBD), yet does not possess appreciable mCpG-specific binding activity. The functional significance of MBD3 in the NuRD complex remains enigmatic, partly because of the limited availability of biochemical approaches, such as immunoprecipitation, to analyze MBD3. In this study, we stably expressed the FIAG-tagged version of MBD3 in HeLa cells. We found that MBD3-FLAG was incorporated into the NuRD complex, and the MBD3-FLAG-containing NuRD complex was efficiently immunoprecipitated by anti-FLAG antibodies. By exploiting this system, we found that MBD3 is phosphorylated in vivo in the late G, and early M phases. Moreover, we found that Aurora-A, a serine/threonine kinase active specifically in the late G(2) and early M phases, phosphorylates MBD3 in vitro, physically associates with MBD3 in vivo, and co-localizes with MBD3 at the centrosomes in the early M phase. Interestingly, HDAC1 is distributed at the centrosomes in a manner similar to MBD3. These results suggest the highly dynamic nature of the temporal and spatial distributions, as well as the biochemical modification, of the NuRD complex in M phase, probably through an interaction with kinases, including Aurora-A. These observations will contribute significantly to the elucidation of the yet-uncharacterized cell cycle-controlled functions of the NuRD complex.	Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Gunma Univ, Sch Med, Dept Internal Med 3, Maebashi, Gumma 3718511, Japan; Nagoya Univ, Sch Med, Dept Biochem 2, Showa Ku, Nagoya, Aichi 4660065, Japan; Kyoto Univ, Grad Sch Biostudies, Sakyo Ku, Kyoto 6068502, Japan	Tokyo Institute of Technology; Gunma University; Nagoya University; Kyoto University	Ishikawa, F (corresponding author), Tokyo Inst Technol, Grad Sch Biosci & Biotechnol, Midori Ku, 4259 Nagatsuta, Yokohama, Kanagawa 2268501, Japan.	fishikaw@lif.kyoto-u.ac.jp	Ishikawa, Fuyuki/AAU-4056-2021	Ishikawa, Fuyuki/0000-0002-5580-2305; Urano, Takeshi/0000-0003-3383-3554				Bellacosa A, 1999, P NATL ACAD SCI USA, V96, P3969, DOI 10.1073/pnas.96.7.3969; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bischoff JR, 1999, TRENDS CELL BIOL, V9, P454, DOI 10.1016/S0962-8924(99)01658-X; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Cai R, 2001, BIOCHEM BIOPH RES CO, V283, P445, DOI 10.1006/bbrc.2001.4786; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Clarke AS, 1999, MOL CELL BIOL, V19, P2515; Crosio C, 2002, MOL CELL BIOL, V22, P874, DOI 10.1128/MCB.22.3.874-885.2002; Feng Q, 2001, GENE DEV, V15, P827; FRANCISCO L, 1994, MOL CELL BIOL, V14, P4731, DOI 10.1128/MCB.14.7.4731; Fukasawa K, 1996, SCIENCE, V271, P1744, DOI 10.1126/science.271.5256.1744; Galasinski SC, 2002, J BIOL CHEM, V277, P19618, DOI 10.1074/jbc.M201174200; GLOVER DM, 1995, CELL, V81, P95, DOI 10.1016/0092-8674(95)90374-7; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hannak E, 2001, J CELL BIOL, V155, P1109, DOI 10.1083/jcb.200108051; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Honda K, 2000, ONCOGENE, V19, P2812, DOI 10.1038/sj.onc.1203609; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Kruhlak MJ, 2001, J BIOL CHEM, V276, P38307; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Lusser A, 1997, EUR J CELL BIOL, V74, P102; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Ohki I, 1999, EMBO J, V18, P6653, DOI 10.1093/emboj/18.23.6653; Pflum MKH, 2001, J BIOL CHEM, V276, P47733, DOI 10.1074/jbc.M105590200; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; Roghi C, 1998, J CELL SCI, V111, P557; Saito M, 2002, J BIOL CHEM, V277, P35434, DOI 10.1074/jbc.M203455200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Schumacher JM, 1998, DEVELOPMENT, V125, P4391; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Shindo M, 1998, BIOCHEM BIOPH RES CO, V244, P285, DOI 10.1006/bbrc.1998.8250; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Tanaka T, 1999, CANCER RES, V59, P2041; Tatematsu K, 2000, GENES CELLS, V5, P677, DOI 10.1046/j.1365-2443.2000.00359.x; Tatsuka M, 1998, CANCER RES, V58, P4811; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Wakefield RID, 1999, J MOL BIOL, V291, P1055, DOI 10.1006/jmbi.1999.3023; WEISS G, 1988, FEBS LETT, V238, P205, DOI 10.1016/0014-5793(88)80257-6; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496	53	46	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48714	48723		10.1074/jbc.M208461200	http://dx.doi.org/10.1074/jbc.M208461200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354758	hybrid			2022-12-25	WOS:000179789600097
J	Sheridan, CM; Heist, EK; Beals, CR; Crabtree, GR; Gardner, P				Sheridan, CM; Heist, EK; Beals, CR; Crabtree, GR; Gardner, P			Protein kinase A negatively modulates the nuclear accumulation of NF-ATc1 by priming for subsequent phosphorylation by glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL ACTIVATION; TRANSCRIPTION FACTOR NFATP; CYCLIN-DEPENDENT KINASES; DNA-BINDING ACTIVITY; NF-AT; CYCLOSPORINE-A; ANTIGEN-RECEPTOR; GENE-EXPRESSION; PHORBOL ESTER; PHOSPHATASE CALCINEURIN	The nuclear localization and transcriptional activity of the NF-ATc family of transcription factors, essential to many developmental, differentiation, and adaptation processes, are determined by the opposing activities of the phosphatase calcineurin, which promotes nuclear accumulation of NF-ATc, and several kinases, which promote cytoplasmic accumulation. Many reports suggest that protein kinase A (PKA) negatively modulates calcineurin-mediated NF-ATc activation. Here we show that overexpression of PKA causes phosphorylation and cytoplasmic accumulation of NF-ATc1 in direct opposition to calcineurin by phosphorylating Ser-245, Ser-269, and Ser-294 in the conserved serine-proline repeat domain, and that mutation of these serines blocks the effect of PKA. Activation of endogenous PKA is similarly able to promote phosphorylation of these sites on NF-ATc1 in two lymphoid cell lines. We further show that a complete block of NF-ATc1 nuclear localization by PKA requires a second kinase activity that can be supplied by glycogen synthase kinase-3 (GSK-3), and that mutation of either the PKA phosphorylation sites or the upstream GSK-3 sites prevents the effect of PKA. Thus, we propose that PKA functions cooperatively as a priming kinase for further phosphorylation by GSK-3 to oppose calcineurin-mediated nuclear accumulation and transcriptional activity of NF-ATc1 and that, through this mechanism, PKA may be an important modulator of many NF-ATc-dependent processes.	Stanford Univ, Program Immunol, Dept Mol Pharmacol, Dept Med, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol & Dev Biol, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Dept Neurobiol, Stanford, CA 94305 USA	Stanford University; Howard Hughes Medical Institute; Stanford University; Stanford University	Gardner, P (corresponding author), Stanford Univ, Program Immunol, Dept Mol Pharmacol, Dept Med, Stanford, CA 94305 USA.	pgardner@stanford.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI036535] Funding Source: NIH RePORTER; NIAID NIH HHS [5P01AI36535] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbott KL, 1998, MOL BIOL CELL, V9, P2905, DOI 10.1091/mbc.9.10.2905; ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Barton K, 1996, NATURE, V379, P81, DOI 10.1038/379081a0; Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; BETZ M, 1991, J IMMUNOL, V146, P108; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Bullock BP, 1998, BIOCHEMISTRY-US, V37, P3795, DOI 10.1021/bi970982t; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Chow CW, 2000, MOL CELL BIOL, V20, P5227, DOI 10.1128/MCB.20.14.5227-5234.2000; Chow CW, 1997, SCIENCE, V278, P1638, DOI 10.1126/science.278.5343.1638; Chow CW, 2000, MOL CELL BIOL, V20, P702, DOI 10.1128/MCB.20.2.702-712.2000; Chuvpilo S, 1999, J IMMUNOL, V162, P7294; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DEGROOT RP, 1992, ONCOGENE, V7, P2281; del Arco PG, 2000, J BIOL CHEM, V275, P13872, DOI 10.1074/jbc.275.18.13872; DURAND DB, 1988, MOL CELL BIOL, V8, P1715, DOI 10.1128/MCB.8.4.1715; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; FIERING S, 1990, GENE DEV, V4, P1823, DOI 10.1101/gad.4.10.1823; FIOL CJ, 1994, J BIOL CHEM, V269, P32187; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Graef IA, 2001, CELL, V105, P863, DOI 10.1016/S0092-8674(01)00396-8; Graef IA, 1999, NATURE, V401, P703, DOI 10.1038/44378; HAMA N, 1995, J EXP MED, V181, P1217, DOI 10.1084/jem.181.3.1217; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Harwood AJ, 2001, CELL, V105, P821, DOI 10.1016/S0092-8674(01)00412-3; Heist EK, 1998, J BIOL CHEM, V273, P19763, DOI 10.1074/jbc.273.31.19763; HO SN, 1995, J BIOL CHEM, V270, P19898, DOI 10.1074/jbc.270.34.19898; Hoessel R, 1999, NAT CELL BIOL, V1, P60, DOI 10.1038/9035; HOEY T, 1995, IMMUNITY, V2, P461, DOI 10.1016/1074-7613(95)90027-6; Hong M, 1997, J BIOL CHEM, V272, P25326, DOI 10.1074/jbc.272.40.25326; Horsley V, 2002, J CELL BIOL, V156, P771, DOI 10.1083/jcb.200111073; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Jimenez JL, 2001, J PHARMACOL EXP THER, V299, P753; Kehlenbach RH, 1998, J CELL BIOL, V141, P863, DOI 10.1083/jcb.141.4.863; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; Klemm JD, 1997, CURR BIOL, V7, P638, DOI 10.1016/S0960-9822(06)00290-9; LACOUR M, 1994, INT IMMUNOL, V6, P1333, DOI 10.1093/intimm/6.9.1333; Leclerc S, 2001, J BIOL CHEM, V276, P251, DOI 10.1074/jbc.M002466200; LEE HJ, 1993, J IMMUNOL, V151, P6135; Li LS, 1999, SCIENCE, V283, P848, DOI 10.1126/science.283.5403.848; Luo C, 1996, MOL CELL BIOL, V16, P3955; MASUDA ES, 1995, MOL CELL BIOL, V15, P2697; MATTILA PS, 1990, EMBO J, V9, P4425, DOI 10.1002/j.1460-2075.1990.tb07893.x; MCCAFFREY PG, 1993, SCIENCE, V262, P750, DOI 10.1126/science.8235597; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MURAMATSU MA, 1989, MOL CELL BIOL, V9, P831, DOI 10.1128/MCB.9.2.831; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Navarro J, 1998, J VIROL, V72, P4712, DOI 10.1128/JVI.72.6.4712-4720.1998; Neal JW, 2001, J BIOL CHEM, V276, P3666, DOI 10.1074/jbc.M004888200; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; Neilson J, 2001, CURR OPIN IMMUNOL, V13, P346, DOI 10.1016/S0952-7915(00)00225-9; NEUMANN M, 1995, EMBO J, V14, P1991, DOI 10.1002/j.1460-2075.1995.tb07191.x; NGHIEM P, 1993, J BIOL CHEM, V268, P5471; NGHIEM P, 1994, NATURE, V371, P347, DOI 10.1038/371347a0; NIGG EA, 1985, EMBO J, V4, P2801, DOI 10.1002/j.1460-2075.1985.tb04006.x; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; OKEEFE SJ, 1992, NATURE, V357, P692, DOI 10.1038/357692a0; Paliogianni F, 1996, CELL IMMUNOL, V171, P95, DOI 10.1006/cimm.1996.0178; PALIOGIANNI F, 1993, J EXP MED, V178, P1813, DOI 10.1084/jem.178.5.1813; Paliogianni F, 1996, CELL IMMUNOL, V168, P33, DOI 10.1006/cimm.1996.0046; PARK JC, 1995, J BIOL CHEM, V270, P20653, DOI 10.1074/jbc.270.35.20653; Peng SL, 2001, IMMUNITY, V14, P13, DOI 10.1016/S1074-7613(01)00085-1; Porter CM, 2000, J BIOL CHEM, V275, P3543, DOI 10.1074/jbc.275.5.3543; PREMACK BA, 1992, AM J PHYSIOL, V263, pC1119, DOI 10.1152/ajpcell.1992.263.6.C1119; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; ROACH PJ, 1991, J BIOL CHEM, V266, P14139; Saneyoshi T, 2002, NATURE, V417, P295, DOI 10.1038/417295a; Scholle F, 2000, J VIROL, V74, P10681, DOI 10.1128/JVI.74.22.10681-10689.2000; Schultz C, 1999, J MED CHEM, V42, P2909, DOI 10.1021/jm9900570; Shan XC, 2000, MOL CELL BIOL, V20, P6945, DOI 10.1128/MCB.20.18.6945-6957.2000; SHAW JP, 1988, SCIENCE, V241, P202, DOI 10.1126/science.3260404; Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0; Stankunas K, 1999, COLD SPRING HARB SYM, V64, P505, DOI 10.1101/sqb.1999.64.505; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; TSURUTA L, 1995, J IMMUNOL, V154, P5255; VANDENHOFF MJB, 1992, NUCLEIC ACIDS RES, V20, P2902, DOI 10.1093/nar/20.11.2902; WANG QM, 1994, BIOCHEMISTRY-US, V33, P143, DOI 10.1021/bi00167a018; WATANABE S, 1994, INT IMMUNOL, V6, P523, DOI 10.1093/intimm/6.4.523; Weiss A, 1991, Semin Immunol, V3, P313; Welsh GI, 1996, J BIOL CHEM, V271, P11410, DOI 10.1074/jbc.271.19.11410; WOODGETT JR, 2001, SCI STKE; Xia Y, 2000, J BIOL CHEM, V275, P1855, DOI 10.1074/jbc.275.3.1855; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zheng-Fischhofer QY, 1998, EUR J BIOCHEM, V252, P542, DOI 10.1046/j.1432-1327.1998.2520542.x; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	100	89	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48664	48676		10.1074/jbc.M207029200	http://dx.doi.org/10.1074/jbc.M207029200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12351631	hybrid			2022-12-25	WOS:000179789600091
J	Taniguchi, E; Toyoshima-Morimoto, F; Nishida, E				Taniguchi, E; Toyoshima-Morimoto, F; Nishida, E			Nuclear translocation of Plk1 mediated by its bipartite nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLO-LIKE KINASE; CELL-CYCLE; PROTEIN-KINASE; SUBCELLULAR-LOCALIZATION; MITOTIC KINASES; PLX1; EXPORT; PHOSPHORYLATES; PURIFICATION; REGULATORS	Polo-like kinase 1 (Plk1), a mammalian ortholog of Drosophila Polo, is a serine-threonine protein kinase implicated in the regulation of multiple aspects of mitosis. The protein level, activity, and localization of Plk1 change during the cell cycle, and its proper subcellular localization is thought to be crucial for its function. Although localization of Plk1 to the centrosome has been established, nuclear localization or nucleocytoplasmic translocation of Plk1 has not been fully addressed. Here we show that Plk1 accumulates in both the nucleus and the cytoplasm in addition to its localization to the centrosome during S and G, phases. Our results identify a conserved region in the kinase domain of Plk1 (residues 134-146) as a functional bipartite nuclear localization signal (NLS) sequence that regulates nuclear translocation of Plk1. The identified NLS is necessary and sufficient for directing nuclear localization of Plk1. This bipartite NLS has an unusually short spacer sequence between two clusters of basic amino acids but is sensitive to RanQ69L, a dominant negative form of Ran, similar to ordinary bipartite NLS. Remarkably, the expression of an NLS-disrupted mutant of Plk1 during S phase was found to arrest the cells in G(2) phase. These results suggest that the bipartite NLS-dependent nuclear localization of Plk1 before mitosis is important for ensuring normal cell cycle progression.	Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Nishida, E (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Cell & Dev Biol, Sakyo Ku, Kyoto 6068502, Japan.			Toyoshima, Fumiko/0000-0002-3698-0034				Abrieu A, 1998, J CELL SCI, V111, P1751; Arnaud L, 1998, CHROMOSOMA, V107, P424, DOI 10.1007/s004120050326; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Donaldson MM, 2001, J CELL SCI, V114, P2357; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Glover DM, 1996, J CELL BIOL, V135, P1681, DOI 10.1083/jcb.135.6.1681; GOLSTEYN RM, 1995, J CELL BIOL, V129, P1617, DOI 10.1083/jcb.129.6.1617; GOLSTEYN RM, 1994, J CELL SCI, V107, P1509; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; HAMANAKA R, 1995, J BIOL CHEM, V270, P21086, DOI 10.1074/jbc.270.36.21086; Jang YJ, 2002, P NATL ACAD SCI USA, V99, P1984, DOI 10.1073/pnas.042689299; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; Lane HA, 1996, J CELL BIOL, V135, P1701, DOI 10.1083/jcb.135.6.1701; Lee KS, 1998, P NATL ACAD SCI USA, V95, P9301, DOI 10.1073/pnas.95.16.9301; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Mundt KE, 1997, BIOCHEM BIOPH RES CO, V239, P377, DOI 10.1006/bbrc.1997.7378; Nasmyth K, 2001, ANNU REV GENET, V35, P673, DOI 10.1146/annurev.genet.35.102401.091334; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Pines J, 1999, NAT CELL BIOL, V1, pE73, DOI 10.1038/11041; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Qian YW, 1998, SCIENCE, V282, P1701, DOI 10.1126/science.282.5394.1701; Qian YW, 2001, MOL BIOL CELL, V12, P1791, DOI 10.1091/mbc.12.6.1791; Toyoshima F, 1998, EMBO J, V17, P2728, DOI 10.1093/emboj/17.10.2728; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Toyoshima-Morimoto F, 2001, NATURE, V410, P215, DOI 10.1038/35065617; Yang J, 1999, TRENDS CELL BIOL, V9, P207, DOI 10.1016/S0962-8924(99)01577-9; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131	31	42	43	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48884	48888		10.1074/jbc.M206307200	http://dx.doi.org/10.1074/jbc.M206307200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12364337	hybrid			2022-12-25	WOS:000179789600118
J	Thomson, LM; Lamont, DJ; Mehlert, A; Barry, JD; Ferguson, MAJ				Thomson, LM; Lamont, DJ; Mehlert, A; Barry, JD; Ferguson, MAJ			Partial structure of glutamic acid and alanine-rich protein, a major surface glycoprotein of the insect stages of Trypanosoma congolense	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; REPETITIVE PROTEIN; O-GLYCOSYLATION; PLASMODIUM-FALCIPARUM; GEL-ELECTROPHORESIS; ANTIGENIC VARIATION; BRUCEI; PROCYCLIN; EXPRESSION; PREDICTION	The tsetse fly transmitted salivarian trypanosome, Trypanosoma congolense of the subgenus Nanomonas, is the most significant of the trypanosomes with respect to the pathology of livestock in sub-Saharan Africa. Unlike the related trypanosome Trypanosoma brucei of the subgenus Trypanozoon, the major surface molecules of the insect stages of T. congolense are poorly characterized. Here, we describe the purification and structural characterization of the glutamic acid and alanine-rich protein, one of the major surface glycoproteins of T. congolense procyclic and epimastigote forms. The glycoprotein is a glycosylphosphatidylinositol-anchored molecule with a galactosylated glycosylphosphatidylinositol anchor containing an sn-1-stearoyl-2-L-3-HPO4-1-(2-O-acyl)-D-myoinositol phospholipid moiety. The 21.6-kDa polypeptide component carries two large mannose- and galactose-containing oligosaccharides linked to threonine residues via phosphodiester linkages. Mass spectrometric analyses of tryptic digests suggest that several or all of the closely related glutamic acid and alanine-rich protein genes are expressed simultaneously in a T. congolense population growing in vitro.	Univ Dundee, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland; Univ Dundee, Post Genom & Mol Interact Ctr, Wellcome Trust Bioctr, Dundee DD1 5EH, Scotland; Univ Glasgow, Wellcome Ctr Mol Parasitol, Glasgow G11 6NR, Lanark, Scotland	University of Dundee; University of Dundee; University of Glasgow	Ferguson, MAJ (corresponding author), Univ Dundee, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.		Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714				Acosta-Serrano A, 1999, J BIOL CHEM, V274, P29763, DOI 10.1074/jbc.274.42.29763; Acosta-Serrano A, 2001, P NATL ACAD SCI USA, V98, P1513, DOI 10.1073/pnas.041611698; AZZOUZ N, 1995, EMBO J, V14, P4422, DOI 10.1002/j.1460-2075.1995.tb00121.x; BAYNE RAL, 1993, MOL BIOCHEM PARASIT, V61, P295, DOI 10.1016/0166-6851(93)90075-9; BEECROFT RP, 1993, MOL BIOCHEM PARASIT, V61, P285, DOI 10.1016/0166-6851(93)90074-8; Butikofer P, 1997, BIOCHEM J, V326, P415; Butikofer P, 1999, J CELL SCI, V112, P1785; Butikofer P, 2002, MOL BIOCHEM PARASIT, V119, P7, DOI 10.1016/S0166-6851(01)00382-6; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; Di Noia JM, 2002, J EXP MED, V195, P401, DOI 10.1084/jem.20011433; Eisenhaber B, 1998, PROTEIN ENG, V11, P1155, DOI 10.1093/protein/11.12.1155; Eisenhaber B, 1999, J MOL BIOL, V292, P741, DOI 10.1006/jmbi.1999.3069; Ferguson M. A. J., 1992, LIPID MODIFICATION P, P191; FERGUSON MAJ, 1993, BIOCHEM J, V291, P51, DOI 10.1042/bj2910051; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; Gerold P, 1996, MOL BIOCHEM PARASIT, V75, P131, DOI 10.1016/0166-6851(95)02518-9; Hansen JE, 1997, NUCLEIC ACIDS RES, V25, P278, DOI 10.1093/nar/25.1.278; Hansen JE, 1998, GLYCOCONJUGATE J, V15, P115, DOI 10.1023/A:1006960004440; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; Haynes PA, 1998, GLYCOBIOLOGY, V8, P1, DOI 10.1093/glycob/8.1.1; Haynes PA, 1996, GLYCOBIOLOGY, V6, P869, DOI 10.1093/glycob/6.8.869; HITCHCOCK PJ, 1983, EUR J BIOCHEM, V133, P685, DOI 10.1111/j.1432-1033.1983.tb07517.x; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; ILG T, 1994, J BIOL CHEM, V269, P24073; KONIG E, 1989, NUCLEIC ACIDS RES, V17, P8727, DOI 10.1093/nar/17.21.8727; LEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; Mehlert A, 1999, MOL BIOCHEM PARASIT, V98, P291, DOI 10.1016/S0166-6851(98)00168-6; Mehlert A, 1998, J MOL BIOL, V277, P379, DOI 10.1006/jmbi.1997.1600; Moody-Haupt S, 2000, J MOL BIOL, V297, P409, DOI 10.1006/jmbi.2000.3577; MOWATT MR, 1987, MOL CELL BIOL, V7, P2838, DOI 10.1128/MCB.7.8.2838; Naik RS, 2000, J EXP MED, V192, P1563, DOI 10.1084/jem.192.11.1563; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nozaki T, 1996, MOL BIOCHEM PARASIT, V82, P245, DOI 10.1016/0166-6851(96)02741-7; Pays E, 1998, MOL BIOCHEM PARASIT, V91, P3, DOI 10.1016/S0166-6851(97)00183-7; Rangarajan D, 2000, MOL BIOCHEM PARASIT, V105, P281, DOI 10.1016/S0166-6851(99)00190-5; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; RODITI I, 1987, NATURE, V325, P272, DOI 10.1038/325272a0; RODITI I, 1989, J CELL BIOL, V108, P737, DOI 10.1083/jcb.108.2.737; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; Rudd PM, 1997, J BIOL CHEM, V272, P7229, DOI 10.1074/jbc.272.11.7229; Ruepp S, 1999, MOL BIOCHEM PARASIT, V98, P151, DOI 10.1016/S0166-6851(98)00159-5; TREUMANN A, 1995, J BIOL CHEM, V270, P6088, DOI 10.1074/jbc.270.11.6088; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Vanhamme L, 2001, TRENDS PARASITOL, V17, P338, DOI 10.1016/S1471-4922(01)01922-5; Vassella E, 2001, J MOL BIOL, V312, P597, DOI 10.1006/jmbi.2001.5004	46	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48899	48904		10.1074/jbc.M208942200	http://dx.doi.org/10.1074/jbc.M208942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12368279	hybrid			2022-12-25	WOS:000179789600120
J	Vanik, DL; Surewicz, WK				Vanik, DL; Surewicz, WK			Disease-associated F198S mutation increases the propensity of the recombinant prion protein for conformational conversion to scrapie-like form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMISSIBLE SPONGIFORM ENCEPHALOPATHIES; CELL-FREE FORMATION; THERMODYNAMIC STABILITY; SECONDARY STRUCTURE; AMYLOID FIBRILS; YEAST; AGGREGATION	The critical step in the pathogenesis of transmissible spongiform. encephalopathies (prion diseases) is the conversion of a cellular prion protein (PrPc) into a protease-resistant, beta-sheet rich form (PrPSc). Although the disease transmission normally requires direct interaction between exogenous PrPSc and endogenous PrPC, the pathogenic process in hereditary prion diseases appears to develop spontaneously (i.e. not requiring infection with exogenous PrPSc). To gain insight into the molecular basis of hereditary spongiform encephalopathies, we have characterized the biophysical properties of the recombinant human prion protein variant containing the mutation (Phe(198) --> Ser) associated with familial Gerstmann-Straussler-Scheinker disease. Compared with the wild-type protein, the F198S variant shows a dramatically increased propensity to self-associate into beta-sheet-rich oligomers. In a guanidine HCl-containing buffer, the transition of the F198S variant from a normal alpha-helical conformation into an oligomeric beta-sheet structure is about 50 times faster than that of the wild-type protein. Importantly, in contrast to the wildtype PrP, the mutant protein undergoes a spontaneous conversion to oligomeric beta-sheet structure even in the absence of guanidine HCl or any other denaturants. In addition to beta-sheet structure, the oligomeric form of the protein is characterized by partial resistance to proteinase K digestion, affinity for amyloid-specific dye, thioflavine T, and fibrillar morphology. The increased propensity of the F198S variant to undergo a conversion to a PrPSc-like form correlates with a markedly decreased thermodynamic stability of the native alpha-helical conformer of the mutant protein. This correlation supports the notion that partially unfolded intermediates may be involved in conformational conversion of the prion protein.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	wks3@po.ewru.edu			NINDS NIH HHS [NS38604] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Apetri AC, 2002, J BIOL CHEM, V277, P44589, DOI 10.1074/jbc.C200507200; Baskakov IV, 2001, J BIOL CHEM, V276, P19687, DOI 10.1074/jbc.C100180200; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Canet D, 2002, NAT STRUCT BIOL, V9, P308, DOI 10.1038/nsb768; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; Caughey B, 2001, ADV VIRUS RES, V56, P277, DOI 10.1016/S0065-3527(01)56031-5; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; Gambetti P, 1999, COLD SPRING HARBOR M, V38, P509; GIACCONE G, 1992, P NATL ACAD SCI USA, V89, P9349, DOI 10.1073/pnas.89.19.9349; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; HURLE MR, 1994, P NATL ACAD SCI USA, V91, P5446, DOI 10.1073/pnas.91.12.5446; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Khurana R, 2001, BIOCHEMISTRY-US, V40, P3525, DOI 10.1021/bi001782b; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; Lindquist S, 1997, CELL, V89, P495, DOI 10.1016/S0092-8674(00)80231-7; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; NAIKI H, 1989, ANAL BIOCHEM, V177, P244, DOI 10.1016/0003-2697(89)90046-8; Nicholson EM, 2002, J MOL BIOL, V316, P807, DOI 10.1006/jmbi.2001.5347; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1998, P NATL ACAD SCI USA, V95, P11667, DOI 10.1073/pnas.95.20.11667; SAFAR J, 1993, PROTEIN SCI, V2, P2206, DOI 10.1002/pro.5560021220; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Sparrer HE, 2000, SCIENCE, V289, P595, DOI 10.1126/science.289.5479.595; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; SUREWICZ WK, 1988, BIOCHIM BIOPHYS ACTA, V952, P115, DOI 10.1016/0167-4838(88)90107-0; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Weissmann C, 1996, FEBS LETT, V389, P3, DOI 10.1016/0014-5793(96)00610-2; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6	43	62	64	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49065	49070		10.1074/jbc.M207511200	http://dx.doi.org/10.1074/jbc.M207511200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12372829	hybrid			2022-12-25	WOS:000179789600140
J	Venkataraman, RN; MacLachlan, TK; Chai, XM; El-Deiry, WS; Marmorstein, R				Venkataraman, RN; MacLachlan, TK; Chai, XM; El-Deiry, WS; Marmorstein, R			Structure-based design of p18(INK4c) proteins with increased thermodynamic stability and cell cycle inhibitory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR P16(INK4A); DEPENDENT KINASE CDK6; CRYSTAL-STRUCTURE; INK4 INHIBITORS; WILD-TYPE; GENE; P18; REFINEMENT; MUTATIONS; CANCER	p18(INK4c), is a member of the INK4 family of proteins that regulate the G, to S cell cycle transition by binding to and inhibiting the pRb kinase activity of cyclin-dependent kinases 4 and 6. The p16(INK4a) member of the INK4 protein family is altered in a variety of cancers and structure-function studies of the INK4 proteins reveal that the vast majority of missense tumor-derived p16(INK4a) mutations reduce protein thermodynamic stability. Based on this observation, we used p18(INK4c) as a model to test the proposal that INK4 proteins with increased stability might have enhanced cell cycle inhibitory activity. Structure-based mutagenesis was used to prepare p18(INK4c) mutant proteins with a predicted increase in stability. Using this approach, we report the generation of three mutant p18(INK4C) proteins, F71N, F82Q, and F92N, with increased stability toward thermal denaturation of which the F71N mutant also showed an increased stability to chemical denaturation. The x-ray crystal structures of the F71N, F82Q, and F92N p18(INK4C) mutant proteins were determined to reveal the structural basis for their increased stability properties. Significantly, the F71N mutant also showed enhanced CDK6 interaction and cell cycle inhibitory activity in vivo, as measured using co-immunoprecipitation and transient transfection assays, respectively. These studies show that a structure-based approach to increase the thermodynamic stability of INK4 proteins can be exploited to prepare more biologically active molecules with potential applications for the development of molecules to treat p16(INK4a)-mediated cancers.	Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Dept Biochem & Mol Biophys, Philadelphia, PA 19104 USA; Univ Penn, Dept Chem, Philadelphia, PA 19104 USA	The Wistar Institute; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Marmorstein, R (corresponding author), Univ Penn, Wistar Inst, Philadelphia, PA 19104 USA.			El-Deiry, Wafik/0000-0002-9577-8266				Brotherton DH, 1998, NATURE, V395, P244, DOI 10.1038/26164; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507; Gemma A, 1996, INT J CANCER, V68, P605, DOI 10.1002/(SICI)1097-0215(19961127)68:5<605::AID-IJC9>3.0.CO;2-2; GEWIRTH D, 1993, HKL VERSION 1 0 MANU; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONES TA, 1996, MANUAL O VERSION 6 1; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1994, SCIENCE, V264, P440; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lapointe J, 1996, CANCER RES, V56, P4586; Luh FY, 1997, NATURE, V389, P999, DOI 10.1038/40202; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miller CW, 1997, ONCOGENE, V15, P231, DOI 10.1038/sj.onc.1201185; OKUDA T, 1995, BLOOD, V85, P2321, DOI 10.1182/blood.V85.9.2321.bloodjournal8592321; Pace C N, 1986, Methods Enzymol, V131, P266; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Pohl U, 1999, BRAIN PATHOL, V9, P639; Pollock PM, 1996, GENE CHROMOSOME CANC, V15, P77, DOI 10.1002/(SICI)1098-2264(199602)15:2<77::AID-GCC1>3.0.CO;2-0; RICE LM, 1994, PROTEINS, V19, P277, DOI 10.1002/prot.340190403; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Ruas M, 1999, ONCOGENE, V18, P5423, DOI 10.1038/sj.onc.1202918; Russo AA, 1998, NATURE, V395, P237, DOI 10.1038/26155; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SmithSorensen B, 1996, HUM MUTAT, V7, P294, DOI 10.1002/(SICI)1098-1004(1996)7:4<294::AID-HUMU2>3.0.CO;2-9; Somasundaram K, 1997, NATURE, V389, P187, DOI 10.1038/38291; Tevelev A, 1996, BIOCHEMISTRY-US, V35, P9475, DOI 10.1021/bi960211+; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Venkataramani R, 1998, NAT STRUCT BIOL, V5, P74, DOI 10.1038/nsb0198-74; YANG R, 1995, CANCER RES, V55, P2503; Zhang B, 1996, J BIOL CHEM, V271, P28734, DOI 10.1074/jbc.271.46.28734	38	11	11	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48827	48833		10.1074/jbc.M208061200	http://dx.doi.org/10.1074/jbc.M208061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12370184	hybrid			2022-12-25	WOS:000179789600111
J	Ji, HB; Gupta, A; Okamoto, S; Blum, MD; Tan, LJ; Goldring, MB; Lacy, E; Roy, AL; Terhorst, C				Ji, HB; Gupta, A; Okamoto, S; Blum, MD; Tan, LJ; Goldring, MB; Lacy, E; Roy, AL; Terhorst, C			T cell-specific expression of the murine CD3 delta promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V-BETA PROMOTER; TFII-I; BINDING PROTEIN; NATURAL-KILLER; GENE PROMOTER; CD4 ENHANCER; FACTOR YY1; TATA-LESS; ELEMENT; TRANSCRIPTION	T cell-specific expression of human and mouse CD3delta is known to be governed by an enhancer element immediately downstream from the gene. Here we demonstrate by transgenic and in vitro studies that the murine CD3delta (mCD3delta) promoter prefers to be expressed in cells of the T lineage. Deletion analyses of a promoter segment (-401/+48 bp) followed by transient transfections indicate that upstream elements between -149 and -112 bp contribute to full expression of the gene. Furthermore, a core promoter region -37/+29 appears to contribute to a T cell specificity. Using substitution mutant scanning, four positive and one negative regulatory elements were found within the mCD3delta core promoter. The first two positive elements comprise two classical initiator-like sites, which recruit TFII-I, whereas a third contains a functional Ets binding site. Immediately adjacent to the observed transcription start site is a negative element that utilizes the transcription regulator YY1. The last positive regulatory element contains a potentially functional CREB binding site and the minor transcriptional start site. Because NERF-2, Elf-1, and Ets-1 are expressed preferentially in lymphocytes and because, in addition, YY1 represses the promoter activity strongly in non-T cells, we conclude that the combination of these transcription factors contributes to the T cell-specific expression pattern of mouse CD3delta.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Rheumatol, Boston, MA 02215 USA; Harvard Inst Med, New England Baptist Bone & Joint Inst, Boston, MA 02115 USA; Cornell Univ, Weill Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA; Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Harvard Medical School; New England Baptist Hospital; Cornell University; Memorial Sloan Kettering Cancer Center; Tufts University	Ji, HB (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Immunol, RE-206,330 Brookline Ave, Boston, MA 02215 USA.			Lacy, Elizabeth/0000-0001-5457-0728	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI017651, R01AI045150, R37AI017651, R21AI017651, R56AI045150] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045378] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-45150, AI-17651] Funding Source: Medline; NIAMS NIH HHS [AR-45378] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Barbeau B, 1999, ONCOGENE, V18, P5535, DOI 10.1038/sj.onc.1202913; Bassuk AG, 1998, MOL MED, V4, P392, DOI 10.1007/BF03401746; Bennett MK, 1999, J BIOL CHEM, V274, P13025, DOI 10.1074/jbc.274.19.13025; BLUM MD, 1993, J EXP MED, V177, P1343, DOI 10.1084/jem.177.5.1343; CHEN CH, 1989, P NATL ACAD SCI USA, V86, P2351, DOI 10.1073/pnas.86.7.2351; Cheriyath V, 2000, J BIOL CHEM, V275, P26300, DOI 10.1074/jbc.M002980200; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; Ellmeier W, 1999, ANNU REV IMMUNOL, V17, P523, DOI 10.1146/annurev.immunol.17.1.523; GALY A, 1995, IMMUNITY, V3, P459, DOI 10.1016/1074-7613(95)90175-2; GEORGOPOULOS K, 1990, EMBO J, V9, P109, DOI 10.1002/j.1460-2075.1990.tb08086.x; GEORGOPOULOS K, 1992, MOL CELL BIOL, V12, P747, DOI 10.1128/MCB.12.2.747; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; Halle JP, 1997, MOL CELL BIOL, V17, P4220, DOI 10.1128/MCB.17.8.4220; Ikawa T, 1999, J EXP MED, V190, P1617, DOI 10.1084/jem.190.11.1617; LORENZ WW, 1991, P NATL ACAD SCI USA, V88, P4438, DOI 10.1073/pnas.88.10.4438; ManzanoWinkler B, 1996, J BIOL CHEM, V271, P12076, DOI 10.1074/jbc.271.20.12076; Mayall TP, 1997, GENE DEV, V11, P887, DOI 10.1101/gad.11.7.887; Montano MA, 1996, P NATL ACAD SCI USA, V93, P12376, DOI 10.1073/pnas.93.22.12376; Rellahan BL, 1998, J IMMUNOL, V160, P2794; Riquet FB, 2001, J BIOL CHEM, V276, P38665, DOI 10.1074/jbc.M009881200; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; SAITO H, 1987, P NATL ACAD SCI USA, V84, P9131, DOI 10.1073/pnas.84.24.9131; Sarafova S, 1999, J BIOL CHEM, V274, P16126, DOI 10.1074/jbc.274.23.16126; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; Tung J W, 2001, BMC Mol Biol, V2, P5, DOI 10.1186/1471-2199-2-5; VANDENELSEN P, 1986, P NATL ACAD SCI USA, V83, P2944; WURSTER AL, 1994, MOL CELL BIOL, V14, P6452, DOI 10.1128/MCB.14.10.6452; Ye JP, 1996, MOL CELL BIOL, V16, P157; Ye JP, 1996, MOL CELL BIOL, V16, P4744; Ye JP, 1999, J BIOL CHEM, V274, P26661, DOI 10.1074/jbc.274.38.26661; Zhou TY, 2001, J BIOL CHEM, V276, P25503, DOI 10.1074/jbc.M102875200	31	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47898	47906		10.1074/jbc.M201025200	http://dx.doi.org/10.1074/jbc.M201025200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324448	hybrid			2022-12-25	WOS:000179663700137
J	Roda, RH; Balakrishnan, M; Kim, JK; Roques, BP; Fay, PJ; Bambara, RA				Roda, RH; Balakrishnan, M; Kim, JK; Roques, BP; Fay, PJ; Bambara, RA			Strand transfer occurs in retroviruses by a pause-initiated two-step mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 REVERSE-TRANSCRIPTASE; TYPE-1 NUCLEOCAPSID PROTEIN; RNASE-H ACTIVITY; STRONG-STOP DNA; IN-VITRO; GENETIC-RECOMBINATION; SECONDARY STRUCTURE; INTERNAL REGIONS; COPY-CHOICE	Recombination promotes retrovirus evolution. It involves transferring a growing DNA primer from one genomic RNA template in the virus to the other. Strand transfer results in vitro suggested that pausing of the reverse transcriptase during synthesis allows enhanced RNase H cleavage of the initial, or donor, RNA template that facilitates primer interaction with the acceptor template. Hairpins are common structures in retrovirus RNAs that induce pausing. Analyzing primer transfers in hairpins by base substitution markers showed transfer sites well beyond the site of pausing. We developed methods to distinguish the initial site of primer-acceptor template interaction from the site of primer,terminus transfer. The strand transfer mechanism was confirmed to involve two steps. In the first, the acceptor template invades the primer-donor complex. However, the primer terminus continues elongation on the donor RNA. The interacting primer and acceptor strands then propagate by branch migration to catch the advancing primer terminus. Some distance downstream of the invasion site the primer terminus transfers, marking the genetic shift from donor to acceptor. Nucleocapsid protein (NC) is known to influence primer elongation and strand exchange. The presence of NC increased the efficiency of transfers but did not appear to alter the fundamental transfer mechanism.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; CNRS, INSERM,U266, UMR 8600,Dept Pharmacochim Mol & Struct, UER Sci Pharmaceut & Biol, F-75270 Paris, France	University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, 601 Elmwood Ave,Box 712, Rochester, NY 14642 USA.	robert_bambara@urmc.rochester.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049573, F31GM020911] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49573, 5 F31 GM20911-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson JA, 1998, J VIROL, V72, P1186, DOI 10.1128/JVI.72.2.1186-1194.1998; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; BERKHOUT B, 1995, J MOL BIOL, V252, P59, DOI 10.1006/jmbi.1994.0475; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Brincat JL, 2002, J VIROL, V76, P88, DOI 10.1128/JVI.76.1.88-95.2002; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; DARLIX JL, 1995, J MOL BIOL, V254, P523, DOI 10.1006/jmbi.1995.0635; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1992, BIOCHIM BIOPHYS ACTA, V1131, P270, DOI 10.1016/0167-4781(92)90025-U; DIAZ RS, 1995, J VIROL, V69, P3273, DOI 10.1128/JVI.69.6.3273-3281.1995; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; GILBOA E, 1979, CELL, V18, P93, DOI 10.1016/0092-8674(79)90357-X; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GU ZX, 1995, ANTIMICROB AGENTS CH, V39, P1888, DOI 10.1128/AAC.39.8.1888; Guo JH, 2000, J VIROL, V74, P8980, DOI 10.1128/JVI.74.19.8980-8988.2000; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Harrison GP, 1998, NUCLEIC ACIDS RES, V26, P3433, DOI 10.1093/nar/26.14.3433; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HU WS, 1992, J VIROL, V66, P4457, DOI 10.1128/JVI.66.7.4457-4463.1992; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; Hunter E, 1978, Curr Top Microbiol Immunol, V79, P295; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Jetzt AE, 2000, J VIROL, V74, P1234, DOI 10.1128/JVI.74.3.1234-1240.2000; KAWAKAMI T, 1987, VIROLOGY, V158, P300, DOI 10.1016/0042-6822(87)90202-9; KELLAM P, 1995, J VIROL, V69, P669, DOI 10.1128/JVI.69.2.669-674.1995; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; Klasens BIF, 1999, BBA-GENE STRUCT EXPR, V1444, P355, DOI 10.1016/S0167-4781(99)00011-1; KLAVER B, 1994, NUCLEIC ACIDS RES, V22, P137, DOI 10.1093/nar/22.2.137; Kulpa D, 1997, EMBO J, V16, P856, DOI 10.1093/emboj/16.4.856; Li XG, 1996, J VIROL, V70, P4996, DOI 10.1128/JVI.70.8.4996-5004.1996; LOBEL LI, 1985, J VIROL, V53, P447, DOI 10.1128/JVI.53.2.447-455.1985; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Negroni M, 2000, P NATL ACAD SCI USA, V97, P6385, DOI 10.1073/pnas.120520497; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; Ohi Y, 2000, J VIROL, V74, P8324, DOI 10.1128/JVI.74.18.8324-8334.2000; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PRASAD VR, 1993, REVERSE TRANSCRIPTAS, P135; ROBERTSON DL, 1995, NATURE, V374, P124, DOI 10.1038/374124b0; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; SKALKA AM, 1982, J CELL BIOCHEM, V19, P293, DOI 10.1002/jcb.240190311; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P14778, DOI 10.1021/bi971963m; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; WATSON JD, 1987, MOL BIOL GENE, P313; Wisniewski M, 2002, J BIOL CHEM, V277, P28400, DOI 10.1074/jbc.M201645200; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Wu WX, 1996, J VIROL, V70, P7132, DOI 10.1128/JVI.70.10.7132-7142.1996; XU H, 1987, P NATL ACAD SCI USA, V84, P8553, DOI 10.1073/pnas.84.23.8553; Yu H, 1998, J BIOL CHEM, V273, P28384, DOI 10.1074/jbc.273.43.28384; ZHANG JY, 1993, SCIENCE, V259, P234, DOI 10.1126/science.8421784; Zhang JY, 2000, J VIROL, V74, P2313, DOI 10.1128/JVI.74.5.2313-2322.2000; Zhang WH, 2002, J VIROL, V76, P7473, DOI 10.1128/JVI.76.15.7473-7484.2002; Zuker M, 1999, NATO ASI 3 HIGH TECH, V70, P11	61	56	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46900	46911		10.1074/jbc.M208638200	http://dx.doi.org/10.1074/jbc.M208638200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370183	hybrid			2022-12-25	WOS:000179663700011
J	Bouhss, A; Josseaume, N; Severin, A; Tabei, K; Hugonnet, JE; Shlaes, D; Mengin-Lecreulx, D; van Heijenoort, J; Arthur, M				Bouhss, A; Josseaume, N; Severin, A; Tabei, K; Hugonnet, JE; Shlaes, D; Mengin-Lecreulx, D; van Heijenoort, J; Arthur, M			Synthesis of the L-alanyl-L-alanine cross-bridge of Enterococcus faecalis peptidoglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAM RESISTANCE; BACTERIAL CELL-WALLS; STREPTOCOCCUS-PNEUMONIAE; GLYCOPEPTIDE RESISTANCE; STAPHYLOCOCCUS-AUREUS; IDENTIFICATION; ACTIVATION; GENES	The enzymatic synthesis of the complete L-alanyl(1)-L-alanine, side chain of the peptidoglycan precursors of Enterococcus faecalis was obtained in vitro using purified enzymes. The pathway involved alanyl-tRNA synthetase and two ligases, BppA1 and BppA2, that specifically transfer alanine from Ala-tRNA to the first and second positions of the side chain, respectively. The structure of the UDP-N-acetylmuramoyl-L-Ala-gamma-D-Glu-L-Lys(N-epsilon-L-Ala(1)-L-Ala(2))-D-Ala-D-Ala product of BppA1 and BppA2 was confirmed by mass spectrometry (MS) and MS/MS analyses. The peptidoglycan structure of the wild-type E. faecalis strain JH2-2 was determined by tandem reverse-phase high-pressure liquid chromatography-MS revealing that most muropeptides contained two L-alanyl residues in the cross-bridges and in the free N-terminal ends; Deletion of. the bppAg gene was associated with production of muropeptides containing a single alanyl residue at these positions. The relative abundance of monomers, dimers, trimers, and tetramers in the peptidoglycan of the bppA2 mutant indicated that precursors containing an incomplete side chain were efficiently used by the DD-transpeptidases in the cross-linking reaction. However, the bppA2 deletion impaired expression of intrinsic beta-lactam resistance suggesting that the low affinity penicillin-binding protein 5 did not function optimally with precursors substituted by a single alanine.	Univ Paris 06, INSERM, Unite Format & Rech Broussais Hotel Dieu, Lab Rech Mol Antibiot,E0004, F-75270 Paris 06, France; Univ Paris 11, CNRS, Inst Biochim Biophys Mol & Cellulaire, UMR 8619, F-91405 Orsay, France; Wyeth Ayerst Res, Pearl River, NY 10965 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; Pfizer	Arthur, M (corresponding author), Univ Paris 06, INSERM, Unite Format & Rech Broussais Hotel Dieu, Lab Rech Mol Antibiot,E0004, 15 Rue Ecole Med, F-75270 Paris 06, France.		HUGONNET, Jean-Emmanuel/ABC-7914-2021; HUGONNET, Jean-Emmanuel/H-3581-2014; Arthur, Michel/G-3680-2013	HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; HUGONNET, Jean-Emmanuel/0000-0003-4150-0944; Arthur, Michel/0000-0003-1007-636X; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Arthur M, 1997, J BACTERIOL, V179, P97, DOI 10.1128/jb.179.1.97-106.1997; Arthur M, 1998, MOL MICROBIOL, V30, P819, DOI 10.1046/j.1365-2958.1998.01114.x; ARTHUR M, 1993, ANTIMICROB AGENTS CH, V37, P1563, DOI 10.1128/AAC.37.8.1563; Benson TE, 2002, STRUCTURE, V10, P1107, DOI 10.1016/S0969-2126(02)00807-9; BOUDEWIJN L, 1996, ANTIMICROB AGENTS CH, V40, P863; Bouhss A, 2001, J BACTERIOL, V183, P5122, DOI 10.1128/JB.183.17.5122-5127.2001; Filipe SR, 2000, J BIOL CHEM, V275, P27768; Filipe SR, 2000, P NATL ACAD SCI USA, V97, P4891, DOI 10.1073/pnas.080067697; Hegde SS, 2001, J BIOL CHEM, V276, P6998, DOI 10.1074/jbc.M008591200; Holtje JV, 1998, MICROBIOL MOL BIOL R, V62, P181; JACOB AE, 1974, J BACTERIOL, V117, P360, DOI 10.1128/JB.117.2.360-372.1974; Mainardi JL, 2000, J BIOL CHEM, V275, P16490, DOI 10.1074/jbc.M909877199; Mainardi JL, 1998, MICROBIOL-UK, V144, P2679, DOI 10.1099/00221287-144-10-2679; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MURRAY BE, 1990, CLIN MICROBIOL REV, V3, P46, DOI 10.1128/CMR.3.1.46-65.1990; PLAPP R, 1970, J BIOL CHEM, V245, P3667; Rohrer S, 1999, P NATL ACAD SCI USA, V96, P9351, DOI 10.1073/pnas.96.16.9351; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; STAUDENBAUER W, 1972, J BIOL CHEM, V247, P5095; Stranden AM, 1997, J BACTERIOL, V179, P9, DOI 10.1128/jb.179.1.9-16.1997; TRIEUCUOT P, 1990, NUCLEIC ACIDS RES, V18, P3660, DOI 10.1093/nar/18.12.3660; Tschierske M, 1999, FEMS MICROBIOL LETT, V171, P97, DOI 10.1016/S0378-1097(98)00586-2; Weber B, 2000, FEMS MICROBIOL LETT, V188, P81, DOI 10.1016/S0378-1097(00)00214-7	23	61	64	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45935	45941		10.1074/jbc.M207449200	http://dx.doi.org/10.1074/jbc.M207449200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324463	hybrid			2022-12-25	WOS:000179529300031
J	Bitterman, KJ; Anderson, RM; Cohen, HY; Latorre-Esteves, M; Sinclair, DA				Bitterman, KJ; Anderson, RM; Cohen, HY; Latorre-Esteves, M; Sinclair, DA			Inhibition of silencing and accelerated aging by nicotinamide, a putative negative regulator of yeast Sir2 and human SIRT1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; PROTEIN SIR2; DEACETYLASE ACTIVITY; HISTONE DEACETYLASE; DNA-REPLICATION; GENE FAMILY; NAD; IDENTIFICATION; REPRESSION	The Saccharomyces cerevisiae Sir2 protein is an NAD(+)-dependent histone deacetylase that plays a critical role in transcriptional silencing, genome stability, and longevity. A human homologue of Sir2, SIRT1, regulates the activity of the p53 tumor suppressor and inhibits apoptosis. The Sir2 deacetylation reaction generates two products: O-acetyl-ADP-ribose and nicotinamide, a precursor of nicotinic acid and a form of niacin/vitamin B-3. We show here that nicotinamide strongly inhibits yeast silencing, increases rDNA recombination, and shortens replicative life span to that of a sir2 mutant. Nicotinamide abolishes silencing and leads to an eventual delocalization of Sir2 even in G(1)-arrested cells, demonstrating that silent heterochromatin requires continual Sir2 activity. We show that physiological concentrations of nicotinamide noncompetitively inhibit both Sir2 and SIRT1 in vitro. The degree of inhibition by nicotinamide (IC50 < 50 muM) is equal to or better than the most effective known synthetic inhibitors of this class of proteins. We propose a model whereby nicotinamide inhibits deacetylation by binding to a conserved pocket adjacent to NAD(+), thereby blocking NAD(+) hydrolysis. We discuss the possibility that nicotinamide is a physiologically relevant regulator of Sir2 enzymes.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.	david_Sinclair@hms.harvard.edu	Latorre-Esteves, Magda/GMW-6353-2022	Cohen, Haim Y./0000-0002-6613-8710; Sinclair, David/0000-0002-9936-436X	NIA NIH HHS [AG11972-01] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson RM, 2002, J BIOL CHEM, V277, P18881, DOI 10.1074/jbc.M111773200; Armstrong CM, 2002, MOL BIOL CELL, V13, P1427, DOI 10.1091/mbc.01-10-0482; BARTON AA, 1950, J GEN MICROBIOL, V4, P84, DOI 10.1099/00221287-4-1-84; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Borra MT, 2002, J BIOL CHEM, V277, P12632, DOI 10.1074/jbc.M111830200; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Courey AJ, 2001, GENE DEV, V15, P2786; DIETRICH LS, 1971, AM J CLIN NUTR, V24, P800; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Fischle W, 2001, BIOCHEM CELL BIOL, V79, P337, DOI 10.1139/bcb-79-3-337; FOSTER JW, 1990, J BACTERIOL, V172, P4187, DOI 10.1128/jb.172.8.4187-4196.1990; Gasch AP, 2000, MOL BIOL CELL, V11, P4241, DOI 10.1091/mbc.11.12.4241; Gasser SM, 1998, CIBA F SYMP, V214, P114; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Ghidelli S, 2001, EMBO J, V20, P4522, DOI 10.1093/emboj/20.16.4522; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; GOTTLIEB S, 1989, CELL, V56, P771, DOI 10.1016/0092-8674(89)90681-8; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grozinger CM, 2001, J BIOL CHEM, V276, P38837, DOI 10.1074/jbc.M106779200; HAGINO Y, 1968, J BIOL CHEM, V243, P4980; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; HOSHINO J, 1984, BIOCHIM BIOPHYS ACTA, V801, P250, DOI 10.1016/0304-4165(84)90074-6; IJICHI H, 1966, J BIOL CHEM, V241, P3701; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Kaanders JHAM, 2002, INT J RADIAT ONCOL, V52, P769, DOI 10.1016/S0360-3016(01)02678-5; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Kirchmaier AL, 2001, SCIENCE, V291, P646, DOI 10.1126/science.291.5504.646; Knip M, 2000, DIABETOLOGIA, V43, P1337, DOI 10.1007/s001250051536; Kuo MH, 1998, BIOESSAYS, V20, P615, DOI 10.1002/(SICI)1521-1878(199808)20:8<615::AID-BIES4>3.0.CO;2-H; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Langley E, 2002, EMBO J, V21, P2383, DOI 10.1093/emboj/21.10.2383; Li YC, 2001, SCIENCE, V291, P650, DOI 10.1126/science.291.5504.650; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Llorente B, 2000, FEBS LETT, V475, P237, DOI 10.1016/S0014-5793(00)01698-7; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Moazed D, 2001, CURR OPIN CELL BIOL, V13, P232, DOI 10.1016/S0955-0674(00)00202-7; Moskvina E, 1998, YEAST, V14, P1041, DOI 10.1002/(SICI)1097-0061(199808)14:11<1041::AID-YEA296>3.0.CO;2-4; Park PU, 1999, MOL CELL BIOL, V19, P3848; RINE J, 1987, GENETICS, V116, P9; Sandmeier JJ, 2002, GENETICS, V160, P877; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; Sinclair DA, 1998, TRENDS BIOCHEM SCI, V23, P131, DOI 10.1016/S0968-0004(98)01188-8; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smythe GA, 2002, ANAL BIOCHEM, V301, P21, DOI 10.1006/abio.2001.5490; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Swiecilo A, 2000, ACTA BIOCHIM POL, V47, P355; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; Wood JG, 2002, TRENDS PHARMACOL SCI, V23, P1, DOI 10.1016/S0165-6147(00)01891-5; Yoshida M, 2001, CANCER CHEMOTH PHARM, V48, pS20, DOI 10.1007/s002800100300	66	776	832	0	70	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45099	45107		10.1074/jbc.M205670200	http://dx.doi.org/10.1074/jbc.M205670200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12297502	hybrid			2022-12-25	WOS:000179404800066
J	Abramovich, C; Chavez, EA; Lansdorp, PM; Humphries, RK				Abramovich, C; Chavez, EA; Lansdorp, PM; Humphries, RK			Functional characterization of multiple domains involved in the subcellular localization of the hematopoietic Pbx interacting protein (HPIP)	ONCOGENE			English	Article						hematopoietic Pbx interacting protein; cellular localization; nuclear import; nuclear export; microtubules	NUCLEAR EXPORT SIGNAL; IN-VIVO; GENE-EXPRESSION; CELLS CAUSES; HOX; BINDING; CRM1; OVEREXPRESSION; PREP1; ASSOCIATION	We have previously reported the cloning of the Hematopoietic Pbx Interacting Protein (HPIP), a novel protein discovered through its interaction with Pbx1. HPIP is expressed in early hematopoietic precursors, can bind all members of the Pbx family and can inhibit the transcriptional activation of the oncogene E2A-Pbx. To further understand the function of HPIP, we have analysed its cellular localization and characterized its functional localization domains. Using fluorescence microscopy to follow the distribution of different HPIP sequences fused to GFP, we found that HPIP localizes predominantly to cytoskeletal fibers but has the potential ability to shuttle between the nucleus and the cytosol. The cytoskeletal localization of HPIP is mediated by an N-terminal leucine rich region (between as 190-218) and can be disrupted by the microtubule destabilizing drug vincristine. The HPIP C-terminal domain (aa 443731) bears a nuclear export activity that is blocked by the CRM1 inhibitor Leptomycin B. In addition, we found two basic amino acid regions located between as 485505 and as 695-720 that contain nuclear import activities attenuated by nuclear export. These observations support a model in which the constitutive attachment of HPIP to the cytoskeleton could be modified by changes in functional domains implicated in nuclear export, import and cytoskeleton binding sequences, allowing the molecule to shuttle between the nucleus and the cytosol.	British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Med, Vancouver, BC V6T 2B5, Canada	British Columbia Cancer Agency; University of British Columbia	Humphries, RK (corresponding author), British Columbia Canc Agcy, Terry Fox Lab, 601 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.			Humphries, Richard/0000-0003-0540-7005; Lansdorp, Peter/0000-0001-7435-1071	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065430] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL65430] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abramovich C, 2000, J BIOL CHEM, V275, P26172, DOI 10.1074/jbc.M001323200; Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; ADAM EJH, 1994, J CELL BIOL, V125, P547, DOI 10.1083/jcb.125.3.547; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Buske C, 2001, BLOOD, V97, P2286, DOI 10.1182/blood.V97.8.2286; Capecchi MR, 1997, COLD SPRING HARB SYM, V62, P273, DOI 10.1101/SQB.1997.062.01.034; CORSETTI MT, 1995, J CELL SCI, V108, P187; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; Fuller JF, 1999, BLOOD, V93, P3391, DOI 10.1182/blood.V93.10.3391.410k26_3391_3400; Goudet G, 1999, J BIOL CHEM, V274, P4067, DOI 10.1074/jbc.274.7.4067; Graf L, 2001, BIOL BLOOD MARROW TR, V7, P486, DOI 10.1053/bbmt.2001.v7.pm11669215; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lawrence HJ, 1996, STEM CELLS, V14, P281, DOI 10.1002/stem.140281; LEE KK, 2002, J BIOL CHEM, V22, P22; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; SAUVAGEAU G, 1995, GENE DEV, V9, P1753, DOI 10.1101/gad.9.14.1753; Sauvageau G, 1997, IMMUNITY, V6, P13, DOI 10.1016/S1074-7613(00)80238-1; Selleri L, 2001, DEVELOPMENT, V128, P3543; Shen WF, 1999, MOL CELL BIOL, V19, P3051; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; Thorsteinsdottir U, 2001, MOL CELL BIOL, V21, P224, DOI 10.1128/MCB.21.1.224-234.2001; Veraksa A, 2000, MOL GENET METAB, V69, P85, DOI 10.1006/mgme.2000.2963; Zhu JY, 1999, NATURE, V398, P256, DOI 10.1038/18473	33	28	31	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6766	6771		10.1038/sj.onc.1205784	http://dx.doi.org/10.1038/sj.onc.1205784			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360403				2022-12-25	WOS:000178315800006
J	Gad, S; Caux-Moncoutier, V; Pages-Berhouet, S; Gauthier-Villars, M; Coupier, I; Pujol, P; Frenay, M; Gilbert, B; Maugard, C; Bignon, YJ; Chevrier, A; Rossi, A; Fricker, JP; Nguyen, TD; Demange, L; Aurias, A; Bensimon, A; Stoppa-Lyonnet, D				Gad, S; Caux-Moncoutier, V; Pages-Berhouet, S; Gauthier-Villars, M; Coupier, I; Pujol, P; Frenay, M; Gilbert, B; Maugard, C; Bignon, YJ; Chevrier, A; Rossi, A; Fricker, JP; Nguyen, TD; Demange, L; Aurias, A; Bensimon, A; Stoppa-Lyonnet, D			Significant contribution of large BRCA1 gene rearrangements in 120 French breast and ovarian cancer families	ONCOGENE			English	Article						BRCA1 mutations; rearrangements; breast-ovarian cancer	KB DELETION; COMBED DNA; IDENTIFICATION; MUTATIONS; REGION; INDIVIDUALS; DUPLICATION; SEQUENCE; LIES	Genetic linkage data have shown that alterations of the BRCA1 gene are responsible for the majority of hereditary breast-ovarian cancers. However, BRCA1 germline mutations are found much less frequently than expected, especially as standard PCR-based mutation detection approaches focus on point and small gene alterations. In order to estimate the contribution of large gene rearrangements to the BRCA1 mutation spectrum, we have extensively analysed a series of 120 French breast-ovarian cancer cases. Thirty-eight were previously found carrier of a BRCA1 point mutation, 14 of a BRCA2 point mutation and one case has previously been reported as carrier of a large BRCA1 deletion. The remaining 67 cases were studied using the BRCA1 bar code approach on combed DNA which allows a panoramic view of the BRCA1 region. Three additional rearrangements were detected: a recurrent 23.8 kb deletion of exons 8-13, a 17.2 kb duplication of exons 3-8 and a 8.6 kb duplication of exons 18-20. Thus, in our series, BRCA1 large rearrangements accounted for 3.3% (4/120) of breast-ovarian cancer cases and 9.5% (4/42) of the BRCA1 gene mutation spectrum, suggesting that their screening is an important step that should be now systematically included in genetic testing surveys.	Inst Curie, Serv Genet Oncol, Med Sect, F-75248 Paris 05, France; CHU Arnaud Villeneuve, Montpellier, France; Ctr Antoine Lacassagne, F-06054 Nice, France; CHU Dupuytren, Limoges, France; Ctr Rene Gauducheau, F-44035 Nantes, France; Ctr Jean Perrin, Clermont Ferrand, France; Hop Charles Nicolle, Rouen, France; Ctr Paul Strauss, Strasbourg, France; Inst Jean Godinot, Reims, France; Inst Curie, INSERM, U509 Pathol Mol Canc, F-75248 Paris 05, France; Inst Pasteur, ADN, Biophys Lab, Paris, France	UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite de Montpellier; CHU de Montpellier; UNICANCER; Centre Antoine Lacassagne; CHU Limoges; UNICANCER; Institut de Cancerologie de l'Ouest (ICO); UNICANCER; Centre Jean Perrin; CHU de Rouen; UNICANCER; Centre Paul Strauss; UNICANCER; Institut Jean Godinot; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Stoppa-Lyonnet, D (corresponding author), Inst Curie, Serv Genet Oncol, Med Sect, 26 Rue Ulm, F-75248 Paris 05, France.	dominique.stoppa-lyonnet@curie.net	, bignon/Y-3243-2019	GAD (LAPITEAU), Sophie/0000-0002-3158-6791				Armour JAL, 2000, NUCLEIC ACIDS RES, V28, P605, DOI 10.1093/nar/28.2.605; Barker DF, 1996, GENOMICS, V38, P215, DOI 10.1006/geno.1996.0618; BROWN MA, 1995, P NATL ACAD SCI USA, V92, P4362, DOI 10.1073/pnas.92.10.4362; Brown MA, 1996, ONCOGENE, V12, P2507; Bruder CEG, 2001, HUM MOL GENET, V10, P271, DOI 10.1093/hmg/10.3.271; Carson N, 1999, AM J HUM GENET, V65, pA287; Charbonnier F, 2000, CANCER RES, V60, P2760; CLAUS EB, 1991, AM J HUM GENET, V48, P232; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Gad S, 2001, J MED GENET, V38, P388, DOI 10.1136/jmg.38.6.388; Gad S, 2001, GENE CHROMOSOME CANC, V31, P75, DOI 10.1002/gcc.1120; Laurendeau I, 1999, CLIN CHEM, V45, P982; Mazoyer S, 2000, AM J HUM GENET, V67, P207, DOI 10.1086/302974; Michalet X, 1997, SCIENCE, V277, P1518, DOI 10.1126/science.277.5331.1518; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Montagna M, 1999, ONCOGENE, V18, P4160, DOI 10.1038/sj.onc.1202754; Nordling M, 1998, CANCER RES, V58, P1372; Pages S, 2001, BRIT J CANCER, V84, P482, DOI 10.1054/bjoc.2000.1627; Payne SR, 2000, GENE CHROMOSOME CANC, V29, P58, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1008>3.0.CO;2-F; PetrijBosch A, 1997, NAT GENET, V17, P341, DOI 10.1038/ng1197-341; Puget N, 1999, AM J HUM GENET, V64, P300, DOI 10.1086/302211; Puget N, 1997, CANCER RES, V57, P828; Puget N, 1999, CANCER RES, V59, P455; Rohlfs EM, 2000, HUM GENET, V107, P385, DOI 10.1007/s004390000372; Rohlfs EM, 2000, GENE CHROMOSOME CANC, V28, P300, DOI 10.1002/1098-2264(200007)28:3<300::AID-GCC8>3.0.CO;2-1; Serova O, 1996, AM J HUM GENET, V58, P42; Smith TM, 1996, GENOME RES, V6, P1029, DOI 10.1101/gr.6.11.1029; StoppaLyonnet D, 1997, AM J HUM GENET, V60, P1021; Swensen J, 1997, HUM MOL GENET, V6, P1513, DOI 10.1093/hmg/6.9.1513; Unger MA, 2000, AM J HUM GENET, V67, P841, DOI 10.1086/303076; Wagner T, 1999, GENOMICS, V62, P369, DOI 10.1006/geno.1999.6026; Wang T, 2001, GENE CHROMOSOME CANC, V31, P91, DOI 10.1002/gcc.1110; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0; Xu CF, 1997, HUM MOL GENET, V6, P1057, DOI 10.1093/hmg/6.7.1057	34	73	81	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6841	6847		10.1038/sj.onc.1205685	http://dx.doi.org/10.1038/sj.onc.1205685			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360411				2022-12-25	WOS:000178315800015
J	Papi, A; Papadopoulos, NG; Stanciu, LA; Bellettato, CM; Pinamonti, S; Degitz, K; Holgate, ST; Johnston, SL				Papi, A; Papadopoulos, NG; Stanciu, LA; Bellettato, CM; Pinamonti, S; Degitz, K; Holgate, ST; Johnston, SL			Reducing agents inhibit rhinovirus-induced up-regulation of the rhinovirus receptor intercellular adhesion molecule-1 (ICAM-1) in respiratory epithelial cells	FASEB JOURNAL			English	Article						asthma; rhinitis; oxidants; nuclear factor kappa B	NF-KAPPA-B; OBSTRUCTIVE PULMONARY-DISEASE; TNF-ALPHA; ENDOTHELIAL-CELLS; TRANSCRIPTIONAL REGULATION; OXIDATIVE STRESS; LOWER AIRWAYS; EXPRESSION; ACTIVATION; GLUTATHIONE	Rhinoviruses are the major cause of common colds and of asthma exacerbations. Intercellular adhesion molecule-1 (ICAM-1) has a central role in airway inflammation and is the receptor for 90% of rhinoviruses. Rhinovirus infection of airway epithelium induces ICAM-1. Because redox state is directly implicated in inflammatory responses via molecular signaling mechanisms, here we studied the effects of reducing agents on rhinovirus-induced ICAM-1 expression, mRNA upregulation, promoter activation, and nuclear factor activation. To investigate the effects of rhinovirus infection on the intracellular redox balance, we also studied whether rhinovirus infection triggers the production of reactive oxygen species. We found that reduced (GSH) but not oxidized (GSSG) glutathione (1-100 muM) inhibited in a dose-dependent manner rhinovirus-induced ICAM-1 up-regulation and mRNA induction in primary bronchial and A549 respiratory epithelial cells. GSH but not GSSG also inhibited rhinovirus-induced ICAM-1 promoter activation and rhinovirus-induced NF-kappaB activation. In parallel, we found that rhinovirus infection induced a rapid increase of intracellular superoxide anion that was maximal at the time of NF-kappaB activation. This oxidant generation was completely inhibited by GSH. We conclude that redox-mediated intracellular pathways represent an important target for the therapeutic control of rhinovirus-induced diseases.	Univ Ferrara, Res Ctr Asthma & COPD, I-44100 Ferrara, Italy; Univ Southampton, Southampton, Hants, England; Univ Athens, Allergy Unit, Dept Pediat 2, GR-10679 Athens, Greece; Univ London Imperial Coll Sci Technol & Med, Dept Resp Med, Natl Heart & Lung Inst, London, England; Univ Ferrara, Dept Cell Biol, I-44100 Ferrara, Italy; Univ Munich, Dept Dermatol, D-8000 Munich, Germany	University of Ferrara; University of Southampton; National & Kapodistrian University of Athens; Imperial College London; University of Ferrara; University of Munich	Papi, A (corresponding author), Univ Ferrara, Res Ctr Asthma & COPD, Via Savonarla, I-44100 Ferrara, Italy.	ppa@dns.unife.it	N.G., Papadopoulos/L-8670-2013; Stanciu, Luminita A/B-8384-2012; Papi, alberto/AAC-1888-2019; Papadopoulos, Nikolaos/ABE-1774-2021; Johnston, Sebastian Lennox/I-2423-2012	N.G., Papadopoulos/0000-0002-4448-3468; Papadopoulos, Nikolaos/0000-0002-4448-3468; Johnston, Sebastian Lennox/0000-0003-3009-9200; Papadopoulos, Nikolaos/0000-0002-2508-3872; PAPI, ALBERTO/0000-0002-6924-4500				Atmar RL, 2001, LUNG BIOL HEALTH DIS, V154, P259; CALHOUN WJ, 1994, J CLIN INVEST, V94, P2200, DOI 10.1172/JCI117581; Chen CC, 2001, CELL SIGNAL, V13, P543, DOI 10.1016/S0898-6568(01)00171-1; Cho S, 1998, BIOCHEM BIOPH RES CO, V253, P104, DOI 10.1006/bbrc.1998.9697; Corne JM, 2002, LANCET, V359, P831, DOI 10.1016/S0140-6736(02)07953-9; Doull IJM, 1997, BMJ-BRIT MED J, V315, P858, DOI 10.1136/bmj.315.7112.858; FRAENKEL DJ, 1995, AM J RESP CRIT CARE, V151, P879; Gern JE, 1997, AM J RESP CRIT CARE, V155, P1159, DOI 10.1164/ajrccm.155.3.9117003; GREVE JM, 1989, CELL, V56, P839, DOI 10.1016/0092-8674(89)90688-0; Grunberg K, 2000, CLIN EXP ALLERGY, V30, P1015; Halliwell B., 1999, FREE RADICAL BIOL ME; Iantomasi T, 1997, BBA-BIOMEMBRANES, V1330, P274; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; Janssen-Heininger YMW, 2000, FREE RADICAL BIO MED, V28, P1317, DOI 10.1016/S0891-5849(00)00218-5; JEFFERSON TO, 2001, COCHRANE DATABASE SY, V3; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Johnston SL., 1997, DIAGNOSTIC PROCEDURE, P553; Krunkosky TM, 2000, AM J RESP CELL MOL, V22, P685, DOI 10.1165/ajrcmb.22.6.3925; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; Li NX, 1999, FASEB J, V13, P1137, DOI 10.1096/fasebj.13.10.1137; LOOK DC, 1994, J BIOL CHEM, V269, P8952; MULLER S, 1995, J INVEST DERMATOL, V104, P970, DOI 10.1111/1523-1747.ep12606225; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Papi A, 1999, J BIOL CHEM, V274, P9707, DOI 10.1074/jbc.274.14.9707; Papi A, 2000, J ALLERGY CLIN IMMUN, V105, P318, DOI 10.1016/S0091-6749(00)90082-4; Pinamonti S, 1996, FREE RADICAL BIO MED, V21, P147, DOI 10.1016/0891-5849(96)00030-5; Rahman I, 2000, EUR RESPIR J, V16, P534, DOI 10.1034/j.1399-3003.2000.016003534.x; Seemungal T, 2001, AM J RESP CRIT CARE, V164, P1618, DOI 10.1164/ajrccm.164.9.2105011; STANWAY G, 1994, ENCY VIROLOGY, V3, P1253; True AL, 2000, AM J PHYSIOL-LUNG C, V279, pL302, DOI 10.1152/ajplung.2000.279.2.L302; UNCAPHER CR, 1991, VIROLOGY, V180, P814, DOI 10.1016/0042-6822(91)90098-V; Van Klaveren RJ, 1999, FREE RADICAL RES, V30, P371, DOI 10.1080/10715769900300411; WEGNER CD, 1990, SCIENCE, V247, P456, DOI 10.1126/science.1967851; WILSON NM, 1990, ARCH DIS CHILD, V65, P407, DOI 10.1136/adc.65.4.407; Winther B, 1998, AM J RHINOL, V12, P17, DOI 10.2500/105065898782102954	35	38	41	0	1	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1934	+		10.1096/fj.02-0118fje	http://dx.doi.org/10.1096/fj.02-0118fje			15	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368227				2022-12-25	WOS:000179167600018
J	Bild, AH; Mendoza, FJ; Gibson, EM; Huang, M; Villanueva, J; Garrington, TP; Jove, R; Johnson, GL; Gibson, SB				Bild, AH; Mendoza, FJ; Gibson, EM; Huang, M; Villanueva, J; Garrington, TP; Jove, R; Johnson, GL; Gibson, SB			MEKK1-induced apoptosis requires TRAIL death receptor activation and is inhibited by AKT/PKB through inhibition of MEKK1 cleavage	ONCOGENE			English	Article						apoptosis; serine threonine kinases; signal transduction; death receptors; caspases; MAPK	FAS LIGAND EXPRESSION; DECOY RECEPTORS; PROTEIN-KINASE; CANCER-CELLS; MUTATIONS; GENES; INVOLVEMENT; RESISTANCE; INDUCTION; CASPASES	MEK kinase 1 (MEKK1) induces apoptosis through the activation of caspases. The mechanism for MEKK1-induced apoptosis involves caspase-mediated cleavage of MEKK1, releasing a pro-apoptotic 91 kDa kinase fragment that serves to further amplify caspase activation in a feedback loop. Both cleavage of MEKK1 and increased expression of death receptor 4 (DR4, TRAILR1) and death receptor 5 (DR5, TRAILR2) occur following exposure of cells to genotoxins. Overexpression of kinase inactive MEKK1 inhibits MEKK1-mediated apoptosis and effectively blocks death receptor upregulation following etoposide treatment. Herein, we investigate the role of death receptor activation and the ability of AKT/PKB (AKT) to inhibit cell death in MEKK1-induced apoptosis. We show that by preventing DR4 and DR5 activation through expression of decoy receptor 1 (DcR1) and dominant negative FADD, we inhibit MEKK1-induced apoptosis. Furthermore, expression of 91 kDa MEKK1 increased DR4 and FAS mRNA and protein levels. MEKK1-induced apoptosis is amplified by blocking PI-3 kinase activation and overexpression of AKT blocked both MEKK1-induced apoptosis and caspase activation. AKT overexpression also prevented the cleavage of endogenous MEKK1 by genotoxins. AKT did not, however, block MEKK1-induced JNK activation, showing that regulation of the JNK pathway by MEKK1 is independent of its role in regulation of apoptosis. Thus, MEKK1-induced apoptosis requires TRAIL death receptor activation and is blocked by AKT through inhibition of MEKK1 cleavage.	Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; Univ Colorado, Dept Pharmacol, Denver, CO 80262 USA; H Lee Moffit Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	University of Manitoba; University of Colorado System; University of Colorado Denver	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, 675 McDermot Ave, Winnipeg, MB R3E 0V9, Canada.			Gibson, Spencer/0000-0003-0119-732X				Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Asselin E, 2001, CANCER RES, V61, P1862; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; Friesen C, 1996, NAT MED, V2, P574, DOI 10.1038/nm0596-574; Gebauer G, 2000, INT J ONCOL, V16, P321; Gibson S, 1999, J BIOL CHEM, V274, P10916, DOI 10.1074/jbc.274.16.10916; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; GOLSTEIN P, 1997, CURR BIOL, V7, P750; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; Griffith TS, 1998, CURR OPIN IMMUNOL, V10, P559, DOI 10.1016/S0952-7915(98)80224-0; Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Lee SH, 2001, ONCOGENE, V20, P399, DOI 10.1038/sj.onc.1204103; Lin H, 2001, BIOCHEM J, V353, P299, DOI 10.1042/0264-6021:3530299; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Schlesinger Thomas K., 1998, Frontiers in Bioscience, V3, pD1181; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Shin MS, 2001, CANCER RES, V61, P4942; Soh JW, 2001, J BIOL CHEM, V276, P16406, DOI 10.1074/jbc.C100079200; Straus SE, 2001, BLOOD, V98, P194, DOI 10.1182/blood.V98.1.194; Tran J, 1999, BIOCHEM BIOPH RES CO, V264, P781, DOI 10.1006/bbrc.1999.1589; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Widmann C, 1997, ONCOGENE, V15, P2439, DOI 10.1038/sj.onc.1201421; Widmann C, 1998, MOL CELL BIOL, V18, P2416, DOI 10.1128/MCB.18.4.2416; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911	36	17	18	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6649	6656		10.1038/sj.onc.1205819	http://dx.doi.org/10.1038/sj.onc.1205819			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242663				2022-12-25	WOS:000178202300011
J	Soe, K; Hartmann, H; Schlott, B; Stevnsner, T; Grosse, F				Soe, K; Hartmann, H; Schlott, B; Stevnsner, T; Grosse, F			The tumor suppressor protein p53 stimulates the formation of the human topoisomerase I double cleavage complex in vitro	ONCOGENE			English	Article						topoisomerase I; p53; DNA damage; repair; recombination; genomic instability	DOUBLE-STRAND BREAKS; INDUCED DNA-DAMAGE; WILD-TYPE; COVALENT COMPLEXES; TERMINAL DOMAIN; REPLICATING DNA; T-ANTIGEN; REPAIR; CAMPTOTHECIN; CELLS	Previous studies have shown that human topoisomerase I interacts directly with the tumor-suppressor protein p53. In the past few years it has repeatedly been suggested that topoisomerase I and p53 may play a joint role in the response to genotoxic stress. This led to the suggestion that p53 and human topoisomerase I may cooperate in the process of DNA repair and/or apoptosis. Recently we have demonstrated that a human topoisomerase I cleavage complex can be recognized by an additional topoisomerase I molecule and thereby form a so-called double cleavage complex. The double cleavage complex creates an about 13 nucleotides long single-stranded gap that may provide an entry site for recombinational repair events. Here we demonstrate that p53 stimulates both the DNA relaxation activity as well as the formation of the human topoisomerase I double cleavage complex by at least a factor of six. Stimulation of topoisomerase I activity by p53 is mediated via the central part of topoisomerase I. We also show that human, bovine, and murine p53 stimulate human topoisomerase I relaxation activity equally well. From these results it is conceivable that p53's stimulatory activity on topoisomerase I may play a role in DNA recombination and repair as well as in apoptosis.	Inst Mol Biotechnol, Dept Biochem, D-07745 Jena, Germany; Aarhus Univ, Dept Biol Mol & Struct, Danish Ctr Mol Gerontol, DK-8000 Aarhus C, Denmark	Aarhus University	Grosse, F (corresponding author), Inst Mol Biotechnol, Dept Biochem, Beutenbergstr 11, D-07745 Jena, Germany.		Soe, Kent/N-3618-2017	Soe, Kent/0000-0001-7402-314X; Hartmann, Hella/0000-0002-7133-7474; Stevnsner, Tinna/0000-0003-1007-0427				Albor A, 1998, CANCER RES, V58, P2091; BISCHOFF JR, 1990, P NATL ACAD SCI USA, V87, P4766, DOI 10.1073/pnas.87.12.4766; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao YA, 1997, CANCER RES, V57, P5584; Christiansen K, 1999, BBA-GENE STRUCT EXPR, V1489, P249, DOI 10.1016/S0167-4781(99)00198-0; Degtyareva N, 2001, J BIOL CHEM, V276, P8778, DOI 10.1074/jbc.M006795200; DEQUIEDT F, 1995, DNA SEQUENCE, V5, P261, DOI 10.3109/10425179509030977; FRIEDMAN PN, 1993, P NATL ACAD SCI USA, V90, P3319, DOI 10.1073/pnas.90.8.3319; FROSINA G, 1992, CARCINOGENESIS, V13, P1371, DOI 10.1093/carcin/13.8.1371; Gobert C, 1999, P NATL ACAD SCI USA, V96, P10355, DOI 10.1073/pnas.96.18.10355; Gobert C, 1996, BIOCHEMISTRY-US, V35, P5778, DOI 10.1021/bi952327w; Haluska P, 1998, NUCLEIC ACIDS RES, V26, P1841, DOI 10.1093/nar/26.7.1841; Haluska P, 1999, NUCLEIC ACIDS RES, V27, P2538, DOI 10.1093/nar/27.12.2538; Jayaraman L, 1999, CELL MOL LIFE SCI, V55, P76, DOI 10.1007/s000180050271; JONES JC, 1991, MUTAT RES, V255, P155, DOI 10.1016/0921-8777(91)90049-U; Labourier E, 1998, NUCLEIC ACIDS RES, V26, P2955, DOI 10.1093/nar/26.12.2955; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; Lanza A, 1996, J BIOL CHEM, V271, P6978, DOI 10.1074/jbc.271.12.6978; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; Mao YH, 2000, CANCER RES, V60, P4538; Mao YH, 2002, P NATL ACAD SCI USA, V99, P1235, DOI 10.1073/pnas.022631899; May P, 1999, ONCOGENE, V18, P7621, DOI 10.1038/sj.onc.1203285; Megonigal MD, 1997, J BIOL CHEM, V272, P12801, DOI 10.1074/jbc.272.19.12801; Pouliot JJ, 1999, SCIENCE, V286, P552, DOI 10.1126/science.286.5439.552; Pouliot JJ, 2001, GENES CELLS, V6, P677, DOI 10.1046/j.1365-2443.2001.00452.x; Pourquier P, 2000, P NATL ACAD SCI USA, V97, P1885, DOI 10.1073/pnas.97.4.1885; Pourquier P, 2001, CANCER RES, V61, P53; Pourquier P, 1997, J BIOL CHEM, V272, P26441, DOI 10.1074/jbc.272.42.26441; Pourquier P, 1999, J BIOL CHEM, V274, P8516, DOI 10.1074/jbc.274.13.8516; Pourquier P, 1997, J BIOL CHEM, V272, P7792, DOI 10.1074/jbc.272.12.7792; RYAN AJ, 1991, NUCLEIC ACIDS RES, V19, P3295, DOI 10.1093/nar/19.12.3295; Sigal A, 2000, CANCER RES, V60, P6788; SNAPKA RM, 1988, MOL CELL BIOL, V8, P515, DOI 10.1128/MCB.8.2.515; Soe K, 2001, NUCLEIC ACIDS RES, V29, P3195, DOI 10.1093/nar/29.15.3195; SQUIRES S, 1991, J CELL SCI, V100, P883; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1841, DOI 10.1093/carcin/14.9.1841; STEWART AF, 1987, CELL, V50, P1109, DOI 10.1016/0092-8674(87)90177-2; STEWART AF, 1990, CELL, V60, P141; Stewart L, 1996, J BIOL CHEM, V271, P7602, DOI 10.1074/jbc.271.13.7602; STURZBECHER HW, 1992, ONCOGENE, V7, P1513; Subramanian D, 1998, CANCER RES, V58, P976; THIELMANN HW, 1993, CARCINOGENESIS, V14, P2341, DOI 10.1093/carcin/14.11.2341; TSAO YP, 1993, CANCER RES, V53, P5908; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WANG Y, 1993, GENE DEV, V7, P2575, DOI 10.1101/gad.7.12b.2575; Weisshart K, 2000, J BIOL CHEM, V275, P17328, DOI 10.1074/jbc.M000717200; Wood Richard D., 1995, Methods (Orlando), V7, P163, DOI 10.1006/meth.1995.1022; Wu JX, 1997, NUCLEIC ACIDS RES, V25, P4181, DOI 10.1093/nar/25.21.4181; YANG L, 1987, P NATL ACAD SCI USA, V84, P950, DOI 10.1073/pnas.84.4.950; Yang SW, 1996, P NATL ACAD SCI USA, V93, P11534, DOI 10.1073/pnas.93.21.11534	50	10	11	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6614	6623		10.1038/sj.onc.1205912	http://dx.doi.org/10.1038/sj.onc.1205912			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242659				2022-12-25	WOS:000178202300007
J	Endlich, N; Sunohara, M; Nietfeld, W; Wolski, EW; Schiwek, D; Kranzlin, B; Gretz, N; Kriz, W; Eickhoff, H; Endlich, K				Endlich, N; Sunohara, M; Nietfeld, W; Wolski, EW; Schiwek, D; Kranzlin, B; Gretz, N; Kriz, W; Eickhoff, H; Endlich, K			Analysis of differential gene expression in stretched podocytes: osteopontin enhances adaptation of podocytes to mechanical stress	FASEB JOURNAL			English	Article						glomerular hypertension; nephron degeneration; cDNA array; actin cytoskeleton; DOCA-salt	FAWN-HOODED RAT; GLOMERULAR INJURY; HEMODYNAMIC BASIS; GLOMERULOSCLEROSIS; CELLS; TRANSGLUTAMINASE; HYPERTENSION; NEPHROPATHY; CORTACTIN; ADHESION	Glomerular hypertension is a major determinant advancing progression to end-stage renal failure. Podocytes, which are thought to counteract pressure-mediated capillary expansion, are increasingly challenged in glomerular hypertension. Studies in animal models of glomerular hypertension indicate that glomerulosclerosis develops from adhesions of the glomerular tuft to Bowman's capsule due to progressive podocyte loss. However, the molecular alterations of podocytes in glomerular hypertension are unknown. In this study, we determined the changes in gene expression in podocytes induced by mechanical stress in vitro (cyclic biaxial stretch, 0.5 Hz, 5% linear strain, 3 days) using cDNA arrays (6144 clones). Sixteen differentially regulated genes were identified, suggesting alterations of cell-matrix interaction, mitochondrial/metabolic function, and protein synthesis/degradation in stretched podocytes. The transcript for the matricellular protein osteopontin (OPN) was most strongly up-regulated by stretch (approximately threefold). By reverse transcriptase-polymer chain reaction, up-regulation of OPN mRNA was also detected in glomeruli of rats treated for 2.5 wk with desoxycorticosterone acetate-salt, an animal model of glomerular hypertension. In cultured podocytes, OPN coating induced a motile phenotype increasing actin nucleation proteins at cell margins and reducing stress fibers and focal adhesions. Intriguingly, additional OPN coating of collagen IV-coated membranes accelerated stretch-induced actin reorganization and markedly diminished podocyte loss at higher strain. This study delineates the molecular response of podocytes to mechanical stress and identifies OPN as a stretch-adapting molecule in podocytes.	Univ Heidelberg, Inst Anat & Zellbiol 1, Dept Anat & Cell Biol, INF 307, D-69120 Heidelberg, Germany; Max Planck Inst Mol Genet, D-14195 Berlin, Germany; Univ Heidelberg, Klinikum Mannheim, Med Res Ctr, D-68167 Mannheim, Germany	Ruprecht Karls University Heidelberg; Max Planck Society; Ruprecht Karls University Heidelberg	Endlich, K (corresponding author), Univ Heidelberg, Inst Anat & Zellbiol 1, Dept Anat & Cell Biol, INF 307, D-69120 Heidelberg, Germany.	karlhans.endlich@urz.uni-heidelberg.de	Endlich, Karlhans/G-5485-2013; Sunohara, Masataka/ABA-4095-2020	Endlich, Karlhans/0000-0001-6052-6061				Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; DURVASULA RV, 2001, J AM SOC NEPHROL, V12, pA3514; DWORKIN LD, 1984, J CLIN INVEST, V73, P1448, DOI 10.1172/JCI111349; Eickhoff H, 2000, GENOME RES, V10, P1230, DOI 10.1101/gr.10.8.1230; Endlich N, 2001, J AM SOC NEPHROL, V12, P413, DOI 10.1681/ASN.V123413; Endlich N, 2001, EXP NEPHROL, V9, P436; GENTILE V, 1992, J CELL BIOL, V119, P463, DOI 10.1083/jcb.119.2.463; Hartner A, 2001, AM J KIDNEY DIS, V38, P153, DOI 10.1053/ajkd.2001.25209; HAYWARD A, 2001, J AM SOC NEPHROL, V12, pA2402; Holthofer H, 1999, FASEB J, V13, P523, DOI 10.1096/fasebj.13.3.523; Kerjaschki D, 1996, J AM SOC NEPHROL, V7, P2518; KleinNulend J, 1997, J CELL PHYSIOL, V170, P174, DOI 10.1002/(SICI)1097-4652(199702)170:2<174::AID-JCP9>3.0.CO;2-L; KRETZLER M, 1994, VIRCHOWS ARCH, V425, P181; KRIZ W, 1994, KIDNEY INT, V45, P369, DOI 10.1038/ki.1994.47; Kriz W, 1998, KIDNEY INT, V54, P687, DOI 10.1046/j.1523-1755.1998.00044.x; Kriz W, 1998, J AM SOC NEPHROL, V9, P381; Lan HY, 1998, KIDNEY INT, V53, P136, DOI 10.1046/j.1523-1755.1998.00748.x; Meier-Ewert S, 1998, NUCLEIC ACIDS RES, V26, P2216, DOI 10.1093/nar/26.9.2216; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Nanda N, 2001, J BIOL CHEM, V276, P20673, DOI 10.1074/jbc.M010846200; OBryan GT, 1997, SEMIN NEPHROL, V17, P93; Petermann AT, 2002, KIDNEY INT, V61, P40, DOI 10.1046/j.1523-1755.2002.00102.x; Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798; Ricardo SD, 2000, AM J PHYSIOL-RENAL, V278, pF708, DOI 10.1152/ajprenal.2000.278.5.F708; Rohrmoser MM, 1996, KIDNEY BLOOD PRESS R, V19, P263, DOI 10.1159/000174086; Schwenger V, 1999, NEPHRON, V83, P202, DOI 10.1159/000045512; SIMONS JL, 1993, J AM SOC NEPHROL, V3, P1775; Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063; Solin ML, 2001, KIDNEY INT, V59, P481, DOI 10.1046/j.1523-1755.2001.059002481.x; TOJO A, 1990, VIRCHOWS ARCH A, V417, P389, DOI 10.1007/BF01606027; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; van Dokkum RPE, 1999, AM J PHYSIOL-REG I, V276, pR855, DOI 10.1152/ajpregu.1999.276.3.R855; van Dokkum RPE, 1999, AM J PHYSIOL-REG I, V276, pR189, DOI 10.1152/ajpregu.1999.276.1.R189; van Rodijnen WF, 2002, HYPERTENSION, V39, P111, DOI 10.1161/hy1201.096817; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Welsch T, 2001, AM J PHYSIOL-RENAL, V281, pF769, DOI 10.1152/ajprenal.2001.281.4.F769; Xie YS, 2001, KIDNEY INT, V60, P1645, DOI 10.1046/j.1523-1755.2001.00032.x; Yaoita E, 2001, CELL TISSUE RES, V304, P339	40	77	78	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	SEP	2002	16	11					1850	+		10.1096/fj.02-0125fje	http://dx.doi.org/10.1096/fj.02-0125fje			24	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	601JC	12354696				2022-12-25	WOS:000178441800005
J	Zuo, YH; Deutscher, MP				Zuo, YH; Deutscher, MP			Mechanism of action of RNase T	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNASE ACTIVITY; MATURATION; PRECURSORS	Escherichia coli RNase T, an RNA-processing enzyme and a member of the DEDD exonuclease superfamily, was examined using sequence analysis and site-directed mutagenesis. Like other DEDD exonucleases, RNase T was found to contain three conserved Exo motifs that included four invariant acidic residues. Mutagenesis of these motifs revealed that they are essential for RNase T activity, indicating that they probably form the RNase T catalytic center in a manner similar to that found in other DEDD exonucleases. We also identified by sequence analysis three short, but highly conserved, sequence segments rich in positively charged residues. Site-directed mutagenesis of these regions indicated that they are involved in substrate binding. Additional analysis revealed that residues within the C-terminal region of RNase T are essential for RNase T dimerization and, consequently, for RNase T activity. These data define the domains necessary for RNase T action, and together with information in the accompanying article, have led to the formulation of a detailed model for the structure and mechanism of action of RNase T.	Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA	University of Miami	Deutscher, MP (corresponding author), Univ Miami, Sch Med, Dept Biochem & Mol Biol, Miami, FL 33101 USA.	mdeutsch@med.miami.edu	Zuo, Yuhong/H-7392-2012	Zuo, Yuhong/0000-0003-1810-4580	NIGMS NIH HHS [GM 16317] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEESE LS, 1991, EMBO J, V10, P25, DOI 10.1002/j.1460-2075.1991.tb07917.x; BERNAD A, 1989, CELL, V59, P219, DOI 10.1016/0092-8674(89)90883-0; DEUTSCHER MP, 1985, P NATL ACAD SCI USA, V82, P6427, DOI 10.1073/pnas.82.19.6427; Deutscher MP, 2001, PROG NUCLEIC ACID RE, V66, P67; DEUTSCHER MP, 1985, J BIOL CHEM, V260, P7067; KOONIN EV, 1993, NUCLEIC ACIDS RES, V21, P2521, DOI 10.1093/nar/21.10.2521; LI ZW, 1995, P NATL ACAD SCI USA, V92, P6883, DOI 10.1073/pnas.92.15.6883; Li ZW, 1996, J BIOL CHEM, V271, P1133, DOI 10.1074/jbc.271.2.1133; Li ZW, 1996, J BIOL CHEM, V271, P1127, DOI 10.1074/jbc.271.2.1127; Li ZW, 1999, RNA, V5, P139, DOI 10.1017/S1355838299981669; Li ZW, 1998, P NATL ACAD SCI USA, V95, P2856, DOI 10.1073/pnas.95.6.2856; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; PADMANABHA KP, 1991, J BACTERIOL, V173, P1376, DOI 10.1128/jb.173.4.1376-1381.1991; REUVEN NB, 1993, FASEB J, V7, P143, DOI 10.1096/fasebj.7.1.8422961; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Viswanathan M, 1998, J BIOL CHEM, V273, P35126, DOI 10.1074/jbc.273.52.35126; Zuo YH, 1999, NUCLEIC ACIDS RES, V27, P4077, DOI 10.1093/nar/27.20.4077; Zuo YH, 2002, J BIOL CHEM, V277, P50160, DOI 10.1074/jbc.M207707200; Zuo YH, 2002, J BIOL CHEM, V277, P29654, DOI 10.1074/jbc.M204252200; Zuo YH, 2001, NUCLEIC ACIDS RES, V29, P1017, DOI 10.1093/nar/29.5.1017	20	25	28	4	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50155	50159		10.1074/jbc.M207706200	http://dx.doi.org/10.1074/jbc.M207706200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12364334	hybrid			2022-12-25	WOS:000180028900135
J	Chang, JS; Henry, K; Wolf, BL; Geli, M; Lemmon, SK				Chang, JS; Henry, K; Wolf, BL; Geli, M; Lemmon, SK			Protein phosphatase-1 binding to Scd5p is important for regulation of actin organization and endocytosis in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE/THREONINE KINASE PRK1P; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; GLYCOGEN ACCUMULATION; CLATHRIN DEFICIENCY; BUDDING YEAST; TYPE-1; PHOSPHORYLATION; CYTOSKELETON; ENCODES	SCD5, an essential gene, encodes a protein important for endocytosis and actin organization in yeast. Previous two-hybrid screens showed that Scd5p interacts with Glc7p, a yeast Ser/Thr-specific protein phosphatase-1 (PP1) that participates in a variety of cellular processes. PP1 substrate specificity in vivo is regulated by association with different regulatory or targeting subunits, many of which have a consensus PP1-binding site ((V/I)XT, with a basic residue at the -1 or -2 position). Scd5p contains two of these potential PP1-binding motifs: KVDF (amino acids 240-243) and KKVRF (amino acids 272-276). Deletion analysis mapped the PP1-binding domain to a region of Scd5p containing these motifs. Therefore, the consequence of mutating these two potential PP1-binding sites was examined. Although mutation of KVDF had no effect, alteration of KKVRF dramatically reduced Scd5p interaction with Glc7p and resulted in temperature-sensitive growth. Furthermore, this mutation caused defects in fluid phase and receptor-mediated endocytosis and actin organization. Overexpression of GLC7 suppressed the temperature-sensitive growth of the KKVRF mutant and partially rescued the actin organization phenotype. These results provide evidence that Scd5p is a PP1 targeting subunit for regulation of actin organization and endocytosis or that Scd5p is a PP1 substrate, which regulates the function of Scd5p in these processes.	Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; Heidelberg Univ, Zentrum Biochem, D-69120 Heidelberg, Germany	Case Western Reserve University; Ruprecht Karls University Heidelberg	Lemmon, SK (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, 10900 Euclid Ave, Cleveland, OH 44106 USA.	skl@po.ewru.edu	Chang, Ji Suk/N-1957-2017; Geli, Maria Isabel/L-3246-2014	Geli, Maria Isabel/0000-0002-3452-6700; Lemmon, Sandra/0000-0002-8022-130X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM020082, R01GM055796] Funding Source: NIH RePORTER; NIGMS NIH HHS [F31 GM20082, R01 GM55796] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1991, METHOD ENZYMOL, V194, P729; AIYAR A, 1993, BIOTECHNIQUES, V14, P366; Anderson C, 2001, J BACTERIOL, V183, P821, DOI 10.1128/JB.183.3.821-829.2001; Andrews PD, 2000, J CELL SCI, V113, P507; Balguerie A, 1999, J CELL SCI, V112, P2529; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOTSTEIN D, 1979, GENE, V8, P17, DOI 10.1016/0378-1119(79)90004-0; CANNON JF, 1994, GENETICS, V136, P485; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Cope MJTV, 1999, J CELL BIOL, V144, P1203, DOI 10.1083/jcb.144.6.1203; Dombek KM, 1999, MOL CELL BIOL, V19, P6029; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; FENG ZH, 1991, J BIOL CHEM, V266, P23796; Fong NM, 2000, J BIOL CHEM, V275, P35034, DOI 10.1074/jbc.M005541200; FRANCOIS JM, 1992, EMBO J, V11, P87, DOI 10.1002/j.1460-2075.1992.tb05031.x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; HARDY TA, 1993, J BIOL CHEM, V268, P23799; Henry KR, 2002, MOL BIOL CELL, V13, P2607, DOI 10.1091/mbc.E02-01-0012; HISAMOTO N, 1995, MOL CELL BIOL, V15, P3767; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huang DQ, 1996, MOL CELL BIOL, V16, P4357; Huang DQ, 1998, MOL CELL BIOL, V18, P3289, DOI 10.1128/MCB.18.6.3289; Huang DQ, 1996, GENETICS, V143, P119; Huang HB, 1999, J BIOL CHEM, V274, P7870, DOI 10.1074/jbc.274.12.7870; HUBBARD MJ, 1989, EUR J BIOCHEM, V186, P701, DOI 10.1111/j.1432-1033.1989.tb15263.x; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; James P, 1996, GENETICS, V144, P1425; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; Kaiser C, 1994, METHODS YEAST GENETI, P169; Katayama H, 2001, J BIOL CHEM, V276, P46219, DOI 10.1074/jbc.M107540200; MACKELVIE SH, 1995, MOL CELL BIOL, V15, P3777; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; Miller JH., 1972, EXPT MOL GENETICS; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; MUNN AL, 1995, MOL BIOL CELL, V6, P1721, DOI 10.1091/mbc.6.12.1721; Nelson KK, 1996, MOL BIOL CELL, V7, P245, DOI 10.1091/mbc.7.2.245; NELSON KK, 1993, MOL CELL BIOL, V13, P521, DOI 10.1128/MCB.13.1.521; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; PARK IK, 1994, J BIOL CHEM, V269, P28919; PRINGLE JR, 1991, METHOD ENZYMOL, V194, P565; ROCKMILL B, 1990, GENETICS, V126, P563; Sanz P, 2000, MOL CELL BIOL, V20, P1321, DOI 10.1128/MCB.20.4.1321-1328.2000; Schillace RV, 2001, J BIOL CHEM, V276, P12128, DOI 10.1074/jbc.M010398200; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; SIKORSKI RS, 1989, GENETICS, V122, P19; Stark MJR, 1996, YEAST, V12, P1647, DOI 10.1002/(SICI)1097-0061(199612)12:16<1647::AID-YEA71>3.0.CO;2-Q; STEPP JD, 1995, MOL BIOL CELL, V6, P41, DOI 10.1091/mbc.6.1.41; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; STUART JS, 1994, MOL CELL BIOL, V14, P896, DOI 10.1128/MCB.14.2.896; SUTTON A, 1991, MOL CELL BIOL, V11, P2133, DOI 10.1128/MCB.11.4.2133; Tachikawa H, 2001, J CELL BIOL, V155, P797, DOI 10.1083/jcb.200107008; Tanaka J, 1998, BIOCHEMISTRY-US, V37, P16697, DOI 10.1021/bi980782x; Trinkle-Mulcahy L, 1999, J CELL SCI, V112, P157; Tu JL, 1996, MOL CELL BIOL, V16, P4199; TU JL, 1995, EMBO J, V14, P5939, DOI 10.1002/j.1460-2075.1995.tb00282.x; TUNG HYL, 1995, MOL CELL BIOL, V15, P6064; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Watson HA, 2001, MOL BIOL CELL, V12, P3668, DOI 10.1091/mbc.12.11.3668; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wu X, 2001, MOL GENET GENOMICS, V265, P622, DOI 10.1007/s004380100455; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; Zeng GH, 2001, MOL BIOL CELL, V12, P3759, DOI 10.1091/mbc.12.12.3759; Zeng GS, 1999, J CELL BIOL, V144, P71, DOI 10.1083/jcb.144.1.71; Zhao SM, 1997, J BIOL CHEM, V272, P28368, DOI 10.1074/jbc.272.45.28368	67	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48002	48008		10.1074/jbc.M208471200	http://dx.doi.org/10.1074/jbc.M208471200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12356757	hybrid			2022-12-25	WOS:000179789600006
J	Gomez, E; Pritchard, C; Herbert, TP				Gomez, E; Pritchard, C; Herbert, TP			cAMP-dependent protein kinase and Ca2+ influx through L-type voltage-gated calcium channels mediate Raf-independent activation of extracellular regulated kinase in response to glucagon-like peptide-1 in pancreatic beta-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							B-RAF; MAP KINASE; INSULIN-SECRETION; NUCLEAR TRANSLOCATION; TYROSINE-PHOSPHATASE; DNA-SYNTHESIS; CYCLIC-AMP; LINE MIN6; GLUCOSE; PATHWAY	Glucagon like peptide-1 (GLP1) is a G(s)-coupled receptor agonist that exerts multiple effects on pancreatic beta-cells, including the stimulation of insulin gene expression and secretion. In this report, we show that treatment of the mouse pancreatic beta-cell line MIN6 with GLP1 leads to the glucose-dependent activation of Erk. These effects are mimicked by forskolin, a direct activator of adenylate cyclase, and blocked by H89, an inhibitor of cAMP-dependent protein kinase. Additionally, we provide evidence that GLP1-stimulated activation of Erk requires an influx of calcium through L-type voltage-gated calcium channels and the activation of calcium/calmodulin-dependent protein kinase II. GLP1-stimulated activation of Erk is blocked by inhibitors of MEK, but GLP1 does not induce the activation of A-Raf, B-Raf, C-Raf, or Ras. Additionally, dominant negative forms of Ras(N17) and Rap1(N17) fail to block GLP1-stimulated activation of Erk. In conclusion, our results indicate that, in the presence of stimulatory concentrations of glucose, GLP1 stimulates the activation of Erk through a mechanism dependent on MEK but independent of both Raf and Ras. This requires 1) the activation of cAMP-dependent protein kinase, 2) an influx of extracellular Ca2+ through L-type voltage-gated calcium channels, and 3) the activation of CaM kinase II.	Univ Leicester, Dept Biochem, Leicester LE1 7RH, Leics, England	University of Leicester	Herbert, TP (corresponding author), Univ Leicester, Dept Biochem, Adrian Bldg,Univ Rd, Leicester LE1 7RH, Leics, England.		Tuluc, Petronel/C-2527-2011	Pritchard, Catrin/0000-0003-1859-4487; Herbert, Terence/0000-0001-5402-0814				Benes C, 1999, BIOCHEM J, V340, P219, DOI 10.1042/0264-6021:3400219; Benes C, 1998, J BIOL CHEM, V273, P15507, DOI 10.1074/jbc.273.25.15507; Bhatt HS, 2000, BIOCHEM PHARMACOL, V60, P1655, DOI 10.1016/S0006-2952(00)00483-4; Blanco-Aparicio C, 1999, J CELL BIOL, V147, P1129, DOI 10.1083/jcb.147.6.1129; Bode HP, 1999, ENDOCRINOLOGY, V140, P3919, DOI 10.1210/en.140.9.3919; Buteau J, 1999, DIABETOLOGIA, V42, P856, DOI 10.1007/s001250051238; Buteau J, 2001, DIABETES, V50, P2237, DOI 10.2337/diabetes.50.10.2237; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Dolmetsch RE, 2001, SCIENCE, V294, P333, DOI 10.1126/science.1063395; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Easom RA, 1997, ENDOCRINOLOGY, V138, P2359, DOI 10.1210/en.138.6.2359; Fan GH, 1999, MOL PHARMACOL, V56, P39, DOI 10.1124/mol.56.1.39; Ginnan R, 2002, AM J PHYSIOL-CELL PH, V282, pC754, DOI 10.1152/ajpcell.00335.2001; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Holz GG, 1999, J BIOL CHEM, V274, P14147, DOI 10.1074/jbc.274.20.14147; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; HOLZ GG, 1993, NATURE, V361, P362, DOI 10.1038/361362a0; HOLZ GG, 1995, J BIOL CHEM, V270, P17749, DOI 10.1074/jbc.270.30.17749; Huser M, 2001, EMBO J, V20, P1940, DOI 10.1093/emboj/20.8.1940; ISHIHARA H, 1993, DIABETOLOGIA, V36, P1139, DOI 10.1007/BF00401058; Marais R, 1997, J BIOL CHEM, V272, P4378, DOI 10.1074/jbc.272.7.4378; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Montrose-Rafizadeh C, 1999, ENDOCRINOLOGY, V140, P1132, DOI 10.1210/en.140.3.1132; Muthalif MM, 1996, J BIOL CHEM, V271, P30149, DOI 10.1074/jbc.271.47.30149; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Perfetti R, 2000, EUR J ENDOCRINOL, V143, P717, DOI 10.1530/eje.0.1430717; Qiu WS, 2000, J BIOL CHEM, V275, P31921, DOI 10.1074/jbc.M003327200; Saxena M, 1999, NAT CELL BIOL, V1, P305, DOI 10.1038/13024; Schmitt JM, 2001, MOL CELL BIOL, V21, P3671, DOI 10.1128/MCB.21.11.3671-3683.2001; Skelly RH, 1996, DIABETES, V45, P37, DOI 10.2337/diabetes.45.1.37; Stork PJS, 2002, TRENDS CELL BIOL, V12, P258, DOI 10.1016/S0962-8924(02)02294-8; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166; Williams CL, 1996, BIOCHEM PHARMACOL, V51, P707, DOI 10.1016/S0006-2952(95)02393-3; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366	39	128	134	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48146	48151		10.1074/jbc.M209165200	http://dx.doi.org/10.1074/jbc.M209165200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12364324	hybrid			2022-12-25	WOS:000179789600024
J	Vadnais, J; Nault, G; Daher, Z; Amraei, M; Dodier, Y; Nabi, IR; Noel, J				Vadnais, J; Nault, G; Daher, Z; Amraei, M; Dodier, Y; Nabi, IR; Noel, J			Autocrine activation of the hepatocyte growth factor receptor/Met tyrosine kinase induces tumor cell motility by regulating pseudopodial protrusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; LUNG-CARCINOMA CELLS; CANINE KIDNEY-CELLS; C-MET PROTOONCOGENE; PHOSPHATIDYLINOSITOL 3-KINASE; PROGNOSTIC-SIGNIFICANCE; MET/HGF RECEPTOR; EPITHELIAL-CELLS; RENAL-CARCINOMA; EXPRESSION	The multiple beta-actin rich pseudopodial protrusions of the invasive variant of Moloney sarcoma virus (MSV)-transformed epithelial MDCK cells (MSV-MDCK-INV) are strongly labeled for phosphotyrosine. Increased tyrosine phosphorylation among a number of proteins was detected in MSV-MDCK-INV cells relative to untransformed and MSV-transformed MDCK cells, especially for the hepatocyte growth factor receptor (HGF-R), otherwise known as c-met proto-oncogene. Cell surface expression of HGF-R was similar in the three cell lines, indicating that HGF-R is constitutively phosphorylated in MSV-MDCK-INV cells. Both the tyrosine kinase inhibitor herbimycin A and the HGFalpha antibody abolished HGF-R phosphorylation, induced retraction of pseudopodial protrusions, and promoted the establishment of cell-cell contacts as well as the apparition of numerous stabilizing stress fibers in MSV-MDCK-INV cells. Furthermore, anti-HGFalpha antibody abolished cell motility among MSV-MDCK-INV cells. Conditioned medium from MSV-MDCK-INV cells induced MDCK cell scattering, indicating that HGF is secreted by MSV-MDCK-INV cells. HGF titration followed by a subsequent washout of the antibodies led to renewed pseudopodial protrusion and cellular movement. We therefore show that activation of the tyrosine kinase activity of HGF-R/Met via an autocrine HGF loop is directly responsible for pseudopodial protrusion, thereby explaining the motile and invasive potential of this model epithelium-derived tumor cell line.	Univ Montreal, Fac Med, Dept Physiol, Grp Rech Transport Membranaire, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Dept Pathol & Biol Cellulaire, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Noel, J (corresponding author), Univ Montreal, Fac Med, Dept Physiol, Grp Rech Transport Membranaire, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Nabi, Ivan R/C-5493-2009; Nabi, Ivan/GWZ-5144-2022	Nabi, Ivan/0000-0002-0670-0513				Adachi T, 1996, HEPATOLOGY, V23, P1244; Arencibia I, 1997, J IMMUNOL, V159, P1853; Auersperg N, 1997, J CELL PHYSIOL, V173, P261, DOI 10.1002/(SICI)1097-4652(199711)173:2<261::AID-JCP32>3.0.CO;2-G; AUSPRUNK DH, 1977, MICROVASC RES, V14, P53, DOI 10.1016/0026-2862(77)90141-8; Balkovetz DF, 1998, MICROSC RES TECHNIQ, V43, P456, DOI 10.1002/(SICI)1097-0029(19981201)43:5<456::AID-JEMT11>3.0.CO;2-2; Balkovetz DF, 1999, INT REV CYTOL, V186, P225; Bardelli A, 1997, BBA-REV CANCER, V1333, pM41, DOI 10.1016/S0304-419X(97)00026-7; BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BIRCHMEIER C, 1993, ANNU REV CELL BIOL, V9, P511, DOI 10.1146/annurev.cb.09.110193.002455; Birchmeier W, 1997, CIBA F SYMP, V212, P230; Borset M, 1996, J BIOL CHEM, V271, P24655, DOI 10.1074/jbc.271.40.24655; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CARRAWAY KL, 1995, BIOESSAYS, V17, P171, DOI 10.1002/bies.950170212; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; CLARK P, 1994, J CELL SCI, V107, P1265; FERRACINI R, 1995, ONCOGENE, V10, P739; Furge KA, 2000, ONCOGENE, V19, P5582, DOI 10.1038/sj.onc.1203859; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; Gual P, 2000, ONCOGENE, V19, P1509, DOI 10.1038/sj.onc.1203514; GUIRGUIS R, 1987, NATURE, V329, P261, DOI 10.1038/329261a0; Herrera R, 1998, J CELL SCI, V111, P1039; HUMPHREY PA, 1995, AM J PATHOL, V147, P386; ITAKURA Y, 1994, CANCER LETT, V83, P235, DOI 10.1016/0304-3835(94)90325-5; Jeffers M, 1998, P NATL ACAD SCI USA, V95, P14417, DOI 10.1073/pnas.95.24.14417; Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445; Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976; Kamikura DM, 2000, MOL CELL BIOL, V20, P3482, DOI 10.1128/MCB.20.10.3482-3496.2000; KRAMER RH, 1986, CANCER RES, V46, P1980; Lagana A, 2000, J CELL SCI, V113, P3649; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; Le PU, 1998, CANCER RES, V58, P1631; Maheshwari G, 2001, J CELL BIOL, V155, P1123, DOI 10.1083/jcb.200109060; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOHLER JL, 1987, J UROLOGY, V137, P544, DOI 10.1016/S0022-5347(17)44103-6; MUELLER SC, 1991, J CELL SCI, V99, P213; MULLERGLAUSER W, 1985, CELL BIOL INT REP, V9, P447, DOI 10.1016/0309-1651(85)90153-5; Nabi IR, 1999, J CELL SCI, V112, P1803; Nakajima M, 1999, CANCER, V85, P1894; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; NAZ RK, 1994, MOL REPROD DEV, V38, P431, DOI 10.1002/mrd.1080380411; Nguyen TN, 2000, EXP CELL RES, V258, P171, DOI 10.1006/excr.2000.4929; OTSUBO Y, 1982, J ORAL PATHOL MED, V11, P159, DOI 10.1111/j.1600-0714.1982.tb00152.x; Prat M, 1998, J CELL SCI, V111, P237; Rahimi N, 1996, CELL GROWTH DIFFER, V7, P263; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; RUSSO RG, 1981, J CELL BIOL, V91, P459, DOI 10.1083/jcb.91.2.459; Scarpino S, 1999, J PATHOL, V189, P570; Schmidt L, 1998, CANCER RES, V58, P1719; Scotlandi K, 1996, AM J PATHOL, V149, P1209; Simard D, 1996, BIOCHEM BIOPH RES CO, V219, P122, DOI 10.1006/bbrc.1996.0192; Sipeki S, 1999, CELL SIGNAL, V11, P885, DOI 10.1016/S0898-6568(99)00060-1; Stella MC, 1999, INT J BIOCHEM CELL B, V31, P1357, DOI 10.1016/S1357-2725(99)00089-8; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Takayama H, 1997, P NATL ACAD SCI USA, V94, P701, DOI 10.1073/pnas.94.2.701; Tokunou M, 2001, AM J PATHOL, V158, P1451, DOI 10.1016/S0002-9440(10)64096-5; TSAO MS, 1993, CELL GROWTH DIFFER, V4, P571; Tuck AB, 1996, AM J PATHOL, V148, P225; Ueki T, 1997, HEPATOLOGY, V25, P619, DOI 10.1002/hep.510250321; Vande Woude GF, 1997, CIBA F SYMP, V212, P119; Webb CP, 1996, J CELL SCI, V109, P2371; Yamamura S, 1996, FEBS LETT, V382, P193, DOI 10.1016/0014-5793(96)00175-5	63	13	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48342	48350		10.1074/jbc.M209481200	http://dx.doi.org/10.1074/jbc.M209481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12372820	hybrid			2022-12-25	WOS:000179789600050
J	del Pozo, AM; Lacadena, V; Mancheno, JM; Olmo, N; Onaderra, M; Gavilanes, JG				del Pozo, AM; Lacadena, V; Mancheno, JM; Olmo, N; Onaderra, M; Gavilanes, JG			The antifungal protein AFP of Aspergillus giganteus is an oligonucleotide/oligosaccharide binding (OB) fold-containing protein that produces condensation of DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD-SHOCK PROTEIN; ESCHERICHIA-COLI; DEOXYRIBONUCLEIC-ACID; ANTITUMOR AGENT; ALPHA-SARCIN; EXPRESSION; CLONING; IDENTIFICATION; REPLICATION; SEQUENCE	The antifungal protein AFP is a small polypeptide of 51 amino acid residues secreted by Aspergillus giganteus. Its potent activity against phytopathogenic fungi converts AFP in a promising tool in plant protection. However, no data have been reported regarding the mode of action of AFP. The three-dimensional structure of this protein, a small and compact beta barrel composed of five highly twisted antiparallel beta strands, displays the characteristic features of the oligonuclootide/oligosaccharide binding (OB fold) structural motif. A comparison of the structures of AFP and OB fold-containing proteins shows this structural similarity despite the absence of any significant sequence similarity. AFP, like most OB fold-containing proteins, binds nucleic acids. The protein promotes charge neutralization and condensation of DNA as demonstrated by electrophoretic mobility shift and ethidium bromide displacement assays. Nucleic acid produces quenching of the protein fluorescence emission. This nucleic acid interacting ability of AFP may be related to the antifungal activity of this small polypeptide.	Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Quim, E-28040 Madrid, Spain	Complutense University of Madrid	del Pozo, AM (corresponding author), Univ Complutense Madrid, Dept Bioquim & Biol Mol, Fac Quim, E-28040 Madrid, Spain.	alvaro@bbm1.ucm.es; ppgf@bbm1.ucm.es	LÓPEZ, NIEVES OLMO/K-5266-2014; Gavilanes, Jose G./K-5307-2014; Martinez-del-Pozo, Alvaro/L-8556-2014; Mancheno, Jose/K-4984-2014; OÑADERRA, Mercedes/H-2527-2015	LÓPEZ, NIEVES OLMO/0000-0002-8013-5313; Gavilanes, Jose G./0000-0002-6852-341X; Martinez-del-Pozo, Alvaro/0000-0003-0043-5939; Mancheno, Jose/0000-0001-6943-3291; OÑADERRA, Mercedes/0000-0003-2564-5609				Antson AA, 2000, CURR OPIN STRUC BIOL, V10, P87, DOI 10.1016/S0959-440X(99)00054-8; Bloomfield VA, 1996, CURR OPIN STRUC BIOL, V6, P334, DOI 10.1016/S0959-440X(96)80052-2; BRAMHILL D, 1988, CELL, V52, P743, DOI 10.1016/0092-8674(88)90412-6; BULSINK H, 1988, EUR J BIOCHEM, V176, P597, DOI 10.1111/j.1432-1033.1988.tb14319.x; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; CAMPOSOLIVAS R, 1995, BIOCHEMISTRY-US, V34, P3009, DOI 10.1021/bi00009a032; CHATTORAJ DK, 1978, J MOL BIOL, V121, P327, DOI 10.1016/0022-2836(78)90367-4; Draper DE, 1999, NUCLEIC ACIDS RES, V27, P381, DOI 10.1093/nar/27.2.381; DURAND M, 1975, BIOCHEMISTRY-US, V14, P563, DOI 10.1021/bi00674a016; FULLER RS, 1984, CELL, V38, P889, DOI 10.1016/0092-8674(84)90284-8; GERSHON H, 1993, BIOCHEMISTRY-US, V32, P7143, DOI 10.1021/bi00079a011; Golan R, 1999, BIOCHEMISTRY-US, V38, P14069, DOI 10.1021/bi990901o; Gottschalk S, 1996, GENE THER, V3, P448; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; HARD T, 1988, EUR BIOPHYS J BIOPHY, V16, P231, DOI 10.1007/BF00261265; Hase M, 1998, J BIOL CHEM, V273, P28651, DOI 10.1074/jbc.273.44.28651; Jiang WN, 1997, J BIOL CHEM, V272, P196; Kobayashi T, 1997, J BIOL CHEM, V272, P15154, DOI 10.1074/jbc.272.24.15154; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Lacadena J, 1995, ARCH BIOCHEM BIOPHYS, V324, P273, DOI 10.1006/abbi.1995.0040; Lee DG, 1999, BIOCHEM BIOPH RES CO, V263, P646, DOI 10.1006/bbrc.1999.1428; Lopez MM, 1999, J BIOL CHEM, V274, P33601, DOI 10.1074/jbc.274.47.33601; MARMUR J, 1961, J MOL BIOL, V3, P208, DOI 10.1016/S0022-2836(61)80047-8; MartinezRuiz A, 1997, BBA-PROTEIN STRUCT M, V1340, P81, DOI 10.1016/S0167-4838(97)00038-1; Marx F, 1995, GENE, V167, P167, DOI 10.1016/0378-1119(95)00701-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Meyer V, 2002, MOL GENET GENOMICS, V266, P747, DOI 10.1007/s00438-001-0609-6; MILLER H, 1987, METHOD ENZYMOL, V152, P145; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAKAYA K, 1990, EUR J BIOCHEM, V193, P31, DOI 10.1111/j.1432-1033.1990.tb19300.x; Oldach KH, 2001, MOL PLANT MICROBE IN, V14, P832, DOI 10.1094/MPMI.2001.14.7.832; OLSON BH, 1965, APPL MICROBIOL, V13, P322, DOI 10.1128/AEM.13.3.322-326.1965; OLSON BH, 1965, APPL MICROBIOL, V13, P314, DOI 10.1128/AEM.13.3.314-321.1965; Sambrook J, 2001, MOL CLONING LAB MANU; Sommerville J, 1999, BIOESSAYS, V21, P319, DOI 10.1002/(SICI)1521-1878(199904)21:4<319::AID-BIES8>3.3.CO;2-V; Vila L, 2001, MOL PLANT MICROBE IN, V14, P1327, DOI 10.1094/MPMI.2001.14.11.1327; WILSON RW, 1979, BIOCHEMISTRY-US, V18, P2192, DOI 10.1021/bi00578a009; WNENDT S, 1994, CURR GENET, V25, P519, DOI 10.1007/BF00351672; WNENDT S, 1990, NUCLEIC ACIDS RES, V18, P3987, DOI 10.1093/nar/18.13.3987	39	31	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46179	46183		10.1074/jbc.M207472200	http://dx.doi.org/10.1074/jbc.M207472200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351633	hybrid			2022-12-25	WOS:000179529300064
J	May, MJ; Marienfeld, RB; Ghosh, S				May, MJ; Marienfeld, RB; Ghosh, S			Characterization of the I kappa B-kinase NEMO binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IKK-BETA SUBUNIT; LIVER DEGENERATION; ALPHA-SUBUNIT; MICE LACKING; ACTIVATION; GAMMA; PHOSPHORYLATION; RECRUITMENT; COMPONENT; COMPLEX	Proinflammatory activation of NF-kappaB requires an upstream kinase complex (IkappaB-kinase; IKK) composed of two catalytic subunits (IKKalpha and IKKbeta) and a noncatalytic regulatory component named NEMO (NF-kappaB essential modulator). NEMO interacts with a COOH-terminal sequence within both IKKs termed the NEMO-binding domain (NBD), and a cell-permeable NBD peptide blocks NEMO/lKKbeta interactions and inhibits tumor necrosis factor-alpha-induced NF-kappaB. We report here that a peptide encompassing the NBD not only blocked association of both IKKs with NEMO but also disrupted preformed NEMO/IKK complexes in vitro. Furthermore, peptide blocking and alanine-scanning mutation studies revealed differences between the NBDs of IKKalpha and IKKbeta, and mutational analysis of the IKKbeta NBD identified the physical properties required at each position to maintain association with NEMO. Finally, we demonstrate that loss of NEMO-binding by IKKbeta through deletion of the NBD renders it catalytically active and that potential phosphorylation within the IKKbeta NBD may serve as a signal to down-regulate IKK activity. Our findings therefore provide critical insight into the physical properties of the NBD that will be valuable for the design of drugs aimed at disrupting the IKK complex and also reveal potential regulatory mechanisms controlling the function of the IKK complex.	Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Mol Biophys & Biochem, Howard Hughes Med Inst, New Haven, CT 06520 USA	Howard Hughes Medical Institute; Yale University; Howard Hughes Medical Institute; Yale University	Ghosh, S (corresponding author), Yale Univ, Sch Med, Immunobiol Sect, Howard Hughes Med Inst, 310 Cedar St, New Haven, CT 06520 USA.	sankar.ghosh@yale.edu		May, Michael/0000-0002-2485-3716				Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Cao YX, 2001, CELL, V107, P763, DOI 10.1016/S0092-8674(01)00599-2; Chu WM, 1999, IMMUNITY, V11, P721, DOI 10.1016/S1074-7613(00)80146-6; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; D'Acquisto Fulvio, 2002, Mol Interv, V2, P22, DOI 10.1124/mi.2.1.22; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harhaj EW, 1997, J BIOL CHEM, V272, P5409, DOI 10.1074/jbc.272.9.5409; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Karin M, 2000, SEMIN IMMUNOL, V12, P85, DOI 10.1006/smim.2000.0210; Kwak YT, 2000, J BIOL CHEM, V275, P14752, DOI 10.1074/jbc.M001039200; Li QT, 1999, GENE DEV, V13, P1322, DOI 10.1101/gad.13.10.1322; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; Smahi A, 2000, NATURE, V405, P466; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Tchernof A, 2000, DIABETES, V49, P1709, DOI 10.2337/diabetes.49.10.1709; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Yamamoto Y, 2001, J BIOL CHEM, V276, P36327, DOI 10.1074/jbc.M104090200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	42	121	127	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45992	46000		10.1074/jbc.M206494200	http://dx.doi.org/10.1074/jbc.M206494200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244103	hybrid			2022-12-25	WOS:000179529300039
J	Hansen, MDH; Ehrlich, JS; Nelson, WJ				Hansen, MDH; Ehrlich, JS; Nelson, WJ			Molecular mechanism for orienting membrane and actin dynamics to nascent cell-cell contacts in epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; RAC1 SMALL GTPASES; ANNEXIN-II; ADHESION; CYTOSKELETON; LAMELLIPODIA; RECRUITMENT; ACTIVATION; PROTEIN; BINDING	The small GTPase Rac1 has been implicated in regulation of cell migration and cell-cell adhesion in epithelial cells. Little is known, however, about the spatial and temporal coordination of Rac1 activity required to balance these competing processes. We fractionated endogenous Rac1-containing protein complexes from membranes of Madin-Darby canine kidney cells and identified three major complexes comprising a Rac1(.)PAK (p21-activated kinase) complex, and 11 S and 16 S Rac1 complexes. Significantly, Rac1 shifts from the 11 S to a 16 S particle during initiation of cell-cell adhesion. This shift may reflect a diffusion trapping mechanism by which these Rac1 complexes are localized to cadherin-mediated cell-cell contacts through an interaction with annexin II.	Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA	Stanford University	Nelson, WJ (corresponding author), Stanford Univ, Sch Med, Dept Cellular & Mol Physiol, Stanford, CA 94305 USA.				NIGMS NIH HHS [R37 GM035527, 5T32GM07365, GM35527, R01 GM035527] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035527, R01GM035527, T32GM007365] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams CL, 1998, J CELL BIOL, V142, P1105, DOI 10.1083/jcb.142.4.1105; Angres B, 1996, J CELL BIOL, V134, P549, DOI 10.1083/jcb.134.2.549; Balch C, 1997, EXP CELL RES, V237, P259, DOI 10.1006/excr.1997.3817; Ehrlich JS, 2002, DEV CELL, V3, P259, DOI 10.1016/S1534-5807(02)00216-2; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; Filipenko NR, 2001, J BIOL CHEM, V276, P5310, DOI 10.1074/jbc.M009710200; Ghitescu LD, 2001, DIABETES, V50, P1666, DOI 10.2337/diabetes.50.7.1666; Hansen MDH, 2001, CURR BIOL, V11, P356, DOI 10.1016/S0960-9822(01)00091-4; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; Jou TS, 1998, J CELL BIOL, V142, P101, DOI 10.1083/jcb.142.1.101; Jou TS, 1998, J CELL BIOL, V142, P85, DOI 10.1083/jcb.142.1.85; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kim SH, 2000, J BIOL CHEM, V275, P36999, DOI 10.1074/jbc.M003430200; Merrifield CJ, 2001, CURR BIOL, V11, P1136, DOI 10.1016/S0960-9822(01)00321-9; Nakagawa M, 2001, J CELL SCI, V114, P1829; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; Noren NK, 2001, J BIOL CHEM, V276, P33305, DOI 10.1074/jbc.C100306200; Oliferenko S, 1999, J CELL BIOL, V146, P843, DOI 10.1083/jcb.146.4.843; Oliferenko S, 2000, J CELL BIOL, V148, P1159, DOI 10.1083/jcb.148.6.1159; REGNOUF F, 1991, J NEUROCHEM, V56, P1985, DOI 10.1111/j.1471-4159.1991.tb03457.x; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; Vasioukhin V, 2000, CELL, V100, P209, DOI 10.1016/S0092-8674(00)81559-7; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WAISMAN DM, 1995, MOL CELL BIOCHEM, V149, P301, DOI 10.1007/BF01076592; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4	25	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45371	45376		10.1074/jbc.M207747200	http://dx.doi.org/10.1074/jbc.M207747200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244058	hybrid, Green Accepted			2022-12-25	WOS:000179404800100
J	Mochizuki, S; Brassart, B; Hinek, A				Mochizuki, S; Brassart, B; Hinek, A			Signaling pathways transduced through the elastin receptor facilitate proliferation of arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FOCAL ADHESION KINASE; GROWTH-FACTOR RECEPTOR; ELASTIN/LAMININ-BINDING-PROTEIN; EXTRACELLULAR-MATRIX; TYROSINE KINASE; BETA-GALACTOSIDASE; COUPLED RECEPTORS; LAMININ RECEPTOR; ALPHA(V)BETA(3) INTEGRIN	In this report we demonstrate that soluble peptides, elastin degradation products stimulate proliferation of arterial smooth muscle cells. We show that these effects are due to generation of intracellular signals transduced through the cell surface elastin receptor, which consists of peripheral 67-kDa elastin-binding protein (EBP) (spliced variant of beta-galactosidase), immobilized to the transmembrane sialidase and the protective protein. We found that elastin receptor-transduced signaling triggers activation of G proteins, opening Of L-type calcium channels, and a sequential activation of tyrosine kinases: FAK, c-Src, platelet-derived growth factor-receptor kinase and then Ras-Raf-MEK1/2-ERK1/2 phosphorylation cascade. This, in turn, causes an increase in expression of cyclins and cyclin-dependent kinases, and a consequent increase in cellular proliferation. The EBP-transduced signals also induce tyrosine kinase-dependent phosphorylation of beta-tubulin, LC3, microtubule-associated protein 1, and a-actin and troponin-T, which could be linked to reorganization of cytoskeleton. We have also disclosed that induction of these signals can be abolished by anti-EBP antibody or by galactosugars, which cause shedding of EBP from the cell surface. Moreover, elastin-derived peptides did not induce proliferation of EBP-deficient cells derived from patients bearing a nonsense mutation of the P-galactosidase gene or sialidase-deficient cells from patients with congenital sialidosis.	Hosp Sick Children, Cardiovasc Res Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Lab Med & Pathol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto	Hinek, A (corresponding author), Hosp Sick Children, Cardiovasc Res Program, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	alek.hinek@sickkids.ca	Hinek, Aleksander/V-8790-2019					AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; BARTFELD NS, 1993, J BIOL CHEM, V268, P17270; Bendeck MP, 2000, ARTERIOSCL THROM VAS, V20, P1467, DOI 10.1161/01.ATV.20.6.1467; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; Boudreau J, 1999, BIOCHEM J, V339, P481, DOI 10.1042/0264-6021:3390481; BOUDREAU N, 1991, LAB INVEST, V64, P187; Brassart B, 2001, J BIOL CHEM, V276, P5222, DOI 10.1074/jbc.M003642200; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; CHIAVEGATO A, 1993, CARDIOSCIENCE, V4, P75; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FAURY G, 1995, J VASC RES, V32, P112, DOI 10.1159/000159084; FLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914, DOI 10.1073/pnas.91.25.11914; Fujimoto N, 2000, J INVEST DERMATOL, V115, P633, DOI 10.1046/j.1523-1747.2000.00117.x; FULOP T, 2001, SOC BIOL, V195, P157; GROSSO LE, 1993, BIOCHEMISTRY-US, V32, P13369, DOI 10.1021/bi00211a052; GROSSO LE, 1993, MATRIX, V13, P157, DOI 10.1016/S0934-8832(11)80074-0; Hance KA, 2002, J VASC SURG, V35, P254, DOI 10.1067/mva.2002.120382; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hinek A, 2000, AM J PATHOL, V156, P925, DOI 10.1016/S0002-9440(10)64961-9; HINEK A, 1994, CELL ADHES COMMUN, V2, P185, DOI 10.3109/15419069409004436; HINEK A, 1992, EXP CELL RES, V203, P344, DOI 10.1016/0014-4827(92)90008-V; HINEK A, 1991, J CLIN INVEST, V88, P2083, DOI 10.1172/JCI115538; Hinek A, 2000, AM J HUM GENET, V67, P23, DOI 10.1086/302968; HINEK A, 1988, SCIENCE, V239, P1539, DOI 10.1126/science.2832941; HINEK A, 1993, J CLIN INVEST, V91, P1198, DOI 10.1172/JCI116280; Hinek A, 1996, BIOL CHEM, V377, P471; HINEK A, 1981, CONNECT TISSUE RES, V8, P181, DOI 10.3109/03008208109152371; Hirata A, 2000, BRIT J PHARMACOL, V131, P1521, DOI 10.1038/sj.bjp.0703730; HORNEBECK W, 1985, EXTRACELLULAR MATRIX, P269; ILLC D, 1995, NATURE, V377, P539; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Ju HS, 1996, CAN J CARDIOL, V12, P1259; JUNG S, 1988, J NEUROPATH EXP NEUR, V57, P429; Kamisato S, 1997, J BIOCHEM-TOKYO, V121, P862; KAMISATO S, 1999, PEPTIDE SCI, V12, P61; Kamoun A, 1995, CELL ADHES COMMUN, V3, P273, DOI 10.3109/15419069509081013; Kenagy RD, 1996, ARTERIOSCL THROM VAS, V16, P1373, DOI 10.1161/01.ATV.16.11.1373; Kimura T, 1997, CIRCULATION, V96, P475; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Li X, 1998, EMBO J, V17, P2574, DOI 10.1093/emboj/17.9.2574; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; Lukong KE, 2001, J BIOL CHEM, V276, P46172, DOI 10.1074/jbc.M104547200; Lukong KE, 2001, J BIOL CHEM, V276, P17286, DOI 10.1074/jbc.M100460200; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; MACLEOD DC, 1994, J AM COLL CARDIOL, V23, P59, DOI 10.1016/0735-1097(94)90502-9; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MECHAM RP, 1991, J CELL BIOL, V113, P187, DOI 10.1083/jcb.113.1.187; MECHAM RP, 1989, J BIOL CHEM, V264, P16652; MECHAM RP, 1989, BIOCHEMISTRY-US, V28, P3716, DOI 10.1021/bi00435a014; Morelli MAC, 1997, J PEPT RES, V49, P492; Morris AJ, 1999, PHYSIOL REV, V79, P1373, DOI 10.1152/physrev.1999.79.4.1373; Nebigil CG, 2000, P NATL ACAD SCI USA, V97, P2591, DOI 10.1073/pnas.050282397; Oak JN, 2001, MOL PHARMACOL, V60, P92, DOI 10.1124/mol.60.1.92; OHO S, 1994, AM J PATHOL, V145, P202; Ozer RS, 2000, MOL BIOL CELL, V11, P3573, DOI 10.1091/mbc.11.10.3573; Papakonstanti EA, 2000, CELL PHYSIOL BIOCHEM, V10, P257, DOI 10.1159/000016366; Peterszegi G, 1996, CR ACAD SCI III-VIE, V319, P799; Privitera S, 1998, J BIOL CHEM, V273, P6319, DOI 10.1074/jbc.273.11.6319; Raines EW, 2000, ANN NY ACAD SCI, V902, P39; RAINES EW, 1993, BRIT HEART J, V69, pS30; RAO GN, 1995, J BIOL CHEM, V270, P27871, DOI 10.1074/jbc.270.46.27871; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Salazar EP, 1999, J BIOL CHEM, V274, P28371, DOI 10.1074/jbc.274.40.28371; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Soga S, 1998, J BIOL CHEM, V273, P822, DOI 10.1074/jbc.273.2.822; Sundberg C, 1996, J CELL BIOL, V132, P741, DOI 10.1083/jcb.132.4.741; Suto F, 2000, EUR J PHARMACOL, V409, P213, DOI 10.1016/S0014-2999(00)00827-X; SZEWCZYK B, 1988, ANAL BIOCHEM, V168, P48, DOI 10.1016/0003-2697(88)90008-5; Thyberg J, 1996, INT REV CYTOL, V169, P183, DOI 10.1016/S0074-7696(08)61987-7; Urban Z, 2002, AM J HUM GENET, V71, P30, DOI 10.1086/341035; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; VARGA Z, 1989, FEBS LETT, V258, P5, DOI 10.1016/0014-5793(89)81602-3; WACHI H, 1995, FEBS LETT, V368, P215, DOI 10.1016/0014-5793(95)00641-L; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WRENN DS, 1988, J BIOL CHEM, V263, P2280; Yuasa K, 1999, J BIOL CHEM, V274, P37429, DOI 10.1074/jbc.274.52.37429; ZANELLATO AMC, 1991, CIRC RES, V68, P1349, DOI 10.1161/01.RES.68.5.1349; Zhou B, 1998, CIRC RES, V83, P481, DOI 10.1161/01.RES.83.5.481	86	182	198	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44854	44863		10.1074/jbc.M205630200	http://dx.doi.org/10.1074/jbc.M205630200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244048	hybrid			2022-12-25	WOS:000179404800035
J	Okumoto, S; Schmidt, R; Tegeder, M; Fischer, WN; Rentsch, D; Frommer, WB; Koch, W				Okumoto, S; Schmidt, R; Tegeder, M; Fischer, WN; Rentsch, D; Frommer, WB; Koch, W			High affinity amino acid transporters specifically expressed in xylem parenchyma and developing seeds of Arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-SPECIFICITY; PHLOEM TRANSFER; YEAST; PERMEASE; SUCROSE; LEAVES; COMPLEMENTATION; THALIANA; SEQUENCE; NITROGEN	Arabidopsis amino acid transporters (AAPs) show individual temporal and spatial expression patterns. A new amino acid transporter, AAP8 was isolated by reverse transcription-PCR. Growth and transport assays in comparison to AAP1-5 characterize AAP8 and AAP6 as high affinity amino acid transport systems from Arabidopsis. Histochemical promoter-beta-glucuronidase (GUS) studies identified AAP6 expression in xylem parenchyma, cells requiring high affinity transport due to the low amino acid concentration in xylem sap. AAP6 may thus function in uptake of amino acids from xylem. Histochemical analysis of AAP8 revealed stage-dependent expression in siliques and developing seeds. Thus AAP8 is probably responsible for import of organic nitrogen into developing seeds. The only missing transporter of the family AAP7 was nonfunctional in yeast with respect to amino acid transport, and expression was not detectable. Therefore, AAP6 and -8 are the only members of the family able to transport aspartate with physiologically relevant affinity. AAP1, -6 and -8 are the closest AAP paralogs. Although AAP1 and AAP8 originate from a duplicated region on chromosome I, biochemical properties and expression pattern diverged. Overlapping substrate specificities paired with individual properties and expression patterns point to specific functions of each of the AAP genes in nitrogen distribution rather than to mere redundancy.	Zentrum Mol Biol Pflanzen, ZMBP, D-72076 Tubingen, Germany; Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Inst Plant Sci, CH-3013 Bern, Switzerland	Eberhard Karls University of Tubingen; Washington State University	Koch, W (corresponding author), Zentrum Mol Biol Pflanzen, ZMBP, Morgenstelle 1, D-72076 Tubingen, Germany.	wolfgang.koch@zmbp.uni-tuebingen.de	Frommer, Wolf B/K-5042-2017; Frommer, Wolf B/A-8256-2008	Frommer, Wolf B/0000-0001-6465-0115; Frommer, Wolf B/0000-0001-6465-0115; Rentsch, Doris/0000-0003-4313-7683				ALLEN RD, 1989, PLANT CELL, V1, P623, DOI 10.1105/tpc.1.6.623; Arabidopsis Genome Initiative, 2000, Nature (London), V408, P796, DOI 10.1038/35048692; Atkins C, 2000, AUST J PLANT PHYSIOL, V27, P531, DOI 10.1071/PP99129; Bechtold N, 1998, METH MOL B, V82, P259; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Boorer KJ, 1997, J BIOL CHEM, V272, P13040, DOI 10.1074/jbc.272.20.13040; Boorer KJ, 1996, J BIOL CHEM, V271, P2213, DOI 10.1074/jbc.271.4.2213; Chang HC, 1997, J BIOL CHEM, V272, P30552, DOI 10.1074/jbc.272.48.30552; Chen LS, 2001, PLANT PHYSIOL, V125, P1813, DOI 10.1104/pp.125.4.1813; DeWitt ND, 1996, PLANT PHYSIOL, V112, P833, DOI 10.1104/pp.112.2.833; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; ERICSON ML, 1991, EUR J BIOCHEM, V197, P741, DOI 10.1111/j.1432-1033.1991.tb15966.x; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Finkelstein RR, 2000, PLANT CELL, V12, P599, DOI 10.1105/tpc.12.4.599; Fischer WN, 1998, TRENDS PLANT SCI, V3, P188, DOI 10.1016/S1360-1385(98)01231-X; Fischer WN, 2002, PLANT J, V29, P717, DOI 10.1046/j.1365-313X.2002.01248.x; FISCHER WN, 1995, J BIOL CHEM, V270, P16315, DOI 10.1074/jbc.270.27.16315; Frommer WB, 1995, P NATL ACAD SCI USA, V92, P12036, DOI 10.1073/pnas.92.26.12036; FROMMER WB, 1993, P NATL ACAD SCI USA, V90, P5944, DOI 10.1073/pnas.90.13.5944; Guilfoyle T, 1998, PLANT PHYSIOL, V118, P341, DOI 10.1104/pp.118.2.341; HARPER JF, 1994, MOL GEN GENET, V244, P572, DOI 10.1007/BF00282747; Hayashi H, 1997, PLANT SOIL, V196, P233, DOI 10.1023/A:1004254124898; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Higo K, 1999, NUCLEIC ACIDS RES, V27, P297, DOI 10.1093/nar/27.1.297; Hirner B, 1998, PLANT J, V14, P535, DOI 10.1046/j.1365-313X.1998.00151.x; HSU LC, 1993, P NATL ACAD SCI USA, V90, P7441, DOI 10.1073/pnas.90.16.7441; JESCHKE WD, 1990, RECENT ADV PHLOEM TR; Kim SY, 1997, PLANT J, V11, P1237, DOI 10.1046/j.1365-313X.1997.11061237.x; KWART M, 1993, PLANT J, V4, P993, DOI 10.1046/j.1365-313X.1993.04060993.x; LAM HM, 1995, PLANT CELL, V7, P887, DOI 10.1105/tpc.7.7.887; LI ZC, 1990, PLANT PHYSIOL, V94, P268, DOI 10.1104/pp.94.1.268; LI ZC, 1991, PLANT PHYSIOL, V96, P1338, DOI 10.1104/pp.96.4.1338; LOHAUS G, 1995, BOT ACTA, V108, P270, DOI 10.1111/j.1438-8677.1995.tb00860.x; Maathuis FJM, 1997, PLANT PHYSIOL, V114, P1141, DOI 10.1104/pp.114.4.1141; MANSFIELD SG, 1991, CAN J BOT, V69, P461, DOI 10.1139/b91-063; Marchant A, 2002, PLANT CELL, V14, P589, DOI 10.1105/tpc.010354; Martin T., 1992, GUS protocols: using the GUS gene as a reporter of gene expression., P23; MCNEIL DL, 1979, PLANT PHYSIOL, V63, P1076, DOI 10.1104/pp.63.6.1076; MINET M, 1992, PLANT J, V2, P417; Miranda M, 2001, PLANT J, V28, P61, DOI 10.1046/j.1365-313X.2001.01129.x; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; PATE JS, 1975, PLANTA, V122, P11, DOI 10.1007/BF00385400; PATE JS, 1977, PLANT PHYSIOL, V59, P506, DOI 10.1104/pp.59.3.506; PATRICK JW, 1995, AUST J PLANT PHYSIOL, V22, P681, DOI 10.1071/PP9950681; Rentsch D, 1996, PLANT CELL, V8, P1437, DOI 10.1105/tpc.8.8.1437; RIESMEIER JW, 1993, PLANT CELL, V5, P1591, DOI 10.1105/tpc.5.11.1591; SCHOBERT C, 1990, PLANTA, V181, P85, DOI 10.1007/BF00202328; SOLDAL T, 1978, PHYSIOL PLANTARUM, V43, P181, DOI 10.1111/j.1399-3054.1978.tb02561.x; SWOFFORD DL, 2001, PHYLOGENETIC ANAL US; Tegeder M, 2000, PLANT PHYSIOL, V122, P319, DOI 10.1104/pp.122.2.319; VANBEL AJE, 1984, PLANT SCI LETT, V35, P81, DOI 10.1016/0304-4211(84)90162-7; VANBEL AJE, 1979, PLANT SCI LETT, V15, P285, DOI 10.1016/0304-4211(79)90121-4; VANBEL AJE, 1980, PLANT SCI LETT, V19, P101, DOI 10.1016/0304-4211(80)90085-1; Wipf D, 2002, TRENDS BIOCHEM SCI, V27, P139, DOI 10.1016/S0968-0004(01)02054-0; Xiang CB, 1999, PLANT MOL BIOL, V40, P711, DOI 10.1023/A:1006201910593	55	132	151	7	46	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45338	45346		10.1074/jbc.M207730200	http://dx.doi.org/10.1074/jbc.M207730200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244056	hybrid			2022-12-25	WOS:000179404800096
J	Chen, J; Xiong, JY; Liu, HY; Chernenko, G; Tang, SC				Chen, J; Xiong, JY; Liu, HY; Chernenko, G; Tang, SC			Distinct BAG-1 isoforms have different anti-apoptotic functions in BAG-1-transfected C33A human cervical carcinoma cell line	ONCOGENE			English	Article						BAG-1 isoforms; apoptosis; Bcl-2; Bax; p53; caspase-3	ENHANCED EXPRESSION; ENDOCERVICAL CELLS; CHAPERONE ACTIVITY; PROTEIN BAG-1; RECEPTOR; BCL-2; ACTIVATION; RESISTANCE; GENES; RAP46	BAG-1 protein can be expressed as four isoforms of 50, 46, 33 and 29 kDa with different subcellular localizations, which may have different functions in antiapoptosis, but the exact mechanism remains unclear. We constructed BAG-1 full length and deletion mutated plasmids in a pCR3.1 vector and established stable transfections of BAG-I isoforms in low BAG-1 expressing C33A cells. Treatment of the transfected cells with cisplatin, staurosporine, paclitaxel and doxorubicine showed that BAG-1 p50, p46 and p33 isoforms enhanced the resistance to apoptosis. BAG-I p50, p46 and p33 exhibited different degrees of apoptosis inhibition in the transfected cells and BAG-I p46 isoform had the most pronounced effect on anti-apoptosis. BAG-I p29 failed to protect the transfected cells from apoptosis. Resistance to apoptosis by BAG-1 isoforms was correlated with decreased caspase-3 activation. We also detected the expression of Bax, Bak, p53, Bcl-2, BCl-X-L, AIF and MRP1 by Western blots. Bcl-2 protein expression was significantly increased in p50, p46 and p33 transfected cells, while the expression of Bax, Bak, p53, BCl-X-L and MRP1 was essentially unchanged. These in vitro results suggest that distinct isoforms of BAG-1 have different anti-apoptotic functions and their functions may be correlated to increased Bcl-2 expression.	Univ Miami, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA; Mem Univ Newfoundland, Fac Med, St John, NF A1B 3V6, Canada	University of Miami; Memorial University Newfoundland	Tang, SC (corresponding author), Univ Miami, Sylvester Comprehens Canc Ctr, 1475 NW 12th Ave, Miami, FL 33136 USA.	stang@med.miami.edu						Adachi M, 1998, LEUKEMIA LYMPHOMA, V30, P483, DOI 10.3109/10428199809057561; Antoku K, 2001, BIOCHEM BIOPH RES CO, V286, P1003, DOI 10.1006/bbrc.2001.5512; Bardelli A, 1996, EMBO J, V15, P6205, DOI 10.1002/j.1460-2075.1996.tb01009.x; Brimmell M, 1999, BRIT J CANCER, V81, P1042, DOI 10.1038/sj.bjc.6690805; Clevenger CV, 1997, MOL ENDOCRINOL, V11, P608, DOI 10.1210/me.11.5.608; Crocoll A, 2000, MECH DEVELOP, V91, P355, DOI 10.1016/S0925-4773(99)00284-1; Ding ZH, 2000, BIOCHEM BIOPH RES CO, V270, P415, DOI 10.1006/bbrc.2000.2432; Ding ZH, 2000, INT J CANCER, V87, P818, DOI 10.1002/1097-0215(20000915)87:6<818::AID-IJC10>3.0.CO;2-M; Froesch BA, 1998, J BIOL CHEM, V273, P11660, DOI 10.1074/jbc.273.19.11660; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kullmann M, 1998, J BIOL CHEM, V273, P14620, DOI 10.1074/jbc.273.23.14620; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; Niyaz Y, 2001, J CELL SCI, V114, P1839; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Rorke S, 2001, INT J CANCER, V95, P317, DOI 10.1002/1097-0215(20010920)95:5<317::AID-IJC1055>3.0.CO;2-J; Schneikert J, 1999, J CELL BIOL, V146, P929, DOI 10.1083/jcb.146.5.929; Schulz JB, 1997, J NEUROCHEM, V69, P2075; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Takahashi N, 2001, BIOCHEM BIOPH RES CO, V286, P807, DOI 10.1006/bbrc.2001.5473; Takayama S, 1999, J BIOL CHEM, V274, P781, DOI 10.1074/jbc.274.2.781; Takayama S, 1997, EMBO J, V16, P4887, DOI 10.1093/emboj/16.16.4887; TAKAYAMA S, 1995, CELL, V80, P279, DOI 10.1016/0092-8674(95)90410-7; Tang SC, 1999, J CLIN ONCOL, V17, P1710, DOI 10.1200/JCO.1999.17.6.1710; Terada S, 1997, CYTOTECHNOLOGY, V25, P17, DOI 10.1023/A:1007954103572; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Wang HG, 1996, P NATL ACAD SCI USA, V93, P7063, DOI 10.1073/pnas.93.14.7063; Witcher M, 2001, EXP CELL RES, V265, P167, DOI 10.1006/excr.2001.5176; Yang XL, 1999, ONCOGENE, V18, P4546, DOI 10.1038/sj.onc.1202843; Yang XL, 1999, CLIN CANCER RES, V5, P1816; Yang XL, 1998, ONCOGENE, V17, P981, DOI 10.1038/sj.onc.1202032; Yang XL, 1998, MOL CARCINOGEN, V22, P95, DOI 10.1002/(SICI)1098-2744(199806)22:2<95::AID-MC4>3.3.CO;2-Y; Yang XL, 1997, J CELL BIOCHEM, V66, P309, DOI 10.1002/(SICI)1097-4644(19970901)66:3<309::AID-JCB4>3.3.CO;2-Y; Zapata JM, 1998, BREAST CANCER RES TR, V47, P129, DOI 10.1023/A:1005940832123; Zeiner M, 1999, P NATL ACAD SCI USA, V96, P10194, DOI 10.1073/pnas.96.18.10194; Zeiner M, 1997, EMBO J, V16, P5483, DOI 10.1093/emboj/16.18.5483; ZEINER M, 1995, P NATL ACAD SCI USA, V92, P11465, DOI 10.1073/pnas.92.25.11465	40	35	40	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7050	7059		10.1038/sj.onc.1205845	http://dx.doi.org/10.1038/sj.onc.1205845			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370827				2022-12-25	WOS:000178424900008
J	Alberti, I; Bernard, G; Rouquette-Jadanian, AK; Pelassy, C; Pourtein, M; Aussel, C; Bernard, A				Alberti, I; Bernard, G; Rouquette-Jadanian, AK; Pelassy, C; Pourtein, M; Aussel, C; Bernard, A			CD99 isoform expression dictates T-cell functional outcomes	FASEB JOURNAL			English	Article						adhesion; apoptosis; glycosphingolipidic rafts; sphingomyelin	PROTEIN-KINASE-C; VASCULAR ENDOTHELIUM; E2 MOLECULE; APOPTOSIS; ADHESION; RECEPTOR; DOMAIN; ENGAGEMENT; ANTIBODIES; TRIGGERS	CD99, a unique integral membrane protein present on the surface of all human T cells, has previously been shown to regulate cell function and fate. In peripheral T cells, it triggers immediate activation of alpha4beta1 integrin and cell arrest on inflamed vascular endothelium, whereas it mediates an apoptotic signal in double-positive thymocytes undergoing the selection process. Two isoforms of CD99 exist, a long form corresponding to the full-length protein and a short form harboring a deletion in the intracytoplasmic segment. Here, we show that while peripheral T cells display exclusive expression of the long form, double-positive thymocytes express both isoforms. Moreover, differential expression of these two CD99 molecules can lead to distinct functional outcomes. Expression of the long form in a CD99-deficient Jurkat T cell line is sufficient to promote CD99-induced cell adhesion, whereas coexpression of the two isoforms is required to trigger T-cell death. When coexpressed, the two proteins form covalent heterodimers, which locate within glycosphingolipidic rafts and induce sphingomyelin degradation. Cholesterol depletion experiments show that this localization is required for the induction of apoptosis. Thus, the surface expression pattern of CD99 isoforms determines T-cell functional outcomes.	Univ Nice, Immunol Lab, F-06108 Nice 2, France; Univ Nice, INSERM, U343, F-06108 Nice 2, France	UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Bernard, A (corresponding author), Hop Archet, INSERM, U343, F-06202 Nice 3, France.	u343@unice.fr		ROUQUETTE-JAZDANIAN, Alexandre K./0000-0003-2646-0040				ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; AUBRIT F, 1989, EUR J IMMUNOL, V19, P1431, DOI 10.1002/eji.1830190813; AUSSEL C, 1993, BIOCHEMISTRY-US, V32, P10096, DOI 10.1021/bi00089a027; BERNARD A, 1984, J IMMUNOL, V132, P2338; BERNARD A, 1988, J IMMUNOL, V140, P1802; Bernard G, 2000, EUR J IMMUNOL, V30, P3061, DOI 10.1002/1521-4141(200010)30:10<3061::AID-IMMU3061>3.0.CO;2-M; Bernard G, 1997, J IMMUNOL, V158, P2543; BERNARD G, 1995, J IMMUNOL, V154, P26; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; ELLIS NA, 1994, NAT GENET, V8, P285, DOI 10.1038/ng1194-285; Fouchet C, 2000, BLOOD, V95, P1819, DOI 10.1182/blood.V95.5.1819.005k05_1819_1826; GELIN C, 1991, EUR J IMMUNOL, V21, P715, DOI 10.1002/eji.1830210326; GELIN C, 1989, EMBO J, V8, P3253, DOI 10.1002/j.1460-2075.1989.tb08485.x; Guiter GE, 1999, CANCER CYTOPATHOL, V87, P141; Hahn JH, 1997, J IMMUNOL, V159, P2250; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Lee JY, 2000, J BIOL CHEM, V275, P29290, DOI 10.1074/jbc.M000170200; Montixi C, 1998, EMBO J, V17, P5334, DOI 10.1093/emboj/17.18.5334; Pettersen RD, 1999, J IMMUNOL, V162, P7031; Pettersen RD, 2001, J IMMUNOL, V166, P4931, DOI 10.4049/jimmunol.166.8.4931; Ruggiero G, 1996, J IMMUNOL, V156, P3737; Schenkel AR, 2002, NAT IMMUNOL, V3, P143, DOI 10.1038/ni749; Scotlandi K, 2000, CANCER RES, V60, P5134; SMITH CA, 1989, NATURE, V337, P181, DOI 10.1038/337181a0; Ticchioni M, 2001, FASEB J, V15, P341, DOI 10.1096/fj.99-0833com; Tsuchida M, 2000, J BIOL CHEM, V275, P1344, DOI 10.1074/jbc.275.2.1344; Veldman RJ, 2001, BIOCHEM J, V355, P859, DOI 10.1042/bj3550859; Yonemura S, 1998, J CELL BIOL, V140, P885, DOI 10.1083/jcb.140.4.885; Yonemura S, 1999, J CELL BIOL, V145, P1497, DOI 10.1083/jcb.145.7.1497; Zen K, 1996, IMMUNOBIOLOGY, V195, P323, DOI 10.1016/S0171-2985(96)80049-0; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	32	58	62	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1946	+		10.1096/fj.02-0049fje	http://dx.doi.org/10.1096/fj.02-0049fje			23	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368226				2022-12-25	WOS:000179167600020
J	Neal, JW; Clipstone, NA				Neal, JW; Clipstone, NA			Calcineurin mediates the calcium-dependent inhibition of adipocyte differentiation in 3T3-L1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KEY SIGNALING ENZYME; TRANSCRIPTION FACTORS; CYCLOSPORINE-A; PPAR-GAMMA; MOLECULAR REGULATION; CLONAL EXPANSION; GENE-EXPRESSION; MAP KINASE; IN-VIVO; ADIPOGENESIS	Recent studies have revealed that the calcium-dependent serine/threonine phosphatase calcineurin mediates the effects of intracellular calcium in many different cell types. In this study we investigated the role of calcineurin in the regulation of adipocyte differentiation. We found that the specific calcineurin inhibitors cyclosporin A and FK506 overcame the antiadipogenic effect of calcium ionophore on the differentiation of 3T3-L1 preadipocytes. This finding suggests that calcineurin is responsible for mediating the previously documented Ca2+-dependent inhibition of adipogenesis. We further demonstrate that the expression of a constitutively active calcineurin mutant potently inhibits the ability of 3T3-L1 cells to undergo adipocyte differentiation by preventing expression of the proadipogenic transcription factors peroxisome proliferator-activated receptor gamma (PPARgamma) and CCAAT/enhancer-binding protein a (C/EBPalpha). This calcineurin-mediated block in adipocyte differentiation is rescued by ectopic expression of PPARgamma1. Finally, we demonstrate that inhibition of endogenous calcineurin activity with either FK506 or a specific calcineurin inhibitory peptide enhances differentiation of 3T3-L1 cells in response to suboptimal adipogenic stimuli, suggesting that endogenous calcineurin activity normally sets a signaling threshold that antagonizes efficient adipocyte differentiation. Collectively, these data indicate that calcineurin acts as a Ca2+-dependent molecular switch that negatively regulates commitment to adipocyte differentiation by preventing the expression of critical proadipogenic transcription factors.	Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine	Clipstone, NA (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Microbiol Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NIGMS NIH HHS [R29 GM 55292] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM055292] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOULJOUD MS, 1995, TRANSPLANT P, V27, P1121; Aramburu J, 1999, SCIENCE, V285, P2129, DOI 10.1126/science.285.5436.2129; BIERER BE, 1990, SCIENCE, V250, P556, DOI 10.1126/science.1700475; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bost F, 2002, BIOCHEM J, V361, P621, DOI 10.1042/0264-6021:3610621; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; CLIPSTONE NA, 1993, ANN NY ACAD SCI, V696, P20; Cowherd RM, 1999, SEMIN CELL DEV BIOL, V10, P3, DOI 10.1006/scdb.1998.0276; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; deMora JF, 1997, MOL CELL BIOL, V17, P6068, DOI 10.1128/MCB.17.10.6068; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Engelman JA, 1999, J BIOL CHEM, V274, P35630, DOI 10.1074/jbc.274.50.35630; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Fruhbeck G, 2001, AM J PHYSIOL-ENDOC M, V280, pE827, DOI 10.1152/ajpendo.2001.280.6.E827; GAILLARD D, 1989, BIOCHEM J, V257, P389, DOI 10.1042/bj2570389; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; Ho IC, 1998, P NATL ACAD SCI USA, V95, P15537, DOI 10.1073/pnas.95.26.15537; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Lee MY, 2001, BIOCHEM BIOPH RES CO, V281, P1241, DOI 10.1006/bbrc.2001.4494; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; LIN FT, 1992, GENE DEV, V6, P533, DOI 10.1101/gad.6.4.533; MacDougald OA, 2002, TRENDS ENDOCRIN MET, V13, P5, DOI 10.1016/S1043-2760(01)00517-3; MATHIEU RL, 1994, EUR J CLIN INVEST, V24, P195, DOI 10.1111/j.1365-2362.1994.tb00988.x; Miller CW, 1996, ENDOCRINOLOGY, V137, P5641, DOI 10.1210/en.137.12.5641; MOR E, 1995, TRANSPLANT P, V27, P1126; Morrison RF, 1999, J BIOL CHEM, V274, P17088, DOI 10.1074/jbc.274.24.17088; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Ntambi JM, 1996, DIFFERENTIATION, V60, P151, DOI 10.1007/s002580050145; Porse BT, 2001, CELL, V107, P247, DOI 10.1016/S0092-8674(01)00516-5; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Reusch JEB, 2000, MOL CELL BIOL, V20, P1008, DOI 10.1128/MCB.20.3.1008-1020.2000; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Rosen ED, 2000, ANNU REV CELL DEV BI, V16, P145, DOI 10.1146/annurev.cellbio.16.1.145; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; SALE EM, 1995, EMBO J, V14, P674, DOI 10.1002/j.1460-2075.1995.tb07046.x; Shi H, 2000, PHYSIOL GENOMICS, V3, P75, DOI 10.1152/physiolgenomics.2000.3.2.75; Smas CM, 1999, J BIOL CHEM, V274, P12632, DOI 10.1074/jbc.274.18.12632; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Tang QQ, 1999, GENE DEV, V13, P2231, DOI 10.1101/gad.13.17.2231; Tong Q, 2000, SCIENCE, V290, P134, DOI 10.1126/science.290.5489.134; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VASSAUX G, 1992, J BIOL CHEM, V267, P11092; Visscher TLS, 2001, ANNU REV PUBL HEALTH, V22, P355, DOI 10.1146/annurev.publhealth.22.1.355; Wu ZD, 1996, MOL CELL BIOL, V16, P4128; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987	51	85	85	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49776	49781		10.1074/jbc.M207913200	http://dx.doi.org/10.1074/jbc.M207913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12351639	hybrid			2022-12-25	WOS:000180028900090
J	Bezzine, S; Bollinger, JG; Singer, AG; Veatch, SL; Keller, SL; Gelb, MH				Bezzine, S; Bollinger, JG; Singer, AG; Veatch, SL; Keller, SL; Gelb, MH			On the binding preference of human groups IIA and X phospholipases A(2) for membranes with anionic phospholipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR PHYSIOLOGICAL-ROLE; INTERFACIAL BINDING; ARACHIDONIC-ACID; TRYPTOPHAN RESIDUES; CATALYSIS; RELEASE; PHOSPHATIDYLCHOLINE; ACTIVATION; SUBSTRATE; VENOM	Mammals contain 9-10 secreted phospholipases A(2) (sPLA(2)s) that display widely different affinities for membranes, depending on the phospholipid composition. The much higher enzymatic activity of human group X sPLA(2) (hGX) compared with human group IIA sPLA(2) (hGIIA) on phosphatidylcholine (PC)-rich vesicles is due in large part to the higher affinity of the former enzyme for such vesicles; this result also holds when vesicles contain cholesterol and sphingomyelin. The inclusion of anionic phosphatidylserine in PC vesicles dramatically enhances interfacial binding and catalysis of hGILA but not of hGX. This is the result of the large number of lysine and arginine residues scattered over the entire surface of hGIIA, which cause the enzyme to form a supramolecular aggregate with multiple vesicles. Thus, high affinity binding of hGIIA to anionic vesicles is a complex process and cannot be attributed to a few basic residues on its interfacial binding surface, as is also evident from mutagenesis studies. The main reason hGIIA binds poorly to PC-rich vesicles is that it lacks a tryptophan residue on its interfacial binding surface, a residue that contributes to the high affinity binding of hGX to PC-rich vesicles. Results show that the lag in the onset of hydrolysis of PC vesicles by hGIIA is due in part to the poor affinity of this enzyme for these vesicles. Binding affinity of hGIIA, hGX, and their mutants to PC-rich vesicles is well correlated to the ability of these enzymes to act on the PC-rich outer plasma membrane of mammalian cells.	Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Phys, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Gelb, MH (corresponding author), Univ Washington, Dept Chem, Box 351700, Seattle, WA 98195 USA.	gelb@chem.washington.edu	Veatch, Sarah L/G-9512-2016	Veatch, Sarah L/0000-0002-9317-2308; gelb, michael/0000-0001-7000-5219; Keller, Sarah/0000-0001-5919-0185	NHLBI NIH HHS [HL36236] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1987, PHOSPHOLIPASES; ARAKISASAKI K, 1995, INVEST OPHTH VIS SCI, V36, P614; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balsinde J, 1999, ANNU REV PHARMACOL, V39, P175, DOI 10.1146/annurev.pharmtox.39.1.175; Bayburt T, 1997, BIOCHEMISTRY-US, V36, P3216, DOI 10.1021/bi961659d; BAYBURT T, 1993, BIOCHEMISTRY-US, V32, P573, DOI 10.1021/bi00053a024; Beers SA, 2002, J BIOL CHEM, V277, P1788, DOI 10.1074/jbc.M109777200; Berg OG, 2001, CHEM REV, V101, P2613, DOI 10.1021/cr990139w; Berg OG, 2002, INTERFACIAL ENZYME K; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; Buckland AG, 2000, BBA-MOL CELL BIOL L, V1484, P195, DOI 10.1016/S1388-1981(00)00018-4; BUSER CA, 1994, BIOCHEMISTRY-US, V33, P13093, DOI 10.1021/bi00248a019; Canaan S, 2002, J BIOL CHEM, V277, P30984, DOI 10.1074/jbc.M203649200; CHANG LS, 1993, BIOCHIM BIOPHYS ACTA, V1202, P216, DOI 10.1016/0167-4838(93)90007-E; Dennis EA, 1983, ENZYMES, P307; DUDLER T, 1992, BIOCHIM BIOPHYS ACTA, V1165, P201, DOI 10.1016/0005-2760(92)90188-2; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Feng JW, 2002, J BIOL CHEM, V277, P19867, DOI 10.1074/jbc.M200938200; Foreman-Wykert AK, 1999, J CLIN INVEST, V103, P715, DOI 10.1172/JCI5468; Gadd ME, 2000, BIOCHEMISTRY-US, V39, P9623, DOI 10.1021/bi000322f; Gesquiere L, 2002, BIOCHEMISTRY-US, V41, P4911, DOI 10.1021/bi015757x; Ghomashchi F, 1998, BIOCHEMISTRY-US, V37, P6697, DOI 10.1021/bi972525i; GHOMASHCHI F, 1991, BIOCHEMISTRY-US, V30, P7318, DOI 10.1021/bi00243a037; Han SK, 1997, J BIOL CHEM, V272, P3573, DOI 10.1074/jbc.272.26.16152; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Henshaw JB, 1998, BIOCHEMISTRY-US, V37, P10709, DOI 10.1021/bi9728809; Hixon MS, 1998, BIOCHEMISTRY-US, V37, P8516, DOI 10.1021/bi980416d; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P475, DOI 10.1016/0005-2736(86)90544-4; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; JAIN MK, 1986, BIOCHIM BIOPHYS ACTA, V860, P462, DOI 10.1016/0005-2736(86)90543-2; Keller SL, 1998, PHYS REV LETT, V81, P5019, DOI 10.1103/PhysRevLett.81.5019; KINKAID AR, 1995, BIOCHEM J, V308, P507, DOI 10.1042/bj3080507; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; Koduri RS, 2002, J BIOL CHEM, V277, P5849, DOI 10.1074/jbc.M109699200; Koumanov K, 1997, BIOCHEM J, V326, P227, DOI 10.1042/bj3260227; Koumanov KS, 1998, BIOCHEM J, V336, P625, DOI 10.1042/bj3360625; Lin Y, 1998, SCIENCE, V279, P1925, DOI 10.1126/science.279.5358.1925; MaoQiang M, 1996, J INVEST DERMATOL, V106, P57, DOI 10.1111/1523-1747.ep12327246; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1997, CRIT REV IMMUNOL, V17, P225, DOI 10.1615/CritRevImmunol.v17.i3-4.10; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; Pan YH, 2002, J BIOL CHEM, V277, P29086, DOI 10.1074/jbc.M202531200; Qu XD, 1998, INFECT IMMUN, V66, P2791, DOI 10.1128/IAI.66.6.2791-2797.1998; RAMIREZ F, 1991, PROTEINS, V9, P229, DOI 10.1002/prot.340090402; Richmond BL, 2001, GASTROENTEROLOGY, V120, P1193, DOI 10.1053/gast.2001.23254; Schadow A, 2001, J INVEST DERMATOL, V116, P31, DOI 10.1046/j.1523-1747.2001.00179.x; SCOTT DL, 1994, ADV PROTEIN CHEM, V45, P53; Snitko Y, 1997, BIOCHEMISTRY-US, V36, P14325, DOI 10.1021/bi971200z; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; YING HP, 2001, BIOCHEMISTRY-US, V40, P609; Yu BZ, 2000, BIOCHEMISTRY-US, V39, P12312, DOI 10.1021/bi000740k; YU BZ, 1993, BIOCHEMISTRY-US, V32, P6485, DOI 10.1021/bi00076a024; [No title captured]	57	111	111	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48523	48534		10.1074/jbc.M203137200	http://dx.doi.org/10.1074/jbc.M203137200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12244093	hybrid			2022-12-25	WOS:000179789600074
J	Bodnar, RJ; Xi, XD; Li, ZY; Berndt, MC; Du, XP				Bodnar, RJ; Xi, XD; Li, ZY; Berndt, MC; Du, XP			Regulation of glycoprotein Ib-IX-von Willebrand factor interaction by cAMP-dependent protein kinase-mediated phosphorylation at Ser(166) of glycoprotein Ib beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN-BINDING PROTEIN; CYCLIC-AMP; MEMBRANE GLYCOPROTEIN; VONWILLEBRAND-FACTOR; CYTOPLASMIC DOMAIN; PLATELET-ADHESION; V COMPLEX; INTEGRIN ALPHA(IIB)BETA(3); MONOCLONAL-ANTIBODY; SIGNALING PROTEIN	The platelet receptor for von Willebrand factor (VWF), glycoprotein (GP) Ib-IX, mediates initial platelet adhesion and activation. It is known that the cytoplasmic domain of GPIbbeta is phosphorylated at Ser(166) by cAMP-dependent protein kinase (PKA). To understand the physiological role of GPIbbeta phosphorylation, a GPIb-IX mutant replacing Ser(166) of GPIbbeta with alanine (S166A) and a deletion mutant lacking residues 166-181 of GPIbbeta (Delta165) were constructed. These mutants, expressed in Chinese hamster ovary (CHO) cells, showed an enhanced VWF-binding function compared with wild type GPIb-IX. Treatment of CHO cells expressing wild type GPIb-IX with a PKA inhibitor, PKI, reduced Ser(166) phosphorylation and also enhanced VWF binding to GPIb-IX. Furthermore, cells expressing S166A or Delta165 mutants showed a significantly enhanced adhesion to immobilized VWF under flow conditions. Consistent with the studies in CHO cells, treatment of platelets with PKI enhanced VWF binding to platelets. In contrast, a PKA stimulator, forskolin, reduced VWF binding and VWF-induced platelet agglutination, which was reversed by PKI. Thus, PKA-mediated phosphorylation of GPIbbeta at Ser(166) negatively regulates VWF binding to GPIb-IX and is one of the mechanisms by which PKA mediates platelet inhibition.	Univ Illinois, Dept Pharmacol, Coll Med, Chicago, IL 60612 USA; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Monash University	Du, XP (corresponding author), Univ Illinois, Dept Pharmacol, Coll Med, 835 S Wolcott Ave, Chicago, IL 60612 USA.		Berndt, Michael C/D-5580-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062350] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62350, R01 HL062350] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDREWS RK, 1991, J BIOL CHEM, V266, P7144; ANDREWS RK, 1989, BIOCHEMISTRY-US, V28, P8317, DOI 10.1021/bi00447a009; Andrews RK, 2001, BLOOD, V98, P681, DOI 10.1182/blood.V98.3.681; Andrews RK, 1998, BIOCHEMISTRY-US, V37, P638, DOI 10.1021/bi970893g; ANDREWS RK, 1992, J BIOL CHEM, V267, P18605; Andrews RK, 1999, THROMB HAEMOSTASIS, V82, P357, DOI 10.1055/s-0037-1615854; Bodnar RJ, 1999, J BIOL CHEM, V274, P33474, DOI 10.1074/jbc.274.47.33474; BOOTH WJ, 1984, BIOCHEM BIOPH RES CO, V118, P495, DOI 10.1016/0006-291X(84)91330-5; Calverley DC, 1998, BLOOD, V91, P1295, DOI 10.1182/blood.V91.4.1295; COLLER BS, 1981, BLOOD, V57, P846; Cranmer SL, 1999, J BIOL CHEM, V274, P6097, DOI 10.1074/jbc.274.10.6097; Cunningham JG, 1996, J BIOL CHEM, V271, P11581, DOI 10.1074/jbc.271.19.11581; DEMARCO L, 1985, J CLIN INVEST, V75, P1198, DOI 10.1172/JCI111816; DU XP, 1994, J BIOL CHEM, V269, P18287; DU XP, 1991, CELL, V65, P409, DOI 10.1016/0092-8674(91)90458-B; Du XP, 1996, J BIOL CHEM, V271, P7362, DOI 10.1074/jbc.271.13.7362; Englund GD, 2001, J BIOL CHEM, V276, P16952, DOI 10.1074/jbc.M008048200; FOX JEB, 1989, J BIOL CHEM, V264, P9520; FOX JEB, 1987, J BIOL CHEM, V262, P12627; GRIGGS TR, 1973, P NATL ACAD SCI USA, V70, P2814, DOI 10.1073/pnas.70.10.2814; Gu MY, 1999, J CELL BIOL, V147, P1085, DOI 10.1083/jcb.147.5.1085; HETTASCH JM, 1987, BIOCHIM BIOPHYS ACTA, V931, P49, DOI 10.1016/0167-4889(87)90049-8; HICKEY MJ, 1989, P NATL ACAD SCI USA, V86, P6773, DOI 10.1073/pnas.86.17.6773; KROLL MH, 1991, J CLIN INVEST, V88, P1568, DOI 10.1172/JCI115468; LERNER RA, 1981, P NATL ACAD SCI-BIOL, V78, P3403, DOI 10.1073/pnas.78.6.3403; Li ZY, 2001, J BIOL CHEM, V276, P42226, DOI 10.1074/jbc.M106129200; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LOPEZ JA, 1988, P NATL ACAD SCI USA, V85, P2135, DOI 10.1073/pnas.85.7.2135; LOPEZ JA, 1992, J BIOL CHEM, V267, P12851; LOPEZ JA, 1994, BLOOD COAGUL FIBRIN, V5, P97; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; Mannucci PM, 2001, BLOOD, V98, P2730, DOI 10.1182/blood.V98.9.2730; Perrault C, 2001, THROMB HAEMOSTASIS, V86, P1238, DOI 10.1055/s-0037-1616057; PUSZKIN EG, 1990, BLOOD, V76, P1572; Ruan C G, 1986, Zhonghua Nei Ke Za Zhi, V25, P547; RUAN CG, 1987, BLOOD, V69, P570; RUAN CG, 1986, ZHONGHUA NEI KE ZA Z, V25, P576; Ruggeri Z M, 1991, Prog Hemost Thromb, V10, P35; Ryningen A, 1998, BBA-LIPID LIPID MET, V1394, P235, DOI 10.1016/S0005-2760(98)00106-4; SALZMAN EW, 1972, NEW ENGL J MED, V286, P358; Savage B, 1996, CELL, V84, P289, DOI 10.1016/S0092-8674(00)80983-6; SLACK SM, 1994, THROMB HAEMOSTASIS, V72, P777; van der Plas RM, 1999, BLOOD, V93, P3798, DOI 10.1182/blood.V93.11.3798.411k07_3798_3802; Veyradier A, 2001, BLOOD, V98, P1765, DOI 10.1182/blood.V98.6.1765; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; Williamson D, 2002, J BIOL CHEM, V277, P2151, DOI 10.1074/jbc.M109384200; WYLER B, 1986, BIOCHEM J, V234, P373, DOI 10.1042/bj2340373	48	63	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47080	47087		10.1074/jbc.M208329200	http://dx.doi.org/10.1074/jbc.M208329200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12361948	hybrid			2022-12-25	WOS:000179663700033
J	Echtay, KS; Murphy, MP; Smith, RAJ; Talbot, DA; Brand, MD				Echtay, KS; Murphy, MP; Smith, RAJ; Talbot, DA; Brand, MD			Superoxide activates mitochondrial uncoupling protein 2 from the matrix side - Studies using targeted antioxidants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE MITOCHONDRIA; PROTON LEAK; COENZYME-Q; FATTY-ACIDS; UCP3; YEAST; EXPRESSION; OBESITY; GENE; NUCLEOTIDES	Superoxide activates nucleotide-sensitive mitochondrial proton transport through the uncoupling proteins UCP1, UCP2, and UCP3 (Echtay, K. S., et al. (2002) Nature 415, 1482-1486). Two possible mechanisms were proposed: direct activation of the UCP proton transport mechanism by superoxide or its products and a cycle of hydroperoxyl radical entry coupled to UCP-catalyzed superoxide anion export. Here we provide evidence for the first mechanism and show that superoxide activates UCP2 in rat kidney mitochondria from the matrix side of the mitochondrial inner membrane: (i) Exogenous superoxide inhibited matrix aconitase, showing that external superoxide entered the matrix. (ii) Superoxide-induced uncoupling was abolished by low concentrations of the mitochondrially targeted antioxidants 10(6'-ubiquinonyl)decyltriphenylphosphonium (mitoQ) or 2- [2-(triphenylphosphonio)ethyl]-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-6-ol bromide (mitoVit E), which are ubiquinone (Q) or tocopherol derivatives targeted to the matrix by covalent attachment to triphenylphosphonium cation. However, superoxide-induced uncoupling was not affected by similar concentrations of the nontargeted antioxidants Q(o), Q(1), decylubiquinone, vitamin E, or 6-hydroxy-2,5,7,8-tetramethylchroman 2-carboxylic acid (TROLOX) or of the mitochondrially targeted but redox-inactive analogs decyltriphenylphosphonium or 4-chlorobutyltriphenylphosphonium. Thus matrix superoxide appears to be necessary for activation of UCP2 by exogenous superoxide. (iii) When the reduced to oxidized ratio of mitoQ accumulated by mitochondria was increased by inhibiting cytochrome oxidase, it induced nucleotide-sensitive uncoupling that was not inhibited by external superoxide dismutase. Under these conditions quinols are known to produce superoxide, and because mitoQ is localized within the mitochondrial matrix this suggests that production of superoxide in the matrix was sufficient to activate UCP2. Furthermore, the superoxide did not need to be exported or to cycle across the inner membrane to cause uncoupling. We conclude that superoxide (or its products) exerts its uncoupling effect by activating the proton transport mechanism of uncoupling proteins at the matrix side of the mitochondrial inner membrane.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Chem, Dunedin, New Zealand	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago	Brand, MD (corresponding author), MRC, Dunn Human Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.	martin.brand@mrc-dunn.cam.ac.uk	Murphy, Michael P/C-2120-2009; Brand, Martin D/A-9423-2012	Murphy, Michael P/0000-0003-1115-9618; Brand, Martin D/0000-0003-4418-6153; Talbot, Darren/0000-0001-6845-0049				Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; Brand M. D., 1995, BIOENERGETICS, V154, P62; Brand MD, 2002, BIOCHEM J, V368, P597, DOI 10.1042/BJ20021077; Brand MD, 2000, EXP GERONTOL, V35, P811, DOI 10.1016/S0531-5565(00)00135-2; Brand MD, 1999, INT J OBESITY, V23, pS4, DOI 10.1038/sj.ijo.0800936; BRAND MD, 1990, BIOCHIM BIOPHYS ACTA, V1018, P128, DOI 10.1016/0005-2728(90)90232-S; Cadenas S, 2002, J BIOL CHEM, V277, P2773, DOI 10.1074/jbc.M109736200; Couplan E, 2002, J BIOL CHEM, V277, P26268, DOI 10.1074/jbc.M202535200; Echtay KS, 2000, NATURE, V408, P609, DOI 10.1038/35046114; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Echtay KS, 2001, BIOCHEM SOC T, V29, P763; Echtay KS, 1999, FEBS LETT, V450, P8, DOI 10.1016/S0014-5793(99)00460-3; Echtay KS, 2002, NATURE, V415, P96, DOI 10.1038/415096a; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fink BD, 2002, J BIOL CHEM, V277, P3918, DOI 10.1074/jbc.M107955200; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Gardner PR, 2002, METHOD ENZYMOL, V349, P9, DOI 10.1016/S0076-6879(02)49317-2; Garlid KD, 2000, BBA-BIOENERGETICS, V1459, P383, DOI 10.1016/S0005-2728(00)00175-4; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; Guerini D, 2002, EUR J BIOCHEM, V269, P1373, DOI 10.1046/j.1432-1033.2002.02773.x; GUIDOT DM, 1995, J CLIN INVEST, V96, P1131, DOI 10.1172/JCI118100; Harper JA, 2002, BIOCHEM J, V361, P49, DOI 10.1042/0264-6021:3610049; Heidkaemper D, 2000, FEBS LETT, V480, P265, DOI 10.1016/S0014-5793(00)01949-9; Himms-Hagen J, 2001, EXP BIOL MED, V226, P78, DOI 10.1177/153537020122600204; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Jekabsons MB, 2002, BIOCHEM J, V366, P565, DOI 10.1042/BJ20020469; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Klingenberg M, 2001, BBA-BIOENERGETICS, V1504, P128, DOI 10.1016/S0005-2728(00)00242-5; Kowaltowski AJ, 1998, FEBS LETT, V425, P213, DOI 10.1016/S0014-5793(98)00231-2; Krauss S, 2002, P NATL ACAD SCI USA, V99, P118, DOI 10.1073/pnas.012410699; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; Nedergaard J, 2001, BBA-BIOENERGETICS, V1504, P82, DOI 10.1016/S0005-2728(00)00247-4; NegreSalvayre A, 1997, FASEB J, V11, P809, DOI 10.1096/fasebj.11.10.9271366; Papa S, 1997, MOL CELL BIOCHEM, V174, P305, DOI 10.1023/A:1006873518427; Pastore D, 2000, FEBS LETT, V470, P88, DOI 10.1016/S0014-5793(00)01292-8; Pecqueur C, 2001, J BIOL CHEM, V276, P8705, DOI 10.1074/jbc.M006938200; Rial E, 2001, BBA-BIOENERGETICS, V1504, P70, DOI 10.1016/S0005-2728(00)00240-1; Ricquier D, 2000, BIOCHEM J, V345, P161, DOI 10.1042/0264-6021:3450161; Rolfe DFS, 1999, AM J PHYSIOL-CELL PH, V276, pC692, DOI 10.1152/ajpcell.1999.276.3.C692; ROLFE DFS, 1994, BBA-BIOENERGETICS, V1188, P405, DOI 10.1016/0005-2728(94)90062-0; Samec S, 1998, DIABETES, V47, P1693, DOI 10.2337/diabetes.47.11.1693; Smith RAJ, 1999, EUR J BIOCHEM, V263, P709, DOI 10.1046/j.1432-1327.1999.00543.x; Stuart JA, 2001, BIOCHEM J, V356, P779, DOI 10.1042/0264-6021:3560779; Stuart JA, 2001, BBA-BIOENERGETICS, V1504, P144, DOI 10.1016/S0005-2728(00)00243-7; Stuart JA, 2001, J BIOL CHEM, V276, P18633, DOI 10.1074/jbc.M011566200; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Winkler E, 2001, BIOCHEM BIOPH RES CO, V282, P334, DOI 10.1006/bbrc.2001.4563; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	51	326	340	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47129	47135		10.1074/jbc.M208262200	http://dx.doi.org/10.1074/jbc.M208262200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12372827	hybrid			2022-12-25	WOS:000179663700039
J	Koshimizu, T; Ueno, S; Tanoue, A; Yanagihara, N; Stojilkovic, SS; Tsujimoto, G				Koshimizu, T; Ueno, S; Tanoue, A; Yanagihara, N; Stojilkovic, SS; Tsujimoto, G			Heteromultimerization modulates P2X receptor functions through participating extracellular and C-terminal subdomains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTERIOR-PITUITARY-CELLS; ION CHANNELS; ATP RECEPTOR; SENSORY NEURONS; DESENSITIZATION; SUBUNITS; IDENTIFICATION; PHARMACOLOGY; EXPRESSION; SITE	P2X purinergic receptors (P2XRs) differ among themselves with respect to their ligand preferences and channel kinetics during activation, desensitization, and recovery. However, the contributions of distinct receptor subdomains to the subtype-specific behavior have been incompletely characterized. Here we show that homomeric receptors having the extracellular domain of the P2X(3) subunit in the P2X(2a)-based backbone (P2X(2a)/X(3)ex) mimicked two intrinsic functions of P2X(3)R, sensitivity to alphabeta-methylene ATP and ecto-ATPase-dependent recovery from endogenous desensitization; these two functions were localized to the N- and C-terminal halves of the P2X(3) extracellular loop, respectively. The chimeric P2X(2a)R/X(3)ex receptors also desensitized with accelerated rates compared with native P2X(2a)R, and the introduction of P2X(2) C-terminal splicing into the chimeric subunit (P2X(2b)/X(3)ex) further increased the rate of desensitization. Physical and functional heteromerization of native P2X(2a) and P2X(2b) subunits was also demonstrated. In heteromeric receptors, the ectodomain of P2X(3) was a structural determinant for ligand selectivity and recovery from desensitization, and the C terminus of P2X(2) was an important factor for the desensitization rate. Furthermore, [gamma-P-32]8-azido ATP, a photoreactive agonist, was effectively cross-linked to P2X(3) subunit in homomeric receptors but not in heteromeric P2X(2) + P2X(3)Rs. These results indicate that heteromeric receptors formed by distinct P2XR subunits develop new functions resulting from integrative effects of the participating extracellular and C-terminal subdomains.	NICHD, Dept Mol & Cell Pharmacol, NIH, Bethesda, MD 20892 USA; NICHD, Endocrinol & Reprod Res Branch, NIH, Bethesda, MD 20892 USA; Univ Occupat & Environm Hlth, Dept Pharmacol, Japan Sch Med, Tokyo 1548567, Japan	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Occupational & Environmental Health - Japan	Tsujimoto, G (corresponding author), Natl Res Inst Child Hlth & Dev, Dept Mol Cell Pharmacol, Setagaya Ku, 3-35-31 Taishido, Tokyo 154, Japan.		Koshimizu, Taka-aki/G-2740-2015	Koshimizu, Taka-aki/0000-0001-5292-7535	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BEAN BP, 1992, TRENDS PHARMACOL SCI, V13, P87, DOI 10.1016/0165-6147(92)90032-2; Beckstead MJ, 2000, MOL PHARMACOL, V57, P1199; Boue-Grabot E, 2000, J BIOL CHEM, V275, P10190, DOI 10.1074/jbc.275.14.10190; BRAKE AJ, 1994, NATURE, V371, P519, DOI 10.1038/371519a0; Brandle U, 1997, FEBS LETT, V404, P294, DOI 10.1016/S0014-5793(97)00128-2; Buck KJ, 1998, METHOD ENZYMOL, V296, P466; BURNSTOCK G, 1990, ANN NY ACAD SCI, V603, P1; CHEN CC, 1995, NATURE, V377, P428, DOI 10.1038/377428a0; Di Virgilio Francesco, 2001, Trends in Pharmacological Sciences, V22, P5; EDWARDS FA, 1992, NATURE, V359, P144, DOI 10.1038/359144a0; Ennion S, 2000, J BIOL CHEM, V275, P29361, DOI 10.1074/jbc.M003637200; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jiang LH, 2000, J BIOL CHEM, V275, P34190, DOI 10.1074/jbc.M005481200; Khakh BS, 2001, PHARMACOL REV, V53, P107; Koshimizu T, 2000, ENDOCRINOLOGY, V141, P4091, DOI 10.1210/en.141.11.4091; Koshimizu T, 1999, J BIOL CHEM, V274, P37651, DOI 10.1074/jbc.274.53.37651; Koshimizu T, 1998, MOL ENDOCRINOL, V12, P901, DOI 10.1210/me.12.7.901; Koshimizu T, 1998, J BIOL CHEM, V273, P12853, DOI 10.1074/jbc.273.21.12853; Koshimizu TA, 2000, MOL PHARMACOL, V58, P936, DOI 10.1124/mol.58.5.936; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Le KT, 1998, J NEUROSCI, V18, P7152; LEWIS C, 1995, NATURE, V377, P432, DOI 10.1038/377432a0; Lewis CJ, 1998, BRIT J PHARMACOL, V124, P1463, DOI 10.1038/sj.bjp.0702001; Lynch KJ, 1999, MOL PHARMACOL, V56, P1171, DOI 10.1124/mol.56.6.1171; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; Radford KM, 1997, J NEUROSCI, V17, P6529; Ralevic V, 1998, PHARMACOL REV, V50, P413; Simon J, 1997, MOL PHARMACOL, V52, P237, DOI 10.1124/mol.52.2.237; Stojilkovic SS, 2001, TRENDS ENDOCRIN MET, V12, P218, DOI 10.1016/S1043-2760(01)00387-3; Tomic M, 1996, J BIOL CHEM, V271, P21200, DOI 10.1074/jbc.271.35.21200; Torres GE, 1998, MOL PHARMACOL, V54, P989, DOI 10.1124/mol.54.6.989; Torres GE, 1999, J BIOL CHEM, V274, P6653, DOI 10.1074/jbc.274.10.6653; Torres GE, 1999, J BIOL CHEM, V274, P22359, DOI 10.1074/jbc.274.32.22359; WARLAND JJI, 1987, BRIT J PHARMACOL, V92, P871, DOI 10.1111/j.1476-5381.1987.tb11393.x; Werner P, 1996, P NATL ACAD SCI USA, V93, P15485, DOI 10.1073/pnas.93.26.15485; Zhou Z, 1998, BIOCHEM BIOPH RES CO, V252, P541, DOI 10.1006/bbrc.1998.9689	36	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46891	46899		10.1074/jbc.M205274200	http://dx.doi.org/10.1074/jbc.M205274200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12361958	hybrid			2022-12-25	WOS:000179663700010
J	Sbrissa, D; Ikonomov, OC; Deeb, R; Shisheva, A				Sbrissa, D; Ikonomov, OC; Deeb, R; Shisheva, A			Phosphatidylinositol 5-phosphate biosynthesis is linked to PIKfyve and is involved in osmotic response pathway in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; LIPID KINASE; FAB1P; POLYPHOSPHOINOSITIDE; 4,5-BISPHOSPHATE; 3,5-BISPHOSPHATE; ACCUMULATION; TRAFFICKING; ADIPOCYTES; INCREASE	The cellular functions, regulation and enzymology of phosphatidylinositol (PtdIns) 5-P, the newest addition to the family of phosphoinositides (PI), are still elusive. Whereas a kinase that uses PtdIns-5-P as an intracellular substrate has been assigned, a kinase that produces it remained to be identified. Here we report that PIKfyve, the enzyme found to synthesize PtdIns-5-P in vitro and PtdIns-3,5-P-2 in vitro and in vivo, is responsible for PtdIns-5-P production in a cellular context. Evidence is based on examination of two groups of cell types by two independent approaches. First, [P-32]orthophosphate-labeled cells (Sf9, 3T3-L1 fibroblasts, and 3T3-L1 adipocytes) that show a high pressure liquid chromatography (HPLC)-detectable peak of the PtdIns-5-P head group at basal conditions demonstrated a 20-50% increase in radioactive PtdIns-5-P amounts upon expression of PIK-fyve(WT). Second, cell types (HEK293), in which the basal levels of radioactive PtdIns-5-P were undetectable by HPLC head group analysis, demonstrated higher in vitro type II PIP kinase-directed conversion of the endogenous PtdIns-5-P pool into PtdIns-4,5-P-2, when induced to express PIKfyveWT. Conversely, a decrease by 60% in the conversion of PtdIns-5-P to PtdIns-4,5-P-2 was associated with induced expression of the dominant-negative kinase-deficient PIKfyve(K1831E) mutant in HEK293 cells. When 3T3-L1 fibroblasts and 3T3-L1 adipocytes were subjected to osmotic shock, levels of PtdIns-5-P measured by both approaches were found to decrease profoundly upon a hypo-osmotic stimulus. Together, these results identify PIKfyve as an enzyme responsible for PtdIns-5-P biosynthesis and indicate a role for PtdIns-5-P in osmotic response pathways in mammalian cells.	Wayne State Univ, Sch Med, Dept Physiol, Detroit, MI 48201 USA	Wayne State University	Shisheva, A (corresponding author), Wayne State Univ, Sch Med, Dept Physiol, 540 E Canfield, Detroit, MI 48201 USA.	ashishev@med.wayne.edu			NIDDK NIH HHS [DK58058] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058058] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Bonangelino CJ, 2002, J CELL BIOL, V156, P1015, DOI 10.1083/jcb.200201002; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; Chen D, 1999, MOL CELL BIOL, V19, P4684; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; Clarke JH, 2001, BIOCHEM J, V357, P905, DOI 10.1042/0264-6021:3570905; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; DeWald DB, 2001, PLANT PHYSIOL, V126, P759, DOI 10.1104/pp.126.2.759; Dove SK, 2002, CURR BIOL, V12, P885, DOI 10.1016/S0960-9822(02)00891-6; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; EINSPAHR KJ, 1988, J BIOL CHEM, V263, P5775; Fruman DA, 1999, CELL, V97, P817, DOI 10.1016/S0092-8674(00)80792-8; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hughes WE, 2000, BIOCHEM J, V350, P337, DOI 10.1042/0264-6021:3500337; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Ikonomov OC, 2002, ENDOCRINOLOGY, V143, P4742, DOI 10.1210/en.2002-220615; Ikonomov OC, 2002, J BIOL CHEM, V277, P9206, DOI 10.1074/jbc.M108750200; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Janez A, 2000, J BIOL CHEM, V275, P26870; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; McEwen RK, 1999, J BIOL CHEM, V274, P33905, DOI 10.1074/jbc.274.48.33905; Meijer HJG, 2001, BIOCHEM J, V360, P491, DOI 10.1042/0264-6021:3600491; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Pical C, 1999, J BIOL CHEM, V274, P38232, DOI 10.1074/jbc.274.53.38232; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Sbrissa D, 1999, J BIOL CHEM, V274, P21589, DOI 10.1074/jbc.274.31.21589; Sbrissa D, 2000, BIOCHEMISTRY-US, V39, P15980, DOI 10.1021/bi001897f; SCHACHT J, 1981, METHOD ENZYMOL, V72, P623; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 1998, J BIOL CHEM, V273, P18040, DOI 10.1074/jbc.273.29.18040; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Wishart MJ, 2001, CELL, V105, P817, DOI 10.1016/S0092-8674(01)00414-7; York JD, 2001, ADV ENZYME REGUL, V41, P57, DOI 10.1016/S0065-2571(00)00025-X	39	97	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47276	47284		10.1074/jbc.M207576200	http://dx.doi.org/10.1074/jbc.M207576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12270933	hybrid			2022-12-25	WOS:000179663700057
J	Shchors, K; Yehiely, F; Kular, RK; Kotlo, KU; Brewer, G; Deiss, LP				Shchors, K; Yehiely, F; Kular, RK; Kotlo, KU; Brewer, G; Deiss, LP			Cell death inhibiting RNA (CDIR) derived from a 3 '-untranslated region binds AUF1 and heat shock protein 27	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; DOUBLE-STRANDED-RNA; MESSENGER-RNA; RICH ELEMENT; HNRNP-D; ALPHA-TROPOMYOSIN; GENE-EXPRESSION; STABILITY; KINASE; CLONING	Regulators of programmed cell death were previously identified using a technical knockout genetic screen. Among the elements that inhibited interferon-gamma-induced apoptosis of HeLa cells was a 441-nucleotide fragment derived from the 3'-untranslated region (UTR) of KIAA0425, a gene of unknown function. This fragment was termed cell death inhibiting RNA (CDIR). Deletion and mutation analyses of CDIR were employed to identify the features required for its anti-apoptotic activity. Single nucleotide alterations within either copy of the duplicated U-rich motif found in the CDIR sequence abolished the anti-apoptotic activity of CDIR and altered its in vitro association with a protein complex. Further analysis of the CDIR-binding complex indicated that it contained heat shock protein 27 (Hsp27) and the regulator of mRNA turnover AUF1 (heterogeneous nuclear ribonucleoprotein D). In addition, recombinant AUF1 bound directly to CDIR. Furthermore, expression of another AUF1-binding RNA element, derived from the 3'-UTR of c-myc, inhibited apoptosis. We also demonstrate that the level and the stability of p21(waf1/Cip1/sdi1) mRNA, a target of AUF1 with anti-apoptotic activity, were increased in CDIR-transfected cells. The level of mRNA and protein of Bcl-2, another anti-apoptotic gene, containing an AUF1 binding site in its 3'-UTR was also increased in CDIR-transfected cells. Our data suggest that AUF1 regulates apoptosis by altering mRNA turnover. We propose that CDIR inhibits apoptosis by acting as a competitive inhibitor of AUF1, preventing AUF1 from binding to its targets.	Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Rutgers State University New Brunswick; Rutgers State University Medical Center	Deiss, LP (corresponding author), Univ Illinois, Dept Biol Mol, M-C 669,900 S Ashland Ave, Chicago, IL 60607 USA.				NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; ARRIGO AP, 1988, MOL CELL BIOL, V8, P5059, DOI 10.1128/MCB.8.12.5059; Bhattacharya S, 1999, NUCLEIC ACIDS RES, V27, P1464, DOI 10.1093/nar/27.6.1464; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; Buzby JS, 1999, J BIOL CHEM, V274, P33973, DOI 10.1074/jbc.274.48.33973; Capaccioli S, 1996, ONCOGENE, V13, P105; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Clemens MJ, 1997, INT J BIOCHEM CELL B, V29, P945, DOI 10.1016/S1357-2725(96)00169-0; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Davis S, 1996, P NATL ACAD SCI USA, V93, P508, DOI 10.1073/pnas.93.1.508; DECKER CJ, 1995, CURR OPIN CELL BIOL, V7, P386, DOI 10.1016/0955-0674(95)80094-8; DEISS LP, 1991, SCIENCE, V252, P117, DOI 10.1126/science.1901424; DEISS LP, 1995, GENE DEV, V9, P15, DOI 10.1101/gad.9.1.15; Eversole A, 2000, MOL CELL BIOL, V20, P5425, DOI 10.1128/MCB.20.15.5425-5432.2000; Fan HZ, 1996, CANCER RES, V56, P4366; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Goswami PC, 2000, J BIOL CHEM, V275, P38384, DOI 10.1074/jbc.M005298200; Guhaniyogi J, 2001, GENE, V265, P11, DOI 10.1016/S0378-1119(01)00350-X; Henics T, 1999, J BIOL CHEM, V274, P17318, DOI 10.1074/jbc.274.24.17318; Hobeika AC, 1999, J INTERF CYTOK RES, V19, P1351, DOI 10.1089/107999099312812; Jiang TJ, 2001, P NATL ACAD SCI USA, V98, P920, DOI 10.1073/pnas.021561498; Jupe ER, 1996, EXP CELL RES, V224, P128, DOI 10.1006/excr.1996.0120; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; Kimchi A, 1998, BBA-REV CANCER, V1377, pF13, DOI 10.1016/S0304-419X(98)00002-X; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Lapucci A, 2002, J BIOL CHEM, V277, P16139, DOI 10.1074/jbc.M201377200; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MOGRIDGE J, 1995, GENE DEV, V9, P2831, DOI 10.1101/gad.9.22.2831; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; Powell AJ, 1998, EXP CELL RES, V240, P252, DOI 10.1006/excr.1998.3937; Raca G, 2000, NUCLEIC ACIDS RES, V28, P3943, DOI 10.1093/nar/28.20.3943; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; Reiter A, 1998, BLOOD, V92, P1735, DOI 10.1182/blood.V92.5.1735.417k11_1735_1742; Roninson IB, 2002, CANCER LETT, V179, P1, DOI 10.1016/S0304-3835(01)00847-3; Sirenko OI, 1997, MOL CELL BIOL, V17, P3898, DOI 10.1128/MCB.17.7.3898; Smedley D, 1999, GENOMICS, V60, P244, DOI 10.1006/geno.1999.5918; TASSET D, 1990, CELL, V62, P1177, DOI 10.1016/0092-8674(90)90394-T; vanderMaarel SM, 1996, HUM MOL GENET, V5, P887, DOI 10.1093/hmg/5.7.887; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wilkinson MF, 2001, BIOESSAYS, V23, P775, DOI 10.1002/bies.1113; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 2001, J BIOL CHEM, V276, P44450, DOI 10.1074/jbc.M108521200; Wilson GM, 2001, J BIOL CHEM, V276, P8695, DOI 10.1074/jbc.M009848200; Xiao S, 1998, NAT GENET, V18, P84, DOI 10.1038/ng0198-84; Xu NH, 2001, MOL CELL BIOL, V21, P6960, DOI 10.1128/MCB.21.20.6960-6971.2001; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652; Zornig M, 2001, BBA-REV CANCER, V1551, pF1, DOI 10.1016/S0304-419X(01)00031-2	53	26	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47061	47072		10.1074/jbc.M202272200	http://dx.doi.org/10.1074/jbc.M202272200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356764	hybrid			2022-12-25	WOS:000179663700031
J	Alberti, S; Demand, J; Esser, C; Emmerich, N; Schild, H; Hohfeld, J				Alberti, S; Demand, J; Esser, C; Emmerich, N; Schild, H; Hohfeld, J			Ubiquitylation of BAG-1 suggests a novel regulatory mechanism during the sorting of chaperone substrates to the proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							E3 UBIQUITIN LIGASE; U-BOX; 26 S; MOLECULAR CHAPERONES; HSC70 CHAPERONE; QUALITY-CONTROL; PROTEIN; SUBUNIT; CHIP; DOMAIN	BAG-1 is a ubiquitin domain protein that links the molecular chaperones Hsc70 and Hsp70 to the proteasome. During proteasomal sorting BAG-1 can cooperate with another co-chaperone, the carboxyl terminus of Hsc70-interacting protein CHIP. CHIP was recently identified as a Hsp70- and Hsp90-associated. ubiquitin ligase that labels chaperone-presented proteins with the degradation marker ubiquitin. Here we show that BAG-1 itself is a substrate of the CHIP ubiquitin ligase in vitro and in vivo. CHIP mediates attachment of ubiquitin moieties to BAG-1 in conjunction with ubiquitin-conjugating enzymes of the LTbc4/5 family. Ubiquitylation of BAG-1 is strongly stimulated when a ternary Hsp70-BAG-1-CHIP complex is formed. Complex formation results in the attachment of an atypical polyubiquitin chain to BAG-1, in which the individual ubiquitin moieties are linked through lysine 11. The noncanonical polyubiquitin chain does not induce the degradation of BAG-1, but it stimulates a degradation-independent association of the co-chaperone with the proteasome. Remarkably, this stimulating activity depends on the simultaneous presentation of the integrated ubiquitin-like domain of BAG-1. Our data thus reveal a cooperative recognition of sorting signals at the proteolytic complex. Attachment of polyubiquitin chains to delivery factors may represent a novel mechanism to regulate protein sorting to the proteasome.	Univ Bonn, Inst Zellbiol & Bonner Forum Biomed, D-53121 Bonn, Germany; Max Planck Inst Biochem, Abt Mol Zellbiol, D-82152 Martinsried, Germany; Univ Tubingen, Inst Zellbiol, Immunol Abt, D-72076 Tubingen, Germany	University of Bonn; Max Planck Society; Eberhard Karls University of Tubingen	Hohfeld, J (corresponding author), Univ Bonn, Inst Zellbiol & Bonner Forum Biomed, Ulrich Haberland Str 61A, D-53121 Bonn, Germany.	hoehfeld@uni-bonn.de	Alberti, Simon/ABB-8277-2021; Alberti, Simon/B-2822-2017	Alberti, Simon/0000-0003-4017-6505				Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; Baboshina OV, 1996, J BIOL CHEM, V271, P2823, DOI 10.1074/jbc.271.5.2823; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Cyr DM, 2002, TRENDS BIOCHEM SCI, V27, P368, DOI 10.1016/S0968-0004(02)02125-4; Demand J, 2001, CURR BIOL, V11, P1569, DOI 10.1016/S0960-9822(01)00487-0; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; Elsasser S, 2002, NAT CELL BIOL, V4, P725, DOI 10.1038/ncb845; Emmerich NPN, 2000, J BIOL CHEM, V275, P21140, DOI 10.1074/jbc.M000740200; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hiyama H, 1999, J BIOL CHEM, V274, P28019, DOI 10.1074/jbc.274.39.28019; Hofmann RM, 2001, J BIOL CHEM, V276, P27936, DOI 10.1074/jbc.M103378200; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Jentsch S, 2000, TRENDS CELL BIOL, V10, P335, DOI 10.1016/S0962-8924(00)01785-2; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kleijnen MF, 2000, MOL CELL, V6, P409, DOI 10.1016/S1097-2765(00)00040-X; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lam YA, 2002, NATURE, V416, P763, DOI 10.1038/416763a; Luders J, 2000, J BIOL CHEM, V275, P14817, DOI 10.1074/jbc.275.20.14817; Luders J, 1998, BIOL CHEM, V379, P1217, DOI 10.1515/bchm.1998.379.10.1217; Luders J, 2000, J BIOL CHEM, V275, P4613, DOI 10.1074/jbc.275.7.4613; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Murata S, 2001, EMBO REP, V2, P1133, DOI 10.1093/embo-reports/kve246; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; Sondermann H, 2001, SCIENCE, V291, P1553, DOI 10.1126/science.1057268; Sourisseau T, 2001, J CELL SCI, V114, P1409; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Takayama S, 1998, CANCER RES, V58, P3116; vanNocker S, 1996, MOL CELL BIOL, V16, P6020; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5; Walters KJ, 2002, BIOCHEMISTRY-US, V41, P1767, DOI 10.1021/bi011892y; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; Wiederkehr T, 2002, CURR BIOL, V12, pR26, DOI 10.1016/S0960-9822(01)00644-3; Xie YM, 2000, P NATL ACAD SCI USA, V97, P2497, DOI 10.1073/pnas.060025497; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; You JX, 2001, J BIOL CHEM, V276, P19871, DOI 10.1074/jbc.M100034200; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	45	143	150	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45920	45927		10.1074/jbc.M204196200	http://dx.doi.org/10.1074/jbc.M204196200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297498	hybrid			2022-12-25	WOS:000179529300029
J	Arnaudeau, S; Frieden, M; Nakamura, K; Castelbou, C; Michalak, M; Demaurex, N				Arnaudeau, S; Frieden, M; Nakamura, K; Castelbou, C; Michalak, M; Demaurex, N			Calreticulin differentially modulates calcium uptake and release in the endoplasmic reticulum and mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; OVEREXPRESSION; INFLUX; ENTRY; APOPTOSIS; OSCILLATIONS; ACTIVATION; DEPLETION; INCREASES; DECREASES	To study the role of calreticulin in Ca2+ homeostasis and apoptosis, we generated cells inducible for full-length or truncated calreticulin and measured Ca2+ signals within the cytosol, the endoplasmic reticulum (ER), and mitochondria with "cameleon" indicators. Induction of calreticulin increased the free Ca2+ concentration within the ER lumen, [Ca2+](ER), from 306 +/- 31 to 595 +/- 53 muM, and doubled the rate of ER refilling. [Ca2+](ER) remained elevated in the presence of thapsigargin, an inhibitor of SERCA-type Ca2+ ATPases. Under these conditions, store-operated Ca2+ influx appeared inhibited but could be reactivated by decreasing [Ca2+](ER) with the low affinity Ca2+ chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine. In contrast, [Ca2+](ER) decreased much faster during stimulation with carbachol. The larger ER release was associated with a larger cytosolic Ca2+ response and, surprisingly, with a shorter mitochondrial Ca2+ response. The reduced mitochondrial signal was not associated with visible morphological alterations of mitochondria or with disruption of the contacts between mitochondria and the ER but correlated with a reduced mitochondrial membrane potential. Altered ER and mitochondrial Ca2+ responses were also observed in cells expressing an N-truncated calreticulin but not in cells overexpressing calnexin, a P-domain containing chaperone, indicating that the effects were mediated by the unique C-domain of calreticulin. In conclusion, calreticulin overexpression increases Ca2+ fluxes across the ER but decreases mitochondrial Ca2+ and membrane potential. The increased Ca2+ turnover between the two organelles might damage mitochondria, accounting for the increased susceptibility of cells expressing high levels of calreticulin to apoptotic stimuli.	Univ Geneva, Med Ctr 1, Dept Physiol, CH-1211 Geneva 4, Switzerland; Univ Alberta, Canadian Inst Hlth Res, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada	University of Geneva; Institute for Work & Health; University of Alberta; University of Alberta	Demaurex, N (corresponding author), Univ Geneva, Med Ctr 1, Dept Physiol, CH-1211 Geneva 4, Switzerland.			, Kimitoshi/0000-0003-4903-2428; Demaurex, Nicolas/0000-0002-9933-6772; Frieden, Maud/0000-0001-7135-0874				Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BASTIANUTTO C, 1995, J CELL BIOL, V130, P847, DOI 10.1083/jcb.130.4.847; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Brini M, 2000, EMBO J, V19, P4926, DOI 10.1093/emboj/19.18.4926; CAMACHO P, 1995, CELL, V82, P765, DOI 10.1016/0092-8674(95)90473-5; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; Csordas G, 1999, EMBO J, V18, P96, DOI 10.1093/emboj/18.1.96; De Giorgi F, 2000, CELL CALCIUM, V28, P365, DOI 10.1054/ceca.2000.0177; Duchen MR, 1999, J PHYSIOL-LONDON, V516, P1, DOI 10.1111/j.1469-7793.1999.001aa.x; Fasolato C, 1998, MOL BIOL CELL, V9, P1513, DOI 10.1091/mbc.9.6.1513; Foyouzi-Youssefi R, 2000, P NATL ACAD SCI USA, V97, P5723, DOI 10.1073/pnas.97.11.5723; Fraser SA, 2000, J IMMUNOL, V164, P4150, DOI 10.4049/jimmunol.164.8.4150; GERSTEN DM, 1990, BIOCHIM BIOPHYS ACTA, V1096, P20, DOI 10.1016/0925-4439(90)90007-C; Hajnoczky G, 1999, J BIOL CHEM, V274, P14157, DOI 10.1074/jbc.274.20.14157; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hofer AM, 1998, J CELL BIOL, V140, P325, DOI 10.1083/jcb.140.2.325; Hoth M, 1997, J CELL BIOL, V137, P633, DOI 10.1083/jcb.137.3.633; John LM, 1998, J CELL BIOL, V142, P963, DOI 10.1083/jcb.142.4.963; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281; Missiaen L, 2002, J BIOL CHEM, V277, P6898, DOI 10.1074/jbc.M110939200; Missiaen L, 2001, J BIOL CHEM, V276, P39161, DOI 10.1074/jbc.M104044200; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; Nakamura K, 2000, J CELL BIOL, V150, P731, DOI 10.1083/jcb.150.4.731; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Pinton P, 2000, J CELL BIOL, V148, P857, DOI 10.1083/jcb.148.5.857; Putney JW, 1999, BIOESSAYS, V21, P38; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rizzuto R, 2000, J PHYSIOL-LONDON, V529, P37, DOI 10.1111/j.1469-7793.2000.00037.x; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; SPARAGNA GC, 1995, J BIOL CHEM, V270, P27510, DOI 10.1074/jbc.270.46.27510; Szalai G, 1999, EMBO J, V18, P6349, DOI 10.1093/emboj/18.22.6349; Wang Z, 1997, P NATL ACAD SCI USA, V94, P12999, DOI 10.1073/pnas.94.24.12999; Waser M, 1997, J CELL BIOL, V138, P547, DOI 10.1083/jcb.138.3.547; Xu W, 2000, J BIOL CHEM, V275, P36676, DOI 10.1074/jbc.M002041200	48	129	150	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46696	46705		10.1074/jbc.M202395200	http://dx.doi.org/10.1074/jbc.M202395200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324449	hybrid, Green Published			2022-12-25	WOS:000179529300128
J	Desai, A; Turetsky, D; Vasudevan, K; Buonanno, A				Desai, A; Turetsky, D; Vasudevan, K; Buonanno, A			Analysis of transcriptional regulatory sequences of the N-methyl-D-aspartate receptor 2A subunit gene in cultured cortical neurons and transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESTRICTIVE SILENCER FACTOR; HETEROMERIC NMDA RECEPTORS; EXCITATORY AMINO-ACIDS; RNAS ENCODING SUBUNITS; CENTRAL-NERVOUS-SYSTEM; SODIUM-CHANNEL GENE; SPINAL-CORD NEURONS; MESSENGER-RNAS; RAT-BRAIN; DEVELOPMENTAL-CHANGES	The postnatal appearance and up-regulation of the NR2A subunit of the N-methyl-D-aspartate receptor contributes to the functional heterogeneity of the receptor during development. To elucidate the molecular mechanisms that regulate the neural and developmental specific expression of NR2A, an upstream similar to9-kb region of the gene harboring the promoter was isolated and characterized in transgenic mice and transfected cortical neurons. Transgenic mouse lines generated with luciferase reporter constructs driven by either 9 or 1 kb of upstream sequence selectively transcribe the transgene in brain, as compared with other non-neural tissues. Reporter luciferase levels in dissociated cultures made from these mice are over 100-fold greater in neuronal/glial co-cultures than in pure glial cultures. Analysis of NR2A 5'-nested deletions in transfected cultures of cortical neurons and glia indicate that while sequences residing upstream of - 1079 bp augment NR2A neuronal expression, sequences between -486 and -447 bp are sufficient to maintain neuronal preference. An RE1/NRSE element is not necessary for NR2A neuron specificity. Furthermore, comparison of the 5'-deletion constructs in cortical neurons grown for 5, 8, 11, or 14 days in vitro indicate that sequences between -1253 and -1180 bp are necessary for maturational up-regulation of NR2A. Thus, different cis-acting sequences control the regional and temporal expression of NR2A, implicating distinct regulatory pathways.	NICHD, LDN, Mol Neurobiol Sect, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Buonanno, A (corresponding author), NICHD, LDN, Mol Neurobiol Sect, NIH, Bldg 49,Rm 5A38,49 Convent Dr, Bethesda, MD 20892 USA.							Ahn S, 2000, ANNU REV PHYSIOL, V62, P803, DOI 10.1146/annurev.physiol.62.1.803; AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1993, BIOCHIM BIOPHYS ACTA, V1152, P197, DOI 10.1016/0005-2736(93)90249-Y; Barria A, 2002, NEURON, V35, P345, DOI 10.1016/S0896-6273(02)00776-6; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; Borges K, 2001, J BIOL CHEM, V276, P25929, DOI 10.1074/jbc.M009105200; CARMIGNOTO G, 1992, SCIENCE, V258, P1007, DOI 10.1126/science.1279803; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Das S, 1998, NATURE, V393, P377, DOI 10.1038/30748; Flint AC, 1997, J NEUROSCI, V17, P2469; Gottmann K, 1997, J NEUROSCI, V17, P2766; Hogan B, 1994, MANIPULATING MOUSE E; Huang F, 1997, J BIOL CHEM, V272, P8618, DOI 10.1074/jbc.272.13.8618; IKEDA K, 1992, FEBS LETT, V313, P34, DOI 10.1016/0014-5793(92)81178-O; Iwasato T, 1997, NEURON, V19, P1201, DOI 10.1016/S0896-6273(00)80412-2; Jones A, 1996, J NEUROCHEM, V67, P907; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; KROWCZYNSKA AM, 1989, NUCLEIC ACIDS RES, V17, P6408, DOI 10.1093/nar/17.15.6408; Kutsuwada T, 1996, NEURON, V16, P333, DOI 10.1016/S0896-6273(00)80051-3; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; Li JH, 1998, EUR J NEUROSCI, V10, P1704, DOI 10.1046/j.1460-9568.1998.00169.x; Lonnerberg P, 1996, J BIOL CHEM, V271, P33358, DOI 10.1074/jbc.271.52.33358; Lu HC, 2001, NEURON, V32, P619, DOI 10.1016/S0896-6273(01)00501-3; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; MANDEL G, 1993, ANNU REV NEUROSCI, V16, P323, DOI 10.1146/annurev.ne.16.030193.001543; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MAYER ML, 1987, PROG NEUROBIOL, V28, P197, DOI 10.1016/0301-0082(87)90011-6; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Mu WT, 1999, MOL BRAIN RES, V67, P137, DOI 10.1016/S0169-328X(99)00049-2; Myers SJ, 1998, J NEUROSCI, V18, P6723; Myers SJ, 1999, ANNU REV PHARMACOL, V39, P221, DOI 10.1146/annurev.pharmtox.39.1.221; Nishi M, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-23-j0003.2001; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PorteraCailliau C, 1996, J NEUROCHEM, V66, P692, DOI 10.1046/j.1471-4159.1996.66020692.x; Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263; RESINK A, 1995, J NEUROCHEM, V64, P558; Roche KW, 2001, NAT NEUROSCI, V4, P794, DOI 10.1038/90498; Rose K, 1993, IN VITRO BIOL METHOD, P46; SAKIMURA K, 1995, NATURE, V373, P151, DOI 10.1038/373151a0; Sasner M, 1996, J BIOL CHEM, V271, P21316, DOI 10.1074/jbc.271.35.21316; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; Schoenherr CJ, 1996, P NATL ACAD SCI USA, V93, P9881, DOI 10.1073/pnas.93.18.9881; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; Sprengel R, 1998, CELL, V92, P279, DOI 10.1016/S0092-8674(00)80921-6; Standley S, 2000, NEURON, V28, P887, DOI 10.1016/S0896-6273(00)00161-6; Stephenson FA, 2001, CURR DRUG TARGETS, V2, P233, DOI 10.2174/1389450013348461; Suchanek B, 1997, BIOL CHEM, V378, P929; SUCHANEK B, 1995, J BIOL CHEM, V270, P41, DOI 10.1074/jbc.270.1.41; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; Takahashi T, 1996, J NEUROSCI, V16, P4376; Thompson CL, 2000, NEUROSCI LETT, V283, P85, DOI 10.1016/S0304-3940(00)00930-7; Tovar KR, 1999, J NEUROSCI, V19, P4180; Tsien JZ, 1996, CELL, V87, P1317, DOI 10.1016/S0092-8674(00)81826-7; WANG YH, 1995, J NEUROCHEM, V65, P176; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WICKS IP, 1995, HUM GENE THER, V6, P317, DOI 10.1089/hum.1995.6.3-317; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; Wood MW, 1996, J BIOL CHEM, V271, P8115, DOI 10.1074/jbc.271.14.8115; WUENSCHELL CW, 1990, NEURON, V4, P595, DOI 10.1016/0896-6273(90)90117-X; Xia ZG, 1996, J NEUROSCI, V16, P5425; YAMAZAKI M, 1992, FEBS LETT, V300, P39, DOI 10.1016/0014-5793(92)80160-I; ZHONG J, 1995, J NEUROCHEM, V64, P531; ZHONG J, 1994, MOL PHARMACOL, V45, P846	78	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46374	46384		10.1074/jbc.M203032200	http://dx.doi.org/10.1074/jbc.M203032200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12356765	hybrid			2022-12-25	WOS:000179529300088
J	Evguenieva-Hackenberg, E; Schiltz, E; Klug, G				Evguenieva-Hackenberg, E; Schiltz, E; Klug, G			Dehydrogenases from all three domains of life cleave RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-A VIRUS; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; RHODOBACTER-CAPSULATUS; BINDING-PROTEIN; RIBOZYME CATALYSIS; ESCHERICHIA-COLI; ROSSMANN FOLD; IDENTIFICATION; RIBONUCLEASE; SEQUENCE	Specific interactions of glyceraldehy-de-3-phosphate dehydrogenase (GAPDH) with RNA have been reported both in vitro and in vivo. We show that eukaryotic and bacterial GAPDH and two proteins from. the hyperthermophilic archaeon Sulfolobus solfataricus, which are annotated as dehydrogenases, cleave RNA producing similar degradation patterns. RNA cleavage is most efficient at 60 degreesC, at MgCl2, concentrations up to 5 mm, and takes place between pyrimidine and adenosine. The RNase active center of the putative aspartate semialdehyde dehydrogenase from S. solfataricus is located within the N-terminal 73 amino acids, which comprise the first mononucleotide-binding site (if the predicted Rossmann fold. Thus, RNA cleavage has to be taken into account in the ongoing discussion of the possible biological function of RNA binding by dehydrogenases.	Univ Giessen, Inst Mikrobiol & Mol Biol, D-35392 Giessen, Germany; Univ Freiburg, Inst Organ Chem & Biochem, D-79104 Freiburg, Germany	Justus Liebig University Giessen; University of Freiburg	Evguenieva-Hackenberg, E (corresponding author), Univ Giessen, Inst Mikrobiol & Mol Biol, Heinrich Buff Ring 26-32, D-35392 Giessen, Germany.		Evguenieva-Hackenberg, Elena/ABA-8876-2020; Klug, Gabriele/K-5322-2014	Evguenieva-Hackenberg, Elena/0000-0001-7270-3168; Klug, Gabriele/0000-0002-3527-5093				Ausubel F. M., 1988, CURRENT PROTOCOLS MO; Baker ME, 1998, BIOCHEM BIOPH RES CO, V248, P250, DOI 10.1006/bbrc.1998.8951; Conrad C, 1998, NUCLEIC ACIDS RES, V26, P4446, DOI 10.1093/nar/26.19.4446; De BP, 1996, J BIOL CHEM, V271, P24728, DOI 10.1074/jbc.271.40.24728; Evguenieva-Hackenberg E, 2000, J BACTERIOL, V182, P4719, DOI 10.1128/JB.182.17.4719-4729.2000; Griffoni C, 2001, BBA-MOL CELL BIOL L, V1530, P32, DOI 10.1016/S1388-1981(00)00166-9; Heck C, 1996, MOL MICROBIOL, V20, P1165, DOI 10.1111/j.1365-2958.1996.tb02637.x; James CL, 2002, BIOCHEMISTRY-US, V41, P3720, DOI 10.1021/bi015909o; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; LI HL, 1993, NUCLEIC ACIDS RES, V21, P1919, DOI 10.1093/nar/21.8.1919; Lin SS, 2000, VIROLOGY, V271, P46, DOI 10.1006/viro.2000.0302; LIN YZ, 1990, BIOCHIM BIOPHYS ACTA, V1038, P247, DOI 10.1016/0167-4838(90)90212-X; MALHOTRA OP, 1995, EUR J BIOCHEM, V227, P556, DOI 10.1111/j.1432-1033.1995.tb20424.x; MATSUDA T, 1997, NUCL ACIDS S SER, V37, P187; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MORGENEGG G, 1986, J NEUROCHEM, V47, P54; Moussaoui M, 1996, J BIOL CHEM, V271, P4687; Nagy E, 2000, BIOCHEM BIOPH RES CO, V275, P253, DOI 10.1006/bbrc.2000.3246; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; Paris S, 2002, PROTEIN EXPRES PURIF, V24, P99, DOI 10.1006/prep.2001.1538; Petrik J, 1999, J GEN VIROL, V80, P3109, DOI 10.1099/0022-1317-80-12-3109; Py B, 1996, NATURE, V381, P169, DOI 10.1038/381169a0; Rauhut R, 1996, NUCLEIC ACIDS RES, V24, P1246, DOI 10.1093/nar/24.7.1246; Schultz DE, 1996, J BIOL CHEM, V271, P14134, DOI 10.1074/jbc.271.24.14134; SINGH R, 1993, SCIENCE, V259, P365, DOI 10.1126/science.8420004; Sioud M, 1996, J MOL BIOL, V257, P775, DOI 10.1006/jmbi.1996.0201; Sirover MA, 1999, BBA-PROTEIN STRUCT M, V1432, P159, DOI 10.1016/S0167-4838(99)00119-3; THOMAS D, 1989, MOL GEN GENET, V217, P149, DOI 10.1007/BF00330954; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Viola RE, 2001, ACCOUNTS CHEM RES, V34, P339, DOI 10.1021/ar000057q; Yang JJ, 1996, PLANT CELL, V8, P1409, DOI 10.1105/tpc.8.8.1409; Yi MY, 2000, J VIROL, V74, P6459, DOI 10.1128/JVI.74.14.6459-6468.2000; Zang WQ, 1998, VIROLOGY, V248, P46, DOI 10.1006/viro.1998.9255	33	42	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46145	46150		10.1074/jbc.M208717200	http://dx.doi.org/10.1074/jbc.M208717200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359717	hybrid			2022-12-25	WOS:000179529300059
J	Kalandadze, A; Wu, Y; Robinson, MB				Kalandadze, A; Wu, Y; Robinson, MB			Protein kinase C activation decreases cell surface expression of the GLT-1 subtype of glutamate transporter - Requirement of a carboxyl-terminal domain and partial dependence on serine 486	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTRAL-NERVOUS-SYSTEM; HUMAN DOPAMINE TRANSPORTER; SEROTONIN TRANSPORTERS; PHORBOL ESTER; BRAIN; PHOSPHORYLATION; TRAFFICKING; MODULATION; CLEARANCE; RECEPTOR	Na+-dependent glutamate transporters are required for the clearance of extracellular glutamate and influence both physiological and pathological effects of this excitatory amino acid. In the present study, the effects of a protein kinase C (PKC) activator on the cell surface expression and activity of the GLT-1 subtype of glutamate transporter were examined in two model systems, primary co-cultures of neurons and astrocytes that endogenously express GLT-1 and C6 glioma cells transfected with GLT-1. In both systems, activation of PKC with phorbol ester caused a decrease in GLT-1 cell surface expression. This effect is opposite to the one observed for the EAAC1 subtype of glutamate transporter (Davis, K. E., Straff, D. J., Weinstein, E. A., Bannerman, P. G., Correale, D. M., Rothstein, J. D., and Robinson, M. B. (1998) J. Neurosci. 18, 2475-2485). Several recombinant chimeric proteins between GLT-1 and EAAC1 transporter subtypes were generated to identify domains required for the subtype-specific redistribution of GLT-1. We identified a carboxyl-terminal domain consisting of 43 amino acids (amino acids 475-517) that is required for PKC-induced GLT-1 redistribution. Mutation of a non-conserved serine residue at position 486 partially attenuated but did not completely abolish the PKC-dependent redistribution of GLT-1. Although we observed a phorbol ester-dependent incorporation of P-32 into immunoprecipitable GLT-1, mutation of serine 486 did not reduce this signal. We also found that chimeras containing the first 446 amino acids of GLT-1 were not functional unless amino acids 475-517 of GLT-1 were also present. These non-functional transporters were not as efficiently expressed on the cell surface and migrated to a smaller molecular weight, suggesting that a subtype-specific interaction is required for the formation of functional transporters. These studies demonstrate a novel effect of PKC on GLT-1 activity and define a unique carboxyl-terminal domain as an important determinant in cellular localization and regulation of GLT-1.	Univ Penn, Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Childrens Hosp Philadelphia, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Robinson, MB (corresponding author), 502N Abramson Pediat Res Bldg,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	Robinson@pharm.med.upenn.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD026979] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039011, R01NS029868] Funding Source: NIH RePORTER; NICHD NIH HHS [HD26979] Funding Source: Medline; NINDS NIH HHS [NS39011, NS29868] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amara S G, 1998, Adv Pharmacol, V42, P164; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; Beckman ML, 2000, NEUROSCIENTIST, V6, P199, DOI 10.1177/107385840000600310; BECKMAN ML, 1999, J NEUROSCI RC, V9, P1; Bergles DE, 1997, NEURON, V19, P1297, DOI 10.1016/S0896-6273(00)80420-1; Blakely RD, 2000, CURR OPIN NEUROBIOL, V10, P328, DOI 10.1016/S0959-4388(00)00088-X; Carrick T., 1999, Society for Neuroscience Abstracts, V25, P426; CASADO M, 1993, J BIOL CHEM, V268, P27313; Chang MY, 2001, J NEUROCHEM, V77, P754, DOI 10.1046/j.1471-4159.2001.00284.x; Czech MP, 1999, J BIOL CHEM, V274, P1865, DOI 10.1074/jbc.274.4.1865; Danbolt NC, 2001, PROG NEUROBIOL, V65, P1, DOI 10.1016/S0301-0082(00)00067-8; Daniels GM, 1999, J BIOL CHEM, V274, P35794, DOI 10.1074/jbc.274.50.35794; Davis KE, 1998, J NEUROSCI, V18, P2475; Dowd LA, 1996, MOL PHARMACOL, V49, P465; FAGG GE, 1983, NEUROSCIENCE, V9, P701, DOI 10.1016/0306-4522(83)90263-4; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FONNUM F, 1984, J NEUROCHEM, V42, P1, DOI 10.1111/j.1471-4159.1984.tb09689.x; Ganel R, 1998, J NEUROCHEM, V70, P993; Geisler C, 1998, J BIOL CHEM, V273, P21316, DOI 10.1074/jbc.273.33.21316; Gonzalez MI, 2002, MOL PHARMACOL, V62, P901, DOI 10.1124/mol.62.4.901; Grunewald M, 1998, NEURON, V21, P623, DOI 10.1016/S0896-6273(00)80572-3; Grunewald M, 2000, J BIOL CHEM, V275, P9684, DOI 10.1074/jbc.275.13.9684; Haugeto O, 1996, J BIOL CHEM, V271, P27715, DOI 10.1074/jbc.271.44.27715; Kanai Y, 1995, NEUROREPORT, V6, P2357, DOI 10.1097/00001756-199511270-00020; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Katagiri H, 2001, EUR J NEUROSCI, V14, P547, DOI 10.1046/j.0953-816x.2001.01664.x; Kazanietz MG, 2000, BIOCHEM PHARMACOL, V60, P1417, DOI 10.1016/S0006-2952(00)00470-6; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Melikian HE, 1999, J NEUROSCI, V19, P7699; MENNERICK S, 1994, NATURE, V368, P59, DOI 10.1038/368059a0; Nicholson B, 1996, J BIOL CHEM, V271, P12159, DOI 10.1074/jbc.271.21.12159; Oliet SHR, 2001, SCIENCE, V292, P923, DOI 10.1126/science.1059162; Otis TS, 1997, SCIENCE, V277, P1515, DOI 10.1126/science.277.5331.1515; Palos TP, 1996, MOL BRAIN RES, V37, P297, DOI 10.1016/0169-328X(95)00331-L; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; Qian Y, 1997, J NEUROSCI, V17, P45, DOI 10.1523/JNEUROSCI.17-01-00045.1997; Ramamoorthy S, 1999, SCIENCE, V285, P763, DOI 10.1126/science.285.5428.763; Robinson M B, 1997, Adv Pharmacol, V37, P69; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Robinson MB, 1998, NEUROCHEM INT, V33, P479, DOI 10.1016/S0197-0186(98)00055-2; ROBINSON MB, 1993, J NEUROCHEM, V61, P2099, DOI 10.1111/j.1471-4159.1993.tb07447.x; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Sakai N, 1997, J NEUROCHEM, V68, P2618; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Schlag BD, 1998, MOL PHARMACOL, V53, P355, DOI 10.1124/mol.53.3.355; Seal RP, 2000, NEURON, V25, P695, DOI 10.1016/S0896-6273(00)81071-5; SHIN JY, 1991, J BIOL CHEM, V266, P10658; Sims KD, 1999, CRIT REV NEUROBIOL, V13, P169, DOI 10.1615/CritRevNeurobiol.v13.i2.30; Sims KD, 2000, J BIOL CHEM, V275, P5228, DOI 10.1074/jbc.275.7.5228; Tan J, 1999, J PHARMACOL EXP THER, V289, P1600; Tanaka K, 1997, SCIENCE, V276, P1699, DOI 10.1126/science.276.5319.1699; Trotti D, 2001, J BIOL CHEM, V276, P576, DOI 10.1074/jbc.M003779200; Whitworth TL, 2001, J BIOL CHEM, V276, P42932, DOI 10.1074/jbc.M107638200; Xiang B, 2001, J BIOL CHEM, V276, P4709, DOI 10.1074/jbc.M006187200	56	116	120	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45741	45750		10.1074/jbc.M203771200	http://dx.doi.org/10.1074/jbc.M203771200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324450	hybrid			2022-12-25	WOS:000179529300005
J	Karnak, D; Lee, S; Margolis, B				Karnak, D; Lee, S; Margolis, B			Identification of multiple binding partners for the amino-terminal domain of synapse-associated protein 97	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLARIZED EPITHELIAL-CELLS; TUMOR-SUPPRESSOR PROTEIN; BASOLATERAL MEMBRANE; GLYCOPHORIN-C; COMPLEX; RECEPTOR; MLIN-7; CLONING; SURFACE; SAP97	Multiprotein complexes mediate static and dynamic functions to establish and maintain cell polarity in both epithelial cells and neurons. Membrane-associated guanylate kinase (MAGUK) proteins are thought to be scaffolding molecules in these processes and bind multiple proteins via their obligate postsynaptic density (PSD)95/Disc Large/Zona Occludens-1, Src homology 3, and guanylate kinase-like domains. Subsets of MAGUK proteins have additional protein-protein interaction domains. An additional domain we identified in SAP97 called the MAGUK recruitment (MRE) domain binds the LIN-2,7 amino-terminal (L27N) domain of mLIN-2/CASK, a MAGUK known to bind mLIN-7. Here we show that SAP97 binds two other mLIN-7 binding MAGUK proteins. One of these MAGUK proteins, DLG3, coimmunoprecipitates with SAP97 in lysates from rat brain and transfected Madin-Darby canine kidney cells. This interaction requires the AIRE domain of SAP97 and surprisingly, both the L27N and L27 carboxyl-terminal (L27C) domains of DLG3. We also demonstrate that SAP97 can interact with the MAGUK protein, DLG2, but not the highly related protein, PALS2. The ability of SAP97 to interact with multiple MAGUK proteins is likely to be important for the targeting of specific protein complexes in polarized cells.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan	Margolis, B (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Karnak, Demet/AAP-9959-2020	Karnak, Demet/0000-0001-8463-9802	NIDDK NIH HHS [2-P50-DK39255] Funding Source: Medline; NIGMS NIH HHS [GM08353, 5-T32-GM07544] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK039255] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008353, T32GM007544] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Borg JP, 1996, MOL CELL BIOL, V16, P6229; Borg JP, 1998, J BIOL CHEM, V273, P31633, DOI 10.1074/jbc.273.48.31633; Butz S, 1998, CELL, V94, P773, DOI 10.1016/S0092-8674(00)81736-5; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; Chetkovich DM, 2002, J NEUROSCI, V22, P6415; Chishti AH, 1998, TRENDS BIOCHEM SCI, V23, P281, DOI 10.1016/S0968-0004(98)01237-7; Cohen AR, 1998, J CELL BIOL, V142, P129, DOI 10.1083/jcb.142.1.129; Colledge M, 2000, NEURON, V27, P107, DOI 10.1016/S0896-6273(00)00013-1; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; Doerks T, 2000, TRENDS BIOCHEM SCI, V25, P317, DOI 10.1016/S0968-0004(00)01599-1; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; Harris BZ, 2002, J BIOL CHEM, V277, P34902, DOI 10.1074/jbc.M205856200; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; Kamberov E, 2000, J BIOL CHEM, V275, P11425, DOI 10.1074/jbc.275.15.11425; Lee S, 2002, MOL CELL BIOL, V22, P1778, DOI 10.1128/MCB.22.6.1778-1791.2002; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; MARFATIA SM, 1995, J BIOL CHEM, V270, P715, DOI 10.1074/jbc.270.2.715; Mok H, 2002, J NEUROSCI, V22, P5253; Mostov KE, 2000, CURR OPIN CELL BIOL, V12, P483, DOI 10.1016/S0955-0674(00)00120-4; MULLER BM, 1995, J NEUROSCI, V15, P2354, DOI 10.1523/JNEUROSCI.15-03-02354.1995; Nix SL, 2000, J BIOL CHEM, V275, P41192, DOI 10.1074/jbc.M002078200; Nunomura W, 2000, J BIOL CHEM, V275, P24540, DOI 10.1074/jbc.M002492200; Perego C, 1999, EMBO J, V18, P2384, DOI 10.1093/emboj/18.9.2384; Roh MH, 2002, J CELL BIOL, V157, P161, DOI 10.1083/jcb.200109010; Setou M, 2000, SCIENCE, V288, P1796, DOI 10.1126/science.288.5472.1796; Straight SW, 2000, AM J PHYSIOL-RENAL, V278, pF464, DOI 10.1152/ajprenal.2000.278.3.F464; Straight SW, 2001, MOL BIOL CELL, V12, P1329, DOI 10.1091/mbc.12.5.1329; Tavalin SJ, 2002, J NEUROSCI, V22, P3044, DOI 10.1523/JNEUROSCI.22-08-03044.2002; Wu HJ, 1998, J CELL SCI, V111, P2365; Yeaman C, 1999, PHYSIOL REV, V79, P73, DOI 10.1152/physrev.1999.79.1.73	30	51	54	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46730	46735		10.1074/jbc.M208781200	http://dx.doi.org/10.1074/jbc.M208781200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351654	hybrid			2022-12-25	WOS:000179529300132
J	Xia, Z; Sniderman, AD; Cianflone, K				Xia, Z; Sniderman, AD; Cianflone, K			Acylation-stimulating protein (ASP) deficiency induces obesity resistance and increased energy expenditure in ob/ob mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE-TISSUE; FATTY-ACID; LIPOPROTEIN-LIPASE; FOOD-INTAKE; DENSITY-LIPOPROTEIN; METABOLIC-RATE; LEPTIN; HYPERTRIGLYCERIDEMIA; GLUCOSE; MUSCLE	Acylation-stimulating protein (ASP) acts as a paracrine signal to increase triglyceride synthesis in adipocytes. ASP administration results in more rapid postprandial lipid clearance. In mice, C3 (the precursor to ASP) knockout results in ASP deficiency and leads to reduced body fat and leptin levels. The protective potential of ASP deficiency against obesity and involvement of the leptin pathway were examined in ob/ob C3(-/-) double knockout mice (2KO). Compared with age-matched ob/ob mice, 2KO mice had delayed postprandial triglyceride and fatty acid clearance; associated with decreased body weight (4-17 weeks age: male: -13.7%, female: -20.6%, p < 0.0001) and HOMA (homeostasis model assessment) index (-37.7%), suggesting increased insulin sensitivity. By contrast, food intake in 2KO mice was +9.1% higher over ob/ob mice (p < 0.001, 2KO 5.1 +/- 0.2 g/day, ob/ob 4.5 +/- 0.2 g/day, wild type 2.6 +/- 0.1 g/day). The hyperphagia/leanness was balanced by a 28.5% increase in energy expenditure (oxygen consumption: 2KO, 131 +/- 8.9 ml/h; ob/ob, 102 +/- 4.5 ml/h; p < 0.01; wild type, 144 8.9 ml/h). These results suggest that the ASP regulation of energy storage may influence energy expenditure and dynamic metabolic balance.	McGill Univ, Ctr Hlth, Mike Rosenbloom Lab Cardiovasc Res, Montreal, PQ H3A 1A1, Canada	McGill University	Cianflone, K (corresponding author), Royal Victoria Hosp, 687 Pine Ave W,H7-30, Montreal, PQ H3A 1A1, Canada.	katherine.cianflone@mcgill.ca						Argyropoulos G, 2002, J APPL PHYSIOL, V92, P2187, DOI 10.1152/japplphysiol.00994.2001; BALDO A, 1995, J LIPID RES, V36, P1415; Barzilai N, 1997, J CLIN INVEST, V100, P3105, DOI 10.1172/JCI119865; Breslow MJ, 1999, AM J PHYSIOL-ENDOC M, V276, pE443, DOI 10.1152/ajpendo.1999.276.3.E443; Charlesworth JA, 1998, INT J OBESITY, V22, P1096, DOI 10.1038/sj.ijo.0800733; CIANFLONE K, 1995, INT J OBESITY, V19, P604; CIANFLONE K, 1995, EUR J CLIN INVEST, V25, P817, DOI 10.1111/j.1365-2362.1995.tb01690.x; CIANFLONE K, 1994, BIOCHEMISTRY-US, V33, P9489, DOI 10.1021/bi00198a014; Cianflone K, 1997, J ENDOCRINOL, V155, P203, DOI 10.1677/joe.0.1550203; Cianflone K, 1999, SEMIN CELL DEV BIOL, V10, P31, DOI 10.1006/scdb.1998.0272; Circolo A, 1999, IMMUNOPHARMACOLOGY, V42, P135, DOI 10.1016/S0162-3109(99)00021-1; Commins SP, 1999, ENDOCRINOLOGY, V140, P292, DOI 10.1210/en.140.1.292; FUHBECK G, 1997, BIOCH BIOPHYS REV CO, V240, P590; GERMINARIO R, 1993, METABOLISM, V42, P574, DOI 10.1016/0026-0495(93)90215-A; Goudriaan JR, 2001, ARTERIOSCL THROM VAS, V21, P1488, DOI 10.1161/hq0901.095147; HAMMOND VA, 1987, METABOLISM, V36, P308, DOI 10.1016/0026-0495(87)90199-5; Havel PJ, 1999, AM J CLIN NUTR, V70, P305; Havel PJ, 1999, DIABETES, V48, P334, DOI 10.2337/diabetes.48.2.334; HUGLI TE, 1990, CURR TOP MICROBIOL, V153, P181; Hwa JJ, 1997, AM J PHYSIOL-REG I, V272, pR1204, DOI 10.1152/ajpregu.1997.272.4.R1204; Kalant D., 1995, Clinical and Investigative Medicine, V18, pB10; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Marti A, 1998, BIOCHEM BIOPH RES CO, V246, P859, DOI 10.1006/bbrc.1998.8539; Maslowska M, 1999, EUR J CLIN INVEST, V29, P679, DOI 10.1046/j.1365-2362.1999.00514.x; Maslowska M, 1997, J LIPID RES, V38, P1; MATTACKS CA, 1988, INT J OBESITY, V12, P585; MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883; Mistry AM, 1997, J NUTR, V127, P2065; MIYOSHI H, 1988, J CLIN INVEST, V81, P1545, DOI 10.1172/JCI113487; Mueller WM, 1998, ENDOCRINOLOGY, V139, P551, DOI 10.1210/en.139.2.551; Muller G, 1997, J BIOL CHEM, V272, P10585, DOI 10.1074/jbc.272.16.10585; Murray I, 1999, J BIOL CHEM, V274, P36219, DOI 10.1074/jbc.274.51.36219; Murray I, 1997, J LIPID RES, V38, P2492; Murray I, 2000, ENDOCRINOLOGY, V141, P1041, DOI 10.1210/en.141.3.1041; Namae M, 1998, LAB ANIM SCI, V48, P103; Newsholme E A, 1976, Biochem Soc Symp, P61; Newsholme E A, 1978, Biochem Soc Symp, P183; NEWSHOLME EA, 1980, NEW ENGL J MED, V302, P400, DOI 10.1056/NEJM198002143020711; Niskanen L, 1997, INT J OBESITY, V21, P309, DOI 10.1038/sj.ijo.0800406; Ohinata K, 2002, PEPTIDES, V23, P127, DOI 10.1016/S0196-9781(01)00588-5; Reidy SP, 2002, AM J PHYSIOL-ENDOC M, V282, pE312, DOI 10.1152/ajpendo.00037.2001; Rolfe DFS, 1997, PHYSIOL REV, V77, P731, DOI 10.1152/physrev.1997.77.3.731; Saleh J, 1998, J LIPID RES, V39, P884; Saleh J, 2001, INT J OBESITY, V25, P705, DOI 10.1038/sj.ijo.0801613; Scantlebury T, 1998, J BIOL CHEM, V273, P20903, DOI 10.1074/jbc.273.33.20903; Scarpace PJ, 1997, AM J PHYSIOL-ENDOC M, V273, pE226, DOI 10.1152/ajpendo.1997.273.1.E226; SCHUPF N, 1983, J NEUROIMMUNOL, V5, P305, DOI 10.1016/0165-5728(83)90051-6; SHIMADA M, 1993, J BIOL CHEM, V268, P17924; TAGLIAFERRO AR, 1990, INT J OBESITY, V14, P957; TAO YZ, 1997, BIOCHIM BIOPHYS ACTA, V1344, P211; Van Hermelen V, 1999, J BIOL CHEM, V274, P18243, DOI 10.1074/jbc.274.26.18243; Weinstock PH, 1995, J CLIN INVEST, V96, P2555, DOI 10.1172/JCI118319; Wetsel RA, 1999, J BIOL CHEM, V274, P19429, DOI 10.1074/jbc.274.27.19429; Yagyu H, 2002, J BIOL CHEM, V277, P10037, DOI 10.1074/jbc.M109966200; YASRUEL Z, 1991, LIPIDS, V26, P495, DOI 10.1007/BF02536592; YASUSHI I, 1990, SCIENCE, V249, P790; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	57	87	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45874	45879		10.1074/jbc.M207281200	http://dx.doi.org/10.1074/jbc.M207281200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244109	hybrid			2022-12-25	WOS:000179529300022
J	Mercier, JF; Salahpour, A; Angers, S; Breit, A; Bouvier, M				Mercier, JF; Salahpour, A; Angers, S; Breit, A; Bouvier, M			Quantitative assessment of beta(1)- and beta(2)-adrenergic receptor homo- and heterodimerization by bioluminescence resonance energy transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAILING HUMAN HEARTS; HORMONE RECEPTOR; TRANSFER BRET; DIMERIZATION; PROTEIN; OLIGOMERIZATION; IDENTIFICATION; SUBTYPES; DOPAMINE; FAILURE	Quantitative bioluminescence resonance energy transfer (BRET) analysis was applied to the study of beta(1)- and beta(2)-adrenergic receptor homo- and heterodimerization. To assess the relative affinity between each of the protomers, BRET saturation experiments were carried out in HEK-293T cells. beta(1)- and beta(2)-adrenergic receptors were found to have similar propensity to engage in homo- and heterotropic interactions suggesting that, at equivalent expression levels of the two receptor subtypes, an equal proportion of homo- and heterodimers would form. Analysis of the data also revealed that, at equimolar expression levels of energy donor and acceptor, more than 80% of the receptor molecules exist as dimers and that this high incidence of receptor dimerization is insensitive to receptor density for expression levels varying between 1.4 and 26.9 pmol of receptor/mg of membrane protein. Taken together, these results indicate that most of the receptors expressed in cells exist as constitutive dimers and that, at least in undifferentiated fibroblasts, the proportion of homo- and heterodimers between the closely related beta(1)- and beta(2)-adrenergic receptors is determined by their relative levels of expression.	Univ Montreal, Dept Biochim, Montreal, PQ H3C 3J7, Canada; Univ Montreal, Grp Rech Syst Nerveux Autonome, Montreal, PQ H3C 3J7, Canada	Universite de Montreal; Universite de Montreal	Bouvier, M (corresponding author), Univ Montreal, Dept Biochim, CP 6128,Succursale Ctr Ville, Montreal, PQ H3C 3J7, Canada.		Angers, Stephane/E-1432-2014; Bouvier, Michel/H-2758-2014	Angers, Stephane/0000-0001-7241-9044; Bouvier, Michel/0000-0003-1128-0100				Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Boivin V, 2001, KIDNEY INT, V59, P515, DOI 10.1046/j.1523-1755.2001.059002515.x; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; BRISTOW MR, 1993, J AM COLL CARDIOL, V22, pA61, DOI 10.1016/0735-1097(93)90465-D; BRISTOW MR, 1986, CIRC RES, V59, P297, DOI 10.1161/01.RES.59.3.297; BRISTOW MR, 1982, NEW ENGL J MED, V307, P205, DOI 10.1056/NEJM198207223070401; Brodde OE, 1999, PHARMACOL REV, V51, P651; BRODDE OE, 1983, CIRC RES, V53, P752, DOI 10.1161/01.RES.53.6.752; Brodde OE, 1998, J CARDIOVASC PHARM, V31, P585, DOI 10.1097/00005344-199804000-00018; Brodie J, 2001, WATER SCI TECHNOL, V43, P203, DOI 10.2166/wst.2001.0540; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; DELMONTE F, 1993, CIRCULATION, V88, P854, DOI 10.1161/01.CIR.88.3.854; FRIELLE T, 1987, P NATL ACAD SCI USA, V84, P7920, DOI 10.1073/pnas.84.22.7920; GARZON J, 1995, MOL PHARMACOL, V47, P738; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Kenworthy AK, 1998, J CELL BIOL, V142, P69, DOI 10.1083/jcb.142.1.69; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Laurent CE, 2001, AM J PHYSIOL-REG I, V280, pR355, DOI 10.1152/ajpregu.2001.280.2.R355; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; MELLON P, 1981, CELL, V27, P279, DOI 10.1016/0092-8674(81)90411-6; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; NGUYEN CT, 1995, BIOMED J, V2, P34; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Petrecca K, 1998, J ANAT, V192, P517, DOI 10.1046/j.1469-7580.1998.19240517.x; Ramsay D, 2002, BIOCHEM J, V365, P429, DOI 10.1042/BJ20020251; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rodriguez-Frade JM, 1999, P NATL ACAD SCI USA, V96, P3628, DOI 10.1073/pnas.96.7.3628; Roess DA, 2000, ENDOCRINOLOGY, V141, P4518, DOI 10.1210/en.141.12.4518; SANO M, 1993, LIFE SCI, V52, P1063, DOI 10.1016/0024-3205(93)90199-D; STEINFATH M, 1992, BRIT J PHARMACOL, V105, P463, DOI 10.1111/j.1476-5381.1992.tb14276.x; VEATCH W, 1977, J MOL BIOL, V113, P89, DOI 10.1016/0022-2836(77)90042-0; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Vila-Coro AJ, 2000, P NATL ACAD SCI USA, V97, P3388, DOI 10.1073/pnas.050457797; Xu JG, 2001, J BIOL CHEM, V276, P41310, DOI 10.1074/jbc.M107480200; Xu Y, 1999, P NATL ACAD SCI USA, V96, P151, DOI 10.1073/pnas.96.1.151; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539	44	401	415	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44925	44931		10.1074/jbc.M205767200	http://dx.doi.org/10.1074/jbc.M205767200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244098	hybrid			2022-12-25	WOS:000179404800044
J	Won, JJ; Yim, JB; Kim, TK				Won, JJ; Yim, JB; Kim, TK			Opposing regulatory roles of E2F in human telomerase reverse transcriptase (hTERT) gene expression in human tumor and normal somatic cells	FASEB JOURNAL			English	Article						E2F-1; Sp1; pRB; repressor; activator	REPRESSES TRANSCRIPTION; CYCLE; PROMOTER; ELEMENTS; SP1; IDENTIFICATION; KERATINOCYTES; INSTABILITY; ACTIVATION; COMPONENT	Telomerase activity is closely correlated with cellular proliferative activity in human tissues. Human cells with high proliferative potential, such as tumor cells or stem cells, exhibit telomerase activity, whereas most normal human somatic cells do not. Telomerase activity is tightly regulated by the expression of its catalytic subunit human telomerase reverse transcriptase (hTERT). Through an expression cloning approach, we identified E2F-1 as a repressor of the hTERT gene in human tumor cells. Ectopic expression of E2F-1 repressed hTERT promoter activity by inhibiting Spl activation of the hTERT promoter. In contrast to the repressor function of E2F-1 in human tumor cells, we demonstrated that E2F-1 is an activator of the hTERT gene in normal human somatic cells. Ectopically expressed E2F-1 activated the hTERT promoter through a noncanonical DNA binding site. E2F-1, E2F-2, and E2F-3 (but not E2F-4 and E2F-5) repressed hTERT promoter activity in human tumor cells, whereas they activated it in normal somatic cells. These contrasting effects of E2F transcription factors on the hTERT promoter could underlie the paradoxical biological activities of E2F, which can both promote and inhibit cellular proliferation and tumorigenesis.	Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea; Seoul Natl Univ, Inst Mol Biol & Genet, Natl Creat Res Initiat Ctr Genet Reprogramming, Seoul 151742, South Korea; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Inst Chem & Cell Biol, Boston, MA 02115 USA	Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Harvard University; Harvard Medical School	Kim, TK (corresponding author), Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305701, South Korea.	tkkim@mail.kaist.ac.kr						Blasco MA, 1997, CELL, V91, P25, DOI 10.1016/S0092-8674(01)80006-4; Botz J, 1996, MOL CELL BIOL, V16, P3401; CARTWRIGHT P, 2000, J BIOL CHEM, V275, P41219; Chiu CP, 1997, P SOC EXP BIOL MED, V214, P99; Chou WC, 2001, J CLIN INVEST, V108, P1541, DOI 10.1172/JCI14064; COUNTER CM, 1992, EMBO J, V11, P1921, DOI 10.1002/j.1460-2075.1992.tb05245.x; CRESS WD, 1993, MOL CELL BIOL, V13, P6314, DOI 10.1128/MCB.13.10.6314; Crowe DL, 2001, NUCLEIC ACIDS RES, V29, P2789, DOI 10.1093/nar/29.13.2789; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Gonzalez-Suarez E, 2001, EMBO J, V20, P2619, DOI 10.1093/emboj/20.11.2619; Greider CW, 1996, ANNU REV BIOCHEM, V65, P337, DOI 10.1146/annurev.bi.65.070196.002005; HarleBachor C, 1996, P NATL ACAD SCI USA, V93, P6476, DOI 10.1073/pnas.93.13.6476; Harrington L, 1997, GENE DEV, V11, P3109, DOI 10.1101/gad.11.23.3109; Harrington L, 1997, SCIENCE, V275, P973, DOI 10.1126/science.275.5302.973; HIYAMA K, 1995, J IMMUNOL, V155, P3711; HSIAO KM, 1994, GENE DEV, V8, P1526, DOI 10.1101/gad.8.13.1526; Humbert PO, 2000, GENE DEV, V14, P690; JOHNSON DG, 1994, GENE DEV, V8, P1514, DOI 10.1101/gad.8.13.1514; Johnston A, 2000, STAND, V2, P27; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Klapper W, 2001, MECH AGEING DEV, V122, P695, DOI 10.1016/S0047-6374(01)00223-8; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Kyo S, 1997, CANCER RES, V57, P610; Lee HW, 1998, NATURE, V392, P569, DOI 10.1038/33345; Lee TA, 2000, ONCOGENE, V19, P2257, DOI 10.1038/sj.onc.1203556; Leone G, 1998, GENE DEV, V12, P2120, DOI 10.1101/gad.12.14.2120; Lin SY, 1996, MOL CELL BIOL, V16, P1668; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Oh S, 2000, ONCOGENE, V19, P1485, DOI 10.1038/sj.onc.1203439; Oh S, 1999, BIOCHEM BIOPH RES CO, V263, P361, DOI 10.1006/bbrc.1999.1366; Oh S, 1999, J BIOL CHEM, V274, P37473, DOI 10.1074/jbc.274.52.37473; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; Pendino F, 2001, P NATL ACAD SCI USA, V98, P6662, DOI 10.1073/pnas.111464998; Ramirez RD, 1997, J INVEST DERMATOL, V108, P113, DOI 10.1111/1523-1747.ep12285654; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sears R, 1997, MOL CELL BIOL, V17, P5227, DOI 10.1128/MCB.17.9.5227; Shin EK, 1996, J BIOL CHEM, V271, P12261, DOI 10.1074/jbc.271.21.12261; Tahara H, 1999, ONCOGENE, V18, P1561, DOI 10.1038/sj.onc.1202458	40	53	58	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	OCT	2002	16	12					1943	+		10.1096/fj.02-0311fje	http://dx.doi.org/10.1096/fj.02-0311fje			25	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	614BN	12368233				2022-12-25	WOS:000179167600025
J	Willcocks, JP; Mulquiney, PJ; Ellory, JC; Veech, RL; Radda, GK; Clarke, K				Willcocks, JP; Mulquiney, PJ; Ellory, JC; Veech, RL; Radda, GK; Clarke, K			Simultaneous determination of low free Mg2+ and pH in human sickle cells using P-31 NMR spectroscopy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-MAGNETIC-RESONANCE; INTRACELLULAR FREE MAGNESIUM; ANEMIA RED-CELLS; ADENOSINE 5'-TRIPHOSPHATE; DISSOCIATION-CONSTANT; STABILITY-CONSTANTS; POTASSIUM-TRANSPORT; HUMAN-ERYTHROCYTES; IONIZED MAGNESIUM; KINETIC-MODEL	The concentrations of free magnesium, [Mg2+](free), [H+], and [ATP] are important in the dehydration of red blood cells from patients with sickle cell anemia, but they are not easily measured. Consequently, we have developed a rapid, noninvasive NMR spectroscopic method using the phosphorus chemical shifts of ATP and 2,3-diphosphoglycerate (DPG) to determine [Mg2+](free) and pH(i) simultaneously in fully oxygenated whole blood. The method employs theoretical equations expressing the observed chemical shift as a function of pH, K+, and [Mg2+](free), over a pH range of 5.75-8.5 and [Mg2+](free) range 0-5 mm. The equations were adjusted to allow for the binding of hemoglobin to ATP and DPG, which required knowledge of the intracellular concentrations of ATP, DPG, K+, and hemoglobin. Normal oxygenated whole blood (n = 33) had a pH(i) of 7.20. +/- 0.02, a [Mg2+](free) of 0.41 +/- 0.03 mM and [DPG] of 7.69 +/- 0.47 mm. Under the same conditions, whole sickle blood (n = 9) had normal [ATP] but significantly lower pH(i) (7.10 +/- 0.03) and [Mg2+](free) (0.32 +/- 0.05 mM) than normal red cells, whereas [DPG] (10.8 +/- 1.2 mm) was significantly higher. Because total magnesium was normal in sickle cells, the lower [Mg2+](free) could be attributed to increased [DPG] and therefore greater magnesium binding capacity of sickle cells.	Univ Oxford, Dept Biochem, Oxford OX1 3QU, England; Univ Oxford, Dept Physiol, Oxford OX1 3QU, England; NIAAA, Rockville, MD 20852 USA	University of Oxford; University of Oxford; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Clarke, K (corresponding author), Univ Oxford, Dept Biochem, S Parks Rd, Oxford OX1 3QU, England.	Kieran.Clarke@bioch.ox.ac.uk			British Heart Foundation [PS/02/002/14893] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000099] Funding Source: NIH RePORTER	British Heart Foundation(British Heart Foundation); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ACHILLES W, 1972, ACTA BIOL MED GER, V29, P531; ALTURA BM, 1995, ALCOHOL, V12, P131, DOI 10.1016/0741-8329(94)00072-7; BERGER H, 1973, EUR J BIOCHEM, V38, P553, DOI 10.1111/j.1432-1033.1973.tb03090.x; BRUGNARA C, 1989, ANN NY ACAD SCI, V565, P96, DOI 10.1111/j.1749-6632.1989.tb24155.x; Clarke K, 1996, J BIOL CHEM, V271, P21142, DOI 10.1074/jbc.271.35.21142; CORASH LM, 1974, J LAB CLIN MED, V84, P147; De Franceschi L, 2000, BRIT J HAEMATOL, V108, P284; DeFranceschi L, 1997, J CLIN INVEST, V100, P1847, DOI 10.1172/JCI119713; Duley L, 2002, LANCET, V359, P1877, DOI 10.1016/s0140-6736(02)08778-0; ELLORY JC, 1983, J PHYSIOL-LONDON, V340, P1; FLATMAN P, 1977, NATURE, V267, P360, DOI 10.1038/267360a0; FLATMAN PW, 1988, J PHYSIOL-LONDON, V397, P471, DOI 10.1113/jphysiol.1988.sp017013; FLATMAN PW, 1980, J PHYSIOL-LONDON, V300, P19, DOI 10.1113/jphysiol.1980.sp013148; GARFINKEL L, 1984, BIOCHEMISTRY-US, V23, P3547, DOI 10.1021/bi00310a025; GERBER G, 1974, EUR J BIOCHEM, V45, P39, DOI 10.1111/j.1432-1033.1974.tb03527.x; GEVEN WB, 1991, CLIN CHEM, V37, P2076; GOLDBERG RN, 1991, BIOPHYS CHEM, V40, P241, DOI 10.1016/0301-4622(91)80024-L; GOLDING EM, 1995, MAGNET RESON MED, V33, P467, DOI 10.1002/mrm.1910330403; GUPTA RK, 1983, BIOCHEM BIOPH RES CO, V117, P210, DOI 10.1016/0006-291X(83)91562-0; GUPTA RK, 1983, PHYSIOL CHEM PHYS, V15, P265; GUPTA RK, 1978, J BIOL CHEM, V253, P6165; GUPTA RK, 1980, J BIOL CHEM, V255, P3987; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Jaeger BR, 2001, THER APHER, V5, P252, DOI 10.1046/j.1526-0968.2001.00350.x; KAPERONIS AA, 1979, BRIT J HAEMATOL, V43, P391, DOI 10.1111/j.1365-2141.1979.tb03766.x; LAM YF, 1979, BLOOD, V54, P196; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; LONDON RE, 1991, ANNU REV PHYSIOL, V53, P241, DOI 10.1146/annurev.physiol.53.1.241; MARJANOVIC M, 1993, J PHYSIOL-LONDON, V470, P559, DOI 10.1113/jphysiol.1993.sp019875; MOON RB, 1973, J BIOL CHEM, V248, P7276; MOSHER TJ, 1992, MAGNET RESON MED, V24, P163, DOI 10.1002/mrm.1910240117; Mulquiney PJ, 1997, NMR BIOMED, V10, P129, DOI 10.1002/(SICI)1099-1492(199705)10:3<129::AID-NBM459>3.0.CO;2-2; Mulquiney PJ, 1997, EUR J BIOCHEM, V245, P71, DOI 10.1111/j.1432-1033.1997.00071.x; NOGUCHI CT, 1981, BLOOD, V58, P1057; NOGUCHI CT, 1983, J CLIN INVEST, V72, P846, DOI 10.1172/JCI111055; ORTIZ OE, 1986, BLOOD, V67, P710; ORTIZ OE, 1990, J PHYSIOL-LONDON, V427, P211, DOI 10.1113/jphysiol.1990.sp018168; OUWERKERK R, 1989, BIOCHIM BIOPHYS ACTA, V1010, P294, DOI 10.1016/0167-4889(89)90052-9; PECORARO VL, 1984, BIOCHEMISTRY-US, V23, P5262, DOI 10.1021/bi00317a026; Raftos JE, 1999, EUR J BIOCHEM, V263, P635, DOI 10.1046/j.1432-1327.1999.00506.x; RAMIREZ F, 1980, BIOCHIM BIOPHYS ACTA, V589, P21, DOI 10.1016/0005-2728(80)90129-2; RESNICK LM, 1990, AM J HYPERTENS, V3, P373, DOI 10.1093/ajh/3.5.373; RINK TJ, 1982, J CELL BIOL, V95, P189, DOI 10.1083/jcb.95.1.189; ROBERTS JKM, 1981, BIOCHEMISTRY-US, V20, P5389, DOI 10.1021/bi00522a006; SCARPA A, 1982, TECH CELL PHYSL, V127, P1; STEPHENSON EW, 1977, J GEN PHYSIOL, V69, P1, DOI 10.1085/jgp.69.1.1; TEHRANI AY, 1982, BLOOD CELLS, V8, P245; VASAVADA KV, 1984, J INORG BIOCHEM, V21, P323, DOI 10.1016/0162-0134(84)85054-0; VEECH RL, 1994, ALCOHOL CLIN EXP RES, V18, P1040, DOI 10.1111/j.1530-0277.1994.tb00081.x; WERNER A, 1985, BIOMED BIOCHIM ACTA, V44, P185; Willcocks JP, 2000, BIOPHYS J, V78, p449A; Willcocks JP, 1999, BIOPHYS J, V76, pA233; WILLIAMS GD, 1993, ANAL BIOCHEM, V214, P458, DOI 10.1006/abio.1993.1523; Zhang WQ, 1997, ANAL BIOCHEM, V251, P246, DOI 10.1006/abio.1997.2238	54	24	26	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49911	49920		10.1074/jbc.M207551200	http://dx.doi.org/10.1074/jbc.M207551200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12297506	hybrid			2022-12-25	WOS:000180028900106
J	Patikoglou, GA; Koelle, MR				Patikoglou, GA; Koelle, MR			An N-terminal region of Caenorhabditis elegans RGS proteins EGL-10 and EAT-16 directs inhibition of G alpha(o) versus G alpha(q) signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; HETEROTRIMERIC G-PROTEINS; C-ELEGANS; MAMMALIAN-CELLS; REGULATORS; DOMAIN; GAIP; G(Q)ALPHA; PATHWAYS; BEHAVIOR	Regulator of G protein signaling (RGS) proteins contain an RGS domain that inhibits Galpha signaling by activating Galpha GTPase activity. Certain RGS proteins also contain a Ggamma-like (GGL) domain and a poorly characterized but conserved N-terminal region. We assessed the functions of these subregions in the Caenorhabditis elegans RGS proteins EGL-10 and EAT-16, which selectively inhibit GOA-1 (Galpha(o)) and EGL-30 (Galpha(q)), respectively. Using transgenes in C. elegans, we expressed EGL-10, EAT-16, their subregions, or EGL-10/EAT-16 chimeras. The chimeras showed that the GGL/RGS region of either protein can act on either GOA-1 or EGL-30 and that a key factor determining Ga target selectivity is the manner in which the N-terminal and GGL/RGS regions are linked. We also found that coexpressing N-terminal and GGL/RGS fragments of EGL-10 gave full EGL-10 activity, whereas either fragment alone gave little activity. Biochemical analysis showed that coexpressing the two fragments caused both to increase in abundance and also caused the GGL/RGS fragment to move to the membrane, where the N-terminal fragment is localized. By coimmunoprecipitation, we found that the N-terminal fragment complexes with the C-terminal fragment and its associated Gbeta subunit, GPB-2. We conclude that the N-terminal region directs inhibition of Galpha signaling by forming a complex with the GGL/RGS region and affecting its stability, membrane localization, and Galpha target specificity.	Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	Yale University	Koelle, MR (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, 333 Cedar St,SHM C-E30, New Haven, CT 06520 USA.							Axelrod JD, 1998, GENE DEV, V12, P2610, DOI 10.1101/gad.12.16.2610; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Brundage L, 1996, NEURON, V16, P999, DOI 10.1016/S0896-6273(00)80123-3; Chase DL, 2001, CURR BIOL, V11, P222, DOI 10.1016/S0960-9822(01)00071-9; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Diverse-Pierluissi MA, 1999, J BIOL CHEM, V274, P14490, DOI 10.1074/jbc.274.20.14490; Dong MQ, 2000, GENE DEV, V14, P2003; Hajdu-Cronin YM, 1999, GENE DEV, V13, P1780, DOI 10.1101/gad.13.14.1780; He W, 2000, J BIOL CHEM, V275, P37093, DOI 10.1074/jbc.M006982200; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Heximer SP, 1997, P NATL ACAD SCI USA, V94, P14389, DOI 10.1073/pnas.94.26.14389; Hoffman GA, 2000, J BIOL CHEM, V275, P37533, DOI 10.1074/jbc.M005751200; Hu G, 2002, P NATL ACAD SCI USA, V99, P9755, DOI 10.1073/pnas.152094799; Huang CF, 1997, P NATL ACAD SCI USA, V94, P6159, DOI 10.1073/pnas.94.12.6159; Ingi T, 1998, J NEUROSCI, V18, P7178; Koelle MR, 1996, CELL, V84, P115, DOI 10.1016/S0092-8674(00)80998-8; Lishko PV, 2002, J BIOL CHEM, V277, P24376, DOI 10.1074/jbc.M203237200; Mello C, 1995, METHOD CELL BIOL, V48, P451; MENDEL JE, 1995, SCIENCE, V267, P1652, DOI 10.1126/science.7886455; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Popov S, 1997, P NATL ACAD SCI USA, V94, P7216, DOI 10.1073/pnas.94.14.7216; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SEGALAT L, 1995, SCIENCE, V267, P1648, DOI 10.1126/science.7886454; Shuey DJ, 1998, J NEUROCHEM, V70, P1964; Skiba NP, 2001, J BIOL CHEM, V276, P37365, DOI 10.1074/jbc.M106431200; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4	28	35	38	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47004	47013		10.1074/jbc.M208186200	http://dx.doi.org/10.1074/jbc.M208186200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354761	hybrid			2022-12-25	WOS:000179663700024
J	Schwenger, GTF; Kok, CC; Arthaningtyas, E; Thomas, MA; Sanderson, CJ; Mordvinov, VA				Schwenger, GTF; Kok, CC; Arthaningtyas, E; Thomas, MA; Sanderson, CJ; Mordvinov, VA			Specific activation of human interleukin-5 depends on de novo synthesis of an AP-1 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-3; CIS-REGULATORY ELEMENTS; NUCLEAR FACTOR; T-CELLS; GENE-EXPRESSION; TH2-SPECIFIC EXPRESSION; PROTEIN-KINASE; CYCLIC-AMP; TH2 CELLS; PROMOTER	It is clear from the biology of eosinophilia that a specific regulatory mechanism must exist. Because interleukin-5 (IL5) is the key regulatory cytokine, it follows that a gene-specific control of IL5 expression must exist that differs even from closely related cytokines such as IL4. Two features of IL5 induction make it unique compared with other cytokines; first, induction by cyclic adenosine monophosphate (cAMP), which inhibits other T-cell-derived cytokines, and second, sensitivity to protein synthesis inhibitors, which have no effect on other cytokines. This study has utilized the activation of different transcription factors by different stimuli in a human T-cell line to study the role of conserved lymphokine element 0 (CLE0) in the specific induction of IL5. In unstimulated cells the ubiquitous Oct-1 binds to CLE0. Stimulation induces de novo synthesis of the AP-1 members JunD and Fra-2, which bind to CLE0. The amount of IL5 produced correlates with the production of the AP-1 complex, suggesting a key role in IL5 expression. The formation of the AP-1 complex is essential, but the rate-limiting step is the synthesis of AP-1, especially Fra-2. This provides an explanation for the sensitivity of IL5 to protein synthesis inhibitors and a mechanism for the specific induction of IL5 compared with other cytokines.	Western Australian Inst Med Res, Mol Immunol Grp, Perth, WA 6000, Australia; Curtin Univ Technol, Sch Biomed Sci, Perth, WA 6000, Australia; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland; Free Univ Brussels, Fac Med, Expt Immunol Lab, B-1070 Brussels, Belgium	University of Western Australia; Curtin University; University of Lausanne; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Schwenger, GTF (corresponding author), Western Australian Inst Med Res, Mol Immunol Grp, Level 5,MRF Bldg,Rear 50 Murray St, Perth, WA 6000, Australia.	gretchen@cyllene.uwa.edu.au	Mordvinov, Viatcheslav A/S-8277-2017	Mordvinov, Viatcheslav A/0000-0002-6173-0774				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; BOHJANEN PR, 1990, P NATL ACAD SCI USA, V87, P5283, DOI 10.1073/pnas.87.14.5283; Chen CH, 2000, J IMMUNOL, V165, P5597, DOI 10.4049/jimmunol.165.10.5597; CHEN D, 1994, J EXP MED, V179, P931, DOI 10.1084/jem.179.3.931; Coombe DR, 1998, J IMMUNOL METHODS, V215, P145, DOI 10.1016/S0022-1759(98)00081-7; CORRIGAN CJ, 1992, IMMUNOL TODAY, V13, P501, DOI 10.1016/0167-5699(92)90026-4; De Boer ML, 1999, INT J BIOCHEM CELL B, V31, P1221, DOI 10.1016/S1357-2725(99)00069-2; DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373; DENHERTOG J, 1992, NUCLEIC ACIDS RES, V20, P125, DOI 10.1093/nar/20.1.125; DERIGS HG, 1990, LEUKEMIA, V4, P471; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; GRUARTGOUILLEUX V, 1995, EUR J IMMUNOL, V25, P1431, DOI 10.1002/eji.1830250544; GRUDA MC, 1994, ONCOGENE, V9, P2537; JAIN JN, 1993, J IMMUNOL, V151, P837; JENKINS F, 1995, J IMMUNOL, V155, P1240; Karlen S, 1996, BLOOD, V88, P211; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; KARLEN S, 1997, INT REV IMMUNOL, V16, P227; KEES UR, 1994, J IMMUNOL METHODS, V168, P1, DOI 10.1016/0022-1759(94)90202-X; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; LEE HJ, 1993, J IMMUNOL, V151, P6135; Lee HJ, 1998, J IMMUNOL, V160, P2343; Leung DYM, 1998, MOL GENET METAB, V63, P157, DOI 10.1006/mgme.1998.2682; Li-Weber M, 1998, J IMMUNOL, V161, P1380; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; Mordvinov VA, 1999, J IMMUNOL METHODS, V228, P163, DOI 10.1016/S0022-1759(99)00088-5; NAORA H, 1995, EXP HEMATOL, V23, P597; NAORA H, 1994, BLOOD, V83, P3620; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NOVAK TJ, 1990, P NATL ACAD SCI USA, V87, P9353, DOI 10.1073/pnas.87.23.9353; PERLMUTTER RM, 1993, ANNU REV IMMUNOL, V11, P451, DOI 10.1146/annurev.iy.11.040193.002315; Ranganath S, 1998, J IMMUNOL, V161, P3822; RINCON M, 1994, EMBO J, V13, P4370, DOI 10.1002/j.1460-2075.1994.tb06757.x; SANDERSON CJ, 1988, IMMUNOL REV, V102, P29, DOI 10.1111/j.1600-065X.1988.tb00740.x; SANDERSON CJ, 1992, BLOOD, V79, P3101, DOI 10.1182/blood.V79.12.3101.3101; Sanderson CJ, 1999, LUNG BIOL HEALTH DIS, V125, P267; Schandene L, 1996, J CLIN INVEST, V97, P309, DOI 10.1172/JCI118417; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schwenger GTF, 2001, J BIOL CHEM, V276, P48502, DOI 10.1074/jbc.M107836200; Short JD, 2002, J BIOL CHEM, V277, P32697, DOI 10.1074/jbc.M204553200; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; STRANICK KS, 1995, J BIOL CHEM, V270, P20575, DOI 10.1074/jbc.270.35.20575; Thomas MA, 1999, EUR J BIOCHEM, V265, P300, DOI 10.1046/j.1432-1327.1999.00732.x; THOMAS RS, 1995, ONCOGENE, V11, P2135; TOMINAGA A, 1988, J IMMUNOL, V140, P1175; VANSTRAATEN JFM, 1994, CYTOKINE, V6, P229, DOI 10.1016/1043-4666(94)90017-5; WARREN DJ, 1985, IMMUNOLOGY, V54, P615; WIERENGA EA, 1991, J IMMUNOL, V147, P2942; Yazgan O, 2002, J BIOL CHEM, V277, P29710, DOI 10.1074/jbc.M204552200; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	52	18	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47022	47027		10.1074/jbc.M207414200	http://dx.doi.org/10.1074/jbc.M207414200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354764	hybrid			2022-12-25	WOS:000179663700026
J	Yan, G; Lennarz, WJ				Yan, G; Lennarz, WJ			Studies on the function of oligosaccharyl transferase subunits - Stt3p is directly involved in the glycosylation process	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE OLIGOSACCHARYLTRANSFERASE; ASPARAGINE-LINKED GLYCOSYLATION; AMINO-ACID-SEQUENCE; ACTIVITY IN-VIVO; YEAST OLIGOSACCHARYLTRANSFERASE; ENDOPLASMIC-RETICULUM; PROTEIN COMPLEX; GLYCOPROTEIN-BIOSYNTHESIS; N-GLYCOSYLATION; 50-KDA SUBUNIT	In the yeast, Saccharomyces cerevisiae, oligosaccharyl transferase (OT) is composed of nine different transmembrane proteins. Using a glycosylatable peptide containing a photoprobe, we previously found that only one essential subunit, Ost1p, was specifically labeled by the photoprobe and recently have shown that it does not contain the recognition domain for the glycosylatable sequence Asn-Xaa-Thr/Ser. In this study we utilized additional glycosylatable peptides containing two photoreactive groups and found that these were linked to Stt3p and Ost3p. Stt3p is the most conserved subunit in the OT complex, and therefore 21 block mutants in the lumenal region were prepared. Of the 14 lethal mutant proteins only two, as well as one temperature-sensitive mutant protein, were incorporated into the OT complex. However, using microsomes prepared from these three strains, the labeling of Ost1p was markedly decreased upon photoactivation with the Asn-Bpa-Thr photoprobe. Based on the block mutants single amino acid mutations were prepared and analyzed. From all of these results, we conclude that the sequence from residues 516 to 520, WWDYG in Stt3p, plays a central role in glycosylatable peptide recognition and/or the catalytic glycosylation process.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Lennarz, WJ (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.	wlennarz@notes.ce.sunysb.edu			NIGMS NIH HHS [GM33185] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033185, R37GM033185] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER D, 1990, P NATL ACAD SCI USA, V87, P355, DOI 10.1073/pnas.87.1.355; Baldwin RL, 2002, SCIENCE, V295, P1657, DOI 10.1126/science.1069893; BAUSE E, 1981, BIOCHEM J, V195, P639, DOI 10.1042/bj1950639; BREUER W, 1995, EUR J BIOCHEM, V228, P689, DOI 10.1111/j.1432-1033.1995.0689m.x; Chi JH, 1996, J BIOL CHEM, V271, P3132, DOI 10.1074/jbc.271.6.3132; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; EVANS PA, 1991, PROTEINS, V9, P248, DOI 10.1002/prot.340090404; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; HEESEN ST, 1992, EMBO J, V11, P2071, DOI 10.1002/j.1460-2075.1992.tb05265.x; HEESEN ST, 1993, EMBO J, V12, P279, DOI 10.1002/j.1460-2075.1993.tb05654.x; HEESEN ST, 1991, EUR J CELL BIOL, V56, P8; HERSCOVICS A, 1993, FASEB J, V7, P540, DOI 10.1096/fasebj.7.6.8472892; IMPERIALI B, 1991, BIOCHEMISTRY-US, V30, P4374, DOI 10.1021/bi00232a002; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7944, DOI 10.1021/ja00046a069; Imperiali B, 1995, BIOORGAN MED CHEM, V3, P1565, DOI 10.1016/0968-0896(95)00142-5; IMPERIALI B, 1992, J AM CHEM SOC, V114, P7942, DOI 10.1021/ja00046a068; Karaoglu D, 1997, J BIOL CHEM, V272, P32513, DOI 10.1074/jbc.272.51.32513; KARAOGLU D, 1995, J CELL BIOL, V130, P567, DOI 10.1083/jcb.130.3.567; Kelleher DJ, 1997, P NATL ACAD SCI USA, V94, P4994, DOI 10.1073/pnas.94.10.4994; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; KELLEHER DJ, 1994, J BIOL CHEM, V269, P12908; Kim H, 2000, P NATL ACAD SCI USA, V97, P1516, DOI 10.1073/pnas.040556797; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KNAUER R, 1994, FEBS LETT, V344, P83, DOI 10.1016/0014-5793(94)00356-4; Knauer R, 1999, J BIOL CHEM, V274, P17249, DOI 10.1074/jbc.274.24.17249; KUMAR V, 1994, J BIOL CHEM, V269, P13451; KUMAR V, 1995, ARCH BIOCHEM BIOPHYS, V320, P217, DOI 10.1016/0003-9861(95)90003-9; MARSHALL RD, 1972, ANNU REV BIOCHEM, V41, P673, DOI 10.1146/annurev.bi.41.070172.003325; NILSSON I, 1993, J BIOL CHEM, V268, P5798; PATHAK R, 1995, BIOCHEMISTRY-US, V34, P4179, DOI 10.1021/bi00013a005; PATHAK R, 1995, FEBS LETT, V362, P229, DOI 10.1016/0014-5793(95)00253-6; PLESS DD, 1977, P NATL ACAD SCI USA, V74, P134, DOI 10.1073/pnas.74.1.134; Reiss G, 1997, EMBO J, V16, P1164, DOI 10.1093/emboj/16.6.1164; ROOS J, 1994, P NATL ACAD SCI USA, V91, P1485, DOI 10.1073/pnas.91.4.1485; SILBERSTEIN S, 1995, J CELL BIOL, V131, P371, DOI 10.1083/jcb.131.2.371; SILBERSTEIN S, 1995, J CELL BIOL, V128, P525, DOI 10.1083/jcb.128.4.525; Silberstein S, 1996, FASEB J, V10, P849, DOI 10.1096/fasebj.10.8.8666161; Spirig U, 1997, MOL GEN GENET, V256, P628, DOI 10.1007/s004380050611; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; WELPLY JK, 1986, ARCH BIOCHEM BIOPHYS, V246, P808, DOI 10.1016/0003-9861(86)90337-1; WELPLY JK, 1985, J BIOL CHEM, V260, P6459; Yan Q, 1999, J BIOL CHEM, V274, P5021, DOI 10.1074/jbc.274.8.5021; Yan Q, 1999, BIOCHEM BIOPH RES CO, V266, P684, DOI 10.1006/bbrc.1999.1886; YOSHIDA S, 1992, MOL GEN GENET, V231, P337, DOI 10.1007/BF00292700; YOSHIDA S, 1995, GENE, V164, P167, DOI 10.1016/0378-1119(95)00431-5; ZUFFEREY R, 1995, EMBO J, V14, P4949, DOI 10.1002/j.1460-2075.1995.tb00178.x	47	126	131	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47692	47700		10.1074/jbc.M208136200	http://dx.doi.org/10.1074/jbc.M208136200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359722	hybrid			2022-12-25	WOS:000179663700111
J	Berdiev, BK; Xia, JZ; Jovov, B; Markert, JM; Mapstone, TB; Gillespie, GY; Fuller, CM; Bubien, JK; Benos, DJ				Berdiev, BK; Xia, JZ; Jovov, B; Markert, JM; Mapstone, TB; Gillespie, GY; Fuller, CM; Bubien, JK; Benos, DJ			Protein kinase C isoform antagonism controls BNaC2 (ASIC1) function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPITHELIAL NA+ CHANNEL; PLANAR LIPID BILAYERS; SENSING ION CHANNELS; GLIOBLASTOMA CELL-LINES; CARDIAC CA2+ CHANNELS; GATED CATION CHANNELS; EPSILON-PKC ISOZYME; MOLECULAR-CLONING; SODIUM-CHANNEL; SENSORY NEURONS	We explored the involvement of protein kinase C (PKC) and its isoforms in the regulation of BNaC2. Reverse transcriptase PCR evaluation of PKC isoform expression at the level of mRNA revealed the presence of alpha and epsilon/epsilon' in all glioma cell lines analyzed; most, but not all cell lines expressed delta and zeta. No messages were found for the betaI and betaII isotypes of PKC in the tumor cells. Normal astrocytes expressed beta but not gamma. The essential features of these results were confirmed at the protein level by Western analysis. This disproportionate pattern of PKC isoform expression in glioma cell lines was further echoed in the functional effects of these PKC isoforms on BNaC2 activity in bilayers. PKC holoenzyme or the combination of PKCbetaI and PKCbetaII isoforms inhibited BNaC2. Neither PKCepsilon nor PKCzeta or their combination had any effect on BNaC2 activity in bilayers. The inhibitory effect of the PKCbetaI and PKCbetaII mixture on BNaC2 activity was abolished by a 5-fold excess of a PKCepsilon and PKCzeta combination. PKC holoenzymes, PKCbetaI, PKCbetaII, PKCdelta, PKCepsilon, and PKCzeta phosphorylated BNaC2 in vitro. In patch clamp experiments,the combination of PKCbetaI and PKCbetaII inhibited the basally activated inward Na+ conductance. The variable expression of the PKC isotypes and their functional antagonism in regulating BNaC2 activity support the idea that the participation of multiple PKC isotypes contributes to the overall activity of BNaC2.	Univ Alabama Birmingham, Dept Physiol & Biophys, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Emory Univ, Dept Neurosurg, Atlanta, GA 30322 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Emory University	Benos, DJ (corresponding author), Univ Alabama Birmingham, Dept Physiol & Biophys, 1918 Univ Blvd,MCLM 704, Birmingham, AL 35294 USA.	benos@physiology.uab.edu	Fuller, Cathy/B-4046-2011	Gillespie, George/0000-0001-6436-9542	NCI NIH HHS [CA71933] Funding Source: Medline; NIDDK NIH HHS [DK37206] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA071933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037206, R56DK037206] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Anzai N, 2002, J BIOL CHEM, V277, P16655, DOI 10.1074/jbc.M201087200; Awayda MS, 2000, J GEN PHYSIOL, V115, P559, DOI 10.1085/jgp.115.5.559; AWAYDA MS, 1995, AM J PHYSIOL-CELL PH, V268, pC1450, DOI 10.1152/ajpcell.1995.268.6.C1450; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Berdiev BK, 2001, J BIOL CHEM, V276, P38755, DOI 10.1074/jbc.M107266200; Biagini G, 2001, NEUROBIOL DIS, V8, P45, DOI 10.1006/nbdi.2000.0331; Bianchi L, 2002, NEURON, V34, P337, DOI 10.1016/S0896-6273(02)00687-6; BROOKS SPJ, 1992, ANAL BIOCHEM, V201, P119, DOI 10.1016/0003-2697(92)90183-8; Bubien JK, 1999, AM J PHYSIOL-CELL PH, V276, pC1405, DOI 10.1152/ajpcell.1999.276.6.C1405; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Cho KK, 1999, INT J DEV NEUROSCI, V17, P447, DOI 10.1016/S0736-5748(99)00054-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CIVAN MM, 1987, J MEMBRANE BIOL, V97, P193, DOI 10.1007/BF01869222; Corey DP, 1996, SCIENCE, V273, P323, DOI 10.1126/science.273.5273.323; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Donson AM, 2000, J NEURO-ONCOL, V47, P109, DOI 10.1023/A:1006406208376; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Els WJ, 1998, AM J PHYSIOL-CELL PH, V275, pC120; Garcia-Anoveros J, 2001, J NEUROSCI, V21, P2678, DOI 10.1523/JNEUROSCI.21-08-02678.2001; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Grunder S, 2000, NEUROREPORT, V11, P1607; Gunthorpe NJ, 2001, PFLUG ARCH EUR J PHY, V442, P668; Hruska-Hageman AM, 2002, BIOCHEM J, V361, P443, DOI 10.1042/0264-6021:3610443; Hu KL, 2000, AM J PHYSIOL-HEART C, V279, pH2658, DOI 10.1152/ajpheart.2000.279.6.H2658; Ishibashi K, 1998, BIOCHEM BIOPH RES CO, V245, P589, DOI 10.1006/bbrc.1998.8483; ISMAILOV II, 1995, KIDNEY INT, V48, P1167, DOI 10.1038/ki.1995.400; Ismailov II, 1997, J PHYSIOL-LONDON, V504, P287, DOI 10.1111/j.1469-7793.1997.287be.x; Johnson MB, 2001, J CEREBR BLOOD F MET, V21, P734, DOI 10.1097/00004647-200106000-00011; Jovov B, 1999, J BIOL CHEM, V274, P37845, DOI 10.1074/jbc.274.53.37845; Korchak HM, 2001, AM J PHYSIOL-CELL PH, V281, pC514, DOI 10.1152/ajpcell.2001.281.2.C514; Kress M, 1999, TRENDS PHARMACOL SCI, V20, P112, DOI 10.1016/S0165-6147(99)01294-8; KRISHTAL OA, 1981, NEUROSCI LETT, V24, P243, DOI 10.1016/0304-3940(81)90164-6; KRISHTAL OA, 1980, NEUROSCIENCE, V5, P2325, DOI 10.1016/0306-4522(80)90149-9; LING BN, 1989, AM J PHYSIOL, V256, pF1094, DOI 10.1152/ajprenal.1989.256.6.F1094; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Lo CF, 1999, ANN NY ACAD SCI, V868, P431, DOI 10.1111/j.1749-6632.1999.tb11307.x; Mandil R, 2001, CANCER RES, V61, P4612; McCleskey EW, 1999, ANNU REV PHYSIOL, V61, P835, DOI 10.1146/annurev.physiol.61.1.835; MOHRMANN M, 1987, AM J PHYSIOL, V253, pF372, DOI 10.1152/ajprenal.1987.253.2.F372; NUMANN R, 1991, SCIENCE, V254, P115, DOI 10.1126/science.1656525; OH YS, 1993, AM J PHYSIOL, V265, pC85, DOI 10.1152/ajpcell.1993.265.1.C85; Park MJ, 2000, NEUROSCI LETT, V290, P201, DOI 10.1016/S0304-3940(00)01358-6; PEREZ G, 1994, BIOPHYS J, V66, P1022, DOI 10.1016/S0006-3495(94)80883-5; Price MP, 2000, NATURE, V407, P1007, DOI 10.1038/35039512; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Reeh P W, 2001, Curr Opin Pharmacol, V1, P45, DOI 10.1016/S1471-4892(01)00014-5; REVAN S, 1991, J PHYSL, V433, P145; ROUCH AJ, 1993, AM J PHYSIOL, V265, pF569, DOI 10.1152/ajprenal.1993.265.4.F569; Sharif TR, 2001, INT J MOL MED, V7, P373; Sharif TR, 1999, INT J ONCOL, V15, P237; Shimkets RA, 1998, P NATL ACAD SCI USA, V95, P3301, DOI 10.1073/pnas.95.6.3301; Song JC, 2001, AM J PHYSIOL-CELL PH, V281, pC649, DOI 10.1152/ajpcell.2001.281.2.C649; STEA A, 1995, NEURON, V15, P929, DOI 10.1016/0896-6273(95)90183-3; Stockando JD, 2000, J BIOL CHEM, V275, P25760, DOI 10.1074/jbc.M003615200; Ugawa S, 2001, NEUROREPORT, V12, P2865, DOI 10.1097/00001756-200109170-00022; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6; WANG WH, 1992, ANNU REV PHYSIOL, V54, P81; Wemmie JA, 2002, NEURON, V34, P463, DOI 10.1016/S0896-6273(02)00661-X; Wood JN, 1997, ANNU REV PHYSIOL, V59, P457, DOI 10.1146/annurev.physiol.59.1.457; Xiao GQ, 2001, AM J PHYSIOL-CELL PH, V281, pC1477, DOI 10.1152/ajpcell.2001.281.5.C1477; XIAO HG, 1994, J NEUROSURG, V81, P734, DOI 10.3171/jns.1994.81.5.0734; YANASE M, 1986, AM J PHYSIOL, V250, pC517, DOI 10.1152/ajpcell.1986.250.3.C517; YANG J, 1993, NEURON, V10, P127, DOI 10.1016/0896-6273(93)90305-B; Yiangou YG, 2001, EUR J GASTROEN HEPAT, V13, P891, DOI 10.1097/00042737-200108000-00003; Zhang ZH, 1997, CIRC RES, V80, P720, DOI 10.1161/01.RES.80.5.720	75	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45734	45740		10.1074/jbc.M208995200	http://dx.doi.org/10.1074/jbc.M208995200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244121	hybrid			2022-12-25	WOS:000179529300004
J	Teyssier, C; Chen, DG; Stallcup, MR				Teyssier, C; Chen, DG; Stallcup, MR			Requirement for multiple domains of the protein arginine methyltransferase CARM1 in its transcriptional coactivator function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR FUNCTION; STEROID-RECEPTORS; ZINC-FINGER; DNA-BINDING; ACTIVATION; ACETYLATION; ESTROGEN; FAMILY; YEAST; ACETYLTRANSFERASE	The p160 coactivator complex plays a critical role in transcriptional activation by nuclear receptors and possibly other classes of DNA-binding transcriptional activators. The complex contains at least one of three p160 coactivators (SRC-1, GRIP1/TIF2, or pCIP/RAC3/ACTR/ AIB1/TRAM1), a histone acetyltransferase such as CBP or p300, and the histone methyltransferase CARM1 (coactivator-associated arginine methyltransferase 1). Methylation of histone H3 and possibly other proteins in the transcription initiation complex by CARM1 occurs along with acetylation of histones and other proteins by CBP and p300 to help remodel chromatin structure and recruit RNA polymerase II. Here we show that other domains of CARM1 are required for the coactivator function of CARM1 in addition to the methyltransferase activity. The methyltransferase GRIP1, binding, and homo-oligomerization activities all reside in the central region of CARM1, which is highly conserved among the entire protein arginine methyltransferase family. In addition to this conserved domain, the unique N- and C-terminal regions of CARM1 were also required for enhancement of transcriptional activation by nuclear receptors. While the N-terminal region has no known activity at present, the C-terminal part of CARM1 contains an autonomous activation domain, suggesting that it interacts with other proteins that help to mediate CARM1 coactivator function.	Univ So Calif, Dept Pathol, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Stallcup, MR (corresponding author), Univ So Calif, Dept Pathol, HMR 301,2011 Zonal Ave, Los Angeles, CA 90089 USA.		Teyssier, Catherine/AAC-2395-2020	Teyssier, Catherine/0000-0003-4937-6503				Bauer UM, 2002, EMBO REP, V3, P39, DOI 10.1093/embo-reports/kvf013; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen DG, 2000, J BIOL CHEM, V275, P40810, DOI 10.1074/jbc.M005459200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Enmark E, 1996, MOL ENDOCRINOL, V10, P1293, DOI 10.1210/me.10.11.1293; Frankel A, 2000, J BIOL CHEM, V275, P32974, DOI 10.1074/jbc.M006445200; Glass CK, 2000, GENE DEV, V14, P121; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goodman RH, 2000, GENE DEV, V14, P1553; GREEN S, 1988, EMBO J, V7, P3037, DOI 10.1002/j.1460-2075.1988.tb03168.x; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; LEE HW, 1977, BIOCHEMISTRY-US, V16, P78, DOI 10.1021/bi00620a013; Lee YH, 2002, MOL CELL BIOL, V22, P3621, DOI 10.1128/MCB.22.11.3621-3632.2002; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Liu Z, 2001, P NATL ACAD SCI USA, V98, P12426, DOI 10.1073/pnas.231474798; Ma H, 1999, MOL CELL BIOL, V19, P6164; Ma H, 2001, CURR BIOL, V11, P1981, DOI 10.1016/S0960-9822(01)00600-5; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McBride AE, 2000, J BIOL CHEM, V275, P3128, DOI 10.1074/jbc.275.5.3128; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Rho J, 2001, J BIOL CHEM, V276, P11393, DOI 10.1074/jbc.M008660200; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Webb P, 1998, MOL ENDOCRINOL, V12, P1605, DOI 10.1210/me.12.10.1605; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Zhang X, 2000, EMBO J, V19, P3509, DOI 10.1093/emboj/19.14.3509	39	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46066	46072		10.1074/jbc.M207623200	http://dx.doi.org/10.1074/jbc.M207623200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351636	hybrid			2022-12-25	WOS:000179529300048
J	Yang, J; Wu, J; Jiang, H; Mortensen, R; Austin, S; Manning, DR; Woulfe, D; Brass, LF				Yang, J; Wu, J; Jiang, H; Mortensen, R; Austin, S; Manning, DR; Woulfe, D; Brass, LF			Signaling through G(i) family members in platelets - Redundancy and specificity in the regulation of adenylyl cyclase and other effectors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; GLYCOPROTEIN-IB-BETA; CYCLIC-NUCLEOTIDES; INTACT PLATELETS; AGGREGATION; PROSTACYCLIN; CALCIUM; CELLS; PHOSPHORYLATION; IDENTIFICATION	Platelet responses at sites of vascular injury are regulated by intracellular cAMP levels, which rise rapidly when prostacyclin (PGI(2)) is released from endothelial cells. Platelet agonists such as ADP and epinephrine suppress PGI(2)-stimulated cAMP formation by activating receptors coupled to G(i) family members, four of which are present in platelets. To address questions about the specificity of receptor:G protein coupling, the regulation of cAMP formation in vivo and the contribution of G(i)-mediated pathways that do not involve adenylyl cyclase, we studied platelets from mice that lacked the a subunits of one or more of the three most abundantly expressed G(i) family members and compared the results with platelets from mice that lacked the PGI(2) receptor, IP. As reported previously, loss of G(i2alpha) or G(zalpha) inhibited aggregation in response to ADP and epinephrine, respectively, producing defects that could not be reversed by adding an adenylyl cyclase inhibitor. Platelets that lacked both G(i2alpha) and G(zalpha) showed impaired responses to both agonists, but the impairment was no greater than in the individual knockouts. Loss of G(i3alpha) had no effect either alone or in combination with G(zalpha) Loss of either G(zalpha) or G(i2alpha) impaired the ability of ADP and epinephrine to inhibit PGI(2)-stimulated adenylyl cyclase activity and caused a 40%-50% rise in basal cAMP levels, whereas loss of G(i3alpha) did not. Conversely, deletion of IP abolished responses to PGI(2) and caused cAMP levels to fall by 30%, effects that did not translate into enhanced responsiveness to agonists ex vivo. From these results we conclude that 1) cAMP levels in circulating platelets reflect ongoing signaling through G(i2), G(z), and IP, but not G(i3); 2) platelet epinephrine (alpha(2A)-adrenergic) and ADP (P2Y12) receptors display strong preferences among Gi family members with little evidence of redundancy; and 3) these receptor preferences do not extend to G(i3). Finally, the failure of ADP and epinephrine to inhibit basal, as opposed to PGI(2)-stimulated, cAMP formation highlights the need during platelet activation for G(i) signaling pathways that involve effectors other than adenylyl cyclase.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Michigan, Dept Physiol & Med Endocrine, Ann Arbor, MI 48109 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Michigan System; University of Michigan	Brass, LF (corresponding author), Univ Penn, Dept Med, Rm 913 BRB-II,421 Curie Blvd, Philadelphia, PA 19104 USA.				NHLBI NIH HHS [HL-45181, HL-54500] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045181, P50HL054500] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Austin SC, 2001, ARTERIOSCL THROM VAS, V21, P709; Bertoni A, 2002, J BIOL CHEM, V277, P25715, DOI 10.1074/jbc.M202791200; Brass S, 2001, NATURE, V409, P145, DOI 10.1038/35051688; Cheng Y, 2002, SCIENCE, V296, P539, DOI 10.1126/science.1068711; Daniel JL, 1999, THROMB HAEMOSTASIS, V82, P1322; EIGENTHALER M, 1992, EUR J BIOCHEM, V205, P471, DOI 10.1111/j.1432-1033.1992.tb16803.x; FISCHER TH, 1989, BIOCHEM BIOPH RES CO, V159, P644, DOI 10.1016/0006-291X(89)90043-0; FOX JEB, 1987, J BIOL CHEM, V262, P12627; GAGNON AW, 1991, BLOOD, V78, P1247; Gorman R R, 1978, Adv Cyclic Nucleotide Res, V9, P597; HALLAM TJ, 1985, BIOCHEM J, V232, P373, DOI 10.1042/bj2320373; Haslam RJ, 1999, THROMB HAEMOSTASIS, V82, P412; HATHAWAY DR, 1979, P NATL ACAD SCI USA, V76, P1653, DOI 10.1073/pnas.76.4.1653; HIRSCH E, 2001, FASEB J, V15, P307; Jain M, 2001, AM J PHYSIOL-HEART C, V280, pH569, DOI 10.1152/ajpheart.2001.280.2.H569; Jantzen HM, 2001, J CLIN INVEST, V108, P477; Jin JG, 1998, P NATL ACAD SCI USA, V95, P8070, DOI 10.1073/pnas.95.14.8070; KASERGLANZMANN R, 1977, BIOCHIM BIOPHYS ACTA, V466, P429, DOI 10.1016/0005-2736(77)90336-4; KASERGLANZMANN R, 1979, BIOCHIM BIOPHYS ACTA, V558, P34; Keularts IMLW, 2000, J BIOL CHEM, V275, P1763, DOI 10.1074/jbc.275.3.1763; Kim S, 2002, BLOOD, V99, P3629, DOI 10.1182/blood.V99.10.3629; Manganello JM, 1999, J BIOL CHEM, V274, P28003, DOI 10.1074/jbc.274.39.28003; MILLER OV, 1976, J CYCLIC NUCL PROT, V2, P79; MILLS DCB, 1971, BIOCHEM J, V121, P185, DOI 10.1042/bj1210185; MONCADA S, 1976, NATURE, V263, P663, DOI 10.1038/263663a0; Murata T, 1997, NATURE, V388, P678, DOI 10.1038/41780; Nagata K, 2000, CIRC RES, V87, P903, DOI 10.1161/01.RES.87.10.903; Ryningen A, 1998, BBA-LIPID LIPID MET, V1394, P235, DOI 10.1016/S0005-2760(98)00106-4; Schwarz UR, 2001, BIOCHEM PHARMACOL, V62, P1153, DOI 10.1016/S0006-2952(01)00760-2; WALLACH D, 1978, J BIOL CHEM, V253, P4739; WARDELL MR, 1989, J BIOL CHEM, V264, P15656; WATSON SP, 1984, J BIOL CHEM, V259, P3199; WEKSLER BB, 1977, P NATL ACAD SCI USA, V74, P3922, DOI 10.1073/pnas.74.9.3922; WEKSLER BB, 1978, J CLIN INVEST, V62, P923, DOI 10.1172/JCI109220; WILLIAMS AG, 1990, BLOOD, V76, P721; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Yang J, 2000, P NATL ACAD SCI USA, V97, P9984, DOI 10.1073/pnas.180194597; ZAHAVI M, 1984, THROMB HAEMOSTASIS, V52, P205	38	111	113	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46035	46042		10.1074/jbc.M208519200	http://dx.doi.org/10.1074/jbc.M208519200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297509	hybrid			2022-12-25	WOS:000179529300044
J	Mokros, T; Rehm, A; Droese, J; Oppermann, M; Lipp, M; Hopken, UE				Mokros, T; Rehm, A; Droese, J; Oppermann, M; Lipp, M; Hopken, UE			Surface expression and endocytosis of the human cytomegalovirus-encoded chemokine receptor US28 is regulated by agonist-independent phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-TERMINAL TAIL; KINASE-C; CELLS; CCR5; DESENSITIZATION; INTERNALIZATION; IDENTIFICATION; INFECTION; DOMAIN	Human cytomegalovirus encodes the G protein-coupled chemokine receptor homologue US28 that binds several CC chemokines and sequesters extracellular chemokines from the environment of infected cells. Mechanistically, it has been shown that US28 undergoes rapid constitutive receptor endocytosis and recycling. Monoclonal antibodies were raised that allowed the characterization of a ligand-independent phosphorylation and low surface expression of the US28 receptor in transiently transfected HEK293A cells. Phosphoamino acid analysis defined C-terminal serine and threonine residues as phospho-acceptor sites for constitutive receptor phosphorylation. Coexpression of G protein-coupled receptor kinase-2 and US28 enhanced ligand-independent receptor phosphorylation. C-terminal serine to alanine mutagenesis of US28 resulted in a decreased phosphorylation rate that correlated with enhanced surface expression. Maximal surface expression was detected when all C-terminal serines were substituted. Exchange of all C-terminal serines also significantly reduced receptor endocytosis. Thus, constitutive US28 phosphorylation regulates receptor endocytosis and receptor surface display and may thereby provide a pathogenic mechanism for a potential decoy function of the virally encoded receptor.	Max Delbruck Ctr Mol Med, Dept Tumorgenet & Immunogenet, D-13092 Berlin, Germany; Dept Hematol Oncol & Tumorimmunol, D-13092 Berlin, Germany; Univ Klinikum Charite, Dept Hematol Oncol & Tumorimmunol, Robert Rossle Klin, D-13125 Berlin, Germany; Univ Gottingen, Dept Immunol, D-37075 Gottingen, Germany	Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Gottingen	Hopken, UE (corresponding author), Max Delbruck Ctr Mol Med, Dept Tumorgenet & Immunogenet, Robert Rossle Str 10, D-13092 Berlin, Germany.		Lipp, Martin/G-2235-2010	Lipp, Martin/0000-0002-0087-2672				Aragay AM, 1998, FEBS LETT, V430, P37, DOI 10.1016/S0014-5793(98)00495-5; Arvanitakis L, 1996, BLOOD, V88, P2648, DOI 10.1182/blood.V88.7.2648.bloodjournal8872648; Bergmann M, 1998, J BIOL CHEM, V273, P6607, DOI 10.1074/jbc.273.12.6607; Billstrom MA, 1999, AM J RESP CELL MOL, V21, P163, DOI 10.1165/ajrcmb.21.2.3673; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; Carman CV, 1998, CURR OPIN NEUROBIOL, V8, P335, DOI 10.1016/S0959-4388(98)80058-5; Casarosa P, 2001, J BIOL CHEM, V276, P1133, DOI 10.1074/jbc.M008965200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fraile-Ramos A, 2001, MOL BIOL CELL, V12, P1737, DOI 10.1091/mbc.12.6.1737; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GAO JL, 1994, J BIOL CHEM, V269, P28539; Kledal TN, 1998, FEBS LETT, V441, P209, DOI 10.1016/S0014-5793(98)01551-8; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Kraft K, 2001, J BIOL CHEM, V276, P34408, DOI 10.1074/jbc.M102782200; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; Leurs R, 1998, TRENDS BIOCHEM SCI, V23, P418, DOI 10.1016/S0968-0004(98)01287-0; Oppermann M, 1999, J BIOL CHEM, V274, P8875, DOI 10.1074/jbc.274.13.8875; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Ploegh HL, 1998, SCIENCE, V280, P248, DOI 10.1126/science.280.5361.248; Pronin AN, 1997, J BIOL CHEM, V272, P3806, DOI 10.1074/jbc.272.6.3806; Rosenkilde MM, 2001, ONCOGENE, V20, P1582, DOI 10.1038/sj.onc.1204191; Smit MJ, 2002, J VIROL, V76, P1744, DOI 10.1128/JVI.76.4.1744-1752.2002; Streblow DN, 1999, CELL, V99, P511, DOI 10.1016/S0092-8674(00)81539-1; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Waldhoer M, 2002, J VIROL, V76, P8161, DOI 10.1128/JVI.76.16.8161-8168.2002; Winstel R, 1996, P NATL ACAD SCI USA, V93, P2105, DOI 10.1073/pnas.93.5.2105	28	60	65	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45122	45128		10.1074/jbc.M208214200	http://dx.doi.org/10.1074/jbc.M208214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244063	hybrid			2022-12-25	WOS:000179404800069
J	Lauritsen, KJ; List, HJ; Reiter, R; Wellstein, A; Riegel, AT				Lauritsen, KJ; List, HJ; Reiter, R; Wellstein, A; Riegel, AT			A role for TGF-beta in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cells	ONCOGENE			English	Article						AIBl; coactivator; breast cancer; antiestrogen; all-trans retinoic acid; TGF-beta	GROWTH-FACTOR-BETA; DEPENDENT ACTIVATION; EXPRESSION; GENE; HORMONE; AMPLIFICATION; TRANSCRIPTION; INVASIVENESS; POSITIVITY; INHIBITION	AIB1 (amplified in breast cancer 1) is a nuclear receptor coactivator gene amplified and overexpressed in breast cancer. However, the mechanisms by which AIB1 is regulated are unclear. Here we show that 17beta-estradiol represses AIB1 mRNA and protein expression in MCF-7 human breast cancer cells primarily by suppressing AIB1 gene transcription. Estrogen levels present in fetal calf serum are sufficient to maintain AIB1 mRNA and protein at low basal levels, and this repression is reversed by the addition of antiestrogens or all-trans retinoic acid. Interestingly, cycloheximide inhibition experiments revealed that secondary protein synthesis was necessary to induce AIB1 expression by antiestrogens and retinoids. Experiments with TGF-beta and TGF-beta blocking antibodies demonstrated that this growth factor modulates AIB1 expression and showed that the antiestrogen and retinoid induction of AIB1 gene expression is mediated at least in part through TGF-beta. These data reveal a mechanism of estrogen-induced down-modulation of the overall hormone sensitivity of cells through feedback inhibition of coactivator gene expression. These data also suggest that antiestrogens can shift the sensitivity of cells to nonestrogenic proliferative signaling by increasing cellular levels of AIB1 This effect may play a role in breast cancer progression and resistance to drug treatment.	Georgetown Univ, Vincent T Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA; Georgetown Univ, Vincent T Lombardi Canc Ctr, Dept Pharmacol, Washington, DC 20007 USA	Georgetown University; Georgetown University	Riegel, AT (corresponding author), Georgetown Univ, Vincent T Lombardi Canc Ctr, Dept Oncol, E307,3970 Reservoir Rd, Washington, DC 20007 USA.			Wellstein, Anton/0000-0002-0570-4950				Akiyama N, 2000, MOL CELL BIOL, V20, P3266, DOI 10.1128/MCB.20.9.3266-3273.2000; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Bai JW, 2000, CELL, V103, P1047, DOI 10.1016/S0092-8674(00)00208-7; Bautista S, 1998, CLIN CANCER RES, V4, P2925; Belandia B, 2000, J BIOL CHEM, V275, P30801, DOI 10.1074/jbc.C000484200; Bouras T, 2001, CANCER RES, V61, P903; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Choudhury A, 2000, J BIOL CHEM, V275, P33929, DOI 10.1074/jbc.M005115200; Degitz SJ, 1998, TERATOLOGY, V58, P197, DOI 10.1002/(SICI)1096-9926(199811)58:5<197::AID-TERA6>3.0.CO;2-8; Dumont N, 2000, BREAST CANCER RES, V2, P125, DOI 10.1186/bcr44; Farina AR, 1998, INT J CANCER, V75, P721; Ghadimi BM, 1999, AM J PATHOL, V154, P525, DOI 10.1016/S0002-9440(10)65298-4; Guan XY, 1996, CANCER RES, V56, P3446; Jakowlew SB, 2000, PEPTIDES, V21, P1831, DOI 10.1016/S0196-9781(00)00344-2; KAREY KP, 1988, CANCER RES, V48, P4083; KNABBE C, 1987, CELL, V48, P417, DOI 10.1016/0092-8674(87)90193-0; Koli KM, 1997, J BIOL CHEM, V272, P8296, DOI 10.1074/jbc.272.13.8296; Lee SK, 1999, MOL ENDOCRINOL, V13, P1924, DOI 10.1210/me.13.11.1924; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; LIPPMAN ME, 1975, NATURE, V256, P592, DOI 10.1038/256592a0; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; List HJ, 2001, BREAST CANCER RES TR, V68, P21, DOI 10.1023/A:1017910924390; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Nephew KP, 2000, BIOL REPROD, V63, P361, DOI 10.1095/biolreprod63.2.361; Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7; ONATE SA, 1995, SCIENCE, V270, P1354; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Reiter R, 2001, J BIOL CHEM, V276, P39736, DOI 10.1074/jbc.M104744200; Sakakura C, 2000, INT J CANCER, V89, P217; SEGARS JH, 1993, MOL CELL BIOL, V13, P2258, DOI 10.1128/MCB.13.4.2258; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; VINDELOV LL, 1983, CYTOMETRY, V3, P323, DOI 10.1002/cyto.990030503; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Wang DH, 1999, J BIOL CHEM, V274, P12840, DOI 10.1074/jbc.274.18.12840; Wang ZY, 2000, P NATL ACAD SCI USA, V97, P13549, DOI 10.1073/pnas.260463097; WELCH DR, 1990, P NATL ACAD SCI USA, V87, P7678, DOI 10.1073/pnas.87.19.7678; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Yue JB, 2000, J BIOL CHEM, V275, P30765, DOI 10.1074/jbc.M000039200	43	49	50	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7147	7155		10.1038/sj.onc.1205943	http://dx.doi.org/10.1038/sj.onc.1205943			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370804				2022-12-25	WOS:000178504600002
J	Furuta, S; Miura, K; Copeland, T; Shang, WH; Oshima, A; Kamata, T				Furuta, S; Miura, K; Copeland, T; Shang, WH; Oshima, A; Kamata, T			Light Chain 3 associates with a Sos1 guanine nucleotide exchange factor: its significance in the Sos1-mediated Rac1 signaling leading to membrane ruffling	ONCOGENE			English	Article						Sos1; Rac1; light chain 3	PROTEIN; BINDING; RAS; AUTOPHAGOSOME; ACTIVATION; DOMAIN; YEAST; MSOS1	A 19 kDa protein was identified to associate with the Dbl oncogene homology domain of Sos1 (Sos-DH) and was purified from rat brains by GST-Sos-DH affinity chromatography. Peptide sequencing revealed that the protein is identical to light chain 3 (LC3), a microtubule-associated protein. LC3 coimmunoprecipitated with Sos1, and GST-LC3 was capable of forming complexes with Sos1 in in vitro GST-pull down assay. Furthermore, LC3 was colocalized with Sos1 in cells, as determined by immunohistochemistry. While Sos1 stimulated the guanine nucleotide exchange reaction on Rac1, LC3 suppressed the ability of Sos1 to activate Rac1 in in vitro experiments using COS cell lysates. Consistent with this, overexpression of LC3 decreased the level of active GTP-bound Rac1 in COS cells. Sos1 expression induced membrane ruffling, a downstream target for Rac1, but LC3 expression inhibited this biological effect of Sos1. These findings suggest that LC3 interacts with Sos1 and thereby negatively regulates the Sos1-dependent Rac1 activation leading to membrane ruffling.	Shinshu Univ, Sch Med, Dept Biochem & Mol Biol, Matsumoto, Nagano 3908621, Japan; NCI, Frederick Canc Res & Dev Ctr, IRSP, SAIC Frederick, Frederick, MD 21702 USA; NCI, Frederick Canc Res & Dev Ctr, Wlodawers Program Struct Biol, Frederick, MD 21702 USA	Shinshu University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kamata, T (corresponding author), Shinshu Univ, Sch Med, Dept Biochem & Mol Biol, 3-1-1 Asahi, Matsumoto, Nagano 3908621, Japan.							Downward J, 1996, CANCER SURV, V27, P87; Glaven JA, 1999, J BIOL CHEM, V274, P2279, DOI 10.1074/jbc.274.4.2279; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamata T, 1998, MOL BRAIN RES, V54, P219, DOI 10.1016/S0169-328X(97)00332-X; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Kubiseski TJ, 1997, J BIOL CHEM, V272, P1799, DOI 10.1074/jbc.272.3.1799; LI BQ, 1992, SCIENCE, V256, P1456, DOI 10.1126/science.1604323; Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257; MANN SS, 1994, J BIOL CHEM, V269, P11492; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Qian XL, 1998, MOL CELL BIOL, V18, P771, DOI 10.1128/MCB.18.2.771; VAN AL, 1997, GENE DEV, V11, P2295; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; WANG W, 1995, NAT GENET, V10, P294, DOI 10.1038/ng0795-294; Whitehead IP, 1997, BBA-REV CANCER, V1332, pF1, DOI 10.1016/S0304-419X(96)00040-6	15	13	15	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7060	7066		10.1038/sj.onc.1205790	http://dx.doi.org/10.1038/sj.onc.1205790			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370828				2022-12-25	WOS:000178424900009
J	Mamane, Y; Grandvaux, N; Hernandez, E; Sharma, S; Innocente, SA; Lee, JM; Azimi, N; Lin, R; Hiscott, J				Mamane, Y; Grandvaux, N; Hernandez, E; Sharma, S; Innocente, SA; Lee, JM; Azimi, N; Lin, R; Hiscott, J			Repression of IRF-4 target genes in human T cell leukemia virus-1 infection	ONCOGENE			English	Review						human T cell leukemia virus; interferon regulatory factors; cyclin B1; transcription	INTERFERON REGULATORY FACTOR-4; NF-KAPPA-B; HUMAN-IMMUNODEFICIENCY-VIRUS; REPLICATION PROTEIN-A; TYPE-1 TAX PROTEIN; I HTLV-I; CYCLIN B1; TRANSCRIPTION FACTOR; KINASE IKK; MOLECULAR MECHANISM	The human T cell leukemia/lymphotropic virus-1 (HTLV-I) is the etiologic agent of adult T cell leukemia (ATL), an aggressive and fatal leukemia of CD4+ T lymphocytes. Interferon regulatory factor-4 (IRF-4) was shown previously to be constitutively expressed in T cells infected with HTLV-1. In this study, we investigated the role of IRF-4 gene regulation in the context of HTLV-1 infection using gene array technology and IRF-4 expressing T cells. Many potential IRF-4 regulated genes were identified, the vast majority of which were repressed by IRF-4 expression. Cyclin B1, a G2-M checkpoint protein identified as an IRF-4 repressed gene in the array, was further characterized in the context of HTLV-1 infection. All HTLV-1 infected cell lines and ATL patient lymphocytes demonstrated a dramatic decrease in cyclin B1 levels; subsequent analysis of the cyclin B1 promoter identified two sites important in IRF-4 binding and repression of cyclin B1 expression. Furthermore, IRF-4-mediated repression of cyclin B1 led to a significant decrease in CDC2 kinase activity in HTLV-1 infected T cells. IRF-4 expression in HTLV-1 infected T cells also downregulated other genes implicated in the mitotic checkpoint as well as genes involved in actin cytoskeletal rearrangement, DNA repair, apoptosis, metastasis and immune recognition. Several of the identified genes are dysregulated in ATL and may provide important mechanistic information concerning pathways critical to the emergence of ATL.	McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol & Immunol, Montreal, PQ H3T 1E2, Canada; Hamilton Reg Canc Ctr, Hamilton, ON L8V 1C3, Canada; NCI, NIH, Bethesda, MD 20892 USA	Lady Davis Institute; McGill University; McGill University; McMaster University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hiscott, J (corresponding author), McGill Univ, Lady Davis Inst Med Res, Terry Fox Mol Oncol Grp, 3755 Cote Ste Catherine, Montreal, PQ H3T 1E2, Canada.		Lin, Rongtuan/A-1442-2008	Lin, Rongtuan/0000-0002-2238-3503				Arthur WT, 2001, MOL BIOL CELL, V12, P2711, DOI 10.1091/mbc.12.9.2711; Bochkareva E, 2000, J BIOL CHEM, V275, P27332; Brass AL, 1996, GENE DEV, V10, P2335, DOI 10.1101/gad.10.18.2335; Brien TP, 1998, MODERN PATHOL, V11, P870; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Campbell MS, 2001, J CELL SCI, V114, P953; CANN AJ, 1996, FIELDS VIROLOGY; Cannavo G, 2001, BLOOD, V97, P1756, DOI 10.1182/blood.V97.6.1756; Carbone A, 2001, BLOOD, V97, P744, DOI 10.1182/blood.V97.3.744; Carbone A, 2000, BRIT J HAEMATOL, V111, P247, DOI 10.1046/j.1365-2141.2000.02329.x; Chapman HA, 1999, THROMB HAEMOSTASIS, V82, P291; Chatterjee D, 2000, ANTICANCER RES, V20, P4477; Chu ZL, 1999, J BIOL CHEM, V274, P15297, DOI 10.1074/jbc.274.22.15297; Clark PR, 2001, CELL STRESS CHAPERON, V6, P121, DOI 10.1379/1466-1268(2001)006<0121:TIHAAM>2.0.CO;2; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Dianov GL, 1999, BIOCHEMISTRY-US, V38, P11021, DOI 10.1021/bi9908890; Dib K, 2000, FRONT BIOSCI-LANDMRK, V5, pD438, DOI 10.2741/Pathology; Duell EJ, 2001, CANCER EPIDEM BIOMAR, V10, P217; Edlich RF, 2000, J EMERG MED, V18, P109, DOI 10.1016/S0736-4679(99)00173-0; EISENBEIS CF, 1995, GENE DEV, V9, P1377, DOI 10.1101/gad.9.11.1377; Gaidano G, 2000, LEUKEMIA, V14, P563, DOI 10.1038/sj.leu.2401748; Grumont RJ, 2000, J EXP MED, V191, P1281, DOI 10.1084/jem.191.8.1281; Gupta S, 1999, J EXP MED, V190, P1837, DOI 10.1084/jem.190.12.1837; Gupta S, 2001, J IMMUNOL, V166, P6104, DOI 10.4049/jimmunol.166.10.6104; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hapke S, 2001, MOL CELL BIOL, V21, P2118, DOI 10.1128/MCB.21.6.2118-2132.2001; Himmelmann A, 1997, BLOOD, V90, P3984, DOI 10.1182/blood.V90.10.3984; Hiscott J, 2001, J CLIN INVEST, V107, P143, DOI 10.1172/JCI11918; Hrdlickova R, 2001, MOL CELL BIOL, V21, P6369; Iida S, 1997, NAT GENET, V17, P226, DOI 10.1038/ng1097-226; Imaizumi Y, 2001, JPN J CANCER RES, V92, P1284, DOI 10.1111/j.1349-7006.2001.tb02151.x; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Itoyama A, 2001, BLOOD, V97, P3612, DOI 10.1182/blood.V97.11.3612; Iwanaga R, 2001, ONCOGENE, V20, P2055, DOI 10.1038/sj.onc.1204304; Jackman MR, 1997, CANCER SURV, V29, P47; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kaida A, 2000, ONCOGENE, V19, P827, DOI 10.1038/sj.onc.1203387; KAMADA N, 1992, CANCER RES, V52, P1481; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; KASAI T, 2001, J BIOL CHEM, V29, P29; Katula KS, 1997, CELL GROWTH DIFFER, V8, P811; Lacana E, 1997, J IMMUNOL, V158, P5129; Lemasson I, 2001, J BIOL CHEM, V276, P15720, DOI 10.1074/jbc.M100131200; Lemoine FJ, 2001, J BIOL CHEM, V276, P31851, DOI 10.1074/jbc.M105195200; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Lin RT, 1999, MOL CELL BIOL, V19, P959; Liu AX, 2001, P NATL ACAD SCI USA, V98, P6192, DOI 10.1073/pnas.111137198; Liu AX, 2001, MOL CELL BIOL, V21, P6906, DOI 10.1128/MCB.21.20.6906-6912.2001; Lo KWH, 1999, BIOCHEMISTRY-US, V38, P7498, DOI 10.1021/bi990034n; Louvet-Vallee S, 2000, BIOL CELL, V92, P305, DOI 10.1016/S0248-4900(00)01078-9; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Mamane Y, 2000, IMMUNITY, V12, P129, DOI 10.1016/S1074-7613(00)80166-1; Mamane Y, 2002, J INTERF CYTOK RES, V22, P135, DOI 10.1089/107999002753452746; Manjili MH, 2002, FRONT BIOSCI-LANDMRK, V7, pD43, DOI 10.2741/manjili; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Marecki S, 2000, CELL BIOCHEM BIOPHYS, V33, P127, DOI 10.1385/CBB:33:2:127; Mashal RD, 1996, CANCER RES, V56, P4159; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meraro D, 1999, J IMMUNOL, V163, P6468; Mittrucker HW, 1997, SCIENCE, V275, P540, DOI 10.1126/science.275.5299.540; Molinari M, 2000, CELL PROLIFERAT, V33, P261, DOI 10.1046/j.1365-2184.2000.00191.x; Muchardt C, 2001, ONCOGENE, V20, P3067, DOI 10.1038/sj.onc.1204331; Murakami H, 1999, VIRCHOWS ARCH, V434, P153, DOI 10.1007/s004280050319; Nagulapalli S, 1998, MOL CELL BIOL, V18, P4639, DOI 10.1128/MCB.18.8.4639; Neuveut C, 2002, FRONT BIOSCI-LANDMRK, V7, pD157, DOI 10.2741/neuveut; Ng T, 2001, EMBO J, V20, P2723, DOI 10.1093/emboj/20.11.2723; Nilsson I, 2000, Prog Cell Cycle Res, V4, P107; OConnor PM, 1997, CANCER SURV, V29, P151; Ohshima K, 1999, J PATHOL, V189, P539, DOI 10.1002/(SICI)1096-9896(199912)189:4&lt;539::AID-PATH465&gt;3.0.CO;2-T; Pawlak G, 2001, CURR OPIN GENET DEV, V11, P41, DOI 10.1016/S0959-437X(00)00154-4; Pise-Masison CA, 2000, MOL CELL BIOL, V20, P3377, DOI 10.1128/MCB.20.10.3377-3386.2000; Pise-Masison CA, 1998, J VIROL, V72, P1165, DOI 10.1128/JVI.72.2.1165-1170.1998; Pise-Masison CA, 2000, AIDS RES HUM RETROV, V16, P1669, DOI 10.1089/08892220050193128; Porter LA, 2000, BLOOD, V95, P2645; Poullet P, 2001, J BIOL CHEM, V276, P37686, DOI 10.1074/jbc.M106175200; Rosenbauer F, 1999, BLOOD, V94, P4274, DOI 10.1182/blood.V94.12.4274.424k05_4274_4281; SADAMORI N, 1991, CANCER GENET CYTOGEN, V51, P131, DOI 10.1016/0165-4608(91)90019-Q; SADAMORI N, 1991, ACTA HAEMATOL-BASEL, V86, P14; Satoh S, 2001, J BIOL CHEM, V276, P39290, DOI 10.1074/jbc.M107026200; Schmidt M, 2000, J CLIN ONCOL, V18, P3331, DOI 10.1200/JCO.2000.18.19.3331; Seasholtz TM, 1999, MOL PHARMACOL, V55, P949, DOI 10.1124/mol.55.6.949; Senderowicz AM, 2000, ONCOGENE, V19, P6600, DOI 10.1038/sj.onc.1204085; Senderowicz AM, 2000, JNCI-J NATL CANCER I, V92, P376, DOI 10.1093/jnci/92.5.376; Sharma S, 2000, AIDS RES HUM RETROV, V16, P1613, DOI 10.1089/08892220050193047; SHARMA S, 2002, IN PRESS J IMMUNOL; Song YH, 2000, J CELL BIOCHEM, V80, P229; Soria JC, 2000, CANCER RES, V60, P4000; Sun SC, 2000, AIDS RES HUM RETROV, V16, P1591, DOI 10.1089/08892220050193001; Suzuki T, 1999, VIROLOGY, V259, P384, DOI 10.1006/viro.1999.9760; Suzuki T, 1996, EMBO J, V15, P1607, DOI 10.1002/j.1460-2075.1996.tb00505.x; Tanaka Y, 1998, BLOOD, V91, P3909; Taylor WR, 1999, MOL BIOL CELL, V10, P3607, DOI 10.1091/mbc.10.11.3607; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Tirnauer JS, 2000, J CELL BIOL, V149, P761, DOI 10.1083/jcb.149.4.761; Tsukasaki K, 2001, BLOOD, V97, P3875, DOI 10.1182/blood.V97.12.3875; Tsukasaki K, 2000, BEST PRACT RES CL HA, V13, P231, DOI 10.1053/beha.1999.0070; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; Wang IK, 2000, PHARMACOL TOXICOL, V86, P83, DOI 10.1034/j.1600-0773.2000.d01-16.x; Weinert T, 1997, SCIENCE, V277, P1450, DOI 10.1126/science.277.5331.1450; Xiao GT, 2000, ONCOGENE, V19, P5198, DOI 10.1038/sj.onc.1203894; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamagata T, 1996, MOL CELL BIOL, V16, P1283; Yao J, 2000, FRONT BIOSCI-LANDMRK, V5, pD138, DOI 10.2741/Yao; Yoshida M, 2001, ANNU REV IMMUNOL, V19, P475, DOI 10.1146/annurev.immunol.19.1.475	108	23	23	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6751	6765		10.1038/sj.onc.1205843	http://dx.doi.org/10.1038/sj.onc.1205843			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360402				2022-12-25	WOS:000178315800005
J	Pene, F; Claessens, YE; Muller, O; Viguie, F; Mayeux, P; Dreyfus, F; Lacombe, C; Bouscary, D				Pene, F; Claessens, YE; Muller, O; Viguie, F; Mayeux, P; Dreyfus, F; Lacombe, C; Bouscary, D			Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma	ONCOGENE			English	Article						multiple myeloma; phosphatidylinositol 3-kinase; P70-S6-kinase; p27(Kip1); Skp2	FORKHEAD TRANSCRIPTION FACTOR; DEPENDENT KINASE INHIBITOR; CELL-CYCLE PROGRESSION; GROWTH-FACTOR-I; CONSTITUTIVE ACTIVATION; FACTOR FKHR-L1; TUMOR-GROWTH; S6 KINASE; SURVIVAL; EXPRESSION	Multiple myeloma (MM) is a plasma cell malignancy preliminary localized in the bone marrow and characterized by its capacity to disseminate. IL-6 and IGF-1 have been shown to mediate proliferative and anti-apoptotic signals in plasmocytes. However, in primary plasma-cell leukemia (PCL) and in end-stage aggressive extramedullar disease, the cytokine requirement for both effects may be not mandatory. This suggests that constitutive activation of signaling pathways occurs. One of the signaling pathways whose deregulation may play an oncogenic role in MM is the phosphatidylinositol 3-kinase (PI 3-K) pathway. In human growth factor-independent MM cell lines OPM2 and RPMI8226, we show that the PI 3-K inhibitors LY294002 and Wortmannin strongly inhibited cell proliferation, whereas inhibition of the mammalian Target Of Rapamycin (mTOR)/P70-S6-kinase (P70(S6K)) pathway with rapamycin or of the Mitogen-Activated Protein Kinase (MAPK) pathway with PD98059 had minimal effect on proliferation. In both cell lines, constitutive activation of the PI 3-K/Akt/FKHRL-1, mTOR/P70(S6K) and MAPK pathways was detected. LY294002 inhibited phosphorylation of Akt, FKHRL-1 and P70(S6K) but had no effect on ERK1/2 phosphorylation, indicating that the PI 3-K and MAPK pathways are independent. IGF-1 but not IL-6 increased phosphorylation of Akt, FKHRL-1 and P70(S6K). Purified plasmocytes from four patients with MM and two patients with primary PCL were studied. In three of them including the two patients with PCL, constitutive phosphorylation of Akt, FKHRL-1 and P70(S6K) was present, inhibited by LY294002 and enhanced by IGF-1. In these patients with constitutive Akt activation, normal PTEN expression was detected. PI 3-K inhibition induced caspase-dependent apoptosis as confirmed by inhibition with the large spectrum caspase inhibitor Z-VAD-FMK and cleavage of pro-caspase-3. Both cell lines spontaneously expressed Skp2 and cyclin D1 proteins at high levels but no p27(Kip1) protein. In the presence of LY294002, cell-cycle arrest in G0/G1 was observed, p27(Kip1) protein expression was up-regulated whereas the expression of both Skp2 and cyclin D1 dramatically diminished. PI 3-K-dependent GSK-3alpha/beta constitutive phosphorylation was also detected in OPM2 cells that may contribute to high cyclin D1 expression. Overall, our results suggest that PI 3-K has a major role in the control of proliferation and apoptosis of growth factor-independent MM cell lines. Most of the biological effects of PI 3-K activation in these cell lines may be mediated by the opposite modulation of p27(Kip1) and Skp2 protein expression. Moreover, constitutive activation of this pathway is a frequent event in the biology of MM in vivo and may be more frequently observed in PCL.	Univ Paris 05, CNRS, UMR 8104, IFR 116,INSERM,U567,Inst Cochin,Dept Hematol, F-75014 Paris, France; Hop Cochin, APHP, Serv Hematol Clin & Biol, Paris, France; Hop Hotel Dieu, APHP, Lab Cytogenet, F-75181 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Hotel-Dieu - APHP; UDICE-French Research Universities; Universite Paris Cite	Bouscary, D (corresponding author), Univ Paris 05, CNRS, UMR 8104, IFR 116,INSERM,U567,Inst Cochin,Dept Hematol, 27 Rue Faubourg St Jacques, F-75014 Paris, France.			Bouscary, Didier/0000-0003-3654-5064; Pene, Frederic/0000-0003-3639-3849				Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Aoki M, 2001, P NATL ACAD SCI USA, V98, P136, DOI 10.1073/pnas.011528498; Barata JT, 2001, BLOOD, V98, P1524, DOI 10.1182/blood.V98.5.1524; Brennan P, 1999, MOL CELL BIOL, V19, P4729; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chang HW, 1997, SCIENCE, V276, P1848, DOI 10.1126/science.276.5320.1848; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Feng LX, 2000, J BIOL CHEM, V275, P25572, DOI 10.1074/jbc.M002218200; Ferlin M, 2000, BRIT J HAEMATOL, V111, P626, DOI 10.1046/j.1365-2141.2000.02364.x; FREUND GG, 1993, J IMMUNOL, V151, P1811; Ge NL, 2000, BLOOD, V96, P2856; Ge NL, 2000, ONCOGENE, V19, P4091, DOI 10.1038/sj.onc.1203801; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hosoi H, 1999, CANCER RES, V59, P886; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Hyun T, 2000, BLOOD, V96, P3560, DOI 10.1182/blood.V96.10.3560.h8003560_3560_3568; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KLEIN B, 1995, BLOOD, V85, P863, DOI 10.1182/blood.V85.4.863.bloodjournal854863; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; Latres E, 2001, P NATL ACAD SCI USA, V98, P2515, DOI 10.1073/pnas.041475098; Li WQ, 2000, CANCER RES, V60, P3909; Mahalingam M, 1996, MOL CELL BIOL, V16, P405; Mamillapalli R, 2001, CURR BIOL, V11, P263, DOI 10.1016/S0960-9822(01)00065-3; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nguyen H, 1999, MOL CELL BIOL, V19, P1190; Ogata A, 1997, J IMMUNOL, V159, P2212; Parada Y, 2001, J BIOL CHEM, V276, P23572, DOI 10.1074/jbc.M101885200; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Puthier D, 1999, EUR J IMMUNOL, V29, P3945, DOI 10.1002/(SICI)1521-4141(199912)29:12<3945::AID-IMMU3945>3.0.CO;2-O; Shayesteh L, 1999, NAT GENET, V21, P99, DOI 10.1038/5042; SHI YF, 1995, CANCER RES, V55, P1982; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Takuwa N, 1999, MOL CELL BIOL, V19, P1346; Tinhofer I, 2000, BLOOD, V95, P610, DOI 10.1182/blood.V95.2.610; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Tsvetkov LM, 1999, CURR BIOL, V9, P661, DOI 10.1016/S0960-9822(99)80290-5; Tu YP, 2000, CANCER RES, V60, P6763	48	272	309	1	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6587	6597		10.1038/sj.onc.1205923	http://dx.doi.org/10.1038/sj.onc.1205923			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242656				2022-12-25	WOS:000178202300004
J	Blanco, R; Carrasco, L; Ventoso, I				Blanco, R; Carrasco, L; Ventoso, I			Cell killing by HIV-1 protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SACCHAROMYCES-CEREVISIAE; RETROVIRAL PROTEINASES; VIRAL INFECTIVITY; KAPPA-B; T-CELLS; APOPTOSIS; MEMBRANE; TYPE-1; YEAST	The human immunodeficiency virus protease (HIV-1 PR) was expressed both in the yeast Saccharomyces cerevisiae and in mammalian cells. Inducible expression of HIV-1 PR arrested yeast growth, which was followed by cell lysis. The lytic phenotype included loss of plasma membrane integrity and cell wall breakage leading to the release of cell content to the medium. Given that neither poliovirus 2A protease nor 2BC protein, both being highly toxic for S. cerevisiae, were able to produce similar effects, it seems that this lytic phenotype is specific of HIV-1 PR. Drastic alterations in membrane permeability preceded the lysis in yeast expressing HIV-1 PR. Cell killing and lysis provoked by HIV-1 PR were also observed in mammalian cells. Thus, COS7 cells expressing the protease showed increased plasma membrane permeability and underwent lysis by necrosis with no signs of apoptosis. Strikingly, the morphological alterations induced by HIV-1 PR in yeast and mammalian cells were similar in many aspects. To our knowledge, this is the first report of a viral protein with such an activity. These findings contribute to the present knowledge on HIV-1-induced cytopathogenesis.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Bioquim & Biol Celular, E-28049 Madrid, Spain; Univ Autonoma Madrid, Ctr Biol Mol Severo Ochoa, CSIC, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Ventoso, I (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Bioquim & Biol Celular, E-28049 Madrid, Spain.	iventoso@cnb.uam.es	Ventoso, Iván/N-4018-2014; Carrasco, Luis/E-2435-2012; Carrasco, Luis/H-3001-2017; Blanco, Raquel/M-4290-2015	Ventoso, Iván/0000-0001-7887-3520; Carrasco, Luis/0000-0003-3833-8835; Blanco, Raquel/0000-0001-5477-5379				Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; Andrews PD, 2000, J CELL SCI, V113, P507; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; BALDARI C, 1985, GENE, V35, P27, DOI 10.1016/0378-1119(85)90154-4; Barco A, 2000, VIROLOGY, V266, P352, DOI 10.1006/viro.1999.0043; BARCO A, 1995, FEBS LETT, V371, P4, DOI 10.1016/0014-5793(95)00841-V; BARCO A, 1995, GENE, V156, P19, DOI 10.1016/0378-1119(94)00872-P; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; BAUM EZ, 1990, P NATL ACAD SCI USA, V87, P5573, DOI 10.1073/pnas.87.14.5573; BONNET D, 1990, J VIROL, V64, P5628, DOI 10.1128/JVI.64.11.5628-5632.1990; Cao J, 1996, J VIROL, V70, P1340, DOI 10.1128/JVI.70.3.1340-1354.1996; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; CLOYD MW, 1991, VIROLOGY, V181, P500, DOI 10.1016/0042-6822(91)90882-C; DELAFUENTE JM, 1992, YEAST, V8, P39, DOI 10.1002/yea.320080104; FAUCI AS, 1993, SCIENCE, V262, P1011, DOI 10.1126/science.8235617; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; GARCIA JV, 1991, NATURE, V350, P508, DOI 10.1038/350508a0; Gu JR, 1997, MOL CELL BIOL, V17, P4033, DOI 10.1128/MCB.17.7.4033; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; JAKS T, 1989, NATURE, V331, P280; KAPLAN AH, 1991, P NATL ACAD SCI USA, V88, P4528, DOI 10.1073/pnas.88.10.4528; KAPLAN AH, 1994, J VIROL, V68, P6782, DOI 10.1128/JVI.68.10.6782-6786.1994; KOHL NE, 1988, P NATL ACAD SCI USA, V85, P4686, DOI 10.1073/pnas.85.13.4686; Kolesnitchenko V, 1997, J VIROL, V71, P9753, DOI 10.1128/JVI.71.12.9753-9763.1997; KONVALINKA J, 1995, J VIROL, V69, P7180, DOI 10.1128/JVI.69.11.7180-7186.1995; KRAUSSLICH HG, 1991, P NATL ACAD SCI USA, V88, P3213, DOI 10.1073/pnas.88.8.3213; Labonte JA, 2000, J VIROL, V74, P10690, DOI 10.1128/JVI.74.22.10690-10698.2000; LEVY JA, 1993, MICROBIOL REV, V57, P183, DOI 10.1128/MMBR.57.1.183-289.1993; LI CJ, 1995, SCIENCE, V268, P429, DOI 10.1126/science.7716549; MACREADI IG, 1995, P NATL ACAD SCI USA, V74, P4835; McCune JM, 2001, NATURE, V410, P974, DOI 10.1038/35073648; MEYAARD L, 1992, SCIENCE, V257, P217, DOI 10.1126/science.1352911; OROSZLAN S, 1990, CURR TOP MICROBIOL, V157, P153; Plymale DR, 1999, AIDS, V13, P1827, DOI 10.1097/00002030-199910010-00004; RIVIERE Y, 1991, NATURE, V350, P625, DOI 10.1038/350625a0; Sambrook KJ, 1989, MOL CLONING LAB MANU; SCHNEIDER J, 1988, CELL, V54, P363, DOI 10.1016/0092-8674(88)90199-7; Shimizu S, 1996, ONCOGENE, V12, P2045; SHOEMAN RL, 1990, P NATL ACAD SCI USA, V87, P6336, DOI 10.1073/pnas.87.16.6336; Shoeman RL, 2001, MOL BIOL CELL, V12, P143, DOI 10.1091/mbc.12.1.143; SODROSKI J, 1986, NATURE, V322, P3105; Strack PR, 1996, P NATL ACAD SCI USA, V93, P9571, DOI 10.1073/pnas.93.18.9571; TAKEO K, 1989, FEMS MICROBIOL LETT, V61, P297, DOI 10.1016/0378-1097(89)90214-0; TERAI C, 1991, J CLIN INVEST, V87, P1710, DOI 10.1172/JCI115188; TOMASSELLI AG, 1991, J BIOL CHEM, V266, P14548; Ventoso I, 2001, P NATL ACAD SCI USA, V98, P12966, DOI 10.1073/pnas.231343498; Vogt VM, 1996, CURR TOP MICROBIOL, V214, P95; Voss TG, 1996, J VIROL, V70, P5447, DOI 10.1128/JVI.70.8.5447-5454.1996; WALLIN M, 1990, J GEN VIROL, V71, P1985, DOI 10.1099/0022-1317-71-9-1985; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	52	56	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JAN 10	2003	278	2					1086	1093		10.1074/jbc.M205636200	http://dx.doi.org/10.1074/jbc.M205636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	634CF	12370191	hybrid			2022-12-25	WOS:000180321900052
J	Zhang, HB; Howard, EM; Roepe, PD				Zhang, HB; Howard, EM; Roepe, PD			Analysis of the antimalarial drug resistance protein Pfcrt expressed in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARASITE PLASMODIUM-FALCIPARUM; DIGESTIVE VACUOLAR PH; CODON USAGE PATTERNS; HUMAN MDR-1 PROTEIN; SACCHAROMYCES-CEREVISIAE; HETEROLOGOUS EXPRESSION; ESCHERICHIA-COLI; MALARIA PARASITE; PICHIA-PASTORIS; DIHYDROFOLATE-REDUCTASE	Mutations in the novel membrane protein Pfcrt were recently found to be essential for chloroquine resistance (CQR) in Plasmodium falciparum, the parasite responsible for most lethal human malaria (Fidock, D. A., Nomura, T., Talley, A. K., Cooper, R. A., Dzekunov, S. M., Ferdig, M. T., Ursos, L. M., Sidhu, A. B., Naude, B., Deitsch, K. W., Su, X. Z., Wootton, J. C., Roepe, P. D., and Wellems, T. E. (2000) Mol. Cell 6, 861-871). Pfcrt is localized to the digestive vacuolar membrane of the intraerythrocytic parasite and may function as a transporter. Study of this putative transport function would be greatly assisted by overexpression in yeast followed by characterization of membrane vesicles. Unfortunately, the very high AT content of malarial genes precludes efficient heterologous expression. Thus, we back-translated Pfcrt to design idealized genes with preferred yeast codons, no long poly(A) sequences, and minimal stem-loop structure. We synthesized a designed gene with a two-step PCR method, fused this to N- and C-terminal sequences to aid membrane insertion and purification, and now report efficient expression of wild type and mutant Pfcrt proteins in the plasma membrane of Saccharomyces cerevisiae and Pichia pastoris yeast. To our knowledge, this is the first successful expression of a full-length malarial parasite integral membrane protein in yeast. Purified membranes and inside-out plasma membrane vesicle preparations were used to analyze wild type versus CQR-conferring mutant Pfcrt function, which may include effects on H+ transport (Dzekunov, S., Ursos, L. M. B., and Roepe, P. D. (2000) Mol. Biochem. Parasitol. 110, 107-124), and to perfect a rapid purification of biotinylated Pfcrt. These data expand on the role of Pfcrt in conferring CQR and define a productive route for analysis of important P. falciparum transport proteins and membrane associated vaccine candidates.	Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Chem, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Program Tumor Biol, Washington, DC 20007 USA	Georgetown University; Georgetown University; Georgetown University	Roepe, PD (corresponding author), Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Dept Chem, 37th & O St, Washington, DC 20007 USA.	roepep@georgetown.edu			NIAID NIH HHS [AI 45957] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI045957] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersen B, 1998, PROTEIN EXPRES PURIF, V13, P111, DOI 10.1006/prep.1998.0862; BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Bray PG, 1999, J CELL BIOL, V145, P363, DOI 10.1083/jcb.145.2.363; Carter NS, 2001, TRENDS PARASITOL, V17, P142, DOI 10.1016/S1471-4922(00)01806-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; Doring F, 1998, MOL MEMBR BIOL, V15, P79, DOI 10.3109/09687689809027522; Duvel K, 1999, NUCLEIC ACIDS RES, V27, P4751, DOI 10.1093/nar/27.24.4751; Dzekunov SM, 2000, MOL BIOCHEM PARASIT, V110, P107, DOI 10.1016/S0166-6851(00)00261-9; EVANS GL, 1995, J BIOENERG BIOMEMBR, V27, P43, DOI 10.1007/BF02110330; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; Fidock DA, 2000, MOL CELL, V6, P861, DOI 10.1016/S1097-2765(05)00077-8; Fritz F, 1999, BIOCHEMISTRY-US, V38, P4214, DOI 10.1021/bi981929n; Gardner MJ, 1999, CURR OPIN GENET DEV, V9, P704, DOI 10.1016/S0959-437X(99)00032-5; Glerum DM, 1997, J BIOL CHEM, V272, P19088, DOI 10.1074/jbc.272.30.19088; GOFFEAU A, 1988, METHOD ENZYMOL, V157, P528; Graber JH, 1999, NUCLEIC ACIDS RES, V27, P888, DOI 10.1093/nar/27.3.888; GRIBSKOV M, 1984, NUCLEIC ACIDS RES, V12, P539, DOI 10.1093/nar/12.1Part2.539; Guo ZJ, 1996, TRENDS BIOCHEM SCI, V21, P477, DOI 10.1016/S0968-0004(96)10057-8; Gupta SS, 2000, FEBS LETT, V481, P77, DOI 10.1016/S0014-5793(00)01977-3; KARCZ SR, 1994, MOL BIOCHEM PARASIT, V65, P123, DOI 10.1016/0166-6851(94)90121-X; Kiser GL, 2001, ARCH BIOCHEM BIOPHYS, V390, P195, DOI 10.1006/abbi.2001.2385; KUCHLER K, 1992, P NATL ACAD SCI USA, V89, P2302, DOI 10.1073/pnas.89.6.2302; Lerner-Marmarosh N, 1999, J BIOL CHEM, V274, P34711, DOI 10.1074/jbc.274.49.34711; MARTINEY JA, 1995, J BIOL CHEM, V270, P22393, DOI 10.1074/jbc.270.38.22393; McIntosh MT, 2001, MOL BIOCHEM PARASIT, V114, P183, DOI 10.1016/S0166-6851(01)00251-1; MENENDEZ A, 1995, ANAL BIOCHEM, V230, P308, DOI 10.1006/abio.1995.1479; Milek RLB, 2000, VACCINE, V18, P1402, DOI 10.1016/S0264-410X(99)00392-8; Musto H, 1999, J MOL EVOL, V49, P27, DOI 10.1007/PL00006531; MUSTO H, 1995, GENE, V152, P127, DOI 10.1016/0378-1119(94)00708-Z; OHSUMI Y, 1981, J BIOL CHEM, V256, P2079; Pan WQ, 1999, NUCLEIC ACIDS RES, V27, P1094, DOI 10.1093/nar/27.4.1094; Prapunwattana P, 1996, MOL BIOCHEM PARASIT, V83, P93, DOI 10.1016/S0166-6851(96)02756-9; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; ROMANOS MA, 1992, YEAST, V8, P423, DOI 10.1002/yea.320080602; Santai CT, 1999, BIOCHEMISTRY-US, V38, P4227, DOI 10.1021/bi981930m; SAUL A, 1988, MOL BIOCHEM PARASIT, V27, P35, DOI 10.1016/0166-6851(88)90022-9; SHARP PM, 1988, NUCLEIC ACIDS RES, V16, P8207, DOI 10.1093/nar/16.17.8207; SIRAWARAPORN W, 1990, BIOCHEMISTRY-US, V29, P10779, DOI 10.1021/bi00500a009; STEMMER WPC, 1995, GENE, V164, P49, DOI 10.1016/0378-1119(95)00511-4; Ursos LMB, 2002, MED RES REV, V22, P465, DOI 10.1002/med.10016; Ursos LMB, 2000, MOL BIOCHEM PARASIT, V110, P125, DOI 10.1016/S0166-6851(00)00262-0; van Helden J, 2000, NUCLEIC ACIDS RES, V28, P1000; Wang HC, 2001, MOL BIOL EVOL, V18, P792, DOI 10.1093/oxfordjournals.molbev.a003861; WEBER JL, 1987, GENE, V52, P103, DOI 10.1016/0378-1119(87)90399-4; Weiss HM, 1998, BIOCHEM J, V330, P1137, DOI 10.1042/bj3301137; Withers-Martinez C, 1999, PROTEIN ENG, V12, P1113, DOI 10.1093/protein/12.12.1113; Woodrow CJ, 2000, P NATL ACAD SCI USA, V97, P9931, DOI 10.1073/pnas.170153097; Yelin R, 2001, BBA-BIOMEMBRANES, V1510, P426, DOI 10.1016/S0005-2736(00)00374-6	49	130	132	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49767	49775		10.1074/jbc.M204005200	http://dx.doi.org/10.1074/jbc.M204005200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12351620	hybrid			2022-12-25	WOS:000180028900089
J	Soejima, K; Yuguchi, M; Mizuguchi, J; Tomokiyo, K; Nakashima, T; Nakagaki, T; Iwanaga, S				Soejima, K; Yuguchi, M; Mizuguchi, J; Tomokiyo, K; Nakashima, T; Nakagaki, T; Iwanaga, S			The 99 and 170 loop-modified factor VIIa mutants show enhanced catalytic activity without tissue factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION-FACTOR VIIA; ACTIVATED PROTEIN-C; X-RAY STRUCTURE; BLOOD-COAGULATION; FACTOR-IX; CRYSTAL-STRUCTURE; ENZYMATIC-ACTIVITY; SITE; SUBSTRATE; COMPLEX	To elucidate the functions of the surface loops of VIIa, we prepared two mutants, VII-30 and VII-39. The VII-30 mutant had all of the residues in the 99 loop replaced with those of trypsin. In the VII-39 mutant, both the 99 and 170 loops were replaced with those of trypsin. The k(cat)/K-m value for hydrolysis of the chromogenic peptidyl substrate S-2288 by VIIa-30 (103 mM(-1)s(-1)) was 3-fold higher than that of wild-type VIIa (30.3 mM(-1) s(-1)) in the presence of soluble tissue factor (sTF). This enhancement was due to a decrease in the K-m value but not to an increase in the k(cat) value. On the other hand, the k(cat)/K-m value for S-2288 hydrolysis by VIIa-39 (17.9 mM(-1) s(-1)) was 18-fold higher than that of wild-type (1.0 mM(-1) s(-1)) in the absence of sTF, and the value was almost the same as that of wild-type measured in the presence of sTF. This enhancement was due to not only a decrease in the K-m value but also to an increase in the k(cat) value. These results were in good agreement with their susceptibilities to a subsite 1-directed serine protease inhibitor. In our previous paper (Soejima, K., Mizuguchi, J., Yuguchi, M., Nakagaki, T., Higashi, S., and Iwanaga, S. (2001) J. Biol. Chem. 276, 17229 -17235), the replacement of the 170 loop of VIIa with that of trypsin induced a 10-fold enhancement of the k(cat) value for S-2288 hydrolysis as compared with that of wild-type VIIa in the absence of sTF. These results suggested that the 99 and the 170 loop structures of VIIa independently affect the K-m and k(cat) values, respectively. Furthermore, we studied the effect of mutations on proteolytic activity toward S-alkylated lysozyme as a macromolecular substrate and the activation of natural macromolecular substrate factor X.	Chemoserotherapeut Res Inst, Blood Prod Res Dept, Kumamoto 8691298, Japan; Chemoserotherapeut Res Inst, Res Dept 1, Kumamoto 8691298, Japan		Mizuguchi, J (corresponding author), Chemoserotherapeut Res Inst, Blood Prod Res Dept, Kumamoto 8691298, Japan.							Bajaj SP, 2001, J BIOL CHEM, V276, P16302, DOI 10.1074/jbc.M011680200; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; Bode W, 1997, THROMB HAEMOSTASIS, V78, P501; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; BRANDSTETTER H, 1995, P NATL ACAD SCI USA, V92, P9796, DOI 10.1073/pnas.92.21.9796; Brandstetter H, 1996, J BIOL CHEM, V271, P29988, DOI 10.1074/jbc.271.47.29988; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Dennis MS, 2000, NATURE, V404, P465, DOI 10.1038/35006574; Eigenbrot C, 2002, TRENDS CARDIOVAS MED, V12, P19, DOI 10.1016/S1050-1738(01)00139-6; Eigenbrot C, 2001, STRUCTURE, V9, P627, DOI 10.1016/S0969-2126(01)00624-4; FERNLUND P, 1975, J BIOL CHEM, V250, P6125; HAGEN FS, 1986, P NATL ACAD SCI USA, V83, P2412, DOI 10.1073/pnas.83.8.2412; Higashi S, 1997, J BIOL CHEM, V272, P25724, DOI 10.1074/jbc.272.41.25724; HIGASHI S, 1992, J BIOL CHEM, V267, P17990; HIGASHI S, 1994, J BIOL CHEM, V269, P18891; Higashi S, 1996, J BIOL CHEM, V271, P26569, DOI 10.1074/jbc.271.43.26569; Hopfner KP, 1998, P NATL ACAD SCI USA, V95, P9813, DOI 10.1073/pnas.95.17.9813; Hopfner KP, 1997, EMBO J, V16, P6626, DOI 10.1093/emboj/16.22.6626; Kamata K, 1998, P NATL ACAD SCI USA, V95, P6630, DOI 10.1073/pnas.95.12.6630; Kemball-Cook G, 1999, J STRUCT BIOL, V127, P213, DOI 10.1006/jsbi.1999.4158; Kirchhofer D, 1997, TRENDS CARDIOVAS MED, V7, P316, DOI 10.1016/S1050-1738(97)00094-7; Kolkman JA, 2000, BIOCHEMISTRY-US, V39, P7398, DOI 10.1021/bi992735q; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; LAWSON JH, 1992, J BIOL CHEM, V267, P4834; Mather T, 1996, EMBO J, V15, P6822, DOI 10.1002/j.1460-2075.1996.tb01073.x; Mertens K, 1999, THROMB HAEMOSTASIS, V82, P209; MILETICH JP, 1981, METHOD ENZYMOL, V80, P221; NAKAGAKI T, 1991, BIOCHEMISTRY-US, V30, P10819, DOI 10.1021/bi00109a001; OKAZAKI K, 1985, ANAL BIOCHEM, V145, P87, DOI 10.1016/0003-2697(85)90330-6; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; Pereira PJB, 1998, NATURE, V392, P306, DOI 10.1038/32703; Perona JJ, 1997, J BIOL CHEM, V272, P29987, DOI 10.1074/jbc.272.48.29987; Persson E, 2001, J BIOL CHEM, V276, P29195, DOI 10.1074/jbc.M102187200; Persson E, 2001, P NATL ACAD SCI USA, V98, P13583, DOI 10.1073/pnas.241339498; Petrovan RJ, 2000, BIOCHEMISTRY-US, V39, P14457, DOI 10.1021/bi0009486; Petrovan RJ, 2001, J BIOL CHEM, V276, P6616, DOI 10.1074/jbc.M004726200; Pike ACW, 1999, P NATL ACAD SCI USA, V96, P8925, DOI 10.1073/pnas.96.16.8925; Rezaie AR, 1996, J BIOL CHEM, V271, P23807, DOI 10.1074/jbc.271.39.23807; RUF W, 1991, J BIOL CHEM, V266, P2158; SHIGEMATSU Y, 1992, J BIOL CHEM, V267, P21329; Soejima K, 2001, J BIOL CHEM, V276, P17229, DOI 10.1074/jbc.M009206200; Sorensen BB, 1997, J BIOL CHEM, V272, P11863, DOI 10.1074/jbc.272.18.11863; WILDGOOSE P, 1989, BLOOD, V73, P1888; Zhang E, 1999, J MOL BIOL, V285, P2089, DOI 10.1006/jmbi.1998.2452	44	18	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49027	49035		10.1074/jbc.M203091200	http://dx.doi.org/10.1074/jbc.M203091200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12364340	hybrid			2022-12-25	WOS:000179789600136
J	Beinker, P; Schlee, S; Groemping, Y; Seidel, R; Reinstein, J				Beinker, P; Schlee, S; Groemping, Y; Seidel, R; Reinstein, J			The N terminus of C1pB from Thermus thermophilus is not essential for the chaperone activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLECULAR CHAPERONES; TRANSFER-RNA; PROTEIN; CLPB; DNAK; DOMAINS; BINDING; SYSTEM; ATPASE	ClpB from Thermus thermophilus belongs to the Clp/Hsp100 protein family and reactivates protein aggregates in cooperation with the DnaK chaperone system. The mechanism of protein reactivation and interaction with the DnaK system remains unclear. ClpB possesses two nucleotide binding domains, which are essential for function and show a complex allosteric behavior. The role of the N-terminal domain that precedes the first nucleotide binding domain is largely unknown. We purified and characterized an N-terminal shortened ClpB variant (ClpBDeltaN; amino acids 140-854), which remained active in refolding assays with three different substrate proteins. In addition the N-terminal truncation did not significantly change the nucleotide binding affinities, the nucleotide-dependent oligomerization, and the allosteric behavior of the protein. In contrast casein binding and stimulation of the ATPase activity by kappa-casein were affected. These results suggest that the N-terminal domain is not essential for the chaperone function, does not influence the binding of nucleotides, and is not involved in the formation of intermolecular contacts. It contributes to the casein binding site of ClpB, but other substrate proteins do not necessarily interact with the N terminus. This indicates a substantial difference in the binding mode of kappa-casein that is often used as model substrate for ClpB and other possibly more suitable substrate proteins.	Max Planck Inst Mol Physiol, Phys Biochem Abt, D-44227 Dortmund, Germany	Max Planck Society	Reinstein, J (corresponding author), Max Planck Inst Mol Physiol, Phys Biochem Abt, Otto Hahn Str 11, D-44227 Dortmund, Germany.	joachim.reinstein@mpi-dortmund.mpg.de						Barnett ME, 2000, J BIOL CHEM, V275, P37565, DOI 10.1074/jbc.M005211200; Ben-Zvi AP, 2001, J STRUCT BIOL, V135, P84, DOI 10.1006/jsbi.2001.4352; BERGMEYER HU, 1962, METHODEN ENZYMATI ED, P573; Bochtler M, 2000, NATURE, V403, P800, DOI 10.1038/35001629; Cashikar AG, 2002, MOL CELL, V9, P751, DOI 10.1016/S1097-2765(02)00499-9; Clarke AK, 2000, J BACTERIOL, V182, P7092, DOI 10.1128/JB.182.24.7092-7096.2000; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Dougan DA, 2002, MOL CELL, V9, P673, DOI 10.1016/S1097-2765(02)00485-9; EHRESMAN.B, 1973, ANAL BIOCHEM, V54, P454, DOI 10.1016/0003-2697(73)90374-6; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Groemping Y, 2001, J MOL BIOL, V305, P1173, DOI 10.1006/jmbi.2000.4373; HIRATSUKA T, 1983, BIOCHIM BIOPHYS ACTA, V742, P496, DOI 10.1016/0167-4838(83)90267-4; Klostermeier D, 1999, J MOL BIOL, V287, P511, DOI 10.1006/jmbi.1999.2636; Lenzen CU, 1998, CELL, V94, P525, DOI 10.1016/S0092-8674(00)81593-7; Liu ZH, 2002, J MOL BIOL, V321, P111, DOI 10.1016/S0022-2836(02)00591-0; Lo JH, 2001, PROTEIN SCI, V10, P551, DOI 10.1110/ps.41401; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; PARK SK, 1993, J BIOL CHEM, V268, P20170; PARSELL DA, 1994, J BIOL CHEM, V269, P4480; REINSTEIN J, 1990, BIOCHEMISTRY-US, V29, P7440, DOI 10.1021/bi00484a013; Schlee S, 2001, J MOL BIOL, V306, P889, DOI 10.1006/jmbi.2001.4455; SEOL JH, 1994, J BIOL CHEM, V269, P29468; Singh SK, 2001, J BIOL CHEM, V276, P29420, DOI 10.1074/jbc.M103489200; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Sousa MC, 2000, CELL, V103, P633, DOI 10.1016/S0092-8674(00)00166-5; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; Tek V, 2002, PROTEIN SCI, V11, P1192, DOI 10.1110/ps.4860102; Thrall SH, 1996, BIOCHEMISTRY-US, V35, P4609, DOI 10.1021/bi9526387; Watanabe YH, 2002, J BIOL CHEM, V277, P5804, DOI 10.1074/jbc.M109349200; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	33	69	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47160	47166		10.1074/jbc.M207853200	http://dx.doi.org/10.1074/jbc.M207853200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351638	hybrid			2022-12-25	WOS:000179663700042
J	Chung, KT; Shen, Y; Hendershot, LM				Chung, KT; Shen, Y; Hendershot, LM			BAP, a mammalian BiP-associated protein, is a nucleotide exchange factor that regulates the ATPase activity of BiP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP70 CHAPERONE ACTIVITY; IMMUNOGLOBULIN HEAVY-CHAIN; ENDOPLASMIC-RETICULUM; DNAJ HOMOLOG; ER STRESS; IN-VIVO; MOLECULAR CHAPERONES; NEGATIVE REGULATOR; SECRETORY PATHWAY; BINDING-PROTEIN	We identified a mammalian BiP-associated protein, BAP, using a yeast two-hybrid screen that shared low homology with yeast Sls1p/Sil1p and mammalian HspBP1, both of which regulate the ATPase activity of their Hsp70 partner. BAP encoded an similar to54-kDa protein with an N-terminal endoplasmic reticulum (ER) targeting sequence, two sites of N-linked glycosylation, and a C-terminal ER retention sequence. Immunofluorescence staining demonstrated that BAP co-localized with GRP94 in the endoplasmic reticulum. BAP was ubiquitously expressed but showed the highest levels of expression in secretory organ tissues, a pattern similar to that observed with BiP. BAP binding was affected by the conformation of the ATPase domain of BiP based on in vivo binding studies with BiP mutants. BAP stimulated the ATPase activity of BiP when added alone or together with the ER DnaJ protein, ERdj4, by promoting the release of ADP from BiP. Together, these data demonstrate that BAP serves as a nucleotide exchange factor for BiP and provide insights into the mechanisms that control protein folding in the mammalian ER.	St Jude Childrens Res Hosp, Dept Tumor Cell Biol, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Sci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Hendershot, LM (corresponding author), Dept Tumor Cell Biol, 332 N Lauderdale, Memphis, TN 38105 USA.	linda.hendershot@stjude.org	Hendershot, Linda/N-8124-2018	Hendershot, Linda/0000-0002-5473-0274	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054068] Funding Source: NIH RePORTER; NCI NIH HHS [CA21765] Funding Source: Medline; NIGMS NIH HHS [GM54068] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bai C, 1996, METHOD ENZYMOL, V273, P331; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bies C, 1999, BIOL CHEM, V380, P1175, DOI 10.1515/BC.1999.149; Bimston D, 1998, EMBO J, V17, P6871, DOI 10.1093/emboj/17.23.6871; BOORSTEIN WR, 1994, J MOL EVOL, V38, P1; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chevalier M, 2000, J BIOL CHEM, V275, P19620, DOI 10.1074/jbc.M001333200; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; GAUT JR, 1993, J BIOL CHEM, V268, P7248; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; HAAS IG, 1983, NATURE, V306, P387, DOI 10.1038/306387a0; HAAS IG, 1994, EXPERIENTIA, V50, P1012, DOI 10.1007/BF01923455; Hamman BD, 1998, CELL, V92, P747, DOI 10.1016/S0092-8674(00)81403-8; HAMMOND C, 1995, CURR OPIN CELL BIOL, V7, P523, DOI 10.1016/0955-0674(95)80009-3; Hendershot L, 1996, P NATL ACAD SCI USA, V93, P5269, DOI 10.1073/pnas.93.11.5269; Hohfeld J, 1997, EMBO J, V16, P6209, DOI 10.1093/emboj/16.20.6209; Johnson BD, 1998, J BIOL CHEM, V273, P3679, DOI 10.1074/jbc.273.6.3679; Kabani M, 2000, MOL CELL BIOL, V20, P6923, DOI 10.1128/MCB.20.18.6923-6934.2000; Kabani M, 2002, MOL CELL BIOL, V22, P4677, DOI 10.1128/MCB.22.13.4677-4689.2002; Lee YK, 1999, MOL BIOL CELL, V10, P2209, DOI 10.1091/mbc.10.7.2209; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; Miao BJ, 1997, J MOL BIOL, V265, P541, DOI 10.1006/jmbi.1996.0762; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; Nollen EAA, 2000, MOL CELL BIOL, V20, P1083, DOI 10.1128/MCB.20.3.1083-1088.2000; Nollen EAA, 2001, J BIOL CHEM, V276, P4677, DOI 10.1074/jbc.M009745200; Raynes DA, 1998, J BIOL CHEM, V273, P32883, DOI 10.1074/jbc.273.49.32883; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen Y, 2002, J BIOL CHEM, V277, P15947, DOI 10.1074/jbc.M112214200; Skowronek MH, 1999, BIOL CHEM, V380, P1133, DOI 10.1515/BC.1999.142; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; Tyson JR, 2000, EMBO J, V19, P6440, DOI 10.1093/emboj/19.23.6440; Vanhove M, 2001, IMMUNITY, V15, P105, DOI 10.1016/S1074-7613(01)00163-7; WEI JY, 1995, J BIOL CHEM, V270, P26677, DOI 10.1074/jbc.270.44.26677; Yu M, 2000, J BIOL CHEM, V275, P24984, DOI 10.1074/jbc.M000739200	40	140	143	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47557	47563		10.1074/jbc.M208377200	http://dx.doi.org/10.1074/jbc.M208377200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356756	hybrid			2022-12-25	WOS:000179663700094
J	Francis, SH; Bessay, EP; Kotera, J; Grimes, KA; Liu, L; Thompson, WJ; Corbin, JD				Francis, SH; Bessay, EP; Kotera, J; Grimes, KA; Liu, L; Thompson, WJ; Corbin, JD			Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; PROTEIN; SITES; PDE5	Substrate binding to the phosphodiesterase-5 (PDE5) catalytic site increases cGMP binding to the regulatory domain (R domain). The latter promotes PDE5 phosphorylation by cyclic nucleotide-dependent protein kinases, which activates catalysis, enhances allosteric cGMP binding, and causes PDE5A1 to apparently elongate. A human PDE5A1 R domain fragment (Val(46)-Glu(539)) containing the phosphorylation site (Ser(102)) and allosteric cGMP-binding sites was studied. The rate, cGMP dependence, and stoichiometry of phosphorylation of the PDE5 R domain by the catalytic subunit of cAMP-dependent protein kinase are comparable with that of the holoenzyme. Migration in native polyacrylamide gels suggests that either cGMP binding or phosphorylation produces distinct conformers of the R domain. Phosphorylation of the R domain increases affinity for cGMP similar to10-fold (K-D values 97.8+/-17 and 10.0+/-0.5 nM for unphospho- and phospho-R domains, respectively). [3 H]cGMP dissociates from the phospho-R domain with a single rate (t(1/2)=339+/-30 min) compared with the biphasic pattern of the unphospho-R domain (t(1/2)=39.0+/-4.8 and 265+/-28 min, for the fast and slow components, respectively). Thus, cGMP-directed regulation of PDE5 phosphorylation and the resulting increase in cGMP binding affinity occur largely within the R domain. Conformational change(s) elicited by phosphorylation of the R domain within the PDE5 holoenzyme may also cause or participate in stimulating catalysis.	Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, Nashville, TN 37232 USA; Univ S Alabama, Sch Med, Dept Pharmacol, Mobile, AL 36688 USA; Cell Pathways Inc, Horsham, PA 19044 USA	Vanderbilt University; University of South Alabama	Francis, SH (corresponding author), Vanderbilt Univ, Sch Med, Dept Physiol & Mol Biophys, 221 Kirkland Hall, Nashville, TN 37232 USA.	sharron.francis@mcmail.vanderbilt.edu			NHLBI NIH HHS [HL46494] Funding Source: Medline; NIDDK NIH HHS [DK40029, DK58277] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040029, R01DK058277] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aravind L, 1997, TRENDS BIOCHEM SCI, V22, P458, DOI 10.1016/S0968-0004(97)01148-1; BEAVO JA, 1971, J BIOL CHEM, V246, P3841; CHARBONNEAU H, 1990, P NATL ACAD SCI USA, V87, P288, DOI 10.1073/pnas.87.1.288; Charbonneau H., 1990, CYCLIC NUCLEOTIDE PH, P267; Corbin JD, 2000, EUR J BIOCHEM, V267, P2760, DOI 10.1046/j.1432-1327.2000.01297.x; FLOCKHART DA, 1984, BRAIN RECEPTOR MET A, P209; Francis SH, 2001, PROG NUCLEIC ACID RE, V65, P1; FRANCIS SH, 1980, J BIOL CHEM, V255, P620; Francis SH, 1998, METHODS, V14, P81, DOI 10.1006/meth.1997.0567; Johnson LN, 1997, ADV SEC MESS PHOSPH, V31, P11; Liu L, 2002, CELL SIGNAL, V14, P45, DOI 10.1016/S0898-6568(01)00216-9; Loughney K, 1998, GENE, V216, P139, DOI 10.1016/S0378-1119(98)00303-5; Manganiello V.C., 1990, CYCLIC NUCLEOTIDE PH, P61; McAllisterLucas LM, 1995, J BIOL CHEM, V270, P30671, DOI 10.1074/jbc.270.51.30671; MCALLISTERLUCAS LM, 1993, J BIOL CHEM, V268, P22863; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Mullershausen F, 2001, J CELL BIOL, V155, P271, DOI 10.1083/jcb.200107001; Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200; Soderling SH, 2000, CURR OPIN CELL BIOL, V12, P174, DOI 10.1016/S0955-0674(99)00073-3; STROOP SD, 1991, J BIOL CHEM, V266, P23802; THOMAS MK, 1990, J BIOL CHEM, V265, P14971; THOMAS MK, 1990, J BIOL CHEM, V265, P14964; Turko IV, 1998, BIOCHEM J, V329, P505; Weber G, 1975, Adv Protein Chem, V29, P1, DOI 10.1016/S0065-3233(08)60410-6; WYATT TA, 1998, AM J PHYSIOL, V274, P448; YAMAZAKI A, 1980, J BIOL CHEM, V255, P1619	26	68	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47581	47587		10.1074/jbc.M206088200	http://dx.doi.org/10.1074/jbc.M206088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359732	hybrid			2022-12-25	WOS:000179663700097
J	Miras, S; Salvi, D; Ferro, M; Grunwald, D; Garin, J; Joyard, J; Rolland, N				Miras, S; Salvi, D; Ferro, M; Grunwald, D; Garin, J; Joyard, J; Rolland, N			Non-canonical transit peptide for import into the chloroplast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETAINE-ALDEHYDE DEHYDROGENASE; OUTER ENVELOPE MEMBRANE; PROTEIN IMPORT; MOLECULAR CHARACTERIZATION; QUINONE OXIDOREDUCTASE; SPINACH-CHLOROPLASTS; TARGETING SIGNAL; MESSENGER-RNA; COMPONENTS; APPARATUS	The large majority of plastid proteins are nuclear-encoded and, thus, must be imported within these organelles. Unlike most of the outer envelope proteins, targeting of proteins to all other plastid compartments (inner envelope membrane, stroma, and thylakoid) is strictly dependent on the presence of a cleavable transit sequence in the precursor N-terminal region. In this paper, we describe the identification of a new envelope protein component (ceQORH) and demonstrate that its subcellular localization is limited to the inner membrane of the chloroplast envelope. Immunopurification, microsequencing of the natural envelope protein and cloning of the corresponding full-length cDNA demonstrated that this protein is not processed in the N-terminal region during its targeting to the inner envelope membrane. Transient expression experiments in plant cells were performed with truncated forms of the ceQORH protein fused to the green fluorescent protein. These experiments suggest that neither the N-terminal nor the C-terminal are essential for chloroplastic localization of the ceQORH protein. These observations are discussed in the frame of the endosymbiotic theory of chloroplast evolution and suggest that a domain of the ceQORH bacterial ancestor may have evolved so as to exclude the general requirement of an N-terminal plastid transit sequence.	Univ Grenoble 1, CEA, CNRS, UMR 5019,Lab Physiol Cellulaire Vegetale, F-38054 Grenoble 9, France; CEA, INSERM, ERM 0201, Lab Chim Prot, F-38054 Grenoble 9, France; CEA Grenoble, Dept Reponse & Dynam Cellulaires, CEA, INSERM,Lab Canaux Ion & Signalisat E9931, F-38054 Grenoble 9, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); CEA; Institut National de la Sante et de la Recherche Medicale (Inserm)	Rolland, N (corresponding author), Univ Grenoble 1, CEA, CNRS, UMR 5019,Lab Physiol Cellulaire Vegetale, F-38054 Grenoble 9, France.	nrolland@cea.fr	FERRO, Myriam/O-6588-2014; ROLLAND, Norbert/B-4405-2012	FERRO, Myriam/0000-0002-4222-6847; ROLLAND, Norbert/0000-0003-1959-6636				[Anonymous], METHODS CHLOROPLAST; Bischoff M, 2001, PLANT PHYSIOL, V125, P1891, DOI 10.1104/pp.125.4.1891; BLOCK MA, 1983, J BIOL CHEM, V258, P3273; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bruce BD, 2001, BBA-MOL CELL RES, V1541, P2, DOI 10.1016/S0167-4889(01)00149-5; Chaal BK, 1998, J BIOL CHEM, V273, P689, DOI 10.1074/jbc.273.2.689; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; Cline K, 1996, ANNU REV CELL DEV BI, V12, P1, DOI 10.1146/annurev.cellbio.12.1.1; DEBOER AD, 1991, BIOCHIM BIOPHYS ACTA, V1071, P221, DOI 10.1016/0304-4157(91)90015-O; Ferro M, 2002, P NATL ACAD SCI USA, V99, P11487, DOI 10.1073/pnas.172390399; Folsch H, 1996, EMBO J, V15, P479, DOI 10.1002/j.1460-2075.1996.tb00380.x; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herrmann JM, 2000, CURR OPIN MICROBIOL, V3, P210, DOI 10.1016/S1369-5274(00)00077-1; HOFMANN K, 1993, BIOL CHEM HOPPESEYLE, V374, P166, DOI DOI 10.1515/BCHM3.1993.374.1-6.143; Jackson-Constan D, 2001, PLANT PHYSIOL, V125, P1567, DOI 10.1104/pp.125.4.1567; JagerVottero P, 1997, P NATL ACAD SCI USA, V94, P1597, DOI 10.1073/pnas.94.4.1597; JOYARD J, 1983, J BIOL CHEM, V258, P1; KEEGSTRA K, 1989, ANNU REV PLANT PHYS, V40, P471, DOI 10.1146/annurev.pp.40.060189.002351; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KO K, 1995, J BIOL CHEM, V270, P28601, DOI 10.1074/jbc.270.48.28601; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kouranov A, 1999, J BIOL CHEM, V274, P25181, DOI 10.1074/jbc.274.35.25181; Li HM, 1997, J BIOL CHEM, V272, P10968; Liu MQ, 2000, J BIOL CHEM, V275, P29400, DOI 10.1074/jbc.M002173200; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; NOBREGA FG, 1992, EMBO J, V11, P3821, DOI 10.1002/j.1460-2075.1992.tb05474.x; PFANNER N, 1987, J BIOL CHEM, V262, P14851; PINADUWAGE P, 1996, J BIOL CHEM, V271, P32907; RAO PV, 1992, J BIOL CHEM, V267, P96; RATHINASABAPATHI B, 1994, PLANTA, V193, P155, DOI 10.1007/BF00192524; Rohl T, 1999, FEBS LETT, V460, P491, DOI 10.1016/S0014-5793(99)01399-X; Sato N, 1998, PLANT CELL, V10, P859, DOI 10.1105/tpc.10.5.859; Schleiff E, 2000, PLANTA, V211, P449, DOI 10.1007/s004250000357; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Seigneurin-Berny D, 1999, PLANT J, V19, P217, DOI 10.1046/j.1365-313X.1999.00511.x; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; Stahl T, 1999, J BIOL CHEM, V274, P37467, DOI 10.1074/jbc.274.52.37467; THORN JM, 1995, J MOL BIOL, V249, P785, DOI 10.1006/jmbi.1995.0337; Tranel PJ, 1996, PLANT CELL, V8, P2093, DOI 10.1105/tpc.8.11.2093; TRANEL PJ, 1995, EMBO J, V14, P2436, DOI 10.1002/j.1460-2075.1995.tb07241.x; VANDERVERE PS, 1995, P NATL ACAD SCI USA, V92, P7177, DOI 10.1073/pnas.92.16.7177; VANTHOF R, 1991, FEBS LETT, V291, P350, DOI 10.1016/0014-5793(91)81318-3; VANTHOF R, 1993, J BIOL CHEM, V268, P4037; WERETILNYK EA, 1989, ARCH BIOCHEM BIOPHYS, V271, P56, DOI 10.1016/0003-9861(89)90255-5; WERETILNYK EA, 1990, P NATL ACAD SCI USA, V87, P2745, DOI 10.1073/pnas.87.7.2745; WU C, 1993, J BIOL CHEM, V26, P19384	48	128	142	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47770	47778		10.1074/jbc.M207477200	http://dx.doi.org/10.1074/jbc.M207477200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12368288	Green Published, hybrid			2022-12-25	WOS:000179663700121
J	Ozcan, S				Ozcan, S			Two different signals regulate repression and induction of gene expression by glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; SACCHAROMYCES-CEREVISIAE; PROTEIN-KINASE; HEXOSE TRANSPORTERS; BUDDING YEAST; SENSORS; DEREPRESSION; MECHANISMS; MUTANTS; CELLS	In addition to being the universal carbon and energy source, glucose also regulates gene expression in many organisms. In the yeast Saccharomyces cerevisiae glucose regulates gene expression via two different pathways known as the glucose repression and glucose induction pathways. The signal for glucose induction of hexose transporter (HX7) genes is generated via two glucose-transporter like molecules, Snf3 and Rgt2. A strain lacking both sensors is unable to induce RXT gene expression and is defective in glucose uptake. The snf3 rgt2 double mutant is also defective in glucose repression of transcription, raising the possibility that Snf3 and Rgt2 are also involved in generating the glucose repression signal. In this report, I show that induction and repression of gene expression by glucose in yeast is regulated by two independent signals. While the signal for induction of HXT gene expression is generated by Snf3 and Rgt2 glucose receptors, the repression signal requires the uptake and metabolism of glucose. In addition, the glucose induction of the HXT genes is required for repression of gene expression by glucose. Therefore the glucose repression defect of the snt3 rgt2 strain is indirect and is due to the lack of glucose uptake in this double mutant.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, Lexington, KY 40536 USA	University of Kentucky	Ozcan, S (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Chandler Med Ctr, 800 Rose St,MN 608, Lexington, KY 40536 USA.							Carlson M, 1999, CURR OPIN MICROBIOL, V2, P202, DOI 10.1016/S1369-5274(99)80035-6; CARLSON M, 1981, GENETICS, V98, P25; CIRIACY M, 1977, MOL GEN GENET, V154, P213, DOI 10.1007/BF00330840; Foufelle F, 1998, Curr Opin Clin Nutr Metab Care, V1, P323, DOI 10.1097/00075197-199807000-00002; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Johnston M, 1999, TRENDS GENET, V15, P29, DOI 10.1016/S0168-9525(98)01637-0; Lafuente MJ, 2000, MOL MICROBIOL, V35, P161, DOI 10.1046/j.1365-2958.2000.01688.x; Meijer MMC, 1998, J BIOL CHEM, V273, P24102, DOI 10.1074/jbc.273.37.24102; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Reifenberger E, 1997, EUR J BIOCHEM, V245, P324, DOI 10.1111/j.1432-1033.1997.00324.x; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wilson WA, 1996, CURR BIOL, V6, P1426, DOI 10.1016/S0960-9822(96)00747-6; Ye L, 1999, J BACTERIOL, V181, P4673, DOI 10.1128/JB.181.15.4673-4675.1999; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; ZIMMERMANN FK, 1977, MOL GEN GENET, V151, P95, DOI 10.1007/BF00446918	22	29	29	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46993	46997		10.1074/jbc.M208726200	http://dx.doi.org/10.1074/jbc.M208726200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12351652	hybrid			2022-12-25	WOS:000179663700022
J	Terao, Y; Kawabata, S; Nakata, M; Nakagawa, I; Hamada, S				Terao, Y; Kawabata, S; Nakata, M; Nakagawa, I; Hamada, S			Molecular characterization of a novel fibronectin-binding protein of Streptococcus pyogenes strains isolated from toxic shock-like syndrome patients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCUS; STAPHYLOCOCCUS-AUREUS; GENOME SEQUENCE; SURFACE PROTEIN; CYSTEINE PROTEASE; SEROTYPE M3; GENE; IDENTIFICATION; ACTIVATION; MULTIPLE	Group A Streptococcus pyogenes has surface-located fibronectin (Fn)-binding proteins known to be a major virulence factor, which adheres to and invades host cells. We present a novel Fn-binding protein of group A streptococcus serotype M3 and M18 strains isolated from patients with toxic shock-like syndrome (TSLS). By searching the whole genome sequence of an M3 strain from a TSLS patient, an open reading frame was found among the putative surface proteins. It possessed an LPXTG motif and Fn-binding repeat domains in the C-terminal region and was designated as FbaB (Fn-binding protein of group A streptococci type B). The fbaB gene was found in all M3 and M18 strains examined, although not in other M serotypes. Furthermore, FbaB protein was expressed on the cell surface of TSLS strains but not on non-TSLS ones. Enzyme-linked immunosorbent assay and ligand blotting revealed that recombinant FbaB exhibits a strong Fn-binding ability. An FbaB-deficient mutant strain showed 6-fold lower adhesion and invasion efficiencies to HEp-2 cells than the wild type. Moreover, mortality was decreased in mice infected with the mutant strain in comparison to the wild type. These data suggest that FbaB is etiologically involved in the development of invasive streptococcal diseases.	Osaka Univ, Dept Oral & Mol Microbiol, Grad Sch Dent, Suita, Osaka 5650871, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi, Saitama 3320012, Japan	Osaka University; Japan Science & Technology Agency (JST)	Kawabata, S (corresponding author), Osaka Univ, Dept Oral & Mol Microbiol, Grad Sch Dent, 1-8 Yamadaoka, Suita, Osaka 5650871, Japan.	kawabata@dent.osaka-u.ac.jp		Nakata, Masanobu/0000-0003-1686-5415; Terao, Yutaka/0000-0002-4450-5583				Beckmann C, 2002, INFECT IMMUN, V70, P2869, DOI 10.1128/IAI.70.6.2869-2876.2002; Beres SB, 2002, P NATL ACAD SCI USA, V99, P10078, DOI 10.1073/pnas.152298499; CAPARON MG, 1991, METHOD ENZYMOL, V204, P556; Courtney HS, 1999, MOL MICROBIOL, V32, P89, DOI 10.1046/j.1365-2958.1999.01328.x; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; Eichenbaum Z, 1996, INFECT IMMUN, V64, P1956, DOI 10.1128/IAI.64.6.1956-1960.1996; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; Fogg GC, 1997, J BACTERIOL, V179, P6172, DOI 10.1128/jb.179.19.6172-6180.1997; FRITHZ E, 1989, MOL MICROBIOL, V3, P1111, DOI 10.1111/j.1365-2958.1989.tb00261.x; Gilot P, 1999, INFECT IMMUN, V67, P6698; HAMADA S, 1991, INFECT IMMUN, V59, P4161, DOI 10.1128/IAI.59.11.4161-4167.1991; HAUSER AR, 1991, J CLIN MICROBIOL, V29, P1562, DOI 10.1128/JCM.29.8.1562-1567.1991; HUANG TT, 1989, MOL MICROBIOL, V3, P197, DOI 10.1111/j.1365-2958.1989.tb01808.x; Inagaki Y, 2000, J INFECT DIS, V181, P975, DOI 10.1086/315299; Jaffe J, 1996, MOL MICROBIOL, V21, P373, DOI 10.1046/j.1365-2958.1996.6331356.x; Kingsley RA, 2002, MOL MICROBIOL, V43, P895, DOI 10.1046/j.1365-2958.2002.02805.x; KREIKEMEYER B, 1995, MOL MICROBIOL, V17, P137, DOI 10.1111/j.1365-2958.1995.mmi_17010137.x; Massey RC, 2001, CELL MICROBIOL, V3, P839, DOI 10.1046/j.1462-5822.2001.00157.x; MCGAVIN MJ, 1993, J BIOL CHEM, V268, P23946; McIver KS, 2002, MOL MICROBIOL, V43, P1591, DOI 10.1046/j.1365-2958.2002.02849.x; MCIVER KS, 1995, J BACTERIOL, V177, P6619, DOI 10.1128/jb.177.22.6619-6624.1995; Murakami J, 2002, EPIDEMIOL INFECT, V128, P397, DOI 10.1017/S0950268802006854; Nakagawa I, 2001, CELL MICROBIOL, V3, P395, DOI 10.1046/j.1462-5822.2001.00122.x; NATANSON S, 1995, J INFECT DIS, V171, P871, DOI 10.1093/infdis/171.4.871; Ozeri V, 2001, MOL MICROBIOL, V41, P561, DOI 10.1046/j.1365-2958.2001.02535.x; Ozeri V, 1998, MOL MICROBIOL, V30, P625, DOI 10.1046/j.1365-2958.1998.01097.x; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; Podbielski A, 1999, MOL MICROBIOL, V31, P1051, DOI 10.1046/j.1365-2958.1999.01241.x; PYTELA R, 1985, CELL, V40, P191, DOI 10.1016/0092-8674(85)90322-8; Raeder R, 1998, RES MICROBIOL, V149, P539, DOI 10.1016/S0923-2508(99)80001-1; Rasmussen M, 2000, INFECT IMMUN, V68, P6370, DOI 10.1128/IAI.68.11.6370-6377.2000; Rasmussen M, 1999, J BIOL CHEM, V274, P15336, DOI 10.1074/jbc.274.22.15336; Rocha CL, 1999, INFECT IMMUN, V67, P2720, DOI 10.1128/IAI.67.6.2720-2728.1999; RUSSELL RRB, 1992, J BIOL CHEM, V267, P4631; Sambrook J, 2001, MOL CLONING LAB MANU; SCHMIDT KH, 1993, FEMS IMMUNOL MED MIC, V7, P135; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; Smoot JC, 2002, P NATL ACAD SCI USA, V99, P4668, DOI 10.1073/pnas.062526099; STEVENS DL, 1989, NEW ENGL J MED, V321, P1, DOI 10.1056/NEJM198907063210101; Stockbauer KE, 1999, P NATL ACAD SCI USA, V96, P242, DOI 10.1073/pnas.96.1.242; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; TALKINGTON DF, 1993, INFECT IMMUN, V61, P3369, DOI 10.1128/IAI.61.8.3369-3374.1993; TAO L, 1992, GENE, V120, P105, DOI 10.1016/0378-1119(92)90016-I; Terao Y, 2001, MOL MICROBIOL, V42, P75, DOI 10.1046/j.1365-2958.2001.02579.x; Terao Y, 2002, INFECT IMMUN, V70, P993; THERN A, 1995, J IMMUNOL, V154, P375; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Whatmore AM, 2001, MICROBIOL-UK, V147, P419, DOI 10.1099/00221287-147-2-419	50	88	88	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47428	47435		10.1074/jbc.M209133200	http://dx.doi.org/10.1074/jbc.M209133200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359713	hybrid			2022-12-25	WOS:000179663700078
J	Watanabe, H; Vriens, J; Suh, SH; Benham, CD; Droogmans, G; Nilius, B				Watanabe, H; Vriens, J; Suh, SH; Benham, CD; Droogmans, G; Nilius, B			Heat-evoked activation of TRPV4 channels in a HEK293 cell expression system and in native mouse aorta endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSAICIN-RECEPTOR; CATION CHANNEL; SENSORY NEURONS; NOXIOUS HEAT; ION-CHANNEL; CURRENTS; MECHANISMS; PROTEIN; AGONIST; OTRPC4	We have compared activation by heat of TRPV4 channels, heterogeneously expressed in HEK293 cells, and endogenous channels in mouse aorta endothelium (MAEC). Increasing the temperature above 25degreesC activated currents and increased [Ca2+](i) in HEK293 cells transfected with TRPV4 and in MAEC. When compared with activation of TRPV4 currents by the selective ligand 4alphaPDD (alpha-phorbol 12,13-didecanoate), heat-activated currents in both systems showed the typical biophysical properties of currents through TRPV4, including their single channel conductance. Deletion of the three N-terminal ankyrin binding domains of TRPV4 abolished current activation cells by heat in HEK293. In inside-out patches, TRPV4 could not be activated by heat but still responded to the ligand 4alphaPDD. In MAEC, the same channel is activated under identical conditions as in the HEK expression system. Our data indicate that TRPV4 is a functional temperature-sensing channel in native endothelium, that is likely involved in temperature-dependent Ca2+ signaling. The failure to activate TRPV4 channels by heat in inside-out patches, which responded to 4alphaPDD, may indicate that heat activation depends on the presence of an endogenous ligand, which is missing in inside-out patches.	Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, B-3000 Louvain, Belgium; GlaxoSmithKline, Neurol CEDD, Harlow CM19 5AW, Essex, England	KU Leuven; GlaxoSmithKline	Nilius, B (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Dept Physiol, Campus Gasthuisberg ,Herestr 49, B-3000 Louvain, Belgium.		Vriens, Joris/G-9966-2018	Vriens, Joris/0000-0002-2502-0409				Basavappa S, 1998, J NEUROPHYSIOL, V79, P1441, DOI 10.1152/jn.1998.79.3.1441; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Colbert HA, 1997, J NEUROSCI, V17, P8259; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Guler AD, 2002, J NEUROSCI, V22, P6408; Gunthorpe MJ, 2002, TRENDS PHARMACOL SCI, V23, P183, DOI 10.1016/S0165-6147(02)01999-5; Hoffmann EK, 2000, CELL PHYSIOL BIOCHEM, V10, P273, DOI 10.1159/000016356; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; Hwang SW, 2000, P NATL ACAD SCI USA, V97, P6155, DOI 10.1073/pnas.97.11.6155; Jordt SE, 2002, CELL, V108, P421, DOI 10.1016/S0092-8674(02)00637-2; Kanzaki M, 1999, NAT CELL BIOL, V1, P165, DOI 10.1038/11086; Liedtke W, 2000, CELL, V103, P525, DOI 10.1016/S0092-8674(00)00143-4; McKemy DD, 2002, NATURE, V416, P52, DOI 10.1038/nature719; Minson CT, 2001, J APPL PHYSIOL, V91, P1619, DOI 10.1152/jappl.2001.91.4.1619; Montell C, 2002, MOL CELL, V9, P229, DOI 10.1016/S1097-2765(02)00448-3; Nilius B, 2001, PFLUG ARCH EUR J PHY, V443, P227, DOI 10.1007/s004240100676; Peier AM, 2002, SCIENCE, V296, P2046, DOI 10.1126/science.1073140; Peier AM, 2002, CELL, V108, P705, DOI 10.1016/S0092-8674(02)00652-9; Schumacher MA, 2000, J BIOL CHEM, V275, P2756, DOI 10.1074/jbc.275.4.2756; Schwarz S, 2000, J PHYSIOL-LONDON, V528, P539, DOI 10.1111/j.1469-7793.2000.00539.x; Smart D, 2000, BRIT J PHARMACOL, V129, P227, DOI 10.1038/sj.bjp.0703050; Smith GD, 2002, NATURE, V418, P186, DOI 10.1038/nature00894; Strotmann R, 2000, NAT CELL BIOL, V2, P695, DOI 10.1038/35036318; Suh SH, 1999, PFLUG ARCH EUR J PHY, V438, P612, DOI 10.1007/s004240051084; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Viana F, 2002, NAT NEUROSCI, V5, P254, DOI 10.1038/nn809; Voets T, 2002, J BIOL CHEM, V277, P33704, DOI 10.1074/jbc.M204828200; Vyklicky L, 1999, J PHYSIOL-LONDON, V517, P181, DOI 10.1111/j.1469-7793.1999.0181z.x; Watanabe H, 2002, J BIOL CHEM, V277, P13569, DOI 10.1074/jbc.M200062200; Wei L, 2001, BMC Physiol, V1, P3, DOI 10.1186/1472-6793-1-3; Wissenbach U, 2000, FEBS LETT, V485, P127, DOI 10.1016/S0014-5793(00)02212-2; Xu HX, 2002, NATURE, V418, P181, DOI 10.1038/nature00882	36	474	508	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47044	47051		10.1074/jbc.M208277200	http://dx.doi.org/10.1074/jbc.M208277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354759	Green Submitted, hybrid			2022-12-25	WOS:000179663700029
J	West, JM; Tsuruta, H; Kantrowitz, ER				West, JM; Tsuruta, H; Kantrowitz, ER			Stabilization of the R allosteric structure of Escherichia coli aspartate transcarbamoylase by disulfide bond formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTROPIC INTERACTIONS; HOMOTROPIC COOPERATIVITY; QUATERNARY STRUCTURE; KINETIC MECHANISM; CATALYTIC CHAIN; DOMAIN CLOSURE; TRANSITION; CARBAMOYLTRANSFERASE; MODEL; CONSEQUENCES	Here we report the first use of disulfide bond formation to stabilize the R allosteric structure of Escherichia coli aspartate transcarbamoylase. In the R allosteric state, residues in the 240s loop from two catalytic chains of different subunits are close together, whereas in the T allosteric state they are far apart. By substitution of Ala-241 in the 240s loop of the catalytic chain with cysteine, a disulfide bond was formed between two catalytic chains of different subunits. The cross-linked enzyme did not exhibit cooperativity for aspartate. The maximal velocity was increased, and the concentration of aspartate required to obtain one-half the maximal velocity, [Asp](0.5), was reduced substantially. Furthermore, the allosteric effectors ATP and CTP did not alter the activity of the cross-linked enzyme. When the disulfide bonds were reduced by the addition of 1,4-dithio-DL-threitol the resulting enzyme had kinetic parameters very similar to those observed for the wild-type enzyme and regained the ability to be activated by ATP and inhibited by CTP. Small-angle x-ray scattering was used to verify that the cross-linked enzyme was structurally locked in the R state and that this enzyme after reduction with 1,4-dithio-DL-threitol could undergo an allosteric transition similar to that of the wild-type enzyme. The complete abolition of homotropic and heterotropic regulation from stabilizing the 240s loop in its closed position in the R state, which forms the catalytically competent active site, demonstrates the significance that the quaternary structural change and closure of the 240s loop has in the functional mechanism of aspartate transcarbamoylase.	Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA; Stanford Linear Accelerator Ctr, Stanford Synchrotron Radiat Lab, Menlo Pk, CA 94025 USA	Boston College; Stanford University; United States Department of Energy (DOE); SLAC National Accelerator Laboratory	Kantrowitz, ER (corresponding author), Boston Coll, Merkert Chem Ctr, Dept Chem, Chestnut Hill, MA 02467 USA.				NCRR NIH HHS [P41RR01209] Funding Source: Medline; NIGMS NIH HHS [GM26237] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001209] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026237] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER DP, 1993, BIOCHEMISTRY-US, V32, P10150, DOI 10.1021/bi00089a034; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHAN WWC, 1981, CAN J BIOCHEM CELL B, V59, P461, DOI 10.1139/o81-064; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P680; ENNS CA, 1979, J BIOL CHEM, V254, P6180; ENNS CA, 1978, J BIOL CHEM, V253, P2511; FETLER L, 1995, BIOCHEMISTRY-US, V34, P15654, DOI 10.1021/bi00048a008; GERHART JC, 1968, BIOCHEMISTRY-US, V7, P538, DOI 10.1021/bi00842a600; GERHART JC, 1967, J BIOL CHEM, V242, P2886; GERHART JC, 1962, J BIOL CHEM, V237, P891; HOWLETT GJ, 1977, BIOCHEMISTRY-US, V16, P5091, DOI 10.1021/bi00642a023; HSUANYU Y, 1989, BIOCHIM BIOPHYS ACTA, V995, P54, DOI 10.1016/0167-4838(89)90232-X; HSUANYU Y, 1987, ARCH BIOCHEM BIOPHYS, V259, P316, DOI 10.1016/0003-9861(87)90498-X; Jin L, 1999, PROTEINS, V37, P729, DOI 10.1002/(SICI)1097-0134(19991201)37:4<729::AID-PROT21>3.0.CO;2-F; KANTROWITZ ER, 1988, SCIENCE, V241, P669, DOI 10.1126/science.3041592; KANTROWITZ ER, 1990, TRENDS BIOCHEM SCI, V15, P53, DOI 10.1016/0968-0004(90)90176-C; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUSE KL, 1987, J MOL BIOL, V193, P527, DOI 10.1016/0022-2836(87)90265-8; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LADJIMI MM, 1988, BIOCHEMISTRY-US, V27, P276, DOI 10.1021/bi00401a042; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE BH, 1995, J BIOL CHEM, V270, P15620, DOI 10.1074/jbc.270.26.15620; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOODY MF, 1979, J MOL BIOL, V133, P517, DOI 10.1016/0022-2836(79)90405-4; NEWTON CJ, 1990, BIOCHEMISTRY-US, V29, P1444, DOI 10.1021/bi00458a015; NEWTON CJ, 1990, P NATL ACAD SCI USA, V87, P2309, DOI 10.1073/pnas.87.6.2309; NOWLAN SF, 1985, J BIOL CHEM, V260, P4712; ORNSTEIN L, 1964, ANN NY ACAD SCI, V121, P321, DOI 10.1111/j.1749-6632.1964.tb14207.x; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PASTRALANDIS SC, 1978, J BIOL CHEM, V253, P4624; PERBAL B, 1972, J MOL BIOL, V70, P511, DOI 10.1016/0022-2836(72)90556-6; Sakash JB, 2000, J BIOL CHEM, V275, P752, DOI 10.1074/jbc.275.2.752; SCHACHMAN HK, 1988, J BIOL CHEM, V263, P18583; SILVER RS, 1983, J MOL BIOL, V168, P729, DOI 10.1016/S0022-2836(83)80072-2; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; TAUC P, 1994, PROTEIN SCI, V3, P1998, DOI 10.1002/pro.5560031112; TAUC P, 1982, J MOL BIOL, V155, P155, DOI 10.1016/0022-2836(82)90442-9; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WILD JR, 1989, P NATL ACAD SCI USA, V86, P46, DOI 10.1073/pnas.86.1.46; XU W, 1988, BIOCHEMISTRY-US, V27, P5507, DOI 10.1021/bi00415a018	40	8	8	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47300	47304		10.1074/jbc.M209913200	http://dx.doi.org/10.1074/jbc.M209913200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359710	hybrid			2022-12-25	WOS:000179663700060
J	Aiello, DP; Fu, LW; Miseta, A; Bedwell, DM				Aiello, DP; Fu, LW; Miseta, A; Bedwell, DM			Intracellular glucose 1-phosphate and glucose 6-phosphate levels modulate Ca2+ homeostasis in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN COUPLED RECEPTOR; YEAST SECRETORY PATHWAY; TRANSCRIPTION FACTOR; H+/CA2+ EXCHANGE; GENE-EXPRESSION; CALCIUM INFLUX; CA-2+ INFLUX; LACKING PMR1; PUMP PMR1; PHOSPHOGLUCOMUTASE	The enzyme phosphoglucomutase plays a key role in cellular metabolism by virtue of its ability to interconvert Glc-1-P and Glc-6-P. It was recently shown that a yeast strain lacking the major isoform of phosphoglucomutase (pgm2Delta) accumulates a high level of Glc-1-P and exhibits several phenotypes related to altered Ca2+ homeostasis when D-galactose is utilized as the carbon source (Fu, L., Miseta, A., Hunton, D., Marchase, R. B., and Bedwell, D. M. (2000) J. Biol. Chem 275, 5431-5440). These phenotypes include increased Ca2+ uptake and accumulation and sensitivity to high environmental Ca2+ levels. In the present study, we overproduced the enzyme UDP-Glc pyrophosphorylase to test whether the overproduction of a downstream metabolite produced from Glc-1-P can also mediate changes in Ca2+ homeostasis. We found that overproduction of UDP-Glc did not cause any alterations in Ca2+ uptake or accumulation. We also examined whether Glc-6-P can influence cellular Ca2+ homeostasis. A yeast strain lacking the beta-subunit of phosphofructokinase (ptk2Delta) accumulates a high level of Glc-6-P (Huang, D., Wilson, W. A., and Roach, P. J. (1997) J. BioL Chem. 272, 22495-22501). We found that this increase in Glc-6-P led to a 1.5-2-fold increase in total cellular Ca2+. We also found that the pgm2Delta/pfk2Delta strain, which accumulated high levels of both Glc-6-P and Glc-1-P, no longer exhibited the Ca2+-related phenotypes associated with high Glc-1-P levels in the pgm2Delta mutant. These results provide strong evidence that cellular Ca2+ homeostasis is coupled to the relative levels of Glc-6-P and Glc-1-P in yeast.	Univ Alabama, Dept Microbiol, Birmingham, AL 35294 USA; Univ Pecs, Sch Med, Dept Clin Chem, H-7624 Pecs, Hungary	University of Alabama System; University of Alabama Birmingham; University of Pecs	Bedwell, DM (corresponding author), Univ Alabama, Dept Microbiol, BBRB 432,Box 8,1530 3rd Ave S, Birmingham, AL 35294 USA.			Bedwell, David/0000-0002-6605-818X; Fu, Karl/0000-0001-5386-9429; Miseta, Attila/0000-0002-7984-3347				Adams Alison, 1997, P99; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; ARVANITIDIS A, 1994, J BIOL CHEM, V269, P8911; BENEDETTI A, 1988, J BIOL CHEM, V263, P3466; BENEDETTI A, 1985, BIOCHIM BIOPHYS ACTA, V816, P267, DOI 10.1016/0005-2736(85)90494-8; BERGER W, 1984, HUM NEUROBIOL, V3, P163; BERGMEYER HU, 1985, METHOD ENZYMAT AN, V7, P524; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; Chen PY, 1998, DIABETES, V47, P874, DOI 10.2337/diabetes.47.6.874; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; Coons DM, 1997, YEAST, V13, P9, DOI 10.1002/(SICI)1097-0061(199701)13:1<9::AID-YEA51>3.0.CO;2-U; Cronin SR, 2002, J CELL BIOL, V157, P1017, DOI 10.1083/jcb.200203052; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; DARAN JM, 1995, EUR J BIOCHEM, V233, P520, DOI 10.1111/j.1432-1033.1995.520_2.x; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; DEY NB, 1994, J BIOL CHEM, V269, P27143; Dlugai S, 2001, FEBS LETT, V505, P389, DOI 10.1016/S0014-5793(01)02854-X; DUNN T, 1994, J BIOL CHEM, V269, P7273; Durr G, 1998, MOL BIOL CELL, V9, P1149, DOI 10.1091/mbc.9.5.1149; EILAM Y, 1990, J GEN MICROBIOL, V136, P2537, DOI 10.1099/00221287-136-12-2537; EMR SD, 1986, J CELL BIOL, V102, P523, DOI 10.1083/jcb.102.2.523; Fu LW, 2000, J BIOL CHEM, V275, P5431, DOI 10.1074/jbc.275.8.5431; FU LW, 1995, J BACTERIOL, V177, P3087, DOI 10.1128/jb.177.11.3087-3094.1995; FULCERI R, 1990, BIOCHIM BIOPHYS ACTA, V1022, P129, DOI 10.1016/0005-2736(90)90409-H; Gerin I, 2002, FEBS LETT, V517, P257, DOI 10.1016/S0014-5793(02)02640-6; Gerin I, 1997, FEBS LETT, V419, P235, DOI 10.1016/S0014-5793(97)01463-4; Halachmi D, 1996, FEBS LETT, V392, P194, DOI 10.1016/0014-5793(96)00799-5; Huang DQ, 1997, J BIOL CHEM, V272, P22495, DOI 10.1074/jbc.272.36.22495; IIDA H, 1990, J BIOL CHEM, V265, P13391; JONES JS, 1990, YEAST, V6, P363, DOI 10.1002/yea.320060502; Kraakman L, 1999, MOL MICROBIOL, V32, P1002, DOI 10.1046/j.1365-2958.1999.01413.x; Lafuente MJ, 2000, MOL MICROBIOL, V35, P161, DOI 10.1046/j.1365-2958.2000.01688.x; Lin BC, 2000, HUM GENET, V107, P526, DOI 10.1007/s004390000404; Lin BC, 1998, J BIOL CHEM, V273, P31656, DOI 10.1074/jbc.273.48.31656; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; LU M, 1994, J BACTERIOL, V176, P5847, DOI 10.1128/JB.176.18.5847-5851.1994; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARCHASE RB, 1993, J BIOL CHEM, V268, P8341; Marchi V, 1999, FEBS LETT, V454, P181, DOI 10.1016/S0014-5793(99)00803-0; MARSHALLCARLSON L, 1990, MOL CELL BIOL, V10, P1105, DOI 10.1128/MCB.10.3.1105; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miseta A, 1999, J BIOL CHEM, V274, P5939, DOI 10.1074/jbc.274.9.5939; Miseta A, 1999, FEBS LETT, V451, P132, DOI 10.1016/S0014-5793(99)00519-0; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; NAKAJIMASHIMADA J, 1991, P NATL ACAD SCI USA, V88, P6878, DOI 10.1073/pnas.88.15.6878; OH D, 1990, MOL CELL BIOL, V10, P1415, DOI 10.1128/MCB.10.4.1415; Ozcan S, 1998, EMBO J, V17, P2566, DOI 10.1093/emboj/17.9.2566; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Putney James W. Jr, 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P143; Rolland F, 2000, MOL MICROBIOL, V38, P348, DOI 10.1046/j.1365-2958.2000.02125.x; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; Schmidt MC, 1999, MOL CELL BIOL, V19, P4561; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Strayle J, 1999, EMBO J, V18, P4733, DOI 10.1093/emboj/18.17.4733; Suzuki C, 1999, MOL MICROBIOL, V32, P813, DOI 10.1046/j.1365-2958.1999.01400.x; Tisi R, 2002, FEBS LETT, V520, P133, DOI 10.1016/S0014-5793(02)02806-5; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200	60	31	32	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					45751	45758		10.1074/jbc.M208748200	http://dx.doi.org/10.1074/jbc.M208748200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351653	hybrid			2022-12-25	WOS:000179529300006
J	Bellemare, DR; Shaner, L; Morano, KA; Beaudoin, J; Langlois, J; Labbe, S				Bellemare, DR; Shaner, L; Morano, KA; Beaudoin, J; Langlois, J; Labbe, S			Ctr6, a vacuolar membrane copper transporter in Schizosaccharomyces pombe	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; METAL-ION TRANSPORT; SACCHAROMYCES-CEREVISIAE; IRON UPTAKE; FISSION YEAST; MOLECULAR CHARACTERIZATION; METALLOCHAPERONE COX17; SUPEROXIDE-DISMUTASE; MUTATIONAL ANALYSIS; FERRIC REDUCTASE	Aerobic organisms possess efficient systems for the transport of copper. This involves transporters that mediate the passage of copper across biological membranes to reach essential intracellular copper-requiring enzymes. In this report, we identify a new copper transporter in Schizosaccharomyces pombe, encoded by the ctr6(+) gene. The transcription of ctr6(+) is induced under copper-limiting conditions. This regulation is mediated by the cis-acting promoter element CuSE (copper-signaling element) through the copper-sensing transcription factor Cuf1. An S. pombe strain bearing a disrupted ctr6Delta allele displays a strong reduction of copper,zinc superoxide dismutase activity. When the ctr6+ gene is overexpressed from the thiamine-inducible nmt1(+) promoter, the cells are unable to grow on medium containing exogenous copper. Surprisingly, this copper-sensitive growth phenotype is not due to an increase of copper uptake at the cell surface. Instead, copper delivery across the plasma membrane is reduced. Consistently, this results in repressing ctr4(+) gene expression. By using a functional ctr6(+) epitope-tagged allele expressed under the control of its own promoter, we localize the Ctr6 protein on the membrane of vacuoles. Furthermore, we demonstrate that Ctr6 is an integral membrane protein that can trimerize. Moreover, we show that Ctr6 harbors a putative copper-binding Met-X-His-Cys-X-Met-X-Met motif in the amino terminus, which is essential for its function. Our findings suggest that under conditions in which copper is scarce, Ctr6 is required as a means to mobilize stored copper from the vacuole to the cytosol.	Univ Sherbrooke, Dept Biochim, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; Univ Sherbrooke, Dept Med Nucl & Radiobiol, Fac Med, Sherbrooke, PQ J1H 5N4, Canada; CHU Sherbrooke, Sherbrooke PET Ctr, Sherbrooke, PQ J1H 5N4, Canada; Univ Texas, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Sherbrooke; University of Sherbrooke; University of Sherbrooke; University of Texas System	Labbe, S (corresponding author), Univ Sherbrooke, Dept Biochim, Fac Med, 3001 12e Ave Nord, Sherbrooke, PQ J1H 5N4, Canada.	Simon.Labbe@USherbrooke.ca		Morano, Kevin/0000-0002-5992-0253; Labbe, Simon/0000-0002-4947-523X				ALFA C, 1993, EXPT FISSION YEASTS; Askwith C, 1998, TRENDS BIOCHEM SCI, V23, P135, DOI 10.1016/S0968-0004(98)01192-X; ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; Beaudoin J, 2001, J BIOL CHEM, V276, P15472, DOI 10.1074/jbc.M011256200; Beers J, 1997, J BIOL CHEM, V272, P33191, DOI 10.1074/jbc.272.52.33191; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; Bellemare DR, 2001, GENE, V273, P191, DOI 10.1016/S0378-1119(01)00591-1; Bezanilla M, 1997, MOL BIOL CELL, V8, P2693, DOI 10.1091/mbc.8.12.2693; Carr HS, 2002, J BIOL CHEM, V277, P31237, DOI 10.1074/jbc.M204854200; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; COTTAREL G, 1993, CURR GENET, V23, P547, DOI 10.1007/BF00312650; Crapo J D, 1978, Methods Enzymol, V53, P382; Culotta VC, 1997, J BIOL CHEM, V272, P23469, DOI 10.1074/jbc.272.38.23469; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1994, J BIOL CHEM, V269, P25660; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; Eide DJ, 2000, ADV MICROB PHYSIOL, V43, P1, DOI 10.1016/S0065-2911(00)43001-8; EIDE DJ, 1993, MOL GEN GENET, V241, P447, DOI 10.1007/BF00284699; Eide DJ, 1998, ANNU REV NUTR, V18, P441, DOI 10.1146/annurev.nutr.18.1.441; Forsburg SL, 1997, GENE, V191, P191, DOI 10.1016/S0378-1119(97)00058-9; Forsburg SL, 2000, NAT GENET, V25, P263, DOI 10.1038/77015; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; Gaits F, 1999, MOL BIOL CELL, V10, P2647, DOI 10.1091/mbc.10.8.2647; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; Glerum DM, 1996, J BIOL CHEM, V271, P14504, DOI 10.1074/jbc.271.24.14504; HALLIWELL B, 1992, FEBS LETT, V307, P108, DOI 10.1016/0014-5793(92)80911-Y; HALLIWELL B, 1984, BIOCHEM J, V219, P1, DOI 10.1042/bj2190001; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; Heaton D, 2000, J BIOL CHEM, V275, P37582, DOI 10.1074/jbc.M006639200; Heaton DN, 2001, BIOCHEMISTRY-US, V40, P743, DOI 10.1021/bi002315x; Hiser L, 2000, J BIOL CHEM, V275, P619, DOI 10.1074/jbc.275.1.619; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Huffman DL, 2001, ANNU REV BIOCHEM, V70, P677, DOI 10.1146/annurev.biochem.70.1.677; KAMPFENKEL K, 1995, J BIOL CHEM, V270, P28479, DOI 10.1074/jbc.270.47.28479; Knight SAB, 1996, GENE DEV, V10, P1917, DOI 10.1101/gad.10.15.1917; KNIGHT SAB, 1994, MOL CELL BIOL, V14, P7792, DOI 10.1128/MCB.14.12.7792; Koch KA, 1996, MOL CELL BIOL, V16, P724; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Labbe S, 1999, J BIOL CHEM, V274, P36252, DOI 10.1074/jbc.274.51.36252; Labbe S, 1999, TRENDS MICROBIOL, V7, P500, DOI 10.1016/S0966-842X(99)01638-8; Labbe Simon, 2002, P571; Lee J, 2002, J BIOL CHEM, V277, P4380, DOI 10.1074/jbc.M104728200; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Martins LJ, 1998, J BIOL CHEM, V273, P23716, DOI 10.1074/jbc.273.37.23716; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; McNabb DS, 1997, BIOTECHNIQUES, V22, P1134, DOI 10.2144/97226rr01; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; Pasion SG, 1999, MOL BIOL CELL, V10, P4043, DOI 10.1091/mbc.10.12.4043; Pelletier B, 2002, J BIOL CHEM, V277, P22950, DOI 10.1074/jbc.M202682200; Pena MMO, 2000, J BIOL CHEM, V275, P33244, DOI 10.1074/jbc.M005392200; Pena MMO, 1999, J NUTR, V129, P1251, DOI 10.1093/jn/129.7.1251; Portnoy ME, 2001, MOL GENET GENOMICS, V265, P873, DOI 10.1007/s004380100482; PREDKI PF, 1992, J BIOL CHEM, V267, P5842; PRENTICE HL, 1992, NUCLEIC ACIDS RES, V20, P621, DOI 10.1093/nar/20.3.621; Puig S, 2002, CURR OPIN CHEM BIOL, V6, P171, DOI 10.1016/S1367-5931(02)00298-3; Puig S, 2002, J BIOL CHEM, V277, P26021, DOI 10.1074/jbc.M202547200; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; Rentzsch A, 1999, CURR GENET, V35, P103, DOI 10.1007/s002940050438; Szczypka MS, 1997, YEAST, V13, P1423, DOI 10.1002/(SICI)1097-0061(199712)13:15<1423::AID-YEA190>3.3.CO;2-3; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Valentine JS, 1997, SCIENCE, V278, P817, DOI 10.1126/science.278.5339.817; Veenhoff LM, 2002, TRENDS BIOCHEM SCI, V27, P242, DOI 10.1016/S0968-0004(02)02077-7; Wood V, 2002, NATURE, V415, P871, DOI 10.1038/nature724; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632; Zhou H, 2001, J BIOL CHEM, V276, P20529, DOI 10.1074/jbc.M102004200	72	67	71	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46676	46686		10.1074/jbc.M206444200	http://dx.doi.org/10.1074/jbc.M206444200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244050	hybrid			2022-12-25	WOS:000179529300126
J	Garrel, G; Lozach, A; Bachir, LK; Laverriere, JN; Counis, R				Garrel, G; Lozach, A; Bachir, LK; Laverriere, JN; Counis, R			Pituitary adenylate cyclase-activating polypeptide stimulates nitric-oxide synthase type I expression and potentiates the cGMP response to gonadotropin-releasing hormone of rat pituitary gonadotrophs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; NEURONAL NADPH DIAPHORASE; LUTEINIZING-HORMONE; GROWTH-HORMONE; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; RECEPTOR GENE; CYCLIC-AMP; NATRIURETIC PEPTIDE; ALPHA-T3-1 CELLS	Nitric-oxide synthase type I (NOS I) is expressed primarily in gonadotrophs and in folliculo-stellate cells of the anterior pituitary. In gonadotrophs, the expression and the activity of NOS I are stimulated by gonadotropin-releasing hormone (GnRH) under both experimental and physiological conditions. In the present study, we show that pituitary adenylate cyclase-activating polypeptide (PACAP) is twice as potent as GnRH at increasing NOS I levels in cultured rat anterior pituitary cells. The action of PACAP is detectable after 4-6 h and maximal at 24 h, this effect is mimicked by 8-bromo-cAMP and cholera toxin and suppressed by H89 suggesting a mediation through the cAMP pathway. Surprisingly, NADPH diaphorase staining revealed that these changes occurred in gonadotrophs exclusively although PACAP and cAMP, in contrast to GnRH, have the potential to target several types of pituitary cells including folliculo-stellate cells. There was no measurable alteration in NOS I mRNA levels after cAMP or PACAP induction. PACAP also stimulated cGMP synthesis, which was maximal within 15 min and independent of cAMP, however, only part resulted from NOS I/soluble guanylate cyclase activation implying that in contrast to GnRH, PACAP has a dual mechanism in cGMP production. Interestingly, induction of NOS I by PACAP markedly enhanced the capacity of gonadotrophs to produce cGMP in response to GnRH. The fact that PACAP may act on gonadotrophs to alter NOS I levels, generate cGMP, and potentiate the cGMP response to GnRH, suggests that cGMP could play important cellular functions.	Univ Paris 06, CNRS, UMR 7079, F-75252 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Counis, R (corresponding author), Univ Paris 06, CNRS, UMR 7079, Case 256, F-75252 Paris 05, France.	Raymond.Counis@snv.jussieu.fr	Laverriere, Jean-Noel/L-3286-2017; GARREL, Ghislaine/L-2654-2017	Laverriere, Jean-Noel/0000-0003-0442-1358; GARREL, Ghislaine/0000-0001-8547-1191				Alarid ET, 1996, DEVELOPMENT, V122, P3319; Andric SA, 2001, J BIOL CHEM, V276, P844, DOI 10.1074/jbc.M004406200; Bachir LK, 2001, ENDOCRINOLOGY, V142, P4631, DOI 10.1210/en.142.11.4631; Belsham DD, 1996, EMBO J, V15, P538, DOI 10.1002/j.1460-2075.1996.tb00386.x; BHAT GK, 1995, NEUROENDOCRINOLOGY, V62, P187, DOI 10.1159/000127004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CECCATELLI S, 1993, P NATL ACAD SCI USA, V90, P11292, DOI 10.1073/pnas.90.23.11292; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; Choi EJ, 2000, MOL BRAIN RES, V80, P35, DOI 10.1016/S0169-328X(00)00116-9; COUNIS R, 1991, TRENDS ENDOCRIN MET, V2, P181, DOI 10.1016/1043-2760(91)90016-G; COUNIS R, 1999, ENCY REPROD, V2, P507; CULLER MD, 1991, ENDOCRINOLOGY, V129, P2260, DOI 10.1210/endo-129-4-2260; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; DUHAU L, 1991, J IMMUNOASSAY, V12, P233, DOI 10.1080/01971529108055069; DUVILANSKI BH, 1995, P NATL ACAD SCI USA, V92, P170, DOI 10.1073/pnas.92.1.170; Evans JJ, 1999, ENDOCR REV, V20, P46, DOI 10.1210/er.20.1.46; Fowkes RC, 2000, J ENDOCRINOL, V166, P195, DOI 10.1677/joe.0.1660195; Fowkes RC, 2000, TRENDS ENDOCRIN MET, V11, P333, DOI 10.1016/S1043-2760(00)00288-5; FOWKES RC, 2002, 84 ANN M END SOC SAN, P332; FRANDSEN EK, 1976, LIFE SCI, V18, P529, DOI 10.1016/0024-3205(76)90331-3; Garrel G, 1998, ENDOCRINOLOGY, V139, P2163, DOI 10.1210/en.139.4.2163; GARREL G, 1995, NEUROENDOCRINOLOGY, V62, P514, DOI 10.1159/000127042; GHARIB SD, 1990, ENDOCR REV, V11, P177, DOI 10.1210/edrv-11-1-177; Gobbetti A, 1999, BIOL REPROD, V60, P1217, DOI 10.1095/biolreprod60.5.1217; Grandclement B, 1995, J NEUROENDOCRINOL, V7, P939, DOI 10.1111/j.1365-2826.1995.tb00739.x; GUPTA RK, 1979, CLIN CHEM, V25, P752; Harmar AJ, 1998, PHARMACOL REV, V50, P265; HART GR, 1992, J ENDOCRINOL, V134, P33, DOI 10.1677/joe.0.1340033; HARTT DJ, 1995, BIOCHEM BIOPH RES CO, V214, P918, DOI 10.1006/bbrc.1995.2374; HOPE BT, 1991, P NATL ACAD SCI USA, V88, P2811, DOI 10.1073/pnas.88.7.2811; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; KATO M, 1992, ENDOCRINOLOGY, V131, P2133, DOI 10.1210/en.131.5.2133; KAWAKAMI M, 1980, ENDOCRINOLOGY, V106, P626, DOI 10.1210/endo-106-2-626; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; Kostic TS, 2001, MOL ENDOCRINOL, V15, P1010, DOI 10.1210/me.15.6.1010; Koves K, 1996, ANN NY ACAD SCI, V805, P648; LERRANT Y, 1995, ENDOCRINOLOGY, V136, P2803, DOI 10.1210/en.136.7.2803; LLOYD RV, 1995, AM J PATHOL, V146, P86; Lozach A, 1998, MOL CELL ENDOCRINOL, V143, P43, DOI 10.1016/S0303-7207(98)00135-X; MATTERI RL, 1987, DOMEST ANIM ENDOCRIN, V4, P157, DOI 10.1016/0739-7240(87)90011-7; MCARDLE CA, 1994, ENDOCRINOLOGY, V134, P2599, DOI 10.1210/en.134.6.2599; McArdle CA, 1996, TRENDS ENDOCRIN MET, V7, P168, DOI 10.1016/1043-2760(96)00051-3; Mitchell P, 2001, CURR OPIN CELL BIOL, V13, P320, DOI 10.1016/S0955-0674(00)00214-3; MIYATA A, 1989, BIOCHEM BIOPH RES CO, V164, P567, DOI 10.1016/0006-291X(89)91757-9; Murthy KS, 1998, AM J PHYSIOL-CELL PH, V275, pC1409, DOI 10.1152/ajpcell.1998.275.6.C1409; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; NAOR Z, 1980, ENDOCRINOLOGY, V107, P1438, DOI 10.1210/endo-107-5-1438; NAOR Z, 1980, J BIOL CHEM, V255, P342; Pincas H, 2001, MOL ENDOCRINOL, V15, P319, DOI 10.1210/me.15.2.319; Pincas H, 2001, J BIOL CHEM, V276, P23562, DOI 10.1074/jbc.M100563200; Pinilla L, 1999, HORM RES, V51, P242, DOI 10.1159/000023378; Pinilla L, 1999, J ENDOCRINOL INVEST, V22, P340, DOI 10.1007/BF03343571; Prevot V, 2000, BRAIN RES REV, V34, P27, DOI 10.1016/S0165-0173(00)00035-7; Qian X, 1999, ENDOCRINE, V11, P123, DOI 10.1385/ENDO:11:2:123; Rawlings SR, 1996, ENDOCR REV, V17, P4, DOI 10.1210/er.17.1.4; SCHOMERUS E, 1994, ENDOCRINOLOGY, V134, P315, DOI 10.1210/en.134.1.315; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SPENGLER D, 1992, MOL ENDOCRINOL, V6, P1931, DOI 10.1210/me.6.11.1931; STEINER AL, 1972, J BIOL CHEM, V247, P1106; TATSUNO I, 1991, ENDOCRINOLOGY, V129, P1797, DOI 10.1210/endo-129-4-1797; Thomas P, 1996, ENDOCRINOLOGY, V137, P2979, DOI 10.1210/en.137.7.2979; TSUJII T, 1994, ENDOCRINOLOGY, V135, P826, DOI 10.1210/en.135.3.826; TSUJII T, 1995, LIFE SCI, V56, P1103, DOI 10.1016/0024-3205(95)00047-A; TSUJII T, 1995, MOL CELL ENDOCRINOL, V113, P123, DOI 10.1016/0303-7207(95)03613-C; Vankelecom H, 1997, MOL CELL ENDOCRINOL, V129, P157, DOI 10.1016/S0303-7207(97)04054-9; Vaudry D, 2000, PHARMACOL REV, V52, P269; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Yamada K, 1997, NEUROENDOCRINOLOGY, V65, P147, DOI 10.1159/000127175; Yu WH, 1997, ENDOCRINOLOGY, V138, P5055, DOI 10.1210/en.138.11.5055; ZWILLER J, 1981, BIOCHEM BIOPH RES CO, V101, P1381, DOI 10.1016/0006-291X(81)91600-4	72	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46391	46401		10.1074/jbc.M203763200	http://dx.doi.org/10.1074/jbc.M203763200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244042	hybrid			2022-12-25	WOS:000179529300090
J	Schreiner, SJ; Schiavone, AP; Smithgall, TE				Schreiner, SJ; Schiavone, AP; Smithgall, TE			Activation of STAT3 by the Src family kinase Hck requires a functional SH3 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASES; DNA-BINDING ACTIVITY; C-SRC; V-SRC; CRYSTAL-STRUCTURE; GROWTH-FACTOR; 3-DIMENSIONAL STRUCTURE; MYELOID CELLS; HUMAN CANCER; IN-VIVO	STAT3 is a member of a family of transcription factors with Src homology 2 (SH2) domains that are activated by tyrosine phosphorylation in response to a wide variety of cytokines and growth factors. In this study, we investigated the mechanism of STAT3 activation by the Src family of nonreceptor tyrosine kinases, which have been linked to STAT activation in both normal and transformed cell types. Using Sf-9 insect cells, we demonstrate direct STAT3 tyrosine phosphorylation and stimulation of DNA binding activity by five members of the Src kinase family (Src, Hck, Lyn, Fyn, and Fgr). We also observed stable STAT3-Src family kinase complex formation in this system. Recombinant Src family kinase SH3 domains were sufficient for interaction with STAT3, suggesting a mechanistic basis for the Src kinase-STAT3 interaction. To test the contribution of Src family kinase SH3 domains to the recruitment and activation of STAT3 in vivo, we used Rat-2 fibroblasts expressing activated mutants of the myeloid Src family member Hck. Transformation of fibroblasts by an activated Hck mutant lacking the negative regulatory tail tyrosine residue (Hck-YF) induced strong DNA binding activity of endogenous STAT3. Inactivation of Hck SH3 function by Ala replacement of a conserved Trp residue (W93A mutant) completely abolished STAT3 activation by Hck-YF and reduced transforming activity by 50% without affecting Hck kinase activity. Finally, overexpression of STAT3 in Rat-2 cells transiently stimulated Hck and c-Src kinase activity in the absence of extracellular signals, an effect that was dependent upon a putative SH3 binding motif in STAT3. These results support a model in which Src family kinases recruit STAT3 through an SH3-dependent mechanism, resulting in transient kinase activation and STAT3 phosphorylation.	Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, Pittsburgh, PA 15261 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Smithgall, TE (corresponding author), Univ Pittsburgh, Sch Med, Dept Mol Genet & Biochem, E1240 Biomed Sci Tower, Pittsburgh, PA 15261 USA.	tsmithga@pitt.edu			NCI NIH HHS [CA81398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081398] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Biscardi JS, 1999, ADV CANCER RES, V76, P61; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Boonyaratanakornkit V, 2001, MOL CELL, V8, P269, DOI 10.1016/S1097-2765(01)00304-5; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; BRIGGS SD, 1995, J BIOL CHEM, V270, P14718, DOI 10.1074/jbc.270.24.14718; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Briggs SD, 2000, BIOCHEMISTRY-US, V39, P489, DOI 10.1021/bi992504j; Briggs SD, 2001, J BIOL CHEM, V276, P25605, DOI 10.1074/jbc.M103244200; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bromberg JF, 1998, MOL CELL BIOL, V18, P2553, DOI 10.1128/MCB.18.5.2553; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chaturvedi P, 1998, ONCOGENE, V16, P1749, DOI 10.1038/sj.onc.1201972; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Corey SJ, 1999, BLOOD, V93, P1, DOI 10.1182/blood.V93.1.1; Denny MF, 1999, J BIOL CHEM, V274, P5146, DOI 10.1074/jbc.274.8.5146; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Hassaine G, 2001, J BIOL CHEM, V276, P16885, DOI 10.1074/jbc.M009076200; Horvath CM, 2000, TRENDS BIOCHEM SCI, V25, P496, DOI 10.1016/S0968-0004(00)01624-8; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; Lowell CA, 1996, GENE DEV, V10, P1845, DOI 10.1101/gad.10.15.1845; Lund TC, 1999, CELL SIGNAL, V11, P789, DOI 10.1016/S0898-6568(99)00045-5; Lund TC, 1997, J VIROL, V71, P6677, DOI 10.1128/JVI.71.9.6677-6682.1997; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; Nelson KL, 1998, J BIOL CHEM, V273, P7072, DOI 10.1074/jbc.273.12.7072; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Pellicena P, 2002, FRONT BIOSCI-LANDMRK, V7, pD256, DOI 10.2741/pellicen; Pellicena P, 2001, J BIOL CHEM, V276, P28190, DOI 10.1074/jbc.M100055200; Peters KL, 1999, CELL SIGNAL, V11, P507, DOI 10.1016/S0898-6568(99)00021-2; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Reddy EP, 2000, ONCOGENE, V19, P2532, DOI 10.1038/sj.onc.1203594; REYNOLDS PJ, 1992, ONCOGENE, V7, P1949; Rogers JA, 1996, J BIOL CHEM, V271, P17519, DOI 10.1074/jbc.271.29.17519; SAKSELA K, 1995, EMBO J, V14, P484, DOI 10.1002/j.1460-2075.1995.tb07024.x; Schindler T, 1999, MOL CELL, V3, P639, DOI 10.1016/S1097-2765(00)80357-3; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Skorski T, 1998, BLOOD, V91, P406, DOI 10.1182/blood.V91.2.406.406_406_418; Smithgall TE, 2000, ONCOGENE, V19, P2612, DOI 10.1038/sj.onc.1203477; Susa M, 2000, TRENDS PHARMACOL SCI, V21, P489, DOI 10.1016/S0165-6147(00)01567-4; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VEILLETTE A, 1992, ONCOGENE, V7, P971; Wang YZ, 2000, ONCOGENE, V19, P2075, DOI 10.1038/sj.onc.1203548; Williams JC, 1998, TRENDS BIOCHEM SCI, V23, P179, DOI 10.1016/S0968-0004(98)01202-X; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; YU CL, 1995, SCIENCE, V269, P81, DOI 10.1126/science.7541555; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	63	134	135	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45680	45687		10.1074/jbc.M204255200	http://dx.doi.org/10.1074/jbc.M204255200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244095	hybrid			2022-12-25	WOS:000179404800135
J	Zhang, WJ; Yatskievych, TA; Cao, X; Antin, PB				Zhang, WJ; Yatskievych, TA; Cao, X; Antin, PB			Regulation of Hex gene expression by a Smads-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEINS; GROWTH-FACTOR-BETA; HOMEOBOX GENE; DNA-BINDING; LIVER DEVELOPMENT; INDUCTION; HEART; SPECIFICATION; TRANSCRIPTION; ELEMENTS	The homeobox gene Hex is expressed in multiple cell types during embryogenesis and is required for liver and monocyte development. Hex is expressed in the foregut region of late gastrula avian and mammalian embryos in a pattern that overlaps with expression of bone morphogenetic proteins (BMPs). Here we investigate the relationship between BMP signaling and Hex gene expression. We find that Hex expression in avian anterior lateral endoderm is regulated by autocrine BMP signaling. Characterization of the mouse Hex gene promoter identified a 71-nucleotide BMP-responsive element (BRE) that is required for up-regulation of Hex by an activated BMP signaling pathway. The Hex BRE binds Smad4 and Smad1-Smad4 complexes in vitro, and in transfection assays, it is responsive to Smad1 and Smad4 but not to Smad2 and Smad4 or Smad3 and Smad4. The BRE contains two copies of a GCCGnCGC-like motif that in Drosophila is the binding site for Mad and Madea followed by two CAGAG boxes that are similar to sequences required for transforming growth factor-beta/activin responsiveness of several vertebrate genes. Mutation of the GC elements, but not the two CAGAG boxes, abolishes Smads responsiveness in the intact Hex promoter, whereas mutations in both the GC elements and CAGAG boxes show that they act cooperatively to confer Smads responsiveness to the Hex promoter. The Hex BRE can confer Smads responsiveness to a heterologous promoter, and in this context, both the GC-rich elements and the CAGAG boxes are required for Smads-dependent promoter activity. An element almost identical to the Hex BRE is present within the BMP-responsive Nkx2-5 gene promoter, suggesting that the Hex BRE represents a common response element for genes regulated by BMP signaling in the foregut region of the embryo.	Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ 85724 USA; Univ Alabama Birmingham, Sch Med, Dept Pathol, Birmingham, AL 35294 USA	University of Arizona; University of Alabama System; University of Alabama Birmingham	Antin, PB (corresponding author), Univ Arizona, Dept Cell Biol & Anat, Tucson, AZ 85724 USA.	pba@u.arizona.edu		Antin, Parker/0000-0001-9066-7412	NHLBI NIH HHS [HL54133] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054133] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andree B, 1998, MECH DEVELOP, V70, P119, DOI 10.1016/S0925-4773(97)00186-X; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Barron M, 2000, DEV DYNAM, V218, P383, DOI 10.1002/(SICI)1097-0177(200006)218:2<383::AID-DVDY11>3.0.CO;2-P; BODMER R, 1993, DEVELOPMENT, V118, P719; Bogue CW, 2000, DEV DYNAM, V219, P84, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1028>3.0.CO;2-5; Chen YG, 1998, GENE DEV, V12, P2144, DOI 10.1101/gad.12.14.2144; CROMPTON MR, 1992, NUCLEIC ACIDS RES, V20, P5661, DOI 10.1093/nar/20.21.5661; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; FRASCH M, 1995, NATURE, V374, P464, DOI 10.1038/374464a0; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Henningfeld KA, 2000, J BIOL CHEM, V275, P21827, DOI 10.1074/jbc.M000978200; Hogan BLM, 1996, GENE DEV, V10, P1580, DOI 10.1101/gad.10.13.1580; Ishida W, 2000, J BIOL CHEM, V275, P6075, DOI 10.1074/jbc.275.9.6075; Jiang SW, 1996, NUCLEIC ACIDS RES, V24, P3278, DOI 10.1093/nar/24.16.3278; Johnson K, 1999, J BIOL CHEM, V274, P20709, DOI 10.1074/jbc.274.29.20709; Jung JN, 1999, SCIENCE, V284, P1998, DOI 10.1126/science.284.5422.1998; Keng VW, 2000, BIOCHEM BIOPH RES CO, V276, P1155, DOI 10.1006/bbrc.2000.3548; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; Korchynskyi O, 2002, J BIOL CHEM, V277, P4883, DOI 10.1074/jbc.M111023200; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Labbe E, 1998, MOL CELL, V2, P109, DOI 10.1016/S1097-2765(00)80119-7; Ladd AN, 1998, DEV BIOL, V204, P407, DOI 10.1006/dbio.1998.9094; LEDOUARIN N, 1964, J EMBRYOL EXP MORPH, V12, P651; LEDOUARIN NM, 1975, MED BIOL, V53, P427; Liberatore CM, 2002, DEV BIOL, V244, P243, DOI 10.1006/dbio.2002.0604; Lopez-Rovira T, 2002, J BIOL CHEM, V277, P3176, DOI 10.1074/jbc.M106826200; Lough J, 2000, DEV DYNAM, V217, P327, DOI 10.1002/(SICI)1097-0177(200004)217:4<327::AID-DVDY1>3.3.CO;2-B; Lough J, 1996, DEV BIOL, V178, P198, DOI 10.1006/dbio.1996.0211; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; Myint Z, 1999, J BIOCHEM-TOKYO, V125, P795, DOI 10.1093/oxfordjournals.jbchem.a022351; NEW DAT, 1955, J EMBRYOL EXP MORPH, V3, P320; Newman CS, 1997, MECH DEVELOP, V66, P83, DOI 10.1016/S0925-4773(97)00092-0; Reddi A. Hari, 1997, Cytokine and Growth Factor Reviews, V8, P11, DOI 10.1016/S1359-6101(96)00049-4; Rodriguez TA, 2001, DEV BIOL, V234, P304, DOI 10.1006/dbio.2001.0265; Rossi JM, 2001, GENE DEV, V15, P1998, DOI 10.1101/gad.904601; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Schlange T, 2000, MECH DEVELOP, V91, P259, DOI 10.1016/S0925-4773(99)00311-1; Schultheiss TM, 1997, GENE DEV, V11, P451, DOI 10.1101/gad.11.4.451; SCHULTHEISS TM, 1999, HEART DEV, P52; Searcy RD, 1998, DEVELOPMENT, V125, P4461; Shi XM, 1999, J BIOL CHEM, V274, P13711, DOI 10.1074/jbc.274.19.13711; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shi YQ, 2000, DEV BIOL, V224, P226, DOI 10.1006/dbio.2000.9802; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Walters MJ, 2001, MECH DEVELOP, V100, P263, DOI 10.1016/S0925-4773(00)00535-9; Xu X, 1998, GENE DEV, V12, P2354, DOI 10.1101/gad.12.15.2354; Yanagisawa J, 1999, SCIENCE, V283, P1317, DOI 10.1126/science.283.5406.1317; Yatskievych TA, 1999, MECH DEVELOP, V80, P107, DOI 10.1016/S0925-4773(98)00204-4; Zaret KS, 2000, MECH DEVELOP, V92, P83, DOI 10.1016/S0925-4773(99)00326-3; Zaret KS, 1996, ANNU REV PHYSIOL, V58, P231, DOI 10.1146/annurev.physiol.58.1.231; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zhou S, 1998, MOL CELL, V2, P121, DOI 10.1016/S1097-2765(00)80120-3; Zhu XL, 1996, DEV DYNAM, V207, P429, DOI 10.1002/(SICI)1097-0177(199612)207:4<429::AID-AJA7>3.0.CO;2-J	57	41	42	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45435	45441		10.1074/jbc.M208056200	http://dx.doi.org/10.1074/jbc.M208056200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12270938	hybrid			2022-12-25	WOS:000179404800107
J	Courtois, S; Verhaegh, G; North, S; Luciani, MG; Lassus, P; Hibner, U; Oren, M; Hainaut, P				Courtois, S; Verhaegh, G; North, S; Luciani, MG; Lassus, P; Hibner, U; Oren, M; Hainaut, P			Delta N-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53	ONCOGENE			English	Article						p53; Delta N-p53; p53 isoforms; N-terminal domain; cell cycle	PROTEOLYTIC CLEAVAGE; FUNCTIONAL DOMAIN; DNA-BINDING; IN-VITRO; PROTEIN; TRANSLATION; INITIATION; MDM2; P63; IDENTIFICATION	The tumor suppressor protein p53 is ubiquitously expressed as a major isoform of 53 kD, but several forms of lower molecular weight have been observed. Here, we describe a new isoform, DeltaN-p53, produced by internal initiation of translation at codon 40 and lacking the N-terminal first transactivation domain. This isoform has impaired transcriptional activation capacity, and does not complex with the p53 regulatory protein Mdm2. Furthermore, DeltaN-p53 oligomerizes with full-length p53 (FL-p53) and negatively regulates its transcriptional and growth-suppressive activities. Consistent with the lack of Mdm2 binding, DeltaN-p53 does not accumulate in response to DNA-damage, suggesting that this isoform is not involved in the response to genotoxic stress. However, in serum-starved cells expressing wild-type p53, DeltaN-p53 becomes the predominant p53 form during the synchronous progression into S phase after serum stimulation. These results suggest that DeltaN-p53 may play a role as a transient, negative regulator of p53 during cell cycle progression.	Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 08, France; CNRS, UMR5535, Inst Genet Mol, F-34293 Montpellier 5, France; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	World Health Organization; International Agency for Research on Cancer (IARC); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Montpellier; Weizmann Institute of Science	Hainaut, P (corresponding author), Int Agcy Res Canc, Grp Mol Carcinogenesis, 150 Cours Albert Thomas, F-69372 Lyon 08, France.	hainaut@iarc.fr	Hainaut, Pierre/B-6018-2012; Verhaegh, Gerald/L-4708-2015	Hainaut, Pierre/0000-0002-1303-1610; Verhaegh, Gerald/0000-0003-0227-2280; Hibner, Urszula/0000-0002-5520-7311; Oren, Moshe/0000-0003-4311-7172; Lassus, Patrice/0000-0002-2785-7843				Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Baptiste N, 2002, ONCOGENE, V21, P9, DOI 10.1038/sj/onc/1205015; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Barraille P, 1999, BIOCHEM BIOPH RES CO, V257, P84, DOI 10.1006/bbrc.1999.0334; Blankenship C, 1999, ONCOGENE, V18, P1529, DOI 10.1038/sj.onc.1202473; Candau R, 1997, ONCOGENE, V15, P807, DOI 10.1038/sj.onc.1201244; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Hainaut P, 2000, ADV CANCER RES, V77, P81; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; Kubbutat MHG, 1997, MOL CELL BIOL, V17, P460, DOI 10.1128/MCB.17.1.460; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; LEGROS Y, 1994, ONCOGENE, V9, P2071; Levrero M, 2000, J CELL SCI, V113, P1661; LIU XL, 1994, CARCINOGENESIS, V15, P1969, DOI 10.1093/carcin/15.9.1969; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; Milner J, 1991, CURR OPIN CELL BIOL, V3, P282, DOI 10.1016/0955-0674(91)90153-P; Molinari M, 1996, ONCOGENE, V13, P2077; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Okorokov AL, 1997, ONCOL RES, V9, P267; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; REICH NC, 1983, MOL CELL BIOL, V3, P2143, DOI 10.1128/MCB.3.12.2143; Scharnhorst V, 1999, J BIOL CHEM, V274, P23456, DOI 10.1074/jbc.274.33.23456; Schreiber M, 1999, GENE DEV, V13, P607, DOI 10.1101/gad.13.5.607; STEPHEN CW, 1995, J MOL BIOL, V248, P58, DOI 10.1006/jmbi.1995.0202; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; UNGER T, 1993, MOL CELL BIOL, V13, P5186, DOI 10.1128/MCB.13.9.5186; Veldhoen N, 1999, ONCOGENE, V18, P7026, DOI 10.1038/sj.onc.1203182; Verhaegh GW, 1997, MOL CELL BIOL, V17, P5699, DOI 10.1128/MCB.17.10.5699; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Walker KK, 1996, P NATL ACAD SCI USA, V93, P15335, DOI 10.1073/pnas.93.26.15335; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2002, TRENDS GENET, V18, P90, DOI 10.1016/S0168-9525(02)02595-7; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu JH, 1998, J BIOL CHEM, V273, P13030, DOI 10.1074/jbc.273.21.13030	38	211	217	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 3	2002	21	44					6722	6728		10.1038/sj.onc.1205874	http://dx.doi.org/10.1038/sj.onc.1205874			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360399				2022-12-25	WOS:000178315800002
J	Cipollo, JF; Costello, CE; Hirschberg, CB				Cipollo, JF; Costello, CE; Hirschberg, CB			The fine structure of Caenorhabditis elegans N-glycans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE SPECTROSCOPY; ASPARAGINE-LINKED OLIGOSACCHARIDES; SACCHAROMYCES-CEREVISIAE MUTANT; GLYCOPROTEIN-BIOSYNTHESIS; ACANTHOCHEILONEMA-VITEAE; ENDOPLASMIC-RETICULUM; CONGENITAL DISORDER; O-GLYCANS; LEWIS-X; PHOSPHORYLCHOLINE	We report the fine structure of a nearly contiguous series of N-glycans from the soil nematode Caenorhabditis elegans. Five major classes are revealed including high mannose, mammalian-type complex, hybrid, fuco-pausimannosidic (five mannose residues or fewer substituted with fucose), and phosphocholine oligosaccharides. The high mannose, complex, and hybrid N-glycan series show a high degree of conservation with the mammalian biosynthetic pathways. The fuco-pausimannosidic glycans contain a novel terminal fucose substitution of mannose. The phosphocholine oligosaccharides are high mannose type and are multiply substituted with phosphocholine. Although phosphocholine oligosaccharides are known immunomodulators in human nematode and trematode infections, C. elegans is unique as a non-parasitic nematode containing phosphocholine N-glycans. Therefore, studies in C. elegans should aid in the elucidation of the biosynthetic pathway(s) of this class of biomedically relevant compounds. Results presented here show that C. elegans has a functional orthologue for nearly every known enzyme found to be deficient in congenital disorders of glycosylation types I and II. This nematode is well characterized genetically and developmentally. Therefore, elucidation of its N-glycome, as shown in this report, may place it among the useful systems used to investigate human disorders of glycoconjugate synthesis such as the congenital disorders of glycosylation syndromes.	Boston Univ, Goldman Sch Grad Dent, Dept Cell & Mol Biol, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	Boston University; Boston University	Hirschberg, CB (corresponding author), Boston Univ, Goldman Sch Grad Dent, Dept Cell & Mol Biol, 715 Albany St,Evans 437, Boston, MA 02118 USA.	chirschb@bu.edu		Costello, Catherine/0000-0003-1594-5122; Hirschberg, Carlos/0000-0003-2299-7721	NCRR NIH HHS [P41 RR 10888, S10 RR 15942] Funding Source: Medline; NIGMS NIH HHS [GM 30365] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015942, P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030365, R37GM030365] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aebi M, 1999, Glycoconj J, V16, P669; BACIC A, 1990, EXP PARASITOL, V71, P483, DOI 10.1016/0014-4894(90)90074-M; BEARDEN JC, 1978, BIOCHIM BIOPHYS ACTA, V533, P525, DOI 10.1016/0005-2795(78)90398-7; BENDIAK B, 1988, ANAL BIOCHEM, V175, P96, DOI 10.1016/0003-2697(88)90366-1; BERMAN E, 1981, J BIOL CHEM, V256, P6657; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; BOLLAG MD, 1990, PROTEIN METHODS, P95; BRISSON JR, 1983, BIOCHEMISTRY-US, V22, P3680, DOI 10.1021/bi00284a022; BROCKHAUSEN I, 1992, CARBOHYD RES, V236, P281, DOI 10.1016/0008-6215(92)85022-R; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; CARVER JP, 1981, BIOCHEMISTRY-US, V20, P6607, DOI 10.1021/bi00526a014; Chantret I, 2002, J BIOL CHEM, V277, P25815, DOI 10.1074/jbc.M203285200; Chen SH, 1999, J BIOL CHEM, V274, P288, DOI 10.1074/jbc.274.1.288; Cipollo JF, 2001, J BIOL CHEM, V276, P21828, DOI 10.1074/jbc.M010896200; Cipollo JF, 2000, J BIOL CHEM, V275, P4267, DOI 10.1074/jbc.275.6.4267; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; COHEN RE, 1980, BIOCHEMISTRY-US, V19, P4345, DOI 10.1021/bi00559a031; Deehan MR, 2001, J IMMUNOL, V166, P7462, DOI 10.4049/jimmunol.166.12.7462; DUBOIS M, 1956, ANAL CHEM, V28, P350, DOI 10.1021/ac60111a017; Freeze HH, 2001, GLYCOBIOLOGY, V11, p129R, DOI 10.1093/glycob/11.12.129R; Gerdt S, 1999, EUR J BIOCHEM, V266, P952, DOI 10.1046/j.1432-1327.1999.00937.x; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; Hagen FK, 1998, J BIOL CHEM, V273, P8268, DOI 10.1074/jbc.273.14.8268; Hansske B, 2002, J CLIN INVEST, V109, P725, DOI 10.1172/JCI200214010; HARD K, 1991, GLYCOCONJUGATE J, V8, P17, DOI 10.1007/BF00731639; Haslam SM, 1996, J BIOL CHEM, V271, P30561, DOI 10.1074/jbc.271.48.30561; Haslam SM, 1999, J BIOL CHEM, V274, P20953, DOI 10.1074/jbc.274.30.20953; Haslam SM, 1998, MOL BIOCHEM PARASIT, V93, P143, DOI 10.1016/S0166-6851(98)00020-6; Haslam SM, 1997, MOL BIOCHEM PARASIT, V85, P53, DOI 10.1016/S0166-6851(96)02807-1; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Houston KM, 1996, J PARASITOL, V82, P320, DOI 10.2307/3284169; Huang HH, 2001, GLYCOBIOLOGY, V11, P395, DOI 10.1093/glycob/11.5.395; Jaeken J, 2001, ANNU REV GENOM HUM G, V2, P129, DOI 10.1146/annurev.genom.2.1.129; Khoo KH, 2001, GLYCOBIOLOGY, V11, P149, DOI 10.1093/glycob/11.2.149; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kranz C, 2001, J CLIN INVEST, V108, P1613, DOI 10.1172/JCI200113635; Morelle W, 2000, MOL BIOCHEM PARASIT, V109, P171, DOI 10.1016/S0166-6851(00)00241-3; MOREMEN KW, 1994, GLYCOBIOLOGY, V4, P113, DOI 10.1093/glycob/4.2.113; Mulloy B, 1996, MOL BIOTECHNOL, V6, P241, DOI 10.1007/BF02761706; Natsuka S, 2002, J BIOCHEM, V131, P807, DOI 10.1093/oxfordjournals.jbchem.a003169; PFEIFFER G, 1992, EUR J BIOCHEM, V205, P961, DOI 10.1111/j.1432-1033.1992.tb16863.x; Schenk B, 2001, J CLIN INVEST, V108, P1687, DOI 10.1172/JCI200113419; STAUDACHER E, 1992, GLYCOCONJUGATE J, V9, P82, DOI 10.1007/BF00731703; TOWNSEND R R, 1991, Glycobiology, V1, P139, DOI 10.1093/glycob/1.2.139; TRIMBLE RB, 1991, J BIOL CHEM, V266, P22807; TRIMBLE RB, 1986, J BIOL CHEM, V261, P9815; TRIMBLE RB, 1992, GLYCOBIOLOGY, V2, P57, DOI 10.1093/glycob/2.1.57; VANKUIK JA, 1986, EUR J BIOCHEM, V159, P297; Verostek MF, 2000, ANAL BIOCHEM, V278, P111, DOI 10.1006/abio.1999.4433; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12104; VEROSTEK MF, 1993, J BIOL CHEM, V268, P12095; VEROSTEK MF, 1995, GLYCOBIOLOGY, V5, P671, DOI 10.1093/glycob/5.7.671; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; Warren CE, 2002, GLYCOBIOLOGY, V12, p8G; Watanabe S, 2002, J BIOL CHEM, V277, P5090, DOI 10.1074/jbc.M110548200	55	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49143	49157		10.1074/jbc.M208020200	http://dx.doi.org/10.1074/jbc.M208020200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12361949	hybrid			2022-12-25	WOS:000180028900008
J	Idel, S; Ellinghaus, P; Wolfrum, C; Nofer, JR; Gloerich, J; Assmann, G; Spener, F; Seedorf, U				Idel, S; Ellinghaus, P; Wolfrum, C; Nofer, JR; Gloerich, J; Assmann, G; Spener, F; Seedorf, U			Branched chain fatty acids induce nitric oxide-dependent apoptosis in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-ALPHA; PALMITATE-INDUCED APOPTOSIS; NECROSIS-FACTOR-ALPHA; PHYTANIC ACID; PPAR-ALPHA; REFSUM-DISEASE; PRISTANIC ACID; EXPRESSION; SYNTHASE; PROTEIN	Clinical observations in patients with peroxisomal disorders and studies employing corresponding mouse models have shown that supraphysiological concentrations of dietary branched chain fatty acids (BCFAs) are associated with a high level of toxicity, which is poorly understood at present. Here we show that phytanic and pristanic acid, two BCFAs that are metabolized in peroxisomes, promote apoptosis in cultured vascular smooth muscle cells of human, rat, and porcine origin. Under the conditions used, the apoptosis-promoting effect of BCFAs was neither shared by saturated or unsaturated straight chain fatty acids nor by artificial peroxisome proliferators, which, like phytanic and pristanic acid, have been shown to activate the peroxisome proliferator-activated receptor a (PPARalpha). We could demonstrate, however, that BCFA induced tumor necrosis factor a (TNFalpha) activation and secretion, which is an obligatory step required for induction of apoptosis by BCFAs. Furthermore, incubation of VSMCs with BCFA increased inducible nitric-oxide synthase (iNOS) mRNA and protein concentrations markedly within 2 h of treatment. Correspondingly, apoptosis was significantly reduced when the cells were co-treated with the competitive NOS inhibitors monomethyl-L-arginine monoacetate and aminoguanidine. Moreover, co-incubation with TGFbeta1, previously shown to destabilize iNOS mRNA, also abolished apoptosis. These results establish a new signaling cascade in which natural BCFA induced NO-dependent apoptosis, which is apparently triggered by autocrine secretion of TNFalpha in cultured VSMCs.	Univ Munster, Inst Arteriosclerosis Res, D-48149 Munster, Germany; Univ Munster, Dept Biochem, D-48149 Munster, Germany; Univ Munster, Inst Clin Chem & Lab Med, Cent Lab, D-48149 Munster, Germany; Univ Utrecht, Inst Biomembranes & Biochem Lipids, NL-3584 CH Utrecht, Netherlands	University of Munster; University of Munster; University of Munster; Utrecht University	Seedorf, U (corresponding author), Univ Munster, Inst Arteriosclerosis Res, Domagkstr 3, D-48149 Munster, Germany.		Gloerich, Jolein/L-4327-2015	Gloerich, Jolein/0000-0001-5976-8426; Seedorf, Udo/0000-0003-4652-5358; Wolfrum, Christian/0000-0002-3862-6805				Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Champagne MJ, 1999, HYPERTENSION, V33, P906, DOI 10.1161/01.HYP.33.3.906; Chinetti G, 1998, J BIOL CHEM, V273, P25573, DOI 10.1074/jbc.273.40.25573; Ellinghaus P, 1999, J BIOL CHEM, V274, P2766, DOI 10.1074/jbc.274.5.2766; FINDER J, 1995, AM J PHYSIOL-LUNG C, V268, pL862, DOI 10.1152/ajplung.1995.268.5.L862; FRANKS DJ, 1984, J CELL PHYSIOL, V119, P41, DOI 10.1002/jcp.1041190108; Geng YJ, 1996, ARTERIOSCL THROM VAS, V16, P19, DOI 10.1161/01.ATV.16.1.19; IDZIOREK T, 1995, J IMMUNOL METHODS, V185, P249, DOI 10.1016/0022-1759(95)00172-7; Inoue I, 1998, BIOCHEM BIOPH RES CO, V246, P370, DOI 10.1006/bbrc.1998.8622; Jansen GA, 1997, NAT GENET, V17, P190, DOI 10.1038/ng1097-190; Kitareewan S, 1996, MOL BIOL CELL, V7, P1153, DOI 10.1091/mbc.7.8.1153; Kong JY, 2000, BBA-MOL CELL BIOL L, V1485, P45, DOI 10.1016/S1388-1981(00)00028-7; Lemotte PK, 1996, EUR J BIOCHEM, V236, P328, DOI 10.1111/j.1432-1033.1996.00328.x; Leong KG, 2000, HISTOL HISTOPATHOL, V15, P1303, DOI 10.14670/HH-15.1303; Mihalik SJ, 1997, NAT GENET, V17, P185, DOI 10.1038/ng1097-185; NAKAYAMA I, 1994, J BIOL CHEM, V269, P11628; Nishio E, 1996, BIOCHEM BIOPH RES CO, V221, P163, DOI 10.1006/bbrc.1996.0563; Paumen MB, 1997, J BIOL CHEM, V272, P3324, DOI 10.1074/jbc.272.6.3324; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Plenz G, 1997, ARTERIOSCL THROM VAS, V17, P2489, DOI 10.1161/01.ATV.17.11.2489; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; Shimabukuro M, 1998, P NATL ACAD SCI USA, V95, P2498, DOI 10.1073/pnas.95.5.2498; Spink J, 1997, J BIOL CHEM, V272, P24417, DOI 10.1074/jbc.272.39.24417; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; van Grunsven EG, 1998, P NATL ACAD SCI USA, V95, P2128, DOI 10.1073/pnas.95.5.2128; Verhoeven NM, 1998, J INHERIT METAB DIS, V21, P697, DOI 10.1023/A:1005476631419; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Wanders R.J., 2001, METABOLIC MOL BASES, P3219; Wang H, 1998, AM J PHYSIOL-HEART C, V274, pH1132, DOI 10.1152/ajpheart.1998.274.4.H1132; Wolfrum C, 1999, J LIPID RES, V40, P708; Zhang HF, 2000, BRIT J PHARMACOL, V130, P270, DOI 10.1038/sj.bjp.0703284; Zomer AWM, 2000, J LIPID RES, V41, P1801	32	53	55	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49319	49325		10.1074/jbc.M204639200	http://dx.doi.org/10.1074/jbc.M204639200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12368296	hybrid			2022-12-25	WOS:000180028900028
J	Bencsath, KP; Podgorski, MS; Pagala, VR; Slaughter, CA; Schulman, BA				Bencsath, KP; Podgorski, MS; Pagala, VR; Slaughter, CA; Schulman, BA			Identification of a multifunctional binding site on Ubc9p required for Smt3p conjugation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; PROTEIN MODIFICATION; ACTIVATING ENZYME; SUMO CONJUGATION; UBIQUITIN; COMPLEX; PATHWAY; INSIGHTS; SYSTEM; NEDD8	Ubiquitin-like proteins (ub-lps) are conjugated by a conserved enzymatic pathway, involving ATP-dependent activation at the C terminus by an activating enzyme (E1) and formation of a thiolester intermediate with a conjugating enzyme (E2) prior to ligation to the target. Ubc9, the E2 for SUMO, synthesizes polymeric chains in the presence of its El and MgATP. To better understand conjugation of ub-lps, we have performed mutational analysis of Saccharomyces cerevisiae Ubc9p, which conjugates the SUMO family member Smt3p. We have identified Ubc9p surfaces involved in thiolester bond and Smt3p-Smt3p chain formation. The residues involved in thiolester bond formation map to a surface we show is the E1 binding site, and E2s for other ub-lps are likely to bind to their E1s at a homologous site. We also find that this same surface binds Smt3p. A mutation that impairs binding to El but not Smt3p impairs thiolester bond formation, suggesting that it is the El interaction at this site that is crucial. Interestingly, other E2s and their relatives also use this same surface for binding to ubiquitin, E3s, and other proteins, revealing this to be a multipurpose binding site and suggesting that the entire E1-E2-E3 pathway has coevolved for a given ub-1p.	St Jude Childrens Res Hosp, Dept Biol Struct, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Hartwell Ctr Bioinformat & Biotechnol, Memphis, TN 38105 USA; St Jude Childrens Res Hosp, Dept Genet Tumor Cell Biol, Memphis, TN 38105 USA	St Jude Children's Research Hospital; St Jude Children's Research Hospital; St Jude Children's Research Hospital	Schulman, BA (corresponding author), St Jude Childrens Res Hosp, Dept Biol Struct, 332 N Lauderdale,MS 311, Memphis, TN 38105 USA.	Brenda.schulman@stjude.org			NATIONAL CANCER INSTITUTE [R25CA023944, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [2 P30 CA 21765-24-25, R25 CA023944] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bernier-Villamor V, 2002, CELL, V108, P345, DOI 10.1016/S0092-8674(02)00630-X; CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; COOK WJ, 1992, J BIOL CHEM, V267, P15116; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; Gong LM, 1997, J BIOL CHEM, V272, P28198, DOI 10.1074/jbc.272.45.28198; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gong LM, 1999, J BIOL CHEM, V274, P12036, DOI 10.1074/jbc.274.17.12036; GOSINK MM, 1995, P NATL ACAD SCI USA, V92, P9117, DOI 10.1073/pnas.92.20.9117; HAAS AL, 1982, J BIOL CHEM, V257, P329; HAAS AL, 1988, J BIOL CHEM, V263, P13268; Hamilton KS, 2001, STRUCTURE, V9, P897, DOI 10.1016/S0969-2126(01)00657-8; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Ichimura Y, 2000, NATURE, V408, P488, DOI 10.1038/35044114; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, J BIOL CHEM, V272, P26799, DOI 10.1074/jbc.272.43.26799; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Liakopoulos D, 1998, EMBO J, V17, P2208, DOI 10.1093/emboj/17.8.2208; Lin YQ, 2002, J BIOL CHEM, V277, P21913, DOI 10.1074/jbc.M109398200; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; McKenna S, 2001, J BIOL CHEM, V276, P40120, DOI 10.1074/jbc.M102858200; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Moraes TF, 2001, NAT STRUCT BIOL, V8, P669, DOI 10.1038/90373; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; PITLUK ZW, 1995, MOL CELL BIOL, V15, P1210; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Salceda S, 1997, J BIOL CHEM, V272, P22642, DOI 10.1074/jbc.272.36.22642; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; Schmidt D, 2002, P NATL ACAD SCI USA, V99, P2872, DOI 10.1073/pnas.052559499; Schulman BA, 2000, NATURE, V408, P381, DOI 10.1038/35042620; Schwarz SE, 1998, P NATL ACAD SCI USA, V95, P560, DOI 10.1073/pnas.95.2.560; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SULLIVAN ML, 1991, J BIOL CHEM, V266, P23878; Tateishi K, 2001, J CELL BIOL, V155, P571, DOI 10.1083/jcb.200104035; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Whitby FG, 1998, J BIOL CHEM, V273, P34983, DOI 10.1074/jbc.273.52.34983; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	59	105	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47938	47945		10.1074/jbc.M207442200	http://dx.doi.org/10.1074/jbc.M207442200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354763	hybrid			2022-12-25	WOS:000179663700141
J	Kawano, R; Matsuo, N; Tanaka, H; Nasu, M; Yoshioka, H; Shirabe, K				Kawano, R; Matsuo, N; Tanaka, H; Nasu, M; Yoshioka, H; Shirabe, K			Identification and characterization of a soluble cadherin-7 isoform produced by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE SUBSTRATE; CELL-ADHESION MOLECULE; T-CADHERIN; CYTOPLASMIC DOMAIN; PROTEIN; EXPRESSION; FRAGMENT; CATENIN; MARKER; FAMILY	We identified an alternative mRNA encoding a novel cadherin-7 isoform by reverse transcriptase-PCR of RNA from day 12 chicken embryos. The alternative mRNA contains 49 bases of insertion in the premembrane region, leading to the substitution of 14 amino acids and the introduction of a premature stop codon. Identification of a 49-bp insertion sequence in the genomic DNA corresponding to the intron of the cadherin-7 gene suggests that alternative splicing is the cause of the alternative mRNA. Transient expression of the variant form in COS-7 or 293 cells produced a soluble protein. Aggregation assays and immunoprecipitation showed that the variant protein interacts with full-length cadherin-7 in vitro and in vivo and inhibits full-length cadherin-7-mediated cell adhesion. Immunohistochemistry revealed that the variant form was strongly expressed in dermomyotomes rather than in migrating neural crest cells, in contrast to the full-length cadherin-7, suggesting differential regulation of splicing and possible roles of variant cadherin-7 in the development of dermomyotomes and other tissues.	Oita Med Univ, Dept Anat Biol & Med, Oita 8795593, Japan; Oita Med Univ, Dept Infect Dis, Oita 8795593, Japan; Kumamoto Univ, Grad Sch Med Sci, Div Dev Neurobiol, Kumamoto 8600811, Japan	Oita University; Oita University; Kumamoto University	Kawano, R (corresponding author), Oita Med Univ, Dept Anat Biol & Med, Oita 8795593, Japan.	riekawa@oita-med.ac.jp						BLASCHUK OW, 1990, J MOL BIOL, V211, P679, DOI 10.1016/0022-2836(90)90065-T; Bolz H, 2001, NAT GENET, V27, P108, DOI 10.1038/83667; Chan AOO, 2001, GUT, V48, P808, DOI 10.1136/gut.48.6.808; Di Palma F, 2001, NAT GENET, V27, P103, DOI 10.1038/83660; Doyle DD, 1998, J BIOL CHEM, V273, P6937, DOI 10.1074/jbc.273.12.6937; FERGUSON MAJ, 1988, ANNU REV BIOCHEM, V57, P285; Fredette BJ, 1996, DEVELOPMENT, V122, P3163; Fujita Y, 2002, NAT CELL BIOL, V4, P222, DOI 10.1038/ncb758; Gadducci A, 1999, ANTICANCER RES, V19, P769; Gofuku J, 1998, BRIT J CANCER, V78, P1095, DOI 10.1038/bjc.1998.634; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; HAMBURGER V, 1951, J MORPHOL, V88, P49, DOI 10.1002/jmor.1050880104; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; Kawaguchi J, 1999, J BONE MINER RES, V14, P764, DOI 10.1359/jbmr.1999.14.5.764; Knudsen KA, 2000, HUM PATHOL, V31, P961, DOI 10.1053/hupa.2000.9074; LIU FT, 1979, BIOCHEMISTRY-US, V18, P690, DOI 10.1021/bi00571a022; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NAKAGAWA S, 1995, DEVELOPMENT, V121, P1321; Nakagawa S, 1998, DEVELOPMENT, V125, P2963; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Noe V, 2001, J CELL SCI, V114, P111; Nollet F, 2000, J MOL BIOL, V299, P551, DOI 10.1006/jmbi.2000.3777; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; PARADIES NE, 1993, J NEUROSCI RES, V36, P33, DOI 10.1002/jnr.490360105; RANSCHT B, 1991, NEURON, V7, P391, DOI 10.1016/0896-6273(91)90291-7; Redies C, 2000, PROG NEUROBIOL, V61, P611, DOI 10.1016/S0301-0082(99)00070-2; REYNOLDS AB, 1994, MOL CELL BIOL, V14, P8333, DOI 10.1128/MCB.14.12.8333; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Schmidt M, 2000, DEVELOPMENT, V127, P4105; SHIBAMOTO S, 1995, J CELL BIOL, V128, P949, DOI 10.1083/jcb.128.5.949; Soler AP, 2002, J CELL BIOCHEM, V85, P180, DOI 10.1002/jcb.10126; Sugimoto K, 1996, J BIOL CHEM, V271, P11548, DOI 10.1074/jbc.271.19.11548; TAKEICHI M, 1977, J CELL BIOL, V75, P464, DOI 10.1083/jcb.75.2.464; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; TANIHARA H, 1994, J CELL SCI, V107, P1697; WHEELOCK MJ, 1987, J CELL BIOCHEM, V34, P187, DOI 10.1002/jcb.240340305	41	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47679	47685		10.1074/jbc.M205328200	http://dx.doi.org/10.1074/jbc.M205328200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12364338	hybrid			2022-12-25	WOS:000179663700109
J	Lents, NH; Keenan, SM; Bellone, C; Baldassare, JJ				Lents, NH; Keenan, SM; Bellone, C; Baldassare, JJ			Stimulation of the Raf/MEK/ERK cascade is necessary and sufficient for activation and Thr-160 phosphorylation of a nuclear-targeted CDK2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; S-PHASE ENTRY; PROTEIN-KINASE; RETINOBLASTOMA PROTEIN; SUBSTRATE-SPECIFICITY; ECTOPIC EXPRESSION; CELL-PROLIFERATION; RESTRICTION POINT; G(1) PROGRESSION; IN-VITRO	The activity of cyclin-dependent kinase 2 is required for G(1)-S-phase progression of the eukaryotic cell cycle. In this study, we examine the activation of CDK2-cyclin E by constructing a CDK2 that is constitutively targeted to the nucleus. Activation of CDK2 requires the removal of two inhibitory phosphates (Thr-14 and Tyr-15) and the addition of one activating phosphate (Thr-160) by a nuclear localized CDK-activating kinase, which is thought to be constitutively active. Surprisingly, nuclear localized CDK2-NLS and CDK2-NLS(A14,F15), which lacks the inhibitory phosphorylation sites, require serum to become active, despite complexing with expressed cyclin E. We show that inhibition of mitogen-mediated ERK activation by treatment with U0126, a selective MEK inhibitor, or expression of dominant-negative ERK markedly reduces the phosphorylation of Thr-160 and enzymatic activity of both CDK2-NLS constructs. Consistent with a role for ERK in Thr-160 phosphorylation, expression of constitutively active Raf-1 induces Thr-160 phosphorylation of CDK2-NLS in serum-arrested cells, an effect that is blocked by treatment with U0126. Taken together, these data show a new role for ERK in G1 cell cycle progression: In addition to its role in stimulating cyclin D1 expression and nuclear translocation of CDK2, ERK regulates Thr-160 phosphorylation of CDK2-cyclin E.	St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA; St Louis Univ, Sch Med, Dept Mol Microbiol & Immunol, St Louis, MO 63104 USA	Saint Louis University; Saint Louis University	Baldassare, JJ (corresponding author), St Louis Univ, Sch Med, Dept Pharmacol & Physiol Sci, St Louis, MO 63104 USA.	baldasjj@slu.edu						BATES S, 1994, ONCOGENE, V9, P71; Blanchard DA, 2000, ONCOGENE, V19, P4184, DOI 10.1038/sj.onc.1203761; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; Chiariello M, 2000, BIOCHEM J, V349, P869, DOI 10.1042/bj3490869; Chow KNB, 1996, MOL CELL BIOL, V16, P7173; DENT P, 1995, MOL CELL BIOL, V15, P4125; DEVAULT A, 1995, EMBO J, V14, P5027, DOI 10.1002/j.1460-2075.1995.tb00185.x; Dietrich C, 1997, EXP CELL RES, V232, P72, DOI 10.1006/excr.1997.3507; DOU QP, 1993, CANCER RES, V53, P1493; Dubravka D, 2000, CELL RES, V10, P1, DOI 10.1038/sj.cr.7290031; DYNLACHT BD, 1994, GENE DEV, V8, P1772, DOI 10.1101/gad.8.15.1772; Espinoza FH, 1996, SCIENCE, V273, P1714, DOI 10.1126/science.273.5282.1714; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Goel R, 2002, J BIOL CHEM, V277, P18640, DOI 10.1074/jbc.M108995200; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Harper JW, 1998, GENE DEV, V12, P285, DOI 10.1101/gad.12.3.285; HARPER JW, 1993, CELL, V75, P805; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; Kaldis P, 2000, EUR J BIOCHEM, V267, P4213, DOI 10.1046/j.1432-1327.2000.01455.x; KATO J, 1993, GENE DEV, V7, P331; Keenan SM, 2001, J BIOL CHEM, V276, P22404, DOI 10.1074/jbc.M100409200; KNOBLICH JA, 1994, CELL, V77, P107, DOI 10.1016/0092-8674(94)90239-9; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; Larochelle S, 1998, GENE DEV, V12, P370, DOI 10.1101/gad.12.3.370; Leng XH, 1997, CURR BIOL, V7, P709, DOI 10.1016/S0960-9822(06)00301-0; MACDONALD SG, 1993, MOL CELL BIOL, V13, P6615, DOI 10.1128/MCB.13.11.6615; Martinez AM, 1997, EMBO J, V16, P343, DOI 10.1093/emboj/16.2.343; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; Nagahara H, 1999, P NATL ACAD SCI USA, V96, P14961, DOI 10.1073/pnas.96.26.14961; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PARDEE AB, 1974, P NATL ACAD SCI USA, V71, P1286, DOI 10.1073/pnas.71.4.1286; Phillips-Mason PJ, 2000, J BIOL CHEM, V275, P18046, DOI 10.1074/jbc.M909194199; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; Rossignol M, 1997, EMBO J, V16, P1628, DOI 10.1093/emboj/16.7.1628; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; SEBASTIAN B, 1993, P NATL ACAD SCI USA, V90, P3521, DOI 10.1073/pnas.90.8.3521; Sexl V, 1999, ONCOGENE, V18, P573, DOI 10.1038/sj.onc.1202362; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; TAM SW, 1994, ONCOGENE, V9, P2663; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAKRAKLIDES V, 2002, J BIOL CHEM; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Weber JD, 1997, J BIOL CHEM, V272, P32966, DOI 10.1074/jbc.272.52.32966; Winey M, 1999, CURR BIOL, V9, pR449, DOI 10.1016/S0960-9822(99)80279-6; Yankulov KY, 1997, EMBO J, V16, P1638, DOI 10.1093/emboj/16.7.1638; Zhao JY, 1998, GENE DEV, V12, P456, DOI 10.1101/gad.12.4.456	57	66	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47469	47475		10.1074/jbc.M207425200	http://dx.doi.org/10.1074/jbc.M207425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12359725	hybrid			2022-12-25	WOS:000179663700083
J	Miyazaki, K; Kawamoto, T; Tanimoto, K; Nishiyama, M; Honda, H; Kato, Y				Miyazaki, K; Kawamoto, T; Tanimoto, K; Nishiyama, M; Honda, H; Kato, Y			Identification of functional hypoxia response elements in the promoter region of the DEC1 and DEC2 genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR 1-ALPHA; UBIQUITIN-PROTEASOME PATHWAY; HUMAN ERYTHROPOIETIN GENE; TUMOR-SUPPRESSOR PROTEIN; LACTATE-DEHYDROGENASE-A; LOOP-HELIX PROTEIN; TRANSCRIPTION FACTOR; FACTOR-I; CHONDROGENIC DIFFERENTIATION; REPRESSES TRANSCRIPTION	Adaptation to hypoxia is a crucial process both physiologically (i.e. in chondrocytes) and pathologically (i.e. in tumor cells). Previous studies have shown that DEC1, a basic helix-loop-helix transcription factor, is induced by hypoxia in glioma cells (Ivanova, A. V., Ivanov, S. V., Danilkovitch-Miagkova, A., and Lerman, M. I. (2001) J. Biol. Chem. 276,15306-15315). In the present study, we found that hypoxia or CoCl2 enhanced the mRNA expression of DEC2, as well as DEC1, within 24 h in chondrogenic ATDC5, 293T, and HeLa cells. In luciferase assays, the regions between -524 and -401 in the DEC1 promoter, and between -863 and -258 in the DEC2 promoter, were responsible for the hypoxia- or hypoxia-inducible factor-1alpha (HIF-1alpha)-induced transcription. In these regions, we identified functional hypoxia response elements (HREs) that bound to HIF-1alpha and HIF-1beta. In addition to an HIF-1 binding site consensus sequence, the DEC1 HRE had cAMP response element-like and CACAG sequences, which were also involved in the transcription activation in response to HIF-1alpha. Although the DEC2 HRE did not have a cAMP response element-like or CACAG sequence, it showed a higher affinity for HIF-1 than did the DEC1 HRE. Because DEC1 and DEC2 are directly inducible by HIF-1, these transcription factors may be crucial for the adaptation to hypoxia.	Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Dept Dev Biol, Minami Ku, Hiroshima 7348553, Japan; Hiroshima Univ, Dept Translat Canc Res, Div Clin & Expt Oncol, Res Inst Radiat Biol & Med,Minami Ku, Hiroshima 7348553, Japan	Hiroshima University; Hiroshima University; Hiroshima University	Kato, Y (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Dent & Med Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.		, 河本健/D-7938-2015; Keiji, Tanimoto/U-1839-2019	, 河本健/0000-0003-3337-1775; Keiji, Tanimoto/0000-0003-4912-4197				Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Ebert BL, 1998, MOL CELL BIOL, V18, P4089, DOI 10.1128/MCB.18.7.4089; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; Fujimoto K, 2001, BIOCHEM BIOPH RES CO, V280, P164, DOI 10.1006/bbrc.2000.4133; Garriga-Canut M, 2001, J BIOL CHEM, V276, P14821, DOI 10.1074/jbc.M011619200; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jiang BH, 1996, J BIOL CHEM, V271, P17771, DOI 10.1074/jbc.271.30.17771; Kallio PJ, 1997, P NATL ACAD SCI USA, V94, P5667, DOI 10.1073/pnas.94.11.5667; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Lee SG, 2001, FEBS LETT, V507, P259, DOI 10.1016/S0014-5793(01)02989-1; Lok CN, 1999, J BIOL CHEM, V274, P24147, DOI 10.1074/jbc.274.34.24147; Mazure NM, 2002, CANCER RES, V62, P1158; Mukhopadhyay CK, 2000, J BIOL CHEM, V275, P21048, DOI 10.1074/jbc.M000636200; Nakamasu K, 1999, BBA-GENE STRUCT EXPR, V1447, P258, DOI 10.1016/S0167-4781(99)00173-6; Oikawa M, 2001, BIOCHEM BIOPH RES CO, V289, P39, DOI 10.1006/bbrc.2001.5927; Rolfs A, 1997, J BIOL CHEM, V272, P20055, DOI 10.1074/jbc.272.32.20055; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Schipani E, 2001, GENE DEV, V15, P2865; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Semenza GL, 2000, J APPL PHYSIOL, V88, P1474, DOI 10.1152/jappl.2000.88.4.1474; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; SEMENZA GL, 1991, P NATL ACAD SCI USA, V88, P5680, DOI 10.1073/pnas.88.13.5680; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shukunami C, 1996, J CELL BIOL, V133, P457, DOI 10.1083/jcb.133.2.457; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Teramoto M, 2001, J BIOCHEM-TOKYO, V129, P391, DOI 10.1093/oxfordjournals.jbchem.a002869; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	40	175	179	1	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47014	47021		10.1074/jbc.M204938200	http://dx.doi.org/10.1074/jbc.M204938200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12354771	hybrid			2022-12-25	WOS:000179663700025
J	Young, SH; Wu, SV; Rozengurt, E				Young, SH; Wu, SV; Rozengurt, E			Ca2+-stimulated Ca2+ oscillations produced by the Ca2+-sensing receptor require negative feedback by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-SENSING RECEPTOR; FOCAL ADHESION KINASE; TYROSINE PHOSPHORYLATION; ACTIVATION; STIMULATION; BRADYKININ; MECHANISM; FREQUENCY; BOMBESIN	We examined the role of protein kinase C (PKC) in the mechanism and regulation of intracellular Ca2+ concentration ([Ca2+](i)) oscillations elicited by an increase in the extracellular concentration of Ca2+ ([Ca2+](e)) in human embryonic kidney 293 cells expressing the Ca2+ sensing receptor (CaR). Exposure to the PKC inhibitors bisindolylmaleimide I (GF I) or Ro-31-8220 converted oscillatory responses to transient, non-oscillatory responses, significantly reducing the percentage of cells that showed [Ca2+](i) oscillations but without decreasing the overall response to increase in [Ca2+](e). Exposure to 100 nm phorbol 12,13-dibutyrate, a direct activator of PKC, eliminated [Ca2+](i) oscillations. Addition of phorbol 12,13-dibutyrate at lower concentrations (3 and 10 nm) did not eliminate the oscillations but greatly reduced their frequency in a dose-dependent manner. Co-expression of CaR with constitutively active mutants of PKC (either epsilon or beta(1) isoforms) also reduced [Ca2+](i) oscillation frequency. Expression of a mutant CaR in which the major PKC phosphorylation site is altered by substitution of alanine for threonine (T888A) eliminated oscillatory behavior, producing [Ca2+](i) responses almost identical to those produced by the wild type CaR exposed to PKC inhibitors. These results support a model in which phosphorylation of the CaR at the inhibitory threonine 888 by PKC provides the negative feedback needed to cause [Ca2+](i) oscillations mediated by this receptor.	Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Unit Signal Transduct & Gastrointestinal Canc, CURE Digest Dis Res Ctr,Div Digest Dis, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Rozengurt, E (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med,Dept Med, Unit Signal Transduct & Gastrointestinal Canc, CURE Digest Dis Res Ctr,Div Digest Dis, Rm 11-124,Warren Hall,900 Vet Ave, Los Angeles, CA 90095 USA.	erozengurt@mednet.ucla.edu			NATIONAL CANCER INSTITUTE [P50CA090388] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK017294, R01DK056930, R01DK017294] Funding Source: NIH RePORTER; NCI NIH HHS [P50 CA90388] Funding Source: Medline; NIDDK NIH HHS [DK 55003, DK 56930, DK 17294] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai M, 1998, J BIOL CHEM, V273, P21267, DOI 10.1074/jbc.273.33.21267; BERRIDGE MJ, 1990, J BIOL CHEM, V265, P9583; Breitwieser GE, 2001, AM J PHYSIOL-CELL PH, V280, pC1412, DOI 10.1152/ajpcell.2001.280.6.C1412; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Buchan AMJ, 2001, GASTROENTEROLOGY, V120, P1128, DOI 10.1053/gast.2001.23246; Cheng I, 1997, GASTROENTEROLOGY, V112, pA1139; Codazzi F, 2001, CURR BIOL, V11, P1089, DOI 10.1016/S0960-9822(01)00326-8; Conigrave AD, 2000, P NATL ACAD SCI USA, V97, P4814, DOI 10.1073/pnas.97.9.4814; Dale LB, 2001, J BIOL CHEM, V276, P35900, DOI 10.1074/jbc.M103847200; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; Hendy GN, 2000, HUM MUTAT, V16, P281, DOI 10.1002/1098-1004(200010)16:4<281::AID-HUMU1>3.0.CO;2-A; HO C, 1995, NAT GENET, V11, P389, DOI 10.1038/ng1295-389; Hu QH, 1999, J BIOL CHEM, V274, P33995, DOI 10.1074/jbc.274.48.33995; Kawabata S, 1996, NATURE, V383, P89, DOI 10.1038/383089a0; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Needham LK, 1998, J BIOL CHEM, V273, P14626, DOI 10.1074/jbc.273.23.14626; NEWTON AC, 1995, J BIOL CHEM, V270, P28495, DOI 10.1074/jbc.270.48.28495; Newton AC, 1998, BBA-REV BIOMEMBRANES, V1376, P155, DOI 10.1016/S0304-4157(98)00003-3; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oancea E, 1998, CELL, V95, P307, DOI 10.1016/S0092-8674(00)81763-8; Oda Y, 2000, J BIOL CHEM, V275, P1183, DOI 10.1074/jbc.275.2.1183; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Riccardi D, 1998, AM J PHYSIOL-RENAL, V274, pF611, DOI 10.1152/ajprenal.1998.274.3.F611; Schaefer M, 2001, FASEB J, V15, P1634, DOI 10.1096/fj.00-0824fje; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; Soderling TR, 2001, J BIOL CHEM, V276, P3719, DOI 10.1074/jbc.R000013200; Taylor CW, 2001, CURR BIOL, V11, pR352, DOI 10.1016/S0960-9822(01)00192-0; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; Usachev YM, 2002, NEURON, V33, P113, DOI 10.1016/S0896-6273(01)00557-8; Waldron RT, 2001, J BIOL CHEM, V276, P32606, DOI 10.1074/jbc.M101648200; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; Young SH, 2002, AM J PHYSIOL-CELL PH, V282, pC1414, DOI 10.1152/ajpcell.00432.2001; Yuan JZ, 2000, J BIOL CHEM, V275, P2157, DOI 10.1074/jbc.275.3.2157; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200; Zugaza JL, 1996, EMBO J, V15, P6220, DOI 10.1002/j.1460-2075.1996.tb01012.x; Zugaza JL, 1997, J BIOL CHEM, V272, P23952, DOI 10.1074/jbc.272.38.23952	41	44	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46871	46876		10.1074/jbc.M207083200	http://dx.doi.org/10.1074/jbc.M207083200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356761	hybrid			2022-12-25	WOS:000179663700007
J	Hall, DB; Struhl, K				Hall, DB; Struhl, K			The VP16 activation domain interacts with multiple transcriptional components as determined by protein-protein cross-linking in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA BOX-BINDING; HISTONE ACETYLTRANSFERASE; SACCHAROMYCES-CEREVISIAE; SWI/SNF COMPLEX; SAGA COMPLEX; FACTOR TFIIB; RECRUITMENT; PROMOTER; DISTINCT; COACTIVATOR	Transcriptional activator proteins recruit the RNA polymerase II machinery and chromatin-modifying activities to promoters. Biochemical experiments indicate that activator proteins can associate with a large number of proteins, and many such proteins have been proposed to be direct targets of activators. However, there is great uncertainty about which biochemical interactions are physiologically relevant. Here, we develop a formaldehyde-based cross-linking procedure to identify protein-protein interactions that occur under physiological conditions. We show that the VP16 activation domain directly interacts with TATA-binding protein (TBP), TFIIB, and the SAGA histone acetylase complex in vivo.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA.	kevin@hms.harvard.edu		Hall, Daniel B/0000-0002-5085-8334				BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Chou S, 1997, MOL CELL BIOL, V17, P6794, DOI 10.1128/MCB.17.12.6794; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberharter A, 1999, MOL CELL BIOL, V19, P6621; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; HENGARTNER CJ, 1995, GENE DEV, V9, P897, DOI 10.1101/gad.9.8.897; HOPE IA, 1988, NATURE, V333, P635, DOI 10.1038/333635a0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; HORI R, 1995, P NATL ACAD SCI USA, V92, P6047, DOI 10.1073/pnas.92.13.6047; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; Katan-Khaykovich Y, 2002, GENE DEV, V16, P743, DOI 10.1101/gad.967302; Keaveney M, 1998, MOL CELL, V1, P917, DOI 10.1016/S1097-2765(00)80091-X; KLEIN C, 1994, SCIENCE, V266, P280, DOI 10.1126/science.7939664; KOBAYASHI N, 1995, MOL CELL BIOL, V15, P6465; Koh SS, 1998, MOL CELL, V1, P895, DOI 10.1016/S1097-2765(00)80088-X; Kotani T, 2000, P NATL ACAD SCI USA, V97, P7178, DOI 10.1073/pnas.120074297; Kuo MH, 2000, MOL CELL, V6, P1309, DOI 10.1016/S1097-2765(00)00129-5; Kuras L, 2000, SCIENCE, V288, P1244, DOI 10.1126/science.288.5469.1244; Kuras L, 1999, NATURE, V399, P609, DOI 10.1038/21239; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; Li XY, 2000, SCIENCE, V288, P1242, DOI 10.1126/science.288.5469.1242; Li XY, 1999, NATURE, V399, P605, DOI 10.1038/21232; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Melcher K, 2000, J MOL BIOL, V301, P1097, DOI 10.1006/jmbi.2000.4034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; Myers LC, 2000, ANNU REV BIOCHEM, V69, P729, DOI 10.1146/annurev.biochem.69.1.729; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Neely KE, 2002, MOL CELL BIOL, V22, P1615, DOI 10.1128/MCB.22.6.1615-1625.2002; Nishikawa J, 1997, P NATL ACAD SCI USA, V94, P85, DOI 10.1073/pnas.94.1.85; Papamichos-Chronakis M, 2002, MOL CELL, V9, P1297, DOI 10.1016/S1097-2765(02)00545-2; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; Ptashne M, 1997, NATURE, V386, P569, DOI 10.1038/386569a0; REGIER JL, 1993, P NATL ACAD SCI USA, V90, P883, DOI 10.1073/pnas.90.3.883; Reid JL, 2000, MOL CELL, V6, P1297, DOI 10.1016/S1097-2765(00)00128-3; Roberts SM, 1997, GENETICS, V147, P451; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sanders SL, 2002, MOL CELL BIOL, V22, P6000, DOI 10.1128/MCB.22.16.6000-6013.2002; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Shen F, 1996, J BIOL CHEM, V271, P4827; Sterner DE, 1999, MOL CELL BIOL, V19, P86; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; STRUHL K, 1989, ANNU REV BIOCHEM, V58, P1051, DOI 10.1146/annurev.bi.58.070189.005155; Struhl K, 1996, CELL, V84, P179, DOI 10.1016/S0092-8674(00)80970-8; TANSEY WP, 1995, P NATL ACAD SCI USA, V92, P10550, DOI 10.1073/pnas.92.23.10550; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Tora L, 2002, GENE DEV, V16, P673, DOI 10.1101/gad.976402; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; Yudkovsky N, 1999, GENE DEV, V13, P2369, DOI 10.1101/gad.13.18.2369	67	99	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46043	46050		10.1074/jbc.M208911200	http://dx.doi.org/10.1074/jbc.M208911200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297514	hybrid			2022-12-25	WOS:000179529300045
J	Leivonen, SK; Chantry, A; Hakkinen, L; Han, JH; Kahari, VM				Leivonen, SK; Chantry, A; Hakkinen, L; Han, JH; Kahari, VM			Smad3 mediates transforming growth factor-beta-induced collagenase-3 (matrix metalloproteinase-13) expression in human gingival fibroblasts - Evidence for cross-talk between Smad3 and p38 signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; DEPENDENT TRANSCRIPTIONAL ACTIVATION; GENE COL7A1 PROMOTER; TGF-BETA; FUNCTIONAL-CHARACTERIZATION; DERMAL FIBROBLASTS; INHIBITOR-1 GENE; BINDING-ELEMENT; JUN FAMILY; CELLS	Transforming growth factor-beta (TGF-beta) is a potent inducer of collagenase-3 (NIMP-13) gene expression in human gingival fibroblasts, and this requires activation of the p38 mitogen-activated protein kinase pathway. Here, we have constructed recombinant adenoviruses harboring genes for hemagglutinin-tagged Smad2, Smad3, and Smad4 and used these in dissecting the role of Smads, the signaling mediators of TGF-beta, in regulation of endogenous MMP-13 gene expression in human gingival fibroblasts. Adenoviral expression of Smad3, but not Smad2, augmented the TGF-beta-elicited induction of MMP-13 expression. In addition, adenoviral gene delivery of dominant negative Smad3 blocked the TGF-beta-induced MMP-13 expression in gingival fibroblasts. Co-expression of Smad3 with constitutively active MKK3b and MKK6b, the upstream activators of p38, resulted in nuclear translocation of Smad3 in the absence of TGF-beta and in induction of MMP-13 expression. The induction of MMP-13 expression by Smad3 and constitutively active mutants of MKK3b or MKK6b was blocked by specific p38 inhibitor SB203580 and by the dominant negative form of p38alpha. These results show that TGF-beta-induced expression of human MMP-13 gene in gingival fibroblasts is dependent on the activation of two distinct signaling pathways (i.e. Smad3 and p38alpha). In addition, these findings provide evidence for a novel type of crosstalk between Smad and p38 mitogen-activated protein kinase signaling cascades, which involves activation of Smad3 by p38alpha.	Univ Turku, Ctr Biotechnol, FIN-20520 Turku, Finland; Abo Akad Univ, Ctr Biotechnol, FIN-20520 Turku, Finland; Univ Turku, Dept Med Biochem, FIN-20520 Turku, Finland; Univ Turku, Dept Dermatol, FIN-20520 Turku, Finland; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England; Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA	University of Turku; Abo Akademi University; University of Turku; University of Turku; University of East Anglia; University of British Columbia; Scripps Research Institute	Kahari, VM (corresponding author), Univ Turku, Ctr Biotechnol, Tykistokatu 6 B, FIN-20520 Turku, Finland.	veli-matti.kahari@utu.fi	Kahari, Veli-Matti/T-4925-2019; Leivonen, Suvi-Katri/AAK-3096-2021; Hakkinen, Lari/B-2228-2016; Han, J/G-4671-2010; Kähäri, Veli-Matti/E-5144-2011	Kahari, Veli-Matti/0000-0003-2421-9368; Kähäri, Veli-Matti/0000-0003-2421-9368				Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Ala-Aho R, 2002, INT J CANCER, V97, P283, DOI 10.1002/ijc.1619; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; Blanchette F, 2001, J BIOL CHEM, V276, P33986, DOI 10.1074/jbc.M100093200; BOUKAMP P, 1990, CANCER RES, V50, P2840; Brown JD, 1999, J BIOL CHEM, V274, P8797, DOI 10.1074/jbc.274.13.8797; Chen SJ, 1999, J INVEST DERMATOL, V112, P49, DOI 10.1046/j.1523-1747.1999.00477.x; de Caestecker MP, 1998, GENE DEV, V12, P1587, DOI 10.1101/gad.12.11.1587; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dooley S, 2001, FEBS LETT, V502, P4, DOI 10.1016/S0014-5793(01)02656-4; FORT P, 1985, NUCLEIC ACIDS RES, V13, P1431, DOI 10.1093/nar/13.5.1431; Foschi M, 1997, EMBO J, V16, P6439, DOI 10.1093/emboj/16.21.6439; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; Hocevar BA, 1999, EMBO J, V18, P1345, DOI 10.1093/emboj/18.5.1345; Hua XX, 1999, P NATL ACAD SCI USA, V96, P13130, DOI 10.1073/pnas.96.23.13130; Hua XX, 1998, GENE DEV, V12, P3084, DOI 10.1101/gad.12.19.3084; Jaakkola P, 2000, GENE THER, V7, P1640, DOI 10.1038/sj.gt.3301293; Jin G, 1997, J BIOL CHEM, V272, P26620, DOI 10.1074/jbc.272.42.26620; Johansson N, 2000, J CELL SCI, V113, P227; Johansson N, 2000, CELL MOL LIFE SCI, V57, P5, DOI 10.1007/s000180050495; Johansson N, 1997, DEV DYNAM, V208, P387, DOI 10.1002/(SICI)1097-0177(199703)208:3<387::AID-AJA9>3.0.CO;2-E; Johansson N, 1997, CELL GROWTH DIFFER, V8, P243; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; KESKIOJA J, 1988, J BIOL CHEM, V263, P3111; Liberati NT, 1999, P NATL ACAD SCI USA, V96, P4844, DOI 10.1073/pnas.96.9.4844; MAKELA JK, 1988, NUCLEIC ACIDS RES, V16, P349, DOI 10.1093/nar/16.1.349; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mauviel A, 1996, J BIOL CHEM, V271, P10917, DOI 10.1074/jbc.271.18.10917; Nagarajan RP, 1999, J BIOL CHEM, V274, P31229, DOI 10.1074/jbc.274.44.31229; Nagarajan RP, 1999, J BIOL CHEM, V274, P33412, DOI 10.1074/jbc.274.47.33412; Nakao A, 1997, NATURE, V389, P631, DOI 10.1038/39369; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; Pardali K, 2000, J BIOL CHEM, V275, P29244, DOI 10.1074/jbc.M909467199; Pendas AM, 1997, GENOMICS, V40, P222, DOI 10.1006/geno.1996.4554; Piek E, 1999, INT J CANCER, V80, P756, DOI 10.1002/(SICI)1097-0215(19990301)80:5<756::AID-IJC21>3.0.CO;2-N; Qing J, 2000, J BIOL CHEM, V275, P38802, DOI 10.1074/jbc.M004731200; Ravanti L, 2001, FASEB J, V15, P1098, DOI 10.1096/fj.00-0588fje; Ravanti L, 1999, J BIOL CHEM, V274, P37292, DOI 10.1074/jbc.274.52.37292; Reunanen N, 2002, J BIOL CHEM, V277, P32360, DOI 10.1074/jbc.M204296200; Sato M, 2002, J INVEST DERMATOL, V118, P704, DOI 10.1046/j.1523-1747.2002.01719.x; Souchelnytskyi S, 1997, J BIOL CHEM, V272, P28107, DOI 10.1074/jbc.272.44.28107; StahleBackdahl M, 1997, LAB INVEST, V76, P717; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; Stopa M, 2000, J BIOL CHEM, V275, P29308, DOI 10.1074/jbc.M003282200; Stroschein SL, 1999, J BIOL CHEM, V274, P9431, DOI 10.1074/jbc.274.14.9431; Tardif G, 2001, J RHEUMATOL, V28, P1631; Verrecchia F, 2002, J INVEST DERMATOL, V118, P211, DOI 10.1046/j.1523-1747.2002.01641.x; Vindevoghel L, 1998, J BIOL CHEM, V273, P13053, DOI 10.1074/jbc.273.21.13053; Vindevoghel L, 1998, P NATL ACAD SCI USA, V95, P14769, DOI 10.1073/pnas.95.25.14769; von Gersdorff G, 2000, J BIOL CHEM, V275, P11320, DOI 10.1074/jbc.275.15.11320; Wang YB, 1998, J BIOL CHEM, V273, P2161, DOI 10.1074/jbc.273.4.2161; Wang YB, 1998, J BIOL CHEM, V273, P5423, DOI 10.1074/jbc.273.10.5423; Watanabe H, 2001, J BIOL CHEM, V276, P14466, DOI 10.1074/jbc.M005724200; Werner F, 2000, J BIOL CHEM, V275, P36653, DOI 10.1074/jbc.M004536200; Wicks SJ, 2000, MOL CELL BIOL, V20, P8103, DOI 10.1128/MCB.20.21.8103-8111.2000; WILKINSON GWG, 1992, NUCLEIC ACIDS RES, V20, P2233, DOI 10.1093/nar/20.9.2233; Wong C, 1999, MOL CELL BIOL, V19, P1821; Yuan WH, 2001, J BIOL CHEM, V276, P38502, DOI 10.1074/jbc.M107081200; Zhang Y, 1998, NATURE, V394, P909, DOI 10.1038/29814	59	94	97	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46338	46346		10.1074/jbc.M206535200	http://dx.doi.org/10.1074/jbc.M206535200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270924	hybrid			2022-12-25	WOS:000179529300084
J	Mao, JZ; Li, L; McManus, M; Wu, JP; Cui, NR; Jiang, C				Mao, JZ; Li, L; McManus, M; Wu, JP; Cui, NR; Jiang, C			Molecular determinants for activation of G-protein-coupled inward rectifier K(+) (GIRK) channels by extracellular acidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNELS; SODIUM-DEPENDENT ACTIVATION; XENOPUS-OOCYTES; SYNAPTIC-TRANSMISSION; HISTIDINE-RESIDUES; KIR4.1 CHANNELS; PH SENSITIVITY; BETA-GAMMA; INHIBITION; RECEPTOR	Synaptic cleft acidification occurs following vesicle release. Such a pH change may affect synaptic transmissions in which G-protein-coupled inward rectifier K(+) (GIRK) channels play a role. To elucidate the effect of extracellular pH (pH(0)) on GIRK channels, we performed experiments on heteromeric GIRK1/GIRK4 channels expressed in Xenopus oocytes. A decrease in pH(0) to 6.2 augmented GIRK1/GIRK4 currents by similar to30%. The channel activation was reversible and dependent on pH. levels. This effect was produced by selective augmentation of single channel conductance without change in the open-state probability. To determine which subunit was involved, we took advantage of homomeric expression of GIRK1 and GIRK4 by introducing a single mutation. We found that homomeric GIRK1-F137S and GIRK4-S143T channels were activated at pH(0) 6.2 by similar to20 and similar to70%, respectively. Such activation was eliminated when a histidine residue in the M1-H5 linker was mutated to a non-titratable glutamine, i.e. H116Q in GIRK1 and H120Q in GIRK4. Both of these histidines were required for pH sensing of the heteromeric channels, because the mutation of one of them diminished but not abolished the pH(0) sensitivity. The pH(0) sensitivity of the heteromeric channels was completely lost when both were mutated. Thus, these results suggest that the GIRK-mediated synaptic transmission is determined by both neurotransmitter and protons with the transmitter accounting for only 70% of the effect on postsynaptic cell and protons released together with the transmitter contributing to the other 30%.	Georgia State Univ, Dept Biol, Atlanta, GA 30302 USA	University System of Georgia; Georgia State University	Jiang, C (corresponding author), Georgia State Univ, Dept Biol, 24 Peachtree Ctr Ave, Atlanta, GA 30302 USA.	cjiang@gsu.edu	mcmanus, michael/AAB-1239-2020	mcmanus, michael/0000-0003-3013-6569; Wu, Jianping/0000-0002-2684-6122	NHLBI NIH HHS [HL58410, R01 HL058410, R01 HL067890] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058410, R01HL067890] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ballanyi K, 1999, PROG NEUROBIOL, V59, P583, DOI 10.1016/S0301-0082(99)00009-X; Chanchevalap S, 2000, J BIOL CHEM, V275, P7811, DOI 10.1074/jbc.275.11.7811; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Cohen NA, 1996, J BIOL CHEM, V271, P32301, DOI 10.1074/jbc.271.50.32301; COULTER KL, 1995, NEURON, V15, P1157, DOI 10.1016/0896-6273(95)90103-5; Dascal N, 1997, CELL SIGNAL, V9, P551, DOI 10.1016/S0898-6568(97)00095-8; Dutar P, 2000, J NEUROPHYSIOL, V84, P2284, DOI 10.1152/jn.2000.84.5.2284; Hedin KE, 1996, NEURON, V16, P423, DOI 10.1016/S0896-6273(00)80060-4; Hill JJ, 2001, J BIOL CHEM, V276, P5505, DOI 10.1074/jbc.M008213200; Ho IHM, 1999, J PHYSIOL-LONDON, V520, P645, DOI 10.1111/j.1469-7793.1999.00645.x; Ho IHM, 1999, J BIOL CHEM, V274, P8639, DOI 10.1074/jbc.274.13.8639; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Hughes BA, 2000, AM J PHYSIOL-CELL PH, V279, pC771, DOI 10.1152/ajpcell.2000.279.3.C771; Johnson SM, 1996, J APPL PHYSIOL, V80, P2120, DOI 10.1152/jappl.1996.80.6.2120; Kaila Kai, 1998, P3; Kim D, 1999, J PHYSIOL-LONDON, V517, P59, DOI 10.1111/j.1469-7793.1999.0059z.x; Kobayashi T, 1996, BRIT J PHARMACOL, V119, P73, DOI 10.1111/j.1476-5381.1996.tb15679.x; Kobayashi T, 1999, NAT NEUROSCI, V2, P1091, DOI 10.1038/16019; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Kreienkamp HJ, 1997, FEBS LETT, V419, P92, DOI 10.1016/S0014-5793(97)01437-3; Lei WB, 2001, J BIOL CHEM, V276, P16720, DOI 10.1074/jbc.M100207200; Lewohl JM, 1999, NAT NEUROSCI, V2, P1084, DOI 10.1038/16012; Liao YJ, 1996, J NEUROSCI, V16, P7137; Liu YJ, 1997, ANNU REV NEUROSCI, V20, P125; Luscher C, 1997, NEURON, V19, P687, DOI 10.1016/S0896-6273(00)80381-5; McPhee JC, 1998, J BIOL CHEM, V273, P34696, DOI 10.1074/jbc.273.52.34696; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Nattie E, 1999, PROG NEUROBIOL, V59, P299, DOI 10.1016/S0301-0082(99)00008-8; OTERO AS, 1988, SCIENCE, V242, P443, DOI 10.1126/science.3051383; Pearson WL, 1999, J PHYSIOL-LONDON, V514, P639, DOI 10.1111/j.1469-7793.1999.639ad.x; Qu ZQ, 1999, J BIOL CHEM, V274, P13783, DOI 10.1074/jbc.274.20.13783; Qu ZQ, 2000, J BIOL CHEM, V275, P31573, DOI 10.1074/jbc.M003473200; Rogalski SL, 2001, J BIOL CHEM, V276, P14855, DOI 10.1074/jbc.M010097200; SMITH JC, 1995, LUNG BIOL HEALTH DIS, V82, P463; Stevens EB, 1999, MOL PHARMACOL, V55, P1020, DOI 10.1124/mol.55.6.1020; Sui JL, 1996, J GEN PHYSIOL, V108, P381, DOI 10.1085/jgp.108.5.381; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Vivaudou M, 1997, J BIOL CHEM, V272, P31553, DOI 10.1074/jbc.272.50.31553; Weigl LG, 2001, MOL PHARMACOL, V60, P282, DOI 10.1124/mol.60.2.282; Xu HX, 2001, J BIOL CHEM, V276, P38690, DOI 10.1074/jbc.M106595200; Xu HX, 2001, J BIOL CHEM, V276, P12898, DOI 10.1074/jbc.M009631200; Xu HX, 2000, AM J PHYSIOL-CELL PH, V279, pC1464, DOI 10.1152/ajpcell.2000.279.5.C1464; Yamada M, 1998, PHARMACOL REV, V50, P723; Yang ZJ, 1999, J PHYSIOL-LONDON, V520, P921, DOI 10.1111/j.1469-7793.1999.00921.x; YULI I, 1987, SCIENCE, V235, P340, DOI 10.1126/science.3798116; Zhang JS, 1999, CURR BIOL, V9, P1458, DOI 10.1016/S0960-9822(00)80115-3; Zhou W, 2001, P NATL ACAD SCI USA, V98, P6482, DOI 10.1073/pnas.111447798; Zhu GY, 1999, J PHYSIOL-LONDON, V516, P699, DOI 10.1111/j.1469-7793.1999.0699u.x; Zhu GY, 2000, J CELL PHYSIOL, V183, P53, DOI 10.1002/(SICI)1097-4652(200004)183:1<53::AID-JCP7>3.3.CO;2-I; [No title captured]	50	16	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46166	46171		10.1074/jbc.M205438200	http://dx.doi.org/10.1074/jbc.M205438200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12361957	hybrid			2022-12-25	WOS:000179529300062
J	Phadtare, S; Tyagi, S; Inouye, M; Severinov, K				Phadtare, S; Tyagi, S; Inouye, M; Severinov, K			Three amino acids in Escherichia coli CspE surface-exposed aromatic patch are critical for nucleic acid melting activity leading to transcription antitermination and cold acclimation of cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SOLUTION NMR STRUCTURE; SHOCK PROTEIN CSPA; RNA; BINDING; FAMILY; DOMAIN; CONDENSATION; SUBUNIT; DNA	Cold-shock proteins of the CspA family of Escherichia coli help the cells to acclimate to low temperature conditions through an unknown mechanism. In vitro, these proteins bind to single-stranded nucleic acids and destabilize nucleic acid secondary structures. An unusual surface-exposed patch of 6 evolutionarily conserved aromatic amino acids is thought to be involved in RNA binding by the cold-shock proteins. Here we investigated the functional role of the aromatic patch in E. coli CspE by substituting individual aromatic residues with positively charged Arg residues. These substitutions do not affect the RNA binding activity of the CspE mutants. We show that substitutions of three centrally located aromatic patch amino acid residues, Phe(17), Phe(30), and His(32), abolish the ability of the mutant CspE to acclimatize cells to cold, antiterminate transcription and melt nucleic acids but have no effect on RNA binding. On the other hand, peripherally located Trp(10), Phe(19), and Phe(33) can be substituted with Arg without loss of any of the in vivo and in vitro CspE functions tested. The results thus indicate that these aromatic patch residues have clearly distinct functional roles and further extend the correlation between the essential function of CspA homologues in cold acclimation and their ability to antiterminate transcription.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA; Publ Hlth Res Inst, Newark, NJ 07103 USA; Rutgers State Univ, Waksman Inst, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick	Severinov, K (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, 675 Hoes Lane, Piscataway, NJ 08854 USA.		Severinov, Konstantin/C-8545-2016	Tyagi, Sanjay/0000-0001-7303-5827	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059295, R37GM019043, R01GM019043] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 59295, GM 19043] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bae WH, 2000, P NATL ACAD SCI USA, V97, P7784, DOI 10.1073/pnas.97.14.7784; CHATTERJEE S, 1993, J BIOCHEM, V114, P663, DOI 10.1093/oxfordjournals.jbchem.a124234; Feng WQ, 1998, BIOCHEMISTRY-US, V37, P10881, DOI 10.1021/bi980269j; Feng Y, 2001, J BIOL CHEM, V276, P31651, DOI 10.1074/jbc.M102855200; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Hanna MM, 1998, J MOL BIOL, V282, P227, DOI 10.1006/jmbi.1998.2005; Hillier BJ, 1998, FOLD DES, V3, P87, DOI 10.1016/S1359-0278(98)00014-5; Hu KH, 1996, GENETICS, V143, P1521; Jiang WN, 1997, J BIOL CHEM, V272, P196; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; KAJITA Y, 1995, J BIOL CHEM, V270, P22167, DOI 10.1074/jbc.270.38.22167; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; Phadtare S, 1999, CURR OPIN MICROBIOL, V2, P175, DOI 10.1016/S1369-5274(99)80031-9; Phadtare S, 2000, BACTERIAL STRESS RESPONSES, P33; Phadtare S, 1999, MOL MICROBIOL, V33, P1004, DOI 10.1046/j.1365-2958.1999.01541.x; Phadtare S, 2002, J BIOL CHEM, V277, P7239, DOI 10.1074/jbc.M111496200; Phadtare S, 2001, J BACTERIOL, V183, P1205, DOI 10.1128/JB.183.4.1205-1214.2001; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHRODER K, 1995, MOL MICROBIOL, V16, P699, DOI 10.1111/j.1365-2958.1995.tb02431.x; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; Vu DM, 2001, PROTEIN SCI, V10, P2028, DOI 10.1110/ps.16201; WOLFFE AP, 1994, BIOESSAYS, V16, P245, DOI 10.1002/bies.950160407; Xia B, 2001, MOL MICROBIOL, V40, P179, DOI 10.1046/j.1365-2958.2001.02372.x; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zakharova N, 1998, J BIOL CHEM, V273, P24912, DOI 10.1074/jbc.273.38.24912	26	60	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46706	46711		10.1074/jbc.M208118200	http://dx.doi.org/10.1074/jbc.M208118200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12324471	hybrid			2022-12-25	WOS:000179529300129
J	St-Pierre, B; Flock, G; Zacksenhaus, E; Egan, SE				St-Pierre, B; Flock, G; Zacksenhaus, E; Egan, SE			Stra13 homodimers repress transcription through class B E-box elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEIN; BETA-CASEIN GENE; TUMOR-SUPPRESSOR; DNA-BINDING; ENHANCER; IDENTIFICATION; EXPRESSION; DROSOPHILA; ACTIVATION; HYPOXIA	A mammalian basic helix-loop-helix protein known variably as Stra13, Sharp2, and Dec1 has been implicated in cell activation, proliferation, and differentiation. Indeed, Stra13 null mice develop age-induced antoimmunity as a result of impaired T-lymphocyte activation, leading ultimately to the accumulation of autoreactive T-cells and B-cells. Stra13 is expressed in embryonic as well as adult tissues derived from neuroectoderm, mesoderm, and endoderm and has been associated with response to hypoxia, suggesting a complex role for this protein and the highly related Sharp1/Dec2 protein in homeostatic regulation. Whereas Stra13 is known to regulate many important cellular functions and is known to cross-regulate biological responses to other basic helix-loop-helix containing transcription factors, including c-Myc and USF, it is unclear if this protein binds directly to DNA. Indeed, the basic domain of Stra13 contains a proline residue at an unprecedented position. Herein, we have determined that Stra13 binds with high affinity to CACGTG class B E-box elements as a homodimer with preference for elements preceded by T and/or followed by A residues. In addition, transient transfection experiments reveal that Stra13 represses transcription when bound to these and related sites. Our data suggest that Stra13 regulates cellular functions through antagonism of E-box activator proteins and also through active repression from E-box elements.	Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Hosp Sick Children, Program Canc Res, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON, Canada; Univ Toronto, Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Lab Med, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Pathobiol, Toronto, ON M5G 2M1, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M1, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Egan, SE (corresponding author), Toronto Gen Res Inst, Univ Hlth Network, Div Cell & Mol Biol, 67 Coll St, Toronto, ON M5G 2M1, Canada.		Zacksenhaus, Eldad/AAD-3584-2020					BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; Boudjelal M, 1997, GENE DEV, V11, P2052, DOI 10.1101/gad.11.16.2052; Dear TN, 1997, ONCOGENE, V14, P891, DOI 10.1038/sj.onc.1200912; Dhar M, 2001, ONCOGENE, V20, P4750, DOI 10.1038/sj.onc.1204637; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Jennings BH, 1999, MOL CELL BIOL, V19, P4600; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; Massari ME, 2000, MOL CELL BIOL, V20, P429, DOI 10.1128/MCB.20.2.429-440.2000; OELLERS N, 1994, MOL GEN GENET, V244, P465, DOI 10.1007/BF00583897; Rossner MJ, 1997, MOL CELL NEUROSCI, V9, P460, DOI 10.1006/mcne.1997.0640; RUDEN DM, 1991, NATURE, V350, P250, DOI 10.1038/350250a0; Shen M, 1997, BIOCHEM BIOPH RES CO, V236, P294, DOI 10.1006/bbrc.1997.6960; Shen M, 2001, EUR J CELL BIOL, V80, P329, DOI 10.1078/0171-9335-00167; Sun H, 2000, P NATL ACAD SCI USA, V97, P4058, DOI 10.1073/pnas.070526297; Sun H, 2001, NAT IMMUNOL, V2, P1040, DOI 10.1038/ni721; Teramoto M, 2001, J BIOCHEM-TOKYO, V129, P391, DOI 10.1093/oxfordjournals.jbchem.a002869; TIETZE K, 1992, P NATL ACAD SCI USA, V89, P6152, DOI 10.1073/pnas.89.13.6152; Wartmann M, 1996, J BIOL CHEM, V271, P31863, DOI 10.1074/jbc.271.50.31863; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yoon DY, 2001, BIOCHEM BIOPH RES CO, V288, P882, DOI 10.1006/bbrc.2001.5867; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zawel L, 2002, P NATL ACAD SCI USA, V99, P2848, DOI 10.1073/pnas.261714999	24	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46544	46551		10.1074/jbc.M111652200	http://dx.doi.org/10.1074/jbc.M111652200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12297495	hybrid			2022-12-25	WOS:000179529300109
J	Xue, T; Li, RA				Xue, T; Li, RA			An external determinant in the S5-P linker of the pacemaker (HCN) channel identified by sulfhydryl modification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE MUTAGENESIS; CYCLIC-NUCLEOTIDE; POTASSIUM CHANNEL; LINING RESIDUES; SODIUM-CHANNELS; SLOW INACTIVATION; CHARGED RESIDUES; MOLECULAR-BASIS; ALPHA-SUBUNIT; ION CHANNELS	Hyperpolarization-activated, cyclic nucleotide-gated (HCN) channels underlie spontaneous rhythmic activities in the heart and brain. Sulfhydryl miodification of ion channels is a proven approach for studying their structure-function relationships; here we! examined the effects of the hydrophilic sulfhydryl-modifying agents methanethiosulfonate ethylammonium (MTSEA(+)) and methanethiosulfonate ethylsulfonate (MTSES-) on wildtype (WT) and engineered HCN1 channels. External application of MTSEA(+) to WT channels irreversibly reduced whole-cell currents (I-MTSEA/I-Control = 42 +/- 2%), slowed activation and deactivation kinetics (similar to7- and similar to3-fold at -140 and -20 mV, respectively), and produced hyperpolarizing shifts of steady-state activation (V-1/2(MTSEA) = -125.8 +/- 9.0 mV versus V-1/2(Control) = -76.4 +/- 1.6 mV). Sequence inspection revealed the presence of five endogenous cysteines in the transmembrane domains of HCN1: three are putatively close to the extracellular milieu (Cys(303), cys(318), and Cys(347) in the S5, S5-P, and P segments, respectively), whereas the remaining two are likely to be cytoplasmic or buried. To identify the molecular constituent(s) responsible for the effects of MTSEA(+), we mutated the three "external" cysteines individually to serine. C303S did not yield measurable currents. Whereas C347S channels remained sensitive to MTSEA(+), C318S was not modified (I-MTSEA/I-Control = 101 +/- 2%, V-1/2(MTSEA) = -78.4 +/- 1.1 mV, and V-1/2(Control) = -79.8 +/- 2.3 mV). Likewise, WT (but not C318S) channels were sensitive to MTSES-. Despite their opposite charges, MTSES- produced changes directionally similar to those effected by MTSEA+ (I-MTSES/I-Control = 22 +/- 1.6% and V-1/2(MTSES) = -145.9 +/- 4.9 mV). We conclude that S5-P CyS318 of HCN1 is externally accessible and that the external pore vestibule and activation gating of HCN channels are allosterically coupled.	Johns Hopkins Univ, Inst Mol Cardiobiol, Sch Med, Baltimore, MD 21205 USA	Johns Hopkins University	Li, RA (corresponding author), Johns Hopkins Univ, Inst Mol Cardiobiol, Sch Med, 720 Rutland Ave,Ross 844, Baltimore, MD 21205 USA.		Xue, Tian/G-9009-2018		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052768] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL-52768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; AZENE E, 2002, IN PRESS CIRCULATION; Balser JR, 1996, J PHYSIOL-LONDON, V494, P431, DOI 10.1113/jphysiol.1996.sp021503; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; Chen C, 2001, J GEN PHYSIOL, V117, P491, DOI 10.1085/jgp.117.5.491; Chiamvimonvat N, 1996, NEURON, V16, P1037, DOI 10.1016/S0896-6273(00)80127-0; Chiamvimonvat N, 1996, J PHYSIOL-LONDON, V491, P51, DOI 10.1113/jphysiol.1996.sp021195; Clapham DE, 1998, NEURON, V21, P5, DOI 10.1016/S0896-6273(00)80508-5; Creighton T. E, 1997, PROTEINS STRUCTURES; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; Gauss R, 1998, NATURE, V393, P583, DOI 10.1038/31248; HENRIKSON CA, 2002, IN PRESS CIRCULATION; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Horn R, 1998, METHOD ENZYMOL, V293, P145; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kaupp UB, 2001, ANNU REV PHYSIOL, V63, P235, DOI 10.1146/annurev.physiol.63.1.235; Li RA, 2000, J GEN PHYSIOL, V115, P81, DOI 10.1085/jgp.115.1.81; Li RA, 2001, CIRCULATION, V104, P309; LU Q, 1995, SCIENCE, V268, P304, DOI 10.1126/science.7716526; Ludwig A, 1998, NATURE, V393, P587, DOI 10.1038/31255; Ludwig A, 1999, CELL PHYSIOL BIOCHEM, V9, P179, DOI 10.1159/000016315; Marten I, 1998, BIOPHYS J, V74, P2953, DOI 10.1016/S0006-3495(98)78002-6; Pardo-Lopez L, 2002, J BIOL CHEM, V277, P16403, DOI 10.1074/jbc.M200460200; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Santoro B, 1999, ANN NY ACAD SCI, V868, P741, DOI 10.1111/j.1749-6632.1999.tb11353.x; Santoro B, 1998, CELL, V93, P717, DOI 10.1016/S0092-8674(00)81434-8; Sun ZP, 1996, NEURON, V16, P141, DOI 10.1016/S0896-6273(00)80031-8; Townsend C, 1997, J GEN PHYSIOL, V110, P23, DOI 10.1085/jgp.110.1.23; Tsushima RG, 1997, J GEN PHYSIOL, V109, P463, DOI 10.1085/jgp.109.4.463; Tsushima RG, 1997, J GEN PHYSIOL, V110, P59, DOI 10.1085/jgp.110.1.59; Ulens C, 2001, J BIOL CHEM, V276, P6069, DOI 10.1074/jbc.C000738200; Xue T, 2002, CIRC RES, V90, P1267, DOI 10.1161/01.RES.0000024390.97889.C6; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315	37	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46233	46242		10.1074/jbc.M204915200	http://dx.doi.org/10.1074/jbc.M204915200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351622	hybrid			2022-12-25	WOS:000179529300071
J	Mao, XR; Moerman, AM; Barger, SW				Mao, XR; Moerman, AM; Barger, SW			Neuronal kappa B-binding factors consist of Sp1-related proteins - Functional implications for autoregulation of N-methyl-D-aspartate receptor-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; TRANSCRIPTION FACTOR; GLUTAMATE NEUROTOXICITY; REPRESS TRANSCRIPTION; SUBUNIT GENE; CELL-DEATH; IN-VITRO; ACTIVATION; SP1; APOPTOSIS	Neurons contain a protein factor capable of binding DNA elements normally bound by the transcription factor NF-kappaB. However, several lines of evidence suggest that this neuronal kappaB-binding factor (NKBF) is not bona fide NF-kappaB. We have identified NkappaBF from cultures of neocortical neurons as a complex containing proteins related to Sp1. This complex was bound by antibodies to Sp1, Sp3, and Sp4 and was competed from binding to an NF-kappaB element by an oligonucleotide, containing an Sp1-binding site. This Sp1 oligonucleotide detected an abundant factor in neuronal nuclei that migrated in electrophoretic mobility shift assays at a position consistent with NKBF. Expression of transfected Sp1 stimulated transcription in a manner dependent upon a kappaB cis-element. Similar to our previous reports for NKBF (Mao, X., Moerman, A. M., Lucas, M. M., and Barger, S. W. (1999) J. Neurochem. 73, 1851-1858 and Moerman, A. M., Mao, X., Lucas, M. M., and Barger, S. W. (1999) Mol. Brain Res. 67, 303-315), the activity of the Sp1-related factor was reduced by activation of ionotropic glutamate receptors, consistent with proteolytic degradation of all three Sp1-related factors. Expression of the N-methyl-D-aspartate receptor-1 (NR1) subunit of glutamate receptors correlated with the activity of the Sp1-related factor, specifically through an Sp1 element in the NR1 promoter. These data provide the first evidence that Sp1 or related family members are responsible for kappaB-binding activity and are involved in a negative feedback for NR1 in central nervous system neurons.	Univ Arkansas Med Sci, Dept Anat & Neurobiol, Little Rock, AR 72205 USA; Univ Arkansas Med Sci, Dept Geriatr, Little Rock, AR 72205 USA; Ctr Geriatr Res Educ & Clin, Cent Arkansas Vet Healthcare Syst, Little Rock, AR 72205 USA	University of Arkansas System; University of Arkansas Medical Sciences; University of Arkansas System; University of Arkansas Medical Sciences; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Central Arkansas Veterans Healthcare System	Barger, SW (corresponding author), Reynolds Ctr Aging, 629 S Elm St,807, Little Rock, AR 72205 USA.			Moerman-Herzog, Andrea/0000-0002-5969-8939; Barger, Steven/0000-0001-6049-6480	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS009630] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG012411] Funding Source: NIH RePORTER; NIA NIH HHS [2P01AG12411-04A1003] Funding Source: Medline; NINDS NIH HHS [F32 NS09630] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMMENDOLA R, 1992, J BIOL CHEM, V267, P17944; AMMENDOLA R, 1994, EUR J BIOCHEM, V225, P483, DOI 10.1111/j.1432-1033.1994.t01-1-00483.x; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; Bachis A, 2001, J NEUROSCI, V21, P3104, DOI 10.1523/JNEUROSCI.21-09-03104.2001; Bai G, 1997, J BIOL CHEM, V272, P5936, DOI 10.1074/jbc.272.9.5936; Bai G, 1998, J BIOL CHEM, V273, P1086, DOI 10.1074/jbc.273.2.1086; BAI G, 1995, J BIOL CHEM, V270, P7737, DOI 10.1074/jbc.270.13.7737; Behl C, 2000, J NEURAL TRANSM, V107, P393, DOI 10.1007/s007020070082; Bigger CB, 1997, J BIOL CHEM, V272, P25976, DOI 10.1074/jbc.272.41.25976; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; CONDORELLI DF, 1994, NEUROCHEM RES, V19, P489, DOI 10.1007/BF00967329; CORRADIN SB, 1993, GLIA, V7, P255, DOI 10.1002/glia.440070309; Follesa P, 1996, J NEUROSCI, V16, P2172; Grilli M, 1996, J BIOL CHEM, V271, P15002, DOI 10.1074/jbc.271.25.15002; GUERRINI L, 1995, P NATL ACAD SCI USA, V92, P9077, DOI 10.1073/pnas.92.20.9077; HAGEN G, 1995, J BIOL CHEM, V270, P24989, DOI 10.1074/jbc.270.42.24989; Hirano F, 1998, MOL CELL BIOL, V18, P1266, DOI 10.1128/MCB.18.3.1266; Kalkhoven E, 1996, J BIOL CHEM, V271, P6217, DOI 10.1074/jbc.271.11.6217; Kaltschmidt B, 1999, P NATL ACAD SCI USA, V96, P9409, DOI 10.1073/pnas.96.16.9409; KALTSCHMIDT C, 1995, P NATL ACAD SCI USA, V92, P9618, DOI 10.1073/pnas.92.21.9618; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Kwon HS, 1999, J BIOL CHEM, V274, P20, DOI 10.1074/jbc.274.1.20; Li YK, 2000, J NEUROSCI, V20, P149, DOI 10.1523/JNEUROSCI.20-01-00149.2000; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; Mao XR, 1999, J NEUROCHEM, V73, P1851; Mao XR, 1998, NEUROREPORT, V9, P759, DOI 10.1097/00001756-199803090-00036; Moerman AM, 1999, MOL BRAIN RES, V67, P303, DOI 10.1016/S0169-328X(99)00091-1; Qin ZH, 2000, MOL BRAIN RES, V80, P111, DOI 10.1016/S0169-328X(00)00147-9; RAY A, 1994, P NATL ACAD SCI USA, V91, P752, DOI 10.1073/pnas.91.2.752; Reynolds IJ, 1999, ANN NY ACAD SCI, V893, P33, DOI 10.1111/j.1749-6632.1999.tb07816.x; Rickers A, 1999, EUR J BIOCHEM, V261, P269, DOI 10.1046/j.1432-1327.1999.00273.x; SAKAI T, 1995, J BIOCHEM-TOKYO, V118, P621, DOI 10.1093/oxfordjournals.jbchem.a124955; Schinder AF, 1996, J NEUROSCI, V16, P6125; SONNENBERG JL, 1989, J NEUROSCI RES, V24, P72, DOI 10.1002/jnr.490240111; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Supp DM, 1996, DEV BIOL, V176, P284, DOI 10.1006/dbio.1996.0134; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; SZEKELY AM, 1990, MOL PHARMACOL, V38, P624; Webster GA, 1999, MOL CELL BIOL, V19, P3485; Xia ZG, 1996, J NEUROSCI, V16, P5425; Yabe T, 2001, J BIOL CHEM, V276, P43313, DOI 10.1074/jbc.M107831200	44	36	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44911	44919		10.1074/jbc.M204292200	http://dx.doi.org/10.1074/jbc.M204292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244044	hybrid			2022-12-25	WOS:000179404800042
J	Fathallah-Shaykh, HM; Rigen, M; Zhao, LJ; Bansal, K; He, B; Engelhard, HH; Cerullo, L; Von Roenn, K; Byrne, R; Munoz, L; Rosseau, GL; Glick, R; Lichtor, T; DiSavino, E				Fathallah-Shaykh, HM; Rigen, M; Zhao, LJ; Bansal, K; He, B; Engelhard, HH; Cerullo, L; Von Roenn, K; Byrne, R; Munoz, L; Rosseau, GL; Glick, R; Lichtor, T; DiSavino, E			Mathematical modeling of noise and discovery of genetic expression classes in gliomas	ONCOGENE			English	Article						glioma; genetics; mathematical modeling; mathematical computing; genetic techniques	CANDIDATE TUMOR-SUPPRESSOR; UBIQUITIN-PROTEIN LIGASE; BOX BINDING-PROTEIN; HUMAN ASTROCYTOMAS; COLORECTAL-CANCER; POLYSIALIC ACID; CHROMOSOME 8P; BREAST-CANCER; HUMAN BRAIN; CELL-LINE	The microarray array experimental system generates noisy data that require validation by other experimental methods for measuring gene expression. Here we present an algebraic modeling of noise that extracts expression measurements true to a high degree of confidence. This work profiles the expression of 19200 cDNAs in 35 human gliomas; the experiments are designed to generate four replicate spots/gene with switching of probes. The validity of the extracted measurements is confirmed by: (1) cluster analysis that generates a molecular classification differentiating glioblastoma from lower-grade tumors and radiation necrosis; (2) By what other investigators have reported in gliomas using paradigms for assaying molecular expression other than gene profiling; and (3) Real-time RT-PCR. The results yield a genetic analysis of gliomas and identify classes of genetic expression that link novel genes to the biology of gliomas.	Rush Presbyterian St Lukes Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; Rush Presbyterian St Lukes Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA; Univ Illinois, Dept Neurosurg, Chicago, IL 60612 USA; Cook Cty Hosp, Dept Neurosurg, Chicago, IL 60612 USA	Rush University; Rush University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; John H Stroger Junior Hospital Cook County	Fathallah-Shaykh, HM (corresponding author), Rush Univ, Med Ctr, 2242 W Harrison St,suite 200, Chicago, IL 60612 USA.			Engelhard, Herbert/0000-0003-4993-9265; Fathallah-Shaykh, Hassan/0000-0002-2690-7685; Rosseau, Gail/0000-0002-5392-435X	NATIONAL CANCER INSTITUTE [R29CA078825, R01CA081367] Funding Source: NIH RePORTER; NCI NIH HHS [R29-CA78825, R01-CA81367] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Alter O, 2000, P NATL ACAD SCI USA, V97, P10101, DOI 10.1073/pnas.97.18.10101; AOYAMA A, 1993, INT J CANCER, V55, P760, DOI 10.1002/ijc.2910550511; Becker SA, 1996, CANCER RES, V56, P5092; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BIANCHI AB, 1991, P NATL ACAD SCI USA, V88, P7590, DOI 10.1073/pnas.88.17.7590; Bittner M, 2000, NATURE, V406, P536, DOI 10.1038/35020115; BOECK R, 2001, J BIOL CHEM, V271, P431; Casson AG, 1997, INT J CANCER, V72, P739, DOI 10.1002/(SICI)1097-0215(19970904)72:5<739::AID-IJC6>3.0.CO;2-T; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; Deng YB, 2000, P NATL ACAD SCI USA, V97, P12050, DOI 10.1073/pnas.97.22.12050; Denhardt DT, 2001, ANNU REV PHARMACOL, V41, P723, DOI 10.1146/annurev.pharmtox.41.1.723; Dunlop J, 1999, BRAIN RES, V839, P235, DOI 10.1016/S0006-8993(99)01714-X; EVERITT BS, 1993, CLUSTER ANAL, P55; Feng GS, 1996, J BIOL CHEM, V271, P12129, DOI 10.1074/jbc.271.21.12129; Fournier MV, 1999, CANCER RES, V59, P3748; Genini M, 1996, INT J CANCER, V66, P571; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; HIGUCHI M, 1993, ACTA NEUROPATHOL, V85, P481; Hildebrandt H, 1998, CANCER RES, V58, P779; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Imbert A, 1996, GENOMICS, V32, P29, DOI 10.1006/geno.1996.0073; Ise T, 1999, CANCER RES, V59, P342; KAGAN J, 1995, ONCOGENE, V11, P2121; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; KERANGUEVEN F, 1995, ONCOGENE, V10, P1023; Kim S, 2000, AM J PATHOL, V156, P1345, DOI 10.1016/S0002-9440(10)65005-5; KOCHI N, 1983, ACTA NEUROPATHOL, V59, P119, DOI 10.1007/BF00691597; Kohda T, 2001, GENES CELLS, V6, P237, DOI 10.1046/j.1365-2443.2001.00412.x; Landry CF, 1997, CANCER RES, V57, P4098; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Lee MLT, 2000, P NATL ACAD SCI USA, V97, P9834, DOI 10.1073/pnas.97.18.9834; Lerebours F, 1999, INT J CANCER, V81, P854, DOI 10.1002/(SICI)1097-0215(19990611)81:6<854::AID-IJC3>3.0.CO;2-1; Lerebours F, 1999, GENE CHROMOSOME CANC, V25, P147, DOI 10.1002/(SICI)1098-2264(199906)25:2<147::AID-GCC10>3.0.CO;2-Z; Marr HS, 2000, CELL TISSUE RES, V302, P139, DOI 10.1007/s004410000277; Matsumoto S, 2000, FEMS MICROBIOL LETT, V182, P297, DOI 10.1016/S0378-1097(99)00606-0; Muir D, 1996, J NEURO-ONCOL, V30, P199; Munch C, 2001, J NEUROL NEUROSUR PS, V71, P675, DOI 10.1136/jnnp.71.5.675; NAKAMURA T, 1992, ONCOGENE, V7, P733; Ohta S, 1997, BIOCHEM BIOPH RES CO, V237, P307, DOI 10.1006/bbrc.1997.7113; Okamoto T, 2000, ONCOGENE, V19, P6194, DOI 10.1038/sj.onc.1204029; Oyake T, 1996, MOL CELL BIOL, V16, P6083; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; Richardson RM, 2001, BIOCHEMISTRY-US, V40, P3583, DOI 10.1021/bi0019242; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; Sage EH, 1997, NAT MED, V3, P144; SAITOH Y, 1995, LAB INVEST, V72, P55; Salicioni AM, 2000, GENOMICS, V69, P54, DOI 10.1006/geno.2000.6315; Schevzov G, 1997, MOL CELL NEUROSCI, V8, P439, DOI 10.1006/mcne.1997.0599; Shibao K, 1999, INT J CANCER, V83, P732; STAMM S, 1993, P NATL ACAD SCI USA, V90, P9857, DOI 10.1073/pnas.90.21.9857; SWISSHELM K, 1995, P NATL ACAD SCI USA, V92, P4472, DOI 10.1073/pnas.92.10.4472; Tanaka F, 2000, CANCER RES, V60, P3072; Ue T, 1998, INT J CANCER, V79, P127, DOI 10.1002/(SICI)1097-0215(19980417)79:2<127::AID-IJC5>3.0.CO;2-V; Vocke CD, 1996, CANCER RES, V56, P2411; VONDEIMLING A, 1992, CANCER RES, V52, P4277; Yamato T, 1999, CYTOGENET CELL GENET, V87, P291, DOI 10.1159/000015452; YANG HY, 1994, MOL CHEM NEUROPATHOL, V21, P155, DOI 10.1007/BF02815349; Yaremko ML, 1996, GENE CHROMOSOME CANC, V16, P189, DOI 10.1002/(SICI)1098-2264(199607)16:3<189::AID-GCC6>3.0.CO;2-V; Zoladek T, 1997, GENETICS, V145, P595	60	20	24	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 17	2002	21	47					7164	7174		10.1038/sj.onc.1205654	http://dx.doi.org/10.1038/sj.onc.1205654			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	602KN	12370806				2022-12-25	WOS:000178504600004
J	Wu, Y; Pan, SJ; Lu, WP; Lin, SH; Kuang, J				Wu, Y; Pan, SJ; Lu, WP; Lin, SH; Kuang, J			Hp95 promotes anoikis and inhibits tumorigenicity of HeLa cells	ONCOGENE			English	Article						Hp95; anoikis; tumorigenicity; cell morphology	SIGNAL-TRANSDUCTION; PROTEIN; GENE; APOPTOSIS; ADHESION; CLONING; ALG-2; IDENTIFICATION; ASTROCYTES; INTEGRINS	p95 is a putative signal transduction protein of similar to 95 kDa that contains multiple tyrosine residues that are conserved from yeast to human, a Src phosphorylation consensus sequence and a proline-rich C-terminus that binds SH3-domains. Previous studies have established that mammalian p95 is physically associated with proteins that regulate apoptotic induction and cell transformation; however, it is unclear whether p95 is a positive or negative regulator in these processes. Moreover, a p95 partner protein has been localized at both focal adhesions and actin-cytoskeletons in rat astrocytes. However, there is no evidence that mammalian p95 has roles in regulating cell adhesion or morphology. In this study, we examined the effects of p95 on the anchorage-independent growth and tumorigenicity of malignant HeLa cells, and on the growth and morphology of non-transformed NIH3T3 cells. In HeLa cells, p95 overexpression promoted detachment-induced apoptosis (anoikis), inhibited detachment of viable cells from substratum and reduced tumorigenicity. In NIH3T3 cells, p95 overexpression promoted flat cell morphology and slowed cell proliferation, whereas p95 downregulation had opposite effects. These findings indicate that the mammalian p95 is a positive regulator in apoptotic signaling and a negative regulator in cell transformation. They also suggest that p95 has roles in regulating cell adhesion and morphology.	Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Kuang, J (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Box 019,1515 Holcombe Blvd, Houston, TX 77030 USA.				NATIONAL CANCER INSTITUTE [P30CA016672] Funding Source: NIH RePORTER; NCI NIH HHS [CA16672] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; ARAI T, 1976, GANN, V67, P493; Assoian RK, 2001, CURR OPIN GENET DEV, V11, P48, DOI 10.1016/S0959-437X(00)00155-6; Bogler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6; Braga V, 2000, NAT CELL BIOL, V2, pE182, DOI 10.1038/35036433; BUNGE R, 1979, J SUPRAMOL STR CELL, V11, P175, DOI 10.1002/jss.400110207; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Che SL, 1997, BBA-GENE STRUCT EXPR, V1354, P231, DOI 10.1016/S0167-4781(97)00112-7; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Danen EHJ, 2001, J CELL PHYSIOL, V189, P1, DOI 10.1002/jcp.1137; Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318; Krebs J, 2000, BBA-MOL CELL RES, V1498, P153, DOI 10.1016/S0167-4889(00)00091-4; Kuang J, 2001, CLIN CANCER RES, V7, P3629; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; ROCKWELL SC, 1972, J NATL CANCER I, V49, P735; Ruoslahti E, 1996, EXP CELL RES, V227, P1, DOI 10.1006/excr.1996.0243; Spiryda LB, 1998, J CELL SCI, V111, P3253; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wu Y, 2001, DIFFERENTIATION, V67, P139, DOI 10.1046/j.1432-0436.2001.670406.x	22	41	41	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6801	6808		10.1038/sj.onc.1205849	http://dx.doi.org/10.1038/sj.onc.1205849			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360406				2022-12-25	WOS:000178315800010
J	Hoogeveen, AT; Rossetti, S; Stoyanova, V; Schonkeren, J; Fenaroli, A; Schiaffonati, L; van Unen, L; Sacchi, N				Hoogeveen, AT; Rossetti, S; Stoyanova, V; Schonkeren, J; Fenaroli, A; Schiaffonati, L; van Unen, L; Sacchi, N			The transcriptional corepressor MTG16a contains a novel nucleolar targeting sequence deranged in t (16;21)-positive myeloid malignancies	ONCOGENE			English	Article						MTG16; t (16;21)-positive myeloid malignancies; chromosome translocation; nucleolus; transcriptional co-repressor; histone deacetylases	HIV-1 REGULATORY PROTEINS; T(8-21) FUSION PROTEIN; SUBCELLULAR-LOCALIZATION; REPRESSES TRANSCRIPTION; ACUTE-LEUKEMIA; GENE; ETO; FAMILY; NUCLEAR; MEMBER	The MTG (Myeloid Translocation Gene) proteins are a family of novel transcriptional corepressors. We report that MTG16a, a protein isoform encoded by the MTG16 gene deranged by the t (16; 21) in myeloid malignancies, is targeted to the nucleolus. The amino acid sequence necessary for nucleolar localization was mapped to the MTG16a N-terminal region. MTG16a, like MTG8, the nuclear corepressor deranged by the t (8; 21), is capable to interact with specific histone deacetylases (HDACs) suggesting that the protein may mediate silencing of nucleolar gene transcription. In addition, MTG16a is capable to form oligomers with other MTG proteins. As a consequence of the t (16; 21) the AML1 DNA-binding domain replaces the MTG16a N-terminal region. The AML1-MTG16 fusion protein is targeted to the nucleoplasm where it is capable to oligomerize with MTG16a and interact with HDAC1 and HDAC3. The deficiency of HDAC-containing complexes at nucleolar sites and the accumulation of HDAC-containing complexes at AML1-sites may be critical in the pathogenesis of t (16; 21) myeloid malignancies.	Erasmus Univ, Dept Clin Genet, NL-3000 DR Rotterdam, Netherlands; Univ Brescia, Dept Biomed Sci & Biotechnol, Brescia, Italy; Univ Milan, San Paolo Univ Hosp, Milan, Italy; Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA	Erasmus University Rotterdam; University of Brescia; University of Milan; Johns Hopkins University; Johns Hopkins Medicine	Hoogeveen, AT (corresponding author), Erasmus Univ, Dept Clin Genet, POB 1738, NL-3000 DR Rotterdam, Netherlands.							Akhmanova A, 2000, J CELL SCI, V113, P4463; Amann JM, 2001, MOL CELL BIOL, V21, P6470, DOI 10.1128/MCB.21.19.6470-6483.2001; ANASTASSOVAKRISTEVA M, 1977, J CELL SCI, V25, P103; ASOU H, 1991, BLOOD, V77, P2031; Calabi F, 1998, GENOMICS, V52, P332, DOI 10.1006/geno.1998.5429; Davis JN, 1999, ONCOGENE, V18, P1375, DOI 10.1038/sj.onc.1202412; Downing JR, 1999, BRIT J HAEMATOL, V106, P296, DOI 10.1046/j.1365-2141.1999.01377.x; ERICKSON P, 1992, BLOOD, V80, P1825; Evert BO, 1999, HUM MOL GENET, V8, P1169, DOI 10.1093/hmg/8.7.1169; FEINSTEIN PG, 1995, GENETICS, V140, P573; Gamou T, 1998, BLOOD, V91, P4028, DOI 10.1182/blood.V91.11.4028.411a45_4028_4037; Gelmetti V, 1998, MOL CELL BIOL, V18, P7185, DOI 10.1128/MCB.18.12.7185; Gross CT, 1996, EMBO J, V15, P1961, DOI 10.1002/j.1460-2075.1996.tb00547.x; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hildebrand D, 2001, J BIOL CHEM, V276, P9889, DOI 10.1074/jbc.M010582200; Kitabayashi I, 1998, MOL CELL BIOL, V18, P846, DOI 10.1128/MCB.18.2.846; Kubota S, 1999, ONCOGENE, V18, P1503, DOI 10.1038/sj.onc.1202429; Lutterbach B, 1998, MOL CELL BIOL, V18, P7176, DOI 10.1128/MCB.18.12.7176; Lutterbach B, 1998, MOL CELL BIOL, V18, P3604, DOI 10.1128/MCB.18.6.3604; McCLINTOCK BARBARA, 1934, ZEITSCHR ZELLJORSCH U MIKROSK ANAT, V21, P294, DOI 10.1007/BF00374060; Melnick AM, 2000, MOL CELL BIOL, V20, P2075, DOI 10.1128/MCB.20.6.2075-2086.2000; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; MIYOSHI H, 1993, EMBO J, V12, P2715, DOI 10.1002/j.1460-2075.1993.tb05933.x; Morohoshi F, 2000, GENE, V241, P287, DOI 10.1016/S0378-1119(99)00481-3; NISSON PE, 1992, CANCER GENET CYTOGEN, V63, P81, DOI 10.1016/0165-4608(92)90384-K; Pikaard CS, 2000, TRENDS GENET, V16, P495, DOI 10.1016/S0168-9525(00)02113-2; Sacchi N, 1996, ONCOGENE, V12, P437; Sacchi N, 1998, ONCOGENE, V16, P2609, DOI 10.1038/sj.onc.1201824; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; SCHMIDTZACHMANN MS, 1993, J CELL SCI, V105, P799; Shimada H, 2000, BLOOD, V96, P655; SIOMI H, 1988, CELL, V55, P197, DOI 10.1016/0092-8674(88)90043-8; Sullivan GJ, 2001, EMBO J, V20, P2867, DOI 10.1093/emboj/20.11.2867; Tamanini F, 2000, HUM MOL GENET, V9, P1487, DOI 10.1093/hmg/9.10.1487; Wang JX, 1998, P NATL ACAD SCI USA, V95, P10860, DOI 10.1073/pnas.95.18.10860; Wood JD, 2000, J CELL BIOL, V150, P939, DOI 10.1083/jcb.150.5.939; Zhai WG, 2000, MOL CELL BIOL, V20, P5930, DOI 10.1128/MCB.20.16.5930-5938.2000; Zhang JS, 2001, MOL CELL BIOL, V21, P156, DOI 10.1128/MCB.21.1.156-163.2001	38	29	32	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	SEP 26	2002	21	43					6703	6712		10.1038/sj.onc.1205882	http://dx.doi.org/10.1038/sj.onc.1205882			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	597BM	12242670				2022-12-25	WOS:000178202300018
J	Jang, SB; Kim, YG; Cho, YS; Suh, PG; Kim, KH; Oh, BH				Jang, SB; Kim, YG; Cho, YS; Suh, PG; Kim, KH; Oh, BH			Crystal structure of SEDL and its implications for a genetic disease spondyloepiphyseal dysplasia tarda	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETICULUM-GOLGI TRANSPORT; N-TERMINAL DOMAIN; T-SNARE SSO1P; ENDOPLASMIC-RETICULUM; MEMBRANE-FUSION; PROTEIN; COMPLEX; YEAST; TRAPP; IDENTIFICATION	SEDL is an evolutionarily highly conserved protein in eukaryotic organisms. Deletions or point mutations in the SEDL gene are responsible for the genetic disease spondyloepiphyseal dysplasia tarda (SEDT), an X-linked skeletal disorder. SEDL has been identified as a component of the transport protein particle (TRAPP), critically involved in endoplasmic reticulum-to-Golgi vesicle transport. Herein, we report the 2.4 Angstrom resolution structure of SEDL, which reveals an unexpected similarity to the structures of the N-terminal regulatory domain of two SNAREs, Ykt6p and Sec22b, despite no sequence homology to these proteins. The similarity and the presence of unusually many solvent-exposed apolar residues of SEDL suggest that it serves regulatory and/or adaptor functions through multiple protein-protein interactions. Of the four known missense mutations responsible for SEDT, three mutations (S73L, F83S, V130D) map to the protein interior, where the mutations would disrupt the structure, and the fourth (D47Y) on a surface at which the mutation may abrogate functional interactions with a partner protein.	Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Pohang 790784, Kyungbuk, South Korea; Pohang Accelerator Lab, Pohang 790784, Kyungbuk, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Oh, BH (corresponding author), Pohang Univ Sci & Technol, Natl Creat Res Initiat Ctr Biomol Recognit, Pohang 790784, Kyungbuk, South Korea.		Suh, Pann-Ghill/F-3610-2010; Oh, Byung-Ha/C-2061-2011					Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen YA, 1999, CELL, V97, P165, DOI 10.1016/S0092-8674(00)80727-8; Dreyer SD, 1998, CLIN GENET, V54, P464; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Dulubova I, 2001, NAT STRUCT BIOL, V8, P258, DOI 10.1038/85012; Gecz J, 2000, GENOMICS, V69, P242, DOI 10.1006/geno.2000.6326; Gedeon AK, 1999, NAT GENET, V22, P400, DOI 10.1038/11976; Gedeon AK, 2001, AM J HUM GENET, V68, P1386, DOI 10.1086/320592; Ghosh AK, 2001, MOL CELL BIOL, V21, P655, DOI 10.1128/MCB.21.2.655-662.2001; Gonzalez LC, 2001, J BIOL CHEM, V276, P24203, DOI 10.1074/jbc.M101584200; Grunebaum E, 2001, J MED GENET, V38, P409, DOI 10.1136/jmg.38.6.409; Hay JC, 1997, CELL, V89, P149, DOI 10.1016/S0092-8674(00)80191-9; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Jahn R, 1999, ANNU REV BIOCHEM, V68, P863, DOI 10.1146/annurev.biochem.68.1.863; Jang SB, 2002, ACTA CRYSTALLOGR D, V58, P564, DOI 10.1107/S0907444902001403; Jones S, 2000, MOL BIOL CELL, V11, P4403, DOI 10.1091/mbc.11.12.4403; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LIAN JP, 1994, NATURE, V372, P698, DOI 10.1038/372698a0; Lowe M, 2000, CURR BIOL, V10, pR407, DOI 10.1016/S0960-9822(00)00505-4; MacKenzie JJ, 1996, J MED GENET, V33, P823, DOI 10.1136/jmg.33.10.823; Martinez-Arca S, 2000, J CELL BIOL, V149, P889, DOI 10.1083/jcb.149.4.889; McNew JA, 1997, J BIOL CHEM, V272, P17776, DOI 10.1074/jbc.272.28.17776; Munson M, 2000, NAT STRUCT BIOL, V7, P894; Nicholson KL, 1998, NAT STRUCT BIOL, V5, P793, DOI 10.1038/1834; RAY R, 1991, MOL CELL BIOL, V11, P2154, DOI 10.1128/MCB.11.4.2154; ROSE GD, 1985, SCIENCE, V229, P834, DOI 10.1126/science.4023714; ROSSI G, 1995, MOL BIOL CELL, V6, P1769, DOI 10.1091/mbc.6.12.1769; Sacher M, 2000, EUR J CELL BIOL, V79, P71, DOI 10.1078/S0171-9335(04)70009-6; Sacher M, 2001, METHOD ENZYMOL, V329, P234; Sacher M, 2001, MOL CELL, V7, P433, DOI 10.1016/S1097-2765(01)00190-3; Sanjuan R, 1999, YEAST, V15, P351, DOI 10.1002/(SICI)1097-0061(19990315)15:4<351::AID-YEA364>3.0.CO;2-L; SOGAARD M, 1994, CELL, V78, P937, DOI 10.1016/0092-8674(94)90270-4; Sutton RB, 1998, NATURE, V395, P347, DOI 10.1038/26412; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tochio H, 2001, SCIENCE, V293, P698, DOI 10.1126/science.1062950; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu DL, 2000, J BIOL CHEM, V275, P39631, DOI 10.1074/jbc.M007684200; Zhang T, 2001, J BIOL CHEM, V276, P27480, DOI 10.1074/jbc.M102786200	38	70	78	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					49863	49869		10.1074/jbc.M207436200	http://dx.doi.org/10.1074/jbc.M207436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12361953	hybrid			2022-12-25	WOS:000180028900100
J	Morrow, IC; Rea, S; Martin, S; Prior, IA; Prohaska, R; Hancock, JF; James, DE; Parton, RG				Morrow, IC; Rea, S; Martin, S; Prior, IA; Prohaska, R; Hancock, JF; James, DE; Parton, RG			Flotillin-1/Reggie-2 traffics to surface raft domains via a novel Golgi-independent pathway - Identification of a novel membrane targeting domain and a role for palmitoylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; PLASMA-MEMBRANE; CELL-SURFACE; LIPID RAFTS; H-RAS; IN-VIVO; MICRODOMAINS; TRANSPORT; STOMATIN; CAVEOLAE	Flotillins are lipid raft-associated proteins, which have been implicated in neuronal regeneration and insulin signaling. We now show that newly synthesized flotillin-1 reaches the plasma membrane via a Sar1-independent and brefeldin A-resistant targeting pathway. Consistent with post-translational membrane association of flotillin, protease sensitivity experiments suggest that flotillin-1 is not a transmembrane protein but is associated with the cytoplasmic face of the plasma membrane. The N terminus of flotillin contains a prohibitin-like domain (PHB), which shows homology to a number of proteins associated with raft domains including stomatin, podocin, and prohibitin. We show that the PHB domain of flotillin can efficiently target a heterologous protein, green fluorescent protein, to the plasma membrane. Another PHB-containing protein, stomatin, traffics to the plasma membrane via the conventional secretory pathway. Plasma membrane association of both full-length flotillin and the green fluorescent protein-tagged PHB domain of flotillin is dependent on palmitoylation and requires a conserved cysteine residue, Cys-34, in the PHB domain. The results identify a novel targeting mechanism for plasma membrane association of flotillin-1 involving a Golgi-independent trafficking pathway, the PHB domain, and palmitoylation.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Funct & Appl Genom, St Lucia, Qld 4072, Australia; Univ Queensland, Ctr Microscopy & Microanal, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Univ Vienna, Inst Med Biochem, A-1030 Vienna, Austria; Univ Queensland, Sch Med, Dept Pathol, Queensland Canc Fund Lab Expt Oncol, Brisbane, Qld 4069, Australia	University of Queensland; University of Queensland; University of Queensland; University of Queensland; University of Vienna; University of Queensland	Parton, RG (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.		Rea, Shane/F-4073-2014; Parton, Robert G/C-5673-2009; Martin, Sally/A-7150-2010; Morrow, Isabel/E-8632-2012	Parton, Robert G/0000-0002-7494-5248; Martin, Sally/0000-0001-9294-5404; Hancock, John/0000-0003-0542-4710; Prior, Ian/0000-0002-4055-5161; James, David/0000-0001-5946-5257				Apolloni A, 2000, MOL CELL BIOL, V20, P2475, DOI 10.1128/MCB.20.7.2475-2487.2000; ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown RE, 1998, J CELL SCI, V111, P1; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Dermine JF, 2001, J BIOL CHEM, V276, P18507, DOI 10.1074/jbc.M101113200; DRAB M, 2001, SCIENCE, V9, P9; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gkantiragas I, 2001, MOL BIOL CELL, V12, P1819, DOI 10.1091/mbc.12.6.1819; IKONEN E, 1995, FEBS LETT, V358, P273, DOI 10.1016/0014-5793(94)01444-6; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; Parat MO, 2001, J BIOL CHEM, V276, P15776, DOI 10.1074/jbc.M006722200; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Parton RG, 2001, METHOD ENZYMOL, V333, P172; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Razani B, 2002, MOL CELL BIOL, V22, P2329, DOI 10.1128/MCB.22.7.2329-2344.2002; Razani B, 2002, J BIOL CHEM, V277, P8635, DOI 10.1074/jbc.M110970200; Richards AA, 2002, MOL BIOL CELL, V13, P1750, DOI 10.1091/mbc.01-12-0592; Roselli S, 2002, AM J PATHOL, V160, P131, DOI 10.1016/S0002-9440(10)64357-X; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Sabharanjak S, 2002, DEV CELL, V2, P411, DOI 10.1016/S1534-5807(02)00145-4; Schulte T, 1997, DEVELOPMENT, V124, P577; Schwarz K, 2001, J CLIN INVEST, V108, P1621, DOI 10.1172/JCI200112849; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Snyers L, 1999, FEBS LETT, V449, P101, DOI 10.1016/S0014-5793(99)00417-2; Snyers L, 1998, J BIOL CHEM, V273, P17221, DOI 10.1074/jbc.273.27.17221; Snyers L, 1999, EUR J CELL BIOL, V78, P802, DOI 10.1016/S0171-9335(99)80031-4; Steglich G, 1999, MOL CELL BIOL, V19, P3435; STEWART GW, 1993, BIOCHIM BIOPHYS ACTA, V1225, P15, DOI 10.1016/0925-4439(93)90116-I; Stuermer CAO, 2001, MOL BIOL CELL, V12, P3031, DOI 10.1091/mbc.12.10.3031; Tavernarakis N, 1999, TRENDS BIOCHEM SCI, V24, P425, DOI 10.1016/S0968-0004(99)01467-X; Tryggvason K, 2001, CURR OPIN NEPHROL HY, V10, P543, DOI 10.1097/00041552-200107000-00009; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; Webb Y, 2000, J BIOL CHEM, V275, P261, DOI 10.1074/jbc.275.1.261; Zhu YW, 1999, BLOOD, V93, P2404, DOI 10.1182/blood.V93.7.2404.407k13_2404_2410	45	170	175	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48834	48841		10.1074/jbc.M209082200	http://dx.doi.org/10.1074/jbc.M209082200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12370178	hybrid			2022-12-25	WOS:000179789600112
J	Rogers, MA; Langbein, L; Winter, H; Ehmann, C; Praetzel, S; Schweizer, J				Rogers, MA; Langbein, L; Winter, H; Ehmann, C; Praetzel, S; Schweizer, J			Characterization of a first domain of human high glycine-tyrosine and high sulfur keratin-associated protein (KAP) genes on chromosome 21q22.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TYPE-I; CYSTEINE-RICH PROTEINS; HUMAN HAIR KERATINS; DIFFERENTIAL EXPRESSION; MESSENGER-RNA; CDNA CLONES; SHEEP WOOL; FOLLICLE; FAMILY; ORGANIZATION	Analysis of the EBI/GeneBank(TM) data base using non-human hair keratin-associated protein (KAP) cDNA sequences as a query resulted in the identification of a first domain of high glycine-tyrosine and high sulfur KAP genes located on human chromosome 21q22.1. This domain, present on the DNA accession numbers AP001078 and AP001709, was similar to535 kb in size and contained 17 high glycine-tyrosine and 7 high sulfur KAP genes, as well as 9 KAP pseudogenes. Based on amino acid sequence comparisons of the encoded proteins, the KAP genes could be divided into seven high glycine-tyrosine gene families (KAP6-KAP8, and KAP19-KAP22) and four high sulfur gene families (KAP11, KAP13, KAP15, and KAP23). The high glycine-tyrosine genes described here appear to represent the complete set of this type of KAP genes present in the human genome. Both systematic cDNA isolation studies from an arrayed scalp cDNA library and in situ hybridization expression studies of all of the KAP genes identified in the 21q22.1 region revealed varying degrees and regions of expression of 11 members of the high tyrosine-glycine genes and 6 members of the high sulfur KAP genes in the hair forming compartment.	German Canc Res Ctr, Sect Normal & Neoplast Epidermal Differentiat B05, D-69120 Heidelberg, Germany; German Canc Res Ctr, Div Cell Biol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; German Cancer Research Center (DKFZ)	Rogers, MA (corresponding author), German Canc Res Ctr, Sect Normal & Neoplast Epidermal Differentiat B05, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Rogers, Michael A./J-9803-2012	Rogers, Michael A./0000-0002-3728-2107				Anderson L, 1997, ELECTROPHORESIS, V18, P533, DOI 10.1002/elps.1150180333; Aoki N, 1997, J BIOL CHEM, V272, P30512, DOI 10.1074/jbc.272.48.30512; Aoki N, 1998, J INVEST DERMATOL, V111, P804, DOI 10.1046/j.1523-1747.1998.00387.x; Cole SE, 1998, GENOMICS, V54, P437, DOI 10.1006/geno.1998.5590; DOPHEIDE TA, 1973, EUR J BIOCHEM, V34, P120, DOI 10.1111/j.1432-1033.1973.tb02737.x; FRATINI A, 1993, J BIOL CHEM, V268, P4511; FRATINI A, 1994, J INVEST DERMATOL, V102, P178, DOI 10.1111/1523-1747.ep12371759; FRENKEL MJ, 1989, GENOMICS, V4, P182, DOI 10.1016/0888-7543(89)90298-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; Gillespie J.M., 1983, BIOCH PHYSL SKIN, P475; Gillespie J.M., 1991, PHYSL BIOCH MOL BIOL, P625; GILLESPIE JM, 1972, COMP BIOCHEM PHYSIOL, V41, P723, DOI 10.1016/0305-0491(72)90085-5; Gillespie JM, 1990, CELLULAR MOL BIOL IN, P95; Gygi SP, 1999, MOL CELL BIOL, V19, P1720, DOI 10.1128/mcb.19.3.1720; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; HUH N, 1994, J INVEST DERMATOL, V102, P716, DOI 10.1111/1523-1747.ep12375385; JENKINS BJ, 1994, J INVEST DERMATOL, V103, P310, DOI 10.1111/1523-1747.ep12394770; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; KUCZEK E, 1985, EUR J BIOCHEM, V146, P89, DOI 10.1111/j.1432-1033.1985.tb08623.x; KUCZEK ES, 1987, EUR J BIOCHEM, V166, P79, DOI 10.1111/j.1432-1033.1987.tb13486.x; Kuhn F, 1999, MECH DEVELOP, V86, P193, DOI 10.1016/S0925-4773(99)00115-X; LANGBEIN L, 1993, DIFFERENTIATION, V55, P57, DOI 10.1111/j.1432-0436.1993.tb00033.x; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; Langbein L, 2001, J BIOL CHEM, V276, P35123, DOI 10.1074/jbc.M103305200; MACKINNON PJ, 1991, MAMM GENOME, V1, P53, DOI 10.1007/BF00350846; MACKINNON PJ, 1990, J CELL BIOL, V111, P2587, DOI 10.1083/jcb.111.6.2587; MARSHALL RC, 1980, P 6 INT WOOL TEXT RE, P147; MCNAB AR, 1990, P NATL ACAD SCI USA, V87, P6848, DOI 10.1073/pnas.87.17.6848; Miklos GLG, 2001, PROTEOMICS, V1, P169, DOI 10.1002/1615-9861(200102)1:2<169::AID-PROT169>3.0.CO;2-C; Mitsui S, 1998, GENE, V208, P123, DOI 10.1016/S0378-1119(97)00607-0; Perez C, 1999, GENE, V227, P137, DOI 10.1016/S0378-1119(98)00616-7; Powell B C, 1997, EXS, V78, P59; POWELL BC, 1983, NUCLEIC ACIDS RES, V11, P5327, DOI 10.1093/nar/11.16.5327; POWELL BC, 1995, DIFFERENTIATION, V58, P227, DOI 10.1046/j.1432-0436.1995.5830227.x; Reymond A, 2002, GENOMICS, V79, P824, DOI 10.1006/geno.2002.6781; ROGERS GE, 1993, J INVEST DERMATOL, V101, pS50, DOI 10.1111/1523-1747.ep12362626; Rogers MA, 1998, J BIOL CHEM, V273, P26683, DOI 10.1074/jbc.273.41.26683; Rogers MA, 1997, DIFFERENTIATION, V61, P187, DOI 10.1046/j.1432-0436.1997.6130187.x; Rogers MA, 2001, J BIOL CHEM, V276, P19440, DOI 10.1074/jbc.M100657200; Rogers MA, 2000, J INVEST DERMATOL, V114, P464, DOI 10.1046/j.1523-1747.2000.00910.x; Shimomura Y, 2002, J INVEST DERMATOL, V118, P226, DOI 10.1046/j.0022-202x.2001.01653.x; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; Stenn KS, 2001, PHYSIOL REV, V81, P449, DOI 10.1152/physrev.2001.81.1.449; SWART LS, 1973, BIOCHEM J, V133, P641, DOI 10.1042/bj1330641; SWART LS, 1976, P 5 INT WOOL TEXT RE, P254; Takaishi M, 1998, J INVEST DERMATOL, V111, P128, DOI 10.1046/j.1523-1747.1998.00241.x; Tkatchenko AV, 2001, DEVELOPMENT, V128, P1547; Winter H, 2001, HUM GENET, V108, P37, DOI 10.1007/s004390000439; ZHUMABAEVA BD, 1992, MOL BIOL+, V26, P550	50	84	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48993	49002		10.1074/jbc.M206422200	http://dx.doi.org/10.1074/jbc.M206422200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359730	hybrid			2022-12-25	WOS:000179789600132
J	Rousset, R; Wharton, DA; Zimmermann, G; Scott, MP				Rousset, R; Wharton, DA; Zimmermann, G; Scott, MP			Zinc-dependent interaction between dishevelled and the Drosophila Wnt antagonist naked cuticle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING; SIGNALING PATHWAY; BETA-CATENIN; PROTEIN; DOMAIN; PDZ; MEMBRANE; KINASE; TRANSCRIPTION; MOTIFS	During Drosophila development, the naked cuticle (nkd) gene attenuates wingless/Wnt signaling through a negative feedback loop mechanism. Fly and vertebrate Nkd proteins contain a putative calcium-binding EF-hand motif, the EFX domain, that interacts with the basic/PDZ region of the Wnt signal transducer, dishevelled (Dsh). Here we show that Dsh binding by Drosophila Nkd in vitro is mediated by the EFX domain as well as an adjacent C-terminal sequence. In vivo data suggest that both of these regions contribute to the ability of Nkd to antagonize Wnt signaling. Mutations in the Nkd EF-hand designed to eliminate potential ion binding affected Nkd-Dsh interactions in the yeast two-hybrid assay but not in the glutathione S-transferase pull-down assay. Addition of the chelating agent EDTA abolished the in vitro Nkd-Dsh interaction. Surprisingly zinc, but not calcium, was able to restore Nkd-Dsh binding, suggesting a zinc-mediated interaction. Calcium 45- and zinc 65-blotting experiments show that Nkd is a zinc-binding metalloprotein. The results further clarify how Nkd may antagonize Wnt signaling via interaction with Dsh, and identify a novel zinc-binding domain in Drosophila Nkd that collaborates with the conserved EFX domain to bind Dsh.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Genet, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Scott, MP (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA.	scott@pmgm2.stanford.edu	Rousset, Raphael/E-5908-2017	Rousset, Raphael/0000-0002-4999-403X	Howard Hughes Medical Institute Funding Source: Medline; NICHD NIH HHS [K08 HD 01164-06] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K08HD001164] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Andersson M, 1997, PROTEIN SCI, V6, P1139, DOI 10.1002/pro.5560060602; Bray S, 2000, CURR BIOL, V10, pR155, DOI 10.1016/S0960-9822(00)00330-4; Brodersen DE, 1999, BIOCHEMISTRY-US, V38, P1695, DOI 10.1021/bi982483d; Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CELIS JE, 1990, FEBS LETT, V262, P159, DOI 10.1016/0014-5793(90)80179-M; Cuajungco MP, 1997, NEUROBIOL DIS, V4, P137, DOI 10.1006/nbdi.1997.0163; Cuppen E, 1998, MOL BIOL CELL, V9, P671, DOI 10.1091/mbc.9.3.671; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; Fanning AS, 1999, CURR OPIN CELL BIOL, V11, P432, DOI 10.1016/S0955-0674(99)80062-3; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GEISER JR, 1991, CELL, V65, P949, DOI 10.1016/0092-8674(91)90547-C; Gribenko AV, 1998, J MOL BIOL, V283, P679, DOI 10.1006/jmbi.1998.2116; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hino SI, 2001, MOL CELL BIOL, V21, P330, DOI 10.1128/MCB.21.1.330-342.2001; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; James P, 1996, GENETICS, V144, P1425; JURGENS G, 1984, ROUX ARCH DEV BIOL, V193, P283, DOI 10.1007/BF00848157; Lee JS, 1999, J BIOL CHEM, V274, P21464, DOI 10.1074/jbc.274.30.21464; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Maekawa K, 1999, BIOCHEM J, V337, P179, DOI 10.1042/0264-6021:3370179; Maret W, 2000, J NUTR, V130, p1455S, DOI 10.1093/jn/130.5.1455S; Maret W, 1997, P NATL ACAD SCI USA, V94, P2233, DOI 10.1073/pnas.94.6.2233; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; MAZEN A, 1988, ANAL BIOCHEM, V172, P39, DOI 10.1016/0003-2697(88)90408-3; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Mochizuki T, 1996, SCIENCE, V272, P1339, DOI 10.1126/science.272.5266.1339; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Park M, 2002, NAT CELL BIOL, V4, P20, DOI 10.1038/ncb716; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Polakis P, 2000, GENE DEV, V14, P1837; PUTKEY JA, 1989, J BIOL CHEM, V264, P12370; Radisky D, 1999, J BIOL CHEM, V274, P4481, DOI 10.1074/jbc.274.8.4481; Rousset R, 2001, GENE DEV, V15, P658, DOI 10.1101/gad.869201; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; SCHIFF LA, 1988, P NATL ACAD SCI USA, V85, P4195, DOI 10.1073/pnas.85.12.4195; Schofield RMS, 1997, J EXP BIOL, V200, P3235; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Strovel ET, 2000, J BIOL CHEM, V275, P2399, DOI 10.1074/jbc.275.4.2399; Sun TQ, 2001, NAT CELL BIOL, V3, P628, DOI 10.1038/35083016; TANAKA T, 1995, NATURE, V376, P444, DOI 10.1038/376444a0; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; VALLEE BL, 1993, PHYSIOL REV, V73, P79, DOI 10.2466/pr0.1993.73.1.79; VALLEE BL, 1984, ADV ENZYMOL RAMB, V56, P283; vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X; Wei Y, 1999, BIOCHEMISTRY-US, V38, P14534, DOI 10.1021/bi9911233; Wharton KA, 2001, DEV BIOL, V234, P93, DOI 10.1006/dbio.2001.0238; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Xia HH, 1997, J CELL BIOL, V139, P507, DOI 10.1083/jcb.139.2.507; Yan D, 2001, P NATL ACAD SCI USA, V98, P3802, DOI 10.1073/pnas.071041898; YANAGAWA SI, 1995, GENE DEV, V9, P1087, DOI 10.1101/gad.9.9.1087; Zeng WL, 2000, NATURE, V403, P789, DOI 10.1038/35001615	56	26	31	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49019	49026		10.1074/jbc.M203246200	http://dx.doi.org/10.1074/jbc.M203246200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12354775	hybrid			2022-12-25	WOS:000179789600135
J	van der Kleij, D; Latz, E; Brouwers, JFHM; Kruize, YCM; Schmitz, M; Kurt-Jones, EA; Espevik, T; de Jong, EC; Kapsenberg, ML; Golenbock, DT; Tielens, AGM; Yazdanbakhsh, M				van der Kleij, D; Latz, E; Brouwers, JFHM; Kruize, YCM; Schmitz, M; Kurt-Jones, EA; Espevik, T; de Jong, EC; Kapsenberg, ML; Golenbock, DT; Tielens, AGM; Yazdanbakhsh, M			A novel host-parasite lipid cross-talk - Schistosomal lyso-phosphatidylserine activates Toll-like receptor 2 and affects immune polarization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN DENDRITIC CELLS; BACTERIAL LIPOPROTEINS; TEGUMENTAL MEMBRANES; T-CELLS; TLR2; LIPOPOLYSACCHARIDE; RECOGNITION; MATURATION; MANSONI; MICE	Schistosome infections are characterized by prominent T cell hyporesponsiveness during the chronic stage of infection. We found that schistosome-specific phosphatidylserine (PS) activated TLR2 and affected dendritic cells such that mature dendritic cells gained the ability to induce the development of IL-10-producing regulatory T cells. Using mass spectrometry, schistosomal lysophosphatidylserine (lyso-PS) was identified as the TLR2-activating molecule. This activity appears to be a unique property of schistosomal lyso-PS, containing specific acyl chains, because neither a synthetic lyso-PS (16:0) nor PS isolated from the mammalian host activates TLR2. Taken together, these findings provide evidence for a novel host-parasite interaction that may be central to long term survival of the parasite and limited host pathology with implications beyond parasitology.	Leiden Univ, Med Ctr, Dept Parasitol, NL-2300 RC Leiden, Netherlands; Univ Utrecht, Fac Vet Med, Dept Biochem & Cell Biol, NL-3508 TD Utrecht, Netherlands; Univ Massachusetts, Sch Med, Dept Med, Div Infect Dis, Worcester, MA 01655 USA; Norwegian Univ Sci & Technol, Inst Canc Res & Mol Biol, N-7489 Trondheim, Norway; Univ Amsterdam, Acad Med Ctr, Dept Cell Biol & Histol, NL-1100 DD Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1100 DD Amsterdam, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Utrecht University; University of Massachusetts System; University of Massachusetts Worcester; Norwegian University of Science & Technology (NTNU); University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam	Yazdanbakhsh, M (corresponding author), Leiden Univ, Med Ctr, Dept Parasitol, Postbus 2600, NL-2300 RC Leiden, Netherlands.		Latz, Eicke/H-3951-2014; Yazdanbakhsh, Maria/AAI-3996-2020; Brouwers, Jos F/AAH-1444-2019	Latz, Eicke/0000-0003-1488-5666; Yazdanbakhsh, Maria/0000-0002-7666-1441; Brouwers, Jos F/0000-0003-2924-3279; Tielens, Aloysius/0000-0002-5485-1105				Aliprantis AO, 1999, SCIENCE, V285, P736, DOI 10.1126/science.285.5428.736; ALLAN D, 1987, MOL BIOCHEM PARASIT, V23, P123, DOI 10.1016/0166-6851(87)90147-2; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brouwers JFHM, 1999, PARASITOLOGY, V119, P287, DOI 10.1017/S0031182099004679; Brouwers JFHM, 1998, MOL BIOCHEM PARASIT, V96, P49, DOI 10.1016/S0166-6851(98)00103-0; Brouwers JFHM, 1998, J LIPID RES, V39, P344; Cella M, 1999, J EXP MED, V189, P821, DOI 10.1084/jem.189.5.821; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; de Jong EC, 2002, J IMMUNOL, V168, P1704, DOI 10.4049/jimmunol.168.4.1704; Flo TH, 2000, J IMMUNOL, V164, P2064, DOI 10.4049/jimmunol.164.4.2064; Grogan JL, 1996, EUR J IMMUNOL, V26, P1365, DOI 10.1002/eji.1830260628; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hertz CJ, 2001, J IMMUNOL, V166, P2444, DOI 10.4049/jimmunol.166.4.2444; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; Jankovic D, 2002, IMMUNITY, V16, P429, DOI 10.1016/S1074-7613(02)00278-9; Jonuleit H, 2000, J EXP MED, V192, P1213, DOI 10.1084/jem.192.9.1213; Kadowaki N, 2001, J EXP MED, V194, P863, DOI 10.1084/jem.194.6.863; Kalinski P, 1999, IMMUNOL TODAY, V20, P561, DOI 10.1016/S0167-5699(99)01547-9; King CL, 1996, J IMMUNOL, V156, P4715; Kobayashi K, 2002, NATURE, V416, P194, DOI 10.1038/416194a; Le LQ, 2001, IMMUNITY, V14, P561, DOI 10.1016/S1074-7613(01)00145-5; Lien E, 1999, J BIOL CHEM, V274, P33419, DOI 10.1074/jbc.274.47.33419; MAIZELS RM, 1993, NATURE, V365, P797, DOI 10.1038/365797a0; McGuirk P, 2002, J EXP MED, V195, P221, DOI 10.1084/jem.20011288; Means TK, 1999, J IMMUNOL, V163, P6748; Michelsen KS, 2001, J BIOL CHEM, V276, P25680, DOI 10.1074/jbc.M011615200; Muhlradt PF, 1997, J EXP MED, V185, P1951, DOI 10.1084/jem.185.11.1951; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; Noss EH, 2001, J IMMUNOL, V167, P910, DOI 10.4049/jimmunol.167.2.910; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Re F, 2001, J BIOL CHEM, V276, P37692, DOI 10.1074/jbc.M105927200; ROUSER G, 1969, METHOD ENZYMOL, V14, P272; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Sewell DL, 2002, IMMUNOL LETT, V82, P101, DOI 10.1016/S0165-2478(02)00025-1; Sharif S, 2001, NAT MED, V7, P1057, DOI 10.1038/nm0901-1057; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; Takeuchi O, 2001, INT IMMUNOL, V13, P933, DOI 10.1093/intimm/13.7.933; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; van der Kleij D, 1999, INFECT IMMUN, V67, P5946, DOI 10.1128/IAI.67.11.5946-5950.1999; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Walterscheid JP, 2002, J EXP MED, V195, P171, DOI 10.1084/jem.20011450; Yazdanbakhsh M, 2002, SCIENCE, V296, P490, DOI 10.1126/science.296.5567.490; Yazdanbakhsh M, 2001, TRENDS IMMUNOL, V22, P372, DOI 10.1016/S1471-4906(01)01958-5; Zhang GL, 2001, J CLIN INVEST, V107, P13, DOI 10.1172/JCI11837	48	479	494	0	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48122	48129		10.1074/jbc.M206941200	http://dx.doi.org/10.1074/jbc.M206941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12359728	Green Published, hybrid			2022-12-25	WOS:000179789600021
J	Hase, H; Kanno, Y; Kojima, H; Morimoto, C; Okumura, K; Kobata, T				Hase, H; Kanno, Y; Kojima, H; Morimoto, C; Okumura, K; Kobata, T			CD27 and CD40 inhibit p53-independent mitochondrial pathways in apoptosis of B cells induced by B cell receptor ligation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN RECEPTOR; BCL-X; MEDIATED APOPTOSIS; LYMPHOMA-CELLS; P53; LYMPHOCYTES; EXPRESSION; PROTEINS; MEMBER; FAMILY	B cells in the germinal center are known to undergo apoptosis after B cell receptor (BCR) ligation, a process relevant to immunological tolerance. Human CD27 is a B cell co-stimulatory molecule. The aim of this study was to compare the effects of CD27 and CD40 signals on BCR-mediated apoptosis of B cells. BCR ligation activated mitochondrial apoptotic pathways including down-regulation of Bcl-X-L, dissipation of mitochondrial transmembrane potential, release of cytochrome c, and activation of caspase-9. Each of these effects was significantly inhibited by CD27 and CD40. Bik expression was weakly but significantly down-regulated by CD27 but up-regulated by CD40. BCR ligation resulted in p53 activation including its phosphorylation at Ser(15), nuclear translocation, and target gene p53AIP1 induction. CD27 and CD40 clearly suppressed these processes. Analyses that used dominant-negative p53 variants revealed a low but still substantial level of BCR-mediated apoptosis and intact mitochondria-mediated apoptotic pathway. These pathways were further inhibited by CD27 and CD40, although the cells showed no p53 phosphorylation or p53AIP1 expression. Our results suggested that, at the mitochondrial level, CD27 and CD40 co-stimulatory signals regulated the p53-amplified apoptotic pathway in B cells through the inhibition of p53-independent apoptotic pathway primarily induced by BCR ligation.	Dokkyo Univ, Sch Med, Inst Med Sci, Div Immunol, Mibu, Tochigi 3210293, Japan; Univ Tokyo, Inst Med Sci, Div Clin Immunol, Adv Clin Res Ctr, Tokyo 1088639, Japan; Juntendo Univ, Sch Med, Dept Immunol, Tokyo 1138421, Japan	Dokkyo Medical University; University of Tokyo; Juntendo University	Kobata, T (corresponding author), Dokkyo Univ, Sch Med, Inst Med Sci, Div Immunol, 880 Kitakobayashi, Mibu, Tochigi 3210293, Japan.	tkobata@dokkyomed.ac.jp						Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Agematsu K, 2000, IMMUNOL TODAY, V21, P204, DOI 10.1016/S0167-5699(00)01605-4; Akiba H, 1998, J BIOL CHEM, V273, P13353, DOI 10.1074/jbc.273.21.13353; An SK, 1996, FEBS LETT, V386, P115, DOI 10.1016/0014-5793(96)00427-9; Berard R, 1999, J IMMUNOL, V163, P4655; Bouchon A, 2000, EUR J IMMUNOL, V30, P69, DOI 10.1002/1521-4141(200001)30:1<69::AID-IMMU69>3.0.CO;2-#; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; Craxton A, 1999, ADV IMMUNOL, V73, P79, DOI 10.1016/S0065-2776(08)60786-5; Doi T, 1999, INT IMMUNOL, V11, P933, DOI 10.1093/intimm/11.6.933; Fang W, 1998, IMMUNITY, V9, P35, DOI 10.1016/S1074-7613(00)80586-5; Ghia P, 1998, BLOOD, V91, P244, DOI 10.1182/blood.V91.1.244.244_244_251; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; GOODNOW CC, 1995, ADV IMMUNOL, V59, P279, DOI 10.1016/S0065-2776(08)60633-1; GRAVESTEIN LA, 1995, INT IMMUNOL, V7, P551, DOI 10.1093/intimm/7.4.551; Hagiyama H, 1999, ONCOGENE, V18, P4091, DOI 10.1038/sj.onc.1202772; Hendriks J, 2000, NAT IMMUNOL, V1, P433, DOI 10.1038/80877; Jacquot S, 1997, J IMMUNOL, V159, P2652; Jiang AM, 2001, J IMMUNOL, V166, P6025, DOI 10.4049/jimmunol.166.10.6025; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; Klein U, 1998, J EXP MED, V188, P1679, DOI 10.1084/jem.188.9.1679; KOBATA T, 1995, P NATL ACAD SCI USA, V92, P11249, DOI 10.1073/pnas.92.24.11249; Kroesen BJ, 2001, J BIOL CHEM, V276, P13606, DOI 10.1074/jbc.M009517200; Kruse N, 1997, J IMMUNOL METHODS, V210, P195, DOI 10.1016/S0022-1759(97)00188-9; Lee HH, 1999, P NATL ACAD SCI USA, V96, P9136, DOI 10.1073/pnas.96.16.9136; Lens SMA, 1998, J IMMUNOL, V160, P6083; Morimoto S, 2000, J IMMUNOL, V164, P4097, DOI 10.4049/jimmunol.164.8.4097; MOTOYAMA N, 1995, SCIENCE, V267, P1506, DOI 10.1126/science.7878471; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Oshima H, 1998, INT IMMUNOL, V10, P517, DOI 10.1093/intimm/10.4.517; Prasad KVS, 1997, P NATL ACAD SCI USA, V94, P6346, DOI 10.1073/pnas.94.12.6346; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Shick L, 1997, CELL GROWTH DIFFER, V8, P121; Siegel RM, 2000, NAT IMMUNOL, V1, P469, DOI 10.1038/82712; Suzuki T, 2001, J IMMUNOL, V166, P5567, DOI 10.4049/jimmunol.166.9.5567; Tangye SG, 1998, J EXP MED, V188, P1691, DOI 10.1084/jem.188.9.1691; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; VOUDSEN KH, 2000, CELL, V103, P691; WANG ZH, 1995, J IMMUNOL, V155, P3722; Wu M, 1998, J EXP MED, V187, P1671, DOI 10.1084/jem.187.10.1671; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637	40	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					46950	46958		10.1074/jbc.M209050200	http://dx.doi.org/10.1074/jbc.M209050200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12324477	hybrid			2022-12-25	WOS:000179663700016
J	Holst, B; Elling, CE; Schwartz, TW				Holst, B; Elling, CE; Schwartz, TW			Metal ion-mediated agonism and agonist enhancement in melanocortin MC1 and MC4 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TACHYKININ NK-1 RECEPTOR; TRANSMEMBRANE DOMAIN-III; ALLOSTERIC INTERACTIONS; CONFORMATIONAL-CHANGES; MOLECULAR-BASIS; MORBID-OBESITY; LIGAND-BINDING; NK1 RECEPTOR; ZINC-SITE; ALPHA-MSH	An endogenous metal-ion site in the melanocortin MC1 and MC4 receptors was characterized mainly in transiently transfected COS-7 cells. ZnCl2 alone stimulated signaling through the Gs pathway with a potency of 11 and 13 muM and an efficacy of 50 and 20% of that of alpha-melanocortin stimulating hormone (alpha-MSH) in the MC1 and MC4 receptors, respectively. In the presence of peptide agonist, Zn(II) acted as an enhancer on both receptors, because it shifted the dose-response curves to the left: most pronounced was a 6-fold increase in alpha-MSH potency on the MC1 receptor. The effect of the metal ion appeared to be additive, because the maximal cAMP response for alpha-MSH in the presence of Zn(II) was 60% above the maximal response for the peptide alone. The affinity of Zn(II) could be increased through binding of the metal ion in complex with small hydrophobic chelators. The binding affinities and profiles were similar for a number of the 2,2'-bipyridine and 1,10-phenanthroline analogs in complex with Zn(II) in the MC1 and MC4 receptors. However, the potencies and efficacies of the metal-ion complexes were very different in the two receptors, and close to full agonism was obtained in the MC1 receptor. Metal ion-chelator complexes having antagonistic properties were also found. An initial attempt to map the metal-ion binding site in the MC1 receptor indicated that Cys(271) in extracellular loop 3 and possibly Asp(119) at the extracellular end of TM-III, which are both conserved among all MC receptors, are parts of the site. It is concluded that the function of the MCI and MC4 receptors can be positively modulated by metal ions acting both as partial agonists and as potentiators for other agonists, including the endogenous peptide ligand alpha-MSH at Zn(II) concentrations that could be physiological. Furthermore, the metal ion-chelator complexes may serve as leads in the development of novel melanocortin receptor modulators.	Univ Copenhagen, Panum Inst, Inst Pharmacol, Mol Pharmacol Lab, DK-2200 Copenhagen, Denmark; 7TM Pharma AS, DK-2100 Copenhagen, Denmark	University of Copenhagen	Holst, B (corresponding author), Univ Copenhagen, Panum Inst, Inst Pharmacol, Mol Pharmacol Lab, Blegdamsvej 3, DK-2200 Copenhagen, Denmark.		Solano, Francisco/G-5001-2013	Solano, Francisco/0000-0001-9612-761X; Schwartz, Thue W./0000-0002-0261-6904; Holst, Birgitte/0000-0001-7432-097X				ASSAF SY, 1984, NATURE, V308, P734, DOI 10.1038/308734a0; Barsh GS, 2000, NATURE, V404, P644, DOI 10.1038/35007519; Beattie JH, 1998, P NATL ACAD SCI USA, V95, P358, DOI 10.1073/pnas.95.1.358; Chen AS, 2000, NAT GENET, V26, P97, DOI 10.1038/79254; Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6; Dinulescu DM, 2000, J BIOL CHEM, V275, P6695, DOI 10.1074/jbc.275.10.6695; Elling CE, 1999, P NATL ACAD SCI USA, V96, P12322, DOI 10.1073/pnas.96.22.12322; Elling CE, 2000, BIOCHEMISTRY-US, V39, P667, DOI 10.1021/bi991777b; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; Elling CE, 1996, EMBO J, V15, P6213, DOI 10.1002/j.1460-2075.1996.tb01011.x; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Farooqi IS, 2000, J CLIN INVEST, V106, P271, DOI 10.1172/JCI9397; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; GETHER U, 1993, J BIOL CHEM, V268, P7893; Hadley ME, 1999, ANN NY ACAD SCI, V885, P1; He L, 2001, NAT GENET, V27, P40, DOI 10.1038/83741; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; Holst B, 2000, MOL PHARMACOL, V58, P263, DOI 10.1124/mol.58.2.263; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huang EP, 1997, P NATL ACAD SCI USA, V94, P13386, DOI 10.1073/pnas.94.25.13386; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; Kenakin TP., 1993, PHARM ANAL DRUG RECE, V2; Lazareno S, 2000, MOL PHARMACOL, V58, P194, DOI 10.1124/mol.58.1.194; Leppik RA, 2000, MOL PHARMACOL, V57, P436, DOI 10.1124/mol.57.3.436; Loland CJ, 2002, P NATL ACAD SCI USA, V99, P1683, DOI 10.1073/pnas.032386299; Luger TA, 2000, ANN NY ACAD SCI, V917, P232; Marks DL, 2001, RECENT PROG HORM RES, V56, P359, DOI 10.1210/rp.56.1.359; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; Norregaard L, 1998, EMBO J, V17, P4266, DOI 10.1093/emboj/17.15.4266; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; PEREZCASTEJON C, 1994, HISTOL HISTOPATHOL, V9, P259; PETERS S, 1987, SCIENCE, V236, P589, DOI 10.1126/science.2883728; Rink L, 2001, BIOMETALS, V14, P367, DOI 10.1023/A:1012986225203; Robinson SW, 2000, ANNU REV GENET, V34, P687, DOI 10.1146/annurev.genet.34.1.687; Rosenkilde MM, 1998, FEBS LETT, V439, P35, DOI 10.1016/S0014-5793(98)01331-3; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; Sheikh SP, 1996, NATURE, V383, P347, DOI 10.1038/383347a0; SMART TG, 1994, PROG NEUROBIOL, V42, P393, DOI 10.1016/0301-0082(94)90082-5; STE ML, 2000, P NATL ACAD SCI USA, V97, P12339; STRADER CD, 1991, J BIOL CHEM, V266, P5; SURRATT CK, 1994, J BIOL CHEM, V269, P20548; Swaminath G, 2002, MOL PHARMACOL, V61, P65, DOI 10.1124/mol.61.1.65; Thirstrup K, 1996, J BIOL CHEM, V271, P7875, DOI 10.1074/jbc.271.14.7875; Vaisse C, 2000, J CLIN INVEST, V106, P253, DOI 10.1172/JCI9238; Van der Ploeg LHT, 2002, P NATL ACAD SCI USA, V99, P11381, DOI 10.1073/pnas.172378699; Vandenberg RJ, 1998, MOL PHARMACOL, V54, P189, DOI 10.1124/mol.54.1.189; Wessells H, 1998, J UROLOGY, V160, P389, DOI 10.1016/S0022-5347(01)62903-3; WESTBROOK GL, 1987, NATURE, V328, P640, DOI 10.1038/328640a0; Wikberg JES, 1999, EUR J PHARMACOL, V375, P295, DOI 10.1016/S0014-2999(99)00298-8; Yang Y, 2000, BIOCHEMISTRY-US, V39, P14900, DOI 10.1021/bi001684q; Yang YK, 1997, J BIOL CHEM, V272, P23000, DOI 10.1074/jbc.272.37.23000	56	82	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47662	47670		10.1074/jbc.M202103200	http://dx.doi.org/10.1074/jbc.M202103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12244039	hybrid			2022-12-25	WOS:000179663700107
J	Rodionov, DG; Honing, S; Silye, A; Kongsvik, TL; von Figura, K; Bakke, O				Rodionov, DG; Honing, S; Silye, A; Kongsvik, TL; von Figura, K; Bakke, O			Structural requirements for interactions between leucine-sorting signals and clathrin-associated adaptor protein complex AP3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANNOSE 6-PHOSPHATE RECEPTOR; MHC CLASS-II; CARBOXYL CYTOPLASMIC TAIL; INVARIANT CHAIN; LIMP-II; MEMBRANE-PROTEINS; VESICLE FORMATION; COATED VESICLES; GAMMA-ADAPTIN; TRANS-GOLGI	Cytoplasmic tails of LIMPII and the invariant chain contain similar leucine-based sorting signals, but the invariant chain interacts only with AP1 and AP2, whereas LIMPII interacts strongly with AP3. In a series of in vitro experiments, we investigated the effect of residues upstream of the leucine pairs and demonstrated that these residues determine adapter binding, and certain residues favor interactions with AP3. Furthermore, constructs that interacted stronger with AP3 interacted weakly with AP1 and vice versa. Exchanging residues upstream of the leucine-based signal in LIMPII with those of the invariant chain reduced LIMPII binding to AP3 in vitro, and in vivo the corresponding LIMPII mutant was rerouted via the plasma membrane like the invariant chain. These preferential interactions of different leucine signals with different AP complexes may thus be the determining step sorting proteins from the trans-Golgi network to their final destinations. Proteins that interact with AP3 are sorted directly to endosomes/lysosomes, whereas proteins that interact with AP1 are sorted via a different route. At the same time, constructs that exhibited specificity for either AP1 or AP3 might still interact with AP2, suggesting that AP2 may recognize a wider variety of leucine signals. This is consistent with the suggested role of AP2 in internalization of proteins containing general leucine-based signals, including proteins that have been missorted to the plasma membrane.	Univ Oslo, Dept Biol, Div Mol Cell Biol, N-0316 Oslo, Norway; Univ Gottingen, Inst Biochem 2, D-37073 Gottingen, Germany	University of Oslo; University of Gottingen	Bakke, O (corresponding author), Univ Oslo, Dept Biol, Div Mol Cell Biol, POB 1050 Blindern, N-0316 Oslo, Norway.			Bakke, Oddmund/0000-0003-4843-7626				AGUILAR RC, 2001, J BIOL CHEM, V3, P3; Bakke O, 1999, IMMUNOL REV, V172, P171, DOI 10.1111/j.1600-065X.1999.tb01365.x; BARRIOCANAL JG, 1986, J BIOL CHEM, V261, P6755; Bergeland T, 2001, CURR BIOL, V11, P644, DOI 10.1016/S0960-9822(01)00177-4; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; BREMNES B, 1994, J CELL SCI, V107, P2021; Bremnes T, 1998, IMMUNOTECHNOLOGY, V4, P21, DOI 10.1016/S1380-2933(98)00008-6; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Darsow T, 1998, J CELL BIOL, V142, P913, DOI 10.1083/jcb.142.4.913; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Dell'Angelica EC, 1999, J BIOL CHEM, V274, P7278, DOI 10.1074/jbc.274.11.7278; Dell'Angelica EC, 1998, SCIENCE, V280, P431, DOI 10.1126/science.280.5362.431; Distel B, 1998, J BIOL CHEM, V273, P186, DOI 10.1074/jbc.273.1.186; Faundez V, 1998, CELL, V93, P423, DOI 10.1016/S0092-8674(00)81170-8; Folsch H, 1999, CELL, V99, P189, DOI 10.1016/S0092-8674(00)81650-5; Germain RN, 1996, IMMUNOL REV, V151, P5, DOI 10.1111/j.1600-065X.1996.tb00701.x; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; HONING S, 1995, J CELL BIOL, V128, P321, DOI 10.1083/jcb.128.3.321; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Honing S, 1996, EMBO J, V15, P5230, DOI 10.1002/j.1460-2075.1996.tb00908.x; JONSSON U, 1991, BIOTECHNIQUES, V11, P620; Kang S, 1998, J BIOL CHEM, V273, P20644, DOI 10.1074/jbc.273.32.20644; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; Kirchhausen T, 1997, CURR OPIN CELL BIOL, V9, P488, DOI 10.1016/S0955-0674(97)80024-5; Kongsvik TL, 2002, J BIOL CHEM, V277, P16484, DOI 10.1074/jbc.M201583200; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Le Borgne R, 2001, J CELL SCI, V114, P2831; LINDNER R, 1994, CELL BIOL LAB HDB, P1; MANFREDI JJ, 1987, J BIOL CHEM, V262, P12182; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; NORDENG TW, 2002, MOL BIOL CELL; Obermuller S, 2002, J CELL SCI, V115, P185; Ohno H, 1998, J BIOL CHEM, V273, P25915, DOI 10.1074/jbc.273.40.25915; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Rapoport I, 1998, EMBO J, V17, P2148, DOI 10.1093/emboj/17.8.2148; Robinson MS, 2001, CURR OPIN CELL BIOL, V13, P444, DOI 10.1016/S0955-0674(00)00235-0; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Shi GY, 1998, J CELL BIOL, V143, P947, DOI 10.1083/jcb.143.4.947; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; SIMMEN T, 2002, NAT CELL BIOL; Simpson F, 1997, J CELL BIOL, V137, P835, DOI 10.1083/jcb.137.4.835; SOSA MA, 1993, J BIOL CHEM, V268, P12537; Storch S, 2001, J BIOL CHEM, V276, P4298, DOI 10.1074/jbc.M005548200; VEGA MA, 1991, J BIOL CHEM, V266, P16269; Vowels JJ, 1998, EMBO J, V17, P2482, DOI 10.1093/emboj/17.9.2482; WIGLER M, 1979, CELL, V16, P777, DOI 10.1016/0092-8674(79)90093-X; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	54	24	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47436	47443		10.1074/jbc.M207149200	http://dx.doi.org/10.1074/jbc.M207149200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12370188	hybrid			2022-12-25	WOS:000179663700079
J	Franzen, R; Fabbro, D; Aschrafi, A; Pfeilschifter, J; Huwiler, A				Franzen, R; Fabbro, D; Aschrafi, A; Pfeilschifter, J; Huwiler, A			Nitric oxide induces degradation of the neutral ceramidase in rat renal mesangial cells and is counterregulated by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FULL-LENGTH CDNA; EXTRACELLULAR ATP; PROSTAGLANDIN SYNTHESIS; FEEDBACK INHIBITION; MOLECULAR-CLONING; DELTA-ISOENZYMES; ALPHA; INVOLVEMENT; ACTIVATION; PHOSPHORYLATION	Ceramide levels are strongly increased by stimulation of renal mesangial cells with nitric oxide (NO). This effect was shown previously to be due to a dual action of NO, comprising an activation of sphingomyelinases and an inhibition of ceramidase activity. In this study we show that the NO-triggered inhibition of neutral ceramidase activity is paralleled by a down-regulation at the protein level. A complete loss of neutral ceramidase protein is obtained after 24 h of stimulation. Whereas the selective proteasome inhibitor lactacystin blocked NO-evoked ceramidase degradation, several caspase inhibitors were ineffective. Moreover, the NO-induced degradation is reversed by the protein kinase C (PKC) activator, 12-O-tetradecanoyIphorbol-13-acetate (TPA), and also by the physiological PKC activators platelet-derived growth factor-BB (PDGF), angiotensin 11 and ATP, resulting in a normalization of neutral ceramidase protein as well as activity. In vivo phosphorylation studies using P-32(i)-labeled mesangial cells revealed that TPA, PDGF, angiotensin H, and ATP trigger an increased phosphorylation of the neutral ceramidase, which is blocked by the broad spectrum PKC inhibitor Ro-31 8220 but not by CGP 41251, which has a preferential action on Ca2+-dependent isoforms, thus suggesting the involvement of a Ca2+-independent PKC isoform. In vitro phosphorylation assays using recombinant PKC isoenzymes and neutral ceramidase immunoprecipitated from unstimulated mesangial cells show that particularly the PKC-delta isoform and to a lesser extent the PKC-alpha isoform are efficient in directly phosphorylating neutral ceramidase. In summary, our data show that NO is able to induce degradation of neutral ceramidase, thereby promoting accumulation of ceramide in the cell. This effect is reversed by PKC activation, most probably by the PKC-alpha isoenzyme, which can directly phosphorylate and thereby prevent neutral ceramidase degradation. These novel regulatory interactions will provide therapeutically valuable information to target neutral ceramidase stability and subsequent ceramide accumulation.	Goethe Univ Frankfurt, Pharmazentrum Frankfurt, Klinikum, D-60590 Frankfurt, Germany; Novartis Pharma Inc, Dept Oncol, CH-4002 Basel, Switzerland	Goethe University Frankfurt; Novartis	Huwiler, A (corresponding author), Goethe Univ Frankfurt, Pharmazentrum Frankfurt, Klinikum, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Huwiler@em.uni-frankfurt.de		Aschrafi, Armaz/0000-0003-4089-0960				Bao J, 2000, J BIOL CHEM, V275, P26178, DOI 10.1074/jbc.M002367200; Beck KF, 1999, J EXP BIOL, V202, P645; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brune B, 1998, EUR J PHARMACOL, V351, P261, DOI 10.1016/S0014-2999(98)00274-X; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; CHIH JJ, 1979, BIOCHEM PHARMACOL, V28, P2404, DOI 10.1016/0006-2952(79)90709-3; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Franzen R, 2001, J BIOL CHEM, V276, P35382, DOI 10.1074/jbc.M102153200; FUJIWARA S, 1988, MOL CELL BIOL, V8, P4700, DOI 10.1128/MCB.8.11.4700; Geiges D, 1997, BIOCHEM PHARMACOL, V53, P865, DOI 10.1016/S0006-2952(96)00885-4; Huwiler A, 1999, BIOCHEM BIOPH RES CO, V258, P60, DOI 10.1006/bbrc.1999.0582; Huwiler A, 2000, BRIT J PHARMACOL, V129, P612, DOI 10.1038/sj.bjp.0703077; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Huwiler A, 2000, BBA-MOL CELL BIOL L, V1485, P63, DOI 10.1016/S1388-1981(00)00042-1; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; HUWILER A, 1991, BIOCHEM J, V279, P441, DOI 10.1042/bj2790441; HUWILER A, 1992, FEBS LETT, V300, P259, DOI 10.1016/0014-5793(92)80858-E; HUWILER A, 1993, EXP NEPHROL, V1, P19; HUWILER A, 1994, BRIT J PHARMACOL, V113, P1455, DOI 10.1111/j.1476-5381.1994.tb17160.x; Jun CD, 1999, J IMMUNOL, V162, P3395; Kaszkin M, 1998, FEBS LETT, V440, P163, DOI 10.1016/S0014-5793(98)01445-8; KNOWLES RG, 1994, BIOCHEM J, V298, P249, DOI 10.1042/bj2980249; KRONCKE KD, 1995, BIOL CHEM H-S, V376, P327; Leung CH, 2001, BIOCHEM BIOPH RES CO, V285, P283, DOI 10.1006/bbrc.2001.5164; Levade T, 1999, BBA-MOL CELL BIOL L, V1438, P1, DOI 10.1016/S1388-1981(99)00038-4; Li CM, 1998, GENOMICS, V50, P267, DOI 10.1006/geno.1998.5334; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; MARTE BM, 1994, CELL GROWTH DIFFER, V5, P239; Meinhardt G, 2000, EUR J CELL BIOL, V79, P824, DOI 10.1078/0171-9335-00100; MEYER T, 1989, INT J CANCER, V43, P851, DOI 10.1002/ijc.2910430519; Mitsutake S, 1997, ANAL BIOCHEM, V247, P52, DOI 10.1006/abio.1997.2022; Mitsutake S, 2001, J BIOL CHEM, V276, P26249, DOI 10.1074/jbc.M102233200; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; OCHSNER M, 1993, EUR J PHARM-MOLEC PH, V245, P15, DOI 10.1016/0922-4106(93)90164-5; Perry DK, 1998, BBA-MOL CELL BIOL L, V1436, P233, DOI 10.1016/S0005-2760(98)00145-3; PFEILSCHIFTER J, 1995, KIDNEY INT, V48, pS50; PFEILSCHIFTER J, 1990, BIOCHEM J, V272, P469, DOI 10.1042/bj2720469; PFEILSCHIFTER J, 1990, CELL SIGNAL, V2, P129; Pfeilschifter J, 2000, NEWS PHYSIOL SCI, V15, P11; Pfeilschifter J, 2002, KIDNEY INT, V61, P809, DOI 10.1046/j.1523-1755.2002.00225.x; Pfeilschifter J, 2001, EUR J PHARMACOL, V429, P279, DOI 10.1016/S0014-2999(01)01326-7; PFEILSCHIFTER J, 1991, CELL SIGNAL, V3, P413, DOI 10.1016/0898-6568(91)90072-3; Pfeilschifter J, 2001, PFLUG ARCH EUR J PHY, V442, P479, DOI 10.1007/s004240100586; PFEILSCHIFTER J, 1986, FEBS LETT, V203, P262, DOI 10.1016/0014-5793(86)80755-4; Riboni L, 1997, PROG LIPID RES, V36, P153, DOI 10.1016/S0163-7827(97)00008-8; SAVILL J, 1995, EXP NEPHROL, V3, P149; STEFFAN NM, 1995, J IMMUNOL, V155, P4685; Tani M, 2000, J BIOL CHEM, V275, P11229, DOI 10.1074/jbc.275.15.11229; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335	50	41	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46184	46190		10.1074/jbc.M204034200	http://dx.doi.org/10.1074/jbc.M204034200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359735	hybrid			2022-12-25	WOS:000179529300065
J	Itoh, A; Schilmiller, AL; McCaig, BC; Howe, GA				Itoh, A; Schilmiller, AL; McCaig, BC; Howe, GA			Identification of a jasmonate-regulated allene oxide synthase that metabolizes 9-hydroperoxides of linoleic and linolenic acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIVINYL ETHER SYNTHASE; MOLECULAR-CLONING; FATTY-ACIDS; HYDROPEROXIDE ISOMERASE; SUBSTRATE-SPECIFICITY; GENETIC-ANALYSIS; CORN GERM; LIPOXYGENASE; BIOSYNTHESIS; DEFENSE	Allene oxide synthase (AOS) is a cytochrome P-450 (CYP74A) that catalyzes the first step in the conversion of 13-hydroperoxy linolenic acid to jasmonic acid and related signaling molecules in plants. Here, we report the molecular cloning and characterization of a novel AOS-encoding cDNA (LeAOS3) from Lycopersicon esculentum whose predicted amino acid sequence classifies it as a member of the CYP74C subfamily of enzymes that was hitherto not known to include AOSs. Recombinant LeAOS3 expressed in Escherichia coli showed spectral characteristics of a P-450. The enzyme transformed 9-and 13-hydroperoxides of linoleic and linolenic acid to alpha-ketol, gamma-ketol, and cyclopentenone compounds that arise from spontaneous hydrolysis of Unstable allene oxides, indicating that the enzyme is an AOS. Kinetic assays demonstrated that LeAOS3 was approximate to10-fold morel active against 9-hydroperoxides than the corresponding 13-isomers. LeAOS3 transcripts accumulated in roots, but were undetectable in aerial parts of mature plants. In contrast to wild-type plants, LeAOS3 expression was undetectable in roots of a tomato mutaint that is defective in jasmonic acid signaling. These findings suggest that LeAOS3 plays a role in the metabolism of 9-lipoxygenase-derived hydroperoxides in roots, and that this branch of oxylipin biosynthesis is regulated by the jasmonate signaling cascade.	Michigan State Univ, US DOE, Plant Res Lab, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA	Michigan State University; United States Department of Energy (DOE); Michigan State University	Howe, GA (corresponding author), Michigan State Univ, US DOE, Plant Res Lab, E Lansing, MI 48824 USA.	howeg@msu.edu	Howe, Gregg A/N-1887-2014	Howe, Gregg A/0000-0002-9218-979X; Schilmiller, Anthony/0000-0001-7069-7120				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BRASH AR, 1988, P NATL ACAD SCI USA, V85, P3382, DOI 10.1073/pnas.85.10.3382; Caldelari D, 1998, PHYTOCHEMISTRY, V47, P599, DOI 10.1016/S0031-9422(97)00443-3; Chapple C, 1998, ANNU REV PLANT PHYS, V49, P311, DOI 10.1146/annurev.arplant.49.1.311; ESHED Y, 1994, EUPHYTICA, V79, P175, DOI 10.1007/BF00022516; FENG P, 1979, LIPIDS, V14, P710, DOI 10.1007/BF02533895; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; Froehlich JE, 2001, PLANT PHYSIOL, V125, P306, DOI 10.1104/pp.125.1.306; GARDNER HW, 1970, J LIPID RES, V11, P311; GARDNER HW, 1975, LIPIDS, V10, P602, DOI 10.1007/BF02532724; GEMZELLDANIELSSON K, 1994, HUM REPROD, V9, P1626, DOI 10.1093/oxfordjournals.humrep.a138763; Gobel C, 2001, J BIOL CHEM, V276, P6267, DOI 10.1074/jbc.M008606200; GRECHKIN AN, 1994, BBA-LIPID LIPID MET, V1213, P199, DOI 10.1016/0005-2760(94)90027-2; Grechkin AN, 2000, BIOCHEM J, V352, P501, DOI 10.1042/0264-6021:3520501; Hamberg M, 2000, LIPIDS, V35, P353, DOI 10.1007/s11745-000-532-z; HAMBERG M, 1988, BIOCHEM BIOPH RES CO, V156, P543, DOI 10.1016/S0006-291X(88)80876-3; HAMBERG M, 1990, ARCH BIOCHEM BIOPHYS, V276, P518, DOI 10.1016/0003-9861(90)90753-L; HAMBERG M, 1987, BIOCHIM BIOPHYS ACTA, V920, P76, DOI 10.1016/0005-2760(87)90313-4; HAMBERG M, 1988, ADV PROSTAGLANDIN TH, V19, P64; HECKER M, 1989, J BIOL CHEM, V264, P141; Howe GA, 2000, PLANT PHYSIOL, V123, P711, DOI 10.1104/pp.123.2.711; Howe GA, 2002, CURR OPIN PLANT BIOL, V5, P230, DOI 10.1016/S1369-5266(02)00250-9; Itoh A, 2001, J BIOL CHEM, V276, P3620, DOI 10.1074/jbc.M008964200; Kolomiets MV, 2001, PLANT CELL, V13, P613, DOI 10.1105/tpc.13.3.613; LAU SMC, 1993, BIOCHEMISTRY-US, V32, P1945, DOI 10.1021/bi00059a010; Laudert D, 1998, PLANT J, V15, P675, DOI 10.1046/j.1365-313x.1998.00245.x; Li L, 2002, P NATL ACAD SCI USA, V99, P6416, DOI 10.1073/pnas.072072599; Li L, 2001, PLANT PHYSIOL, V127, P1414, DOI 10.1104/pp.010705; MASUI H, 1989, PHYTOCHEMISTRY, V28, P2613, DOI 10.1016/S0031-9422(00)98051-8; Matsui K, 2000, FEBS LETT, V481, P183, DOI 10.1016/S0014-5793(00)01997-9; Maucher H, 2000, PLANT J, V21, P199, DOI 10.1046/j.1365-313x.2000.00669.x; Paquette SM, 2000, DNA CELL BIOL, V19, P307, DOI 10.1089/10445490050021221; Quackenbush J, 2000, NUCLEIC ACIDS RES, V28, P141, DOI 10.1093/nar/28.1.141; Rance I, 1998, P NATL ACAD SCI USA, V95, P6554, DOI 10.1073/pnas.95.11.6554; Rusterucci C, 1999, J BIOL CHEM, V274, P36446, DOI 10.1074/jbc.274.51.36446; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sivasankar S, 2000, PLANT PHYSIOL, V122, P1335, DOI 10.1104/pp.122.4.1335; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SONG WC, 1991, SCIENCE, V253, P781, DOI 10.1126/science.1876834; SONG WC, 1993, P NATL ACAD SCI USA, V90, P8519, DOI 10.1073/pnas.90.18.8519; Staswick PE, 1998, PLANT J, V15, P747, DOI 10.1046/j.1365-313X.1998.00265.x; Stintzi A, 2001, P NATL ACAD SCI USA, V98, P12837, DOI 10.1073/pnas.211311098; Straus DS, 2001, MED RES REV, V21, P185, DOI 10.1002/med.1006.abs; Stumpe M, 2001, FEBS LETT, V507, P371, DOI 10.1016/S0014-5793(01)03019-8; SWOFORD DL, 2000, PAUP ASTERISK PHYLOG; TANKSLEY SD, 1992, GENETICS, V132, P1141; Tijet N, 2001, ARCH BIOCHEM BIOPHYS, V386, P281, DOI 10.1006/abbi.2000.2218; Turner JG, 2002, PLANT CELL, V14, pS153, DOI 10.1105/tpc.000679; VICK BA, 1991, LIPIDS, V26, P315, DOI 10.1007/BF02537143; VICK BA, 1979, PLANT PHYSIOL, V63, P490, DOI 10.1104/pp.63.3.490; VICK BA, 1984, PLANT PHYSIOL, V75, P458, DOI 10.1104/pp.75.2.458; VICK BA, 1983, BIOCHEM BIOPH RES CO, V111, P470, DOI 10.1016/0006-291X(83)90330-3; Vijayan P, 1998, P NATL ACAD SCI USA, V95, P7209, DOI 10.1073/pnas.95.12.7209; Weber H, 1999, PLANT CELL, V11, P485, DOI 10.1105/tpc.11.3.485; Yokoyama M, 2000, PLANT CELL PHYSIOL, V41, P110, DOI 10.1093/pcp/41.1.110; Ziegler J, 2001, PHYTOCHEMISTRY, V58, P729, DOI 10.1016/S0031-9422(01)00284-9; ZIMMERMAN DC, 1970, PLANT PHYSIOL, V46, P445, DOI 10.1104/pp.46.3.445	57	75	83	1	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46051	46058		10.1074/jbc.M207234200	http://dx.doi.org/10.1074/jbc.M207234200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351632	hybrid			2022-12-25	WOS:000179529300046
J	Gerasimovskaya, EV; Ahmad, S; White, CW; Jones, PL; Carpenter, TC; Stenmark, KR				Gerasimovskaya, EV; Ahmad, S; White, CW; Jones, PL; Carpenter, TC; Stenmark, KR			Extracellular ATP is an autocrine/paracrine regulator of hypoxia-induced adventitial fibroblast growth - Signaling through extracellular signal-regulated kinase-1/2 and the Egr-1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CELL PROLIFERATION; ACTIVATED PROTEIN-KINASE; PULMONARY-ARTERY; INDUCED RELEASE; P2X RECEPTORS; UP-REGULATION; SHEAR-STRESS; IN-VITRO; NUCLEOTIDES; EXPRESSION	Important autocrine/paracrine functions for the adenine nucleotides have been proposed in several tissues. We addressed the possibility that extracellular ATP would modulate/mediate hypoxia-induced adventitial fibroblast growth. Acute hypoxia (3% O-2, 10-60 min) increased extracellular ATP concentrations in adventitial fibroblasts and in lung microvascular endothelial cells, and chronic hypoxia (3% O-2, 14-30 days) markedly attenuated the rate of extracellular ATP hydrolysis by ecto-nucleotidase(s). Exogenous ATP stimulated [H-3]thymidine incorporation in fibroblasts as did UTP, ADPbeta, 2-methylthioadenosine triphosphate, adenosine 5'-(alpha,beta-methylene)triphosphate, and benzoylbenzoyl-ATP (2'-3'-O-(4-benzoylbenzoyl)-ATP), indicating that both P2Y and P2X purinoceptors can mediate mitogenic responses. Suramin (100 muM), Cibacron blue 3GA (100 pm), and pyridoxalphosphate-6-azophenyl-2',-4'-disulfonic acid (100 muM) as well as apyrase (5 units/ml) attenuated hypoxia- and ATP-induced and DNA synthesis, indicating activation and a functional role of purinoceptors under hypoxic conditions. ATP-induced DNA synthesis was augmented by hypoxia in an additive fashion, whereas ATP and hypoxia synergistically increased growth factor-induced DNA synthesis, again suggesting that ATP and hypoxia utilize similar signaling pathways to induce proliferation. Indeed, we found that ATP (100 pm) and hypoxia (3% 02) induced expression and activation of Egr-1 transcription factor, and both stimuli acted, in part, through a Galpha(i)/ERK1/2-dependent signaling pathway. Suramin, Cibacron blue 3GA, and apyrase attenuated hypoxia-induced ERK1/2 activation and Egr-1 expression. We conclude that hypoxia induces ATP release from endothelial cells and fibroblasts and that the activation of P2 purinoceptors is involved in the regulation of DNA synthesis by fibroblasts under hypoxic conditions.	Univ Colorado, Hlth Sci Ctr, Dev Lung Biol Res Lab, Dept Pediat, Denver, CO 80262 USA; Natl Jewish Med & Res Ctr, Dept Pediat, Denver, CO 80206 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; National Jewish Health	Gerasimovskaya, EV (corresponding author), Univ Colorado, Hlth Sci Ctr, Dev Lung Biol Res Lab, Dept Pediat, Res Bridge,B131,4200 E 9th Ave, Denver, CO 80262 USA.	Evgenia.Gerasimovskaya@UCHSC.edu	ahmad, shama/GNH-1803-2022; Carpenter, Todd/A-7503-2011; stenmark, kurt/AAH-3124-2022; stenmark, kurt/AFI-6776-2022	ahmad, shama/0000-0003-1049-5054; Carpenter, Todd/0000-0002-9855-0021; Jones, Peter Lloyd/0000-0003-1445-4081	NHLBI NIH HHS [HL 14985, HL 56481] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abbracchio MP, 1998, JPN J PHARMACOL, V78, P113, DOI 10.1254/jjp.78.113; Beigi R, 1999, AM J PHYSIOL-CELL PH, V276, pC267, DOI 10.1152/ajpcell.1999.276.1.C267; Belknap JK, 1997, AM J RESP CELL MOL, V16, P366, DOI 10.1165/ajrcmb.16.4.9115746; BODIN P, 1995, EXPERIENTIA, V51, P256, DOI 10.1007/BF01931108; Braunstein GM, 2001, J BIOL CHEM, V276, P6621, DOI 10.1074/jbc.M005893200; BROWN HA, 1991, MOL PHARMACOL, V40, P648; Burnstock G, 2002, ARTERIOSCL THROM VAS, V22, P364, DOI 10.1161/hq0302.105360; Chung TW, 1997, J BIOL CHEM, V272, P3064, DOI 10.1074/jbc.272.5.3064; Communi D, 2000, CELL SIGNAL, V12, P351, DOI 10.1016/S0898-6568(00)00083-8; DAS M, 1995, AM J PHYSIOL-LUNG C, V269, pL660, DOI 10.1152/ajplung.1995.269.5.L660; Das M, 2001, J BIOL CHEM, V276, P15631, DOI 10.1074/jbc.M010690200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Davidson JD, 2001, WOUND REPAIR REGEN, V9, P175, DOI 10.1046/j.1524-475x.2001.00175.x; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Di Virgilio F, 2002, BRIT J PHARMACOL, V135, P831, DOI 10.1038/sj.bjp.0704524; Dowd FJ, 1999, ARCH ORAL BIOL, V44, P1055, DOI 10.1016/S0003-9969(99)00100-4; DUBYAK GR, 1993, AM J PHYSIOL, V265, pC577, DOI 10.1152/ajpcell.1993.265.3.C577; Dubyak GR, 2002, AM J PHYSIOL-CELL PH, V282, pC242, DOI 10.1152/ajpcell.00522.2001; Erlinge D, 1998, GEN PHARMACOL-VASC S, V31, P1, DOI 10.1016/S0306-3623(97)00420-5; Ferguson DR, 1997, J PHYSIOL-LONDON, V505, P503, DOI 10.1111/j.1469-7793.1997.503bb.x; FILTZ TM, 1994, MOL PHARMACOL, V46, P8; FORRESTER T, 1977, J PHYSIOL-LONDON, V268, P371, DOI 10.1113/jphysiol.1977.sp011862; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; Graff RD, 2000, ARTHRITIS RHEUM-US, V43, P1571, DOI 10.1002/1529-0131(200007)43:7<1571::AID-ANR22>3.3.CO;2-C; GRIERSON JP, 1995, J BIOL CHEM, V270, P4451, DOI 10.1074/jbc.270.9.4451; Hamada K, 1998, J BIOL CHEM, V273, P6334, DOI 10.1074/jbc.273.11.6334; Harden TK, 1997, TRENDS PHARMACOL SCI, V18, P43, DOI 10.1016/S0165-6147(97)89795-7; Hofer G, 1996, J BIOL CHEM, V271, P28306, DOI 10.1074/jbc.271.45.28306; Homolya L, 2000, J CELL BIOL, V150, P1349, DOI 10.1083/jcb.150.6.1349; Kaczmarek E, 1996, J BIOL CHEM, V271, P33116, DOI 10.1074/jbc.271.51.33116; KATSURAGI T, 1991, J PHARMACOL EXP THER, V259, P513; KENNEDY C, 1995, TRENDS PHARMACOL SCI, V16, P168, DOI 10.1016/S0165-6147(00)89010-0; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Khachigian LM, 1997, ARTERIOSCL THROM VAS, V17, P2280, DOI 10.1161/01.ATV.17.10.2280; Khachigian LM, 1997, CIRC RES, V81, P457, DOI 10.1161/01.RES.81.4.457; Khakh BS, 2001, PHARMACOL REV, V53, P107; KINANE TB, 1994, J BIOL CHEM, V269, P27503; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lo LW, 2001, J CELL PHYSIOL, V188, P304, DOI 10.1002/jcp.1124; MITCHELL CH, 2001, J PHYSL, V334, P193; Moser TL, 2001, P NATL ACAD SCI USA, V98, P6656, DOI 10.1073/pnas.131067798; Nakamura E, 2000, AM J PHYSIOL-CELL PH, V279, pC510, DOI 10.1152/ajpcell.2000.279.2.C510; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; NUPENKO EV, 1991, BIOCHIM BIOPHYS ACTA, V1091, P213, DOI 10.1016/0167-4889(91)90064-5; Ostrom RS, 2000, J BIOL CHEM, V275, P11735, DOI 10.1074/jbc.275.16.11735; PEARSON JD, 1979, NATURE, V281, P384, DOI 10.1038/281384a0; Pirotton S, 1996, J AUTON PHARMACOL, V16, P353, DOI 10.1111/j.1474-8673.1996.tb00052.x; Ralevic V, 1998, PHARMACOL REV, V50, P413; Robson SC, 1997, J EXP MED, V185, P153, DOI 10.1084/jem.185.1.153; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; SchulzeLohoff E, 1996, J AUTON PHARMACOL, V16, P381, DOI 10.1111/j.1474-8673.1996.tb00058.x; Schwiebert LM, 2002, AM J PHYSIOL-CELL PH, V282, pC289, DOI 10.1152/ajpcell.01387.2000; SEDAA KO, 1990, J PHARMACOL EXP THER, V252, P1060; Solini A, 1999, J CELL SCI, V112, P297; Stenmark KR, 1997, ANNU REV PHYSIOL, V59, P89, DOI 10.1146/annurev.physiol.59.1.89; TORRY DJ, 1994, J CLIN INVEST, V93, P1525, DOI 10.1172/JCI117131; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Welsh DJ, 1998, AM J RESP CRIT CARE, V158, P1757, DOI 10.1164/ajrccm.158.6.9706054; WESTFALL DP, 1990, ANN NY ACAD SCI, V603, P300; Wilden PA, 1998, AM J PHYSIOL-HEART C, V275, pH1209, DOI 10.1152/ajpheart.1998.275.4.H1209; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yan SF, 1999, J BIOL CHEM, V274, P15030, DOI 10.1074/jbc.274.21.15030; YANG SM, 1994, CIRC RES, V74, P401, DOI 10.1161/01.RES.74.3.401; Yu SM, 1996, MOL PHARMACOL, V50, P1000; ZHANG M, 2000, J PHYSL, V15, P143	66	105	109	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44638	44650		10.1074/jbc.M203012200	http://dx.doi.org/10.1074/jbc.M203012200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244041	hybrid			2022-12-25	WOS:000179404800008
J	Kozak, KR; Crews, BC; Morrow, JD; Wang, LH; Ma, YH; Weinander, R; Jakobsson, PJ; Marnett, LJ				Kozak, KR; Crews, BC; Morrow, JD; Wang, LH; Ma, YH; Weinander, R; Jakobsson, PJ; Marnett, LJ			Metabolism of the endocannabinoids, 2-arachidonylglycerol and anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and ethanolamides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HUMAN-PLATELETS; 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE; CYCLOOXYGENASE-2 COX-2; ARACHIDONIC-ACID; COLON-CANCER; ACTIVE-SITE; D SYNTHASE; PURIFICATION; BIOSYNTHESIS	Cyclooxygenase-2 (COX-2) action on the endocannabinoids, 2-arachidonylglycerol (2-AG) and anandamide (AEA), generates prostaglandin glycerol esters (PG-G) and ethanolamides (PG-EA), respectively. The diversity of PG-Gs and PG-EAs that can be formed enzymatically following COX-2 oxygenation of endocannabinoids was examined in cellular and subcellular systems. In cellular systems, glycerol esters and ethanolamides of PGE(2), PGD(2), and PGF(2alpha) were major products of the endocannabinoid-derived COX-2 products, PGH(2)-G and PGH(2)-EA. The sequential action of purified COX-2 and thromboxane synthase on AEA and 2-AG provided thromboxane A(2) ethanolamide and glycerol ester, respectively. Similarly, bovine prostacyclin synthase catalyzed the isomerization of the intermediate endoperoxides, PGH(2)-G and PGH(2)-EA, to the corresponding prostacyclin derivatives. Quantification of the efficiency of prostaglandin and thromboxane synthase-directed endoperoxide isomerization demonstrated that PGE, PGD, and PGI synthases catalyze the isomerization of PGH(2)-G at rates approaching those observed with PGH(2). In contrast, thromboxane synthase was far more efficient at catalyzing PGH(2) isomerization than at catalyzing the isomerization of PGH(2)-G. These results define the in vitro diversity of endocannabinoid-derived prostanoids and will permit focused investigations into their production and potential biological actions in vivo.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Ctr Mol Toxicol, Nashville, TN 37232 USA; Univ Houston, Dept Internal Med, Div Hematol, Houston, TX 77030 USA; Aventis Pharmaceut, Resp RA Dis Grp, Bridgewater, NJ 08807 USA; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; University of Houston System; University of Houston; Sanofi-Aventis; Karolinska Institutet	Marnett, LJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.		Jakobsson, Per-Johan/ABC-5594-2021		NATIONAL CANCER INSTITUTE [P01CA077839, P01CA068484, R01CA089450] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048831] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM015431, T32GM007347, P50GM015431] Funding Source: NIH RePORTER; NCI NIH HHS [CA68484, CA77839, CA89450] Funding Source: Medline; NIDDK NIH HHS [DK48831] Funding Source: Medline; NIEHS NIH HHS [ES00267] Funding Source: Medline; NIGMS NIH HHS [GM15431, GM07347] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Catella-Lawson F, 1999, J PHARMACOL EXP THER, V289, P735; CHO MJ, 1978, PROSTAGLANDINS, V15, P943, DOI 10.1016/0090-6980(78)90037-0; CHRISTHAZELHOF E, 1979, BIOCHIM BIOPHYS ACTA, V572, P43, DOI 10.1016/0005-2760(79)90198-X; Coffey RJ, 1997, P NATL ACAD SCI USA, V94, P657, DOI 10.1073/pnas.94.2.657; DENNIS EA, 1991, FASEB J, V5, P2068, DOI 10.1096/fasebj.5.7.1901288; DEWITT DL, 1983, J BIOL CHEM, V258, P3285; DICZFALUSY U, 1979, FEBS LETT, V105, P291, DOI 10.1016/0014-5793(79)80632-8; DICZFALUSY U, 1980, BIOCHEM BIOPH RES CO, V94, P1417, DOI 10.1016/0006-291X(80)90577-X; Ek M, 2001, NATURE, V410, P430, DOI 10.1038/35068632; ENSOR CM, 1994, BBA-PROTEIN STRUCT M, V1208, P151, DOI 10.1016/0167-4838(94)90172-4; Gupta RA, 2000, P NATL ACAD SCI USA, V97, P13275, DOI 10.1073/pnas.97.24.13275; HAMBERG M, 1973, P NATL ACAD SCI USA, V70, P899, DOI 10.1073/pnas.70.3.899; HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994; HAMMARSTROM S, 1980, J BIOL CHEM, V255, P518; HAMMARSTROM S, 1977, P NATL ACAD SCI USA, V74, P3691, DOI 10.1073/pnas.74.9.3691; HAMMARSTROM S, 1982, ARCH BIOCHEM BIOPHYS, V214, P431, DOI 10.1016/0003-9861(82)90047-9; HAURAND M, 1985, J BIOL CHEM, V260, P5059; HECKER M, 1987, ARCH BIOCHEM BIOPHYS, V254, P124, DOI 10.1016/0003-9861(87)90088-9; HECKER M, 1989, J BIOL CHEM, V264, P141; Hsu PY, 1999, J BIOL CHEM, V274, P762, DOI 10.1074/jbc.274.2.762; Jakobsson PJ, 1999, P NATL ACAD SCI USA, V96, P7220, DOI 10.1073/pnas.96.13.7220; Kalgutkar AS, 2000, P NATL ACAD SCI USA, V97, P925, DOI 10.1073/pnas.97.2.925; Kalgutkar AS, 1998, J MED CHEM, V41, P4800, DOI 10.1021/jm980303s; Kanaoka Y, 2000, EUR J BIOCHEM, V267, P3315, DOI 10.1046/j.1432-1327.2000.01362.x; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Kozak KR, 2000, J BIOL CHEM, V275, P33744, DOI 10.1074/jbc.M007088200; Kozak KR, 2002, J BIOL CHEM, V277, P23278, DOI 10.1074/jbc.M201084200; Kozak KR, 2001, J BIOL CHEM, V276, P36993, DOI 10.1074/jbc.M105854200; KUNGCHAO DTY, 1980, BIOCHIM BIOPHYS ACTA, V614, P1, DOI 10.1016/0005-2744(80)90161-8; Landino LM, 1996, P NATL ACAD SCI USA, V93, P15069, DOI 10.1073/pnas.93.26.15069; MARNETT LJ, 1977, BIOCHEMISTRY-US, V16, P4303, DOI 10.1021/bi00638a027; McAdam BF, 1999, P NATL ACAD SCI USA, V96, P272, DOI 10.1073/pnas.96.1.272; MONCADA S, 1977, LANCET, V1, P18; OHNO H, 1978, J BIOCHEM-TOKYO, V84, P1485, DOI 10.1093/oxfordjournals.jbchem.a132272; PATRIGNANI P, 1982, J CLIN INVEST, V69, P1366, DOI 10.1172/JCI110576; Rao CV, 1997, CANCER RES, V57, P3717; Rowlinson SW, 1999, J BIOL CHEM, V274, P23305, DOI 10.1074/jbc.274.33.23305; SALMON JA, 1982, METHOD ENZYMOL, V86, P477; SHIMIZU T, 1979, J BIOL CHEM, V254, P5222; Smith WL, 2001, J CLIN INVEST, V107, P1491, DOI 10.1172/JCI13271; Sugiura T, 2002, PROSTAG LEUKOTR ESS, V66, P173, DOI 10.1054/plef.2001.0356; THALERDAO H, 1976, ADV PROSTAG THROMB R, V1, P177; Ueno N, 2001, J BIOL CHEM, V276, P34918, DOI 10.1074/jbc.M100429200; Wang LH, 1996, J BIOL CHEM, V271, P19970, DOI 10.1074/jbc.271.33.19970; WATANABE K, 1985, J BIOL CHEM, V260, P7035; WHITTAKER N, 1977, Tetrahedron Letters, V32, P2805; Yu M, 1997, J BIOL CHEM, V272, P21181, DOI 10.1074/jbc.272.34.21181	47	291	295	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44877	44885		10.1074/jbc.M206788200	http://dx.doi.org/10.1074/jbc.M206788200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244105	hybrid			2022-12-25	WOS:000179404800038
J	Omote, H; Al-Shawi, MK				Omote, H; Al-Shawi, MK			A novel electron paramagnetic resonance approach to determine the mechanism of drug transport by P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; PLASMA-MEMBRANE; CYTOPLASMIC LEAFLET; ATPASE ACTIVITY; BINDING; PROTEIN; CELLS; HOECHST-33342; EFFLUX; SITES	ATP-driven pumping of a variety of drugs out of cells by the human P-glycoprotein poses a serious problem to medical therapy. High level heterologous expression of human P-glycoprotein, in the yeast Saccharomyces cerevisiae, has facilitated biophysical studies in purified proteoliposome preparations. Membrane permeability of transported drugs and consequent lack of an experimentally defined drug position have made resolution of the transport mechanism difficult by classical techniques. To overcome these obstacles we devised a novel EPR spin-labeled verapamil for use as a transport substrate. Spin-labeled verapamil was an excellent transport substrate with apparent turnover number, K-m and K-i values of 5.8 s(-1), 4 mum, and 210 muM, respectively, at pH 7.4 and 37 degreesC. The apparent affinities were similar to10-fold higher than for unlabeled verapamil. Spin-labeled verapamil stimulated ATPase activity similar to5-fold, was relatively hydrophilic, and had a very low flip-flop rate, making it an ideal transport substrate. The K-m for MgATP activation of transport was 0.8 mm. By measuring the mobility of spin-labeled verapamil during transport experiments, we were able to resolve the location of the drug in proteoliposome suspensions. Steady state gradients of spin-labeled verapamil within the range of K-i/K-m ratios were observed.	Univ Virginia, Dept Mol Physiol & Biol Phys, Charlottesville, VA 22908 USA	University of Virginia	Al-Shawi, MK (corresponding author), Univ Virginia, Dept Mol Physiol & Biol Phys, POB 800736, Charlottesville, VA 22908 USA.		OMOTE, Hiroshi/B-1635-2011		NIGMS NIH HHS [GM52502] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052502] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlShawi MK, 1997, J BIOL CHEM, V272, P2300; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; ANDREE HAM, 1994, ANAL BIOCHEM, V222, P465, DOI 10.1006/abio.1994.1518; Bolhuis H, 1996, EMBO J, V15, P4239, DOI 10.1002/j.1460-2075.1996.tb00798.x; Eytan GD, 1996, J BIOL CHEM, V271, P12897, DOI 10.1074/jbc.271.22.12897; Figler RA, 2000, ARCH BIOCHEM BIOPHYS, V376, P34, DOI 10.1006/abbi.2000.1712; FLEWELLING RF, 1986, BIOPHYS J, V49, P531, DOI 10.1016/S0006-3495(86)83663-3; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, DOI [10.1007/978-1-4757-3061-6, 10.1007/978-1-4757-3061-6_6, DOI 10.1007/978-1-4757-3061-6_6]; Regev R, 1999, EUR J BIOCHEM, V259, P18, DOI 10.1046/j.1432-1327.1999.00037.x; Romsicki Y, 1999, BIOCHEMISTRY-US, V38, P6887, DOI 10.1021/bi990064q; Seelig A, 2000, EUR J PHARM SCI, V12, P31, DOI 10.1016/S0928-0987(00)00177-9; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Shapiro AB, 1997, EUR J BIOCHEM, V250, P130, DOI 10.1111/j.1432-1033.1997.00130.x; Shapiro AB, 1998, EUR J BIOCHEM, V254, P181, DOI 10.1046/j.1432-1327.1998.2540181.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P115, DOI 10.1111/j.1432-1033.1997.00115.x; Shapiro AB, 1997, EUR J BIOCHEM, V250, P122, DOI 10.1111/j.1432-1033.1997.00122.x; Sharom FJ, 1997, J MEMBRANE BIOL, V160, P161, DOI 10.1007/s002329900305; URBATSCH IL, 1994, BIOCHEMISTRY-US, V33, P7069, DOI 10.1021/bi00189a008; van Veen HW, 2000, EMBO J, V19, P2503, DOI 10.1093/emboj/19.11.2503; Victor KG, 2001, BIOPHYS J, V81, P2241, DOI 10.1016/S0006-3495(01)75871-7; White SH, 2001, J BIOL CHEM, V276, P32395, DOI 10.1074/jbc.R100008200; YUSA K, 1989, CANCER RES, V49, P5002; ZAMORA JM, 1988, MOL PHARMACOL, V33, P454	27	65	67	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					45688	45694		10.1074/jbc.M206479200	http://dx.doi.org/10.1074/jbc.M206479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244102	hybrid			2022-12-25	WOS:000179404800136
J	Xiang, XQ; Zang, MW; Waelde, CA; Wen, R; Luo, ZJ				Xiang, XQ; Zang, MW; Waelde, CA; Wen, R; Luo, ZJ			Phosphorylation of (SSYY341)-S-338 regulates specific interaction between Raf-1 and MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NEGATIVE REGULATION; CATALYTIC DOMAIN; ACTIVATES RAF-1; B-RAF; AKT; PATHWAY; GROWTH; CELLS; DIFFERENTIATION	The present study characterizes the interaction between the Raf-1 kinase domain and MEK1 and examines whether the magnitude of their interaction correlates to the ability of Raf to phosphorylate MEK1. Here we show that the minimal domain required for the Raf kinase activity starts from tryptophan 342. Maximal binding of the Raf kinase domain to MEK1 and its kinase activity are achieved upon phosphorylation of the region (SSYY341)-S-338 in response to 4beta-12-O-tetradecanoylphorbol-13-acetate (TPA), or mutation of Y340Y341 to aspartic acids. Conversely, the TPA-stimulated MEK binding and kinase activity are diminished when this region is deleted or Ser(338) and Ser(339) are mutated to alanines. We also show that the integrity of the Raf ATP-binding site is necessary for the interaction between Raf-1 and MEK1. Furthermore, two MEK-binding sites are identified; the first is localized between amino acids 325 and 349, and the second is within the region between amino acids 350 and 648. Separately, the binding of each site to MEK1 is weak, but in a cis context, they give rise to a much stronger association, which can be further stimulated by TPA. Finally, we find that tryptophan 342, which is conserved among the Raf family and other protein kinases, is essential for the Ser(338) phosphorylation of the full-length Raf and its binding to MEK1. Taken together, our results indicate that the phosphorylation of Ser(338) and Tyr(341) on Raf exerts an important effect on reconfiguring the two MEK-binding sites. As a result, these two sites coordinate to form a high affinity MEK-binding epitope, leading to a marked increase in Raf kinase activity.	Boston Univ, Sch Med, Diabet & Metab Res Unit, Endocrinol Sect,Evans Dept Med, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Univ Penn, Sch Med, Dept Ophthalmol, Philadelphia, PA 19104 USA	Boston University; Boston University; University of Pennsylvania	Luo, ZJ (corresponding author), Boston Univ, Sch Med, Diabet & Metab Res Unit, Endocrinol Sect,Evans Dept Med, 650 Albany St,Rm 820, Boston, MA 02118 USA.		Luo, Zhijun/AAE-9302-2019	Luo, Zhijun/0000-0001-8105-5289; Zang, Mengwei/0000-0002-2502-2586; Luo, Zhijun/0000-0003-3509-4046	NIGMS NIH HHS [GM 57959] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057959] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham D, 2000, J BIOL CHEM, V275, P22300, DOI 10.1074/jbc.M003259200; Barnard D, 1998, ONCOGENE, V17, P1539, DOI 10.1038/sj.onc.1202061; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; Chiloeches A, 2001, MOL CELL BIOL, V21, P2423, DOI 10.1128/MCB.21.7.2423-2434.2001; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; Diaz B, 1997, MOL CELL BIOL, V17, P4509, DOI 10.1128/MCB.17.8.4509; FABIAN JR, 1993, MOL CELL BIOL, V13, P7170, DOI 10.1128/MCB.13.11.7170; Gonfloni S, 1997, EMBO J, V16, P7261, DOI 10.1093/emboj/16.24.7261; Guan KL, 2000, J BIOL CHEM, V275, P27354; Hayne C, 2000, J BIOL CHEM, V275, P31876, DOI 10.1074/jbc.M002766200; King AJ, 2001, FEBS LETT, V497, P6, DOI 10.1016/S0014-5793(01)02425-5; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kubicek M, 2002, J BIOL CHEM, V277, P7913, DOI 10.1074/jbc.M108733200; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; Light Y, 2002, MOL CELL BIOL, V22, P4984, DOI 10.1128/MCB.22.14.4984-4996.2002; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Luo ZJ, 1996, NATURE, V383, P181, DOI 10.1038/383181a0; Marais R, 1998, SCIENCE, V280, P109, DOI 10.1126/science.280.5360.109; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; McPherson RA, 2000, ONCOGENE, V19, P3616, DOI 10.1038/sj.onc.1203678; Moelling K, 2002, J BIOL CHEM, V277, P31099, DOI 10.1074/jbc.M111974200; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; THERRIEN M, 1995, CELL, V83, P879, DOI 10.1016/0092-8674(95)90204-X; WATSON R, 1982, P NATL ACAD SCI-BIOL, V79, P4078, DOI 10.1073/pnas.79.13.4078; WHITEHURST CE, 1995, J BIOL CHEM, V270, P5594, DOI 10.1074/jbc.270.10.5594; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zang MW, 2001, J BIOL CHEM, V276, P25157, DOI 10.1074/jbc.M100152200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	37	31	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44996	45003		10.1074/jbc.M203953200	http://dx.doi.org/10.1074/jbc.M203953200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12244094	hybrid			2022-12-25	WOS:000179404800053
J	Briggs, J; Chamboredon, S; Castellazzi, M; Kerry, JA; Bos, TJ				Briggs, J; Chamboredon, S; Castellazzi, M; Kerry, JA; Bos, TJ			Transcriptional upregulation of SPARC, in response to c-Jun overexpression, contributes to increased motility and invasion of MCF7 breast cancer cells	ONCOGENE			English	Article						SPARC; osteonectin; c-Jun; target genes	EXTRACELLULAR-MATRIX PROTEIN; CHICKEN-EMBRYO FIBROBLASTS; GENE-EXPRESSION; GLUCOCORTICOID RECEPTOR; V-JUN; NEOPLASTIC PROGRESSION; FUNCTIONAL ANTAGONISM; OVARIAN-CANCER; FAMILY MEMBERS; HUMAN-MELANOMA	Overexpression of the c-Jun proto-oncogene in MCF7 breast cancer cells results in a variety of phenotype changes related to malignant progression including increased motility and invasion. Concurrent with these phenotypic effects are changes in the expression of multiple gene targets. We previously demonstrated that expression of the SPARC/osteonectin gene, while undetectable in the MCF7 cell line, is highly induced in response to stable c-Jun overexpression (c-Jun/MCF7). Because the SPARC gene product is associated with tumor cell invasion in a variety of different cancers, we have examined its role in mediating the phenotypic changes induced by c-Jun in MCF7 cells. We found that antisense mediated suppression of SPARC dramatically inhibits both motility and invasion in this c-Jun/MCF7 model. In contrast, stable overexpression of SPARC in the parental MCF7 cell line is not sufficient to stimulate cell motility or invasion. Examination of the promoter region of the human SPARC gene reveals three non-canonical AP-1 sites. We demonstrate that one of these sites binds c-Jun/Fra1 heterodimers in vitro, but that this and the other AP-1 like sites are dispensable with respect to c-Jun stimulated SPARC promoter activation. Deletion analysis identified a region between -120 and -70 as a c-Jun responsive element sufficient to induce maximal promoter activation. This region does not contain any AP-1 sites but does mediate binding by SP1 'like' complexes. Furthermore, this region is necessary for SP1/SP3 responsiveness in Drosophila SL2 cells. These results demonstrate that SPARC plays an important role in stimulating motility and the invasive behavior of c-Jun/MCF7 cells and that SPARC promoter activation by c-Jun appears to occur through an indirect mechanism.	Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, Norfolk, VA 23501 USA; Ecole Normale Super Lyon, INSERM, Unite Virol Humaine, U412, F-69364 Lyon 07, France	Eastern Virginia Medical School; Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bos, TJ (corresponding author), Eastern Virginia Med Sch, Dept Microbiol & Mol Cell Biol, POB 1980, Norfolk, VA 23501 USA.				NATIONAL CANCER INSTITUTE [R01CA051982] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA51982] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bamberger AM, 1999, INT J CANCER, V84, P533, DOI 10.1002/(SICI)1097-0215(19991022)84:5<533::AID-IJC16>3.0.CO;2-J; Basso J, 2000, ONCOGENE, V19, P4876, DOI 10.1038/sj.onc.1203863; BELLAHCENE A, 1995, AM J PATHOL, V146, P95; BENBROOK DM, 1990, ONCOGENE, V5, P295; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Bos TJ, 1999, INT J CANCER, V81, P404, DOI 10.1002/(SICI)1097-0215(19990505)81:3<404::AID-IJC14>3.0.CO;2-I; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Brown TJ, 1999, GYNECOL ONCOL, V75, P25, DOI 10.1006/gyno.1999.5552; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; Chinenov Y, 2001, ONCOGENE, V20, P2438, DOI 10.1038/sj.onc.1204385; COLOMBO MP, 1991, EUR J CANCER, V27, P58, DOI 10.1016/0277-5379(91)90062-I; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DECESARE D, 1995, ONCOGENE, V11, P365; Dennig J, 1996, EMBO J, V15, P5659, DOI 10.1002/j.1460-2075.1996.tb00950.x; GEE JMW, 1995, INT J CANCER, V64, P269, DOI 10.1002/ijc.2910640410; Gee JMW, 2000, INT J CANCER, V89, P177, DOI 10.1002/(SICI)1097-0215(20000320)89:2<177::AID-IJC13>3.0.CO;2-0; Gilles C, 1998, CANCER RES, V58, P5529; Graham JD, 1997, EUR J CANCER, V33, P1654, DOI 10.1016/S0959-8049(97)00182-2; Greenwood JA, 1998, MICROSC RES TECHNIQ, V43, P420, DOI 10.1002/(SICI)1097-0029(19981201)43:5<420::AID-JEMT8>3.0.CO;2-B; HADMAN M, 1993, ONCOGENE, V8, P1895; Hadman M, 1996, ONCOGENE, V12, P135; Horne GM, 1996, BRIT J CANCER, V73, P29, DOI 10.1038/bjc.1996.6; Jacob K, 1999, CANCER RES, V59, P4453; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Kato Yasumasa, 2000, Pathology Oncology and Research, V6, P24; Kim Youn Wha, 1998, Journal of Korean Medical Science, V13, P652; KOBIERSKI LA, 1991, P NATL ACAD SCI USA, V88, P10222, DOI 10.1073/pnas.88.22.10222; Kraemer M, 1999, CELL GROWTH DIFFER, V10, P193; Ledda F, 1997, J INVEST DERMATOL, V108, P210, DOI 10.1111/1523-1747.ep12334263; Ledda MF, 1997, NAT MED, V3, P171, DOI 10.1038/nm0297-171; Majello B, 1997, J BIOL CHEM, V272, P4021, DOI 10.1074/jbc.272.7.4021; METTOUCHI A, 1994, EMBO J, V13, P5668, DOI 10.1002/j.1460-2075.1994.tb06905.x; Milde-Langosch K, 2000, INT J CANCER, V87, P468, DOI 10.1002/1097-0215(20000815)87:4<468::AID-IJC2>3.0.CO;2-R; Mok SC, 1996, ONCOGENE, V12, P1895; Motamed K, 1999, INT J BIOCHEM CELL B, V31, P1363, DOI 10.1016/S1357-2725(99)00090-4; Nishitani J, 1999, J BIOL CHEM, V274, P5454, DOI 10.1074/jbc.274.9.5454; Porte H, 1998, CLIN CANCER RES, V4, P1375; PORTE H, 1995, INT J CANCER, V64, P70, DOI 10.1002/ijc.2910640114; PORTER PL, 1995, J HISTOCHEM CYTOCHEM, V43, P791, DOI 10.1177/43.8.7622842; Reed MJ, 1996, CURR TOP MICROBIOL, V213, P81; Rinehart-Kim J, 2000, INT J CANCER, V88, P180, DOI 10.1002/1097-0215(20001015)88:2<180::AID-IJC6>3.0.CO;2-H; Rosenblatt S, 1997, BIOCHEM J, V324, P311, DOI 10.1042/bj3240311; RYSECK RP, 1991, ONCOGENE, V6, P533; Sambrook J., 1989, MOL CLONING LAB MANU; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SCHULE R, 1990, CELL, V62, P1217, DOI 10.1016/0092-8674(90)90397-W; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; Smith LM, 1999, ONCOGENE, V18, P6063, DOI 10.1038/sj.onc.1202989; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; STEIN B, 1993, MOL CELL BIOL, V13, P3964, DOI 10.1128/MCB.13.7.3964; Sturm RA, 2002, CANCER RES, V62, P226; Thomas R, 2000, CLIN CANCER RES, V6, P1140; TINIAKOS DG, 1994, J PATHOL, V172, P19, DOI 10.1002/path.1711720106; TOURAY M, 1991, ONCOGENE, V6, P1227; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Vial E, 2000, ONCOGENE, V19, P1772, DOI 10.1038/sj.onc.1203493; Vial E, 2000, ONCOGENE, V19, P5020, DOI 10.1038/sj.onc.1203867; Vogt PK, 2001, ONCOGENE, V20, P2365, DOI 10.1038/sj.onc.1204443; Yamanaka M, 2001, J UROLOGY, V166, P2495, DOI 10.1016/S0022-5347(05)65623-6; Yan Q, 1999, J HISTOCHEM CYTOCHEM, V47, P1495, DOI 10.1177/002215549904701201; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YANGYEN HF, 1991, NEW BIOL, V3, P1206; Yiu GK, 2001, AM J PATHOL, V159, P609, DOI 10.1016/S0002-9440(10)61732-4; Zajchowski DA, 2001, CANCER RES, V61, P5168	68	95	102	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 10	2002	21	46					7077	7091		10.1038/sj.onc.1205857	http://dx.doi.org/10.1038/sj.onc.1205857			15	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370830				2022-12-25	WOS:000178424900011
J	Day, CH; Fanger, GR; Retter, MW; Hylander, BL; Penetrante, RB; Houghton, RL; Zhang, XQ; McNeill, PD; Maltez, A; Nolasco, M; Badaro, R; Cheever, MA; Reed, SG; Dillon, DC; Watanabe, Y				Day, CH; Fanger, GR; Retter, MW; Hylander, BL; Penetrante, RB; Houghton, RL; Zhang, XQ; McNeill, PD; Maltez, A; Nolasco, M; Badaro, R; Cheever, MA; Reed, SG; Dillon, DC; Watanabe, Y			Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera	ONCOGENE			English	Article						antibody; KLK4; prostase; prostate cancer; protein expression	KALLIKREIN GENE FAMILY; SUPPRESSION SUBTRACTIVE HYBRIDIZATION; SERINE-PROTEASE; ANTIGEN; LOCALIZATION; MEMBER	The ability to identify prostate tumor or prostate tissue specific genes that are expressed at high levels and use their protein products as targets could greatly aid in the diagnosis and treatment of prostate cancer. Using a polymerase chain reaction (PCR)-based subtraction technique, we have recovered the recently described KLK4 (prostase) gene from human prostate cDNA. In this study, KLK4 gene expression in human prostate tumors was further characterized using cDNA quantitative PCR and immunohistochemistry, demonstrating that the gene is specifically expressed at both the mRNA and protein levels in normal human prostate tissue, and in both primary and metastatic prostate tumor samples. Quantitative mRNA analysis also demonstrated low level expression including adrenal gland, salivary gland and thyroid. Finally, it was demonstrated that prostate cancer patient sera contain antibodies that bind specifically to recombinant KLK4 protein. This antibody has been used to detect KLK4-specific peptides in epitope mapping experiments. The relatively specific expression profile and elevated level of KLK4 mRNA and protein in both tumor and normal prostate tissues, in addition to detectable KLK4-specific antibody in cancer patient sera, supports additional efforts to determine if KLK4 can play a role in the diagnosis of prostate cancer, the monitoring of residual disease, or act as a target for immunotherapy.	Corixa Corp, Seattle, WA 98104 USA; Roswell Pk Canc Inst, Dept Immunol, Buffalo, NY 14263 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98195 USA; Infect Dis Res Inst, Seattle, WA 98104 USA	Corixa; Roswell Park Cancer Institute; University of Washington; University of Washington Seattle	Day, CH (corresponding author), Corixa Corp, 1124 Columbia St,Suite 200, Seattle, WA 98104 USA.	day@corixa.com			NCI NIH HHS [CA76822] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABIAAD AS, 1992, J UROLOGY, V147, P952, DOI 10.1016/S0022-5347(17)37431-1; Babcook JS, 1996, P NATL ACAD SCI USA, V93, P7843, DOI 10.1073/pnas.93.15.7843; Chen YT, 1997, P NATL ACAD SCI USA, V94, P1914, DOI 10.1073/pnas.94.5.1914; Daher R, 1998, CLIN CHEM LAB MED, V36, P671, DOI 10.1515/CCLM.1998.120; Diatchenko L, 1999, METHOD ENZYMOL, V303, P349; Diatchenko L, 1996, P NATL ACAD SCI USA, V93, P6025, DOI 10.1073/pnas.93.12.6025; Dong Y, 2001, CLIN CANCER RES, V7, P2363; DuPont BR, 1999, CYTOGENET CELL GENET, V86, P212, DOI 10.1159/000015340; Greenlee RT, 2000, CA-CANCER J CLIN, V50, P7, DOI 10.3322/canjclin.50.1.7; Houghton RL, 2001, MOL DIAGN, V6, P79, DOI 10.2165/00066982-200106020-00003; Myers SA, 2001, J CLIN ENDOCR METAB, V86, P2323, DOI 10.1210/jc.86.5.2323; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nelson PS, 1999, P NATL ACAD SCI USA, V96, P3114, DOI 10.1073/pnas.96.6.3114; Obiezu CV, 2001, CLIN CANCER RES, V7, P2380; SISSONS GRJ, 1992, BRIT J RADIOL, V65, P861, DOI 10.1259/0007-1285-65-778-861; Stephenson SA, 1999, J BIOL CHEM, V274, P23210, DOI 10.1074/jbc.274.33.23210; Thiounn N, 1997, UROLOGY, V50, P245, DOI 10.1016/S0090-4295(97)00272-0; Watson MA, 1999, CANCER RES, V59, P3028; Yousef GM, 1999, CANCER RES, V59, P4252	19	27	27	0	2	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	OCT 10	2002	21	46					7114	7120		10.1038/sj.onc.1205786	http://dx.doi.org/10.1038/sj.onc.1205786			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	601AX	12370833				2022-12-25	WOS:000178424900014
J	Touz, MC; Gottig, N; Nash, TE; Lujan, HD				Touz, MC; Gottig, N; Nash, TE; Lujan, HD			Identification and characterization of a novel secretory granule calcium-binding protein from the early branching eukaryote Giardia lamblia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYST WALL PROTEIN; ENDOPLASMIC-RETICULUM; PRIMITIVE EUKARYOTE; INTRACELLULAR CALCIUM; MOLECULAR CHAPERONES; ANTIGENIC VARIATION; VESICLE FORMATION; CELLS; TRANSPORT; GOLGI	Giardia lamblia is a flagellate protozoan that infects humans and other mammals and the most frequently isolated intestinal parasite worldwide. Giardia trophozoites undergo essential biological changes to survive outside the intestine of their host by differentiating into infective cysts. Cyst formation, or encystation, is considered one of the most primitive adaptive responses developed by eukaryotes early in evolution and crucial for the transmission of the parasite among susceptible hosts. During this process, proteins that will assemble into the extracellular cyst wall (CWP1 and CWP2) are transported to the cell surface within encystation-specific secretory vesicles (ESVs) by a developmentally regulated secretory pathway. Cyst wall proteins (CWPs) are maintained as a dense material inside the ESVs, but after exocytosis, they form the fibrillar matrix of the cyst wall. Little is known about the molecular mechanisms involved in granule biogenesis and discharge in Giardia, as well as the assembly of the extracellular wall. In this work, we provide evidences that a novel 54-kDa protein that exclusively localizes to the ESVs is induced during encystation similar to CWPs, proteolytically processed during granule maturation, and able to bind calcium in vitro. The gene encoding this molecule predicts a novel protein (called gGSP for (G) under bar. lamblia (G) under bar ranule-(s) under bar pecific (P) under bar rotein) without homology to any other protein reported in public databases. Nevertheless, it possesses characteristics of calcium-sequestering molecules of higher eukaryotes. Inhibition of gGSP expression abolishes cyst wall formation, suggesting that this secretory granule protein regulates Ca2+-dependent degranulation of ESVs during cyst wall formation.	Univ Nacl Cordoba, Catedra Bioquim & Biol Mol, Fac Ciencias Med, RA-5000 Cordoba, Argentina; NIAID, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA	National University of Cordoba; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Lujan, HD (corresponding author), Univ Nacl Cordoba, Catedra Bioquim & Biol Mol, Fac Ciencias Med, Pabellon Argentina 2 Piso, RA-5000 Cordoba, Argentina.			TOUZ, MARIA/0000-0002-6769-6896	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000161, ZIAAI000161] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adam RD, 2000, INT J PARASITOL, V30, P475, DOI 10.1016/S0020-7519(99)00191-5; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERER R, 1977, J ULTRA MOL STRUCT R, V60, P21, DOI 10.1016/S0022-5320(77)80037-3; Arvan Peter, 1992, Trends in Cell Biology, V2, P327; BILINSKI M, 1981, J CELL BIOL, V88, P179, DOI 10.1083/jcb.88.1.179; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BOUCHER SEM, 1990, INFECT IMMUN, V58, P3516, DOI 10.1128/IAI.58.11.3516-3522.1990; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; CAMPBELL KP, 1983, J BIOL CHEM, V258, P1267; Carruthers Vern B., 1999, Parasitology International, V48, P1; Chilcoat ND, 1996, J CELL BIOL, V135, P1775, DOI 10.1083/jcb.135.6.1775; Coppens I, 1999, EUR J CELL BIOL, V78, P463, DOI 10.1016/S0171-9335(99)80073-9; CRAIG EA, 1994, CELL, V78, P365, DOI 10.1016/0092-8674(94)90416-2; DIERKS T, 1993, PHILOS T ROY SOC B, V339, P335, DOI 10.1098/rstb.1993.0032; Dittie AS, 1997, EMBO J, V16, P4859, DOI 10.1093/emboj/16.16.4859; Elmendorf HG, 2001, MOL BIOCHEM PARASIT, V113, P157, DOI 10.1016/S0166-6851(01)00211-0; FAUBERT G, 1991, EXP PARASITOL, V72, P345, DOI 10.1016/0014-4894(91)90080-G; FEELY DE, 1990, HUMAN PARASITIC DIS; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; Gerasimenko OV, 1996, PFLUG ARCH EUR J PHY, V432, P1055, DOI 10.1007/s004240050234; GERDES HH, 1989, J BIOL CHEM, V264, P12009; Gillin FD, 1996, ANNU REV MICROBIOL, V50, P679, DOI 10.1146/annurev.micro.50.1.679; KEISTER DB, 1983, T ROY SOC TROP MED H, V77, P487, DOI 10.1016/0035-9203(83)90120-7; Knodler LA, 1999, J BIOL CHEM, V274, P29805, DOI 10.1074/jbc.274.42.29805; KRAUSE KH, 1990, BIOCHEM J, V270, P545, DOI 10.1042/bj2700545; KULIAWAT R, 1994, J CELL BIOL, V126, P77, DOI 10.1083/jcb.126.1.77; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; Lujan HD, 1996, BIOL CELL, V86, P11, DOI 10.1016/0248-4900(96)89519-0; LUJAN HD, 1995, J BIOL CHEM, V270, P29307, DOI 10.1074/jbc.270.49.29307; LUJAN HD, 1995, J BIOL CHEM, V270, P4612, DOI 10.1074/jbc.270.9.4612; Lujan HD, 1997, MICROBIOL MOL BIOL R, V61, P294; LUJAN HD, 1997, PARASITOL TODAY, V14, P446; LUJAN HD, 1996, P NATL ACAD SCI USA, V93, P7627; MacGowan GA, 2001, J BIOMED OPT, V6, P23, DOI 10.1117/1.1316091; McArthur AG, 2001, MOL BIOL EVOL, V18, P1455, DOI 10.1093/oxfordjournals.molbev.a003931; McNew JA, 2000, NATURE, V407, P153, DOI 10.1038/35025000; Meldolesi J, 1998, TRENDS BIOCHEM SCI, V23, P10, DOI 10.1016/S0968-0004(97)01143-2; Meng TC, 1996, MOL BIOCHEM PARASIT, V79, P103, DOI 10.1016/0166-6851(96)02636-9; MOWATT MR, 1995, MOL MICROBIOL, V15, P955, DOI 10.1111/j.1365-2958.1995.tb02364.x; NASH TE, 1989, EXP PARASITOL, V68, P238, DOI 10.1016/0014-4894(89)90104-5; NASH TE, 1993, P NATL ACAD SCI USA, V90, P5489, DOI 10.1073/pnas.90.12.5489; NASH TE, 1988, J IMMUNOL, V141, P636; Nickel W, 1999, P NATL ACAD SCI USA, V96, P12571, DOI 10.1073/pnas.96.22.12571; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Orci L, 1998, P NATL ACAD SCI USA, V95, P2279, DOI 10.1073/pnas.95.5.2279; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Pelham HRB, 2000, CELL, V102, P713, DOI 10.1016/S0092-8674(00)00060-X; Petersen OH, 2001, TRENDS NEUROSCI, V24, P271, DOI 10.1016/S0166-2236(00)01787-2; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Sambrook J., 2002, MOL CLONING LAB MANU; Schiavo G, 1997, P NATL ACAD SCI USA, V94, P997, DOI 10.1073/pnas.94.3.997; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shin DW, 2000, FEBS LETT, V486, P178, DOI 10.1016/S0014-5793(00)02246-8; SMITH SJ, 1988, TRENDS NEUROSCI, V11, P458, DOI 10.1016/0166-2236(88)90199-3; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; Soltys BJ, 1996, J CELL SCI, V109, P1909; Stroh A, 1999, EUR J CELL BIOL, V78, P151, DOI 10.1016/S0171-9335(99)80094-6; Touz MC, 2002, J BIOL CHEM, V277, P8474, DOI 10.1074/jbc.M110250200; Verbsky JW, 1998, MOL BIOL CELL, V9, P497, DOI 10.1091/mbc.9.2.497; YOO SH, 1990, J BIOL CHEM, V265, P13446; Yuasa K, 2000, PLANT PHYSIOL, V124, P1069, DOI 10.1104/pp.124.3.1069	61	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 27	2002	277	52					50557	50563		10.1074/jbc.M202558200	http://dx.doi.org/10.1074/jbc.M202558200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	631QD	12354777	hybrid			2022-12-25	WOS:000180177700049
J	Chang, TH; Milne, KG; Guther, MLS; Smith, TK; Ferguson, MAJ				Chang, TH; Milne, KG; Guther, MLS; Smith, TK; Ferguson, MAJ			Cloning of Trypanosoma brucei and Leishmania major genes encoding the GlcNAc-phosphatidylinositol De-N-acetylase of glycosylphosphatidylinositol biosynthesis that is essential to the African Sleeping sickness parasite	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE ANCHOR; INOSITOL-ACYLATION; SUBSTRATE-SPECIFICITY; GPI BIOSYNTHESIS; VIRULENCE FACTOR; PIG-L; PATHWAY; PRECURSORS; PROTEINS; ENZYME	The second step of glycosylphosphatidylinositol anchor biosynthesis in all eukaryotes is the conversion of D-GlcNAcalpha1-6-D-myo-inositol-1-HPO4-sn-1,2-diacylglycerol (GlcNAc-PI) to D-GlcNalpha1-6-D-myo-inositol-1-HPO4-sn-1,2-diacylglycerol by GlcNAc-PI de-N-acetylase. The genes encoding this activity are PIG-L and GPI12 in mammals and yeast, respectively. Fragments of putative GlcNAc-P1 de-N-acetylase genes from Trypanosoma brucei and Leishmania major were identified in the respective genome project data bases. The full-length genes TbGPI12 and LmGPI12 were subsequently cloned, sequenced, and shown to complement a PIG-L-deficient Chinese hamster ovary cell line and restore surface expression of GPI-anchored proteins. A tetracycline-inducible bloodstream form T. brucei TbGPI12 conditional null mutant cell line was created and analyzed under nonpermissive conditions. TbGPI12 mRNA levels were reduced to undetectable levels within 8 h of tetracycline removal, and the cells died after 3-4 days. This demonstrates that TbGPI12 is an essential gene for the tsetse-transmitted parasite that causes Nagana in cattle and African sleeping sickness in humans. It also validates GlcNAc-PI de-N-acetylase as a potential drug target against these diseases. Washed parasite membranes were prepared from the conditional null mutant parasites after 48 h without tetracycline. These membranes were shown to be greatly reduced in GlcNAc-PI de-N-acetylase activity, but they retained their ability to make GlcNAc-PI and to process D-GlcNalpha1-6-D-myo-inositol-1-HPO4-sn-1,2-diacylglycerol to later glycosylphosphatidylinositol intermediates. These results suggest that the stabilities of other glycosylphosphatidylinositol pathway enzymes are not dependent on GlcNAc-PI de-N-acetylase levels.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Biol Chem & Mol Microbiol, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Ferguson, Michael A. J./F-7829-2010	Ferguson, Michael A. J./0000-0003-1321-8714				Chen R, 1998, P NATL ACAD SCI USA, V95, P9512, DOI 10.1073/pnas.95.16.9512; COTTAZ S, 1993, J CHEM SOC P1, V1, P2945; Cross GAM, 1996, BIOESSAYS, V18, P283, DOI 10.1002/bies.950180406; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; Ferguson MAJ, 1999, BBA-MOL BASIS DIS, V1455, P327, DOI 10.1016/S0925-4439(99)00058-7; Ferguson MAJ, 2000, P NATL ACAD SCI USA, V97, P10673, DOI 10.1073/pnas.97.20.10673; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; Gerold P, 1999, BIOCHEM J, V344, P731, DOI 10.1042/0264-6021:3440731; Guha-Niyogi A, 2001, GLYCOBIOLOGY, V11, p45R, DOI 10.1093/glycob/11.4.45R; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; Guther MLS, 2001, EMBO J, V20, P4923, DOI 10.1093/emboj/20.17.4923; Heise N, 1996, J BIOL CHEM, V271, P16877, DOI 10.1074/jbc.271.28.16877; HIROSE S, 1992, J BIOL CHEM, V267, P16968; Ilg T, 2000, PARASITOL TODAY, V16, P489, DOI 10.1016/S0169-4758(00)01791-9; Kinoshita T, 2000, CURR OPIN CHEM BIOL, V4, P632, DOI 10.1016/S1367-5931(00)00151-4; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; MENON AK, 1990, J BIOL CHEM, V265, P9033; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; MILNE KG, 1994, J BIOL CHEM, V269, P16403; MILNE KG, 1992, EUR J BIOCHEM, V208, P309, DOI 10.1111/j.1432-1033.1992.tb17188.x; Milne KG, 2001, MOL BIOCHEM PARASIT, V112, P301, DOI 10.1016/S0166-6851(00)00369-8; Morita Y. S., 2000, OLIGOSACCHARIDES CHE, P417; Morita YS, 2000, J BIOL CHEM, V275, P14147, DOI 10.1074/jbc.275.19.14147; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Nakamura N, 1997, J BIOL CHEM, V272, P15834, DOI 10.1074/jbc.272.25.15834; Newton GL, 2000, J BACTERIOL, V182, P6958, DOI 10.1128/JB.182.24.6958-6963.2000; PUOTI A, 1993, J BIOL CHEM, V268, P7215; Ralton JE, 1998, J BIOL CHEM, V273, P4245, DOI 10.1074/jbc.273.7.4245; Ralton JE, 2002, BIOCHEM J, V363, P365, DOI 10.1042/0264-6021:3630365; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; Sharma DK, 1999, GLYCOBIOLOGY, V9, P415, DOI 10.1093/glycob/9.4.415; Sharma DK, 1997, BIOCHEM J, V328, P171; Smith TK, 1997, BIOCHEM J, V326, P393, DOI 10.1042/bj3260393; Smith TK, 1997, EMBO J, V16, P6667, DOI 10.1093/emboj/16.22.6667; Smith TK, 1996, J BIOL CHEM, V271, P6476, DOI 10.1074/jbc.271.11.6476; Smith TK, 2001, EMBO J, V20, P3322, DOI 10.1093/emboj/20.13.3322; Spath GF, 2000, P NATL ACAD SCI USA, V97, P9258, DOI 10.1073/pnas.160257897; Striepen B, 1999, BIOCHEMISTRY-US, V38, P1478, DOI 10.1021/bi981884q; Sutterlin C, 1998, BIOCHEM J, V332, P153; Turco SJ, 2001, TRENDS PARASITOL, V17, P223, DOI 10.1016/S1471-4922(01)01895-5; Watanabe R, 2000, EMBO J, V19, P4402, DOI 10.1093/emboj/19.16.4402; Watanabe R, 1999, BIOCHEM J, V339, P185, DOI 10.1042/0264-6021:3390185; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X	51	64	65	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 20	2002	277	51					50176	50182		10.1074/jbc.M208374200	http://dx.doi.org/10.1074/jbc.M208374200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	629AU	12364327	hybrid			2022-12-25	WOS:000180028900138
J	Diaz, AR; Mansilla, MC; Vila, AJ; de Mendoza, D				Diaz, AR; Mansilla, MC; Vila, AJ; de Mendoza, D			Membrane topology of the acyl-lipid desaturase from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEAROYL-COA DESATURASE; ALKALINE-PHOSPHATASE; ALKANE HYDROXYLASE; HISTIDINE-RESIDUES; PROTEIN; GENE; EXPRESSION; SEQUENCE; ENCODES; CARRIER	The Bacillus subtilis acyl-lipid desaturase (Delta5-Des) is an iron-dependent integral membrane protein, able to selectively introduce double bonds into long chain fatty acids. Structural information on membrane-bound desaturases is still limited, and the present topological information is restricted to hydropathy plots or sequence comparison with the evolutionary related alkane hydroxylase. The topology of Delta5-Des was determined experimentally in Escherichia coli using a set of nine different fusions of N-terminal fragments of Delta5-Des with the reporter alkaline phosphatase (Delta5-Des-PhoA). The alkaline phosphatase activities of cells expressing the Delta5-Des-PhoA fusions, combined with site-directed mutagenesis of His residues identified in most desaturases, suggest that a tripartite motif of His essential for catalysis is located on the cytoplasmic phase of the membrane. These data, together with surface Lys biotinylation experiments, support a model for Delta5-Des as a polytopic membrane protein with six transmembrane- and one membrane-associated domain, which likely represents a substrate-binding motif. This study provides the first experimental evidence for the topology of a plasma membrane fatty acid desaturase. On the basis of our results and the presently available hydrophobicity profile of many acyl-lipid desaturases, we propose that these enzymes contain a new transmembrane domain that might play a critical role in the desaturation of fatty acids esterified in glycerolipids.	Univ Nacl Rosario, Inst Biol Mol & Celular Rosario, RA-2000 Rosario, Argentina; Univ Nacl Rosario, Dept Microbiol, RA-2000 Rosario, Argentina; Univ Nacl Rosario, Dept Quim Biol, Area Biofis, Fac Ciencias Bioquim & Farmaceut, RA-2000 Rosario, Argentina	National University of Rosario; National University of Rosario; National University of Rosario	de Mendoza, D (corresponding author), Univ Nacl Rosario, Inst Biol Mol & Celular Rosario, Suipacha 531,S2002LRK, RA-2000 Rosario, Argentina.	diegonet@citynet.net.ar	Mansilla, María/R-8500-2019	Mansilla, María/0000-0002-1444-8661; Vila, Alejandro/0000-0002-7978-3233				Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Aguilar PS, 2001, EMBO J, V20, P1681, DOI 10.1093/emboj/20.7.1681; AVELANGEMACHEREL MH, 1995, FEBS LETT, V361, P111, DOI 10.1016/0014-5793(95)00163-4; BOYD D, 1993, J BACTERIOL, V175, P553, DOI 10.1128/JB.175.2.553-556.1993; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Cho HP, 1999, J BIOL CHEM, V274, P471, DOI 10.1074/jbc.274.1.471; Cho HP, 1999, J BIOL CHEM, V274, P37335, DOI 10.1074/jbc.274.52.37335; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; de Mendoza D., 2001, BACILLUS SUBTILIS IT, P43; ENOCH HG, 1976, J BIOL CHEM, V251, P5095; GRAU R, 1993, MOL MICROBIOL, V8, P535, DOI 10.1111/j.1365-2958.1993.tb01598.x; Green DH, 2000, J BACTERIOL, V182, P278, DOI 10.1128/JB.182.2.278-285.2000; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; Mitaku S, 1999, PROTEIN ENG, V12, P953, DOI 10.1093/protein/12.11.953; MURATA N, 1995, BIOCHEM J, V308, P1; Mustardy L, 1996, P NATL ACAD SCI USA, V93, P10524, DOI 10.1073/pnas.93.19.10524; OHLROGGE J, 1995, PLANT CELL, V7, P957, DOI 10.1105/tpc.7.7.957; OKAYASU T, 1981, ARCH BIOCHEM BIOPHYS, V206, P21, DOI 10.1016/0003-9861(81)90061-8; PUGH EL, 1977, J BIOL CHEM, V252, P68; PUGH EL, 1979, LIPIDS, V14, P159, DOI 10.1007/BF02533867; Shanklin J, 1998, ANNU REV PLANT PHYS, V49, P611, DOI 10.1146/annurev.arplant.49.1.611; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; STUKEY JE, 1990, J BIOL CHEM, V265, P20144; THIEDE MA, 1986, J BIOL CHEM, V261, P3230; Tocher DR, 1998, PROG LIPID RES, V37, P73, DOI 10.1016/S0163-7827(98)00005-8; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VANBEILEN JB, 1992, J BIOL CHEM, V267, P9194; vanGeest M, 1996, J BIOL CHEM, V271, P25582, DOI 10.1074/jbc.271.41.25582; Zhu QS, 1999, J BIOL CHEM, V274, P27898, DOI 10.1074/jbc.274.39.27898	32	55	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					48099	48106		10.1074/jbc.M208960200	http://dx.doi.org/10.1074/jbc.M208960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12324476	hybrid			2022-12-25	WOS:000179789600018
J	Woo, AL; Gildea, LA; Tack, LM; Miller, ML; Spicer, Z; Millhorn, DE; Finkelman, FD; Hassett, DJ; Shull, GE				Woo, AL; Gildea, LA; Tack, LM; Miller, ML; Spicer, Z; Millhorn, DE; Finkelman, FD; Hassett, DJ; Shull, GE			In vivo evidence for interferon-gamma-mediated homeostatic mechanisms in small intestine of the NHE3 Na+/H+ exchanger knockout model of congenital diarrhea	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY-BOWEL-DISEASE; MACROPHAGE CELL-LINE; RAT DISTAL COLON; IFN-GAMMA; MESSENGER-RNA; DIFFERENTIAL REGULATION; MOLECULAR-CLONING; GENE-EXPRESSION; NITRIC-OXIDE; INTRAEPITHELIAL LYMPHOCYTES	Mice lacking NHE3, the major absorptive Na+/H+ exchanger in the intestine, are the only animal model of congenital diarrhea. To identify molecular changes underlying compensatory mechanisms activated in chronic diarrheas, cDNA microarrays and Northern blot analyses were used to compare global mRNA expression patterns in small intestine of N-HE3-deficient and wildtype mice. Among the genes identified were members of the RegIII family of growth factors, which may contribute to the increased absorptive area, and a large number of interferon-gamma-responsive genes. The latter finding is of particular interest, since interferon-gamma has been shown to regulate ion transporter activities in intestinal epithelial cells. Serum interferon-gamma was elevated 5-fold in NHE3-deficient mice; however, there was no evidence of inflammation, and unlike conditions such as inflammatory bowel disease, levels of other cytokines were unchanged. In addition, quantitative PCR analysis showed that up-regulation of interferon-gamma mRNA was localized to the small intestine and did not occur in the colon, spleen, or kidney. These in vivo data suggest that elevated interferon-gamma, produced by gut-associated lymphoid tissue in the small intestine, is part of a homeostatic mechanism that is activated in response to the intestinal absorptive defect in order to regulate the fluidity of the intestinal tract.	Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Environm Hlth, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Genome Res Inst, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati	Shull, GE (corresponding author), Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	shullge@ucmail.uc.edu			NIAID NIH HHS [R21-AI46972, R01-AI44971, R01-AI40541] Funding Source: Medline; NIDDK NIH HHS [R124-DK58811, R01-DK50594, T32-DK07727] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044971, R21AI046972, R01AI040541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007727, R01DK050594] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Affleck DG, 2001, J INTERF CYTOK RES, V21, P1, DOI 10.1089/107999001459105; ALLEN RD, 1993, EUR J IMMUNOL, V23, P333, DOI 10.1002/eji.1830230205; BANDEIRA A, 1990, J EXP MED, V172, P239, DOI 10.1084/jem.172.1.239; Ben-Asouli Y, 2002, CELL, V108, P221, DOI 10.1016/S0092-8674(02)00616-5; BESANCON F, 1994, AM J PHYSIOL-CELL PH, V267, pC1398, DOI 10.1152/ajpcell.1994.267.5.C1398; Boehm U, 1997, ANNU REV IMMUNOL, V15, P749, DOI 10.1146/annurev.immunol.15.1.749; Boehm U, 1998, J IMMUNOL, V161, P6715; BOOKSTEIN C, 1994, J CLIN INVEST, V93, P106, DOI 10.1172/JCI116933; Cabral A, 2001, J BIOL CHEM, V276, P19231, DOI 10.1074/jbc.M100336200; CHANG EB, 1990, GASTROENTEROLOGY, V98, P1518, DOI 10.1016/0016-5085(90)91084-J; Chiba T, 2000, J GASTROENTEROL, V35, pU11; Chikano S, 2000, GUT, V47, P779, DOI 10.1136/gut.47.6.779; Cho JH, 1998, AM J PHYSIOL-CELL PH, V274, pC586, DOI 10.1152/ajpcell.1998.274.3.C586; COLGAN SP, 1994, AM J PHYSIOL, V267, pC402, DOI 10.1152/ajpcell.1994.267.2.C402; Cougnon M, 1996, J BIOL CHEM, V271, P7277, DOI 10.1074/jbc.271.13.7277; DE SK, 1990, J BIOL CHEM, V265, P15267; Dey A, 2000, BBA-MOL CELL RES, V1497, P135, DOI 10.1016/S0167-4889(00)00053-7; Dieckgraefe BK, 2000, PHYSIOL GENOMICS, V4, P1; Dodson BD, 1996, AM J PHYSIOL-GASTR L, V271, pG347, DOI 10.1152/ajpgi.1996.271.2.G347; DOERRLER W, 1994, CYTOKINE, V6, P478, DOI 10.1016/1043-4666(94)90074-4; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; DUSETTI NJ, 1995, J BIOL CHEM, V270, P22417, DOI 10.1074/jbc.270.38.22417; ERROI A, 1993, INFECT IMMUN, V61, P4356, DOI 10.1128/IAI.61.10.4356-4359.1993; FARBER JM, 1992, MOL CELL BIOL, V12, P1535, DOI 10.1128/MCB.12.4.1535; Finkelman FD, 1999, INT IMMUNOL, V11, P1811, DOI 10.1093/intimm/11.11.1811; FINKELMAN FD, 1987, J IMMUNOL, V138, P2826; FINKELMAN FD, 1988, J IMMUNOL, V140, P1022; FRANKLIN MR, 1985, J INTERFERON RES, V5, P265, DOI 10.1089/jir.1985.5.265; Gawenis LR, 2002, GASTROENTEROLOGY, V122, pA539; Gawenis LR, 2002, AM J PHYSIOL-GASTR L, V282, pG776, DOI 10.1152/ajpgi.00297.2001; Gergel D, 1996, BIOCHEMISTRY-US, V35, P16186, DOI 10.1021/bi962043r; GOODMAN T, 1988, NATURE, V333, P855, DOI 10.1038/333855a0; GREGOIRE F, 1992, J CELL PHYSIOL, V151, P300, DOI 10.1002/jcp.1041510211; GUYGRAND D, 1991, J EXP MED, V173, P471, DOI 10.1084/jem.173.2.471; Hahm KB, 2001, GUT, V49, P190, DOI 10.1136/gut.49.2.190; Hayday A, 2001, NAT IMMUNOL, V2, P997, DOI 10.1038/ni1101-997; HEEGER P, 1992, KIDNEY INT, V41, P220, DOI 10.1038/ki.1992.31; Heinzel FP, 1996, J IMMUNOL, V157, P4521; Hoogerwerf WA, 1996, AM J PHYSIOL-GASTR L, V270, pG29, DOI 10.1152/ajpgi.1996.270.1.G29; Iwasaki A, 1999, J EXP MED, V190, P229, DOI 10.1084/jem.190.2.229; JOTWANI R, 1994, MICROBIOL IMMUNOL, V38, P763, DOI 10.1111/j.1348-0421.1994.tb01854.x; Jump RL, 2002, J IMMUNOL, V168, P6113, DOI 10.4049/jimmunol.168.12.6113; KOMANO H, 1995, P NATL ACAD SCI USA, V92, P6147, DOI 10.1073/pnas.92.13.6147; KURODA K, 1995, IMMUNOLOGY, V84, P153; Lawrance IC, 2001, HUM MOL GENET, V10, P445, DOI 10.1093/hmg/10.5.445; Ledoussal C, 2001, AM J PHYSIOL-GASTR L, V281, pG1385, DOI 10.1152/ajpgi.2001.281.6.G1385; Leishman AJ, 2001, SCIENCE, V294, P1936, DOI 10.1126/science.1063564; Lorenz JN, 2002, J BIOL CHEM, V277, P37871, DOI 10.1074/jbc.M205627200; LYONS CR, 1992, J BIOL CHEM, V267, P6370; MacDonald TT, 2000, SCAND J IMMUNOL, V51, P2; Malakooti J, 1999, AM J PHYSIOL-GASTR L, V277, pG383, DOI 10.1152/ajpgi.1999.277.2.G383; MEEUSEN E, 1993, EUR J IMMUNOL, V23, P1112, DOI 10.1002/eji.1830230520; Monshouwer M, 1996, TOXICOL APPL PHARM, V137, P237, DOI 10.1006/taap.1996.0077; Okamura H, 1998, CURR OPIN IMMUNOL, V10, P259, DOI 10.1016/S0952-7915(98)80163-5; Oprins JCJ, 2000, AM J PHYSIOL-CELL PH, V278, pC463, DOI 10.1152/ajpcell.2000.278.3.C463; ORLOWSKI J, 1992, J BIOL CHEM, V267, P9331; ORLOWSKI J, 1988, J BIOL CHEM, V263, P10436; Overbergh L, 1999, CYTOKINE, V11, P305, DOI 10.1006/cyto.1998.0426; PAULNOCKKING D, 1985, J IMMUNOL, V135, P632; Pothoulakis C, 2000, ANN NY ACAD SCI, V915, P347; POWELL DW, 1995, TXB GASTROENTEROLOGY, P813; RAETZ CRH, 1991, FASEB J, V5, P2652, DOI 10.1096/fasebj.5.12.1916089; REDINI F, 1988, BIOCHEM BIOPH RES CO, V155, P786, DOI 10.1016/S0006-291X(88)80564-3; Rivett AJ, 2001, BIOCHIMIE, V83, P363; Rocha F, 2001, AM J PHYSIOL-CELL PH, V280, pC1224, DOI 10.1152/ajpcell.2001.280.5.C1224; Rogler G, 1998, WORLD J SURG, V22, P382, DOI 10.1007/s002689900401; Sangan PC, 1997, AM J PHYSIOL-CELL PH, V272, pC685, DOI 10.1152/ajpcell.1997.272.2.C685; Schultheis PJ, 1998, NAT GENET, V19, P282, DOI 10.1038/969; SCHULTZ DR, 1990, SEMIN ARTHRITIS RHEU, V20, P129, DOI 10.1016/0049-0172(90)90055-K; Seta KA, 2001, J BIOL CHEM, V276, P44405, DOI 10.1074/jbc.M103346200; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Spicer Z, 2001, AM J PHYSIOL-GASTR L, V281, pG1369, DOI 10.1152/ajpgi.2001.281.6.G1369; STRASSMANN G, 1994, J EXP MED, V180, P2365, DOI 10.1084/jem.180.6.2365; Sugi K, 2001, GASTROENTEROLOGY, V120, P1393, DOI 10.1053/gast.2001.24045; SWEIRY JH, 1989, J CLIN INVEST, V83, P844, DOI 10.1172/JCI113967; TAKAHASHI H, 1993, CANCER RES, V53, P1612; Tapner M, 1996, HEPATOLOGY, V24, P367; TEITELL M, 1994, CRIT REV IMMUNOL, V14, P1; Towne JE, 2000, AM J RESP CELL MOL, V22, P34, DOI 10.1165/ajrcmb.22.1.3818; TSE CM, 1992, J BIOL CHEM, V267, P9340; Waite KJ, 2001, J BIOL CHEM, V276, P7062, DOI 10.1074/jbc.M007894200; Wang H, 2001, BIOCHEM BIOPH RES CO, V286, P869, DOI 10.1006/bbrc.2001.5482; WATANABE SI, 1995, J BIOL CHEM, V270, P12191, DOI 10.1074/jbc.270.20.12191; WATANABE T, 1994, P NATL ACAD SCI USA, V91, P3589, DOI 10.1073/pnas.91.9.3589; Wong WM, 1999, GUT, V44, P890, DOI 10.1136/gut.44.6.890; Xiang SD, 2001, IMMUNOL CELL BIOL, V79, P472, DOI 10.1046/j.1440-1711.2001.01033.x; Yang YH, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.4.e15; Yin ZN, 2000, J IMMUNOL, V164, P3056, DOI 10.4049/jimmunol.164.6.3056; Yoo D, 2000, AM J PHYSIOL-GASTR L, V279, pG1323, DOI 10.1152/ajpgi.2000.279.6.G1323; Yu LCH, 2000, ANN NY ACAD SCI, V915, P247; ZIEGLERHEITBROCK HWL, 1995, J INFLAMM, V45, P13; ZURAW BL, 1990, J BIOL CHEM, V265, P12664	92	36	36	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	DEC 13	2002	277	50					49036	49046		10.1074/jbc.M205288200	http://dx.doi.org/10.1074/jbc.M205288200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	624YK	12370192	hybrid			2022-12-25	WOS:000179789600137
J	Crisp, RJ; Knauer, MF; Knauer, DJ				Crisp, RJ; Knauer, MF; Knauer, DJ			Protease nexin 1 is a potent urinary plasminogen activator inhibitor in the presence of collagen type IV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; UROKINASE RECEPTOR; IN-VITRO; THROMBIN; BINDING; HEPARIN; SPECIFICITY; COMPLEXES; CELLS; BRAIN	Protease nexin 1 (PN1) in solution forms inhibitory complexes with thrombin or urokinase, which have opposing effects on the blood coagulation cascade. An initial report provided data supporting the idea that PN1 target protease specificity is under the influence of collagen type IV (1). Although collagen type IV demonstrated no effect on the association rate between PN1 and thrombin, the study reported that the association rate between PN1 and urokinase was allosterically reduced 10-fold. This has led to the generally accepted idea that the primary role of PN1 in the brain is to act as a rapid thrombin inhibition and clearance mechanism during trauma and loss of vascular integrity. In studies to identify the structural determinants of PN1 that mediate the allosteric interaction with collagen type IV, we found that protease specificity was only affected after transient exposure of PN1 to acidic conditions that mimic the elution protocol from a monoclonal antibody column. Because PN1 used in previous studies was purified over a monoclonal antibody column, we propose that the allosteric regulation of PN1 target protease specificity by collagen type IV is a result of the purification protocol. We provide both biochemical and kinetic data to support this conclusion. This finding is significant because it implies that PN1 may play a much larger role in the modeling and remodeling of brain tissues during development and is not simply an extravasated thrombin clearance mechanism as previously suggested.	Univ Calif Irvine, Dept Cellular & Dev Biol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Knauer, DJ (corresponding author), Univ Calif Irvine, Dept Cellular & Dev Biol, Irvine, CA 92697 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007311, R01GM034001] Funding Source: NIH RePORTER; NIGMS NIH HHS [T32GM07311-27, GM34001-12] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKER JB, 1980, CELL, V21, P37, DOI 10.1016/0092-8674(80)90112-9; Cunningham DD, 1997, ADV EXP MED BIOL, V425, P67; DONOVAN FM, 1994, J BIOL CHEM, V269, P17199; Donovan FM, 1998, J BIOL CHEM, V273, P12746, DOI 10.1074/jbc.273.21.12746; EHRLICH HJ, 1990, J BIOL CHEM, V265, P13029; FARRELL DH, 1988, J CELL PHYSIOL, V134, P179, DOI 10.1002/jcp.1041340203; GETTINS P, 1992, HEMATOL ONCOL CLIN N, V6, P1393, DOI 10.1016/S0889-8588(18)30282-X; GUENTHER J, 1985, EMBO J, V4, P1963, DOI 10.1002/j.1460-2075.1985.tb03878.x; GYETKO MR, 1994, J CLIN INVEST, V93, P1380, DOI 10.1172/JCI117114; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; Knauer DJ, 2000, J BIOL CHEM, V275, P37340, DOI 10.1074/jbc.M003909200; KNAUER DJ, 1983, J CELL PHYSIOL, V117, P385, DOI 10.1002/jcp.1041170314; Knauer MF, 1999, J BIOL CHEM, V274, P275, DOI 10.1074/jbc.274.1.275; Knauer MF, 1997, J BIOL CHEM, V272, P12261, DOI 10.1074/jbc.272.19.12261; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; Kridel SJ, 1996, J BIOL CHEM, V271, P20935, DOI 10.1074/jbc.271.34.20935; KUHN K, 1994, MATRIX BIOL, V14, P439; MANSUY IM, 1993, DEVELOPMENT, V119, P1119; OKADA SS, 1995, EXP CELL RES, V217, P180, DOI 10.1006/excr.1995.1077; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; REINHARD E, 1994, J NEUROSCI RES, V37, P256, DOI 10.1002/jnr.490370211; ROSENBERG RD, 1977, SEMIN HEMATOL, V14, P427; ROSENBLATT DE, 1987, BRAIN RES, V415, P40, DOI 10.1016/0006-8993(87)90267-8; SAPPINO AP, 1993, J CLIN INVEST, V92, P679, DOI 10.1172/JCI116637; SCOTT RW, 1985, J BIOL CHEM, V260, P7029; SOMMER J, 1987, BIOCHEMISTRY-US, V26, P6407, DOI 10.1021/bi00394a016; TOLLEFSEN DM, 1982, J BIOL CHEM, V257, P2162; VANNOSTRAND WE, 1988, BIOCHEMISTRY-US, V27, P2176, DOI 10.1021/bi00406a054; VerdiereSahuque M, 1996, EXP CELL RES, V222, P70, DOI 10.1006/excr.1996.0009; WAGNER SL, 1989, J BIOL CHEM, V264, P611; Wagner SN, 1996, HISTOCHEM CELL BIOL, V105, P53, DOI 10.1007/BF01450878	32	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47285	47291		10.1074/jbc.M204813200	http://dx.doi.org/10.1074/jbc.M204813200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356769	hybrid			2022-12-25	WOS:000179663700058
J	Roti, ECR; Myers, CD; Ayers, RA; Boatman, DE; Delfosse, SA; Chan, EKL; Ackerman, MJ; January, CT; Robertson, GA				Roti, ECR; Myers, CD; Ayers, RA; Boatman, DE; Delfosse, SA; Chan, EKL; Ackerman, MJ; January, CT; Robertson, GA			Interaction with GM130 during HERG ion channel trafficking - Disruption by type 2 congenital long QT syndrome mutations	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEFECTIVE PROTEIN TRAFFICKING; INHERITED CARDIAC-ARRHYTHMIA; AMINO-TERMINAL DOMAIN; GOLGI MATRIX PROTEIN; POTASSIUM CHANNEL; K+-CHANNEL; ENDOPLASMIC-RETICULUM; KINASE-C; MUTANT; GENE	Many mutations in the Human Ether-a-go-go-Related Gene (HERG) cause type 2 congenital long QT syndrome (LQT2) by disrupting trafficking of the HERG-encoded potassium channel. Beyond observations that some mutations trap channels in the endoplasmic reticulum, little is known about how trafficking fails. Even less is known about what checkpoints are encountered in normal trafficking. To identify protein partners encountered as HERG channels are transported among subcellular compartments, we screened a human heart library with the C terminus of HERG using yeast two-hybrid technology. Among the proteins isolated was GM130, a Golgi-associated protein involved in vesicular transport. The interaction mapped to two non-contiguous regions of HERG and to a region just upstream of the GRASP-65 interaction domain of GM130. GM130 did not interact with the N or C terminus of either KvLQT1 or Shaker channels. LQT2-causing mutations in the HERG C terminus selectively disrupted interactions with GM130 but not Tara, another HERG-interacting protein. Native GM130 and stably expressed HERG were co-immunoprecipitated from HEK-293 cells using GM130 antibodies. In rat cardiac myocytes and HEK-293 cells, confocal immunocytochemistry showed co-localization of GM130 and HERG to the Golgi apparatus. Overexpression of GM130 suppressed HERG current amplitude in Xenopus oocytes, as if by providing an excess of substrate at the Golgi checkpoint. These findings indicate that GM130 plays a previously undefined role in cargo transport. We propose that the cytoplasmic C terminus of HERG participates in the tethering or possibly targeting of HERG-containing vesicles within the Golgi via its interaction with GM130.	Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; The Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; Mayo Clin & Mayo Fdn, Dept Internal Med, Div Cardiovasc Dis, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Pediat, Div Pediat Cardiol, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Mol Pharmacol, Rochester, MN 55905 USA; Univ Wisconsin, Dept Med, Sect Cardiovasc Med, Madison, WI 53792 USA	University of Wisconsin System; University of Wisconsin Madison; Scripps Research Institute; Mayo Clinic; Mayo Clinic; Mayo Clinic; University of Wisconsin System; University of Wisconsin Madison	Robertson, GA (corresponding author), Univ Wisconsin, Dept Physiol, 1300 Univ Ave, Madison, WI 53706 USA.		Chan, Edward K. L./B-5671-2009	Chan, Edward K. L./0000-0003-3938-9503; Robertson, Gail/0000-0003-4694-5790	NHLBI NIH HHS [R01-HL55973, R01-HL60723, R01-HL68868] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055973, R01HL060723, R01HL068868] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackerman MJ, 1998, MAYO CLIN PROC, V73, P250, DOI 10.4065/73.3.250; Alvarez C, 2001, J BIOL CHEM, V276, P2693, DOI 10.1074/jbc.M007957200; Aydar E, 2001, J PHYSIOL-LONDON, V534, P1, DOI 10.1111/j.1469-7793.2001.t01-3-00001.x; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Barr FA, 1998, EMBO J, V17, P3258, DOI 10.1093/emboj/17.12.3258; Barr FA, 1997, CELL, V91, P253, DOI 10.1016/S0092-8674(00)80407-9; Berthet M, 1999, CIRCULATION, V99, P1464, DOI 10.1161/01.CIR.99.11.1464; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; Choukroun GJ, 2000, J CLIN INVEST, V106, P983, DOI 10.1172/JCI8914; Corse E, 2002, J VIROL, V76, P1273, DOI 10.1128/JVI.76.3.1273-1284.2002; Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Eystathioy T, 2000, J AUTOIMMUN, V14, P179, DOI 10.1006/jaut.1999.0359; FAWCETT DW, 1969, J CELL BIOL, V42, P1, DOI 10.1083/jcb.42.1.1; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; FRITZLER MJ, 1993, J EXP MED, V178, P49, DOI 10.1084/jem.178.1.49; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; He JQ, 2000, J PHYSIOL-LONDON, V524, P807, DOI 10.1111/j.1469-7793.2000.00807.x; Jakymiw A, 2000, J BIOL CHEM, V275, P4137, DOI 10.1074/jbc.275.6.4137; James P, 1996, GENETICS, V144, P1425; Keating MT, 1996, CURR OPIN GENET DEV, V6, P326, DOI 10.1016/S0959-437X(96)80010-4; Kiehn J, 2000, TRENDS CARDIOVAS MED, V10, P205, DOI 10.1016/S1050-1738(00)00071-2; Laitinen P, 2000, Hum Mutat, V15, P580, DOI 10.1002/1098-1004(200006)15:6<580::AID-HUMU16>3.3.CO;2-S; Lambert G, 2001, J BIOL CHEM, V276, P20340, DOI 10.1074/jbc.M011209200; Lees-Miller JP, 2000, CIRC RES, V86, P507, DOI 10.1161/01.RES.86.5.507; Marra P, 2001, NAT CELL BIOL, V3, P1101, DOI 10.1038/ncb1201-1101; MCNUTT NS, 1969, J CELL BIOL, V42, P46, DOI 10.1083/jcb.42.1.46; Moyer BD, 2001, TRAFFIC, V2, P268, DOI 10.1034/j.1600-0854.2001.1o007.x; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Nakamura N, 1995, J CELL BIOL, V131, P1715, DOI 10.1083/jcb.131.6.1715; PAPAZIAN DM, 1987, SCIENCE, V237, P749, DOI 10.1126/science.2441470; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Robertson GA, 2000, CIRC RES, V86, P492, DOI 10.1161/01.RES.86.5.492; RODEN DM, 1995, J CARDIOVASC ELECTR, V6, P1023, DOI 10.1111/j.1540-8167.1995.tb00379.x; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SANGUINETTI MC, 1991, AM J PHYSIOL, V260, pH393, DOI 10.1152/ajpheart.1991.260.2.H393; Sanguinetti MC, 1996, P NATL ACAD SCI USA, V93, P2208, DOI 10.1073/pnas.93.5.2208; SARASTE J, 1991, J CELL SCI, V100, P415; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Seemann J, 2000, MOL BIOL CELL, V11, P635, DOI 10.1091/mbc.11.2.635; Seipel K, 2001, J CELL SCI, V114, P389; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Wang JL, 1998, J GEN PHYSIOL, V112, P637, DOI 10.1085/jgp.112.5.637; Wang JL, 2000, J GEN PHYSIOL, V115, P749, DOI 10.1085/jgp.115.6.749; Wang Q, 1996, NAT GENET, V12, P17, DOI 10.1038/ng0196-17; Zhou ZF, 1998, BIOPHYS J, V74, P230, DOI 10.1016/S0006-3495(98)77782-3; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061	51	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47779	47785		10.1074/jbc.M206638200	http://dx.doi.org/10.1074/jbc.M206638200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12270925	hybrid			2022-12-25	WOS:000179663700122
J	Smith, DE; Ketchem, RR; Moore, H; Anderson, Z; Renshaw, BR; Friend, DJ; Sims, JE				Smith, DE; Ketchem, RR; Moore, H; Anderson, Z; Renshaw, BR; Friend, DJ; Sims, JE			A single amino acid difference between human and monkey interleukin (IL)-1 beta dictates effective binding to soluble type II IL-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; CRYSTAL-STRUCTURE; DECOY RECEPTOR; PROTEIN; IDENTIFICATION; ANTAGONIST; SEQUENCE; SITES; GENES	Soluble type II interleukin (IL)-1 receptor (sIL1R-II) binds human IL-1beta with high affinity and neutralizes its activity. Recombinant sIL1R-II is considered a potentially useful anti-IL-1 therapeutic, and preclinical studies have been undertaken with this molecule in primates. To better understand the cytokine-receptor interactions occurring in this nonhuman context, monkey IL-1 and IL1R-II were cloned, and their binding abilities were examined in vitro. IL-1beta from cynomolgus monkey was capable of binding and activating the human type I IL-1 receptor. However, unlike human IL-1beta, it was unable to effectively bind and become neutralized by sIL1R-II. Human and cynomolgus IL-1beta proteins are 96% identical, differing by only six amino acids. Structural and mutational analysis revealed that the unique sIL1R-II binding ability of human IL-1beta is due to a single amino acid difference compared with monkey IL-1beta.	Amgen Corp, Seattle, WA 98101 USA		Smith, DE (corresponding author), Amgen Corp, 51 Univ St, Seattle, WA 98101 USA.		Ketchem, Randal R/K-2258-2017; Ketchem, Randal/AAB-4372-2020	Ketchem, Randal R/0000-0002-7821-2682; Ketchem, Randal/0000-0002-7821-2682; Sims, John/0000-0002-5667-9185				Attur MG, 2002, J IMMUNOL, V168, P2001, DOI 10.4049/jimmunol.168.4.2001; Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Bessis N, 2000, EUR J IMMUNOL, V30, P867, DOI 10.1002/1521-4141(200003)30:3<867::AID-IMMU867>3.0.CO;2-M; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; CAMACHO NP, 1993, BIOCHEMISTRY-US, V32, P8749, DOI 10.1021/bi00085a005; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; Dinarello C A, 1998, Int Rev Immunol, V16, P457, DOI 10.3109/08830189809043005; EVANS RJ, 1995, J BIOL CHEM, V270, P11477, DOI 10.1074/jbc.270.19.11477; GIRI JG, 1995, EMBO J, V14, P3654, DOI 10.1002/j.1460-2075.1995.tb00035.x; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GRUTTER MG, 1994, PROTEIN ENG, V7, P663, DOI 10.1093/protein/7.5.663; Itoh S, 1999, J IMMUNOL, V162, P7434; Liu CL, 1996, J BIOL CHEM, V271, P20965, DOI 10.1074/jbc.271.34.20965; Mantovani A, 2001, TRENDS IMMUNOL, V22, P328, DOI 10.1016/S1471-4906(01)01941-X; Marti-Renom MA, 2000, ANNU REV BIOPH BIOM, V29, P291, DOI 10.1146/annurev.biophys.29.1.291; Morris AE, 1997, ANIMAL CELL TECHNOLOGY, P529; MURZIN AG, 1992, J MOL BIOL, V223, P531, DOI 10.1016/0022-2836(92)90668-A; Schreuder H, 1997, NATURE, V386, P194, DOI 10.1038/386194a0; SHAANAN B, 1992, SCIENCE, V257, P961, DOI 10.1126/science.1502561; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Totsuka K, 1998, INT ARCH ALLERGY IMM, V116, P40, DOI 10.1159/000023923; VEERAPANDIAN B, 1992, PROTEINS, V12, P10, DOI 10.1002/prot.340120103; Vigers GPA, 1997, NATURE, V386, P190, DOI 10.1038/386190a0; VILLINGER F, 1995, J IMMUNOL, V155, P3946	25	7	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	DEC 6	2002	277	49					47619	47625		10.1074/jbc.M206636200	http://dx.doi.org/10.1074/jbc.M206636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	622TT	12356774	hybrid			2022-12-25	WOS:000179663700102
J	Anjos, S; Nguyen, A; Ounissi-Benkalha, H; Tessier, MC; Polychronakos, C				Anjos, S; Nguyen, A; Ounissi-Benkalha, H; Tessier, MC; Polychronakos, C			A common autoimmunity predisposing signal peptide variant of the cytotoxic T-lymphocyte antigen 4 results in inefficient glycosylation of the susceptibility allele	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CTLA-4 GENE POLYMORPHISM; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; DIABETES-MELLITUS IDDM; GRAVES-DISEASE; ENDOPLASMIC-RETICULUM; CHROMOSOME 2Q33; HASHIMOTOS-THYROIDITIS; CONFERS SUSCEPTIBILITY; NEGATIVE REGULATOR; ADDISONS-DISEASE	A common T17A polymorphism. in the signal peptide of the cytotoxic T-lymphocyte antigen 4 (CTLA-4), a T-cell receptor that negatively regulates immune responses, is associated with risk for autoimmune disease. Because the polymorphism is absent from the mature protein, we hypothesized that its biological effect must involve early stages of protein processing, prior to signal peptide cleavage. Constructs representing the two alleles were compared by in vitro translation, in the presence of endoplasmic reticulum. membranes. We studied glycosylation by endoglycosidase H digestion and glycosylation mutant constructs, cleavage of peptide with inhibitors, and membrane integration by ultracentrifugation and proteinase K sensitivity. A major cleaved and glycosylated product was seen for both alleles of the protein but a band representing incomplete glycosyIation was markedly more abundant in the predisposing Ala allele (32.7 +/- 1.0 versus 10.6% +/- 1.2 for Thr, p < 10(-9)). In addition, differential intracellular/surface partitioning was studied with co-transfection of the alleles fused to distinct fluorescent proteins in COS-1 cells. By quantitative confocal microscopy we found a higher ratio of cell surface/total CTLAThr(17) versus CTLAAla(17) (p = 0.01). Our findings corroborate observations, in other proteins, that the signal peptide can determine the efficiency of post-translational modifications other than cleavage and suggest inefficient processing of the autoimmunity predisposing Ala allele as the explanation for the genetic effect.	McGill Univ, Ctr Hlth, Endocrine Genet Lab, Dept Pediat,Div Pediat Endocrinol, Montreal, PQ H3H 1P3, Canada; McGill Univ, Lady Davis Inst Med Res, Montreal, PQ H3H 1P3, Canada	McGill University; Lady Davis Institute; McGill University	Polychronakos, C (corresponding author), McGill Univ, Ctr Hlth, Endocrine Genet Lab, Dept Pediat,Div Pediat Endocrinol, 2300 Tupper, Montreal, PQ H3H 1P3, Canada.		Polychronakos, Constantin/B-8151-2008	Polychronakos, Constantin/0000-0002-7624-6635				Awata T, 1998, DIABETES, V47, P128, DOI 10.2337/diab.47.1.128; Bachmann MF, 1999, J IMMUNOL, V163, P1128; Barbesino G, 1998, J CLIN ENDOCR METAB, V83, P1580, DOI 10.1210/jc.83.5.1580; Barrat FJ, 1999, P NATL ACAD SCI USA, V96, P8645, DOI 10.1073/pnas.96.15.8645; Beuret N, 1999, J BIOL CHEM, V274, P18965, DOI 10.1074/jbc.274.27.18965; Chambers CA, 1997, IMMUNITY, V7, P885, DOI 10.1016/S1074-7613(00)80406-9; Chen XM, 2001, J BIOL CHEM, V276, P2411, DOI 10.1074/jbc.M007723200; DELEAGE G, 1987, ANAL BIOCHEM, V163, P292, DOI 10.1016/0003-2697(87)90226-0; Djilali-Saiah I, 1998, GUT, V43, P187, DOI 10.1136/gut.43.2.187; Donner H, 1997, J CLIN ENDOCR METAB, V82, P4130, DOI 10.1210/jc.82.12.4130; Donner H, 1997, J CLIN ENDOCR METAB, V82, P143, DOI 10.1210/jc.82.1.143; Dubuisson J, 2000, J BIOL CHEM, V275, P30605, DOI 10.1074/jbc.M004326200; Eagar TN, 2002, EUR J IMMUNOL, V32, P972, DOI 10.1002/1521-4141(200204)32:4<972::AID-IMMU972>3.0.CO;2-M; Ellgaard L, 1999, SCIENCE, V286, P1882, DOI 10.1126/science.286.5446.1882; GAVEL Y, 1990, PROTEIN ENG, V3, P433, DOI 10.1093/protein/3.5.433; Giscombe R, 2002, J RHEUMATOL, V29, P950; Heward JM, 1999, J CLIN ENDOCR METAB, V84, P2398, DOI 10.1210/jc.84.7.2398; Holopainen PM, 2001, J IMMUNOL, V167, P2457, DOI 10.4049/jimmunol.167.5.2457; Holst B, 1996, EMBO J, V15, P3538, DOI 10.1002/j.1460-2075.1996.tb00723.x; Hurwitz AA, 1997, J NEUROIMMUNOL, V73, P57, DOI 10.1016/S0165-5728(96)00168-3; ITO M, 1993, J CLIN INVEST, V91, P2565, DOI 10.1172/JCI116494; Karandikar NJ, 2000, J NEUROIMMUNOL, V109, P173, DOI 10.1016/S0165-5728(00)00322-2; Karandikar NJ, 1996, J EXP MED, V184, P783, DOI 10.1084/jem.184.2.783; KARAPLIS AC, 1995, J BIOL CHEM, V270, P1629, DOI 10.1074/jbc.270.4.1629; Karplus K, 1998, BIOINFORMATICS, V14, P846, DOI 10.1093/bioinformatics/14.10.846; KASTURI L, 1995, J BIOL CHEM, V270, P14756, DOI 10.1074/jbc.270.24.14756; Kemp EH, 1998, CLIN ENDOCRINOL, V49, P609; King AL, 2002, J MED GENET, V39, P51, DOI 10.1136/jmg.39.1.51; Kotsa K, 1997, CLIN ENDOCRINOL, V46, P551, DOI 10.1046/j.1365-2265.1997.1710996.x; Kouki T, 2000, J IMMUNOL, V165, P6606, DOI 10.4049/jimmunol.165.11.6606; Kouki T, 2002, J ENDOCRINOL INVEST, V25, P208, DOI 10.1007/BF03343992; Krummel MF, 1996, J EXP MED, V183, P2533, DOI 10.1084/jem.183.6.2533; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lee KM, 1998, SCIENCE, V282, P2263, DOI 10.1126/science.282.5397.2263; LEUNG HT, 1995, J BIOL CHEM, V270, P25107, DOI 10.1074/jbc.270.42.25107; Li Y, 1996, P NATL ACAD SCI USA, V93, P9606, DOI 10.1073/pnas.93.18.9606; Linsley PS, 1996, IMMUNITY, V4, P535, DOI 10.1016/S1074-7613(00)80480-X; Luhder F, 1998, J EXP MED, V187, P427, DOI 10.1084/jem.187.3.427; Marron MP, 2000, DIABETES, V49, P492, DOI 10.2337/diabetes.49.3.492; Marron MP, 1997, HUM MOL GENET, V6, P1275, DOI 10.1093/hmg/6.8.1275; Matoba S, 1998, J BIOL CHEM, V273, P18841, DOI 10.1074/jbc.273.30.18841; Maurer M, 2002, IMMUNOGENETICS, V54, P1, DOI 10.1007/s00251-002-0429-9; Metzler WJ, 1997, NAT STRUCT BIOL, V4, P527, DOI 10.1038/nsb0797-527; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nistico L, 1996, HUM MOL GENET, V5, P1075, DOI 10.1093/hmg/5.7.1075; Nithiyananthan R, 2002, THYROID, V12, P3, DOI 10.1089/105072502753451896; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Perrin PJ, 1996, J IMMUNOL, V157, P1333; RACCHI M, 1993, J BIOL CHEM, V268, P5735; ShakinEshleman SH, 1996, J BIOL CHEM, V271, P6363, DOI 10.1074/jbc.271.11.6363; TIVOL EA, 1995, IMMUNITY, V3, P541, DOI 10.1016/1074-7613(95)90125-6; Todd JA, 1996, HUM MOL GENET, V5, P1443, DOI 10.1093/hmg/5.Supplement_1.1443; Tomer Y, 2001, J CLIN ENDOCR METAB, V86, P1687, DOI 10.1210/jc.86.4.1687; Vaidya B, 1999, HUM MOL GENET, V8, P1195, DOI 10.1093/hmg/8.7.1195; Vaidya B, 2002, RHEUMATOLOGY, V41, P180, DOI 10.1093/rheumatology/41.2.180; VanDerAuwera BJ, 1997, CLIN EXP IMMUNOL, V110, P98, DOI 10.1111/j.1365-2249.1997.t01-1-512-ce1410.x; WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X; Walunas TL, 1998, J IMMUNOL, V160, P3855; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Yanagawa T, 1997, THYROID, V7, P843, DOI 10.1089/thy.1997.7.843; YANAGAWA T, 1995, J CLIN ENDOCR METAB, V80, P41, DOI 10.1210/jc.80.1.41	62	222	230	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46478	46486		10.1074/jbc.M206894200	http://dx.doi.org/10.1074/jbc.M206894200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244107	hybrid			2022-12-25	WOS:000179529300101
J	Anthony, LC; Burgess, RR				Anthony, LC; Burgess, RR			Conformational flexibility in or sigma(70) region 2 during transcription initiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; DNA-BINDING; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DISULFIDE BOND; OPEN COMPLEX; CORE; PROMOTER; SUBUNIT; SITE	Prokaryotic RNA polymerase holoenzyme is composed of core subunits (alpha(2)betabeta'omega) plus a sigma factor that confers promoter specificity allowing for regulation of gene expression. Holoenzyme is known to undergo several conformational changes during the multiple steps of transcription initiation. However, the effects of these changes on the functions of specific regions have not been well characterized. In this work, we addressed the role of possible conformational change in region 2 of Escherichia coli sigma(70) by engineering disulfide bonds that "lock" region 2.1 with region 2.2 and region 2.2 with region 2.3. When these mutant holoenzymes were characterized for gross defects in multiple-round transcription, we found that insertion of either disulfide bond did not result in a fundamental block, indicating that the disulfide-containing holoenzymes are active. However, both disulfide-containing holoenzymes exhibited defects in formation and stability of the open complex. Our results suggest that conformational flexibility within sigma(70) region 2 facilitates open complex formation and transcription initiation.	Univ Wisconsin, McArdle Lab Canc Res, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Burgess, RR (corresponding author), Univ Wisconsin, McArdle Lab Canc Res, 1400 Univ Ave, Madison, WI 53706 USA.	burgess@oncology.wisc.edu		Burgess, Richard/0000-0001-9545-3165	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028575] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMOUYAL M, 1987, J MOL BIOL, V195, P795, DOI 10.1016/0022-2836(87)90485-2; Anthony LC, 2002, J BACTERIOL, V184, P2634, DOI 10.1128/JB.184.10.2634-2641.2002; Arthur TM, 2000, J BIOL CHEM, V275, P23113, DOI 10.1074/jbc.M002040200; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; Barker MM, 2001, J MOL BIOL, V305, P673, DOI 10.1006/jmbi.2000.4327; Bowers CW, 1999, EMBO J, V18, P709, DOI 10.1093/emboj/18.3.709; BUC H, 1985, BIOCHEMISTRY-US, V24, P2712, DOI 10.1021/bi00332a018; Buc H, 1997, CURR BIOL, V7, pR97, DOI 10.1016/S0960-9822(06)00047-9; BURGESS RR, 1969, NATURE, V221, P43, DOI 10.1038/221043a0; Burgess RR, 2001, CURR OPIN MICROBIOL, V4, P126, DOI 10.1016/S1369-5274(00)00177-6; Callaci S, 1999, MOL CELL, V3, P229, DOI 10.1016/S1097-2765(00)80313-5; Callaci S, 1998, J BIOL CHEM, V273, P32995, DOI 10.1074/jbc.273.49.32995; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; Craig ML, 1998, J MOL BIOL, V283, P741, DOI 10.1006/jmbi.1998.2129; Darst SA, 1998, J STRUCT BIOL, V124, P115, DOI 10.1006/jsbi.1998.4057; DeHaseth PL, 1998, J BACTERIOL, V180, P3019, DOI 10.1128/JB.180.12.3019-3025.1998; Dombkowski AA, 2000, PROTEIN ENG, V13, P679, DOI 10.1093/protein/13.10.679; DOMBROSKI AJ, 1993, CELL MOL BIOL RES, V39, P311; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; Gruber TM, 2001, MOL CELL, V8, P21, DOI 10.1016/S1097-2765(01)00292-1; HARRIS SJ, 1995, BIOCHEMISTRY-US, V34, P8752, DOI 10.1021/bi00027a026; HELMANN JD, 1988, ANNU REV BIOCHEM, V57, P839, DOI 10.1146/annurev.bi.57.070188.004203; Ko DC, 1998, GENE DEV, V12, P3276, DOI 10.1101/gad.12.20.3276; KOVACIC RT, 1987, J BIOL CHEM, V262, P13654; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; LESLEY SA, 1989, BIOCHEMISTRY-US, V28, P7728, DOI 10.1021/bi00445a031; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; METZGER W, 1993, J MOL BIOL, V232, P35, DOI 10.1006/jmbi.1993.1368; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Murakami KS, 2002, SCIENCE, V296, P1285, DOI 10.1126/science.1069595; Owens JT, 1998, P NATL ACAD SCI USA, V95, P6021, DOI 10.1073/pnas.95.11.6021; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; Ross W, 1998, J BACTERIOL, V180, P5375, DOI 10.1128/JB.180.20.5375-5383.1998; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; SAUER RT, 1986, BIOCHEMISTRY-US, V25, P5992, DOI 10.1021/bi00368a024; SHANER SL, 1982, BIOCHEMISTRY-US, V21, P5539, DOI 10.1021/bi00265a025; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; STEARMAN RS, 1988, BIOCHEMISTRY-US, V27, P7571, DOI 10.1021/bi00419a059; Storch MM, 1999, BIOCHEMISTRY-US, V38, P5054, DOI 10.1021/bi982158q; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; Tiebel B, 1998, EMBO J, V17, P5112, DOI 10.1093/emboj/17.17.5112; TRAVERS AA, 1969, NATURE, V222, P537, DOI 10.1038/222537a0; TRAYERS AA, 1969, NATURE, V223, P1107; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	47	11	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46433	46441		10.1074/jbc.M208205200	http://dx.doi.org/10.1074/jbc.M208205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359719	hybrid			2022-12-25	WOS:000179529300095
J	Harder, J; Schroder, JM				Harder, J; Schroder, JM			RNase 7, a novel innate immune defense antimicrobial protein of healthy human skin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EOSINOPHIL CATIONIC PROTEIN; BETA-DEFENSIN; HUMAN BETA-DEFENSIN-1; PEPTIDE ANTIBIOTICS; INDUCIBLE PEPTIDE; EXPRESSION; RIBONUCLEASE; KERATINOCYTES; FAMILY; HBD-1	We analyzed healthy human skin for the presence of endogenous antimicrobial proteins that might explain the unusually high resistance of human skin against infections. A novel 14.5-kDa antimicrobial ribonuclease, termed RNase 7, was isolated from skin-derived stratum corneum. RNase 7 exhibited potent ribonuclease activity and thus may contribute to the well known ribonuclease activity of human skin. RNase 7 revealed broad spectrum antimicrobial activity against many pathogenic microorganisms and remarkably potent activity (lethal dose of 90% < 30 nm) against a vancomycin-resistant Enterococcus faecium. Molecular cloning from skinderived primary keratinocytes and purification of RNase 7 from supernatants of cultured primary keratinocytes indicate that keratinocytes represent the major cellular source in skin and that RNase 7 is secreted. RNase 7 mRNA expression was detected in various epithelial tissues including skin, respiratory tract, genitourinary tract, and at a low level, in the gut. In addition to a constitutive expression, RNase 7 mRNA was induced in cultured primary keratinocytes by interleukin-1beta, interferon-gamma, and bacterial challenge. This is the first report demonstrating RNases as a novel class of epithelial inducible antimicrobial proteins, which may play an important role in the innate immune defense system of human epithelia.	Univ Hosp Kiel, Dept Dermatol, Clin Res Unit, D-24105 Kiel, Germany	University of Kiel; Schleswig Holstein University Hospital	Schroder, JM (corresponding author), Univ Hosp Kiel, Dept Dermatol, Clin Res Unit, Schittenhelmstr 7, D-24105 Kiel, Germany.	jschroeder@dermatology.uni-kiel.de	Harder, Jürgen/B-3162-2010; Schroeder, Jens M/B-3994-2009	Harder, Jurgen/0000-0002-4075-4603				BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Domachowske JB, 1998, J INFECT DIS, V177, P1458, DOI 10.1086/515322; Domachowske JB, 1998, NUCLEIC ACIDS RES, V26, P3358, DOI 10.1093/nar/26.14.3358; FETT JW, 1985, BIOCHEMISTRY-US, V24, P5480, DOI 10.1021/bi00341a030; Frohm M, 1997, J BIOL CHEM, V272, P15258, DOI 10.1074/jbc.272.24.15258; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Fulton C, 1997, LANCET, V350, P1750, DOI 10.1016/S0140-6736(05)63574-X; Garcia JRC, 2001, FASEB J, V15, P1819, DOI 10.1096/fj.00-0865fje; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Harder J, 2000, AM J RESP CELL MOL, V22, P714, DOI 10.1165/ajrcmb.22.6.4023; Harder J, 2001, J BIOL CHEM, V276, P5707, DOI 10.1074/jbc.M008557200; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Krisanaprakornkit S, 1998, INFECT IMMUN, V66, P4222; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; LEHRER RI, 1989, J IMMUNOL, V142, P4428; Liu AY, 2002, J INVEST DERMATOL, V118, P275, DOI 10.1046/j.0022-202x.2001.01651.x; Noso N, 1996, J IMMUNOL, V156, P1946; O'Neil DA, 1999, J IMMUNOL, V163, P6718; ROSENBERG HF, 1995, J BIOL CHEM, V270, P7876, DOI 10.1074/jbc.270.14.7876; Rosenberg HF, 1998, CELL MOL LIFE SCI, V54, P795, DOI 10.1007/s000180050208; ROSENBERG HF, 1995, J BIOL CHEM, V270, P30234; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schittek B, 2001, NAT IMMUNOL, V2, P1133, DOI 10.1038/ni732; Schroder JM, 1999, BIOCHEM PHARMACOL, V57, P121, DOI 10.1016/S0006-2952(98)00226-3; SCHRODER JM, 1992, J INVEST DERMATOL, V98, P241, DOI 10.1111/1523-1747.ep12556058; Schroder JM, 1999, INT J BIOCHEM CELL B, V31, P645, DOI 10.1016/S1357-2725(99)00013-8; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Wiedow O, 1998, BIOCHEM BIOPH RES CO, V248, P904, DOI 10.1006/bbrc.1998.9069; Zhang JZ, 2002, NUCLEIC ACIDS RES, V30, P1169, DOI 10.1093/nar/30.5.1169	31	312	348	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46779	46784		10.1074/jbc.M207587200	http://dx.doi.org/10.1074/jbc.M207587200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244054	hybrid			2022-12-25	WOS:000179529300138
J	Kiianitsa, K; Solinger, JA; Heyer, WD				Kiianitsa, K; Solinger, JA; Heyer, WD			Rad54 protein exerts diverse modes of ATPase activity on duplex DNA partially and fully covered with Rad51 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; ESCHERICHIA-COLI RECA; YEAST SWI/SNF COMPLEX; SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENT; FUNCTIONAL INTERACTIONS; RECOMBINATIONAL REPAIR; MEIOTIC RECOMBINATION; BINDING PROPERTIES; DEPENDENT ATPASE	Rad54 protein is a Snf2-like ATPase with a specialized function in the recombinational repair of DNA damage. Rad54 is thought to stimulate the search of homology via formation of a specific complex with the presynaptic Rad51 filament on single-stranded DNA. Herein, we address the interaction of Rad54 with Rad51 filaments on double-stranded (ds) DNA, an intermediate in DNA strand exchange with unclear functional significance. We show that Saccharomyces cerevisiae Rad54 exerts distinct modes of ATPase activity on partially and fully saturated filaments of Rad51 protein on dsDNA. The highest ATPase activity is observed on dsDNA containing short patches of yeast Rad51 filaments resulting in a 6-fold increase compared with protein-firee DNA. This enhanced ATPase mode of yeast Rad54 can also be elicited by partial filaments of human Rad51 protein but to a lesser extent. In contrast, the interaction of Rad54 protein with duplex DNA fully covered with Rad51 is entirely species-specific. When yeast Rad51 fully covers dsDNA, Rad54 protein hydrolyzes ATP in a reduced mode at 60-80% of its rate on protein-free DNA. Instead, saturated filaments with human Rad51 fail to support the yeast Rad54 ATPase. We suggest that the interaction of Rad54 with dsDNA-Rad51 complexes is of functional importance in homologous recombination.	Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA; Univ Calif Davis, Sect Mol & Cellular Biol, Ctr Genet & Dev, Davis, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis	Heyer, WD (corresponding author), Univ Calif Davis, Div Biol Sci, Microbiol Sect, Davis, CA 95616 USA.				NIGMS NIH HHS [R01-GM58015] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058015] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bazett-Jones DP, 1999, MOL CELL BIOL, V19, P1470; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; Bianco P. R., 1998, FRONT BIOSCI, V3, pD570; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Chanet R, 1996, MOL CELL BIOL, V16, P4782; Citterio E, 2000, MOL CELL BIOL, V20, P7643, DOI 10.1128/MCB.20.20.7643-7653.2000; Clever B, 1999, YEAST, V15, P721, DOI 10.1002/(SICI)1097-0061(19990630)15:9<721::AID-YEA414>3.0.CO;2-W; Clever B, 1997, EMBO J, V16, P2535, DOI 10.1093/emboj/16.9.2535; DICAPUA E, 1982, J MOL BIOL, V157, P87, DOI 10.1016/0022-2836(82)90514-9; DONOVAN JW, 1994, GENE DEV, V8, P2552, DOI 10.1101/gad.8.21.2552; Egelman EH, 2001, J MOL BIOL, V309, P539, DOI 10.1006/jmbi.2001.4686; EISEN JA, 1995, NUCLEIC ACIDS RES, V23, P2715, DOI 10.1093/nar/23.14.2715; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gasior SL, 1998, GENE DEV, V12, P2208, DOI 10.1101/gad.12.14.2208; Gavin I, 2001, MOL CELL, V7, P97, DOI 10.1016/S1097-2765(01)00158-7; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Havas K, 2000, CELL, V103, P1133, DOI 10.1016/S0092-8674(00)00215-4; HAYS SL, 1995, P NATL ACAD SCI USA, V92, P6925, DOI 10.1073/pnas.92.15.6925; Jiang H, 1996, J BIOL CHEM, V271, P33181, DOI 10.1074/jbc.271.52.33181; JOHNSON RD, 1995, MOL CELL BIOL, V15, P4843; Kanaar R, 1996, CURR BIOL, V6, P828, DOI 10.1016/S0960-9822(02)00606-1; Kiianitsa K, 1997, P NATL ACAD SCI USA, V94, P7837, DOI 10.1073/pnas.94.15.7837; KODADEK T, 1988, BIOCHEMISTRY-US, V27, P3210, DOI 10.1021/bi00409a013; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; Krejci L, 2001, MOL CELL BIOL, V21, P966, DOI 10.1128/MCB.21.3.966-976.2001; Logie C, 1997, EMBO J, V16, P6772, DOI 10.1093/emboj/16.22.6772; Mazin AV, 2000, MOL CELL, V6, P583, DOI 10.1016/S1097-2765(00)00057-5; Mazin AV, 2000, EMBO J, V19, P1148, DOI 10.1093/emboj/19.5.1148; McIlwraith MJ, 2000, J MOL BIOL, V304, P151, DOI 10.1006/jmbi.2000.4180; Namsaraev EA, 1998, J BIOL CHEM, V273, P6177, DOI 10.1074/jbc.273.11.6177; New JH, 1998, NATURE, V391, P407, DOI 10.1038/34950; OGAWA T, 1995, ADV BIOPHYS, V31, P93, DOI 10.1016/0065-227X(95)99385-3; PALLADINO F, 1992, GENETICS, V132, P23; Paques F, 1999, MICROBIOL MOL BIOL R, V63, P349; Pazin MJ, 1997, CELL, V88, P737, DOI 10.1016/S0092-8674(00)81918-2; Petukhova G, 1999, J BIOL CHEM, V274, P29453, DOI 10.1074/jbc.274.41.29453; Petukhova G, 1998, NATURE, V393, P91, DOI 10.1038/30037; Quinn J, 1996, NATURE, V379, P844, DOI 10.1038/379844a0; Ristic D, 2001, P NATL ACAD SCI USA, V98, P8454, DOI 10.1073/pnas.151056798; SCHILD D, 1995, GENETICS, V140, P115; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; Shinohara A, 1998, NATURE, V391, P404, DOI 10.1038/34943; Shinohara A, 1998, GENES CELLS, V3, P145, DOI 10.1046/j.1365-2443.1998.00176.x; Shinohara M, 2000, P NATL ACAD SCI USA, V97, P10814, DOI 10.1073/pnas.97.20.10814; Solinger JA, 2001, P NATL ACAD SCI USA, V98, P8447, DOI 10.1073/pnas.121009898; Solinger JA, 2001, J MOL BIOL, V307, P1207, DOI 10.1006/jmbi.2001.4555; Song BW, 2000, J BIOL CHEM, V275, P15895, DOI 10.1074/jbc.M910244199; Stasiak A, 1988, GENETIC RECOMBINATIO, P265; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; Sugiyama T, 1998, P NATL ACAD SCI USA, V95, P6049, DOI 10.1073/pnas.95.11.6049; SUNG P, 1994, SCIENCE, V265, P1241, DOI 10.1126/science.8066464; Sung P, 1997, GENE DEV, V11, P1111, DOI 10.1101/gad.11.9.1111; SUNG P, 1995, CELL, V82, P453, DOI 10.1016/0092-8674(95)90434-4; Sung P, 1997, J BIOL CHEM, V272, P28194, DOI 10.1074/jbc.272.45.28194; Swagemakers SMA, 1998, J BIOL CHEM, V273, P28292, DOI 10.1074/jbc.273.43.28292; Tan TLR, 1999, CURR BIOL, V9, P325, DOI 10.1016/S0960-9822(99)80142-0; Van Komen S, 2000, MOL CELL, V6, P563, DOI 10.1016/S1097-2765(00)00055-1; Zaitseva EM, 1999, J BIOL CHEM, V274, P2907, DOI 10.1074/jbc.274.5.2907	58	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46205	46215		10.1074/jbc.M207967200	http://dx.doi.org/10.1074/jbc.M207967200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12359723	hybrid			2022-12-25	WOS:000179529300068
J	Long, DJ; Iskander, K; Gaikwad, A; Arin, M; Roop, DR; Knox, R; Barrios, R; Jaiswal, AK				Long, DJ; Iskander, K; Gaikwad, A; Arin, M; Roop, DR; Knox, R; Barrios, R; Jaiswal, AK			Disruption of dihydronicotinamide riboside : quinone oxidoreductase 2 (NQO2) leads to myeloid hyperplasia of bone marrow and decreased sensitivity to menadione toxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DT-DIAPHORASE; INCREASED SUSCEPTIBILITY; CANCER-CHEMOTHERAPY; MITOMYCIN-C; MOUSE SKIN; GENE; CARCINOGENESIS; BIOACTIVATION; POLYMORPHISM; NAD(P)H	Dilrydronicotinamide riboside (NRH):quinone oxidoreductase 2 (NQO2) is a flavoenzyme that catalyzes the reductive metabolism of quinones. To examine the in vivo role of NQO2, NQO2-null. (NQO2-/-) mice were generated using targeted gene disruption. Mice lacking NQO2 gene expression showed no detectable developmental abnormalities and were indistingruishable from wild-type (NQO2+/+) mice. However, NQO2-null mice exhibited myeloid hyperplasia of the bone marrow and increased neutrophils, basophils, eosinophils, and platelets in the peripheral blood. Decreased apoptosis of bone marrow cells and circulating granulocytes contributed to myeloid hyperplasia and hyperactivity of bone marrow in NQO2-null mice. The hematological changes in NQO2-/- mice were specifically associated with loss of the NQO2 gene because histological analysis of various tissues including spleen, thymus, blood cultures, and urine analysis demonstrated no sign of infection. NQO2-null mice also demonstrated decreased toxicity when exposed to menadione or menadione with NRH. These results establish a role for NQO2 in protection against myelogenous hyperplasia and in metabolic activation of menadione, leading to hepatic toxicity. The NQO2-null mice are a model for NQO2 deficiency in humans and can be used to determine the role of this enzyme in sensitivities to toxicity and carcinogenesis.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Pathol, Houston, TX 77030 USA; Enact Pharma PLC, Salisbury SP4 0JQ, Wilts, England	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine	Jaiswal, AK (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES007943] Funding Source: NIH RePORTER; NIEHS NIH HHS [R01 ES07943] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Begleiter A, 1997, ONCOL RES, V9, P371; Boyer MJ, 1997, ONCOL RES, V9, P391; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen S, 2000, FREE RADICAL BIO MED, V29, P276, DOI 10.1016/S0891-5849(00)00308-7; CHESIS PL, 1984, P NATL ACAD SCI-BIOL, V81, P1696, DOI 10.1073/pnas.81.6.1696; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; DEFLORA S, 1985, CANCER RES, V45, P3188; Dinkova-Kostova LT, 2000, FREE RADICAL BIO MED, V29, P231, DOI 10.1016/S0891-5849(00)00300-2; Foster CE, 1999, BIOCHEMISTRY-US, V38, P9881, DOI 10.1021/bi990799v; Gaikwad A, 2001, J BIOL CHEM, V276, P22559, DOI 10.1074/jbc.M101053200; Jaiswal AK, 1999, PHARMACOGENETICS, V9, P413, DOI 10.1097/00008571-199906000-00020; JAISWAL AK, 1990, BIOCHEMISTRY-US, V29, P1899, DOI 10.1021/bi00459a034; Joseph P, 1996, INT J CANCER, V65, P263; Knox RJ, 2000, CANCER RES, V60, P4179; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Larson RA, 1999, BLOOD, V94, P803, DOI 10.1182/blood.V94.2.803.414k44_803_807; LIND C, 1985, ARCH BIOCHEM BIOPHYS, V280, P226; Long DJ, 2000, CANCER RES, V60, P5913; Long DJ, 2000, GENE, V252, P107, DOI 10.1016/S0378-1119(00)00221-3; Long DJ, 2001, JNCI-J NATL CANCER I, V93, P1166, DOI 10.1093/jnci/93.15.1166; Moran JL, 1999, P NATL ACAD SCI USA, V96, P8150, DOI 10.1073/pnas.96.14.8150; OBRIEN PJ, 1991, CHEM-BIOL INTERACT, V80, P1, DOI 10.1016/0009-2797(91)90029-7; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Rauth AM, 1997, ONCOL RES, V9, P339; RILEY RJ, 1992, BIOCHEM PHARMACOL, V43, P1657, DOI 10.1016/0006-2952(92)90694-E; ROSS D, 1994, ONCOL RES, V6, P493; Ross D, 2000, CHEM-BIOL INTERACT, V129, P77, DOI 10.1016/S0009-2797(00)00199-X; Rothman N, 1997, CANCER RES, V57, P2839; SARTORELLI AC, 1994, ONCOL RES, V6, P501; SARVANKUMAR D, 2000, CURR TOP CELL REGUL, V36, P201; SHAW PM, 1991, EUR J BIOCHEM, V195, P171, DOI 10.1111/j.1432-1033.1991.tb15691.x; Smith MT, 1999, P NATL ACAD SCI USA, V96, P7624, DOI 10.1073/pnas.96.14.7624; TYBULEWICZ VLJ, 1991, CELL, V65, P1153, DOI 10.1016/0092-8674(91)90011-M; WORKMAN P, 1993, CANCER METAST REV, V12, P73, DOI 10.1007/BF00689802; WORKMAN P, 1994, ONCOL RES, V6, P461; Wu KB, 1997, ARCH BIOCHEM BIOPHYS, V347, P221, DOI 10.1006/abbi.1997.0344; Zhao QJ, 1997, P NATL ACAD SCI USA, V94, P1669, DOI 10.1073/pnas.94.5.1669	38	95	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46131	46139		10.1074/jbc.M208675200	http://dx.doi.org/10.1074/jbc.M208675200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12351651	hybrid			2022-12-25	WOS:000179529300057
J	MacLeod, KJ; Husain, RD; Gage, DA; Ahn, K				MacLeod, KJ; Husain, RD; Gage, DA; Ahn, K			Constitutive phosphorylation of human endothelin-converting enzyme-1 isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR COMPARTMENT; MOLECULAR-CLONING; SUBCELLULAR LOCALIZATIONS; PROTEIN; CELLS; ECE-1; KINASE; METALLOPROTEASE; EXPRESSION; MEMBRANE	To investigate the phosphorylation of human endothelin-converting enzyme-1 (hECE-1) and identify potential residues involved, both in vivo and in vitro phosphorylation labeling assays of hECE-1 isoforms were performed in combination with site-directed mutagenesis and mass spectrometric analyses. Initial studies found that endogenous hECE-1 was constitutively phosphorylated in a primary endothelial cell line. The four known isoforms of hECE-1 expressed in this cell line (1a, 1b, 1c, and 1d) were then cloned by reverse transcription-PCR to determine which isoform(s) may be phosphorylated. The isoforms differ only in the first portion of their short aminoterminal cytoplasmic domains whereas their transmembrane domains and ectodomains of the proteins are identical. Isoforms 1b, 1c, and 1d but not 1a, were constitutively phosphorylated in vivo when expressed in Chinese hamster ovary cells and casein kinase I readily phosphorylated the immunopurified isoforms in vitro. Site-directed mutagenesis established that two conserved serine residues, Ser(18) and Ser(20), (numbering based on isoform 1c) form at least one phosphorylation site in these three isoforms. Mutant forms of 1b, 1c, and 1d were constructed in which a single alanine was introduced at either serine residue and a double mutant for each isoform was constructed as well in which both serines were replaced with alanine. Phosphorylation of the single mutants was greatly reduced and was nearly abolished in the double mutants in both in vivo and in vitro labeling assays. Analysis by MALDI-MS of (32)p-labeled proteolytic peptides derived from wild type 1c and the lc mutants supported both Ser(18) and Ser(20) as phosphorylated residues. These data demonstrate the first finding that hECE-1 is constitutively phosphorylated within its cytoplasmic domain in an isoform-specific manner.	Pfizer Global Res & Dev, Dept CNS Mol Sci, Ann Arbor Labs, Ann Arbor, MI 48105 USA; Pfizer Global Res & Dev, Dept Discovery Technol, Ann Arbor Labs, Ann Arbor, MI 48105 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA	Pfizer; Pfizer; Michigan State University	MacLeod, KJ (corresponding author), Pfizer Global Res & Dev, Dept CNS Mol Sci, Ann Arbor Labs, 2800 Plymouth Rd, Ann Arbor, MI 48105 USA.							[Anonymous], 1995, Nat Genet, V11, P130; Azarani A, 1998, BIOCHEM J, V333, P439, DOI 10.1042/bj3330439; Barnes K, 1998, HYPERTENSION, V31, P3, DOI 10.1161/01.HYP.31.1.3; Barnes K, 1996, J CELL SCI, V109, P919; Cailler F, 1999, BIOCHEM J, V341, P119, DOI 10.1042/0264-6021:3410119; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; Fahnoe DC, 2000, J CARDIOVASC PHARM, V36, pS22, DOI 10.1097/00005344-200036051-00009; Ganju RK, 1996, BLOOD, V88, P4159; Hoang MV, 1997, BIOCHEM J, V327, P23, DOI 10.1042/bj3270023; INOUE A, 1989, P NATL ACAD SCI USA, V86, P2863, DOI 10.1073/pnas.86.8.2863; Johnson GD, 1999, J BIOL CHEM, V274, P4053, DOI 10.1074/jbc.274.7.4053; LEE S, 1991, P NATL ACAD SCI USA, V88, P6353, DOI 10.1073/pnas.88.14.6353; MacLeod KJ, 2001, J BIOL CHEM, V276, P30608, DOI 10.1074/jbc.M103928200; MALFROY B, 1988, FEBS LETT, V229, P206, DOI 10.1016/0014-5793(88)80828-7; NISHIKORI K, 1991, NEUROCHEM INT, V18, P535, DOI 10.1016/0197-0186(91)90152-4; OHNAKA K, 1993, J BIOL CHEM, V268, P26759; Orzechowski HD, 1997, J MOL MED-JMM, V75, P512, DOI 10.1007/s001090050136; Orzechowski HD, 2001, MOL PHARMACOL, V60, P1332, DOI 10.1124/mol.60.6.1332; Pulgar V, 1999, EUR J BIOCHEM, V260, P520, DOI 10.1046/j.1432-1327.1999.00195.x; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Russell FD, 1999, BRIT J PHARMACOL, V126, P391, DOI 10.1038/sj.bjp.0702315; Russell FD, 1998, CIRC RES, V83, P314, DOI 10.1161/01.RES.83.3.314; Schweizer A, 1997, BIOCHEM J, V328, P871, DOI 10.1042/bj3280871; SHIMADA K, 1994, J BIOL CHEM, V269, P18275; TAKAHASHI M, 1993, J BIOL CHEM, V268, P21394; Tullai JW, 2000, J BIOL CHEM, V275, P36514, DOI 10.1074/jbc.M001843200; Valdenaire O, 1999, EUR J BIOCHEM, V264, P341, DOI 10.1046/j.1432-1327.1999.00602.x; VALDENAIRE O, 1995, J BIOL CHEM, V270, P29794; Valdenaire O, 1999, J CELL SCI, V112, P3115; XU D, 1994, CELL, V78, P473, DOI 10.1016/0092-8674(94)90425-1	30	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46355	46363		10.1074/jbc.M207972200	http://dx.doi.org/10.1074/jbc.M207972200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12244060	hybrid			2022-12-25	WOS:000179529300086
J	Terry-Lorenzo, RT; Elliot, E; Weiser, DC; Prickett, TD; Brautigan, DL; Shenolikar, S				Terry-Lorenzo, RT; Elliot, E; Weiser, DC; Prickett, TD; Brautigan, DL; Shenolikar, S			Neurabins recruit protein phosphatase-1 and inhibitor-2 to the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE MYOSIN PHOSPHATASE; FILAMENT-BINDING PROTEIN; RABBIT SKELETAL-MUSCLE; RAT-LIVER NUCLEI; CATALYTIC SUBUNIT; SMOOTH-MUSCLE; SERINE/THREONINE PHOSPHATASES; PHOSPHORYLASE-PHOSPHATASE; REGULATORY SUBUNIT; TARGETING SUBUNIT	Inhibitor-2 (I-2) bound protein phosphatase-1 (PP1) and several PP1-binding proteins from rat brain extracts, including the actin-binding proteins, neurabin I and neurabin II. Neurabins from rat brain lysates were sedimented by I-2 and its structural homologue, I-4. The central domain of both neurabins bound PP1 and I-2, and mutation of a conserved PP1-binding motif abolished neurabin binding to both proteins. Microcystin-LR, a PP1 inhibitor, also attenuated I-2 binding to neurabins. Immunoprecipitation of neurabin I established its association with PP1 and I-2 in HEK293T cells and suggested that PP1 mediated I-2 binding to neurabins. The C terminus of I-2, although not required for PP1 binding, facilitated PP1 recruitment by neurabins, which also targeted I-2 to polymerized F-actin. Mutations that attenuated PP1 binding to I-2 and neurabin I suggested distinct and overlapping sites for these two proteins on the PP1 catalytic subunit. Immunocytochemistry in epithelial cells and cultured hippocampal neurons showed that endogenous neurabin II and I-2 colocalized at actin-rich structures, consistent with the ability of neurabins to target the PP1(.)I-2 complex to actin cytoskeleton and regulate cell morphology.	Duke Univ, Ctr Med, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Univ Virginia, Sch Med, Ctr Cell Signaling, Charlottesville, VA 22908 USA	Duke University; University of Virginia	Shenolikar, S (corresponding author), Duke Univ, Ctr Med, Dept Pharmacol & Canc Biol, LSRC C315,Res Dr, Durham, NC 27710 USA.				NIGMS NIH HHS [GM56362] Funding Source: Medline; NINDS NIH HHS [NS41063] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056362] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041063] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adler HT, 1999, MOL CELL BIOL, V19, P7050; Agarwal-Mawal A, 2001, J BIOL CHEM, V276, P23712, DOI 10.1074/jbc.M010002200; Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Baker SH, 1997, GENETICS, V145, P615; BALLOU LM, 1983, BIOCHEMISTRY-US, V22, P3393, DOI 10.1021/bi00283a014; Brady MJ, 1997, J BIOL CHEM, V272, P20198, DOI 10.1074/jbc.272.32.20198; Cohen PTW, 2002, J CELL SCI, V115, P241; Connor JH, 1999, J BIOL CHEM, V274, P22366, DOI 10.1074/jbc.274.32.22366; Connor JH, 1998, J BIOL CHEM, V273, P27716, DOI 10.1074/jbc.273.42.27716; Connor JH, 2000, J BIOL CHEM, V275, P18670, DOI 10.1074/jbc.M909312199; Connor JH, 2001, MOL CELL BIOL, V21, P6841, DOI 10.1128/MCB.21.20.6841-6850.2001; Damer CK, 1998, J BIOL CHEM, V273, P24396, DOI 10.1074/jbc.273.38.24396; DEGUZMAN A, 1988, METHOD ENZYMOL, V159, P356; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; Dinischiotu A, 1997, FEBS LETT, V402, P141, DOI 10.1016/S0014-5793(96)01514-1; Egloff MP, 1997, EMBO J, V16, P1876, DOI 10.1093/emboj/16.8.1876; Eto M, 1999, BIOCHEMISTRY-US, V38, P16952, DOI 10.1021/bi992030o; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; GOLDBERG J, 1995, NATURE, V376, P745, DOI 10.1038/376745a0; Goslin K., 1998, CULTURING NERVE CELL, P339; GRUPPUSO PA, 1985, J BIOL CHEM, V260, P4288; Hata Y, 1999, CELL MOL LIFE SCI, V56, P461, DOI 10.1007/s000180050445; HEMMINGS BA, 1982, FEBS LETT, V150, P319, DOI 10.1016/0014-5793(82)80760-6; HIRAGA A, 1986, EUR J BIOCHEM, V161, P763, DOI 10.1111/j.1432-1033.1986.tb10505.x; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; Hsieh-Wilson LC, 1999, BIOCHEMISTRY-US, V38, P4365, DOI 10.1021/bi982900m; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; JAGIELLO I, 1995, J BIOL CHEM, V270, P17257, DOI 10.1074/jbc.270.29.17257; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Koyama M, 2000, FEBS LETT, V475, P197, DOI 10.1016/S0014-5793(00)01654-9; Kwon YG, 1997, P NATL ACAD SCI USA, V94, P3536, DOI 10.1073/pnas.94.8.3536; Li L, 1998, J PHYSIOL-LONDON, V508, P871, DOI 10.1111/j.1469-7793.1998.871bp.x; Liu J, 2000, BIOCHEM J, V346, P77, DOI 10.1042/0264-6021:3460077; McAvoy T, 1999, BIOCHEMISTRY-US, V38, P12943, DOI 10.1021/bi991227d; Nakanishi H, 1997, J CELL BIOL, V139, P951, DOI 10.1083/jcb.139.4.951; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; Oliver C.J., 1998, FRONT BIOSCI, V3, P961; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; PLATT T, 1972, EXPT MOL GENETICS, P352; Ramaswamy NT, 1998, GENETICS, V149, P57; Sakisaka T, 1999, ONCOGENE, V18, P1609, DOI 10.1038/sj.onc.1202451; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Senba S, 1999, J BIOCHEM-TOKYO, V125, P354, DOI 10.1093/oxfordjournals.jbchem.a022294; SHENOLIKAR S, 1994, ANNU REV CELL BIOL, V10, P55, DOI 10.1146/annurev.cellbio.10.1.55; Shirato H, 2000, BIOCHEMISTRY-US, V39, P13848, DOI 10.1021/bi001326n; Stephens DJ, 2000, BIOCHEM J, V345, P185, DOI 10.1042/0264-6021:3450185; Strack S, 1999, J COMP NEUROL, V413, P373; STRALFORS P, 1985, EUR J BIOCHEM, V149, P295, DOI 10.1111/j.1432-1033.1985.tb08926.x; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Terry-Lorenzo RT, 2000, J BIOL CHEM, V275, P2439, DOI 10.1074/jbc.275.4.2439; WANG QM, 1995, J BIOL CHEM, V270, P18352, DOI 10.1074/jbc.270.31.18352; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Winder DG, 2001, NAT REV NEUROSCI, V2, P461, DOI 10.1038/35081514; Wu J, 1996, BIOCHEMISTRY-US, V35, P13858, DOI 10.1021/bi961669e; Wu XL, 2001, BIOCHEMISTRY-US, V40, P7410, DOI 10.1021/bi002796k; Yang J, 2000, J BIOL CHEM, V275, P22635, DOI 10.1074/jbc.M003082200	57	61	62	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 29	2002	277	48					46535	46543		10.1074/jbc.M206960200	http://dx.doi.org/10.1074/jbc.M206960200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	620JB	12270929	hybrid			2022-12-25	WOS:000179529300108
J	Apetri, AC; Surewicz, WK				Apetri, AC; Surewicz, WK			Kinetic intermediate in the folding of human prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMODYNAMIC STABILITY; AGGREGATION; CONVERSION; TRANSITION; MECHANISM; DISEASES; DOMAIN; STATE; ACID; PRP	Transmissible spongiform encephalopathies are associated with the conversion of cellular prion protein, PrPC, into a misfolded oligomeric form, PrPSc. Here we have examined the kinetics of folding and unfolding reactions for the recombinant human prion protein C-terminal fragment 90-231 at pH 4.8 and 7.0. The stopped-flow data provide clear evidence for the population of an intermediate on the refolding pathway of the prion protein as indicated by a pronounced curvature in chevron plots and the presence of significant burst phase amplitude in the refolding kinetics. In addition to its role in the normal prion protein folding, this intermediate likely represents a crucial monomeric precursor of the pathogenic PrPSc isoform.	Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Dept Chem, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University	Surewicz, WK (corresponding author), Case Western Reserve Univ, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038604] Funding Source: NIH RePORTER; NINDS NIH HHS [NS38604] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; CAUGHEY B, 1991, J VIROL, V65, P6597, DOI 10.1128/JVI.65.12.6597-6603.1991; Caughey B, 2000, NAT MED, V6, P751, DOI 10.1038/77476; CAUGHEY BW, 1991, BIOCHEMISTRY-US, V30, P7672, DOI 10.1021/bi00245a003; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; Fersht A., 1999, STRUCTURE MECH PROTE; Hornemann S, 1998, P NATL ACAD SCI USA, V95, P6010, DOI 10.1073/pnas.95.11.6010; Hosszu LLP, 1999, NAT STRUCT BIOL, V6, P740, DOI 10.1038/11507; Jackson GS, 1999, SCIENCE, V283, P1935, DOI 10.1126/science.283.5409.1935; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Knaus KJ, 2001, NAT STRUCT BIOL, V8, P770, DOI 10.1038/nsb0901-770; Krantz BA, 2000, BIOCHEMISTRY-US, V39, P11696, DOI 10.1021/bi000792+; Liemann S, 1999, BIOCHEMISTRY-US, V38, P3258, DOI 10.1021/bi982714g; MICHOLSON EM, 2002, J MOL BIOL, V316, P807; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; Morillas M, 2001, BIOCHEMISTRY-US, V40, P6982, DOI 10.1021/bi010232q; Otzen DE, 1999, BIOCHEMISTRY-US, V38, P6499, DOI 10.1021/bi982819j; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RICK R, 1996, NATURE, V382, P180; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; Silow M, 1997, P NATL ACAD SCI USA, V94, P6084, DOI 10.1073/pnas.94.12.6084; Swietnicki W, 1998, J BIOL CHEM, V273, P31048, DOI 10.1074/jbc.273.47.31048; Swietnicki W, 2000, BIOCHEMISTRY-US, V39, P424, DOI 10.1021/bi991967m; Swietnicki W, 1997, J BIOL CHEM, V272, P27517, DOI 10.1074/jbc.272.44.27517; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; Wildegger G, 1999, NAT STRUCT BIOL, V6, P550, DOI 10.1038/9323; Zahn R, 2000, P NATL ACAD SCI USA, V97, P145, DOI 10.1073/pnas.97.1.145	31	80	82	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 22	2002	277	47					44589	44592		10.1074/jbc.C200507200	http://dx.doi.org/10.1074/jbc.C200507200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	618EE	12356762				2022-12-25	WOS:000179404800001
J	Liu, LM; Yoon, JH; Dammann, R; Pfeifer, GP				Liu, LM; Yoon, JH; Dammann, R; Pfeifer, GP			Frequent hypermethylation of the RASSF1A gene in prostate cancer	ONCOGENE			English	Article						RASSF1A; methylation; tumor suppressor gene; prostate cancer	TUMOR-SUPPRESSOR GENE; HUMAN-CHROMOSOME 3P21.3; ANDROGEN RECEPTOR GENE; CPG ISLAND; EPIGENETIC INACTIVATION; METHYLATION PATTERNS; BREAST CANCERS; LUNG-CANCER; PROGRESSION; PROMOTER	Recently, we have cloned and characterized the Ras association domain family 1A gene (RASSF1A) at 3p21.3, from which loss of genetic material is one of the most frequent events in several types of human solid tumors. The CpG island promoter region of this gene is highly methylated in several human cancers, most notably in small cell lung cancer, breast cancer, and renal cell carcinoma. In this study, we have analysed the methylation status of RASSF1A in primary prostate tumors and in the prostate cancer cell line LNCaP. In total, 37 out of 52 tumors (71%) were methylated at the promoter region of RASSF1A. The relative frequency of methylation was higher in more aggressive tumors compared with less malignant tumors. For instance, tumors with a Gleason score of 7-10 (25 out of 30, 83%) were significantly more methylated compared with Gleason 4-6 tumors (11 out of 20, 55%, P=0.032, Fisher's exact test). Coincident with a hypermethylated promoter, transcripts of RASSF1A were missing in LNCaP cells. Expression of RASSF1A was restored with 5-aza-2'-deoxycytidine, a DNA methylation inhibitor. In conclusion, our data suggest that epigenetic inactivation of RASSF1A by methylation is a very common event in prostate cancer and might be involved in the progression of the disease. Testing for RASSF1A methylation should become useful in prostate cancer early detection and diagnosis and might aid prognosis by gauging the potential status of progression.	Beckman Res Inst, City Hope Canc Ctr, Dept Biol, Duarte, CA 91010 USA; Univ Halle Wittenberg, Inst Human Genet & Med Biol, D-06097 Halle Saale, Germany	City of Hope; Beckman Research Institute of City of Hope; Martin Luther University Halle Wittenberg	Pfeifer, GP (corresponding author), Beckman Res Inst, City Hope Canc Ctr, Dept Biol, Duarte, CA 91010 USA.				NCI NIH HHS [CA88873] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA088873] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agathanggelou A, 2001, ONCOGENE, V20, P1509, DOI 10.1038/sj.onc.1204175; Baylin SB, 2000, TRENDS GENET, V16, P168, DOI 10.1016/S0168-9525(99)01971-X; Burbee DG, 2001, JNCI-J NATL CANCER I, V93, P691, DOI 10.1093/jnci/93.9.691; Cairns P, 2001, CLIN CANCER RES, V7, P2727; CLARK SJ, 1994, NUCLEIC ACIDS RES, V22, P2990, DOI 10.1093/nar/22.15.2990; Cui J, 2001, PROSTATE, V46, P249, DOI 10.1002/1097-0045(20010215)46:3<249::AID-PROS1030>3.0.CO;2-#; Dahiya R, 1997, INT J CANCER, V71, P20, DOI 10.1002/(SICI)1097-0215(19970328)71:1<20::AID-IJC5>3.3.CO;2-G; Dammann R, 2001, CANCER RES, V61, P3105; Dammann R, 2000, NAT GENET, V25, P315, DOI 10.1038/77083; Dreijerink K, 2001, P NATL ACAD SCI USA, V98, P7504, DOI 10.1073/pnas.131216298; Elo JP, 2001, ANN MED, V33, P130, DOI 10.3109/07853890109002068; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; Goessl C, 2001, UROLOGY, V58, P335, DOI 10.1016/S0090-4295(01)01268-7; GUMERLOCK PH, 1991, CANCER RES, V51, P1632; Herman JG, 1996, P NATL ACAD SCI USA, V93, P9821, DOI 10.1073/pnas.93.18.9821; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Kito H, 2001, PROSTATE, V49, P110, DOI 10.1002/pros.1124; Kok K, 1997, ADV CANCER RES, V71, P27, DOI 10.1016/S0065-230X(08)60096-2; Lee MG, 2001, CANCER RES, V61, P6688; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; Lerman MI, 2000, CANCER RES, V60, P6116; Li LC, 2000, CANCER RES, V60, P702; Li LC, 2001, J UROLOGY, V166, P705, DOI 10.1016/S0022-5347(05)66047-8; Lin XH, 2001, AM J PATHOL, V159, P1815, DOI 10.1016/S0002-9440(10)63028-3; Lo KW, 2001, CANCER RES, V61, P3877; Marcelli M, 2000, CANCER RES, V60, P944; Montgomery JS, 2001, J PATHOL, V195, P138, DOI 10.1002/1096-9896(200109)195:2<138::AID-PATH961>3.0.CO;2-Y; Nakayama T, 2000, LAB INVEST, V80, P1789, DOI 10.1038/labinvest.3780190; Nelson JB, 1997, CANCER RES, V57, P35; Nwosu V, 2001, HUM MOL GENET, V10, P2313, DOI 10.1093/hmg/10.20.2313; Ortiz-Vega S, 2002, ONCOGENE, V21, P1381, DOI 10.1038/sj.onc.1205192; Ostrander EA, 2000, AM J HUM GENET, V67, P1367, DOI 10.1086/316916; Ozen M, 2000, ANTICANCER RES, V20, P1905; Pao MM, 2001, HUM MOL GENET, V10, P903, DOI 10.1093/hmg/10.9.903; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Rokman A, 2001, CANCER RES, V61, P6038; Sekido Y, 1998, ONCOGENE, V16, P3151, DOI 10.1038/sj.onc.1201858; Singal R, 2001, CANCER RES, V61, P4820; Tavtigian SV, 2001, NAT GENET, V27, P172, DOI 10.1038/84808; Vos MD, 2000, J BIOL CHEM, V275, P35669, DOI 10.1074/jbc.C000463200; Wang L, 2001, CANCER RES, V61, P6494; Wistuba II, 2000, CANCER RES, V60, P1949; Wu YQ, 2001, CANCER RES, V61, P8651; Xiong ZG, 1997, NUCLEIC ACIDS RES, V25, P2532, DOI 10.1093/nar/25.12.2532; Yoon JH, 2001, INT J CANCER, V94, P212, DOI 10.1002/ijc.1466	47	123	141	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	OCT 3	2002	21	44					6835	6840		10.1038/sj.onc.1205814	http://dx.doi.org/10.1038/sj.onc.1205814			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	599CD	12360410				2022-12-25	WOS:000178315800014
